"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03880240","Gamma Induction for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: Transcranial Alternating Current Stimulation (tACS)|Other: Sham Transcranial Alternating Current Stimulation","PET amyloid burden|PET tau deposition|Incidence of Treatment-Emergent Adverse Events|Change in Gamma activity|Alzheimer's Disease Assessment Scale -Cog Score|Follow-up Amyloid PET burden|Follow-up Cognitive Evaluation","Beth Israel Deaconess Medical Center|Massachusetts General Hospital|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","45 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019P000092|R01AG060981","August 5, 2019","November 2023","November 2023","March 19, 2019",,"August 30, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03880240"
2,"NCT03645993","Early Onset Alzheimer's Disease Genomic Study","TGen","Recruiting","No Results Available","Alzheimer Disease","Genetic: Genetic Testing","Biomarkers found in blood","Baylor Research Institute|Translational Genomics Research Institute","All","40 Years to 65 Years   (Adult, Older Adult)",,"2","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","017-176","June 16, 2017","June 16, 2022","June 16, 2022","August 24, 2018",,"October 7, 2019","Baylor Scott & White AT&T Memory Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03645993"
3,"NCT03827733","Gut Microbiota and Alzheimer's Diseases",,"Recruiting","No Results Available","Alzheimer Disease",,"Gut amyloid-beta 42","Shanghai 10th People's Hospital|Massachusetts General Hospital","All","60 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","dsyy004","February 1, 2018","December 31, 2019","December 31, 2020","February 1, 2019",,"April 9, 2019","Shanghai Tenth People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03827733"
4,"NCT03168997","Memantine Treatment in Alzheimer's Disease Patients",,"Unknown status","No Results Available","Alzheimer Disease","Drug: Memantine Hydrochloride","ADAS-cog change","Wei Cuibai|Xuanwu Hospital, Beijing","All","50 Years and older   (Adult, Older Adult)","Phase 4","222","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17237T","July 15, 2017","September 30, 2018","December 31, 2018","May 30, 2017",,"May 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03168997"
5,"NCT03522129","Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: CT1812|Drug: Placebo","Measuring the displacement of Amyloid beta oligomers into cerebrospinal fluid (CSF)","Cognition Therapeutics","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COG0104","May 16, 2018","September 30, 2019","December 31, 2019","May 11, 2018",,"February 26, 2019","Clinilabs Drug Development Corporation, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03522129"
6,"NCT03690193","Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease","KDRAFT","Completed","No Results Available","Alzheimer Disease","Behavioral: Ketogenic Diet","Proportion of days positive for urinary ketone production|Change in blood ketone levels induced by ketogenic diet|Change in cognitive performance on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog)|Change in cognitive performance on the Mini-Mental State Exam (MMSE)|Dietary intake characterization prior to and after ketogenic diet initiation","University of Kansas Medical Center","All","Child, Adult, Older Adult","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13796","December 3, 2013","January 6, 2017","January 6, 2017","October 1, 2018",,"October 1, 2018",,,"https://ClinicalTrials.gov/show/NCT03690193"
7,"NCT03622905","ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: DBS-f On|Device: DBS Off","Change From Baseline Over Time at 12 months on the Ingegrated Alzheimer's Disease Rating Scale (iADRS) [ Time Frame: From Baseline to month 12 ]|Change From Baseline Over Time at 12 months on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) [ Time Frame: From Baseline to month 12 ]","Functional Neuromodulation Ltd","All","65 Years and older   (Older Adult)","Not Applicable","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FNMI-002","August 1, 2019","October 1, 2023","October 1, 2024","August 9, 2018",,"September 16, 2019","Barrow Neurological Institute, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Texas, Austin, Texas, United States|Toronto Western Hospital, Toronto, Ontario, Canada|Universitätmedizin Charité Berlin, Berlin, Germany|Universitätklinikum Köln, Cologne, Germany|Klinik für Neurologie Universitätsklinikum, Kiel, Germany|Universität Magdeburg, Magdeburg, Germany|Technische Universität München, Munich, Germany|Universitätklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03622905"
8,"NCT03896698","Feasibility Study of Transcranial Ultrasound Stimulation on Alzheimer's Disease Patients","TUS","Not yet recruiting","No Results Available","Alzheimer Disease","Device: Transcranial Ultrasound Stimulation","Device and procedure related adverse events recording|Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)|Clinical Dementia Rating (CDR)|Neuropsychiatric Inventory Questionnaire (NPI-Q)|Transcranial Doppler (TCD)|Magnetic Resonance Image (MRI)","National Yang Ming University|Taipei Veterans General Hospital, Taiwan","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Device Feasibility","TUS01","May 1, 2019","August 31, 2020","November 30, 2020","April 1, 2019",,"April 2, 2019","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03896698"
9,"NCT02208193","Alzheimer's Disease, Art and Garden","JAZ ART","Unknown status","No Results Available","Alzheimer Disease","Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension","Comparaison of the number of language acts in each category between AD and controls subjects|Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),|Scores obtained with the "" MemoArtZ "" tool (MAZ) to evaluate the memorization of artistic elements of the garden,|Scores from the "" General Esthetic Preference "" (GEP) tool to evaluate the consistency of general esthetic appreciations,|obtained with the specific mood assessment scale (CSDD) for subjects in group A|Score obtained with the specific assessment of emotional events scale (AES) for all subjects.","Central Hospital, Nancy, France","All","60 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014-A00139-38","July 2014","October 2016","September 2017","August 4, 2014",,"July 30, 2015","CHU Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT02208193"
10,"NCT03978338","A Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Mild Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: brain polypeptide solution|Other: same package of placebo","Changes of Alzheimer's Disease Assessment Scale—Cognitive Subscale(ADAS-cog) scores|Changes of Alzheimer's Disease Collaborative research group-Activities of Daily Living(ADCS-ADL)scores|Changes of Pittsburgh sleep quality index (PSQI) scores|Changes of Neuropsychiatric Inventory(NPI )scores|Changes of ( Mini-Mental State Examination )MMSE scores|Changes of Montreal Cognitive Assessment (MoCA) scores","Peking Union Medical College Hospital|Zhitong Biopharma CO.,LTD","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HS-1959","July 2019","May 2020","September 2020","June 7, 2019",,"June 11, 2019",,,"https://ClinicalTrials.gov/show/NCT03978338"
11,"NCT04040348","Alzheimer's Disease Stem Cells Multiple Infusions",,"Recruiting","No Results Available","Alzheimer Disease","Biological: 100 million cells allogeneic hMSC|Biological: 200 million cells allogeneic hMSC","Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Olfactory function over time as assessed by the Odor Identification test.|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume","Bernard (Barry) Baumel|University of Miami","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20190438","September 16, 2019","September 1, 2021","September 1, 2021","July 31, 2019",,"September 17, 2019","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04040348"
12,"NCT02290912","Gray Matters Alzheimer's Disease Prevention Intervention",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Health education program","Picture Vocabulary|Flanker Inhibitory Control and Attention Test|List Sorting Working Memory Test|Oral Symbol Digit Test|Montreal Cognitive Assessment|Rey Auditory Verbal Learning Test|Controlled Oral Word Association Test|Blood pressure|Body mass index|Insulin|Systemic inflammation|Skin carotenoid status|Triglycerides|HDL Cholesterol|LDL Cholesterol|Total cholesterol|Depression|Motivation|Sleep Quality|Stress|Emotional Support|Friendship|Hostility|Loneliness|Physical Activity - Moderate|Physical Activity - Vigorous|Nutrition|Readiness for Change|Metacognition","Utah State University","All","40 Years to 64 Years   (Adult)","Not Applicable","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","5606","April 2014","December 2014","December 2014","November 14, 2014",,"December 3, 2015",,,"https://ClinicalTrials.gov/show/NCT02290912"
13,"NCT02947893","Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","AD","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Placebo Capsule(s) Once a Day by Mouth|Drug: Nilotinib Capsule(s) Once a Day by Mouth","Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values|Effects of Nilotinib treatment on measurement of Nilotinib in the CSF","Georgetown University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-0315","January 2017","December 2019","February 2020","October 28, 2016",,"March 13, 2019","Georgetown University Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02947893"
14,"NCT03340571","Blood Biomarker of Alzheimer's Disease (AD)",,"Recruiting","No Results Available","Alzheimer Disease",,"Biological marker of Alzheimer's disease","Duke University","All","50 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00085997","March 12, 2018","July 2019","July 2019","November 13, 2017",,"June 11, 2019","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03340571"
15,"NCT03090854","Cholinergic Markers Alzheimer's Disease","CHOLINE","Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: ADASCog","Neuropsychological test (ADASCog)|Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria|Difference of CSF Ach AND AChE activity between responder and non responder groups|Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.","Assistance Publique - Hôpitaux de Paris","All","50 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","K160402|2016-AO1639-42","November 6, 2017","May 5, 2020","May 5, 2020","March 27, 2017",,"July 25, 2019","Centre Mémoire de Ressources et de Recherche Paris Nord, Paris, France",,"https://ClinicalTrials.gov/show/NCT03090854"
16,"NCT02253043","The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)","Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)|Clinical Dementia Rating Scale","Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PINS-002","May 2014","December 2018","December 2018","October 1, 2014",,"October 14, 2016","Beijing Tiantan Hospital, Beijing, Beijing, China|301 Hospatl, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02253043"
17,"NCT01867372","Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes",,"Terminated","No Results Available","Alzheimer's Disease",,"Accelerated preclinical changes in brain structure and function in specific regions will predict which individuals develop cognitive impairment and Alzheimer s disease|Changes in brain structure are predictors of cognitive decline and impairment though neuroimaging assessments","National Institute on Aging (NIA)|Johns Hopkins University|National Institutes of Health Clinical Center (CC)","All","20 Years and older   (Adult, Older Adult)",,"213","NIH|Other","Observational","Time Perspective: Other","999903328|03-AG-N328","March 10, 2003","September 22, 2014","September 22, 2014","June 4, 2013",,"September 24, 2019","Johns Hopkins University, Baltimore, Maryland, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01867372"
18,"NCT03352557","Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease","TANGO","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: BIIB092|Drug: Placebo","Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Percentage of Participants With Anti-BIIB092 Antibodies in Serum Over Time up to Week 90","Biogen","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","654","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","251AD201|2017-002901-37","May 3, 2018","July 9, 2021","June 30, 2024","November 24, 2017",,"September 20, 2019","Research Site, Birmingham, Alabama, United States|Xenoscience Inc, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Carlsbad, California, United States|Positron Research International, Fremont, California, United States|Neuropain Medical Center, Fresno, California, United States|V Royter, MD, APMC, Hanford, California, United States|Research Site, Irvine, California, United States|Research Site, Lancaster, California, United States|Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Research Site, Palo Alto, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, New Haven, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Melbourne, Orlando, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Stuart, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, The Villages, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|McLean Hospital, Belmont, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S. Marks, M.D., P.C., Plymouth, Massachusetts, United States|Research Site, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Research Site, New York, New York, United States|AD-CARE, University of Rochester, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Research Site, East Providence, Rhode Island, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Baylor Colledge of Medicine, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|The Memory Clinic, Inc., Bennington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Box Hill, Victoria, Australia|Research Site, Caulfield, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Strasbourg Cedex, Bas Rhin, France|Research Site, Bordeaux Cedex, Gironde, France|Research Site, Toulouse Cedex 9, Haute Garonne, France|Research Site, Montpellier, Herault, France|Research Site, Rennes cedex 2, Ille Et Vilaine, France|Research Site, Nantes cedex 1, Loire Atlantique, France|Research Site, Villeurbanne, Rhone, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Böblingen, Baden Wuertemberg, Germany|Research Site, Mannheim, Baden Wuerttemberg, Germany|Research Site, Ulm, Baden Wuerttemberg, Germany|Research Site, Muenchen, Bayern, Germany|Research Site, Frankfurt, Hessen, Germany|Research Site, Bonn, Nordrhein Westfalen, Germany|Research Site, Altenburg, Thueringen, Germany|Research Site, Berlin, Germany|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Roma, Italy|Research Site, Vicenza, Italy|Research Site, Obu-shi, Aichi-Ken, Japan|Research Site, Chiba-shi, Chiba-Ken, Japan|Research Site, Kawasaki-shi, Kanagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Kurashiki-shi, Okayama-Ken, Japan|Research Site, Suita-shi, Osaka-Fu, Japan|Research Site, Shinjuku-ku, Tokyo-To, Japan|Research Site, Bydgoszcz, Poland|Research Site, Lublin, Poland|Research Site, Sopot, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Getxo, Vizcaya, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Malmo, Sweden|Research Site, Molndal, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03352557"
19,"NCT02097056","Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease","SAVE","Completed","Has Results","Alzheimer's Disease","Drug: Donepezil HCL","Overall Summary of Adverse Events (AEs)|Change From Baseline in the Mini-Mental State Examination (MMSE) Score|Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores","Eisai Korea Inc.|Eisai Inc.","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 4","171","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ART-M082-401","February 2014","May 2015","May 2015","March 26, 2014","June 27, 2016","June 27, 2016","Chungju, Chungcheongbuk-do, Korea, Republic of|Ansan, Gyeonggi-do, Korea, Republic of|Buchoen, Gyeonggi-do, Korea, Republic of|Seongnam, Gyeonggi-do, Korea, Republic of|Jinju, Gyeongsangnam-do, Korea, Republic of|Iksan, Jeollabuk-do, Korea, Republic of|Hwasun, Jeollanam-do, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Incheon, Korea, Republic of|Jeju, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02097056"
20,"NCT02158910","A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients","AID","Completed","No Results Available","Alzheimer's Disease","Drug: Aricept","Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.","Eisai Korea Inc.|Eisai Inc.","All","Child, Adult, Older Adult",,"2231","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ART-M082-601","March 2015","June 2016","June 2016","June 9, 2014",,"March 7, 2017","Busan, Korea, Republic of|Chungcheongbuk-do, Korea, Republic of|Chungcheongnam-do, Korea, Republic of|Daegu, Korea, Republic of|Gangwon-do, Korea, Republic of|Gwangju, Korea, Republic of|Gyeonggji-do, Korea, Republic of|Gyeongsangbuk-do, Korea, Republic of|Gyeongsangnam-do, Korea, Republic of|Jeju-do, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02158910"
21,"NCT02946710","P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid","P75NTR-MND","Completed","No Results Available","Alzheimer Disease","Biological: cerebrospinal fluid","Concentration of p75NTR-ECD total|Concentration of p75NTR-ECD bound to Aβ1-40 and Aβ1-42|expression of p75NTR-ECD between patient groups","University Hospital, Toulouse","All","40 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","14 7317 02","December 2014","June 2017","December 2017","October 27, 2016",,"April 3, 2018","University Hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02946710"
22,"NCT02220738","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-957|Other: Placebo for ABT-957","Pharmacokinetic evaluation of the two ABT-957 diastereomers|Number of subjects with adverse events","AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-334","September 2014","March 2016","March 2016","August 20, 2014",,"June 16, 2016","Site Reference ID/Investigator# 129545, Glendale, California, United States|Site Reference ID/Investigator# 129435, Orlando, Florida, United States|Site Reference ID/Investigator# 129641, New York, New York, United States|Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02220738"
23,"NCT02005380","Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation",,"Completed","No Results Available","Alzheimer's Disease","Other: Text-based task|Other: Graphic-based Task","NASA Task Load Index Measure|Test Score","German-Jordanian University","All","60 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GJU001","November 2013","November 2013","November 2013","December 9, 2013",,"December 9, 2013","Darat Samir Shamma, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02005380"
24,"NCT01078168","Alzheimer`s Disease Acitretin Medication","ADAM","Completed","Has Results","Alzheimer Disease","Drug: Acitretin|Drug: Placebo","Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline","K. Lieb|Alzheimer Forschungsinitiative e.V. (AFI)|Johannes Gutenberg University Mainz","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ADAM|2009-011881-27","March 2010","January 2013","May 2013","March 2, 2010","February 2, 2018","February 2, 2018","Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany|Universität Rostock, Rostock, Germany",,"https://ClinicalTrials.gov/show/NCT01078168"
25,"NCT02899091","Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: CB-AC-02|Biological: Placebo","Number of Adverse Events|Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score|Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score|Changes from the baseline in GDS (Global Deterioration Scale)|Changes from the baseline in CDR (Clinical Dementia Rating) Score|Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score|Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score|Change in CIBIC (Clinician Interview Based Impression of Change)-plus|Changes from the baseline in SF-36|Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)|Change in Brain MRI (Magnetic Responance imaging)|Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging|Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging|Changes of band power in qEEG (Quantitative electroencephalography)","CHABiotech CO., Ltd","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHA-PAD-101","September 2016","December 2021","December 2021","September 14, 2016",,"September 6, 2019","Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02899091"
26,"NCT01689948","Alzheimer Disease : Rehabilitation's Intervention at Home","pré MATAPA","Terminated","No Results Available","Alzheimer's Disease","Behavioral: Home rehabilitation therapy","Evaluation of the mean scores of Instrumental Activities of Daily Living (IADL)|Evaluation of the mean scores of Neuro Psychiatric Inventory (NPI)|Evaluation of the mean scores of Zarit's scale (caregiver burden)|Alcohol consumption for the patient and the caregiver|Evaluation of the mean scores of Mini Mental State Examination (MMSE)(meaning evaluation of patient's cognitive impairment)|Evaluation of the mean scores of Goal Attainment scales (GAS) (meaning evaluation of the satisfaction of the patient and of her/his caregiver)","Nantes University Hospital","All","65 Years and older   (Older Adult)","Not Applicable","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RC12_0080","October 2012","May 2014","September 2014","September 21, 2012",,"October 15, 2014","Bellier Hospital, CHU of Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT01689948"
27,"NCT03959553","GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)",,"Not yet recruiting","No Results Available","Moderate Alzheimer's Disease","Drug: GV1001|Drug: Normal saline","Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog)|Alzheimer's Disease Assessment Scale-cognitive (ADAS cog)|Clinician's Interview-Based Impression of Change (CIBIC)-Plus|Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Mini-Mental State Examination (MMSE)","GemVax & Kael","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KG7/2017","September 1, 2019","August 31, 2021","February 28, 2022","May 22, 2019",,"May 27, 2019",,,"https://ClinicalTrials.gov/show/NCT03959553"
28,"NCT01715350","Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease","ADD","Completed","No Results Available","Alzheimer's Disease","Drug: PM012|Drug: Placebo","ADAS-cog|CDR|K-IADL|NPI|K-MMSE|VAS|AE","GMP BIO Co., LTD.|ADM Korea Inc","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PM012-P2","May 2012","September 2014","June 2015","October 26, 2012",,"April 18, 2016","Kyung Hee University Oriental Medicine Hospital, Seoul, Dongdaemun-gu, Korea, Republic of|National Health Insurance Corporation Ilsan Hospital, Goyang, Ilsandong-gu, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Paldal-gu, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01715350"
29,"NCT01782742","Bexarotene Amyloid Treatment for Alzheimer's Disease","BEAT-AD","Completed","Has Results","Alzheimer's Disease","Drug: Bexarotene|Drug: Placebo","Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain|Primary Outcome by Genotype (ALL SUBJECTS)|Primary Outcome by Genotype (NON ApoE4 CARRIERS)|Primary Outcome by Genotype (ApoE4 CARRIERS)|Primary Outcome by Genotype (HETEROZYGOTE ApoE4 CARRIERS)|Primary Outcome by Genotype (HOMOZYGOTE ApoE4 CARRIERS)|Change in MMSE Score in ALL Subjects From Baseline to Week 4|Change in ADAS-Cog Score in ALL Subjects From Baseline to Week 4|Change in the Global Clinical Dementia Rating Score in ALL Subjects From Baseline to Week 4|Change in NPI Scores in ALL Subjects From Baseline to Week 4|Change in the Activities of Daily Living (ADCS-ADL) Score in ALL Subjects From Baseline to Week 4|Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (ALL SUBJECTS)|Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1-42 (Non ApoE4 Carriers)|Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in All Subjects|Change in the Ratio of Beta Amyloid 42 to Beta Amyloid 40 in Non ApoE4 Carriers","The Cleveland Clinic","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CCF-IRB 12-783","February 2013","August 2014","December 2014","February 4, 2013","February 12, 2016","February 12, 2016","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT01782742"
30,"NCT01908010","Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-354|Drug: Placebo","Vital signs|ECG (electrocardiogram)|Neurological exam|Laboratory tests|Number of subject with adverse events|C-SSRS (Columbia-Suicide Severity Rating Scale)|Pharmacokinetic parameters","AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-080","July 2013","November 2013","November 2013","July 25, 2013",,"December 11, 2013","Site Reference ID/Investigator# 106999, Miami, Florida, United States|Site Reference ID/Investigator# 106998, Orlando, Florida, United States|Site Reference ID/Investigator# 107000, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01908010"
31,"NCT03408041","Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters",,"Completed","No Results Available","Alzheimer Disease","Other: Medical file data extraction","Age|Sex|Ethnic origin|Symptoms-diagnose time interval|Scheltens scale","Murielle Surquin|Brugmann University Hospital","All","Child, Adult, Older Adult",,"129","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHUB-parameters Alzheimer","May 1, 2016","October 1, 2017","October 1, 2017","January 23, 2018",,"January 23, 2018","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03408041"
32,"NCT01703117","Riluzole in Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Riluzole|Drug: Placebo","Imaging Biomarkers N-acetylaspartate (NAA) and FDG-PET values in regions of interest|Cognitive function (neuropsychological tests); Glutamate levels obtained through MRS","Icahn School of Medicine at Mount Sinai|Rockefeller University","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 18-0623|APE-0792","November 2013","November 2020","November 2020","October 10, 2012",,"March 18, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01703117"
33,"NCT02565511","A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","Generation S1","Active, not recruiting","No Results Available","Alzheimer's Disease","Biological: CAD106 Immunotherapy|Other: Placebo to CAD106|Drug: CNP520|Other: Placebo to CNP520","Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Number of participants with Adverse Events as a measure of Safety and Tolerability|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in Alzheimer's Disease related biomarkers|Change in APCC Test Score|Change in CDR-SOB|Aβ-specific immune response","Novartis Pharmaceuticals|Banner Alzheimer's Institute|National Institute on Aging (NIA)|Alzheimer's Association|Amgen|Novartis","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","481","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAPI015A2201J|2015-002715-15|1UF1AG046150-01","November 30, 2015","December 31, 2024","March 31, 2025","October 1, 2015",,"October 4, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun City Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|University of Southern California Keck School of Medicine Alzheimer Disease Research Center, Los Angeles, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Novartis Investigative Site, Basalt, Colorado, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Florida Atlantic University, Clinical Translational Research Unit, Boca Raton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Meridien Research, Maitland, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Mount Sinai Medical Center - The Wien Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Compass Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|NeuroStudies, Decatur, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States|Via Christi Research, Wichita, Kansas, United States|Sanders Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Memory Disorders Program, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center, Eatontown, New Jersey, United States|The Memory Center of Northeastern New York, Latham, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Nathan S. Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical center, Durham, North Carolina, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|University Hospitals Cleveland Medical Center / Case Western Reserve University, Beachwood, Ohio, United States|Novartis Investigative Site, Centerville, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Memory Health Center at Summit Research Network, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis - CBRI, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|CNS Healthcare, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center & Memory Care, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center, Houston, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Universal Research Group, Tacoma, Washington, United States|The Medical College of WI, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg Heights, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Münster, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wenzenbach, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Westbruy On Trym, Bristol, United Kingdom|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02565511"
34,"NCT03790982","Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease","WAY","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Placebo of AD-35 60mg /AD-35 30mg|Drug: Placebo of AD-35 60mg /AD-35 60mg|Drug: AD-35 30 mg + Placebo of AD-35 30 mg|Drug: AD-35 60 mg","Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 11 scores|Changes in Alzheimer's Disease Cooperative Study-clinical global impression of change (ADCS-CGIC ) scores|Changes in ADAS-Cog11 scores","Zhejiang Hisun Pharmaceutical Co. Ltd.","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AD-35-II-01","December 1, 2018","December 30, 2020","July 30, 2021","January 1, 2019",,"January 1, 2019","The Department of Neurosurgery, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03790982"
35,"NCT01883648","Study to Evaluate Coconut Oil for Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Coconut Oil Beverage|Other: Placebo Beverage","Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in behaviors measured by Neuropsychiatric Inventory|Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in functional ability measured by Activities of Daily Living (ADCS-ADLs)|Measure changes in Ketone & C-Reactive Protein assays from research blood samples throughout study during the 2 treatment periods from Baseline to Month 6 (change during a total 6 month period of time).|Adverse events related to coconut oil usage during 6 months of treatment periods (change during a total 6 month period of time).","University of South Florida","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Byrd AD-001","June 2013","February 1, 2017","February 1, 2017","June 21, 2013",,"April 28, 2017","USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01883648"
36,"NCT03656042","To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Filgrastim (75mcg/0.3ml)","Alzheimer's Disease Assessment Scale, Cognitive subscale ─ Chinese version (ADAS-Cog-C)|Mini-mental State Examination (MMSE)|Clinical Dementia Rating Scale (CDR)|AD Cooperative Study - Clinical Global Impression of change (ADCS-CGIC )|Lawton and Brody Scale for Instrumental Activities of Daily Living (IADL)|Neuropsychiatric Inventory (NPI)|Ten-point clock test (TPCT)|CD34+ cell number for G-CSF treatment group|Trail making test (TMT)(Part A))|Change from baseline in whole brain volume determined by MRI","Chang Gung Memorial Hospital","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","96-0272A-ASAD-061202","March 2009","July 2014","August 2014","September 3, 2018",,"September 3, 2018","Chang Gung Memorial Hospital, Taoyuan, Taiwan R.o.c, Taiwan",,"https://ClinicalTrials.gov/show/NCT03656042"
37,"NCT01428453","A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: 250mg rilapladib|Drug: placebo","Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24|Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24|Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24|Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24|Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24|Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24|Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24|Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24|Change From Baseline (Day 0) in CogState Battery Overall Composite Score|Change From Baseline (Day 0) in CogState Battery Attention Composite Score","GlaxoSmithKline","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","114458","October 1, 2011","February 4, 2013","February 18, 2013","September 5, 2011","September 24, 2018","September 24, 2018","GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Gatineau, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Oldenburg, Schleswig-Holstein, Germany|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Lørenskog, Norway|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Castellón de La Plana, Spain|GSK Investigational Site, Getafe/Madrid, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01428453"
38,"NCT01608061","ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease","ADvance","Unknown status","No Results Available","Alzheimer Disease","Device: DBS-f on|Device: DBS-f off","The study will assess the acute and long-term safety of the system. A detailed assessment of all device and/or therapy related adverse events will be conducted.|Efficacy outcomes include: improvement in ADAS-cog 13 at twelve months, improvement in the CDR and changes in glucose metabolism measured by FDG-PET at twelve months","Functional Neuromodulation Ltd","All","45 Years to 85 Years   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FNMI-001","May 2012","June 2015","September 2018","May 30, 2012",,"February 16, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Research Institute at Sun City, Sun City, Arizona, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Johns Hopkins Bayview, Baltimore, Maryland, United States|Hospital of the University of Pennsylvania: Penn Memory Clinic, Philadelphia, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01608061"
39,"NCT03055741","Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",,"Completed","No Results Available","Mild-moderate Alzheimer's Disease","Drug: Donepezil|Drug: DHP1401|Drug: Placebo","Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)|Clinical Dementia Rating Sum of Box Korean version(CDR-SB)|Neuropsychiatric Inventory-Q Korean version(NPI-Q)|K-MMSE|Korean Instrumental Activity of Daily Living(K-IADL)|Korean Trial Masking Test-elderly's version(K-TMT-e)","Daehwa Pharmaceutical Co., Ltd.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1401CS-2","December 28, 2016","February 2019","August 2019","February 16, 2017",,"August 20, 2019","The Catholic University of Korea, Bucheon, ST. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Suwon-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju-si, Jeollanam-do, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daejeon Eulji Medical Center, Daejeon, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chung-ang University Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03055741"
40,"NCT01624389","Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study","Alzheimer's","Unknown status","No Results Available","Alzheimer's Disease","Drug: F18-AV45","Rate of conversion from NC, EMCI, LMCI to AD.","Chang Gung Memorial Hospital","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","101-1074A1","January 2012","January 2015","January 2015","June 20, 2012",,"June 20, 2012","Tzu-Chen-Yen, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01624389"
41,"NCT02079909","Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)",,"Completed","Has Results","Alzheimer's Disease","Drug: T-817MA-H|Drug: T-817MA-L|Drug: Placebo","ADAS-cog Change From Baseline to Week 52|CGIC|ADCS-ADL Change From Baseline to Week 52","FUJIFILM Toyama Chemical Co., Ltd.|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","482","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T817MAUS202","March 2014","May 5, 2017","May 5, 2017","March 6, 2014","August 9, 2018","February 26, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|UCSD Comprehensive Alzheimer's Program, La Jolla, California, United States|UC Irvine Medical Center, Orange, California, United States|Geriatric and Adult Psychiatry, LCC, Hamden, Connecticut, United States|Yale University, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Georgetown University Clinical Research Unit, Washington, District of Columbia, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|University of Miami Miller-School of Medicine, Miami, Florida, United States|Scientific Clinical Research, Inc, North Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Meridien Research, Tampa, Florida, United States|Neuro Trials Research, Inc, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|Indiana Medical Research, Elkhart, Indiana, United States|Indiana University Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas/Clinical and Translational Science Unit, Fairway, Kansas, United States|University of Kentucky Sanders-Brown Center on Aging Clinic, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Acadia Hospital, Bangor, Maine, United States|Boston University Alzheimer's Disease Center, Boston, Massachusetts, United States|University of Michigan Health System/ Michigan Clinical Research Unit, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Bronson Neurobehvioral Health, Paw Paw, Michigan, United States|University of Nebraska Medical Center(Geri Psych), Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Global Medical Institutes, LLC;Princeton Medical Institute, Princeton, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Alzheimer's Disease Research Center of Mount Sinai, New York, New York, United States|Columbia University Medical Center Sergievsky Center Taub Institute, New York, New York, United States|The Nathan S. Kline Instituite for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University (WFU) School of Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University/ University Hospitals Case Medical Center, Beachwood, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Hospital at the University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Alzheimer Disease Research Center, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, LTD., Willow Grove, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Vanderbilt University Medical Center -VUIIS, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Cary J. Kohlenberg MD., SC dba IPC Research, Waukesha, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02079909/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02079909"
42,"NCT03790774","Neurofeedback in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Behavioral: Neurofeedback","EEG spectral content: within-session change in theta band activity|EEG spectral content: between-session change in theta band activity|Change in Woodcock-Johnson Tests of Achievement IV: Sentence Reading Fluency|Change in Letter Cancellation Task: speed|Change in Letter Cancellation Task: accuracy|Change in Forwards and Backwards Letter Span Task|The Reading Confidence and Emotions Questionnaire (RCEQ)|Discourse Comprehension Test|Wechsler Adult Intelligence Scale 4th Edition: Digit Span Subtest|BCI letter identification task metrics: AUC|BCI letter identification task metrics: ITR|EEG spectral content: within-session change in alpha band activity|EEG spectral content: between-session change in alpha band activity|EEG spectral content: within-session change in beta band activity|EEG spectral content: between-session change in beta band activity","Oregon Health and Science University|National Institutes of Health (NIH)|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","50 Years to 89 Years   (Adult, Older Adult)","Not Applicable","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00018984|R01DC009834-09S1","June 6, 2019","July 2020","July 2020","January 1, 2019",,"August 29, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03790774"
43,"NCT01354444","Trial of Carvedilol in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Carvedilol|Drug: Placebo","Hopkins Verbal Learning Test (HVLT) Scores at Baseline, 3, and 6 Months|Effect of Carvedilol Treatment in Cerebrospinal Fluid (CSF) Levels of Amyloid-beta Oligomers","Johns Hopkins University|Icahn School of Medicine at Mount Sinai","All","up to 100 Years   (Child, Adult, Older Adult)","Phase 4","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NA_00035546","June 2011","December 2016","January 2017","May 16, 2011","February 6, 2018","February 6, 2018","Johns Hopkins School of Medicine Bayview Campus, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01354444"
44,"NCT03625622","Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Mild to Moderate Alzheimer's Disease","Drug: AR1001|Drug: Placebo","ADAS-Cog 13|ADCS-CGIC|MMSE-2|NPI|GDS|C-SSRS|QOL-AD|Treatment related adverse events","AriBio Co., Ltd.","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR1001-ADP2-US01","January 15, 2019","June 1, 2020","August 1, 2020","August 10, 2018",,"April 1, 2019","Advanced Clinical Research, Inc., Banning, California, United States|Northern California Research, Sacramento, California, United States|Meridien Research, Lakeland, Florida, United States|Meridien - Maitland, Maitland, Florida, United States|IMIC, Inc, Palmetto Bay, Florida, United States|Meridien Research - St Petersburg, Saint Petersburg, Florida, United States|Meridien Research - Spring Hill, Spring Hill, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Advanced Clinical Research, Meridian, Idaho, United States|Rapid Medical Research, Beachwood, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Advanced Clinical Research - Cedar Park, Cedar Park, Texas, United States|FMC Science, Lampasas, Texas, United States|Advanced Clinical Research, Inc., West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03625622"
45,"NCT04042922","High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: GENUS device (Active Settings)|Device: GENUS device (Sham Settings)","Feasibility of gamma frequency stimulation|Tolerability of gamma frequency stimulation|Safety of gamma frequency stimulation","Massachusetts Institute of Technology","All","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","1902706647","April 19, 2019","April 30, 2021","April 30, 2021","August 2, 2019",,"August 2, 2019","Massachusetts Institute of Technology, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04042922"
46,"NCT03739905","ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: Blood Brain Barrier (BBB) Disruption","Device and procedure related adverse events|BBB Disruption and Closure|Change in Alzheimer's Disease Assessment Scale-Cognition|Change in Amyloid Tracer uptake","InSightec|Focused Ultrasound Foundation","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AL003","December 6, 2018","December 2019","December 2019","November 14, 2018",,"March 28, 2019","Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03739905"
47,"NCT01254448","Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: TC-5619|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetic profiles|Markers of inflammation in cerebrospinal fluid|Markers of inflammation in plasma","Targacept Inc.","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","TC-5619-238-CLP-003","September 2010","March 2011","May 2011","December 6, 2010",,"September 4, 2013","Collaborative Neuroscience Network, Long Beach, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Comprehensive Phase One, Miramar, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Center For Clinical Research, Atlanta, Georgia, United States|Princeton Medical Institutes, Princeton, New Jersey, United States|Community Clinical Research, Austin, Texas, United States|Aspen Clinical Research, Orem, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01254448"
48,"NCT03507790","A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",,"Recruiting","No Results Available","Mild to Moderate Alzheimer's Disease","Drug: CT1812|Drug: Placebo","Number of study participants with treatment related adverse events and serious adverse events","Cognition Therapeutics","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COG0201","October 2, 2018","June 30, 2020","July 31, 2020","April 25, 2018",,"August 15, 2019","Imaging Endpoints, Scottsdale, Arizona, United States|JEM Research Institute, Atlantis, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Compass Research LLC- Bioclinica Research, The Villages, Florida, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Austin Health, Ivanhoe, Victoria, Australia|St Vincent's Hospital Sydney, Ivanhoe, Victoria, Australia|Alfred Health, Melbourne, Victoria, Australia|Melbourne Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03507790"
49,"NCT03671889","ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: Blood Brain Barrier (BBB) Disruption","Device and procedure related adverse events","InSightec","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","AL002","September 28, 2018","December 2020","December 2024","September 14, 2018",,"March 28, 2019","Weill Cornell Medicine, New York, New York, United States|The Ohio State University -Wexner Medical Center, Columbus, Ohio, United States|West Virginia University Rockefeller Neuroscience Center, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03671889"
50,"NCT01966666","A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: TPI-287 2 mg/m2|Drug: TPI-287 6.3 mg/m2|Drug: TPI-287 20 mg/m2|Drug: Placebo","Maximum tolerated dose of TPI-287|TPI-287 levels in blood plasma and cerebrospinal fluid","University of California, San Francisco","All","50 Years to 82 Years   (Adult, Older Adult)","Phase 1","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TPI287-AD-001","November 2013","August 2019","November 2019","October 21, 2013",,"April 5, 2019","UCSF Memory and Aging Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01966666"
51,"NCT03867253","Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease","ETHERAL-US","Recruiting","No Results Available","Mild to Moderate Alzheimer's Disease","Drug: ORY-2001 Low dose|Drug: ORY-2001 High dose|Drug: Placebo","Treatment Emergent Adverse Events|Withdrawn patients due to TEAEs|Cohen-Mansfield Agitation Inventory (CMAI)|Clinician version of the Apathy Evaluation Scale (AES-C)|14-item Alzheimer's Disease Assessment Scale-Cognitive|Computerized Cognitive Test battery|Mini-Mental State Examination (MMSE)|Clinical Dementia Rating Scale Sum of Boxes|Cornell Scale for Depression in Dementia (CSDD)","Oryzon Genomics S.A.|Alzheimer’s Drug Discovery Foundation","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","33","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL05-ORY-2001US","May 16, 2019","November 15, 2020","November 15, 2020","March 7, 2019",,"June 14, 2019","Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Central Miami Medical Institute, LLC, Miami, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03867253"
52,"NCT02586909","12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension",,"Terminated","No Results Available","Alzheimer's Disease","Drug: RVT-101 35 mg tablets","Occurrence of adverse events (AEs) and or reported changes in physical examinations, vital signs measurements, electrocardiograms (ECGs), routine laboratory assessments","Axovant Sciences Ltd.","All","50 Years to 86 Years   (Adult, Older Adult)","Phase 3","1100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RVT-101-3002","April 2016","March 2018","March 2018","October 27, 2015",,"March 20, 2018","US112, Phoenix, Arizona, United States|US220, Tucson, Arizona, United States|US096, Rancho Mirage, California, United States|US195, Santa Ana, California, United States|US016, Simi Valley, California, United States|US106, Temecula, California, United States|US179, Hamden, Connecticut, United States|US171, Norwich, Connecticut, United States|US088, Atlantis, Florida, United States|US007, Brooksville, Florida, United States|US002, Hallandale Beach, Florida, United States|US140, Hialeah, Florida, United States|US216, Miami, Florida, United States|US110, Miami, Florida, United States|US172, North Palm Beach, Florida, United States|US003, Orlando, Florida, United States|US256, Pensacola, Florida, United States|US037, Tampa, Florida, United States|US042, Tampa, Florida, United States|US004, The Villages, Florida, United States|US048, Atlanta, Georgia, United States|US046, Atlanta, Georgia, United States|US217, Columbus, Georgia, United States|US111, Baton Rouge, Louisiana, United States|US095, Shreveport, Louisiana, United States|US116, Newton, Massachusetts, United States|US174, Quincy, Massachusetts, United States|US144, Hattiesburg, Mississippi, United States|US094, Las Vegas, Nevada, United States|US135, Berlin, New Jersey, United States|US197, Lawrenceville, New Jersey, United States|US057, Manchester, New Jersey, United States|US215, Mount Arlington, New Jersey, United States|US209, Toms River, New Jersey, United States|US036, West Long Branch, New Jersey, United States|US001, Albany, New York, United States|US049, Brooklyn, New York, United States|US097, New Hyde Park, New York, United States|US044, New York, New York, United States|US150, Chapel Hill, North Carolina, United States|US185, Charlotte, North Carolina, United States|US008, Cincinnati, Ohio, United States|US113, Cleveland, Ohio, United States|US119, Shaker Heights, Ohio, United States|US134, Portland, Oregon, United States|US169, Media, Pennsylvania, United States|US162, Plains, Pennsylvania, United States|US148, Willow Grove, Pennsylvania, United States|US043, San Antonio, Texas, United States|US143, Orem, Utah, United States|US149, Charlottesville, Virginia, United States|US170, Spokane, Washington, United States|AR130, La Plata, Buenos Aires, Argentina|AR101, Buenos Aires, Argentina|AR060, Buenos Aires, Argentina|AR084, Ciudad Autonoma de Buenos Aire, Argentina|AR027, Ciudad Autonoma de Buenos Aire, Argentina|AR012, Ciudad Autonoma de Buenos Aire, Argentina|AR160, Ciudad Autonoma de Buenos Aire, Argentina|AR028, Ciudad Autonoma de Buenos Aire, Argentina|AR035, Ciudad Autonoma de Buenos Aire, Argentina|AR040, Ciudad Autónoma de Buenos Aire, Argentina|AR081, Ciudad Autónoma de Buenos Aire, Argentina|AR051, Córdoba, Argentina|AR137, Córdoba, Argentina|AR126, Córdoba, Argentina|AR210, Mendoza, Argentina|AR219, Mendoza, Argentina|AR059, Santiago del Estero, Argentina|AU227, Caulfield, Australia|AU032, Heidelberg West, Australia|AU011, Hornsby, Australia|AU138, West Perth, Australia|BU125, Ruse, Bulgaria|BU131, Sofia, Bulgaria|BU073, Varna, Bulgaria|CA054, Kelowna, British Columbia, Canada|CA188, Kelowna, British Columbia, Canada|CA186, Penticton, British Columbia, Canada|CA141, West Vancouver, British Columbia, Canada|CA147, Newmarket, Ontario, Canada|CA196, North York, Ontario, Canada|CA236, Gatineau, Quebec, Canada|CH212, Antofagasta, II Región, Chile|CH076, Santiago, Region Metropolitana, Chile|CH061, Santiago, Región Metropolitana, Chile|CH075, Santiago, Región Metropolitana, Chile|CR069, Zagreb, Croatia|CR122, Zagreb, Croatia|CR070, Zagreb, Croatia|CZE128, Praha 10, Czechia|CZE132, Praha 2, Czechia|CZE129, Praha 6, Czechia|CZE207, Praha, Czechia|CZE161, Rychnov nad Kneznou, Czechia|FR231, Lille Cedex, France|FR182, Marseille Cedex 5, France|FR221, Paris Cedex, France|FR202, Villeurbanne, France|GE206, Bad Homburg, Germany|GE091, Berlin, Germany|GE071, Berlin, Germany|GE139, Berlin, Germany|GE230, Cologne, Germany|GE252, Ellwangen, Germany|GE180, Leipzig, Germany|GE228, Mannheim, Germany|GE017, Munchen, Germany|GE157, Nürnberg, Germany|GE098, Ulm, Germany|GE251, Westerstede, Germany|IT053, Brescia, Italy|IT124, Cefalu, Italy|IT030, Pavia, Italy|IT103, Perugia, Italy|IT072, Roma, Italy|IT029, Roma, Italy|IT183, Rome, Italy|IT175, Rome, Italy|IT085, Torino, Italy|SK066, Busan, Korea, Republic of|SK067, Seoul, Korea, Republic of|SK190, Seoul, Korea, Republic of|PO013, Bialystok, Poland|PO024, Bydgoszcz, Poland|PO010, Bydgoszcz, Poland|PO107, Katowice, Poland|PO092, Katowice, Poland|PO009, Poznan, Poland|PO014, Szczecin, Poland|PO074, Warszawa, Poland|SE164, Belgrade, Serbia|SE193, Belgrade, Serbia|SE090, Belgrade, Serbia|SE155, Kragujevac, Serbia|SE031, Novi Kneževac, Serbia|SE165, Vršac, Serbia|SI052, Singapore, Singapore|SI026, Singapore, Singapore|SL056, Banska Bystrica, Slovakia|SL200, Dubnica nad Vahom, Slovakia|SL078, Krompachy, Slovakia|SL078, Krompachy, Slovakia|SL077, Svidník, Slovakia|SP249, Alicante, Spain|SP176, Barcelona, Spain|SP022, Barcelona, Spain|SP021, Barcelona, Spain|SP250, Barcelona, Spain|SP194, Donostia, Gipuzkoa, Spain|SP222, Getxo-Vizcaya, Spain|SP184, Sant Cugat Del Valles, Barcelona, Spain|TA121, Taoyuan, Taiwan|UK063, Bath, United Kingdom|UK038, Blackpool, United Kingdom|UK233, Cambridge, United Kingdom|UK033, Carnoch, United Kingdom|UK211, Epping, United Kingdom|UK234, Guildford, United Kingdom|UK055, Leeds, United Kingdom|UK039, London, United Kingdom|UK034, Manchester, United Kingdom|UK087, Oxford, United Kingdom|UK235, Plymouth, United Kingdom|UK100, Sheffield, United Kingdom|UK064, Southampton, United Kingdom|UK152, Southampton, United Kingdom|UK153, Swindon, United Kingdom|UK154, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02586909"
53,"NCT03269149","Tango for Alzheimer's Disease Patients' Caregivers",,"Recruiting","No Results Available","Alzheimer's Disease","Other: Adapted Tango Dance|Behavioral: Educational lectures","Change in interleukin-7|Change in interleukin-8|Change in interleukin-9|Change in Interleukin-10|Change in interferon induced protein 10|Change in macrophage derived chemokine|Change in monocyte chemoattractant protein 1|Change in transforming growth factor alpha|Change in tumor necrosis factor alpha|Change in C-reactive protein|Change in serum amyloid protein|Change in Montreal Cognitive Assessment (MoCA)|Change in the Tower of London test|Change in the Stroop interference test|Change in Trails B test|Change in Digit Span test|Change in Buschke Selective Reminding Test|Change in Reverse Corsi Blocks test|Change in Brooks spatial memory test|Change in the Body position spatial task (BPST)|Change in Fullerton Advanced Balance Scale|Change in 30-second chair stand|Change in gait speed|Change in Positive Aspects of Caregiving (PAC) Scale|Change in Pearlin Caregiver Stress Scale|Change in the Zarit Burden Interview|Change in the Center for Epidemiologic Studies Depression Scale (CES-D)|Change in DEMQOL: Dementia Quality of Life measure (Carer v4)","Emory University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00097348","September 19, 2017","July 2021","July 2021","August 31, 2017",,"September 4, 2019","Atlanta VA Medical Center, Emory University, Executive Park, Wesley Woods, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03269149"
54,"NCT03290274","Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease","ECP-EA","Recruiting","No Results Available","Alzheimer Disease","Device: Deep brain stimulation (fornix)|Device: Deep brain stimulation (Basal nucleus of Meynert)","Security","Hospital San Carlos, Madrid","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ECP-EA","March 1, 2017","December 1, 2019","December 1, 2019","September 21, 2017",,"September 21, 2017","Hospital Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03290274"
55,"NCT01935024","Benefits of Exercise in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Other: Personalized Exercise Regimen","Neuropsychological Test Battery","University Health Network, Toronto","All","60 Years to 95 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-5749-AE","August 1, 2013","April 2020","April 2020","September 4, 2013",,"September 25, 2019","Toronto Western Hospital, WW5-449, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01935024"
56,"NCT02292238","Benfotiamine in Alzheimer's Disease: A Pilot Study","Benfotiamine","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Benfotiamine","ADAS-cog as the primary clinical outcome|Brain glucose utilization|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI).|Clinical Dementia Rating Scale (CDR).|Buschke Selective Reminding Test (SRT).","Burke Medical Research Institute|Burke Rehabilitation Hospital|Columbia University|National Institute on Aging (NIA)|Alzheimer’s Drug Discovery Foundation|Montefiore-Albert Einstein College of Medicine","All","60 Years and older   (Adult, Older Adult)","Phase 2","76","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRC-451|1R01AG043679-01A1","November 2014","November 2019","November 2019","November 17, 2014",,"February 28, 2019","Burke, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT02292238"
57,"NCT02615002","Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Piromelatine|Drug: Placebo","Change from baseline in Computerized neuropsychological test battery (cNTB)|Change from baseline in Global Impression of Change (CGIC)|Change from baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS-MCI-ADL)|Change from baseline in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog14)|Safety and tolerability of piromelatine","Neurim Pharmaceuticals Ltd.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NeuP11-AD2","November 2015","November 2019","November 30, 2019","November 25, 2015",,"August 21, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Citrials Inc, Bellflower, California, United States|Alliance for Research, Long Beach, California, United States|Renew Behavioral Health, Inc, Long Beach, California, United States|ABS Health LLC, Pomona, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Sharp Mesa Vista Clinical research, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Research Center For Clinical Studies, Inc, Norwalk, Connecticut, United States|Pioneer Clinical research, Coconut Creek, Florida, United States|University of Miami, Coral Gables, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|New Life Medical Research Center, Hialeah, Florida, United States|Galiz reserach, Hialeah, Florida, United States|Biomed Research Institute, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Advanced Clinical research Network, Miami, Florida, United States|Medical Research Group of central Florida Inc., Orange City, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Infinity Clinical Research, LLC., Sunrise, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Rowe Neurology, Lenexa, Kansas, United States|KU School of Medicine-Wichita, Wichita, Kansas, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Pharmasite Research INC, Baltimore, Maryland, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, P.A., Hattiesburg, Mississippi, United States|Galen Research, Chesterfield, Missouri, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|The Neurocognitive Institute, LLC, Mount Arlington, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Dent Neurosciences Research Center, Inc, Amherst, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|New Hope Clinical research, Charlotte, North Carolina, United States|Richard H. Weisler, M.D., P.A. & Associates, Raleigh, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Red river medical research Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC., Tulsa, Oklahoma, United States|The Clinical research Center LLC, Jenkintown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Shepherd Clinical Research LLC, Lewisville, Texas, United States|Radiant Research, San Antonio, Texas, United States|Grayline Research Center, Wichita Falls, Texas, United States|Aspen Clinical research, Orem, Utah, United States|Wasatch Clinical Research LLC, Salt Lake City, Utah, United States|Zain Research, Llc, Richland, Washington, United States|SSM Health/Dean Medical Group, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02615002"
58,"NCT01767311","A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5.0 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo","Core Study: Change from Baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months|Core Study and Extension Phase: Safety will be assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs)|Core Study: Change from Baseline at 18 Months in Brain Amyloid Pathophysiology as Measured by Amyloid Positron Emission Tomography (PET)|Core Study: Change from Baseline in the ADCOMS at 18 Months|Core Study: Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) at 18 Months|Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months|Core Study: Change from Baseline in Cerebrospinal fluid (CSF) Biomarkers (Aβ[1-42], t-tau, and p-tau) at 18 Months|Core Study: Change from Baseline in Total Hippocampal Volume at 18 Months as Measured by Volumetric Magnetic Resonance Imaging (vMRI)|Core Study: Change from Baseline at 12 Months in Brain Amyloid Pathophysiology as Measured by Amyloid PET|Core Study: Change from baseline at 12 months on clinical status for the following assessments: ADCOMS, CDR-SB, and ADAS-cog|Core Study: Change from Baseline in CSF Biomarkers (Aβ[1-42], t-tau, and p-tau) at 12 Months|Core Study: Change from Baseline in Total Hippocampal Volume at 6 and 12 Months as Measured by vMRI|Core Study: Change from Baseline in Left and Right Hippocampal Volume at 6, 12, and 18 Months as Measured by vMRI|Core Study: Change from Baseline in Whole Brain Volume at 6, 12, and 18 Months as Measured by vMRI|Core Study: Change from Baseline in Total Ventricular Volume at 6, 12, and 18 Months as Measured by vMRI|Extension Phase: Change from Baseline in Brain Amyloid Levels as Measured by Amyloid PET at at 3 months (Cohort 1) or 6 months (Cohort 2), and 12 and 24 months|Extension Phase: Change from end of Core Study in Brain Amyloid Levels as Measured by Amyloid PET at the Baseline of Extension Phase|Extension Phase: Percentage of Amyloid Positive Participants Over Time","Eisai Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BAN2401-G000-201|2012-002843-11","December 20, 2012","August 2021","November 24, 2021","January 14, 2013",,"July 17, 2019","Facility #1, Birmingham, Alabama, United States|Facility #1, Phoenix, Arizona, United States|Facility #1, Tucson, Arizona, United States|Facility #1, Carson, California, United States|Facility #1, Lomita, California, United States|Facility #1, Long Beach, California, United States|Facility #1, Los Alamitos, California, United States|Facility #1, Los Angeles, California, United States|Facility #2, Los Angeles, California, United States|Facility #3, Los Angeles, California, United States|Facility #1, Orange, California, United States|Facility #1, Oxnard, California, United States|Facility #1, San Diego, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, New Haven, Connecticut, United States|Facility #2, New Haven, Connecticut, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Boca Raton, Florida, United States|Facility #2, Boca Raton, Florida, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Deerfield Beach, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Fort Myers, Florida, United States|Facility #1, Hallandale Beach, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #1, Lake Worth, Florida, United States|Facility #1, Leesburg, Florida, United States|Facility #2, Leesburg, Florida, United States|Facility #1, Miami Springs, Florida, United States|Facility #1, Miami, Florida, United States|Facility #2, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #1, Naples, Florida, United States|Facility #1, Ocala, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Saint Petersburg, Florida, United States|Facility #1, Sunrise, Florida, United States|Facility #3, Tampa, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #2, Atlanta, Georgia, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Chicago, Illinois, United States|Facility #1, Elk Grove Village, Illinois, United States|Facility #1, Elkhart, Indiana, United States|Facility #1, Indianapolis, Indiana, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Lexington, Kentucky, United States|Facility #1, Boston, Massachusetts, United States|Facility #2, Boston, Massachusetts, United States|Facility #1, Burlington, Massachusetts, United States|Facility #1, Newton, Massachusetts, United States|Facility #1, Ann Arbor, Michigan, United States|Facility #1, East Lansing, Michigan, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Lansing, Michigan, United States|Facility #1, West Bloomfield, Michigan, United States|Facility #1, Saint Louis, Missouri, United States|Facility #1, Eatontown, New Jersey, United States|Facility #1, Toms River, New Jersey, United States|Facility #1, Albany, New York, United States|Facility #1, Amherst, New York, United States|Facility #1, Latham, New York, United States|Facility #1, New York, New York, United States|Facility #2, New York, New York, United States|Facility #1, Rochester, New York, United States|Facility #2, Rochester, New York, United States|Facility #1, Charlotte, North Carolina, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #2, Oklahoma City, Oklahoma, United States|Facility #2, Portland, Oregon, United States|Facility #1, Portland, Oregon, United States|Facility #1, Abington, Pennsylvania, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Knoxville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #2, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #2, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Richmond, Virginia, United States|Facility #1, Milwaukee, Wisconsin, United States|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Kingston, Ontario, Canada|Facility #2, London, Ontario, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Toronto, Ontario, Canada|Facility #1, Greenfield Park, Quebec, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Verdun, Quebec, Canada|Facility #1, Québec city, Canada|Facility #1, Strasbourg Cedex, Bas Rhin, France|Facility #1, Toulouse, Haute Garonne, France|Facility #1, Paris Cedex 10, Paris, France|Facility #1, Bron Cedex, France|Facility #1, Paris, France|Facility #1, Rennes Cedex 9, France|Facility #1, Villeurbanne, France|Facility #1, Gunzburg, Baden Wuerttemberg, Germany|Facility #1, Karlstadt Am Main, Bayern, Germany|Facility #1, Hoppegarten, Berlin, Germany|Facility #1, Hannover, Niedersachsen, Germany|Facility #1, Mittweida, Sachsen, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #3, Berlin, Germany|Facility #1, Guenzburg, Germany|Facility #1, Hamburg, Germany|Facility #1, Heidelberg, Germany|Facility #1, Leipzig, Germany|Facility #1, Mannheim, Germany|Facility #1, Muenchen, Germany|Facility #1, Tuebingen, Germany|Facility #1, Brescia, Italy|Facility #1, Genova, Italy|Facility #1, Milano, Italy|Facility #1, Parma, Italy|Facility #1, Perugia, Italy|Facility #1, Pisa, Italy|Facility #1, Roma, Italy|Facility #2, Roma, Italy|Facility #3, Roma, Italy|Eisai Trial Site #1, Otake-shi, Hiroshima-Ken, Japan|Eisai Trial Site #1, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #2, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #3, Himeji-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Kobe-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Nishinomiya-shi, Hyogo-Ken, Japan|Eisai Trial Site #1, Kyoto-shi, Kyoto-Fu, Japan|Eisai Trial Site #1, Kurashiki-shi, Okayama-Ken, Japan|Eisai Trial Site #1, Osaka-shi, Osaka-Fu, Japan|Eisai Trial Site #1, Saitama-shi, Saitama-Ken, Japan|Eisai Trial Site #1, Itabashi-ku, Tokyo-To, Japan|Eisai Trial Site #1, Shinjuku-ku, Tokyo-To, Japan|Eisai Trial Site #2, Shinjuku-ku, Tokyo-To, Japan|Facility #1, Seongnam-si, Gyeonggi-do, Korea, Republic of|Facility #1, Busan, Gyeongsangnam-do, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #1, Amsterdam, Netherlands|Facility #1, Sant Cugat Del Vallés, Barcelona, Spain|Facility #1, San Sebastian, Guipuzcoa, Spain|Facility #1, Barakaldo, Vizcaya, Spain|Facility #1, Alicante, Spain|Facility #1, Barcelona, Spain|Facility #1, Madrid, Spain|Facility #2, Madrid, Spain|Facility #1, Sevilla, Spain|Facility #1, Malmö, Sweden|Facility #1, Mölndal, Sweden|Facility #1, Stockholm, Sweden|Facility #1, Uppsala, Sweden|Facility #1, London, Greater London, United Kingdom|Facility #1, Isleworth, Middlesex, United Kingdom|Facility #1, Glasgow, Renfrewshire, United Kingdom|Facility #1, Bath, United Kingdom|Facility #2, London, United Kingdom|Facility #1, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01767311"
59,"NCT03860792","Therapeutic Diets in Alzheimer's Disease","TDAD","Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Ketogenic Diet|Behavioral: Therapeutic Lifestyles Changes Diet","Change in cognitive performance on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCog11)|Change in cognitive performance on the Mini-Mental State Exam (MMSE)|Change in cognitive performance on the Logical Memory Test (LMT)|Change in cognitive performance by Stroop test|Change in Clinical Dementia Rating (CDR)|Change in cerebral concentration of N-Acetylaspartate (NAA)|Change in blood platelet mitochondrial function|Change in self-reported symptoms by study partner","University of Kansas Medical Center|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00143457","October 2019","July 2023","November 2023","March 4, 2019",,"October 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03860792"
60,"NCT03472183","Exploration of the Enteric Nervous System in Alzheimer Disease","SYNEMA","Recruiting","No Results Available","Alzheimer Disease","Other: biopsies of colon","Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.|Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.|Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease|Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.","Nantes University Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC17_0252","April 26, 2018","April 26, 2020","August 25, 2020","March 21, 2018",,"April 26, 2018","Nantes university Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT03472183"
61,"NCT00870519","Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects",,"Terminated","No Results Available","Alzheimer's Disease","Drug: I-123-MNI-168|Drug: 123-I MNI-168","To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain,|To acquire initial safety data following injection of (123I) MNI-168.","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-168-01","January 2009","December 2010","December 2010","March 27, 2009",,"April 3, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00870519"
62,"NCT00762411","Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","IDENTITY-2","Completed","Has Results","Alzheimer's Disease","Drug: LY450139|Drug: Placebo","Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) at 76 Weeks|Change From Baseline in the Resource Utilization in Dementia-Lite (RUD-Lite) up to 76 Weeks|Change From Baseline in the EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 76 Weeks|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) at 76 Weeks|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) 4 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-tau) Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 16 Weeks After Cessation of Study Drug","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","1111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11271|H6L-MC-LFBC","September 2008","April 2011","April 2011","September 30, 2008","September 25, 2014","February 16, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hallandale Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manhasset, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint John, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Esztergom, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iwate, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saltillo, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belgrade, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kragujevac, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskisehir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samsun, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kherson, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00762411"
63,"NCT01569516","Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Octohydroaminoacridine Succinate Tablets|Drug: Octohydroaminoacridine succinate Tablets|Drug: Placebo","Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input|Activities of Daily Living:Activities of Daily Living Scale（ADL)|Mental behavior: neuropsychiatric questionnaire (NPI)","Changchun Huayang High-tech Co., Ltd|Beijing Bionovo Medicine Development Co., Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","288","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCHY2010L00161-HPAD2","June 2011","July 2012","October 2012","April 3, 2012",,"April 9, 2012","Guangzhou Brain Hospital, Guangzhou, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|Hebei mental health center, Baoding, Hebei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The first Affiliated Hospital of Jilin University, Changchun, Jilin, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China|Beijing HuiLongGuan Hospital, Beijing, China|Beijing Shijitan Hospital, EMU, Beijing, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Shanghai Tenth People's hospital, Shanghai, China|Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01569516"
64,"NCT01555827","Retinal Neurodegenerative Signs in Alzheimer's Diseases","SIGNAL","Completed","No Results Available","Alzheimer's Disease","Other: Ophthalmological examination & Questionnaire","RNFL thickness measured on a peri-papillary scan of SD-OCT examination.|Glaucomatous optic nerve damage observed on colour photographs (cup/disc ratio)|Retinal microvascular abnormalities (microaneurysms, micro-hemorrhage, cotton wool spots, arteriovenous nicking), observed on retinal colour photography|Macular abnormalities observed on retinal colour photographs (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, other retinal diseases)|Macular abnormalities observed on macular scans in SD-OCT (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, epiretinal membranes, other retinal diseases).|Macular abnormalities observed in autofluorescence imaging (increased autofluorescence, decreased autofluorescence, reticular drusen, atrophic AMD, other abnormalities)|Macular and peripheral abnormalities diagnosed in wide-field retinal imaging|Retinal blood flow velocity (RFI)|Intraocular pressure|axial length","University Hospital, Bordeaux","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHUBX2011/19","March 12, 2012","June 7, 2014","June 7, 2014","March 15, 2012",,"November 13, 2017","CHU Bordeaux - hôpital Pellegrin, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT01555827"
65,"NCT02406027","An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum",,"Terminated","Has Results","Alzheimer Disease","Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 25 mg|Drug: Placebo|Drug: JNJ-54861911, 5 mg","Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels|Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha and sAPP-beta) Levels|Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Plasma Amyloid Beta (ABeta) (1-38, 1-40, 1-42) Levels|Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Tau Protein and Phosphorylated Tau (p-Tau) Protein Level","Janssen Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR106978|54861911ALZ2004|2014-004274-41","July 2, 2015","June 28, 2018","June 28, 2018","April 1, 2015","September 9, 2019","September 9, 2019","Gent, Belgium|Hoboken, Belgium|Montpellier Cedex 5, France|Paris, France|Toulouse, France|Essen, Germany|Homburg, Germany|Luebeck, Germany|Tübingen, Germany|Ulm, Germany|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Terrasa Barcelona, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02406027/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02406027/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02406027"
66,"NCT02260674","A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: JNJ-54861911, 10 milligram (mg)|Drug: JNJ-54861911, 50 mg|Drug: Placebo","Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Relationship Between Dose and Exposure of JNJ-54861911 With Safety|Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels|Percent Change From Baseline in Plasma ABeta 1-40 Levels and sAPP Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels|Relationship Between Changes in CSF and Plasma ABeta Species and sAPP Fragments With Safety|Maximum Plasma Concentration (Cmax) of JNJ-54861911|Time to Reach the Maximum Plasma or CSF concentration (Tmax)|Area Under the Plasma/CSF Concentration-time Curve From Time 0 to tau Hours Post Dosing (AUCtau)","Janssen Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CR105240|54861911ALZ2002|2014-002159-24","November 2014","June 2016","June 2016","October 9, 2014",,"March 3, 2017","Gent, Belgium|Hoboken, Belgium|Montpellier Cedex 5, France|Paris, France|Toulouse, France|Essen, Germany|Halle, Germany|Hamburg N/A, Germany|Homburg, Germany|Luebeck, Germany|Tübingen, Germany|Ulm, Germany|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Terrasa Barcelona N/A, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02260674"
67,"NCT02916056","2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Azeliragon 5mg","Adverse Events|Clinical Safety Laboratory Tests|Electrocardiogram|Vital Signs|The slope of change over time in Alzheimer's Disease Assessment Scale - cognitive measure (ADAS-cog)|The slope of change over time in Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb)|The slope of change over time in Mini-Mental State Exam (MMSE)|The slope of change over time in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale|The slope of change over time in Neuropsychiatric Inventory Questionnaire (NPI)|Change from baseline in measures of Alzheimer's Disease Assessment Scale - cognitive measure (ADAS-cog)|Change from baseline in measures of Mini-Mental State Exam (MMSE)|Change from baseline in measures of Clinical Dementia Rating (CDR) scale|Change from baseline in measures of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale|Change from baseline in measures of Continuous Oral Word Association Task (COWAT)|Change from baseline in measures of Category Fluency Test (CFT)|Change from baseline in measures of Trail Making Test|Change from baseline in measures of Neuropsychiatric Inventory Questionnaire (NPI)","vTv Therapeutics","All","50 Years and older   (Adult, Older Adult)","Phase 3","298","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTP488-303","December 2016","June 1, 2018","June 1, 2018","September 27, 2016",,"May 17, 2019","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Fullerton, California, United States|Glendale, California, United States|Imperial, California, United States|Irvine, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Riverside, California, United States|San Bernardino, California, United States|Santa Ana, California, United States|Atlantis, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|The Villages, Florida, United States|Columbus, Georgia, United States|Chicago, Illinois, United States|Fairway, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Quincy, Massachusetts, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Saint Louis, Missouri, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Lake Success, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Cordova, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Kirkland, Washington, United States|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02916056"
68,"NCT03801642","Dapagliflozin In Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Dapagliflozin|Other: Placebo","Cerebral N Acetyl-Aspartate (NAA)","Jeff Burns, MD|University of Kansas Medical Center","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dapa in AD","January 29, 2019","October 2020","October 2020","January 11, 2019",,"June 5, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03801642"
69,"NCT01005862","Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365|Drug: Placebo","Fractional Clearance rate of ABeta peptide in CSF|Area under the ratio of CSF labeled/unlabeled ABETA time curve from onset of clearance to 36h following start of infusion|PF-04360365 concentrations and ABETA concentrations in plasma and CSF|Ratio of labeled/unlabeled leucine in plasma and CSF post labeled leucine administration|Adverse events, vital signs, clinical labs, electrocardiograms, physical / neurologic examinations, Columbia Suicide Severity Rating Scale, MRI","Pfizer","All","21 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A9951011","March 2010","September 2012","September 2012","November 2, 2009",,"September 26, 2012","Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01005862"
70,"NCT01841905","Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease","Scope","Unknown status","No Results Available","Alzheimer's Disease","Other: Observational Study","Groton Maze Learning Test|CogState One-Back Learning (OBK) Task|12-Item International Shopping List Test - Immediate and Delayed Recall (CogState)|Rentz Face-Name Association Test|Stark Pattern Separation Test|Minnesota Cognitive Acuity Scale (MCAS)|Saliva Sample for DNA Analyses (ApoE and BDNF genotyping)|Non-invasive imaging of macula, retinal function and visual fields|CogState Once-Card learning (OCL) Task|Amyloid and Alzheimer's Psycho-educational Session|Tokyo Subway Navigation|MAC-Q","Rhode Island Hospital|Pfizer|Heidelberg Engineering, Inc.|Neurotrack|Optovue|Avid Pharmaceuticals","All","55 Years to 80 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","900,421-477","July 2013","December 2016","December 2016","April 29, 2013",,"January 20, 2016","Lifespan, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01841905"
71,"NCT03991988","Montelukast Therapy on Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Montelukast|Drug: Placebo oral tablet","Number of participants with any gastrointestinal (GI) symptoms|Number of participants with reported anaphylaxis|Number of participants with elevated liver enzymes|Change in prothrombin time (PT)/ international normalized ratio (INR)|Change in Neuropsychiatric Inventory Questionnaire (NPI-Q)|Number of patients with seizures|Number of discontinuations from Montelukast|Change in CSF amyloid|Change in CSF tau|Change in Clinical Dementia Rating (CDR)|Change in NIH Toolbox Cognition battery (NIHTB-CB)","Emory University","All","50 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00111553","September 25, 2019","August 2021","August 2021","June 19, 2019",,"September 30, 2019","Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States|Executive Park, Atlanta, Georgia, United States|Wesley Woods, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03991988"
72,"NCT00987090","Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer's Disease","Biological: Clinic and neuropsychologic evaluation|Radiation: MRI|Procedure: PET|Biological: Apolipoprotein E genotyping|Biological: Study of cerebrospinal fluid","to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.|to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.","Assistance Publique Hopitaux De Marseille","All","45 Years to 90 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008/24|2008-A01213-52","October 2009","September 2016",,"September 30, 2009",,"October 23, 2015","Assistance Publique - Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT00987090"
73,"NCT03417986","Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers","drainAD","Active, not recruiting","No Results Available","Alzheimer Disease","Drug: TEP","Efflux of Amyloid beta peptides (Group mean changes from baseline)|Scores obtained in psychometric tests [Cognition]|Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]|Cerebrospinal fluid (CSF) levels of Tau","Immungenetics AG","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMU-AD-001","November 24, 2017","July 2021","July 2021","January 31, 2018",,"February 27, 2019","Klinik für Psychiatrie und Psychotherapie Universitätsmedizin Göttingen, Göttingen, Germany|Zentralinstitut für seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg,, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT03417986"
74,"NCT00675090","Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK239512|Drug: Placebo","Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.|Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.","GlaxoSmithKline","All","50 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H3B109689","February 21, 2008","June 16, 2009","June 16, 2009","May 8, 2008",,"July 7, 2017","GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Prague 10, Czechia|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Cambridgeshire, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Southall, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00675090"
75,"NCT00945672","A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365 10 mg/kg|Biological: PF-04360365 7.5 mg/kg|Drug: placebo","Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)|Brain amyloid burden|CSF abeta|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A9951007","August 2009","June 2011","June 2011","July 24, 2009",,"May 5, 2016","Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Molndal, Sweden|Pfizer Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00945672"
76,"NCT01406145","A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil",,"Completed","No Results Available","Alzheimer's Disease","Drug: ASP0777|Drug: Placebo","Number and percentage of subjects with adverse events|Pharmacokinetic assessment of AUC, maximum concentration (Cmax), minimum concentration (Cmin) and time to maximum concentration (tmax) through analysis of blood samples","Astellas Pharma Inc","All","50 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0777-CL-0030","June 16, 2011","November 4, 2011","November 4, 2011","August 1, 2011",,"January 30, 2019","Pacific Research Network, Inc., San Diego, California, United States|MD Clinical, Hallandale Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01406145"
77,"NCT01847586","Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease","TMS-AD","Completed","No Results Available","Alzheimer's Disease","Procedure: Paired Associative Stimulation|Procedure: Paired Associative Stimulation-Control","Paired Associated Stimulation induced Long-term potentiation as a measure of neuroplasticity in the dorsolateral prefrontal cortex|N-back Task","Centre for Addiction and Mental Health","All","65 Years and older   (Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","215/2012","April 2013","October 2016","October 2017","May 7, 2013",,"January 24, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01847586"
78,"NCT02518412","Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease","tDCS","Unknown status","No Results Available","Alzheimer Disease","Other: tDCS|Other: Placebo tDCS","Neuropsychological testing","University of Tromso","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012/1890(REK)","May 2013","February 2016","February 2016","August 7, 2015",,"August 11, 2015","Department of Psychology, University of Tromsø, Tromsø, Norway",,"https://ClinicalTrials.gov/show/NCT02518412"
79,"NCT00912288","A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease",,"Terminated","Has Results","Alzheimer Disease","Drug: Dimebon 20 mg po TID|Drug: Placebo po TID","Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26|Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) (ADCS-ADLsev) Score at Week 26|Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 26|Sum of the Delusions and Hallucinations Sub-domain Scores of the NPI|Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 26|Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Scores|Resource Utilization in Dementia-Lite Version (RUD-Lite)|Euro Quality of Life - 5 Domain (EQ-5D) Assessment|Population Pharmacokinetic (PK) Analysis|Number of Participants With Adverse Events (AEs)","Pfizer|Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B1451006","September 2009","August 2010","August 2010","June 3, 2009","October 2, 2012","October 2, 2012","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Delray Beach, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Cordova, Tennessee, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Guenzburg, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Mittweida, Germany|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Gyula, Hungary|Pfizer Investigational Site, Szekesfehervar, Hungary|Pfizer Investigational Site, Amadora, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Michalovce, Slovakia|Pfizer Investigational Site, Roznava, Slovakia|Pfizer Investigational Site, Zilina, Slovakia|Pfizer Investigational Site, Algorta, Getxo, Bilbao, Spain|Pfizer Investigational Site, Salt, Girona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Kocaeli, Turkey|Pfizer Investigational Site, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT00912288"
80,"NCT04081285","Epigenetic Biomarkers for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease",,"DNA methylation|RNA-seq microbiome|Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog)","Chinese University of Hong Kong","All","50 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2018.441","September 1, 2019","December 31, 2023","December 31, 2023","September 9, 2019",,"September 18, 2019","The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04081285"
81,"NCT03809351","UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy","AV1451 ADC","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: [F-18]AV-1451-PET","Measurement of pathological tau deposition in the brain.","University of Alabama at Birmingham","All","50 Years and older   (Adult, Older Adult)","Phase 1","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R19-006","June 1, 2020","June 1, 2022","June 1, 2024","January 18, 2019",,"September 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03809351"
82,"NCT00937352","A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Bapineuzumab","Clinically important changes in safety assessment results including vital signs, weight, clinical laboratory tests, electrocardiograms (ECGs), brain magnetic resonance imaging (MRI), physical and neurological examinations, and infusion site assessments.|To evaluate the efficacy of long term treatment of IV administered bapineuzumab in subjects with AD.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","51 Years and older   (Adult, Older Adult)","Phase 3","896","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELN115727-351","July 2009","September 2012","September 2012","July 13, 2009",,"December 20, 2013","University of Alabama Hospital, Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Sciences Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neurology Center, Oceanside, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California at Davis, Alzheimer's Disease Research Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Neurology Specialists, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, PA, Fort Lauderdale, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Clinical Physiology Associates, Inc, Fort Myers, Florida, United States|Emerald Coast Mood and Memory, PA., Fort Walton Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials Inc., Miami, Florida, United States|Miami Research Associates, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, School of Medicine, Atlanta, Georgia, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Medical Research and Health Education Foundation, Inc, Columbus, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc., Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|CBH Health, LLC, Rockville, Maryland, United States|Brigham and Women's Hospital, Dept. of Neurology, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc., Haverhill, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, PC, Plymouth, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University School of Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Lous, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, LLC, Princeton, New Jersey, United States|Shore Neurology, PA, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Advanced BioBehavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|Parker Jewish Institute for Health Care and Rehabilitation, New Hyde Park, New York, United States|New York University School of Medicine/Psychiarty, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Ohio State University, Dept. of Neurology, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, LLC, Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Psychiatric Consultants, PC, Nashville, Tennessee, United States|Senior Adults Specialty Research (SASR), Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dept. of Neurology, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Landeskrankenhaus- Universitätsklinikum Graz, Graz, Styria, Austria|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Queens University Memorial Clinics, Kingston, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Neurology Research Inc, Toronto, Ontario, Canada|Toronto Centre for Memory and Aging, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada|Neuro Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montréal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00937352"
83,"NCT00733642","Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365 1 mg/kg|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 5 mg/kg|Biological: PF-04360365 10 mg/kg","To examine the safety and tolerability of a single dose of PF-04360365 in subjects with mild-to-moderate AD.|To characterize the pharmacokinetic profile of PF-04360365 following administration of an IV infusion in subjects with mild-to-moderate AD.|To evaluate the relationship of PF-04360365 plasma exposure and Aβ plasma exposure.","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A9951008","August 2008","July 2009","July 2009","August 13, 2008",,"July 28, 2009","Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00733642"
84,"NCT01251718","Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: donepezil hydrochloride","ADAS-Jcog (test of cognitive function)|Adverse events/adverse drug reactions","Eisai Co., Ltd.|Eisai Inc.","All","Child, Adult, Older Adult",,"894","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ART06T","December 1, 2010","October 14, 2015","February 18, 2016","December 2, 2010",,"February 27, 2017","Anjo, Aichi, Japan|Nagoya, Aichi, Japan|Daisen, Akita, Japan|Hirosaki, Aomori, Japan|Towada, Aomori, Japan|Ichihara, Chiba, Japan|Kashiwa, Chiba, Japan|Sakura, Chiba, Japan|Iyo, Ehime, Japan|Matsuyama, Ehime, Japan|Niihama, Ehime, Japan|Toon, Ehime, Japan|Kitakyushu, Fukuoka, Japan|Omuta, Fukuoka, Japan|Ukiha, Fukuoka, Japan|Iwaki, Fukushima, Japan|Mizunami, Gifu, Japan|Fujioka, Gumma, Japan|Fukuyama, Hiroshima, Japan|Kure, Hiroshima, Japan|Miyoshi, Hiroshima, Japan|Otake, Hiroshima, Japan|Hakodate, Hokkaido, Japan|Nayoro, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sunagawa, Hokkaido, Japan|Aioi, Hyogo, Japan|Akashi, Hyogo, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Moriya, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Kita, Kagawa, Japan|Mitoyo, Kagawa, Japan|Ebina, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Nankoku, Kochi, Japan|Uji, Kyoto, Japan|Suzuka, Mie, Japan|Tsu, Mie, Japan|Yokkaichi, Mie, Japan|Sendai, Miyagi, Japan|Kitamorokata, Miyazaki, Japan|Iida, Nagano, Japan|Matsumoto, Nagano, Japan|Okaya, Nagano, Japan|Sasebo, Nagasaki, Japan|Ikoma, Nara, Japan|Kashihara, Nara, Japan|Saiki, Oita, Japan|Yufu, Oita, Japan|Kurashiki, Okayama, Japan|Izumisano, Osaka, Japan|Kaizuka, Osaka, Japan|Matsubara, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Suita, Osaka, Japan|Fukaya, Saitama, Japan|Hanno, Saitama, Japan|Iruma, Saitama, Japan|Koshigaya, Saitama, Japan|Sayama, Saitama, Japan|Masuda, Shimane, Japan|Hamamatsu, Shizuoka, Japan|Adachi, Tokyo, Japan|Bunkyo, Tokyo, Japan|Hachioji, Tokyo, Japan|Itabashi, Tokyo, Japan|Katsushika, Tokyo, Japan|Machida, Tokyo, Japan|Meguro, Tokyo, Japan|Minato, Tokyo, Japan|Nakano, Tokyo, Japan|Setagaya, Tokyo, Japan|Shinjuku, Tokyo, Japan|Taito, Tokyo, Japan|Toshima, Tokyo, Japan|Kurayoshi, Tottori, Japan|Nanto, Toyama, Japan|Kinokawa, Wakayama, Japan|Tendo, Yamagata, Japan|Hagi, Yamaguchi, Japan|Shunan, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Akita, Japan|Chiba, Japan|Fukuoka, Japan|Fukushima, Japan|Gifu, Japan|Hiroshima, Japan|Kagoshima, Japan|Kochi, Japan|Kyoto, Japan|Nara, Japan|Niigata, Japan|Oita, Japan|Okayama, Japan|Osaka, Japan|Shizuoka, Japan|Yamanashi, Japan",,"https://ClinicalTrials.gov/show/NCT01251718"
85,"NCT00710684","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: SB-742457 15mg|Drug: SB-742457 35mg|Drug: Placebo|Drug: donepezil 5-10mg","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24|Change From Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at Week 24|Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24|Change From Baseline in ADAS-Cog Total Score at Week 12, 36 and 48|Change From Baseline in CDR-SB Score at Week 12, 36 and 48|Change From Baseline in RBANS Score at Week 12, 36 and 48|Change From Baseline in Alzheimer's Disease Co-operative Study Group - Activities of Daily Living Inventory (ADCS- ADL) Total Score at Weeks 12, 24, 36 and 48|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 24 and 48|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During Treatment Phase|Number of Participants With Parameters of Clinical Concern - Hematology|Number of Participants With Parameters of Clinical Concern - Clinical Chemistry|Exposure Estimates for SB-742457 : Area Under the Concentration Time Curve Over the Dosing Interval at Steady State (AUCτss)|Exposure Estimates for SB-742457 : Minimum Concentrations at Steady State (Cmin-ss)|Exposure Estimates for Donepezil (Cavgss)|Change From Baseline in ADAS-Cog Scale in Participants With APOE4 Gene|Change From Baseline in CDR-SB Scale in Participants With APOE4 Gene|Change From Baseline in RBANS Scale in Participants With APOE4 Gene","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","682","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AZ3110866","July 1, 2008","May 21, 2010","November 16, 2010","July 4, 2008","December 7, 2017","December 7, 2017","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Manchester, New Jersey, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Ballarat, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Melnik, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Pardubice, Czechia|GSK Investigational Site, Plzen, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 1, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice A Cancello - Caserta, Campania, Italy|GSK Investigational Site, Cassino (FR), Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Castellanza (VA), Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Lido Di Camaiore (LU), Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Valdagno (VI), Veneto, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, San Sebastián, Spain|GSK Investigational Site, San Vicente Del Raspeig/Alicante, Spain|GSK Investigational Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00710684"
86,"NCT03289143","A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: RO7105705|Drug: Placebo|Drug: [18F]GTP1","Change from baseline on the CDR-Sum of Boxes|Percentage of Participants with Adverse Events|Change From Baseline on the Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline on the Alzheimer's Disease Assessment Scale−Cognitive Subscale 13|Change from baseline on the Amsterdam Instrumental Activity of Daily Living questionnaire|Change from baseline on the Alzheimer's Disease Cooperative Study Group−Activities of Daily Living Inventory|Serum concentrations of RO7105705 at specified timepoints|Presence of anti-drug antibodies during the study relative to their presence at baseline","Genentech, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","457","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GN39763|2017-001800-31","October 4, 2017","June 24, 2020","September 20, 2022","September 20, 2017",,"October 8, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|California Clinical Trials, Glendale, California, United States|University of California Irvine, Irvine, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Stanford Neuroscience Health Center (SNHC), Palo Alto, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Neurological Research Inst, Santa Monica, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University; Global Health, Atlanta, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Brigham & Women's Hosp; TIMI Study Grp, Boston, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|Health Partners Institute for Education and Research, Saint Paul, Minnesota, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Albany Medical College; Neurology, Albany, New York, United States|Empire Neurology PC; MS Center of Northeastern NY, Latham, New York, United States|Columbia Univ Medical Center, New York, New York, United States|University of Rochester; AD-CARE, Rochester, New York, United States|Summit Research Network Inc., Portland, Oregon, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|New Orleans Center For Clinical Research, Knoxville, Tennessee, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|St Vincents Medical Centre, Darlinghurst, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Queensland University of Technology, Mermaid Waters, Queensland, Australia|Eastern Clinical Research Unit; Pharmacy, Box Hill, Victoria, Australia|HammondCare Aged Psychiatry Clinical Trials, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit, Melbourne, Victoria, Australia|Neuro Trials Victoria, Noble Park, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|UZ Brussel, Brussel, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta Campus Westlaan, Roeselare, Belgium|Vancouver Island Health Research Centre, Victoria, British Columbia, Canada|JBN Medical Diagnostic Services; Clinical Trials Division, Burlington, Ontario, Canada|Parkwood Institute, Mental Health Care Building, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|Center For Clinical and Basic Research (Ccbr); Site Management Organisation, Aalborg, Denmark|CCBR - Ballerup - DK, Ballerup, Denmark|CCBR - Vejle - DK, Vejle, Denmark|Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage, Bordeaux, France|Hopital Neurologique Pierre Wertheimer, Bron, France|Hopital Roger Salengro, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Fernand Widal Centre, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|CHU Hautepierre; ACTR Association Recherche Clinique Rhumatologie, Strasbourg, France|CHU Strasbourg - Hôpital Hautepierre, Strasbourg, France|Hopital de La Grave, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Klinikum Bayreuth; Krankenhaus Hohe Warte, Bayreuth, Germany|Praxis Dr. med. Volker Shumann, Berlin, Germany|Studienambulanz emovis GmbH; St. Joseph Krankenhaus, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Neurologisch-psychiatrische Praxis am Brosepark, Berlin, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Kardiologie, Mainz, Germany|Klinikum rechts der Isar der TU München; Klinik & Poliklinik für Neurologie, München, Germany|Universitätsklinikum Münster, Stabsstelle Apotheke, Münster, Germany|ZNS Siegen im MVZ Weidenau, Siegen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Neurologia, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria San Martino; Dip. di Neuroscienze Oftalmologia e Genetica, Genova, Liguria, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|IRCCS Centro San Giovanni di Dio FBF, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - LE, Puglia, Italy|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NZOZ VITO-MED Sp.z o.o., Gliwice, Poland|M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4; Klinika Nefrologii, Lublin, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland|EroMedis, Szczecin, Poland|AMED Medical Center, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Fundación ACE; Servicio de Neurología, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital de Cantoblanco; Servicio de Geriatria, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Länssjukhuset Ryhov, Jönköping, Sweden|Länssjukhuset Kalmar; Oncology, Kalmar, Sweden|Skane University Hospital Malmo/Lund, Dept.of Hematology and Coagulation Disorders, Malmö, Sweden|Sahlgrenska Univ Hospital Mölndal; Department of Nephrology, Mölndal, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Murray Royal Hospital; Psychiatry of Old Age (POA) Hub, Dundee, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, GT LON, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Derriford Hospital; Neurology, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Re:Cognition Health Guildford, Surrey, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03289143"
87,"NCT01028911","A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: PF-03654746|Drug: Placebo","Number of Participants With Clinically Significant Vital Sign Abnormalities|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Clinically Significant Laboratory Test Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Physical Examination|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Baseline|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 5|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 10|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 15|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 20|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 25|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 30|Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Follow-up|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 5|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 10|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 15|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 20|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 25|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 30|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Follow-up|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 5|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 10|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 15|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 20|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 25|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 30|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Follow-up|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-03654746|Maximum Serum Concentration (Cmax) for PF-03654746|Time to Reach Maximum Observed Serum Concentration (Tmax) for PF-03654746|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for Donepezil|Maximum Plasma Concentration (Cmax) for Donepezil|Time to Reach Maximum Observed Plasma Concentration (Tmax) for Donepezil","Pfizer","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A8801016","December 2009","May 2010","May 2010","December 9, 2009","June 4, 2014","June 4, 2014","Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01028911"
88,"NCT00988598","A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PF-04447943|Drug: Placebo","vital signs|ECGs|Physical and Neurological examinations|Laboratory tests|adverse events|Plasma concentrations of PF 04447943 over time|Plasma concentrations of donepezil over time","Pfizer","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B0401008","October 2009","July 2010","July 2010","October 2, 2009",,"August 9, 2010","Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00988598"
89,"NCT03503331","UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy","PiB ADC","Recruiting","No Results Available","Alzheimer Disease","Drug: [C-11]PiB-PET/MRI","Measurement of pathological beta-amyloid in the brain","University of Alabama at Birmingham","All","50 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-300001005","April 20, 2018","April 1, 2024","April 1, 2024","April 19, 2018",,"May 20, 2019","University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03503331"
90,"NCT00731224","Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.","CARE","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal patch","Proportion of patients who can reach the target rivastigmine patch size of 10 cm2 and stay on it for at least 8 weeks.|Mini-Mental State Examination (MMSE), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Global Deterioration Scale (GDS), caregiver burden (Zarit Burden Interview).|Patient compliance (drug accounting)","Novartis Pharmaceuticals|Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","380","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DAU01","July 2008","October 2011","October 2011","August 8, 2008",,"March 28, 2017","Novartis Investigative Site, East Gosford, New South Wales, Australia|Novartis Investigative Site, Gosford, New South Wales, Australia|Novartis Investigative Site, Hornsby, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Chemside, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Nedlands, Australia|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Bundang, Seongnam, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Seremban, Negeri Sembilan, Malaysia|Novartis Investigative Site, Ipoh, Perak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Selangor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Atakum / Samsun, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Emek / Ankara, Turkey|Novartis Investigative Site, Etlik / Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Konya, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Meselik / Eskisehir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Uskudar / Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00731224"
91,"NCT03352258","Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Radiation: Low dose radiotherapy","Safety and adverse event associated with low dose brain RT|Change in brain amyloid deposits|Neuropsychological performances","Thomas Zilli|University Hospital, Geneva","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-01715","November 17, 2017","December 30, 2019","December 30, 2020","November 24, 2017",,"September 27, 2019","Geneva University Hospital, Geneva 14, Switzerland",,"https://ClinicalTrials.gov/show/NCT03352258"
92,"NCT00357357","European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients",,"Completed","No Results Available","Alzheimer's Disease","Drug: HF0220","Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients|Validate biochemical markers relevant to Alzheimer's disease|Assess the suitability of chosen HF0220 dose levels for future studies","Hunter-Fleming Ltd","All","55 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HF0220/003|2005-005791-32","July 2006","August 2008","August 2008","July 27, 2006",,"August 21, 2008","King George Hospital, Visakhapatnam, Andh Prad, India|Manipal Hospital,, Bangalore, Karna, India|Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India|Nizam's Institute of Medical Sciences,, Hyderabaad, Panjagutta, India|Madras Medical College & Government General Hospital, Chennai, Tamilnadu, India|Malmo University Hospital, Malmo, Sweden|Karolinksa Institute, Stockholm, Sweden|Research Institute for Care of the Elderly, Bath, United Kingdom|Memory Assessment and Research Centre, Southampton, United Kingdom|Kingshill Research Centre, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00357357"
93,"NCT01311492","Exercise Trial for Alzheimer's Disease","EXTRA","Completed","No Results Available","Alzheimer's Disease","Behavioral: Healthy Lifestyle Program|Behavioral: Physical Activity Intervention","Effect of exercise on cognitive decline|Measuring the effects of exercise on depression, metabolic indices, and changes in overall function.|Evidence based feasibility for conducting exercise interventions in the Alzheimer's Disease population.","Pennington Biomedical Research Center|St. James Place of Baton Rouge","All","65 Years and older   (Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","PBRC10035","March 2011","April 2013","April 2013","March 9, 2011",,"May 27, 2013","Programs of All-Inclusive Care for the Elderly (PACE), Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01311492"
94,"NCT00646269","Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease","ETNA3","Completed","No Results Available","Alzheimer's Disease","Behavioral: Standard intervention protocol|Behavioral: Standard intervention protocol + Cognitive training therapy|Behavioral: Standard intervention protocol + Reminiscence therapy|Behavioral: Standard intervention protocol + ""Made-to-measure"" program","Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower)|Cognitive abilities (ADAS-cog)|Functional abilities in activities of daily living (DAD scale)|Behavioural disturbance (NPI)|Apathy (Apathy Inventory)|Quality of life (Quol-AD)|Depression (MADRS)","University Hospital, Bordeaux|Caisse Nationale de Solidarité pour l'Autonomie|National Health Insurance Fund for Unemployed Workers|Direction Générale de la Santé, France|Institut National de la Santé Et de la Recherche Médicale, France|Université Victor Segalen Bordeaux 2","All","50 Years and older   (Adult, Older Adult)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2007/17","March 2008","December 2010","December 2012","March 28, 2008",,"August 1, 2013","CH Agen, Agen, France|CHU Amiens Nord, Amiens, France|Centre Mémoire de Ressources et de Recherches de Bordeaux, CHU de Bordeaux, Bordeaux, France|Hôpital Pellegrin, Bordeaux, France|CHU Côte de Nacre, Caen, France|Centre pour Personnes Agées, Colmar, France|Centre de Gériatrie, DAX, France|Hôpital Dupuytren, Draveil, France|Pôle de Gérontologie CHICAS, Gap, France|Les Fontaines de Monjous, Gradignan, France|CMRR & Neuropsychologie, Pavillon de Neurologie, CHU de Grenoble, Grenoble, France|Centre Hospitalier La Rochelle, La rochelle, France|Association AA83 Alzheimer Aidants Var Etablissement "" Les pensées "", La Seyne sur Mer, France|Centre Hospitalier de Libourne, Libourne, France|CHU Limoges, Limoges, France|Hôpital Privé Gériatrique Les Magnolias, Longjumeau, France|Centre Hospitalier Bretagne Sud, Lorient, France|Groupe Hospitalier Saint-Augustin, Malestroit, France|Hôpital Sainte-Marguerite, Marseille, France|Centre Antonin Balmes, Montpellier, France|Hôpital Gui de Chauliac, Montpellier, France|Clinique Neurologique, CHU Nord, Nantes, France|Centre Mémoire, Hôpital Pasteur,, Nice, France|Hôpital Broca, Paris, France|Hôpital de la Salpétrière,, Paris, France|Centre Hospitalier des Pyrénées, Pau, France|Hôpital de Jour Gériatrique, Pau, France|Hôpital Xavier-Arnozan, Pessac, France|CHI Poissy-saint-germain-en-laye, Poissy, France|Hôpital de Jour gériatrique, Poitiers, France|CHU de Rennes, Rennes, France|Hôpital de Jour Gériatrique, Saint Raphaël, France|CHRU de Saint-Etienne, Saint-Etienne, France|Centre hospitalier Ariège Couserans, Saint-Girons, France|Hôpitaux universitaires de Strasbourg, Strasbourg, France|Bagatelle, Talence, France|CHIC Marmande - Tonneins, Tonneins, France|CHU Purpan-Casselardit, Toulouse, France|Hôpital des Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT00646269"
95,"NCT03300180","Caregiver Outcomes of Alzheimer's Disease Screening","COADS","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Collaborative Dementia Care Program|Other: Screening Only","Short Form Health Survey (SF-36)|Depressive symptoms|Anxiety symptoms|Caregiving preparedness|Caregiving self efficacy","Indiana University","All","65 Years and older   (Older Adult)","Not Applicable","3600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","1705649205","October 15, 2018","October 1, 2021","September 30, 2023","October 3, 2017",,"October 25, 2018","Eskenazi Hospital, Indianapolis, Indiana, United States|IU Health-Primary Care Clinics, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03300180"
96,"NCT02494531","Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging","AVILL","Recruiting","No Results Available","Alzheimer Disease","Radiation: Fluorodeoxyglucose-PET|Radiation: florbetapir F 18-PET","Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate MCI patients|Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate AD patients,|Comparison of the amyloid deposit location between the 2 groups (literate and illiterate)|correlation between amyloid load and metabolism dysfunction using Fluorodeoxyglucose (FDG)-PET in each groups","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P120134","May 2015","January 2019","January 2020","July 10, 2015",,"December 5, 2016","Hospital Avicenne-Neurology, Bobigny, France",,"https://ClinicalTrials.gov/show/NCT02494531"
97,"NCT00381381","The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Donepezil","CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)|CERAD-K|Neuropsychiatry Inventory (NPI)|GDS-K (Geriatric Depression Scale-Korean) Score After Treatment","Eisai Korea Inc.|Eisai Inc.","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 4","199","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EKI-6-004","May 2006","August 2008","December 2008","September 27, 2006","July 27, 2012","August 31, 2012","Seoul National University Bundang Hospital, Bundang, Korea, Republic of|Hallym University Medical Center, Changwon, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Kunkuk University Chungju Hospital, Chungju, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gyeonggi Province Geriatric Hospital, Gyeonggi, Korea, Republic of|Uijeongbu St. Mary's Hospital, Gyeonggi, Korea, Republic of|Jeju National University Hospital, Jeju, Korea, Republic of|Jeonju City Welfare Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Inje University Pusan Paik Hospital, Pusan, Korea, Republic of|Kunkuk University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00381381"
98,"NCT03971994","Emotion and Attention in Alzheimer's Disease (ATEMMA)","ATEMMA","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Facial expression recognition task","Classic recognition score|Classic fixation time faces|Fixation time scenes|Classic fMRI activity|Alternative recognition score|Alternative fixation time faces|Alternative fMRI activity","University Hospital, Grenoble","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","2018/113","May 31, 2019","July 27, 2021","July 27, 2021","June 3, 2019",,"June 3, 2019","Grenoble University Hospital, La Tronche, France",,"https://ClinicalTrials.gov/show/NCT03971994"
99,"NCT01538212","Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease","ACT","Completed","No Results Available","Alzheimer's Disease",,"Physician's Overall Assessment of Patient Status at the beginning of Axona treatment and the most recent assessment|Changes from baseline in patient's living situation|Changes from baseline in patient's medications for the treatment of AD|Changes from baseline in patient's medications for psychiatric conditions related to AD|Changes from baseline in patient's memory and ability to carry out instrumental activities of daily living as assessed by caregivers|Adverse events assessed by physician's as being possibly associated with the use of Axona","Cerecin","All","50 Years and older   (Adult, Older Adult)",,"55","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AX-11-009","January 2012","October 2012","October 2012","February 24, 2012",,"April 18, 2016",,,"https://ClinicalTrials.gov/show/NCT01538212"
100,"NCT02925650","Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease","DISCOVER","Recruiting","No Results Available","Alzheimer's Disease","Drug: Posiphen|Drug: Placebo","Safety and Tolerability: Reports of adverse events or study discontinuations|AUC of Posiphen and its metabolites in plasma and CSF|Fractional synthesis rate of Aβ40 in CSF using the SILK™ technique|Concentration of soluble biomarkers of Alzheimer's disease in CSF|Assessment of cognitive assessments|Assessment of mental status effects|Assessment of neuropsychiatric effects","QR Pharma Inc.|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","QR15001|ADC-042-DISC","March 2, 2017","December 31, 2019","December 31, 2019","October 6, 2016",,"June 7, 2019","UCSD Alzheimer's Disease Research Center, La Jolla, California, United States|IU Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington University Sleep Medicine Center, Brentwood, Missouri, United States|Columbia University Medical Center Sergievsky Center Taub Institute, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02925650"
101,"NCT01478204","A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,"Sleep disturbances measures by Scores on the Pittsburgh Sleep Quality Index (PSQI) Scale|The Level of Daytime Sleepiness determined by the Scores on the Epworth Sleepiness Scale","Janssen-Cilag, S.A.","All","60 Years and older   (Adult, Older Adult)",,"925","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR017509|GALALZ4037","June 2008","June 2009","July 2009","November 23, 2011",,"October 31, 2012",,,"https://ClinicalTrials.gov/show/NCT01478204"
102,"NCT01424436","Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient",,"Completed","No Results Available","Alzheimer's Disease","Biological: GSK933776","The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.|To assess the safety and tolerability after single dose of GSK933776 administration.","GlaxoSmithKline","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","113043","May 19, 2010","December 8, 2011","December 8, 2011","August 29, 2011",,"June 14, 2017","GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01424436"
103,"NCT03101085","S-Equol in Alzheimer's Disease 2 Trial","SEAD2","Recruiting","No Results Available","Alzheimer Disease","Drug: S-equol|Other: Placebo","Difference in cytochrome oxidase/citrate synthase (COX/CS) activity|Safety laboratories evaluation and participant/study partner reporting of symptoms or adverse events|Montreal Cognitive Assessment (MoCA) Determine if S-equol influences participant scores.|Alzheimer's Disease Assessment Scale-Cognitive Portion (ADASCog-11) Determine if S-equol influences participant scores.|Logical Memory Test (LMT) - immediate and delayed recall Determine if S-equol influences participant scores.|Stroop Test Determine if S-equol influences participant scores.|Pattern of COX activity changes while on the active treatment versus placebo arms of this crossover study.","Russell Swerdlow, MD|Ausio Pharmaceuticals, LLC|University of Kansas Medical Center","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SEAD2","May 5, 2017","March 30, 2020","June 30, 2020","April 4, 2017",,"October 1, 2019","Clinical and Translational Science Unit, Fairway, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03101085"
104,"NCT03856359","Trial of Rifaximin in Probable Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Rifaximin 550 milligrams (MG)","Change in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG)|Occurrence of Adverse Events|Change in Serum neuronal markers|Change in Serum pro-inflammatory markers|Change in gut microbiota|Change in tolerability as measured by number of Adverse Events (AE).|Change in cognitive performance on the Mini-Mental State Exam (MMSE)|Changes in Safety measures as measured by treatment emergent AEs as reported by the subject|Changes in Complete Blood Count (CBC)|Changes in blood pressure|Changes in pulse|Changes in Chemistry values|Changes in Liver Function Test (LFT) will be measured by ALT and AST lab results from baseline|Changes in C Difficile infection","Duke University|Bausch Health Americas, Inc.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00093318","April 9, 2019","February 2021","February 2021","February 27, 2019",,"April 11, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03856359"
105,"NCT00757939","A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)",,"Completed","No Results Available","Alzheimer's Disease","Other: MRI|Other: FDG-PET","Regional cerebral blood flow, as measured by dASL.|Rate of cerebral glucose consumption, MRglc, as measured by fludeoxyglucose-PET (FDG-PET)|Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) response","Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","0000-068|2008_547","September 2008","October 2010","October 2010","September 23, 2008",,"August 11, 2015",,,"https://ClinicalTrials.gov/show/NCT00757939"
106,"NCT03998423","Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease","AMBITION","Recruiting","No Results Available","Alzheimer Disease","Biological: Fecal Microbiota Transplant","Safety: Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest.|Feasibility: Participant recruitment rate|Feasibility: Eligibility|Feasibility: Procedures completed.|Feasibility: Retention|Change in gut composition: Engraftment of fecal microbial transplant as assessed by 16S rRNA sequencing of recipient stool sample|Cognition: Change in Montreal Cognitive Assessment (MoCA) score|Cognition: Change in results of Repeatable Battery for the Assessment of Neuropsychological Status|Cognition: Change in the results of Trail Making Test Part A and Part B|Metabolic/physiological measure: Change in the level of Hemoglobin A1C|Metabolic/physiological measure: Change in the level of fasting glucose|Metabolic/physiological measure: Change in the level of fasting insulin|Metabolic/physiological measure: Change in the level of C-reactive protein|Metabolic/physiological measure: Change in the blood lipid profile|Metabolic/physiological measure: Change in the blood pressure|Metabolic/physiological measure: Change in body weight|Metabolic/physiological measure: Change in the body composition by measuring body fat percentage|Change in insulin resistance indexed by the homeostatic model assessment-insulin resistance (HOMA-IR) method|Change in physical activity as measured by Actigraphy watch|Change in Sleep as measured by Actigraphy watch|Change in CSF biomarkers|Change in serum/plasma metabolites on an average of one week pre and post FMT|Function: Change in total score on the Bristol Activities of Daily Living Scale","University of Wisconsin, Madison|Wisconsin Partnership Program","All","45 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMBITION|2018-0283","October 2019","May 31, 2022","May 31, 2022","June 26, 2019",,"October 8, 2019","University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03998423"
107,"NCT01796314","Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life","THERAD","Completed","No Results Available","Alzheimer Disease","Behavioral: Therapeutic Educational Program","Quality of life|Caregiver quality of life","University Hospital, Toulouse","All","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","RC31/11/255|PREQHOS n°11 255 07","January 2013","February 2017","February 2017","February 21, 2013",,"June 1, 2018","CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01796314"
108,"NCT03752463","NMDA Enhancer for the Treatment of Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: DAOI-A group|Drug: DAOI-B group|Drug: DAOI-C group|Drug: Placebo oral capsule","Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24|Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24|Change from baseline in speed of processing (Category Fluency) at week 24|Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24|Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24","Chang Gung Memorial Hospital|Ministry of Science and Technology, Taiwan","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","105-3412C","May 22, 2015","December 31, 2019","December 31, 2019","November 26, 2018",,"November 26, 2018","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03752463"
109,"NCT03373604","Imaging Tau in Alzheimer's Disease and Normal Aging",,"Enrolling by invitation","No Results Available","Alzheimer Disease","Drug: 18F-MK-6240|Procedure: Lumbar Puncture (optional)","18F-MK-6240 binding (standardized uptake value ratio)|Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 2","175","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR4352|K23AG052633-02|2R56AG034189-06A1|K24AG045334|R01AG055299|R01AG050440-02S1","December 11, 2017","August 20, 2021","August 20, 2021","December 14, 2017",,"August 19, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03373604"
110,"NCT03036280","A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_","MissionAD2","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Elenbecestat (E2609)|Drug: Placebo","Core Study: Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at 24 Months|Open-Label Extension Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs)|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Vital Signs Values|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings|Open-Label Extension Phase: Number of Participants With Abnormal Physical Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Neurological Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Laboratory Safety Test Values|Open-Label Extension Phase: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)|Open-Label Extension Phase: Number of Events of Possible Signals of Drug Abuse Potential|Open-Label Extension Phase: Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) Findings|Core Study: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 24 Months|Core Study: Change From Baseline in Amyloid Positron Emission Tomography Standardized Uptake Value Ratio (PET SUVR) at 24 Months for Brain Amyloid Levels|Open-Label Extension Phase: Change From Core Study Baseline in CDR-SB at Months 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADCOMS at Month 24|Open-Label Extension Phase: Change From Core Study Baseline in Mini Mental State Examination (MMSE) at Months 4, 8, 12, 16, 20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Functional Assessment Questionnaire (FAQ) at Months 4, 8,12,16,20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Alzheimer's Disease Assessment Scale-Cognition14 (ADAS-cog14) at Months 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) at Months 12, 24|Open-Label Extension Phase: Time to Conversion to Dementia for Participants who were not Clinically Staged as Dementia at Core Study Baseline Based on Clinical Diagnosis","Eisai Co., Ltd.|Biogen|Eisai Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","950","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2609-G000-302|2016-004128-42","December 29, 2016","November 21, 2023","November 21, 2023","January 30, 2017",,"September 19, 2019","Facility #1, Gilbert, Arizona, United States|Facility #1, Phoenix, Arizona, United States|Facility #1, Little Rock, Arkansas, United States|Facility #1, Bellflower, California, United States|Facility #1, Glendale, California, United States|Facility #1, Irvine, California, United States|Facility #1, Laguna Hills, California, United States|Facility #1, Lomita, California, United States|Facility #1, Los Angeles, California, United States|Facility #1, Oceanside, California, United States|Facility #1, Palo Alto, California, United States|Facility #1, Riverside, California, United States|Facility #2, Santa Ana, California, United States|Facility #1, Santa Ana, California, United States|Facility #1, Santa Monica, California, United States|Facility #1, New Haven, Connecticut, United States|Facility #1, Stamford, Connecticut, United States|Facility #1, Aventura, Florida, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Hialeah, Florida, United States|Facility #2, Jacksonville, Florida, United States|Facility #1, Lake Worth, Florida, United States|Facility #1, Maitland, Florida, United States|Facility #1, Melbourne, Florida, United States|Facility #1, Miami Lakes, Florida, United States|Facility #1, Miami Springs, Florida, United States|Facility #2, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #5, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #1, North Miami, Florida, United States|Facility #1, Ocala, Florida, United States|Facility #1, Orange City, Florida, United States|Facility #1, Ormond Beach, Florida, United States|Facility #1, Palmetto Bay, Florida, United States|Facility #1, Pembroke Pines, Florida, United States|Facility #1, Pinellas Park, Florida, United States|Facility #1, Saint Petersburg, Florida, United States|Facility #1, West Palm Beach, Florida, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Newnan, Georgia, United States|Facility #1, Honolulu, Hawaii, United States|Facility #1, Chicago, Illinois, United States|Facility #1, Elk Grove Village, Illinois, United States|Facility #1, Schaumburg, Illinois, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Baton Rouge, Louisiana, United States|Facility #1, Plymouth, Massachusetts, United States|Facility #1, Hattiesburg, Mississippi, United States|Facility #1, Creve Coeur, Missouri, United States|Facility# 1, Saint Louis, Missouri, United States|Facility #1, Las Vegas, Nevada, United States|Facility #1, Toms River, New Jersey, United States|Facility #1, Albany, New York, United States|Facility #1, Glens Falls, New York, United States|Facility #1, Manhasset, New York, United States|Facility #1, Woodmere, New York, United States|Facility #1, Charlotte, North Carolina, United States|Facility #2, Charlotte, North Carolina, United States|Facility #1, Beachwood, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Medford, Oregon, United States|Facility #1, Portland, Oregon, United States|Facility #1, Norristown, Pennsylvania, United States|Facility #1, Plains, Pennsylvania, United States|Facility #1, Knoxville, Tennessee, United States|Facility #1, Dallas, Texas, United States|Facility #1, DeSoto, Texas, United States|Facility #1, Greenville, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, Mansfield, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, West Jordan, Utah, United States|Facility #2, Richmond, Virginia, United States|Facility #1, Richmond, Virginia, United States|Facility #1, Toronto, Ontario, Canada|Facility #1, Gatineau, Quebec, Canada|Facility #1, Greenfield Park, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Verdun, Quebec, Canada|Facility #1, Santiago, Metropolitan Region, Chile|Facility #2, Santiago, Metropolitan Region, Chile|Facility #4, Santiago, Metropolitan Region, Chile|Facility #3, Santiago, Metropolitan Region, Chile|Facility #1, Antofagasta, Chile|Facility #3, Beijing, Beijing, China|Facility #2, Beijing, Beijing, China|Facility #1, Beijing, Beijing, China|Facility #4, Beijing, Beijing, China|Facility #7, Beijing, Beijing, China|Facility #8, Beijing, Beijing, China|Facility #6, Beijing, Beijing, China|Facility #1, Chongqing, Chongqing, China|Facility #1, Fuzhou, Fujian, China|Facility #1, Guangzhou, Guangdong, China|Facility #2, Guangzhou, Guangdong, China|Facility #5, Guangzhou, Guangdong, China|Facility #4, Guangzhou, Guangdong, China|Facility #3, Guangzhou, Guangdong, China|Facility #1, Shenzhen, Guangdong, China|Facility #1, Zhengzhou, Henan, China|Facility #1, Changchun, Jilin, China|Facility #1, Xi'ning City, Qinghai, China|Facility #3, Shanghai, Shanghai, China|Facility #4, Shanghai, Shanghai, China|Facility #2, Shanghai, Shanghai, China|Facility #1, Taiyuan, Shanxi, China|Facility #1, Xi'an, Shanxi, China|Facility #1, Chengdu, Sichuan, China|Facility #1, Tianjin, Tianjin, China|Facility #2, Hangzhou, Zheijang, China|Facility #1, Hangzhou, Zheijang, China|Facility #1, Shanghai, China|Facility #1, Zagreb, Croatia|Facility #2, Zagreb, Croatia|Facility #3, Zagreb, Croatia|Facility #4, Zagreb, Croatia|Facility #1, Brno, Czechia|Facility #2, Brno, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Praha 6, Czechia|Facility #1, Rychnov nad Kneznou, Czechia|Facility #1, Ballerup, Copenhagen, Denmark|Facility #1, Vejle, Region Sonerjylland, Denmark|Facility #1, Aalborg, Denmark|Facility #1, Helsinki, Finland|Facility #1, Kuopio, Finland|Facility #1, Oulu, Finland|Facility #1, Turku, Finland|Facility #1, Limoges, France|Facility #1, Nice, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, TOURS Cedex, France|Facility #1, Vienne, France|Facility #1, Villefranche-sur-Saône, France|Facility #1, Villeurbanne, France|Facility #1, Mannheim, Baden Wurttemberg, Germany|Facility #1, Muenchen, Bavaria, Germany|Facility #1, Munchen, Bayern, Germany|Facility #1, Koeln, Deutschland, Germany|Facility #1, Schwerin, Mecklenburg Vorpommern, Germany|Facility #1, Siegen, North Rhine-Westphalia, Germany|Facility #1, Mittweida, Saxony, Germany|Facility #1, Freiburg, Germany|Facility #1, Hamburg, Germany|Facility #1, Ulm, Germany|Facility #1, Komarom, Esztergom, Hungary|Facility #2, Budapest, Hungary|Facility #1, Budapest, Hungary|Facility #1, Cefalu, Palermo, Italy|Facility #1, Ancona, Italy|Facility #2, Brescia, Italy|Facility #1, Chieti, Italy|Facility #3, Milano, Italy|Facility #2, Milano, Italy|Facility #1, Orbassano, Italy|Facility #1, Pisa, Italy|Facility #1, Pozzilli, Italy|Facility #1, Roma, Italy|Facility #2, Rome, Italy|Facility #1, Rome, Italy|Facility #1, Salerno, Italy|Facility #1, Torino, Italy|Facility #2, Verona, Italy|Eisai Trial Site 1, Nagoya, Aichi, Japan|Eisai Trial Site 1, Hirosaki-city, Aomori, Japan|Eisai Trial Site 2, Chiba-shi, Chiba, Japan|Eisai Trial Site 1, Chiba-shi, Chiba, Japan|Eisai Trial Site 1, Inzai, Chiba, Japan|Eisai Trial Site 1, Urayasu, Chiba, Japan|Eisai Trial Site 1, Koriyama, Fukushima, Japan|Eisai Trial Site 1, Isezaki-city, Gunma, Japan|Eisai Trial Site 1, Maebashi city, Gunma, Japan|Eisai Trial Site 3, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 2, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 1, Sapporo, Hokkaido, Japan|Eisai Trial Site 1, Toride, Ibaraki, Japan|Eisai Trial Site 1, Kanazawa-shi, Ishikawa, Japan|Eisai Trial Site 1, Morioka-shi, Iwate, Japan|Eisai Trial Site 1, Atsugi-shi, Kanagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 1, Kamakura-shi, Kanagawa, Japan|Eisai Trial Site 1, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site 1, Yokohama, Kanagawa, Japan|Eisai Trial Site 2, Yokohama, Kanagawa, Japan|Eisai Trial Site 1, Chuo-ku, Niigata-city/Niigata, Japan|Eisai Trial Site 1, Nagaoka, Niigata, Japan|Eisai Trial Site 1, Iruma-gun, Saitama, Japan|Eisai Trial Site 1, Kasukabe City, Saitama, Japan|Eisai Trial Site 1, Koshigaya-shi, Saitama, Japan|Eisai Trial Site 2, Koshigaya-shi, Saitama, Japan|Eisai Trial Site 1, Saitama city, Saitama, Japan|Eisai Trial Site 1, Shizuoka-city, Shizuoka, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 3, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 4, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Hachioji, Tokyo, Japan|Eisai Trial Site 1, Katsushika-ku, Tokyo, Japan|Eisai Trial Site 1, Koto-ku, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Mitaka City, Tokyo, Japan|Eisai Trial Site 1, Nerima-ku, Tokyo, Japan|Eisai Trial Site 2, Ota-ku, Tokyo, Japan|Eisai Trial Site 1, Ota-ku, Tokyo, Japan|Eisai Trial Site 1, Shibuya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site 2, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Gwangju-si, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Guadalajara, Jalisco, Mexico|Facility #1, Monterrey, Nuevo Leon, Mexico|Facility #2, Monterrey, Nuevo Leon, Mexico|Facility #1, Mexico City, Mexico|Facility #1, Katowice, Silesia, Poland|Facility #1, Bialystok, Poland|Facility #1, Bydgoszcz, Poland|Facility #1, Krakow, Poland|Facility #2, Krakow, Poland|Facility #1, Pruszcz Gdanski, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimaräes, Creixomil, Portugal|Facility #1, Braga, Portugal|Facility #1, Matosinhos, Portugal|Facility #1, Santa Maria da Feira, Portugal|Facility #1, Torres Vedras, Portugal|Facility #1, Singapore, Singapore|Facility #2, Singapore, Singapore|Facility #1, Svidnik, Slovak Republic, Slovakia|Facility #1, Banska Bystrica, Slovakia|Facility #2, Bratislava, Slovakia|Facility #1, Bratislava, Slovakia|Facility #3, Bratislava, Slovakia|Facility #1, Dubnica nad Vahom, Slovakia|Facility #1, Kosice, Slovakia|Facility #1, Roznava, Slovakia|Facility #1, Pinelands, Cape Town, South Africa|Facility #1, Johannesburg, Gauteng, South Africa|Facility #2, Cape Town, Western Cape, South Africa|Facility #1, Cape Town, Western Cape, South Africa|Facility #1, George, Western Cape, South Africa|Facility #2, Barcelona, Catalunya, Spain|Facility #1, San Sebastian, Gipuzkoa, Spain|Facility #1, Castilla Y Leon, Zamora, Spain|Facility #3, Barcelona, Spain|Facility #1, Barcelona, Spain|Facility #1, Madrid, Spain|Facility #4, Madrid, Spain|Facility #2, Madrid, Spain|Facility #3, Madrid, Spain|Facility #1, Salamanca, Spain|Facility #1, Sevilla, Spain|Facility #1, Changhua County, Taiwan|Facility #1, Changhua, Taiwan|Facility #2, Kaohsiung City, Taiwan|Facility #1, New Taipei City, Taiwan|Facility #1, Taichung City, Taiwan|Facility #1, Tainan City, Taiwan|Facility #1, Taipei, Taiwan|Facility #2, Taipei, Taiwan|Facility #1, Taiwan, Taiwan|Facility #1, Taoyuan City, Taiwan|Facility #1, Birmingham, United Kingdom|Facility #1, Guildford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03036280"
111,"NCT03884023","Effect of REST in the Alzheimer Disease Continuum","ERADC","Not yet recruiting","No Results Available","Alzheimer's Disease",,"Rate of Gene polymorphism in rs2227902 and rs3796529.|Concentration of REST protein","Dongzhimen Hospital, Beijing","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","DZMEC-KY-2019-11","June 28, 2019","November 30, 2019","February 12, 2020","March 21, 2019",,"April 16, 2019","Dongzhimen Hospital,Beijing University of Chinese Medicine, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03884023"
112,"NCT01058941","Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Lipoic acid and fish oil concentrate|Drug: Placebo","Change From Baseline in Activities of Daily Living (ADL) at 18 Months|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months","Oregon Health and Science University","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01AG033613-01A1","September 2010","December 2014","December 2014","January 29, 2010","April 13, 2017","April 13, 2017","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01058941"
113,"NCT04070378","Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease","DARZAD","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: Daratumumab Injection","ADAS-cog/11|ADAS-cog/12|MMSE|CDR-SB|ADCOMS|Treatment Emergent Adverse Effects|Treatment Emergent Serious Adverse Effects","Marc L Gordon, MD|Janssen Scientific Affairs, LLC|Northwell Health","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","54767414ALZ001","October 1, 2019","December 31, 2021","June 1, 2022","August 27, 2019",,"August 27, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04070378/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04070378"
114,"NCT01870453","Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer Disease",,"Cognitive Function","Massachusetts General Hospital|Alzheimer's Association","All","Child, Adult, Older Adult",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MassGH-001|HAT-12-237963","October 2013","December 2018","December 2018","June 6, 2013",,"August 16, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01870453"
115,"NCT03295110","Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases","Lili smart","Unknown status","No Results Available","Alzheimer Disease","Other: Functionalities of the Lili Smart Solution activated|Other: Functionalities of the Lili Smart Solution non activated","Caregiver's burden evolution|Evolution of the caregiver's anxiety level|Evolution of the caregiver's depressive symptomatology|Evolution of the caregiver's quality of life|Evolution of the patient's quality of life|Evolution of the patient's independence|Number of falls|Number of run aways|Number of drugs prescribed to the caregiver and the patient|Indirect medical costs and direct non-medical costs|Evaluation of the caregiver's adherence to the Lili Smart solution|Evaluation of patient's adherence to the Lili Smart solution","Hospices Civils de Lyon|Lili smart","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","69HCL16_0706","February 13, 2018","September 2019","September 2019","September 27, 2017",,"March 13, 2018","Hopital des Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT03295110"
116,"NCT00611312","Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Cognitive Training","Composite score of 5 cognitive tests including 1)WAIS digit span, 2) word fluency, 3) trail making test-A 4) Rey Osterrieth complex figure and 5) MMSE|Brain activity during functional brain imaging","University of Kansas|Alzheimer's Association|University of Kansas Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IIRG-07-57789|11008","February 2008","May 2012","September 2012","February 8, 2008",,"October 3, 2012","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00611312"
117,"NCT04063124","Senolytic Therapy to Modulate Progression of Alzheimer's Disease","SToMP-AD","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: Dasatinib + Quercetin","Brain penetrance of Dasatinib (D)|Brain penetrance of Quercetin (Q)|Complete blood count (CBC)|Comprehensive Metabolic Panel (CMP)|Plasma level of Quercetin|Plasma level of Dasatanib|Electronic gait mapping under single and dual-task conditions|Grip Strength|Short Physical Performance Battery|Montreal Cognitive Assessment (MoCA)|Wechsler lV Memory Scale|Benson Figure|Hopkins Verbal Learning Test - Revised (HVLT-R)|Clinical Global Impressions - Improvement Scale (CGI-I)|Lawton's Instrumental Activities of Daily Living Scale","The University of Texas Health Science Center at San Antonio|Mayo Clinic","All","65 Years and older   (Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20190222H","December 2019","August 31, 2020","December 31, 2020","August 21, 2019",,"September 13, 2019","Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04063124"
118,"NCT04010175","Digital Cognitive Remote Training in Alzheimer's Disease (MA-EIAD)","DCRT-AD","Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Control - Cognitive training in a practitioner's office one time per week|Behavioral: Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Behavioral: Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week","Influence of the training on experimental tasks|Influence of the training on neuropsychological tests|Influence of the training on global quality of life","Hospices Civils de Lyon","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","69HCL18_0881","September 2019","May 2022","May 2022","July 8, 2019",,"July 8, 2019","Service de Neuropsychologie - Hôpital Neurologique, Hospices Civils de Lyon, Bron, France",,"https://ClinicalTrials.gov/show/NCT04010175"
119,"NCT02956486","A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","MissionAD1","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Elenbecestat (E2609)|Drug: Placebo","Core Study: Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at 24 Months|Open-Label Extension Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs)|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Vital Signs Values|Open-Label Extension Phase: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings|Open-Label Extension Phase: Number of Participants With Abnormal Physical Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Neurological Examination Findings|Open-Label Extension Phase: Number of Participants With Abnormal Laboratory Safety Test Values|Open-Label Extension Phase: Number of Participants with Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)|Open-Label Extension Phase: Number of Events of Possible Signals of Drug Abuse Potential|Open-Label Extension Phase: Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) Findings|Core Study: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 24 Months|Core Study: Change From Baseline in Amyloid Positron Emission Tomography Standardized Uptake Value Ratio (PET SUVR) at 24 Months for Brain Amyloid Levels|Open-Label Extension Phase: Change From Core Study Baseline in CDR-SB at Month 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADCOMS at Month 24|Open-Label Extension Phase: Change From Core Study Baseline in Mini Mental State Examination (MMSE) at Months 4, 8, 12, 16, 20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Functional Assessment Questionnaire (FAQ) at Months 4, 8,12,16,20, 24|Open-Label Extension Phase: Change From Core Study Baseline in Alzheimer's Disease Assessment Scale-Cognition14 (ADAS-cog14) at Months 12, 24|Open-Label Extension Phase: Change From Core Study Baseline in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) at Months 12, 24|Open-Label Extension Phase: Time to Conversion to Dementia for Participants who were not Clinically Staged as Dementia at Core Study Baseline Based on Clinical Diagnosis","Eisai Co., Ltd.|Biogen|Eisai Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","950","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2609-G000-301|2016-003928-23","October 20, 2016","November 21, 2023","November 21, 2023","November 7, 2016",,"September 19, 2019","Facility #1, Chandler, Arizona, United States|Facility #1, Colton, California, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Imperial, California, United States|Facility #1, Irvine, California, United States|Facility #1, Lemon Grove, California, United States|Facility #1, Oceanside, California, United States|Facility #2, Oceanside, California, United States|Facility #1, Oxnard, California, United States|Facility #1, Panorama City, California, United States|Facility #1, San Diego, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Aventura, Florida, United States|Facility #2, Aventura, Florida, United States|Facility #1, Boynton Beach, Florida, United States|Facility #1, Coral Gables, Florida, United States|Facility #2, Coral Gables, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Miami, Florida, United States|Facility #11, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #10, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #2, Orlando, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #3, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Pompano Beach, Florida, United States|Facility #1, Port Charlotte, Florida, United States|Facility #1, Port Orange, Florida, United States|Facility #1, Spring Hill, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Suwanee, Georgia, United States|Facility #1, Meridian, Idaho, United States|Facility #1, Northbrook, Illinois, United States|Facility #2, Wichita, Kansas, United States|Facility #1, Boston, Massachusetts, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Chesterfield, Missouri, United States|Facility #1, O'Fallon, Missouri, United States|Facility #2, Saint Louis, Missouri, United States|Facility #1, Saint Peters, Missouri, United States|Facility #1, Mount Arlington, New Jersey, United States|Facility #2, Springfield, New Jersey, United States|Facility #1, West Long Branch, New Jersey, United States|Facility #1, Amherst, New York, United States|Facility #1, Brooklyn, New York, United States|Facility #1, New York, New York, United States|Facility #1, Canton, Ohio, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Cleveland, Ohio, United States|Facility #1, Dayton, Ohio, United States|Facility #1, Lakewood, Ohio, United States|Facility #1, Westerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Portland, Oregon, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, Media, Pennsylvania, United States|Facility #1, Philadelphia, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Providence, Rhode Island, United States|Facility #1, Port Royal, South Carolina, United States|Facility #1, Cordova, Tennessee, United States|Facility #2, Nashville, Tennessee, United States|Facility #1, Nashville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Hampton, Virginia, United States|Facility #1, Madison, Wisconsin, United States|Facility #2, Caba, Buenos Aires, Argentina|Facility #1, Caba, Buenos Aires, Argentina|Facility #4, Caba, Buenos Aires, Argentina|Facility #3, Caba, Buenos Aires, Argentina|Facility #1, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #3, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #2, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #1, Cordoba, Capital, Argentina|Facility #1, Rosario, Santa Fe, Argentina|Facility #4, Buenos Aires, Argentina|Facility #5, Caba, Argentina|Facility #2, Cordoba, Argentina|Facility #3, Cordoba, Argentina|Facility #1, Santa Fe, Argentina|Facility #1, Darlinghurst, New South Wales, Australia|Facility #1, Macquarie Park, New South Wales, Australia|Facility #1, Tumbi Umbi, New South Wales, Australia|Facility #1, Brisbane, Queensland, Australia|Facility #1, Caulfield, Victoria, Australia|Facility #1, Geelong, Victoria, Australia|Facility #1, Heidelberg, Victoria, Australia|Facility #1, Malvern, Victoria, Australia|Facility #2, Melbourne, Victoria, Australia|Facility #1, Parkville, Victoria, Australia|Facility #1, Nedlands, Western Australia, Australia|Facility #3, Melbourne, Australia|Facility #1, Vienna, Austria|Facility #1, Pleven, Bulgaria|Facility #1, Plovdiv, Bulgaria|Facility #1, Ruse, Bulgaria|Facility #4, Sofia, Bulgaria|Facility #3, Sofia, Bulgaria|Facility #1, Sofia, Bulgaria|Facility #2, Sofia, Bulgaria|Facility #1, Kamloops, British Columbia, Canada|Facility #1, Kelowna, British Columbia, Canada|Facility #1, West Vancouver, British Columbia, Canada|Facility #1, Halifax, Nova Scotia, Canada|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Hradec Kralove, Czechia|Facility #1, Kladno, Czechia|Facility #1, Olomouc, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Montpellier, Herault, France|Facility #1, Bordeaux, France|Facility #1, Bron Cedex, France|Facility #1, Marseille Cedex 05, France|Facility #1, Nantes, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, Toulouse, France|Facility #1, Neuburg, Bayern, Germany|Facility #1, Hoppegarten, Brandenburg, Germany|Facility #1, Oranienburg, Brandenburg, Germany|Facility #1, Frankfurt, Hessen, Germany|Facility #1, Leipzig, Saxony, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #1, Gera, Germany|Facility #1, Homburg/Saar, Germany|Facility #1, Schwerin, Germany|Facility #5, Athens, Greece|Facility #4, Athens, Greece|Eisai Trial Site 1, Anjo-shi, Aichi, Japan|Eisai Trial Site 1, Nagoya-shi, Aichi, Japan|Eisai Trial Site 1, Obu-shi, Aichi, Japan|Eisai Trial Site 1, Yoshida-gun, Fukui, Japan|Eisai Trail Site 1, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 1, Omuta-shi, Fukuoka, Japan|Eisai Trial Site 1, Fujioka-shi, Gunma, Japan|Eisai Trial Site 1, Otake-shi, Hiroshima, Japan|Eisai Trial Site 2, Himeji-shi, Hyogo, Japan|Eisai Trial Site 1, Himeji, Hyogo, Japan|Eisai Trial Site 1, Kobe, Hyogo, Japan|Facility #1, Miki, Kagawa, Japan|Eisai Trial Site 3, Takamatsu City, Kagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 4, Kyoto City, Kyoto, Japan|Eisai Trial Site 1, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 2, Kyoto-shi, Kyoto, Japan|Eisai Trial site 5, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 1, Shimogyo-ku, Kyoto, Japan|Eisai Trial Site 1, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site 2, Okayama-shi, Okayama-ken, Japan|Eisai Trial Site 1, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 2, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 1, Okayama-shi, Okayama, Japan|Eisai Trial Site 1, Hirakata, Osaka, Japan|Eisai Trial Site 1, Naniwa-Ku, Osaka, Japan|Eisai Trial Site 1, Osaka-shi, Osaka, Japan|Eisai Trial Site 3, Osaka-shi, Osaka, Japan|Eisai Trial Site 2, Osaka-shi, Osaka, Japan|Eisai Trial site 2, Sakai-shi, Osaka, Japan|Eisai Trial Site 1, Suita-shi, Osaka, Japan|Eisai Trial Site 2, Suita-shi, Osaka, Japan|Eisai Trial Site 1, Suminoe-ku, Osaka, Japan|Eisai Trial Site 1, Kanzaki-gun, Saga, Japan|Eisai Trial Site 1, Otsu-shi, Shiga, Japan|Eisai Trial Site 2, Otsu, Shiga, Japan|Eisai Trial Site 1, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Kodaira-shi, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Setagaya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Sumida-ku, Tokyo, Japan|Eisai Trial Site 1, Hofu-shi, Yamaguchi, Japan|Eisai Trial Site 1, Kumamoto, Japan|Eisai Trial Site 3, Kyoto, Japan|Eisai Trial Site 1, Osaka, Japan|Facility #1, Bucheon-si, Gyeonggi-do, Korea, Republic of|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Busan, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #1, Katowice, Poland|Facility #1, Kielce, Poland|Facility #1, Krakow, Poland|Facility #1, Poznari, Poland|Facility #1, Poznań, Poland|Facility #1, Siemianowice Śląskie, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimarães, Portugal|Facility #1, Moscow, Russian Federation|Facility #1, Bratislava, Slovakia|Facility #1, Elche, Alicante, Spain|Facility #1, Sant Cugat Del Valles, Barcelona, Spain|Facility #1, Getxo, Bizkaia, Spain|Facility #1, Donostia/San Sebastian, Gipuzkoa, Spain|Facility #1, Palma de Mallorca, Illes Balears, Spain|Facility #1, El Palmar, Murcia, Spain|Facility #1, Barcelona, Spain|Facility #2, Madrid, Spain|Facility #1, Madrid, Spain|Facility #1, Valencia, Spain|Facility #2, Valencia, Spain|Facility #1, Cambridge, Cambridgeshire, United Kingdom|Facility #1, Chester, Cheshire, United Kingdom|Facility #1, Winwick, Warrington, Cheshire, United Kingdom|Facility #1, Plymouth, Devon, United Kingdom|Facility #1, Bournemouth, Dorset, United Kingdom|Facility #1, Crowborough, East Sussex, United Kingdom|Facility #1, Manchester, Greater Manchester, United Kingdom|Facility #1, Southampton, Hampshire, United Kingdom|Facility #1, Glasgow, Lanarkshire, United Kingdom|Facility #1, Blackpool, Lancashire, United Kingdom|Facility #1, Preston, Lancashire, United Kingdom|Facility #2, London, Middlesex, United Kingdom|Facility #1, Bath, North East Somerset, United Kingdom|Facility #1, Oxford, Oxfordshire, United Kingdom|Facility #1, Aberdeen, Scotland, United Kingdom|Facility #1, Sheffield, South Yorkshire, United Kingdom|Facility #1, Leatherhead, Surrey, United Kingdom|Facility #1, Birmingham, West Midlands, United Kingdom|Facility #1, Swindon, Wilts, United Kingdom|Facility #2, Glasgow, United Kingdom|Facility #1, Guildford, United Kingdom|Facility #1, London, United Kingdom|Facility #4, London, United Kingdom|Facility #3, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02956486"
120,"NCT02045056","Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease",,"Completed","No Results Available","Preclinical Alzheimer's Disease","Drug: Gemfibrozil|Drug: Placebo","Safety|microRNA-107 levels|beta-amyloid levels|Free and cued selective reminding test (FCSRT)|Paired associates learning (PAL)","Gregory Jicha, 323-5550|University of Kentucky","All","65 Years to 90 Years   (Older Adult)","Early Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R01AG042419","May 2014","June 30, 2018","June 2019","January 24, 2014",,"October 8, 2019","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02045056"
121,"NCT01638949","Multi-modal Neuroimaging in Alzheimer's Disease","IMAP+","Recruiting","No Results Available","Alzheimer's Disease","Behavioral: Memory assessment|Biological: Circulating biomarkers measure|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations","Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","295","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011-A01493-38","May 2012","December 2021",,"July 12, 2012",,"April 9, 2014","GIP Cyceron, Caen, Calvados, France|Inserm - EPHE - University of Caen U1077, Caen, France|University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01638949"
122,"NCT02841605","Enteric Nervous System in Alzheimer Disease","ENTEROMA","Unknown status","No Results Available","Alzheimer Disease","Procedure: Rectosigmoidoscopy with colonic biopsies|Procedure: Colonoscopy with colonic biopsies","Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry","Nantes University Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","RC15_0458","October 2016","May 2019","May 2019","July 22, 2016",,"July 22, 2016","University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT02841605"
123,"NCT04079803","PTI-125 for Mild-to-moderate Alzheimer's Disease Patients",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Placebo oral tablet|Drug: PTI-125 50 mg tablet|Drug: PTI-125 100 mg oral tablet","Cerebrospinal fluid P-tau, neurofilament light chain, neurogranin, T-tau, YKL-40, Abeta42 (pg/mL)|Paired Associates Learning test|Spatial Working Memory test|Plasma neurofilament light chain, neurogranin, T-tau, YKL-40, Abeta42 (pg/mL)","Cassava Sciences, Inc.|National Institute on Aging (NIA)","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","60","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTI-125-02|R44AG060878","August 15, 2019","January 15, 2020","April 15, 2020","September 5, 2019",,"September 5, 2019","Cognitive Clinical Trials, Gilbert, Arizona, United States|Cognitive Clinical Trials, Surprise, Arizona, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Cognitive Clinical Trials, Bellevue, Nebraska, United States|Cognitive Clinical Trials, Omaha, Nebraska, United States|Centex Studies, Inc., Houston, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04079803"
124,"NCT00088673","Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease",,"Unknown status","No Results Available","Alzheimer Disease","Drug: 3APS","The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.|The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.","Bellus Health Inc","All","50 Years and older   (Adult, Older Adult)","Phase 3","950","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CL-758007","June 2004",,,"August 3, 2004",,"February 28, 2007","Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, a division of Xenoscience, Phoenix, Arizona, United States|Central Arkansas Research, Hot Springs, Arkansas, United States|Margolin Brain Institute, Fresno, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Radiant Research, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|Yale University, Alzheimer's Disesase Research Unit, New Haven, Connecticut, United States|New England Research Institute, Stamford, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Neuropsychiatric Research Center of SouthWest Florida, Fort Myers, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Tukoi Institute for Clinical Research, Miami, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Quantum Laboratories Inc at the Memory Disorders Clinic, North Broward Medical Center, Pompano Beach, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Byrd Alzheimer’s Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida, Suncoast Gerontology Center, Tampa, Florida, United States|Premiere Research Institute Palm Beach Neurology, West Palm Beach, Florida, United States|Comprehensive Neurology Specialists, PC, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Southern Illinois University (SIU) School of Medicine, Department of Neurology, Springfield, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Mood & Memory Clinic - Dr Aronson, Farmington Hills, Michigan, United States|Memory Enhancement Center, Long Branch, New Jersey, United States|Neurological Associates of Albany, Albany, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|NYU School of Medicine, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Nathan S. Kline Institute, Orangeburg, New York, United States|University of Rochester-Program in Neurobehavioral Therapeutics, Rochester, New York, United States|Richard H. Weisler, MD, PA and Associates, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Department of Psychiatry and Behavioral Medicine, Winston-Salem, North Carolina, United States|University Memory and Aging Center, Cleveland, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Clinical Pharmaceuticals Trials, Inc., Tulsa, Oklahoma, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Farber Institute for Neurosciences, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh ADRC, Pittsburgh, Pennsylvania, United States|CNS Research, Inc., East Providence, Rhode Island, United States|Memory and Aging Program, Butler Hospital, Providence, Rhode Island, United States|MUSC - Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, United States|Clinical Research Services at Tennessee Christian Medical Center, Madison, Tennessee, United States|University of Texas Mental Sciences Institute, Houston, Texas, United States|Air Force Villages-Freedom House Research (Study open to Air Force Village residents only), San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Calgary, Alberta, Canada|The Medical Arts Health Research Group, a Division of PCT Networks, Inc., Penticton, British Columbia, Canada|St. Joseph's Hospital, Saint-John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Queen's University, Kingston, Ontario, Canada|Geriatric Clinical Trials Group, Parkwood Hospital, London, Ontario, Canada|Ottawa, Ontario, Canada|Gerontion Research, Toronto, Ontario, Canada|Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Recherche Clinique de Neurologie, Montreal, Quebec, Canada|Jewish General Hospital- Memory Clinic, Montreal, Quebec, Canada|Centre de recherche Novabyss, Sherbrooke, Quebec, Canada|McGill Centre for Studies in Aging, Verdun (Montreal), Quebec, Canada|Hôpital de l'Enfant-Jésus, Ville de Quebec, Quebec, Canada|Memory & Motor Skills Disorders Clinic, Ville de Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00088673"
125,"NCT03939286","Multimodal Imaging Study on Physical Activity in Patients With Alzheimer`s Disease","DEMENTIA-MOVE","Recruiting","No Results Available","Alzheimer Disease","Other: Clinical-neurological and neuropsychological tests|Diagnostic Test: Blood sampling|Other: Assessment of physical activity via fitness tracker/diary|Other: MRI-examinations","Metabolic changes of the brain induced by intervention program|Structural changes of the brain induced by intervention program","RWTH Aachen University","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19-064","April 8, 2019","April 2021","October 2021","May 6, 2019",,"May 7, 2019","RWTH Aachen University Hospital, Aachen, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT03939286"
126,"NCT04055376","Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia","Device: GENUS device (Active Settings)|Device: GENUS device (Sham Settings)","Feasibility of at-home light and sound stimulation: amount of time of device usage per day|Safety of daily at-home light and sound stimulation: questionnaire","Massachusetts Institute of Technology","All","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","1903763319","August 14, 2019","April 30, 2021","April 30, 2021","August 13, 2019",,"August 26, 2019","Massachusetts Institute of Technology, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04055376"
127,"NCT00076440","Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study",,"Completed","No Results Available","Alzheimer Disease","Drug: Leuprolide acetate",,"Voyager Pharmaceutical Corporation|National Institute on Aging (NIA)","Male","65 Years and older   (Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0051","December 2003","March 2007","March 2007","January 26, 2004",,"December 11, 2009","Margolin Brain Institute, Fresno, California, United States|Bay Area Research Institute, Lafayette, California, United States|Southwest Clinical Research, Rancho Mirage, California, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Middleton VA Wisconsin Alzheimer's Institute, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00076440"
128,"NCT00100334","Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PPI-1019 (APAN)","Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.","PRAECIS Pharmaceuticals Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1019-04-01","December 2004",,"August 2005","December 30, 2004",,"September 19, 2006","Silverado Senior Living, San Juan Capistrano, California, United States",,"https://ClinicalTrials.gov/show/NCT00100334"
129,"NCT00555204","Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-089|Drug: placebo","Safety and Tolerability|Pharmacokinetics (how the body handles the study drug)|Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory)","Abbott","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","337","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-876","November 2007","June 2009",,"November 8, 2007",,"August 23, 2011","Phoenix, Arizona, United States|Sun City, Arizona, United States|Fresno, California, United States|San Diego, California, United States|Santa Ana, California, United States|Santa Monica, California, United States|Hamden, Connecticut, United States|New Haven, Connecticut, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Hallendale, Florida, United States|Hialeah, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Palm Beach Gardens, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Paducah, Kentucky, United States|Pittsfield, Massachusetts, United States|Grand Rapids, Michigan, United States|St Louis, Missouri, United States|Long Branch, New Jersey, United States|Nutley, New Jersey, United States|Princeton, New Jersey, United States|Ridgewood, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|New York, New York, United States|Staten Island, New York, United States|Hickory, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Cleveland, Ohio, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00555204"
130,"NCT02685787","Early Counseling and Support for Alzheimer's Disease Caregivers","D_CareGiver","Unknown status","No Results Available","Alzheimer's Disease","Behavioral: Psychosocial Intervention|Behavioral: Educational Intervention on AD","Care-giver burden measured with Zarit Burden Inventory (ZBI)|Care-giver burden measured with ZBI|Caregiver depression measured using the Hospital Anxiety and Depression Scale (HADS)|Behavioural and psychological symptoms of dementia (BPSD) using the Neuropsychiatric Inventory (NPI)|BPSD using the Revised Memory and Behaviour Checklist (RMBC)|Patient quality-of-life measure with Logdson's Quality of Life AD|Care-giver quality-of-life measure with Euro-Quality of Life","Azienda Sanitaria Locale N.1 dell'Umbria|Azienda Ospedaliera di Perugia|Azienda Ospedaliera di Terni|Azienda Unità Sanitaria Locale Umbria n. 2","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GR-2009-1607340","April 2012","January 2017","December 2017","February 19, 2016",,"February 19, 2016","USL Umbria 1, Perugia, Italy",,"https://ClinicalTrials.gov/show/NCT02685787"
131,"NCT00663936","Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: T-817MA|Drug: Placebo","Evaluation of the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment.|Secondary objectives are to evaluate the safety of T-817MA and the activities of daily living (ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.","FUJIFILM Toyama Chemical Co., Ltd.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","373","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AA4437420","April 2008","May 2011","June 2011","April 22, 2008",,"November 5, 2013","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Northwest NeuroSpecialists, Tucson, Arizona, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Southwest Institute for Clinical Research, Inc., Rancho Mirage, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Radiant Research, Denver, Colorado, United States|Geriatric and Adult Psychiatry, LCC, Hamden, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|NeuroPsychiatric Center of the Palm Beaches, Boynton Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Anchor Research Center, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Columbus Research & Wellness Institute, Columbus, Georgia, United States|Agewell, Indianapolis, Indiana, United States|Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Memory Enhancement Center of America, Toms River, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Alzheimer's Disease Center, U. of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|The Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Clinical Trials of America, Inc., Winston Salem, North Carolina, United States|The Clinical Trials Center, Jenkintown, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Innovative Clinical Trials, San Antonio, Texas, United States|IPC Research, Waukesha, Wisconsin, United States|St. Joseph's Hospital, St. John, New Brunswick, Canada|Toronto Memory Program, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00663936"
132,"NCT03821857","Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: 18-F-Flortaucipir","18F-Flortaucipir PET imaging|Pittsburgh compound-B PET imaging","Mayo Clinic","Female","55 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-008476","August 2019","March 2023","May 2023","January 30, 2019",,"August 29, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03821857"
133,"NCT04118764","Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound",,"Not yet recruiting","No Results Available","Alzheimer Disease","Device: Neuronavigation-guided single-element focused ultrasound transducer|Drug: Definity|Other: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|Other: Positron Emission Tomography (PET)|Other: Amyvid","Total Number of Individuals with Successful Opening of the BBB|Total number of Safety Events Related to Opening of BBB|Percent Change in Amyloid PET Signal Intensity|Change in Mini-Mental State Examination (MMSE) Score","Elisa Konofagou|National Institute on Aging (NIA)|Columbia University","All","50 Years and older   (Adult, Older Adult)","Not Applicable","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","AAAS5163|R01AG038961","October 2019","July 2020","July 2020","October 8, 2019",,"October 8, 2019",,,"https://ClinicalTrials.gov/show/NCT04118764"
134,"NCT01380288","Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine","CAREER","Completed","No Results Available","Alzheimer's Disease","Drug: rivastigmine patch","The changes of cognitive function as measured by ADAS-Cog|MMSE (Mini-Mental State Examination)|Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)|Caregiver burden scale|Adverse events","Dong-A University|Novartis Korea Ltd.","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","300","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","neuropark","June 2011","December 2016","December 31, 2017","June 27, 2011",,"February 5, 2018","Holy Family Hospital, The Catholic Univerisy of Korea, School of Medicine, Bucheon, Korea, Republic of|Busan National University Hospital, Busan, Korea, Republic of|Busan Paik Hospital, Inje University College of Medicine, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Daegu Fatima Hospital, Daegu, Korea, Republic of|Keimyung University School of Medicine, Daegu, Korea, Republic of|Kyungpook National University School of Medicine, Daegu, Korea, Republic of|Myongji Hospital, Kwandong University College of Medicine, Goyang, Korea, Republic of|Dongguk University International Hospital, Ilsan, Korea, Republic of|National Health Insurance Corporation Ilsan Hospital, Ilsan, Korea, Republic of|Inha University College of Medicine, Incheon, Korea, Republic of|Gyeongsang National University College of Medicine, Jinju, Korea, Republic of|Chonnam National University, Medical School, Kwangju, Korea, Republic of|Seoul National Unviersity College of Medicine, Clinical neuroscience center, Seoul National Unviersity Bundang Hospital, Seongnam, Korea, Republic of|The Catholic Univerisy of Korea, School of Medicine, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01380288"
135,"NCT03712787","An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)",,"Enrolling by invitation","No Results Available","Alzheimer's Disease","Drug: ABBV-8E12","Adverse Events","AbbVie","All","57 Years to 87 Years   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-570|2018-000268-26","March 22, 2019","October 8, 2026","October 8, 2026","October 19, 2018",,"April 16, 2019","Banner University MC Phoenix /ID# 203959, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 204012, Sun City, Arizona, United States|Irvine Clinical Research /ID# 204000, Irvine, California, United States|University of California, San /ID# 204011, San Francisco, California, United States|Brain Matters Research /ID# 203957, Delray Beach, Florida, United States|Southwest Florida Neuropsych /ID# 203956, Fort Myers, Florida, United States|Mayo Clinic /ID# 203995, Jacksonville, Florida, United States|Bioclinica Research /ID# 203992, Orlando, Florida, United States|University of South Florida /ID# 204009, Tampa, Florida, United States|Bioclinica Reseach /ID# 204010, The Villages, Florida, United States|Emory University /ID# 203999, Atlanta, Georgia, United States|Atlanta Center for Medical Res /ID# 204006, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 204004, Decatur, Georgia, United States|Advocate Lutheran General Hosp /ID# 203993, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 203952, Springfield, Illinois, United States|Indiana University /ID# 203989, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 203960, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 203996, Lexington, Kentucky, United States|Massachusetts General Hospital /ID# 203954, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 204003, Boston, Massachusetts, United States|Princeton Medical Institute /ID# 203953, Princeton, New Jersey, United States|North Shore University Hospital /ID# 203994, New Hyde Park, New York, United States|Duke Univ Med Ctr /ID# 203958, Durham, North Carolina, United States|Oregon Health and Science University /ID# 203997, Portland, Oregon, United States|Rhode Island Hospital /ID# 204005, Providence, Rhode Island, United States|Vanderbilt University Med Ctr /ID# 203951, Nashville, Tennessee, United States|Kerwin Research Center /ID# 203998, Dallas, Texas, United States|Houston Methodist Hospital /ID# 204002, Houston, Texas, United States|University of Utah /ID# 203991, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 203990, Alexandria, Virginia, United States|St Vincent's Centre for Applied Medical Research, Translational Research Centre /ID# 204903, Darlinghurst, New South Wales, Australia|Griffith University /ID# 204905, Southport, Queensland, Australia|Austin Hospital /ID# 204906, Heidelberg, Victoria, Australia|Royal Melbourne Hospital /ID# 208079, Parkville, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 204904, Nedlands, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 204963, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 204965, Leuven, Belgium|Centre Hospitalier Universitaire du Sart Tilman (CHU de Liège) /ID# 204964, Liège, Belgium|University of British Columbia /ID# 204122, Vancouver, British Columbia, Canada|Parkwood Institute /ID# 204121, London, Ontario, Canada|Toronto Memory Program /ID# 204120, Toronto, Ontario, Canada|Clinical Research Services Turku /ID# 205924, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 204538, Kuopio, Finland|AOU di Modena /ID# 203904, Modena, Emilia-Romagna, Italy|AO Univ Policlinico Agostino G /ID# 203906, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 203901, Milano, Lombardia, Italy|IRCCS - San Giovanni di /ID# 203903, Brescia, Italy|Fondazione IRCCS Cà Granda Osp /ID# 203902, Milan, Italy|Azienda Ospedaliera di Perugia /ID# 203905, Perugia, Italy|Princess Margaret Hospital /ID# 204907, Christchurch, New Zealand|Fundacion CITA Alzheimer /ID# 204521, Donostia, Pais Vasco, Spain|Hospital Clinic de Barcelona /ID# 204519, Barcelona, Spain|Fundacio ACE /ID# 204520, Barcelona, Spain|Hospital Universitario Doce de /ID# 204518, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03712787"
136,"NCT02080364","Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease","STEADFAST","Terminated","No Results Available","Alzheimer's Disease","Drug: Azeliragon|Drug: Placebo","Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) total score|Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures|Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan|Change from Baseline in Neuropsychiatric Inventory (NPI)|Change from Baseline in Mini-Mental State Examination (MMSE)|Change from Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)|Change from Baseline in Continuous Oral Word Association Task (COWAT)|Change from Baseline in Category Fluency Test (CFT)|Change from Baseline in Resource Utilization in Dementia (RUD)|Change from Baseline in Dementia Quality of Life (DEMQOL)|Change from Baseline in Plasma Amyloid Beta|Proportion of Responders based on ADAS-cog|Proportion of Responders based on CDR-SB|Adverse Events","vTv Therapeutics","All","50 Years and older   (Adult, Older Adult)","Phase 3","880","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TTP488-301","April 2015","June 1, 2018","June 1, 2018","March 6, 2014",,"May 17, 2019","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Fullerton, California, United States|Glendale, California, United States|Imperial, California, United States|Irvine, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Long Beach, California, United States|Orange, California, United States|Riverside, California, United States|San Bernardino, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Chicago, Illinois, United States|Fairway, Kansas, United States|Prairie Village, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Quincy, Massachusetts, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Lake Success, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Media, Pennsylvania, United States|Norristown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Kirkland, Washington, United States|Richland, Washington, United States|Southport, Queensland, Australia|Caulfield, Victoria, Australia|Geelong, Victoria, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|West Perth, Western Australia, Australia|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Kentville, Nova Scotia, Canada|Chatham, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada|Cork, Ireland|Dublin 8, Ireland|Galway, Ireland|Christchurch, Canterbury, New Zealand|Christchurch, Canterbury, New Zealand|Cape Town, South Africa|Cape Town, South Africa|Johannesburg, South Africa|St. George, South Africa|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northampton, United Kingdom|Oxford, United Kingdom|Penarth, United Kingdom|Preston, United Kingdom|Sheffield, United Kingdom|Southhampton, United Kingdom|Swindon, United Kingdom|Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02080364"
137,"NCT02585934","Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study",,"Completed","Has Results","Alzheimer's Disease","Drug: RVT-101|Drug: Placebo","Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24|Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24|The Dependence Scale (DS) Score Change From Baseline to Week 24|Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24|ADAS-Cog-13 Score Change From Baseline to Week 24|Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma","Axovant Sciences Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVT-101-3001","October 2015","September 2017","September 2017","October 26, 2015","December 5, 2018","December 5, 2018","US112, Phoenix, Arizona, United States|US220, Tucson, Arizona, United States|US168, Encino, California, United States|US117, Fullerton, California, United States|US214, Los Angeles, California, United States|US189, Pasadena, California, United States|US096, Rancho Mirage, California, United States|US0195, Santa Ana, California, United States|US016, Simi Valley, California, United States|US106, Temecula, California, United States|US179, Hamden, Connecticut, United States|US171, Norwich, Connecticut, United States|US088, Atlantis, Florida, United States|US007, Brooksville, Florida, United States|US002, Hallandale Beach, Florida, United States|US140, Hialeah, Florida, United States|US216, Miami, Florida, United States|US110, Miami, Florida, United States|US172, North Palm Beach, Florida, United States|US003, Orlando, Florida, United States|US256, Pensacola, Florida, United States|US037, Tampa, Florida, United States|US042, Tampa, Florida, United States|US004, The Villages, Florida, United States|US048, Atlanta, Georgia, United States|US046, Atlanta, Georgia, United States|US217, Columbus, Georgia, United States|US111, Baton Rouge, Louisiana, United States|US095, Shreveport, Louisiana, United States|US116, Newton, Massachusetts, United States|US174, Quincy, Massachusetts, United States|US144, Hattiesburg, Mississippi, United States|US094, Las Vegas, Nevada, United States|US135, Berlin, New Jersey, United States|US197, Lawrenceville, New Jersey, United States|US057, Manchester, New Jersey, United States|US215, Mount Arlington, New Jersey, United States|US209, Toms River, New Jersey, United States|US036, West Long Branch, New Jersey, United States|US001, Albany, New York, United States|US049, Brooklyn, New York, United States|US097, New Hyde Park, New York, United States|US177, New Windsor, New York, United States|US142, New York, New York, United States|US044, New York, New York, United States|US150, Chapel Hill, North Carolina, United States|US185, Charlotte, North Carolina, United States|US113, Beachwood, Ohio, United States|US136, Cincinnati, Ohio, United States|US008, Cincinnati, Ohio, United States|US119, Shaker Heights, Ohio, United States|US134, Portland, Oregon, United States|US169, Media, Pennsylvania, United States|US187, Philadelphia, Pennsylvania, United States|US162, Plains, Pennsylvania, United States|US148, Willow Grove, Pennsylvania, United States|US115, Houston, Texas, United States|US043, San Antonio, Texas, United States|US143, Orem, Utah, United States|US149, Charlottesville, Virginia, United States|US170, Spokane, Washington, United States|AR130, La Plata, Buenos Aires, Argentina|AR041, La Plata, Buenos Aires, Argentina|AR101, Buenos Aires, Argentina|AR060, Buenos Aires, Argentina|AR084, Ciudad Autónoma de Buenos Aire, Argentina|AR027, Ciudad Autónoma de Buenos Aire, Argentina|AR012, Ciudad Autónoma de Buenos Aire, Argentina|AR160, Ciudad Autónoma de Buenos Aire, Argentina|AR040, Ciudad Autónoma de Buenos Aire, Argentina|AR028, Ciudad Autónoma de Buenos Aire, Argentina|AR081, Ciudad Autónoma de Buenos Aire, Argentina|AR035, Ciudad Autónoma de Buenos Aire, Argentina|AR051, Cordoba, Argentina|AR137, Cordoba, Argentina|AR210, Mendoza, Argentina|AR219, Mendoza, Argentina|AR059, Santiago del Estero, Argentina|AU227, Caulfield, Australia|AU079, Chermside, Australia|AU032, Heidelberg West, Australia|AU062, Herston, Australia|AU011, Hornsby, Australia|AU138, West Perth, Australia|BU125, Ruse, Bulgaria|BU131, Sofia, Bulgaria|BU198, Sofia, Bulgaria|BU073, Varna, Bulgaria|CA151, Medicine Hat, Alberta, Canada|CA120, Kamloops, British Columbia, Canada|CA054, Kelowna, British Columbia, Canada|CA188, Kelowna, British Columbia, Canada|CA186, Penticton, British Columbia, Canada|CA141, West Vancouver, British Columbia, Canada|CA147, Newmarket, Ontario, Canada|CA196, North York, Ontario, Canada|CA237, Toronto, Ontario, Canada|CA236, Gatineau, Quebec, Canada|CH212, Antofagasta, II Región, Chile|CH076, Santiago, Region Metropolitana, Chile|CH061, Santiago, Región Metropolitana, Chile|CH075, Santiago, Región Metropolitana, Chile|CR069, Zagreb, Croatia|CR122, Zagreb, Croatia|CR068, Zagreb, Croatia|CR070, Zagreb, Croatia|CR083, Zagreb, Croatia|CZ128, Praha 10, Czechia|CZ207, Praha 10, Czechia|CZ132, Praha 2, Czechia|CZ129, Praha 6, Czechia|CZ161, Rychnov nad Kneznou, Czechia|FR231, Lille Cedex, France|FR182, Marseille Cedex 5, France|FR221, Paris Cedex, France|FR202, Villeurbanne, France|GE206, Bad Homburg, Germany|GE091, Berlin, Germany|GE071, Berlin, Germany|GE139, Berlin, Germany|GE230, Cologne, Germany|GE252, Ellwangen, Germany|GE180, Leipzig, Germany|GE228, Mannheim, Germany|GE017, Munchen, Germany|GE157, Nürnberg, Germany|GE098, Ulm, Germany|GE251, Westerstede, Germany|IT053, Brescia, Italy|IT124, Cefalù, Italy|IT030, Pavia, Italy|IT103, Perugia, Italy|IT072, Roma, Italy|IT183, Roma, Italy|IT029, Roma, Italy|IT175, Rome, Italy|IT085, Torino, Italy|SK066, Busan, Korea, Republic of|SK067, Seoul, Korea, Republic of|SK190, Seoul, Korea, Republic of|PO013, Bialystok, Poland|PO024, Bydgoszcz, Poland|PO010, Bydgoszcz, Poland|PO107, Katowice, Poland|PO092, Katowice, Poland|PO023, Krakow, Poland|PO025, Krakow, Poland|PO009, Poznan, Poland|PO014, Szczecin, Poland|PO074, Warszawa, Poland|SE164, Belgrade, Serbia|SE090, Belgrade, Serbia|SE166, Belgrade, Serbia|SE193, Belgrade, Serbia|SE155, Kragujevac, Serbia|SE031, Novi Knezevac, Serbia|SE165, Vrsac, Serbia|SI052, Singapore, Singapore|SI026, Singapore, Singapore|SL056, Banska Bystrica, Slovakia|SL192, Bratislava, Slovakia|SL200, Dubnica nad Váhom, Slovakia|SL191, Kosice, Slovakia|SL078, Krompachy, Slovakia|SL077, Svidnik, Slovakia|SP249, Alicante, Spain|SP176, Barcelona, Spain|SP022, Barcelona, Spain|SP021, Barcelona, Spain|SP250, Barcelona, Spain|SP019, Ceuta, Spain|SP194, Donostia, Spain|SP222, Getxo, Spain|SP018, Madrid, Spain|SP093, Madrid, Spain|SP184, Sant Cugat del Vallès, Spain|SP020, Terrassa, Spain|TA065, Kaohsiung, Taiwan|TA086, Taipei, Taiwan|TA121, Taoyuan, Taiwan|UK063, Bath, United Kingdom|UK038, Blackpool, United Kingdom|UK233, Cambridge, United Kingdom|UK033, Cannock, United Kingdom|UK211, Epping, United Kingdom|UK234, Guildford, United Kingdom|UK055, Leeds, United Kingdom|UK039, London, United Kingdom|UK034, Manchester, United Kingdom|UK229, Norwich, United Kingdom|UK087, Oxford, United Kingdom|UK235, Plymouth, United Kingdom|UK100, Sheffield, United Kingdom|UK064, Southampton, United Kingdom|UK152, Southampton, United Kingdom|UK153, Swindon, United Kingdom|UK154, Warrington, United Kingdom","""Study Protocol: Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/Prot_000.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Addendum Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02585934"
138,"NCT01948791","16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients","INSTINCT","Completed","Has Results","Alzheimer's Disease","Drug: ENA713","Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|Change From Baseline in Mini-Mental State Examination (MMSE)|Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Score|Change From Baseline in Caregiver Burden Inventory (CBI) Score","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","222","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713BCN05","August 2014","September 2015","September 2015","September 24, 2013","February 13, 2017","February 13, 2017","Novartis Investigative Site, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01948791"
139,"NCT02839187","Neuro Imaging and Multimodal Alzheimer's Disease","NIMAD","Completed","No Results Available","Alzheimer Disease","Radiation: Neuroimaging","fixing the AV-45 during PET|Deposition of amyloid protein|Standard Cognitive function|Specific memory evaluation","University Hospital, Toulouse","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","07 306 02","June 2010","May 2012","May 2012","July 20, 2016",,"May 11, 2017","University Hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02839187"
140,"NCT00478205","Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg)","Change From Baseline to Week 24 in SIB Total Score|Overall Change From Baseline in Modified CIBIC+ to Week 24|Change From Baseline to Week 24 in ADCS-ADL Total Score|Change From Baseline to Week 24 in MMSE Total Score","Eisai Inc.|Eisai Limited","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 3","1467","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","E2020-G000-326|2006-004888-54","June 2007","June 2009",,"May 24, 2007","February 5, 2013","July 11, 2014","MedTrials, Inc., Hickory, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00478205"
141,"NCT02377713","A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.",,"Completed","No Results Available","Alzheimer's Disease","Drug: KHK6640|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Kyowa Kirin Co., Ltd.","All","55 Years to 84 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6640-002","March 2015","September 2016","September 2016","March 4, 2015",,"December 7, 2016","Tokyo, Sumida-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02377713"
142,"NCT01554202","Multi-modal Neuroimaging in Alzheimer's Disease","IMAP","Active, not recruiting","No Results Available","Alzheimer's Disease","Behavioral: assessment of memory|Biological: circulating tPA dosage|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations","Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","295","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2007-A00414-49","January 2008","December 2021",,"March 14, 2012",,"March 6, 2013","University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01554202"
143,"NCT02880956","A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: ABBV-8E12|Drug: placebo for ABBV-8E12","Adverse Events|Clinical Dementia Rating - Sum of Boxes (CDR-SB)|University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief)|Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12|Area under the concentration time curve (AUC) for ABBV-8E12|Time to Cmax (Tmax) for ABBV-8E12|Maximum observed serum concentration (Cmax) for ABBV-8E12|Mini-Mental State Examination (MMSE)|24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients with Mild Cognitive Impairment (ADCS-MCI-ADL-24)|Functional Activities Questionnaire (FAQ)|Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI).|Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14)|Neuropsychiatry Inventory (NPI)","AbbVie","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","453","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-566|2016-001634-10","October 17, 2016","April 30, 2021","July 28, 2021","August 26, 2016",,"September 24, 2019","Banner University MC Phoenix /ID# 151536, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 151895, Sun City, Arizona, United States|Irvine Clinical Research /ID# 162331, Irvine, California, United States|Ucsd /Id# 152467, La Jolla, California, United States|Ray Dolby Brain Health Center /ID# 154965, San Francisco, California, United States|Univ California, San Francisco /ID# 152053, San Francisco, California, United States|Brain Matters Research /ID# 147796, Delray Beach, Florida, United States|Southwest Florida Neuropsych /ID# 162332, Fort Myers, Florida, United States|Mayo Clinic /ID# 151236, Jacksonville, Florida, United States|Bioclinica Research /ID# 147804, Orlando, Florida, United States|University of South Florida /ID# 151890, Tampa, Florida, United States|Bioclinica Reseach /ID# 151633, The Villages, Florida, United States|Emory University Hospital /ID# 151492, Atlanta, Georgia, United States|Atlanta Center for Medical Res /ID# 151550, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 152746, Decatur, Georgia, United States|Great Lakes Clinical Trials /ID# 152754, Chicago, Illinois, United States|Advocate Lutheran General Hosp /ID# 152052, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 151769, Springfield, Illinois, United States|Indiana University /ID# 151861, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 152753, Lexington, Kentucky, United States|Johns Hopkins Bayview Med Cnt /ID# 151893, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 151770, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 151882, Boston, Massachusetts, United States|Hattiesburg Clinic /ID# 202388, Hattiesburg, Mississippi, United States|Princeton Medical Institute /ID# 152934, Princeton, New Jersey, United States|Scott Research Inc. /ID# 151880, Laurelton, New York, United States|North Shore University Hospital /ID# 151632, New Hyde Park, New York, United States|Duke University Medical Center /ID# 147828, Durham, North Carolina, United States|Oregon Health and Science University /ID# 151690, Portland, Oregon, United States|Keystone Clinical Studies LLC /ID# 202305, Norristown, Pennsylvania, United States|Rhode Island Hospital /ID# 151538, Providence, Rhode Island, United States|Vanderbilt Univ Med Ctr /ID# 154547, Nashville, Tennessee, United States|Kerwin Research Center /ID# 147815, Dallas, Texas, United States|Houston Methodist Hospital /ID# 154810, Houston, Texas, United States|McGovern Medical School /ID# 204860, Houston, Texas, United States|University of Utah /ID# 151858, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 154863, Alexandria, Virginia, United States|St. Vincent's Hospital, Darlinghurst /ID# 152632, Darlinghurst, New South Wales, Australia|Griffith University /ID# 152635, Southport, Queensland, Australia|Austin Hospital /ID# 152637, Heidelberg, Victoria, Australia|Royal Melbourne Hospital /ID# 202633, Parkville, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 152634, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Re /ID# 152826, West Perth, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 152847, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 152642, Leuven, Belgium|CHC Liege /ID# 152846, Liege, Belgium|Parkwood Institute /ID# 164204, London, Ontario, Canada|Toronto Memory Program /ID# 147863, Toronto, Ontario, Canada|Rigshospitalet, Memory Clinic /ID# 153192, Copenhagen Ø, Hovedstaden, Denmark|Clinical Research Services Turku /ID# 152845, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 152959, Kuopio, Finland|AOU di Modena /ID# 152394, Modena, Emilia-Romagna, Italy|AO Univ Policlinico Agostino G /ID# 152396, Rome, Lazio, Italy|AOU Policlinico Umberto I /ID# 163144, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 152391, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 152401, Milan, Lombardia, Italy|IRCCS - San Giovanni di /ID# 152395, Brescia, Italy|Azienda Ospedaliera di Perugia /ID# 152397, Perugia, Italy|National Hospital Organization Omuta Hospital /ID# 210478, Omuta-shi, Fukuoka, Japan|Hyogo Brain and Heart Center /ID# 209526, Himeji-shi, Hyogo, Japan|Shonan Kamakura General Hospital /ID# 210021, Kamakura-shi, Kanagawa, Japan|Rakuwakai Otowarehabilitation Hospital /ID# 209330, Kyoto-shi, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center /ID# 209289, Matsumoto-shi, Nagano, Japan|Osaka Saiseikai Nakatsu Hospital /ID# 209960, Osaka-shi, Osaka, Japan|MI Clinic /ID# 210134, Toyonaka-shi, Osaka, Japan|Shizuoka Institute of Epilepsy and Neurological Disorders /ID# 209208, Shizuoka-shi, Shizuoka, Japan|National Center of Neurology and Psychiatry /ID# 209179, Kodaira, Tokyo, Japan|Yamagata Tokushukai Hospital /ID# 209868, Yamagata-shi, Yamagata, Japan|Universitair Medisch Centrum Utrecht /ID# 163576, Utrecht, Netherlands|CGM Research Trust /ID# 152827, Burwood Christchurch, New Zealand|Fundacion CITA Alzheimer /ID# 152645, Donostia, Pais Vasco, Spain|Hospital Clinic de Barcelona /ID# 152646, Barcelona, Spain|Fundacio ACE /ID# 152643, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 153703, Madrid, Spain|Hospital Universitario Doce de /ID# 152647, Madrid, Spain|Sahlgrenska US Mölndal /ID# 154465, Mölndal, Vastra Gotalands Lan, Sweden|Karolinska University Hospital /ID# 156705, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT02880956"
144,"NCT01841125","Escitalopram for the Treatment of Depression in Alzheimer's Disease","Escitalopram","Completed","No Results Available","Alzheimer's Disease","Drug: escitalopram|Drug: Placebo","Change in CSDD(Cornell scale for depression in dementia) from baseline after 12 weeks of between treatment groups|Change from baseline in CSDD(Cornell scale for depression in dementia) at week 4, 8, 16 and 24.|Change from baseline in K-MMSE at week 12 and 24.|Change from baseline in ADAS-Cog at week 12 and 24.|Change from baseline in NPIQ at week 12 and 24.|Change from baseline in S-IADL at week 12 and 24.|Change from baseline in GDS-15 at week 4, 8, 12, 16 and 24.|Change from baseline in CDR at week 12 and 24.|Change from baseline in CDR sum of box at week 12 and 24.|Change from baseline in Pittsburgh Sleep Quality Index at week 12 and 24.","Konkuk University Medical Center","All","50 Years and older   (Adult, Older Adult)","Phase 4","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ADD_E_2010","November 2011","July 2014","July 2014","April 26, 2013",,"August 13, 2014","MedicalExcellence, Seoul, Secho-gu banpo-dong, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01841125"
145,"NCT03605667","Study of BHV-4157 in Alzheimer's Disease","T2 Protect AD","Recruiting","No Results Available","Alzheimer Disease","Drug: troriluzole|Drug: Placebo oral capsule","The change in Alzheimers Disease Assessment Scale Cognitive Subscale (ADAS-Cog 11) from baseline to week 48 between the BHV-4157 treatment group and the placebo group","Biohaven Pharmaceuticals, Inc.|Alzheimer's Disease Cooperative Study (ADCS)","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","292","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHV4157-203","July 31, 2018","December 5, 2020","December 20, 2020","July 30, 2018",,"October 11, 2019","Xenoscience, Inc., Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|SC3 Research Group - Pasadena, Pasadena, California, United States|Geriatric and Adult Psychiatry, Hamden, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Ki Health PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH, Stamford, Connecticut, United States|Brain Matters Research, Delray Beach, Florida, United States|University of Miami, Miami, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Northern Light Acadia Hospital, Bangor, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Galen Research, Chesterfield, Missouri, United States|Cleveland Clinic Lou Ruvo Center, Las Vegas, Nevada, United States|Princeton Medical Institute, Princeton, New Jersey, United States|James J. Peters VAMC, Bronx, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Department of Geriatrics, Syracuse, New York, United States|Case Western Reserve University, Beachwood, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Geisinger Medical Clinic, Wilkes-Barre, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|CBRI, Roper Hospital, Charleston, South Carolina, United States|Vanderbilt Memory & Alzheimer's Center, Nashville, Tennessee, United States|The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases,University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03605667"
146,"NCT01529619","Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal patch","Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J cog)|Adverse Events, Serious Adverse Events, Adverse event leading to discontinuation of study drug|Change From Baseline in Disability Assessment for Dementia (DAD)|Change From Baseline in Mini-Mental State Examination (MMSE)|Change From Baseline in Japanese version of the Clinical global impression of change (J-CGIC)|Change From Baseline in Modified Crichton Scale|Formulation usability questionnaire","Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713D1403","March 2012","December 2013","December 2013","February 9, 2012",,"November 18, 2016","Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Miyoshi-city, Hiroshima, Japan|Novartis Investigative Site, Ohtake, Hiroshima, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Kamakura-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Koshi-city, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT01529619"
147,"NCT03887455","A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease","Clarity AD","Recruiting","No Results Available","Early Alzheimer's Disease","Drug: BAN2401|Drug: Placebo","Core Study: Change from Baseline in the CDR-SB at 18 Months|Extension Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs)|Extension Phase: Change from Core Study Baseline in CDR-SB|Core Study: Change from Baseline in the Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR) Composite at 18 Months|Core Study: Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 18 Months|Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale 14 (ADAS-cog14) at 18 Months","Eisai Inc.|Biogen","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","1566","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BAN2401-G000-301|2018-004739-58","March 27, 2019","February 24, 2022","March 7, 2024","March 25, 2019",,"July 12, 2019","Neurological Associates of Tucson dba Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|UCSF Memory and Aging Center, San Francisco, California, United States|North Bay Neuroscience Research Institute, Sebastopol, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Advanced Clinical Research Network, Coral Gables, Florida, United States|Neuropsychiatric Research Center of Southwest FL, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Galiz Research, Miami Springs, Florida, United States|BioMed Research Institute, Miami, Florida, United States|Vitae Research Center, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Allied Biomedical Research (Clinical Trial), Miami, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Quantum Laboratories Inc., Pompano Beach, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|Columbus Memory Center, Columbus, Georgia, United States|Waypoint Research, LLC, Decatur, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S. Marks, MD. P.C., Plymouth, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|New York University Medical Center PRIME, New York, New York, United States|University of Rochester, Rochester, New York, United States|ANI Neurology, PLLC d/b/a Alzheimer's Memory Center, Charlotte, North Carolina, United States|Insight Clinical Trials, LLC, Beachwood, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Summit Research Network (OR) Inc., Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital - Memory and Aging Program, Providence, Rhode Island, United States|Coastal Neurology, P.A., Port Royal, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Alliance for Multispecialty Research LLC, New Orleans Center for Clinical Research / Volunteer Research Group, an AMR company, Knoxville, Tennessee, United States|Senior Adult Specialty Research, Austin, Texas, United States|Baylor College of Medicine AD and Memory Disorders Center, Houston, Texas, United States|DBA The Memory Clinic, Bennington, Vermont, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Kingfisher Cooperative LLC, Spokane, Washington, United States|Okanagan Clinical Trials, Kelowna, Columbia, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais, Gatineau, Quebec, Canada|MoCA Clinic and Institute/NeuroSearch Developpements Inc., Greenfield Park, Quebec, Canada|Hôpital de Hautepierre, Strasbourg Cedex, Bas Rhin, France|Hopital de la Timone, Marseille, Cedex 05, France|Hôpital Gui de Chauliac, Montpellier, Cedex 5, France|Hopital Guillaume et RenÃ LaÃnnec, Nantes, Cedex, France|Groupe Hospitalier Pitie-Salpetriere, Paris, Cedex, France|Centre de Recherche Clinique du Gérontopôle, Toulouse, Haute Garonne, France|Hôpital neurologique Pierre Wertheimer, Toulouse, Haute Garonne, France|Hôpital Lariboisière, Paris cedex 10, Paris, France|Eisai Trial Site #5, Günzburg, Baden Wuerttemberg, Germany|Eisai Trial Site #2, Mannheim, Baden-Wurttemberg, Germany|Eisai Trial Site #1, Bielefeld, Germany|Eisai Trial Site #4, Erbach, Germany|Eisai Trial Site #3, Munchen, Germany|Ospedale ""Card. G. Panico"" -, Tricase, LE, Italy|Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genova, Genova, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - U.O.S.D. Malattie Neurodegenerative, Milano, Italy|ASST-Monza, Ospedale San Gerardo, Monza, Italy|Prima Clinica Neurologica, Primo Policlinico AOU ""L. Vanvitelli"", Napoli, Italy|Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Universita` Sapienza di Roma - Dipartimento di Neuroscienze Umane, Roma, Italy|Eisai Trial Site #4, Obu-shi, Aichi, Japan|Eisai Trial Site #15, Chiba-shi, Chiba, Japan|Eisai Trial Site #6, Yoshida-gun, Fukui, Japan|Eisai Trial Site #1, Fujioka-shi, Gunma, Japan|Eisai Trial Site #32, Otake, Hiroshima, Japan|Eisai Trial Site #30, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site #28, Himeji-shi, Hyogo, Japan|Eisai Trial Site #19, Kobe-shi, Hyogo, Japan|Eisai Trial Site #24, Toride-shi, Ibaraki, Japan|Eisai Trial Site #9, Kahoku, Ishikawa, Japan|Eisai Trial Site #7, Atsugi-shi, Kanagawa, Japan|Eisai Trial Site #17, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site #20, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site #2, Yokohama-shi, Kanagawa, Japan|Keimei Memorial Hospital, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site #22, Niigata-shi, Niigata, Japan|Eisai Trial Site #16, Kurashiki-shi, Okayama, Japan|Eisai Trial Site #8, Hirakata, Osaka, Japan|Eisai Trial Site #26, Suita-shi, Osaka, Japan|Eisai Trial Site #18, Saitama-shi, Saitama, Japan|Eisai Trial Site #31, Otsu-shi, Shiga, Japan|Eisai Trial Site #5, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site #29, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site #13, Hachioji-shi, Tokyo, Japan|Eisai Trial Site #12, Musashino-shi, Tokyo, Japan|Eisai Trial Site #23, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site #25, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site #10, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site #3, Yamagata-shi, Yamagata, Japan|Eisai Trial Site #21, Hofu, Yamaguchi, Japan|Eisai Trial Site #14, Ube-shi, Yamaguchi, Japan|Eisai Trial Site #11, Osaka, Japan|Eisai Trial Site #27, Osaka, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Centro CAE Oroitu, Getxo, Bizkaia, Spain|Fundación CITA-alzheimer Findazioa, Donostia San Sebastian, Gipuzkoa, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Fundacion ACE, Barcelona, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|Centro de Salud La Alamedilla, Salamanca, Spain|Hospital Victoria Eugenia - Cruz Roja, Sevilla, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Gothenburg, Västra Götalandslän, Sweden|Memory Clinic, Malmö University Hospital, Malmö, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Uppsala, Sweden|Re:Cognition Health, Plymouth, Devon, United Kingdom|Memory Assessment & Research Centre (MARC),, Southampton, Hampshire, United Kingdom|MAC Clinical Research Blackpool, Blackpool, Lancashire, United Kingdom|Sheffield Memory Service, Sheffield, South Yorkshire, United Kingdom|Re:Cognition Health Ltd, Birmingham, United Kingdom|Re:Cognition Health Ltd, Guildford, United Kingdom|Re:Cognition Health Ltd, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03887455"
148,"NCT01560585","Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Isotretinoin","Change from Baseline to Six month timepoint in the score on the Alzheimer's disease Assessment Scale- Cognitive subscale|Number and types of adverse effects","University Hospitals Cleveland Medical Center","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISOTRT-01","April 2012","August 2014","August 2014","March 22, 2012",,"August 28, 2014","Parkway Medical Building, Beachwood, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01560585"
149,"NCT04088643","4Hz Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Device: transcranial alternating current stimulation|Device: sham stimulation","Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version)|Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).|Change in brain volume and white matter integrity|Change in brain connectivity|Change in Mini-mental State Examination|Change in Montreal Cognitive Assessment|Change in Clinical Dementia Rating Scale sum of the boxes|Change in memory function|Change in Digit span forward|Change in Digit span backward|Change in Trail Making Test|Change in Boston Naming Test|Change in Neuropsychiatric Inventory (NPI)|Change in Geriatric Depression Scale (GDS)|Change in Activities of Daily Living|Side-effects of tACS","Xuanwu Hospital, Beijing","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018077","October 2019","October 2021","December 2021","September 13, 2019",,"September 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04088643"
150,"NCT03823404","GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: COR388 capsule|Drug: Placebo capsule","Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)|ADCS-ADL|CDR-SB","Cortexyme Inc.","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","573","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COR388-010","March 28, 2019","December 31, 2021","December 31, 2022","January 30, 2019",,"September 25, 2019","Xenoscience, Inc., Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Alliance Research, Long Beach, California, United States|CITRIALS, Riverside, California, United States|CITRIALS, Santa Ana, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Southern California Research LLC, Simi Valley, California, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|Qtrials, Inc., Miami, Florida, United States|Future Care Solutions, LLC, Miami, Florida, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Sensible Healthcare LLC, Ocoee, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Brain Matters Research at the Kane Center, Stuart, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Columus Memory Center, Columbus, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Alexian Brothers Neurosciences Research, Elk Grove Village, Illinois, United States|Activmed Practices and Research, Methuen, Massachusetts, United States|The Boston Center for Memory, Newton, Massachusetts, United States|Anil Nair MD, Alzheimer's Disease Center, Quincy, Massachusetts, United States|Memory Center, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Princeton Medical Institute, Princeton, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Disease Research & Neurology Center of Neurological Associates of Albany, Albany, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Spri Clinicaltrials, Llc, Brooklyn, New York, United States|Mid Hudson Medical Research, New Windsor, New York, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Insight Clinical Trials, LLC, Beachwood, Ohio, United States|Neurology Diagnostics Inc., Dayton, Ohio, United States|Memory Health Center at Summit Research Network, Portland, Oregon, United States|Northeastern Pennsylvania Memory and Alzheimer's Center, Plains, Pennsylvania, United States|Kerwin Research Center, Dallas, Texas, United States|Neurology Consultants of Dallas, Dallas, Texas, United States|Clinical Trial Network, Houston, Texas, United States|University of Virginia Adult Neurology, Charlottesville, Virginia, United States|Recognition Health, Fairfax, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Indywidualna Specjalistyczna Praktyka Lekarska, Gdańsk, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Centrum Medyczne Plejady, Kraków, Poland|Krakowska Akademia Neurologii, Kraków, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|NZOZ Wrocławskie Centrum Alzheimerowskie, Wrocław, Poland",,"https://ClinicalTrials.gov/show/NCT03823404"
151,"NCT03790709","ANAVEX2-73 for Treatment of Early Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: High dose ANAVEX2-73|Drug: Mid dose ANAVEX2-73|Drug: Placebo oral capsule","ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)|ADCS-ADL (Activities of Daily Living)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|CDR-SB (Clinical Dementia Rating Scale Sum of Boxes)|RSCAQ sleep score","Anavex Life Sciences Corp.|Anavex Australia Pty Ltd.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","450","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANAVEX2-73-AD-004","July 3, 2018","December 31, 2020","March 31, 2021","January 1, 2019",,"August 6, 2019","Central Coast Neurosciences Research, Central Coast, New South Wales, Australia|Hornsby (Northern Sydney Health), Hornsby, New South Wales, Australia|KaRa MINDS, Macquarie Park, New South Wales, Australia|St Vincent Hospital Sydney, Sydney, New South Wales, Australia|University of Sydney, Sydney, New South Wales, Australia|Gold Coast Memory Disorders Clinic, Southport, Quennsland, Australia|The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH), Adelaide, South Australia, Australia|Penninsula Therapeutic and Research Group, Frankston, Victoria, Australia|Geelong Private Medical Centre, Geelong, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|Hammond Care, Malvern, Victoria, Australia|Alfred Health, Melbourne, Victoria, Australia|Austin Health, Melbourne, Victoria, Australia|Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital (RMH), Parkville, Victoria, Australia|McCusker, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03790709"
152,"NCT03846232","Detection of Cerebral Proteinopathy in Alzheimer's Disease Through Magnetic Resonance Imaging","T1rho","Recruiting","No Results Available","Alzheimer Disease","Other: No intervention","Detection of abnormal cerebral protein levels","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Hospital Clinic of Barcelona","All","60 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","T1rho/BBRC2017","February 12, 2019","December 31, 2019","December 31, 2020","February 19, 2019",,"February 21, 2019","Barcelonabeta Brain Research Center, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03846232"
153,"NCT03703856","Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Memantine|Drug: Placebo","Change from baseline measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 weeks|Change from baseline measure in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at 8, 16 and 24 weeks","University of California, San Diego","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 4","88","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01AG059640-01","January 31, 2019","August 2023","August 2023","October 12, 2018",,"June 3, 2019","Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03703856"
154,"NCT01850238","Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Biological: AADvac1|Other: Placebo","Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease|Immunogenicity of AADvac1","Axon Neuroscience SE","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AXON CO 18700|2012-003916-29","May 2013","March 2015","March 2015","May 9, 2013",,"October 12, 2015","Medizinische Universitat Graz, Graz, Steiermark, Austria|Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria|Medizinische Universitat Wien, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01850238"
155,"NCT03991624","Lack of Decision-making in Patients With Alzheimer's Disease : Functions Involved and the Daily Consequences","MAPdP","Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: cognitive assessment|Other: Inhibition evaluation|Other: Assessment of mental flexibility|Other: Evaluation of the update|Other: working memory|Other: episodic memory","Score obtained (the number of correct answers) by participants in tasks evaluating decision-making|Score obtained in task evaluating executive functions|Score obtained in task evaluating working memory|Scores obtained in tasks evaluating episodic memory|Scores obtained from the quality of life questionnaire.|Scores obtained from autonomy questionnaire.","Centre Hospitalier Universitaire de Saint Etienne","All","60 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","18CH237|2019-A00174-53","September 27, 2019","March 2021","April 2021","June 19, 2019",,"October 1, 2019","Laboratoire d'Etude des Mécanismes Cognitifs, Bron, France|CHU de Saint Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT03991624"
156,"NCT03325205","MR Guided tDCS in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Other: Anodal tDCS|Other: Sham tDCS","Performance on Neuropsychological tests|Hippocampal volume","University of Tromso|Helse Nord","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017/794 (REK)","August 22, 2017","June 30, 2019","December 30, 2020","October 30, 2017",,"October 30, 2017","Department of Psychology, University of Northern Norway, Tromsø, Norway",,"https://ClinicalTrials.gov/show/NCT03325205"
157,"NCT03923569","Epileptiform Activity During REM Sleep in Alzheimer's Disease","EREMAD","Not yet recruiting","No Results Available","Alzheimer Disease, Early Onset","Diagnostic Test: Overnight polysomnography|Diagnostic Test: blood sample|Diagnostic Test: high-resolution MRI scan|Behavioral: neuropsychological evaluation","Epileptiform activity during REM sleep|Number of epileptiform activity according to sleep-wake cycle|Frequency of epileptiform activity according to sleep-wake cycle|lateralization of epileptiform activity according to sleep-wake cycle|localization of epileptiform activity according to sleep-wake cycle|Comparison of sleep characterization between the two groups: total sleep time|Comparison of sleep characterization between the two groups: number of sleep cycles|Comparison of sleep characterization between the two groups: time spent awake during the night|Comparison of sleep characterization between the two groups: index of micro-awakenings|Comparison of sleep characterization between the two groups: distribution of different sleep stages in time|Comparison of sleep characterization between the two groups: distribution of different sleep stages in percentage|Comparison of sleep characterization between the two groups: index of periodic movements|Comparison of sleep characterization between the two groups: index of hypopnea|Comparison of memory scores at the overnight retention test between the two groups","University Hospital, Toulouse|Centre de Recherches sur la Cognition Animale (CRCA – UMR5169 CNRS/UPS)|Centre de Recherche Cerveau & Cognition (CerCo – UMR5549 CNRS/UPS)|Toulouse NeuroImaging Center (ToNIC – UMR 1214 Inserm/UPS)|Fondation Plan Alzheimer|IHNPS/FHU HoPeS","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/18/0265|2018-A02229-46","April 2019","April 2022","April 2022","April 22, 2019",,"April 22, 2019","Toulouse University Hospital, Toulouse, Occitanie, France",,"https://ClinicalTrials.gov/show/NCT03923569"
158,"NCT03748706","PTI-125 for Mild-to-moderate Alzheimer's Disease Patients",,"Completed","No Results Available","Alzheimer Disease","Drug: PTI-125, 100 mg tablets","Maximum Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax)|Last Quantifiable Plasma Concentration (Clast)|Time to Last Quantifiable Plasma Concentration (Tlast)|Area Under the Curve (AUC)|Minimum Plasma Concentration (Cmin)|PTI-125DX (biomarker)|Biomarker assay","Pain Therapeutics|National Institute on Aging (NIA)|Cassava Sciences, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","12","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTI-125-03|R44AG060878","March 7, 2019","May 8, 2019","May 8, 2019","November 21, 2018",,"September 6, 2019","Insite Clinical Research, DeSoto, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03748706"
159,"NCT01054976","The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Galantamine","Change From Baseline in Simple Reaction Time|Change From Baseline in Choice Reaction Time|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Change From Baseline in Korean Version of Disability Assessment for Demential Scale (DAD-K)|Change From Baseline in Seoul-Instrumental Activities of Daily Livings (S-IADL)","Janssen Korea, Ltd., Korea","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","99","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015850|GAL-KOR-21|GALALZ4039","October 2006","February 2009","February 2009","January 22, 2010","December 24, 2012","December 24, 2012",,,"https://ClinicalTrials.gov/show/NCT01054976"
160,"NCT00973518","Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)",,"Completed","No Results Available","Alzheimer's Disease",,"Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects|Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects|Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test)|Identification and characterization of Orasi SNI test features that correlate with AD medications being taken by AD subjects|Identification, characterization and comparison of scan results generated by MEG and EEG","Orasi Medical, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)",,"160","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADD 09-02","September 2009","June 2010","June 2010","September 9, 2009",,"August 13, 2010","Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00973518"
161,"NCT03342326","Lexical Priming by Music in Alzheimer's Disease and Healthy Aging","PriMus","Recruiting","No Results Available","Alzheimer Disease","Other: Exposure to familiar songs|Other: Music Experience Questionnaire|Other: Implicit tasks memory|Other: Questionnaires","Reaction time difference for the treatment of words that have been presented in sing condition in the exposure phase versus words presented in spoken condition.|Reaction time difference for processing words associated with songs presented by their melody alone versus new words (not presented in the exhibition phase).","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1708117|2017-A02686-47","April 3, 2018","February 2020","February 2020","November 14, 2017",,"February 12, 2019","CHU de Saint Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT03342326"
162,"NCT02327182","Safety Study of MT-4666 in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: MT-4666","Safety of 2 fixed doses of EVP-6124 in subjects with Alzheimer's disease. Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, Columbia Suicide Severity Rating Scale (C-SSRS)|Change in Mini Mental State Examination (MMSE)|Change in Neuropsychiatric Inventory (NPI) total score","Mitsubishi Tanabe Pharma Corporation","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","117","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P211-05","December 2014","September 2015","October 2015","December 30, 2014",,"November 13, 2015","Investigational site, Osaka, Kansai, Japan",,"https://ClinicalTrials.gov/show/NCT02327182"
163,"NCT01189084","Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: Observational","Immunogenicity|Efficacy","United Biomedical|Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital","All","50 Years to 80 Years   (Adult, Older Adult)",,"14","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UBI Protocol V118-obs","April 2010",,"July 2011","August 26, 2010",,"July 13, 2011","National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01189084"
164,"NCT02129452","Olfactory Neuroepithelial Tissue of Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease",,"Pathological evidence of Alzheimer disease in the olfactory neuroepithelium","Seoul National University Hospital","All","18 Years to 85 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","1301056458","January 2013","December 2014","February 2015","May 2, 2014",,"May 27, 2015","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02129452"
165,"NCT00523666","Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Galantamine (Reminyl®)|Drug: Placebo/Galantamine (Reminyl®)",,"Ludwig-Maximilians - University of Munich","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DTI001|EudraCT 2005-003762-41","September 2006",,"September 2008","August 31, 2007",,"August 31, 2007","Ludwig-Maximilian University of Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00523666"
166,"NCT00645190","A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Galantamine HBr","Primary endpoint (ADAS-cog/11) decreased 5.4 ± 6.4 and 4 .0 ± 7.3 in galantamine and Donepezil group respectively after 16-week treatment from baseline of 22.5 ± 9.3 and 23.3 ± 9.7 respectively, showing the non-inferiority in term of efficacy.|Secondary endpoint is responder rate. It showed 78% responder rate in galantamine group and 58% responder rate in Donepezil group after 16 weeks.","Xian-Janssen Pharmaceutical Ltd.","All","40 Years and older   (Adult, Older Adult)","Phase 3","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR005803","March 2004",,"February 2005","March 27, 2008",,"May 19, 2011",,,"https://ClinicalTrials.gov/show/NCT00645190"
167,"NCT00377715","Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Dimebon|Drug: Placebo","Alzheimer's Disease Assessment Scale - cognitive subscale|Clinical Global Impression of Change|Safety Assessed By Number of Participants With Adverse Events|Pharmacokinetic (PK) parameter of Dimebon: Cmax","Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DIM02","September 2005","August 2006",,"September 18, 2006",,"November 11, 2015","Mental Health Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00377715"
168,"NCT02912169","Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Procedure: Liposuction under local anesthesia|Biological: Infusion of AD-SVF via IV and Intranasal","Clinical Improvement in Mini Mental State Examination (MMSE)|Adverse Event|Clinical Improvement in Functional Activities Questionnaire (FAQ)|Clinical Improvement in Activities of Daily Living Questionnaire (ADL)|Clinical Improvement in Geriatric Depression Scale (GDS)","Ageless Regenerative Institute","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AD-US-ALZ-001","November 1, 2015","November 15, 2017","November 15, 2017","September 23, 2016",,"November 24, 2017","Ageless Regenerative Institute LLC, Aventura, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02912169"
169,"NCT03539380","TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease",,"Available","No Results Available","Alzheimer Disease","Drug: TRx0237",,"TauRx Therapeutics Ltd","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"TRx-237-040",,,,"May 28, 2018",,"September 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03539380"
170,"NCT00423085","Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine transdermal patch|Drug: Placebo","Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)|Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)|Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)|Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)|Change From Baseline in Mini-Mental State Examination (MMSE)|Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)|Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)|Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale","Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","859","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CENA713D1301|CENA713D1301E1","January 2007","March 2009","April 2010","January 17, 2007","May 25, 2011","February 10, 2014","Novartis Investigative Site, Hokkaido region, Hokkaido, Japan",,"https://ClinicalTrials.gov/show/NCT00423085"
171,"NCT00100282","Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PPI-1019 (APAN)","Clinical (adverse events, vital signs, ECG) and laboratory (chemistry, hematology) parameters|Single dose pharmacokinetic parameters","PRAECIS Pharmaceuticals Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1019-03-01","May 2003",,"June 2005","December 28, 2004",,"September 19, 2006","Department of Psychiatry & Human Behavior at the University California, Irvine, Orange, California, United States|Global Medical Institutes LLC, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00100282"
172,"NCT02884492","Imaging Tau in Alzheimer's Disease and Normal Aging",,"Terminated","Has Results","Alzheimer's Disease","Drug: 18F-THK-5351|Procedure: Lumbar Puncture (optional)","18F-THK-5351 Standardized Uptake Value Ratio","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","50 Years and older   (Adult, Older Adult)","Phase 2","17","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAQ7868|1K23AG052633-01","July 2016","June 30, 2017","June 30, 2017","August 31, 2016","November 19, 2018","November 19, 2018","Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02884492/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02884492"
173,"NCT04057807","Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: LPS","An altered reactivity of microglia|Effects of aging on MARI|Effects of amyloid on MARI|Effects of MARI on cognition","Yale University","All","55 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","1611018611","March 29, 2017","September 2020","September 2021","August 15, 2019",,"August 19, 2019","Alzheimer's Disease Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04057807"
174,"NCT02968875","Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training","MARAE","Completed","No Results Available","Alzheimer's Disease","Device: Endurance Training|Other: therapeutic education meetings","Measuring the effect of a program of endurance training (ET), on the levels of plasma BDNF.|Measuring the effect of training on the psychological performance by using questionnaire MMSE|Measuring the effect of training on the psychological performance by using questionnaire: Rey auditory verbal learning test (RAVLT)|Measuring the effect of training on the psychological performance by using questionnaire: quality of life (QoL-AD)|Stress test|Measuring the effect of training on the physiological performance with a walk test of 6 minutes.","University Hospital Center of Martinique","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15/B/03","July 2015","December 2017","February 2018","November 21, 2016",,"May 28, 2018","CHU de Martinique, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT02968875"
175,"NCT03757325","Study to Evaluate DNL747 in Subjects With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: DNL747|Drug: Placebo","Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Subjects with clinically significant neurological examination abnormalities|Number of Subjects with laboratory test abnormalities|Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL747|Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL747|Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL747|Pharmacokinetic terminal disposition rate constant (λz) with the respective t1/2 of DNL747|Pharmacokinetic measure of CSF concentrations of DNL747|Pharmacodynamic measure of pS166 in PBMCs","Denali Therapeutics Inc.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DNLI-D-0002","February 13, 2019","August 2019","August 2019","November 28, 2018",,"April 25, 2019","QPS Miami Research Associates, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Diana Kerwin Research Center, Dallas, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|QPS, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03757325"
176,"NCT03828747","A Study of RO7105705 in Patients With Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: RO7105705|Drug: Placebo|Drug: [18F]GTP1","Change from baseline to Week 49 in cognitive function as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11)|Change from baseline to Week 49 in functional capacities as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL)|Change from baseline to Week 49 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change from baseline to Week 49 on the Mini-Mental State Examination (MMSE)|Percentage of Participants with Adverse Events|Serum concentration of RO7105705 at specified timepoints|Incidence of anti-drug antibodies (ADAs) during the study relative to the prevalence of ADAs at baseline","Genentech, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GN40040","January 30, 2019","September 24, 2021","September 24, 2021","February 4, 2019",,"October 8, 2019","Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Stanford University; Stanford Clinical Cancer Ctr, Palo Alto, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Molecular Neuroimaging; MRI/PET, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Orlando, Orlando, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Brigham and Womens Hospital; Center for Alzheimer Research & Treatment, Boston, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|Health Partners Center for Memory and Aging, Saint Paul, Minnesota, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Empire Neurology PC; MS Center of Northeastern NY, Latham, New York, United States|University of Rochester; AD-CARE, Rochester, New York, United States|Summit Research Network Inc., Portland, Oregon, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital; Movement Disorders Program, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|The Memory Clinic, Bennington, Vermont, United States|Hopital Neurologique Pierre Wertheimer, Bron, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|Hopital des Charpennes, Villeurbanne, France|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|PRATIA MCM Kraków, Kraków, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznan, Poland|Osrodek Badan Klinicznych Euromedis, Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Centrum Medyczne AMED, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Fundacio ACE, Barcelona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03828747"
177,"NCT03131453","A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","Generation S2","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: CNP520 50mg|Drug: CNP520 15mg|Other: Placebo to CNP520","Time to event|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in cerebral amyloid angiopathy (CAA)|Change on volume of brain regions|Change in amyloid deposition as measured by standardized uptake ratio (SUVR) of positron emission tomography (PET) scan with amyloid radiotracer|Change in CSF levels of Aβ40, Aβ42|Change in CSF levels of total tau and phosphorylated tau|Number of participants with adverse events as a measure of safety|Change in neurofibrillary tangle burden as measured by standardized uptake ratio (SUVR) of PET scans with tau radiotracer (where available)","Novartis Pharmaceuticals|Amgen|Banner Alzheimer's Institute|Novartis","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1145","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCNP520A2202J|2016-002976-28","August 3, 2017","July 30, 2024","March 31, 2025","April 27, 2017",,"October 7, 2019","Banner Alzheimer's Institute, 901 East Willetta Street, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B, Sun City, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|ATP Clinical Research Inc, 3151 Airway Avenue T 3, Costa Mesa, California, United States|Novartis Investigative Site, Garden Grove, California, United States|Irvine Center for Clinical Res, 2515 McCabe Way, Irvine, California, United States|Torrance Clinical Research Institute, 25043 Narbonne Avenue, Lomita, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|Mountain Neurological Research, 350 Market Street, Suite 316, Basalt, Colorado, United States|Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100, Colorado Springs, Colorado, United States|Denver Neurological Clinic, 950 E Harvard Ave, Denver, Colorado, United States|Yale University, One Church Street, Suite 600, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlantis, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., 800 NW 17th Avenue, Delray Beach, Florida, United States|Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102, Lake Worth, Florida, United States|Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States|Novartis Investigative Site, Melbourne, Florida, United States|Novartis Investigative Site, Merritt Island, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|New Horizon Research Center, 11880 SW 40 St., Suite 405, Miami, Florida, United States|Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112, Miami, Florida, United States|Compass Research, LLC,100 West Gore Street, Suite 202, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Palm Beach Gardens, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Roskamp Institute, Inc., 2040 Whitfield Avenue, Sarasota, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Hawaii Pacific Neuroscience, 2230 Liliha st 104, Honolulu, Hawaii, United States|Advanced Clinical Research, 2950 E Magic View Dr, Suite 182, Meridian, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Fairway, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|QUEST Research Institute, 28595 Orchard Lake Road, Suite 301, Farmington Hills, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Hattiesburg Clinic, 415 South 28th Avenue, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209, Albuquerque, New Mexico, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Latham, New York, United States|NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226, New York, New York, United States|Novartis Investigative Site, Orangeburg, New York, United States|Novartis Investigative Site, Rochester, New York, United States|ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408, Tulsa, Oklahoma, United States|Summit Research Network, 2701 NW Vaughn St, Suite 350, Portland, Oregon, United States|OHSU Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|Novartis Investigative Site, Jenkintown, Pennsylvania, United States|Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100, Willow Grove, Pennsylvania, United States|Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave, East Providence, Rhode Island, United States|Butler Hospital, 345 Blackstone Blvd., Providence, Rhode Island, United States|Roper Hospital, 316 Calhoun Street 5th Floor, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Bennington, Vermont, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Cordoba, ARG, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Mar del Plata, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg West, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, 1 Valleybrook Drive Suite 400, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Guang Zhou, China|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Strasbourg, Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, PARIS Cedex 13, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villeurbanne, France|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Tōon, Ehime, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Kodaira, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Suwon, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Hertogenbosch, Netherlands|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Torres Vedras, Portugal|Novartis Investigative Site, Guaynabo, Puerto Rico|Inspira Clinical Research, Ave Hostos 405, San Juan, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Rosebank, Johannesburg, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, ZAF, South Africa|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, New Taipei City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03131453"
178,"NCT03920826","Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease (TRANSFORM-AD)",,"Recruiting","No Results Available","Alzheimer Disease","Device: transcranial alternating current stimulation|Device: sham stimulation","Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).|Change in brain volume and white matter integrity|Change in brain connectivity|Change in amyloid deposit in brain|Change in Mini-mental State Examination|Change in Montreal Cognitive Assessment|Change in Clinical Dementia Rating Scale sum of the boxes|Change in memory function|Change in Digit span forward|Change in Digit span backward|Change in Trail Making Test|Change in Boston Naming Test|Change in Neuropsychiatric Inventory (NPI)|Change in Geriatric Depression Scale (GDS)|Change in Activities of Daily Living|Side-effects of tACS","Xuanwu Hospital, Beijing","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018077-XZ1","September 11, 2019","October 2021","December 2021","April 19, 2019",,"September 16, 2019","Xuanwu Hospital, Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03920826"
179,"NCT03448601","Alzheimer's Disease and Precision Medicine Research With American Indian and Alaska Native People",,"Not yet recruiting","No Results Available","Alzheimer Disease","Other: Non-tailored intervention group|Other: Culturally tailored intervention group","AD-PM Module Completion|Cohort Enrollment Questionnaire|Willingness to Participate in Research Questionnaire|Alzheimer's Disease (AD) Knowledge Scale|Attitudes about Precision Medicine self-report survey|Self-Administered Gerocognitive Exam (SAGE)|Orthogonal Cultural Identification Scale","University of Colorado, Denver|Washington State University|University of Arizona","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","17-1627","August 1, 2019","May 2022","August 31, 2022","February 28, 2018",,"April 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03448601"
180,"NCT00411580","Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Biological: CAD106|Drug: Placebo","Tolerability/safety assessments (physical/neurol.exam., ECG, vital signs, standard and special immunological laboratory evaluations, MRIs, EEGs, AE/SAE monitoring).|Antibody titers (IgM and IgM titers against amyloid and carrier protein).|Immune response, cognitive and functional assessments","Novartis Pharmaceuticals|Novartis","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCAD106A2101","June 2005","December 2008","December 2008","December 14, 2006",,"March 29, 2013","Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00411580"
181,"NCT01227564","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Biological: ACC-001 3 μg/ QS-21 50 μg|Biological: ACC-001 10 μg/ QS-21 50 μg|Other: Placebo- Phosphate buffered saline (PBS)","Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs)","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2571010|3134K1-2208","February 2011","February 2014","February 2014","October 25, 2010","February 25, 2016","February 25, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Banner Lakes Imaging Center, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Southwest PET Institute, Tucson, Arizona, United States|University of Arizona, Health Sciences Center - Department of Neurology, Tucson, Arizona, United States|Universal Medical Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, LLC, Tucson, Arizona, United States|Radiology Limited, Tucson, Arizona, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|GCRC (Drug administered), New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Clinical Research Unit, Washington, District of Columbia, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Georgetown University Medical Center Department of Neurology, Washington, District of Columbia, United States|Meridien Research, Brooksville, Florida, United States|Florida Neurology Group PL, Fort Myers, Florida, United States|Internal Medicine Associates of Lee County, MD, PA, Fort Myers, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Florida Radiology Leasing, Limited Liability Corporation, Fort Myers, Florida, United States|Radiology Regional Center, Fort Myers, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Massachusetts General Hospital (For PET only), Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Steinberg Diagnostic Imaging, Las Vegas, Nevada, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Incorporated, Eatontown, New Jersey, United States|Satatoga PET Associates, Clifton Park, New York, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Baylor College of Medicine, Department of Neurology, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy Inc., Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01227564"
182,"NCT03901105","Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: flortaucipir F18","Assessment of reader visual interpretation of flortaucipir F 18 PET imaging to predict risk of cognitive and functional deterioration within 18 months of scan.|Inter-reader reliability of reader interpretation of flortaucipir F 18 PET imaging.|Assessment of reader visual interpretation of flortaucipir F 18 PET imaging to predict risk of CMD, measured by Mini-Mental State Examination (MMSE).|Assessment of reader visual interpretation of flortaucipir F 18 PET imaging to predict risk of CMD, measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog11).|Assessment of reader visual interpretation of flortaucipir F 18 PET imaging to predict risk of CMD, measured by Pfeffer Functional Activities Questionnaire (FAQ).|Assessment of reader visual interpretation of flortaucipir F 18 PET imaging to predict risk of CMD, measured by CDR Global change.|Assessment of risk ratio between τAD++ and non-τAD++.|Assessment of reader visual interpretation of the flortaucipir F 18 PET imaging uptake to predict mean change of cognitive and functional deterioration.","Avid Radiopharmaceuticals","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-PX01","March 28, 2019","April 28, 2019","April 28, 2019","April 3, 2019",,"May 29, 2019","American College of Radiology, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03901105"
183,"NCT03038035","The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study","ATHENE","Unknown status","No Results Available","Alzheimer Disease","Drug: MLC901|Drug: Placebo","Evaluating the safety of MLC901 when it is given in combination with the standard treatment.The safety will be evaluated by adverse events, vital signs, ECG and laboratory tests, physical and neurological examinations at 6 months.|Evaluate the effect of MLC901 as add on therapy to standard treatments for 6 months on cognitive function in patients with mild to moderate AD using Alzheimer's Disease Assessment Scale- cognitive subscale (ADAS- Cog).|Evaluate the effect of MLC901 as add on therapy to standard treatments for 6 months on cognitive function in patients with mild to moderate AD using Mini Mental State Examination (MMSE).|Evaluate the long term safety of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study with adverse events, vital signs, ECG and laboratory tests, physical and neurological examination at 1 year.|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS- CGIC).|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS- ADL23)|Evaluate the long term effect on disease progression of MLC901 as add-on treatment to standard treatments for up to 1 year in an open extension study by assessing Neuropsychiatric Inventory (NPI).","National University Hospital, Singapore","All","50 Years to 120 Years   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MLC901-2","December 2016","June 2018","June 2019","January 31, 2017",,"January 31, 2017","National University Hospital, Sg, Singapore",,"https://ClinicalTrials.gov/show/NCT03038035"
184,"NCT03405662","Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease","PBMbiomarker","Recruiting","No Results Available","Alzheimer Disease","Device: Vielight Neuro Gamma|Other: Sham Vielight Neuro Gamma","Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|Change in performance on Color Trails Test (CTT)|Change on the Neuropsychiatriac Inventory (NPI)|Change on the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)|Change in blood levels of MCP-1.|Change in CSF levels of MCP-1|Change in blood levels of Aβ42.|Change in CSF levels of Aβ42.|Change in blood levels of UCH-L1.|Change in CSF levels of UCH-L1.|Change in blood levels of BDNF.|Change in CSF levels of BDNF","University of California, San Francisco","All","50 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OsherRAP","August 16, 2018","May 31, 2019","December 31, 2019","January 23, 2018",,"October 1, 2018","VA Health Care System, San Francisco, California, United States|UCSF Memory and Aging Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03405662"
185,"NCT00675623","A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease","CONNECTION","Completed","No Results Available","Alzheimer's Disease","Drug: Dimebon|Drug: Placebo","To determine the effect of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).|To determine the effect of Dimebon as compared to placebo on the primary measure of global function, the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus).|To determine the effect of Dimebon as compared to placebo on a measure of self care and daily function, the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL).|To determine the effect of Dimebon as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI).","Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CONNECTION|DIM14","May 2008","December 2009",,"May 9, 2008",,"September 27, 2016","Phoenix, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|Rancho Mirage, California, United States|Hamden,, Connecticut, United States|New Haven, Connecticut, United States|Norwalk, Connecticut, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Paducah, Kentucky, United States|Newton, Massachusetts, United States|Ann Arbor, Michigan, United States|St. Louis, Missouri, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|New York City, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Morganton, North Carolina, United States|Centerville, Ohio, United States|Norristown, Pennsylvania, United States|Austin, Texas, United States|Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00675623"
186,"NCT03656159","Evaluation of a New CBT for People With Alzheimer's Disease and Their Caregivers",,"Recruiting","No Results Available","Alzheimer Disease","Behavioral: Cognitive-Behavioral group therapy|Behavioral: Non directive support Group","Change in psychological distress assessed by Kessler Psychological Distress Scale (K10) (for patients with AD and caregivers)|Change in intensity of anxious symptoms assessed by Geriatric Anxiety Inventory (GAI) (for patients with AD only)|Change in severity of worries assessed by Abbreviated Penn State Worry Questionnaire (PSWQ-A) (for patients with AD and caregivers)|Change in intensity of depressive symptoms assessed by Geriatric Depression Scale (GDS-15) (for patients with AD only)|Change in severity of depression assessed by Patient Health Questionnaire (PHQ-9) (for patients with AD and caregivers)|Change in quality of sleep assessed by Insomnia Severity Index (ISI) (for patients with AD and caregivers)|Change in level of functioning assessed by Disability Assessment for Dementia (DAD) (for caregivers only)|Change in quality of life assessed by Quality of Life-Alzheimer's Disease (QOL-AD) (for patients with AD and caregivers)|Change in quality of life assessed by Short-Form Health Survey (SF-12) (for caregivers only)|Change in satisfaction with life assessed by Satisfaction with life 5-scale (SWLS) (for patients with AD only)|Change in pleasant activities assessed by a questionnaire from ""Entrevue Profil du Loisir, version 4.0"" (for patients with AD and caregivers)|Change in medication taken and support received (for patients with AD and caregivers)|Change in sociovocational integration assessed by Community Integration Questionnaire (CIQ) (for patients with AD only)|Change in general cognitive functioning assessed by The Montreal Cognitive Assessment (MoCA) (for patients with AD only)|Change in language and semantic memory assessed by Boston Naming Test (for patients with AD only)|Change in language and semantic memory assessed by verbal fluency test (for patients with AD only)|Change in episodic memory assessed by Rey Auditory Verbal Learning Test (RAVLT) (for patients with AD only)|Change in memory assessed by Famous Faces Test (for patients with AD only)|Change in memory assessed by Self-evaluation Questionnaire (QAM-A) (for patients with AD only)|Change in short-term memory assessed by digit span subtest from The Wechsler Memory Scale (WMS-III) (for patients with AD only)|Change in memory and visuocontructional praxis assessed by Rey-Osterrieth Complex Figure (for patients with AD only)|Change in executive functions assessed by Frontal Assessment Battery (FAB) (for patients with AD only)|Change in executive functions assessed by Trail Making Test A and B (for patients with AD only)|Change in executive functions assessed by Stroop-Victoria (for patients with AD only)|Change in visuoperceptive and visuospatial functions assessed by Clock drawings (for patients with AD only)","Dr Sébastien Grenier|Alzheimer Society of Canada|Université de Montréal|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CRIUGM-006","January 2017","December 2019","June 2020","September 3, 2018",,"September 3, 2018","Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03656159"
187,"NCT02547818","Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease","COGNITE","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: ALZT-OP1a|Drug: ALZT-OP1b|Other: Placebo ALZT-OP1a|Other: Placebo ALZT-OP1b","Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Number of Treatment Emergent Adverse Events (TEAE)","AZTherapies, Inc.|PharmaConsulting Group|KCAS Bio|APCER Life Sciences","All","55 Years to 79 Years   (Adult, Older Adult)","Phase 3","620","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZT-001","September 2015","December 2020","December 2020","September 11, 2015",,"July 25, 2019","Cognitive Clinical Trials, Gilbert, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Cognitive Clinical Trials, Scottsdale, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Artemis Clinical Research, Riverside, California, United States|CITrials, Riverside, California, United States|Northern California Research, Sacramento, California, United States|Syrentys Clinical Research, Santa Ana, California, United States|Mile High Research Center, Denver, Colorado, United States|TOPAZ Clinical Research, Apopka, Florida, United States|Parkinson's Disease & Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Galiz Clinical Research, Hialeah, Florida, United States|The Neurology Research Group, Miami, Florida, United States|Premier Clinical Research Institute, Miami, Florida, United States|Next Phase Research Alliance - Cano Health, Miami, Florida, United States|IMIC, Inc., Miami, Florida, United States|Next Phase Research Alliance - MetroMed, Miami, Florida, United States|Next Phase Research Alliance, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Coastal Health Care, Freeport, Maine, United States|Samuel and Alexia Bratton Memory Clinic, Easton, Maryland, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|The Alzheimer's Disease Center, Quincy, Massachusetts, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Cognitive Clinical Trials, Bellevue, Nebraska, United States|Cognitive Clinical Trials, Omaha, Nebraska, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, New York, New York, United States|Winifred Masterson Burke Medical Research Institute, White Plains, New York, United States|ANI Neurology, PLLC Alzheimer's Memory Center, Charlotte, North Carolina, United States|PMG Winston-Salem, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Insight Clincial Trials, Shaker Heights, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Palmetto Health, Columbia, South Carolina, United States|Metrolina Neurological Associates, PA, Rock Hill, South Carolina, United States|CNS Healthcare, Memphis, Tennessee, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Kingfisher Cooperative, Spokane, Washington, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Pacific Private Clinic, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Geelong Private Medical Centre, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|UMBAL ""Dr. Georgi Stranski"" EAD, Pleven, Bulgaria|MHAT ""Central Onco Hospital"" Ltd., Plovdiv, Bulgaria|MBAL Ruse AD, Ruse, Bulgaria|""First MHAT - Sofia"" EAD, Sofia, Bulgaria|Heritage Medical Research Clinic, The University of Calgary, Calgary, Alberta, Canada|Medical Arts Health Research, Penticton, British Columbia, Canada|Medical Arts Health Research, West Vancouver, British Columbia, Canada|Okanagan Clinical Trials, Kelowna, Britsh Columbia, Canada|Montreal Neurological Research Institute, Québec, Montreal, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research, Kentville, Nova Scotia, Canada|JBN Medical, Burlington, Ontario, Canada|The Centre for Memory and Aging, East York, Ontario, Canada|Cliniuqe de la Memoire de l'Outouais, Gatineau, Quebec, Canada|Neurosanatio, s.r.o., Litomyšl, Czech Republic, Czechia|Neurologie MU - Ondrej Koci, s.r.o., Novy Bor, Czech Republic, Czechia|CT Center MaVfe, s.r.o, Olomouc, Czech Republic, Czechia|Vestra Clinics, s.r.o., Rychnov Nad Kněžnou, Czech Republic, Czechia|NEUROHK, s.r.o., Chocen, Czechia|Psychiatricka ambulance, Hradec Kralove, Czechia|Psychiatricka ambulance Supervize s.r.o., Kutná Hora, Czechia|A-shine, s.r.o., Plzen, Czechia|Clintrial.s.r.o., Praha, Czechia|Fakultni nemocnice v Motole Neurologicka klinika 2.LF UK a FN Motol, Praha, Czechia|INEP medical s.r.o., Praha, Czechia|Neurologia Klinika Semmelweis Egyetem, Budapest, Hungary|Vaszary Kolos Korhaz, Esztergom, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Cermed Pawel Hernik, Bialystok, Poland|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Przychondnia Srodmiescie, Bydgoszcz, Poland|Centrum Medyczne KERMED, Bydgoszcz, Poland|Centrum Medyczne Plejady, Kraków, Poland|Centrum Opieki Zdrowotnej Orkan-Med, Ksawerow, Poland|Centrum Medyczne im. Dr Karola Jonschera w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|CRC Sp. Zo.o., Poznan, Poland|Euromedis Sp. Zo.o, Szczecin, Poland",,"https://ClinicalTrials.gov/show/NCT02547818"
188,"NCT00051909","Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: LY451395",,"Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6764|H6N-MC-LEAM","November 2002",,"June 2003","January 20, 2003",,"July 19, 2006","Beverly Hills, California, United States|Fresno, California, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Miami Beach, Florida, United States|Boston, Massachusetts, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00051909"
189,"NCT03290326","tACS for Amyloid-β Reduction in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Device: Transcranial Alternating Current Stimulation (tACS)","Incidence of Treatment-Emergent Adverse Events|PET Amyloid burden|EEG gamma-band spectral power|Adas-Cog score","Beth Israel Deaconess Medical Center","All","45 Years and older   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P000373","November 27, 2017","May 14, 2019","May 14, 2019","September 21, 2017",,"August 29, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03290326"
190,"NCT00479557","Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Biological: ACC-001 + QS-21|Biological: ACC-001|Biological: QS-21|Drug: Placebo: Phosphate buffered saline","Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)|Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)","Pfizer|Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","86","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-200|B2571004|2006-002061-39","May 2007","January 2013","January 2013","May 28, 2007","January 1, 2016","January 1, 2016","Groupe Hospitalier Pitie-Salpetriere, Paris, Cedex 13 (MRI), France|Hôpital Pitié-Salpétrière, Paris Cedex 13, Paris, France|Hopital Pellegrin-Centre Mémoire de Recherche et de Ressources, Bordeaux, France|CHRU de Lille, Lille (MRI), France|CHRU de Lille, Lille, France|Hôpital Sainte-Marguerite, MARSEILLE cedex 5, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|Clinique de L'Union, St JEAN, France|Hôpital LA GRAVE, TOULOUSE Cedex 9, France|Chru Purpan, Toulouse, France|Clinique PASTEUR, Toulouse, France|Unversitätsklinikum Freiburg, Freiburg, Baden- Württemberg, Germany|Klinik fuer Psychiatrie und Psychotherapie, Charite Universitaetsmedizin Berlin, Berlin, Germany|Zentralinstitut fuer Seelische Gesundheit, Frankenthal, Germany|Klinik fuer Psychiatrie und Psychotherapie, Goettingen, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Technische Universitaet Muenchen, Klinikum rechts der Isar, München, Germany|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinico y Provincial, Barcelona, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00479557"
191,"NCT00309725","A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.",,"Completed","No Results Available","Alzheimer's Disease","Drug: galantamine","Hourly mean heart rates and PR intervals during each of the 24-hour Holter monitoring periods; Twenty-four hour mean, minimum and maximum heart rates and PR intervals during each of the 24-hour Holter monitoring periods|Pharmacokinetics and other safety parameters including ECG parameters were other parameters of interest.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","Child, Adult, Older Adult","Phase 3","139","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR012118",,,"October 1999","April 3, 2006",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00309725"
192,"NCT02719834","Behavioral Expressions in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Acetaminophen|Other: Placebo","Mobilization-Observation-Behaviour-Intensity-Dementia Pain Scale (MOBID-2) will be used for changes between the groups at baseline, weeks 2, 4, 6 and 8|Cohen-Mansfield Agitation Inventory (CMAI) will be used for changes between the groups at baseline, weeks 2,4, 6 and 8","University of Florida|Florida Department of Health","All","65 Years and older   (Older Adult)",,"4","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201600020|6AZ10","April 2016","February 9, 2017","February 2018","March 25, 2016",,"March 2, 2018","Oak Hammock Continuing Care Retirement Faculty, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02719834"
193,"NCT03491150","An Open-Label Crenezumab Study in Patients With Alzheimer's Disease","CREAD OLE","Completed","No Results Available","Alzheimer's Disease","Drug: Crenezumab (RO5490245)","Percentage of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","Child, Adult, Older Adult","Phase 3","149","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BN40031|2017-002702-12","April 11, 2018","May 31, 2019","May 31, 2019","April 9, 2018",,"September 24, 2019","Shankle Clinic, Newport Beach, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|MMP Neurology, Scarborough, Maine, United States|Precise Research Centers, Flowood, Mississippi, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Albany Medical Faculty Physicians COmmunity Division. The Neurology Group, Albany, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Oklahoma Clinical Research, Oklahoma City, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|University of North Texas Health Science Center; Fort Worth Patient Care Center, Fort Worth, Texas, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Caulfield Hospital; Aged Psychiatry Research Unit, Caulfield, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Neurodegenerative Disorders Research; Neurology, West Perth, Western Australia, Australia|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Terveystalo Tampere, Tampere, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital La Grave; Place Lange, Toulouse Cedec, France|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Prince of Wales Hospital; Dept. of Medicine & Therapeutics, Hong Kong, Hong Kong|Fondazione Santa Lucia IRCCS, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Vilnius University Hospital Santariskiu Clinic, Vilnius, Lithuania|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|SHI City Psychoneurological Dispensary #7 (with Hospital), St. Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Hospital General Universitario de Albacete; Servicio de Neurología, Albacete, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|National Medical Academy of Postgraduate Education named after P.L.Shupik; Neurology Department #1, Kiev, Ukraine|D.F.Chebotarev Institute of Gerontology NAMS;Depart of Age Physiology&Pathology of Nervous System, Kiev, Ukraine|Surrey and Borders NHS Foundation Trust; Research and Development Departmant; Abraham Cowley Unit, Chertsey, United Kingdom|Charing Cross Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Campus for Ageing and Vitality, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03491150"
194,"NCT00301574","An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.",,"Completed","No Results Available","Alzheimer Disease","Drug: galantamine","Change from baseline to the end of the study in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)|Change from baseline to the end of the study in CIBIC plus-J subscales (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ]).","Janssen Pharmaceutical K.K.","All","45 Years and older   (Adult, Older Adult)","Phase 3","398","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR003301","April 2001",,"February 2004","March 13, 2006",,"May 17, 2011",,,"https://ClinicalTrials.gov/show/NCT00301574"
195,"NCT03927040","Transcranial Electromagnetic Treatment Against Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease|Alzheimer Disease, Late Onset","Device: MemorEM 1000","ADAS-cog score|Levels of Blood and CSF Alzheimer's markers|Adverse Event Assessment|Rey AVLT score|Digit span score|MMSE score|Global Deterioration score|Trails A & B score|Clock draw score","NeuroEM Therapeutics, Inc.|University of South Florida Health / Byrd Alzheimer's Institute","All","63 Years to 84 Years   (Adult, Older Adult)","Not Applicable","7","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EM1000-1","April 15, 2019","October 2019","October 2019","April 25, 2019",,"April 26, 2019","Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03927040"
196,"NCT03902548","Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers",,"Recruiting","No Results Available","Alzheimer Disease","Drug: [18F]P16-129","Regional brain uptake of [18F]P16-129 and [18F]florbetapir|Cumulative organ [18F]P16-129 activity for estimates of radiation absorbed dose and effective dose","Five Eleven Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","JH-147896","May 17, 2018","July 2019","October 2019","April 4, 2019",,"April 4, 2019","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03902548"
197,"NCT03720548","A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer Disease","Drug: LY3372993|Drug: Placebo","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3372993 After a Single Dose|PK: Maximum Observed Concentration (Cmax) of LY3372993 After a Single Dose|PK: AUC of LY3372993 at Steady State after Multiple Doses|PK: Cmax of LY3372993 at Steady State After Multiple Doses|Pharmacodynamics (PD): Change from Baseline in Amyloid Load","Eli Lilly and Company","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17019|J1G-MC-LAKA","November 5, 2018","May 14, 2019","May 14, 2019","October 25, 2018",,"June 5, 2019","Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Covance Clinical Research Inc, Daytona Beach, Florida, United States|Avail Clinical Research LLC, DeLand, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|BioClinica Inc, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|BioClinica Inc, The Villages, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Carolina Phase 1 Research (Wake M3), Raleigh, North Carolina, United States|PRA Health Sciences, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03720548"
198,"NCT02537496","Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS","rTMS-AD","Completed","No Results Available","Alzheimer's Disease","Procedure: Repetitive Transcranial Magnetic Stimulation|Procedure: Repetitive Transcranial Magnetic Stimulation - Sham","Change in N-back Task Performance|Changes in Theta Phase-Gamma Amplitude Coupling|Changes in DLPFC Neuroplasticity|Changes in Cognitive Function Measures Scores|Validating a new scale for insight in Alzheimer's disease.","Centre for Addiction and Mental Health|Brain & Behavior Research Foundation|University of Toronto","All","55 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","005/2015","January 14, 2016","October 10, 2018","October 10, 2018","September 1, 2015",,"February 28, 2019","Center for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02537496"
199,"NCT03121066","Transcranial Magnetic Stimulation for Alzheimer's Disease Treatment","TMSAD","Not yet recruiting","No Results Available","Alzheimer Disease","Device: Active Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation","Change in Cognitive improvement|Functional capacity changes|Mood changes|Changes in brain connectivity","Universitat Oberta de Catalunya|Consorci Sanitari de Terrassa","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UOCatalunya","October 2018","October 2019","October 2020","April 19, 2017",,"July 6, 2018",,,"https://ClinicalTrials.gov/show/NCT03121066"
200,"NCT00459550","A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK933776|Drug: Placebo to match GSK933776","Adverse events. Changes suggesting potential adverse events detected in the physical & neurological examination, brain MRI, cognitive status, laboratory parameters, ECG & vital signs.|Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre & neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan","GlaxoSmithKline","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","106006","March 12, 2007","May 30, 2011","May 30, 2011","April 12, 2007",,"July 21, 2017","GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Lørenskog, Norway|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00459550"
201,"NCT02279511","ATP in Alzheimer Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ADENOSINE TRIPHOSPHATE|Drug: PLACEBO","Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)|Changes in Cogstate results|Changes in test Mini-Mental State Examination|Changes in synaptic activity after treatment administration Neurological examination|Electrocardiogram results|adverse events","Sara Varea|Fundacion Clinic per a la Recerca Biomédica","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","ECA4A","December 2014","February 2016","February 2016","October 31, 2014",,"March 29, 2017","Fundació ACE, Barcelona, Spain|Hospital Sanitas CIMA, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02279511"
202,"NCT03173846","Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD)","NPAD","Active, not recruiting","No Results Available","Alzheimer Disease",,"Change in cognition","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","45 Years to 79 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALFA-NPAD/BBRC2016","May 5, 2017","October 31, 2018","October 31, 2019","June 2, 2017",,"February 19, 2019","Barcelonabeta Brain Research Center, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03173846"
203,"NCT01504854","Resveratrol for Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Resveratrol|Drug: Placebo","Number of Adverse Events|Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)|Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 2","119","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADC-037-RES","May 2012","March 2014","March 2014","January 6, 2012","June 14, 2016","June 14, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego - Comprehensive Alzheimer's Program, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Case Western Reserve University, Beachwood, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01504854"
204,"NCT01626391","Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: TRx0237|Drug: Placebo","Safety and Tolerability of TRx0237 When Coadministered With an Acetylcholinesterase Inhibitor (AChEI) and/or Memantine","TauRx Therapeutics Ltd","All","up to 90 Years   (Child, Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-237-008","September 2012","March 2013","March 2013","June 22, 2012","July 11, 2014","July 11, 2014","Achim, Germany|Berlin, Germany|Leipzig, Germany|München, Germany|Birmingham, United Kingdom|Bradford, United Kingdom|Crowborough, United Kingdom|Duston, United Kingdom|Oxford, United Kingdom|Sheffield, United Kingdom|St Leonards on Sea, United Kingdom|Staffordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01626391"
205,"NCT03446001","Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease","LUCIDITY","Recruiting","No Results Available","Alzheimer Disease","Drug: TRx0237 8 mg/day|Drug: Placebo|Drug: TRx0237 16 mg/day","Change in Standardized Uptake Value Ratio (SUVR) based on temporal lobe 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|Change in composite cognitive/functional scale (""Composite Scale"")|Number of participants with serious and non-serious adverse events|Change in SUVR based on frontal and parietal lobe 18F-FDG-PET|Change in annualized rate of temporal and parietal lobe atrophy|Change in annualized rate of atrophy in other brain regions|Change in ADAS-cog13 compared to imaging measures|Change in ADCS-ADL23 compared to imaging measures|Change in Composite Scale compared to imaging measures|Change in SUVR (using temporal lobe 18F-FDG-PET) based on the presence or absence of Apolipoprotein E4 allele in subjects by or for whom legally acceptable consent is separately provided","TauRx Therapeutics Ltd","All","up to 90 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-237-039","January 10, 2018","December 2020","December 2020","February 26, 2018",,"May 3, 2019","Hope Research Institute, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Imaging Endpoints Research, Scottsdale, Arizona, United States|Atria Research, Little Rock, Arkansas, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Behavioral Research Specialist, LLC, Glendale, California, United States|Fort Walton Beach Medical Center, Laguna Hills, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|CITrials, Riverside, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Paradigm Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|CITrials, Santa Ana, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Boca Raton Regional Hospital, Marcus Neuroscience Institute, Boca Raton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Alzheimers Research and Treatment Center, Lake Worth, Florida, United States|Wein Center Memory Disorder Clinic, Miami Beach, Florida, United States|Homestead Associates in Research, Inc., Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Cordova Research Institute, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|Florida International Research Center, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Novel Clinical Research Center, Miami, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Health Care Family Rehab and Research, Pembroke Pines, Florida, United States|Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Renstar Medical Research, Wesley Chapel, Florida, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|GA Neurology and Sleep Medicine, Suwanee, Georgia, United States|Advanced Clinical Research, Boise, Idaho, United States|Healthcare Research Network II, Flossmoor, Illinois, United States|Heartland Research Associates, Newton, Kansas, United States|Ochsner Health System, New Orleans, Louisiana, United States|Neurology Specialists of Monmouth County, PA, West Long Branch, New Jersey, United States|University at Buffalo, Buffalo, New York, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|New York University, New York, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Insight Clinical Trials LLC, Beachwood, Ohio, United States|Ohio Clinical Research Partners, Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|The Carl and Edyth Lindner Research Center, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|University of Cincinnati Physicians, West Chester, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, Oklahoma City, Oklahoma, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|NIIP at Quillen College of Medicine, Johnson City, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|University of Texas Health Sciences, San Antonio, Texas, United States|Center for Alzheimer's Care, Imaging and Research (CACIR), Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Re:Cognition Health, Fairfax, Virginia, United States|Virginia Mason Hospital, Seattle, Washington, United States|Universal Research Group, LLC, Tacoma, Washington, United States|UZ Antwerpen, Edegem, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|Okanagan Clinical Trials, Ltd., Kelowna, British Columbia, Canada|True North Clinical Research - Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research, Kentville, Nova Scotia, Canada|JBN Medical Diagnostic Service, Burlington, Ontario, Canada|Clinique de la Mémorie de l'Outaouais, Gatineau, Quebec, Canada|McGill University Faculty of Medicine - McGill Centre for Studies in Aging, Verdun, Quebec, Canada|Alpha Recherche Clinique, Québec, Canada|CHU Bordeaux, Bordeaux, France|Hôpital neurologique - Hospices Civils de Lyon, Bron, France|CHU de Caen, Caen, France|CHU de Limoges, Limoges, France|Timone Adults Hospital, Marseille, France|Guidechauliac Hospital, Montpellier, France|Hospital Guillaume et Rena Laannec, Nantes, France|Geriatrics department, Hôpital de Jour - Pavillon Saint-François, Strasbourg, France|CRC Gerontopole Cite de la Sante, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy|Foundation Institute G.Giglio, Cefalù, Italy|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera San Gerardo - Clinica Neurologica, Monza, Italy|Istituto neurologico Casimiro Mondino, IRCCS, Pavia, Italy|University of Perugia, Ospedale S.M. della Misericordia, Perugia, Italy|A.O.U. Pisa, Pisa, Italy|IRCCS Fondazione Santa Lucia, Roma, Italy|Ospedale San Giovanni Calibita Fatebenefratelli, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|A.Gemelli, Roma, Italy|Policlinico Santa Maria alle Scotte, Siena, Italy|Clinica Neurologica e Neuroriabilitazione, Udine, Italy|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Centrum Medyczne NEUROMED, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Centrum Zdrowia Psychicznego Biomed, Kielce, Poland|Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland|NZOZ Neuro-Kard, Poznań, Poland|Poradnia Neurologiczna z Poradnia Diagnostyki i Leczenia Zaburzen Pamieci, Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Instituto Internacional de Neurociencias Aplicadas, Barcelona, Spain|Hospital General de Catalunya, Barcelona, Spain|Fundacion para la Investigacion Biomedica Universitario 12 de Octubre, Madrid, Spain|Centro de salud de San Juan, Unidad de Investigación Neurociencias, Salamanca, Spain|Hospital Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Birmingham & Solihull Mental Health NHS Foundation, Birmingham, West Midlands, United Kingdom|Re:Cognition Health, Birmingham, United Kingdom|2gether Research, Cheltenham, United Kingdom|Glasgow Memory Clinic Ltd, Glasgow, United Kingdom|Re:Cognition Health, Guildford, United Kingdom|Re:Cognition Health - Central London, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|Northamptonshire Healthcare NH, Northampton, United Kingdom|Re:Cognition Health, Plymouth, United Kingdom|West London Mental Health NHS Trust, Southall, United Kingdom|Moorgreen Hospital, Southampton, United Kingdom|St Georges Hospital, Stafford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03446001"
206,"NCT02094729","A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetics of BAN2401: Maximum Concentration (Cmax)|Pharmacokinetics of BAN2401: time attain to Cmax (tmax)|Pharmacokinetics of BAN2401: Area under the curve (AUC)|Pharmacokinetics of BAN2401: Drug Clearance (CL)|Pharmacokinetics of BAN2401: apparent volume of distribution at steady state (Vss)|Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers|Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401","Eisai Co., Ltd.|Eisai Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BAN2401-J081-104","September 2013","March 2015","May 2015","March 24, 2014",,"June 8, 2015","Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Kurashiki, Okayama, Japan|Koto-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02094729"
207,"NCT03367403","A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: LY3002813|Drug: Placebo","Change from Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change from Baseline in the Alzheimer's Disease Assessment Scale—Cognitive Subscale (ADAS-Cog13) Score|Change from Baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Score|Change from Baseline in the Mini Mental State Examination (MMSE) Score|Change from Baseline in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL) Score|Change from Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan|Change from Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan|Change from Baseline in Brain Volume as Measured by volumetric Magnetic Resonance Imaging (vMRI)","Eli Lilly and Company","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16933|I5T-MC-AACG","December 18, 2017","December 11, 2020","November 12, 2021","December 8, 2017",,"August 5, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Associated Neurologists, PC - Danbury, Danbury, Connecticut, United States|KI Health Partners, LLC d/b/a NE Inst. for Clin. Res., Stamford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Merritt Island Medical Research LLC, Merritt Island, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Compass Research, Orlando, Florida, United States|Palm Beach Neurological Group, Palm Beach Gardens, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|University of Kansas Hospital, Fairway, Kansas, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|McLean Hospital, Belmont, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Insight Clinical Trials, Beachwood, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Neurology, PA, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Cognition Health, Fairfax, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Bruyere Research Institute, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|DIEX Recherche Sherbrooke, Inc, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03367403"
208,"NCT00857649","Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Memantine|Drug: Placebo","Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.|Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.|Efficacy of Memantine on Global Condition Using CIBIC-plus.|Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.|Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10158","December 2003","April 2010","September 2010","March 6, 2009","January 9, 2012","December 5, 2013","CA019, Edmonton, Alberta, Canada|CA033, Kelowna, British Columbia, Canada|CA034, Winnipeg, Manitoba, Canada|CA022, St. John, New Brunswick, Canada|CA046, Kentville, Nova Scotia, Canada|CA045, Pictou, Nova Scotia, Canada|CA032, Burlington, Ontario, Canada|CA029, Orangeville, Ontario, Canada|CA004, Ottawa, Ontario, Canada|CA038, Peterborough, Ontario, Canada|CA009, Toronto, Ontario, Canada|CA037, Windsor, Ontario, Canada|CA005, Beauport, Quebec, Canada|CA023, Greenfield Park, Quebec, Canada|CA013, Montreal, Quebec, Canada|CA031, Sherbrooke, Quebec, Canada|CA012, Sherbrooke, Quebec, Canada|CA030, Vanier, Quebec, Canada|CA017, Verdun, Quebec, Canada|CA015, Regina, Saskatchewan, Canada|CA040, Saskatoon, Saskatchewan, Canada|CA043, Kelowna, Canada|CA042, Penticton, Canada",,"https://ClinicalTrials.gov/show/NCT00857649"
209,"NCT03274817","A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Escitalopram Pill|Drug: Venlafaxine Pill|Drug: Placebo Oral Tablet","Z-score for the hippocampal region of interest in the theta band|Multivariate Z score for overall theta abnormality in the frontal and parieto-temporal regions;|Probability of deterioration from logistic regression predictive of future decline;|Z-score coherence (synchrony) between right central and parietal regions across all bands;|Mean frequency across the total EEG brain spectrum.|Metabolic reduction in the hippocampal formation (a region including the hippocampal subiculum and the entorhinal cortex) assessed bilaterally.|Brief Cognitive Rating Scale Axes I to V total scores|The Mini-Mental State Examination (MMSE) total scores|MAC-Q total score","NYU Langone Health","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","09-0228","July 11, 2017","January 2020","January 2020","September 7, 2017",,"June 19, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03274817"
210,"NCT02247180","Cognitive Rehabilitation in Alzheimer`s Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Behavioral: cognitive rehabilitation|Behavioral: standardized cognitive training","Change from baseline in activities of daily living measured by a test for action regulation and planning skills (HOTAP) to the end of intervention and to follow-up (6 months later)|Change from baseline in activities of daily living measured by an ADL-scale (Bayer-ADL) to the end of intervention and to follow-up (6 months later)|Change from baseline in behavioural memory abilities measured by a behavioural memory test (RBMT) to the end of intervention and to follow-up (6 months later)|Change from baseline in general cognitive state measured by the Consortium to Establish a Registry for Alzheimer´s Disease (CERAD) to the end of intervention and to follow-up (6 months later)|Change from baseline in structural and functional connectivity of the brain measured by MRI to the end of intervention and to follow-up (6 months later)|Change from baseline in depression and quality of life measured by two scales (GDS, DEMQoL) to the end of intervention and to follow-up (6 months later)","University of Rostock|German Center for Neurodegenerative Diseases (DZNE)","All","Child, Adult, Older Adult","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","A 2014-0113","September 2014","May 2015","December 2015","September 23, 2014",,"September 23, 2014","Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany",,"https://ClinicalTrials.gov/show/NCT02247180"
211,"NCT01982578","Genistein as a Possible Treatment for Alzheimer's Disease.","GENIAL","Recruiting","No Results Available","Alzheimer's Disease","Dietary Supplement: Genistein|Other: Placebo","Changes in Amyloid beta concentration in cerebrospinal fluid (CSF)|Changes in MMSE.|Changes in T@M (Memory Alteration Test).|Changes in TAVEC (Verbal Learning Test Spain-COmplutense).|Changes in the Clock test.|Changes in the Barcelona Test.|Changes in Rey Complex figure Test.|Changes in Genistein Pharmacokinetics.|Changes in Equol Pharmacokinetics.","Fundación para la Investigación del Hospital Clínico de Valencia|University of Valencia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INC-GEN-2013-01|U1111-1150-4063","September 1, 2017","September 30, 2020","December 31, 2020","November 13, 2013",,"July 31, 2019","Universitat de València, Valencia, Spain|Hospital General Universitario, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01982578"
212,"NCT01409915","Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Sagramostim|Drug: Saline -- placebo comparator","Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed|Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects","University of Colorado, Denver|The Dana Foundation","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12-1273","March 2011","May 1, 2020","May 30, 2020","August 4, 2011",,"April 17, 2019","University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01409915"
213,"NCT01322373","A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test",,"Unknown status","No Results Available","Alzheimer's Disease",,"Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently between HC and AD subjects.","Orasi Medical, Inc.","All","20 Years to 92 Years   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","ADG 11-01","March 2011","August 2011","August 2011","March 24, 2011",,"March 24, 2011","Noran Neurological Clinic, Minneapolis, Minnesota, United States|Noran Neurology Clinic, Plymouth, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01322373"
214,"NCT00857233","Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Memantine","Number of Patients With Adverse Events (AEs)|Percentage of Patients Who Withdrew Due to Intolerance to Treatment|Long-term Efficacy of Memantine on Behavioural Symptoms Using the Neuropsychiatric Inventory (NPI) - 12 Items Version Total Score.|Long-term Efficacy of Memantine on Cognition Using the Severe Impairment Battery (SIB) Total Score.|Long-term Efficacy of Memantine on Global Condition Using the Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus).|Long-term Efficacy of Memantine on Functioning Using the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item Version Total Score","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 3","297","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10252","June 2004","July 2010","October 2010","March 6, 2009","August 29, 2012","August 29, 2012","CA019, Edmonton, Alberta, Canada|CA033, Kelowna, British Columbia, Canada|CA043, Kelowna, British Columbia, Canada|CA042, Penticton, British Columbia, Canada|CA034, Winnipeg, Manitoba, Canada|CA022, St. John, New Brunswick, Canada|CA045, Pictou, Nova Scotia, Canada|CA032, Burlington, Ontario, Canada|CA029, Orangeville, Ontario, Canada|CA004, Ottawa, Ontario, Canada|CA038, Peterborough, Ontario, Canada|CA009, Toronto, Ontario, Canada|CA005, Beauport, Quebec, Canada|CA023, Greenfield Park, Quebec, Canada|CA013, Montreal, Quebec, Canada|CA012, Sherbrooke, Quebec, Canada|CA030, Vanier, Quebec, Canada|CA017, Verdun, Quebec, Canada|CA015, Regina, Saskatchewan, Canada|CA040, Saskatoon, Saskatchewan, Canada|CA044, Chatham, Canada|CA007, Kentville, Canada|CA046, Kentville, Canada|CA001, Kingston, Canada|CA003, London, Canada|CA002, London, Canada|CA016, Moncton, Canada|CA024, Montreal, Canada|CA014, Montreal, Canada|CA011, Montreal, Canada|CA031, Sherbrooke, Canada|CA006, Toronto, Canada|CA037, Windsor, Canada",,"https://ClinicalTrials.gov/show/NCT00857233"
215,"NCT02694445","Monetary Cost of Alzheimer's Disease in China",,"Unknown status","No Results Available","Alzheimer's Disease","Other: observation","Nationwide cost due to AD","Beijing Friendship Hospital|Chinese Medical Doctor Association","All","60 Years and older   (Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MAC-001","January 2016","May 2016","August 2016","February 29, 2016",,"February 29, 2016","Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02694445"
216,"NCT02017340","A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease","NILVAD","Completed","No Results Available","Alzheimer's Disease","Drug: Nilvadipine|Drug: Placebo","Alzheimer's Disease Assessment Scale (ADAS) Cog|Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Disability Assessment for Dementia (DAD)","Prof Brian Lawlor|University of Dublin, Trinity College|Molecular Medicine Ireland LBG|Alzheimer Europe|Archer Pharmaceuticals, Inc.|E-Search Limited|University College Dublin|King's College London|Istituto Di Ricerche Farmacologiche Mario Negri|University Hospital, Lille|University of Ulm|Szeged University|Göteborg University|University College Cork|Aristotle University Of Thessaloniki|Stichting Katholieke Universiteit|St. James's Hospital, Ireland","All","50 Years and older   (Adult, Older Adult)","Phase 3","511","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NILVAD2012|2012-002764-27|279093","April 24, 2013","December 16, 2016","December 16, 2016","December 20, 2013",,"March 6, 2017","Centre Hospitalier Universitaire d'Amiens (CHU Amiens), Amiens, France|Centre Hospitalier Universitaire de Bethune (CH Bethune), Bethune, France|Centre Hospitalier Universitaire de Caen (CHU Caen), Caen, France|Centre Hospitalier Universitaire de Calais (CHU Calais), Calais, France|Centre Hospitalier Universitaire de Lens (CHU Lens), Lens, France|Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille), Lille, France|Centre Hospitalier Universitaire de Saint Philibert (GHICL), Lille, France|University of Ulm, Ulm, Germany|""G. Papanicolaou"" Hospital, Athens, Greece|""G.Papageorgiou"" Hospital, Athens, Greece|AXEPA Hospital, Athens, Greece|Szeged University, Szeged, Hungary|University College Cork, Cork, Ireland|St James Hospital, Dublin, Ireland|Hospital of Brescia, Brescia, Italy|Hospital Castellanza, Castellanza, Italy|Hospital of Genoa, Genoa, Italy|Hospital of Milan, Milan, Italy|Hospital of Arnhem, Arnhem, Netherlands|Hospital of Maastricht, Maastricht, Netherlands|Hospital of Nijmegen, Nijmegen, Netherlands|Gothenburg Univeristy, Gothenburg, Sweden|Kings College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02017340"
217,"NCT00381238","Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: rosiglitazone","Number of Participants With Adverse Events (AE's)|Mean Change From Baseline in Mini Mental State Examination (MMSE) Total Score|Number of Participants With SAEs|Number of Participants With AE of Peripheral Edema by Grade|Mean Change From Baseline in Vital Signs- Systolic and Diastolic Blood Pressure|Mean Change From Baseline in Vital Signs-heart Rate (HR)|Number of Participants With Vital Signs of Clinical Concern.|Mean Change From Baseline in Vital Signs- Weight|Number of Participants With Clinical Chemistry Parameters of Clinical Concern|Number of Participants With Clinical Chemistry Parameters of Clinical Concern-lipids|Number of Participant's With Hematology Parameters of Clinical Concern","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVA104617","June 20, 2006","February 1, 2009","February 3, 2009","September 27, 2006","May 23, 2017","May 23, 2017","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Belmont, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00381238"
218,"NCT03250741","Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease","DOPAD","Completed","No Results Available","Alzheimer Disease","Drug: Rotigotine transdermal patch|Other: Placebo","Global cognition|Frontal cognitive functions|Activities of daily living|Neurophysiological markers of cortical activity|Neuropsychiatric evaluation","I.R.C.C.S. Fondazione Santa Lucia","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT 2015-002965-43","June 2016","November 2018","November 2018","August 16, 2017",,"December 17, 2018","Santa Lucia Foundation, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT03250741"
219,"NCT02472899","Biomarker Study for Alzheimer's Disease","BiomarkerAD","Unknown status","No Results Available","Alzheimer's Disease","Other: Blood sample","Frequency of monoclonal antibodies and of CD4+ and CD25+ T cells","Beersheva Mental Health Center","All","60 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case Control","CT4525","February 2007","June 2016","June 2016","June 16, 2015",,"May 5, 2016","Beersheva Mental Health Center, Beersheva, Israel",,"https://ClinicalTrials.gov/show/NCT02472899"
220,"NCT03249688","Multimodal Preventive Trial for Alzheimer's Disease","MIND-ADmini","Recruiting","No Results Available","Alzheimer Disease; Prodromal","Other: Regular health advice|Behavioral: Multidomain lifestyle|Dietary Supplement: Medical food","Recruitment rate|Overall adherence to the intervention|Retention rate|Adherence to intervention components|Adherence to healthy lifestyle changes","Karolinska Institutet|University of Eastern Finland|INSERM-University of Toulouse|Saarland University","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","E0750301","October 16, 2017","September 1, 2019","September 1, 2019","August 15, 2017",,"September 19, 2018","Karolinska University Hospital, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03249688"
221,"NCT03288363","Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD)","tDCS-AD","Recruiting","No Results Available","Alzheimer Disease","Device: tDCS","Comparing between the active tDCS group with the placebo tDCS group, the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) score, 12 weeks after the start of the course, in subjects with early Alzheimer's disease","Benjamin CALVET|Centre Hospitalier Esquirol","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-A01527-44","June 6, 2017","June 6, 2021","December 6, 2021","September 20, 2017",,"October 7, 2019","Centre Hospitalier Esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT03288363"
222,"NCT01183806","Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients",,"Completed","No Results Available","Alzheimer Disease","Drug: Rivastigmine|Other: Exercise training program","Patients' Quality of life|Cognition|Caregivers' Quality of life|Activities of daily living|Functional mobility","Federal University of Bahia","All","55 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PA-01","July 2010","January 2012","March 2012","August 18, 2010",,"March 20, 2012","Ferderal University of Bahia - DINEP, Salvador, Bahia, Brazil|Federal University of Bahia, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT01183806"
223,"NCT00217763","European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: 3APS",,"Bellus Health Inc","All","50 Years and older   (Adult, Older Adult)","Phase 3","930","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","CL-758010","September 2005",,"December 2007","September 22, 2005",,"December 10, 2007","Middelheim Ziekenhuis Lindendreef, Antwerp, Belgium|University Hospital Antwerp - Neurology - Prof. Dr. Patrick Cras, MD, PhD, Edegem, Belgium|Memory Clinic University Hospital Gasthuisberg, Neurology Department, Leuven, Belgium|Memory Centre, Polycliniques Brull, CHU de Liège, Liege, Belgium|Besançon, France|Hôpital Pellegrin CHU de Bordeaux, Bordeaux, France|Dijon, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hôpital Sainte Marguerite Service de neuro-geriatrie, Marseille, France|Hôpital Gui de Chauliac - Service de Neurologie du Pr J. Touchon, Montpellier, France|Centre Mémoire de Ressources et de Recherche Hôpital Pasteur, Nice, France|Hôpital BROCA, Paris, France|CHU Reims- Hôpital Sébastopol-Service de médecine interne et Gérontologie Clinique, Reims, France|Hôpital Hôtel Dieu - Consultation de Gérontologie, Rennes, France|CHU Purpan, Toulouse, France|Tours, France|Charité Campus Benjamin Franklin - Universitätsmedizin Berlin - Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Berlin, Germany|Gemeinschaftspraxis, Bochum (Langendreer), Germany|Johann-Wolfgang Goethe-Universität - Klinik für Psychiatrie und Psychotherapie, Frankfurt, Germany|Klinik für Psychiatrie und Psychotherapie - University Hospital Hamburg-Eppendorf - Dept. of Psychiatry and Psychotherapy, Hamburg, Germany|Psychiatrische Universitätsklinik Heidelberg - Sektion für Gerontopsychiatrie - Gedächtnisambulanz, Heidelberg, Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Abteilung für Geriatrische Psychiatrie - Zentralinstitut für seelische Gesundheit - Universität Heidelberg, Mannheim, Germany|Munich, Germany|IRCCS Centro San Giovanni di Dio- Fatebenefratelli, Brescia, Italy|San Martino Hospital - Padiglione Specialita' Fondi, Genova, Italy|Dept. of Neurosciences TCR - University of Modena and Reggio Emilia, Modena, Italy|Perugia, Italy|Department of Neuroscience - Section of Neurology - University of Pisa, Pisa, Italy|Universita' Cattolica del Sacro Cuore, Rome, Italy|Rome, Italy|Vicenza, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Dept. of Neurology and Alzheimer Center - Vrije Universiteit Medical Center, Amsterdam, Netherlands|Blaricum, Netherlands|Memory Clinic UMC St Radboud - Alzheimer Centre, Nijmegen, Netherlands|Bydgoszcz, Poland|Krakow, Poland|Lodz, Poland|Sopot, Poland|Warsaw, Poland|Wroclaw, Poland|Baracaldo, Spain|Fundaciò ACE- Institut Català de Neurociències Aplicades, Barcelona, Spain|Hospital del Mar- Servicio de Neurologia, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Servicio de Neurología, Unitad de Memoria, Barcelona, Spain|Unitat de Valoració de la Memòria i les Demències - Hospital Santa Caterina - Institut d'Assistència Sanitària, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitairo La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal - Unidad de Geriatria, Madrid, Spain|Pamplona, Spain|Linkoping, Sweden|Lund, Sweden|Neuropsychiatric Clinic - University Hospital MAS, Malmo, Sweden|Mölndal, Sweden|Enheten för klinisk Läkemedelsforskning - Minnesmottagningen - Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Memory clinic - Uddevalla Hospital, Uddevalla, Sweden|Memory Clinic -Geriatric Centre - Academic Hospital, Uppsala, Sweden|Memory Clinic - Neuropsychology Center - University Hospital, Basel, Switzerland|Geneva, Switzerland|Research Institute for Care of Elderly - St Martin's Hospital, Bath, United Kingdom|Fylde Medical Clinic, Blackpool, United Kingdom|Memory Assessment Centre, Blackpool, United Kingdom|Wales College of Medicine - Llandough Hospital, Cardiff, United Kingdom|East Sussex, United Kingdom|Glasgow Memory Clinic - Golden Jubilee National Hospital, Glasgow, United Kingdom|Murray Royal Hospital, Perth, United Kingdom|Memory Assessment Centre - Moorgreen Hospital, Southampton, United Kingdom|Kingshill Research Centre - Victoria Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00217763"
224,"NCT03352739","Fornix and NbM as Targets of Stimulation In Alzheimer's Disease","FANTASIA","Recruiting","No Results Available","Alzheimer Disease","Device: DBS of the fornix, power on|Device: DBS of the NbM, power on|Device: DBS of the fornix, power off|Device: DBS of the NbM, power off","Cognitive outcome|Neuroplasticity outcome|Functional outcome|Safety outcome","Xuanwu Hospital, Beijing|Beijing Pins Medical Co., Ltd","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","XuanwuH","December 1, 2017","December 1, 2019","December 1, 2020","November 24, 2017",,"January 11, 2018","Xuanwu Hospital, Capital Medical University., Beijing, China",,"https://ClinicalTrials.gov/show/NCT03352739"
225,"NCT00965588","Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: UB 311","To evaluate safety and tolerability of the vaccine (UB 311).|To evaluate immunogenicity [and efficacy] of the vaccine (UB 311).","United Biomedical|Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","19","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UBI Protocol V118|Protocol V118-AD","February 2009","April 2011","April 2011","August 25, 2009",,"August 23, 2011","National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00965588"
226,"NCT02051244","Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?","SCI-OCT","Unknown status","No Results Available","Alzheimer's Disease",,"Measurement of retinal nerve fiber layer thickness|Cognitive function","Carmel Medical Center","All","60 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","CMC-13-0094-CTIL","February 2014","February 2015","February 2015","January 31, 2014",,"January 31, 2014","Carmel Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT02051244"
227,"NCT03115814","Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease",,"Deep brain stimulation-related disability rates|Clinical Dementia Rating(CDR) score|The Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog)|Mini-Mental State Examination (MMSE) score","Chinese PLA General Hospital","All","40 Years to 80 Years   (Adult, Older Adult)",,"6","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ChinaPLAGH_MZQ","April 17, 2017","October 2018","June 2019","April 14, 2017",,"July 2, 2017","Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03115814"
228,"NCT01047579","A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease","BETTER","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal","Caregiver questionnaire|Safety and Tolerability. Safety assessments include vital signs and adverse events (AEs)","Novartis Pharmaceuticals|Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CENA713DIL01","April 2010","January 2012","January 2012","January 13, 2010",,"February 24, 2017","Novartis Investigative Site, Ashkelon, Israel|Novartis Investigational Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01047579"
229,"NCT02772185","Neurostimulation and Cognitive Intervention in Alzheimer's Disease","NeuroAD","Unknown status","No Results Available","Alzheimer's Disease","Device: active tDCS|Device: sham tDCS|Behavioral: real CT|Behavioral: placebo CT","Change in cognitive function assessed on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)|Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale|Change in visuo-spatial working memory assessed on the Corsi block task|Change in verbal working memory assessed on the Digit Span task|Change in speed of cognitive processing and executive functioning assessed on the Trail Making Test|Change in executive function assessed on the Stroop Color and Word Test|Change in verbal fluency assessed on the FAS Verbal Fluency Test|Change in functional ability assessed on the Disability Assessment Dementia|Change in visual recognition assessed on the Poppelreuter-Ghent's Overlapping Figures test|Change in behavioral and psychological disturbances assessed on the Neuropsychiatric Inventory Questionnaire|Change in subjective burden among caregivers assessed on the Zarit Burden Interview|Change in electrical activity of the brain assessed on the Electroencephalogram (EEG)|Side Effects Questionnaire","Federal University of Paraíba","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NeuroAD","May 2016","May 2018","May 2019","May 13, 2016",,"May 13, 2016","Suellen Andrade, João Pessoa, PB, Brazil",,"https://ClinicalTrials.gov/show/NCT02772185"
230,"NCT03038334","Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: Magnesium sulfate","Change in amyloid deposit|Cognitive Function","Metabolic Therapy Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PR02TCR011-17","February 20, 2017","August 20, 2019","October 20, 2019","January 31, 2017",,"January 31, 2017",,,"https://ClinicalTrials.gov/show/NCT03038334"
231,"NCT03533257","Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease","PEGASUS","Recruiting","No Results Available","Alzheimer Disease","Drug: AMX0035|Drug: Placebo","Quantity of Adverse Events Observed in the Study|MRI Volumetric Imaging|Cognition|Psychiatric Symptoms|MRI Hippocampal Imaging|Functional MRI Imaging","Amylyx Pharmaceuticals Inc.|Alzheimer’s Drug Discovery Foundation|Alzheimer's Association","All","55 Years to 89 Years   (Adult, Older Adult)","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMX-8000","August 27, 2018","July 1, 2020","September 1, 2020","May 23, 2018",,"October 4, 2019","CNS Healthcare - Jacksonville, Jacksonville, Florida, United States|CNS Healthcare - Orlando, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Rowan University, Stratford, New Jersey, United States|Mount Sinai Alzheimer's Disease Research Center, New York, New York, United States|Columbia University, New York, New York, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Center for Biomedical Research, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03533257"
232,"NCT02770482","Amyloid Beta-peptide 1-40 and Alzheimer's Disease","ADAB40","Unknown status","No Results Available","Alzheimer Disease","Biological: spinal fluid collection","Percentage of diagnostic certitude for AD (diagnosed cases)","CHU de Reims","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PA13050","June 2014","June 2016",,"May 12, 2016",,"May 27, 2016","Chu de Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT02770482"
233,"NCT00414622","GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: DMXB-A","CDR|ADAS-cog","CoMentis","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","GTS21-201","November 2006",,"April 2007","December 21, 2006",,"April 19, 2007","Clinical Dept., 280 South San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00414622"
234,"NCT03277573","Salsalate in Patients Mild to Moderate Alzheimer's Disease","SAL-AD","Recruiting","No Results Available","Alzheimer Disease","Drug: Salsalate|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events|Changes in Pharmacokinetic properties of Salsalate in Plasma and Cerebrospinal Fluid|Changes in Pharmacodynamic properties of Salsalate in Cerebrospinal Fluid","Adam Boxer|University of California, San Francisco","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UC-SAL-AD-001","July 21, 2017","July 21, 2019","October 21, 2019","September 11, 2017",,"May 3, 2018","University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03277573"
235,"NCT03560245","A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine",,"Completed","No Results Available","Alzheimer Disease","Drug: Bryostatin|Other: Placebo","Safety: Treatment emergent adverse events (AEs) and serious adverse events (SAEs)|Efficacy: The primary efficacy endpoint is defined as the change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.|The changes from baseline at Weeks 5, 9 and 15 in the Severe Impairment Battery (SIB) total score.|The changes from baseline at Weeks 5, 9, 13 and 15 in the Severe Impairment Battery (SIB) total score for subjects in the Mini Mental State Exam version 2 (MMSE-2) 4-9 stratification group|The changes from baseline at Weeks 5, 9, 13 and 15 in the Severe Impairment Battery (SIB) total score for subjects in the Mini Mental State Exam version 2 (MMSE-2) 10-15 stratification group|Individual patient's slope over time in SIB total score evaluated via Weeks 0, 5, 9, and 13","Neurotrope Bioscience, Inc.|Worldwide Clinical Trials","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","108","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NTRP101-203","June 20, 2018","July 25, 2019","July 25, 2019","June 18, 2018",,"August 20, 2019","Neuro Pain Medical Center, Fresno, California, United States|Nader Pharmacology Research Institute, Los Alamitos, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Southern California Research, LLC, Simi Valley, California, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health / Stein Gerontological Institute, Miami, Florida, United States|Phoenix Medical Research, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Bioclinica Research, The Villages, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Columbus, Georgia, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Insight Clinical Trials, LLC, Shaker Heights, Ohio, United States|Memory Health Center at Summit Research Network, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03560245"
236,"NCT03444870","Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Gantenerumab|Drug: Placebo","Change From Baseline to Week 104 in Global Outcome, as Measured by Clinical Dementia Rating−Sum of Boxes (CDR-SOB)|Change from Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition, Subscale 11 (ADAS-Cog11)|Change from Baseline to Week 104 in Mini-Mental State Examination (MMSE) Total Score|Change from Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADAS-Cog13)|Change from Baseline to Week 104 in Verbal Fluency Task Score|Change from Baseline to Week 104 in Functional Activities Questionnaire (FAQ) Score|Change from Baseline to Week 104 in Coding|Change from Baseline to Week 104 in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Total Score|Percentage of Participants with Adverse Events|Percentage of Participants With Anti-drug Antibody (ADA) to Gantenerumab|Plasma Concentration of Gantenerumab Administered SC|Change from Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a subset of patients up to Week 104|Change from Baseline in Brain Tau Load as Measured by Tau PET Scan in a subset of patients up to Week 104|Change From Baseline in Cerebral Spinal Fluid (CSF) Marker of Disease in a subset of patients - Amyloidbeta 1−42 (Aβ1−42) up to Week 104|Change From Baseline in CSF Marker of Disease in a subset of patients - Total Tau up to Week 104|Change From Baseline in CSF Marker of Disease in a subset of patients - Phosphorylated Tau up to Week 104|Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI) up to Week 104|Change from Baseline to Week 104 in Instrumental Score","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN29922|2017-001364-38","June 6, 2018","May 31, 2022","March 2, 2023","February 23, 2018",,"September 24, 2019","Center for Neurosciences, Tucson, Arizona, United States|CITrials, Inc., Bellflower, California, United States|Global Clinical Trials; Irvine, CA, Irvine, California, United States|Excell Research, Oceanside, California, United States|ASCLEPES Research Centers, Panorama City, California, United States|CITrials, Inc., Riverside, California, United States|Sutter Medical Group, Neurology, Sacramento, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|North Bay Neuro Science Institute, Sebastopol, California, United States|California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States|Upland Clinical Research, Upland, California, United States|Coastal Connecticut Research, Llc, New London, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|SIH Research, Kissimmee, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Global Medical Institues, LLC; Central Miami Medical Institute, South Miami, Florida, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Columbus Memory Center, Columbus, Georgia, United States|Center for Advanced Research & Education, Gainesville, Georgia, United States|University of Chicago; Neurology, Chicago, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Neuropsychiatric Research, Winfield, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, United States|Via Christi Research, Wichita, Kansas, United States|Precise Research Centers, Flowood, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Galen Clinical Research, Chesterfield, Missouri, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, PA, West Long Branch, New Jersey, United States|Neurological Associates of Long Island, PC, Lake Success, New York, United States|Weill Cornell Memory Disorders, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Richard H Weisler, MD, Raleigh, North Carolina, United States|Ohio State University; College of Medicine, Columbus, Ohio, United States|UC Health Neurology, Dayton, Ohio, United States|Oregon Center for Clinical Investigations, Inc, Portland, Oregon, United States|Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University; College of Medicine, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Coastal Neurology, Port Royal, South Carolina, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Clinical Research Associates, Nashville, Tennessee, United States|FutureSearch Trials, LP, Austin, Texas, United States|Senior Adults Specialty Research, Austin, Texas, United States|Neurology Consultants of Dallas; Research Department, Dallas, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Sentara Neurology Specialists, Norfolk, Virginia, United States|Neurological Associates, Inc., Richmond, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|UW Wisconsin-Madison, Madison, Wisconsin, United States|St Vincent's Hospital Sydney; Neurology, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Queensland University of Technology, Mermaid Waters, Queensland, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Peninsula Therapeutic & Research Group, Frankston, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|HammondCare Aged Psychiatry Clinical Trials, Malvern, Victoria, Australia|Neuro Trials Victoria, Noble Park, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|CCBR - Brasilia, Brasilia, DF, Brazil|Flumignano Instituto de Medicina, Curitiba, PR, Brazil|Hospital Nossa Senhora das Graças; Centro de Pesquisas em Neurologia, Curitiba, PR, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil|Clinica Clinilive ltda, Maringa, PR, Brazil|Instituto de Psiquiatria - UFRJ, Rio de Janeiro, RJ, Brazil|Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brazil|Universidade Federal de São Carlos, Sao Carlos, SP, Brazil|Universidade Federal de Sao Paulo - UNIFESP; Neurologia, Sao Paulo, SP, Brazil|Clínica Dr. Norton Sayeg LTDA - EPP, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Neurologia, Sao Paulo, SP, Brazil|The Med Arts Health Rsrch Grp, Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|The Medical Arts Health Research Group, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Center for Diagnosis and Research on Alzheimer's disease, Greenfield Park, Quebec, Canada|Institute Universitaire de Geriatrie de Montreal, Montréal, Quebec, Canada|CHA Hopital de I enfant-Jesus, Quebec City, Quebec, Canada|Q & T Research Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|ALPHA Recherche Clinique, Quebec, Canada|Peking Union Medical College Hospital, Beijing City, China|Beijing Tian Tan Hospital,Capital Medical University, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, China|Tianjin Medical University General Hospital, Tianjin (天津), China|Tangdu Hospital, The Fourth Military Medical University; Neurology Department, Xi'an, China|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|CHU Amiens Hopital Sud; Neurologie, Amiens Cedex1, France|CHU Angers, Angers, France|Hôpital Avicenne; Centre de Recherche Clinique, Bobigny Cedex, France|Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie, Bordeaux, France|Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U102), Bron cedex, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hôpital Lariboisière, Paris, France|CH Pitie Salpetriere; IM2A, Paris, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|CHU Strasbourg - Hôpital Hautepierre, Strasbourg, France|Gerontopole; Centre de Recherche clinique, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin, Berlin, Germany|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|St. Josef-Hospital, Klinik für Neurologie, Bochum, Germany|Universitätsklinikum Düsseldorf; Neurologische Klinik, Düsseldorf, Germany|NeuroCentrum Odenwald; Dres. Reifschneider, Unsorg, Ries, Schumann, Hoffmann, Knoblich, Erbach/Odenwald, Germany|Universitätsklinikum Essen, Elisabeth-Krankenhaus, Klinik für Geriatrie, Haus Berge, Contilia GmbH, Essen, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum f.Psychosoz.Medizin Klinik f.Psychiatrie, Hamburg, Germany|Universitätsklinikum des Saarlandes Klinik f. Psychiatrie und Psychotherapie, Homburg/Saar, Germany|Universitätsklinikum Köln; Klinik und Poliklinik für Psychiatrie und Psychotherapie, Köln, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsmedizin derJohannes Gutenberg-Universität Mainz;Klinik für Psychiatrie und Psychotherapi, Mainz, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|ZNS Siegen im MVZ Weidenau, Siegen, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Forschungszentrum Ruhr, Witten, Germany|Semmelweis University; Department of Neurology, Budapest, Hungary|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Policlinico Universitario Agostino Gemelli; UOC Neurologia, Roma, Lazio, Italy|Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Ambulatorio di Neurologia, Genova, Liguria, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria, Milano, Lombardia, Italy|Casa di Cura Policlinico; Dipartimento di Scienze Neuroriabilitative, Milano, Lombardia, Italy|ASST DI MONZA; Neurologia, Monza, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria, Torino, Piemonte, Italy|Dipartimento delle Patologie Emergenti; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Sicilia, Italy|Medical Corporation Hakuyokai Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Tokyo Bay Advanced Medical and Makuhari Clinic, Chiba, Japan|Inage Neurology and Memory Clinic, Chiba, Japan|Juntendo University Urayasu Hospital, Chiba, Japan|Southern Tohoku Medical Clinic, Fukushima, Japan|Yuai Clinic, Kanagawa, Japan|Shonan Kamakura General Hospital, Kanagawa, Japan|Mishima Hospital, Niigata, Japan|NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan|Shizuoka City Shimizu Hospital, Shizuoka, Japan|Jichiidai Station Brain Clinic, Tochigi, Japan|Yotsuya Medical Cube, Tokyo, Japan|Tokyo Medical & Dental University Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|Nozomi Memory Clinic, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|P-One Clinic, Tokyo, Japan|Yamagata Tokusyukai Hospital, Yamagata, Japan|Vilnius University Hospital Santariskiu Clinics; Neurology, Vilnius, Lithuania|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Peru|Clinica Internacional; Unidad De Investigacion, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, Peru|Hospital Nacional Cayetano Heredia; Servicio de Neurologia, San Martin de Porres, Peru|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, Russian Federation|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Central Clinical Hospital #2 N.A. Semashko OAO RJHD, Moscow, Russian Federation|City Clin Hosp n.a. S.P.Botkin, Moscow, Russian Federation|Samara Psychiatric Hospital, Samara, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|City Psychiatric Hospital #3 of Skvortsov-Stepanov, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|SBHI SR Region Specialized Psychiatric Hospital #2, Stavropol, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, Russian Federation|Llc Lion-Med, Voronezh, Russian Federation|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|UVaMID Hospital Santa Caterina;; Servicio de Neurología, Salt, Girona, Spain|Hospital San Pedro; Servicio de Neurología, Logroño, LA Rioja, Spain|HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatría, Móstoles, Madrid, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría, Salamaca, Salamanca, Spain|Hospital General Universitario de Albacete; Servicio de Neurología, Albacete, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Universitari Quiron Dexeus;; Servicio Neurología, Barcelona, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Ruber Internacional; Servicio de Neurología, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Virgen del Rocío; Servicio de Neurología, Sevilla, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Servicio de Neurología Hospital Viamed Montecanal., Zaragoza, Spain|Changhua Christian Hospital; Neurology, Changhua County, Taiwan|Kaohsiung Medical University Hospital; Neurology, Kaohsiung, Taiwan|Chang Gung Memorial Foundation - Kaohsiung - Neurology, Kaohsiung, Taiwan|China Medical University Hospital; Neurology, Taichung, Taiwan|National Taiwan University Hospital; Neurology, Taipei, Taiwan|Taipei Veterans General Hospital-Neurology, Taipei, Taiwan|Chang Gung Memorial Foundation - Linkou - Neurology, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03444870"
237,"NCT02580305","SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: SUVN-502|Drug: Placebo","Change in cognition|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change in functioning|Change in behavioural disturbance|Depression and Dementia|Risk of suicidality|Change in cognitive aspects of mental function|Safety and tolerability","Suven Life Sciences Limited","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","563","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTP2S1502HT6","September 2015","September 2019","October 2019","October 20, 2015",,"August 26, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro-Pain Medical Center Inc, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Easton Center for Alzheimer's Disease Research at UCLA, Los Angeles, California, United States|Paradigm Research, San Diego, California, United States|Associated Neurologists of South Connecticut, Fairfield, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida - Byrd Alzheimer's Institute, Tampa, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|KU Medical Center Wichita Clinical Trial Unit, Wichita, Kansas, United States|University Of Kentucky, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Acadia Hospital, Bangor, Maine, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Advanced Memory Research Institute of NJ, PC - Internal Medicine, Rahway, New Jersey, United States|Advanced Memory Research Institute, Toms River, New Jersey, United States|Biobehavioral Health, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Mid Hudson Medical Research, New Windsor, New York, United States|New York University, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Upstate University Hospital (SUNY Health Science Center), Syracuse, New York, United States|Five Towns Neuroscience Research, Woodmere, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Alzheimer Memory Center, Charlotte, North Carolina, United States|Richard Weisler, MD, PA, Raleigh, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Northeastern Pennsylvania Memory and Alzheimers Center, Plains, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Shepherd Healthcare, Lewisville, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States|Independent Psychiatric Consultants, SC, dba, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02580305"
238,"NCT02811653","Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease","TAMA","Recruiting","No Results Available","Alzheimer Disease","Device: Brain MRI|Other: neuropsychological evaluation|Biological: Blood","median SRT (simple reaction time) to a stimulus (in milliseconds)","Centre Hospitalier Universitaire, Amiens","All","40 Years to 85 Years   (Adult, Older Adult)","Not Applicable","155","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PI2015_843_0003","December 2015","December 2019","December 2019","June 23, 2016",,"June 23, 2016","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT02811653"
239,"NCT01734395","A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Galantamine","Change From Baseline at Week 16 in Attention Questionnaire Scores (AQS)|Change From Baseline at Week 16 in Burden Interview (BI) Scores|Change From Screening at Week 16 in Mini Mental State Exam Scores (MMSE)","Janssen Korea, Ltd., Korea","All","50 Years and older   (Adult, Older Adult)",,"1882","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CR100958|GAL-KOR-024|GALALZ4045","March 2007","January 2008","January 2008","November 27, 2012","August 5, 2013","August 5, 2013",,,"https://ClinicalTrials.gov/show/NCT01734395"
240,"NCT03047694","A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease","SemantiMATT","Recruiting","No Results Available","Alzheimer Disease","Other: tablet therapy|Other: usual care","variation of performance on naming subtest of the LEXIS|variation of performance on designation subtest of the LEXIS|variation of performance on semantic matching subtest of the LEXIS|variation of performance on DO80 lexico-semantic test|variation of performance on verbal fluency lexico-semantic test|variation of performance on verbal discrimination of BADAE|variation of performance on episodic memory test (RL/RI)|variation of performance on Mini-Mental State Examination (MMSE)|variation of score on depression scale (HAD)|variations on care giver's questionary","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P140707|2015-A01312-47","July 15, 2019","March 2022","July 2022","February 9, 2017",,"August 8, 2019","Hôpital Pitié-Salpêtriere, Paris, France|APHP - Pitié-Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03047694"
241,"NCT00702780","Progression Delaying Effect of Escitalopram in Alzheimer's Disease","ESAD","Completed","Has Results","Alzheimer's Disease","Drug: escitalopram|Drug: placebo","% Change of Hippocampus Volume|% Change of Whole Brain Volume","Seoul National University Hospital|H. Lundbeck A/S","All","40 Years to 90 Years   (Adult, Older Adult)","Not Applicable","74","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNUDC001","November 2008","September 2011","September 2011","June 20, 2008","June 13, 2014","June 13, 2014","Kangwon National University Hospital, Chuncheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00702780"
242,"NCT03363269","Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: ID1201","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) at 12 Weeks","IlDong Pharmaceutical Co Ltd","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ID-BOA-201","April 12, 2016","December 31, 2018","April 17, 2019","December 6, 2017",,"June 4, 2019","Dong-A University Hospital, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Kangwon National University Hospital, Chuncheon, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|Hanyang University Guri Hospital, Guri, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|KunKuk University Hospital, Seoul, Korea, Republic of|Ajou University Medical Center, Suwon, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03363269"
243,"NCT03119961","Blood Brain Barrier Opening in Alzheimer' Disease","BOREAL1","Unknown status","No Results Available","Alzheimer Disease","Device: SONOCLOUD®","Florbetapir SUVr and Fluorodeoxyglucose MUV changes in BBB opening region of interest (ROI)|Adverse events recording","Assistance Publique - Hôpitaux de Paris|CarThera|BPIfrance","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150101|2016-004145-82|B2016-A01637-44","June 26, 2017","April 1, 2019","July 1, 2019","April 19, 2017",,"August 3, 2017","APHP - Pitié-Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03119961"
244,"NCT03186989","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",,"Recruiting","No Results Available","Mild Alzheimer's Disease","Drug: IONIS MAPTRx|Other: Placebo","Incidence and severity of adverse events that are related to treatment with IONIS MAPTRx|Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (trough concentration)|Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (maximum observed drug concentration or Cmax)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (time taken to reach maximal concentration or Tmax)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Plasma terminal elimination half-life (t1/2λz)|Pharmacokinetics after ascending dose-levels of multiple IT bolus administrations on IONIS MAPTRx (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the IT administration (AUCt)","Ionis Pharmaceuticals, Inc.","All","50 Years to 74 Years   (Adult, Older Adult)","Phase 1|Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","ISIS 814907-CS1|NL60032.000.16|2016-002713-22","June 5, 2017","January 31, 2020","February 29, 2020","June 14, 2017",,"August 26, 2019","Montreal Neurological Hospital, Montréal, Canada|Clinical Research Services Turku CRST, Turku, Finland|Charite - Universitaetsmedizin Berlin Campus Mitte, Berlin, Germany|St Josef Hospital, Bochum, Germany|Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany|MVZ Mittweida Gbr, Mittweida, Germany|Universittsklinikum Ulm, Ulm, Germany|VU University Medical Center, Amsterdam, Netherlands|QPS Netherlands BV, Groningen, Netherlands|Minnesmottagningen, Mölndal, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Royal Liverpool University Hospital, Liverpool, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Sheffield Institute for Translational Neuroscience (SITraN), Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03186989"
245,"NCT03093519","A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: KHK6640|Drug: Placebo","Number of Participants with Adverse Events","Kyowa Kirin Co., Ltd.","All","55 Years to 84 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6640-003","March 3, 2017","December 6, 2017","December 6, 2017","March 28, 2017",,"March 20, 2018","Closed information, Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT03093519"
246,"NCT03668405","A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Lu AF20513","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Aβ-specific antibody titre in plasma","H. Lundbeck A/S","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16026B|2014-001797-34","June 26, 2018","February 22, 2019","May 27, 2019","September 12, 2018",,"June 10, 2019","FI001, Turku, Finland|SE002, Malmö, Sweden|SE003, Mölndal, Sweden|SE001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03668405"
247,"NCT03307993","Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Idalopirdine","5-HT6 Receptor Occupancy (RO)|Idalopirdine plasma concentration (CPET)","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17475A","September 22, 2017","February 19, 2018","February 19, 2018","October 12, 2017",,"April 4, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03307993"
248,"NCT01970150","The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer Disease","Device: rTMS real","A change in the quantitative EEG spectra in the frontal lobe, i.e. a change in percentage of theta waves, alpha and beta waves|Improvement on memory and attention","Lawson Health Research Institute","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","104382","February 2014","April 2015","April 2015","October 25, 2013",,"September 7, 2016","Regional Mental Health Care London, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01970150"
249,"NCT03221894","A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Dietary Supplement: GRAPE granules","Mini-Mental State Examination (MMSE)|Activities of Daily Living (ADLs)|Clinical Dementia Rating (CDR)|Neuropsychiatric Inventory (NPI)","Dongzhimen Hospital, Beijing|Beijing Hospital|Chinese PLA General Hospital|Peking University Third Hospital","All","50 Years to 85 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2017-IRT-0810","July 15, 2017","September 2017","September 2017","July 19, 2017",,"July 25, 2017","Dongzhimen Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03221894"
250,"NCT01312363","Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients","X-MEN","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine patch","Number of participants with adverse events|Factors for the disuse of Rivastigmine patch","Seoul National University Hospital|Seoul National University Bundang Hospital|Seoul St. Mary's Hospital|Korea University|Bobath Memorial Hospital|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Hanyang University|Kwandong University Myongji Hospital|Inha University Hospital|SungAe General Hospital|Ewha Womans University|Inje University|Hanyang University Seoul Hospital|Kyunghee University Medical Center|Hallym University Medical Center|Pusan National University Hospital|Konyang University Hospital|Wonkwang University Sanbon Medical Center|Yong-in Hyoja Geriatric Hospital|Jeju National University|Dong-A University Hospital","All","51 Years to 85 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","X-MEN","June 2009","June 2011","July 2011","March 10, 2011",,"May 4, 2016","Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Wonkwang University Sanbon Medical Center, Gunpo-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of|Bobath Memorial Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Yong-in Hyoja Geriatric Hospital, Yongin-si, Gyeonggi-do, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Hallym University Chunchon Hospital, Chunchon, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Jeju National University Hospital, Jeju, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|SungAe General Hospital, Seoul, Korea, Republic of|Chungang University Hospital, Seoul, Korea, Republic of|Ewha Womans University Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Kyung Hee University Medical Center, Seoul, Korea, Republic of|Sanggye Paik Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01312363"
251,"NCT02686190","Effects of Light-therapy in Alzheimer's Disease","ALZ-Light","Completed","No Results Available","Alzheimer's Disease","Other: Luxtherapy","score agitation / aggression scale NPI-nurse|score agitation-aggression scale NPI-nurse","Assistance Publique - Hôpitaux de Paris","All","60 Years and older   (Adult, Older Adult)","Not Applicable","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P081119|IDRCB","July 2012","April 2014","December 2014","February 19, 2016",,"March 17, 2016","Hôpital Charles Foix, Ivry-sur-Seine, France",,"https://ClinicalTrials.gov/show/NCT02686190"
252,"NCT03208491","AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders","AZ@GAME-Eco","Unknown status","No Results Available","Alzheimer Disease","Other: serious games use|Other: usual care","cost utility ratio","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-PRME-01","September 30, 2017","March 30, 2018","December 30, 2018","July 5, 2017",,"July 5, 2017",,,"https://ClinicalTrials.gov/show/NCT03208491"
253,"NCT02772523","Control and Intervention Programme on Alzheimer's Disease Risk Factors","ALFAlife","Active, not recruiting","No Results Available","Alzheimer's Disease","Other: Lifestyle recommendations","Change in Short Version of the Minnesota Leisure Time Physical Activity Questionnaire|Change in 14-item mediterranean diet Questionnaire|Change in Lifestyle Activities Questionnaire (LAQ)","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","45 Years to 78 Years   (Adult, Older Adult)","Not Applicable","409","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ALFAlife/BBRC2015","May 2016","January 2018","May 2019","May 13, 2016",,"August 29, 2018","Barcelonabeta Brain Research Center, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT02772523"
254,"NCT02912936","A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease","MINT-01","Recruiting","No Results Available","Alzheimer's Disease","Dietary Supplement: Ketogenic medium chain triglyceride drink (MCT drink)|Dietary Supplement: Placebo","Number of participants with adverse events, serious adverse events|Plasma ketone concentrations in response to ascending dose of MCT|Area under the plasma concentration versus time curve (AUC) of MCT","University of British Columbia|Université de Sherbrooke","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H15-02537","September 2016","December 2019","December 2019","September 23, 2016",,"December 5, 2018","Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02912936"
255,"NCT03634007","Gene Therapy for APOE4 Homozygote of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Early Onset Alzheimer Disease","Biological: AAVrh.10hPOE2 vector","Safety of AAVrh.10hAPOE2 gene therapy, as measured by number of adverse events or serious adverse events|Maximum tolerated dose of intracisternal delivery of AAVrh.10hAPOE2 gene therapy to APOE4 homozygotes with Alzheimer's disease","Weill Medical College of Cornell University","All","50 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1806019315","September 2019","December 2020","December 2021","August 16, 2018",,"August 26, 2019","Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03634007"
256,"NCT03443973","Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Change From Baseline to Week 104 in Global Outcome, as Measured by Clinical Dementia Rating−Sum of Boxes (CDR-SOB)|Change From Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Subscale Score|Change From Baseline to Week 104 in Mini-Mental State Examination (MMSE) Total Score|Change from Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADAS-Cog13)|Change From Baseline to Week 104 in Verbal Fluency Task Score|Change From Baseline to Week 104 in Functional Activities Questionnaire (FAQ) Score|Change From Baseline to Week 104 in Coding|Change From Baseline to Week 104 in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Total Score|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab|Plasma Concentration of Gantenerumab|Change from Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a subset of patients up to Week 104|Change From Baseline in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Patients up to Week 104|Change From Baseline in Cerebral Spinal Fluid (CSF) Marker of Disease in a Subset of Patients - Amyloid-beta 1−42 (Aβ1−42) up to Week 104|Change From Baseline in CSF Marker of Disease in a Subset of Patients - Total Tau up to Week 104|Change From Baseline in CSF Marker of Disease in a Subset of Patients - Phosphorylated Tau up to Week 104|Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI) up to Week 104|Change from Baseline to Week 104 in Instrumental Score","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN39658|2017-001365-24","August 22, 2018","May 31, 2022","March 2, 2023","February 23, 2018",,"September 24, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Noesis Pharma Clinical Trials, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Health Initiatives Research, PLLC, Fayetteville, Arkansas, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|UCLA - School of Medicine, VA Medical Center, Los Angeles, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Pacific Research Network - PRN, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Southern California Research LLC, Simi Valley, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Christiana Care Swank Memory Care Center, Wilmington, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Global Medical Institues, LLC; Boynton Beach Medical Research Institute, Boynton Beach, Florida, United States|Meridien Research, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|ClinCloud, LLC, Maitland, Florida, United States|Optimus U Corp, Miami, Florida, United States|Allied Biomedical Research Institute, Inc, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare; Ocoee, FL, Ocoee, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Chicago Research Center, Inc., Chicago, Illinois, United States|Heathcare Research Network II, LLC, Flossmoor, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|American Health Network Institute, LLC, Avon, Indiana, United States|University of Kansas Medical Centre, Kansas City, Kansas, United States|Conduct Clinical Trials; Psychiatry Associates of Kansas City, Leawood, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Acadia Hospital, Bangor, Maine, United States|University of Maryland Clinical Neurobehavioral Center, Columbia, Maryland, United States|Brigham and Womens Hospital; Center for Alzheimer Research & Treatment, Boston, Massachusetts, United States|ActivMed Practices and Research, Haverhill, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Missouri Memory Center, Bolivar, Missouri, United States|St Louis University Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center; Dept of Neurological Sciences, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|NJ Institute for Successful Aging, Stratford, New Jersey, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Pioneer Midwood, Brooklyn, New York, United States|UNiversity of Rochester, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|University Hospitals Brain Health & Memory Center, Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Cleveland Clinic; Cleveland Lou Ruvo Center for Brain Health - Neurological Institute, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research, Oklahoma City, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Lehigh Center Clinical Research, Allentown, Pennsylvania, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States|BG Neurology, LLC, Spartanburg, South Carolina, United States|Texas Neurology PA, Dallas, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Shepherd Healthcare, Flower Mound, Texas, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Core Clinical Research, Everett, Washington, United States|Seattle Institute for Biomedical & Clinical Research, Seattle, Washington, United States|Kingfisher Cooperative, Spokane, Washington, United States|Hospital Italiano, Buenos Aires, Argentina|Universidad Maimonides, Caba, Argentina|Instituto Geriatrico Nuestra Señora de las Nieves, Capital Federal, Argentina|CEN Centro Especializado en Neurociencias, Córdoba, Argentina|Instituto Kremer, Córdoba, Argentina|Instituto de Neurociencias San Agustín S.A., La Plata, Argentina|Fundación Scherbovsky, Mendoza, Argentina|AZ Sint Blasius (Dendermonde), Dendermonde, Belgium|UZ Gent, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|Clinique Saint-Joseph, Liège, Belgium|Psicomed Estudios Médicos, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, Croatia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Odense Universitetshospital, Neurologisk Afd. N;Demensklinikken, Odense C, Denmark|Terveystalo Ruoholahti, Helsinki, Finland|University of Eastern Finland, Kuopio, Finland|CRST Oy, Turku, Finland|Yachiyo Hospital, Aichi, Japan|Nagoya Ekisaikai Hospital, Aichi, Japan|National Center for Geriatrics and Gerontology, Aichi, Japan|Fukuoka University Hospital, Fukuoka, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Hyogo Brain and Heart Center at Himeji, Hyogo, Japan|Tsukazaki Hospital, Hyogo, Japan|Matsui Dietary and Dementia Clinic, Hyogo, Japan|Kagawa Prefectural Central Hospital, Kagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|Uji Takeda Hospital, Kyoto, Japan|Nara City Hospital, Nara, Japan|Okayama Kyokuto Hospital, Okayama, Japan|Katayama Medical Clinic, Okayama, Japan|MI Clinic, Osaka, Japan|Kishiwada Tokushukai Hospital, Osaka, Japan|National Hospital Organization Hizen Psychiatric Center, Saga, Japan|Medical corporation Ichiekai Itsuki Hospital, Tokushima, Japan|Tokushima Hospital, Tokushima, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Myongji Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Bucheon St Mary's hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Español; Servicio de Nuerologia, Ciudad de México, Mexico CITY (federal District), Mexico|Grupo Medico de Investigacion Clinica Multidisciplinaria, Mexico City, Mexico CITY (federal District), Mexico|Unidad de investigacion en salud (UIS); Neurociencias, Ciudad de México, Mexico|Hospital Angeles Culiacan; Neurociencias, Culiacan, Mexico|Mexico Centre for Clinical Research, Mexico, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta, Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|NZOZ Vitamed, Bydgoszcz, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych, Plewiska, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland|Pratia S.A., Warszawawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Ośrodek Badawczo-Naukowo-Dydaktyczny Chorób Otępiennych w Ścinawie, Ścinawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Braga; Servico de Neurologia, Braga, Portugal|HUC; Servico de Neurologia, Coimbra, Portugal|Hospital da Senhora da Oliveira-Guimarães; Serviço de Neurologia, Guimarães, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, Portugal|Santa Cruz Behavioral PSC, Bayamon, Puerto Rico|Instituto De Neurologia Dra. Ivonne Fraga, PSC, San Juan, Puerto Rico|Dr Michel A. Woodbury, PSC, San Juan, Puerto Rico|University of Puerto Rico - Medical Science Campus; Internal Medicine, San Juan, Puerto Rico|National University Hospital (NUH); Neuroscience, Singapore, Singapore|National Neuroscience Institute; Neurology, Singapore, Singapore|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Policlínica Guipuzcoa; Servicio de Neurología, Donostia-san Sebastian, Guipuzcoa, Spain|Hospital Universitario de Santa Maria; Servicio de Neurología, Lleida, Lerida, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|CAE OROITU; Servicio de Neurología, Getxo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Instituto Internacional de Neurociencias Aplicadas (IINA); Servicio de Psiquiatría, Barcelona, Spain|Fundación ACE; Servicio de Neurología, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, Spain|Clinica Universitaria Navarra; Servicio Neurologia, Madrid, Spain|Hospital Victoria Eugenia; Servico Neurología, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, Spain|Complejo Asistencial de Zamora; Servicio Psiquiatria, Zamora, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Istanbul Bilim Sisli UTF, Esentepe, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Bezmialem Vakif Univ Medical, Istanbul, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|Royal Cornhill Hospital; OAP Directorate, Aberdeen, United Kingdom|The Rice Centre; Royal United Hospital, Bath, United Kingdom|Re-Cognition, Birmingham, United Kingdom|MAC Clinical Research; Blackpool, Blackpool, United Kingdom|The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre, Cheltenham, United Kingdom|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|MAC Clinical Research; Leeds, Leeds, United Kingdom|St George's Hospital, London, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Campus for Ageing and Vitality, Newcastle Upon Tyne, United Kingdom|Tees,Esk and Wear Valleys NHS Foundation Trust, North Yorkshire, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Derriford Hospital; Neurology, Plymouth, United Kingdom|MAC Clinical Research; Liverpool, Prescot, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|University Southampton NHS Foundation Trust; Wessex Neurologica Centre, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03443973"
257,"NCT00593372","Treatment of Language and Memory in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Behavioral: Spaced Retrieval Training","Number of Successful Memory Tasks Completed Over Study Period.|Change on Mini-Mental State Examination","University of Arkansas","All","21 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","g1-10532-03-07","August 2003","April 2010","April 2010","January 15, 2008","July 20, 2010","January 9, 2017","UAMS Medical Center, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00593372"
258,"NCT00708552","Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: SB-742457|Drug: Donepezil|Drug: Placebo","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24|Clinician's Interview-Based Impression of Change - Plus (CIBIC+) Score at Week 24|Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline Mini Mental State Examination [MMSE] Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline [MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 24|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 24|Change From Baseline in ADAS-Cog Total Score at Week 12|CIBIC+ Score at Week 12|Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 12|Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 12|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score at Weeks 12 and 24|Change From Baseline in Cornell Scale for Depression in Dementia (CSDD) Total Score at Week 24|Change From Baseline in MMSE Total Score at Week 24|Change From Baseline in ADCS-ADL-Basic Score; ADCS-ADL: Instrumental Score and ADCS-ADL: Total Independence Score at Weeks 12 and 24|Number of Participants With Any Adverse Event (Serious and Non-serious) and Serious Adverse Events (SAEs)|Number of Participants With Vital Signs Data of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT)|Number of Participants With Hematology Data of PCC ATOT|Number of Participants With Chemistry Data of PCC ATOT|Change From Baseline in Clinical Chemistry Parameters Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Week 24|Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein at Week 24|Change From Baseline in Clinical Chemistry Parameter Blood Urea Nitrogen /Creatinine Ratio at Week 24|Change From Baseline in Clinical Chemistry Parameters Calcium, CO2 Content/Bicarbonate, Chloride, Glucose, HDL Cholesterol, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen at Week 24|Change From Baseline in Clinical Chemistry Parameters Creatinine, Direct Bilirubin and Total Bilirubin at Week 24|Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Segmented Neutrophils, Total Neutrophils, White Blood Cell Count at Week 24|Change From Baseline in Hematology Parameter Hematocrit|Change From Baseline in Hematology Parameters Hemoglobin and Mean Corpuscle Hemoglobin Concentration at Week 24|Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin at Week 24|Change From Baseline in Hematology Parameter Mean Corpuscle Volume and Mean Platelet Volume at Week 24|Change From Baseline in Hematology Parameter Red Blood Cell Count at Week 24|Number of Participants With Electrocardiogram (ECG) Findings as Assessed by Investigator and Central Cardiologist|Exposure Estimates for SB-742457 Area Under Curve Over the Dosing Interval at Steady State (AUCτss)|Exposure Estimates for SB-742457 Minimum Concentration at Steady State (Cmin-ss)|Exposure Estimates for Donepezil Average Concentration at Steady State (Cavgss)","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","576","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AZ3110865","July 4, 2008","March 1, 2010","March 9, 2010","July 2, 2008","February 12, 2018","July 27, 2018","GSK Investigational Site, Shumen, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 1, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuburg / Donau, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Aguascalientes, Ags, Aguascalientes, Mexico|GSK Investigational Site, Tijuana, Baja California Norte, Mexico|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Durban, South Africa|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Pretoria, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Sunninghill, South Africa",,"https://ClinicalTrials.gov/show/NCT00708552"
259,"NCT02033941","Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Meganatural-Az Grapeseed Extract|Drug: Placebo","pharmacokinetic analysis|primary safety evaluations|AD Biomarkers|cognitive and functional assessments","Hillel Grossman|National Center for Complementary and Integrative Health (NCCIH)|Icahn School of Medicine at Mount Sinai","All","Child, Adult, Older Adult","Phase 2","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 09-0307|5R21AT005510","November 2014","September 2020","September 2020","January 13, 2014",,"March 13, 2019","Mount Sinai Alzheimer's Disease Research Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02033941"
260,"NCT03402659","Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease","REVERSE-SD","Completed","No Results Available","Alzheimer Disease","Drug: neflamapimod|Other: placebo","Improvement in total and delayed recall on the Hopkins Verval Learning Test - Revised (HVLT-R)|Wechsler Memory Scale (WMS) Immediate and delayed Recall|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Mini-Mental State Examination (MMSE)|Cerebrospinal fluid phospho-tau|Cereberspinal fluid amyloid beta 1-40","EIP Pharma Inc|Worldwide Clinical Trials|VU University Medical Center","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","161","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EIP-VX17-745-304","December 29, 2017","June 30, 2019","July 31, 2019","January 18, 2018",,"October 3, 2019","Alliance for Research, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|CITrials, Santa Ana, California, United States|Southern California Research, LLC, Simi Valley, California, United States|Viking Clinical Research, Temecula, California, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts, United States|Manhattan Behavioral Medicine, New York, New York, United States|Alzheimer's Memory Center and Research Institute, Charlotte, North Carolina, United States|Northwest Clinical Research Center, Seattle, Washington, United States|Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s., Choceň, Czechia|Cerebrovaskulární poradna s.r.o., Moravská Ostrava, Czechia|Clintrial S.R.O, Prague, Czechia|Private Psychiatric Centre, Prague, Czechia|Vestra Clinics S.R.O, Rychnov Nad Kněžnou, Czechia|CCBR Clinical Research, Aalborg, Aalborg, Denmark|CCBR Clinical Research, Ballerup, Ballerup, Denmark|CCBR Clinical Research, Vejle, Vejle, Denmark|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekhuis, Breda, Netherlands|MAC Clinical Research Tankersley, Barnsley, United Kingdom|Re:Cognition Health Birmingham, Birmingham, United Kingdom|MAC Clinical Research Blackpool, Blackpool, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|MAC Clinical Research Leeds, Leeds, United Kingdom|MAC Clinical Research Liverpool, Liverpool, United Kingdom|Re:Cognition Health London, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|MAC Clinical Research Manchester, Manchester, United Kingdom|Re:Cognition Health Plymouth, Plymouth, United Kingdom|5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03402659"
261,"NCT01314950","Alzheimer's Disease Multiple Intervention Trial","ADMIT","Completed","No Results Available","Alzheimer's Disease","Behavioral: Home based occupational therapy|Behavioral: Best practices primary care","Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS - ADLI)|Short Physical Performance Battery (SPPB)|Tandem Stand, eyes closed|One Leg Stand, eyes open|Mini Mental State Examination|Word List Learning|Delayed Word List Recall|Grip Strength|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Studies Resource Use Scale|PHQ - 9|GAD - 7|Comorbid Conditions|Adverse Events","Indiana University|National Institute on Aging (NIA)|Regenstrief Institute, Inc.","All","45 Years and older   (Adult, Older Adult)","Not Applicable","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01AG034946-01A1","July 2010","December 2015","December 2015","March 15, 2011",,"March 8, 2016","Wishard Health Services, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01314950"
262,"NCT00334568","Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone XR (extended release) oral tablets|Drug: Placebo","Change in global and regional cerebral glucose metabolism/Cerebral Metabolic Rate for glucose (CMRglu) as measured by the ratio of Ki to K1|Changes in global and regional CMRglu as measured by [18F]FDG uptake.|Global changes in brain structure from baseline as measured by structural MRI from baseline.Vital signs and ECGs.","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AVA100930","December 2004","July 2007","July 2007","June 8, 2006",,"January 14, 2013","GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00334568"
263,"NCT02142777","S-Equol in Alzheimer's Disease (SEAD) Trial","SEAD","Completed","No Results Available","Alzheimer's Disease","Drug: S -Equol|Drug: Placebo","platelet mitochondria cytochrome oxidase (COX) activity|safety of S-equol","Russell Swerdlow, MD|Ausio Pharmaceuticals, LLC|University of Kansas Medical Center","Female","60 Years to 90 Years   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00001228","July 2014","April 2016","April 2016","May 20, 2014",,"August 16, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02142777"
264,"NCT03360552","Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease","EvaMMADom","Not yet recruiting","No Results Available","Alzheimer's Disease","Other: Multidimensional fragility index questionnaire RAI-Home Care|Other: Usual care","Assessment of multidimensional fragility scores","Assistance Publique Hopitaux De Marseille","All","65 Years and older   (Older Adult)","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","2016-54|2017-A01582-51","January 2, 2018","January 1, 2021","January 1, 2021","December 4, 2017",,"December 4, 2017","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03360552"
265,"NCT03283059","Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Octohydroaminoacridine Succinate|Drug: Aricept|Drug: Placebos","Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-Cog)|Clinician's Interview Based Impression of Change - plus (CIBIC+)|Activities of Daily Living (ADL)|Neuropsychiatric Inventory (NPI)","Shanghai Mental Health Center|Changchun Huayang High-tech Co., Ltd|Jiangsu Sheneryang High-tech Co., Ltd","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","600","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","OHAAS-III","August 16, 2017","September 16, 2019","February 16, 2020","September 14, 2017",,"October 10, 2017","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03283059"
266,"NCT03402503","Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease","BUENA","Recruiting","No Results Available","Alzheimer Disease","Drug: Montelukast buccal film|Other: Placebo buccal film","Global Neuropsychological test battery (NTB) Composite|Mini Mental State Examination (MMSE)|Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-items scale (ADCS-ADL23)|Neuropsychiatric Inventory (NPI)|Sheehan Suicide Tracking Scale (S-STS)|Incontinency Frequency Rating|Incidence of Treatment-Emergent Adverse Events","IntelGenx Corp.","All","50 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IGX-CLI-2017-001","November 26, 2018","July 19, 2020","October 19, 2020","January 18, 2018",,"June 20, 2019","Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research, Kentville, Nova Scotia, Canada|Bruyère Research Institute, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Gerontion Research Inc., Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre hospitalier universitaire de Québec -Université Laval, Québec, Quebec, Canada|Centre de recherche sur le vieillissement, CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT03402503"
267,"NCT01068353","Safety and Tolerability of Etanercept in Alzheimer's Disease","STEADI-09","Completed","No Results Available","Alzheimer's Disease","Biological: Etanercept|Other: Placebo","Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)|Difference in change in Alzheimer's Disease Assessment Scale - Cognitive Section (ADAS-cog) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Neuropsychiatric Inventory (NPI) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Clinician's Global Impression of Change (CGIC) and Carer's Impression of Change (Carer-IC) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Mini-Mental State Examination (MMSE) total score between treated and placebo groups from baseline to end point at 6 months|Difference in change in Sickness Behaviour Scale between treated and placebo groups from baseline to end point at 6 months|To establish whether a pro-inflammatory baseline cytokine profile predicts better response to treatment with etanercept|To examine the effects of etanercept on inflammatory markers in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease, and the relationship of these factors with clinical outcome","University of Southampton|Hampshire Hospitals NHS Foundation Trust|Wyeth is now a wholly owned subsidiary of Pfizer","All","55 Years and older   (Adult, Older Adult)","Phase 2","41","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STEADI-09|2009-013400-31","January 2011","December 2013",,"February 12, 2010",,"April 23, 2014","Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01068353"
268,"NCT01126099","Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Prazosin|Drug: Placebo","Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change|Change in Neuropsychiatric Inventory Score|Change in Brief Psychiatric Rating Scale Total Score|Days in Study","Seattle Institute for Biomedical and Clinical Research|National Institute on Aging (NIA)|VA Puget Sound Health Care System","All","Child, Adult, Older Adult","Not Applicable","20","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01AG033133-01A1|5R01AG033133","March 2010","March 2014","March 2014","May 19, 2010","May 21, 2015","May 21, 2015","Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01126099"
269,"NCT02978768","Tai Chi 6-Form Sports Apparatus With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Other: Exercise|Device: Computer-based cognitive training|Device: Physico-Mental rehabilitation Wii","Balance","Chang Gung Memorial Hospital","All","59 Years to 92 Years   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","99-3780B","August 2011","June 2015","June 2015","December 1, 2016",,"December 12, 2016","Chang Gung Memorial Hospital, TaoYuan county, Taiwan",,"https://ClinicalTrials.gov/show/NCT02978768"
270,"NCT02769234","EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer's Disease","Procedure: ERP/EEG test|Procedure: Psychometric testing","Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.|Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.|Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.","Neuronetrix, Inc.|Boston Center for Memory|The Memory Clinic of Vermont|Premiere Research Institute","All","60 Years to 95 Years   (Adult, Older Adult)",,"75","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SRP-1782","May 2016","June 2017","July 2017","May 11, 2016",,"May 30, 2017","Premiere Research Institute, West Palm Beach, Florida, United States|Boston Center for Memory, Brookline, Massachusetts, United States|The Memory Clinic, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02769234"
271,"NCT01374438","3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: MSDC-0160|Drug: Placebo","Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum|Change From Baseline in Global Cognitive Function Tests|Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale|Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale|Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks","Metabolic Solutions Development Company","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSDC-0160-C006","July 2011","March 2013","May 2013","June 16, 2011","November 5, 2014","November 18, 2014","Rush Memorial University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01374438"
272,"NCT02319681","Reminiscence, Anxiety and Early Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Behavioral: Simple Reminiscence (SR)|Behavioral: Attention Control (AC)","Acceptability of SR and AC|Number of times AC was used|Number of times SR was used|Change in Beck Depression Inventory-II (BDI-II) scale|Change in State-Trait Anxiety Inventory (STAI) scale|Change in Katz Instrumental Activities of Daily Living (IADL) scale|Change in Well-Being Picture Scale (WBPS) scale|Change in Short Psychological Well-Being Scale (SPWBS) scale|Change in Revised Memory and Behavior Problems Checklist (RMBPC) scale|Caregiver's mastery of SR intervention technique|Change in levels of cortisol","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00075912","January 2015","December 2016","June 2017","December 18, 2014",,"June 26, 2015","Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02319681"
273,"NCT02245737","An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease","AMARANTH","Terminated","Has Results","Alzheimer´s Disease","Drug: Lanabecestat|Drug: Placebo","Change From Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Change From Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items (ADCS-iADL)|Change From Baseline on the Functional Activities Questionnaire (FAQ) Score|Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change From Baseline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage|Change From Baseline in Neuropsychiatric Inventory (NPI) Score|Change From Baseline on the Mini-Mental State Examination (MMSE)|Pharmacodynamics (PD): Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42|PD: Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40|Change From Baseline in CSF Total Tau|Change From Baseline in CSF Phosphorylated Tau|Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan|Change From Baseline in Tau PET ((Flortaucipir F18)|Change From Baseline in Brain Metabolism Using Fluorodeoxyglucose (FDG)|Change From Baseline in Whole Brain Volume|Pharmacokinetics (PK): Plasma Concentration of Lanabecestat","Eli Lilly and Company|AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","2218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16023|I8D-MC-AZES|2014-002601-38|D5010C00009","September 30, 2014","October 4, 2018","October 4, 2018","September 22, 2014","August 6, 2019","August 6, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Positron Research International, Fremont, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Pacific Research Network Inc, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Direct Helpers Medical Center, Hialeah, Florida, United States|Berma Research, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|MaxBlue Institute, Hialeah, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|Allied Biomedical Research Institute, Inc., Miami, Florida, United States|Advance Medical Research Institute, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|JDH Medical Group, LLC, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLV, Saint Louis, Missouri, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Alzheimer's Research Company, Manchester, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|Alzheimer's Disease and Memory Disorders Center, Buffalo, New York, United States|Empire Neurology, PC, Latham, New York, United States|Clinilabs, Inc (New York), New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|Senior Adults Specialty Research Inc, Austin, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Medical Group of Texas, Fort Worth, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Southern Neurology, Kogarah, New South Wales, Australia|Griffith University, Gold Coast, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Hopital Universitaire Brugmann Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitaire Erasme Brussel, Brussel, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Heilig Hartziekenhuis, Roeselare, Belgium|The Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CSSS-Institut Universitaire Gériatric de Sherbrooke, Sherbrooke, Qubec, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Hopital Maisonneure-Rosemount, Montreal, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|CHU de Toulouse Hopital Purpan, Toulouse, Cedex 9, France|Hopital Neuro Pierre Wertheimer, Bron Cedex, France|CHU Dijonon, Dijon Cedex, France|CHRU Lille - Hopital Roger Salengro, Lille Cedex, France|CHU Hopital de la Timone, Marseille Cedex 05, France|Chu de Nantes Hopital Laennec, Nantes, France|Hopital Broca, Paris, France|Hopital de la Pitie Salpetriere, Paris, France|Hopital Lariboisière, Paris, France|CHU de Toulouse, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Studien und Gedächtniszentrum München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Institut fur Psychogerontologie, Nürnberg, Bayern, Germany|Neurozentrum Prien, Prien am Chiemsee, Bayern, Germany|Institut für Neuropsychiatrie INP3, Wenzenbach, Bayern, Germany|Studienzentrum Nord-West, Westerstede, Niedersachsen, Germany|Praxis Dr. Lauter, Bochum, Nordrhein-Westfalen, Germany|St Josef-Hospital Bochum, Bochum, Nordrhein-Westfalen, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Gemeinschaftspraxis für Neurologie Prof. Gereon Nelles, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Neurologische Praxis Siegen, Siegen, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Sachsen-Anhalt, Germany|Universitätsklinikum Otto-von-Guericke-Universität, Magdeburg, Sachsen-Anhalt, Germany|Pharmakologisches Studienzentrum Chemnitz, Mittweida, Sachsen, Germany|Arztpraxis Dr. Christian Oehlwein, Gera, Thüringen, Germany|Gemeinschaftspraxis Dr. R. Ehret & Dr. W. von Pannwitz, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|PTE KK Pszichiatriai es Pszichoterapias Klinika, Pecs, Baranya, Hungary|Semmelweis Medical University, Budapest, Hungary|Del-pesti Centrumkorház - Orszagos Hematologiai és Infektologiai Intezet, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Univerisity of Szeged, Szeged, Hungary|Ospedale Degli Infermi ASR USSL 12, Ponderano, Biella, Italy|Azienda Ospedaliera San Gerardo, Monza, Milano, Italy|Fondazione San Raffaele Giglio di Cefalu, Cefalu, Palermo, Italy|Universita Di Pisa, Pisa, PI, Italy|Università Politecnica delle Marche Torrette, Ancona, Italy|IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Fondazione Universitaria degli Studi G D'Annunzio, Chieti, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policinico, Milano, Italy|Nuovo Ospedale Civile Sant'Agostino Estense, Modena, Italy|Policlinico Univ. Agostino Gemelli, Roma, Italy|Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza, Roma, Italy|Ospedale San Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Ospedale S. Andrea, Roma, Italy|Azienda Ospedaliera Citta della Salute della Scienza Torino, Torino, Italy|National Institute for Longevity Sciences NCGG, Obu, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Nihon Kokan Hospital, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto-shi, Kyoto, Japan|Ina Central Hospital, Ina, Nagano, Japan|Matsumoto Medical Center, Matsumoto, Nagano, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Shiroma Clinic, Urasoe, Okinawa, Japan|Koshokai aino hospital, Ibaraki, Osaka, Japan|Sakaguchi Clinic, Sakai, Osaka, Japan|National Sanatorium Toneyama Hospital, Toyonaka, Osaka, Japan|Saitama Medical University Hospital, Iruma-Gun, Saitama, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Nozomi Memory Clinic, Mitaka-shi, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya, Tokyo, Japan|Kanauchi Medical Clinic, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Memory Clinic Ochanomizu, Tsukuba, Tokyo, Japan|National Sanatorium Hokuriku Hospital, Nanto, Toyama, Japan|Fukuoka University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Kyoto Minami Hospital, Kyoto, Japan|Utano Hospital, Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|Dong-A University Medical Center, Seogu, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do, Korea, Republic of|The Catholic University of Korea-Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center, Namdong, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|NZOZ Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnoslaskie, Poland|Medycyna Milorzab, Lodz, Lódzkie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska, Katowice, Poland|Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala, Katowice, Poland|Centrum Zdrowia Psychicznego, Kielce, Poland|Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ Neuromed M. I M. Nastaj sp. P., Lublin, Poland|Instytut Medycyny Wsi, Lublin, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Centrum Medyczne, Warszawa, Poland|Centralny Szpital Kliniczny MSW, Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamon, Puerto Rico|Ivonne Z. Jimenez-Velazquez, MD, Carolina, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Michel A. Woodbury-Farina, MD., San Juan, Puerto Rico|SC Med Life SA, Bucuresti, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Policlinica CCBR S.R.L., Bucuresti, Romania|SC Med Life SA, Timisoara, Romania|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Hospital Universitario De Getafe, Madrid, Getafe, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Centro de Atencion Especializada (CAE) OROITU, Getxo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Hospital Univ Sant Joan de Reus, S.A., Reus, Spain|Fundacion CITA Alzheimer, San Sebastian, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom|Cognitive Treatment & Research Unit, Crowborough, East Sussex, United Kingdom|Southern Health NHS, Southampton, Hampshire, United Kingdom|MAC UK Neuroscience Ltd, Blackpool, Lancs, United Kingdom|MAC Clinical Research, Stourton, Leeds, United Kingdom|MAC Clinical Research, Cannock, Staffordshire, United Kingdom|West London Mental Health NHS Trust, Brentford, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Hammersmith Hospital, London, United Kingdom|Guildford Nuffield Hospital, London, United Kingdom|Re-Cognition Health Ltd, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02245737/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02245737/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02245737"
274,"NCT02414347","F 18 T807 Tau PET Imaging of Alzheimer's Disease","T807IND","Enrolling by invitation","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol A","October 2014","October 2019","December 2019","April 10, 2015",,"January 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02414347"
275,"NCT00219232","An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine Transdermal Patch","Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatment|Change in cognition from baseline (week 24 of the double blind phase) at week 52|Clinical global impression of change from baseline at week 52|Change in activities of daily living from baseline at week 52|Change in behavioral symptoms from baseline at week 52|Change in executive function from baseline at week 52","Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","868","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713D2320E1","February 2003","July 2006","July 2006","September 22, 2005",,"February 23, 2017",,,"https://ClinicalTrials.gov/show/NCT00219232"
276,"NCT00722046","Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365 0.1 mg/kg|Biological: PF-04360365 0.5 mg/kg|Biological: PF-04360365 1 mg/kg|Drug: Placebo|Biological: PF-04360365 3 mg/kg|Biological: PF-04360365 8.5 mg/kg","Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)|Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A9951002","December 2008","August 2011","August 2011","July 25, 2008",,"May 5, 2016","Pfizer Investigational Site, Peoria, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Heidelberg West, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Jette, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Sungnam-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Trafford Park, Manchester, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00722046"
277,"NCT02438202","Electroconvulsive Therapy for Treatment of Alzheimer´s Disease","ECTAD","Not yet recruiting","No Results Available","Alzheimer's Disease","Device: Thymatron IV device (Somatics)","Change in Cognition|Change in Mood|Deterioration in Cognition","Central Institute of Mental Health, Mannheim","All","65 Years and older   (Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECTAD","December 2019","January 2020","January 2021","May 8, 2015",,"July 4, 2019",,,"https://ClinicalTrials.gov/show/NCT02438202"
278,"NCT03239561","Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",,"Completed","No Results Available","Alzheimer Disease","Drug: [18F]MNI-1020","Standardized Uptake Value Ratio (SUVR) of [18F]MNI-1020|Plasma Concentration of 18F]MNI-1020 in AD Participants Compared With age Matched Healthy Participants|Number of Participants With Adverse Events|Distribution of tau (Using [18F]MNI-1020) Compared to Amyloid Beta (Using Florbetapir) in Participants With Probable AD","Janssen Research & Development, LLC","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CR108349|64326067EDI0001","September 6, 2017","April 30, 2018","April 30, 2018","August 4, 2017",,"September 12, 2018","Molecular NeuroImaging, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03239561"
279,"NCT02955706","Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Drug: Acetyl-L-Carnitine|Drug: Placebo of Acetyl-L-Carnitine","ADAS-cog|K-MMSE","Dong-A ST Co., Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 4","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NCT_ADC_IV","April 2016","September 2018","February 2019","November 4, 2016",,"November 8, 2016","Konkuk university medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02955706"
280,"NCT03977584","Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Drug: Crenezumab|Drug: Placebo|Other: [^18F]GTP1","Change Over Time in tau Distribution Measured by Standardized Uptake Value Ratio (SUVR) as Assessed by [^18F]GTP1 tau PET Scan","Genentech, Inc.|Banner Alzheimer's Institute","All","30 Years to 60 Years   (Adult)","Phase 2","150","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","BN40199","June 10, 2019","February 25, 2022","February 25, 2022","June 6, 2019",,"June 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03977584"
281,"NCT02074215","Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Other: Aerobic exercises|Other: Stretch exercise","Changes of Memory and executive function related neuropsychological test|Changes of muscle strength of upper and lower extremity and walking speed","National Taiwan University Hospital","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201012136RB","March 2011","December 2012","December 2013","February 28, 2014",,"February 28, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02074215"
282,"NCT00007189","Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)",,"Completed","No Results Available","Alzheimer Disease","Drug: Naproxen Sodium (Aleve)|Drug: Celecoxib (Celebrex)",,"Seattle Institute for Biomedical and Clinical Research|National Institute on Aging (NIA)|VA Puget Sound Health Care System|University of Washington|Johns Hopkins University","All","70 Years and older   (Older Adult)","Phase 3","2625","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","IA0026|U01AG015477","January 2001","May 2007",,"December 14, 2000",,"October 19, 2016","Sun Health Research Institute, Sun City, Arizona, United States|Roskamp Institute Memory Clinic, 10770 N. 46th Street, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Rochester, Rochester, New York, United States|Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00007189"
283,"NCT03008161","Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: NPT088|Drug: Placebo","Number of patients with adverse events|Multiple dose pharmacokinetic (PK) serum concentrations of NPT088|Multiple dose PK CSF concentrations of NPT088|Multiple dose immunogenicity of NPT088","Proclara Biosciences, Inc.|Alzheimer's Association","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","83","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NPT088-CL002","December 2016","February 6, 2019","February 6, 2019","January 2, 2017",,"August 15, 2019","ATP Clinical Research, Inc., Costa Mesa, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Southern California Research, Simi Valley, California, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Compass-The Villages, The Villages, Florida, United States|Medical Research and Health Education Foundation, Columbus, Georgia, United States|NeuroStudies LLC, Decatur, Georgia, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Neurological Associates of Albany, Albany, New York, United States|Integrative Clinical Trials, Inc., Brooklyn, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Abington Neurological Associates, Ltd, Willow Grove, Pennsylvania, United States|Neurology Clinic, PC, Cordova, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03008161"
284,"NCT02031198","18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease","FUNDAMANT","Completed","No Results Available","Alzheimer's Disease","Drug: AADvac1","Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease|Immunogenicity of AADvac1|Patient cognition","Axon Neuroscience SE","All","50 Years to 86 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-AD-002|2013-004499-36","January 2014","August 2016","December 2016","January 9, 2014",,"March 17, 2017","Medizinische Universitat Graz, Graz, Steiermark, Austria|Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria|Medizinische Universitat Wien, Wien, Austria|Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT02031198"
285,"NCT03117738","A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: AstroStem|Other: Placebo-Control","Treatment related adverse events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)|MRI Scan|Biomarkers: Amyloid beta 40, Amyloid beta 42, Amyloid precursor protein intracellular domain (AICD), soluble neuregulin-1 (sNRG-1)","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AST-ADP2-US01","April 3, 2017","August 2019","September 2019","April 18, 2017",,"May 9, 2019","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT03117738"
286,"NCT03112096","A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: [18F]THK-5351","Pharmacokinetics: Maximum Serum Concentration (Cmax) of [18F]THK-5351|Assess global and regional tau deposition as measured by standard uptake value ratio (SUVR) of [18F]THK-5351|Correlation between standard uptake value ratio (SUVR) and distribution volume of ratio(DVR) of [18F]THK-5351 positron emission computed tomography|Optimal scanning time for brain imaging using F-18 THK-5351.|Concentrations of metabolite in plasma of [18F]THK-5351|Number of participants with treatment related adverse events as a measure of safety","Asan Foundation","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","THK-15001","May 17, 2017","August 30, 2018","August 30, 2018","April 13, 2017",,"May 24, 2018","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03112096"
287,"NCT01978548","A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 50 mg|Drug: Placebo","Levels of amyloid beta 1-40 in cerebrospinal (CSF) after treatment at the intended target dose range|Levels of amyloid beta 1-40 in plasma after treatment at the intended target dose range|Maximum observed plasma concentration (Cmax) of JNJ-54861911|Time to reach maximum observed plasma concentration of JNJ-54861911|Area under the plasma concentration time curve (AUC) from 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911|Cerebrospinal fluid exposure of JNJ-54861911|The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple-dose administration in the anticipated target dose range|Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in cerebrospinal fluid after treatment at the intended target dose range|Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in plasma after treatment at the intended target dose range|Levels of amyloid precursor protein (APP) fragments (soluble amyloid precursor protein α [sAPPalpha], sAPPbeta, totalAPP) in CSF after treatment at the intended target dose range|Compare the relationship of amyloid beta 1-40 levels in plasma and cerebrospinal fluid after treatment at the intended target dose range","Janssen Research & Development, LLC","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR103012|54861911ALZ1005|2013-003036-69","December 2013","April 2015","April 2015","November 7, 2013",,"June 25, 2015","Antwerp, Belgium|Gent, Belgium|Hoboken, Belgium|Amsterdam, Netherlands|Barcelona, Spain|Madrid N/A, Spain|Madrid, Spain|Terrassa, Spain|Valencia, Spain|Mölndal, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01978548"
288,"NCT00066157","Alzheimer's Disease: Therapeutic Potential of Estrogen",,"Completed","No Results Available","Alzheimer Disease","Drug: Transdermal estradiol|Drug: Medroxyprogesterone|Drug: Placebo Patch|Drug: Placebo","Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change|Skills of Independent Living: Physical functioning Performance (PFP)|Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)","University of Wisconsin, Madison|National Institute on Aging (NIA)","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2001-477|R01AG017196-03|FDA IRB approval M1285|NIH grant AG17196-03|IA0048","September 2001","December 2007","December 2007","August 5, 2003",,"August 23, 2018","University of Wisconsin Memory Research Program, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00066157"
289,"NCT02756858","An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: ANAVEX2-73","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Score from MMSE (Mini-mental state examination score)|Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)|HAM-D Score (Hamilton Psychiatric Rating Scale for Depression)","Anavex Life Sciences Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANAVEX2-73-003","March 2016","November 2020","November 2020","April 29, 2016",,"May 17, 2018","Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia|Caulfield Hospital, Melbourne, Victoria, Australia|Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia|St. Vincent's Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02756858"
290,"NCT00480220","Specific Care and Assistance Plan for Alzheimer's Disease","PLASA","Completed","No Results Available","Alzheimer's Disease","Procedure: Global care and support program","Evaluate the efficacy of the specific care and assistance plan for Alzheimer's disease in a study randomised within each centre. The main aim of the care plan is to reduce loss of independence.|Impact of the care and assistance plan: - on the mode of the patient's admission to an institution - on utilization of assistance, support and healthcare services (RUD questionnaire) - and on overall clinical evaluation of change (ADCS-CGIC).","University Hospital, Toulouse","All","65 Years and older   (Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","0200601|PHRC","August 2003","August 2007","August 2007","May 30, 2007",,"August 19, 2015","Hospital, Albi, France|Hospital Center, Ales, France|University Hospital, Angers, France|Hospital, Annecy, France|Hospital Center, Bar Le Duc, France|University Hospital, Brest, France|Hospital Center, Carcassonne, France|Service de Gérontologie, Carvin, France|Hospital, Chambery, France|Georges Clémenceau Hospital, Champcueil, France|Hospital Center, Grasse, France|University Hospital, Grenoble, France|Hôpital Charles Foix - La Triade, Ivry-sur-seine, France|Hospital Center, Lannemezan, France|Hospital Center, Lavaur, France|Hospital, Lens, France|University Hospital, Lille, France|Hospital Center, Louviers, France|University Hospital, Lyon, France|University Hospital Sainte Marguerite, Marseille, France|University Hospital, Montpellier, France|University Hospital, Nice, France|University Hospital, Nimes, France|Hospital Center, Niort, France|Hospital Bichat - Claude Bernard, Paris, France|Hospital Center Notre Dame du Bon Secours, Paris, France|University Hospital BROCA - La Rochefoucauld, Paris, France|University Hospital Pitié-Salpétrière, Paris, France|University Hospital Sainte Perrine, Paris, France|Hospital center, Plaisir, France|University Hospital, Reims, France|Hospital Center, Roubaix, France|University Hospital, Rouen, France|Hospital Center, Saint Dizier, France|Hospital Center, Sezanne, France|University Hospital, Hôpital Xavier Arnozan, Toulouse, France|University Hospital, Toulouse, France|Hospital, Valenciennes, France|Hospital Center, Villejuif, France|Hospital, Wasquehal, France",,"https://ClinicalTrials.gov/show/NCT00480220"
291,"NCT02787746","Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease","STDMMAD","Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil","Monitoring and recording the count and incidence of adverse events (AEs)|Monitor and record the number of patients withdrew from trial for adverse events|Change from baseline to 20 weeks in MMSE scores|Change from baseline to 20 weeks in ADL scores|Correlation analysis between Apo-E genotyping and adverse events of donepezil","Beijing Friendship Hospital|Eisai China Inc.|Xuanwu Hospital, Beijing","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","241","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STD-CHINA-001","April 2016","January 2019","March 2019","June 1, 2016",,"March 5, 2019","Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02787746"
292,"NCT00627848","Rivastigmine in Mild Alzheimer's Disease, FMRI Study","ADFRMI","Completed","No Results Available","Alzheimer' Disease","Drug: rivastigmine","FMRI response in face recognition task|treatment response measured by ADAS-cog","Kuopio University Hospital","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","KUH5772749","March 2007","December 2008","December 2008","March 3, 2008",,"October 28, 2011","Kuopio University Hospital, Kuopio, Finland",,"https://ClinicalTrials.gov/show/NCT00627848"
293,"NCT02907567","Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: CT1812|Drug: Placebo","Incidence and review of Treatment Emergent Adverse Events","Cognition Therapeutics","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COG0102","September 2016","August 24, 2017","September 2017","September 20, 2016",,"July 25, 2018","Dr. Phillip Morris, Southport, Queensland, Australia|Austin Health, Ivanhoe, Victoria, Australia|Epworth Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital Hospital, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02907567"
294,"NCT02054208","Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL","Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers","Medipost Co Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-010","February 2014","July 2019","July 2019","February 4, 2014",,"August 17, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02054208"
295,"NCT00082602","Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: galantamine ER","The primary end point occurs at Week 8. The primary outcome measures will be tolerability and safety through rates of adverse events.|The secondary end point occurs at Week 12. The secondary outcome measure will be the Mini Mental State Examination score.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 3","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR004699","May 2004",,"April 2005","May 17, 2004",,"May 20, 2011",,,"https://ClinicalTrials.gov/show/NCT00082602"
296,"NCT01689233","Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: TRx0237 200 mg/day|Drug: Placebo","Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline in Mini-Mental Status Examination (MMSE)|Change from Baseline in Neuropsychiatric Inventory (NPI)|Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in expected decline of whole brain volume as measured by brain MRI","TauRx Therapeutics Ltd","All","up to 89 Years   (Child, Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-237-005","October 2012","May 2016","May 2016","September 21, 2012",,"March 14, 2018","Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States|NoesisPharma Clinical Trials, Phoenix, Arizona, United States|CITrials, Bellflower, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Southern California Research, LLC, Fountain Valley, California, United States|Feldman, Robert MD, Laguna Hills, California, United States|Synergy East, Lemon Grove, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Compass Research, LLC - North Clinic, The Villages, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|CBH Health, LLC, Rockville, Maryland, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Neurological Research Center - Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|MedicalPsych Care, PLLC, Elmsford, New York, United States|Columbia University Taub Institute, New York, New York, United States|Research Foundation for Mental Hygiene, Inc., Orangeburg, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Clinical Trials of America, Inc, Winston-Salem, North Carolina, United States|Neurobehavorial Clinical Research, Canton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|RI Hospital, Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia|University Hospital Brussels Department of Neurology, Bruxelles, Belgium|University Hospital Gent Department of Neurology, Gent, Belgium|Jessa Hospital, Hasselt, Belgium|Regional Hospital Sint-Trudo, Sint-Truiden, Belgium|GasthuisZusters Antwerpen Sint-Augustinus, Wilrijk, Belgium|University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Centre Zagreb, Department of Neurology, Zagreb, Croatia|University Psychiatric Hospital Vrapče, Zagreb, Croatia|University of Eastern Finland, Brain Research Unit Mediteknia, Kuopio, Finland|Clinical Research Services Turku (CRST), Turku, Finland|Hôpitaux Civils de Colmar, Colmar Cedex, France|Hôpital La Grave, Toulouse, France|Hôpital de Charpennes, Villeurbanne, France|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|University Medicine Berlin - Charité, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Arzeneimittelforschung Leipzig GmbH, Leipzig, Germany|Klinik und Poliklinik für Psychiatrie und Psychotherapie Zentrum für Nervenheilkunde - Universitätsklinikum Rostock, Rostock, Germany|A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy|IRCCS San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Fondazione Universita 'G. D'Annunzio di Chieti, Chieti Scalo, Italy|Clinical Neurology Department of Neuroscience (DINOGMI) - University of Genoa, Genova, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma - Unita' di Neurologia, Roma, Italy|Alzheimer Center Southwest Netherlands, Erasmus MC, Rotterdam, Netherlands|Fundacio ACE, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain|Grampian NHS, Royal Cornhill Hospital, Aberdeen, United Kingdom|Sussex Partnership NHS Foundation Trust, Cognitive Treatment and Research Unit, Crowborough, United Kingdom|Re:Cogniton Health, London, United Kingdom|Memory Assessment and Research Centre (MARC), Southampton, United Kingdom|Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01689233"
297,"NCT02792257","Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD)","THC-AD","Recruiting","No Results Available","Alzheimer's Disease","Drug: Dronabinol (Marinol®)|Drug: Placebo","Symptoms of agitation as measured by the Pittsburgh Agitation Scale|Symptoms of agitation as measured by the Neuropsychiatric Inventory, Clinician Version|Adverse events in Dronabinol treatment as compared to placebo","Johns Hopkins University|Mclean Hospital","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00052955","March 1, 2017","August 2020","December 2020","June 7, 2016",,"June 27, 2019","Johns Hopkins University, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02792257"
298,"NCT03056495","Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease","VostatAD01","Recruiting","No Results Available","Alzheimer Disease","Drug: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)","Determination of the maximum-tolerated dose (MTD) in elderly subjects during dose escalation|Incidence of treatment - Emergent Adverse Events (Safety)|Quantification of Vorinostat concentration in blood - pharmacokinetics|association of alterations in the genome-wide transcriptome profile with the dose administered, toxicity and treatment response - pharmacodynamics","German Center for Neurodegenerative Diseases (DZNE)|University Hospital, Bonn|University of Göttingen","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","VostatAD01|2014-005311-17","September 28, 2017","January 2022","March 2022","February 17, 2017",,"August 1, 2019","German Center for Neurodegenerative Diseases, Bonn, Germany|University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Göttingen, Germany",,"https://ClinicalTrials.gov/show/NCT03056495"
299,"NCT01822951","Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)","DAT","Withdrawn","No Results Available","Alzheimer Disease","Drug: Cerebrolysin|Drug: Donepezil","Change from Baseline in ADAS-cog. and CIBIC+ score distribution|Adverse events|Vital signs|Laboratory tests","Ever Neuro Pharma GmbH","All","50 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EVE-AT-0412|2012-004944-31",,"September 2016","December 2016","April 4, 2013",,"October 26, 2015","AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Austria",,"https://ClinicalTrials.gov/show/NCT01822951"
300,"NCT01689246","Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: TRx0237 150 mg/day|Drug: TRx0237 250 mg/day|Drug: Placebo","Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline on Mini-Mental Status Examination (MMSE)|Change in expected decline of whole brain volume as measured by brain MRI","TauRx Therapeutics Ltd","All","up to 89 Years   (Child, Adult, Older Adult)","Phase 3","891","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-237-015","January 2013","November 2015","November 2015","September 21, 2012",,"March 14, 2018","Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States|Feldman, Robert MD, Laguna Hills, California, United States|University of Southern California, Los Angeles, California, United States|Shankle Clinic and Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|CNS Healthcare, Inc, Jacksonville, Florida, United States|Compass Research, LLC-North Clinic, Leesburg, Florida, United States|Miami Research Associates, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|CRI Worldwide, Marlton, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|SPRI, Brooklyn, New York, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Division of Rehabilitation and Aged Care, Hornsby, New South Wales, Australia|Southern Neurology Pty Limited, Kogarah, New South Wales, Australia|Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Randwick, New South Wales, Australia|Discipline of Psychiatry, University of Qld, Herston, Queensland, Australia|Royal Adelaide Hospital Memory Trials Centre, Adelaide, South Australia, Australia|Memory Unit, Neurology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|McCusker Alzheimer's Research Foundation Inc, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research Pty Ltd, Perth, Western Australia, Australia|UMHAT ""Alexandrovska"" Clinic of Neurology Diseases Department of Neurodegenerative and Immune and Infectious Diseases of Central Nervous System with Sector for Treatment of Neuroinfections, Sofia, Bulgaria|UMHAT ""Alexandrovska"" Clinic of Psychiatry First Department of Psychiatry, Sofia, Bulgaria|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research Kentville Inc, Kentville, Nova Scotia, Canada|Toronto Memory Program, North York, Ontario, Canada|University Hospital Centre Zagreb, Zagreb, Croatia|University Psychiatric Hospital Vrapce, Zagreb, Croatia|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|Charité, University Medicine Berlin, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Neurologia Ospedale Maggiore Policlinico, Milano, Italy|Istituto Neurologico Carlo Besta, Milano, Italy|IRCCS Istituto neurologico Casimiro Mondino, Pavia, Italy|Clinica Neurologica, Università di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy|Universita' Cattolica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma- Unita' di Neurologia, Roma, Italy|Dipartimento di Neuroscienze Universita' di Torino, Torino, Italy|Azienda Ospedaliera S.maria Della Misericordia, Udine, Italy|U.O. Di Neurologia Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Dong-A Medical Center, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|University Kuala Lumpur Royal College of Medicine, Ipoh, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Taiping Hospital, Taiping, Malaysia|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Pallmed sp zoo prowadząca NZOZ Dom Sue Ryder; Centrum Psychoneurologii Wieku Podeszłego, Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Gabinet Neurologiczny, Indywidualna Specjalistyczna Praktyka Lekarska, Mosina, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznań, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Usługi Lekarskie Sp.c Palasik, Żabierek, Warszawa, Poland|mMED, Warszawa, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|County Emergency Clinical Hospital Arad, Psychiatry Department, Arad, Romania|CMDTA ""Neomed"", Brasov, Romania|University Emergency Central Military Hospital ""Dr.Carol Davila"", Psychiatry Department, Bucharest, Romania|Psychomedical Consult, Bucharest, Romania|Clinical Municipal Hospital ""Dr. Gavril Curteanu"", Psychiatry Department, Oradea, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Center of Mental Health, Sibiu, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Department of Psychiatry III, Sibiu, Romania|Emergency Clinical County Hospital Sibiu, Neurology Department, Sibiu, Romania|State Budgetary Healthcare Institution of Sverdlovsk region ""Sverdlovsk Regional Clinical Psychiatric Hospital"", Ekaterinburg, Russian Federation|Non-governmental Healthcare Institution ""Central Clinical Hospital #6 of the JSC ""Russian Railways"", Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Gerontopsychiatry department, Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|CityClinical Hospital #34, City Scientific Practical Neurological Center, Novosibirsk, Russian Federation|City Geriatric Medical and Social Center, Saint Petersburg, Russian Federation|Saint Nicholas Psychiatric Hospital, Saint Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n. a. V.M. Bekhterev, Saint Petersburg, Russian Federation|National University Hospital (NUH), Singapore, Singapore|National Neuroscience Institute (NNI), Singapore, Singapore|Tan Tock Seng Hospital (TTSH), Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Hospital Universitario de Ceuta, Ceuta, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|En Chu Kong Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Yang-Ming University School of Medicine, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|NHS Grampian, Department of Old Age Psychiatry Royal Cornhill Hospital, Aberdeen, United Kingdom|RICE - The Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust (BHSCT), Belfast, United Kingdom|The Barberry Centre, Birmingham, United Kingdom|MAC Clinical Research Ltd, Blackpool, United Kingdom|MAC Clinical Research Ltd, Bradford, United Kingdom|MAC Clinical Research Ltd, Cannock, United Kingdom|MAC Clinical Research Ltd, Leeds, United Kingdom|Re: Cognition Health Ltd., London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Dementia Research Centre, London, United Kingdom|MAC Clinical Research Ltd, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01689246"
301,"NCT02529436","Overuse of Antidepressant in Patients With Alzheimer Disease","OVADAD","Completed","No Results Available","Alzheimer Disease",,"AD overuse with off label prescriptions, ie no validated indication or excess in prescription duration.|Prevalence of psychotropic coprescription|Prevalence of the neurologic iatrogenic alerts as defined by the French National Authority for Health|Type and severity of dementia (Mini Mental Status, Frontal Assessment Battery, stage of dementia, etiological diagnosis)|Comorbidities|Coprescription, type and number of prescriber(s)|Type and number of help at home (professional and non professional caregivers)|Non-drug therapy in conjunction with anti-depressant medication : yes or no (if yes, please name the therapy)","Assistance Publique - Hôpitaux de Paris","All","70 Years and older   (Older Adult)",,"54","Other","Observational","Time Perspective: Prospective","AD2015","April 2015","September 2015","December 2015","August 20, 2015",,"September 8, 2016","Hôpital Bretonneau, Paris, France",,"https://ClinicalTrials.gov/show/NCT02529436"
302,"NCT01561053","A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease","AMBAR","Completed","Has Results","Alzheimer's Disease","Biological: Albumin 5%|Biological: Albumin 20%|Biological: Immunoglobulin","Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months)|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score (Changes From Baseline to 14 Months)","Instituto Grifols, S.A.|Grifols Biologicals, LLC","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","347","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IG1002","April 19, 2012","March 6, 2018","March 6, 2018","March 22, 2012","July 31, 2019","July 31, 2019","Northern California Research, Sacramento, California, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Howard University, Washington, District of Columbia, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Largo Medical Center, Largo, Florida, United States|L&L Research Choices, Inc, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Neurology Associates of Osmond Beach, Ormond Beach, Florida, United States|PharmaSeek LLC (DMI Research), Pinellas Park, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|RTR Medical Group, Savannah, Georgia, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Mid-Atlantic Geriatric/ARC, Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Neurology Specialists Inc, Dayton, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario del Vinalopó, Elche, Alicante, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital General de Catalunya, Sant Cugat Del Vallès, Barcelona, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Canary Islands, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Fundació ACE, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Parc Hospitalari Martí i Julià, Girona, Spain|Hospital Universitari de Santa Maria, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Viamed Montecanal, Zaragoza, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01561053/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01561053/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01561053"
303,"NCT01439555","Endothelial Facilitation in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Simvastatin|Drug: L-Arginine|Drug: Tetrahydrobiopterin","Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI)|Change in Cerebral Blood Flow as Measured by Arterial Spin Labeling During Magnetic Resonance Imaging (MRI)|Mini Mental State Examination (MMSE) Scores|Cognitive Assessment Screening Test (CAST)|Clinical Dementia Rating Scale (CDR)|Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)|Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus)","University of Massachusetts, Worcester|The Glass Foundation","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13748","November 2011","November 2017","November 2017","September 23, 2011","July 30, 2019","July 30, 2019","UMass Medical School/ UMass Memorial Medical Center, Worcester, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01439555/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01439555"
304,"NCT04029623","Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease",,"Not yet recruiting","No Results Available","Prodromal Alzheimer's Disease","Other: Partnered Rhythmic Rehabilitation (PRR)|Other: Group walking (WALK)","Change in Four Square Step Test (FSST) Time|Change in Acceptability|Number of Injurious Falls|Attrition|Change in Timed Up and Go (TUG) Test - Cognitive Time|Change in Body Position Spatial Task (BPST)|Change in Lawton Instrumental Activities of Daily Living (IADL) Score|Change in Composite Physical Function (CPF) Scale Score|Change in Short Physical Performance Battery (SPPB) Score|Change in Mini-Balance Evaluation Systems Test (Mini-BESTest) Score|Change in 6 Minute Walk Test (6MWT) Distance|Change in Preferred Gait Speed|Change in Backward Gait Speed|Change in Fast Gait Speed|Change in Clinical Dementia Rating (CDR) Questionnaire Score|Change in Flanker Task Score|Change in Set Shifting Score|Change in Spatial 1-Back Test Score|Change in Dot Counting Test Score|Change in Verbal Fluency Test Score|Change in Reverse Corsi Blocks Levels Completed|Change in Patient Health Questionnaire (PHQ-9) Score|Change in Multidimensional Scale of Perceived Social Support (MSPSS) Score|Change in Montreal Cognitive Assessment (MoCA) Score","Emory University|National Institute on Aging (NIA)","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00110350|1R01AG062691","December 2019","March 2024","March 2024","July 23, 2019",,"September 12, 2019","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04029623"
305,"NCT02759159","The Study of Mechanism of Alzheimer's Disease Using Acupuncture Based on fMRI",,"Unknown status","No Results Available","Alzheimer's Disease","Procedure: true acupuncture|Procedure: sham acupuncture","brain functional connectivity","Xuanwu Hospital, Beijing","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","81471649","June 2016","December 2018","December 2018","May 3, 2016",,"October 5, 2016","Xuanwu hospital, Beijing, Beijing, China|Dongfang Hospital,Beijing University of Chinese Medicine, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02759159"
306,"NCT03375697","A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: JNJ-63733657|Drug: Placebo","Single Ascending Dose (SAD) (Part 1): Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of JNJ-63733657|Multiple Ascending Dose (MAD) (Part 2): Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Maximum Observed Serum Concentration (Cmax) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Area Under the Serum Concentration-time Curve From Time Zero to Time of the Last Observed Quantifiable Concentration (AUC [0-Last]) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-63733657|MAD (Part 2): Area Under the Serum JNJ-63733657 Concentration-time Curve During a Dosing Interval (t) (AUC tau)|MAD (Part 2): Accumulation Ratio (R)|SAD (Part 1) and MAD (Part 2): Total Systemic Clearance (CL) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Volume of Distribution at Steady-State (Vss) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): Terminal Half-Life(t[1/2]) of JNJ-63733657|SAD (Part 1) and MAD (Part 2): JNJ-63733657 Concentration in Cerebrospinal Fluid (CSF)|SAD (Part 1) and MAD (Part 2): Number of Subjects With Anti-JNJ-6373365 Antibodies as a Measure of Immunogenicity|SAD (Part 1) and MAD (Part 2): Percent Change From Baseline in Total, Free, and Bound tau Biomarker Fragments in CSF","Janssen Research & Development, LLC","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108392|63733657EDI1001|2017-003852-21","December 22, 2017","December 20, 2019","December 21, 2019","December 18, 2017",,"August 27, 2019","Clinical Pharmacology Unit, Merksem, Belgium|Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Bonn, Germany|CTC North GmbH & Co. KGim Spectrum am UKE, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Germany|Centre for Human Drug Research, Leiden, Netherlands|Hosp. Clinico San Carlos, Madrid, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03375697"
307,"NCT00561392","Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease","ADEPT","Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine 5 and 10 cm^2 patch","Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study|Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study|Percentage of Participants Who Were Compliant to the 10 cm^2 Patch|Mean Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 24|Mean Change From Baseline in the Trail-making Test Part A Score at Week 24|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score at Week 24|Change From Baseline in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Physician|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Caregiver|Mean Change From Baseline in the Mini-Zarit Inventory Score of Caregiver Burden at Week 24","Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","208","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DDE15","November 2007","November 2008","November 2008","November 21, 2007","March 11, 2011","April 16, 2012","Novartis Investigative Site, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00561392"
308,"NCT02709356","Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease","MCT-MA","Completed","No Results Available","Alzheimer's Disease","Dietary Supplement: 1-month of 60-40 MCT oil|Dietary Supplement: 1-month of C8 MCT oil","Quantification of brain glucose uptake|Quantification of brain acetoacetate uptake","Université de Sherbrooke|Fondation Vitae","All","65 Years and older   (Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2016-547","October 2015","February 2018","February 2018","March 16, 2016",,"October 10, 2018","Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02709356"
309,"NCT02560753","Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: T3D-959","Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region|The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.|Change From Baseline in the Score of the Digit Symbol Substitution Test|Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale","T3D Therapeutics, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T3D959-201","July 2015","May 30, 2016","June 30, 2016","September 25, 2015","July 30, 2018","July 30, 2018","Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|New Hope Clinical Research, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02560753"
310,"NCT00711204","Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease",,"Withdrawn","No Results Available","Severe Alzheimer's Disease","Drug: Donepezil Hydrochloride (Aricept)","CSDD (Cornell Scale for Depression in Dementia).|FAST (Functional Assessment Staging), NPI-10, MMSE (Mini Mental State Examination), DemQol (Dementia Quality of Life).","Eisai Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","E2020-A001-417","January 2008","June 2009",,"July 8, 2008",,"December 10, 2012","Kettlie Joseph Daniels, M.D. Inc., Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00711204"
311,"NCT02908815","Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Device: rTMS active treatment|Device: rTMS sham treatment","Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) change|Stroop Test|Digit Span Test|Verbal Fluency Test (VFT)|Neuropsychiatric Inventory-Questionnaire (NPI-Q)|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Zarit Burden Interview (ZBI)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) effect over time|Semantic Fluency Test (SFT)|Clinical Dementia Rating (CDR) sum of boxes","University of Manitoba","All","55 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","B2016:077","November 2016","November 2020","November 2020","September 21, 2016",,"April 17, 2019","Monash University, Melbourne, Victoria, Australia|Riverview Health Center, Winnipeg, Manitoba, Canada|McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02908815"
312,"NCT02638519","HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Other: Traditional Proton fMRI|Other: Hyperpolarized Xenon-129 fMRI|Drug: Hyperpolarized Xenon-129|Device: 1H-129Xe Dual-Tuned Quadrature Head Coil","Signal-to-Noise Ratio (SNR)|P-Value","Thunder Bay Regional Research Institute|Lakehead University|Thunder Bay Regional Health Sciences Centre","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RP-307-08312015","June 2016","June 2019","June 2019","December 23, 2015",,"August 9, 2018","Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02638519"
313,"NCT03113812","Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABvac40|Drug: Placebo","number of participants with adverse events","Araclon Biotech S.L.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AB1203","January 1, 2014","July 30, 2015","July 30, 2015","April 14, 2017",,"April 14, 2017",,,"https://ClinicalTrials.gov/show/NCT03113812"
314,"NCT00087789","CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF","Safety and tolerability of three different doses of CERE-110 in subjects with mild to moderate Alzheimer's disease","Ceregene|Sangamo Therapeutics","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CERE-110-01","June 2004","May 2010","May 2010","July 16, 2004",,"October 31, 2016","University of California San Diego, San Diego, California, United States|Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00087789"
315,"NCT00951834","Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease","SUN-AK","Completed","No Results Available","Alzheimer's Disease","Drug: Epigallocatechin-Gallate|Drug: Placebo","ADAS-COG (Score 0-70) (Baseline to treatment)|Safety and tolerability of the verum|MMSE (Score 0-30) after 18 months compared to baseline|Time to hospitalisation and Time to death related to AD|Brain atrophy assessed by brain MRI|Baseline-ADAS-COG and Baseline-MMSE as covariates|CIBIC+ and WHO-QOL-Bref|Trail Making Test and MVGT","Charite University, Berlin, Germany","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SUN-AK","October 2009","February 2015","February 2015","August 4, 2009",,"November 29, 2018","Charite University Medicine Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie, Berlin, Germany|Klinik für Neurologie, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00951834"
316,"NCT02991235","Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: PRJ212|Dietary Supplement: Placebo","Efficacy of PRJ212 versus placebo on the memory measured by Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS).|Efficacy of PRJ212 versus placebo on the memory measured by Wechsler Memory Scale (WMS).|Efficacy of PRJ212 versus placebo on the memory measured by memory composite (R-BANS+WMS).","Bioiberica","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","BIO-PRJ-2015-01","December 2016","July 2018","December 2018","December 13, 2016",,"January 19, 2018","Fundació ACE, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02991235"
317,"NCT02854917","Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome",,"Completed","No Results Available","Alzheimer Disease",,"Total number of prescription medications taken throughout the study|Total number of hospitalizations|The total number of new medical conditions|Total number of days of hospice care|Total number of psychotropic medications used|Total number of increases in psychotropic medications|Total number of decreases in psychotropic medications|Total number of cardiac medications taken during the study|Total number arthritic and anti-inflammatory medications taken during the study|Total number of analgesic medications taken during the study|Total number of days hospitalized during the study|Reasons for hospitalizations and hospital diagnoses during the study|Total number of tests and procedures performed during the hospitalizations|Changes in Functional Assessment Staging Disability Score (FAST-DS) at subsequent study visits post hospitalization|Time to death|Cause of death|Caregiver training and support in relation to mortality|Differences in rate of fecal incontinence|Differences in rate of urinary incontinence","NYU Langone Health|Forest Laboratories|Fisher Center for Alzheimer's Research Foundation","All","50 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","12444","July 2016","January 5, 2018","January 5, 2018","August 4, 2016",,"January 25, 2018","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02854917"
318,"NCT00304629","Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: galantamine","The primary outcome is safety as measured by adverse events, laboratory tests, vital signs, weight, physical exam and electrocardiogram|The secondary outcome is effectiveness as measured by a cognitive scale (ADAS) and by activities of daily living (DAD).","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","45 Years and older   (Adult, Older Adult)","Phase 3","241","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR012070","March 2000",,"March 2002","March 20, 2006",,"February 1, 2011",,,"https://ClinicalTrials.gov/show/NCT00304629"
319,"NCT02537626","An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer's Disease","Device: Erchonia ALS Laser|Device: Placebo Laser","Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Alzheimer's Disease Co-Operative Study-Activities of Daily Living Inventory (ADCS-ADL)|Mini Mental State Examination (MMSE)|Study Partner Satisfaction With Overall Outcome Rating","Erchonia Corporation","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC_AD_001","February 15, 2018","December 15, 2018","December 15, 2018","September 1, 2015",,"January 19, 2018","Pruebas Clinicas, Zapopan, Jalisco, Mexico|Neocemod, La Plazuela, Pocitos AGS, Mexico",,"https://ClinicalTrials.gov/show/NCT02537626"
320,"NCT00476008","Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Memantine|Drug: Placebo","The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint).|Fuld Object Memory Evaluation|Rey Complex Figure Test|Trail Making Test - Part A|Trail Making Test - Part B|Mini Mental Status Exam|Useful Field of View|Motor Free Visual Perception Test - Visual Closure Subtest|Cognitive Dementia Rating Scale|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)","Florida Atlantic University|Forest Laboratories","All","60 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NAM-MD-49","July 2007","October 2012","October 2012","May 21, 2007","June 3, 2014","August 11, 2014","Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00476008"
321,"NCT02708485","Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease","MAL","Completed","Has Results","Alzheimer's Disease","Other: Physical exercise","Brain Glucose Consumption|Brain Acetoacetate Consumption","Université de Sherbrooke","All","40 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-043","April 2009","July 2017","July 2017","March 15, 2016","October 16, 2018","October 16, 2018","Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02708485/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02708485"
322,"NCT02760602","A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease","ExpeditionPRO","Terminated","Has Results","Alzheimer's Disease","Drug: Solanezumab|Drug: Placebo","Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog14) Score|Change From Baseline on Alzheimer´s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL)|Change From Baseline on the Mini Mental Status Examination (MMSE)|Change From Baseline on the Montreal Cognitive Assessment (MoCA)|Change From Baseline on the Functional Activities Questionnaire (FAQ)|Change From Baseline on the Neuropsychiatric Inventory (NPI)|Change From Baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)|Change From Baseline on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change From Baseline on the Free and Cued Selective Reminding Test (FCSRT)|Change From Baseline on the Resource Utilization in Dementia-Lite (RUD-Lite)|Change From Baseline on the EuroQol 5-Dimensional Health-Related Quality of Life Scale (EQ-5D)|Change From Baseline on the Quality of Life in Alzheimer's Disease Scale (QoL-AD)|Change From Baseline in Concentration of Plasma Amyloid-β Peptide (Aβ) and Plasma Solanezumab|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)|Change From Baseline in Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Aβ and CSF Tau Proteins|Change From Baseline in Neocortical Tau Deposits Using 18F-AV-1451 PET","Eli Lilly and Company","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16349|H8A-MC-LZBE|2016-000108-27","June 2016","May 2017","May 2017","May 3, 2016","July 24, 2018","October 10, 2019","Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Arizona Health Sciences Center, Tucson, Arizona, United States|Parexel Early Phase Unit at Glendale, Glendale, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|Care Access Research LLC, Santa Clarita, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Care Access Research, Valencia, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Compass Research, Orlando, Florida, United States|Pensacola Research Consultants, Inc., Pensacola, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Christie Clinic, LLC, Champaign, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|ClinVest, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millenium Psychiatric Associates LLC, Creve Coeur, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Healthy Perspectives Innovative Mental Health Services, PL, Nashua, New Hampshire, United States|ActivMed Practices & Research, Inc, Portsmouth, New Hampshire, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Richmond Behavorial Associates, Staten Island, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Summit Research Network Inc, Portland, Oregon, United States|Center for Cognitive Health, Portland, Oregon, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Northeastern Pennsylvania Memory & Alzheimer's Center, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Metrolina Neurological Research Institute, Indian Land, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|FutureSearch Trials, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Univ of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Evergreen Professional Plaza, Kirkland, Washington, United States|Dean Foundation for Health Research and Education, Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Gatineau, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Greenfield Park, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Halifax, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kentville, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., London, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Peterborough, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sherbrooke, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vaasa, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amiens, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chemnitz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pavia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kamakura, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kodaira-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koriyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mitaka-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takamatsu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tsu-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Białystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sopot, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|Cortex, PSC, Las Piedras, Puerto Rico|University Of Puerto Rico, Rio Piedras, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|SomniCare Sleep Institute, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castellon de la Plana, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getxo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sebastian, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmö, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mölndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umeå, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gwei Shan Township, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jhonghe City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelsea, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02760602/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02760602/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02760602"
323,"NCT03114657","A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)","CREAD 2","Completed","No Results Available","Alzheimer's Disease","Drug: Crenezumab|Drug: Placebo","Change from Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Scale Score|Change from Baseline to Week 105 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13) and Alzheimer's Disease Assessment Scale-Cognition 11 (ADAS-Cog-11) Subscale Score|Change from Baseline to Week 105 in Clinical Dementia Rating-Global Score (CDR-GS) and Mini Mental State Exam MMSE|Change from Baseline to Week 105 on Function as assessed by (ADCS-ADL) Total Score and Its (ADCS-iADL) and by the Functional Activities Questionnaire (FAQ) total score|Change from Baseline to Week 105 on a Measure of Dependence Level Assessed from the ADCS-ADL Score|Change from Baseline to Week 105 on Behavior in Neuropsychiatric Inventory Questionnaire (NPI-Q) Total Score|Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score|Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score|European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Domain Scores|Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs)|Percentage of Participants with Anti-Crenezumab Antibodies|Serum Concentration of Crenezumab|Plasma Amyloid Beta (Abeta) Concentrations|Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI)|Cerebrospinal Fluid (CSF) concentration of Crenezumab|Brain Amyloid Load Over Time Measured by Amyloid-PET|Brain Tau Load Over Time Measured by Tau-PET|Cerebrospinal Fluid (CSF) Markers of Disease Over Time","Hoffmann-La Roche","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","806","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BN29553|2016-003288-20","March 29, 2017","June 11, 2019","June 11, 2019","April 14, 2017",,"October 4, 2019","Imaging End Points Clinical Research, Scottsdale, Arizona, United States|Radiant Research, Inc., Tempe, Arizona, United States|Health Initiatives Research, PLLC, Fayetteville, Arkansas, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Senior Clinical Trials, Laguna Hills, California, United States|Uci Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Desert Valley Medical Group, Rancho Mirage, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research LLC, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Neurology Associates Of Ormond Beach, Ormond Beach, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Columbus Memory Center, Columbus, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Advanced Clinical Research, Meridian, Idaho, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|McLean Hospital; First Episode Clinic, Belmont, Massachusetts, United States|Alzheimers Disease Center; Neurology, Winchester, Massachusetts, United States|Health Partners Institute for Education and Research, Saint Paul, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Nebraska Medical Center; Dept of Neurological Sciences, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|State University of New York at Buffalo; Department of Neurology, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Dayton Center for Neuro Disorders, Centerville, Ohio, United States|Carl and Edyth Lindner Center at Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati; Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States|Ohio State University; College of Medicine, Columbus, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Drexel Univ College of Med; Clinical Research Group, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Frontier Institute, Spokane, Washington, United States|Hospital Italiano, Buenos Aires, Argentina|Universidad Maimonides, Caba, Argentina|Hospital Sirio Libanes, Caba, Argentina|DAMIC, Cordoba, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research, Fitzroy, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Royal Melbourne Hospital; Department of Neurology, Parkville, Victoria, Australia|AZ Sint Jan, Brugge, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CCBR - Brasilia, Brasilia, DF, Brazil|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil|Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil|Centro Psiquiatria Sandra Ruschel Ltda, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Clínica Dr. Norton Sayeg LTDA - EPP, Sao Paulo, SP, Brazil|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Providence Care; Mental Health Services, Kingston, Ontario, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Peking University Sixth Hospital; Department of Psychiatry, Beijing, China|Beijing Union Hospital, Beijing, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Shanghai Mental Health Center, Shanghai, China|Tianjin Medical University General Hospital, Tianjin (天津), China|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Laane-Tallinna Keskhaigla, Tallinn, Estonia|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hôpital de Jour du Centre pour Personnes Âgées; Louis Pasteur Neurologie, Colmar, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|Hopital Broca, Paris, France|CH Pitie Salpetriere; IM2A, Paris, France|Hôpital Maison Blanche, Reims, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital des Charpennes, Villeurbanne, France|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|Universitätsklinikum Freiburg, Zentrum für Geriatrie und Gerontologie, Freiburg, Germany|Universitätsklinikum des Saarlandes Klinik f. Psychiatrie und Psychotherapie, Homburg/Saar, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Naval Hospital of Athen;Neurology Clinic, Athens, Greece|Rambam Medical Center, Haifa, Israel|Sheba Medical Center; Psychiatry Department, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia, Roma, Lazio, Italy|Policlinico Universitario Agostino Gemelli; UOC Neurologia, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale Neurologico Besta; UO Neuropatologia, Milano, Lombardia, Italy|Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa, Milano, Lombardia, Italy|Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer, Passirana, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria, Torino, Piemonte, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|National Center for Geriatrics and Gerontology, Aichi, Japan|Hirosaki University Hospital, Aomori, Japan|Inage Neurology and Memory Clinic, Chiba, Japan|Fukuoka Mirai Hospital, Fukuoka, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Tsukazaki Hospital, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa Prefectural Central Hospital, Kagawa, Japan|Fujisawa City Hospital, Kanagawa, Japan|National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto, Japan|Ijinkai Takeda General Hospital, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Saigata Medical Center, Niigata, Japan|Katayama Medical Clinic, Okayama, Japan|AMC Nishi Umeda Clinic, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Asakayama General Hospital, Osaka, Japan|NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan|Showa University East Hospital, Tokyo, Japan|Ebara Hospital, Tokyo, Japan|Kanto Central Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|Tottori University Hospital, Tottori, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Investigacion Biomedica Elemental. Sapi de Cv, Guadalajara, Jalisco, Mexico|Hospital General de México, Mexico City, Mexico CITY (federal District), Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Centro de Estudios Clinicos y Especialidades Médicas, S.C., Monterrey, Mexico|Centro De Atencion E Investigacion Cardiovascular Del Potosi S.C., San Luis Potosí, Mexico|Akershus universitetssykehus HF; Nevroklinikken S203, Lørenskog, Norway|Oslo universitetssykehus HF Ullevål sykehus; Hukommelsesklinikken, Oslo, Norway|Clinica Internacional; Unidad De Investigacion, Lima, Peru|Clinica Anglo Americana; Centro de Investigacion Neurologia II CAA, Lima, Peru|Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia, Lima, Peru|NZOZ Dom Sue Ryder, Bydgoszcz, Poland|Centrum Medyczne Euromedis Sp. z o.o., Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital de Braga; Servico de Neurologia, Braga, Portugal|HUC; Servico de Neurologia, Coimbra, Portugal|Hospital Pedro Hispano; Servico de Neurologia, Matosinhos, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, Portugal|LLC Baltic Medicine, Saint-Petersburg, Sankt Petersburg, Russian Federation|State Healthcare Institution of Sverdlovsk Region Sverdlovsk Regional Clinical Psychiatric Hospita, Yekaterinburg, Sverdlovsk, Russian Federation|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|City Clinical Psychiatry Hospital #1, Nizhny Novgorod, Russian Federation|St Nicolas Psychiatric Hospital; Chair of Psychiatry and Narcology of St. Petersburg Medical Academy, St Petersburg, Russian Federation|Nebbiolo Center for Clinical Trials, Tomsk, Russian Federation|Clinic for Mental disorders Dr Laza Lazarevic, Belgrade, Serbia|Neurology clinic, Clinical Center of Serbia, Belgrade, Serbia|Clinic for neurology, Clinical Center Kragujevac, Kragujevac, Serbia|Flexivest Fourteen Research Centre, Cape Town, South Africa|Private Practice; the Osteoporosis Clinic, Johannesburg, South Africa|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Hospital Santa Caterina, Unitat de Valoració de la memoria i les demencies, Salt, Girona, Spain|Policlínica Guipuzkoa; Servicio de Neurología, Donosti-San Sebastián, Guipuzcoa, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Neurologia, Santiago de Compostela, LA Coruña, Spain|Hospital San Pedro; Servicio de Neurología, Logroño, LA Rioja, Spain|Hospital Universitario de Getafe; Servicio de Geriatria, Getafe, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|CAE Oroitu, BaraKaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Hospital la Magdalena; Servicio de Neurologia, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría; CSM La Alamedilla, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Clínico Universitario de Valladolid; Servicio de Neurología, Valladolid, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Changhua Christian Hospital; Neurology, Changhua County, Taiwan|Kaohsiung Medical University Hospital; Neurology, Kaohsiung, Taiwan|Chang Gung Memorial Foundation - Kaohsiung - Neurology, Kaohsiung, Taiwan|Taipei Medical University - Shuang Ho Hospital - Neurology, New Taipei City, Taiwan|National Taiwan University Hospital; Neurology, Taipei, Taiwan|Chang Gung Memorial Foundation - Linkou - Neurology, Taoyuan, Taiwan|Ankara University School of Medicine; Neurology, Ankara, Turkey|Hacettepe University Medical Faculty; Neurology, Ankara, Turkey|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|The Rice Centre; Royal United Hospital, Bath, United Kingdom|The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre, Cheltenham, United Kingdom|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|Crosshouse Hospital; NHS Ayrshire & Arran, Kilmarnock, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, L7 8xp, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital; Imperial Memory Unit, Level 10 West, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|University Southampton NHS Foundation Trust; Wessex Neurologica Centre, Southampton, United Kingdom|University Hospital North Midlands, Stoke on Trent, United Kingdom|Re:Cognition Health Guildford, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03114657"
324,"NCT02986932","Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease","BBB-Alzheimers","Completed","No Results Available","Alzheimer Disease","Device: BBB opening","Change in contrast enhancement (intensity) following BBB disruption|Change in amyloid uptake|Adverse events|MMSE - Mini Mental State Examination|ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Behavior subscales|NPI - Neuropsychiatry Inventory|GDS - Geriatric Depression Scale|ADCS-ADL - Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory","InSightec","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AL001","December 2016","December 2017","December 2017","December 8, 2016",,"June 14, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02986932"
325,"NCT00469456","Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Memantine|Drug: placebo","Change From Baseline in Functional Linguistic Communication Inventory (FLCI) at Week 12|Change From Baseline in American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS) [Total Score of Social Communication and Communication of Basic Needs Subscores] at Week 12","Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 4","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MEM-MD-71","April 2007","November 2008","November 2008","May 4, 2007","December 7, 2009","December 24, 2009","Forest Investigative Site, East Gosford, New South Wales, Australia|Forest Investigative Site, Hornsby, New South Wales, Australia|Forest Investigative Site, Kogarah, New South Wales, Australia|Forest Investigative Site, Newcastle, New South Wales, Australia|Forest Investigative Site, Randwick, New South Wales, Australia|Forest Investigative Site, Chermside, Queensland, Australia|Forest Investigative Site, Toowoomba, Queensland, Australia|Forest Investigative Site, Adelaide, South Australia, Australia|Forest Investigative Site, Woodville, South Australia, Australia|Forest Investigative Site, Box Hill, Victoria, Australia|Forest Investigative Site, Frankston, Victoria, Australia|Forest Investigative Site, Heidelberg West, Victoria, Australia|Forest Investigative Site, Kew, Victoria, Australia|Forest Investigative Site, Perth, Western Australia, Australia|Forest Investigative Site, Christchurch, New Zealand|Forest Investigative Site, North Shore, New Zealand|Forest Investigative Site, Timaru, New Zealand|Forest Investigative Site, George, E. Cape, South Africa|Forest Investigative Site, Port Elizabeth, E. Cape, South Africa|Forest Investigative Site, Johannesburg, Gauteng, South Africa|Forest Investigative Site, Johannesburg, Gauteng, South Africa|Forest Investigative Site, Pretoria, Gauteng, South Africa|Forest Investigative Site, Durban, KZ-Natal, South Africa|Forest Investigative Site, Cape Town, W. Cape, South Africa|Forest Investigative Site, Cape Town, W. Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00469456"
326,"NCT00501111","Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease","Sirocco","Completed","No Results Available","Alzheimer Disease","Drug: AZD3480|Drug: Donepezil","Change in ADAS-Cog|Change in ADCS-CGIC, Computerized neurological test battery (CDR) and MMSE","AstraZeneca","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","659","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3690C00010|EuDract 2007-00835-24","July 2007","August 2008","August 2008","July 13, 2007",,"July 23, 2014","Research Site, Graz, Osterreich, Austria|Research Site, Innsbruck, Osterreich, Austria|Research Site, Wien, Osterreich, Austria|Research Site, Linz, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Sint-truiden, Belgium|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Verdun, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava - Poruba, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Prostejov, Czech Republic|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel-kronshagen, Germany|Research Site, Leipzig, Germany|Research Site, Lubeck, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Munchen, Germany|Research Site, Nurnberg, Germany|Research Site, Pitesti, Arges, Romania|Research Site, Targu Mures, Mures, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint-petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Salt (girona), Cataluna, Spain|Research Site, Terrassa, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Castellon, Comunidad Valenciana, Spain|Research Site, Palma de Mallorca, Islas Baleares, Spain|Research Site, Baracaldo (vizcaya), Spain|Research Site, Uckfield, E Sussex, United Kingdom|Research Site, Southampton, Hampshire, United Kingdom|Research Site, Blackpool, Lancashire, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, London, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00501111"
327,"NCT01125631","Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365 8.5 mg/kg|Drug: Placebo","Safety of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease dosed for 6 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, immunogenicity and cognitive assessments)|Pharmacokinetics of PF-04360365 following administration of multiple doses in Japanese subjects with mild to moderate Alzheimer's disease. (plasma PF-04360365 concentrations)|Plasma concentration of Aβ species following administration of multiple doses of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease.","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A9951016","May 2010","August 2011","August 2011","May 18, 2010",,"August 12, 2011","Pfizer Investigational Site, Hirosaki, Aomori, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka, Japan|Pfizer Investigational Site, Fukuyama city, Hiroshima, Japan|Pfizer Investigational Site, Kanazawa, Ishikawa, Japan",,"https://ClinicalTrials.gov/show/NCT01125631"
328,"NCT03197740","A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Donepezil patch|Drug: aricept Tab","ADAS-cog|CIBIC-plus","Icure Pharmaceutical Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IPI-003","October 12, 2017","March 31, 2019","November 30, 2019","June 23, 2017",,"February 20, 2019","46 Sites including Konkuk University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03197740"
329,"NCT02409030","Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease","RH-VAL","Completed","No Results Available","Alzheimer Disease",,"Blood markers","Raman Health Technologies, S.L.","All","50 Years to 80 Years   (Adult, Older Adult)",,"700","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","RH-VAL-2013-01","January 2014","November 30, 2016","October 18, 2017","April 6, 2015",,"March 26, 2019","AZ Sint Jan, Brugge, Belgium|UCL St Luc, Brussel, Belgium|Centre Hospitalier d'ARRAS, Arras, France|Hôpital neurologique Pierre Wertheimer, Bron, France|Clinique Neurologique CHRU, Lille, France|Centre Mémoire paris Nord Ile de France GH Saint-Louis Lariboisière Fernand Widal, Paris, France|Cognitive and Behavioral Disease Center and Alzheimer's Institute, Paris, France|Hospital Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain|CITA Alzheimer, Donostia / San Sebastián, San Sebastián, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT02409030"
330,"NCT00982202","Pioglitazone in Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: pioglitazone|Drug: Placebo","Frequency of adverse events|Laboratory abnormalities|Cognition|Activities of Daily Living (ADL)|Behavior|Global function","National Institute on Aging (NIA)|Takeda Pharmaceuticals North America, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","25","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0168|1R01AG018905","January 2002","January 2005","January 2005","September 23, 2009",,"September 23, 2009","University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00982202"
331,"NCT02672306","Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease","SEESUPAD","Active, not recruiting","No Results Available","Alzheimer's Disease","Biological: UCMSCs|Biological: Placebo","Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers","South China Research Center for Stem Cell and Regenerative Medicine|Guangzhou General Hospital of Guangzhou Military Command of PLA|The Third Affiliated Hospital, SUN YAT-SEN University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","UCMSC-1","October 20, 2017","October 2018","October 2019","February 3, 2016",,"April 26, 2018","South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02672306"
332,"NCT00622713","A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","EXTRA","Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine transdermal patch","Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study|Clinical Global Impression of Change (CGI-C) by Physician|Mean Change From Baseline to Week 24 in the 4-item Instrumental Activities of Daily Living (4-IADL) Score|Mean Change From Baseline to Week 24 in the Mini-Mental State Examination (MMSE) Score|Mean Change From Baseline to Week 24 in the Mini-Zarit Inventory Score","Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","228","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DFR08|N° EudraCT : 2007-003405-27","January 2008","January 2009","January 2009","February 25, 2008","July 26, 2011","July 26, 2011","Novartis Investigative Site, Rueil-Malmaison, France",,"https://ClinicalTrials.gov/show/NCT00622713"
333,"NCT02240693","Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo",,"Completed","Has Results","Alzheimer Disease","Drug: BI 409306|Drug: Placebo","Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.|Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)|Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment|Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment|Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment","Boehringer Ingelheim","All","55 Years and older   (Adult, Older Adult)","Phase 2","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1289.5|2013-005031-24","January 15, 2015","September 18, 2017","October 9, 2017","September 16, 2014","November 28, 2018","November 28, 2018","Orange County Neuropsychiatric Research Center LLC, Orange, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Richmond Behavioral Associates, Staten Island, New York, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Landeskrankenhaus Hall, Abt.f. Psychatrie & Psychotherapie A, Hall in Tirol, Austria|Private Practice for Psychiatry and Neurology, Wien, Austria|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|University of Calgary, Calgary, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc., Kentville, Nova Scotia, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Institut universitaire de geriatrie Sherbrooke, Quebec, Canada|HOP Pierre Wertheimer, Bron, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|HOP Jean Bernard, Géria, Poitiers, Poitiers, France|Praxis Dr. med. Volker Schumann, Berlin, Germany|emovis GmbH, Berlin, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für seelische Gesundheit, Mannheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|Neurologie und Psychiatrie / Psychotherapie, Westerstede, Germany|A.O. Spedali Civili di Brescia, Brescia, Italy|Osp. S. Giovanni di Dio, Firenze, Italy|Policlinico Gemelli, Roma, Italy|Brain Research Center, Amsterdam, Netherlands|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Non-Public Outpat. Clinic ""Dom Sue Ryder"", PALLMED Sp. z o.o, Bydgoszcz, Poland|Non-Public Outpatient Clinic ""Synapsa"" Pawel Polrola, Kielce, Kielce, Poland|Mental Health Center Biomed, Kielce, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|Medical Center Senior, Sopot, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Reg. Specialist Hospital Wroclaw, Research & Develop. Center, Wroclaw, Poland|Hospital Fernando Fonseca, EPE, Amadora, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Hospital Universitario Fundación Alcorcón, Alcorcon (Madrid), Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar (murcia), Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Spain|Hospital Mútua Terrassa, Terrasa (Barcelona), Spain|Royal United Hospital, Bath, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Re-Cognition Health, Plymouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02240693/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02240693/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02240693"
334,"NCT03514875","Effects of Mitochondrial-targeted Antioxidant on Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease|Alzheimer Disease, Early Onset","Dietary Supplement: MitoQ|Dietary Supplement: Placebo","Carotid artery blood flow|Oxidative Stress|Cerebrovascular Oxygenation|Brain Electrical Activity|Endothelial Function","University of Nebraska, Omaha","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UNOmaha3","July 1, 2019","July 1, 2020","October 1, 2020","May 2, 2018",,"March 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03514875"
335,"NCT02351453","Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)",,"Completed","No Results Available","Alzheimer Disease",,"Date of institutionalization of AD patients (standardized questionnaire)|The increase formal home help services (measured by a standardized questionnaire and coded as a binary variable)|The delay of institutionalization of AD patients (assessed by a standardized questionnaire and expressed in number of days)","University Hospital, Angers","All","65 Years and older   (Older Adult)",,"207","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011/24","August 2011","February 2013","February 2013","January 30, 2015",,"January 30, 2015","University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT02351453"
336,"NCT02941289","Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease","ARVA-MA","Unknown status","No Results Available","Alzheimer's Disease","Procedure: visual search performance of everyday objects in realistic scenes","Total number of fixations during search|Total duration of fixations during search","Centre Hospitalier Universitaire de Nice","All","65 Years to 75 Years   (Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-AOI-06","November 2016","May 2017","May 2019","October 21, 2016",,"August 23, 2017","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT02941289"
337,"NCT02557464","Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.","ADAL","Unknown status","No Results Available","Alzheimer's Disease","Behavioral: An eye tracking experiment|Behavioral: A neuropsychological evaluation","Eye tracking|The probability that the eyes skip the target word|the initial landing position of the eye in the target word (in letters)|the percentage of refixation done on the target word|the first fixation duration in the target word|the single fixation duration|the percentage of regressive saccade on the target word and the total viewing time|Neuropsychological tests scores","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-AOI-04","November 10, 2015","December 10, 2015","November 2017","September 23, 2015",,"August 23, 2017","Institut Claude Pompidou, Nice, France",,"https://ClinicalTrials.gov/show/NCT02557464"
338,"NCT03316898","A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: AGN-242071|Drug: Placebo|Drug: Donepezil|Drug: Memantine","Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) for Whole Brain, Hippocampal and Dorsolateral Prefrontal Cortices|Percentage of Participants with Treatment-Emergent Adverse Events (TEAE)|Percentage of Participants with Changes from Baseline in Clinically Significant Clinical Laboratory Values|Percentage of Participants with Changes from Baseline in Clinically Significant Vital Signs|Percentage of Participants with Changes from Baseline in Clinically Significant Electrocardiogram (ECG) Findings|Percentage of Participants who have Suicidal Ideation or Behaviours as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)|Clearance of AGN-242071|Volume of Distribution of AGN-242071|Cmax: Maximum Plasma concentration for AGN-242071|AUC: Area Under the Curve for AGN-242071","Allergan","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3142-101-001","September 30, 2018","November 4, 2018","November 4, 2018","October 20, 2017",,"November 2, 2018","ATP Clinical Research, Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Synergy Research Centers, Lemon Grove, California, United States|Collaborative Neuroscience, Long Beach, California, United States|Alliance Research, Long Beach, California, United States|Syrentis Clinical Research, Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT03316898"
339,"NCT00094952","Biomarkers and Early Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease",,,"National Institute on Aging (NIA)","All","60 Years to 80 Years   (Adult, Older Adult)",,"80","NIH","Observational","Time Perspective: Prospective","IA0054|AG022374","April 2003",,"March 2008","October 29, 2004",,"September 18, 2009","Center for Brain Health, Silberstein Institute, New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00094952"
340,"NCT00285077","Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: SR57667B","Adverse events recorded quarterly.|ADAS-cog, CDR, MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2,6,9 and 12 months.","Sanofi","All","50 Years and older   (Adult, Older Adult)","Phase 2","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LTS5283","March 2004","November 2006","November 2006","February 1, 2006",,"December 23, 2008","Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Horslholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Bromma, Sweden",,"https://ClinicalTrials.gov/show/NCT00285077"
341,"NCT02418806","Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres","cuiDem","Completed","No Results Available","Alzheimer's Disease","Behavioral: Psychotherapy groups|Behavioral: Self-help groups","Efficacy of group therapy in caregiver burden measured by Zarit Burden Interview.|Change in caregiver burden from baseline compared to the control and active arms measured by Zarit Burden Interview.|Change in anxiety and depression from baseline compared to the control and active arms measured by Goldberg Scale.|Descriptive analysis of the caregivers' characteristics (sociodemographics, relation wih the AD patient).|Descriptive analysis of the caregiver's cognition using DEM-DETECT Module 1.|Preliminary cost-effectiveness analysis related resources needed to caregivers and Alzheimer patients.|Change in quality of life from baseline compared to the control and active arms measured by Casp-19 and SF-36 questionnaires.|Change in resilience from baseline compared to the control and active arms measured by Connor-Davidson Resilience Scale.|Change in functional social support from baseline compared to the control and active arms using Duke-UNC questionnaire.","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","231","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","cuiDem/FBB-0113","January 2014","July 2014","September 2015","April 16, 2015",,"January 20, 2016","AFA Barcelona, Barcelona, Spain|Centro de día Vitalia, Barcelona, Spain|AFA Burgos, Burgos, Spain|AFA Castellón, Castellón, Spain|AGUAFA, Guadasuar, Spain|AFA Lleida, Lleida, Spain|Centro de envejecimiento saludable, Málaga, Spain|Fundació Ana Ribot, Pallejà, Spain|AVAN, Sabadell, Spain|AFATE, Tenerife, Spain|AFA Terres de l'Ebre, Tortosa, Spain",,"https://ClinicalTrials.gov/show/NCT02418806"
342,"NCT01843075","Evaluating Liraglutide in Alzheimer's Disease","ELAD","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Liraglutide|Drug: Placebo","The change in cerebral glucose metabolic rate|The change in z-scores for the ADAS Exec, MRI changes, microglial activation, and CSF markers|The incidence and severity of treatment emergent adverse events|The change in microglial activation|The change in tau deposition|The change in cortical amyloid","Imperial College London|King's College Hospital NHS Trust|University of Oxford|University of Southampton|Avon and Wiltshire Mental Health Partnership NHS Trust","All","50 Years and older   (Adult, Older Adult)","Phase 2","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U1111-1131-9252","January 2014","December 2019","December 2019","April 30, 2013",,"June 10, 2019","Imperial College, Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01843075"
343,"NCT02711683","DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: DL-3-n-butylphthalide|Drug: Donepezil","Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog)|Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)|Alzheimer's Disease Cooperative Study-Activities of Daily Living(ADCS-ADL)|Neuropsychiatric Inventory(NPI)","First Affiliated Hospital Xi'an Jiaotong University","All","50 Years to 85 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XJTU1AF-CRF-2015-027","March 2016","December 2019","March 2020","March 17, 2016",,"January 29, 2019","First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT02711683"
344,"NCT02359552","Rasagiline Rescue in Alzheimer's Disease Clinical Trial","R2","Completed","No Results Available","Alzheimer's Disease","Drug: Rasagiline|Drug: Placebo","The primary study endpoint is the change from baseline to Week 24 in regional glucose metabolism as measured by standard uptake units regional (SUVR) obtained through the 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET).","The Cleveland Clinic","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14-519","May 2015","August 29, 2018","January 4, 2019","February 10, 2015",,"May 8, 2019","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|Cleveland Clinic Lakewood Hospital, Lakewood, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02359552"
345,"NCT02222181","Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Other: Pharmacotherapy Management","Mini-mental State Examination (MMEE)|Clinical Dementia Rating (CDR)|Systolic Blood Pressure|Total Cholesterol|Triglycerides|Glycemia|Diastolic Blood Pressure","Universidade Estadual Paulista Júlio de Mesquita Filho|Fundação de Amparo à Pesquisa do Estado de São Paulo|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.","All","60 Years and older   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","24947914.5.0000.5426","April 2014","February 2016","March 2016","August 21, 2014","May 6, 2016","May 6, 2016","Centro de Referência do Idoso de Araraquara - CRIA, Araraquara, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02222181"
346,"NCT01893398","Multistimulation Group Therapy for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Other: Multidimensional stimulation group therapy","Change from baseline in behavioral level|Change from baseline in cognitive level|Change from baseline in quality of life","Fondazione Don Carlo Gnocchi Onlus","All","65 Years to 85 Years   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","FdG_AD_01","January 2010","December 2012",,"July 9, 2013",,"July 9, 2013","IRCCS, S Maria Nascente, FOndazione don Gnocchi, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT01893398"
347,"NCT02754830","A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: LY3303560 - IV|Drug: Saline Solution - IV|Drug: LY3303560 - SC","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (Serum): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-∞]) of LY3303560|Pharmacokinetics (Serum): Maximum Drug Concentration (Cmax) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Area Under the Concentration Versus Time Curve (AUC) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Maximum Drug Concentration (Cmax) of LY3303560|Mean Change from Baseline in QT/QT Corrected (QTc) Interval","Eli Lilly and Company","All","30 Years and older   (Adult, Older Adult)","Phase 1","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16120|I8G-MC-LMDA","April 25, 2016","July 10, 2018","July 10, 2018","April 28, 2016",,"July 23, 2018","Parexel Early Phase Unit at Glendale, Glendale, California, United States|PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02754830"
348,"NCT02359864","Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Radiation: 5 daily fractions of 2 Gy|Radiation: 10 daily fractions of 2 Gy","Common Terminology Toxicity Criteria (Version 4.0) - 6 weeks|Common Terminology Toxicity Criteria (Version 4.0) - 3 months|Common Terminology Toxicity Criteria (Version 4.0) - 9 months|Common Terminology Toxicity Criteria (Version 4.0) - 12 months|AMYVID (florbetaben F 18 Injection) PET Scan|Neurocognitive Function - MMSE (Mini Mental Status Exam) 6 weeks change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 3 months change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 9 months change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 12 months change from baseline|Neurocognitive Function - ADAS-Cog - 6 weeks change from baseline|Neurocognitive Function - ADAS-Cog - 3 months change from baseline|Neurocognitive Function - ADAS-Cog - 9 months change from baseline|Neurocognitive Function - ADAS-Cog - 12 months change from baseline|Neurocognitive Function - QOL-AD - 6 weeks change from baseline|Neurocognitive Function - QOL-AD - 3 months change from baseline|Neurocognitive Function - QOL-AD - 9 months change from baseline|Neurocognitive Function - QOL-AD - 12 months change from baseline|Neurocognitive Function - QUALID- 6 weeks change from baseline|Neurocognitive Function - QUALID- 3 months change from baseline|Neurocognitive Function - QUALID- 9 months change from baseline|Neurocognitive Function - QUALID- 12 months change from baseline","William Beaumont Hospitals","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-088; 2017-471","October 1, 2019","May 2021","May 2021","February 10, 2015",,"October 10, 2019","Beaumont Health, Farmington Hills, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02359864"
349,"NCT02686216","Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )","PET","Completed","No Results Available","Alzheimer's Disease","Drug: F-18 THK-5351","The primary outcome measures are to evaluate the dosimetry of novel radiotracer F-18 THK-5351 in human.|Optimal scanning time for brain imaging using F-18 THK-5351.","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","104-2710A","December 2015","April 2016","November 2016","February 19, 2016",,"February 8, 2017",,,"https://ClinicalTrials.gov/show/NCT02686216"
350,"NCT02349191","Omental Transposition Surgery for Mild Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Procedure: Omental transposition for mild Alzheimers disease","Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.|Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.|Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months|Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 12 months|Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 12 months|Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 24 months|Change in Montreal Cognitive Assessment (MoCA) score from baseline at 24 months|Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 24 months|Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 24 months","Bariatric Medicine Institute, Salt Lake City, UT","All","65 Years to 85 Years   (Older Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cottam - 1","March 2016","April 2017","May 2019","January 28, 2015",,"March 22, 2016",,,"https://ClinicalTrials.gov/show/NCT02349191"
351,"NCT00454870","Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: MEM 3454",,"Memory Pharmaceuticals","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","MEM 3454-003","February 2007","October 2007","October 2007","April 2, 2007",,"May 6, 2008","Phoenix, Arizona, United States|Glendale, California, United States|Atlanta, Georgia, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|Willingboro, New Jersey, United States|Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00454870"
352,"NCT00842673","Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ST101|Drug: Placebo","Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)","Sonexa Therapeutics, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST101-A001-201","February 2009","September 2010","September 2010","February 12, 2009",,"June 7, 2012","Costa Mesa, California, United States|Redlands, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Durham, North Carolina, United States|Toledo, Ohio, United States|Jenkinton, Pennsylvania, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00842673"
353,"NCT02362880","Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study",,"Recruiting","No Results Available","Alzheimer Disease","Radiation: Florbetaben","Incidence of Adverse events of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer?s disease.|Proportion of FAD mutation carriers that present positive uptake after FBB-PET through visual examination|Proportion of FAD mutation carriers presenting standardized uptake value ratios (SUVRs) of FBB-PET higher than 1,4.|Areas of significant difference (p<0,05) in regional SUVR between FAD mutation carriers and non-carriers.|Earliest age of positive FBB-PET in FAD mutation carriers.|Individual cortical areas with positive amyloid deposition at visual or semi-quantitative assessment","Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FBB-FAD-2014","February 2015","January 2019","January 2019","February 13, 2015",,"February 8, 2018","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02362880"
354,"NCT00285025","Study of the Effect of SR57667B in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: SR57667B","ADAS-cog, CDR measured at baseline and at 2, 6, 9 and 12 months.|MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2, 6, 9 and 12 months.","Sanofi","All","50 Years and older   (Adult, Older Adult)","Phase 2","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","EFC5286|SR57667B","March 2005",,"September 2005","February 1, 2006",,"February 1, 2006",,,"https://ClinicalTrials.gov/show/NCT00285025"
355,"NCT02792179","Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants",,"Completed","No Results Available","Alzheimer's Disease","Drug: [18F]RO6958948","Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan|Regional Standardized Uptake Value Ratios (SUVR), as Assessed by the Tau PET Brain Scan|Change in SUV for Different Brain Regions|Change in SUVR for Different Brain Regions|Percentage of Participants with Adverse Events","Hoffmann-La Roche","All","25 Years and older   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BP39126","July 19, 2016","September 28, 2016","September 28, 2016","June 7, 2016",,"November 1, 2017","Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02792179"
356,"NCT02820896","A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Placebo|Drug: RO7105705","Number of Participants with Adverse Events|Number of Participants with Dose Limiting Adverse Events (DLAEs)|Change from Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS) Score|Change From Baseline to Week 19 in Global Function as Assessed Using the Clinical Dementia Rating (CDR) Global Score in Alzheimer's Disease Participants|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs)|Serum Concentration of RO7105705 - Single Dose Cohorts: IV Administration|Serum Concentration of RO7105705 - Single Dose Cohorts: SC Administration|Serum Concentration of RO7105705 - Multiple Dose Cohorts: IV Administration|Change From Baseline to Week 19 in Cognitive Function as Assessed Using the Mini-Mental State Examination (MMSE) in Alzheimer's Disease Participants","Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GN39058","June 29, 2016","June 26, 2017","June 26, 2017","July 1, 2016",,"July 21, 2017","New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02820896"
357,"NCT02579252","24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease","ADAMANT","Unknown status","No Results Available","Alzheimer's Disease","Biological: AADvac1|Drug: Placebo","Safety (all-case treatment-emergent adverse events except local reactions)|Clinical Dementia Rating (CDR) Sum of Boxes|Custom cognitive battery (composite standard score)|Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL)|Immunogenicity","Axon Neuroscience SE","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-AD-003|2015-000630-30","March 2016","June 2019","June 2019","October 19, 2015",,"August 29, 2017","Ordination Dr. Bancher, Horn, Niederosterreich, Austria|Universitätsklinik für Neurologie, Graz, Steiermark, Austria|Abteilung Psychiatrie und Psychotherapie, LKH Hall, Hall in Tirol, Tirol, Austria|Universitätsklinikum Innsbruck, Innsbruck, Tirol, Austria|Fakultni nemocnice u sv. Anny v Brne, Mezinarodni centrum klinickeho vyzkumu (ICRC), Centrum pro kognitivni poruchy, Neuro 2, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Neurologicka Klinika, Hradec Kralove, Czechia|Narodni ustav dusevniho zdravi (NÚDZ), Department of cognitive disorders - AD Center, Klecany, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, Czechia|Fakultni nemocnice v Motole, Praha, Czechia|Neuro Centrum Odenwald, Erbach, Rheinland-Pfalz, Germany|Arzneimittelforschung Leipzig (AFL), Leipzig, Sachsen, Germany|Universität Heidelberg, Zentralinstitut für Seelische Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, München, Germany|Praxis Dr. Klaus Christian Steinwachs, Nürnberg, Germany|Universitätsklinikum Ulm, Klinik und Poliklinik für Neurologie, Ulm, Germany|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Pallmed prowadzacy NZOZ Dom Sue Ryder w Bydgoszczy Centrum Psychoneurologii Wieku Podeszlego, Bydgoszcz, Poland|Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland|Care Clinic, Katowice, Poland|Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii, Kraków, Poland|KO-MED Centra Kliniczne Sp. z o.o., Lublin, Poland|Oddzial Neurologiczny, Olsztyn, Poland|NZOZ Neuro-Kard, Poznan, Poland|EUROMEDIS Sp. z o.o., Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Wrocławskie Centrum Alzheimerowskie, Wroclaw, Poland|""Dr. Constantin Gorgos"" Psychiatry Hospital Titan, Bucharest, Romania|Neurologicka ambulancia, Banska Bystrica, Slovakia|Nestatna psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, I. Neurologicka klinika LF UK a UNB, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Psychiatricka klinika LFUK a UNB, Bratislava, Slovakia|Univerzitna nemocnica L Pasteura Kosice, Psychiatricka klinika, Kosice, Slovakia|NEURES, s.r.o. Neurologicka ambulancia, Krompachy, Slovakia|Centrum zdravia R.B.K., s.r.o., Psychiatricka ambulancia, Svidnik, Slovakia|Pro Mente Sana S.R.O., Psychiatricka Ambulancia, Trencin, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Psychiatricke oddelenie, Zilina, Slovakia|Univerzitetni klinični Center Ljubljana, Neurology Clinic, Ljubljana, Slovenia|University Clinical Centre Maribor, Maribor, Slovenia|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmö, Sweden|Sahlgrenska Universitetssjukhuset, Minnesmottagningen, Mölndal, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Akademiska Sjukhuset I Uppsala, Minnes-och geriatrikmottagningen, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02579252"
358,"NCT02492529","Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease","EPMR-MA","Completed","No Results Available","Alzheimer's Disease","Other: Neuropsychological tests|Device: A cranial MRI|Other: Experimental procedure","Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group|Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group|Significant group effect on the pattern of % BOLD signal change in across the brain|Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI)|Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct)","Rennes University Hospital","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2014-A01123-44|35RC14_9777_EPMR-MA","July 21, 2015","December 31, 2017","December 31, 2017","July 8, 2015",,"January 23, 2018","Centre Hospitalier Universitaire, Rennes, France",,"https://ClinicalTrials.gov/show/NCT02492529"
359,"NCT00024531","Lipitor as a Treatment for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Atorvastatin calcium",,"Institute for the Study of Aging (ISOA)|Pfizer|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 2","98","Other|Industry","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0031","October 2000",,"August 2004","September 20, 2001",,"November 9, 2006","Sun Health Research Institute, Sun City, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00024531"
360,"NCT02624778","A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD",,"Completed","No Results Available","Alzheimer Disease","Biological: LY3002813|Drug: Placebo","Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Pharmacokinetics: Serum Concentrations of LY3002813|Change from Baseline in Incidence of Anti-Drug Antibodies","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","16233|I5T-MC-AACD","December 22, 2015","August 28, 2019","August 28, 2019","December 8, 2015",,"September 4, 2019","Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Compass Research, The Villages, Florida, United States|SNBL Clinical Pharmacology Center Inc, Baltimore, Maryland, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Sumida-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02624778"
361,"NCT03765762","A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease",,"Recruiting","No Results Available","Severe Alzheimer Disease","Drug: GRF6019|Other: Placebo","Incidence of treatment-emergent adverse events (safety)|Tolerability of GRF6019 as assessed by number of patients completing the dosing regimen|The Mini-Mental State Examination (MMSE) score|Severe Impairment Battery (SIB)|Alzheimer's Disease Cooperative Study Group Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-Severe)|Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Plus Caregiver Input (ADCS-CGIC)|Neuropsychiatric Inventory Nursing Home (NPI-NH) Version|Neuropsychiatric Inventory (NPI) Caregiver version","Alkahest, Inc.","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alkahest study 6019-202","January 15, 2019","March 2020","March 2020","December 5, 2018",,"September 24, 2019","Cognitive Clinical Trials, Gilbert, Arizona, United States|Cognitive Clinical Trials, Mesa, Arizona, United States|Cognitive Clinical Trials, Phoenix, Arizona, United States|Pacific Research Network, San Diego, California, United States|Riverside Clinical Research, Edgewater, Florida, United States|Bio Behavioral Health, Toms River, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03765762"
362,"NCT02484547","221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease","EMERGE","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Aducanumab (BIIB037)|Drug: Placebo","Change from baseline in CDR-SB score|Change from baseline in MMSE score|Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 items) (ADAS-Cog 13)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) (ADCS-ADL-MCI) score","Biogen","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1605","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","221AD302|2015-000967-15","September 30, 2015","January 30, 2020","April 30, 2022","June 29, 2015",,"April 24, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Xenoscience Inc., Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Memory Impairments, Irvine, California, United States|Renewal Behavioral Health, Long Beach, California, United States|USC Keck School of Medicine, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|University of California San Diego Medical Center, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Colorado Denver, Aurora, Colorado, United States|IMMUNOe International Research Centers, Thornton, Colorado, United States|Associated Neurologists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Florida Atlantic University, Boca Raton, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories Inc., Deerfield Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Josephson, Wallack, Munshower Neurology, PC, Indianapolis, Indiana, United States|McLean Hospital, Belmont, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Hattiesburg Clinic, PA, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|ActivMed Practices & Research, Portsmouth, New Hampshire, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Dublin, Ohio, United States|Lehigh Center for Clinical Research, LLC, Allentown, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|Senior Adult Specialty Research, Austin, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Clinical Neuroscience Research Association, Inc, Bennington, Vermont, United States|University of Washington Medical Center, Seattle, Washington, United States|Northwest Neurological, PLLC, Spokane, Washington, United States|A.Z. Klina, Brasschaat, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, Belgium|Centre Neurologique & de Réadaptation Fonctionnelle, Fraiture-en-Condroz, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge - Campus Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Health Research., Kamloops, British Columbia, Canada|Health Research, West Vancouver, British Columbia, Canada|True North Clinical Research - Halifax Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc, Kentville, Nova Scotia, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|St. Joseph's HC- Parkwood Institute, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, Canada|DIEX Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Hospital Research Centre, Verdun, Quebec, Canada|Terveystalo Kamppi, Helsinki, Finland|Itä-Suomen yliopisto, Aivotutkimusyksikkö, Kuopio, Finland|CRST, Clinical Research Services Turku, Turku, Finland|Hôpital de la Timone, Marseille, Bouches-du-Rhône, France|CHU de Toulouse - Hôpital Purpan, Toulouse cedex 9, Haute Garonne, France|Centre de Recherche Clinique du Gérontopôle - Cité de la Santé, Toulouse, Haute Garonne, France|Hôpital Gui de Chauliac, Montpellier, Herault, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, Ille Et Vilaine, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 1, Loire Atlantique, France|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|Hôpital des Charpennes, Villeurbanne, Rhone, France|Hôpital Fernand Widal, Paris, France|Bezirkskrankenhaus Guenzburg, Guenzburg, Baden Wuerttemberg, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Baden Wuerttemberg, Germany|Nervenfachaerztlichen Gemeinschaftspraxis Ulm, Ulm, Baden Wuerttemberg, Germany|Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany|Klinik Hohe Warte Bayreuth, Bayreuth, Bayern, Germany|Institut fuer Schlaganfall- und Demenzforschung (ISD), Muenchen, Bayern, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Bayern, Germany|Neuropraxis Muenchen Sued, Unterhaching, Bayern, Germany|Praxis Dr. Kluenemann, Wenzenbach, Bayern, Germany|Neuro Centrum Odenwald, Erbach, Hessen, Germany|Schwerpunktpraxis fuer Neurologie, Psychiatrie und Klinische Studien, Bielefeld, Nordrhein Westfalen, Germany|Universitaetsklinikum Duesseldorf AoeR, Duesseldorf, Nordrhein Westfalen, Germany|Universitaetsklinikum Muenster, Muenster, Nordrhein Westfalen, Germany|Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung, Siegen, Nordrhein Westfalen, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Rheinland Pfalz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Kopfzentrum Leipzig, Leipzig, Sachsen, Germany|Klinikum Altenburger Land GmbH, Altenburg, Thueringen, Germany|emovis GmbH, Berlin, Germany|Neurologie im Tempelhofer Hafen, Berlin, Germany|Ospedale degli Infermi, Ponderano, Biella, Italy|Azienda Ospedaliera Card. G. Panico, Tricase, Lecce, Italy|ASST di Monza, Monza, Milano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy|Fondazione Santa Lucia IRCCS, Roma, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Research Site, Obu-shi, Aichi-Ken, Japan|Research Site, Toon-shi, Ehime-Ken, Japan|Research Site, Fukuoka-shi, Fukuoka-Ken, Japan|Research Site, Kurume-shi, Fukuoka-Ken, Japan|Research Site, Otake-shi, Hiroshima-Ken, Japan|Research Site, Amagasaki-shi, Hyogo-Ken, Japan|Research Site, Himeji-shi, Hyogo-Ken, Japan|Research Site, Kobe-shi, Hyogo-Ken, Japan|Research Site, Kita-gun, Kagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Tsu-shi, Mie-Ken, Japan|Research Site, Nishisonogi-gun, Nagasaki-Ken, Japan|Research Site, Yufu-shi, Oita-Ken, Japan|Research Site, Kurashiki-shi, Okayama-Ken, Japan|Research Site, Okayama-shi, Okayama-Ken, Japan|Research Site, Tsukubo-Gun, Okayama-Ken, Japan|Research Site, Kishiwada-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Sennan-shi, Osaka-Fu, Japan|Research Site, Suita-shi, Osaka-Fu, Japan|Research Site, Toyonaka-Shi, Osaka-Fu, Japan|Research Site, Iwata-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Kennemer Gasthuis, Zuid, Haarlem, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|PALLMED Sp. z o.o., Bydgoszcz, Poland|COPERNICUS Podmiot Leczniczy Sp. z o. o.,, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|Neuro-Care Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|SPZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz, Poland|Centrum Diagnostyczno - Terapeutyczne ""MEDICUS"" Sp.z o.o., Lubin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Neurologiczny NZOZ Centrum Leczenia SM, Plewiska, Poland|NZOZ ""NEURO-KARD"", ""Ilkowski i Partnerzy"" Sp. Partn. Lek., Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|NZOZ ""SENIOR"" Poradnia Psychogeriatryczna, Sopot, Poland|Osrodek Badan Klinicznych EUROMEDIS, Szczecin, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Hospital General Universitario de Elche, Elche, Alicante, Spain|ALTHAIA Hospital Sant Joan de Deu, Manresa, Barcelona, Spain|Complejo Hospitalario de Caceres, Caceres, Cáceres, Spain|Hospital Universitario Reina Sofía, Cordoba, Córdoba, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Skånes Universitetssjukhus, Malmö, Malmö, Sweden|Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus, Mölndal, Sweden|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Universitären Psychiatrischen Kliniken Basel (UPK), Basel, Switzerland|Inselspital - Universitaetsspital Bern, Bern, Switzerland|Medizinisches Zentrum MZB Biel, Biel/Bienne, Switzerland|Hôpitaux Universitaires de Genève - HUG, Geneve 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Ospedale Civico, Lugano, Switzerland|Institut fuer Regenerative Medizin (IREM) der Universitaet Zuerich, Zentrum fuer Praevention und Demenztherapie, Schlieren, Switzerland",,"https://ClinicalTrials.gov/show/NCT02484547"
363,"NCT02477800","221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease","ENGAGE","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Aducanumab (BIIB037)|Drug: Placebo","Change from baseline in CDR-SB score|Change from baseline in MMSE score|Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 items) (ADAS-Cog 13)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) (ADCS-ADL-MCI) score","Biogen","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1605","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","221AD301|2015-000966-72","August 31, 2015","January 30, 2020","April 30, 2022","June 23, 2015",,"April 24, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|California Neuroscience Research Medical Group Inc., Sherman Oaks, California, United States|Southern California Research LLC, Simi Valley, California, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research Main, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|USF Health Byrd Institute, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Compass Research Main, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Via Christi Research, a division of Via Christi Hospitals Wichita, Inc., Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Brigham & Women's Hosp End/Dbt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Donald S. Marks, M.D., P.C., Plymouth, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Las Vegas Medical research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|New York University Medical Center PRIME, New York, New York, United States|University of Rochester, Rochester, New York, United States|ANI Neurology, PLLC d/b/a Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Northeastern Pennsylvania Memory and Alzheimer's Center, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|University of Tennessee Medical Center. Knoxville, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Gosford, East Gosford, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|KARA Institute for Neurological Diseases, North Ryde, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Toowoomba Base Hospital, Toowoomba, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Neurodegenerative Disorders Research, West Perth, Western Australia, Australia|LKH - Universitaetsklinikum Graz, Graz, Austria|Christian-Doppler-Klinik - Universitätsklinikum Salzburg, Salzburg, Austria|Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|UBC Hospital, Vancouver, British Columbia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|The Montreal Neurological Institute, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|CCBR - Ballerup - DK, Ballerup, Denmark|Rigshospitalet, København Ø, Denmark|CCBR - Vejle - DK, Vejle, Denmark|CCBR - Ålborg - DK, Ålborg, Denmark|CHU Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Bas Rhin, France|Hopital Louis Pasteur Colmar, Strasbourg, Bas Rhin, France|Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux, Gironde, France|CHU Reims - Hôpital Maison Blanche, Reims, Marne, France|Hopital Neurologique Pierre Wertheimer, Bron Cedex, Rhone, France|Groupe hospitalier Broca - La Rochefoucauld - La Collégiale, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Praxis Dr. Scholz, Boeblingen, Baden Wuerttemberg, Germany|Aerztliche Gemeinschaftspraxis, Ostfildern, Baden Wuerttemberg, Germany|Neuro MVZ Stuttgart, Stuttgart, Baden Wuerttemberg, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Bayern, Germany|Praxis Dr. med. Bergmann, Neuburg, Bayern, Germany|Neurologische Gemeinschaftspraxis Kassel, Kassel, Hessen, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany|Universitaetsklinikum Aachen AOeR, Aachen, Nordrhein Westfalen, Germany|Universitaetsklinikum Bonn AoeR, Bonn, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Cologne, Nordrhein Westfalen, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Ancona, Italy|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Ospedale San Raffaele, Milano, Italy|Casa di Cura del Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Research Site, Chiba-Shi, Chiba-Ken, Japan|Research Site, Inzai-shi, Chiba-Ken, Japan|Research Site, Kurume-shi, Fukuoka-ken, Japan|Research Site, Aizuwakamatsu-shi, Fukushima-Ken, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Atsugi-shi, Kanagawa-Ken, Japan|Research Site, Kamakura-shi, Kanagawa-Ken, Japan|Research Site, Kawasaki-Shi, Kanagawa-Ken, Japan|Yokohama-shi, Kanagawa-ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Nagaoka-shi, Niigata-Ken, Japan|Research Site, Iruma-gun, Saitama-Ken, Japan|Research Site, Kasukabe-shi, Saitama-Ken, Japan|Research Site, Bunkyo-ku, Tokyo-To, Japan|Research Site, Shinjuku-ku (I), Tokyo-To, Japan|Research Site, Shinjuku-ku, Tokyo-To, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Yamagata-shi, Yamagata-Ken, Japan|Research Site, Itabashi-ku, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kiyose-shi, Japan|Research Site, Kodaira-shi, Japan|Inha University Hospital, Incheon, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal|Hospital de Braga, Braga, Portugal|Centro Hospitalar e Universitário de Coimbra E.P.E, Coimbra, Portugal|CUF Alvalade, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|Campus Neurologico Senior, Torres Vedras, Portugal|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Fundacio ACE, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Clinica Ruber, Madrid, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Southmead Hospital, Bristol, Avon, United Kingdom|Re:Cognition Health Ltd, London, Greater London, United Kingdom|Charing Cross Hospital, London, Greater London, United Kingdom|The National Hospital for Neurology and Neurosurgery Centre, London, Greater London, United Kingdom|Salford Royal, Salford, Greater Manchester, United Kingdom|The University of Edinburgh, Edinburgh, Lothian Region, United Kingdom|Manchester Royal Infirmary, Blackburn, Merseyside, United Kingdom|The RICE Centre, Bath, Somerset, United Kingdom|Glasgow Memory Clinic Ltd, Glasgow, Strathclyde, United Kingdom|Stobhill ACH Hospital, Glasgow, Strathclyde, United Kingdom|Ninewells Hospital, Dundee, Tayside Region, United Kingdom|Newcastle University, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Kingshill Research Centre, Chippenham, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02477800"
364,"NCT00089882","Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II",,"Completed","No Results Available","Alzheimer Disease","Procedure: APOE Genetic susceptibility testing",,"National Institute on Aging (NIA)|National Human Genome Research Institute (NHGRI)","All","18 Years and older   (Adult, Older Adult)",,"360","NIH","Observational","Time Perspective: Prospective","IA0057|2R01HG002213-04|Boston University SOM: H-23380","May 2003","September 2006","September 2006","August 18, 2004",,"July 23, 2009","Howard University College of Medicine, National Human Genome Center, Washington, District of Columbia, United States|Boston University School of Medicine, Alzheimer's Disease Center, Boston, Massachusetts, United States|Weill Medical College of Cornell University, Memory Disorders Program, New York, New York, United States|Case Western Reserve University, Memory and Aging Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00089882"
365,"NCT00688207","Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone (Extended Release)","AUC (0-inf) and Cmax of RSG XR|AUC(0-t), t1/2 and tmax for RSG XR","GlaxoSmithKline","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVA109941","April 2008","September 2008","September 2008","June 2, 2008",,"November 7, 2016","GSK Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00688207"
366,"NCT01420315","The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease","DEVIT-ALZ","Completed","No Results Available","Alzheimer's Disease",,"serum 25(OH)D levels","Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","50 Years and older   (Adult, Older Adult)",,"502","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","VDGT-01|G-123456789","August 2011","August 2012","August 2012","August 19, 2011",,"February 18, 2013","Gulhane Medical School Training Hospital, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01420315"
367,"NCT02389413","Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease","SAPHIR","Completed","No Results Available","Alzheimer's Disease","Drug: PQ912 oral|Other: Placebo","Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)|Exploratory clinical measures (measured by a questionnaire)|Change from baseline of a panel of concept and AD-related biomarkers in Cerebrospinal fluid (CSF) (measured by Analysis of several biochemical assays)|Change from baseline in brain functional connectivity (measured by Magnetic Resonance Imaging (MRI) analysis)|Change from baseline in functional connectivity and network Analysis in electroencephalography (EEG)","Probiodrug AG|Julius Clinical, The Netherlands|VU University Medical Center","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","120","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PBD01071|2014-001967-11","March 2015","April 2017","April 2017","March 17, 2015",,"June 1, 2017","Ziekenhuis Netwerk Antwerpen / Geheugenkliniek, Hoboken, Belgium|Kliininen tutkimuskeskus, Kuopio, Finland|Oulu University Hospital, Oulu, Finland|CRST Oy, Turku, Finland|CHU Bordeaux Pellegrin (CMRR), Bordeaux, France|CHU François Mitterand (Centre Mémoire Ressources Recherche (CMRR)), Dijon, France|CHRU de Lille / Hôpital Roger Salengro, Lille Cedex, France|Hôpital La Grave / Centre de Recherche Clinique, Toulouse Cedex 9, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsmedizin Göttingen / Klinik für Psychiatrie und Psychotherapie, Göttingen, Germany|Universitätsklinikum Halle (Saale) Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik, Halle (Saale), Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung, Magdeburg, Germany|Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster / Klinik für Allgemeine Neurologie, Münster, Germany|Universitätsmedizin Rostock / Zentrum für Nervenheilkunde/ Klinik für Psychosomatik und Psychotherapeutische Medizin, Rostock, Germany|Neurologische Universitätsklinik Ulm, Ulm, Germany|Alzheimer Research Center, Amsterdam, Netherlands|Hospital de la Santa Creu i Sant Pau, Neurology Department, Memory Unit, Barcelona, Spain|Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain|Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Verksamheten för neuropsykiatri Sahlgrenska universitetssjukhuset, Mölndal, Sweden",,"https://ClinicalTrials.gov/show/NCT02389413"
368,"NCT03744312","Imaging Inflammation in Alzheimer's Disease With 11C-ER176",,"Recruiting","No Results Available","Alzheimer Disease","Drug: 11C-ER176|Drug: Florbetaben","11C-ER176 total distribution volume|11C-ER176 Standardized Uptake Value Ratio","William Charles Kreisl|Columbia University","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR6570","September 10, 2018","July 20, 2021","July 20, 2021","November 16, 2018",,"January 31, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03744312"
369,"NCT00800709","Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Memantine","biological markers of CSF|18[F]-FDG-PET of brain|cognitive function|behavior and activities of daily living|short term memory","Shanghai Mental Health Center|H. Lundbeck A/S","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIT_12484A","July 2008","October 2010","October 2010","December 2, 2008",,"December 3, 2010","Department of Psychogeriatrics，Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00800709"
370,"NCT00678431","Randomized Trial of a Nutritional Supplement in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Dietary Supplement: Resveratrol with Glucose, and Malate|Dietary Supplement: Placebo","Alzheimer Disease Assessment Scale (ADAScog)|CGIC","US Department of Veterans Affairs|Alzheimer's Association|Icahn School of Medicine at Mount Sinai|VA Office of Research and Development","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","27","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0553-06-071","January 2008","December 2010","June 2011","May 15, 2008",,"November 15, 2012","James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00678431"
371,"NCT01181921","The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer Disease","Drug: Galantamine","Change From Baseline in Sleep/Wake Patterns as Measured by Actigraph at 12 Weeks","Janssen-Cilag, S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 4","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR015586|GALALZ4041|2009-013689-18","May 2011","June 2011","June 2011","August 13, 2010","August 14, 2012","May 1, 2014","Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01181921"
372,"NCT00679627","A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Galantamine|Drug: Placebo","Change From Baseline in the Mini-Mental State Examination (MMSE) Score|The Number of Deaths Reported in Participants|Change From Baseline in Disability Assessment in Dementia (DAD) Scores|Change From Baseline in Patient Accommodation Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)|Change From Baseline in Caregiver Time Spent With the Patient Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)|Change From Baseline in Institutional Status|Change From Baseline in the Mini-Mental State Examination (MMSE) Subscales (Orientation, Registration, Attention and Calculation, Recall, and Language)|Change From Baseline in the Disability Assessment in Dementia (DAD) Subscales (Initiation, Planning and Organization, Effective Performance, Basic, Instrumental, and Leisure)","Janssen Research & Development, LLC","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 3","2051","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR012463|GALALZ3005","June 2008","April 2012","May 2012","May 19, 2008","September 2, 2013","September 19, 2013","Hradec Kralove, Czech Republic|Mìlník 1, Czech Republic|Olomouc, Czech Republic|Ostrava 3, Czech Republic|Ostrava, Czech Republic|Praha 2, Czech Republic|Praha 8, Czech Republic|Tallinn N/A, Estonia|Tallinn, Estonia|Tartu, Estonia|Viljandi N/A, Estonia|Vorumaa, Estonia|Limoges, France|Bad Aibling, Germany|Bad Homburg, Germany|Bad Honnef, Germany|Bamberg, Germany|Berlin, Germany|Bielefeld, Germany|Bochum, Germany|Butzbach, Germany|Franfurt, Germany|Fürth, Germany|Gelsenkirchen, Germany|Göttingen, Germany|Hamburg, Germany|Hannover, Germany|Hattingen, Germany|Karlstadt, Germany|Leverkusen, Germany|Lüneburg, Germany|Mittweida, Germany|Mönchengladbach, Germany|Nürnberg, Germany|Oldenburg, Germany|Ulm, Germany|Unterhaching, Germany|Westerstede, Germany|Wiesbaden, Germany|Athens, Greece|Heraklion Crete, Greece|Thessalonikis, Greece|Riga, Latvia|Kaunas, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Arad, Romania|Bucharest Sector 5, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Constanta, Romania|Craiova, Romania|Iasi, Romania|Tg Mures, Romania|Ekaterinburg, Russian Federation|Kazan N/A, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar N/A, Russian Federation|Krasnodar, Russian Federation|Lipetsk, Russian Federation|Moscow Russia, Russian Federation|Moscow, Russian Federation|Nizny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Rostov-On-Don, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Smolensk Region N/A, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|St.Petersburg, Russian Federation|Tomsk Na, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Bratislava, Slovakia|Dubnica Nad Vahom, Slovakia|Kosice, Slovakia|Plesivec, Slovakia|Senkvice, Slovakia|Spisska Nova Ves, Slovakia|Vranov Nad Toplou, Slovakia|Kamnik, Slovenia|Lesce, Slovenia|Ljubljana, Slovenia|Maribor, Slovenia|Chernivtsy, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkov, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Lvov, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00679627"
373,"NCT02670083","CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Crenezumab|Drug: Placebo","Change from baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score|Change from Baseline to Week 105 on Cognition, as assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (subscales) 13 (ADAS-Cog-13) and 11 (ADAS-Cog-11)|Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Gloal Score (CDR-GS)|Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE)|Change from Baseline to Week 105 on function as assessed by the ADCS-ADL total score and the ADCS-instrumental subscore|Change from Baseline to Week 105 on a measure of dependence derived from the ADCS-ADL score|Change from Baseline to Week 105 assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score|Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score|EQ-5D Questionnaire Domain Score|Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs)|Percentage of Participants with Anti-Crenezumab Antibodies|Serum Concentration of Crenezumab|Plasma Amyloid Beta (Abeta) Concentrations|Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI)|Cerebrospinal Fluid (CSF) Concentration of Crenezumab|Brain Amyloid Load Over Time Measured by Amyloid-PET|Brain Tau Load Over Time Measured by Tau-PET|Cerebrospinal Fluid (CSF) Markers of Disease Over Time","Hoffmann-La Roche","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","813","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BN29552","March 22, 2016","May 31, 2019","May 31, 2019","February 1, 2016",,"September 24, 2019","Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|American Neuropsychiatric Research Institute Inc, Carson, California, United States|Pharmacology Research Inst, Encino, California, United States|Alliance for Wellness, dba Alliance for Research, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|USC Keck School Of Medicine, Los Angeles, California, United States|UCLA Medical Center, Department of Neurology, Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Shankle Clinic, Newport Beach, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|North Bay Neuro Science Institute, Sebastopol, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Mile High Research Center, Denver, Colorado, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions Inc; Jacksonville Clinic, Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Merritt - Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|Maine Research Associates, Auburn, Maine, United States|MMP Neurology, Scarborough, Maine, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, PA, West Long Branch, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Albany Medical Faculty Physicians COmmunity Division. The Neurology Group, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Columbia University Medical Center, New York, New York, United States|South Shore Neurologic Associates P.C., Patchogue, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|UC Health Neurology, Dayton, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|Oklahoma Clinical Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Central States Research, Tulsa, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Neural Net Research; Neural Net Research, Portland, Oregon, United States|Drexel Univ College of Med; Clinical Research Group, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Roper Hospital Laboratory, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|University of North Texas Health Science Center; Fort Worth Patient Care Center, Fort Worth, Texas, United States|Radiant Research, Inc., Salt Lake City, Utah, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Caulfield Hospital; Aged Psychiatry Research Unit, Caulfield, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Neurodegenerative Disorders Research; Neurology, West Perth, Western Australia, Australia|LKH Hall;Abteilung für Psychiatrie und Psychotherapie A, Hall in Tirol, Austria|Konventhospital Barmherzige Brüder; Neurologie I, Linz, Austria|UZ Gent, Gent, Belgium|UMHAT Sveti Georgi Clinic of neurology, Plovdiv, Bulgaria|MHAT National Cardiology Hospital, EAD; Neurology, Sofia, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, Bulgaria|Alexandrovska hospital; Neurology Department, Sofia, Bulgaria|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|CHA Hopital de I enfant-Jesus, Quebec City, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Hospital Clínica Biblica, San José, Costa Rica|Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, Croatia|The University Hospital Brno, Brno, Czechia|Charles University, Medical faculty, Hradec Kralove ;Department of Neurology, Hradec Králové, Czechia|General Teaching Hospital, Departmetn of Neurology, Praha, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Terveystalo Tampere, Tampere, Finland|CRST Oy, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Lariboisiere, Paris, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|CHU Toulouse - La Grave, Toulouse, France|Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Neurologie, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Psychiatrie & Psychotherapie, Dresden, Germany|Evang. Krankenhaus Bethanien; Fachkrankenhaus für Psychiatrie, Psychosomatik und Psychotherapie, Greifswald, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, Germany|Steinwachs Klaus; Arztpraxis fur Neurologie u. Psychiatrie, Nürnberg, Germany|Klinik und Poliklinik für Psychiatrie und Psychotherapie der Uni. Regensburg am Bezirksklinikum, Regensburg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Forschungszentrum Ruhr, Witten, Germany|Prince of Wales Hospital; Dept. of Medicine & Therapeutics, Hong Kong, Hong Kong|Queen Mary Hospital, Division of Geriatric Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Medicine & Geriatrics, Tuen Mun, Hong Kong|Dr. Kenessey Albert Korhaz-Rendelointezet; Pszichiatria I, Balassagyarmat, Hungary|Semmelweis University; Department of Neurology, Budapest, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak - Jósa András Oktatókórház; Pszichiátria, Nyíregyháza, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Szent Borbala Korhaz; Neurologiai es Stroke Osztaly, Tatabánya, Hungary|Jávorszky Ödön Kórház, Neurológia és stroke osztály, VAC, Hungary|Azienda Sanitaria Provinciale Di Catanzaro-P.O. Giovanni Paolo II; Centro Regionale Di Neurogenetica, Lamezia Terme (CZ), Calabria, Italy|Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Ambulatorio di Neurologia, Genova, Liguria, Italy|Irccs Aou San Martino - Ist; Dipartimento Di Medicina Interna, Genova, Liguria, Italy|Casa di Cura Policlinico; Dipartimento di Scienze Neuroriabilitative, Milano, Lombardia, Italy|Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa, Milano, Lombardia, Italy|Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer, Passirana, Lombardia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; S.C. Geriatria, Perugia, Umbria, Italy|National Center for Geriatrics and Gerontology, Aichi, Japan|Fukuoka Mirai Hospital, Fukuoka, Japan|Miyoshi Clinic of Neurology, Hananosato, Hiroshima, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa Prefectural Central Hospital, Kagawa, Japan|Fujisawa City Hospital, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto, Japan|Ijinkai Takeda General Hospital, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto, Japan|Mie University Hospital, Mie, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Saigata Medical Center, Niigata, Japan|Katayama Medical Clinic, Okayama, Japan|AMC Nishi Umeda Clinic, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|Ebara Hospital, Tokyo, Japan|Kanto Central Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|Tottori University Hospital, Tottori, Japan|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|KyungHee Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Kaunas Medical University Hospital; Department of Neurology, Kaunas, Lithuania|Vilnius University Hospital Santariskiu Clinic, Vilnius, Lithuania|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON ; Poradnia Neurologiczna, Bialystok, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|KOPERNICUS Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznan, Poland|Clinical Research Center Sp. z o.o. MEDIC-R Spółka Komandytowa, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Optimum, Warszawa, Poland|Centralny Szpital Kliniczny MSWiA Klinika Neurologii, Warszawa, Poland|Uniwersytet Medyczny w Lodzi Katedra Psychiatrii, Łódź, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, Portugal|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|SHI City Psychoneurological Dispensary #7, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|University Medical Centre, Ljubljana, Slovenia|University Medical Centre Maribor, Maribor, Slovenia|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan de Deu; Servicio de Neurología, Manresa, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría, Salamaca, Salamanca, Spain|Hospital General Universitario de Albacete; Servicio de Neurología, Albacete, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Hospital Lucus Augusti; Servicio de Neurología, Lugo, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, Murcia, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, Spain|Servicio de Neurología Hospital Viamed Montecanal., Zaragoza, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|Hacettepe University School of Medicine; Neurology, Ankara, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Regional mental hospital; Department of psychiatry, psychology and sexology, Lviv, KIEV Governorate, Ukraine|National Medical Academy of Postgraduate Education named after P.L.Shupik; Neurology Department #1, Kiev, Ukraine|D.F.Chebotarev Institute of Gerontology NAMS;Depart of Age Physiology&Pathology of Nervous System, Kiev, Ukraine|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Coventry and Warwickshire Partnership NHS Trust, Coventry, United Kingdom|St George's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Campus for Ageing and Vitality, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Torbay Hospital, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02670083"
374,"NCT02600130","Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo","To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.","Longeveron LLC","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00-0000-01","August 2016","March 2020","March 2020","November 9, 2015",,"December 17, 2018","UCLA School of Medicine, Los Angeles, California, United States|Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02600130"
375,"NCT02166827","Effects of a NeuroAD System, for the Treatment of Alzheimer Disease",,"Terminated","No Results Available","Alzheimer's Disease","Device: NeuroAD|Device: Sham TMS+Cog","Efficacy","Neuronix Ltd","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX-LT1","November 2014","November 2015","November 2015","June 18, 2014",,"March 31, 2017","Shaare Zedek, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02166827"
376,"NCT00838110","A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Dimebon|Drug: Placebo","Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 2|Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 2|Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 1|Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 2|Percentage of Participants With Adverse Events (AEs) in Cohort 1|Percentage of Participants With Adverse Events (AEs) in Cohort 2","Pfizer|Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B1451027","February 2009","January 2010","January 2010","February 6, 2009","February 8, 2013","December 6, 2018","Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Pueblo, Colorado, United States|Pfizer Investigational Site, Hockessin, Delaware, United States|Pfizer Investigational Site, Bradenton, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Walton Beach, Florida, United States|Pfizer Investigational Site, Fruitland Park, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plant City, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, Port Orange, Florida, United States|Pfizer Investigational Site, Saint Petersburg, Florida, United States|Pfizer Investigational Site, Saint Petersburg, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Burr Ridge, Illinois, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Elkhart, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Greenfield, Indiana, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, West Yarmouth, Massachusetts, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Great Falls, Montana, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Toms River, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Amherst, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Orchard Park, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Bridgeville, Pennsylvania, United States|Pfizer Investigational Site, Grove City, Pennsylvania, United States|Pfizer Investigational Site, Indiana, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Scotland, Pennsylvania, United States|Pfizer Investigational Site, Upper Saint Clair, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Murrells Inlet, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Orangeburg, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Carrollton, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Grand Prairie, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, Williamsburg, Virginia, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Charleston, West Virginia, United States|Pfizer Investigational Site, La Crosse, Wisconsin, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Surrey, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Kentville, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Cayey, Puerto Rico|Pfizer Investigational Site, Cidra, Puerto Rico|Pfizer Investigational Site, Rio Piedras, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00838110"
377,"NCT00842816","Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ST101|Drug: Placebo","Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)","Sonexa Therapeutics, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST101-A001-202","February 2009","May 2011","May 2011","February 12, 2009",,"June 7, 2012","Tucson, Arizona, United States|Costa Mesa, California, United States|Redlands, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Hamden, Connecticut, United States|Brooksville, Florida, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Decatur, Georgia, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Jenkinton, Pennsylvania, United States|Norristown, Pennsylvania, United States|East Providence, Rhode Island, United States|Houston, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Kirkland, Washington, United States|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00842816"
378,"NCT02353598","A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Crenezumab dose level 1|Drug: Crenezumab dose level 2|Drug: Crenezumb dose level 3|Drug: Placebo","Number of participants with anti-crenezumab antibodies|Number of participants with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, as determined using the columbia-cuicide severity rating scale (C-SSRS)|Number of participants with changes from baseline in vital signs, electrocardiogram (ECG) and clinical laboratory results|Number of participants with amyloid-related imaging abnormalities-hemorrhage (ARIA-H)|Number of participants with adverse events (AEs) and serious adverse events (SAEs) according to national cancer institute common terminology criteria for adverse events, version 4.0 (NCICTCAE v4.0)|Number of participants with of non-serious AEs of special interest|Number of participants with amyloid-related imaging abnormalities-edema/effusion (ARIA-E)|Serum concentration of crenezumab","Genentech, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GN29632","February 26, 2015","November 30, 2016","March 26, 2019","February 3, 2015",,"July 24, 2019","Mayo Clinic Scottsdale, Phoenix, Arizona, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Bioclinica Orlando, Orlando, Florida, United States|Bioclinica The Villages, The Villages, Florida, United States|Indiana University School Of Medicine; Department Of Neurology, Indianapolis, Indiana, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|UNiversity of Rochester, Rochester, New York, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare; Clinical Biotechnology Research Institute, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02353598"
379,"NCT02431468","A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Bryostatin 1|Other: Placebo","Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events|Efficacy: Change From Baseline in Severe Impairment Battery (SIB) in the Full Analysis Set (FAS)|Secondary Efficacy Endpoints","Neurotrope Bioscience, Inc.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NTRP-101-202","November 2015","February 2017","February 2017","May 1, 2015","July 6, 2018","July 6, 2018","Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Nader Pharmacology Research Institute, Los Alamitos, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of South Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J. Gary Booker, MD APMC Clinical Drug Trials, Shreveport, Louisiana, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Atlantic Neuroscience Institute, Springfield, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Parker Jewish Institute for Health Care and Rehabilitation, New Hyde Park, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Sunstone Clinical Research, Medford, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Neurology Clinic, PC, Cordova, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02431468/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02431468/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02431468"
380,"NCT02388152","Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer Disease","Drug: Lu AF20513, low dose|Drug: Lu AF20513, medium dose|Drug: Lu AF20513, high dose|Drug: Lu AF20513, double high dose","Safety and tolerability assessed by composite outcome measure consisting of absolute values and changes from baseline in: adverse events, clinical safety laboratory tests, vital signs|Antibody titre","H. Lundbeck A/S","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16026A|2014-001797-34","March 2015","January 21, 2019","July 4, 2019","March 13, 2015",,"July 17, 2019","AT001, Wien, Austria|FI001, Turku, Finland|SE002, Malmö, Sweden|SE003, Mölndal, Sweden|SE001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02388152"
381,"NCT02640092","Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: [18F]GTP1","Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)13|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Volumetric Magnetic Resonance Imaging (MRI) Measures|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Cerebrospinal Fluid (CSF) Markers|Percentage of Participants With Adverse Events (AEs)|Test-Retest Variability Based on [18F]GTP1 PET Scans","Genentech, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GN30009|G0097","December 23, 2015","June 11, 2019","June 11, 2019","December 28, 2015",,"April 11, 2019","Molecular NeuroImaging, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Acadia Clinical Research; Dr. Henderson's Office, Bangor, Maine, United States|Donald S. Marks, M.D., P.C.; Medical Center, Plymouth, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Advanced Medical Research, Maumee, Ohio, United States|Lehigh Center Clinical Research, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02640092"
382,"NCT01284387","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease","ACCTION","Completed","No Results Available","Alzheimer's Disease","Biological: ACC-001 (vanutide cridificar)","To evaluate the effect of ACC-001 in combination with an adjuvant immunostimulatory agent (QS-21), administered intramuscularly compared to placebo on cerebral amyloid burden in subjects with mild to moderate Alzheimer's disease.|To evaluate the safety and tolerability of 2 dosage levels of ACC-001 plus QS-21 vs. placebo in subjects with mild to moderate AD.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in disease biomarkers.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in measurements of immunogenicity.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in cognitive and functional scales.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in health outcome measures.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACC-001-ALZ-2001","January 2011","January 2014","February 2014","January 27, 2011",,"January 5, 2015","Janssen AI Investigational Site, Sun City, Arizona, United States|Janssen AI Investigational Site, La Jolla, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Los Angeles, California, United States|Janssen AI Investigational Site, Oxnard, California, United States|Janssen AI Investigational Site, San Diego, California, United States|Janssen AI Investigational Site, San Francisco, California, United States|Janssen AI Investigational Site, Washington, District of Columbia, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Ocala, Florida, United States|Janssen AI Investigational Site, Orlando, Florida, United States|Janssen AI Investigational Site, Sunrise, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, West Palm Beach, Florida, United States|Janssen AI Investigational Site, Scarborough, Maine, United States|Janssen AI Investigational Site, Boston, Massachusetts, United States|Janssen AI Investigational Site, Kansas City, Missouri, United States|Janssen AI Investigational Site, Las Vegas, Nevada, United States|Janssen AI Investigational Site, Princeton, New Jersey, United States|Janssen AI Investigational Site, Albany, New York, United States|Janssen AI Investigational Site, New York, New York, United States|Janssen AI Investigational Site, Centerville, Ohio, United States|Janssen AI Investigational Site, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01284387"
383,"NCT03784183","Neuropsychological and Neurophysiological Effects of Cognitive Stimulation in Patients With Alzheimer's Disease and Mild Cognitive Impairment",,"Recruiting","No Results Available","Alzheimer Disease","Other: Cognitive Stimulation (CS)","Change in global cognition as assessed by Mini Mental State Examination|Change in dementia severity as assessed by Clinical Dementia Rating Scale|Change in frontal functions as assessed by Frontal Assessment Battery|Change in verbal memory as assessed by Rey Auditory Verbal Learning Test|Change in attention as assessed by Visual Search Test|Change in visuospatial functions as assessed by Clock Drawing Test|Change in naming as assessed by Boston Naming Test|Change in synaptic plasticity as assessed by Paired Associative Stimulation|Change in blinking as assessed by Blink Rate Evaluation","University of Roma La Sapienza","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BSP-2018","September 27, 2018","October 1, 2020","October 1, 2020","December 21, 2018",,"December 21, 2018","Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT03784183"
384,"NCT02670993","Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease","LACME","Completed","No Results Available","Alzheimer's Disease","Behavioral: Singing sessions.|Behavioral: Painting sessions.","Score at the EVS = simplified visual scale|Score at the EN (digital scale) scale|Score at the BPI (Brief Pain Inventory) scale : Brief pain Inventory","Centre Hospitalier Universitaire de Saint Etienne","All","60 Years and older   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1508071|2015-A01404-45","January 2016","May 2016","June 2016","February 2, 2016",,"September 20, 2016","Hospices civils de Lyon, Lyon, France|Chu Saint Etienne, Saint Etienne, France",,"https://ClinicalTrials.gov/show/NCT02670993"
385,"NCT02551809","Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients",,"Completed","No Results Available","Alzheimer's Disease","Biological: UB-311|Drug: Placebo","Tolerability and safety profile of UB-311 assessed via recording of all Adverse Events.|Immunogenicity of UB-311 measured by change from baseline in anti-Aβ antibody level|Change from baseline in cognitive: Alzheimer´s Disease Assessment Scale- Cognitive (ADAS-Cog)|Change from baseline in function: Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change from baseline in cognition: Mini-Mental State Examination (MMSE)|Change from baseline in global assessment: Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change from baseline in behavioral assessment: Neuropsychiatric Inventory (NPI)|Change of amyloid burden from baseline in 18F-AV-45 PET imaging in selected brain areas","United Neuroscience Ltd.","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","V203-AD","October 2015","August 2018","August 2018","September 16, 2015",,"January 23, 2019","Kaohsiung Chang Gung Memorial Hospital (KS-CGMH), Kaohsiung, Taiwan|National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital (TVGH), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital (LK-CGMH), Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02551809"
386,"NCT04004702","Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)","LAPSE","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: Levetiracetam","Change in Neuropsychiatric Inventory Score (NPI)|Change in Clinical Dementia Rating Sum of Boxes (CDR-SOB)|Change in Alzheimer's Disease Cooperative study - Clinical Global Impression of Change (ADCS-CGIC)|Change in EuroQol 5-Dimension (EQ-5D)|Change in Mini-Mental State Exam (MMSE)","Walter Reed National Military Medical Center","All","Child, Adult, Older Adult","Phase 2","65","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06272019","January 2020","December 2024","June 2025","July 2, 2019",,"July 2, 2019","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04004702"
387,"NCT00277810","Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: lecozotan SR (SRA-333)","All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales|Score change from baseline to 24 weeks on functional and behavioral scales","Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3098B1-203, 3098B1-204","March 2006","June 2008","June 2008","January 16, 2006",,"February 21, 2013","Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|La Jolla, California, United States|Orange, California, United States|Delray Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hallandale, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|S. Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|St. Louis, Missouri, United States|Long Branch, New Jersey, United States|Manchester Twp., New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|Staten Island, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Bennington, Vermont, United States|Av. Belgrano, Argentina|Buenos Aires, Argentina|Calle Adolfo Alsina, Argentina|Cervino, Argentina|Galvan, Argentina|Gascon, Argentina|Larrea, Argentina|Nueva York, Argentina|Pilar, Argentina|Adelaide, Australia|East Gosford, Australia|Hornsby, Australia|Randwick, Australia|Victoria, Australia|Edmonton, Alberta, Canada|Medicine Hat, Alberta, Canada|Moncton, New Brunswick, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Bordeaux, France|Montpellier, France|Nice, France|Toulouse, France|Roma, Italy|Roma, Italy|Gdansk - Wrzeszcz, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Sopot, Poland|Szczecin, Poland|Bloemfontein, South Africa|Cape Town, South Africa|Johannesburg, South Africa|Somerset West, South Africa|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Belfast, United Kingdom|Glasgow, United Kingdom|Sheffield, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00277810"
388,"NCT02167256","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: AZD0530 100mg daily|Drug: AZD0530 125mg daily|Drug: Placebo","Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging|Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs.|The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function|Percent Change in Brain Volume Before and After Treatment|Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42)","Yale University|Alzheimer's Therapeutic Research Institute","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1404013830|4UH3TR000967-02","December 2014","February 27, 2018","February 27, 2018","June 19, 2014","August 14, 2019","August 14, 2019","Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Wien Center for Clinical Research/Mount Sinai Medical Center, Miami Beach, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|University of Washington, Seattle, Washington, United States|University of British Columbia, Clinic for AD & Related Disorders, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02167256/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02167256"
389,"NCT00599469","Far Infrared Treatment for Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Radiation: Far Infrared Radiation (5μm to 20μm wavelength)","Management and Cure of Alzheimer's Disease|Management and Cure of Dementia","GAAD Medical Research Institute Inc.","All","Child, Adult, Older Adult","Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GAAD-AD-CTP1","February 2008","March 2009","April 2009","January 23, 2008",,"August 17, 2009","The Centre for Incurable Diseases, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00599469"
390,"NCT03520998","A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Mild to Moderate Alzheimer Disease","Drug: GRF6019","Incidence of treatment-emergent adverse events (safety)|The Mini-Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)|The Grooved Pegboard Test|The Category Fluency Test (CFT)|The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)|The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCSCGIC)|The Neuropsychiatric Inventory Questionnaire (NPI-Q)|The Savonix Neurocognitive Assessments and Digit Span","Alkahest, Inc.","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK6019-201","April 16, 2018","May 24, 2019","May 24, 2019","May 10, 2018",,"July 16, 2019","Synergy East, Lemon Grove, California, United States|CNS Network, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Behavioral Clinical Research, North Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Serenity Inpatient, DeSoto, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03520998"
391,"NCT01900665","Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo","EXPEDITION 3","Terminated","Has Results","Alzheimer's Disease","Drug: Solanezumab|Drug: Placebo","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)|Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)|Change From Baseline in Mini-Mental State Examination (MMSE)|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)|Change From Baseline in Functional Activities Questionnaire (FAQ)|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change From Baseline in Neuropsychiatric Inventory (NPI)|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)|Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)|Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)|Percentage of Participants of Cognitive and Functional Responders|Change From Baseline in Plasma Amyloid-Beta (Aβ) Species|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)|Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan|Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels","Eli Lilly and Company","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","2129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15136|H8A-MC-LZAX","July 2013","October 2016","February 2017","July 16, 2013","March 14, 2018","October 9, 2019","Xenoscience, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|ANI Arizona Neurological Institute Research, PC, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Arizona Health Sciences Center, Tucson, Arizona, United States|American Neuropsychiatric Research Institute, Inc, Carson, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|University of California - San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research, Lomita, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Apostle Clinical Trials, Inc, Long Beach, California, United States|Univ of Southern California Medical Center, Los Angeles, California, United States|University of California Los Angeles School of Medicine, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Anderson Clinical Research, Redlands, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|St. Joseph Health, Santa Rosa, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Radiant Research, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Norwalk, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Parkinson's Disease and Movement Disorders, Boca Raton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Cohen Medical Associates P.A., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Hialeah, Florida, United States|Infinity Clinical Research . LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Mayo Clinic of Jacksonville, Jacksonville, Florida, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Neurology Clinical Research, Inc, Sunrise, Florida, United States|Axiom Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CTT Consultants, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Baptist Physician's Lexington, Lexington, Kentucky, United States|Private Office: J. Gary Booker, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Maine Neurology, Scarborough, Maine, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Univ of Nebraska Med Center, Omaha, Nebraska, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Albuquerque Neurosciences, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Richmond Behavorial Associates, Staten Island, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Valley Medical Research, Centerville, Ohio, United States|Ohio State Univ College Of Medicine, Columbus, Ohio, United States|Neurology Specialists Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Red River Medical Center, LLC, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Drexel University College of Medicine at EPPI, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|University Psychiatry Associates Avera Health, Sioux Falls, South Dakota, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|Vanderbilt Univeristy School of Medicine, Nashville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Diagnostic Research Group, San Antonio, Texas, United States|Radiant Research, Murray, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|National Clinical Research - Norfolk Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Blue Ridge Research Center, Roanoke, Virginia, United States|Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caulfield, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bron, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reims, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villeurbanne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boeblingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westerstede, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponderano (BI), Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sopot, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barakaldo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guipuzcoa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt-Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jönköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Crowborough, East Sussex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greater London, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01900665"
392,"NCT00744978","Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Varenicline|Drug: Placebo","Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6|Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3|Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3|Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6|Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6|Neuropsychiatric Inventory (NPI) Total Score at Week 3|Neuropsychiatric Inventory (NPI) Total Score at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3|Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6","Pfizer","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A3051101","July 2009","November 2010","November 2010","September 1, 2008","November 22, 2011","November 22, 2011","Pfizer Investigational Site, Seongnam, Gyunggido, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Suwon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00744978"
393,"NCT02434718","Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease","PROPEL","Completed","No Results Available","Alzheimer's Disease","Drug: Aducanumab|Drug: Placebo","Incidence and nature of adverse events (AE) / serious adverse events(SAE)|Clinically significant changes in vital signs and 12-lead electrocardiogram (ECG) data; abnormalities in neurological and physical examinations|Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis)|Area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞)|AUC from time zero to time of the last measurable concentration (AUC0-last)|Maximum observed concentration (Cmax)|Time to Cmax (Tmax)|Elimination half-life (t1/2)|Volume of distribution at steady state (Vss)|Clearance (CL) after a single IV infusion of aducanumab|Incidence of anti-aducanumab antibodies in serum","Biogen","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","221AD104","June 30, 2015","December 9, 2016","December 9, 2016","May 5, 2015",,"April 10, 2017","Research Site, Toon, Ehime, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Kamakura, Kanagawa, Japan|Research Site, Kanzaki, Saga, Japan|Research Site, Kodaira, Tokoyo, Japan|Research Site, Shinjuku, Tokoyo, Japan|Research Site, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT02434718"
394,"NCT00053599","Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study",,"Completed","No Results Available","Alzheimer Disease","Drug: Simvastatin",,"National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)","All","50 Years and older   (Adult, Older Adult)","Phase 3","400","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0038|ADC-015-LL","December 2002","October 2007","October 2007","February 4, 2003",,"July 28, 2009","University of Alabama, Birmingham, Birmingham, Alabama, United States|Barrow Neurology Group, Phoenix, Arizona, United States|Arizona Health Sciences Center, University of Arizona, Tucson, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University/VA Aging Clinical Research Center, Palo Alto, California, United States|University of California, Davis, Sacramento, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Memory Disorder Program, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Baumel Eisner Neuromedical Institute, Boca Raton, Florida, United States|Mayo Clinic (Jacksonville), Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Rush University, Chicago, Illinois, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Kentucky, Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan at Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis University, St. Louis, Missouri, United States|Washington University, St. Louis School of Medicine, St. Louis, Missouri, United States|SUNY Downstate, Brooklyn, New York, United States|New York University School Of Medicine, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Stony Brook, Stonybrook, New York, United States|Neurological Care of NY, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|University of Pennsylvania School of Medicine, Alzheimer's Disease Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown University-Memorial Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas, Southwestern Medical School, Dallas, Texas, United States|Baylor College of Medicine, Alzheimer's Disease Research Center, Houston, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|University of Washington at Seattle, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00053599"
395,"NCT01940952","Zydena on Cognitive Function of Alzheimer's Disease Patients",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|Drug: Placebo + Donepezil 5mg or 10mg|Drug: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg","Change in cognitive function|Change in behavioral symptoms|Change in brain function","Samsung Medical Center|Dong-A Pharmaceutical Co., Ltd.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","210","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-03-065","September 2013","August 2015",,"September 12, 2013",,"September 12, 2013","Samguns Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01940952"
396,"NCT00930059","A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PF-04447943|Drug: Placebo","Change from baseline on Alzheimer's Disease Assessment Scale (Cognitive Subscale)|Change from baseline on Neuropsychiatric Inventory|Clinical Global Impression - Improvement|Safety Assessments (including adverse events, vital signs, electrocardiograms, laboratory tests)|Plasma Concentrations of PF-04447943","Pfizer","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B0401005","September 2009","September 2010","September 2010","June 30, 2009",,"April 16, 2013","Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Vista, California, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plantation, Florida, United States|Pfizer Investigational Site, Joliet, Illinois, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Newton, Massachusetts, United States|Pfizer Investigational Site, Cedarhurst, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Cordova, Tennessee, United States|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Antofagasta, II Region, Chile|Pfizer Investigational Site, Providencia, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, La Florida, Santiago, Chile|Pfizer Investigational Site, Valdivia, XIV Region, Chile|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Pardubice, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Rychnov nad Kneznou, Czech Republic|Pfizer Investigational Site, Strakonice, Czech Republic",,"https://ClinicalTrials.gov/show/NCT00930059"
397,"NCT02127476","A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: KHK6640|Drug: Matching Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin Pharmaceutical Development, Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6640-001|2013-002873-23","July 2014","May 2017","May 2017","April 30, 2014",,"June 1, 2017","UZ Gent, De Pintelaan 185, Gent, Belgium|Clinical Research Services Turku (CRST), Itäinen Pitkäkatu 4B,, Turku, Finland|Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands|University Medical Centre Groningen (UMCG), Alzheimer Research Centre, Groningen, Netherlands|Clinical Centre of Serbia, Neurology Clinic, Dr Subotica Starijeg 6 ,, Belgrade, Serbia|Military Medical Academy, Crnotravska 17,, Belgrade, Serbia|Memory Clinic, Malmo Minneskliniken, Memory Research Unit, Hs 33,, Malmö, Sweden|Sahlgrenska Gothenburg, Minnesmottagningen, Wallinsgatan 6, Mölndal, Sweden|Karolinska Stockholm Karolinska University Hospital, Huddinge, Dept. of Geriatrics/Memory Disorders Unit, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02127476"
398,"NCT01128361","Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)",,"Completed","Has Results","Alzheimer's Disease","Behavioral: Aerobic Exercise|Behavioral: Stretching","Memory Composite|Executive Function Composite|Disability Assessment for Dementia|Cornell Scale for Depression in Dementia","Jeff Burns, MD|University of Kansas Medical Center","All","55 Years and older   (Adult, Older Adult)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11969","May 2010","April 2015","April 2015","May 21, 2010","March 13, 2017","March 13, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01128361"
399,"NCT02386306","Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: GC021109|Other: Placebo","Assessment of the number and severity of treatment-emergent AEs (TEAEs) following single oral doses of GC021109 and placebo from Day 1 through Day 28|Estimate of the pharmacokinetic (PK) parameters of multiple, escalating dose levels of GC021109: AUC0-t, AUC0-24, AUC0-inf, AUC%extrap, CL/F, Cmax, Tmax, λz, and t1/2.|Determine the effect of multiple, escalating dose levels of GC021109 on potential biomarkers of activities.","GliaCure, Inc.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GC-100-02","February 2015","October 2015","October 2015","March 11, 2015",,"February 3, 2016","Collaborative Neuroscience Network, Long Beach, California, United States|Quantum laboratories / Memory Disorder Center, Deerfield Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02386306"
400,"NCT02221947","Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Bryostatin 1|Drug: Placebo","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD","Neurotrope Bioscience, Inc.|Blanchette Rockefeller Neurosciences Insitute","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NTRP101-201","June 2014","December 2014","December 2014","August 21, 2014","April 21, 2016","November 6, 2017","California Clinical Trials Medical Center, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02221947"
401,"NCT00040378","Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)",,"Completed","No Results Available","Alzheimer Disease","Drug: alphatocopherol|Drug: Selenium|Drug: Placebo replacement for vitamin E|Drug: Placebo replacement for Selenium","incidence of dementia (including Alzheimer's disease)","Frederick Schmitt|National Institute on Aging (NIA)|National Cancer Institute (NCI)|University of Kentucky","Male","60 Years to 90 Years   (Adult, Older Adult)",,"4246","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IA0033|5R01AG019241","May 2002","January 2014","August 2016","June 27, 2002",,"March 14, 2018","University of Alabama at Birmingham Preventive Medicine, Birmingham, Alabama, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|University of California, San Diego - Chula Vista, Chula Vista, California, United States|Glendale Memorial Hospital, Glendale, California, United States|University of California, San Diego, La Jolla, California, United States|VA Medical Center, Loma Linda, California, United States|VAMC Long Beach, Long Beach, California, United States|Northridge Hospital Medical Center, Northridge, California, United States|Santa Rosa Memorial Hospital Regional CCOP, Santa Rosa, California, United States|LABIOMED (Los Angeles Biomedical) Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Lionel B. Katchem, Upland, California, United States|Rocky Mountain CC/Poudre Valley Hospital, Fort Collins, Colorado, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|George Washington University Medical Center, Washington, District of Columbia, United States|DC United MBCCOP, Washington, District of Columbia, United States|Baptist Medical Center, Jacksonville, Florida, United States|Kaiser Southeast Permanente Medical Group, Tucker, Georgia, United States|Bliss Cancer Center/McFarland Clinic/Mary Greely MC, Ames, Iowa, United States|Cedar Rapids CCOP, Cedar Rapids, Iowa, United States|Genesis Medical Center, Davenport, Iowa, United States|Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, Sioux City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Stormont-Vail Health Care/Cotton O'Neil Clinic, Topeka, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Our Lady of Bellefonte Hospital Inc., Ashland, Kentucky, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Louisville VA Medical Center, Louisville, Kentucky, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Berkshire Hematology Oncology/Bershire Medical Center, Pittsfield, Massachusetts, United States|Bixby Oncology Center, Adrian, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Grand Rapids Clinical Oncology Program CCOP, Grand Rapids, Michigan, United States|Monroe Clinic, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Duluth CCOP, Duluth, Minnesota, United States|St. John's Regional Medical Center, Joplin, Missouri, United States|St. John's Health System, Springfield, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Benefis Health Care, Great Falls, Montana, United States|Good Samaritan Health Systems - Cancer Center, Kearney, Nebraska, United States|Cancer Resource Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Missouri Valley Cancer Cons CCOP/Creighton University, Omaha, Nebraska, United States|Washoe Medical Center, Reno, Nevada, United States|VAMC New Jersey Health Care System, East Orange, New Jersey, United States|Warren Hospital, Phillipsburg, New Jersey, United States|Riverview Medical Center, Red Bank, New Jersey, United States|Stratton Veterans Affairs Medical Center, Albany, New York, United States|Bassett Research Institute, Cooperstown, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Columbus CCOP, Columbus, Ohio, United States|Fremont Memorial Hospital, Fremont, Ohio, United States|NW Ohio Oncology Center/St. Luke's Hospital, Maumee, Ohio, United States|St. Charles Hospital, Oregon, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Medical Center, Toledo, Ohio, United States|Toledo CCOP, Toledo, Ohio, United States|Toledo Clinic Inc., Toledo, Ohio, United States|Muskogee Regional Medical Center, Muskogee, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|York Cancer Center/Wellspan Health, York, Pennsylvania, United States|Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Baptist Memorial Hospital - Memphis, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Methodist Regional Cancer Center, Oak Ridge, Tennessee, United States|Methodist Hospitals of Dallas, Dallas, Texas, United States|Scott & White CCOP, Temple, Texas, United States|Cascadia Clinical Trials at St. Joseph Hospital, Bellingham, Washington, United States|Virginia Mason CCOP, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Northwest Hospital, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Sinai Samaritan Medical Center, Milwaukee, Wisconsin, United States|Ottawa General Hospital, Ottawa, Ontario, Canada|San Juan Dr. I. Gonzalez Martinez/Centro Medico, San Juan, Puerto Rico|Altamira Family Medicine, San Juan, Puerto Rico|Centro Clinico San Patricio, San Juan, Puerto Rico|Miguel Sosa Padilla, MD/San Juan City Hospital, San Juan, Puerto Rico|VAMC San Juan, San Juan, Puerto Rico|San Juan City Hospital - PR, Hematology Oncology Office, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00040378"
402,"NCT01872598","Masitinib in Patients With Mild to Moderate Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: Masitinib|Drug: Placebo","ADCS-ADL|ADAS-Cog|MMSE|CIBIC-plus","AB Science","All","50 Years and older   (Adult, Older Adult)","Phase 3","721","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AB09004","January 2012","December 2019","December 2019","June 7, 2013",,"June 17, 2019","MHAT Sveta Marina, Varna, Bulgaria|General Hospital of Thessaloniki, Thessaloniki, Greece|Centrum Zdrowia Stołeczna 7, Białystok, Poland|Spitalul Universitar de Urgenta Elias, Bucuresti, Romania|Hospital Universitario Ramón y Cajal, Madrid, Spain|Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov, Dnipropetrovsk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01872598"
403,"NCT02972658","A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia",,"Terminated","Has Results","Alzheimer's Disease","Drug: Lanabecestat","Change From Baseline Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Change From Baseline Analysis on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items (ADCS-iADL)|Change From Baseline on the Functional Activities Questionnaire (FAQ) Score|Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change From Baseline on the Mini-Mental Status Examination (MMSE)|Change From Baseline Analysis on the ADAS-Cog13","Eli Lilly and Company|AstraZeneca","All","55 Years and older   (Adult, Older Adult)","Phase 3","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16557|I8D-MC-AZFD|2016-003440-36","March 15, 2017","October 2, 2018","October 2, 2018","November 23, 2016","July 4, 2019","July 4, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Pacific Research Network Inc, San Diego, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester School of Medicine, Rochester, New York, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Lindner Research Center, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Radiant Research, Greer, South Carolina, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|The Memory Clinic, Bennington, Vermont, United States|Southern Neurology, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Hopital Universitaire Brugmann Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitaire Erasme Brussel, Brussel, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Elizabeth Bruyere Health Centre, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire La Timone, Marseille, Cedex 05, France|CHRU de Lille- Hôpital Roger Salengro, Lille, Cedex, France|CHU de Toulouse Hopital Purpan, Toulouse, Cedex, France|Hopital Neuro Pierre Wertheimer, Bron Cedex, France|CHU Bocage CMRR, Dijon, France|Hopital Broca, Paris, France|Hôpital de la Pitié-Salpêtrière, Paris, France|Hôpital Fernand Widal, Paris, France|Chu de Nantes Hopital Laennec, Saint-Herblain, France|Centre de Recherche Clinique du Gérontopôle Cité de la Santé, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Studien und Gedächtniszentrum München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Gemeinschaftspraxis für Neurologie und Psychiatrie, Westerstede, Niedersachsen, Germany|DataMed Klinische Studien GmbH, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Neurologische Praxis Siegen, Siegen, Nordrhein-Westfalen, Germany|Pharm Studienzentrum Chemnitz, Mittweida, Sachsen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|SE Neurologiai Klinika, Budapest, Hungary|National Institute for Longevity Sciences NCGG, Obu, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Nihon Kokan Hospital, Kawasaki, Kanagawa, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Shiroma Clinic, Urasoe, Okinawa, Japan|Sakaguchi Clinic, Sakai, Osaka, Japan|National Sanatorium Toneyama Hospital, Toyonaka, Osaka, Japan|Memory Clinic Ochanomizu, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|National Sanatorium Hokuriku Hospital, Nanto, Toyama, Japan|Fukuoka University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Utano Hospital, Kyoto, Japan|Osaka City University Hospital, Osaka, Japan|Dong-A University Medical Center, Seogu, Busan, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Inha University Hospital, Junggu, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska, Katowice, Poland|Centrum Zdrowia Psychicznego Biomed - Jan Latala, Kielce, Poland|Krakowska Akademia Neurologii, Krakow, Poland|Medycyna Milorzab, Lodz, Poland|Instytut Medycyny Wsi, Lublin, Poland|Centrum Medyczne Neuroprotect, Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|SC Med Life SA, Bucuresti, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Hospital Universitario De Getafe, Madrid, Getafe, Spain|CITA Alzheimer, San Sebastian, Guipuzcoa, Spain|Centro de Atencion Especializada (CAE) OROITU, Getxo, Vizcaya, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Son Espases, Palma De Mallorca, Spain|Hospital Universitario Dr Pesset, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Re-Cognition Health Ltd, London, Greater London, United Kingdom|MAC Clinical Research-Manchester, Manchester, Greater Manchester, United Kingdom|MAC Clinical Research, Blackpool, Lancashire, United Kingdom|West London Mental Health NHS Trust, Isleworth, London, United Kingdom|MAC Clinical Research, Cannock, Staffordshire, United Kingdom|Re-Cognition Health Ltd, Guildford, Surrey, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|MAC Clinical Research, Leeds, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02972658/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02972658/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02972658"
404,"NCT02051608","A Study of Gantenerumab in Participants With Mild Alzheimer Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Mean Change From Baseline in Alzheimer's Disease Activity Scale-Cognitive subscale 13 (ADAS-Cog13) scores at Week 104|Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores at week 104|Part 2: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Total Tau (t-tau) in CSF at Week 104|Change From Baseline in phosphorylated tau [p-tau]in CSF at Week 104|Change From Baseline in Abeta 1-42 levels in CSF at Week 104|Change From Baseline in Hippocampal Volume, as Assessed by Magnetic Resonance Image (MRI) at Week 104|Change From Baseline in Whole Brain Volume, as assessed by MRI at Week 104|Change From Baseline in Cortical thickness, as assessed by MRI at Week 104|Change From Baseline in Ventricular Volume, as Assessed by MRI at Week 104|Change From Baseline in Clinical Dementia Rating Global Score (CDR-GS) at Week 104|Change From Baseline in CDR Sum of Boxes (SB) at Week 104|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104|Change From Baseline in NPI Domain Score at Week 104|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 104|Safety: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs)|Percentage of Participants with anti-gantenerumab antibodies|Change From Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS) Over Week 152|Pharmacokinetics: Apparent Total Clearance (CL/F) of gantenerumab|Pharmacokinetics: Apparent Volume of Distribution (V/F) of gantenerumab|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of gantenerumab|Pharmacokinetics: Time to Reach Maximum Plasma Concentrations (Tmax) of gantenerumab|Pharmacokinetics: Minimum Observed Plasma Concentration (Cmin) of gantenerumab|Pharmacokinetics: Area Under Plasma Concentration (AUC) -Time Curve of gantenerumab|Quality of Life - Change From Baseline in Alzheimer's Dementia (QoL-AD) Global Score at Week 104|Efficacy: Change From Baseline in Symptom Guide Facilitated (GAS) at Week 104|Efficacy: Change from Baseline in Dependence Scale (DS) at Week 104|Efficacy: Change From Baseline in Resource Utilization Dementia-Lite (RUD - Life) Scale at Week 104|Change From Baseline in Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) at Week 104|Time to Clinical Decline (as measured by Confirmed greater than or equal to [>=] 2-point decline on MMSE, Loss of >= 1 or 2 points on one or more ADL and I ADL, respectively)|Change from Baseline in Clinical Composite Score (Prespecified Items From The ADAS-Cog, MMSE, and CDR) at Week 104","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","389","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN28745|2013-003390-95","March 27, 2014","November 20, 2020","November 20, 2020","January 31, 2014",,"August 7, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Pacific Research Network - PRN, San Diego, California, United States|California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|University of South Florida, Tampa, Florida, United States|Bioclinica The Villages, The Villages, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Ocean Rheumatology, Toms River, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Richard H Weisler, MD, Raleigh, North Carolina, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|University of Utah, Center for Alzheimer's Care Imaging & Research, Salt Lake City, Utah, United States|Instituto Neurologia Bs As, Ciudad Autonoma de Bs As, Argentina|Instituto de Neurología y Neurorehabilitación del Litoral (INNEL), Santa Fé, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, Bulgaria|MBAL St. Marina; First Neurology Department, Varna, Bulgaria|University of Calgary; Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Queens University - Hotel Dieu Hospital, Kingston, Ontario, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|University of Eastern Finland, Kuopio, Finland|CRST Oy, Turku, Finland|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|CHU Rennes - hopital Hotel Dieu; Consultation Memoire - Gerontologie, Rennes, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital la Grave; Gerontopole - Centre de Recherche Clinique, Toulouse, France|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|Universitätsklinik Göttingen; Klinik für Psychiatrie und Psychotherapie; Gedächtnisambulanz, Göttingen, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Klinikum rechts der Isar der TU München; Klinikapotheke, Muenchen, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Clinica Humanamente, Ciudad de Guatemala, Guatemala|Edificio Multimédica, Ciudad De Guatemlala, Guatemala|Semmelweis University; Department of Neurology, Budapest, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|ASST DI MONZA; Neurologia, Monza, Lombardia, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|Medical Corporation Hakuyokai Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-east Hospital; Neurology, Chiba, Japan|Juntendo University Urayasu Hospital; Neurology, Chiba, Japan|Fukuoka University Hospital; Neurology and Health Care, Fukuoka, Japan|Maebashi Red Cross Hospital; Neurology, Gunma, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Hyogo Brain and Heart Center at Himeji; Department of Aging Brain and Cognitive Disorders, Hyogo, Japan|Shonan Kamakura General Hospital; Neurology, Kanagawa, Japan|National Hospital Organization Utano National Hospital; Neurology, Kyoto, Japan|Nagasaki kita Hospital; Neurology, Nagasaki, Japan|Mishima Hospital; psychiatry, Niigata, Japan|Oita University Hospital; Neurology, Oita, Japan|Kurashiki Heisei Hospital; Neurology, Okayama, Japan|Osaka City University Hospital; Geriatric Medicine and Neurology, Osaka, Japan|Shizuoka City Shimizu Hospital; Neurology, Shizuoka, Japan|Dong-A University Medical Center, Busan, Korea, Republic of|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Inha University Hospital; Neurology Department, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Brain Research Center B.V, Amsterdam, Netherlands|Erasmus Mc - Locatie Centrum; Dept of Neurology, Rotterdam, Netherlands|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|St. Petersburg GUZ City Psychiatric Hospital #6, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Policlínica Guipuzkoa; Servicio de Neurología, Donosti-San Sebastián, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|CHUV; Centre Leenaards de la Mémoire, Lausanne, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Dokuz Eylul University Medicine Faculty; Noroloji Departmani, Izmir, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Preston Hosptial, Preston, United Kingdom|Memory Service North, Sheffield, United Kingdom|Memory Assesment and Research Centre (MARC), Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02051608"
405,"NCT01864655","Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: saracatinib|Drug: Placebo","Number of Participants with Adverse Events on AZD0530|CNS availability of AZD0530 after oral dosing|Effects of AZD0530 on cognitive function in patients with Alzheimer's disease|Effect of AZD0530 on brain glucose metabolism in patients with Alzheimer's disease","Stephen M. Strittmatter|Yale University","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1UH2TR000967-01","July 2013","March 2014",,"May 29, 2013",,"June 13, 2014","Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01864655"
406,"NCT00063310","ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation",,"Completed","No Results Available","Alzheimer Disease","Drug: Leuprolide acetate",,"Voyager Pharmaceutical Corporation|National Institute on Aging (NIA)","Female","65 Years and older   (Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0047|IND 66,415","March 2003","February 2006","February 2006","June 26, 2003",,"December 11, 2009","Sun Health Research Institute, Sun City, Arizona, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Meridien Research, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00063310"
407,"NCT00348192","SB-742457 And Donepezil In Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: SB-742457|Drug: donepezil","Change in cognition and function after 24 weeks.|Change in behavioral symptoms, activities of daily living and caregiver burden after 24 weeks Changes in all symptoms at 8 and 12 weeks Safety and tolerability PK (pharmacokinetic) profiling. Efficacy related to ApoE and HTR6 status","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AZ3106242","May 2006",,,"July 4, 2006",,"June 2, 2009","GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Valparaiso, Valparaíso, Chile|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Swindon, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00348192"
408,"NCT02006641","Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil","STARBEAM","Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Drug: Idalopirdine","Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Number of Participants With Clinical Improvement|Number of Participants With Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS)","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 3","858","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14862A|2012-004764-22","February 2014","December 2016","December 2016","December 10, 2013","February 20, 2018","February 20, 2018","US338, Phoenix, Arizona, United States|US342, Fayetteville, Arkansas, United States|US322, Anaheim, California, United States|US305, Carson, California, United States|US346, Costa Mesa, California, United States|US327, Fullerton, California, United States|US315, Lomita, California, United States|US351, Oceanside, California, United States|US307, Redlands, California, United States|US301, Santa Rosa, California, United States|US337, New London, Connecticut, United States|US332, Stamford, Connecticut, United States|US308, Delray Beach, Florida, United States|US320, Hallandale Beach, Florida, United States|US347, Hialeah, Florida, United States|US340, Lake Worth, Florida, United States|US303, Miami, Florida, United States|US313, Miami, Florida, United States|US335, Naples, Florida, United States|US345, Orange City, Florida, United States|US309, Palm Beach Gardens, Florida, United States|US302, Sunrise, Florida, United States|US304, Atlanta, Georgia, United States|US360, Augusta, Georgia, United States|US318, Decatur, Georgia, United States|US334, Lake Charles, Louisiana, United States|US350, Belmont, Massachusetts, United States|US344, Boston, Massachusetts, United States|US310, Saint Paul, Minnesota, United States|US321, Hattiesburg, Mississippi, United States|US330, Creve Coeur, Missouri, United States|US339, Manchester, New Jersey, United States|US312, Staten Island, New York, United States|US316, Charlotte, North Carolina, United States|US336, Winston-Salem, North Carolina, United States|US323, Cincinnati, Ohio, United States|US349, Cleveland, Ohio, United States|US306, Columbus, Ohio, United States|US352, Lakewood, Ohio, United States|US333, Oklahoma City, Oklahoma, United States|US314, Allentown, Pennsylvania, United States|US324, Pittsburgh, Pennsylvania, United States|US341, Pittsburgh, Pennsylvania, United States|US325, Reading, Pennsylvania, United States|US319, Port Royal, South Carolina, United States|US356, Cordova, Tennessee, United States|US343, Fort Worth, Texas, United States|US354, Houston, Texas, United States|AR303, Banfield, Argentina|AR301, Ciudad Autonoma Buenos Aires, Argentina|AR304, Ciudad Autonoma Buenos Aires, Argentina|AR308, Ciudad Autonoma Buenos Aires, Argentina|AR311, Ciudad Autonoma Buenos Aires, Argentina|AR313, Ciudad Autonoma Buenos Aires, Argentina|AR314, Ciudad Autonoma Buenos Aires, Argentina|AR315, Ciudad Autonoma Buenos Aires, Argentina|AR312, Ciudad Autonoma de Buenos Aires, Argentina|AR309, Cordoba, Argentina|AR307, Córdoba, Argentina|AR305, Godoy Cruz, Argentina|AR310, Mendoza, Argentina|AR302, Santa Fe, Argentina|AR306, Santiago del Estero, Argentina|BR307, Curitiba, Brazil|BR309, Curitiba, Brazil|BR301, Rio de Janeiro, Brazil|BR306, Rio de Janeiro, Brazil|BR308, San Paolo, Brazil|CA301, Halifax, Canada|CA302, Kelowna, Canada|CA306, Montreal, Canada|CA304, Qubec, Canada|CA303, Sherbrooke, Canada|CA305, Toronto, Canada|HR304, Zabok, Croatia|HR301, Zagreb, Croatia|HR302, Zagreb, Croatia|HR303, Zagreb, Croatia|CZ305, Brno, Czechia|CZ306, Chocen, Czechia|CZ309, Chocen, Czechia|CZ308, Pardubice, Czechia|CZ310, Praha 10 - Strasnice, Czechia|CZ304, Praha 10, Czechia|CZ307, Praha 2, Czechia|CZ301, Praha 6, Czechia|CZ303, Praha 6, Czechia|CZ302, Rychnov nad Kneznou, Czechia|EE301, Tallinn, Estonia|EE303, Tallin, Estonia|EE302, Tartu, Estonia|FI302, Kuopio, Finland|FI303, Oulu, Finland|FI301, Turku, Finland|FR301, Bordeaux, France|FR308, Bron, France|FR307, Colmar cedex, France|FR304, Dijon, France|FR309, Elancourt, France|FR302, Marseille cedex 5, France|FR303, Nice Cedex 1, France|FR306, Reims, France|FR305, Rouen, France|HU304, Budapest, Hungary|HU305, Budapest, Hungary|HU301, Esztergom, Hungary|HU303, Gyor, Hungary|HU302, Szeged, Hungary|IE301, Cork, Ireland|IL302, Haifa, Israel|IL303, Holon, Israel|IL304, Ramat Gan, Israel|IT306, Brescia, Italy|IT309, Brescia, Italy|IT311, Genova, Italy|IT312, Monza, Italy|IT302, Naples, Italy|IT313, Palermo, Italy|IT307, Perugia, Italy|IT301, Pisa, Italy|IT305, Roma, Italy|IT308, Roma, Italy|IT304, Torino, Italy|IT310, Torrette, Italy|KR303, Busan, Korea, Republic of|KR301, Incheon, Korea, Republic of|KR308, Seongnam-si, Korea, Republic of|KR302, Seoul, Korea, Republic of|KR304, Seoul, Korea, Republic of|KR305, Seoul, Korea, Republic of|KR306, Seoul, Korea, Republic of|KR307, Seoul, Korea, Republic of|KR309, Seoul, Korea, Republic of|LT302, Kaunas, Lithuania|LT303, Kaunas, Lithuania|LT301, Vilnius, Lithuania|LT304, Vilnius, Lithuania|PL301, Bialystok, Poland|PL304, Bydgoszcz, Poland|PL308, Gdynia, Poland|PL309, Krakow, Poland|PL302, Lodz, Poland|PL310, Lubin, Poland|PL306, Lublin, Poland|PL307, Oswiecim, Poland|PL303, Poznan, Poland|PT301, Amadora, Portugal|PT302, Coimbra, Portugal|TW301, Kaohsiung, Taiwan|TW302, Kaohsiung, Taiwan|TW303, Taichung, Taiwan|TW304, Taipei, Taiwan|TW305, Taipei, Taiwan|GB307, Amersham, United Kingdom|GB301, Glasgow, United Kingdom|GB303, London, United Kingdom|GB308, London, United Kingdom|GB306, Plymouth, United Kingdom|GB305, Preston, United Kingdom|GB304, Southampton, United Kingdom|GB302, Swindon, United Kingdom|GB309, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02006641"
409,"NCT00666445","Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test",,"Completed","No Results Available","Alzheimer's Disease",,"Sensitivity and specificity for test under investigation to diagnose probable Alzheimer's Disease.","Orasi Medical, Inc.|Noran Neurological Clinic|Minneapolis Veterans Affairs Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)",,"150","Industry|Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","ADG-08-01","April 2008","December 2009","December 2009","April 25, 2008",,"August 13, 2010","Veterans Affairs Medical Center (Brain Science Center), Minneapolis, Minnesota, United States|Veterans Affairs Medical Center (Geriatric Research, Education and Clinical Center), Minneapolis, Minnesota, United States|Noran Neurology Clinic, Plymouth, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00666445"
410,"NCT00065767","Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Raloxifene",,"University of Wisconsin, Madison|National Institute on Aging (NIA)","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0049|1R01AG029624-01|IRB M1285","September 2001","March 2005","March 2005","August 4, 2003",,"October 5, 2015","University of Wisconsin Memory Research Program, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00065767"
411,"NCT01295957","Alzheimer's Disease Reminiscence Quality of Life",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: reminiscence therapy|Behavioral: comparison group|Other: control","self rated quality of life|Social engagement scale","Universidad Nacional de Rosario","All","65 Years to 87 Years   (Older Adult)","Phase 4","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PSI851","January 2010","August 2010","November 2010","February 15, 2011",,"February 15, 2011","Faculty of Psychology, Rosario, Santa Fe, Argentina",,"https://ClinicalTrials.gov/show/NCT01295957"
412,"NCT02244541","Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease","ANAVEX","Completed","No Results Available","Alzheimer's Disease","Drug: ANAVEX2-73 Oral|Drug: ANAVEX2-73 Intravenous","To determine maximum tolerated dose of Anavex2-73.|PK sampling- blood test results|Mini-mental state examination score (MMSE)|Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)|Cogstate Brief Battery (CBB) Score and International Shopping List Task (ISLT) Score|Electroencephalographic activity, including event-related potentials (EEG/ERP)|Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score|Rosen Modified Hachinski Ischemic Score (RM/HIS10)","Anavex Life Sciences Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANAVEX2-73-002","December 2014","November 2015","November 2016","September 19, 2014",,"November 28, 2018","Melbourne Health - The Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia|Caulfield Hospital, Melbourne, Victoria, Australia|Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia|St. Vincent's Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02244541"
413,"NCT02064920","Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)",,"Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Drug: Donepezil","One-card Learning (OCL) Measurement Over 12 Weeks of Treatment|Percentage of Correct Responses in the OCL Task Over 12 Weeks of Treatment","Merck Sharp & Dohme Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","0000-318","April 22, 2014","July 13, 2016","July 13, 2016","February 17, 2014","August 1, 2017","October 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02064920"
414,"NCT01617577","Efficacy and Safety of Filgrastim in Alzheimer's Disease","FFAD","Completed","Has Results","Alzheimer's Disease","Drug: G-CSF; filgrastim|Drug: Placebo","Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )","University of South Florida","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADDF-GCSF","June 2009","February 2012","February 2012","June 12, 2012","December 27, 2012","December 27, 2012","USF/Byrd Alzheimer's Center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01617577"
415,"NCT03554226","Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study","A3C","Active, not recruiting","No Results Available","Alzheimer Disease","Behavioral: NeuroPsychiatric Inventory Clinician (NPI-C)","Severity of A/A with NeuroPsychiatric Inventory Clinician (NPI-C)|The clinical relevance of the change observed by the clinician with Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)|Cohen-Mansfield Agitation Inventory|Quality of Life QoL-AD","University Hospital, Toulouse|Ethypharm","All","60 Years and older   (Adult, Older Adult)","Not Applicable","330","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/14/7163|2014-A00673-44","November 1, 2014","December 31, 2018","December 31, 2018","June 13, 2018",,"June 13, 2018","Toulouse University Hospital (CHU de Toulouse), Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03554226"
416,"NCT04002583","48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease",,"Not yet recruiting","No Results Available","Early Onset Alzheimer Disease","Diagnostic Test: Computer assisted ambulatory electroencephalogram","Electrographic seizures: Number of subjects with electrographic seizures","Mayo Clinic","All","40 Years to 64 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19-003078","January 1, 2020","January 2021","January 2021","June 28, 2019",,"September 27, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04002583"
417,"NCT04042532","Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia",,"Not yet recruiting","No Results Available","Alzheimer Disease, Early Onset","Device: Theta-burst stimulation (TBS)","Change from baseline MMSE total scores immediately after TBS intervention|Change from baseline MMSE total scores 4 weeks after TBS intervention|Change from baseline ADAS-Cog total scores immediately after TBS intervention|Change from baseline ADAS-Cog total scores 4 weeks after TBS intervention|The standard uptake values changes of FDG-PET","Chang Gung Memorial Hospital","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201802104A0","August 1, 2019","July 31, 2022","July 31, 2022","August 2, 2019",,"August 2, 2019",,,"https://ClinicalTrials.gov/show/NCT04042532"
418,"NCT01837641","A Study of LY3002813 in Participants With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Biological: LY3002813-IV|Biological: LY3002183-SC|Drug: Placebo-IV","Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15082|I5T-MC-AACC","May 3, 2013","August 24, 2016","August 24, 2016","April 23, 2013",,"December 26, 2017","Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Compass Research, Orlando, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|PRAHealthSciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumida-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01837641"
419,"NCT01238458","Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers","[18F]AV-45","Unknown status","No Results Available","Alzheimer's Disease","Drug: [18F]AV-45 PET amyloid binding imaging","To expand the safety database of [18F]AV-45 PET imaging","Chang Gung Memorial Hospital","All","50 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","98-1852A","November 2009","November 2011","June 2013","November 10, 2010",,"September 28, 2012",,,"https://ClinicalTrials.gov/show/NCT01238458"
420,"NCT01736579","Long-Term Study of IGIV, 10% in Alzheimer´s Disease",,"Terminated","Has Results","Alzheimer´s Disease","Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)","Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Temporally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Causally Associated With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Infusions Discontinued, Slowed or Interrupted Due to an Adverse Event (AE) or Serious Adverse Event (SAE)|Total Score of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog)|Total Score of the Cognitive Subscale of the Severe Impairment Battery (SIB)|Alzheimer's Disease Cooperative Study (ADCS) - Activities of Daily Living (ADL) Inventory (ADCS-ADL/ ADCS-ADL-severe)|Mini Mental State Examination (MMSE)|Neuropsychiatric Inventory (NPI) Score|Logsdon Quality of Life in Alzheimer's Disease (QOL-AD)|EQ-5D Questionnaire (Proxy Version)|Healthcare Resource Utilization Questionnaire (HRUQ)|Caregiver Burden Questionnaire|Time to Skilled Nursing Facility Placement|Volumetric MRI","Baxalta now part of Shire|Shire","All","51 Years and older   (Adult, Older Adult)","Phase 3","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","161202","November 2012","June 2013","June 2013","November 29, 2012","August 23, 2016","October 23, 2017","Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01736579"
421,"NCT01955161","Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil","STARSHINE","Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Drug: Idalopirdine","Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS)","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 3","933","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14861A|2012-004763-45","October 2013","July 2016","July 2016","October 7, 2013","September 19, 2017","September 19, 2017","US027, Birmingham, Alabama, United States|US012, Phoenix, Arizona, United States|US024, Little Rock, Arkansas, United States|US053, Glendale, California, United States|US023, Imperial, California, United States|US015, La Jolla, California, United States|US045, Long Beach, California, United States|US002, Los Angeles, California, United States|US058, San Francisco, California, United States|US018, Santa Ana, California, United States|US060, Denver, Colorado, United States|US042, Boca Raton, Florida, United States|US021, Bradenton, Florida, United States|US050, Brooksville, Florida, United States|US019, Orlando, Florida, United States|US038, Port Charlotte, Florida, United States|US001, West Palm Beach, Florida, United States|US020, Atlanta, Georgia, United States|US048, Kailua, Hawaii, United States|US030, Chicago, Illinois, United States|US051, Joliet, Illinois, United States|US040, Indianapolis, Indiana, United States|US036, Freeport, Maine, United States|US032, Newton, Massachusetts, United States|US035, Kalamazoo, Michigan, United States|US041, Flowood, Mississippi, United States|US054, Saint Louis, Missouri, United States|US046, Princeton, New Jersey, United States|US028, Toms River, New Jersey, United States|US044, Toms River, New Jersey, United States|US049, Albany, New York, United States|US010, Amherst, New York, United States|US014, Manhasset, New York, United States|US008, New York, New York, United States|US029, New York, New York, United States|US056, New York, New York, United States|US037, Orangeburg, New York, United States|US043, Staten Island, New York, United States|US007, Centerville, Ohio, United States|US006, Columbus, Ohio, United States|US052, Edmond, Oklahoma, United States|US026, Portland, Oregon, United States|US057, Jenkintown, Pennsylvania, United States|US047, Arlington, Virginia, United States|US025, Madison, Wisconsin, United States|US004, Milwaukee, Wisconsin, United States|AR002, Buenos Aires, Argentina|AR003, Buenos Aires, Argentina|AR006, Buenos Aires, Argentina|AR007, Buenos Aires, Argentina|AR009, Cordoba, Argentina|AR004, Mar del Plata, Argentina|AR005, Mendoza, Argentina|AR008, Mendoza, Argentina|AR010, Rosario, Argentina|BE003, Brugge, Belgium|BE002, Brussels, Belgium|BE004, Bruxelles, Belgium|BE005, Leuven, Belgium|BE001, Roeselare, Belgium|BE006, Thuin, Belgium|BG005, Plovdiv, Bulgaria|BG001, Sofia, Bulgaria|BG002, Sofia, Bulgaria|BG003, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG006, Sofia, Bulgaria|BG007, Varna, Bulgaria|CA002, Gatineau, Canada|CA006, London, Canada|CA008, Newmarket, Canada|CA001, Toronto, Canada|CA004, Toronto, Canada|CL004, Antofagasta, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL001, Valdivia, Chile|CZ006, Brno, Czechia|CZ007, Kutna Hora, Czechia|CZ004, Pardubice, Czechia|CZ003, Praha 10, Czechia|CZ001, Praha 2, Czechia|CZ002, Praha 6, Czechia|CZ005, Rychnov nad Kneznou, Czechia|DK003, Aarhus N, Denmark|DK001, Copenhagen, Denmark|DK002, Odense C, Denmark|FR006, Besancon Cedex, France|FR008, Limoges Cedex1, France|FR003, Nantes Cedex, France|FR005, Paris cedex 10, France|FR001, Paris, France|FR004, Saint Etienne Cedex 2, France|FR002, Toulouse, France|DE002, Berlin, Germany|DE006, Ellwangen, Germany|DE010, Günzburg, Germany|DE005, Hannover, Germany|DE007, Heidelberg, Germany|DE009, Munchen, Germany|DE008, Ulm, Germany|DE004, Unterhaching, Germany|IT004, Ancona, Italy|IT006, Brescia, Italy|IT002, Firenze, Italy|IT005, Genoa, Italy|IT003, Lamezia Terme, Italy|IT001, Milano, Italy|IT007, Palermo, Italy|PL004, Gliwice, Poland|PL007, Katowice, Poland|PL005, Poznan, Poland|PL006, Sopot, Poland|PL002, Szczecin, Poland|PL003, Warszawa, Poland|PL008, Wroclaw, Poland|RO002, Bucharest, Romania|RO001, Tirgu Mures, Romania|ZA003, Bloemfontein, South Africa|ZA006, Cape Town, South Africa|ZA007, Cape Town, South Africa|ZA004, George, South Africa|ZA005, Port Elizabeth, South Africa|ZA001, Pretoria, South Africa|ZA002, Rosebank, South Africa|ES002, Alicante, Spain|ES006, Barcelona, Spain|ES005, Manresa, Spain|ES004, Salamanca, Spain|ES001, San Sebastian, Spain|ES003, Santiago de Compostela, Spain|UA008, Dnipropetrovsk, Ukraine|UA006, Kherson,Vil. Stepanivka, Ukraine|UA005, Kyiv, Ukraine|UA007, Kyiv, Ukraine|UA001, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01955161"
422,"NCT03518073","A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease (AD)","Drug: LY3303560|Drug: Placebo","Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)|Change from Baseline on the Alzheimer's Disease Assessment Scale—Cognitive Subscale (ADAS-Cog13) Score|Change from Baseline on the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL) Score|Change from Baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Score|Change from Baseline on the Mini Mental Status Examination (MMSE) Score|Change from Baseline in Aggregated Tau Deposition|Change from Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)|Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants with Treatment Emergent Anti-LY3303560 Antibodies","Eli Lilly and Company","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16124|I8G-MC-LMDC","April 30, 2018","August 23, 2021","October 22, 2021","May 8, 2018",,"October 4, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Pharmacology Research Institute, Encino, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|National Research Institute, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network Inc, San Diego, California, United States|Univ of California San Francisco, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Julie B. Schwartzbard, MD, PA, Aventura, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|VIN - Victor Faradji, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|BioClinica Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Brain Matters Research - Stuart, Stuart, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lindner Research Center, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Cincinnati Health Neurology, Dayton, Ohio, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Cognition Health, Fairfax, Virginia, United States|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|National Center for Geriatrics and Gerontology, Obu City, Aichi, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|Utano Hospital, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT03518073"
423,"NCT02006654","Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor","STARBRIGHT","Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Drug: Idalopirdine","Change in Cognition|Change in Global Impression|Change in Daily Functioning|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS)","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 3","734","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14863A|2012-004765-40","March 2014","January 2017","January 2017","December 10, 2013","February 7, 2018","February 7, 2018","US612, Mesa, Arizona, United States|US625, Bellflower, California, United States|US626, Costa Mesa, California, United States|US604, Oxnard, California, United States|US627, Santa Ana, California, United States|US609, Danbury, Connecticut, United States|US614, Norwalk, Connecticut, United States|US608, Deerfield Beach, Florida, United States|US616, Hialeah, Florida, United States|US620, Miami, Florida, United States|US603, North Palm Beach, Florida, United States|US631, Port Charlotte, Florida, United States|US622, Elk Grove Village, Illinois, United States|US611, Elkhart, Indiana, United States|US606, Prairie Village, Kansas, United States|US601, Farmington Hills, Michigan, United States|US607, Saint Louis, Missouri, United States|US613, Lawrenceville, New Jersey, United States|US635, Manchester, New Jersey, United States|US630, Toms River, New Jersey, United States|US621, Albany, New York, United States|US632, Staten Island, New York, United States|US633, Charlotte, North Carolina, United States|US623, Oklahoma City, Oklahoma, United States|US618, Norristown, Pennsylvania, United States|US619, Houston, Texas, United States|AU603, Caulfield, Australia|AU609, Glen Iris, Australia|AU602, Heidelberg West, Australia|AU604, Kanwal, Australia|AU606, Newcastle, Australia|AU601, West Perth, Australia|AU610, Woodville south, Australia|BR608, Belo Horizonte, Brazil|BR609, Itapira, Brazil|BR607, Rio de Janeiro, Brazil|CZ602, Chocen, Czechia|CZ608, Chocen, Czechia|CZ605, Havlickuv Brod, Czechia|CZ606, Kladno, Czechia|CZ603, Plzen, Czechia|CZ601, Prague, Czechia|CZ607, Praha 10 - Strasnice, Czechia|CZ604, Praha 6, Czechia|DE612, Bad Homburg, Germany|DE610, Bad Honnef, Germany|DE609, Berlin, Germany|DE617, Berlin, Germany|DE604, Erbach, Germany|DE611, Freiburg, Germany|DE607, Gelsenkirchen, Germany|DE605, Homburg, Germany|DE608, Karlstadt, Germany|DE602, Mittweida, Germany|DE601, Munich, Germany|DE606, Rostock, Germany|DE603, Ulm, Germany|DE616, Unterhaching, Germany|IL605, Bat Yam, Israel|IL601, Haifa, Israel|IL604, Holon, Israel|IL602, Ramat Gan, Israel|IL603, Tel Aviv, Israel|KR601, Seongnam-si, Korea, Republic of|KR602, Seoul, Korea, Republic of|KR603, Seoul, Korea, Republic of|KR604, Seoul, Korea, Republic of|MX602, Mexico, Mexico|MX601, Monterrey, Mexico|MX603, Monterrey, Mexico|MX604, Monterrey, Mexico|MX605, Monterrey, Mexico|MX606, Saltillo, Mexico|RS602, Belgrade, Serbia|RS603, Kragujevac, Serbia|RS601, Novi Sad, Serbia|SG601, Singapore, Singapore|SG602, Singapore, Singapore|SK601, Banska Bystrica, Slovakia|SK603, Bratislava, Slovakia|SK605, Bratislava, Slovakia|SK604, Rimavska Sobota, Slovakia|SK602, Svidnik, Slovakia|ES601, Barcelona, Spain|ES603, Barcelona, Spain|ES604, Barcelona, Spain|ES608, Barcelona, Spain|ES611, Bilbao, Spain|ES612, Burgos, Spain|ES602, Lleida, Spain|ES613, Madrid, Spain|ES610, Sant Cugat del Vallès, Spain|ES606, Sevilla, Spain|ES605, Terrassa, Spain|ES607, Valencia, Spain|CH603, Biel, Switzerland|CH605, Lausanne, Switzerland|CH602, Les Acacias, Switzerland|CH601, Schlieren, Switzerland|TR602, Balova, Turkey|TR601, Istanbul, Turkey|TR603, İstanbul, Turkey|TR605, Istanbul, Turkey|TR606, Izmir, Turkey|TR607, Samsun, Turkey|GB601, Brentford, United Kingdom|GB603, Northampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02006654"
424,"NCT01082965","Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Donepezil|Drug: Placebo","Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8|Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8|Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8|Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8|Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8","Pfizer","All","50 Years and older   (Adult, Older Adult)","Not Applicable","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","A9001437","July 2010","July 2012","July 2012","March 9, 2010","September 12, 2013","September 12, 2013","Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01082965"
425,"NCT02079246","Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","STAR Extension","Completed","Has Results","Alzheimer's Disease","Drug: Idalopirdine 60 mg","Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX|Number of TEAEs in the OLEX-MEM|Change in Cognition|Clinical Global Impression Score|Change in Daily Functioning|Change in Behavioural Disturbance|Change in Cognitive Aspects of Mental Function","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 3","1463","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14861B|2013-000001-23","April 7, 2014","July 6, 2017","July 6, 2017","March 5, 2014","August 10, 2018","August 10, 2018","US027, Birmingham, Alabama, United States|US012, Phoenix, Arizona, United States|US338, Phoenix, Arizona, United States|US024, Little Rock, Arkansas, United States|US351, Carlsbad, California, United States|US346, Costa Mesa, California, United States|US327, Fullerton, California, United States|US023, Imperial, California, United States|US045, Long Beach, California, United States|US307, Redlands, California, United States|US058, San Francisco, California, United States|US018, Santa Ana, California, United States|US301, Santa Rosa, California, United States|US021, Bradenton, Florida, United States|US050, Brooksville, Florida, United States|US308, Delray Beach, Florida, United States|US320, Hallandale Beach, Florida, United States|US347, Hialeah, Florida, United States|US340, Lake Worth, Florida, United States|US303, Miami, Florida, United States|US313, Miami, Florida, United States|US345, Orange City, Florida, United States|US019, Orlando, Florida, United States|US309, Palm Beach Gardens, Florida, United States|US038, Port Charlotte, Florida, United States|US302, Sunrise, Florida, United States|US304, Atlanta, Georgia, United States|US360, Augusta, Georgia, United States|US048, Kailua, Hawaii, United States|US030, Chicago, Illinois, United States|US040, Indianapolis, Indiana, United States|US334, Lake Charles, Louisiana, United States|US036, Freeport, Maine, United States|US344, Boston, Massachusetts, United States|US035, Kalamazoo, Michigan, United States|US310, Saint Paul, Minnesota, United States|US041, Flowood, Mississippi, United States|US321, Hattiesburg, Mississippi, United States|US339, Manchester, New Jersey, United States|US046, Princeton, New Jersey, United States|US028, Toms River, New Jersey, United States|US044, Toms River, New Jersey, United States|US014, Manhasset, New York, United States|US029, New York, New York, United States|US312, Staten Island, New York, United States|US316, Charlotte, North Carolina, United States|US336, Winston-Salem, North Carolina, United States|US007, Centerville, Ohio, United States|US323, Cincinnati, Ohio, United States|US006, Columbus, Ohio, United States|US306, Columbus, Ohio, United States|US352, Lakewood, Ohio, United States|US333, Oklahoma City, Oklahoma, United States|US026, Portland, Oregon, United States|US057, Jenkintown, Pennsylvania, United States|US324, Pittsburgh, Pennsylvania, United States|US341, Pittsburgh, Pennsylvania, United States|US319, Port Royal, South Carolina, United States|US356, Cordova, Tennessee, United States|US343, Fort Worth, Texas, United States|US354, Houston, Texas, United States|US047, Arlington, Virginia, United States|US025, Madison, Wisconsin, United States|US004, Milwaukee, Wisconsin, United States|AR303, Banfield, Argentina|AR007, Buenos Aires, Argentina|AR003, Ciudad Autonoma Buenos Aires, Argentina|AR304, Ciudad Autonoma Buenos Aires, Argentina|AR308, Ciudad Autonoma Buenos Aires, Argentina|AR311, Ciudad Autonoma Buenos Aires, Argentina|AR313, Ciudad Autonoma Buenos Aires, Argentina|AR314, Ciudad Autonoma Buenos Aires, Argentina|AR312, Ciudad Autonoma de Buenos Aires, Argentina|AR009, Cordoba, Argentina|AR307, Cordoba, Argentina|AR309, Cordoba, Argentina|AR305, Godoy Cruz, Argentina|AR004, Mar del Plata, Argentina|AR005, Mendoza, Argentina|AR008, Mendoza, Argentina|AR310, Mendoza, Argentina|AR010, Rosario, Argentina|AR302, Santa Fe, Argentina|AR306, Santiago del Estero, Argentina|BE003, Brugge, Belgium|BE002, Brussels, Belgium|BE004, Bruxelles, Belgium|BE005, Leuven, Belgium|BE001, Roeselare, Belgium|BR307, Curitiba, Brazil|BR309, Curitiba, Brazil|BR303, Porto Alegre, Brazil|BR301, Rio de Janeiro, Brazil|BR306, Rio de Janeiro, Brazil|BR302, Sao Paulo, Brazil|BR304, São Paulo, Brazil|BR308, São Paulo, Brazil|BG005, Plovdiv, Bulgaria|BG001, Sofia, Bulgaria|BG002, Sofia, Bulgaria|BG003, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG006, Sofia, Bulgaria|CA002, Gatineau, Canada|CA309, Gatineau, Canada|CA301, Halifax, Canada|CA302, Kelowna, Canada|CA006, London, Canada|CA306, Montreal, Canada|CA008, Newmarket, Canada|CA304, Qubec, Canada|CA001, Toronto, Canada|CA305, Toronto, Canada|CA308, Toronto, Canada|CA307, Verdun, Canada|CL004, Antofagasta, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL001, Valdivia, Chile|HR304, Zabok, Croatia|HR301, Zagreb, Croatia|HR302, Zagreb, Croatia|CZ006, Brno, Czechia|CZ309, Chocen, Czechia|CZ306, Hradec Kralove, Czechia|CZ007, Kutna Hora, Czechia|CZ004, Pardubice, Czechia|CZ310, Praha 10 - Strasnice, Czechia|CZ003, Praha 10, Czechia|CZ304, Praha 10, Czechia|CZ001, Praha 2, Czechia|CZ002, Praha 6, Czechia|CZ301, Praha 6, Czechia|CZ303, Praha 6, Czechia|CZ005, Rychnov nad Kneznou, Czechia|DK003, Aarhus N, Denmark|DK001, Copenhagen, Denmark|EE301, Tallinn, Estonia|EE303, Tallin, Estonia|EE302, Tartu, Estonia|FI302, Kuopio, Finland|FI303, Oulu, Finland|FI301, Turku, Finland|FR006, Besancon Cedex, France|FR301, Bordeaux, France|FR308, Bron cedex, France|FR309, Elancourt, France|FR008, Limoges, France|FR302, Marseille cedex 5, France|FR003, Nantes Cedex, France|FR312, Nantes, France|FR303, Nice, France|FR005, Paris cedex 10, France|FR001, Paris, France|FR311, Paris, France|FR306, Reims, France|FR305, Rouen, France|FR004, Saint Priest en Jarez, France|FR313, Saint Priest en Jarez, France|FR002, Toulouse, France|DE002, Berlin, Germany|DE006, Ellwangen, Germany|DE005, Hannover, Germany|DE007, Heidelberg, Germany|DE009, Munchen, Germany|DE008, Ulm, Germany|DE004, Unterhaching, Germany|HU304, Budapest, Hungary|HU305, Budapest, Hungary|HU301, Esztergom, Hungary|HU302, Szeged, Hungary|IL302, Haifa, Israel|IL303, Holon, Israel|IL304, Ramat Gan, Israel|IT004, Ancona, Italy|IT006, Brescia, Italy|IT306, Brescia, Italy|IT309, Brescia, Italy|IT313, Cefalù, Italy|IT002, Firenze, Italy|IT311, Genova, Italy|IT003, Lamezia Terme, Italy|IT001, Milano, Italy|IT312, Monza, Italy|IT005, Palermo, Italy|IT007, Palermo, Italy|IT307, Perugia, Italy|IT301, Pisa, Italy|IT305, Roma, Italy|IT308, Roma, Italy|IT304, Torino, Italy|IT310, Torrette, Italy|KR303, Busan, Korea, Republic of|KR301, Incheon, Korea, Republic of|KR308, Seongnam-si, Korea, Republic of|KR302, Seoul, Korea, Republic of|KR304, Seoul, Korea, Republic of|KR305, Seoul, Korea, Republic of|KR306, Seoul, Korea, Republic of|KR307, Seoul, Korea, Republic of|KR309, Seoul, Korea, Republic of|LT302, Kaunas, Lithuania|LT303, Kaunas, Lithuania|LT301, Vilnius, Lithuania|LT304, Vilnius, Lithuania|PL301, Bialystok, Poland|PL304, Bydgoszcz, Poland|PL308, Gdynia, Poland|PL004, Gliwice, Poland|PL007, Katowice, Poland|PL309, Krakow, Poland|PL302, Lodz, Poland|PL310, Lubin, Poland|PL306, Lublin, Poland|PL307, Oswiecim, Poland|PL303, Poznan, Poland|PL005, Pozna, Poland|PL006, Sopot, Poland|PL002, Szczecin, Poland|PL311, Szczecin, Poland|PL003, Warszawa, Poland|PL008, Wroclaw, Poland|PT301, Amadora, Portugal|PT302, Coimbra, Portugal|RO002, Bucharest, Romania|RO001, Târgu-Mureş, Romania|ZA003, Bloemfontein, South Africa|ZA006, Cape Town, South Africa|ZA007, Cape Town, South Africa|ZA004, George, South Africa|ZA001, Pretoria, South Africa|ZA002, Rosebank, South Africa|ES006, Barcelona, Spain|ES005, Manresa, Spain|ES004, Salamanca, Spain|ES001, San Sebastian, Spain|ES002, San Vicente del Raspeig, Spain|ES003, Santiago de Compostela, Spain|TW301, Kaohsiung, Taiwan|TW302, Kaohsiung, Taiwan|TW303, Tainan, Taiwan|UA008, Dnipropetrovsk, Ukraine|UA006, Kherson, Ukraine|UA005, Kyiv, Ukraine|UA007, Kyiv, Ukraine|UA001, Lviv, Ukraine|GB307, Amersham, United Kingdom|GB301, Glasgow, United Kingdom|GB303, London, United Kingdom|GB308, London, United Kingdom|GB310, London, United Kingdom|GB306, Plymouth, United Kingdom|GB311, Plymouth, United Kingdom|GB309, Prescot, United Kingdom|GB305, Preston, United Kingdom|GB304, Southampton, United Kingdom|GB302, Swindon, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02079246/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02079246/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02079246"
426,"NCT01921972","The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease","AD-Combi","Completed","No Results Available","Alzheimer's Disease","Drug: Galantamine CR|Drug: Memantine|Drug: Placebo","ADAScog/11|ADCS-ADL|Clinical Dementia Rating|Neuropsychiatric Inventory NPI|Resource Utilization of Dementia Scale (RUD)|Burden Interview (BI)|Adverse Event Reports|Rate of brain atrophy","Charite University, Berlin, Germany|German Federal Ministry of Education and Research","All","50 Years and older   (Adult, Older Adult)","Phase 4","232","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Modul E.2 II","November 2004","November 2008","May 2009","August 14, 2013",,"August 14, 2013",,,"https://ClinicalTrials.gov/show/NCT01921972"
427,"NCT02831283","Imaging Inflammation in Alzheimer's Disease",,"Enrolling by invitation","No Results Available","Alzheimer's Disease","Drug: 11C-PBR28|Drug: 18F-Florbetaben|Procedure: Lumbar puncture (optional)","11C-PBR28 binding (standardized uptake value ratio)|18F-Florbetaben binding (standardized uptake value ratio)|Cerebral spinal fluid (CSF) biomarkers","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAO1151|1K23AG052633-01","June 2016","June 2021","June 2021","July 13, 2016",,"January 31, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02831283"
428,"NCT01559220","Deep Brain Stimulation for the Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Device: Deep Brain Stimulation","Clinical Dementia Rating Scale","Ali Rezai, MD|Ohio State University","All","45 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2011H0362","March 2012","January 2016","January 2016","March 21, 2012",,"March 30, 2017","Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01559220"
429,"NCT01692977","What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate?","JAZ-TOP","Completed","No Results Available","Alzheimer Disease","Other: neuropsychological assessment","Analyze nature and frequency of elements of the "" art, memory and life "" garden used as landmarks by Alzheimer's disease patients|Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.","Central Hospital, Nancy, France","All","65 Years to 90 Years   (Older Adult)","Not Applicable","77","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011-A00993-38","August 2012","October 2014","October 2014","September 26, 2012",,"July 30, 2015","University Hospital of Nancy , Saint Julien Hospital, France, Nancy, France",,"https://ClinicalTrials.gov/show/NCT01692977"
430,"NCT01009255","Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK239512|Drug: Placebo","Change from Baseline (Day 1) in the executive function/working memory composite score in the Cog State battery at Week 16|Change from Baseline (Day 1) in the episodic memory composite score in the CogState battery at Week 16|Change from Baseline (Day 1) in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) total score at Weeks 8 and 16|Change from Baseline (Day 1) in the attention composite score in the CogState battery at Week 16.|Clinician's Interview-Based Impression of Change-plus (CIBIC+) score at Weeks 8 and 16.|Change from Baseline (Day 1) to Weeks 8 and 16 of the Disability Assessment for Dementia scale (DAD) total score|Participant's Global Impression of Change (PGIC) score, Carer's Global Impression of Change (CrGIC) score, and Clinician Global Impression of Change (CGIC) at Week 8 and 16|Change from baseline in the Neuropsychiatric Inventory (NPI) at Weeks 8 and 16|Change from Baseline (Day 1) in Mini Mental State Examination (MMSE) total score at Week 16|Change from baseline during the titration phase, and to Weeks 8 and 16 of the Pittsburgh Sleep Quality Inventory (PSQI) and Epworth Sleepiness Scale (ESS)|Change from Baseline for Bilateral Score from Olfaction Test at Week 16|Plasma concentrations of GSK239512 over period|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Number of participants with vital signs outside clinical concern range (Systolic blood pressure [SBP], diastolic blood pressure [DBP], and heart rate [HR])|Number of participants with hematological and clinical chemistry parameters outside the reference range up to 16 weeks|Number of participants with abnormal electrocardiogram (ECG) over period","GlaxoSmithKline","All","50 Years and older   (Adult, Older Adult)","Phase 2","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110651","November 2, 2009","November 10, 2010","November 10, 2010","November 6, 2009",,"April 13, 2017","GSK Investigational Site, Ruse, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Pardubice, Czech Republic|GSK Investigational Site, Praha 10, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Trutnov, Czech Republic|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Rostov-on-Don, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Levoca, Slovakia|GSK Investigational Site, Michalovce, Slovakia|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01009255"
431,"NCT01716637","Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: Etanercept|Dietary Supplement: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.","Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Montreal Cognitive Assessment (MoCA) score.","Life Extension Foundation Inc.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CL025","February 2010","October 2015","May 2016","October 30, 2012",,"May 12, 2016","Paul H. Wand M.D., P.A., Coral Springs, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01716637"
432,"NCT01565343","A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Mean Cortical to Cerebellum SUVR","Avid Radiopharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A04","April 2008","April 2009","April 2009","March 28, 2012","May 2, 2012","May 10, 2012","Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01565343"
433,"NCT01428362","VI-1121 for the Treatment Alzheimer's Disease","AD-201","Completed","No Results Available","Alzheimer's Disease","Drug: VI-1121|Drug: Placebo","The primary efficacy variable is the change in Alzheimer's Disease Assessment-Cognitive Subscale (ADAS-Cog) score from baseline to Week 12 of each treatment period.|The secondary efficacy endpoint is the mean change in Mini-Mental State Examination (MMSE) score from baseline to Week 12 of each treatment period.|Percentage of subjects who achieve 3-point improvement in ADAS-Cog score from baseline to Week 12 of each treatment period.|Change in Clinician's Interview Based Impression of Change Plus Caregiver's Input (CIBIC-plus) score from baseline to Week 12 of each treatment period|Mean change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score from baseline to Weeks 4, 8, and 12 of each treatment period","VIVUS, Inc.|Medpace, Inc.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AD-201","August 2011","August 2013","August 2013","September 5, 2011",,"December 11, 2013","San Francisco, California, United States|Santa Monica, California, United States|Sunrise, Florida, United States|Louisville, Kentucky, United States|Las Vegas, Nevada, United States|Toms River, New Jersey, United States|New Windsor, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Toledo, Ohio, United States|Plano, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01428362"
434,"NCT03980730","Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance","Elevage","Recruiting","No Results Available","Alzheimer Disease","Drug: Azeliragon|Drug: Placebo","Part 1 : Change from Baseline in the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog14) at Month 6|Part 2: Change from Baseline in the ADAS-cog14 at Month 18|Part 2: Change from Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb) at Month 18|Part 1: Change from Baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb) at Month 6|Part 1: Change from Baseline in the Functional Activities Questionnaire (FAQ) at Month 6|Part 1: Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living (Amsterdam-IADL) at Month 6|Part 1: Change from Baseline in estimated glomerular filtration rate (eGFR) at Month 6|Part 2: Responder status at Months 6, 12, and 18 based on the ADAS-cog14|Part 2: Change from Baseline in FAQ score at Month 18|Part 2: Change from Baseline in Amsterdam-IADL score at Month 18|Part 2: Change from Baseline in MMSE score at Month 18|Part 2: Change from Baseline in eGFR at Month 18|Part 2: Change from Baseline in whole brain volume at Month 18","vTv Therapeutics","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TTP488-305","June 27, 2019","April 2023","July 2023","June 10, 2019",,"September 18, 2019","JEM Research Institute, Atlantis, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Charter Research, Lady Lake, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|ClinCloud, Maitland, Florida, United States|Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States|The Roskamp Institute, Sarasota, Florida, United States|NeuroStudies.net LLC, Decatur, Georgia, United States|Memory Center / Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, Saint Louis, Missouri, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Clarity Clinical Research, East Syracuse, New York, United States|Neurological Associates of Long Island, Lake Success, New York, United States|ANI Neurology dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|ANI Neurology, PLLC, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Summit Research Network, Portland, Oregon, United States|Center for Cognitive Health, Portland, Oregon, United States|Okanagan Clinical Trials Ltd., Kelowna, British Columbia, Canada|True North Clinical Research Inc., Kentville, Nova Scotia, Canada|Recherches Neuro-Hippocampe, Ottawa, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03980730"
435,"NCT02593318","Trial of Oxaloacetate in Alzheimer's Disease (TOAD)","TOAD","Completed","No Results Available","Alzheimer's Disease (AD)","Drug: Oxaloacetate (OAA)","Change in Safety Assessments (safety labs, physical and neurological exams, vital signs, cognitive measures, signs and symptoms)|Change in brain glucose metabolic rate as determined by Fluorodeoxyglucose positron emission tomography (FDG PET)|Change in brain lactate levels as determined by magnetic resonance spectroscopy (MRS)|Correlation between oral OAA intake and plasma levels in 500 mg bid cohort|Correlation between oral OAA intake and plasma levels in 1000 mg bid cohort","Russell Swerdlow, MD|University of Kansas Medical Center","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00002242","October 2015","September 2018","September 2018","November 2, 2015",,"October 12, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02593318"
436,"NCT01852110","Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)",,"Terminated","Has Results","Alzheimer's Disease","Drug: MK-7622|Drug: Placebo|Drug: AChEI","Change From Baseline in the 11-item Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at Week 12 (Stage 1, MK-7622 45 mg Versus Placebo)|Change From Baseline in ADAS-Cog11 Score at Week 12 (Stage 2, MK-7622 45 mg and 15 mg Versus Placebo)|Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Who Discontinued Study Drug Due to an AE|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) at Week 24 (Combining Stage 1 and 2, MK-7622 45 mg Versus Placebo)|Change From Baseline in Composite Cognition Score-3 Domain (CCS-3D) at Week 12 (Stage 1, MK-7622 45 mg Versus Placebo)|Change From Baseline in CCS-3D at Week 12 (Stage 2, MK-7622 45 mg and 15 mg Versus Placebo)","Merck Sharp & Dohme Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","7622-012|2013-000937-11|MK-7622-012","October 22, 2013","April 11, 2016","April 11, 2016","May 13, 2013","February 7, 2018","September 18, 2018",,,"https://ClinicalTrials.gov/show/NCT01852110"
437,"NCT01524887","Phase 3 IGIV, 10% in Alzheimer´s Disease",,"Terminated","Has Results","Alzheimer´s Disease","Biological: Immune Globulin Intravenous (Human), 10% Solution|Biological: Human albumin 0.25%","Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)|Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory|ADCS-Clinical Global Impression of Change (CGIC) at 18 Months|Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)|Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement|Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)|Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)|Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Number of Participants Experiencing Any AEs and/or SAEs|Number of Infusions Temporally Associated With AEs and/or SAEs|Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion|Number of Infusions Causally Associated With AEs and/or SAEs|Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE","Baxalta now part of Shire|Shire","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","161003|2011-000914-21","January 2012","July 2013","July 2013","February 2, 2012","March 31, 2015","November 24, 2017","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Long Beach, California, United States|San Diego, California, United States|Santa Ana, California, United States|Boca Raton, Florida, United States|Delray Beach, Florida, United States|Edgewater, Florida, United States|Orlando, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Paducah, Kentucky, United States|Saint Paul, Minnesota, United States|Olive Branch, Mississippi, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Chester, New Jersey, United States|Eatontown, New Jersey, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Albany, New York, United States|Brooklyn, New York, United States|Latham, New York, United States|Manhasset, New York, United States|New Hyde Park, New York, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Milwaukee, Wisconsin, United States|Woodville South, South Australia, Australia|Edegem, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Roeselare, Belgium|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Sherbrooke, Quebec, Canada|Akashi, Japan|Akita, Japan|Azumino, Japan|Chiba, Japan|Fukui, Japan|Kyoto, Japan|Niigata, Japan|Osaka, Japan|Saga, Japan|Tokushima, Japan|Tokyo, Japan|Lublin, Poland|Scinawa, Poland|Warszawa, Poland|Cruces-Barakaldo, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Uckfield, East Sussex, United Kingdom|Bath, United Kingdom|Brentford, United Kingdom|Brighton, United Kingdom|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01524887"
438,"NCT01680588","Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Drug: [18F]NAV4694","[18F]NAV4694 PET visual assessment by centralized readers|Assess the incidence of adverse events after a single dose of [18F]NAV4694|Evaluate [18F]NAV4694 PET quantitative assessment|Determine correlation of neuro-psychiatric tests with [18F]NAV4694 imaging|Assess changes in laboratory values after a single dose of [18F]NAV4694","Navidea Biopharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAV4-01","August 2012","December 2018","December 2018","September 7, 2012",,"March 30, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana Medical Research, Indianapolis, Indiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy Medical Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT01680588"
439,"NCT03179501","NP001, Alzheimer's Disease, and Blood Markers of Inflammation",,"Terminated","No Results Available","Alzheimer Disease","Drug: NP001|Drug: Placebo","Inflammatory monocyte-associated biomarkers|Adverse Events","Beau Nakamoto|Neuraltus Pharmaceuticals, Inc.|University of Hawaii","All","55 Years and older   (Adult, Older Adult)","Phase 1","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H039","September 1, 2017","July 31, 2018","July 31, 2018","June 7, 2017",,"October 22, 2018","University of Hawaii Clinics at Kakaako, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT03179501"
440,"NCT01565291","A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Mean Cortical to Cerebellum SUVR|Precuneus to Cerebellum SUVR","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A01","June 2007","January 2008","January 2008","March 28, 2012","May 3, 2012","May 18, 2012","Research Site, Baltimore, Maryland, United States|Research Site, North East, Maryland, United States|Research Site, Long Branch, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01565291"
441,"NCT00743743","Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer Disease","Dietary Supplement: Longevinex brand resveratrol supplement|Dietary Supplement: placebo","cognition|function|behavior","Medical College of Wisconsin","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Resveratrol2008","September 2008","June 2010","December 2010","August 29, 2008",,"August 24, 2015",,,"https://ClinicalTrials.gov/show/NCT00743743"
442,"NCT01231295","Isotopic Imaging for Prodromal Alzheimer's Disease","ISALP","Completed","No Results Available","Alzheimer Disease",,"The difference between AUCs for PET and SPECT imaging","Centre Hospitalier Universitaire de Nīmes","All","70 Years and older   (Older Adult)",,"143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PHRC-N/2009/POK-01|2009-013476-53","February 2011","September 2016","September 2016","November 1, 2010",,"February 1, 2017","CHU d'Amiens - Hôpital Sud, Amiens Cedex 1, France|CHU d'Angers - Hôtel-Dieu, Angers, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CHU de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, France|APHP - Hôpital Albert Chenevier, Creteil Cedex, France|APHP - Hôpital Charles Foix, Ivry Sur Seine Cedex, France|CHRU de Lille - Hôpital Claude Huriez, Lille, France|CHRU de Lille - Hôpital Roger Salengro, Lille, France|APHP - Hôpital Emile Roux, Limeil Brevannes Cedex, France|APHM - Hôpital La Timone Adultes, Marseille cedex 5, France|CHU de Montpellier - Hôpital Gui de Chauliac, Montpellier Cedex 5, France|CHU de Nancy - Hôpital Central, Nancy, France|CHU de Nice - Hôpitaux L'Archet 1 et 2, Nice, France|CHU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France|APHP - Groupe Hospitalier Pitié-Salpetrière, Paris cedex 13, France|APHP - Hôpital Lariboisière, Paris, France|APHP - Hôpital Broca, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Reims - Hôpital Maison Blanche, Reims, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, France|CHRU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|CHRU de Toulouse - Hôpital Garonne, Toulouse cedex 9, France|CHRU de Toulouse - Hôpital Purpan, Toulouse Cedex 9, France|CHRU de Tours - Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT01231295"
443,"NCT00715858","A Pilot Study of Inflammatory Markers in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: doxycycline|Drug: rifampin|Drug: placebo","IL-1beta|TNF-alpha|MCP-1|IL-4|IL-10|Other inflammatory markers.","McMaster University|The Physicians' Services Incorporated Foundation","All","50 Years and older   (Adult, Older Adult)","Phase 3","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R07-63","May 2008","August 2009","October 2009","July 15, 2008",,"February 4, 2009","St.Peter's Hospital, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00715858"
444,"NCT00692588","MRI to Measure Treatment With Antibiotics in Alzheimer's Disease","DARAD-MRI","Completed","No Results Available","Alzheimer's Disease",,"Changes in MRI Pre Vs Post Treatment|Comparison of Normal Controls Vs Alzheimer's Disease using MRI","St. Joseph's Healthcare Hamilton|St. Peter's Hospital|St. Peter's Centre for Studies in Aging","All","50 Years and older   (Adult, Older Adult)",,"58","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","R.P. #07-2949","June 2008","June 2010","June 2010","June 6, 2008",,"April 6, 2011","St. Joseph's Healthcare, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00692588"
445,"NCT03624842","Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease",,"No longer available","No Results Available","Late Onset Alzheimer Disease","Drug: Trappsol (R) Cyclo (TM)",,"CTD Holdings, Inc.|Kerwin Research Center, LLC","All","Child, Adult, Older Adult",,,"Industry|Other","Expanded Access:Individual Patients",,"CTDH-AD-EA-001",,,,"August 10, 2018",,"August 10, 2018",,,"https://ClinicalTrials.gov/show/NCT03624842"
446,"NCT01723826","A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab",,"Completed","No Results Available","Alzheimer's Disease","Drug: Crenezumab","Percentage of Participants with Adverse Events|Percentage of Participants by Nature of Adverse Events|Percentage of Participants by Severity of Adverse Events|Percentage of Participants with Human Anti-Therapeutic Antibody (ATA) Formation|Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema/Effusions (ARIA-E)|Percentage of Participants with Amyloid-Related Imaging Abnormalities-Hemorrhage (ARIA-H)","Genentech, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GN28525|2012-003242-33","December 7, 2012","February 8, 2017","February 8, 2017","November 8, 2012",,"February 22, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Pharmacology Research Inst, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Univ of CA San Diego; Neurosciences Comp.Alzheimer's, La Jolla, California, United States|USC School of Medicine, Los Angeles, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|University of California Davis Medical System, Sacramento, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Uni of California San Francisco, San Francisco, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Yale University, New Haven, Connecticut, United States|Florida Atlantic University; College of Medicine, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Indiana Univ School of Med, Indianapolis, Indiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch., Manhasset, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Investigational Drug Service; Univ of Rochester Medical Ctr, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Summit Research Network Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical Uni of South Carolina, North Charleston, South Carolina, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|The Med Arts Health Rsrch Grp, Kelowna, British Columbia, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|St. Joseph's HC-Parkwood Hosp, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont/Polyclinique;Recherche Clinique, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|Hopital Central; Neurologie, Nancy, France|Hopital Nord Laennec, Nantes, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hôpital Civil de Strasbourg, Strasbourg, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General de Catalunya, San Cugat Del Valles, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|The Rice Centre; Royal United Hospital, Bath, United Kingdom|West London Research Unit; Brentford Lodge, Brentford, United Kingdom|Royal Sussex County Hospital, CIRU Level 5, Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery; Dementia Research Center, London, GT LON, United Kingdom|Southampton General Hospital; Pharmacy, Southampton, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Great Western Hosp.; Kingshill Research Ctr, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01723826"
447,"NCT01565330","A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Florbetapir-PET Scan Quality|Mean Cortical to Cerebellum SUVR","Avid Radiopharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A03","March 2008","August 2008","August 2008","March 28, 2012","May 2, 2012","June 18, 2012","Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States|Research Site, Clementon, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01565330"
448,"NCT00000178","Multicenter Trial of Prednisone in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Prednisone",,"National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0002|3U01AG010483-08S2",,,,"November 1, 1999",,"June 24, 2005","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia Presbyterian Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00000178"
449,"NCT03038282","Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients",,"Not yet recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: Chromium Chloride|Other: Individual Exercise","Insulin Resistance|Change in chronic refractory mood disorders","Metabolic Therapy Inc.","All","65 Years and older   (Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R01TCR012617","February 20, 2017","August 20, 2019","October 20, 2019","January 31, 2017",,"January 31, 2017",,,"https://ClinicalTrials.gov/show/NCT03038282"
450,"NCT01676935","This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-126","Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","349","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-427|2011-004780-75","August 2012","March 2014","March 2014","August 31, 2012",,"March 26, 2014","Site Reference ID/Investigator# 73493, Delray Beach, Florida, United States|Site Reference ID/Investigator# 73496, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 73495, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 73494, Staten Island, New York, United States|Site Reference ID/Investigator# 97035, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 73514, Poznan, Poland|Site Reference ID/Investigator# 73515, Szczecin, Poland|Site Reference ID/Investigator# 73516, Kazan, Russian Federation|Site Reference ID/Investigator# 73525, Kazan, Russian Federation|Site Reference ID/Investigator# 73523, Kirov, Russian Federation|Site Reference ID/Investigator# 73521, Moscow, Russian Federation|Site Reference ID/Investigator# 73519, Moscow, Russian Federation|Site Reference ID/Investigator# 73517, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 73520, Saratov, Russian Federation|Site Reference ID/Investigator# 73518, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73524, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 84615, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73522, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73507, Belville, South Africa|Site Reference ID/Investigator# 84614, Cape Town, South Africa|Site Reference ID/Investigator# 73505, George, South Africa|Site Reference ID/Investigator# 73506, Johannesburg, South Africa|Site Reference ID/Investigator# 73533, Donetsk, Ukraine|Site Reference ID/Investigator# 73534, Kiev, Ukraine|Site Reference ID/Investigator# 73535, Poltava, Ukraine|Site Reference ID/Investigator# 73502, Bath, United Kingdom|Site Reference ID/Investigator# 73503, Blackburn, United Kingdom|Site Reference ID/Investigator# 73501, Glasgow, United Kingdom|Site Reference ID/Investigator# 73504, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01676935"
451,"NCT01669876","Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease","ASAP","Terminated","No Results Available","Alzheimer Disease","Dietary Supplement: Anatabloc(R)|Dietary Supplement: Placebo","Number of subjects experiencing adverse effects when using the supplement|Measured changes in blood markers of AD|Changes in global or functional measures of AD in subjects during the course of the study","Rock Creek Pharmaceuticals, Inc.|Roskamp Institute Inc.","All","65 Years to 90 Years   (Older Adult)","Phase 2","85","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RCP-009","August 2012","December 2014","February 2015","August 21, 2012",,"April 30, 2015","Roskamp Institute, Sarasota, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01669876"
452,"NCT01739348","An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)","EPOCH","Terminated","Has Results","Alzheimer's Disease","Drug: Verubecestat (Part I and Part II)|Drug: Placebo (Part I)|Drug: Verubecestat (Part II)","[Part I (Base Study)] Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part I (Base Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part I (Base Study)] Number of Participants Who Experienced an Adverse Event|[Part II (Extension Study)] Number of Participants Who Experienced an Adverse Event|[Part I (Base Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part II (Extension Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part I (Base Study)] Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score|[Part I (Base Study)] Percent Change From Baseline in Total Hippocampal Volume (THV)|[Part I (Base Study)] Fold Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau|[Part I (Base Study)] Change From Baseline in Cortical Amyloid Load Assessed by [18F]Flutemetamol PET Standard Uptake Value Ratio (SUVR)|[Part I (Base Study)] Percentage of Participants Achieving Responder Status|[Part I (Base Study)] Change From Baseline in Neuropsychiatric Inventory (NPI) Score|[Part I (Base Study)] Change From Baseline in Mini-Mental State Examination (MMSE) Score","Merck Sharp & Dohme Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","2211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P07738|MK-8931-017|2011-003151-20|132229","November 30, 2012","April 14, 2017","April 14, 2017","December 3, 2012","May 16, 2018","October 24, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01739348/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01739348"
453,"NCT00867828","Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)","MNEMOSYNE","Completed","No Results Available","Early Onset Alzheimer Disease","Dietary Supplement: Neptune Krill Oil|Dietary Supplement: Fish Oil|Dietary Supplement: Placebo (soy oil)","The primary outcome measure will be the change in Neurological Test Battery between baseline and 24 weeks of treatment.|Secondary outcome measures will include the change in DAD at 24 weeks of treatment, the change in NTB, GDS, DAD, and MMSE at 12 weeks.Safety and tolerability will be assessed by the incidence of treatment emergent adverse events.","NeuroBioPharm Inc.|Neptune Technologies and Bioressources Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 4","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NBP-4209AD","May 2009","July 2010","January 2011","March 24, 2009",,"October 3, 2011","Surrey, British Columbia, Canada|Deer Lake, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Cornwall, Ontario, Canada|Hamilton, Ontario, Canada|Hawkesbury, Ontario, Canada|Newmarket, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Thornhill, Ontario, Canada|Thunder Bay, Ontario, Canada|Dollard Des Ormeaux, Quebec, Canada|Grand-Mere, Quebec, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00867828"
454,"NCT01548430","A Safety Study of TTP4000 in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: TTP4000|Drug: Placebo","Number of participant with adverse events|Evaluation of participant plasma TTP4000 concentrations","vTv Therapeutics","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","TTP4000-101","October 2011","February 2013","February 2013","March 8, 2012",,"February 12, 2015","Miami, Florida, United States|Durham, North Carolina, United States|High Point, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01548430"
455,"NCT00876863","Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF|Procedure: Placebo Surgery","Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Neuropsychological Test Battery|Mini-Mental State Examination (MMSE)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)","Sangamo Therapeutics|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","49","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CERE-110-03|NIH Grant 1R01AG030048-01A1","November 2008","December 2017","December 2017","April 7, 2009",,"July 8, 2019","University of Alabama, Birmingham, Alabama, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00876863"
456,"NCT01324518","Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease","ALPO","Completed","No Results Available","Alzheimer's Disease","Drug: ORM-12741|Drug: Placebo for ORM-12741","Safety measures, i.e. assessing adverse events, vital signs, ECG,safety laboratory values|Efficacy measures on cognitive symptoms, i.e. CDR computerised cognitive test battery, COWAT and CFT|Scores on Neuropsychiatric Inventory NPI assessment scale|Pharmacokinetics of ORM-12741, metabolites and AChE inhibitor|Scores on Cornell Scale for Depression in Dementia CSDD|Scores on Cognitive Failures Questionnaire CFQ|Scores on Clinical Global Impression of Change CGI-C","Orion Corporation, Orion Pharma","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3098006","April 2011","September 2012","October 2012","March 29, 2011",,"October 21, 2014","Clinical Research Services Turku (CRST), Turku, Finland",,"https://ClinicalTrials.gov/show/NCT01324518"
457,"NCT00059410","Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II",,"Completed","No Results Available","Alzheimer Disease",,,"Alzheimer's Association|National Institute on Aging (NIA)","All","Child, Adult, Older Adult",,"210","Other","Observational","Time Perspective: Prospective","IA0045|NIRG-02-3712|BUMC 2002-308","January 2003","September 2005","September 2005","April 28, 2003",,"December 11, 2009","Boston University School of Medicine, Alzheimer's Disease Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00059410"
458,"NCT01690195","Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-126","Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","343","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-428|2012-000537-39","September 2012","February 2014","February 2014","September 21, 2012",,"March 26, 2014","Site Reference ID/Investigator# 84185, Long Beach, California, United States|Site Reference ID/Investigator# 84183, San Francisco, California, United States|Site Reference ID/Investigator# 84187, Hamden, Connecticut, United States|Site Reference ID/Investigator# 84178, Delray Beach, Florida, United States|Site Reference ID/Investigator# 84180, Orlando, Florida, United States|Site Reference ID/Investigator# 84186, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 84182, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 84181, Staten Island, New York, United States|Site Reference ID/Investigator# 84179, Bennington, Vermont, United States|Site Reference ID/Investigator# 84173, Gatineau, Canada|Site Reference ID/Investigator# 84174, Montreal, Canada|Site Reference ID/Investigator# 84177, Peterborough, Canada|Site Reference ID/Investigator# 84175, Toronto, Canada|Site Reference ID/Investigator# 84176, Verdun, Canada|Site Reference ID/Investigator# 84376, Dijon Cedex, France|Site Reference ID/Investigator# 84373, Limoges Cedex, France|Site Reference ID/Investigator# 84374, Paris Cedex 10, France|Site Reference ID/Investigator# 84377, Paris, France|Site Reference ID/Investigator# 84375, Toulouse Cedex 9, France|Site Reference ID/Investigator# 84382, Berlin, Germany|Site Reference ID/Investigator# 84380, Freiburg, Germany|Site Reference ID/Investigator# 84383, Huettenberg, Germany|Site Reference ID/Investigator# 84379, Mittweida, Germany|Site Reference ID/Investigator# 84381, Munich, Germany|Site Reference ID/Investigator# 84378, Schwerin, Germany|Site Reference ID/Investigator# 84385, Athens, Greece|Site Reference ID/Investigator# 84388, Athens, Greece|Site Reference ID/Investigator# 84389, Athens, Greece|Site Reference ID/Investigator# 84386, Haidari, Athens, Greece|Site Reference ID/Investigator# 84390, Thessaloniki, Greece|Site Reference ID/Investigator# 84395, Belville, South Africa|Site Reference ID/Investigator# 84391, Cape Town, South Africa|Site Reference ID/Investigator# 84393, George, South Africa|Site Reference ID/Investigator# 84394, Johannesburg, South Africa|Site Reference ID/Investigator# 84392, Rosebank, South Africa|Site Reference ID/Investigator# 84398, Bath, United Kingdom|Site Reference ID/Investigator# 84397, Glasgow, United Kingdom|Site Reference ID/Investigator# 84400, London, United Kingdom|Site Reference ID/Investigator# 84399, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01690195"
459,"NCT01075763","A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease","REAL","Completed","Has Results","Alzheimer's Disease","Drug: Interferon beta-1a|Drug: Placebo","Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score|Mini Mental Status Examination (MMSE) Score|Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score|Instrumental Activities of Daily Living (IADL) Score|Physical Self-Maintenance Scale (PSMS) Score|Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score|Geriatric Depression Scale (GDS) Score|Global Deterioration Scale Score","Merck KGaA, Darmstadt, Germany|Merck Serono S.P.A., Italy","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","24386","November 2004","May 2008","May 2008","February 25, 2010","April 4, 2012","February 13, 2014","U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina, Catania, CT, Italy",,"https://ClinicalTrials.gov/show/NCT01075763"
460,"NCT03819699","Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD",,"Terminated","No Results Available","Alzheimer Disease","Drug: Lu AF20513|Biological: booster vaccine","AUC|Cmax|Titre response|Amyloid load","H. Lundbeck A/S","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18086A","December 12, 2018","March 11, 2019","June 27, 2019","January 28, 2019",,"July 17, 2019","University of Eastern Finland, Brain Research Unit (FI002), Kuopio, Finland|Clinical Research Services Turku Oy (FI001), Turku, Finland|Karolinska University Hospital, Huddinge (SE001), Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03819699"
461,"NCT03082755","Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Gabapentin Enacarbil|Drug: Placebo Oral Tablet","Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct Observation|Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Caregiver Version.|Nighttime Agitation - Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC).|Sleep Disturbance - Direct Observation|Sleep Disturbance - Behavioral Indicators Test - Restless Legs (BIT-RL)|Sleep Disturbance - Micro-Mini Motionlogger® Actigraph","University of Texas at Austin|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 4","136","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-09-0152|R01AG051588-02","July 1, 2017","March 31, 2021","March 31, 2022","March 17, 2017",,"July 13, 2018","The University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03082755"
462,"NCT01527916","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: placebo|Drug: donepezil|Drug: ABT-126","Alzheimer's Disease Assessment Scale - cognitive subscale|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini Mental Status Exam (MMSE)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","438","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-985|2011-002004-32","February 2012","November 2013","November 2013","February 7, 2012",,"November 19, 2014","Site Reference ID/Investigator# 56503, Delray Beach, Florida, United States|Site Reference ID/Investigator# 56518, Tampa, Florida, United States|Site Reference ID/Investigator# 56514, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 62611, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 56506, Staten Island, New York, United States|Site Reference ID/Investigator# 82994, Jenkintown, Pennsylvania, United States|Site Reference ID/Investigator# 77636, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 56504, Bennington, Vermont, United States|Site Reference ID/Investigator# 62565, Gdynia, Poland|Site Reference ID/Investigator# 62563, Poznan, Poland|Site Reference ID/Investigator# 62562, Szczecin, Poland|Site Reference ID/Investigator# 60945, Kazan, Russian Federation|Site Reference ID/Investigator# 60955, Kazan, Russian Federation|Site Reference ID/Investigator# 60954, Kirov, Russian Federation|Site Reference ID/Investigator# 60951, Moscow, Russian Federation|Site Reference ID/Investigator# 60959, Moscow, Russian Federation|Site Reference ID/Investigator# 60946, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 60950, Saratov, Russian Federation|Site Reference ID/Investigator# 60947, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60958, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60949, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60952, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60911, Belville, South Africa|Site Reference ID/Investigator# 76073, Cape Town, South Africa|Site Reference ID/Investigator# 60912, George, South Africa|Site Reference ID/Investigator# 60910, Johannesburg, South Africa|Site Reference ID/Investigator# 60909, Donetsk, Ukraine|Site Reference ID/Investigator# 60906, Kiev, Ukraine|Site Reference ID/Investigator# 60905, Poltava, Ukraine|Site Reference ID/Investigator# 60960, Bath, United Kingdom|Site Reference ID/Investigator# 60963, Blackburn, United Kingdom|Site Reference ID/Investigator# 60962, Glasgow, United Kingdom|Site Reference ID/Investigator# 60961, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01527916"
463,"NCT00224497","A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: SB-742457","Change in cognition and function after 24 weeks.|Change in behavioural symptoms, activities of daily living and caregiver burden after 24 weeks. Changes in all symptoms at 8 and 12 weeks. Safety and tolerability. PK and dose response profiling. Efficacy related to ApoE status.","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AZ3100603","September 2005",,,"September 23, 2005",,"December 24, 2009","GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Retz, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Valparaiso, Valparaíso, Chile|GSK Investigational Site, Split, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Ostrava, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Rychnov Nad Kneznou, Czech Republic|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Rimavska Sobota, Slovakia|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sant Cugat Del Vallés/, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00224497"
464,"NCT01384344","Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy",,"Completed","No Results Available","Alzheimer Disease","Other: observational","stride and speed walking|For comparison between Alzheimer disease patients with (n=20) or without apathy, we use again stride and speed walking|For reproducibility, we use stride and speed walking|Reliability is the sum of posture's concordance|Relation between LF/HF variations and activity index","Centre Hospitalier Universitaire de Nice","All","65 Years and older   (Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11-PP-03","June 2011","December 2011","June 2012","June 29, 2011",,"December 18, 2012","Hôpital de Cimiez, Nice, France",,"https://ClinicalTrials.gov/show/NCT01384344"
465,"NCT00211159","OmegAD (Omega-3 and Alzheimer's Disease)",,"Completed","No Results Available","Alzheimer's Disease","Drug: EPAX 1050TG","Cognition measured according to ADAS-cog, MMSE scales|Safety, tolerability, blood pressure|Gene expression|Dose-response studies in relation to APOE4 status, to body weight and to gender","Karolinska University Hospital","All","Child, Adult, Older Adult","Not Applicable","204","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","OmegAD#1","December 2000",,,"September 21, 2005",,"July 31, 2017","Karolinska University Hospital Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00211159"
466,"NCT00596024","Lutein and Alzheimer's Disease Study","LAD","Terminated","No Results Available","Alzheimer's Disease","Dietary Supplement: lutein/zeaxanthin|Dietary Supplement: placebo","oxidative damage markers","Oregon Health and Science University|Oregon Partnership for Alzheimer's Research","All","55 Years and older   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","LAD|Alzheimer research fund","December 2007","July 2009","July 2009","January 16, 2008",,"August 12, 2019","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00596024"
467,"NCT01547689","Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease","SEMAD","Unknown status","No Results Available","Alzheimer's Disease","Biological: Human Umbilical Cord Derived MSC","Number of participants with adverse event|Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose","Affiliated Hospital to Academy of Military Medical Sciences|Peking University Third Hospital","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307-CTC-MSC-001|2011AA020114","March 2012","December 2016","December 2016","March 8, 2012",,"February 22, 2016","Department of Hematopoietic Stem Cell Transplantation, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01547689"
468,"NCT00094913","PET Changes in Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer Disease",,,"National Institute on Aging (NIA)","All","20 Years to 90 Years   (Adult, Older Adult)",,"105","NIH","Observational","Time Perspective: Prospective","IA0055|R01AG013616","May 2004",,"April 2005","October 29, 2004",,"May 27, 2009","Center for Brain Health, Silberstein Institute, New York University, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00094913"
469,"NCT00093951","SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: SGS742",,"Saegis Pharmaceuticals|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0061","April 2004","September 2007","September 2007","October 8, 2004",,"December 11, 2009","Phoenix, Arizona, United States|Dedicated Clinical Research, Sun City, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Incorporated, Little Rock, Arkansas, United States|Margolin Brain Institute, Fresno, California, United States|NervePro Research, Irvine, California, United States|Center for Neurologic Studies, La Jolla, California, United States|Neuro Therapeutics, Inc., Pasadena, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Southern California Clinical Research, Inc., San Marino, California, United States|The Mile High Research Center, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|Stamford, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Inc., Boca Raton, Florida, United States|Bradenton Neurology, Inc., Bradenton, Florida, United States|Brain Matters, Inc., Delray Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Allied Clinical Trials, The Neurology Group, Miami, Florida, United States|Tukoi Institute for Clinical Research, Miami, Florida, United States|Ocala Neurodiagnostic Center, Ocala, Florida, United States|Orange City, Florida, United States|Palm Springs, Florida, United States|Pompano Beach, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|CSI Research, Decatur, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Neurology Department, LSU Health Sciences Center, Shreveport, Louisiana, United States|Baystate Medical Center, Springfield, Massachusetts, United States|SW Medical Associates, Las Vegas, Nevada, United States|Manchester, New Jersey, United States|Psychopharmacology Research Association of Princeton, P.C., Princeton, New Jersey, United States|United Health Services Office of Clinical Trials, Johnson City, New York, United States|New York, New York, United States|Raleigh Neurology, Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Memory and Aging Center, Cleveland, Ohio, United States|Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Eugene, Oregon, United States|Medford, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|RI Mood & Memory Research Institute, E Providence, Rhode Island, United States|Madison, Tennessee, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Bellaire, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Texas Medical Research Associates, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Bennington, Vermont, United States|National Clinical Research, Inc., Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00093951"
470,"NCT01677754","A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","MAyflOwer RoAD","Completed","No Results Available","Alzheimer's Disease","Drug: RO4602522|Drug: Placebo|Drug: Donepezil|Drug: Memantine|Drug: Rivastigmine|Drug: Galantamine","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12|Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (<=) 4 Points in ADAS-Cog-11|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12|Change From Baseline in Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) Score at Month 12|Percentage of Participants With Worsening in BEHAVE-AD-FW Score|Change From Baseline in Apathy Evaluation Scale (AES) Score at 12 months|Change From Baseline in Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) Scale Score at 12 months|Percentage of Participants With Worsening in ADCS-CGIC Score|Change From Baseline in Global Deterioration Scale (GDS) Score at 12 months|Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at 12 months|Percentage of Participants with Adverse Events|Percentage of Participants with Change in Lens Opacity Grading|Percentage of Participants with Abnormal Visual Acuity Test Results|Change From Baseline in Michigan Neuropathy Screening Instrument Score|Percentage of Participants Receiving Concomitant Medications|Apparent Total Clearance of the Drug From Plasma After Administration of RO4602522|Apparent Volume of Distribution at Steady State after Administration of RO4602522|Area Under the Plasma Concentration-Time Curve of RO4602522|Maximum Plasma Concentration of RO4602522","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","542","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP28248|2012-000943-29","October 24, 2012","June 12, 2015","June 12, 2015","September 3, 2012",,"May 30, 2017","Advanced Research Center, Inc.;In-Patient Unit, Anaheim, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Torrance Clinical Research, Lomita, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|Comprehensive Clinical Development, Inc.- St. Petersburg, FL, Saint Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|New York University Medical Center;Child Study Center, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Radiant Research, Inc., Wyomissing, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Alzheimer's Research & Clinical Programs, Charleston, South Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia|A.G.Mander Pty Ltd, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|Hollywood Specialist Centre, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research, Subiaco, Western Australia, Australia|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Ingram, Jennifer MD, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Institut Universitaire de gériatrie de Sherbrooke; Service de gériatrie/pavillon Argyll, Sherbrooke, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|NEUROHK s.r.o., Chocen, Czechia|P-P Klinika, Kladno, Czechia|Supervize s.r.o., Kutna Hora - Vnitrni Mesto, Czechia|Nemocnice Na Bulovce, Prague, Czechia|Clintrial,s.r.o., Praha 10, Czechia|AD71 s.r.o., Praha 10, Czechia|Thomayerova nemocnice, Praha 4 - Krc, Czechia|Psychiatry Trial s.r.o., Praha 5, Czechia|Neurologicka ambulance, Praha 6, Czechia|FORBELI s.r.o., Praha 6, Czechia|Centre Hospitalier de la côte Basque, Bayonne, France|Hopital Neurologique Pierre Wertheimer, Bron, France|Hopital Nord Laënnec - CHU Nantes, Nantes, France|Hopital Cimiez; CMRR, Nice, France|Hôpital Lariboisière, Paris, France|Groupe Hospitalier Sud - Hôpital Xavier Arnozan, Pessac, France|Hôpital Maison Blanche, Reims, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|CHU Toulouse - La Grave, Toulouse, France|CHU Tours - Hôpital Bretonneau, Tours, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Hopital des Charpennes, Villeurbanne, France|Gemeinschaftspraxis, Ellwangen, Germany|Henriettenstiftung Hannover, Hannover, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung, Siegen, Germany|Nuovo Ospedale Civile S.Agostino - Estense, Modena, Emilia-Romagna, Italy|Policlinico Universitario Agostino Gemelli; Farmacia, Roma, Lazio, Italy|Fondazione Santa Lucia IRCCS, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Liguria, Italy|Università degli Studi di Genova, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica, Pisa, Toscana, Italy|Università degli studi di Perugia, Perugia, Umbria, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital; Pulmonary Medicine, Incheon, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Specjal. Praktyka Lekarska; Prof. Grzegorz Opala, Katowice, Poland|Centrum Medyczne Dendryt, Katowice, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznan, Poland|NZOZ Syntonia, Pruszcz Gdanski, Poland|NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog, Sopot, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Hospital General Universitario de Elche; Servicio de Farmacia, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain|CAE Oroitu, BaraKaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skanes Universitetssjukhus, Malmo Skanes Universitetssjukhus, Malmo, Malmö, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Cognitive Treatment & Research Unit, Crowborough, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|West London Cognitive Disorders Treatment and Research Unit; Lakeside Metal Health Unit, Isleworth, United Kingdom|Institute of Psychiatry, London, United Kingdom|Norwich Medical School, Norwich, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Memory Service North, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01677754"
471,"NCT01388478","Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: R-pramipexole","Number of Patients with Adverse Events|Reduction of Oxidative Stress|Changes in cerebral glucose metabolism|Effects on Cognitive Performance","Virginia Commonwealth University|University of Kansas Medical Center|Alzheimer’s Drug Discovery Foundation","All","55 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCU-KU-ADDF-2011|20101202","July 2011","January 2014","April 2014","July 6, 2011",,"April 25, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01388478"
472,"NCT00703430","Memantine on Aggression and Agitation of Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Memantine","CMAI score|CBI score|RUD|NPI score","Peking University|H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CN-IIT-12292","March 2008","December 2013","June 2014","June 23, 2008",,"January 25, 2013","Peking University Institute of Mental Health, Beijing, China",,"https://ClinicalTrials.gov/show/NCT00703430"
473,"NCT01885806","Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Apathy","Device: Magnetic Stimulator Magstim Rapid 2|Device: Sham Magnetic Stimulator","Change in apathy symptoms|Change in ADAS-Cog scores|Change in the Zarit Burden Scale","Federal University of Minas Gerais","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 15388913.6.0000.5149","June 2013","December 2014","December 2015","June 25, 2013",,"June 25, 2013","Federal University of Minas Gerais, Belo Horizonte, Outside of U.S., Brazil|Federal University of Minas Gerais, Belo Horizonte, Outside of U.S., Brazil",,"https://ClinicalTrials.gov/show/NCT01885806"
474,"NCT01998841","A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Crenezumab|Drug: Placebo","Change From Baseline in Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score at Week 260|Time to Progression to Mild Cognitive Impairment (MCI) due to AD or to Dementia due to AD|Time to Clinical Dementia Rating (CDR) Scale Global Score of Greater Than (>) Zero|Change From Baseline in CDR Scale - Sum of Boxes at Week 260|Change From Baseline in Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT) at Week 260|Change From Baseline in Measure of Overall Neurocognitive Functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Week 260|Change From Baseline in Mean Cerebral Fibrillar Amyloid Accumulation Standard Uptake Value Ratio (SUVR) as Assessed by Positron Emission Tomography (PET) at Week 260|Change From Baseline in Regional Cerebral Metabolic Rate of Glucose (CMRgI) Using Fluorine-18-Labeled 2-Deoxyglucose (FDG)-PET at Week 260|Change From Baseline in Brain Atrophy Measured by Volumetric Measurements Using Magnetic Resonance Imaging (MRI) at Week 260|Change From Baseline in a tau-Based Cerebral Spinal Fluid (CSF) Biomarker at Week 260|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Anti-Crenezumab Antibodies|CSF Crenezumab Concentration|Serum Crenezumab Concentration","Genentech, Inc.|Banner Alzheimer's Institute|National Institute on Aging (NIA)","All","30 Years to 60 Years   (Adult)","Phase 2","252","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GN28352","December 20, 2013","February 25, 2022","February 25, 2022","December 2, 2013",,"August 7, 2019","Fundacion Cardiomet, Armenia, Colombia|Clínica de Marly, Bogota, Colombia|Grupo Neurociencias de Antioquia, Medellin, Colombia|Hospital San Juan de Dios, Yarumal, Colombia",,"https://ClinicalTrials.gov/show/NCT01998841"
475,"NCT01677572","Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease","PRIME","Terminated","No Results Available","Alzheimer's Disease","Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Drug: Placebo","Number of Participants with Adverse Events|Change from baseline in florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging in certain brain areas.|Multiple dose pharmacokinetic (PK) serum concentrations of Aducanumab|Change from Baseline in Incidence of Anti-Aducanumab Antibodies in Serum.","Biogen","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","221AD103|2012-000349-10","October 5, 2012","March 21, 2019","July 31, 2019","September 3, 2012",,"September 4, 2019","NNS Clinical Research, LLC, Tucson, Arizona, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Alzheimer's Disease Research Unit, Yale University, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical Trials, Inc., Hallandale Beach, Florida, United States|Galiz Research, LLC, Miami Springs, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Infinity Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Neurostudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|CRI Lifetree, Marlton, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Insight Clinical Trials LLC, Beachwood, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Brown Hospital, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01677572"
476,"NCT02021682","CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,"Analysis of SILK blood and CSF Aβ isoforms|Age|CSF tau/ptau|PET/Fluoro-D-glucose (FDG) scan findings.|ApoE|Mutation status|Cognitive measures|Clinical measures|MRI","Washington University School of Medicine|National Institute of Neurological Disorders and Stroke (NINDS)","All","60 Years and older   (Adult, Older Adult)",,"58","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","In Vivo metabolism of ABeta|R01NS065667","December 2013","July 2017","July 2017","December 27, 2013",,"December 5, 2017","Washington University in St. Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02021682"
477,"NCT01482845","A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-126|Drug: Placebo","Safety and tolerability assessments|Pharmacokinetic evaluation profile","Abbott","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","M12-970","November 2011","March 2012","March 2012","December 1, 2011",,"May 2, 2012","Site Reference ID/Investigator# 62908, Glendale, California, United States|Site Reference ID/Investigator# 62904, Hallandale Beach, Florida, United States|Site Reference ID/Investigator# 62903, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01482845"
478,"NCT01397539","Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: BIIB037|Other: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero Extrapolated to Infinity [AUC0-∞]|Area Under the Curve from Time 0 to Time of the Last Measurable Concentration [AUC0-tlast]|Maximum Concentration [Cmax] of BIIB037|Time to Cmax [Tmax]|Elimination Half-life [t1/2]|Clearance [Cl]|Incidence of Anti-BIIB037 Antibodies in Serum","Biogen","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","221AD101","June 2011","August 2013","August 2013","July 19, 2011",,"March 23, 2015","Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Insight Clinical Trials, LLC, Beachwood, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01397539"
479,"NCT03625401","Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease","ROAD","Recruiting","No Results Available","Alzheimer Disease, Early Onset","Drug: AD-35 60mg group|Drug: AD-35 90mg group|Drug: Placebo group","ADAS-cog 11 score|NPI score|ADCS-ADL score|CIBIC+ score","Zhejiang Hisun Pharmaceutical Co. Ltd.|Medpace, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hisun-AD-35-003","October 4, 2018","July 31, 2019","July 31, 2020","August 10, 2018",,"January 11, 2019","Northern California Research, Sacramento, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Meridien Research, Maitland, Florida, United States|Meridien Research, Spring Hill, Florida, United States|NeuroStudies, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Clinilabs, Inc., New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03625401"
480,"NCT01712074","Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil",,"Terminated","Has Results","Alzheimer's Disease","Drug: PF-05212377 (SAM-760)|Other: Placebo","Change From Baseline in ADAS-cog13 Total Score at Week 16|Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 16 (Visit 5)","Pfizer","All","60 Years and older   (Adult, Older Adult)","Phase 2","186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2081011|2014-000830-42","November 2012","September 2015","September 2015","October 23, 2012","March 20, 2017","March 20, 2017","ATP Clinical Research, Inc, Costa Mesa, California, United States|Sun Valley Research Center, Imperial, California, United States|Desert Valley Research, Rancho Mirage, California, United States|RAA - Apex Aquisition, LLC, Santa Ana, California, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital, Temple Radiology, New Haven, Connecticut, United States|Yale University School of Medicine, MRI Research Center (MRI), New Haven, Connecticut, United States|Diagnostic Centers of America, Boynton Beach, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research Inc, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Compass Research LLC-North Clinic, Leesburg, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, Inc., Columbus, Georgia, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Michigan State University, East Lansing, Michigan, United States|Metro Imaging (Imaging only), Creve Coeur, Missouri, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|University of Rochester Medical Center AD-CARE Program   University of Rochester Medical Center, Rochester, New York, United States|University of Rochester Medical Center (MRI Imaging Only), Rochester, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Ohio State University (administrative offices only), Columbus, Ohio, United States|The Ohio State University - 2050, Columbus, Ohio, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Roper Hospital (Imaging Only), Charleston, South Carolina, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Roper St. Francis Pharmacy (IP Shipment/Storage), Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Senior Adults Speciality Research Inc., Austin, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Clinical Neuroscience Research Assoc. d/b/a The Memory Clinic, Bennington, Vermont, United States|Dean Foundation for Health, Research and Education, Middleton, Wisconsin, United States|Cary J. Kohlenberg, MD, dba, IPC Research, Waukesha, Wisconsin, United States|Merrill Hills Manor, Waukesha, Wisconsin, United States|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|Chatham-kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada|Psicomed Estudios Medicos CIA. LTDA, Antofagasta, Ii Region, Chile|Biomedica Research Group, Santiago, Metropolitana, Chile|Especialidades Medicas L Y S, Santiago, Metropolitana, Chile|Espace Sante 2, La Seyne Sur Mer, France|Dr. med. Volker Schumann, Arzt fuer Nervenheilkunde, Berlin, Germany|Praxis Dr. Franz- Arztehaus am KEH mit Epilepsie-Zentrum, Berlin, Germany|Praxis Dr. sc. med. Alexander Schulze, Berlin, Germany|Arzneimittelforschung Leipzig Gmbh, Leipzig, Germany|Praxis fuer Neurologie / Psychiatrie Prof. Dr. Steinwachs, Nuernberg, Germany|Hospital General Universitario De Elche, Elche, Alicante, Spain|Hospital de Cantoblanco, Madrid, Spain|The Research Institute for the Care of Older People Centre, Bath, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom|Berrywood Hospital, Northampton, United Kingdom|Covance Laboratories, Switzerland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01712074"
481,"NCT03455569","A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers",,"Recruiting","No Results Available","Sleep|Alzheimer Disease","Behavioral: Behavioral sleep education|Behavioral: Education only","Sleep efficiency for Alzheimer's disease patients|Total wake time for Alzheimer's disease patients|Sleep quality for caregivers|Cognitive function for Alzheimer's disease patients|Problematic behaviors for Alzheimer's disease patients|Depression for Alzheimer's disease patients|Caregiver burden for caregivers|Stress for caregivers|Depression for caregivers|Inflammation for caregivers|Quality of life for Alzheimer's disease patients","University of California, Los Angeles","All","60 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","1K23AG055668-03","September 11, 2018","October 30, 2021","April 30, 2022","March 6, 2018",,"September 19, 2019","University of California Los Angeles, Los Angeles, California, United States|Veterans Affairs Greater Los Angeles Healthcare System, North Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT03455569"
482,"NCT01179373","Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Device: TMS, H coil","cognitive functioning score by ADAS-COG|Global advancement score by CGI-C|Frontal lobe functioning score by FAB|Daily activity score by ADL","Brainsway","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","10003","August 2010","January 2015","June 2015","August 11, 2010",,"January 25, 2018","Merchav Clinics, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01179373"
483,"NCT00205621","Positron Emission Tomography of Amyloid in Alzheimer's Disease",,"Suspended","No Results Available","Alzheimer's Disease","Device: Positron Emission Tomography","quantification of amyloid binding","VU University Medical Center","Male","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2005/90","October 2005",,"December 2009","September 20, 2005",,"September 8, 2006","VU University Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT00205621"
484,"NCT02860065","CPC-201 Alzheimer's Disease Type Dementia: PET Study",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: CPC-201|Other: Positron emission tomography (PET)","Donepezil Maximum tolerated dose (MTD) change on imaging","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-15","September 30, 2016","June 30, 2017","June 30, 2017","August 9, 2016",,"August 9, 2017","Henry Ford Health System--West Bloomfield Hospital, West Bloomfield Township, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02860065"
485,"NCT01496170","A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])",,"Completed","No Results Available","Alzheimer's Disease","Drug: MK-8931|Drug: Placebo","Mean population Inhibitory Concentration for 50% Effect (IC50) in cerebral spinal fluid (CSF) ß-amyloid peptide 40 (Aß40)|Change in CSF Aß40 concentration determined by time-weighted average from 0 to 24 hours (TWA0-24)|Change in CSF soluble amyloid precursor protein ß (sAPPß ) concentration determined by TWA0-24","Merck Sharp & Dohme Corp.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P07820|MK-8931-010","December 2011","June 2012","June 2012","December 21, 2011",,"October 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01496170"
486,"NCT01926249","A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders","MEMENTO","Active, not recruiting","No Results Available","Alzheimer's Disease (AD) and Related Disorders",,"Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)|Mortality|Loss of autonomy based on functional activity assessment|Institutionalisation|Speed of cognitive decline based on change in cognitive performances|Cardiovascular event (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Longitudinal evolution of biomarkers measured from blood, Cerebro-Spinal Fluid (CSF), structural neuroimaging (MRI) and molecular neuroimaging (18F-FDG PET)","University Hospital, Bordeaux|Fondation Plan Alzheimer","All","18 Years and older   (Adult, Older Adult)",,"2300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2010/47","April 8, 2011","October 2019","October 2019","August 20, 2013",,"July 31, 2019","CHU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|CHU de Besançon, Besancon, France|APHP - Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Bordeaux - Hôpital Xavier-Arnozan, Bordeaux, France|CHU de Brest, Brest, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|Hôpitaux civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint Etienne, France|CHU de Saint-Etienne, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01926249"
487,"NCT01549834","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-126|Drug: placebo","Alzheimer's Disease Assessment Scale - cognitive subscale|Mini Mental Status Exam|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","434","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M11-793|2011-004849-40","March 2012","October 2013","October 2013","March 9, 2012",,"October 31, 2014","Site Reference ID/Investigator# 66528, Fresno, California, United States|Site Reference ID/Investigator# 69602, Long Beach, California, United States|Site Reference ID/Investigator# 66527, San Francisco, California, United States|Site Reference ID/Investigator# 66530, Hamden, Connecticut, United States|Site Reference ID/Investigator# 66522, Delray Beach, Florida, United States|Site Reference ID/Investigator# 66524, Orlando, Florida, United States|Site Reference ID/Investigator# 66531, Tampa, Florida, United States|Site Reference ID/Investigator# 66529, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 66526, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 66525, Staten Island, New York, United States|Site Reference ID/Investigator# 66523, Bennington, Vermont, United States|Site Reference ID/Investigator# 71793, Gatineau, Canada|Site Reference ID/Investigator# 71794, Montreal, Canada|Site Reference ID/Investigator# 71798, Peterborough, Canada|Site Reference ID/Investigator# 71795, Toronto, Canada|Site Reference ID/Investigator# 71796, Verdun, Canada|Site Reference ID/Investigator# 71573, Dijon Cedex, France|Site Reference ID/Investigator# 77833, Limoges Cedex, France|Site Reference ID/Investigator# 68704, Paris Cedex 10, France|Site Reference ID/Investigator# 68706, Paris, France|Site Reference ID/Investigator# 68705, Toulouse Cedex 9, France|Site Reference ID/Investigator# 68768, Berlin, Germany|Site Reference ID/Investigator# 68764, Freiburg, Germany|Site Reference ID/Investigator# 68767, Huettenberg, Germany|Site Reference ID/Investigator# 69960, Mittweida, Germany|Site Reference ID/Investigator# 68765, Munich, Germany|Site Reference ID/Investigator# 69959, Schwerin, Germany|Site Reference ID/Investigator# 68730, Athens, Greece|Site Reference ID/Investigator# 68732, Athens, Greece|Site Reference ID/Investigator# 68733, Athens, Greece|Site Reference ID/Investigator# 68731, Haidari, Athens, Greece|Site Reference ID/Investigator# 68729, Thessaloniki, Greece|Site Reference ID/Investigator# 68735, Thessaloniki, Greece|Site Reference ID/Investigator# 67586, Belville, South Africa|Site Reference ID/Investigator# 67582, Cape Town, South Africa|Site Reference ID/Investigator# 67584, George, South Africa|Site Reference ID/Investigator# 67585, Johannesburg, South Africa|Site Reference ID/Investigator# 67583, Rosebank, South Africa|Site Reference ID/Investigator# 67787, Bath, United Kingdom|Site Reference ID/Investigator# 67784, Glasgow, United Kingdom|Site Reference ID/Investigator# 67786, London, United Kingdom|Site Reference ID/Investigator# 67785, Manchester, United Kingdom|Site Reference ID/Investigator# 67783, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01549834"
488,"NCT00551161","Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: memantine","Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase Monotherapy vs Combination of Memantine and Cholinesterase Inhibitor","Northwell Health|Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 4","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NAM-MD-50","August 2007","December 2011","December 2011","October 30, 2007","December 18, 2013","January 28, 2014","The Litwin-Zucker Research Center, Manhasset, New York, United States",,"https://ClinicalTrials.gov/show/NCT00551161"
489,"NCT01746706","Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).",,"Unknown status","No Results Available","Alzheimer's Disease","Device: PET amyloid tracer (Florbetapir F18 AV45 F18","the assessment of subhippocampal dysfunction","Assistance Publique Hopitaux De Marseille","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011 A00383-38","October 2011","November 2015","November 2017","December 11, 2012",,"April 14, 2017","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT01746706"
490,"NCT01834716","Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study",,"Completed","Has Results","Alzheimer's Disease Prevention","Behavioral: Aerobic vs. Non-Aerobic exercise","Number of Subjects Retained at 6 Months","Mayo Clinic","All","65 Years and older   (Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","12-002817","April 2013","December 2014","December 2014","April 18, 2013","March 29, 2019","March 29, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01834716"
491,"NCT01492374","Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: BMS-241027|Drug: Placebo matching BMS-241027","Safety assessments: based on frequency of Serious Adverse Events (SAEs), frequency of Adverse events (AEs), discontinuation due to AEs and dose reduction|Biomarker Measures: CSF levels of Tau N-terminal domain fragments|Effects of BMS-241027 on CSF levels of the mid-domain Tau fragment|Effects of BMS-241027 on cognitive performance using computerized cognitive tests|Effects of BMS-241027 on connectivity MRI|Maximal observed plasma concentration (Cmax) of BMS-241027 in subjects with mild Alzheimer's disease|Observed plasma concentration at 24 hours post dose (C24) of BMS-241027 in subjects with mild Alzheimer's disease|Time of maximal observed plasma concentration (Tmax) of BMS-241027 in subjects with mild Alzheimer's disease|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-241027 in subjects with mild Alzheimer's disease|Safety assessments: based on vital sign measurements, ECGs and clinical laboratory tests|Effects of BMS-241027 on CSF levels of neurofilaments","Bristol-Myers Squibb","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN167-003|2011-004065-33","February 2012","October 2013","October 2013","December 15, 2011",,"July 24, 2014","Anaheim Clinical Trials Llc, Anaheim, California, United States|Long Beach, California, United States|Ucsf Memory And Aging Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists Of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Compass Research, Llc, Orlando, Florida, United States|Palm Beach Neurological Center Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Brigham And Women'S Hospital, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|The Ohio State University, Columbus, Ohio, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Toulouse, Cedex 9, France|Local Institution, Lille Cedex, France|Local Institution, Paris, France|Local Institution, Berlin, Germany|Local Institution, Heidelberg, Germany|Local Institution, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01492374"
492,"NCT01127633","Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease","EXPEDITION EXT","Terminated","Has Results","Alzheimer's Disease","Drug: Solanezumab|Drug: Placebo","Assess the Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive 14-Item Scale (ADAS-Cog14)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)|Change From Baseline to 104-week Endpoint in Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Change From Baseline to 104-week Endpoint in Neuropsychiatric Inventory (NPI)|Change From Baseline to 104-week Endpoint in Resource Utilization in Dementia - Lite (RUD-Lite) Caregiver Hours|Change From Baseline to 104-week Endpoint in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy)|Change From Baseline to 104-week Endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)|Change From Baseline to 104-week Endpoint in Mini-Mental State Examination (MMSE)|Change From Baseline to 52-week Endpoint in Plasma Amyloid Beta (Aβ) Levels|Change From Baseline to 104-week Endpoint in Volumetric Magnetic Resonance Imaging (vMRI)|Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item Scale (ADAS-Cog11)|Mean Change From Baseline to Endpoint in Amyloid Imaging Parameters in Subjects With Mild Alzheimer's Disease","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","1457","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11935|H8A-MC-LZAO","December 2010","July 2014","February 2017","May 21, 2010","May 3, 2018","October 8, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfield, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange City, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Canton, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Traverse City, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creve Coeur, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amherst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Automona De Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itapira, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medicine Hat, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jönköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalmar, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guishan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niaosong, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uckfield, E Susx, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01127633"
493,"NCT00097916","An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: memantine HCl","Neuropsychiatric Inventory|Cohen Mansfield Agitation Inventory|Clinical Global Impression Scale|ADCS-ADL|Agitation/aggression domain of Neuropsychiatric Inventory (NPI)","Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 3","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","MEM-MD-23","September 2004","April 2006","April 2006","December 2, 2004",,"March 5, 2012","The Forves Norris MDA/ALS Research Center, San Francisco, California, United States|Coastal Communities Hospital, Westminster, California, United States|Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Geriatric Medicine, Honolulu, Hawaii, United States|The Memory Clinic, Bennington, Vermont, United States|Hampton Roads Center for Clinical Research, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00097916"
494,"NCT01357629","Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer´s Disease",,"Safety","Affiris AG","All","Child, Adult, Older Adult",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AFF004E","July 2011","April 2013","November 2013","May 23, 2011",,"December 11, 2013","Studienzentrum der PROSENEX Ambulatoriumsbetriebs GmbH, Vienna, Austria|Univ. Klinik für Psychiatire und Psychotherapie, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01357629"
495,"NCT00006399","Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil|Drug: Estrogen|Drug: Progesterone",,"National Center for Research Resources (NCRR)|Alzheimer's Association|Pfizer|Eisai Inc.|National Institute on Aging (NIA)","Female","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","45","NIH|Other|Industry","Interventional","Masking: Double|Primary Purpose: Treatment","IA0023|2R56AG021476","September 1999","March 2004","March 2004","August 21, 2000",,"January 15, 2009","Clinical Neuroscience Research Unit, University of Vermont, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00006399"
496,"NCT01282619","Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Huperzine A|Drug: huperzine A|Drug: Placebo","Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input|Activities of Daily Living|Neuropsychiatric Inventory","Shandong Luye Pharmaceutical Co., Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LY200901-04","May 2010","June 2012","June 2012","January 25, 2011",,"January 25, 2011","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01282619"
497,"NCT01343966","A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",,"Completed","No Results Available","Alzheimer's Disease","Drug: MABT5102A|Drug: placebo","Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score|Change in Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score","Genentech, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","448","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ABE4869g|ABBY|GN00761","April 30, 2011","February 28, 2014","February 28, 2014","April 28, 2011",,"July 12, 2017","Hope Research Institute, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Pharmacology Research Inst, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Univ of CA San Diego; Neurosciences Comp.Alzheimer's, La Jolla, California, United States|USC School of Medicine, Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|University of California Davis Medical System, Sacramento, California, United States|Pacific Research Network - PRN, San Diego, California, United States|Uni of California San Francisco, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|Florida Atlantic University; College of Medicine, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Compass Research, Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|IU Healthy Partners Adult Neurology Clinic, Indianapolis, Indiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Empire Neurology, PC, Latham, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Investigational Drug Service; Univ of Rochester Medical Ctr, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Ctr of Ohio, Toledo, Ohio, United States|Clinical Trials of America, Inc., Eugene, Oregon, United States|Summit Research Network Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Medical Uni of South Carolina, North Charleston, South Carolina, United States|Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Saibal Nandy Professional Corporation, Medicine Hat, Alberta, Canada|The Med Arts Health Rsrch Grp, Kelowna, British Columbia, Canada|The Med Arts Health Rsrch Grp, Penticton, British Columbia, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, Canada|Capitol District Health Authority, Halilfax, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|Providence Care Centre; Mental Health Site, Kingston, Ontario, Canada|St. Joseph's HC-Parkwood Hosp, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont/Polyclinique;Recherche Clinique, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|Groupe Hospitalier Pellegrin, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Chu Limoges, Limoges, France|Hopital Nord Laennec, Nantes, France|Hopital de Cimiez, Nice, France|Hopital Broca, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hôpital Casselardit; Cons memoire, Toulouse, France|Studienambulanz emovis GmbH; St. Joseph Krankenhaus, Berlin, Germany|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Erlangen; Augenklinik, Erlangen, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany|Inst fur Stedien zur Psych Ges, Mannheim, Germany|Psych Klin der LMU Muenchen, Muenchen, Germany|Ludwig-Maximilians-Univ., Munchen, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Villa Sauer, Praxis für; Neurologie und Psychiatrie, Siegen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Hospital General de Catalunya, San Cugat del Valles, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Albacete, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen de la Macarena;, Sevilla, Spain|The Rice Centre; Royal United Hospital, Bath, United Kingdom|West London Research Unit; Brentford Lodge, Brentford, United Kingdom|Royal Sussex County Hospital, CIRU Level 5, Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery; Dementia Research Center, London, GT LON, United Kingdom|Camden Mews Day Hospital; Camden and Islington, London, United Kingdom|Southampton General Hospital; Pharmacy, Southampton, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Great Western Hosp.; Kingshill Research Ctr, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01343966"
498,"NCT01163825","Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients","NsG0202","Unknown status","No Results Available","Alzheimer's Disease","Drug: Nerve Growth Factor","Adverse events|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)","NsGene A/S|Karolinska Institutet|Stockholm County Council, Sweden","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NsG0202-001","January 2008","December 2011",,"July 16, 2010",,"July 16, 2010","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01163825"
499,"NCT01001637","Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Dietary Supplement: Curcumin Formulation|Dietary Supplement: Placebo","To determine if curcumin formulation affects mental capacity in Alzheimer's patients based on mental exams|To determine if curcumin formulation changes blood concentrations of amyloid-beta","Jaslok Hospital and Research Centre|Pharmanza Herbal Pvt Ltd|Verdure Sciences|University of California, Los Angeles","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Longvida|919820711140","October 2009","June 2010","November 2010","October 26, 2009",,"October 26, 2009","Jaslok Hospital and research centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01001637"
500,"NCT01399125","A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine Patch|Drug: Rivastigmine Capsules|Drug: Placebo to Rivastigmine patch|Drug: Placebo to Rivastigmine capsules","Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)|Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Baseline in Mini-Mental State Examination (MMSE) Total Score","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CENA713D2344","July 2011","May 2013","May 2013","July 21, 2011","August 4, 2014","August 4, 2014","Novartis Investigative Site, Fuzhou, Fujian, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01399125"
501,"NCT00205179","Alzheimer's Disease: Potential Benefit of Isoflavones",,"Completed","No Results Available","Alzheimer's Disease","Drug: Novasoy|Drug: Placebo","Cognitive Data|biological assays of isoflavones and hormones","University of Wisconsin, Madison|National Institutes of Health (NIH)","All","55 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-0048|5K23AG024302-03","January 2005","December 2009","December 2009","September 20, 2005",,"October 5, 2015","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00205179"
502,"NCT00934050","ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: ELND005 (scyllo-inositol)","Treatment Emergent Adverse Events (TEAEs)","OPKO Health, Inc.","All","Child, Adult, Older Adult","Phase 2","103","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ELND005-AD251","June 2009","June 2011","June 2011","July 8, 2009","May 13, 2015","May 13, 2015","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Health Sciences Center, Dept. of Neurology, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Brain Matters Research, Delray Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Dept. of Neurology, Atlanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|Innovative Clinical Concepts, Paducah, Kentucky, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Columbia University Sergievsky Center, New York, New York, United States|AD-CARE, Monroe Community Hospital, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Newtwork, Inc., Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh Alzheimer Disease Research Clinic, Pittsburgh, Pennsylvania, United States|Butler Hospital, Memory and Aging Center, Providence, Rhode Island, United States|Alliance for Neuro Research, LLC dba Absher Neurology, PA, Greenville, South Carolina, United States|Clinical Neuroscience Research Associates, Inc-The Memory Clinic, Bennington, Vermont, United States|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|University of British Columbia Hospital, Division of Neurology, Vancouver, British Columbia, Canada|Parkwood Hospital, London, Ontario, Canada|Sisters of Charity of Ottawa Health Service, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Whitby Mental Health Memory Clinic, Toronto, Ontario, Canada|Gerontion Research, Inc., Toronto, Ontario, Canada|Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont), Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00934050"
503,"NCT02800395","Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease","GERIOX","Recruiting","No Results Available","Alzheimer Disease","Procedure: Malnutrition screening and perioperative nutritional support","Change (evolution) of patient's cognitive profile evaluation measured by MMSE score method during memory consultation follow-up, every 6 months until patient loss.|cognitive profile evaluation at inclusion phase|Présence of cardiovascular risk factor|treatment evaluation|Functionality|Presence of anomalies on cerebral imaging data that evoke neuro-degenerative pathology, by MRI","Hospices Civils de Lyon","All","55 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014.860","December 2014","December 2024","December 2024","June 15, 2016",,"November 20, 2018","Service de Médecine Gériatrique. Groupement Hospitalier Sud. Hospices Civils de Lyon., Pierre Benite, France",,"https://ClinicalTrials.gov/show/NCT02800395"
504,"NCT01397578","A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: MABT5102A|Drug: placebo","Change in brain amyloid load as assessed by amyloid PET imaging|Changes in cerebrospinal fluid (CSF) biomarkers relevant to Alzheimer's disease|Change in brain metabolism as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG PET) imaging|Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS Cog) score","Genentech, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ABE4955g|GN00762","August 31, 2011","April 30, 2014","April 30, 2014","July 19, 2011",,"July 12, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|NNS Clinical Research LLC, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Internal Med Assoc of Lee Cty, Fort Myers, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch., Manhasset, New York, United States|Neurology & Neuroscience Ctr of Ohio, Toledo, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Hopital Central-CHU de Nancy; Pharmacie, Nancy, France|Hôpital Casselardit; Cons memoire, Toulouse, France|Clinique Psychiatrique Univ, Tours Cedex 9, France|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Mutua De Terrasa, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01397578"
505,"NCT00904683","Effect of LY2062430 on the Progression of Alzheimer's Disease","EXPEDITION2","Completed","No Results Available","Alzheimer's Disease","Drug: LY2062430|Drug: Placebo","Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 14-Item Scale (ADAS-Cog14)|Change from Baseline to Week 80 in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Change from Baseline to Week 80 in Neuropsychiatric Inventory (NPI) Score|Change from Baseline to Week 80 in volumetric Magnetic Resonance Imaging (vMRI)|Change from Baseline to Week 80 in Mini-Mental State Examination (MMSE) Score|Change from Baseline to Week 80 in Resource Utilization in Dementia - Lite (RUD-Lite) Score|Change from Baseline to Week 80 in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy) Score|Change from Baseline to Week 80 in Quality of Life in Alzheimer's Disease (QoL-AD) Score|Change from Baseline to Week 80 in Plasma Amyloid Beta Levels|Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item and 12-Item Scale (ADAS-Cog11 and ADAS-Cog12)|Change from Baseline to Week 80 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Score","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","1040","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11934|H8A-MC-LZAN","May 2009","June 2012","June 2012","May 20, 2009",,"December 13, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creve Coeur, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amherst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bankstown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aix En Provence, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joenkoeping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalmar, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uckfield, E Susx, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Syorks, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00904683"
506,"NCT03151382","A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease",,"Unknown status","No Results Available","Alzheimer Disease|Cognitive Function","Drug: Tandospirone Citrate|Drug: Donepezil Hydrochloride","Change of ADAS-cog total score|NPI scale total score|HAMA total score|FAB score|relative power|the image of PET|MMSE score","Zhejiang Provincial People’s Hospital","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SED-AD|SED-AD-2016-001","May 20, 2017","December 31, 2017","June 30, 2018","May 12, 2017",,"May 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03151382"
507,"NCT00606164","Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Bryostatin for Injection|Drug: Placebo","Adverse Events|Alzheimer's Disease Assessment Scale|Clinician's Interview Based Impression of Change|Clinical Dementia Rating Battery|Alzheimer's Disease Cooperative Study - Activities of Daily Living|Severe Impairment Battery|Hopkins Verbal Learning Test-Revised|Temperature|Respiratory rate|Blood pressure|Heart rate|Electrocardiogram|Physical Exam|Hematology|Blood chemistry|Urinalysis|Pharmacokinetics|Protein kinase C activity (pharmacodynamics)","Blanchette Rockefeller Neurosciences Insitute","All","50 Years and older   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRY-201","April 2008","December 2008","December 2008","February 1, 2008",,"February 1, 2008","Chestnut Ridge Center West Virginia University Department of Behavioral Medicine and Psychiatry, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00606164"
508,"NCT00866060","Donepezil and Memantine in Moderate to Severe Alzheimer's Disease","DOMINO-AD","Unknown status","No Results Available","Moderate to Severe Alzheimer's Disease","Drug: Memantine|Drug: Donepezil|Drug: Placebo donepezil|Drug: Placebo memantine","Cognitive Function measured with the Standardised MMSE (SMMSE).|Activities of Daily Living measured with the Bristol Activities of Daily Living scale (BADLS).|Non−cognitive dementia symptoms measured with the Neuropsychiatric Inventory (NPI) and the Cohen−Mansfield Agitation Inventory.|Health−related quality of life measured with the EQ−5D (Euroqol Group 1990) and the DEMQOL−Proxy (Smith et al 2004) − a carer−rated and disease−specific measure of quality of life in dementia.|Care−giver burden measured with the General Health Questionnaire.|Cost effectiveness assessed through consideration of the combination of costs generated from the Client Service Receipt Inventory (CSRI) and the assessments of function and quality of life (BADLS, DEMQOL, EQ−5D).|Institutionalisation defined as permanent transition from living in an independent household to a care home, NHS continuing care unit or hospital and measured with questions taken from the CSRI and telephone interviews.","King's College London","All","Child, Adult, Older Adult","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006/123|ISRCTN49545035|Eudract 2007-001172-36","February 2008","February 2012","June 2013","March 20, 2009",,"March 20, 2009","Institute of Psychiatry, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00866060"
509,"NCT02783573","A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia","DAYBREAK-ALZ","Terminated","Has Results","Alzheimer's Disease","Drug: Lanabecestat|Drug: Placebo","Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog13) Score|Change From Baseline in Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items Score (ADCS-iADL)|Change From Baseline in Functional Activities Questionnaire (FAQ) Score|Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage|Change From Baseline in Neuropsychiatric Inventory (NPI) Score|Change From Baseline on the Mini-Mental State Examination (MMSE)|Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42|Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40|Change From Baseline in CSF Biomarker Total Tau|Change From Baseline in CSF Biomarker Phosphorylated Tau|Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan|Change From Baseline in Regional Cerebral Blood Flow (rCBF) Using Florbetapir Perfusion Scan|Change From Baseline in Whole Brain Volume|Population Pharmacokinetics (PK): Apparent Oral Clearance of Lanabecestat|Population PK: Central Volume of Distribution of Lanabecestat","Eli Lilly and Company|AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","1722","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16024|I8D-MC-AZET|2015-005625-39","July 1, 2016","September 28, 2018","September 28, 2018","May 26, 2016","August 6, 2019","August 6, 2019","Xenoscience, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Four Peaks Neurology, Scottsdale, Arizona, United States|Arizona Neurology, Scottsdale, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|NEA Baptist Clinical, Jonesboro, Arkansas, United States|The Research Center of Southern California, Carlsbad, California, United States|WCCT Global, Costa Mesa, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Research Foundation, San Diego, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Care Access Research, Santa Clarita, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Care Access Research, Valencia, California, United States|Associated Neurologists, PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Morton Plant Hospital, Clearwater, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Cohen Medical Associates P.A., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Gregory A. Kirk MD LLC, Merritt Island, Florida, United States|University of Miami, Miami, Florida, United States|Allied Biomedical Research Institute, Inc., Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Charlotte Neurological Services, Port Charlotte, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Axiom Research, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|Hawaii Medical Center, Honolulu, Hawaii, United States|Advanced Clinical Research LLC, Meridian, Idaho, United States|American Health Network, Avon, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|American Health Network, Muncie, Indiana, United States|University of Kansas Hospital, Fairway, Kansas, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Via Christi Research, Inc., Wichita, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Neurology, Scarborough, Maine, United States|Boston University Medical Center, Boston, Massachusetts, United States|Donald S Marks, Plymouth, Massachusetts, United States|Alzheimers Disease Center, Winchester, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|New York University Medical Center, New York, New York, United States|Behavioral Health Center Research, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Univ CAR, Winston-Salem, North Carolina, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Pearl Clinical Research Inc., Norristown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|Coastal Neurology PA, Port Royal, South Carolina, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|Univ of North Texas Health Science Center, Fort Worth, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|SSM Health Dean Medical Group, Madison, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|The Medical Arts Health Research Group, West Vancouver, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada|CSSS-Institut Universitaire Gériatric de Sherbrooke, Sherbrooke, Qubec, Canada|Recherches Neuro-Hippocampe Inc, Gatineau, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|Douglas Hospital and Research Centre, Verdun, Quebec, Canada|Xuanwu Hospital-Capital Medical University, Beijing, Beijing, China|Beijing 301 Hospital, Beijing, Beijing, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Tangshan Worker Hospital, Tangshan, Hebei, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Zhongda Hospital-Southeast University, Nanjing, Jiangsu, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|Shanghai Tongji Hospital(CCBR site), Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China|Shanghai Huashan Hospital Affil to Fu Dan University, Shanghai, China|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Neurohk s.r.o., Chocen, Czechia|Neuropsychiatrie s.r.o, Hradec Kralove, Czechia|Brain-Soultherapy s.r.o, Kladno, Czechia|A-Shine s.r.o., Plzen, Czechia|Clintrial, s.r.o., Praha 10, Czechia|Neuropsychiatrie s.r.o, Praha 6, Czechia|Medical Services Prague s.r.o., Praha 6, Czechia|Axon Clinical, s.r.o., Praha 8, Czechia|CCBR-Alborg-DK, Aalborg, Denmark|Center For Clinical and Basic Research, Ballerup, Denmark|Rigshospitalet, Copenhagen, Denmark|Center for Clinical and Basic Research -CCBR, Vejle, Denmark|Institut Claude Pompidou - CMRR, Nice, Alpes Maritimes, France|CHU Rennes/Hopital Sud, Rennes Cedex, Ille Et Vilaine, France|CHU Saint Etienne - Hopital Nord, Saint Priest en Jarez, Loire, France|Chu De Nancy Hop D'Adultes De Brabois, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France|CHU d'Amiens-Picardie Hopital Sud, Amiens Cedex 1, France|CHU de Caen Hopital Cote de Nacre, Caen Cedex, France|APHM Hôpital de la Timone, Marseille, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU Strasbourg Hôpital de Hautepierre, Strasbourg Cedex, France|Chu de Toulouse Hopital de La Grave, Toulouse Cedex, France|Praxis Dr. Erich Scholz, Böblingen, Baden-Württemberg, Germany|ISPG - Institut für Studien zur psychischen Gesundheit, Mannheim, Baden-Württemberg, Germany|Praxis für Neurologie und Psychiatrie Dr. med. Roth, Ostfildern, Baden-Württemberg, Germany|Neurozentrum Sophienstraße, Stuttgart, Baden-Württemberg, Germany|Klinikum der Universität München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Neuropraxis München Süd, Unterhaching, Bayern, Germany|Diakoniekrankenhaus Henriettenstiftung Hannover, Hannover, Niedersachsen, Germany|MVZ LiO Berlin, Berlin, Germany|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Spedali Civili - Universita degli Studi, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|SDN - Istituto di Ricerca Diagnostica e Nucleare, Napoli, Italy|Azienda Ospedaliera - Universitaria Pisana, Pisa, Italy|IRCCS Santa Lucia, Roma, Italy|Universita La Sapienza, Roma, Italy|Azienda Ospedaliera Citta della Salute della Scienza Torino, Torino, Italy|Shinwakai Yachiyo Hospital, Anjo-shi, Aichi-Ken, Japan|Nagoya Ekisaikai Hospital, Nagoya-shi, Aichi-Ken, Japan|Kojunkai Daido Hospital, Nagoya-Shi, Aichi-Ken, Japan|Inage Neurology and Memory Clinic, Chiba-shi, Chiba-Ken, Japan|Ehime University Hospital, Toon-Shi, Ehime-Ken, Japan|Jisenkai Nanko Psychiatric Institute, Shirakawa-shi, Fukushima-Ken, Japan|Takeda General Hospital, Aizu-Wakamatsu, Fukushima, Japan|Koseikai Kusatsu Hospital, Hiroshima-shi, Hiroshima-Ken, Japan|NHO Hiroshima-Nishi Medical Center, Otaki-Shi, Hiroshima-Ken, Japan|Yokohama Hospital, Yokohama, Kanagawa, Japan|Koseikai Takeda Hospital, Kyoto-Shi, Kyoto-Fu, Japan|Uji Takeda Hospital, Uji-Shi, Kyoto-Fu, Japan|JADECOM Nara City Hospital, Nara-Shi, Nara-Ken, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Oita University Hospital, Yufu-shi, Oita-Ken, Japan|Katayama Medical Clinic, Kurashiki-shi, Okayama-Ken, Japan|Himuro Neurology Clinic, Osaka-Shi, Osaka-Fu, Japan|Kotobukikai Tominaga Clinic, Osaka-shi, Osaka-Fu, Japan|Kousaiin Hospital, Suita-shi, Osaka-Fu, Japan|NHO Hizen Psychiatric Center, Kanzaki-gun, Saga-Ken, Japan|Shimizu Hospital, Shizuoka-shi, Shizuoka, Japan|Keikokai P-One Clinic, Hachioji-shi, Tokyo-To, Japan|Memory Clinic Ochanomizu, Bunkyo-ku, Tokyo, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Musashino Red Cross Hospital, Musashino, Tokyo, Japan|JOHAS Sanin Rosai Hospital, Yonago-shi, Tottori-Ken, Japan|Aomori Prefectural Centeral Hospital, Aomori, Japan|Ikeuchi Psycho Induced Internal Clinic, Kobe-shi, Japan|Yuge Hospital, Kumamoto, Japan|NHO Niigata Hospital, Niigata, Japan|NHO Hokkaido Medical Center, Sapporo-shi, Japan|Dong-A University Medical Center, Busan, Busan Gwang'yeogsi, Korea, Republic of|The Catholic University of Korea-Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitario de Saltillo, Saltillo, Coahuila, Mexico|Mexico Centre for Clinical Research SA de CV, Mexico City, Distrito Federal, Mexico|Clinical Research Institute S C, Tlalnepantla, Edo De Mex, Mexico|Hospital Univ. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Instituto de Informacion en Salud Mental (INFOSAM), Monterrey, NL, Mexico|Accelerium Clinical Research, Monterrey, Nuevo Leon, Mexico|Centro de Estudios Clinicos y Esp Medicas SC, Monterrey, Nuevo Leon, Mexico|Avix Investigación Clínica, S.C, Monterrey, Nuevo León, Mexico|Emotional Brain B.V., Almere, Netherlands|Brain Research Center, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|EB Utrecht, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands|NZOZ Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnoslaskie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|NZOZ Mach-Med, Chorzow, Poland|Klinika Neurologii Neuro-Care, Katowice, Poland|Globe Badania Kliniczne SP Z O.O., Klodzko, Poland|Prywatny Gabinet Lekarski U.Chyrchel, Lublin, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Clinsante Centrum Medyczne, Torun, Poland|Centrum Medyczne, Warszawa, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego SOMED, Warszawa, Poland|Hospital Fernando Fonseca, Amadora, Portugal|Hospital de Braga, Braga, Portugal|Hospitals da Universidade de Coimbra, Coimbra, Portugal|SAIH Republ. Clinical Hospital of the MoH of Republ. Tatarst, Kazan, Russian Federation|SIH Kemerovo Regional Clinical Hosptial, Kemerovo, Russian Federation|FSBIH Siberian Clinical Center of FMBA, Krasnoyarsk, Russian Federation|LLC City Neurological Centre Sibneuromed, Novosibirsk, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Ultramed, Omsk, Russian Federation|LLC Treatment and Rehabilitation, Rostov-on-Don, Russian Federation|RSBIH Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|Bekhterev Psyconeurological Institute, St. Petersburg, Russian Federation|Central Medical Sanitary Hospital #122, St. Petersburg, Russian Federation|Regional State Institution of Healthcare Tomsk Clinica Psych, Tomsk, Russian Federation|Hospital Cardiovascular San Vicente, San Vicente del Raspeig, Alicante, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Policlinica Guipuzcoa, Donostia, Guipuzcoa, Spain|Hospital Ntra Sra Perpetuo Socorro, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Cardinal Tien Hospital, Sindian City, Taipei County, Taiwan|National Taiwan University Hospital, Douliu, Yunlin County, Taiwan|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Re-Cognition Health Ltd, Plymouth, Devon, United Kingdom|Charlton Lane Hospital, Cheltenham, Gloucestershire, United Kingdom|Re-Cognition Health Ltd, Guildford, Surrey, United Kingdom|Murray Royal Hospital, Perth, Tayside Region, United Kingdom|Victoria Centre, Swindon, Wiltshire, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Re-Cognition Health Ltd, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02783573/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02783573/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02783573"
510,"NCT01122329","A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease","AD","Completed","No Results Available","Alzheimer Disease","Dietary Supplement: caprylidene|Dietary Supplement: Placebo","Regional cerebral blood flow (rCBF)|Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition|To examine the effect of AC-1202 on cognition","University of California, Los Angeles|John Douglas French Foundation","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GG-AC-1202","October 2010","January 2015","January 2015","May 13, 2010",,"March 23, 2015","200 Medical Plaza, UCLA Medical Center, Los Angeles, California, United States|Center for Neurotherapeutics at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01122329"
511,"NCT00265148","Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone|Other: Placebo","Change from baseline in global and regional functional brain activity at 12 months|Change in functional brain activity at other timepoints; changes in cognition and clinical scales of AD status; changes in brain structure; safety and tolerability; changes in blood biomarkers and insulin sensitivity; genetic (apolipoprotein E) status|Changes in global and regional CMRglu between baseline and other scan time points as measured by [18F]FDG uptake.|Changes in cognitive tests and clinical scales of AD status from baseline.|Global changes in brain structure from baseline as measured by structural MRI from baseline.|Changes in blood borne biomarkers from baseline: Markers of glucose metabolism (fasting plasma glucose; fasting plasma insulin: HbA1C); Lipid levels; Inflammatory markers; Immunology markers; Putative markers of disease burden.|Changes in insulin sensitivity from baseline: Homeostasis Model Assessment; Body Mass Index|Polymorphism status with respect to genetic markers: Apolipoprotein-E|Measures of safety and tolerability: Vital signs, 12-Lead ECGs, Haematology and clinical chemistry evaluations, Adverse events, Measures of fluid retention: body weight; haematocrit; clinical examination","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BRL-49653/461","May 2004","July 2008","July 2008","December 14, 2005",,"November 16, 2016","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Belmont, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Swindon, United Kingdom|GSK Investigational Site, West End, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00265148"
512,"NCT03019536","A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: LY3303560 - IV|Drug: Placebo - IV|Drug: Florbetapir F 18|Drug: Flortaucipir F18","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Serum Concentration (Cmax) of LY3303560|Pharmacokinetics: Area Under the Serum Concentration Time Curve During the Dosing Interval (AUC) of LY3303560","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16452|I8G-MC-LMDD|2016-002102-39","January 31, 2017","June 5, 2019","June 5, 2019","January 12, 2017",,"July 3, 2019","Bioclinica, Melbourne, Florida, United States|Bioclinica, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Bioclinica, The Villages, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kurume, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03019536"
513,"NCT01137526","Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-384|Drug: donepezil|Drug: placebo","Change from baseline to final observation in the Alzheimer's Disease Assessment Scale-Cognition portion (ADAS-cog) total score|Mini Mental Status Examination (MMSE) score at Baseline, Weeks 4, 8, and 12|Clinician's Interview Based Impression of Change-plus (CIBIC-plus) score at Baseline, Weeks 4, 8, and 12|Neuropsychiatric Inventory (NPI) score at Baseline, Weeks 4, 8, and 12|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at Baseline, Weeks 4, 8, and 12","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M12-033|2009 017801-12","May 2010","July 2011","July 2011","June 4, 2010",,"January 29, 2013","Site Reference ID/Investigator# 40834, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 36304, Kazan, Russian Federation|Site Reference ID/Investigator# 36306, Kirov, Russian Federation|Site Reference ID/Investigator# 37944, Moscow, Russian Federation|Site Reference ID/Investigator# 26909, Saratov, Russian Federation|Site Reference ID/Investigator# 26904, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 26902, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 36305, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 38383, Yaroslavl, Russian Federation|Site Reference ID/Investigator# 45584, Belville, South Africa|Site Reference ID/Investigator# 47102, George, South Africa|Site Reference ID/Investigator# 45583, Johannesburg, South Africa|Site Reference ID/Investigator# 39855, Donetsk, Ukraine|Site Reference ID/Investigator# 26914, Kharkiv, Ukraine|Site Reference ID/Investigator# 26912, Kiev, Ukraine|Site Reference ID/Investigator# 40484, Lviv, Ukraine|Site Reference ID/Investigator# 27002, Poltava, Ukraine|Site Reference ID/Investigator# 39856, Poltava, Ukraine|Site Reference ID/Investigator# 40482, Simferopil, Ukraine|Site Reference ID/Investigator# 40483, Ternopil, Ukraine|Site Reference ID/Investigator# 35660, Vinnytsia, Ukraine|Site Reference ID/Investigator# 36327, Bath, United Kingdom|Site Reference ID/Investigator# 35657, Blackburn, United Kingdom|Site Reference ID/Investigator# 36330, Crowborough, United Kingdom|Site Reference ID/Investigator# 36326, Glasgow, United Kingdom|Site Reference ID/Investigator# 44123, Ivybridge, Devon, United Kingdom|Site Reference ID/Investigator# 35658, London, United Kingdom|Site Reference ID/Investigator# 35902, Northampton, United Kingdom|Site Reference ID/Investigator# 36328, Oxford, United Kingdom|Site Reference ID/Investigator# 36329, Peterborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01137526"
514,"NCT00880412","A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease","EHT0202/002","Completed","No Results Available","Alzheimer's Disease","Drug: EHT 0202 etazolate|Drug: Placebo","incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.|Assessment of cognition (ADAS-Cog, Neuropsychological Test Battery, MMSE), patient's global functioning (CDR-SB,CGI), patient's behaviour (NPI), daily living activities (ADCS-ADL) and caregiver's burden. Population PK of EHT 0202 and PK/PD profile.","Exonhit","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EHT0202/002","April 2008","June 2009","August 2009","April 13, 2009",,"September 21, 2009","Hôpital Privé Les Magnolias, Ballainvilliers, France|Cabinet Médical, Bergerac, France|Fleyriat Hospital, Bourg en Bresse, France|Cabinet Médical, Dijon, France|Charles Foix Hospital, Ivry sur Seine, France|Cabinet Médical, La Seyne sur Mer, France|Roger Salengro Hospital, Lille, France|Dupuytren Hospital, Limoges, France|Clinique Léopold Bellan, Magnanville, France|Cabinet Médical, Montpellier, France|Cabinet Médical 2, Montpellier, France|CHU Nantes Hôpital Laennec, Nantes, France|Cabinet Médical 2, Nice, France|Cabinet Médical, Nice, France|CHU Cochin Broca, Paris, France|Cabinet Médical, Rambouillet, France|CHU Rennes, Rennes, France|Cabinet Médical, Rodez, France|Cabinet Médical, Rueil Malmaison, France|Cabinet Médical, Saint Brieuc, France|Cabinet Médical, Toulon, France|Purpan-Casselardit Hospital - University of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00880412"
515,"NCT00056628","COGNIShunt® System for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Device: The COGNIShunt® System",,"Eunoe|National Institute on Aging (NIA)","All","62 Years to 85 Years   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","IA0040|Eunoe protocol ID 2000-01|IDE G970117","January 2001",,"October 2004","March 20, 2003",,"September 12, 2006",,,"https://ClinicalTrials.gov/show/NCT00056628"
516,"NCT00348309","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease","REFLECT-2","Completed","Has Results","Alzheimer's Disease","Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo|Other: Donepezil","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48|Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Screening in Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD)|Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility|Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48|Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48|Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48|Change in CDR-SB Total Score at Week 54 Compared to Week 48|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48|Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP)|Mean Change From Baseline in Heart Rate|Mean Change From Baseline in Weight|Change From Baseline in Hemoglobin Values|Change From Baseline in Hematocrit Values|Mean Change From Baseline in Short Term Memory Assessment Score|Change From Baseline in HbA1c at Week 12, Week 24 and Week 36|Number of Participants With Laboratory Potential Clinical Concern (PCC) Values|Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score","GlaxoSmithKline","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1496","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVA102672","July 6, 2006","January 1, 2009","January 28, 2009","July 4, 2006","November 28, 2017","November 28, 2017","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Sherman Oaks, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Nutley, New Jersey, United States|GSK Investigational Site, Princeton, New Jersey, United States|GSK Investigational Site, Stratford, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, South Ogden, Utah, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Godoy Cruz, Mendoza, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Belo Horizonte, Brazil|GSK Investigational Site, Ribeirão Preto, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Medicine Hat, Alberta, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Whitby, Ontario, Canada|GSK Investigational Site, Charlottetown, Prince Edward Island, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 7, Czechia|GSK Investigational Site, Angoulême, France|GSK Investigational Site, Arcachon, France|GSK Investigational Site, Avignon, France|GSK Investigational Site, Bourg en Bresse, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Issy Les Moulineaux, France|GSK Investigational Site, Ivry, France|GSK Investigational Site, Luynes, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pau, France|GSK Investigational Site, Pessac, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Rennes, France|GSK Investigational Site, Rodez, France|GSK Investigational Site, Saint Jean de Luz, France|GSK Investigational Site, Saint Ouen la Rouerie, France|GSK Investigational Site, Saint-Etienne, France|GSK Investigational Site, Saint-Nicolas de Port, France|GSK Investigational Site, Tinteniac, France|GSK Investigational Site, Tours, France|GSK Investigational Site, Verny, France|GSK Investigational Site, Vichy, France|GSK Investigational Site, Boeblingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Neuburg / Donau, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Bockhorn, Niedersachsen, Germany|GSK Investigational Site, Ganderkesee, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Lueneburg, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Remscheid, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Varanasi, India|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice a Cancello Caserta, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Ancona, Marche, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, Arezzo, Toscana, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kochi, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Elche (Alicante), Spain|GSK Investigational Site, Galdakano, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, San Sebastián, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Zuerich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00348309"
517,"NCT01224106","A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104|Part 3: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104|Time to Onset of Dementia|Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104|Mean Change from Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104|Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104|Mean Change From Baseline in CDR-Global Score at Week 104|Mean Change from Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104|Percent Change from Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [p-tau], Amyloid Beta 1-42 [Abeta 1-42], Total tau [t-tau]) at Week 104|Percent Change from Baseline in Hippocampal Volume at Week 104|Percent Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 104|Gantenerumab Plasma Concentration at Different Time Points|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104","Hoffmann-La Roche","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","799","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN25203|2010-019895-66","November 30, 2010","August 28, 2020","August 28, 2020","October 19, 2010",,"August 7, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Yale University ADRU, New Haven, Connecticut, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Roskamp Institute, Inc., Sarasota, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Neurological Research Center, Hattiesburg, Mississippi, United States|CRI Lifetree Marlton, Marlton, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Hospital Italiano, Buenos Aires, Argentina|IME - Instituto Médico Especializado; Ensayos Clínicos, Buenos Aires, Argentina|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, Argentina|CEMIC, Buenos Aires, Argentina|Mulieris, Caba, Argentina|Instituto De Neurología Cognitiva - INECO, Caba, Argentina|FLENI, Caba, Argentina|Instituto Kremer, Córdoba, Argentina|CENPIA; Neurología - Psicología, La Plata, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Prince of Wales Hospital, Academic Department for Old Age Psychiatry, Randwick, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital das Clinicas - UFPR; Ciencias da Saude, Curitiba, PR, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Universidade Federal de Sao Paulo - UNIFESP; Neurologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Psiquiatria, Sao Paulo, SP, Brazil|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Neurological and Psychiatric, Montreal, Quebec, Canada|CHAUQ - Hôpital Enfant-Jésus, Quebec City, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|CIMN Centro de Investigaciones Medicas Neurologicas, Viña De Mar, Chile|St. Anne´s University Hospital; Clinical Trials Department, Brno, Czechia|Fakultní Nemocnice Olomouc; Neurologicka Klinika, Olomouc, Czechia|Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Turku Hospital; PET (Positron Emission Tomography) Center, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU De Caen; Service De Neurologie Dejerine, Caen, France|Hopital B Roger Salengro; Cmrr Lille, Lille, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital de La Grave, Toulouse, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit Abt.Gerontopsychiatrie, Mannheim, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Office of Dr Klaus Steinwachs Neurology & Psychiatry, Nürnberg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Rambam Medical Center, Haifa, Israel|Sheba Medical Center; Psychiatry Department, Ramat Gan, Israel|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Universita' Di Parma Istituto Neurologia, Parma, Emilia-Romagna, Italy|Azienda Ospedaliera Spedali Civili; Scienze Neurologiche, Brescia, Lombardia, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Irccs Ospedale Maggiore Policlinico Di Milano; Scienze Neurologiche, Milano, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, Italy|Uni Di Firenze Dip. Scienze Neurol Psic Sod Neurologia 1, Firenze, Toscana, Italy|Azienda Ospedaliera Universitaria Integrata; Neuroscienze Centro Alzheimer e Disturbi Cognitivi, Verona, Veneto, Italy|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Mexico Americano, Guadalajara, Mexico|Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia, Guadalajara, Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|Centro Medico San Francisco; Geriatrics, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Jeroen Bosch Ziekenhuis; Polikliniek Geriatrie, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy Klinika Psychiatrii, Bydgoszcz, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Sverdlovsk Regional Clinical Psychoneurological War Veteran Hospital, Ekaterinburg, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Clinico Universitario San Carlos; Servicio de Geriatria, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|HUG; Département de santé mentale et de psychiatrie Unité de psychiatrie gériatrique, Chêne-Bourg, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Addenbrooke's Hospital, Cambridge, United Kingdom|Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building, Cardiff, United Kingdom|St Margaret's Hospital, Epping, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Campus for Ageing & Vitality; Clincal Ageing Research Unit, Newcastle, United Kingdom|John Radcliffe Hospital; Nuffield dept. Of medicine, Oxford, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom|Hollins Park Hospital, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01224106"
518,"NCT00581867","Memory and Insulin in Early Alzheimer's Disease","MAIN","Completed","Has Results","Alzheimer's Disease","Drug: Insulin Aspart|Drug: Placebo","fMRI Measure of Hippocampal Activation|Global Cognition","Jeff Burns, MD|University of Kansas Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","10896","October 2007","May 2012","May 2012","December 28, 2007","July 14, 2015","July 14, 2015","University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00581867"
519,"NCT01193608","Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: AAB-003 (PF-05236812)|Other: Placebo","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Laboratory Abnormalities|Number of Participants With Vital Signs of Potential Clinical Concern|Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Abnormal Neurological Examination Findings|Maximum Observed Serum Concentration (Cmax) for AAB-003 at Day 1|Maximum Observed Serum Concentration (Cmax) for AAB-003 at at Week 26|Average Concentration (Cavg) for AAB-003 in Serum at Day 1|Average Concentration (Cavg) for AAB-003 in Serum at Week 26|Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Day 1|Time to Reach Maximum Observed Serum Concentration (Tmax) for AAB-003 at Week 26|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Day 1|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for AAB-003 in Serum at Week 26|Systemic Clearance (CL) for AAB-003 in Serum at Day 1|Systemic Clearance (CL) for AAB-003 in Serum at Week 26|Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Day 1|Volume of Distribution at Steady State (Vss) for AAB-003 in Serum at Week 26|Serum Decay Half-Life (t1/2) for AAB-003 at Day 1|Serum Decay Half-Life (t1/2) for AAB-003 at Week 26|Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants With New Occurrence of Brain Magnetic Resonance Imaging (MRI) Finding|Number of Participants With Vasogenic Edema of All Severity After Each Infusion Visit|Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarization Criteria","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2601001|3245K1-1000","September 2010","October 2013","October 2013","September 2, 2010","February 23, 2017","February 23, 2017","Early Phase Investigational Center, Escondido, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Franck's Pharmacy, Ocala, Florida, United States|Munroe Regional Medical Center, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Imaging of Ocala, Ocala, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|KNI/Southwest Michigan Imaging Center, LLC, Kalamazoo, Michigan, United States|Brentwood Behavioral Healthcare, Flowood, Mississippi, United States|Marty's Pharmacy, Flowood, Mississippi, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|DePaul Health Center, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmacare USA, Edison, New Jersey, United States|Central Jersey Radiology, Oakhurst, New Jersey, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Seoul National University Bundang Hospital, Department of Neurology, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Department of Neurology, Incheon, Korea, Republic of|Samsung Medical Center, Department of Neurology, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Department of Neurology, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01193608"
520,"NCT01094340","Thalidomide for Patients With Mild to Moderate Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Thalidomide","Improve cognition","Banner Health","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1R01AG034155-01","March 2010","December 2012","January 2013","March 26, 2010",,"August 8, 2012","Banner Sun Health Research Institute, Sun City, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01094340"
521,"NCT01049555","Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research","09-PP-06","Completed","No Results Available","Alzheimer's Disease","Other: Actigraphy and video recording signal","assessment of motricity|video recording","Centre Hospitalier Universitaire de Nice","All","65 Years and older   (Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-PP-06","September 2011","September 2012","December 2012","January 14, 2010",,"September 30, 2015","Nice University Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT01049555"
522,"NCT00905372","Effect of LY2062430 on the Progression of Alzheimer's Disease","EXPEDITION","Completed","No Results Available","Alzheimer's Disease","Drug: LY2062430|Drug: Placebo","Change from baseline to endpoint in Alzheimer's Disease Assessment Scale—Cognitive subscore (ADAS-Cog11)|Change from baseline to endpoint in Alzheimer's Disease Cooperative Study—Activities of Daily Living Inventory (ADCS-ADL)|Change from baseline to endpoint in Clinical Dementia Rating—Sum of Boxes (CDR-SB)|Change from baseline to endpoint in Neuropsychiatric Inventory (NPI)|Change from baseline to endpoint in volumetric magnetic resonance imaging (vMRI)|Change from baseline to endpoint in Mini-Mental State Examination (MMSE)|Change from baseline to endpoint in Resource Utilization in Dementia—Lite (RUD-Lite)|Change from baseline to endpoint in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy)|Change from baseline to endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)|Change from baseline to endpoint in plasma LY2062430 to investigate a relationship between plasma LY2062430 and plasma A Beta levels.|Change from baseline to endpoint in plasma A Beta","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6747|H8A-MC-LZAM","May 2009","April 2012","April 2012","May 20, 2009",,"September 25, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuscon, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfield, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange City, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Canton, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Rapids, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Traverse City, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orangeburg, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pueyrredon Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itapira, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medicine Hat, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00905372"
523,"NCT00165724","Alzheimer's Disease Long-term Follow-up Study (ALF Study)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil Hydrochloride","ADAS-cog|MMSE, CDR, GDS, NPI, ADL, SSDQ","Eisai Korea Inc.|Eisai Inc.","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 4","114","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EKI-1002","June 2004","July 2006","December 2006","September 14, 2005",,"May 4, 2012","Bobath Memorial Hospital, Bundang, Korea, Republic of|Bundang Seoul National University Hospital, Bundang, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic University Hospital, Seoul, Korea, Republic of|Eulji University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00165724"
524,"NCT01369225","Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: AAB-003 (PF-05236812)","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern|Number of Participants With Potentially Clinically Important Vital Sign Findings|Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Findings|Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Abnormal Neurological Examination Findings|Number of Participants With Suicidal Ideation or Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Any New Magnetic Resonance Imaging (MRI) Findings","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2601003","July 2011","August 2014","August 2014","June 8, 2011","March 10, 2017","March 10, 2017","MD Clinical, Hallandale Beach, Florida, United States|Munroe Regional Medical Center, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Trinity Care Solutions, Ocala, Florida, United States|Advanced Imaging of Ocala, Ocala, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|KNI Southwest Michigan Imaging Center, LLC, Kalamazoo, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|DePaul Health Center-MRI Department, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Central Jersey Radiology, Oakhurst, New Jersey, United States|Seoul National University Hospital, Department Neurology, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Department of Neurology, Incheon, Korea, Republic of|Samsung Medical Center, Department of Neurology, Seoul, Korea, Republic of|Korea University Anam Hospital IRB, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Department of Neurology, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01369225"
525,"NCT01019421","Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Lu AE58054|Drug: Placebo","Change in cognition after 24 weeks|Change in global function, activities of daily living, safety and tolerability, pharmacokinetics/pharmacodynamics","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 2","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12936A|EudraCT 2009-011845-24","December 2009","December 2011",,"November 25, 2009",,"January 6, 2012","AU004, East Gosford, Australia|AU002, Heidelberg West, Australia|AU005, Kew, Australia|AU001, Nedlands, Australia|AU003, Woodville South, Australia|CA005, Toronto, Ontario, Canada|CA007, Burlington, Canada|CA006, Calgary, Canada|CA008, Gatineau, Canada|CA011, Kamloops, Canada|CA002, Kingston, Canada|CA010, Penticton, Canada|CA004, Sherbrooke, Canada|CA001, Toronto, Canada|CZ001, Kladno, Czech Republic|CZ002, Kutna Hora, Czech Republic|CZ007, Litomerice, Czech Republic|CZ004, Praha 8, Czech Republic|CZ005, Praha, Czech Republic|CZ008, Praha, Czech Republic|CZ006, Praha, Czech Republic|CZ003, Rychnov nad Kneznou, Czech Republic|DE004, Ellwangen, Germany|DE003, Erbach, Germany|DE005, Frankfurt am Main, Germany|DE002, Gunzburg, Germany|DE001, Homburg, Germany|DE006, Leipzig, Germany|DE009, Munich, Germany|DE007, Unterhaching, Germany|IT001, Brescia, Italy|IT005, Brescia, Italy|IT008, Firenze, Italy|IT003, Genova, Italy|IT004, Lamezia Terme, Italy|IT007, Milano, Italy|IT002, Roma, Italy|PL002, Bydgoszcz, Poland|PL001, Krakow, Poland|PL007, Lublin, Poland|PL003, Sopot, Poland|PL009, Szczecin, Poland|PL005, Warszawa, Poland|PL004, Warszaw, Poland|PL008, Warszaw, Poland|ES002, Barcelona, Spain|ES003, Elche, Spain|ES004, Madrid, Spain|ES005, Madrid, Spain|ES006, Majadahonda, Spain|ES001, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT01019421"
526,"NCT02377206","Neuroinflammation and Cognitive Decline in Alzheimer Disease","NICAD","Unknown status","No Results Available","Alzheimer Disease","Other: ADAS-Cog evaluation","Change from baseline in ADAS-Cog score|Quantification of neuroinflammation by [18F]DPA-714 PET imaging","University Hospital, Tours","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRTS13-CH / NICAD","March 2015","March 2017","March 2017","March 3, 2015",,"June 23, 2015","University hospital of Caen, Caen, France|university hospital of Nantes, Nantes, France|University Hospital of Rennes, Rennes, France|University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02377206"
527,"NCT00829374","Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil","CONCERT","Completed","No Results Available","Alzheimer's Disease","Drug: Dimebon|Drug: Placebo comparator","Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input (CIBIC-plus)|Neuropsychiatric Inventory (NPI)|Resource Utilization in Dementia Lite (RUD lite)|Euro Quality of Life 5 (EQ-5D)","Medivation, Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","1003","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DIM18","March 2009","December 2011","December 2011","January 27, 2009",,"September 27, 2016","Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Encino, California, United States|Escondido, California, United States|Fresno, California, United States|Garden Grove, California, United States|La Jolla, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Martinez, California, United States|Newport, California, United States|Paramount, California, United States|Pasadena, California, United States|San Diego, California, United States|San Francisco, California, United States|Boulder, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Eaton, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Las Vegas, Nevada, United States|Mt Arlington, New Jersey, United States|Princeton, New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Beachwood, Ohio, United States|Toledo, Ohio, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Middleton, Wisconsin, United States|Newcastle, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Antwerp, Belgium|Leuven, Belgium|Sint-Truiden, Belgium|Kuppio, Finland|Oulu, Finland|Turku, Finland|Bordeaux, France|Concert, France|Lille, France|Montpellier, France|Nice, France|Toulouse, France|Berlin, Germany|Bochum, Germany|Freiburg, Germany|Hattingen, Germany|Mannheim, Germany|Munich, Germany|Brescia, Italy|Florence, Italy|Genoa, Italy|Perugia, Italy|Rome, Italy|Christchurch, Canterbury, New Zealand|Auckland, New Zealand|Malmo, Sweden|Norrkoping, Sweden|Stockholm, Sweden|Brentford, Middlesex, United Kingdom|Rushden, Northhamptonshire, United Kingdom|Glasgow, Scotland, United Kingdom|Worthington, West Sussex, United Kingdom|Bath, United Kingdom|Blackpool, United Kingdom|Bradford, United Kingdom|Greater Manchester, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Norfolk, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00829374"
528,"NCT00571025","Risk Evaluation and Education for Alzheimer's Disease","REVEAL I","Completed","No Results Available","Alzheimer's Disease","Behavioral: APOE Disclosure","Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES)|Future Attitudes Scale (FAS)|Positive and Negative Affect Schedule (PANAS)","National Human Genome Research Institute (NHGRI)|National Institute on Aging (NIA)","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","301","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IA0126|5R01HG002213","August 2000",,"April 2004","December 11, 2007",,"July 23, 2009","Boston University School of Medicine, Boston, Massachusetts, United States|Weill Medical College of Cornell University, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00571025"
529,"NCT01254773","Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease","SUMMIT AD","Completed","No Results Available","Alzheimer's Disease","Drug: Experimental Bapineuzumab","To evaluate the effect of bapineuzumab administered subcutaneously (SC) at monthly intervals compared to placebo on cerebral amyloid burden in subjects with mild to moderate AD.|To assess the safety of bapineuzumab administered SC at monthly intervals compared to placebo in subjects with mild to moderate AD|To assess the effect of bapineuzumab administered SC at monthly intervals compared to placebo on cognitive and functional endpoints.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAB-001-SC-ALZ-2003","December 2010","January 2013","March 2013","December 7, 2010",,"May 9, 2014","Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, La Habra, California, United States|Janssen AI Investigational Site, Lomita, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Oceanside, California, United States|Janssen AI Investigational Site, Pasadena, California, United States|Janssen AI Investigational Site, Santa Monica, California, United States|Janssen AI Investigational Site, Sherman Oaks, California, United States|Janssen AI Investigational Site, Deerfield Beach, Florida, United States|Janssen AI Investigational Site, Delray Beach, Florida, United States|Janssen AI Investigational Site, Fort Meyers, Florida, United States|Janssen AI Investigational Site, Miami Springs, Florida, United States|Janssen AI Investigational Site, South Miami, Florida, United States|Janssen AI Investigational Site, Atlanta, Georgia, United States|Janssen AI Investigational Site, Indianapolis, Indiana, United States|Janssen AI Investigational Site, Kansas City, Kansas, United States|Janssen AI Investigational Site, Lexington, Kentucky, United States|Janssen AI Investigational Site, Plymouth, Massachusetts, United States|Janssen AI Investigational Site, Farmington Hills, Michigan, United States|Janssen AI Investigational Site, Creve Coeur, Missouri, United States|Janssen AI Investigational Site, St. Louis, Missouri, United States|Janssen AI Investigational Site, Latham, New York, United States|Janssen AI Investigational Site, Winston-Salem, North Carolina, United States|Janssen AI Investigational Site, Dayton, Ohio, United States|Janssen AI Investigational Site, Portland, Oregon, United States|Janssen AI Investigational Site, Philadelphia, Pennsylvania, United States|Janssen AI Investigational Site, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01254773"
530,"NCT00818662","A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease",,"Completed","Has Results","Alzheimer´s Disease","Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg","Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination|Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test|Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class|Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class|Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)|Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits|Number of Participants Experiencing a Clinically Significant Rash","Baxalta now part of Shire|Alzheimer's Disease Cooperative Study (ADCS)|Shire","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 3","390","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","160701","December 2008","December 2012","December 2012","January 8, 2009","October 28, 2014","November 24, 2017","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Irvine, California, United States|La Jolla, California, United States|Los Angeles, California, United States|National City, California, United States|Orange, California, United States|New Haven, Connecticut, United States|Washington, D.C., District of Columbia, United States|Miami Beach, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Burlington, Massachusetts, United States|Paw Paw, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Liverpool, New York, United States|New York, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|North Charleston, South Carolina, United States|Franklin, Tennessee, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Madison, Wisconsin, United States|Vancouver, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00818662"
531,"NCT00888056","Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Procedure: Bilateral chronic electrical stimulation of the hypothalamus/fornix","Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event.|Efficacy will be evaluated using numerous cognitive and memory testing. Neuro-imaging changes after stimulation will be evaluate by morphological MRI and functional imaging (PET). Changes in behavioral and mood scales: evaluate safety","Centre Hospitalier Universitaire de Nice","All","50 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-PP-01","June 2009",,,"April 24, 2009",,"June 27, 2012","CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT00888056"
532,"NCT01018875","Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-288|Drug: donepezil|Drug: placebo","ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion|MMSE: Mini Mental Status Exam|NPI: Neuropsychiatric Inventory|ADCS-ADL: Alzheimer's Disease Cooperative Study|CIBIC-Plus: Clinician Interview-Baed Impression of Change - plus","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-822|2009-010704-29","December 2009","February 2011","February 2011","November 24, 2009",,"June 5, 2018","Site Reference ID/Investigator# 22687, Kazan, Russian Federation|Site Reference ID/Investigator# 22636, Moscow, Russian Federation|Site Reference ID/Investigator# 23702, Moscow, Russian Federation|Site Reference ID/Investigator# 22689, Saratov, Russian Federation|Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22633, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22637, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22632, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22634, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 24563, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22630, Dnipropetrovs'k, Ukraine|Site Reference ID/Investigator# 22625, Donetsk, Ukraine|Site Reference ID/Investigator# 22624, Glevakha, Ukraine|Site Reference ID/Investigator# 22629, Kharkiv, Ukraine|Site Reference ID/Investigator# 24565, Kherson, Ukraine|Site Reference ID/Investigator# 24566, Kiev, Ukraine|Site Reference ID/Investigator# 22622, Kiev, Ukraine|Site Reference ID/Investigator# 22623, Kiev, Ukraine|Site Reference ID/Investigator# 22628, Lugansk, Ukraine|Site Reference ID/Investigator# 43143, Odessa, Ukraine|Site Reference ID/Investigator# 22627, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01018875"
533,"NCT01117948","Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.",,"Terminated","Has Results","Alzheimer´s Disease","Drug: Lornoxicam|Drug: Placebo","Cognitive Performance - ADAS-cog+|Activities of Daily Living - ADCS-ADL; Behavioral/Psychiatric Symptoms - NPI","JSW Lifesciences","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","219","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR081101/CO14950","September 2009","April 2011","April 2011","May 6, 2010","November 29, 2012","February 6, 2013",,,"https://ClinicalTrials.gov/show/NCT01117948"
534,"NCT02788513","BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: BI 425809 dose 1|Drug: BI 425809 dose 2|Drug: BI 425809 dose 3|Drug: BI 425809 dose 4|Drug: Placebo","The change from baseline in ADAS-Cog11 (Alzheimer's Disease Assessment Scale-Cognitive subscale 11 item) total score|Change from baseline in the ADCS-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living) score|CIBIC+ (Clinician's Interview-Based Impression of Change) score","Boehringer Ingelheim","All","55 Years and older   (Adult, Older Adult)","Phase 2","611","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1346.23|2015-005438-24","August 11, 2016","September 12, 2019","October 18, 2019","June 2, 2016",,"September 30, 2019","Axiom Research LLC, Colton, California, United States|Alliance for Wellness, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Santa Ana, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Miami, Florida, United States|Premier Clinical Research Institute, Miami, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Bioclinica Research, The Villages, Florida, United States|Neuro Trials Research Incorporated, Atlanta, Georgia, United States|Millennium Psychiatric Associates LLC, Saint Louis, Missouri, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Northeastern Pennsylvania Memory and Alzheimer Center, Plains, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|The Memory Clinic, Bennington, Vermont, United States|LKH-Univ. Hospital Graz, Graz, Austria|Medical University of Innsbruck, Innsbruck, Austria|SALK Christian-Doppler-Klinik,Paracel.Med.Privatuni.f.Neurol, Salzburg, Austria|Private Practice for Psychiatry and Neurology, Vienna, Austria|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc., Kentville, Nova Scotia, Canada|Bluewater Clinical Research, Sarnia, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Clinique Neuro-Outaouais, Gatineau, Quebec, Canada|Diex Recherche, Sherbrooke, Quebec, Canada|Orton, Helsinki, Finland|University of Eastern Finland, Brain Research Unit, Kuopio, Finland|Terveystalo Lahti, Lahti, Finland|OYS, Neurologian tutkimusyksikkö, Oulu, Finland|CRST - Clinical Research Services Turku, Turku, Finland|HOP Pellegrin, Bordeaux, France|HOP Pierre Wertheimer, Bron, France|HOP Roger Salengro, Lille, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|CHU La Grave-Casselardit - Cité de la Santé, Toulouse, France|HOP de Brabois, Vandoeuvre les Nancy, France|HOP des Charpennes, Villeurbanne, France|Zentrum für klinische Forschung Dr. med. Irma Schöll & Kollegen, Bad Homburg, Germany|Praxis Dr. med. Volker Schumann, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Praxis Dr. Oehlwein, Gera, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Pharmakologisches Studienzentrum Chemnitz, Mittweida, Germany|Institut für Psychogerontologie, Nürnberg, Germany|Neuropraxis München Süd, Unterhaching, Unterhaching, Germany|Naval Hospital of Athens, Athens, Greece|Eginition Hospital, Athens, Greece|University General Hospital Attikon, Athens, Greece|Athens Medical Center, Athens, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Semmelweis University, Budapest, Hungary|CRU Ltd, Neurology Dept., Miskolc, Miskolc, Hungary|University of Szeged, Szeged, Hungary|IRCCS Fondazione Ospedale Maggiore, Milano, Italy|A.O. San Gerardo di Monza, Monza (MB), Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fujita Health University Hospital, Aichi, Toyoake, Japan|Inage Neurology and Memory Clinic, Chiba, Chiba, Japan|Sapporo Medical University Hospital, Hokkaido, Sapporo, Japan|Kagawa University Hospital, Kagawa, Kita-gun, Japan|Kawashima Neurology Clinic, Kanagawa, Fujisawa, Japan|Ishikawa Clinic, Kyoto, Kyoto, Japan|Nara Medical University Hospital, Nara, Kashihara, Japan|Katayama Medical Clinic, Okayama, Kurashiki, Japan|National Hospital Organization Hizen Psychiatric Center, Saga, Kanzaki-gun, Japan|National Center Neurology and Psychiatry, Tokyo, Kodaira, Japan|Nozomi Memory Clinic, Tokyo, Mitaka, Japan|Showa University East Hospital, Tokyo, Shinagawa, Japan|Oslo Universitetssykehus HF, Hukommelsesklinikken, Oslo, Norway|St. Olavs Hospital, Universitetssykehuset i Trondheim, Trondheim, Norway|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Non-Public Outpat. Clinic ""Dom Sue Ryder"", PALLMED Sp. z o.o, Bydgoszcz, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Clin.Research Centre Clinsante SC Ewa Galczak-Nowak,Torun, Torun, Poland|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Sant Joan de Deu de Manresa, Manresa, Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Royal Cornhill Hospital, Aberdeen, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Warneford Hospital, Oxford, United Kingdom|Sheffield Memory Service, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02788513"
535,"NCT00749216","Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Solanezumab","Adverse events|Changes in the extended ADAS-Cog stand for Alzheimer's Disease Assessment Scale-Cognitive subscale|pharmacodynamic of Aβ1-40 and Aβ1-42|Pharmacokinetics","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12025|H8A-JE-LZAK","September 2008","July 2009","July 2009","September 9, 2008",,"June 2, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT00749216"
536,"NCT00658125","Deep Brain Stimulation (DBS) for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Procedure: Bilateral fornix DBS implantation,","memory performance on neuropsychological tests","University Health Network, Toronto","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-0095-B","March 1, 2007","June 30, 2010","June 30, 2010","April 14, 2008",,"September 27, 2019","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00658125"
537,"NCT00230568","EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Aricept","FOME (Fuld Object Memory Evaluation); SDMT (Symbol Digit Modalities Test); NPI (Neuropsychiatric Inventory); MMSE (the Mini-Mental State Examination).","Eisai Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2020-A001-413","December 2005","April 2007","December 2007","October 3, 2005",,"April 1, 2011","21st Century Neurology, Phoenix, Arizona, United States|Alzheimer's Disease and Cognitive Disorders Clinic at Barrow Neurology Institute, Phoenix, Arizona, United States|Pacific Sleep Medicine Services, Inc., El Centro, California, United States|Pacific Sleep Medicine Services, Inc., Los Angeles, California, United States|Pacific Sleep Medicine Services, Inc., San Diego, California, United States|Parkinson's Disease Movement Disorders Center - Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Eastern Research, Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Cuervo Research Group, Miami, Florida, United States|Seth Hochman, MD, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Ocala Neurodiagnostic Center, Ocala, Florida, United States|Memory Disorder Center, Pompano Beach, Florida, United States|Liliana Montoya, MD, Port Charlotte, Florida, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Northwestern Alzheimer's Center, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Lozano, Cosme, MD, Joliet, Illinois, United States|University of Nevada School of Medicine,, Las Vegas, Nevada, United States|ClinSearch Inc., Kenilworth, New Jersey, United States|University of New Mexico School of Medicine, Department of Psychiatry, Albuquerque, New Mexico, United States|New York University School of Medicine, Aging and Dementia Research Center, New York, New York, United States|The Burke Rehabilitation Hospital, White Plains, New York, United States|North Carolina Neuropsychiatry, PA, Charlotte, North Carolina, United States|Clinical Research Associates, Inc., Oklahoma City, Oklahoma, United States|Clinical Research Center, Jenkintown, Pennsylvania, United States|The Penn Ralston Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Mental Sciences Insitute, Houston, Texas, United States|Christopher Ticknor, MD, San Antonio, Texas, United States|University of Texas, Health Science Center-San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00230568"
538,"NCT00804271","Memantine and Validation of a New Alzheimer's Disease Scale",,"Completed","No Results Available","Alzheimer's Disease","Drug: memantine","Validation of new scale regarding content, reliability and responsiveness for DAT symptoms|Assessment of treatment response and correlation of new scale against ADAScog, SIB, NPI, DAD.","Merz Pharmaceuticals GmbH","All","50 Years and older   (Adult, Older Adult)","Phase 3","487","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","MRZ 90001/AD/3001|EudraCT No. 2008-005144-16","December 2008","November 2009","November 2009","December 8, 2008",,"February 22, 2013","University Clinic Gustav Carus, Dresden, Saxony, Germany",,"https://ClinicalTrials.gov/show/NCT00804271"
539,"NCT01238991","Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Biological: ACC-001","Number of Treatment Emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","52 Years to 87 Years   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2571001|3134K1-2207","December 2010","December 2013","December 2013","November 11, 2010","December 22, 2014","December 22, 2014","Meitetsu Hospital, Nagoya, Aichi, Japan|Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan|Shonan Atsugi Hospital, Atsugi, Kanagawa, Japan|Kitasato University East Hospital, Sagamihara-shi, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Koto-ku, Tokyo, Japan|The Tokyo Jikei University School of Medicine, Minato-ku, Tokyo, Japan|Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01238991"
540,"NCT00698165","Observational Study on Costs and Caregiver Burden in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,"Mini-Mental State Examination (MMSE), Disability Assessment for Dementia Scale (DAD), Neuropsychiatric Inventory Questionnaire (NPI-Q)|Resource Utilization in Dementia (RUD)|Short Form - 12 domains instrument (SF-12)|World Health Organization Quality of Life instrument (WHO-QoL)|Zarit Caregiver Burden Interview (ZBI)|15 domains Quality of Life Index instrument (15D)","AstraZeneca|i3 Innovus","All","Child, Adult, Older Adult",,"2400","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EHE 1100","June 2007",,"January 2009","June 17, 2008",,"February 20, 2009","Research Site, Northport, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Brentwood, California, United States|Research Site, Fresno, California, United States|Research Site, LaHabra, California, United States|Research Site, Long Beach, California, United States|Research Site, Denver, Colorado, United States|Research Site, Wetherfield, Connecticut, United States|Research Site, Atlantis, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Titusville, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Canton, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Snellville, Georgia, United States|Research Site, Belleville, Illinois, United States|Research Site, Ft Wayne, Indiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Eaton Rapids, Michigan, United States|Research Site, St. Louis, Missouri, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Beaufort, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Port Arthur, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Witchita Falls, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Gig Harbor, Washington, United States|Research Site, Richland, Washington, United States|Research Site, Cruces, Barakaldo, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, Madrid, Spain|Research Site, Seville, Spain|Research Site, Bergsjo, Sweden|Research Site, Bromma, Sweden|Research Site, Jonkoping, Sweden|Research Site, Karlstad, Sweden|Research Site, Kristianstad, Sweden|Research Site, Lomma, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Ornskoldsvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Uppsala, Sweden|Research Site, Varberg, Sweden|Research Site, Overton, Basingstoke, United Kingdom|Research Site, Eastbourne, East Sussex, United Kingdom|Research Site, Coney Hill, Gloucester, United Kingdom|Research Site, Barnet, Hertfordshire, United Kingdom|Research Site, Wood Green, London, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Chester, United Kingdom|Research Site, Hove, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Romsey, United Kingdom|Research Site, Salisbury, United Kingdom|Research Site, Stanmore, United Kingdom|Research Site, Uckfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00698165"
541,"NCT00996918","A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients",,"Terminated","Has Results","Alzheimer Disease","Drug: Bapineuzumab 0.5 mg/kg|Drug: Bapineuzumab 1.0 m/kg","Number of Participants Reporting a Serious Adverse Event.|Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78|Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.|Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.|Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.|Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.","Pfizer","All","51 Years and older   (Adult, Older Adult)","Phase 3","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3133K1-3002|B2521003","December 2009","November 2012","November 2012","October 16, 2009","January 1, 2014","January 1, 2014","Pfizer Investigational Site, Hornsby, New South Wales, Australia|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Heidelberg Heights, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Caen, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Nantes - Saint Herblain, France|Pfizer Investigational Site, Nice, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Poitiers, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Aichi, Japan|Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Hyogo, Japan|Pfizer Investigational Site, Kagawa, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Nagano, Japan|Pfizer Investigational Site, Okayama, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Tokyo, Japan|Pfizer Investigational Site, 's-Hertogenbosch, Netherlands|Pfizer Investigational Site, Leeuwarden, Netherlands|Pfizer Investigational Site, North Shore, NZ, New Zealand|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Amadora, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Rimavska Sobota, Slovakia|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Terrasa, Barcelona, Spain|Pfizer Investigational Site, Plasencia, Caceres, Spain|Pfizer Investigational Site, Palma de Mallorca, Islas Baleares, Spain|Pfizer Investigational Site, Palma de Mallorca, Islas Baleares, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Burgos, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Basel, BS, Switzerland|Pfizer Investigational Site, Brighton, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom|Pfizer Investigational Site, Penarth, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00996918"
542,"NCT00580931","Safety Study of Nicotinamide to Treat Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Nicotinamide|Drug: Enduramide placebo","Alzheimer's Disease Assessment Scale-Cognitive Subscale","University of California, Irvine|Alzheimer's Association","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIRG-07-61197","January 2008","July 2014","July 2014","December 27, 2007",,"January 25, 2017","UC Irvine School of Medicine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT00580931"
543,"NCT00369603","Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Razadyne ER|Drug: Aricept","Brain activity patterns, as collected via functional magnetic resonance imaging (fMRI), at rest and associated with task performance after 4 weeks of low-dose treatment and after 8-weeks of higher-dose treatment.|Differences in cognitive testing and functional status at pre-treatment baseline and after completion of the 12-week treatment trial.","Duke University|Ortho-McNeil Neurologics, Inc.","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 4","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00011149|GAL-EMR-4026","October 2006","October 2007","November 2007","August 29, 2006",,"April 11, 2013","Joseph & Kathleen Bryan Alzheimer's Disease Research Unit, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00369603"
544,"NCT00948909","Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Placebo|Drug: ABT-126|Drug: donepezil","ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion|MMSE, QoL-AD, CIBIC-plus, NPI, CSDD, ADAS-Cog (13 item) and ADCS-ADL. Note: Acronyms are fully defined in the area titled Detailed Description.","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-984|2009-011424-64","October 2009","November 2010","November 2010","July 29, 2009",,"January 31, 2013","Site Reference ID/Investigator# 19904, Fresno, California, United States|Site Reference ID/Investigator# 23025, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 19905, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 22944, Pleven, Bulgaria|Site Reference ID/Investigator# 22942, Plovdiv, Bulgaria|Site Reference ID/Investigator# 22945, Sofia, Bulgaria|Site Reference ID/Investigator# 22946, Sofia, Bulgaria|Site Reference ID/Investigator# 20276, Litomerice, Czech Republic|Site Reference ID/Investigator# 20273, Plzen, Czech Republic|Site Reference ID/Investigator# 20274, Prague 10, Czech Republic|Site Reference ID/Investigator# 20272, Prague 2, Czech Republic|Site Reference ID/Investigator# 20701, Prague 5, Czech Republic|Site Reference ID/Investigator# 23625, Bratislava, Slovakia|Site Reference ID/Investigator# 23624, Bratislava, Slovakia|Site Reference ID/Investigator# 23622, Michalovce, Slovakia|Site Reference ID/Investigator# 23942, Rimavska Sobota, Slovakia|Site Reference ID/Investigator# 20267, Belville, South Africa|Site Reference ID/Investigator# 20266, Cape Town, South Africa|Site Reference ID/Investigator# 20261, Durban, South Africa|Site Reference ID/Investigator# 21682, George, South Africa|Site Reference ID/Investigator# 20265, Johannesburg, South Africa|Site Reference ID/Investigator# 20271, Port Elizabeth, South Africa|Site Reference ID/Investigator# 20263, Richards Bay, South Africa|Site Reference ID/Investigator# 20187, Blackburn, United Kingdom|Site Reference ID/Investigator# 20183, Bradford, United Kingdom|Site Reference ID/Investigator# 20191, Crowborough, United Kingdom|Site Reference ID/Investigator# 20184, Glasgow, United Kingdom|Site Reference ID/Investigator# 20190, London, United Kingdom|Site Reference ID/Investigator# 20192, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00948909"
545,"NCT00235716","A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","TEAM-AD","Completed","Has Results","Alzheimer's Disease","Drug: dl-alpha-tocopherol|Drug: Memantine|Drug: Placebo","Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline|Mini-Mental State Examination Change From Baseline|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline|Neuropsychiatric Inventory Change From Baseline|Caregiver Activity Survey Change From Baseline|Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level)","US Department of Veterans Affairs|Forest Laboratories|DSM Nutritional Products, Inc.|VA Office of Research and Development","All","40 Years and older   (Adult, Older Adult)","Phase 3","613","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","546","August 2007","September 2012","October 2012","October 10, 2005","January 29, 2014","July 23, 2014","VA Medical Center, Bay Pines, Bay Pines, Florida, United States|VA Medical Center, Miami, Miami, Florida, United States|VA Medical Center, Iowa City, Iowa City, Iowa, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|VA Medical Center, Minneapolis, Minneapolis, Minnesota, United States|Salisbury VAMC, Salisbury, North Carolina, United States|VA Medical Center, Cleveland, Cleveland, Ohio, United States|Ralph H Johnson VA Medical Center, Charleston, Charleston, South Carolina, United States|VA North Texas Health Care System, Dallas, Dallas, Texas, United States|VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States|Wlliam S. Middleton Memorial Veterans Hospital, Madison, Madison, Wisconsin, United States|VA Medical Center, San Juan, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00235716"
546,"NCT00684944","Open Label Study of TRx0014 in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: TRx0014","Cognitive ability measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and by the Mini-Mental State Examination (MMSE).|Dementia severity assessed by the Clinical Dementia Rating - sum of the boxes (CDR-sb).|Daily living activities assessed by the Alzheimer's Disease functional Assessment and Change Scale (ADFACS)","TauRx Therapeutics Ltd","All","Child, Adult, Older Adult","Phase 2","111","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRx-014-009","September 13, 2007","December 2, 2010","December 2, 2010","May 28, 2008",,"April 27, 2018",,,"https://ClinicalTrials.gov/show/NCT00684944"
547,"NCT00018473","Gene-Environment Interactions in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,,"US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult",,,"U.S. Fed","Observational",,"EPID-006-98F","April 1999",,"March 2004","July 5, 2001",,"January 21, 2009","VAMC- Bedford (Station 518), Bedford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00018473"
548,"NCT00933608","Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: memantine|Drug: Placebo","N-acetylaspartate","NYU Langone Health|Forest Laboratories","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 4","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NAM-MD-68","July 2009","September 2011","September 2011","July 7, 2009","October 21, 2014","October 21, 2014","NYU School of Medicine, Dept. of Psychiatry, Center for Brain Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00933608"
549,"NCT00384423","Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept",,"Completed","No Results Available","Alzheimer's Disease","Drug: PRX-03140","Safety and tolerability of PRX-03140 during 2 weeks of treatment.|Electroencephalogram (EEG) changes through 14 days of treatment.|Changes in cognition after 2 weeks of treatment.|Blood concentrations of PRX-03140 and Aricept during 14 days of treatment.","Epix Pharmaceuticals, Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PRX-CP-018","October 2006","October 2007",,"October 6, 2006",,"January 30, 2008","California Clinical Trials Medical Group, Inc, Paramount, California, United States|Southwest CLinical Research, Rancho Mirage, California, United States|Pacific Research Network, Inc, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Torrance Clinical Research, Torrance, California, United States|Research Center for Clinical Studies, Darien, Connecticut, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Berma Research, Plantation, Florida, United States|Meridien Research, St Petersburg, Florida, United States|Comprehensive NeuroScience, Inc, St. Petersburg, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Neurology Specialists, Dayton, Ohio, United States|Saint Johns Office Building, Tulsa, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Alliance for Neuro Research, LLC, Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00384423"
550,"NCT00998764","A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients",,"Terminated","Has Results","Alzheimer Disease","Drug: Bapineuzumab 0.5 mg/kg","Number of Participants Reporting a Serious Adverse Event|Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78|Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Extension Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.|Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.|Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.|Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.|Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.","Pfizer","All","51 Years to 90 Years   (Adult, Older Adult)","Phase 3","494","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3133K1-3003|B2521004|2009-015080-13","December 2009","October 2012","November 2012","October 20, 2009","January 1, 2016","January 1, 2016","University Of Alabama at Birmingham, Birmingham, Alabama, United States|UAB Center for Psychiatric Medicine, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center (Imaging, Phoenix, Arizona, United States|Jeffrey S. Gitt, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologist, PC, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Infusion Center, Greenwich Hospital, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich Hospital, Greenwich, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research LLC, Atlantis, Florida, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Southwest Florida Infusion Care, Inc., Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Neuroscience Research Institute, LLC, Lawrenceville, Georgia, United States|Neurostudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Southern Illinois University School of Medicine Department, Springfield, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Neurological Research Center of Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corp./Merician Institute for Aging, Manchester, New Jersey, United States|Toms River X-Ray, CT & MRI, Toms River, New Jersey, United States|MDR, LiverPool, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|Carolina Neuropsychological Services, Inc., Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State Unviersity, Columbus, Ohio, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Providence Brain Institute-Cognitive Assessment Clinic, Portland, Oregon, United States|Providence Brain Institute, Portland, Oregon, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Bington Memorial Hospital, Abington, Pennsylvania, United States|Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Gosford Hospital; Pharmacy Dept, Gosford, New South Wales, Australia|Hornsby Hospital, Hornsby, New South Wales, Australia|Royal Adelaide Memory Trials Centre, Adelaide, South Australia, Australia|Memory Unit 5C, Department of Neurology, Woodville South, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|Hollywood Hospital; Pharmacy Dept, Nedlands, Western Australia, Australia|The McCusker Foundation for Alzheimer's Disease Research, Nedlands, Western Australia, Australia|ZNA Middelheim, Antwerpen, Belgium|AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Psicomedica Research Group, Santiago, Chile|Ita-Suomen Yliopisto, Kuopio, Finland|University of Turku/CRST, Turku, Finland|CHU Hôpital Pellegrin-Tripode, Bordeaux, France|Hopital Neurologique, Bron, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|Hôpital Roger Salengro, Lille, France|Hôpital la Timone, Marseille cedex 5, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez, Nice, France|Hôpital Pitié-Salpétrière, Paris, France|CHU La Milétrie, Poitiers, France|C.H.U de Reims, Reims, France|Department de Radiologie et d'Imagerie Medicale, Hopital Pontchaillou, Rennes Cedex 9, France|CHRU Hôtel Dieu, Rennes, France|Centre Hospitalier Universitaire Charles Nicolle, Rouen Cedex, France|Hôpital Purpan, Toulouse, France|CHU Purpan - Hôpital Casselardit, Toulouse, France|Sezione di Neurologia - Dipartimento di Neuroscienze, Ancona, Italy|Dipartimento di Neuroscienze,, Catania, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|Yachiyo Hospital, Aichi, Japan|National Hospital Organization Chiba-East Hospital, Chiba-shi, Japan|Kashiwado Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Tokyo National Hospital, Tokyo, Japan|Geriatry, 's-HERTOGENBOSCH, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|The Memory Clinic Limited, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Signet Research, Christchurch, New Zealand|Pallmed Spolka z o.o., Bydgoszcz, Poland|MCD Voxel, Poznan, Poland|NZOZ Neuro-kard, Poznan, Poland|Pracownia Rezonansu Magnetycznego, Warszawa, Poland|SP ZOZ Szpital Wolski, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Lisboa, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrasa, Terrasa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital del Mar, Barcelona, Spain|Fundacio ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Clinica CIMA, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Malmo University Hospital, Malmo, Sweden|Minnes- och geriatrikmottagningen, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Memory Service North, Grenoside Grange Hospital, Grenoside, Sheffield, United Kingdom|Llandough Hospital, Universtity Hospital of Wales, Cardiff, Wales, United Kingdom|MAC UK Neuroscience Ltd., Bradford, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|The Doctors Laboratory Ltd., London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Victoria Hospital, Swindon, United Kingdom|Alliance Medical, Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00998764"
551,"NCT01066546","An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Dimebon tablet for oral administration","Number of Participants With Adverse Events (AEs)|Change From Baseline in Severe Impairment Battery (SIB) at Week 6, 12 and 26|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Version (ADCS-ADLsev) at Week 6, 12 and 26|Change From Baseline in Mini-Mental State Examination (MMSE) at Week 12 and 26|Change From Baseline in Neuropsychiatric Inventory (NPI) at Week 6, 12 and 26|Sum of Delusions and Hallucinations Sub-domain Scores of Neuropsychiatric Inventory (NPI) at Week 26|Change From Baseline in Resource Utilization in Dementia - Lite Version (RUD-Lite) at Week 12 and 26|Change From Baseline in European Quality of Life 5 Domain Scale (EQ-5D) at Week 12 and 16","Pfizer|Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1451030","April 2010","July 2010","July 2010","February 10, 2010","October 2, 2012","October 2, 2012","Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Delray Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01066546"
552,"NCT01129596","Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-",,"Completed","No Results Available","Alzheimer's Disease","Drug: donepezil hydrochloride","The transition of clinical condition is evaluated comparing the result of HDS-R,MMSE with the time of study initiation","Eisai Co., Ltd.|Eisai Inc.","All","Child, Adult, Older Adult",,"10238","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ART05T","June 10, 2010","September 25, 2015","June 23, 2016","May 24, 2010",,"November 5, 2018","Aisai, Aichi, Japan|Chita, Aichi, Japan|Gamagori, Aichi, Japan|Handa, Aichi, Japan|Ichinomiya, Aichi, Japan|Inazawa, Aichi, Japan|Inuyama, Aichi, Japan|Kariya, Aichi, Japan|Kasugai, Aichi, Japan|Komaki, Aichi, Japan|Konan, Aichi, Japan|Nagoya, Aichi, Japan|Nishio, Aichi, Japan|Nisshin, Aichi, Japan|Obu, Aichi, Japan|Okazaki, Aichi, Japan|Owariasahi, Aichi, Japan|Seto, Aichi, Japan|Shinshiro, Aichi, Japan|Tahara, Aichi, Japan|Tokai, Aichi, Japan|Tokoname, Aichi, Japan|Toyoake, Aichi, Japan|Toyohashi, Aichi, Japan|Toyokawa, Aichi, Japan|Toyota, Aichi, Japan|Yatomi, Aichi, Japan|Daisen, Akita, Japan|Katagami, Akita, Japan|Odate, Akita, Japan|Oga, Akita, Japan|Semboku, Akita, Japan|Yokote, Akita, Japan|Yurihonjo, Akita, Japan|Yuzawa, Akita, Japan|Goshogawara, Aomori, Japan|Hachinohe, Aomori, Japan|Hirosaki, Aomori, Japan|Kamikita, Aomori, Japan|Kitatsugaru, Aomori, Japan|Mutsu, Aomori, Japan|Sannohe, Aomori, Japan|Towada, Aomori, Japan|Abiko, Chiba, Japan|Asahi, Chiba, Japan|Choshi, Chiba, Japan|Funabashi, Chiba, Japan|Ichihara, Chiba, Japan|Ichikawa, Chiba, Japan|Inzai, Chiba, Japan|Isumi, Chiba, Japan|Kashiwa, Chiba, Japan|Katori, Chiba, Japan|Kimitsu, Chiba, Japan|Kisarazu, Chiba, Japan|Matsudo, Chiba, Japan|Mobara, Chiba, Japan|Nagareyama, Chiba, Japan|Narita, Chiba, Japan|Sakura, Chiba, Japan|Sambu, Chiba, Japan|Sammu, Chiba, Japan|Tateyama, Chiba, Japan|Togane, Chiba, Japan|Yachimata, Chiba, Japan|Yachiyo, Chiba, Japan|Yotsukaido, Chiba, Japan|Imabari, Ehime, Japan|Iyo, Ehime, Japan|Kamiukena, Ehime, Japan|Matsuyama, Ehime, Japan|Minamiuwa, Ehime, Japan|Niihama, Ehime, Japan|Ozu, Ehime, Japan|Saijo, Ehime, Japan|Seiyo, Ehime, Japan|Shikokuchuo, Ehime, Japan|Toon, Ehime, Japan|Uwajima, Ehime, Japan|Yawatahama, Ehime, Japan|Echizen, Fukui, Japan|Katsuyama, Fukui, Japan|Mikatakaminaka, Fukui, Japan|Obama, Fukui, Japan|Sabae, Fukui, Japan|Sakai, Fukui, Japan|Tsuruga, Fukui, Japan|Asakura, Fukuoka, Japan|Chikugo, Fukuoka, Japan|Chikushino, Fukuoka, Japan|Chikushi, Fukuoka, Japan|Fukutsu, Fukuoka, Japan|Iizuka, Fukuoka, Japan|Itoshima, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kasuya, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Miyako, Fukuoka, Japan|Miyama, Fukuoka, Japan|Nakama, Fukuoka, Japan|Nogata, Fukuoka, Japan|Ogori, Fukuoka, Japan|Omuta, Fukuoka, Japan|Onga, Fukuoka, Japan|Onojo, Fukuoka, Japan|Tagawa, Fukuoka, Japan|Ukiha, Fukuoka, Japan|Yanagawa, Fukuoka, Japan|Yukuhashi, Fukuoka, Japan|Aizuwakamatsu, Fukushima, Japan|Date, Fukushima, Japan|Futaba, Fukushima, Japan|Higashishirakawa, Fukushima, Japan|Ishikawa, Fukushima, Japan|Iwaki, Fukushima, Japan|Kitakata, Fukushima, Japan|Koriyama, Fukushima, Japan|Nihonmatsu, Fukushima, Japan|Onuma, Fukushima, Japan|Soma, Fukushima, Japan|Sukagawa, Fukushima, Japan|Tamura, Fukushima, Japan|Yama, Fukushima, Japan|Ena, Gifu, Japan|Gujo, Gifu, Japan|Hashima, Gifu, Japan|Minokamo, Gifu, Japan|Mizuho, Gifu, Japan|Nakatsugawa, Gifu, Japan|Ogaki, Gifu, Japan|Seki, Gifu, Japan|Tajimi, Gifu, Japan|Takayama, Gifu, Japan|Toki, Gifu, Japan|Yamagata, Gifu, Japan|Fujioka, Gumma, Japan|Isesaki, Gumma, Japan|Kiryu, Gumma, Japan|Kitagumma, Gumma, Japan|Maebashi, Gumma, Japan|Numata, Gumma, Japan|Ora, Gumma, Japan|Ota, Gumma, Japan|Shibukawa, Gumma, Japan|Takasaki, Gumma, Japan|Tatebayashi, Gumma, Japan|Tomioka, Gumma, Japan|Tone, Gumma, Japan|Aki, Hiroshima, Japan|Fuchu, Hiroshima, Japan|Fukuyama, Hiroshima, Japan|Higashihiroshima, Hiroshima, Japan|Kure, Hiroshima, Japan|Mihara, Hiroshima, Japan|Miyoshi, Hiroshima, Japan|Onomichi, Hiroshima, Japan|Otake, Hiroshima, Japan|Shobara, Hiroshima, Japan|Takehara, Hiroshima, Japan|Abashiri, Hokkaido, Japan|Akkeshi, Hokkaido, Japan|Asahikawa, Hokkaido, Japan|Ashibetsu, Hokkaido, Japan|Bibai, Hokkaido, Japan|Chitose, Hokkaido, Japan|Date, Hokkaido, Japan|Ebetsu, Hokkaido, Japan|Eniwa, Hokkaido, Japan|Fukagawa, Hokkaido, Japan|Furano, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Hiroo, Hokkaido, Japan|Hokuto, Hokkaido, Japan|Ishikari, Hokkaido, Japan|Iwamizawa, Hokkaido, Japan|Kameda, Hokkaido, Japan|Kamikawa, Hokkaido, Japan|Kato, Hokkaido, Japan|Kawakami, Hokkaido, Japan|Kitami, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Mombetsu, Hokkaido, Japan|Muroran, Hokkaido, Japan|Nakagawa, Hokkaido, Japan|Nayoro, Hokkaido, Japan|Noboribetsu, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Otaru, Hokkaido, Japan|Rumoi, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Shibetsu, Hokkaido, Japan|Sorachi, Hokkaido, Japan|Soya, Hokkaido, Japan|Sunagawa, Hokkaido, Japan|Tomakomai, Hokkaido, Japan|Yoichi, Hokkaido, Japan|Yufutsu, Hokkaido, Japan|Akashi, Hyogo, Japan|Ako, Hyogo, Japan|Amagasaki, Hyogo, Japan|Asago, Hyogo, Japan|Ashiya, Hyogo, Japan|Awaji, Hyogo, Japan|Himeji, Hyogo, Japan|Itami, Hyogo, Japan|Kakogawa, Hyogo, Japan|Kako, Hyogo, Japan|Kasai, Hyogo, Japan|Kato, Hyogo, Japan|Kawabe, Hyogo, Japan|Kawanishi, Hyogo, Japan|Kobe, Hyogo, Japan|Miki, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Sanda, Hyogo, Japan|Shiso, Hyogo, Japan|Sumoto, Hyogo, Japan|Takarazuka, Hyogo, Japan|Takasago, Hyogo, Japan|Tamba, Hyogo, Japan|Tatsuno, Hyogo, Japan|Toyooka, Hyogo, Japan|Yabu, Hyogo, Japan|Bando, Ibaraki, Japan|Chikusei, Ibaraki, Japan|Higashiibaraki, Ibaraki, Japan|Hitachinaka, Ibaraki, Japan|Hitachiota, Ibaraki, Japan|Hitachi, Ibaraki, Japan|Inashiki, Ibaraki, Japan|Ishioka, Ibaraki, Japan|Joso, Ibaraki, Japan|Kamisu, Ibaraki, Japan|Kasama, Ibaraki, Japan|Koga, Ibaraki, Japan|Mito, Ibaraki, Japan|Moriya, Ibaraki, Japan|Naka, Ibaraki, Japan|Ryugasaki, Ibaraki, Japan|Sashima, Ibaraki, Japan|Takahagi, Ibaraki, Japan|Toride, Ibaraki, Japan|Tsuchiura, Ibaraki, Japan|Tsukubamirai, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Ushiku, Ibaraki, Japan|Yuki, Ibaraki, Japan|Hakusan, Ishikawa, Japan|Kahoku, Ishikawa, Japan|Kanazawa, Ishikawa, Japan|Komatsu, Ishikawa, Japan|Nanao, Ishikawa, Japan|Suzu, Ishikawa, Japan|Wajima, Ishikawa, Japan|Hanamaki, Iwate, Japan|Ichinoseki, Iwate, Japan|Kamaishi, Iwate, Japan|Kitakami, Iwate, Japan|Miyako, Iwate, Japan|Morioka, Iwate, Japan|Ninohe, Iwate, Japan|Oshu, Iwate, Japan|Tono, Iwate, Japan|Ayauta, Kagawa, Japan|Kanonji, Kagawa, Japan|Kita, Kagawa, Japan|Marugame, Kagawa, Japan|Mitoyo, Kagawa, Japan|Sakaide, Kagawa, Japan|Sanuki, Kagawa, Japan|Shozu, Kagawa, Japan|Takamatsu, Kagawa, Japan|Aira, Kagoshima, Japan|Amami, Kagoshima, Japan|Hioki, Kagoshima, Japan|Ibusuki, Kagoshima, Japan|Ichikikushikino, Kagoshima, Japan|Izumi, Kagoshima, Japan|Kanoya, Kagoshima, Japan|Kirishima, Kagoshima, Japan|Makurazaki, Kagoshima, Japan|Minamikyushu, Kagoshima, Japan|Nishinomote, Kagoshima, Japan|Satsumasendai, Kagoshima, Japan|Satsuma, Kagoshima, Japan|Shibushi, Kagoshima, Japan|Soh, Kagoshima, Japan|So, Kagoshima, Japan|Ashigarashimo, Kanagawa, Japan|Atsugi, Kanagawa, Japan|Chigasaki, Kanagawa, Japan|Ebina, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Hiratsuka, Kanagawa, Japan|Isehara, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Miura, Kanagawa, Japan|Naka, Kanagawa, Japan|Odawara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yamato, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Zama, Kanagawa, Japan|Aki, Kochi, Japan|Muroto, Kochi, Japan|Nagaoka, Kochi, Japan|Nankoku, Kochi, Japan|Takaoka, Kochi, Japan|Amakusa, Kumamoto, Japan|Arao, Kumamoto, Japan|Aso, Kumamoto, Japan|Hitoyoshi, Kumamoto, Japan|Kamiamakusa, Kumamoto, Japan|Kamimashiki, Kumamoto, Japan|Koshi, Kumamoto, Japan|Minamata, Kumamoto, Japan|Tamana, Kumamoto, Japan|Uki, Kumamoto, Japan|Yamaga, Kumamoto, Japan|Yatsushiro, Kumamoto, Japan|Fukuchiyama, Kyoto, Japan|Joyo, Kyoto, Japan|Kameoka, Kyoto, Japan|Kizugawa, Kyoto, Japan|Kyotanabe, Kyoto, Japan|Maizuru, Kyoto, Japan|Nagaokakyo, Kyoto, Japan|Nantan, Kyoto, Japan|Soraku, Kyoto, Japan|Tsuzuki, Kyoto, Japan|Uji, Kyoto, Japan|Yosa, Kyoto, Japan|Iga, Mie, Japan|Ise, Mie, Japan|Kameyama, Mie, Japan|Kumano, Mie, Japan|Kuwana, Mie, Japan|Matsusaka, Mie, Japan|Suzuka, Mie, Japan|Tsu, Mie, Japan|Watarai, Mie, Japan|Yokkaichi, Mie, Japan|Ishinomaki, Miyagi, Japan|Iwanuma, Miyagi, Japan|Kesennuma, Miyagi, Japan|Kurihara, Miyagi, Japan|Kurokawa, Miyagi, Japan|Natori, Miyagi, Japan|Osaki, Miyagi, Japan|Oshika, Miyagi, Japan|Sendai, Miyagi, Japan|Shibata, Miyagi, Japan|Shiogama, Miyagi, Japan|Toda, Miyagi, Japan|Tome, Miyagi, Japan|Higashimorokata, Miyazaki, Japan|Hyuga, Miyazaki, Japan|Kobayashi, Miyazaki, Japan|Koyu, Miyazaki, Japan|Kushima, Miyazaki, Japan|Miyakonojo, Miyazaki, Japan|Nichinan, Miyazaki, Japan|Nishiusuki, Miyazaki, Japan|Nobeoka, Miyazaki, Japan|Saito, Miyazaki, Japan|Azumino, Nagano, Japan|Chikuma, Nagano, Japan|Chino, Nagano, Japan|Hanishina, Nagano, Japan|Higashichikuma, Nagano, Japan|Iida, Nagano, Japan|Ina, Nagano, Japan|Kamiminochi, Nagano, Japan|Kiso, Nagano, Japan|Kitaazumi, Nagano, Japan|Kitasaku, Nagano, Japan|Komagane, Nagano, Japan|Komoro, Nagano, Japan|Matsumoto, Nagano, Japan|Okaya, Nagano, Japan|Saku, Nagano, Japan|Shimoina, Nagano, Japan|Shiojiri, Nagano, Japan|Suwa, Nagano, Japan|Suzaka, Nagano, Japan|Ueda, Nagano, Japan|Goto, Nagasaki, Japan|Higashisonogi, Nagasaki, Japan|Isahaya, Nagasaki, Japan|Kitamatsuura, Nagasaki, Japan|Minamishimabara, Nagasaki, Japan|Nishisonogi, Nagasaki, Japan|Omura, Nagasaki, Japan|Sasebo, Nagasaki, Japan|Shimabara, Nagasaki, Japan|Tsushima, Nagasaki, Japan|Unzen, Nagasaki, Japan|Gose, Nara, Japan|Ikoma, Nara, Japan|Kashiba, Nara, Japan|Kashihara, Nara, Japan|Kitakatsuragi, Nara, Japan|Sakurai, Nara, Japan|Tenri, Nara, Japan|Uda, Nara, Japan|Yamatokoriyama, Nara, Japan|Yamatotakada, Nara, Japan|Yoshino, Nara, Japan|Gosen, Niigata, Japan|Joetsu, Niigata, Japan|Kashiwazaki, Niigata, Japan|Minamiuonuma, Niigata, Japan|Mitsuke, Niigata, Japan|Murakami, Niigata, Japan|Nagaoka, Niigata, Japan|Ojiya, Niigata, Japan|Sado, Niigata, Japan|Sanjo, Niigata, Japan|Shibata, Niigata, Japan|Uonuma, Niigata, Japan|Hita, Oita, Japan|Kunisaki, Oita, Japan|Kusu, Oita, Japan|Nakatsu, Oita, Japan|Saiki, Oita, Japan|Tsukumi, Oita, Japan|Usa, Oita, Japan|Usuki, Oita, Japan|Yufu, Oita, Japan|Akaiwa, Okayama, Japan|Asakuchi, Okayama, Japan|Bizen, Okayama, Japan|Kaga, Okayama, Japan|Kasaoka, Okayama, Japan|Kume, Okayama, Japan|Kurashiki, Okayama, Japan|Mimasaka, Okayama, Japan|Niimi, Okayama, Japan|Soja, Okayama, Japan|Takahashi, Okayama, Japan|Tamano, Okayama, Japan|Tomata, Okayama, Japan|Tsuyama, Okayama, Japan|Ginowan, Okinawa, Japan|Ishigaki, Okinawa, Japan|Itoman, Okinawa, Japan|Kunigami, Okinawa, Japan|Miyakojima, Okinawa, Japan|Naha, Okinawa, Japan|Nakagami, Okinawa, Japan|Nanjo, Okinawa, Japan|Tomigusuku, Okinawa, Japan|Urasoe, Okinawa, Japan|Uruma, Okinawa, Japan|Daito, Osaka, Japan|Fujiidera, Osaka, Japan|Habikino, Osaka, Japan|Hannan, Osaka, Japan|Higashiosaka, Osaka, Japan|Hirakata, Osaka, Japan|Ibaraki, Osaka, Japan|Ikeda, Osaka, Japan|Izumiotsu, Osaka, Japan|Izumisano, Osaka, Japan|Izumi, Osaka, Japan|Kadoma, Osaka, Japan|Kaizuka, Osaka, Japan|Kashiwara, Osaka, Japan|Katano, Osaka, Japan|Kawachinagano, Osaka, Japan|Kishiwada, Osaka, Japan|Matsubara, Osaka, Japan|Mino, Osaka, Japan|Moriguchi, Osaka, Japan|Neyagawa, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Sennan, Osaka, Japan|Settsu, Osaka, Japan|Suita, Osaka, Japan|Takaishi, Osaka, Japan|Takatsuki, Osaka, Japan|Tondabayashi, Osaka, Japan|Toyonaka, Osaka, Japan|Toyono, Osaka, Japan|Yao, Osaka, Japan|Imari, Saga, Japan|Kanzaki, Saga, Japan|Karatsu, Saga, Japan|Kishima, Saga, Japan|Nishimatsuura, Saga, Japan|Ogi, Saga, Japan|Takeo, Saga, Japan|Taku, Saga, Japan|Tosu, Saga, Japan|Ureshino, Saga, Japan|Ageo, Saitama, Japan|Asaka, Saitama, Japan|Chichibu, Saitama, Japan|Fujimino, Saitama, Japan|Fujimi, Saitama, Japan|Fukaya, Saitama, Japan|Gyoda, Saitama, Japan|Hanno, Saitama, Japan|Hanyu, Saitama, Japan|Hasuda, Saitama, Japan|Hidaka, Saitama, Japan|Hiki, Saitama, Japan|Honjo, Saitama, Japan|Iruma, Saitama, Japan|Kasukabe, Saitama, Japan|Kawagoe, Saitama, Japan|Kawaguchi, Saitama, Japan|Kazo, Saitama, Japan|Kitaadachi, Saitama, Japan|Kitamoto, Saitama, Japan|Konosu, Saitama, Japan|Koshigaya, Saitama, Japan|Kuki, Saitama, Japan|Kumagaya, Saitama, Japan|Minamisaitama, Saitama, Japan|Niiza, Saitama, Japan|Sakado, Saitama, Japan|Sayama, Saitama, Japan|Soka, Saitama, Japan|Toda, Saitama, Japan|Tokorozawa, Saitama, Japan|Tsurugashima, Saitama, Japan|Wako, Saitama, Japan|Yoshikawa, Saitama, Japan|Higashiomi, Shiga, Japan|Hikone, Shiga, Japan|Inukami, Shiga, Japan|Koka, Shiga, Japan|Kusatsu, Shiga, Japan|Moriyama, Shiga, Japan|Nagahama, Shiga, Japan|Omihachiman, Shiga, Japan|Otsu, Shiga, Japan|Ritto, Shiga, Japan|Takashima, Shiga, Japan|Hamada, Shimane, Japan|Izumo, Shimane, Japan|Kanoashi, Shimane, Japan|Matsue, Shimane, Japan|Nita, Shimane, Japan|Oda, Shimane, Japan|Unnan, Shimane, Japan|Yasugi, Shimane, Japan|Atami, Shizuoka, Japan|Fujieda, Shizuoka, Japan|Fujinomiya, Shizuoka, Japan|Fuji, Shizuoka, Japan|Fukuroi, Shizuoka, Japan|Gotemba, Shizuoka, Japan|Haibara, Shizuoka, Japan|Hamamatsu, Shizuoka, Japan|Ito, Shizuoka, Japan|Iwata, Shizuoka, Japan|Izu, Shizuoka, Japan|Kakegawa, Shizuoka, Japan|Kamo, Shizuoka, Japan|Kikugawa, Shizuoka, Japan|Kosai, Shizuoka, Japan|Mishima, Shizuoka, Japan|Numazu, Shizuoka, Japan|Omaezaki, Shizuoka, Japan|Shimada, Shizuoka, Japan|Shimoda, Shizuoka, Japan|Susono, Shizuoka, Japan|Tagata, Shizuoka, Japan|Ashikaga, Tochigi, Japan|Haga, Tochigi, Japan|Kanuma, Tochigi, Japan|Kawachi, Tochigi, Japan|Moka, Tochigi, Japan|Nasukarasuyama, Tochigi, Japan|Nasu, Tochigi, Japan|Nikko, Tochigi, Japan|Otawara, Tochigi, Japan|Oyama, Tochigi, Japan|Sano, Tochigi, Japan|Utsunomiya, Tochigi, Japan|Anan, Tokushima, Japan|Awa, Tokushima, Japan|Itano, Tokushima, Japan|Mima, Tokushima, Japan|Miyoshi, Tokushima, Japan|Myozai, Tokushima, Japan|Naka, Tokushima, Japan|Naruto, Tokushima, Japan|Yoshinogawa, Tokushima, Japan|Adachi, Tokyo, Japan|Akiruno, Tokyo, Japan|Akishima, Tokyo, Japan|Arakawa, Tokyo, Japan|Bunkyo, Tokyo, Japan|Chiyoda, Tokyo, Japan|Chofu, Tokyo, Japan|Chuo, Tokyo, Japan|Edogawa, Tokyo, Japan|Fuchu, Tokyo, Japan|Fussa, Tokyo, Japan|Hachioji, Tokyo, Japan|Higashiyamato, Tokyo, Japan|Hino, Tokyo, Japan|Inagi, Tokyo, Japan|Itabashi, Tokyo, Japan|Katsushika, Tokyo, Japan|Kita, Tokyo, Japan|Kiyose, Tokyo, Japan|Kodaira, Tokyo, Japan|Koganei, Tokyo, Japan|Kokubunji, Tokyo, Japan|Komae, Tokyo, Japan|Koto, Tokyo, Japan|Kunitachi, Tokyo, Japan|Machida, Tokyo, Japan|Meguro, Tokyo, Japan|Minato, Tokyo, Japan|Mitaka, Tokyo, Japan|Musashino, Tokyo, Japan|Nakano, Tokyo, Japan|Nerima, Tokyo, Japan|Nishitokyo, Tokyo, Japan|Ome, Tokyo, Japan|Ota, Tokyo, Japan|Setagaya, Tokyo, Japan|Shibuya, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku, Tokyo, Japan|Suginami, Tokyo, Japan|Sumida, Tokyo, Japan|Tachikawa, Tokyo, Japan|Tama, Tokyo, Japan|Toshima, Tokyo, Japan|Hino, Tottori, Japan|Iwami, Tottori, Japan|Kurayoshi, Tottori, Japan|Saihaku, Tottori, Japan|Sakaiminato, Tottori, Japan|Yazu, Tottori, Japan|Yonago, Tottori, Japan|Himi, Toyama, Japan|Imizu, Toyama, Japan|Nakaniikawa, Toyama, Japan|Namerikawa, Toyama, Japan|Nanto, Toyama, Japan|Takaoka, Toyama, Japan|Uozu, Toyama, Japan|Arida, Wakayama, Japan|Gobo, Wakayama, Japan|Ito, Wakayama, Japan|Iwade, Wakayama, Japan|Kainan, Wakayama, Japan|Kinokawa, Wakayama, Japan|Nishimuro, Wakayama, Japan|Tanabe, Wakayama, Japan|Nanyo, Yamagata, Japan|Sakata, Yamagata, Japan|Tendo, Yamagata, Japan|Tsuruoka, Yamagata, Japan|Yonezawa, Yamagata, Japan|Hagi, Yamaguchi, Japan|Hikari, Yamaguchi, Japan|Hofu, Yamaguchi, Japan|Iwakuni, Yamaguchi, Japan|Nagato, Yamaguchi, Japan|SanyoOnoda, Yamaguchi, Japan|Shimonoseki, Yamaguchi, Japan|Shunan, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Yanai, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Fuefuki, Yamanashi, Japan|Fujiyoshida, Yamanashi, Japan|Hokuto, Yamanashi, Japan|Kai, Yamanashi, Japan|Kofu, Yamanashi, Japan|Minamitsuru, Yamanashi, Japan|Nirasaki, Yamanashi, Japan|Otsuki, Yamanashi, Japan|Tsuru, Yamanashi, Japan|Aichi, Japan|Akita, Japan|Aomori, Japan|Chiba, Japan|Fukui, Japan|Fukuoka, Japan|Fukushima, Japan|Gifu, Japan|Hiroshima, Japan|Ishikawa, Japan|Iwate, Japan|Kagoshima, Japan|Kochi, Japan|Kumamoto, Japan|Kyoto, Japan|Mie, Japan|Miyagi, Japan|Miyazaki, Japan|Nagano, Japan|Nagasaki, Japan|Nara, Japan|Niigata, Japan|Oita, Japan|Okayama, Japan|Okinawa, Japan|Osaka, Japan|Saga, Japan|Saitama, Japan|Shizuoka, Japan|Tochigi, Japan|Tokushima, Japan|Tottori, Japan|Toyama, Japan|Wakayama, Japan|Yamagata, Japan|Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT01129596"
553,"NCT00120874","Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training",,"Completed","Has Results","Alzheimer's Disease","Behavioral: Individualized management of AD including caregiver training|Drug: Memantine","Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)|Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)|Change From Baseline of the Severe Impairment Battery (SIB)|Change From Baseline of the Mini-Mental State Examination (MMSE)|Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)|Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)|Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency|Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction","NYU Langone Health|Forest Laboratories|Fisher Center for Alzheimer's Research Foundation","All","50 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","H12444-01 A|NAM MD 18","August 2006","November 2011","November 2011","July 19, 2005","July 14, 2016","October 25, 2016","Fisher Alzheimer's Program, New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00120874"
554,"NCT02370524","Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease (AD)","Drug: [18F]T807","Quantitative evaluation of [18F]T807 as a potential PET radioligand for imaging Tau in patients with clinically characterized tauopathies","Molecular NeuroImaging|Institute for Neurodegenerative Disorders|Roche Pharma AG","All","20 Years to 90 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]T807","January 2015","January 2016","January 2016","February 25, 2015",,"March 8, 2017","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02370524"
555,"NCT00088387","Effect of Lithium and Divalproex in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Divalproex|Drug: Lithium",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","35","NIH","Interventional","Primary Purpose: Treatment","040243|04-N-0243","July 2004",,"March 2005","July 26, 2004",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00088387"
556,"NCT00955422","Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","45 Years and older   (Adult, Older Adult)",,"197","NIH","Observational","Time Perspective: Prospective","090198|09-M-0198","July 31, 2009",,"July 6, 2017","August 10, 2009",,"July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00955422"
557,"NCT00106899","ADNI: Alzheimer's Disease Neuroimaging Initiative",,"Completed","No Results Available","Alzheimer's Disease","Procedure: Magnetic Resonance Imaging (MRI)|Procedure: Positron Emission Tomography (PET)|Procedure: Lumbar Puncture (LP)",,"Alzheimer's Disease Cooperative Study (ADCS)|Northern California Institute of Research and Education|National Institute on Aging (NIA)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Foundation for the National Institutes of Health|Alzheimer’s Drug Discovery Foundation|Alzheimer's Association","All","55 Years to 90 Years   (Adult, Older Adult)",,"818","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IA0068|1RC2AG036535|1U01AG024904","July 2005","June 2011","June 2011","April 1, 2005",,"September 16, 2014","University of Alabama, Birmingham, Alabama, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Sun Health / Arizona Consortium, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, Irvine - Brain Imaging Center, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami, Florida, United States|Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Neurological Group, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center/Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Schools of Medicine and Public Health, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Dent Neurological Institute, Orchard Park, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Vancouver, British Columbia, Canada|Parkwood Hospital, London, Ontario, Canada|Saint Joseph's Hospital, London, Ontario, Canada|Sunnybrook and Women's College, Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada|Jewish Hospital Memory Clinic, Quebec, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00106899"
558,"NCT00960531","A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","Has Results","Alzheimer Disease","Biological: ACC-001+ QS21 (3mcg)|Biological: ACC-001 (10 mcg) + QS-21|Biological: ACC-001+QS-21 (30mcg)","Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-2205|B2571008","July 2009","December 2013","December 2013","August 17, 2009","April 1, 2016","April 1, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California - San Francisco, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|General Clinical Research Unit, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Brigham and Woman's Hospital, Boston, Massachusetts, United States|Center for Alzheimer Research and Treatment, Boston, Massachusetts, United States|Barnes Jewish Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Barnes Jewish Hospital at Washington University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Columbia University/Taub Institute, New York, New York, United States|CUMC Research Pharmacy, New York, New York, United States|Butler Hospital, Providence, Rhode Island, United States|Southwestern Vermont Healthcare, Bennington, Vermont, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Inc, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00960531"
559,"NCT01423396","Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease","COVARAD","Recruiting","No Results Available","Alzheimer's Disease|Cardiovascular Risk Factors","Other: optimal care of VRF|Other: standard care","ADAS-Cog|MMSE|MoCA|VADAS-Cog|Trail Making Test|ADL-ADCS|IADL|MADRS|NPI|Zarit Inventory of Burden","University Hospital, Lille|Ministry of Health, France","All","60 Years and older   (Adult, Older Adult)","Not Applicable","406","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2008_28/0914|2009-A00269-48|PHRC 2008/1925|B90419-40","March 15, 2010","March 2021","March 2021","August 25, 2011",,"February 15, 2019","CMRR Lille hopital Roger Salengro, Lille, France",,"https://ClinicalTrials.gov/show/NCT01423396"
560,"NCT00911807","Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease","Combi","Completed","Has Results","Alzheimer Disease","Drug: Cerebrolysin + donepezil|Drug: Cerebrolysin + placebo|Drug: Donepezil + placebo","Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28|Clinical Interview-Based Impression of Change (CIBIC+) Score|Change From Baseline for ADAS-COG+|ADAS-COG+ Responders|Change From Baseline for Original ADAS-COG|CIBIC+ Score|CIBIC+ Responders|Clinical Interview-Based Impression of Severity (CIBIS+) Score|Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)|Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)|Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+|Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])","Ever Neuro Pharma GmbH|acromion GmbH","All","51 Years and older   (Adult, Older Adult)","Phase 2","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EBE-031010","October 2004","April 2008","April 2008","June 2, 2009","June 2, 2009","June 10, 2009","Centro Geriátrico Fuente Salinas, Granada, Spain|EuroEspes Biomedical Research Centre, La Coruna, Spain|Clínica de Memoria, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT00911807"
561,"NCT00895895","Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",,"Terminated","Has Results","Alzheimer Disease","Drug: Placebo|Drug: SAM-531 1.5 mg|Drug: SAM-531 3.0 mg|Drug: SAM-531 5.0 mg|Drug: Donepezil","Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24|Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24|Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24|Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24|Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24|Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24|Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24|Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24|Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24|Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24|Change From Baseline in CANTAB SWM Strategy at Week 24|Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24|Change From Baseline in CANTAB PRM-Percentage Correct at Week 24|Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24|Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24|Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24|Change From Baseline in CANTAB RTI Simple Movement Time at Week 24|Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24|Percentage of Participants Who Were Responders at Week 24","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2","526","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3193A1-2005|B1961007","May 2009","May 2011","May 2011","May 8, 2009","January 31, 2013","January 31, 2013","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Oxnard, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, aTLANTIS, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Plantation, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Sunrise, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Cedarhurst, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Bennington, Vermont, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, C.a.b.a., Buenos Aires, Argentina|Pfizer Investigational Site, Caba, Buenos Aires, Argentina|Pfizer Investigational Site, Ciudad de Buenos Aires, Argentina|Pfizer Investigational Site, Ciudad de Buenos Aires, Argentina|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Vina del Mar, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Pereira, Risaralda, Colombia|Pfizer Investigational Site, Bucamaranga, Santander, Colombia|Pfizer Investigational Site, Cali, Valle, Colombia|Pfizer Investigational Site, Valle del Cauca, Colombia|Pfizer Investigational Site, Shatin, N.T., Hong Kong SAR, China, Hong Kong|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Hachioji, Tokyo, Japan|Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Kumamoto, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Nagano, Japan|Pfizer Investigational Site, Nagasaki, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Saltillo, Coahuila, Mexico|Pfizer Investigational Site, Aguascalientes, Mexico|Pfizer Investigational Site, Auckland, New Zealand|Pfizer Investigational Site, Hamilton, New Zealand|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Craiova, Dolj, Romania|Pfizer Investigational Site, Timisoara, Timis, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Nikolskoe village, Gatchina district, Leningrad region, Russian Federation|Pfizer Investigational Site, Kazan, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Novosibirsk, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, Yaroslavl, Russian Federation|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Bellville, Western Cape, South Africa|Pfizer Investigational Site, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT00895895"
562,"NCT00234637","Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine, memantine","The proportion of responders (cognitive function stable or improved) at the end of phase 2 (vs. end of phase 1).|Change in cognition at weeks 16 and 28 (end of period 1) compared to baseline|Change in caregiver burden at weeks 16 and 28 (end of period 1) compared to baseline|Change in behavior at weeks 16 and 28 (end of period 1) compared to baseline|Change in executive function at weeks 16 and 28 (end of period 1) compared to baseline","Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","204","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713BFR05","November 2003","June 2005","June 2005","October 7, 2005",,"November 17, 2011","Département de Gérontologie Clinique, Limoges, Cedex, France",,"https://ClinicalTrials.gov/show/NCT00234637"
563,"NCT00753662","Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","TMS in AD","Unknown status","No Results Available","Alzheimer's Disease","Device: 1Hz TMS with H2 coil|Device: 10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|Device: SHAM TMS with H2 coil","ADAS-COG|CGI-C, Neuropsychological computerized test (Mindstream),CGI-C,FAB,ADL, Beck Depression Inventory.","Tel-Aviv Sourasky Medical Center|Brainsway","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TASMC-08-AA-0397-CTIL","November 2008","November 2012","November 2012","September 16, 2008",,"September 13, 2011","Tel Aviv Sourasky Medical Center, Neurology Department, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00753662"
564,"NCT01362686","Comparative Research of Alzheimer's Disease Drugs","COMET-AD","Terminated","Has Results","Dementia|Alzheimer's Disease","Drug: Donepezil|Drug: Galantamine|Drug: Rivastigmine","Discontinuation Rates|Neuropsychiatric Inventory (NPI)|Healthy Aging Brain Care (HABC)-Monitor","Indiana University|Agency for Healthcare Research and Quality (AHRQ)","All","65 Years and older   (Older Adult)","Not Applicable","200","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HS019818-01","April 2011","October 2015","October 2015","May 30, 2011","February 27, 2017","February 27, 2017","Touchpoint, Fishers, Indiana, United States|Methodist Center for Geriatric Medicine, Indianapolis, Indiana, United States|University Clinical Neurology, Indianapolis, Indiana, United States|Wishard Health Services, Indianapolis, Indiana, United States|St. Vincent Center for Healthy Aging, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01362686"
565,"NCT03810794","Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment","Other: Acupuncture|Drug: Donepezil","Alzheimer's Disease Assessment Scale-cognition(ADAS-cog)|Minimum Mental State Examination(MMSE)|Alzheimer's Disease Cooperative Study-Activity of Daily Living(ADCS-ADL)|Quality of Life-Alzheimer's Disease(QOL-AD)","Shanghai University of Traditional Chinese Medicine|Shanghai Mental Health Center|Huashan Hospital","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","18401970500","March 1, 2019","March 30, 2021","September 30, 2021","January 21, 2019",,"March 7, 2019","LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China|Shanghai Mental Center, Shanghai Jiaotong University of Medicial School, Shanghai, Shanghai, China|Huashan Hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03810794"
566,"NCT01117818","Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: active: AFFITOPE AD02|Biological: control: Placebo","cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)|cognitive(computerised test battery), global(CDR-sb), behavioral(NPI), biomarker (volumetric MRI)","Affiris AG","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","335","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AFF006|2009-016504-22","September 2010","December 2013","December 2013","May 6, 2010",,"December 11, 2013","Landeskrankenhaus Hall Gedächtnisambulanz, Hall in Tirol, Austria|LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria|Christian Doppler Klinik, Univ. Klinik f. Neurologie, Salzburg, Austria|Studienzentrum der PROSENEX, Ambulatoriumbetriebsges.m.b.H an der Confraternität - Privatklinik Josefstadt, Vienna, Austria|MUW Klin. Pharmakologie und Klinik für Neurologie, Vienna, Austria|MUW, Klin.Abt.f. Biolog. Psychiatrie, Vienna, Austria|SMZ-Ost, Psychiatric Dep., Vienna, Austria|Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju, Rijeka, Croatia|Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia|""BONIFARM"" Poliklinika za kliničku farmakologiju i toksikologiju, Zagreb, Croatia|Klinčki Bolnički Centar Zagreb (REBRO), Klinika za Neurologiju, Zagreb, Croatia|Psihijatrijska Bolnica Vrapče, Zagreb, Croatia|University Thomayer Hospital, Praha 4, Czech Republic|University Hospital Motol, Clinic of Neurology, Praha 5, Czech Republic|CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard, Bordeaux Cedex, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France|Centre Mémoire de Ressources et de Recherche, Service de Neurologie, Montpellier Cedex 05, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU de rennes Site Hôtel Dieu, RENNES Cedex, France|Hopital La Grave, Toulouse, France|Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie, Berlin, Germany|Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie, Hamburg, Germany|Arzneimittelforschung Leipzig GmbH, Studienzentrum, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie, Mannheim, Germany|Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München, Munich, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany|Klinikum Nürnberg Nord, Klinik f. Psychiatrie u. Psychotherapie, Nürnberg, Germany|NeuroPoint GmbH, Ulm/Donau, Germany|EPAMED, s.r.o., Kosice, Slovakia|Psychiatric Hospital Michalovce, Michalovce, Slovakia",,"https://ClinicalTrials.gov/show/NCT01117818"
567,"NCT00939783","An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Dimebon","Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Abnormal Clinically Significant Vital Signs|Percentage of Participants With Abnormal Clinically Significant Laboratory Values|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings","Pfizer|Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","649","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1451029","September 2009","August 2010","August 2010","July 15, 2009","November 14, 2012","November 14, 2012","Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Northport, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Pueblo, Colorado, United States|Pfizer Investigational Site, Hockessin, Delaware, United States|Pfizer Investigational Site, Bradenton, Florida, United States|Pfizer Investigational Site, Brooksville, Florida, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Walton Beach, Florida, United States|Pfizer Investigational Site, Maitland, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Plant City, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Burr Ridge, Illinois, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Elkhart, Indiana, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Greenfield, Indiana, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Hyannis, Massachusetts, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Great Falls, Montana, United States|Pfizer Investigational Site, Eatontown, New Jersey, United States|Pfizer Investigational Site, Oakhurst, New Jersey, United States|Pfizer Investigational Site, Toms River, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Amherst, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Orchard Park, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Winston Salem, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Altoona, Pennsylvania, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Bridgeville, Pennsylvania, United States|Pfizer Investigational Site, Grove City, Pennsylvania, United States|Pfizer Investigational Site, Indiana, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Scotland, Pennsylvania, United States|Pfizer Investigational Site, Upper St. Clair, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Murrells Inlet, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Orangeburg, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Carrollton, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Grand Prairie, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, Williamsburg, Virginia, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Charleston, West Virginia, United States|Pfizer Investigational Site, La Crosse, Wisconsin, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Bay Roberts, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Kentville, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Cayey, Puerto Rico|Pfizer Investigational Site, Cidra, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00939783"
568,"NCT02471196","Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease","Nebula","Completed","No Results Available","Alzheimer's Disease","Drug: ORM-12741|Drug: Placebo","Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale|Efficacy on aggression/agitation symptoms and overall clinical status measured by Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change|Efficacy on cognitive symptoms measured by Cognitive Drug Research computerized test battery|Efficacy on daily living measured by Alzheimer's Disease Co-operative Study - Activities of Daily Living inventory|Safety measured by assessing adverse events|Plasma concentrations of ORM ORM-12741, metabolites and possible other Alzheimer's disease medication|Efficacy on aggression/agitation symptoms measured by Cohen Mansfield Agitation Inventory|Efficacy on cognitive symptoms measured by Alzheimer's Disease Assessment Scale|Safety measured by vital signs|Safety measured by electrocardiogram|Safety measured by laboratory variables","Orion Corporation, Orion Pharma|Janssen Pharmaceuticals","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3098012","August 14, 2015","October 9, 2017","December 4, 2017","June 15, 2015",,"February 15, 2018","Clinical Research Services Turku - CRST Oy, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT02471196"
569,"NCT00886951","Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: I123MNI388/I123MNI390","To determine the reliability of MNI 388/390 as a potential imaging biomarker for amyloid imaging in the brain","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-388/390-01","March 2009","March 2009","March 2009","April 23, 2009",,"April 3, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00886951"
570,"NCT00568776","ELND005 in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: Placebo Control|Drug: ELND005","Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS)|Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Per Protocol Set; PPS)|Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Full Analysis Set; FAS)|Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Per Protocol Set; PPS)|Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score From Baseline to Week 78 (Full Analysis Set; FAS)|Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score From Baseline to Week 78 (Full Analysis Set; FAS)|Change in Neuropsychiatric Inventory (NPI) Score From Baseline to Week 78 (Full Analysis Set; FAS)","OPKO Health, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","353","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELND005-AD201","December 2007","May 2010","May 2010","December 6, 2007","March 29, 2012","May 16, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Health Sciences Center, Dept. of Neurology, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|UCLA Alzheimer's Disease Center, Dept. of Neurology, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|UCSF Medical Center, Dept. of Neurology, San Francisco, California, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University Medical Center, Dept. of Neurology, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Miami Jewish Home and Hospital For The Aged, Miami, Florida, United States|Avision Research Associates, LLC, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Dept. of Neurology, Atlanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|Innovative Clinical Concepts, Paducah, Kentucky, United States|Brigham and Women's Hospital, Dept. of Neurology, Boston, Massachusetts, United States|University of Michigan, Taubman Health Care Center, Dept. of Neurology, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|The Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Sergievsky Center, New York, New York, United States|AD-CARE, Monroe Community Hospital, Rochester, New York, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Newtwork, Inc., Portland, Oregon, United States|Abington Neurological Associates, Inc., Abington, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh Alzheimer Disease Research Clinic, Pittsburgh, Pennsylvania, United States|Butler Hospital, Memory and Aging Center, Providence, Rhode Island, United States|Alliance for Neuro Research, LLC dba Absher Neurology, PA, Greenville, South Carolina, United States|Radiant Research San Antonio, San Antonio, Texas, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc-The Memory Clinic, Bennington, Vermont, United States|University of Vermont Medical Center, Fletcher Allen Health Care, Dept. of Neurology, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|University of British Columbia Hospital, Division of Neurology, Vancouver, British Columbia, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|Saint Joseph's Health Care London, Saint Joseph's Hospital, Dept. of Cognitive Neurology, London, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Sisters of Charity of Ottawa Health Service, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Whitby Mental Health Memory Clinic, Toronto, Ontario, Canada|Gerontion Research, Inc., Toronto, Ontario, Canada|Neuro-Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont), Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00568776"
571,"NCT00594568","Effect of LY450139 on the Long Term Progression of Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: LY450139|Drug: Placebo","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","1537","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7666|H6L-MC-LFAN|CTRI/2009/091/000090","March 2008","May 2011","May 2011","January 15, 2008","September 25, 2014","March 17, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooksville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pompano Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Yarmouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenkintown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hornsby, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, Sydney, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg West, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kew, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brugge, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concepcion, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Chile, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valdivia, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vina Del Mar, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roskilde, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svendborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mikkeli, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goettingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkatta, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thiruvananthapuram, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tirupati, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Varanasi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukui, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellair, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Johannesburg, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosebank, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umhlanga, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albacete, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barakaldo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norrköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uddevalla, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, Banes, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southampton, Hants, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, Merseyside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wilts, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belfast, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoke-On-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00594568"
572,"NCT00432081","Effect of Indomethacin on the Progression of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: indomethacin","Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.|Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months|Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months|Score on the Mini-Mental State Examination at 12 months|Score on the Neuropsychiatric Inventory at 12 months|Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months|The occurrence of adverse events during 12 months of treatment","Radboud University|American Health Assistance Foundation|Netherlands Brain Foundation|Netherlands Alzheimer Foundation","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A2001-15-DDJ|917.46.331","May 2000",,"August 2005","February 6, 2007",,"February 6, 2007","Rijnstate Hospital, Arnhem, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00432081"
573,"NCT00955409","Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: ACC-001+ QS21|Drug: ACC-001|Drug: ACC-001 + QS21","Incidence and severity of treatment emergent adverse events; clinically important changes in safety assessment results including adverse events , vital signs, weight, clinical laboratory tests, ECGs, MRI scans, and physical and neurological examinations.|Change from baseline levels of anti-A-beta IgG, Anti-A-beta IgM and IgG subclass antibody levels at selected time points.","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","Child, Adult, Older Adult","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-2203|B2571007","November 2009","December 2013","December 2013","August 10, 2009",,"January 31, 2014","Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Marseille cedex 5, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Toulouse cedex 9, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Mannheim, Germany|Pfizer Investigational Site, Munich, Germany|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00955409"
574,"NCT00477659","Neural Correlates In Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: donepezil HCl (Aricept)","Functional magnetic resonance imaging to identify neural correlates of cognitive improvement after 3 months of donepezil HCl in subjects w/ mild AD, using the Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion|Mini Mental State Exam, Alzheimer's Disease Assess,emt Scale-cognitive subscale, Neuropsychiatric Inventory and Instrumental Activities of Daily Living scales at screen and week 12.","Eisai Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 4","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A2501055|E2020-A001-416","July 2007","August 2008","August 2008","May 24, 2007",,"May 7, 2009","Pfizer Investigational Site, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00477659"
575,"NCT00015548","CATIE-Alzheimer's Disease Trial",,"Completed","No Results Available","Alzheimer's Disease","Drug: Olanzapine|Drug: Quetiapine|Drug: Risperidone|Drug: Citalopram",,"National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Not Applicable","450","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","N01 MH090001-05|N01 MH90001-AD|DSIR AT","March 2001",,"October 2004","April 23, 2001",,"June 17, 2015","Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|University of California, Irvine Medical Center, Irvine, California, United States|University of Southern California Dept of Psychiatry& Behavioral Sciences, Los Angeles, California, United States|University of California, Los Angeles, VA Medical Center, Los Angeles, California, United States|University of California-San Diego, VA Medical Center, San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Mental Health Advocates, Inc., Boca Raton, Florida, United States|Berma Research Group, Hialeah, Florida, United States|University of South Florida Suncoast Gerontology Center, Tampa, Florida, United States|Palm Beach Neurology/Premiere Research Institute, West Palm Beach, Florida, United States|Emory University - Wesley Woods Health Center, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University Medical School, Chicago, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Millennium Psychiatric Associates, St. Louis, Missouri, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|University of Medicine and Dentistry of New Jersey-Stratford, Stratford, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston Salem, North Carolina, United States|University Hospital Health Systems-Laurelwood Hospital, Willoughby, Ohio, United States|VA Medical Center, Coatesville, Pennsylvania, United States|Mental Illness Research Education and Clinical Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Southwestern Vermont Medical Center- The Memory Clinic, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00015548"
576,"NCT00948259","Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease",,"Completed","No Results Available","Alzheimer´s Disease","Drug: NP031112|Drug: Placebo","Incidence rates and severity of clinical adverse events and lab abnormalities for each dose level and placebo|Effect of treatment with four doses of NP031112 on cognition and depressive mood","Noscira SA","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NP031112-08B03 (CR080901)","December 2008","November 2009","November 2009","July 29, 2009",,"November 11, 2009","Pharmacologische Studiecentrum Chemnitz, Chemnitz, Germany|Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany",,"https://ClinicalTrials.gov/show/NCT00948259"
577,"NCT00959192","Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Biological: ACC-001|Other: QS-21","Incidence of Treatment-emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination|Anti-a-beta IgG Titer at Specified Visits|Anti-a-beta IgM Titer at Specified Visits","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-2206|B2571009","August 2009","January 2013","January 2013","August 14, 2009","January 1, 2016","January 1, 2016","Meitetsu Hospital, Aichi, Japan|Ibaraki Prefectural Central Hospital, Ibaraki, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Kitasato University East Hospital, Kanagawa, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|The Jikei University School of medicine, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00959192"
578,"NCT00672945","A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil",,"Terminated","No Results Available","Alzheimer's Disease","Drug: PRX-03140|Drug: Placebo","Alzheimer's Disease Assessment Scale-Cognitive subscale.","Epix Pharmaceuticals, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","420","Industry","Interventional","Primary Purpose: Treatment","Protocol 01340-202","April 2008","January 2010",,"May 6, 2008",,"July 30, 2009","Barrow Neurological Institute, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Torrance Clinical Research, Torrance, California, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Berma Research Group, Plantation, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Roskamp Institute, Tampa, Florida, United States|Alexian Brothers Neroscience Institute, Elk Grove Village, Illinois, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|The ICPS Group, Norwood, Massachusetts, United States|Memory Center of America, Long Beach, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Neurological Associates of Albany, P.C., Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Neurological Institute, P.A., Charlotte, North Carolina, United States|MedArk, Morgantown, North Carolina, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|RI Mood and Memory Research Institute, East Providence, Rhode Island, United States|Todd Swick, MD, PA, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Vermont, Burlington, Vermont, United States|The Glennan Center for Geriatrics & Gerontology, Eastern Virginia Medical School, Norfolk, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00672945"
579,"NCT00704782","Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: dimebon","To assess the safety of Dimebon in combination with donepezil (Aricept)","Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIM13","April 2008","August 2010","August 2010","June 25, 2008",,"December 10, 2015","Xenoscience, Inc., Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00704782"
580,"NCT00884507","A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Placebo|Drug: RO5313534","Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score|CANTAB tests, MMSE total score, ADCS CGIC, Behave-AD-FW, ADCS-ADL, Zarit Burden interview|AEs, lab parameters, suicidal risk, concomitant medications, physical and neurological examinations.","Hoffmann-La Roche","All","50 Years and older   (Adult, Older Adult)","Phase 2","389","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN22018|2008-004012-13","May 2009","November 2010","November 2010","April 20, 2009",,"November 2, 2016","Orange, California, United States|Torrance, California, United States|Norwalk, Connecticut, United States|Delray Beach, Florida, United States|Ft Myers, Florida, United States|Maitland, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Paducah, Kentucky, United States|Kalamazoo, Michigan, United States|Creve Coeur, Missouri, United States|Eatontown, New Jersey, United States|Albuquerque, New Mexico, United States|White Plains, New York, United States|Portland, Oregon, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Caba, Argentina|Hornsby, New South Wales, Australia|Chermside, Queensland, Australia|Woodville, South Australia, Australia|Medicine Hat, Alberta, Canada|Vancouver, British Columbia, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Verdun, Quebec, Canada|Regina, Saskatchewan, Canada|Montpellier, France|Nice, France|St Herblain, France|Toulouse, France|Günzburg, Germany|Leipzig, Germany|München, Germany|Nürnberg, Germany|Napoli, Campania, Italy|Castellanza, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Aguascalientes, Mexico|Guadalajara, Mexico|Monterrey, Mexico|Saltillo, Mexico|Gdansk, Poland|Leszno, Poland|Torun, Poland|Warszawa, Poland|Bucharest, Romania|Bucharest, Romania|Bratislava, Slovakia|Michalovce, Slovakia|BArcelon, Barcelona, Spain|Salt, Girona, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Malaga, Spain|Blackpool, United Kingdom|Bradford, United Kingdom|Glasgow, United Kingdom|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00884507"
581,"NCT00855868","Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18|Drug: [11C]-PIB","Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With [18F]-AV-45 for Probable Alzheimer's Disease (AD) Versus Cognitively Normal Subjects.","Avid Radiopharmaceuticals|American College of Radiology Imaging Network|General Electric","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","28","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ACRIN PA 4003","March 2009","January 2011","January 2011","March 5, 2009","July 26, 2012","July 26, 2012","Research Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00855868"
582,"NCT00062569","Bathing Persons With Alzheimer's Disease aT Home (The BATH Study)",,"Completed","No Results Available","Alzheimer Disease","Behavioral: Bathing Support Intervention (BSI)|Behavioral: Caregiver reminiscence with coaching","Care Recipient: Resistiveness to care; discomfort|Caregiver: Self-efficacy; interactive behaviors|Caregiver burden & satisfaction","National Institute of Nursing Research (NINR)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","90","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IA0044|R01NR007893-01A1","September 2002","June 2006","June 2006","June 12, 2003",,"March 12, 2009","Boston College, William F. Connell School of Nursing, Chestnut Hill, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00062569"
583,"NCT00039702","Brain Imaging in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: [123] 5-I-A-85380",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"40","NIH","Observational",,"020058|02-M-0058","June 2002",,"September 2004","June 7, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00039702"
584,"NCT00693004","Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: PRX-03140|Drug: Donepezil|Drug: Placebo","Alzheimer's Disease Assessment Scale-Cognitive subscale.","Epix Pharmaceuticals, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","236","Industry","Interventional","Primary Purpose: Treatment","Protocol 03140-203","May 2008","January 2010",,"June 6, 2008",,"July 30, 2009","Barrow Neurological Institute, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Torrance Clinical Research, Torrance, California, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Compass Research, Orlando, Florida, United States|Berma Research Group, Plantation, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Roskamp Institute, Tampa, Florida, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Neurology, Scarborough, Maine, United States|The ICPS Group, Norwood, Massachusetts, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Neurological Institute, P.A., Charlotte, North Carolina, United States|MedArk, Morgantown, North Carolina, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Todd Swick, MD, PA, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Glennan Center for Geriatrics & Gerontology, Eastern Virginia Medical School, Norfolk, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00693004"
585,"NCT00739037","Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer Disease","Drug: Placebo|Drug: PAZ-417","This study is the measurement of a biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).|To measure both amyloid beta peptide 42 (Ab42) and PAZ-417 in both plasma and CSF and assess safety using the results of physical examinations, vital sign measurements, ECGs, cardiac telemetry, standard laboratory tests and collection of AES.","Wyeth is now a wholly owned subsidiary of Pfizer","All","55 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)","3186A1-1103","August 2008","December 2008","December 2008","August 21, 2008",,"August 4, 2009","California Clinical Trials, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00739037"
586,"NCT00566501","Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: 23 mg SR in Study 326|Drug: 10 mg IR in Study 326","Long-term Safety as Measured by Incidence of Adverse Events During the 12 Month Treatment Period|Mean Change From Baseline in MMSE Score|Mean Change From Baseline in SIB Score","Eisai Inc.|Eisai Limited","All","45 Years to 91 Years   (Adult, Older Adult)","Phase 3","915","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2020-G000-328|2006-004890-93","December 2007","August 2010","August 2010","December 3, 2007","June 19, 2012","July 11, 2014","Apex Research Institute, Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT00566501"
587,"NCT00752232","Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Biological: ACC-001|Other: QS-21|Other: PBS","Incidence of Treatment-emergent Adverse Events (AEs) by Severity|Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data|Number of Participants With Abnormalities in Neurological Examination|Anti-a-beta IgG Titer at Specified Visits|Anti-a-beta IgM Titer at Specified Visits","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-2202|B2571006","December 2008","July 2012","July 2012","September 15, 2008","January 1, 2016","January 1, 2016","Suwa Red Cross Hospital, Suwa, Nagano, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Meitetsu Hospital, Aichi, Japan|Ibaraki Prefectural Central Hospital, Ibaraki, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Kitasato University East Hospital, Kanagawa, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00752232"
588,"NCT00000172","Evaluation of Galantamine in the Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Galantamine",,"Janssen, LP|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0009",,,,"November 1, 1999",,"June 24, 2005","University of Alabama, Birmingham, Birmingham, Alabama, United States|James L. Frey, M.D., Ltd., Scottsdale, Arizona, United States|East Bay Neurology, Berkeley, California, United States|University of Southern California, Los Angeles, California, United States|N. County Neurology Assoc., Oceanside, California, United States|University of California Irvine Medical Center, Orange, California, United States|Pacific Research Network (PRN), San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|INC, San Diego, California, United States|The Denver Center for Medical Research, Denver, Colorado, United States|Geriatric and Adult Psychiatry, Hamden, Connecticut, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Ocala Neurodiagnostic Center, Ocala, Florida, United States|Psychiatric Institute of Florida, Orlando, Florida, United States|Neurological Research Institute of Sarasota, PA, Sarasota, Florida, United States|Suncoast Neuroscience Associates, Inc., St. Petersburg, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Chicago Center for Clinical Research, Chicago, Illinois, United States|OSF Center for Senior Health, Peoria, Illinois, United States|Indiana Alzheimer's University Clinic, Indianapolis, Indiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham Behavioral Neurology Group, Boston, Massachusetts, United States|Boston Clinical Research Center, Wellesley Hills, Massachusetts, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Michigan Medical P.C., Grand Rapids, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University, St. Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|Neurology Group of Bergen County, Ridgewood, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Medwise Center, West Long Branch, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|East End Neuropsychiatric Associates, Centereach, New York, United States|St. John's Episcopal Hospital, Far Rockaway, New York, United States|NYU Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|Ohio State University, Columbus, Ohio, United States|Clinical Pharmaceutical Trials, Tulsa, Oklahoma, United States|Oregon Health Sciences University, Portland, Oregon, United States|Pacific NW Clinical Research Center, Portland, Oregon, United States|Institute for Advanced Clinical Research, Elkins Park, Pennsylvania, United States|Neuroscience Center of Westmoreland Neurology, Greensburg, Pennsylvania, United States|Brown University, Pawtucket, Rhode Island, United States|Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, United States|University of Texas, Dallas, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Memory Disorder Center of Vermont, Colchester, Vermont, United States|Virginia Neuroscience Center, Alexandria, Virginia, United States|Prince William Neuroscience Center, Manassas, Virginia, United States|Seattle Clinical Research Center, Seattle, Washington, United States|VAPS Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000172"
589,"NCT00104442","Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine","Changes in specific brain enzyme activity from baseline to week 13|Correlate changes in specific brain enzyme activity at week 13 to cognition and behavior|Changes in levels of protein biomarkers in Alzheimer's disease and neurodegeneration from baseline to week 13|Correlate changes in specific brain enzyme activity after 13 weeks treatment to changes in global functioning at 13 and 26 weeks","Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713BUS25","October 2003",,"April 2006","March 1, 2005",,"December 21, 2007","Novartis Pharmaceuticals, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00104442"
590,"NCT00684281","Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment",,"Completed","No Results Available","Alzheimer's Disease","Other: Neurological and neuropsychological consultation, MRI|Other: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA","Pursue the longitudinal study of a troop of subjects presenting an amnestic MCI in 36 months after the initial diagnosis|Characterize the clinical evolution of these subjects: escalation with appearance of an insanity (of type Alzheimer's disease or of another type: degenerations fronto-temporal, insanity with body of Lewy), stabilization even improvement.|Identify the neuropsychological markers and of neuroimaging structural and metabolic useful in clinical practice which allow to predict an escalation|Identify the neuropsychological markers and of neuroimaging structural and metabolic useful in clinical practice which allow to predict a stabilization or an improvement.|Improve the state of the knowledge on the origin of the confusions mnésiques isolated at the persons of fifty and more years old.|Establish diagnostic criteria which allow to improve the sensibility and the specificity of the premature diagnosis of MY.|Determine if the ultra-premature diagnosis of MY at a stage where the hurts are still confined in the structures under - hippocampiques is possible.|Determine the specific character or not of the infringement of the memory of visual recognition in the novice Alzheimer's disease.|Determine the specific character or not the atrophy and the metabolic modifications of regions under - hippocampiques in the novice Alzheimer's disease.|Inform the existence of process of functional compensation in the population of aMCI, notably to those who show themselves stable or improve.","Assistance Publique Hopitaux De Marseille","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2007-A00851-52|2007-27","July 2008","April 2011","December 2011","May 26, 2008",,"August 28, 2014","Hopital de la Timone- Service de neurologie et de neuropsychologie, Marseille, France",,"https://ClinicalTrials.gov/show/NCT00684281"
591,"NCT02337907","BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.",,"Completed","Has Results","Alzheimer Disease","Drug: Placebo|Drug: BI 409306|Drug: Donepezil","Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.|Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Sister Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)|Change From Baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Total Score After 12-week Treatment|Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment|Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment","Boehringer Ingelheim","All","55 Years and older   (Adult, Older Adult)","Phase 2","329","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1289.7|2013-005040-28","January 21, 2015","September 15, 2017","October 10, 2017","January 14, 2015","November 14, 2018","November 14, 2018","California Neuroscience Research, Sherman Oaks, California, United States|Bioclinica Research, Orlando, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Psychiatry And Alzheimer's Care of Rochester, PLLC, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|ANI Neurology, PLLC, dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|The Memory Clinic, Bennington, Vermont, United States|Private Practice for Psychiatry and Neurology, Wien, Austria|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|AZ Sint-Blasius, Dendermonde, Belgium|UNIV UZ Gent, Gent, Belgium|Mons - UNIV Ambroise Paré, Mons, Belgium|University of Calgary, Calgary, Alberta, Canada|Dr. Alexander McIntyre Inc., Penticton, British Columbia, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|Institut universitaire de geriatrie Sherbrooke, Quebec, Canada|HOP Pellegrin, Bordeaux, France|HOP Bocage, Dijon, France|HOP Timone, Marseille, France|HOP Gui de Chauliac, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP La Pitié Salpêtrière, Paris, France|HOP Jean Bernard, Géria, Poitiers, Poitiers, France|Praxis Dr. med. Volker Schumann, Berlin, Germany|emovis GmbH, Berlin, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Neuro Centrum Science GmbH, Erbach, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Zentralinstitut für seelische Gesundheit, Mannheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|Neurologie und Psychiatrie / Psychotherapie, Westerstede, Germany|P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna, Bologna, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|Azienda Ospedaliera di Parma, Parma, Italy|Jeroen Bosch Ziekenhuis-Hertogenbosch, 's-HERTOGENBOSCH, Netherlands|Brain Research Center, Amsterdam, Netherlands|Podlassian Center of Psychogeriatry, Bialystok, Bialystok, Poland|Mental Health Center Biomed, Kielce, Poland|Non-Public Outpatient Clinic Neuromed M. i M. Nastaj, Lublin, Poland|Inst. of Rural Health, Spec. Outp. Clin. & Rural Occup. Dis., Lublin, Poland|Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners, Poznan, Poland|Medical Center Senior, Sopot, Poland|EUROMEDIS Sp. z o.o., Szczecin, Szczecin, Poland|Reg. Specialist Hospital Wroclaw, Research & Develop. Center, Wroclaw, Poland|Hospital Fernando Fonseca, EPE, Amadora, Portugal|Hospital de Braga-Escala Braga, Braga, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Hospital Senhora Oliveira Guimarães,EPE, Guimarães, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|ULSM, EPE - Hospital Pedro Hispano, Matosinhos, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|Royal United Hospital, Bath, United Kingdom|Ninewells Hospital & Medical School, Dundee, Scotland, United Kingdom|West Devon (Tavistock) CMHT & Memory Clinic (EDI), Ivybridge, United Kingdom|Re-Cognition Health, Plymouth, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02337907/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02337907/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02337907"
592,"NCT01039701","4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease","ROBIN","Completed","No Results Available","Mild to Moderate Alzheimer's Disease","Drug: AZD1446|Drug: Placebo","Nature and incidence of adverse events|To evaluate any effects PK of AZD1446 as an add-on treatment to donepezil on the PK of donepezil|To characterize the PK of AZD1446 as an add-on treatment to donepezil in AD patients|To explore the effects of 3 dose regimens of AZD1446 compared to placebo as an add-on treatment to donepezil on changes in global functioning using ADCS-CGIC","AstraZeneca","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D1950C00006","December 2009","July 2010","July 2010","December 25, 2009",,"August 11, 2010","Research Site, Litomerice, Czech Republic|Research Site, Praha 10 - Strasnice, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykallo, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Bratislava, Slovakia|Research Site, Roznava, Slovakia|Research Site, Zlate Moravce, Slovakia",,"https://ClinicalTrials.gov/show/NCT01039701"
593,"NCT00890890","A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Avagacestat|Drug: Placebo","Safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease as measured by adverse events, vital signs, laboratory assessments, electrocardiograms (ECGs) and Safety Head Magnetic resonance imaging (MRI) findings|Predictive value of Cerebral Spinal Fluid (CSF) biomarkers (Aβ40, and Aβ42, total Tau, total Tau/Aβ42 ratio, phosphorylated Tau) on progression to dementia","Bristol-Myers Squibb","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 2","263","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN156-018|2009-010067-16","May 2009","July 2013","July 2013","April 30, 2009",,"October 12, 2015","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|Banner Alzheimer'S Institute, Phoenix, Arizona, United States|Sun Health Research Institue, Sun City, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Mary S. Easton Center, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Uc Irvine Medical Center, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|University Of California, San Diego, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Md Clinical, Hallandale Beach, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Brigham & Women'S Hospital, Boston, Massachusetts, United States|St Louis University, Saint Louis, Missouri, United States|Washington University School Of Medicine, St. Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center For Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center Of Amercia, Inc., Eatontown, New Jersey, United States|Robert Wood Johnson Medical School, Umdnj, New Brunswick, New Jersey, United States|Global Medical Institutes, Llc, Princeton, New Jersey, United States|Memory Enhancement Center Of Nj, Inc., Toms River, New Jersey, United States|Spri Clinical Trials, Llc, Brooklyn, New York, United States|Nyu Langone Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University Of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Neurology Associates, Pa, Raleigh, North Carolina, United States|Richard H. Weisler, Md, Pa & Assoc., Raleigh, North Carolina, United States|Clinical Trials Of America, Inc., Winston Salem, North Carolina, United States|Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Providence Cognitive Assessment Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research (Sasr), Austin, Texas, United States|The University Of Texas, Dallas, Texas, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Mcw Clinics At Froedtert Hospital, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Turku, Finland|Local Institution, Toulouse, Cedex 9, France|Local Institution, Bordeaux Cedex, France|Local Institution, Dijon, France|Local Institution, Nantes, France|Local Institution, Rennes Cedex 9, France|Local Institution, Molndal, Sweden|Local Institution, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00890890"
594,"NCT00605059","Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects","AV94","Terminated","No Results Available","Alzheimer Disease","Drug: [123I]AV94","To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects|To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a single photon computed tomography (SPECT) brain imaging agent|Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy controls","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AV94","August 2007","June 2008","June 2008","January 30, 2008",,"October 6, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00605059"
595,"NCT00348140","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease","REFLECT-3","Completed","Has Results","Alzheimer's Disease","Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort|Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort|Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort|Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort|Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort|Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort|Change From Baseline in ADAS-Cog Total Score at Weeks 8, 16, 24 and 36|Change From Baseline in CDR-SB Score at Weeks 12, 24 and 36|Change From Screening in Mini Mental State Examination (MMSE) Total Score|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score|Change From Baseline in Domains of the Resource Utilization in Dementia Scale (RUD)- Q1 and Q2 Caregiver Hours|Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Scale Total Score- Thermometer Score|Change From Baseline in EQ-5D Scale Total Score- Utility Score|Change From Baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score|Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48|Change in CDR-SB Total Score for Observed Cases at Week 54 Compared to Week 48|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48|Number of Participants With On-treatment Adverse Events (AEs), Serious Adverse Events (SAEs) and Severity of AEs|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Weight|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Heart Rate (HR)|Change From Baseline in Weight|Change From Baseline in Hemoglobin|Change From Baseline in Hematocrit|Any Time on Treatment Differences in Frequencies of Hematology Data Outside the Reference Range|Any Time on Treatment Differences in Frequencies of Clinical Chemistry Data Outside the Reference Range|Changes From Baseline in Electrocardiogram (ECG) Parameters- HR|Changes From Baseline in ECG Parameters- RR Interval, QT Interval, QTcB, QTcF, PR Interval and QRS Duration|Change From Baseline in HbA1c up to Week 54|Change From Baseline in Short Term Memory Assessment","GlaxoSmithKline","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","1468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVA102670","July 12, 2006","March 20, 2009","March 20, 2009","July 4, 2006","September 5, 2017","September 5, 2017","GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Laguna Hills, California, United States|GSK Investigational Site, Redlands, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, West Yarmouth, Massachusetts, United States|GSK Investigational Site, Eatontown, New Jersey, United States|GSK Investigational Site, Manchester Township, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Amherst, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Jenkintown, Pennsylvania, United States|GSK Investigational Site, Norristown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, East Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Wichita Falls, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Middleton, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Hornsby, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Auchenflower, Queensland, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Cheltenham, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Woluwe-Saint-Lambert, Belgium|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Mirabel, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Trutnov, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Joensuu, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, La Chapelle sur Erdre, France|GSK Investigational Site, La Seyne sur Mer, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Limoges, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Sautron, France|GSK Investigational Site, Toulon, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Valence, France|GSK Investigational Site, Aalen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Calw, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ludwigsburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wiesloch, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Ipoh, Malaysia|GSK Investigational Site, Kelantan, Malaysia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Blaricum, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hilversum, Netherlands|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Torun, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Ljubljana, Slovenia|GSK Investigational Site, Šempeter, Slovenia|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Richards Bay, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Waverley, Bloemfontein, South Africa|GSK Investigational Site, Willows, X14, Pretoria, South Africa|GSK Investigational Site, Baracaldo/Vizcaya, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Falköping, Sweden|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Kalix, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Sundsvall, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Stirling, United Kingdom|GSK Investigational Site, West End, Southampton, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00348140"
596,"NCT00676143","Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients",,"Terminated","Has Results","Alzheimer Disease","Drug: bapineuzumab|Drug: placebo","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78|Change From Baseline in Brain Amyloid Burden at Week 71|Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71|Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)|Change From Baseline in Dependence Scale Total Score at Week 78|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78","Pfizer","All","50 Years to 88 Years   (Adult, Older Adult)","Phase 3","1100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3133K1-3001|B2521002|2007-005995-14","January 2008","October 2012","November 2012","May 12, 2008","June 10, 2016","June 10, 2016","Center for Psychiatric Medicine, Birmingham, Alabama, United States|Participant and Clinical Interactions Resources, Birmingham, Alabama, United States|UAB Clinical Research Pharmacy-Russell Clinic, Birmingham, Alabama, United States|University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|AC Institute, Incorporated, Carson, California, United States|Collaborative Neuroscience Network, Inc, Long Beach, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|Mile HIgh Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Hospital Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Moshe Hasbani, MD, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|MR Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, LLC, Atlantis, Florida, United States|JEM Research Institute, Atlantis, Florida, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|University of South Florida, Tampa, Florida, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|NeuroStudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Southern Illinois University School of Medicine Department, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Univeristy ADCRP, Boston, Massachusetts, United States|General Clincial Research Center (Infusion Location), Boston, Massachusetts, United States|IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong, Boston, Massachusetts, United States|Shields MRI, Dartmouth, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor,, Michigan, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research P.C., Kansas City, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmcare USA, Edison, New Jersey, United States|Alzheimer's Research Corp./Merician Institute for Aging, Manchester, New Jersey, United States|Neurological Care of Central New York, Liverpool, New York, United States|Carolina Neuropsychological Services, Inc, Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging@Martha Moorehouse, Columbs, Ohio, United States|The Ohio State University, Columbs, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Providence Brain Institute, Portland, Oregon, United States|Providence Cognitive Assessment Clinic, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Dr. Michael Gabe (Clinic), Silverton, Oregon, United States|Abington Memorial Hosptial, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Andorra MRI of Flourtown, Flourtown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, Philadelphia, Pennsylvania, United States|University of Pennsylvania-Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MUSC, Charleston, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Inventive Infusions Solutions, San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Bennington, Vermont, United States|Waisman Center (PET only), Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Wm S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States|University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Instituto Medico Congreso, Buenos Aires, Argentina|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Instituto Kremer, Cordoba, Argentina|Gosford Hospital; Pharmacy Dept, Gosford, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital, West Heidelberg, Victoria, Australia|Hollywood Hospital; Pharmacy Dept, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation, Inc., Nedlands, Western Australia, Australia|Medizinische Universitaet Graz, Graz, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|Allg. Krankenhaus der Stadt Wien, Wien, Austria|SZ Sued - Kaiser-Franz-Josef-Spital, Wien, Austria|Donauspital, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas LyS, Santiago, Chile|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|University of Turku / CRST, Turku, Finland|CHU Pellegrin, Bordeaux Cedex, France|Hopital neurologique du Pr A. Vighetto, Bron, France|Centre d'Imagerie medicale de Basse Normandie, Caen, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez C.M.R.R., Nice, France|Service d'Imagerie Medicale, Nice, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|Hôpital Pitié-Salpétrière, Paris, France|Hospital Jean Bernard CIC, Poitiers, France|C.H.U de Reims, Reims, France|CHU de Rennes, Rennes Cedex, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Toulouse - Site Casselardit, Toulouse, France|Charite-Universitätsmedizin Berlin, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Universitaetsklinikum Dresden, Dresden, Germany|Klinikum der Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany|Ortenau Klinikum Offenburg, Offenburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|A.O. Umberto I, Ancona, Italy|Sezione di Neurologia - Dipartimento di Neuroscienze, Ancona, Italy|Clinica Neurologica - II Neurologia, Brescia, Italy|Dipartimento di Neuroscienze,, Catania, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Amphia Ziekenhuis, Breda, Noord Brabant, Netherlands|Tergooi Ziekenhuizen, Hilversum, Noord Holland, Netherlands|Kennemer Gasthuis, Haarlem, The Netherlands, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus MC, Rotterdam, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Klinicki centar Srbije, Belgrade, Serbia|Clinical Centre Kragujevac, Clinic of Psichiatry, Kragujevac, Serbia|Klinicki Centar Vojvodina, Novi Sad, Serbia|Diagnostic Imaging Center, Sremska Kamenica, Serbia|Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Flexivest Fourteen Research Center, Bellville, Western Cape, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Donostia, San Sebastian, Pais Vasco, Spain|Hospital de Cruces, Baracaldo, Vizcalla, Spain|Hospital del Mar, Barcelona, Spain|Fundacio ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Centro Internacional de Medicina Avanzda (CIMA), Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Malmo University Hospital, Malmo, Sweden|Uppsala Imanet AB, Uppsala, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|ORKI, enheten for radiologi, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Research Assessment Centre, Trafford Park, Manchester, United Kingdom|Pollard Park Health Centre, Bradford, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Victoria Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00676143"
597,"NCT00637442","Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)","CASL-AD-01","Unknown status","No Results Available","Alzheimer's Disease","Drug: Reminyl retard","Cerebral perfusion|Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)|Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)|Neuropsychiatric Inventory (NPI)|Mini-Mental-Status-Examination (MMSE)","University Hospital, Bonn|Federal Ministry of Health, Germany","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","University Bonn","February 2008","December 2010",,"March 18, 2008",,"November 9, 2010","Department of Psychiatry, University Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT00637442"
598,"NCT02833870","Non-pharmacological Care of Alzheimer's Disease: Benefice of Musical Interventions","MusicAlzheimer","Completed","No Results Available","Alzheimer's Disease (AD) and Related Disorders","Behavioral: Musical intervention|Behavioral: Non-musical (cooking) intervention|Behavioral: Control with no intervention","Overall score in the Neuropsychiatric Inventory","CHU de Reims","All","60 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","PO13125 252Au12","September 2013","June 2015","June 2015","July 14, 2016",,"January 2, 2017","Chu de Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT02833870"
599,"NCT00667810","Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients",,"Terminated","Has Results","Alzheimer Disease","Drug: bapineuzumab|Drug: placebo","The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78|The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78|The Change From Baseline in Brain Amyloid Burden at Week 71.|The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.|The Change From Baseline in Brain Volume at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to Median Placebo Deterioration on DAD Total Score|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Dependence Scale Total Score at Week 78|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78","Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 3","901","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3133K1-3000|B2521001|2007-005994-79","June 2008","October 2012","August 2013","April 28, 2008","January 8, 2016","January 8, 2016","University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center (IP Mixing Only), Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|ATP Clinical Research, Incorporated, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Infusion Care Pharmacey, Laguna Hills, California, United States|Senior Clinical Trials, Incorporated, Laguna Hills, California, United States|Faculty Physicians and Surgeons of Loma Linda University School of Medicine, Loma Linda, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Coordinated Clinical Research, San Diego, California, United States|LabCorp, San Diego, California, United States|Sharp and Children's MRI Center, LLC, San Diego, California, United States|Sharp Infusion Therapy Center, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Institutional Review Board / Ethics Committee, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|JEM Research Institute LLC, Atlantis, Florida, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|Bradenton Research Center, Incorporated, Bradenton, Florida, United States|North Broward Medical Center, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Imaging, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|South Bay Internal Medicine, Sun City, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Incorporated, Atlanta, Georgia, United States|Columbus Diagnostic Center (MRI), Columbus, Georgia, United States|Medical Research and Health Education Foundation, Incorporated, Columbus, Georgia, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|NeuroStudies.net, Decatur, Georgia, United States|Neurostudies.net, Lawerenceville, Georgia, United States|Neurostudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Center for Senior Health, Peoria, Illinois, United States|Methodist Medical Center Research Department, Peoria, Illinois, United States|Methodist Diagnostic Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Psychology Associates, Mishawaka, Indiana, United States|KU - Wichita, Wichita, Kansas, United States|Drug Shipment/ Storage, Wichitia, Kansas, United States|Four Rivers Clinical Research, Incorporated, Paducah, Kentucky, United States|Radio Pharmacy, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates Inc, New Orleans, Louisiana, United States|James Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|General Clinical Research Center, Boston, Massachusetts, United States|IDS Pharmacy, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc., Haverhill, Massachusetts, United States|Neurocare, Incorporated, Newton, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Marty's Pharmacy, Flowood, Mississippi, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Spectrum Home Solutions, Great Falls, Montana, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Memory Enhancement Center of New Jersey, Inc., Toms River, New Jersey, United States|Northeast Radiology, Brewster, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|AD-CARE, University of Rochester Medical Center, Rochester, New York, United States|University of Rochester/Strong Memorial Hospital, Rochester, New York, United States|Clinical Study Center of Asheville, LLC, Asheville, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Clinical Trials of America, Incorporated, Hickory, North Carolina, United States|The Compounding Pharmacy, Hickory, North Carolina, United States|Carolina Neuropsychological Services, Inc., Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging at Martha Morehouse, Columbus, Ohio, United States|The Ohio State University Hospitals Clinic, Columbus, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Professional Corporation of Psychiatry, Oklahoma City, Oklahoma, United States|Red River Medical Recearch Center, LLC, Oklahoma City, Oklahoma, United States|Flourish Integrative Pharmacy, Oklahoma City, Oklahoma, United States|Providence Brain Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennslyvania, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania (PET), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, IDS Pharmacy, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Translational Research Center (CTRC), Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina Investigational Drug Service, Charleston, South Carolina, United States|Radiant Research, Incorporated, Greer, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Austin Infusion Centers, Austin, Texas, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology, P.A., Dallas, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Healthcare, Bennington, Vermont, United States|The Memory Clinic, Bennington, Vermont, United States|University of Virginia Neurology, Charlottesville, Virginia, United States|University of Virginia General Clinical Research Center, Charlottesville, Virginia, United States|University of Viriginia Investigational Pharmacy, Charlottesville, Virginia, United States|Pacific Medical Centers, Bothell, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital/ Medical and Cognitive Research Unit, West Heidelberg, Victoria, Australia|Hollywood Private Hospital, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation Inc., Nedlands, Western Australia, Australia|Royal Adelaide Hospital, Adelaide SA, Australia|ZNA Middelheim / Neurologie, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|University Hospital Gathuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centre for Memory and Aging, North York, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Recherche ADAPRA Inc., L'Ancienne-Lorette, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Recherche Clinique de Neurologie, Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas L&S, Santiago, Chile|Sestre milosrdnice Zagreb, Zagreb, Croatia|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|Turku University Hospital, Turku, Finland|CHRU Hôtel Dieu, Rennes, Cedex, France|CHU Hopital Nord, Amiens, France|Hôpital Neurologique, Bron, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|Hôpital Roger Salengro, Lille, France|Hopital Sainte Marguerite, Marseille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez, Nice, France|Groupe Hospitalier Pitie-Salpetriere, Paris Cedex 13, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|CHU La Milétrie, Poitiers, France|C.H.U de Reims, Reims, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Purpan - Hôpital Casselardit, Toulouse, France|Klinik fur Psychiatrie und Psychotherapie, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Ortenau Klinikum, Offenburg, Germany|Universitaet Regensburg, Regensburg, Germany|Universita Politecnica delle Marche, Ancona, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Universita degli Studi di Firenze, Firenze, Italy|Ospedale S. Raffaele, Milano, Italy|Ospedale S. Raffaele, Milano, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera S. Gerardo di Monza Università di Milano Bicocca, Monza, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|Tokyo Metoropolitan Health and Med. Treatment Co. Ebara Hosp, Ota-ku, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Tokyo National Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Department of Psychiatry, Seongnam-si, Gyeonggi-do, Korea, Republic of|KonKuk University Hospital, Department of NeuroPsychiatry, Seoul, Korea, Republic of|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Jeroen Bosch Ziekenhuis, s. Hertogenbosch, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ ""SYNAPSA"", ul. Niska 5/1, Kielce, Poland|Szpital Uniwersytecki w Krakowie,Oddzial Kliniczny Klinik Chorób Wewnetrznych, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Interregional clinicodiagnostic center, Kazan, Russian Federation|Nizhny Novgorod regional clinical hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation|Saint-Petersburg State institution of healthcare, City geriatric medico-social center, Saint-Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Saint-Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Chair of nervous system diseases, Saint-Petersburg, Russian Federation|Klinicki centar Vojvodine, Novi Sad, Vojvodina, Serbia|Klinicki centar Srbije, Belgrade, Serbia|Klinicki centar Srbije, Beograd, Serbia|Clinical Centre Kragujevac, Kragujevac, Serbia|1. Neurologicka klinika, Bratislava, Slovakia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Neurologicka klinika, Martin, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Neurologicke oddelenie FNsP Zilina, Zilina, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrasa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Baracaldo, Spain|Hospital del Mar, Barcelona, Spain|Fundació ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Clínica CIMA, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Skanes Universitetssjukhus, Neuropsykiatriska, Malmo, Sweden|PET center, Uppsala, Sweden|The clinic: Minnes- och geriatrikmottagningen, Uppsala, Sweden|MRI Dept: ORKI, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Ltd., Bradford, West Yorkshire, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital NHS Trust, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Kingshill Research Centre, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00667810"
600,"NCT00423228","Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease","BRAINz","Completed","No Results Available","Moderate Alzheimer's Disease","Drug: ZT-1|Drug: Donepezil","Change in the MMSE score from baseline to week 25|Responder rate as defined by at least 2 points improvement in the MMSE score;|Change on the ADAS-Cog 11 items subscale;|Change in the NPI-Q;|Change on the IADL scale;|Patient's convenience questionnaire.","Debiopharm International SA","All","50 Years and older   (Adult, Older Adult)","Not Applicable","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DEB-ZTSR-201|EUDRACT no. 2006-005161-18","February 2007","April 2009","April 2009","January 18, 2007",,"January 14, 2015","Central Coast Neuroscience Research, East Gosford, New South Wales, Australia|Hornsby-Kuring-gai Health Service, Hornsby, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Adelaide Hospital, Adelaïde, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|St George's Hospital, Kew, Victoria, Australia|Austin Health Repatriation Hospital, West Heidelberg, Victoria, Australia|Hollywood Specialist Centre, Nedlands (Perth), Western Australia, Australia|Calgary West Medical Centre, Calgary, Alberta, Canada|Castledowns Medicentre, Edmonton, Alberta, Canada|Saibal Nandy Professional Corporation, Medicine Hat, Alberta, Canada|Parkwood Hospital, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Gerontion Research Inc., Toronto, Ontario, Canada|Neuro Rive-Sud, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|The Medical Arts Health Research Group, Kelowna, Canada|Douglas Hospital Research Center, Montréal, Canada|The Medical Arts Health Research Group, Penticton, Canada|OPMHS, Crowborough, East Sussex, United Kingdom|Glasgow Memory Clinic, Glasgow, Scotland, United Kingdom|Llandough Hospital, Penarth, Wales, United Kingdom|Royal Blackburn Hospital, Blackburn, United Kingdom|Camden and Islington Mental Health Trust, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|New Castle General Hospital, Newcastle upon Tyne, United Kingdom|MARC - Moorgreen Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00423228"
601,"NCT00319891","Computer-Based Training for Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Procedure: Computer-based Cognitive Training","The primary objective of this trial will be to assess the feasibility of using computer-based|cognitive training in an a population with early Alzheimer's Disease.|A standardized set of neuropsychological assessments will be conducted pre- and post-|compuer-based training.","Posit Science Corporation|University of California, San Francisco","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 1","6","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OUT-109-2005","September 2004","October 2006","October 2006","April 27, 2006",,"May 15, 2013","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00319891"
602,"NCT02185053","A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia",,"Completed","No Results Available","Alzheimer's Disease","Drug: CPC-201","Donepezil Maximum tolerated dose (MTD) change","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-07","July 2014","July 2016","July 2016","July 9, 2014",,"July 26, 2016","CPC1, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02185053"
603,"NCT00443417","A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: SK-PC-B70M","ADAS-cog(Alzheimer's Disease Assessment Scale-Cognitive subscale)|MMSE(Mini Mental State Examination)|CDR-SB(Clinical Dementia Rating Sum of Box)|QOL-AD(Quality of Life in Alzheimer's Disease)|Delayed Word-Recall Task|Symbol Digit Modalities Test|Digit Backward|Maze Task|Digit Cancellation Task|Verbal Fluency-Categories|Concentration / Distractibility|GDS","SK Chemicals Co., Ltd.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMART_II_2006","April 2007","January 2009","January 2009","March 6, 2007",,"December 9, 2009","SKchemicalsI nvestigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00443417"
604,"NCT00362024","MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)",,"Terminated","No Results Available","Alzheimer's Disease","Drug: MK0952|Drug: Comparator: Placebo",,"Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0952-004|2006_026","November 2006","November 2007","November 2007","August 9, 2006",,"May 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00362024"
605,"NCT00428090","Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Rosiglitazone","Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in APOE4 Negative Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort|Change From Baseline (W0) in Mean ADAS-Cog Total Score at W8, W16, W24|Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Neuropsychiatric Inventory (NPI) Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Disability Assessment for Dementia (DAD) Scale Total Score at W8, W16, W24|Change From Baseline (W0) in Mean Short Term Memory Assessment Total Score (ADAS-Cog Q1 Plus Q7) at W8, W16, W24|Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Utility|Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Thermometer (Visual Analog Scale [VAS])|Time Spent Caring for Basic and Instrumental Activities Resource Utilization in Dementia (RUD) Scale at W12 and W24|Change From Baseline (W0) in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score at W12 and W24.|Change From Baseline (W0) in Mini Mental State Examination (MMSE) Total Score at W24.|Change From Baseline (W0) in Glycosylated Hemoglobin (HbA1c) at W24.|Number of Participants With Adverse Events Defined by Severity|Number of Participants With Systolic and Diastolic Blood Pressure (SBP and DBP), Heart Rate (HR) and Weight Values of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT).|Change From Baseline (W0) in 12-lead Electrocardiogram (ECG)|Change From Baseline (W0) in Heart Rate (HR) Measured From 12-lead Electrocardiogram (ECG)|Change From Baseline (W0) in Body Weight|Change From Baseline (W0) in Hemoglobin|Change From Baseline (W0) in Hematocrit|Change From Baseline (W0) in Periodic HbA1c Assessment|Number of Par. With Hematology Data of Potential Clinical Concern Any Time on Treatment|Number of Par. With Clinical Chemistry Values of Potential Clinical Concern Any Time on Treatment","GlaxoSmithKline","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","862","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","105640","February 27, 2007","September 1, 2008","September 5, 2008","January 29, 2007","May 19, 2017","May 19, 2017","GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, Reseda, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Fairfield, Connecticut, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Destin, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Sunrise, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, St. Paul, Minnesota, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Kenilworth, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Jenkintown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, DeSoto, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Middleton, Wisconsin, United States|GSK Investigational Site, Graz-Eggenberg, Austria|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Dubrovnik, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Itzehoe, Schleswig-Holstein, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Gyula, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, Tirupati, India|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Cabo Rojo, Puerto Rico|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Derriford, Plymouth, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00428090"
606,"NCT00810147","A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: BMS-708163|Drug: Placebo","Adverse Events|Pharmacodynamics effects of Cerebral Spinal Fluid|Pharmacodynamics effects of the Alzheimer's Disease Assessment Scale - Cognitive Subscale|Pharmacodynamics effects of the Alzheimer's Disease Collaborative Study - Activities of Daily Living scale|Pharmacodynamics effects of the Global clinical impression as assessed with the Clinical Dementia Rating-Sum of Boxes|Characterize Pharmacodynamics/Pharmacokinetics effects of the plasma exposure of BMS-708163 and variability in a population with Alzheimer's disease|Characterize Pharmacodynamics/Pharmacokinetics effects in refining the Pharmacokinetics/Pharmacodynamics model with Phase 2 data|Characterize Pharmacodynamics/Pharmacokinetics effects by exploring correlations between exposure, biomarkers, and clinical effects|Characterize Pharmacodynamics/Pharmacokinetics effects by exploring Pharmacokinetics variability, including the correlation between polymorphisms of CYP enzymes","Bristol-Myers Squibb","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","209","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN156-013|EUDRACT: 2008-005929-11","February 2009","June 2010","June 2010","December 17, 2008",,"October 12, 2015","University Of Alabama At Birmingham, Birmingham, Alabama, United States|21st Century Neurology, Phoenix, Arizona, United States|Banner Alzheimer'S Institute, Phoenix, Arizona, United States|Sun Health Research Institue, Sun City, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Pacific Institute For Medical Research, Inc., Los Angeles, California, United States|Mary S. Easton Center, Los Angeles, California, United States|Pacific Research Network, Inc, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Md Clinical, Hallandale Beach, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Usf Suncoast Alzheimer'S And Gerontology Center, Tampa, Florida, United States|Center For Clinical Trials, Venice, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Memory Enhancement Center Of Amercia, Inc., Eatontown, New Jersey, United States|Global Medical Institutes, Llc, Princeton, New Jersey, United States|Columbia University, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Richard H. Weisler, Md, Pa & Associates, Raleigh, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Professional Neurological Associates, Pc, Dunmore, Pennsylvania, United States|The Clinical Trial Center Llc, Jenkintown, Pennsylvania, United States|R.I. Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|The University Of Texas, Dallas, Texas, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Local Institution, Odense, Denmark|Local Institution, Kuopio, Finland|Local Institution, Turku, Finland|Local Institution, Malmo, Sweden|Local Institution, Molndal, Sweden|Local Institution, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00810147"
607,"NCT02423200","Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD",,"Completed","Has Results","Alzheimer's Disease","Drug: VX-745","Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines|Severe or Serious Adverse Events|Maximal CSF VX-745 Concentration|Episodic Memory Function","EIP Pharma Inc","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EIP14-745-303","April 2015","September 2016","November 2016","April 22, 2015","April 3, 2018","April 3, 2018","Parexel International, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02423200"
608,"NCT00412048","Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease","Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects|Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease","University Hospital, Strasbourg, France","All","55 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3659","April 2012","February 2018","February 2018","December 15, 2006",,"November 14, 2012",,,"https://ClinicalTrials.gov/show/NCT00412048"
609,"NCT02958930","Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Alzheimer Disease, Late Onset","Device: MemorEM 1000","ADAS-Cog|FDG-PET|Resting state fMRI|Diffusion Tensor Imaging (DTI)|Susceptibility-Weighted Imaging (SWI)|Blood and CSF beta-amyloid levels|Blood and CSF tau levels|Blood and CSF markers of immune function|Blood and CSF markers of oxidative stress|Adverse Event Assessment|ADCS-ADL score|MMSE score|Global Deterioration score|Hachinski score|Rey AVLT score|Trails A & B score|Digit span score|Clock draw score","NeuroEM Therapeutics, Inc.|Byrd Alzheimer's Institute, University of South Florida|University Diagnostic Institute, Tampa|Invicro, Boston|Left Coast Engineering, Escondido","All","63 Years and older   (Adult, Older Adult)","Not Applicable","8","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NeuroEM-001|EM 1000-1","October 1, 2017","January 4, 2019","January 11, 2019","November 8, 2016",,"April 23, 2019","Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02958930"
610,"NCT00409279","An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer Disease","Behavioral: Information, counseling and support","Changes in measures of depression, stress, and anxiety","The Jacob and Valeria Langeloth Foundation|National Institute on Aging (NIA)","All","21 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","IA0097|Project #195","September 2003","April 2008","April 2008","December 8, 2006",,"March 3, 2008","Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00409279"
611,"NCT00602680","Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: SSR180711C|Drug: donepezil|Drug: placebo","Change in cognitive performance|Cognitive, global, functional and behaviorial assessments","Sanofi","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PDY10400|SSR180711|EudraCT 2007-001639-80","January 2008","July 2008","July 2008","January 28, 2008",,"July 20, 2009","Sanofi-Aventis Administrative Office, Paris, France",,"https://ClinicalTrials.gov/show/NCT00602680"
612,"NCT00334906","Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)",,"Completed","No Results Available","Alzheimer's Disease","Drug: memantine HCl","Efficacy|Total brain atrophy on MRI|Other measures of brain atrophy on MRI, change from baseline in selected cognitive measures assessing multiple cognitive domains including memory, attention, motor-speed, auditory comprehension, and verbal fluency|Safety","Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 4","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEM-MD-15","July 2005","November 2007",,"June 8, 2006",,"January 7, 2008","Forest Laboratories, Jersey City, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00334906"
613,"NCT00462917","REVEAL III: Risk Evaluation and Education for Alzheimer's Disease","REVEAL","Completed","Has Results","Alzheimer Disease","Behavioral: Pleiotropic info, in-person disclosure|Behavioral: AD-only info, in-person disclosure|Behavioral: Pleiotropic info, phone disclosure|Behavioral: AD-only info, phone disclosure","Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES)","Brigham and Women's Hospital|National Human Genome Research Institute (NHGRI)","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","290","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","IA0113|R01HG002213","March 2007","October 2009","October 2009","April 19, 2007","September 11, 2014","October 23, 2018","Howard University, Washington, District of Columbia, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Case Western Reserve University, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00462917"
614,"NCT00575055","Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg","Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 88 Years   (Adult, Older Adult)","Phase 3","1121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELN115727-302","December 2007","April 2012","April 2012","December 17, 2007",,"November 25, 2013","University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Sciences Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc, Laguna Hills, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neurology Center, Oceanside, California, United States|University of California Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California Davis Alzheimer's Disease Research Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California at San Francisco Medical Center at Parnassus, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne Internal Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, School of Medicine, Atlanta, Georgia, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Educational Foundation, Inc, Columbus, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc, Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates Albany PC, Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced BioBehavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Case Medical Center, Memory and Cognition Center, Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, LLC, Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|University of Virginia, Pittsburgh, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00575055"
615,"NCT00464334","A Study of V950 in People With Alzheimer Disease (V950-001 AM7)",,"Completed","Has Results","Alzheimer Disease","Biological: V950|Biological: ISCOMATRIX™|Biological: Placebo to V950","Number of Participants Who Experienced at Least One Adverse Event|Number of Participants Who Discontinued Study Drug Due to an Adverse Event|Geometric Mean Titer (GMT) of Amyloid Beta (Aβ) Peptide 1-40 Specific Antibodies at Month 7|Mean Fold Change From Baseline in GMT of Aβ Peptide 1-40 Specific Antibodies","Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","V950-001|2007_518","March 2007","January 2012","January 2012","April 23, 2007","December 18, 2012","September 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00464334"
616,"NCT00408525","Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: donepezil","Changes in brain activation patterns as measured in an fMRI.","Vanderbilt University|Vanderbilt University Medical Center","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 1","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","040686","December 2006","August 24, 2012","August 24, 2012","December 7, 2006",,"February 5, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00408525"
617,"NCT00630851","A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil (Aricept)|Drug: Placebo","Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score|Change from baseline in Severe Impairment Battery (SIB) total score|Change from baseline in SIB total score|Change from baseline in Neuropsychiatric Inventory (NPI) total score|Change from inclusion in Mini Mental State Examination (MMSE) total score|Change from baseline in Clinical Global Impression of Improvement (CGI-I) score|Adverse events and laboratory value changes|Change from baseline in modified ADCS-ADL-severe total score","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A2501017","October 2002",,"October 2004","March 7, 2008",,"March 5, 2015","Pfizer Investigational Site, Akersberga, Sweden|Pfizer Investigational Site, Alunda, Sweden|Pfizer Investigational Site, Aneby, Sweden|Pfizer Investigational Site, Arsta, Sweden|Pfizer Investigational Site, Avesta, Sweden|Pfizer Investigational Site, Bengtsfors, Sweden|Pfizer Investigational Site, Bergsjo, Sweden|Pfizer Investigational Site, Boden, Sweden|Pfizer Investigational Site, Borlange, Sweden|Pfizer Investigational Site, Degerfors, Sweden|Pfizer Investigational Site, Eskilstuna, Sweden|Pfizer Investigational Site, Eskilstuna, Sweden|Pfizer Investigational Site, Fritsla, Sweden|Pfizer Investigational Site, Gislaved, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Gullspang, Sweden|Pfizer Investigational Site, Gustavsberg, Sweden|Pfizer Investigational Site, Hedemora, Sweden|Pfizer Investigational Site, Helsingborg, Sweden|Pfizer Investigational Site, Ingelstad, Sweden|Pfizer Investigational Site, Jönköping, Sweden|Pfizer Investigational Site, Kalix, Sweden|Pfizer Investigational Site, Karlstad, Sweden|Pfizer Investigational Site, Katrineholm, Sweden|Pfizer Investigational Site, Kristinehamn, Sweden|Pfizer Investigational Site, Lidkoping, Sweden|Pfizer Investigational Site, Malmo, Sweden|Pfizer Investigational Site, Munkfors, Sweden|Pfizer Investigational Site, Nassjo, Sweden|Pfizer Investigational Site, Ostersund, Sweden|Pfizer Investigational Site, Oxie, Sweden|Pfizer Investigational Site, Partille, Sweden|Pfizer Investigational Site, Rattvik, Sweden|Pfizer Investigational Site, Sandviken, Sweden|Pfizer Investigational Site, Saro, Sweden|Pfizer Investigational Site, Sjuntorp, Sweden|Pfizer Investigational Site, Sollebrunn, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Sunne, Sweden|Pfizer Investigational Site, Trollhattan, Sweden|Pfizer Investigational Site, Tullinge, Sweden|Pfizer Investigational Site, Tyreso, Sweden|Pfizer Investigational Site, Umeå, Sweden|Pfizer Investigational Site, Upplands Väsby, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Varnamo, Sweden|Pfizer Investigational Site, Vaxjo, Sweden|Pfizer Investigational Site, Visby, Sweden|Pfizer Investigational Site, Vännäs, Sweden|Pfizer Investigational Site, Västerås, Sweden|Pfizer Investigational Site, Växjö, Sweden|Pfizer Investigational Site",,"https://ClinicalTrials.gov/show/NCT00630851"
618,"NCT00574132","Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg","Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 88 Years   (Adult, Older Adult)","Phase 3","1331","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELN115727-301","December 2007","June 2012","June 2012","December 17, 2007",,"November 25, 2013","University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Science Center, Tucson, Arizona, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Integrated Medical and Behavioral Associates, Glendale, California, United States|Sun Valley Behavioral Medical Center, Imperial, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego/Shela Marcos Alzheimer's Disease Research Center, La Jolla, California, United States|Senior Clinical Trials, Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Synergy Research, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|The Neurology Center, Oceanside, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|The Southwest Institute for Clinical Research, Inc., Rancho Mirage, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California, Davis, Alzheimer's Disease Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne International Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Broward Research Group, Inc., Pembroke Pines, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University/School of Medicine, Atlanta, Georgia, United States|MS Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Kansas Multi-Specialist Group, Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Memory Wellness Clinic, Springfield, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Coastal Research Associates, Inc., Weymouth, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Coastal Neurology, PA, Dover, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Dept of Neurology, Lebanon, New Hampshire, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|The Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Shore Neurology, P.A., Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, P.C., Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced Bio-Behavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University/Medical Center, New York, New York, United States|Dent Neurologic Institute, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rakesh Ranjan, M.D. & Associates, Inc., Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|University Memory and Aging Center University Hospitals of Cleveland/Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, Inc., Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Associates, Ltd, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburg, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Senior Adults Specialty Research (SASR), Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Inc, Wichita Falls, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|University of Wisconson Medical School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Independent Pyschiatric Consultants, Waukesha, Wisconsin, United States|Medizinische Universität Graz, Graz, Styria, Austria|Medizinische Universität Wien, Wien, Vienna, Austria|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|University of British Columbia (UBC) Hospital, Vancouver, British Columbia, Canada|Hotel Dieu Hospital/Queens University Memorial Clinics, Kingston, Ontario, Canada|Saint Joseph's Health Care London, Saint Joseph's Hospital, London, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Neurology Research Inch./Toronto Memory Program, Toronto, Ontario, Canada|Toronto Centre for Memory and Aging, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Scienes, Whitby, Ontario, Canada|Neuro Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Comite d' ethique de la recherche, Montreal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada|Universitätsklinik Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinik Ulm, Ulm, Baden-wuerttemberg, Germany|Universitätsklinik Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Günzburg, Bayern, Germany|Ludwig-Maximilians-Universität München, München, Bayern, Germany|Klinikum Rechts der Isar der Technischen Universität München, München, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Byern, Germany|Saint Josefs Hospital, Bochum, Nordrhein-westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Saarland, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Sachen, Germany|ABX-CRO advanced pharmaceutical services Forschungsgesellschaft GmbH, Dresden, Saschen, Germany|UKE Hamburg, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00574132"
619,"NCT00498602","Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Biological: ACC-001 + QS-21|Biological: QS-21|Other: Diluent: Phosphate Buffered Saline|Biological: ACC-001","Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)|Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104|Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3134K1-2201|B2571005","November 2007","February 2013","February 2013","July 10, 2007","January 1, 2016","January 1, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of California - San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|General Clinical Research Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|General Clinical Research Center, Washington, District of Columbia, United States|GUMC, Washington, District of Columbia, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Barrnes-Jewish Hospital at Washington University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmcare USA, Edison, New Jersey, United States|Columbia Univ/Taub Institute Irving Ctr for Clinical Researc, New York, New York, United States|CUMC Research Pharmacy, New York, New York, United States|Butler Hospital, Providence, Rhode Island, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00498602"
620,"NCT00439166","Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid",,"Completed","No Results Available","Alzheimer's Disease","Drug: doxycycline|Drug: rifampicin|Drug: Placebo matched to doxycycline|Drug: Placebo matched to Rifampin","Clinical Dementia Rating scale|Standardized Alzheimer's disease Assessment Scale -cognitive subscale","Hamilton Health Sciences Corporation|The Physicians' Services Incorporated Foundation|McMaster University","All","50 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSI 06-47","February 2007","April 2010","December 2010","February 23, 2007",,"March 19, 2018","St.Peter's Hospital, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00439166"
621,"NCT00448799","Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls",,"Completed","No Results Available","Alzheimers Disease","Radiation: [123-I] AV-83 Injection and Imaging Procedures","Assess the dynamic uptake and washout of 123-I AV83|Blood metabolite characterization of 123-I AV39 in healthy and AD subjects to determine the metabolic fate and nature of metabolites|Evaluate the test/retest reproducibility of 123-IAv83 and SPECT in AD subjects and healthy controls.","Molecular NeuroImaging|Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AV-83 001|07-033","March 2007","March 2008","March 2008","March 19, 2007",,"May 13, 2008","Molecular NeuroImaging, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00448799"
622,"NCT00117403","Anti-Oxidant Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid|Drug: Coenzyme Q|Drug: Placebo capsules|Drug: Placebo wafers","effect on cerebrospinal fluid (CSF) biomarkers related to oxidative damage|change in plasma and CSF concentrations of a-beta42 and a-beta40","National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","75","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IA0067","January 2006","September 2007","September 2007","July 6, 2005",,"April 3, 2009","University of Arizona, Tucson, Arizona, United States|University of California- Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Wien Center, Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|Neurological Care of CNY, Syracuse, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00117403"
623,"NCT00456417","Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects",,"Completed","No Results Available","Alzheimers Disease","Drug: 123-I MNI-187 Injection and Imaging Procedures","To assess the dynamic uptake and washout of 123-I MNI-187|Blood metabolite characterization of 123-I MNI-187 in healthy and AD subjects to determine the metabolic fate and nature of metabolites; Evaluate the test/retest reproducibility of 123-I MNI-187 and SPECT in AD subjects and healthy controls","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","All","50 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-187-01","April 2007","December 2007","December 2007","April 5, 2007",,"March 14, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00456417"
624,"NCT00566397","A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PF-04494700|Drug: Placebo","Evaluate the efficacy of PF 04494700 relative to placebo. Change from baseline in a standardized cognitive measure after 18 months of treatment.|Examine the safety and tolerability of PF 04494700 relative to placebo. Adverse events, vital signs, physical exam, neuro exam, 12-lead ECG, lab tests (hematology, blood chemistry, urinalysis) and brain magnetic resonance imaging (MRI).|Evaluate the effects of PF 04494700 on potential biomarkers of RAGE inhibition and amyloid imaging (AV-45, F18 PET)|Evaluate the potential dose response of PF 04494700|Evaluate the pharmacokinetics and characterize the pharmacokinetic (PK)/ pharmacodynamic (PD) relationship of PF 04494700 to potential biomarkers and relevant efficacy and safety endpoints","Pfizer|Alzheimer's Disease Cooperative Study (ADCS)","All","50 Years and older   (Adult, Older Adult)","Phase 2","402","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B0341002","December 2007","December 2010","December 2010","December 3, 2007",,"November 30, 2018","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Martinez, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Palo Alto, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Vista, California, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Miami Beach, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, North Charleston, South Carolina, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00566397"
625,"NCT00814801","An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Drug: Galantamine 16 mg/day|Drug: Galantamine 24 mg/day","Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)|Change From Baseline in the Disability Assessment for Dementia (DAD)|Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)|Change From Baseline in the Mental Function Impairment Scale (MENFIS)","Janssen Pharmaceutical K.K.","All","45 Years and older   (Adult, Older Adult)","Phase 3","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CR010297|GAL-JPN-5","February 2007","September 2008","September 2008","December 25, 2008","July 4, 2012","April 17, 2014","Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT00814801"
626,"NCT00606476","AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Bapineuzumab (AAB-001)","To assess the safety and tolerability of long-term treatment of bapineuzumab in subjects with AD.|To evaluate the efficacy of long-term treatment of bapineuzumab in subjects with AD.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","Child, Adult, Older Adult","Phase 2","194","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","AAB-001-251","December 2006","September 2012","September 2012","February 4, 2008",,"November 25, 2013","Janssen AI Investigational Site, Peoria, Arizona, United States|Janssen AI Investigational Site, Sun City, Arizona, United States|Janssen AI Investigational Site, Encino, California, United States|Janssen AI Investigational Site, Irvine, California, United States|Janssen AI Investigational Site, La Jolla, California, United States|Janssen AI Investigational Site, Los Alamitos, California, United States|Janssen AI Investigational Site, Sacramento, California, United States|Janssen AI Investigational Site, San Francisco, California, United States|Janssen AI Investigational Site, New Haven, Connecticut, United States|Janssen AI Investigational Site, Washington, District of Columbia, United States|Janssen AI Investigational Site, Delray Beach, Florida, United States|Janssen AI Investigational Site, Jacksonville, Florida, United States|Janssen AI Investigational Site, Chicago, Illinois, United States|Janssen AI Investigational Site, Indianapolis, Indiana, United States|Janssen AI Investigational Site, Boston, Massachusetts, United States|Janssen AI Investigational Site, Ann Arbor, Michigan, United States|Janssen AI Investigational Site, Rochester, Minnesota, United States|Janssen AI Investigational Site, St. Louis, Missouri, United States|Janssen AI Investigational Site, Eatontown, New Jersey, United States|Janssen AI Investigational Site, New York City, New York, United States|Janssen AI Investigational Site, Rochester, New York, United States|Janssen AI Investigational Site, Durham, North Carolina, United States|Janssen AI Investigational Site, Portland, Oregon, United States|Janssen AI Investigational Site, PIttsburgh, Pennsylvania, United States|Janssen AI Investigational Site, Providence, Rhode Island, United States|Janssen AI Investigational Site, Dallas, Texas, United States|Janssen AI Investigational Site, Houstan, Texas, United States|Janssen AI Investigational Site, Bennington, Vermont, United States|Janssen AI Investigational Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00606476"
627,"NCT00420420","MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)",,"Completed","Has Results","Alzheimer's Disease","Drug: MK0249|Drug: Comparator: Placebo (unspecified)","Week 4 Change From Baseline in Computerized Neuropsychological Test Battery (CNTB): Short CNTB Summary Score.|Week 4 Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): ADAS-Cog Total Score|Week 4 Change From Baseline in Cognition Summary Score (CSS)","Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0249-011|2006_534","November 2006","August 2008","August 2008","January 11, 2007","November 18, 2010","February 12, 2015",,,"https://ClinicalTrials.gov/show/NCT00420420"
628,"NCT00736775","A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: anti-Abeta|Drug: placebo","Safety and tolerability of single and multiple doses of MABT5102A|Pharmacokinetics of MABT5102A after single and multiple doses|Immunogenicity of MABT5102A after single and multiple doses","Genentech, Inc.","All","50 Years to 86 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ABE4427g","August 2008","May 2010",,"August 18, 2008",,"October 27, 2010",,,"https://ClinicalTrials.gov/show/NCT00736775"
629,"NCT00164749","A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Placebo and ginkgo extract|Drug: Curcumin and ginkgo extract","Change in isoprostane level in plasma|Change in A-beta level in serum|Change in cognitive function (MMSE score)|Change in cholesterol and triglycerides in serum|Change in metals in serum|Level of curcumin in plasma vs. dose","Chinese University of Hong Kong|BUPA Foundation|Kwong Wah Hospital","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CRE-2003.090-T","October 2004","July 2006","July 2006","September 14, 2005",,"April 30, 2008","The Chinese University of Hong Kong, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00164749"
630,"NCT00607308","A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365|Drug: Placebo","To examine the safety and tolerability of a single dose of PF-04360365 in Japanese subjects with mild to moderate AD for one year following dosing.|To characterize the pharmacokinetic, pharmacodynamic and immunogenicity profile of PF-04360365 for one year following dosing.","Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A9951005","February 2008","October 2010","October 2010","February 5, 2008",,"December 7, 2010","Pfizer Investigational Site, Hirosaki, Aomori, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka, Japan|Pfizer Investigational Site, Fukuyama city, Hiroshima, Japan|Pfizer Investigational Site, Tsukuba, Ibaraki, Japan|Pfizer Investigational Site, Niigata-shi, Niigata, Japan|Pfizer Investigational Site, Bunkyo-ku, Tokyo, Japan|Pfizer Investigational Site, Kodaira, Tokyo, Japan|Pfizer Investigational Site, Kanazawa, Japan|Pfizer Investigational Site, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT00607308"
631,"NCT00440050","DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease","DHA","Completed","Has Results","Alzheimer's Disease","Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo","Rate of Change on the ADAS-Cog 11.|Rate of Change on CDR-SOB|ADCS-ADL|Neuropsychiatric Inventory (NPI)","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|DSM Nutritional Products, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","402","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0099|1RC2AG036535|ADC-027-DHA","February 2007","May 2009","May 2009","February 26, 2007","August 30, 2010","September 25, 2014","University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Sun Health Research Institute/Arizona Consortium, Sun City, Arizona, United States|University of California Irvine, Irvine, California, United States|UCSD Shiley-Marcos Alzheimer's Research Center, La Jolla, California, United States|University of Southern California Psychiatry and Behavioral Sciences, Los Angeles, California, United States|UCLA Neurology, Los Angeles, California, United States|Palo Alto Institute for Research & Education, Palo Alto, California, United States|UC-Davis Alzheimer's Disease Center, Sacramento, California, United States|Pacific Research Network, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Dept. of Neurology, Washington, District of Columbia, United States|Howard University College of Medicine, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Byrd Alzheimer's Institute, Tampa, Florida, United States|Emory University Dept. of Psychiatry, Atlanta, Georgia, United States|Northwestern University Cognitive Neurology and Alzheimer Disease Center, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Sanders-Brown Center on Aging/Neurology, Lexington, Kentucky, United States|Johns Hopkins University Division of Cognitive Neuroscience, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Alzheimer's Disease Clinical and Research Program, Boston, Massachusetts, United States|University of Michigan Dept. of Neurology, Ann Arbor, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Mayo Clinic Rochester, Alzheimer's Disease Research Center, Rochester, Minnesota, United States|Saint Louis University, Department of Psychiatry, St. Louis, Missouri, United States|Washington University ADRC-Memory and Aging Project, St. Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Mount Sinai School of Medicine, Bronx, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Services, Winston-Salem, North Carolina, United States|Case Western Reserve University Memory and Aging Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University Neurology, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital Neurology, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Meharry Medical College, Nashville, Tennessee, United States|University of Texas Southwestern-Memory Research Unit, Dallas, Texas, United States|Baylor University Department of Neurology, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Washington/Seattle Institute for Biomedical & Clinical Research, Seattle, Washington, United States|University of Wisconsin Department of Medicine, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00440050"
632,"NCT00439010","Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects",,"Completed","No Results Available","Alzheimers Disease","Drug: [123I] AV 39","Assess the dynamic uptake and washout of 123-I AV39|Blood metabolite characterization of 123-I AV39 in healthy and AD subjects to determine the metabolic fate and nature of metabolites|Evaluate the test/retest reproducibility of 123-I AV39 and SPECT in AD subjects and healthy controls","Molecular NeuroImaging|Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic","AV-39 001","February 2007","January 2008","January 2008","February 22, 2007",,"April 24, 2008","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00439010"
633,"NCT00481520","Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531|Other: placebo","Routine safety and tolerability will be evaluated.|This study will also investigate the pharmacokinetics(PK, how the drug is metabolized) and pharmacodynamics (PD, how the drug affects bodily and mental function) of SAM-531 compared to placebo.","Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","3193A1-2000","June 2007","January 2008","January 2008","June 1, 2007",,"September 30, 2009","Delray Beach, Florida, United States|Hallandale, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Long Branch, New Jersey, United States|New York, New York, United States|Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00481520"
634,"NCT00202124","Double Blind Study of Trp01 in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Tryptophan","1. MMSE score|2. Alzheimer’s Disease Assessment Scale, cognitive subpart (ADAS-Cog) as an evaluation of cognitive functioning|1. Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC)|2. Neuropsychiatric Inventory (NPI)|3. Disability Assessment for Dementia (DAD)|4. Physical Self-Maintenance Scale (PSMS)|5. Functional Activities Questionnaire (FAQ)","Queen's University","All","Child, Adult, Older Adult","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","DFW-TRP01","April 2001",,"March 2002","September 20, 2005",,"September 20, 2005","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00202124"
635,"NCT00142805","Ketasyn in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Ketasyn™ (AC-1202)","Changes measured by Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at all 5 visits|Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change (ADCS-CGIC) at visits 2 through 5|Mini-Mental State Exam (MMSE) at all 5 visits|Changes measured by Electrocardiogram (ECG) at visits 1 and 5|Beta-Hydroxybutyrate pre-dose levels at all 5 visits|Beta-Hydroxybutyrate 2-hour post-dose levels at visits 2, 3, and 4","Cerecin|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0076","October 2004",,"March 2006","September 2, 2005",,"December 31, 2008","21st Century Neurology, a division of Xenoscience Inc., Phoenix, Arizona, United States|Comprehensive NeuroScience, Cerritos, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|The Southwest Institute for Clinical Research, Rancho Mirage, California, United States|Pharmacology Research Institute, Riverside, California, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Baumel-Eisner Neuromedical Institute, Inc., Ft. Lauderdale, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Comprehensive NeuroScience, Melbourne, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Anchor Research Center, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Comprehensive NeuroScience, St. Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Radiant Research, Chicago, Illinois, United States|Multi-Specialty Research Associates of North Carolina, Raleigh, North Carolina, United States|Radiant Research, Portland, Oregon, United States|Radiant Research, Dallas, Texas, United States|Research Across America, Dallas, Texas, United States|Radiant Research, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00142805"
636,"NCT02195596","Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.","EFA-P","Unknown status","No Results Available","Alzheimer Disease","Other: High intensity aerobic exercise+strength|Other: Low intensity aerobic exercise+strength","Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12|Global cognitive performance","Basque Health Service","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","2011111100","April 2013","January 2015","December 2015","July 21, 2014",,"July 21, 2014","Galdakao Hospital/Galdakao C.S., Galdakao, Bilbao, Spain|Basauri C.S., Basauri, Bizkaia, Spain|Hospital Universitario de Basurto, Bilbao, Bizkaia, Spain",,"https://ClinicalTrials.gov/show/NCT02195596"
637,"NCT00471211","Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PBT2","Safety|Change from baseline in biomarkers; Change from baseline in cognitive and global function scales","Prana Biotechnology Limited","All","56 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PBT2-201","December 2006","December 2007","December 2007","May 9, 2007",,"January 16, 2008","Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Falkoping, Sweden|Kalix, Sweden|Kalmar, Sweden|Lund, Sweden|Malmo, Sweden|Stockholm, Sweden|Umea, Sweden|Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00471211"
638,"NCT04041895","Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Other: Audio speech recording","Analysis of speech audio recording describing the ""Cookie-Thief Image"" using proposed computational model designed by PI for determination of Alzheimer's disease|MMSE","East Tennessee State University","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","0218.16sw","August 13, 2018","August 2020","August 2020","August 1, 2019",,"August 1, 2019","East Tennessee State University, Johnson City, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04041895/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04041895"
639,"NCT00191009","Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: atomoxetine hydrochloride|Drug: placebo","To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive|To see if patients taking an Alzheimer's medication plus atomoxetine for approximately 6 months will be superior to an Alzheimer's medication alone as assessed by the Clinician's Interview-Based Impression of Change (CIBIC+) score.|To see if patients taking an Alzheimer's medication plus atomoxetine will display less comorbid psychological symptoms, such as depression, as assessed by the Neuropsychiatric Inventory (NPI). Patients will receive the NPI once before randomization|To see if current Alzheimer's medications plus atomoxetine compared to Alzheimer's medications plus placebo is better at preserving or slowing cognitive decline as measured by the Alzheimer's Disease Cooperative Study Inventory - Activities of|To show that current Alzheimer's drugs can be taken with atomoxetine without significant side effects.","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","7951|B4Z-MC-LYCG","October 2003",,"January 2006","September 19, 2005",,"November 6, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00191009"
640,"NCT00397891","Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease",,"Completed","Has Results","Alzheimer Disease","Drug: bapineuzumab","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Physical Examinations|Number of Participants With Vital Signs of Potential Clinical Importance|Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance|Number of Participants With Laboratory Test Results of Potential Clinical Importance|Number of Participants With Clinically Significant Changes in Neurological Examinations|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52|Maximum Observed Serum Concentration (Cmax) of Bapineuzumab|Time to Reach Maximum Observed Serum Concentration (Tmax) of Bapineuzumab|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Bapineuzumab|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Bapineuzumab|Systemic Clearance (CL) of Bapineuzumab|Volume of Distribution at Steady State (Vss) of Bapineuzumab|Mean Residence Time of Bapineuzumab|Serum Decay Half-Life (t1/2) of Bapineuzumab|Serum Bapineuzumab Concentrations|Number of Participants With Positive Serum Anti-Bapineuzumab Antibody|Plasma Amyloid-beta (x-40) Concentrations","Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","3133K1-102","October 2006","February 2010","February 2010","November 10, 2006","September 4, 2014","September 4, 2014","Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Saitama, Japan|Pfizer Investigational Site, Shizuoka, Japan|Pfizer Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00397891"
641,"NCT00455000","A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: PF-04360365|Drug: Placebo","To examine the safety, tolerability, and pharmacokinetics of a single dose of PF-04360365 in subjects with mild to moderate AD for one year following dosing.|To characterize the pharmacokinetic, pharmacodynamic and immunogenicity profile of PF-04360365 for one year following dosing.","Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A9951001","March 2007","September 2009","September 2009","April 2, 2007",,"October 14, 2009","Pfizer Investigational Site, Heidelberg West, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00455000"
642,"NCT00549601","Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","KAPA","Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Drug: Rivastigmine patch (9.5 mg/day)|Drug: Rivastigmine capsules (6 mg to 12 mg/day)","Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the Study|Percentage of Patients With an AE Involving the Skin (Local Tolerance) Recorded Over the Course of the Study Period (Patch Groups Only)|Percentage of Patients With at Least 1 AE of Any Kind Recorded During the Period of the Study.|Overall Caregiver Satisfaction With Treatment|Overall Patient Satisfaction With Treatment|Change in the Total Mini-Mental State Examination (MMSE) Score From Baseline to Month 1 and Month 3","Novartis","All","60 Years and older   (Adult, Older Adult)","Phase 4","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DES07","September 2007","April 2009","April 2009","October 26, 2007","March 24, 2011","March 24, 2011","Novartis Investigative Site, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00549601"
643,"NCT00500500","Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer Disease","Drug: EGb 761® (Tanakan®)","Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.|Efficacy of EGb 761® on the cognitive functions and safety of EGb 761® at a dosage of 240 mg per day","Ipsen","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2-29-00240-127","July 2005","April 2008","April 2008","July 12, 2007",,"October 11, 2013","Hôpital La Timone, Marseille, France",,"https://ClinicalTrials.gov/show/NCT00500500"
644,"NCT00706186","Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients","ALD","Terminated","No Results Available","Mild Alzheimer's Disease","Drug: Sodium Oxybate","To evaluate and monitor the safety and tolerability of 6 to 9 g/day sodium oxybate in patients with mild Alzheimer's disease (AD) between the ages of 50 and 65 years.","Clayton Sleep Insititute|St. Louis University","All","50 Years to 65 Years   (Adult, Older Adult)","Phase 4","4","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALD Xyrem",,,,"June 27, 2008",,"July 7, 2010","Clayton Sleep Institute, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00706186"
645,"NCT02626572","Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms",,"Completed","No Results Available","Alzheimer's Disease","Drug: S47445 5mg|Drug: S47445 15mg|Drug: S47445 50mg|Drug: Placebo","Change from baseline on 11-item ADAS-Cog|Activities of Daily Living: Disability Assessment for Dementia (DAD)|Cognition: 13-item ADAS-Cog|Cognition: Mini-Mental State Examination (MMSE)|Depressive symptoms: Cornell Scale for Depression in Dementia (CSDD)|Behavioural signs and symptoms: Neuropsychiatric Inventory (NPI)|Global Clinic Assessment of Change: Alzheimer's Disease Cooperative Studies-Clinical Global Impression of Change (ADCS-CGIC)|Functionality: Gait task (GT), measure of speed of walking (unit= meters/ seconds)|Adverse events|Vital signs: heart rate|Vital signs: body temperature|Vital signs: blood pressure|Vital signs: body weight|12-lead ECG|Biological laboratory parameters: number of participants with abnomal laboratory values|Cornell Scale for Depression in Dementia (CSDD, suicide item - item 16)","Institut de Recherches Internationales Servier|Servier","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL2-47445-011|2014‐001519‐38","February 2015","September 2017","September 2017","December 10, 2015",,"August 15, 2018","Trial Tech Tecnologia em Pesquisa com Medicamentos, Curitiba, Brazil|Hospital Universitario Walter Cantidio, Fortaleza, Brazil|Clinilive - Centro de Pesquisas Clinicas, Maringa, Brazil|Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Oswaldo Cruz, Recife, Brazil|Instituto Américo Bairral de Psiquiatria, Centro de Pesquisa, Sao Paulo, Brazil|UNIFESP - Universidade Federal de Sao Paulo, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Medical University of Sofia, Aleksandrovska hospital, Sofia, Bulgaria|National Hospital of Cardiology, Sofia, Bulgaria|University Hospital Sveti Naum, Clinic of Neurology, Sofia, Bulgaria|MHAT Sveta Marina, Varna, Bulgaria|Clínica Oriente, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|Hospital Santiago Oriente, Santiago, Chile|Private practice, Santiago, Chile|Saint Anne s.r.o. Psychiatricka ambulance, Brno, Czechia|Brain-Soultherapy s.r.o., Kladno, Czechia|Bialbi s.r.o., Litomerice, Czechia|AD71 s.r.o. Psychiatricka ambulance - Sudkova, Praha, Czechia|CLINTRIAL s.r.o., Praha, Czechia|FORBELI s.r.o., Neurologicka ambulance, Praha, Czechia|Klinikum Altenburger Land GmbH Neurologische Klinik, Altenburg, Germany|Neuropsychiatrisches Facharztzentrum Stiepel, Bochum, Germany|Universitaetsklinikum des Saarlandes, Klinik für Psychiatrie und Psychotherapie, Homburg / Saar, Germany|ISPG Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida, Germany|Somni Bene, Institut fuer Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Germany|Universitaetsklinik ULM, Poliklinik Neurologie, Ulm, Germany|Private practice, Westerstede, Germany|Semmelweis Egyetem Neurologiai Klinika, Budapest, Hungary|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary|Vaszary Kolos Korhaz Esztergom Neurologiai Osztaly, Esztergom, Hungary|Petz Aladar Megyei Oktato Korhaz Pszihiatriai, Mentalhygienes es Addiktologiai Osztaly, Gyor, Hungary|Private practice, Kalocsa, Hungary|B-A-Z Megyei Korhaz es Egyetemi Oktato Korhaz Stroke, Er- es Neurologiai, Toxikologiai Osztaly, Miskolc, Hungary|Josa Andras Oktatokorhaz Pszihiatriai Osztaly, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont Pszich. es Pszichoter. Klinika, Pecs, Hungary|Szent-Gyorgyi Albert Klinikai Kozpont Pszichiatriai Klinika, Szeged, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz Pszichiatriai Osztaly, Szekesfehervar, Hungary|Memory Clinic Ochanomizu, Bunkyo-ku, Japan|Showakai Clinic, Kagoshima-shi, Japan|Rainbow & Sea Hospital, Karatsu-shi, Japan|Kokan Clinic, Kawasaki-shi, Japan|Social Medical Corporation Kojunkai Daido Hospital, Nagoya, Japan|Nakano General Hospital, Nakano-ku, Japan|Private practice, Saitama-shi, Japan|Private practice, Setagaya-ku, Japan|Seishinkai Okehazama Hospital, Toyoake-shi, Japan|Instituto Biomedico de Investigacion, Aguascalientes, Mexico|Centro de Estudios Clinicos Y Especialidades Medicas Sc, Monterrey, Mexico|Hospital Universitario de Nuevo León, Nuevo León, Mexico|University Hospital of Saltillo, Saltillo, Mexico|Nzoz Centrum Kultury, Higieny I Zdrowia Psychicznego, Bydgoszcz, Poland|Krakowska Akademia Neurologii Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ Neuromed M. i M. Nastaj Sp. Partnerska, Lublin, Poland|Osrodek Alzheimerowski Sp. z o.o., Scinawa, Poland|SENIOR Poradnia Psychogeriatryczna, Sopot, Poland|Centrum Medyczne Neuroprotect, Warszawa, Poland|Interregional Clinico-Diagnostical Centre, Kazan, Russian Federation|First Moscow State Medical University n.a.I.M. Sechenov Clinic of Neurology, Moscow, Russian Federation|Scientific Center of Mental Health Sect of AD and associated disord. Dpt of gerontopsychiatry, Moscow, Russian Federation|Scientific Center of Mental Health Sect of psychosis of elderly ages Dpt of gerontopsychiatry, Moscow, Russian Federation|City geriatric medico-social centre, St. Petersburg, Russian Federation|Medical Military Academy n.a.S.M.Kirov, St. Petersburg, Russian Federation|Psychoneuropathology Dispensary N 10, St. Petersburg, Russian Federation|Co Ltd ""LION-MED"", Voronezh, Russian Federation|Private practice, Bratislava, Slovakia|INVESTA, spol. s r. o. Psychiatricka ambulancia, Kosice, Slovakia|NsP Svatej Barbory Psychiatricke oddelenie, Roznava, Slovakia|Iatros International, Bloemfontein, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Umhlanga Hospital, Durban, South Africa|Excellentis Clinical Trial Consultants, George, South Africa|Apollo Clinical Research, Johannesburg, South Africa|Denmar Hospital, Pretoria, South Africa|Somerset West Trial Centre, Somerset West, South Africa",,"https://ClinicalTrials.gov/show/NCT02626572"
646,"NCT00359944","Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: AC-3933|Other: Sugar Pill","Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)From Best Total Score (0) to Worst Total Score (70)|Clinicians Interview Based Impression of Change (CIBIC)-Plus|Disability Assessment for Dementia (DAD)","Sunovion","All","55 Years and older   (Adult, Older Adult)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AC-3933-271","February 2006","September 2008","September 2008","August 3, 2006","July 2, 2013","July 2, 2013","Clinical Trials Inc., LIttle Rock, Alaska, United States|PsyPharma Clinical Research Inc., Phoenix, Arizona, United States|ClinicalStudies Center LLC, Little Rock, Arkansas, United States|Vertex Clinical Research, Bakersfield, California, United States|East Bay Physicians Medical Grou[, Berkeley, California, United States|Margolin Brain Institute, Fresno, California, United States|Clinical Trials Associates, Mission Viejo, California, United States|University of California, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Memory Disorder Clinic, Deerfield Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Advanced Research Institute of Miami, Miami, Florida, United States|Research Institute of Miami, Miami, Florida, United States|Research Center of Florida Inc., Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Department of Psychiatry and Behavioral Medicine, Tampa, Florida, United States|Stedman Clinical Trials LLC, Tampa, Florida, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Minneapolis, Minnesota, United States|Clinical Psychopharmacology Consultants PA, Saint Louis Park, Minnesota, United States|Precise Research Centers INc., Flowood, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|Odyssey Researcfh, Fargo, North Dakota, United States|Paradigm Research Professionals LLP, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|UT Medical Group Inc., Memphis, Tennessee, United States|Neurological Research Center, Inc., Bennington, Vermont, United States|International Clinical Research Associates LLC, Richmond, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00359944"
647,"NCT00299988","Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Intravenous Immunoglobulin","ADAS-Cog|ADCS-CGIC|3MS|ADCS-ADL|NPI|GDS|QOL|ADCS Pharmacoeconomic Assessment|Plasma and CSF anti-amyloid antibody titers|Plasma and CSF beta amyloid levels|FDG Cerebral Glucose Utilization|PIB Cerebral Amyloid Distribution (PET)|PK11195 Microglial Activation (PET)|Adverse Event Frequency and Severity","Weill Medical College of Cornell University|Baxter BioScience|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0512008265","February 2006","January 2009","April 2010","March 7, 2006",,"November 10, 2010","Weill Medical College of Cornell University, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00299988"
648,"NCT00413621","MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems",,"Completed","No Results Available","Alzheimer's Disease",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","55 Years to 90 Years   (Adult, Older Adult)",,"40","NIH","Observational",,"070050|07-N-0050","December 14, 2006","October 7, 2009",,"December 20, 2006",,"July 2, 2017","Johns Hopkins University, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00413621"
649,"NCT00255086","The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients",,"Completed","Has Results","Alzheimer Disease","Drug: Memantine|Drug: Placebo pill","NAA/Cr Ratio|Mean Change on the ADAS-Cog Score After 1 Year","Stanford University|Palo Alto Veterans Institute for Research|Forest Laboratories","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 3","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","95722","May 2005","June 2009","February 2010","November 17, 2005","April 7, 2017","April 7, 2017","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00255086"
650,"NCT00428389","Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine 5 cm^2 transdermal patch|Drug: Rivastigmine 10 cm^2 transdermal patch","Number of Participants Who Discontinued From the Study Due to Any Reason During the Core Phase of the Study|Number of Participants Who Discontinued From the Study Due to Any Adverse Event (AE) During the Combined Core and Extension Phases of the Study|Number of Participants Who Discontinued From Study Due to Any Reason During Extension Phase|Mean Change From Baseline in the Clinical Global Impression of Change (CGIC) Score at Week 5 and Week 25|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 25 and at the End of Study|Mean Change From Baseline in Neuropsychiatric Inventory - 10 Item (NPI-10) Score at Week 25 and at the End of Study.|Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score at Week 25 and at the End of Study","Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DUS38|CENA713DUS38E1","January 2007","February 2008","February 2008","January 30, 2007","June 27, 2011","June 11, 2014","Dedicated Clinical Research, Sun City, Arizona, United States|ATP Clinical Research, Costa Mesa, California, United States|Margolin Brain Institute, Fresno, California, United States|Investigative site, Denver, Colorado, United States|Berma Research Group, Hialeah, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Premiere Research Institute @ Palm Beach Neurology, West Palm Beach, Florida, United States|Medical Associates of North Georgia, Canton, Georgia, United States|Medical Associates of North Georgia, Cumming, Georgia, United States|Witham Health Services, Lebanon, Indiana, United States|Investigative site, Pittsfield, Massachusetts, United States|Rochester Center For Behavioral Medicine, Rochester Hills, Michigan, United States|Alzheimer's Research Corporation, Manchester, New Hampshire, United States|Investigative site, Long Branch, New Jersey, United States|Neurobehavioral Research, Inc, Cedarhurst, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Investigative site, Centerville, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Investigative site, Eugene, Oregon, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Senior Adults Specialty Research, Austin, Texas, United States|Investigative site, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00428389"
651,"NCT00105105","Mifepristone as Adjunctive Therapy in Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Mifepristone","effects on cognition|effects on behavior and activities of daily living","Corcept Therapeutics|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 2","160","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0069","April 2003","November 2005","November 2005","March 7, 2005",,"December 11, 2009","Pivotal Research Center, Mesa, Arizona, United States|Pivotal Research Center, Peoria, Arizona, United States|ATP Clinical Trials, Fountain Valley, California, United States|UCI Irvine Medical Center, Orange, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|AVI Clinical Research, Torrance, California, United States|Baumel-Eisner Neuromed Inst, Boca Raton, Florida, United States|Baumel-Eisner Neuromed Inst, Ft. Lauderdale, Florida, United States|Clinical Physiology Associates, Ft. Myers, Florida, United States|Baumel-Eisner Neuromed Inst, Miami Beach, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Johnnie B. Byrd, Sr. Alzheimer's Center & Research Inst, Tampa, Florida, United States|Memory Enhancement Center, Long Branch, New Jersey, United States|Eastside Medical Research, New York, New York, United States|Neuro Center of Ohio, Toledo, Ohio, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|International Clinical Research Associates, Richmond, Virginia, United States|International Clinical Research Associates, Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00105105"
652,"NCT00314912","Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Tramiprosate (3APS)","To evaluate the long-term safety of Tramiprosate (3APS).|To provide additional long-term data on the efficacy of Tramiprosate (3APS).","Bellus Health Inc","All","50 Years and older   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CL-758017","May 2006",,,"April 17, 2006",,"July 16, 2007","San Francisco Clinical Research Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00314912"
653,"NCT00083421","Effects of ONO-2506PO in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ONO-2506PO","Cognitive Function Scale|Global Function Scale|ADL Scale|Psychiatric Symptom Scale","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","647","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ONO-2506POU010","June 2004",,"July 2007","June 18, 2004",,"June 13, 2012","Kirkland Clinic, Birmingham, Alabama, United States|Alzheimers Disease Research Center, Birmingham, Alabama, United States|Pivotal Research Center, Mesa, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|UCI Medical Center Neuropsychiatric Center, Orange, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|The Southwest Institute for Clinical Research, Inc, Rancho Mirage, California, United States|Hamid Rabiee, MD, Redding, California, United States|Alzheimers Disease Research Center, Univ of CA, San Diego, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|Pacific Neuroscience Medical Group, Santa Barbara, California, United States|Neurological Research Institute, Santa Monica, California, United States|Radiant Research, Denver, Colorado, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|GAP Clinical Care & Research Center, Hamden, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Neurologic Consultants, Ft. Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Gainsville Open MRI, Gainsville, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Florida, United States|Miami Jewish and Hospital for the Aged, Miami, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Research Site, Port Charlotte, Florida, United States|Suncoast Neuroscience Associates, St. Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|DeKalb Neurology Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Mercer University, Atlanta, Georgia, United States|Rush Alzheimers Disease Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Radiant Research, Hoffman Estates, Illinois, United States|Southern Illinois School of Medicine, Springfield, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Center for Alzheimers Disease and Related Disorders, Indianapolis, Indiana, United States|Agewell, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Cntr - Dept of Psychiatry, New Orleans, Louisiana, United States|J. Gary Booker, M.D., APMC, Shreveport, Louisiana, United States|St. Louis University Medical Center, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Meridian Institue for Aging, Manchester, New Jersey, United States|Mid Atlantic Geriatric Association, Ocean Township, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Upstate Clinical Reserach, LLC, Albany, New York, United States|Upstate Neurology Consults, LLP, Albany, New York, United States|Neurological Associates of Albany, Albany, New York, United States|Neurobehavioral Research Inc., Lawrence, New York, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Global Reserach & Consulting, Olean, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Behavioral Medical Research, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Metrohealth Medical Center, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Infinity Research Group, LLC, Oklahoma City, Oklahoma, United States|Clinical Pharmaceutical Trials, Tulsa, Oklahoma, United States|Medford Neurological and Spine Clinic, Medford, Oregon, United States|Summit Research Network, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Westmoreland Neurology Associates, Inc., Greensburg, Pennsylvania, United States|University of PA, Section Geriatric Psychiatry, Philadelphia, Pennsylvania, United States|Alzheimer Disease Research Center, Univ of Pittsburg, Pittsburg, Pennsylvania, United States|Miriam Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Alzheimers Research and Clinical Programs, North Charleston, South Carolina, United States|Claghorn Lesem Research Clinic, Bellaire, Texas, United States|Memory Research Unit, Univ of Texas Southwest Med Ctr at Dallas, Dallas, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Neurological Consultants, PC, Bennington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Medical College of Wisconsin, Department of Neurology, Milwaukee, Wisconsin, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Inova Health Research, Inc., Kelowna, British Columbia, Canada|University of British Columbia Hospital, Vancouver, British Columbia, Canada|Davidson Memory Clinic, Moncton, New Brunswick, Canada|Parkwood Hospital, Geriatric Medicine, London, Ontario, Canada|SCO Health Centre, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00083421"
654,"NCT02187627","Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",,"Completed","No Results Available","Alzheimer's Disease, Healthy Volunteer","Drug: [11C]RO6924963|Drug: [11C]RO6931643|Drug: [18F]RO6958948","Part 1: Standard Uptake Value (SUV), as Assessed by Tau PET Brain Scan|Part 1: Standard Uptake Value Ratio (SUVR), as Assessed by Tau PET Brain Scan|Part 1: SUV, as Assessed by Tau PET Scan of Whole Body|Part 1: SUVR, as Assessed by Tau PET Scan of Whole Body|Mean Residence Times for Each Organ, as Assessed by Tau PET Scan of Whole Body|Part 1: Distribution Volume (VT), as Assessed by Tau PET Brain Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUVR|Part 2A: Absolute Percentage Difference Between Test and Retest of VT|Part 2B: Effective dose (ED), as Assessed by Whole Body PET Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUV|Percentage of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","25 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BP29409","August 31, 2014","February 29, 2016","February 29, 2016","July 11, 2014",,"January 1, 2019","Parexel International; Harbor Hospital Center, Baltimore, Maryland, United States|Johns Hopkins Universtiy; Radiology Dept, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02187627"
655,"NCT00231946","ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)",,"Completed","No Results Available","Alzheimer's Disease","Drug: VP4896","Cognitive assessment and Caregiver's impression of change at baseline and at weeks 8, 24, 34, and 50.|Ability to perform Activities of Daily Living (ADL) at baseline and weeks 8, 24, 34, and 50. Impression of disease severity assessment at week 50.","Voyager Pharmaceutical Corporation|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Phase 3","555","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0084","September 2005",,,"October 4, 2005",,"September 20, 2007","Pivotal Research Centers, Peoria, Arizona, United States|NeuroSpecialists, PLLC, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Bay Area Research Institute, Lafayette, California, United States|Anderson Clinical Research, Loma Linda, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|David Trader, Los Angeles, California, United States|Synergy Clinical Research, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|North County Neurology Assoc., Oceanside, California, United States|Pharmacology Research Institute, Riverside, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Torrance Clinical Research, Torrance, California, United States|Radiant Research, Denver, Colorado, United States|Colorado Neurology & Headache Center, Denver, Colorado, United States|Comprehensive Neuroscience, Inc., Darien, Connecticut, United States|Geriatric and Adult Psychiatry, Hamden, Connecticut, United States|Meridien Research, Brookville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Neurology Clinical Research, LLC, Plantation, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Palm Beach Neurological Group, West Palm Beach, Florida, United States|Quantum Laboratories, West Palm Beach, Florida, United States|Kuakani Medical Center, Honolulu, Hawaii, United States|Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States|ICPS Group, Boston, Massachusetts, United States|Pivotal Research Centers, Royal Oak, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Medark Clinical Trials, Morgantown, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Neurology Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Pharmaceutical Research-Oregon, Inc., Eugene, Oregon, United States|Clinical Trial Center, LLC., Jenkintown, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Norman Gordon, MD, Providence, Rhode Island, United States|Radiant Research - Greer, Greer, South Carolina, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Bexar Diagnostic Medicine Associates, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Novabyss Inc., Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00231946"
656,"NCT00013650","Effects of an Anti-Inflammatory Drug in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Cyclophosphamate",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","010128|01-M-0128","March 22, 2001",,"April 21, 2008","March 28, 2001",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00013650"
657,"NCT00401167","Memantine for Agitation and Aggression in Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: memantine","Neuropsychiatric Inventory Nursing Home Version|Clinical Global Impression of Change|Neuropsychiatric Inventory Burden Subscale|Cohen Mansfield Agitation Inventory|Modified Nursing Care Assessment Scale|Activities of Daily Living|Quality of Life in Late Stage Dementia","Sunnybrook Health Sciences Centre|Lundbeck Canada Inc.","All","65 Years and older   (Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lundbeck-11267","November 2006","January 2010","January 2010","November 17, 2006",,"May 25, 2012","North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00401167"
658,"NCT00018343","Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen",,"Completed","No Results Available","Alzheimer's Disease","Drug: estrogen",,"US Department of Veterans Affairs|VA Office of Research and Development","Female","50 Years to 90 Years   (Adult, Older Adult)","Phase 2",,"U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AGCG-007-97F","April 1998",,"March 2001","July 5, 2001",,"January 21, 2009","VA Puget Sound Health Care System, Lakewood, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00018343"
659,"NCT02004392","Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025",,"Terminated","No Results Available","Alzheimer's Disease|Dementia","Drug: EVP-6124","Safety of 2 fixed doses of EVP-6124 for up to 52 weeks in subjects with Alzheimer's disease who complete study EVP-6124-024 or EVP-6124-025|Change from Baseline in cognition using the Mini-Mental State Examination (MMSE)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in quality of life using the EuroQol-5D (EQ-5D)|Pharmacoeconomic outcomes using the Resource Utilization in Dementia (RUD-Lite 3.3)|Caregiver perceived burden using the Zarit Burden Interview (ZBI)","FORUM Pharmaceuticals Inc","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-026|2013-002654-75","June 2014","August 2017","August 2017","December 9, 2013",,"May 3, 2016","Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Costa Mesa, California, United States|Culver City, California, United States|Encino, California, United States|Glendale, California, United States|Long Beach, California, United States|Los Alamitos, California, United States|Orange, California, United States|Redding, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Norwich, Connecticut, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Columbus, Georgia, United States|Park Ridge, Illinois, United States|Wichita, Kansas, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Flowood, Mississippi, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Springfield, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|Latham, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Williamsburg, Virginia, United States|Richland, Washington, United States|Geelong, Victoria, Australia|Leuven, Belgium|Kelowna, British Columbia, Canada|Halifax, Nova Scotia, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Praha, Czech Republic|Rychnov nad Kneznou, Czech Republic|Milano, Lombardia, Italy|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Bialystok, Poland|Warszawa, Poland|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, Kwa-Zulu Natal, South Africa|Bellville, Western Cape, South Africa|George, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Terrassa, Barcelona, Spain|Burgos, Spain|Madrid, Spain|Salamanca, Spain|Glasgow, United Kingdom|Isleworth, United Kingdom|Northampton, United Kingdom|Penarth, United Kingdom|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02004392"
660,"NCT00257673","Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: MEM 1003|Drug: Placebo for MEM 1003","Cognitive function|Other Cognitive Assessments, activities of daily living, functional assessments and safety","Memory Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MEM 1003-004","November 2005","October 2007","October 2007","November 23, 2005",,"May 6, 2008","Northport, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|El Centro, California, United States|Riverside, California, United States|San Francisco, California, United States|Torrence, California, United States|Hamden, Connecticut, United States|Washington, DC, District of Columbia, United States|Brooksville, Florida, United States|Chiefland, Florida, United States|Coral Springs, Florida, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Towson, Maryland, United States|Fall River, Massachusetts, United States|St Loius, Missouri, United States|Berlin, New Jersey, United States|Long Branch, New Jersey, United States|Princeton, New Jersey, United States|Ridgewood, New Jersey, United States|Toms River, New Jersey, United States|Albany, New York, United States|Staten Island, New York, United States|Morganton, North Carolina, United States|Portland, Oregon, United States|Colmar, Pennsylvania, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Spartanburg, South Carolina, United States|Johnson City, Tennessee, United States|Bedford, Texas, United States|Bulverde, Texas, United States|San Antonio, Texas, United States|Midvale, Utah, United States|Bennington, Vermont, United States|Norfolk, Virginia, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00257673"
661,"NCT00151398","Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer Disease","Drug: lecozotan SR|Drug: Donepezil","The primary endpoints will be the change from baseline in ADAS-Cog total score and ADCS-CGIC total score.|Secondary efficacy outcome variables include additional cognitive, functional,and behavioral measures.","Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3098B1-201, 3098B1-202|B343-1057, B343-1058","September 2005","March 2008","March 2008","September 8, 2005",,"February 11, 2013","Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|La Jolla, California, United States|Orange, California, United States|Boca Raton, Florida, United States|Delray Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hallandale, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|St. Louis, Missouri, United States|Long Branch, New Jersey, United States|Manchester Twp., New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|Lawrence, New York, United States|Staten Island, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Memphis, Tennessee, United States|Houston, Texas, United States|Bennington, Vermont, United States|Av. Belgrano, Argentina|Calle Adolfo Alsina, Argentina|Cervino, Argentina|Galvan, Argentina|Gascon, Argentina|Larrea, Argentina|Nueva York, Argentina|Pilar, Argentina|Hornsby, New South Wales, Australia|Heidelberg Heights, Victoria, Australia|Edmonton, Alberta, Canada|Medicine Hat, Alberta, Canada|Moncton, New Brunswick, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Westdene, Bloemfontein, South Africa|Observatory, Cape Town, South Africa|Panorama, Cape Town, South Africa|Florida, Johannesburg, South Africa|Bellville, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00151398"
662,"NCT03435861","Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients","VIP","Recruiting","No Results Available","Alzheimer Disease","Drug: VX-745|Drug: placebo","brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)|brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV) 2|brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)3|Neuropsychological assessment to assess the following cognitive functions 1:|Neuropsychological assessment to assess the following cognitive functions 2:|Neuropsychological assessment to assess the following cognitive functions 1.1:|Neuropsychological assessment to assess the following cognitive functions 2.2:|Neuropsychological assessment to assess the following cognitive functions 3:|Neuropsychological assessment to assess the following cognitive functions 4:|Neuropsychological assessment to assess the following cognitive functions 5:|Blood and CSF biomarkers of inflammation1|Blood and CSF biomarkers of inflammation 2|Blood and CSF biomarkers of inflammation 3|Blood and CSF biomarkers of inflammation 4|Blood and CSF biomarkers of inflammation 5|Blood and CSF biomarkers of inflammation 6|Blood and CSF biomarkers of inflammation 7|Blood and CSF biomarkers of inflammation 8|Blood and CSF biomarkers of inflammation 9|Blood and CSF biomarkers of inflammation 10|Blood and CSF biomarkers of inflammation 11|Blood and CSF biomarkers of inflammation 12|Blood and CSF biomarkers of inflammation 13|Blood and CSF biomarkers of inflammation 14|Blood and CSF biomarkers of inflammation 15|Blood and CSF biomarkers of inflammation 16|Blood and CSF biomarkers of inflammation 17|Blood and CSF biomarkers of inflammation 18|Blood and CSF biomarkers of inflammation 19|Blood and CSF biomarkers of inflammation 20|Blood and CSF biomarkers of inflammation 21|Blood and CSF biomarkers of inflammation 22|Blood and CSF biomarkers of inflammation 23|Blood and CSF biomarkers of inflammation 24|Blood and CSF biomarkers of inflammation 25|Blood and CSF biomarkers of inflammation 26|Blood and CSF biomarkers of inflammation 27|Blood and CSF biomarkers of inflammation 28","University Hospital, Toulouse|Fondation Plan Alzheimer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RC31/16/8371","October 8, 2018","January 30, 2020","January 30, 2021","February 16, 2018",,"November 21, 2018","CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03435861"
663,"NCT02262975","A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)","ADOS","Completed","No Results Available","Alzheimer's Disease",,"Treatment discontinuation Rate|Factors leading to donepezil treatment discontinuation|Mean change in treatment duration|Percent change in treatment regimen|Mean change in the scores of cognitive assessments test|Compliance of donepezil: Clinical Rating Scale (CRS)|Compliance of donepezil: Visual Analog Scale (VAS)","Eisai Korea Inc.|Eisai Inc.","All","50 Years to 89 Years   (Adult, Older Adult)",,"532","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ART-M082-602","July 2014","August 2016","August 2016","October 13, 2014",,"December 28, 2016","Beijing, China|Gangwon, China|Hong Kong, China|Nanjing, China|Shaanxi, China|Shanghai, China|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gyeonggi, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Kangwon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Manila, Philippines|Singapore, Singapore|Bangkok, Taiwan|Changhua, Taiwan|Kaohsiung, Taiwan|New Taipei, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Shanghai, Thailand",,"https://ClinicalTrials.gov/show/NCT02262975"
664,"NCT00151333","Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: SRA-333","To determine the safety and tolerability of multiple ascending fixed oral dose in subject with mild to moderate Alzheimer's Disease|To assess the pharmacokinetics and pharmacodynamics of multiple ascending fixed dose.","Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3098A1-200","February 2005","April 2005","April 2005","September 8, 2005",,"September 4, 2009","Phoenix, Arizona, United States|Ft. Lauderdale, Florida, United States|Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00151333"
665,"NCT00305903","Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine, memantine","Safety and tolerability of treatment with memantine and rivastigmine, measured by the incidence of GI adverse events (nausea and vomiting)|Whether patients on rivastigmine and memantine are able to reach and maintain higher doses of rivastigmine compared to historical data of rivastigmine monotherapy","Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713BUS32","March 2006",,"August 2007","March 22, 2006",,"December 21, 2007","Manchester, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00305903"
666,"NCT00633841","Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: AFFITOPE AD02","Tolerability|Immunological and clinical efficacy (evaluated in explorative manner)","Affiris AG","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Affiris 002","February 2008","September 2009","September 2009","March 12, 2008",,"October 19, 2010","Ordination Univ. Doz. Dr. Margot Schmitz, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00633841"
667,"NCT03300726","Synaptic Injury and Functional Connectivity in Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease, Late Onset","Diagnostic Test: CSF analysis|Radiation: Functional MRI","Correlations between CSF biomarker measurements and fMRI measures of functional connectivity at baseline|CSF levels of tau, p-tau181, Abeta42, Ng, and SNAP-25 (pg/ml)|Functional Connectivity measures on functional MRI (r)","Ohio State University","All","60 Years to 95 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017H0255","February 12, 2018","November 30, 2019","December 31, 2019","October 3, 2017",,"January 8, 2019","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03300726/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03300726"
668,"NCT01969136","Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease|Dementia","Drug: Drug: EVP-6124|Drug: Placebo","Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182|Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182|Safety and tolerability of EVP-6124 or Placebo in Subjects with AD|Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in the Mini-Mental State Examination (MMSE)|Change from Baseline in the Controlled Oral Word Association Test (COWAT)","FORUM Pharmaceuticals Inc","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","403","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-025|2013-002653-30","October 2013","January 2017","January 2017","October 25, 2013",,"May 3, 2016","Tucson, Arizona, United States|Little Rock, Arkansas, United States|Culver City, California, United States|Downey, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Oceanside, California, United States|Orange, California, United States|Norwich, Connecticut, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Newton, Massachusetts, United States|Hattiesburg, Mississippi, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Cedarhurst, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Abington, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Richland, Washington, United States|Rosario, Santa Fe, Argentina|Buenos Aires, Argentina|Santa Fe, Argentina|Box Hill, Victoria, Australia|Caulfield South, Victoria, Australia|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Quebec, Canada|Brno, Czech Republic|Chocen, Czech Republic|Hradec Kralove, Czech Republic|Praha 6, Czech Republic|Richnov nad Kneznou, Czech Republic|Bordeaux, France|Caen, France|Paris, France|Homburg, Germany|Mittweida, Germany|Munchen, Germany|Westerstede, Germany|Ancona, Italy|Milano, Italy|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Saltillo, Coahuila, Mexico|Amsterdam, Netherlands|Den Haag, Netherlands|S'Hertogenbosch, Netherlands|Durban, Kwa-Zulu Natal, South Africa|Bellville, Western Cape, South Africa|George, Western Cape, South Africa|Madrid, Spain|Salamanca, Spain|West End, Southampton, United Kingdom|Bath, United Kingdom|Glasgow, United Kingdom|Isleworth, United Kingdom|Northampton, United Kingdom|Penarth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01969136"
669,"NCT01969123","Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease|Dementia","Drug: Drug: EVP-6124|Drug: Placebo","Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog-13) to Day 182|Change from Baseline in the Clinical Dementia Rating Sum of the Boxes (CDR-SB) to Day 182|Safety and tolerability of EVP-6124 or Placebo in Subjects with AD|Change from Baseline in activities of daily living using the Disability Assessment for Dementia (DAD)|Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)|Change from Baseline in the Mini-Mental State Examination (MMSE)|Change from Baseline in the Controlled Oral Word Association Test (COWAT)","FORUM Pharmaceuticals Inc","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","474","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-024|2013-002618-10","October 2013","January 2017","January 2017","October 25, 2013",,"May 3, 2016","Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Encino, California, United States|Glendale, California, United States|Long Beach, California, United States|Redding, California, United States|San Diego, California, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|Weston, Florida, United States|Columbus, Georgia, United States|Douglasville, Georgia, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Chestnut Hill, Massachusetts, United States|Plymouth, Massachusetts, United States|Flowood, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Springfield, New Jersey, United States|Brooklyn, New York, United States|Latham, New York, United States|New York, New York, United States|Staten Island, New York, United States|Wilmington, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Williamsburg, Virginia, United States|Hornsby, New South Wales, Australia|Geelong, Victoria, Australia|West Heidelberg, Victoria, Australia|Brussels, Belgium|Leuven, Belgium|St. Truiden, Belgium|Kelowna, British Columbia, Canada|Chatham, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Nice, France|Paris, France|Rouen, France|Toulouse cedex 9, France|Achim, Germany|Köln, Germany|Munchen, Germany|Nurnberg, Germany|Brescia, Italy|Milano, Italy|Seongnam-si, Gyenggi-go, Korea, Republic of|Busan, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Bialystok, Poland|Bydgoszcz, Poland|Poznan, Poland|Warszawa, Poland|Bellville, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Somerset West, South Africa|Elche, Altcante, Spain|Terrassa, Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01969123"
670,"NCT03270137","Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease","AD-EMTr","Unknown status","No Results Available","Alzheimer Disease|Transcranial Magnetic Stimulation","Device: repetitive transcranial magnetic stimulation- IDLPFC|Device: repetitive transcranial magnetic stimulation - Six regions","Changes on cognitive functioning (ADAS-cog)|Changes on cognitive effects (Mini Mental State)|Changes on behavioral symptoms (NPI)|Changes on depression symptoms (GDS-Yesavage)|Changes on effects on functionality (IDDD)|Changes on Clinical Global Impression (CGI)","Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|National Council of Science and Technology, Mexico","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","SIC-16-001","March 10, 2016","February 28, 2017","August 31, 2017","September 1, 2017",,"September 1, 2017",,,"https://ClinicalTrials.gov/show/NCT03270137"
671,"NCT01561430","Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: LY2886721|Drug: Placebo","Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations|Change From Baseline in Plasma Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in Neuropsychological Test Battery (NTB)|Change From Baseline to 26 Weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Change From Baseline to 26 Weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change From Baseline to 26 Weeks in Mini Mental State Examination (MMSE)|Change From Baseline in Cerebrospinal Fluid (CSF) Tau and Phosphorylated Tau (Ptau)-181 Concentrations","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","13735|I4O-MC-BACC|2011-005217-37","March 2012","August 2013","August 2013","March 23, 2012","May 18, 2018","May 18, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delray Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quincy, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monroe, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sant Cugal Del Valles, Spain",,"https://ClinicalTrials.gov/show/NCT01561430"
672,"NCT02010476","Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men","ADDM","Completed","No Results Available","Alzheimer's Disease",,"Abnormal concentrations of CSF biomarkers related to Alzheimer's disease|Abnormal concentrations of other CSF biomarkers of potential relevance to insulin resistance and Alzheimer's disease","University of Eastern Finland|King's College London|Sahlgrenska University Hospital, Sweden|Janssen Pharmaceutica","Male","55 Years to 70 Years   (Adult, Older Adult)",,"58","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","3971","November 2013","April 2016","April 2016","December 12, 2013",,"May 12, 2016","Department of Neurology and Brain Research Unit, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland",,"https://ClinicalTrials.gov/show/NCT02010476"
673,"NCT03456349","Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care",,"Completed","No Results Available","Alzheimer's Disease","Drug: HTL0018318|Drug: Placebo","Treatment emergent adverse events (TEAEs), Safety and Tolerability","Heptares Therapeutics Limited|Allergan","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HTL0018318-202|2017-000649-34","November 10, 2017","July 16, 2018","July 16, 2018","March 7, 2018",,"July 20, 2018","Syneos, Prague, Czechia|Syneos, Warsaw, Poland|Syneos, Bratislava, Slovakia|Syneos, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03456349"
674,"NCT00099710","Curcumin in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Dietary Supplement: Curcumin C3 Complex","Side effect checklist|Oxidative damage|Inflammation/gliosis|A-beta levels|Tau levels|Total plasma cholesterol, LDL and HDL; ApoE|Plasma curcumin and metabolites|Cognitive and behavioral measures","John Douglas French Foundation|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0065","July 2003","December 2007","December 2007","December 20, 2004",,"December 3, 2009","UCLA Medical Center, Westwood, California, United States",,"https://ClinicalTrials.gov/show/NCT00099710"
675,"NCT01013610","An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease",,"Completed","No Results Available","Mild Alzheimer's Disease","Drug: LNK-754|Drug: Placebo","Safety assessments to include pharmacokinetics, and adverse events","Link Medicine Corporation","All","55 Years and older   (Adult, Older Adult)","Phase 1","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","LNK754-0902-1AB","November 2009","March 2011","March 2011","November 16, 2009",,"March 15, 2011","Dedicated Phase I, Phoenix, Arizona, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Elite Research Insitute, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|St. Louis Clinical Trials, LC, St. Louis, Missouri, United States|Clinical Trial Network, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01013610"
676,"NCT00495417","Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: AFFITOPE AD01|Biological: AFFITOPE AD01 adjuvanted","Tolerability|Immunological and clinical efficacy (evaluated in explorative manner)","Affiris AG","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Affiris 001|EUDRACT Number 2006-007063-90","July 2007","August 2009","August 2009","July 3, 2007",,"October 19, 2010","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00495417"
677,"NCT00329082","Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers",,"Completed","No Results Available","Alzheimer's Disease","Drug: LY2062430|Drug: Placebo","Safety and tolerability|To determine the plasma pharmacokinetics of LY2062430|To evaluate the pharmacokinetic/pharmacodynamic relationships between LY2062430 concentrations and plasma peptide amyloid beta concentrations|To evaluate the changes in thinking and memory","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","6649|H8A-MC-LZAJ","May 2006","May 2008","May 2008","May 24, 2006",,"October 7, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00329082"
678,"NCT00244322","Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: LY450139 dihydrate|Drug: placebo","Safety and tolerability|Determine levels of peptides in blood and spinal fluid that might relate to Alzheimer's disease|Evaluate changes in thinking and memory|Evaluate changes in daily living activities|Determine levels of study drug in blood and spinal fluid","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic","9097|H6L-MC-LFAJ","October 2005",,"December 2006","October 26, 2005",,"May 28, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5hours, EST), or speak with your personal physician, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00244322"
679,"NCT00035204","A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: galantamine","To measure the differences between galantamine and donepazil for sleep and attention, explore methods of measuring sleep in patients with Alzheimer's Disease (AD)and their caregivers and attention in AD patients; GI tolerance|To assess the tolerability, overall effect, quality of life and safety of galantamine compared with donepezil","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 4","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR002002",,,"May 2003","May 3, 2002",,"June 8, 2011",,,"https://ClinicalTrials.gov/show/NCT00035204"
680,"NCT02020356","Music Therapy in Alzheimer's Disease","PRE-MUSICAL","Terminated","No Results Available","Alzheimer's Type Dementia","Behavioral: Music therapy|Behavioral: Placebo","Neuroleptic reduction dose|Durability of treatment effect","University Hospital, Toulouse","All","65 Years to 100 Years   (Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","RC31/12/0385|AOL 2012","April 2013","June 2015","June 2015","December 24, 2013",,"February 6, 2018","University Hospital Toulouse, Toulouse, Midi-Pyrenees, France|EHPAD La Villegiale, Castres, Tarn, France|Residence Christian Bressole, Castres, Tarn, France|EHPAD L'Oustal d'en Thibaud, Labruguiere, Tarn, France|EHPAD Les Quietudes, Lautrec, Tarn, France|EHPAD KORIAN Grand Maison, L'Union, France|Centre Hospitalier Gérard Marchant, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02020356"
681,"NCT02087865","Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease",,"Recruiting","No Results Available","Genetic Risk for Alzheimer's Disease","Drug: donepezil HCL|Drug: Placebo","Change in BOLD response during functional magnetic resonance imaging|Neuropsychological testing scores","The Cleveland Clinic|National Institute on Aging (NIA)","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 4","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other","14-227","May 2014","February 27, 2020","February 27, 2020","March 14, 2014",,"May 6, 2019","Cleveland Clinic Center for Brain Health, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02087865"
682,"NCT03954613","Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease|Cognitive Change","Combination Product: Ebicomb","Change in MOCA total score|Change in GDS total score|Change in ADAS-Cog total score|Change in CDR total score|Change in B-ADL total score|Change in clock drawing test","Neutec Ar-Ge San ve Tic A.Ş","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 4","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEU-05.18","July 1, 2019","December 1, 2020","March 1, 2021","May 17, 2019",,"May 17, 2019",,,"https://ClinicalTrials.gov/show/NCT03954613"
683,"NCT00087724","A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: FK962",,"Astellas Pharma Inc|Astellas Pharma US, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","510","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","03-0-189","July 2004",,"September 2006","July 14, 2004",,"June 7, 2012","Investigational Site, Phoenix, Arizona, United States|Investigational Site, Phoenix, Arizona, United States|Sun City, Arizona, United States|Investigational Site, Tucson, Arizona, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Little Rock, Arkansas, United States|Investigational Site, Fresno, California, United States|Investigational Site, Irvine, California, United States|Investigational Site, Orange, California, United States|Investigational Site, San Francisco, California, United States|Investigational Site, Sherman Oaks, California, United States|Investigational Site, Torrance, California, United States|Investigative Site, Denver, Colorado, United States|Investigational Site, Denver, Colorado, United States|Investigational Site, Darien, Connecticut, United States|Investigational Site, Hamden, Connecticut, United States|Hamden, Connecticut, United States|Investigational Site, Stamford, Connecticut, United States|Investigational Site, Fort Myers, Florida, United States|Investigational Site, Hialeah, Florida, United States|Investigational Site, Hollywood, Florida, United States|Investigational Site, Miami, Florida, United States|Investigational Site, North Miami, Florida, United States|Investigational Site, Ocala, Florida, United States|Investigational Site, Port Charlotte, Florida, United States|Investigational Site, Sarasota, Florida, United States|Investigational Site, Sebring, Florida, United States|Investigational Site, Tampa, Florida, United States|West Palm Beach, Florida, United States|Investigational Site, Snellville, Georgia, United States|Snellville, Georgia, United States|Investigational Site, Elk Grove, Illinois, United States|Investigational Site, Wichita, Kansas, United States|Investigational Site, New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Investigational Site, Newton, Massachusetts, United States|Livonia, Michigan, United States|Hattiesburg, Mississippi, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Las Vegas, Nevada, United States|Investigational Site, Long Branch, New Jersey, United States|Investigational Site, Manchester, New Jersey, United States|Investigational Site, Piscataway, New Jersey, United States|Investigational Site, Albuquerque, New Mexico, United States|Investigational Site, Albany, New York, United States|Investigational Site, Buffalo, New York, United States|Investigational Site, Lawrence, New York, United States|Investigational Site, New York, New York, United States|Investigational Site, White Plains, New York, United States|Charlotte, North Carolina, United States|Investigational Site, Centerville, Ohio, United States|Investigational Site, Columbus, Ohio, United States|Dayton, Ohio, United States|Investigational Site, Dayton, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tulsa, Oklahoma, United States|Investigational Site, Eugene, Oregon, United States|Investigational Site, Medford, Oregon, United States|Investigational Site, Bala Cynwyd, Pennsylvania, United States|Investigational Site, Jenkintown, Pennsylvania, United States|Investigational Site, Pawtucket, Rhode Island, United States|Investigational Site, Johnson City, Tennessee, United States|Investigational Site, Nashville, Tennessee, United States|Investigational Site, Houston, Texas, United States|Investigational Site, San Antonio, Texas, United States|Investigational Site, Wichita Falls, Texas, United States|Investigational Site, Salt Lake City, Utah, United States|Investigational Site, Bennington, Vermont, United States|Burlington, Vermont, United States|Investigational Site, Norfolk, Virginia, United States|Investigational Site, Milwaukee, Wisconsin, United States|Investigational Site, Kelowna, British Columbia, Canada|Investigational Site, Penticton, British Columbia, Canada|Investigational Site, Victoria, British Columbia, Canada|Investigational Site, Sydney, Nova Scotia, Canada|Investigational Site, Barrie, Ontario, Canada|Investigational Site, North York, Ontario, Canada|Investigational Site, North York, Ontario, Canada|Investigational Site, Ottawa, Ontario, Canada|Investigational Site, Sudbury, Ontario, Canada|Investigational Site, Toronto, Ontario, Canada|Investigational Site, Willowdale, Ontario, Canada|Investigational Site, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00087724"
684,"NCT03484143","Neuro RX Gamma - Pivotal Phase",,"Recruiting","No Results Available","Alzheimer Disease","Device: Active Neuro RX Gamma device|Device: Sham Neuro RX Gamma device","Change in Severe Impairment Battery (SIB) score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living for Severe Alzheimer's Disease (ADCS-ADL-Sev)|Change in European Quality of Life Scale (EQ-5 dimensions [5D], proxy version)|Change in Quality of Life in Alzheimer's Disease (QOL-AD)|Change in Neuropsychiatric Inventory Questionnaire (NPI) - including Caregiver Distress ratings|Change in Resource Utilization in Dementia (RUD)","Vielight Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P17.03","June 26, 2019","May 2021","May 2021","March 30, 2018",,"July 11, 2019","Detroit Clinical Research Centre, Detroit, Michigan, United States|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03484143"
685,"NCT00090116","The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Neramexane",,"Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","NER-MD-02","March 2003","March 2005","March 2005","August 26, 2004",,"March 5, 2012","Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|Pharmacology Research Institute, Northridge, California, United States|UCI Medical Center, Orange, California, United States|Pacific Research Network, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurology Clinical Research, Inc., Plantation, Florida, United States|University of South Florida, Tampa, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Indiana Universisty Medical Center, Indianapolis, Indiana, United States|Lexington Clinic, Lexington, Kentucky, United States|J. Gary Booker, MD, Shreveport, Louisiana, United States|Mood and Memory Clinic of Michigan, Farmington Hills,, Michigan, United States|St. Louis University, St. Louis, Missouri, United States|Alzheimer's Research Corporation, Lakehurst, New Jersey, United States|Joel Ross, MD, Long Branch, New Jersey, United States|Ubhc/Umdnj, Piscataway, New Jersey, United States|Upstate Clinical Research, Albany, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Monroe Community Hospital, Rochester, New York, United States|Behavioral Medical Research of Saten Island, PC, Staten Island, New York, United States|Piedmont Medical Research, Winston Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Summit Research Network, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|North Texas Neurology Research, Wichita, Texas, United States|Pioneer Pharmaceutical Research, Midvale, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00090116"
686,"NCT00074529","Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)",,"Completed","No Results Available","Alzheimer's Disease","Drug: MK0677","Cognitive function over 12 month period; safety and tolerability|AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.","Merck Sharp & Dohme Corp.","All","50 Years and older   (Adult, Older Adult)","Phase 2","512","Industry","Interventional","Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0677-030|Formally-BG0812AZ|MK0677-030|2006_412","October 2003","January 2006","January 2006","December 16, 2003",,"July 24, 2015",,,"https://ClinicalTrials.gov/show/NCT00074529"
687,"NCT00069849","A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-089","MMSE","Abbott","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","M03-614","July 2003",,,"October 2, 2003",,"September 4, 2006","Fresno, California, United States|San Diego, California, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Florence, Kentucky, United States|Portland, Oregon, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00069849"
688,"NCT00017940","Gene Therapy for Alzheimer's Disease Clinical Trial",,"Completed","No Results Available","Alzheimer Disease","Genetic: Human Nerve Growth Factor",,"The Shiley Family Trust|Institute for the Study of Aging (ISOA)|University of California, San Diego|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","IA0029",,"November 2003","November 2003","June 22, 2001",,"December 11, 2009","University of California, San Diego, ADRC, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT00017940"
689,"NCT03657732","The Chinese Familial Alzheimer's Network","CFAN","Recruiting","No Results Available","Alzheimer Disease|Familial Alzheimer Disease (FAD)",,"The prevalence of gene mutations in familial Alzheimer's disease in China.|Changes of neuropsychological function in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.|Changes of brain structure in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.|Changes of brain glucose metabolism in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.|Changes of brain amyloid deposition in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.|Changes of brain tau deposition in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.|Changes of humoral biomarkers in pedigree members at different stage of cognitive impairment in familial Alzheimer's disease in China.","Capital Medical University|Beijing Tiantan Hospital|Beijing Chao Yang Hospital|Fu Xing Hospital, Capital Medical University|Peking Union Medical College Hospital|Peking University First Hospital|Peking University Third Hospital|Chinese PLA General Hospital|China-Japan Friendship Hospital|Beijing Geriatric Hospital|The First Affiliated Hospital of Dalian Medical University|Fujian Medical University Union Hospital|Guangzhou Psychiatric Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Handan Central Hospital|Hebei General Hospital|First Hospital of Shijiazhuang City|Tangshan Worker's Hospital|Henan Provincial Hospital|Kaifeng Central Hospital|People's Hospital of Zhengzhou University|First Affiliated Hospital of Harbin Medical University|Tongji Hospital|People's Hospital Affiliated Hubei Medical University|Wuhan University Zhongnan Hospital|The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University|First Hospital of Jilin University|China-Japan Union Hospital, Jilin University|Subei People's Hospital of Jiangsu|Nantong University Affiliated Hospital|Mineral General Hospital, Xuzhou|Jiangxi Provincial People's Hopital|Anshan Central Hospital|The Affiliated Zhongshan Hospital of Dalian University|First Hospital of China Medical University|Baotou Central Hospital|General Hospital of Ningxia Medical University|The People's Hospital of Ningxia|The Affiliated Hospital of Qingdao University|The 88th Hospital of PLA|Qilu Hospital of Shandong University|Qilu Hospital of Shandong University (Qingdao)|Shandong Provincial Hospital|Qingdao Municipal Hospital|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi'an Jiaotong University|Ruijin Hospital|RenJi Hospital|Shanghai Changzheng Hospital|Afﬁliated Hospital of North Sichuan Medical College|Tianjin Huanhu Hospital|Tianjin Medical University General Hospital|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region|Ningbo Medical Center Lihuili Hospital|First Affiliated Hospital of Wenzhou Medical University|First Affiliated Hospital of Zhejiang University|Shao Yifu Hospital of Zhejiang Medical University|Zhejiang Provincial People’s Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|The Second Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Anhui Medical University|People's Hospital of Chongqing|Dongfang Hospital Beijing University of Chinese Medicine|Zigong First People's Hospital","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYXWJ002","January 10, 2008","January 1, 2028","January 1, 2028","September 5, 2018",,"September 5, 2018","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Geriatric Hospital, Changping, Beijing, China|Beijing Chao Yang Hospital, Chaoyang, Beijing, China|China-Japan Friendship Hospital, Chaoyang, Beijing, China|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Fengtai, Beijing, China|Chinese PLA General Hospital, Haidian, Beijing, China|Fu Xing Hospital, Capital Medical University, Haidian, Beijing, China|Peking University Third Hospital, Haidian, Beijing, China|Peking Union Medical College Hospital, Xicheng, Beijing, China|Peking University First Hospital, Xicheng, Beijing, China|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Yuzhong, Chongqing, China|The Second Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China|Fujian Medical University Union Hospital, Fujian, Guangdong, China|Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan, Guangdong, China|First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China|Handan Central Hospital, Handan, Hebei, China|First Hospital of Shijiazhuang City, Shijiazhuang, Hebei, China|Tangshan Worker's Hospital, Tangshan, Hebei, China|Hebei General Hospital, Zhijiazhuang, Hebei, China|First Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|Kaifeng Central Hospital, Kaifeng, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|People's Hospital of Zhengzhou, Zhengzhou, Henan, China|People's Hospital Affiliated Hubei Medical University, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University, Wuhan, Hunan, China|Wuhan University Zhongnan Hospital, Wuhan, Hunan, China|Xiangya Hospital of Central South University, Wuhan, Hunan, China|Nantong University Affiliated Hospital, Nantong, Jiangsu, China|Subei People's Hospital of Jiangsu, Subei, Jiangsu, China|Mineral General Hospital, Xuzhou, Xuzhou, Jiangsu, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|China-Japan friendship Hospital of Jilin university, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|Changda Hospital, Anshan, Anshan, Liaoning, China|Affiliated Zhongshan hospital of Dalian university, Dalian, Liaoning, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|First Hospital of China Medical University, Shenyang, Liaoning, China|Baotou Central Hospital, Baotou, Nei Monggol, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia, Yinchuan, Ningxia, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jining, Shandong, China|Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China|QingDao Municipal Hospital, Qingdao, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|The 88th Hospital of PLA, Tai'an, Shandong, China|Shanghai Changzheng Hospital, Huangpu, Shanghai, China|Ruijin Hospital, Luwan, Shanghai, China|RenJi Hospital, Putong, Shanghai, China|The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shanxi, China|Tang-Du Hospital, Xi'an, Shanxi, China|Afﬁliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China|Zigong First People's Hospital, Zigong, Sichuan, China|Tianjin Medical University General Hospital, Heping, Tianjin, China|Tianjin Huanhu Hospital, Jinnan, Tianjin, China|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Urumqi, Xinjiang, China|First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Shao Yifu Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, Zhejiang, China|First Affiliated Hospital of Wenzhou Medical Univeristy, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03657732"
690,"NCT00912886","Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease","STERMEM","Completed","No Results Available","Alzheimer Disease",,"Plasma concentrations of PREGS determined by GC-MS|Memory scores of the RL-RI test according to the GROBER and BUSCKE test|Plasma concentrations of PREGS metabolites","Assistance Publique - Hôpitaux de Paris","All","70 Years and older   (Older Adult)",,"90","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","P071237","September 2009","September 2011","September 2011","June 3, 2009",,"April 11, 2013","Assistance publique - Hôpitaux de Paris Hôpital Bicêtre, Le Kremlin Bicêtre, France|Inserm Umr 788, Le Kremlin Bicêtre, France|AP-HP Hôpital Rothschild, Paris, France|Assistance Publique - Hôpitaux de Paris Hôpital Broca, Paris, France|Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France|Assistance Publique - Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00912886"
691,"NCT00056225","VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Folate|Drug: Vitamin B6|Drug: Vitamin B12",,"National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years and older   (Adult, Older Adult)","Phase 3","340","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0041","January 2003","June 2007","June 2007","March 10, 2003",,"June 12, 2009","University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Arizona Health Sciences Center, Tucson, Arizona, United States|University of California, Irvine, Institute for Brain Aging and Dementia, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California, Davis, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Georgetown University, Washington, DC, District of Columbia, United States|Howard University, Washington, DC, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Presbyterian/St. Lukes Medical Center, Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Center for Cognitive Aging, Las Vegas, Nevada, United States|ClinSearch, Kenilworth, New Jersey, United States|New York University Medical Center, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Alzheimer's Disease Center, Rochester, New York, United States|University Memory and Aging Center, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health and Science University, Oregon Aging and Alzheimer's Disease Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Alzheimer's Disease and Memory Disorder Clinic, Pawtucket, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00056225"
692,"NCT02573740","Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment",,"Terminated","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: ABT-957|Other: Placebo","Percentage of participants reporting treatment-emergent adverse events|Level of spectrin breakdown product-145 (SBDP-145)","AbbVie","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-730","December 2015","June 2016","June 2016","October 12, 2015",,"July 1, 2016","Site Reference ID/Investigator# 143180, Cypress, California, United States|Site Reference ID/Investigator# 143178, Orlando, Florida, United States|Site Reference ID/Investigator# 149484, The Villages, Florida, United States|Site Reference ID/Investigator# 143181, Marlton, New Jersey, United States|Site Reference ID/Investigator# 143182, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 149481, Dallas, Texas, United States|Site Reference ID/Investigator# 143254, Orem, Utah, United States|Site Reference ID/Investigator# 143179, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 143177, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02573740"
693,"NCT02791191","A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia","NAVIGATE-AD","Terminated","No Results Available","Alzheimer's Disease","Drug: LY3202626|Drug: Placebo","Change from Baseline in Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) of ¹⁸F-AV-1451|Percentage of Participants with Emergent Magnetic Resonance Imaging (MRI) Findings|Percentage of Participants with Amyloid-Related Imaging Abnormalities (ARIA)|Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Scores|Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve at Steady State of LY3202626|Change From Baseline in Plasma Amyloid Beta Aβ₁₋₄₀, ₁₋₄₂, and 1-x Concentration|Change from Baseline on the 13-item Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog₁₃)|Change from Baseline on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-iADL)|Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)","Eli Lilly and Company","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16223|I7X-MC-LLCF","June 16, 2016","July 2, 2018","July 2, 2018","June 6, 2016",,"October 8, 2019","Irvine Clinical Research Center, Irvine, California, United States|Sutter Medical Group, Sacramento, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Ray Dolby Brain Health Center/Sutter Health/CPMC, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|North Bay Neuroscience Institute, Sebastopol, California, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Christiana Care Health Service, Wilmington, Delaware, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Compass Research, Melbourne, Florida, United States|Florida International Research Center, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Axiom Research, Tampa, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|Missouri Memory Center, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millenium Psychiatric Associates LLC, Creve Coeur, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Valley Medical Primary Care, Centerville, Ohio, United States|University of Cincinnati Health Neurology, Dayton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Nantz National Alzheimer Center, Houston, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erina, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herston, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akashi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ikeda, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kasukabe-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nerima-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Setagaya-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takamatsu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wako, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokosuka-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02791191"
694,"NCT00018382","Insulin, Neurogenetics and Memory in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: rosiglitazone",,"US Department of Veterans Affairs|VA Office of Research and Development","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2",,"U.S. Fed","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","AGCG-012-98S","October 1999",,"March 2003","July 5, 2001",,"January 21, 2009","VA Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00018382"
695,"NCT00018278","Electrophysiologic Measures of Treatment Response in Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Aricept|Drug: Exelon|Drug: Nicoderm Patch",,"US Department of Veterans Affairs|VA Office of Research and Development","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 4",,"U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGCG-004-98S","October 1998",,"September 2001","July 5, 2001",,"January 21, 2009","Department of Veterans Affairs, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00018278"
696,"NCT01701089","A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteer, Alzheimer's Disease","Drug: 11C-L-deprenyl-D2|Drug: RO4602522","Change in monoamine oxidase (MAO-B) enzyme activity as measured by in vivo positron emission tomography (PET)|Pharmacokinetics: Plasma concentration of RO4602522|Reduction of 11C-L-deprenyl-D2 tracer uptake by in vivo positron emission tomography (PET)|Safety: incidence of adverse events","Hoffmann-La Roche","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP28253","September 2012","May 2013","May 2013","October 4, 2012",,"November 2, 2016","Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01701089"
697,"NCT00013923","Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Nutritional Supplement",,"National Institute on Aging (NIA)|Burke Medical Research Institute","All","50 Years and older   (Adult, Older Adult)","Phase 2","40","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0027",,"June 2005","June 2005","April 3, 2001",,"December 11, 2009","Burke Medical Research Institute, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT00013923"
698,"NCT01095718","Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease","C3LM-ILAD","Unknown status","No Results Available","Alzheimer Disease","Behavioral: Errorless Learning|Behavioral: Modeling|Behavioral: Trial and Error","The primary outcome of the intervention will be the performance and errors of participants. Each task is comparable as the assessment procedure remains the same across disease stages.|Baseline neuropsychological assessments. Premorbid intelligence level will be estimated by the National Adult Reading Test (NART). The Mini Mental State Examination (MMSE) will be used to assessed cognitive status.","Department of Clinical Research and Innovation|Institut National de la Santé Et de la Recherche Médicale, France|Fondation Médéric Alzheimer|Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ID RCB 2009-A01303-54","March 2010","March 2012",,"March 30, 2010",,"March 26, 2012","CHU de Nice Centre Mémoire, Nice, France",,"https://ClinicalTrials.gov/show/NCT01095718"
699,"NCT04044495","Sleep, Rhythms and Risk of Alzheimer's Disease","AMImage3","Recruiting","No Results Available","Alzheimer Disease|Sleep","Other: Multimodal brain imaging (MRI)|Other: Actimetry|Other: Sleep Diary","Bold Signal|Pittsburgh Sleep Quality Index (PSQI) Score|Mannheim Dream questionnaire (MADRE)|Epworth Sleepiness Scale|Toronto Alexithymia Scale (TAS-20)|Positive and Negative Affective Scale (PANAS)|Emotional Regulation Questionnaire (ERQ)|Actimetry|Sleep diary","University Hospital, Bordeaux","All","65 Years and older   (Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2018/15","September 9, 2019","September 1, 2020","September 1, 2020","August 5, 2019",,"October 8, 2019","CHU de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04044495"
700,"NCT00862940","A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Memantine|Drug: Placebo","Total Brain Atrophy Rate Estimated Using Brain Boundary Shift Integral (BBSI)|Changes in Total Hippocampal Volume (HCV)|Cognitive and Behavioural Outcomes: Controlled Oral Word Association Test (COWAT) Total Score|Cognitive and Behavioural Outcomes: Mini Mental State Examination (MMSE) Total Score","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 4","277","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10112|2004-002614-10","September 2005","February 2009","April 2009","March 17, 2009","June 3, 2011","September 3, 2012",,,"https://ClinicalTrials.gov/show/NCT00862940"
701,"NCT00004845","A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)",,"Completed","No Results Available","Alzheimer Disease","Drug: Rofecoxib|Drug: Naproxen",,"National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years and older   (Adult, Older Adult)","Phase 2|Phase 3",,"NIH|Other","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0021",,"December 2001","December 2001","February 29, 2000",,"December 11, 2009","Barrow Neurological Group, Phoenix, Arizona, United States|University of Arizona, Tucson, Tucson, Arizona, United States|University of California Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Martinez, California, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Boca Raton, Florida, United States|Baumel-Eisner Ft Lauderdale, Ft Lauderdale, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, MiamiBeach, Miami Beach, Florida, United States|University of South Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Kansas University, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|ClinSearch, Inc, Summit, New Jersey, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas, SW Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00004845"
702,"NCT00297362","A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Galantamine hydrobromide","Changes from baseline in Mini-Mental State Examination (MMSE) scale scores|Changes from baseline in Disability Assessment for Dementia (DAD) scale scores|Changes from baseline in Neuropsychiatric Inventory (NPI) scale scores|Changes from baseline in Clinical Global Impression (CGI) scale scores|Changes from baseline in Cornell Scale|Number of patients with Adverse Events as Measure of Safety and Tolerability|Number of patients whose vital signs fell outside the normal ranges|Number of patients whose laboratory test results fell outside the normal ranges","Janssen Cilag Pharmaceutica S.A.C.I., Greece","All","Child, Adult, Older Adult",,"344","Industry","Observational","Time Perspective: Prospective","CR003559|57504DEM4001","June 2004",,"October 2005","February 28, 2006",,"March 26, 2012",,,"https://ClinicalTrials.gov/show/NCT00297362"
703,"NCT01954550","Effects of Aerobic Exercise for Treating Alzheimer's Disease","FIT-AD","Active, not recruiting","No Results Available","Alzheimer's Disease, Late Onset","Behavioral: Cycling exercise|Behavioral: Range of motion/stretching exercise","Change in cognition from baseline to 6 months as measured by the Alzheimer's Disease Assessment Scale - Cognitive Subscale|Change in hippocampal volume as measured by Magnetic Resonance Imaging (MRI)","University of Minnesota - Clinical and Translational Science Institute|Mayo Clinic|University of St Thomas","All","66 Years and older   (Older Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R01AG043392-01A1","March 2014","December 2019","December 2020","October 1, 2013",,"May 13, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01954550"
704,"NCT03062449","Phase IIa L-serine Trial for eAD","LSPI-2","Recruiting","No Results Available","Alzheimer Disease","Drug: L-Serine|Other: Placebo Gummy","Change in score on the Montreal Cognitive Assessment evaluation|Documentation of any adverse events|Changes in complete blood count, liver function test, basic metabolic panel measures.|Change in plasma biomarker levels.|Relationship between Montreal Cognitive Assessment score and plasma biomarker levels","Aleksandra Stark|Brain Chemistry Laboratories, Institute for Ethnomedicine|Dartmouth-Hitchcock Medical Center","All","Child, Adult, Older Adult","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D16180","March 1, 2017","December 31, 2020","December 31, 2020","February 23, 2017",,"September 9, 2019","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT03062449"
705,"NCT00831298","Assessment of Sleep Disturbance in Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Other: Analysis of sleep disturbance","assessment of apathy|assessment of sleep disturbance|determine a genetic relationship between sleep disturbance and alzheimer disease","Centre Hospitalier Universitaire de Nice","All","65 Years and older   (Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","08-PP-07","July 2010","November 2011","November 2011","January 28, 2009",,"December 9, 2011","Centre Mémoire de Ressources et de Recherche, CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT00831298"
706,"NCT00785759","Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers","ALZ201","Completed","No Results Available","Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: AH110690 (18F) Injection","Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.|Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.","GE Healthcare|i3 Statprobe|Medpace, Inc.|Hvidovre Hospital Center Demark Danish Research Centre for Magnetic Resonance","All","25 Years and older   (Adult, Older Adult)","Phase 2","78","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ALZ201","September 2008","March 2009","December 2009","November 5, 2008",,"December 7, 2009","GE Healthcare, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00785759"
707,"NCT04121858","Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Other: Brain Safe App|Other: Attention Control App","Total standardized daily dose (TSDD) - from medical records|Total standardized daily dose (TSDD) - self-report medication inventory|Choice reaction time (CRT)|Simple Reaction Time (SRT)|Digit-Symbol Substitution Test (DSST)|Hopkins Verbal Learning Test (HVLT)|Trail Making Test (TMT) Parts A and B|Health Utilities Index (HUI) Mark 3","Indiana University|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1811254189|R01AG056926","October 9, 2019","October 1, 2023","October 1, 2023","October 10, 2019",,"October 10, 2019","Eskenazi Health, Indianapolis, Indiana, United States|Indiana University Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04121858"
708,"NCT01172145","Treatment of Apathy in Alzheimer's Disease With Modafinil",,"Completed","Has Results","Apathy|Alzheimer's Disease","Drug: Modafinil|Drug: Placebo","Apathy|Lawton Brody Activities of Daily Living Questionnaire|The Direct Assessment of Functional Status Scale|Zarit Burden Inventory","Brown University|National Institute of Mental Health (NIMH)|Cephalon","All","65 Years to 95 Years   (Older Adult)","Phase 3","22","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1F32MH075583-01","July 2005",,"September 2007","July 29, 2010","March 4, 2011","March 4, 2011","Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01172145"
709,"NCT04094129","Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients",,"Not yet recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: Wismemo|Dietary Supplement: Placebo","Mini-Mental State Examination (MMSE) for efficacy|Neuropsychiatric Inventory (NPI) for efficacy and quality of life|Change from baseline in levels of peroxidation and antioxidant profiles (MDA and TAC)|Change from baseline in levels of inflammatory markers (IL-10,IL-6, IL-1 beta, TNF-alpha and TGF-beta)|Change from baseline in levels of inflammatory markers (hs-CRP)|Change from baseline in levels of blood sugar (HbA1c)|Change from baseline in levels of insulin resistance profile (FPG, insulin and HOMA-IR)|Gut microbiota for efficacy|Mini-Nutritional Assessment (MNA) for feasibility and efficacy|Defecation frequency and type for feasibility and efficacy|Zarit's Caregiver Burden Scale for quality of life|Brief Symptom Rating Scale for quality of life|Fatigue scale for quality of life","GenMont Biotech Incorporation|Chang Gung Memorial Hospital","All","55 Years to 95 Years   (Adult, Older Adult)","Not Applicable","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","201801746A3","September 12, 2019","May 22, 2022","May 22, 2022","September 18, 2019",,"September 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04094129"
710,"NCT02343757","Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid",,"Unknown status","No Results Available","Dementia|Alzheimer Disease","Device: PET/MRI","To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI, including direct comparison to corresponding PET/CT images of the same patients.|To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to 2-[F-18]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone.|To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form PET/CT and from PET/MR) using novel software developed specifically for these brain application;","University Hospitals Cleveland Medical Center","All","21 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-12-13","October 2013","December 2016","December 2016","January 22, 2015",,"January 22, 2015","University Hospital Case Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02343757"
711,"NCT04052737","PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Drug: Normal Saline along with standard treatment|Drug: PMZ-1620 (sovateltide) along with standard treatment","Incidence of PMZ-1620 related adverse events|Number of patients not receiving full treatment due to intolerance to PMZ-1620|Changes in clinical progression of AD as measured by Mini-Mental State Examination (MMSE)|Changes in neuropsychiatric inventory (NPI) Score|Changes in Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|Changes in hippocampal atrophy using MRI/CT|Changes in electroencephalograms (EEGs)","Pharmazz, Inc.","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PMZ-1620/CLINICAL-2.2/2017|CTRI/2017/12/011003","March 23, 2018","December 2019","July 2020","August 12, 2019",,"August 13, 2019","Post Graduate Institute of Medical Education and Research, Chandigarh, India|King George's Medical University, Lucknow, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India|Seth GSMC & KEM Hospital, Mumbai, India|All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04052737"
712,"NCT02162264","Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil Hydrochloride","Change From Baseline in the Mini-Mental State Examination (MMSE) Score|Investigations on adverse events and adverse drug reactions","Eisai Co., Ltd.|Eisai Inc.","All","Child, Adult, Older Adult",,"8662","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ART08T","June 1, 2013","May 30, 2015","July 22, 2016","June 12, 2014",,"September 7, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02162264"
713,"NCT03022968","Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)","TEPTAU","Active, not recruiting","No Results Available","Alzheimer Disease|Benson's Disease","Drug: [18F]T807 PET","Tau density on PET imaging|Tau distribution on PET imaging|p-tau CSF biomarkers|βamyloid CSF biomarkers|Cognitive profile with Hamilton depression scale (MADRS)|Cognitive profile with Mini mental state evaluation (MMSE)","University Hospital, Tours","All","50 Years and older   (Adult, Older Adult)","Phase 2","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO14-CH/TEPTAU","January 10, 2017","August 27, 2019","November 25, 2019","January 18, 2017",,"September 26, 2019","University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT03022968"
714,"NCT01120002","Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Tamibarotene|Drug: Placebo","Changes in Alzheimer's Disease Assessment Scale (ADAS-JCog)|Changes in Mini-Mental State Examination (MMSE)|Changes in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Changes in Clinician Interview-Based Assessment of Change Plus Caregiver Information (CIBIC-Plus)","Osaka City University","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OAM80-01","May 2010","December 2012","December 2012","May 10, 2010",,"July 22, 2011","Osaka City University Hospital, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01120002"
715,"NCT02686554","Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia",,"Recruiting","No Results Available","Alzheimer Disease","Other: Neuropsychological assessment","Cognitive Performance|Biomarker","Charite University, Berlin, Germany","All","50 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BIH_CRG2a_TP5","January 2016","January 2019","December 2019","February 19, 2016",,"July 24, 2017","Charité University Medicine, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02686554"
716,"NCT01773915","New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study",,"Unknown status","No Results Available","Alzheimer Disease, Late Onset",,"Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.","Universitaire Ziekenhuizen Leuven","All","65 Years and older   (Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","s54591","December 2012","January 2014","June 2014","January 23, 2013",,"January 14, 2014","UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01773915"
717,"NCT00812565","Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: Placebo|Biological: octagam 10%","Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24)|Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24)|Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion|Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion|Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24|Change From Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24|Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24|Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24|Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24|Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24","Octapharma","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GAM10-04","February 2009","September 2010","September 2010","December 22, 2008","May 5, 2014","May 5, 2014","Octapharma USA, Hoboken, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00812565"
718,"NCT01469351","Identifying Potential Effects of Liraglutide on Degenerative Changes",,"Completed","No Results Available","Alzheimers Disease","Drug: Liraglutide|Drug: non-active study drug","PIB PET scan|Neuro-psychological tests|FDG PET Scan","University of Aarhus","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-000794-31","January 2012","April 2013","April 2013","November 10, 2011",,"April 19, 2013","Aarhus University, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT01469351"
719,"NCT01630525",""" The Eyes Have it "" : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease","LYLO","Completed","No Results Available","Alzheimer's Disease","Other: Neuropsychological assessment|Other: ophthalmologic checkup|Other: Automated non-invasive oculometry","Saccades execution parameters|Neuropsychology tests scores|Pre-defined variables on visual exploration tasks (fixation number and durations, errors).|Number of point fixation in degraded areas and of visual attention induced cards","University Hospital, Bordeaux","All","60 Years and older   (Adult, Older Adult)",,"83","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CHUBX 2011/22","December 2012","December 2015","December 2015","June 28, 2012",,"January 25, 2016","Lyon UniversityHospital, Lyon, France|AP-HM, Marseille, France|CHU de Bordeaux Hôpital Haut Lévêque, Pessac, France",,"https://ClinicalTrials.gov/show/NCT01630525"
720,"NCT03939780","Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients",,"Not yet recruiting","No Results Available","Healthy|Alzheimer Disease","Diagnostic Test: [F18]RO-948|Diagnostic Test: [F18]MK-6240|Diagnostic Test: [F18]AV1451","Tracer kinetics as measured by distribution volume of radioligands|Tracer kinetics as measured by Standard Uptake Volume Ratio of radioligands|Tracer kinetics as measured by distribution volume of radioligands in off-target binding regions|Tracer kinetics as measured by SUVR of radioligands in off-target binding regions|Tracer kinetics as measured by distribution volume of radioligands in participants with high binding of AV-1541|Tracer kinetics as measured by SUVR of radioligands in participants with high binding of AV-1541|Tracer kinetics as measured by volume distribution of radioligands in the hippocampus|Tracer kinetics as measured by SUVR of radioligands in the hippocampus","Johns Hopkins University|National Institute on Aging (NIA)","All","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00193649|1R21AG062314-01","October 2019","January 2023","January 2023","May 7, 2019",,"October 1, 2019","John Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03939780"
721,"NCT03628404","Defining the Genetic Etiology of Alzheimer's Disease in the Faroe Islands",,"Recruiting","No Results Available","Alzheimer Disease|Dementia",,"Sequenom iPLEX genotyping and exome sequencing to identify and characterize genetic contributions to etiology of Alzheimer disease and other dementias|Influence of polychlorinated biphenyl exposure on the risk of AD|Influence of perfluorinated alkylated substance exposure on the risk of AD|Influence of mercury exposure on the risk of AD|MMSE|ACE|NPI-Q|FAQ IADL","Faroese Hospital System","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Other","AD","September 1, 2015","January 1, 2020","January 1, 2020","August 14, 2018",,"August 14, 2018","The Faroses Hospital System, Tórshavn, Faroe Islands",,"https://ClinicalTrials.gov/show/NCT03628404"
722,"NCT00506415","Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",,"Completed","Has Results","Alzheimer Disease","Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period|Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period|Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period|Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period|Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CENA713D2340","June 2007","May 2011","May 2011","July 25, 2007","September 19, 2012","September 19, 2012","Novartis investigative site, Birmingham, Alabama, United States|Novartis investigative site, Gilbert, Arizona, United States|Novartis investigative site, Phoenix, Arizona, United States|Novartis investigative site, Sun City, Arizona, United States|Novartis investigative site, Anaheim, California, United States|Novartis investigative site, Carson, California, United States|Novartis investigative site, Costa Mesa, California, United States|Novartis investigative site, Fullerton, California, United States|Novartis investigative site, La Habra, California, United States|Novartis investigative site, La Jolla, California, United States|Novartis investigative site, National City, California, United States|Novartis investigative site, Redlands, California, United States|Novartis investigative site, San Francisco, California, United States|Novartis investigative site, Fort Collins, Colorado, United States|Novartis investigative site, Longmont, Colorado, United States|Novartis investigative site, Boca Raton, Florida, United States|Novartis investigative site, Bradenton, Florida, United States|Novartis investigative site, Deerfield Beach, Florida, United States|Novartis investigative site, Delray Beach, Florida, United States|Novartis investigative site, Fort Lauderdale, Florida, United States|Novartis investigative site, Gainesville, Florida, United States|Novartis investigative site, Miami Beach, Florida, United States|Novartis investigative site, Pompano Beach, Florida, United States|Novartis investigative site, Port Charlotte, Florida, United States|Novartis investigative site, Sunrise, Florida, United States|Novartis investigative site, West Palm Beach, Florida, United States|Novartis investigative site, Atlanta, Georgia, United States|Novartis investigative site, Macon, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis investigative site, Chicago, Illinois, United States|Novartis investigative site, Springfield, Massachusetts, United States|Novartis investigative site, Flint, Michigan, United States|Novartis investigative site, Flushing, Michigan, United States|Novartis investigative site, Roseville, Michigan, United States|Novartis investigative site, Traverse City, Michigan, United States|Novartis investigative site, Hattiesburg, Mississippi, United States|Novartis investigative site, Ocean Springs, Mississippi, United States|Novartis investigative site, Columbia, Missouri, United States|Novartis investigative site, St. Louis, Missouri, United States|Novartis investigative site, Flemington, New Jersey, United States|Novartis investigative site, Nutley, New Jersey, United States|Novartis investigative site, Somerset, New Jersey, United States|Novartis investigative site, Albany, New York, United States|Novartis investigative site, Syracuse, New York, United States|Novartis investigative site, Greensboro, North Carolina, United States|Novartis investigative site, Morganton, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Canton, Ohio, United States|Novartis investigative site, Columbus, Ohio, United States|Novartis investigative site, Corvallis, Oregon, United States|Novartis investigative site, Portland, Oregon, United States|Novartis investigative site, Beaver, Pennsylvania, United States|Novartis investigative site, Erie, Pennsylvania, United States|Novartis investigative site, Greensburg, Pennsylvania, United States|Novartis investigative site, Pittsburgh, Pennsylvania, United States|Novartis investigative site, Beaufort, South Carolina, United States|Novartis investigative site, Summerville, South Carolina, United States|Novartis investigative site, Brentwood, Tennessee, United States|Novartis investigative site, Nashville, Tennessee, United States|Novartis investigative site, Dallas, Texas, United States|Novartis investigative site, Fort Worth, Texas, United States|Novartis investigative site, Irving, Texas, United States|Novartis investigative site, Charleston, West Virginia, United States|Novartis investigative site, Huntington, West Virginia, United States|Novartis investigative site, Toronto, Ontario, Canada|Novartis investigative site, Calgary, Canada|Novartis investigative site, Edmonton, Canada|Novartis investigative site, Greenfield Park, Canada|Novartis investigative site, Halifax, Canada|Novartis investigative site, London, Canada|Novartis investigative site, Montreal, Canada|Novartis investigative site, Ottawa, Canada|Novartis investigative site, Peterborough, Canada|Novartis investigative site, Quebec, Canada|Novartis investigative site, Regina, Canada|Novartis investigative site, Toronto, Canada|Novartis investigative site, Vancouver, Canada|Novartis investigative site, Winnipeg, Canada|Novartis investigative site, Fains Veel, Alsace Lorraine, France|Novartis investigative site, Dijon, Burgundy, France|Novartis investigative site, Reims, Champagne-Ardenne, France|Novartis investigative site, Bordeaux, France|Novartis investigative site, Bourg en Bresse, France|Novartis investigative site, Caen, France|Novartis investigative site, Cherbourg, France|Novartis investigative site, Dijon, France|Novartis investigative site, Limoges, France|Novartis investigative site, Montpellier, France|Novartis investigative site, Nice, France|Novartis investigative site, Paris, France|Novartis investigative site, Rennes, France|Novartis investigative site, Rodez, France|Novartis investigative site, Bad Neustadt/Saale, Germany|Novartis investigative site, Berlin, Germany|Novartis investigative site, Bonn, Germany|Novartis investigative site, Burg, Germany|Novartis investigative site, Duesseldorf, Germany|Novartis investigative site, Frankfurt, Germany|Novartis investigative site, Giessen, Germany|Novartis investigative site, Koln, Germany|Novartis investigative site, Krefeld, Germany|Novartis investigative site, Leipzig, Germany|Novartis investigative site, Magdeburg, Germany|Novartis investigative site, Mannheim, Germany|Novartis investigative site, Marburg, Germany|Novartis investigative site, Muenchen, Germany|Novartis investigative site, Muenster, Germany|Novartis investigative site, Nuernberg, Germany|Novartis investigative site, Stralsund, Germany|Novartis investigative site, Stuttgart, Germany|Novartis investigative site, Wurzburg, Germany|Novartis investigative site, Milano, Milan, Italy|Novartis investigative site, Ancona, Italy|Novartis investigative site, Arcugnano, Italy|Novartis investigative site, Arezzo, Italy|Novartis investigative site, Bari, Italy|Novartis investigative site, Bologna, Italy|Novartis investigative site, Brescia, Italy|Novartis investigative site, Cagliari, Italy|Novartis investigative site, Catania, Italy|Novartis investigative site, Città di Castello, Italy|Novartis investigative site, Cremona, Italy|Novartis investigative site, Ferrara, Italy|Novartis investigative site, Firenze, Italy|Novartis investigative site, Foggia, Italy|Novartis investigative site, Genova, Italy|Novartis investigative site, La Spezia, Italy|Novartis investigative site, Milano, Italy|Novartis investigative site, Milan, Italy|Novartis investigative site, Modena, Italy|Novartis investigative site, Napoli, Italy|Novartis investigative site, Padova, Italy|Novartis investigative site, Pavia, Italy|Novartis investigative site, Perugia, Italy|Novartis investigative site, Pisa, Italy|Novartis investigative site, Rho, Italy|Novartis investigative site, Rome, Italy|Novartis investigative site, Torino, Italy|Novartis investigative site, Verona, Italy|Novartis investigative site, Barcelona, Spain|Novartis investigative site, Palma de Mallorca, Spain|Novartis investigative site, Basel, Switzerland|Novartis investigative site, Biel, Switzerland|Novartis investigative site, Mendrisio, Switzerland",,"https://ClinicalTrials.gov/show/NCT00506415"
723,"NCT03650816","Cerebrovascular Reactivity in Alzheimer's Disease","VARAD-ET","Not yet recruiting","No Results Available","Alzheimer Disease|Subjective Cognitive Impairment","Other: Doppler ultrasonography|Other: Biospecimen collection","Cerebrovascular reactivity during the CO2 inhalation test in AD patients and control subjects (SCI)|Correlation between cognitive status and différences in CVR CO2|Correlation between cerebrospinal AD markers and CVR CO2|Z score of neuropsychological tests and CVR CO2|Plasma levels of ET-1, bigET-1, ADMA and their correlation with CVR CO2|Plasma renin activity and CVR CO2.","Assistance Publique - Hôpitaux de Paris|Fondation Plan Alzheimer|Naturalia & Biologia","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","APHP180012|IDRCB 2018-A01950-55","September 2019","May 2, 2021","August 2, 2021","August 29, 2018",,"August 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03650816"
724,"NCT00976118","Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: masitinib (AB1010)|Drug: placebo","change from baseline in ADAS-Cog|change from baseline in CIBIC-plus|change from baseline in CDR|change from baseline in MMSE","AB Science","All","50 Years and older   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AB04024","February 2006","July 2008","February 2009","September 14, 2009",,"December 13, 2018",,,"https://ClinicalTrials.gov/show/NCT00976118"
725,"NCT01766336","A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease","Drug: Group 1 ELND005|Drug: Group 2 ELND005","Number of Participants Experiencing Treatment Emergent Adverse Events","OPKO Health, Inc.|Elan Pharmaceuticals","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 2","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELND005-AG251|2012-005524-15","January 2013","August 2015","August 2015","January 11, 2013","May 13, 2016","June 22, 2016","TransitionTIL Investigational Site, Birmingham, Alabama, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Encino, California, United States|TransitionTIL Investigational Site, Escondido, California, United States|TransitionTIL Investigational Site, Fresno, California, United States|TransitionTIL Investigational Site, Long Beach, California, United States|TransitionTIL Investigational Site, Newport Beach, California, United States|TransitionTIL Investigational Site, Orange, California, United States|TransitionTIL Investigational Site, Norwalk, Connecticut, United States|TransitionTIL Investigational Site, Washington, District of Columbia, United States|TransitionTIL Investigational Site, Atlantis, Florida, United States|TransitionTIL Investigational Site, Deerfield Beach, Florida, United States|TransitionTIL Investigational Site, Delray Beach, Florida, United States|TransitionTIL Investigational Site, Lake Worth, Florida, United States|TransitionTIL Investigational Site, Oakland Park, Florida, United States|TransitionTIL Investigational Site, Orlando, Florida, United States|TransitionTIL Investigational Site, Port Charlotte, Florida, United States|TransitionTIL Investigational Site, Sarasota, Florida, United States|TransitionTIL Investigational Site, Columbus, Georgia, United States|TransitionTIL Investigational Site, Savannah, Georgia, United States|TransitionTIL Investigational Site, Springfield, Illinois, United States|TransitionTIL Investigational Site, Easton, Maryland, United States|TransitionTIL Investigational Site, Winchester, Massachusetts, United States|TransitionTIL Investigational Site, St. Paul, Minnesota, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Durham, North Carolina, United States|TransitionTIL Investigational Site, Wilmington, North Carolina, United States|TransitionTIL Investigational Site, Winston Salem, North Carolina, United States|TransitionTIL Investigational Site, Oklahoma City, Oklahoma, United States|TransitionTIL Investigational Site, Portland, Oregon, United States|TransitionTIL Investigational Site, Abington, Pennsylvania, United States|TransitionTIL Investigational Site, Jenkintown, Pennsylvania, United States|TransitionTIL Investigational Site, Norristown, Pennsylvania, United States|TransitionTIL Investigational Site, Pittsburgh, Pennsylvania, United States|TransitionTIL Investigational Site, Port Royal, South Carolina, United States|TransitionTIL Investigational Site, DeSoto, Texas, United States|TransitionTIL Investigational Site, Bellevue, Washington, United States|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Elche, Alicante, Spain|TransitionTIL Investigational Site, Terrassa, Barcelona, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Madrid, Spain|TransitionTIL Investigational Site, Swindon, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01766336"
726,"NCT02360657","Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia",,"Completed","No Results Available","Alzheimer's Disease","Drug: JNJ-54861911, 10 mg|Drug: JNJ-54861911, 50 mg|Drug: Placebo","Levels of Amyloid (A)-beta1-40 in Cerebrospinal Fluid (CSF) After Treatment at the Intended Target Dose Range|Levels of A-beta1-40 in Plasma After Treatment at the Intended Target Dose Range|Maximum Observed Plasma Concentration (Cmax) of JNJ 54861911|Minimum Observed Plasma Concentration (Cmin) of JNJ 54861911|Time to Reach Maximum Observed Concentration (Tmax) of JNJ 54861911|Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)|Cerebrospinal Fluid Exposure of JNJ-54861911|The Number of Participants who Experienced Adverse Events as a Measure of Safety and Tolerability of JNJ-54861911 After Multiple-Dose Administration in the Anticipated Target Dose Range|Levels of A-beta Fragments (A-beta1-37, A-beta1-38, and A-beta1-42) in CSF After Treatment at the Intended Target Dose Range|Levels of A-beta Fragments (A-beta1-37, A-beta1-38, and A-beta1-42) in Plasma After Treatment at the Intended Target Dose Range|Levels of Soluble Amyloid Precursor Protein (APP) Fragments in CSF (sAPP-alpha, sAPP-beta, totalAPP) After Treatment at the Intended Target Dose Range|Compare the Relationship of A-beta1-40 Levels in Plasma and CSF After Treatment at the Intended Dose Range","Janssen Pharmaceutical K.K.","All","65 Years to 85 Years   (Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR106397|54861911ALZ1008","February 16, 2015","September 8, 2015","September 8, 2015","February 10, 2015",,"February 4, 2019","Fukuoka, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02360657"
727,"NCT03393546","Auricular Point Acupressure to Manage Pain in Patients With Alzheimer's Disease and Related Disorders",,"Recruiting","No Results Available","Pain|Alzheimer Disease","Behavioral: Auricular Point Acupressure|Behavioral: Education Control","Change of Pain intensity|Change of Quantitative Sensory Testing (QST)|Change of Neuropsychiatric Inventory Questionnaire (NPI-Q)|Change of Neuropsychiatric Inventory Caregiver Distress (NPI-D)|Change of Caregiver Burden Interview|Change of Quality of life in Alzheimer's Disease (QOL-AD)|Change of Inflammatory Cytokines","Johns Hopkins University","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00168057","August 1, 2018","December 30, 2019","December 30, 2019","January 8, 2018",,"October 16, 2018","Johns Hopkins School of Nursing, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03393546"
728,"NCT01735630","Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: ELND005|Drug: Placebo","Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).|Change From Baseline in Modified-ADCS-CGIC Agitation Scores|Change From Baseline in NPI Total Scores|Change From Baseline in MMSE Scores|Change From Baseline in ADCS-ADL Scores","OPKO Health, Inc.|Elan Pharmaceuticals","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 2","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELND005-AG201|2012-004299-20","November 2012","May 2015","May 2015","November 28, 2012","August 15, 2016","August 15, 2016","TransitionTIL Investigational Site, Birmingham, Alabama, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Phoenix, Arizona, United States|TransitionTIL Investigational Site, Encino, California, United States|TransitionTIL Investigational Site, Escondido, California, United States|TransitionTIL Investigational Site, Fresno, California, United States|TransitionTIL Investigational Site, Irvine, California, United States|TransitionTIL Investigational Site, Long Beach, California, United States|TransitionTIL Investigational Site, Los Alamitos, California, United States|TransitionTIL Investigational Site, Los Angeles, California, United States|TransitionTIL Investigational Site, Newport Beach, California, United States|TransitionTIL Investigational Site, Santa Ana, California, United States|TransitionTIL Investigational Site, Norwalk, Connecticut, United States|TransitionTIL Investigational Site, Washington, District of Columbia, United States|TransitionTIL Investigational Site, Atlantis, Florida, United States|TransitionTIL Investigational Site, Deerfield Beach, Florida, United States|TransitionTIL Investigational Site, Delray Beach, Florida, United States|TransitionTIL Investigational Site, Lake Worth, Florida, United States|TransitionTIL Investigational Site, Miami, Florida, United States|TransitionTIL Investigational Site, Oakland Park, Florida, United States|TransitionTIL Investigational Site, Orlando, Florida, United States|TransitionTIL Investigational Site, Ormond Beach, Florida, United States|TransitionTIL Investigational Site, Port Charlotte, Florida, United States|TransitionTIL Investigational Site, Sarasota, Florida, United States|TransitionTIL Investigational Site, Sunrise, Florida, United States|TransitionTIL Investigational Site, Columbus, Georgia, United States|TransitionTIL Investigational Site, Savannah, Georgia, United States|TransitionTIL Investigational Site, Springfield, Illinois, United States|TransitionTIL Investigational Site, Bangor, Maine, United States|TransitionTIL Investigational Site, Easton, Maryland, United States|TransitionTIL Investigational Site, Winchester, Massachusetts, United States|TransitionTIL Investigational Site, Ann Arbor, Michigan, United States|TransitionTIL Investigational Site, Paw Paw, Michigan, United States|TransitionTIL Investigational Site, St. Paul, Minnesota, United States|TransitionTIL Investigational Site, Hattiesburg, Mississippi, United States|TransitionTIL Investigational Site, Stratford, New Jersey, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Rochester, New York, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Charlotte, North Carolina, United States|TransitionTIL Investigational Site, Durham, North Carolina, United States|TransitionTIL Investigational Site, Wilmington, North Carolina, United States|TransitionTIL Investigational Site, Winston-Salem, North Carolina, United States|TransitionTIL Investigational Site, Oklahoma City, Oklahoma, United States|TransitionTIL Investigational Site, Portland, Oregon, United States|TransitionTIL Investigational Site, Abington, Pennsylvania, United States|TransitionTIL Investigational Site, Jenkintown, Pennsylvania, United States|TransitionTIL Investigational Site, Norristown, Pennsylvania, United States|TransitionTIL Investigational Site, Philadelphia, Pennsylvania, United States|TransitionTIL Investigational Site, Philadelphia, Pennsylvania, United States|TransitionTIL Investigational Site, Pittsburgh, Pennsylvania, United States|TransitionTIL Investigational Site, North Charleston, South Carolina, United States|TransitionTIL Investigational Site, Port Royal, South Carolina, United States|TransitionTIL Investigational Site, Nashville, Tennessee, United States|TransitionTIL Investigational Site, DeSoto, Texas, United States|TransitionTIL Investigational Site, Richmond, Virginia, United States|TransitionTIL Investigational Site, Bellevue, Washington, United States|TransitionTIL Investigational Site, Calgary, Alberta, Canada|TransitionTIL Investigational Site, Kelowna, British Columbia, Canada|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Toronto, Ontario, Canada|TransitionTIL Investigational Site, Regina, Saskatchewan, Canada|TransitionTIL Investigational Site, Elche, Alicante, Spain|TransitionTIL Investigational Site, Getxo, Biscay, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Barcelona, Spain|TransitionTIL Investigational Site, Burgos, Spain|TransitionTIL Investigational Site, Madrid, Spain|TransitionTIL Investigational Site, Bath, United Kingdom|TransitionTIL Investigational Site, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01735630"
729,"NCT02467413","BAC in Patient With Alzheimer's Disease or Vascular Dementia",,"Withdrawn","No Results Available","Alzheimer's Disease|Vascular Dementia","Drug: BAC|Other: BAC Matched Vehicle","Change in Alzheimer's Disease Assessment Scale- Cognitive (ADAS-cog) score at Week-12 visit compared to baseline|Change in ADAS-cog score at all post treatment visits (except Week-12 visit) compared to baseline|Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits|Change in Activities of Daily Living (ADL) score at all post treatment visits compared to baseline|Change in Mini-Mental State Examination (MMSE) score at all post treatment visits compared to baseline|Change in Neuropsychiatric Inventory (NPI) score at all post treatment visits compared to baseline|Adverse event incidence|Change in physical examination results|Net change from baseline in laboratory test results|Net change from baseline in vital signs","Charsire Biotechnology Corp.|A2 Healthcare Taiwan Corporation","All","40 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BAC-01","December 1, 2019","June 2021","December 2021","June 10, 2015",,"July 31, 2019","National Cheng Kung University Hospital, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02467413"
730,"NCT02864303","Use of Saliva for Alzheimer's Disease Diagnosis","SalivALZ","Unknown status","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Other: Saliva samples","Aβ40 and Aβ42|Neuropsychologic tests|ApoE polymorphism","University Hospital, Montpellier","All","55 Years to 80 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","8835","June 2012","December 2018","December 2018","August 12, 2016",,"December 22, 2016","CHRU, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02864303"
731,"NCT01600469","NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: DAOI-B|Other: Placebo","Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24|Change from baseline in Mini Mental Status Examination at week 8, 16 and 24|Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24|Change from baseline in Verbal learning and memory at week 24|Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24","Chang Gung Memorial Hospital","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","99-2452A3","January 2012","May 2013","May 2013","May 17, 2012",,"June 4, 2013","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01600469"
732,"NCT01554683","Seizure Activity in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Seizures","Drug: Low/High/Placebo Dose Keppra (Levetiracetam)","Brain Perfusion Blood Flow fMRI|Free and Cued Selective Reminding Test|Mini Mental Status Exam (MMSE)|Trial Making Test Parts A & B|Phonemic & Category Fluency Test|Boston Naming Test 15-item version","Beth Israel Deaconess Medical Center","All","50 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2011P000303","February 2012","July 1, 2017","July 1, 2017","March 15, 2012",,"February 23, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01554683"
733,"NCT01329601","Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI","ECIF","Unknown status","No Results Available","Dementia of the Alzheimer Type","Behavioral: StaCog, stage specific cognitive Intervention|Behavioral: booklet based training","California Verbal Learning Test|functional cortical activity in fMRI","University of Rostock|DZNE, German Center for Neurodegenerative Disorders, Germany","All","55 Years and older   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Int_HRO_1","January 2011","October 2011","December 2011","April 6, 2011",,"April 6, 2011","Department of Psychiatry, University of Rostock, Rostock, Mecklenburg-Western Pomerania, Germany",,"https://ClinicalTrials.gov/show/NCT01329601"
734,"NCT01609348","Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)","DIADs-3","Completed","Has Results","Alzheimer's Disease|Depression","Drug: Placebo|Drug: Venlafaxine","Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change.","Johns Hopkins University","All","Child, Adult, Older Adult","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NA_00066043","April 2012","December 2016","January 2017","June 1, 2012","January 31, 2018","January 31, 2018","Johns Hopkins at Bayview, Baltimore, Maryland, United States|Reading Hospital, West Reading, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01609348"
735,"NCT01466088","Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil|Drug: AZD3480","Change from baseline in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)|Change from baseline in the Clinician Interview-Based Impression of Change plus carer interview [CIBIC-(+)]|Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Change from baseline in the Neuropsychiatric Inventory (NPI)|Change from baseline in the Mini-Mental State Examination (MMSE)|Change from baseline in the Alzheimer's Disease Related Quality of Life (ADRQL)","Targacept Inc.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","386","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-1734-226-CRD-006","October 2011","May 2014","May 2014","November 7, 2011",,"June 3, 2015","Banner Alzheimer Institute, Phoenix, Arizona, United States|Meridien Research, Brooksville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Policlinic, Chocen, Czech Republic|BRAIN-SOULTHERAPY s.r.o., Kladno, Czech Republic|Bialbi.s.r.o. Psychiatrické oddělení, Litoměřice, Czech Republic|Psychiatricka Ambulance, Olomouc, Czech Republic|Vojenska Nemocnice Psychiatricke oddeleni, Olomouc, Czech Republic|Clintrial, Praha, Czech Republic|PRAGTIS s.r.o., Praha, Czech Republic|Psychosocialni centrum, Prerov, Czech Republic|Crucea Alba - Dr. Oros si Asociatii - Societate Civila Medicala, Oradea, Romania|Spitalul de Psihiatrie Sibiu, Sibiu, Romania|Spitalul Clinic Judetean de Urgenta SIBIU, Sibiu, Romania|Spitalul Clinic Judetean de Urgenta, Clinica Psihiatrie, Timisoara, Romania|Spitalul Clinic Judetean de Urgenta, Clinica Neurologie 2, Timisoara, Romania|Neurologicka Ambulancia, s.r.o., Banska Bystrica, Slovakia|Univerzitna nemocnica Bratislava, Geronto-psychiatrické oddelenie, Bratislava, Slovakia|KONZILIUM s.r.o., Dubnica nad Váhom, Slovakia|Neurologická ambulancia, Krompachy, Slovakia|Dnipropetrovsk Regional Clinical Hospital, Dnipropetrovsk, Ukraine|Donetsk National Medical University of M. Gorky, Donetsk, Ukraine|Donetsk Regional Clinical Psychiatric Hospital, Donetsk, Ukraine|Crimean Republican Institution Psychoneurological Dispensary, Kerch, Ukraine|Central Clinical Hospital Ukrzaliznytsi, Kharkiv, Ukraine|Department of Age Physiology and Pathology of Nervous System; Institute of Gerontology NAMS, Kyiv, Ukraine|Lugansk Regional Clinical Psychoneurological Hospital, Lugansk, Ukraine|Lviv National Medical University named after Galytskyy, Lviv, Ukraine|Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odessa Regional Psychoneurology Dispensary, Odessa, Ukraine|Odessa Regional Psychiatric Hospital # 2, Oleksandrivka, Ukraine|Ukrainian Medical Stomatological Academy, Poltava, Ukraine|Department #3 of the Kherson Regional Psychiatric Hospital, Stepanovka, Ukraine",,"https://ClinicalTrials.gov/show/NCT01466088"
736,"NCT00130429","Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: PYM50028","Hopkins verbal learning test (revised) total word recall after 12 weeks|Cambridge neuropsychological test automated battery (CANTAB) paired associate learning (Phytopharm modified form) total adjusted error score after 12 weeks|Mini mental state examination score|Clinical dementia rating (overall and sum of boxes)|CANTAB rapid visual information processing (RVIP) mean latency|CANTAB RVIP total correct hits|CANTAB spatial working memory within error, between error and strategy scores|Clinicians global impression of change|Disability assessment for dementia score","Phytopharm","All","50 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","P58/09ME/03/04","January 2004",,"September 2005","August 15, 2005",,"August 21, 2009","Oxford Project to Investigate Memory and Ageing, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00130429"
737,"NCT02550665","Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg","ODESA","Completed","No Results Available","Alzheimer's Disease","Drug: donepezil","Incidence of treatment-emergent adverse events (safety and tolerability)|blood WBC|blood BUN|blood Creatinine|blood sodium|blood potassium|blood AST/ALT|weight loss|drug compliance (counting of residual drug)|heart rate on Electrocardiography (ECG)","Asan Medical Center|Dong-A University|Myongji Hospital|Seoul National University Bundang Hospital|Seoul St. Mary's Hospital|Chung-Ang University|Eisai Inc.","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 3","176","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JHongLee","December 2014","August 2016","October 2016","September 15, 2015",,"August 7, 2018","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02550665"
738,"NCT02187276","The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia",,"Completed","No Results Available","Alzheimer Disease, Late Onset","Drug: cholinesterase inhibitors","Cognitive results|Genetic and biochemical analyzes","Federal University of Minas Gerais","All","59 Years to 92 Years   (Adult, Older Adult)",,"129","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0172/2010","June 2009","March 2013","March 2013","July 11, 2014",,"September 12, 2014",,,"https://ClinicalTrials.gov/show/NCT02187276"
739,"NCT02176629","Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease","MeMO-RV2","Completed","No Results Available","MCI|Alzheimer's Disease","Other: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|Other: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)","Evaluate the acceptability of the RV|Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC).","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","14-PP-03","August 2014","February 2015","February 2015","June 27, 2014",,"September 1, 2015","Institut Claude Pompidou, Nice, France",,"https://ClinicalTrials.gov/show/NCT02176629"
740,"NCT01600859","Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)",,"Completed","No Results Available","Alzheimer's Disease","Drug: E2609|Drug: Placebo for E2609","Percent change from baseline in cerebrospinal fluid amyloid-beta levels|Incidence of adverse events","Eisai Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","E2609-A001-101","July 2012","September 2013","October 2013","May 17, 2012",,"December 30, 2016","Glendale, California, United States|Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01600859"
741,"NCT01481961","Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease","ALSTIMAG","Completed","No Results Available","Alzheimer's Disease|Cognition Disorders","Procedure: repetitive Transcranial Magnetic Stimulation (rTMS)","changes in MMSE (Mini Mental State Examination)|changes in HDRS (Hamilton Depression Rating Scale)|changes in STAI (State-Trait Anxiety Inventory)|changes in BDI (Beck Depression Inventory)|changes in HAMA (Hamilton Anxiety Scale)|changes in Mattis DRS (Dementia Rating Scale)|changes in CDR (Clinical Dementia Rate)|changes in Grober Free and Cued Selective Reminding Test|changes in TMT (Trail Making Test)|changes in COT (Crossing Of Test)|changes in IST (Isaacs Set Test)|changes in CDT (Clock-Drawing Test)|changes in Signoret's Battery of Cognitive Efficacy (BEC96)|changes in Rey-complex figure test-copy|changes in Picture naming 80 items test (DO80)|changes in RUD (Resource Utilisation Dementia)|changes in AI (Apathy Inventory)|changes in ADL (Activities of Daily Living)|changes in IADL (Instrumental Activities of Daily Living)|changes in QoL-AD (Quality of Life in Alzheimer's Disease)|changes in CP6 (Questionnaire of recent change in personnality)","Pierre Vandel, MD PhD|Neurology department of CHU Besancon (Dr Rumbach L, Dr Berger E, Dr Galmiche J)|Memory Center of Research and Resources (MCRR) of Besancon (Dr Magnin E)|Rapid-fr network (Dr Galmiche J)|Clinical Investigation Centre for Innovative Technology Network|Funding by French Internal Project Call for Clinical Research(2010-A00659-30)|Centre Hospitalier Universitaire de Besancon","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALSTIMAG","November 2010","May 2012","May 2012","November 30, 2011",,"March 3, 2015","Psychiatric Department of CHU of Besancon, Besancon, France",,"https://ClinicalTrials.gov/show/NCT01481961"
742,"NCT03056729","Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Healthy Volunteer","Drug: BIIB076|Drug: Placebo","Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)|BIIB076 serum pharmacokinetics (PK) concentration levels|PK parameter of BIIB076: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of BIIB076: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)|PK parameter of BIIB076: Maximum observed concentration (Cmax)|PK parameter of BIIB076: Time to reach maximum observed concentration (Tmax)|PK parameter of BIIB076: Terminal elimination half-life (t1/2)|PK parameter of BIIB076: Clearance (CL)|PK parameter of BIIB076: Volume of distribution (Vd)|Number of participants with positive serum BIIB076 antibodies","Biogen","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","243HV101","February 17, 2017","February 14, 2020","February 14, 2020","February 17, 2017",,"September 6, 2019","MD Clinical, Hallandale Beach, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Covance Evansville CRU, Evansville, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|St Louis Clinical Trial, Saint Louis, Missouri, United States|Covance Dallas CRU, Dallas, Texas, United States|Covance CRU, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03056729"
743,"NCT02702817","Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia",,"Completed","No Results Available","Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease","Drug: Naproxen|Drug: Placebo","Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease|frequency and severity of treatment-emergent adverse events|trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status|ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout|biomarkers of inflammatory processes|CSF biomarkers of AD pathogenesis","Douglas Mental Health University Institute|McGill University|Johns Hopkins University","All","55 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","INTREPAD","August 1, 2012","March 31, 2017","July 15, 2017","March 9, 2016",,"August 1, 2017","Douglas Hospital Research Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02702817"
744,"NCT00571064","The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility",,"Completed","Has Results","Mild to Severe Alzheimer's Disease","Drug: Donepezil HCl","Mini Mental State Examination (MMSE) Total Scores by Visit|Change From Baseline in MMSE Total Score by Visit|Caregiver Activity Survey (CAS) Total Time by Visit|Change From Baseline in CAS Total Time by Visit|Neuropsychiatric Inventory (NPI-8) Total Score by Visit|Change From Baseline in NPI-8 Total Score by Visit|Alzheimer Disease-related Quality of Life (ADRQL) Total Score by Visit|Change From Baseline in ADRQL Total Score by Visit|Disability Assessment in Dementia (DAD) Total Score by Visit|Change From Baseline in DAD Total Score by Visit","Eisai Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 4","97","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2020-A001-415","January 2008","December 2008","April 22, 2009","December 11, 2007","March 12, 2018","September 27, 2018","Senior Care, Birmingham, Alabama, United States|21st Century Neurology, Phoenix, Arizona, United States|Psypharma Clinical Research, Phoenix, Arizona, United States|South Coast Clinical Trials, Anaheim, California, United States|AVI Clinical Research, Carson, California, United States|Margolin Brain Institute, Fresno, California, United States|Sarah Sam Olelewe, MD Inc, Hawthorne, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Danbury Clinical Research, LLC, Danbury, Connecticut, United States|Research Center for Clinical Studies, Norwalk, Connecticut, United States|Galiz Research, Miami Springs, Florida, United States|Neuroscience Consultants, Miami, Florida, United States|Universal Clinical research and Technology, Orlando, Florida, United States|Byrd's Alzheimer Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Rush Alzheimer Disease Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove, Illinois, United States|Agewell Health Ltd, Indianapolis, Indiana, United States|Venture Resource Group Inc, Mission, Kansas, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|McLean Hospital Geriatric Psychiatry, Belmont, Massachusetts, United States|Neuroscience Research of the Bershires, Pittsfield, Massachusetts, United States|Horne Research, Las Vegas, Nevada, United States|Bio Behavioral Health, Toms River, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Neurological Associates of Albany, PC, Albany, New York, United States|University Of Buffalo, Buffalo, New York, United States|University of Rochester, Monroe Community Hospital, Rochester, New York, United States|Valley Medical Research, Centerville, Ohio, United States|Infinity Research Group, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Section of Geriatric Psychiatry, Philadelphia, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|CNS Research, INC, East Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Mech Center, Plano, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00571064"
745,"NCT03672474","REGEnLIFE RGn530 - Feasibility Pilot",,"Recruiting","No Results Available","Alzheimer Disease","Device: Photobiomodulation REGEnLIFE RGn530 device|Device: SHAM REGEnLIFE RGn530 device","Orientation (time and space) score (10 items) from the Mini Mental Scale Examination (MMSE)|Sum of free recall (sum of the three learning tests) and of cued recall (sum of free recall and indexed recall) from the Free and Cued Selective Reminding Test (FCSRT)|(3) Digit symbol Substitution test (WAIS-IV coding test)|(4) 2-minutes Category naming test|MATTIS|Trail Making Test A and B|ADAS-Cog|Clinical Dementia Rating|IADL 8 items|Biological Parameters in blood|Biological Parameters in CSF|Electrophysiological Parameter|Actimetry Activity Parameter|Morphological MRI 1.5T hippocampal Scheltens volumetry|Imaging Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) values in regions of interest","University Hospital, Montpellier","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UF 7575","September 7, 2018","October 19, 2018","October 19, 2019","September 14, 2018",,"October 16, 2018","Montpellier University Hospital, Gui de Chauliac, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03672474"
746,"NCT01094145","Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease","MeynD-DBS","Completed","No Results Available","Alzheimer Disease","Other: Deep brain stimulation","cognitive improvement|determination of the optimal stimulation parameter","University of Cologne","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UK-09157","January 2010","January 2013","January 2013","March 26, 2010",,"June 7, 2013","Uni-Klinik Köln AöR, Cologne, North Rhine Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT01094145"
747,"NCT02035553","A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis",,"Completed","Has Results","Alzheimer's Disease Psychosis","Drug: Pimavanserin tartrate|Drug: Placebo","Antipsychotic Efficacy","ACADIA Pharmaceuticals Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-019","November 2013","September 28, 2016","October 27, 2016","January 14, 2014","October 25, 2017","October 25, 2017","London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02035553"
748,"NCT00843518","Treatment for Aggression and Agitation in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: LY451395|Drug: Placebo","Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12|Mean Change From Baseline in 10-Item Version of Neuropsychiatric Inventory (NPI-10) at Week 12|Mean Change From Baseline in the Neuropsychiatric Inventory (NPI) Depression Domain at Week 12|Mean Change From Baseline in the Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 12|Mean Change From Baseline in Cohen-Mansfield Agitation Inventory-Community Version (CMAI-C) at Week 12|Mean Change From Baseline in Cornell Scale for Depression in Dementia (CSDD) at Week 12|Mean Change From Baseline in Total T-Score in the Frontal System Behaviors Scale (FrSBe) at Week 12|Mean Change From Baseline in Clinical Global Impression-Severity-Agitation/Aggression (CGI-S-A/A) at Week 12|Mean Change From Baseline in Clinical Global Impression-Severity-Global Functioning (CGI-S-GF) at Week 12|Mean Change From Baseline in the 14-Item Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog14) at Week 12","Eli Lilly and Company","All","60 Years and older   (Adult, Older Adult)","Phase 2","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12541|H6N-MC-LEAQ","February 2009","June 2011","June 2011","February 13, 2009","November 29, 2017","November 29, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Easton, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flowood, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hickory, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norristown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00843518"
749,"NCT00750282","Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers",,"Completed","Has Results","Alzheimer Disease|Amyloid Beta-Protein","Drug: Florbetaben (BAY94-9172)","Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth|Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.|Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment|Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)|Standard Uptake Value Ratios for Florbetaben Signal","Life Molecular Imaging SA","All","55 Years and older   (Adult, Older Adult)","Phase 2","422","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","311741|2007-002256-42","August 2008","November 2010","November 2010","September 10, 2008","July 16, 2014","July 24, 2014","Sun City, Arizona, United States|Stanford, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States|New York, New York, United States|New York, New York, United States|Providence, Rhode Island, United States|Westmead, New South Wales, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Jülich, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Bunkyo-ku, Tokyo, Japan|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00750282"
750,"NCT00000176","Alzheimer's Disease Prevention Trial",,"Completed","No Results Available","Alzheimer Disease|Memory Disorders","Drug: Estrogen|Drug: Estrogen and Progesterone",,"National Institute on Aging (NIA)","Female","65 Years and older   (Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","IA0018|RO 1AG15922-01",,"September 2007","September 2007","November 1, 1999",,"November 5, 2010","University of Alabama, Birmingham, Alabama, United States|University of California, Irvine, Irvine, California, United States|New England Center for Headache, Stamford, Connecticut, United States|Howard University, Washington, District of Columbia, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|West Florida Regional Medical Center, Pensacola, Florida, United States|North Broward Medical Center, Pompano Beach, Florida, United States|Tallahassee Memorial Health Center, Tallahassee, Florida, United States|St. Mary's Medical Center, West Palm Beach, Florida, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Neurology Group of Bergen County, Ridgewood, New Jersey, United States|Columbia University, New York, New York, United States|Cornell Medical Center, New York Presbyterian Medical Center, New York, New York, United States|New York United Hospital Medical Center, Port Chester, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Pharmaceutical Trials, Tulsa, Oklahoma, United States|Butler Hospital, Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00000176"
751,"NCT01485302","Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients",,"Completed","No Results Available","Alzheimer's Disease","Drug: SAR228810","number of patients with adverse events|AUC|Cmax|t1/2z|brain magnetic resonance imaging|hematology, biochemistry, coagulation|vital signs, ECG","Sanofi","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDR12399|2011-002910-35|U1111-1120-0550","January 2012","February 2015","February 2015","December 5, 2011",,"March 25, 2015","Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 250001, Pierre Bénite, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 710001, Bloemfontein, South Africa|Investigational Site Number 752003, Malmö, Sweden|Investigational Site Number 752002, Mölndal, Sweden|Investigational Site Number 752001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01485302"
752,"NCT01614886","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)",,"Completed","Has Results","Alzheimer's Disease","Drug: Active Comparator|Drug: ENA713","Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation|Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Change From Baseline in Mini-Mental State Examination (MMSE)|Number of Participants With Improvement in Japanese Clinical Global Impression of Change (J-CGIC). Patients With ""Improvement"": a Total of 1. Markedly Improved, 2. Improved, and 3. Slightly|The Percentage of Treatment Retention.","Novartis Pharmaceuticals|Ono Pharmaceutical Co. Ltd|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CENA713D1303","July 2012","May 2014","May 2014","June 8, 2012","May 12, 2015","August 1, 2016","Novartis Investigative Site, Anjo-city, Aichi, Japan|Novartis Investigative Site, Obu-city, Aichi, Japan|Novartis Investigative Site, Seto-city, Aichi, Japan|Novartis Investigative Site, Toyoake-city, Aichi, Japan|Novartis Investigative Site, Akita-city, Akita, Japan|Novartis Investigative Site, Chiba-city, Chiba, Japan|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Fujioka-city, Gumma, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Miyoshi-city, Hiroshima, Japan|Novartis Investigative Site, Kasama-city, Ibaraki, Japan|Novartis Investigative Site, Kamakura-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Koshi-city, Kumamoto, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Kumamoto-city, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Kitamorokata-gun, Miyazaki, Japan|Novartis Investigative Site, Azumino-city, Nagano, Japan|Novartis Investigative Site, Matsumoto-city, Nagano, Japan|Novartis Investigative Site, Nagaoka-city, Niigata, Japan|Novartis Investigative Site, Kurashiki-city, Okayama, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Sakai-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Kanzaki-gun, Saga, Japan|Novartis Investigative Site, Kasukabe-city, Saitama, Japan|Novartis Investigative Site, Kawaguchi-city, Saitama, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, Japan|Novartis Investigative Site, Saitama-city, Saitama, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Tokushima-city, Tokushima, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, Japan|Novartis Investigative Site, Koto-ku, Tokyo, Japan|Novartis Investigative Site, Musashino-city, Tokyo, Japan|Novartis Investigative Site, Ota-ku, Tokyo, Japan|Novartis Investigative Site, Tachikawa-city, Tokyo, Japan|Novartis Investigative Site, Shimonoseki-city, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT01614886"
753,"NCT00001933","Nefiracetam in the Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Nefiracetam",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","990139|99-N-0139","July 1999",,"January 2002","November 4, 1999",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001933"
754,"NCT01417130","Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial","ADAPT-FS","Unknown status","No Results Available","Alzheimer Disease|Dementia",,"Incident Alzheimer's Disease dementia|Trajectory of performance on cognitive tests in relation to ADAPT treatment assignment","Seattle Institute for Biomedical and Clinical Research|VA Puget Sound Health Care System|National Institute on Aging (NIA)|Johns Hopkins University","All","75 Years and older   (Older Adult)",,"1650","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","BREITNERBJ18CO|5U01AG015477-07","August 2009","October 2011","August 2012","August 16, 2011",,"January 9, 2012","Banner Sun Health Research Institute, Sun City, Arizona, United States|The Roskamp Institute, Sarasota, Florida, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Monroe Community Hospital, Rochester, New York, United States|Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01417130"
755,"NCT03503669","Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Behavioral: Memory Training|Behavioral: Kundalini yoga and meditation","Hopkins Verbal Learning Test (HVLT) total recall score","University of California, Los Angeles","Female","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17-001876","May 1, 2018","May 2021","May 2021","April 20, 2018",,"October 11, 2018","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03503669"
756,"NCT02119546","Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease",,"Completed","No Results Available","Mild CognitIve Impairment|Alzheimer's Disease","Other: Aerobic exercise|Other: Stretch exercise","Change from baseline in Color Trails Test at week12 and Week24|Change from baseline in walking speed at week12 and Week24","National Taiwan University Hospital","All","45 Years to 85 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","200912126R","May 2010","September 2012","December 2012","April 21, 2014",,"April 21, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02119546"
757,"NCT01859767","Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.",,"Completed","No Results Available","Alzheimer's Disease","Drug: [123I]MNI-672 SPECT","Number of subjects with adverse events|Clinically significant changes in vital signs|Total I-123 radioactivity in plasma|Standard uptake values (SUV)|Visual analysis","Molecular NeuroImaging","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-672-01","April 2013","March 2015","April 2015","May 22, 2013",,"December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01859767"
758,"NCT02035982","Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Cholinesterase Inhibitor|Drug: Placebo","Clinician's Global Impression of Change (CGIC)|Number of total adverse events","Sunnybrook Health Sciences Centre","All","55 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","107-2010|Grant #12-74","July 2010","May 2014","September 2015","January 14, 2014",,"April 28, 2017","North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02035982"
759,"NCT00083590","Huperzine A in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Huperzine A",,"National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)|Neuro-Hitech","All","55 Years and older   (Adult, Older Adult)","Phase 2","150","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0052|ADC-023|IND 63,997","April 2004","November 2007","November 2007","May 27, 2004",,"February 21, 2008","University of Alabama, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, Alzheimer's Disease Research Center, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|Howard University School of Medicine, Washington, DC, District of Columbia, United States|Georgetown University Medical Center, Memory Disorders Program, Washington, District of Columbia, United States|MD Clinical, Fort Lauderdale, Florida, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|University of South Florida, Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, United States|ICPS Group, Boston, Massachusetts, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, United States|Albany Medical Center, Albany, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Vermont College of Medicine, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00083590"
760,"NCT03061474","Nicotinamide as an Early Alzheimer's Disease Treatment","NEAT","Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Nicotinamide|Drug: Placebo Comparator","Change in p-tau 231|Change in p-tau 181|Change in total tau","University of California, Irvine","All","50 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20163246","July 12, 2017","June 30, 2020","June 30, 2020","February 23, 2017",,"September 26, 2019","University of California, Irvine, Irvine, California, United States|University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03061474"
761,"NCT01876459","Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.","AlphaLewyMa","Unknown status","No Results Available","""Alzheimer's Disease"" and ""Lewy Body Disease""","Other: MRI|Procedure: lumbar puncture|Behavioral: neuropsychological tests","rate of alpha-synuclein in cerebrospinal fluid","University Hospital, Strasbourg, France","All","45 Years and older   (Adult, Older Adult)","Not Applicable","265","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","5330|N° IDRCB 2012-A00992-41","April 2013","April 2015","April 2015","June 12, 2013",,"June 18, 2013","Hôpitaux Universitaires de Strasbourg, Strasbourg, Hôpital de Hautepierre, France",,"https://ClinicalTrials.gov/show/NCT01876459"
762,"NCT00811122","Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly","11C-PIB PET","Unknown status","No Results Available","Alzheimer's Disease","Radiation: 11C-PIB PET Scan|Radiation: FDG-PET Scan","The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals.|Patients with AD scanned with 11C-PIB will have higher standardized uptake values (SUVs) than cognitively normal elderly in brain regions where beta amyloid are expected to be over-expressed.","University of Utah","All","30 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17991","November 2009","April 2018","April 2018","December 18, 2008",,"May 9, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00811122"
763,"NCT02137460","Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease","KBASE","Active, not recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment",,"The amount of brain amyloid deposition|Group difference for each clinical, neuropsychological, structural and functional neuroimaging, tau imaging, genetic, biochemical measures|Change of brain amyloid deposition|Change of clinical, neuropsychological measures|Change of structural and functional neuroimaging measures|Change of biochemical measures|Chage of tau imaging measures","Dong Young Lee|Ministry of Science and ICT, Republic of Korea|Seoul National University|Seoul National University Hospital","All","20 Years to 90 Years   (Adult, Older Adult)",,"920","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KBASE01|NRF-2013M3C7A1072998|NRF-2013M3C7A1069644|NRF-2014M3C7A1046042|NRF-2014M3C7A1046037","May 2014","February 2020","February 2020","May 13, 2014",,"October 5, 2017","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02137460"
764,"NCT00099242","Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia, Alzheimer Type","Drug: rivastigmine transdermal patch","Change in cognition from baseline at week 24|Global clinical impression of change from baseline at week 24|Change from baseline at week 24 in activities of daily living|Change from baseline at week 24 in behavioral symptoms|Change from baseline at week 24 in global cognitive testing|Change from baseline at week 24 in executive function|Change from baseline at week 24 in attention","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1040","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CENA713D2320","November 2003",,"January 2006","December 10, 2004",,"October 13, 2017","Orange, California, United States|San Francisco, California, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Port Charlotte, Florida, United States|West Palm Beach, Florida, United States|Snellville, Georgia, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Long Branch, New Jersey, United States|Manchester Township, New Jersey, United States|Toms River, New Jersey, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Greensburg, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Tacoma, Washington, United States|Santiago, Chile|Valparaiso, Chile|Brno-Bohunice, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Prague, Czechia|Glostrup, Denmark|Hillerod, Denmark|Kobenhavn, Denmark|Kuopio, Finland|Investigative sites, Germany|Guatemala City, Guatemala|Beersheva, Israel|Hifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Lido di Camaiore, Italy|Milano, Italy|Pescara, Italy|Chungbuk, Korea, Republic of|KyungKi-province, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara Jalisco, Mexico|Mexico D.F., Mexico|Monterrey Nuevo Leon, Mexico|Bodo, Norway|Oslo, Norway|Tromso, Norway|Trondheim, Norway|Lima, Peru|Gdansk, Poland|Lublin, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Amadora, Portugal|Coimbra, Portugal|Bayamon, Puerto Rico|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Bratislava, Slovakia|Michalovce, Slovakia|Goteborg, Sweden|Kalmar, Sweden|Stockholm, Sweden|Uppsala, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Ciudad Merida, Estado Merida, Venezuela",,"https://ClinicalTrials.gov/show/NCT00099242"
765,"NCT01478633","Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil",,"Completed","No Results Available","Alzheimer's Disease","Drug: Galantamine","The Change from Baseline in Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) Score at Week 24|The Clinical Global Impression of Change (CGI-C) at Week 24|Proportion of Responders at Week 24","Janssen Pharmaceutical K.K.","All","40 Years and older   (Adult, Older Adult)","Phase 4","102","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR018649|JNS023-JPN-02","September 2011","June 2013","June 2013","November 23, 2011",,"March 26, 2014","Akita, Japan|Izunokuni, Japan|Kochi N/A, Japan|Kumamoto, Japan|Osaka, Japan|Saitama N/A, Japan|Takatsuki, Japan|Tokyo, Japan|Uji, Japan|Urayasu, Japan|Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT01478633"
766,"NCT03507257","Longitudinal Early-onset Alzheimer's Disease Study Protocol","LEADS","Recruiting","No Results Available","Early Onset Alzheimer Disease|Alzheimer Disease|Mild Cognitive Impairment","Drug: Flortaucipir|Drug: Florbetaben","Rate of change in cognition as measured by by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)|Rate of change in cognition as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Rate of change in cognition as measured by the Clinician Judgment of Symptoms form from the NACC UDS.|Rate of change in cognition as measured by the Neurological Examination Findings form from the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).|Change in tau deposition as measured by flortaucipir (18F-AV-1451) Positron Emission Tomography (PET) imaging|Change in amyloid deposition as measured by florbetaben using Positron Emission Tomography (PET) imaging|Change in brain structure using magnetic resonance imaging (MRI)|Change in cerebrospinal fluid (CSF) biomarkers","Liana Apostolova|Alzheimer's Therapeutic Research Institute|National Institute on Aging (NIA)|Alzheimer's Association|Indiana University","All","40 Years to 64 Years   (Adult)",,"600","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATRI-003|R56AG057195","April 30, 2018","August 31, 2022","August 31, 2023","April 25, 2018",,"September 9, 2019","University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Houston Methodist Hospital, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03507257/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03507257"
767,"NCT01807026","A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease|Healthy Volunteers","Drug: LY2886721|Drug: Placebo","Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721|Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721|Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721|Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721|Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40|PD: Cnadir of CSF Aβ 1-40|Cohort C: Mean QTcF Value at Cmax","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15107|I4O-EW-BACX","March 2013","May 2013","May 2013","March 8, 2013","July 19, 2019","July 19, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01807026"
768,"NCT01636596","Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Insulin LISPRO","cerebral glucose metabolism|cognition|general clinical improvement|basal metabolism","Louisiana State University Health Sciences Center Shreveport|Acuity Center","All","50 Years to 95 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H12-166","September 2013","January 2015","January 2015","July 10, 2012",,"March 13, 2014","LSUHSC Shrevport Psychopharmacology Research Clinic, Shreveport, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01636596"
769,"NCT00254033","Apathy Associated With Alzheimer's Disease",,"Completed","No Results Available","Dementia|Alzheimer Disease","Drug: Dextroamphetamine|Drug: Methylphenidate","Addiction Research Centre Inventory (ARCI)|Apathy Evaluation Scale-Caregiver (AES-C)|Profile of Mood States (POMS)|Continuous Performance Test (CPT)|Neuropsychiatric Inventory (NPI)","Sunnybrook Health Sciences Centre|American Health Assistance Foundation","All","55 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","065-2003|AHAF Grant Number: A2003-236","October 2003",,"October 2006","November 15, 2005",,"April 28, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00254033"
770,"NCT03035851","Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias","BIMII","Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Aerobic exercise|Behavioral: Stretch and Strength","Change in Cognition Assessed by Neuropsychological Test Battery|Change in Cerebral Blood Flow Assessed by Transcranial Doppler Ultrasound|Change in Maximal Oxygen Uptake (VO2max) Assessed by Metabolic Cart|Change in Blood Biomarkers Assessed by Elisa Assays|Change in Risk/protective factors Assessed by Questionnaires|Change in Brain Structure and Function Assessed by Neuroimaging Modalities|Change in Sleep Quality Assessed by Polysomnography, Actigraphy and Questionnaires|Change in Health behaviour with appropriate support strategies","University of Calgary|Canadian Institutes of Health Research (CIHR)","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","REB 16-1199","January 2017","June 2024","January 2025","January 30, 2017",,"September 26, 2019","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03035851"
771,"NCT00948766","Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","ACTION","Completed","Has Results","Alzheimer's Disease","Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)|Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)|Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)|Drug: Placebo","Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24|Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24|Core Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24|Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24|Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24|Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24|Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24","Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","716","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CENA713DUS44","July 2009","January 2012","June 2012","July 29, 2009","February 11, 2013","August 28, 2013","Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc, Tempe, Arizona, United States|Northwest Neuro Specialist, PLLC, Tucson, Arizona, United States|IHS Research Center Inc., Conway, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro Pain Medical Center, Fresno, California, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|PCND Neuroscience Research Institute Inc./The Center for Memory and Aging, Poway, California, United States|Anderson Clinical Research, Redlands, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Viking Clinical Research Center, Temecula, California, United States|Collaborative Neuroscience Network, Inc, Torrance, California, United States|Senior Care of Colorado, Aurora, Colorado, United States|Clinical Research Studies Dept. of Clinical Science and Medical Education, Boca Raton, Florida, United States|Quantum Laboratories Memory Disorder Center, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, PA, Fort Lauderdale, Florida, United States|White-Wilson Medical Center, Fort Walton Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Sunrise Clinical Research, Inc, Hollywood, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Integrity Research, LLC, Pensacola, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Center for Clinical Trials, Venice, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Reseach Institute, Lenexa, Kansas, United States|Precise Clinical Research Solutions, Manhattan, Kansas, United States|LSU Health Sciences Center/Department of Psychiatry Psychopharmacology Research Clinic, Shreveport, Louisiana, United States|J. Gary Booker, MD APMC, Shreveport, Louisiana, United States|Pharmasite Research, Baltimore, Maryland, United States|The Samuel and Alexia Bratton Memory Clinic, William Hill Inc, Easton, Maryland, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Michigan Neurology Associates, P.C., Clinton Township, Michigan, United States|Wayne State University/Detroit Medical center, Detroit, Michigan, United States|West Michigan Clinical Research, Muskegon, Michigan, United States|Orr & Associates Memory and Geriatric Behavioral Health Clinic, St. Paul, Minnesota, United States|Neurological Research Clinic, Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Neuroscience Center, Ocean Springs, Mississippi, United States|Sky, LLC., St Louis, Missouri, United States|St. Louis University, St. Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|NeuroCognitive Institute, Mt. Arlington, New Jersey, United States|UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States|UMDNJ-School of Osteopathic Medicine Center, Stratford, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Neurological Care of Central NY, Liverpool, New York, United States|Eastside Comprehensive medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|The Burke Rehabilitation Hospital, White Plains, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc., Winston Salem, North Carolina, United States|Valley Medical Research, Centerville, Ohio, United States|University Neurology, Inc., Cincinnati, Ohio, United States|Cognitive Assessment Clinic, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Department of Veterans Affairs Medical Center, Coatesville, Pennsylvania, United States|Westmoreland Neurology associates, Inc., Greensburg, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Research Protocol Management Specialists, Pittsburg, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Jacinto Medical Group, PA, Baytown, Texas, United States|Future Search Trials, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Radiant Research Inc., San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|TLC Neurology, P.L.L.C, Arlington, Virginia, United States|UVA Neurology, Charlottesville, Virginia, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Independent Psychiatric Consultants, SC, Waukesha, Wisconsin, United States|Metro Medical Center, Bayamon, Puerto Rico|INSPIRA Clinical Research, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00948766"
772,"NCT02886494","A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",,"Completed","No Results Available","Alzheimer's Disease or Vascular Dementia","Drug: BAC|Drug: Matched placebo","Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) score at Week 12 visit compared to baseline|Change in ADAS-cog score at all post treatment visits (except Week 12 visit) compared to baseline|Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) score at all post treatment visits compared to baseline|Change in Mini-Mental State Examination (MMSE) score at all post treatment visits compared to baseline|Change in Neuropsychiatric Inventory (NPI) score at all post treatment visits compared to baseline|Adverse event incidence","Charsire Biotechnology Corp.","All","40 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BAC-02","December 2016","November 1, 2018","November 1, 2018","September 1, 2016",,"July 30, 2019","Clinical Research Consortium, Tempe, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Pacific Research Network, LLC, San Diego, California, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|SPRI, Brooklyn, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02886494"
773,"NCT01035164","Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers",,"Completed","No Results Available","Positron-Emission Tomography|Alzheimer's Disease","Drug: F-18 FEDAA1106 (BAY85-8101)","Visual analysis/description of the uptake and description of brain PET scans|Standardized uptake value (SUV) in various cerebral regions/volumes of interest (ROI/VOI) assumed and found to be involved in the pathophysiology of Alzheimer's disease.|Standard quantification variables derived from 3D PET imaging and brain modeling|Standard Safety Measurement:adverse event collection|Standard Safety Measurement:electrocardiogram|Standard Safety Measurement:safety laboratory|Standard Safety Measurement: vital signs","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91683|2006-006045-14|311401","June 2007","January 2010","January 2010","December 18, 2009",,"January 8, 2015","Amsterdam, Netherlands|Stockholm, Sweden|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01035164"
774,"NCT01849042","Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease","ROMEO-AD","Unknown status","No Results Available","Alzheimer's Disease|Dementia","Drug: Ebixa|Drug: donepezil","AQ-WAB(Western aphasia battery)|ROSA (Relevant Outcome Scale for Alzheimer's Disease)","Konkuk University Medical Center","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROMEO-AD 14394A","January 2013","August 2014","August 2015","May 8, 2013",,"August 13, 2014","Konkuk university medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01849042"
775,"NCT01832350","Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Pseudobulbar Affect (PBA)","Drug: Nuedexta (20/10)","reduction of PBA frequency|reduction of PBA severity","St. Joseph's Hospital and Medical Center, Phoenix|Avanir Pharmaceuticals","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AVP923","December 2012","November 2017","December 2017","April 16, 2013",,"July 12, 2017","Barrow Neurological Institute, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01832350"
776,"NCT02085265","Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients","SARTAN-AD","Recruiting","No Results Available","Alzheimer's Disease|Hypertension","Drug: Perindopril|Drug: Telmisartan","Ventricular enlargement|Safety - Blood pressure|Safety - Vital signs|Safety - Electrolytes|Safety - Adverse Events|Hippocampal volume|Grey/White matter volume|Cognitive and functional measures","Sunnybrook Health Sciences Centre|Alzheimer’s Drug Discovery Foundation|Weston Brain Institute","All","50 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","148-2013","March 2014","March 2020","March 2021","March 12, 2014",,"November 27, 2017","University of Calgary, Calgary, Alberta, Canada|University of Lethbridge, Lethbridge, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Parkwood Institute, London, Ontario, Canada|South East Toronto Family Health Team, Toronto, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|University of Waterloo, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02085265"
777,"NCT01695889","Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?","DEMA","Unknown status","No Results Available","Alzheimer´s Disease|General Anesthesia",,"Exposure to general anesthesia|Exposure to inhaled anesthetics","University Hospital, Linkoeping","All","Child, Adult, Older Adult",,"877","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","DEMA-1","May 2012","July 2016","July 2016","September 28, 2012",,"March 25, 2016","University Hospital, Linkoping, Sweden",,"https://ClinicalTrials.gov/show/NCT01695889"
778,"NCT03748303","Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study","Allo-IM","Not yet recruiting","No Results Available","Alzheimer Dementia","Drug: Allopregnanolone","Safety - Adverse events|Safety - clinical laboratory measures|Safety - clinical assessment|Pharmacokinetic parameter - Cmax|Pharmacokinetic parameter - AUC|Pharmacokinetic parameter - Tmax|Pharmacokinetic parameter - Clearance|Pharmacokinetic parameter - Volume of distribution|Satisfaction and feasibility of home nurse survey","University of Arizona|University of Southern California|Alzheimer's Association","All","55 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AlloPhase1-IM","October 15, 2019","August 2020","October 2020","November 20, 2018",,"September 27, 2019","University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03748303"
779,"NCT03698760","Computerized Olfactory Test - Alzheimer Disease Mild Stage",,"Recruiting","No Results Available","Alzheimer Disease|Olfaction Disorders","Diagnostic Test: Olfactory test","Objective test of evaluation of the olfactory sensitivity|Health condition assessed by self-administered questionnaire (SAQ)|Objective test of evaluation of the olfactory thresholds","Jewish General Hospital","All","60 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2019-1509","June 25, 2019","April 2020","July 2020","October 8, 2018",,"July 25, 2019","Jewish General Hospital, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03698760"
780,"NCT04080544","Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study",,"Not yet recruiting","No Results Available","Alzheimer Disease|Cognitive Decline","Drug: [18F]AV-1451|Procedure: Positron Emission Tomography","Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans|Comparison of Tau Accumultation with Cognitive Decline|Tau SUVr Scores and the Relationship to Participants' Age|Comparison of Tau Accumulation with Amyloid Accumulation|Comparison of Tau SUVr scores with Hippocampal Volume and Cortical Thickness|Comparison of Tau Accumulation with White Matter Integrity|Comparison of Tau Accumulation with Functional MRI|Comparison of Tau Accumulation with Cognition","Neil M Rofsky, MD, MHA|University of Texas Southwestern Medical Center","All","38 Years to 96 Years   (Adult, Older Adult)","Phase 2","125","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 092015-003","September 15, 2019","June 30, 2022","June 30, 2022","September 6, 2019",,"September 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04080544"
781,"NCT03489044","An Investigation of Levetiracetam in Alzheimer's Disease","ILiAD","Enrolling by invitation","No Results Available","Alzheimer Disease|Epilepsy","Drug: Levetiracetam|Drug: Placebo Oral Tablet","Effect of Levetiracetam on hippocampal function in patients with Alzheimer's disease as assessed by a computerised test of hippocampal binding|Number of participants with treatment related serious adverse events as reported on the serious adverse events proforma|Effect of Levetiracetam on mood in patients with Alzheimer's disease|Effect of Levetiracetam on quality of life in patients with Alzheimer's disease as assessed by their principal carer|Effect of Levetiracetam on quality of life in patients with Alzheimer's disease|Determining role of the electroencepahlogram in patients with Alzheimer's disease","University of Oxford|Oxford University Hospitals NHS Trust|Oxford Health NHS Foundation Trust|Northumberland, Tyne and Wear NHS Foundation Trust|UCB Pharma","All","50 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRAS 203849|2016-003109-32","November 2018","November 1, 2019","January 2020","April 5, 2018",,"October 16, 2018","Nuffield Department of Clinical Neuroscience, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03489044"
782,"NCT00086138","Depression in Alzheimer's Disease-2","DIADS-2","Completed","Has Results","Alzheimer's Disease|Depression","Drug: Sertraline (Zoloft)|Drug: Placebo","Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)|Remission According to Cornell Scale for Depression in Dementia Scale","Johns Hopkins University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","131","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","U01MH066136|DATR A4-GPX","July 2004","July 2008","July 2009","June 28, 2004","April 11, 2017","April 11, 2017","University of Southern California, Los Angeles, California, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00086138"
783,"NCT02854033","Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol","ADNI3","Recruiting","No Results Available","Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)",,"Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)|Rate of change in cognition as measured by the Logical Memory Test I and II|Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)|Rate of change in cognition as measured by the Cogstate Brief Battery (CBB)|Rate of change in cognition as measured by the American National Adult Reading Test (ANART)|Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)|Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test|Rate of change in cognition as measured by the Trail Making Test: A and B|Change in tau deposition as measured by 18F-AV-1451|Change in amyloid deposition as measured by Florbetapir|Change in amyloid deposition as measured by Florbetaben|Rate of conversion to MCI or dementia due to AD|Rates of change of glucose metabolism (FDG-PET)|Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers|Change in brain structure using magnetic resonance imaging (MRI)","University of Southern California|Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute","All","55 Years to 90 Years   (Adult, Older Adult)",,"2000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATRI-001|U01AG024904","October 2016","October 2021","October 2021","August 3, 2016",,"October 4, 2019","University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|Long Beach VA Neuropsychiatric Research Program, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, Davis, Walnut Creek, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Albany Medical College, Albany, New York, United States|Dent Neurologic Institute, Buffalo, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas, Southwestern MC at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Clinic for AD & Related, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|St. Joseph's Health Center - Cognitive Neurology, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02854033"
784,"NCT03841539","Nutrition Interventions for Cognitive Enhancement","NICE","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Mediterranean Diet|Dietary Supplement: Study Supplement|Behavioral: Low-fat Diet","Change in a composite global cognition score|Change in Verbal Memory Factor|Change in Visuospatial Processing Factor|Change in Attention Factor|Change in Executive Function Factor|Change in Speed of Processing Factor|Change in brain volume|Change in cerebral antioxidant levels|Change in blood pressure|Change in percentage of total fatty acids by weight|Change in total cholesterol|Change in HDL cholesterol|Change in total/HDL cholesterol ratio|Change in LDL cholesterol|Change in triglycerides|Change in apolipoprotein B|Change in lipoprotein(a) (Lp(a))|Change in high sensitivity C-Reactive Protein (hs-CRP)|Change in lipoprotein-associated phospholipase A2 (Lp-PLA2)|Change in insulin resistance score|Change in fasting glucose|Change in Hemoglobin A1c (HbA1c)|Change in Trimethylamine N-oxide (TMAO)|Change in a composite global cognition score post intervention|Change in Verbal Memory Factor post intervention|Change in Visuospatial Processing Factor post intervention|Change in Attention Factor post intervention|Change in Executive Function Factor post intervention|Change in Speed of Processing Factor post intervention|Measure of dietary adherence post intervention","University of Kansas Medical Center|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STUDY00142752|1R01AG060157-01","March 7, 2019","April 2022","February 2023","February 15, 2019",,"July 24, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03841539"
785,"NCT01461109","Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls",,"Completed","No Results Available","Parkinson Disease|Alzheimer Disease","Drug: [18F] CFPyPB","To assess the dynamic uptake and washout of [18F] CFPyPB|Perform blood metabolite characterization of [18F] CFPyPB|To obtain safety data|Obtain test/retest reproductibility","Institute for Neurodegenerative Disorders","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","GlyT1-01","August 2011","September 2012","May 2014","October 27, 2011",,"June 4, 2014","Institute_Neurodegenerative_Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01461109"
786,"NCT01024660","The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil|Drug: Placebo to match Aricept","CogState Computerized Neurological Test Battery|Neuropsychological Test Battery (NTB)|Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog)|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)","AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","D2285M00010","December 2009","January 2011","January 2011","December 3, 2009",,"February 8, 2011","Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Reearch Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Callao, Lima, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Chojnice, Poland|Research Site, Gdansk, Poland|Research Site, Kalisz, Poland|Research Site, Pila, Poland|Research Site, Poznan, Poland|Research Site, Scinawa, Poland|Research Site, Sopot, Poland|Research Site, Warszawa, Poland|Research Site, Cape Town, Western Cape, South Africa|Research Site, Roodepoort, South Africa",,"https://ClinicalTrials.gov/show/NCT01024660"
787,"NCT00174525","Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: AAB-001","Safety assessments|Blood levels of administered study drug|Cognitive and functional assessments","Pharmacology Research Institute","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PRI#585","April 2005",,"April 2008","September 15, 2005",,"May 9, 2012","Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Northridge, California, United States",,"https://ClinicalTrials.gov/show/NCT00174525"
788,"NCT03255720","Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes",,"Not yet recruiting","No Results Available","Alzheimer Dementia",,"the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease.","Assiut University","All","60 Years to 80 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","diffusion tensor imaging","September 29, 2017","December 1, 2022","December 31, 2022","August 21, 2017",,"September 26, 2017",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03255720/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03255720"
789,"NCT03612622","Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease",,"Recruiting","No Results Available","Transcranial Magnetic Stimulation|Magnetic Resonance Imaging|Alzheimer Disease","Other: transcranial magnetic stimulation","Associative Memory|The changes in MMSE(Mini Mental State Examination)|LMT (Logic Memory Test)|DST (Digital Span Test; Forward and Backward)|TMT (Trail Making Test)|HAMD (Hamilton Depression Scale)|HAMA (Hamilton Anxiety Scale)|NPI (Neuropsychiatric Inventory)|MRI measures|2-BACK(special-version)|changes in Montreal Cognitive Assessment (MoCA)|GDS(Geriatric depression scale)|JLOT(Judgment of line Judgment of line orientation test orientation test)|HVOT(Hooper visual organization test Hooper visual organization test)|The Stroop color test","Anhui Medical University","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anhui medical university","May 1, 2018","December 30, 2020","December 30, 2020","August 2, 2018",,"December 27, 2018","Anhui Medical University, Hefei, Anhui, China",,"https://ClinicalTrials.gov/show/NCT03612622"
790,"NCT03560960","Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease","DTAD","Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: Pramlintide challenge test","Plasma Aβ and t-tau changes|Plasma inflammatory changes|Plasma metabolic changes in blood|Change in MMSE|Change in CDR|Change in NAB|Change in WMS-III Logical Memory|Change in CLOX paradigm|Change in Trailmaking Test Part B|Change in Controlled Oral Word Association Test","Boston University|National Institute on Aging (NIA)","All","60 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","240","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H-37432|1R01AG059424-01","October 2019","July 2023","July 2023","June 19, 2018",,"October 1, 2019","Indiana University Alzheimer Disease Center, Indianapolis, Indiana, United States|BU Alzheimer Disease Center, Boston, Massachusetts, United States|Memory Center VA Boston Healthcare, Jamaica Plain, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03560960"
791,"NCT02829801","Evaluation of the Animal Intervention Used as Therapy","ELIAUT","Unknown status","No Results Available","Alzheimer Disease","Behavioral: AAT and cognitive stimulation and rehabilitation of social tie.|Behavioral: Cognitive stimulation and rehabilitation of social tie.","evaluation of the changes of the well being from baseline until 3 months|evaluation of the changes of psycho-behavioral symptoms of dementia (PBSD) from baseline until 3 months|evaluation of the changes of depressive symptoms from baseline until 3 months|evaluation of the changes of the anxiety from baseline until 3 months|evaluation of the changes of cognitive performances from baseline until 2 months","Hospices Civils de Lyon","All","65 Years and older   (Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","69HCL15_678","March 2, 2016","May 2, 2019","May 2, 2019","July 12, 2016",,"August 9, 2017","Hôpital des Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02829801"
792,"NCT01928420","A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Drug: NIC5-15|Drug: Placebo","Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers|APO-E genotyping","Humanetics Corporation|National Center for Complementary and Integrative Health (NCCIH)|James J. Peters Veterans Affairs Medical Center","All","40 Years to 95 Years   (Adult, Older Adult)","Phase 2","30","Industry|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21AT003302-01A1|MHBB-009-06S","April 2007","June 2014","June 2014","August 26, 2013",,"October 17, 2016","James J Peters Veterans Affairs Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01928420"
793,"NCT03441516","Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia","ALFO-AD","Enrolling by invitation","No Results Available","Alzheimer's Disease","Drug: Alfoatirin® Tab. + Aripezil® Tab.|Drug: Aripezil® Tab.","ADAS-cog|K-MMSE (Korean version of Mini-Mental State Examination)|FAB (Frontal Assessment Battery)|S-IADL (Seoul-Instrumental Activities of Daily Living)|CGA-NPI (Caregiver-Administered Neuropsychiatric Inventory)|Changes in brain metabolism by F-18 FDG brain PET","Yuhan Corporation","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YMC034","April 19, 2018","December 31, 2019","December 31, 2019","February 21, 2018",,"October 17, 2018","Dong-A University Hospital, Busan, Korea, Republic of|Gyeongsang National University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Pusan National University Yangsan Hospital, Busan, Korea, Republic of|Samsung Changwon Hospital, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03441516"
794,"NCT00968097","Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition",,"Terminated","No Results Available","Alzheimer's Disease","Drug: 123-I MNI-340","The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-340.","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","MNI-340-01","April 2008","July 2008","July 2008","August 28, 2009",,"April 3, 2019","The Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00968097"
795,"NCT00921297","Cataract Removal and Alzheimer's Disease",,"Completed","No Results Available","Cataracts|Alzheimer's Disease","Procedure: Immediate Cataract Surgery","Visual acuity, spatial contrast sensitivity, visual perception and cognition|Independent function|Quality of Life|Retinal Nerve Fiber Layer","University Hospitals Cleveland Medical Center|Case Western Reserve University|MetroHealth Medical Center|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","122","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","04-09-21|1R01AG030114","June 2009","March 30, 2017","March 30, 2017","June 16, 2009",,"November 9, 2017","University Hospitals Case Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00921297"
796,"NCT02002819","Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability","LEV-AD","Recruiting","No Results Available","Alzheimer's Disease","Drug: levetiracetam","Changes in Executive Function as Measured by the E.X.A.M.I.N.E.R. Computer Battery|Changes in Epileptiform Activity Frequency|Changes in Cognitive Function|Changes in Behavior and Level of Disability","University of Minnesota - Clinical and Translational Science Institute","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LEV-AD|PCTRB-13-288476","June 2014","December 2019","December 2019","December 6, 2013",,"April 22, 2019","UCSF, San Francisco, California, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02002819"
797,"NCT00065689","High Intensity Light Therapy in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Device: high-intensity light therapy",,"National Center for Complementary and Integrative Health (NCCIH)","All","55 Years and older   (Adult, Older Adult)","Phase 3","107","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","R01AT000212-01A1|SloaneP","March 2003",,"September 2005","August 1, 2003",,"July 26, 2006","John Umstead Hospital, Butner, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00065689"
798,"NCT04044131","Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients",,"Not yet recruiting","No Results Available","Alzheimer Disease|Parkinson Disease","Drug: Metabolic Cofactor Supplementation|Drug: Sorbitol","Mini Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Unified Parkinson's Disease Rating Scale (UPDRS)|Volumetric Magnetic resonance Imaging (MRI) and resting state functional magnetic resonance imaging (rest-fMRI)|Neuropsychiatric Inventory (NPI)|Montreal Cognitive Assessment (MoCA)|Changes in serum omic profile from baseline|Microbiota analysis|Monitoring of adverse events|Change in heart rate from baseline|Change in blood pressure from baseline|Change in waist and hip circumference from baseline|Change in body weight from baseline|Change of complete blood count from baseline|Changes in liver function tests (alkaline phosphatase (ALP), alanine aminotransferase (ALT), Aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total and direct Bilirubin, Albumin) from baseline|Changes in blood lipid levels (total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C)) from baseline|Changes in kidney function tests (creatinine, urea, urate, sodium, potassium) from baseline|Changes in creatinine kinase (CK) level from baseline|Change in thyroid-stimulating hormone (TSH) level from baseline|Change in blood insulin level from baseline|Change in glycated haemoglobin (HbA1c) level from baseline|Changes in blood glucose levels from baseline","Istanbul Medipol University Hospital|ScandiBio Therapeutics AB|Alanya Alaaddin Keykubat University|Sahlgrenska University Hospital, Sweden|KTH Royal Institute of Technology","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Metabolic Cofactor Study","September 1, 2019","September 2020","September 2020","August 5, 2019",,"August 5, 2019",,,"https://ClinicalTrials.gov/show/NCT04044131"
799,"NCT01513967","A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease",,"Completed","No Results Available","Moderate to Severe Alzheimer|Alzheimer Disease","Drug: RPh201, botanical drug product|Drug: Placebo|Drug: RPh201, botanical extract product","The primary objective: to evaluate the safety and tolerability of RPh201 after single and multiple rising doses.|To evaluate efficacy of RPh201 in subjects with AD","Regenera Pharma Ltd|Syneos Health","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RGN-ADC-001","January 2012","June 2015","June 2015","January 20, 2012",,"December 6, 2016","Toronto Memory Program, Toronto, Ontario, Canada|Kendle Early Stage - Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01513967"
800,"NCT01880151","Neuroelectrical Biomarkers for Alzheimer's Disease Stages","ESTIMATE","Unknown status","No Results Available","Alzheimer Disease","Device: EEG","Frequency band charactersitics of the electrophysiological brain response","Institut National de la Santé Et de la Recherche Médicale, France","All","70 Years to 85 Years   (Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","C12-71|2013-A00344-41","June 2013","March 2017","July 2017","June 18, 2013",,"August 31, 2016","Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT01880151"
801,"NCT02703636","NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","ENA1stepswitch","Completed","Has Results","Mild to Moderate Alzheimer's Disease","Drug: Rivastigmine Patch","MMSE Total Score: Change From Baseline to Week 8 and Week 24 (Full Analysis Set)|MMSE Total Score: Change From Baseline to Week 8 and Week 24|Change From Baseline to Week 8 in Mini-Mental State Examination (MMSE) Total Score|Change in Neuropsychiatric Inventory - 10 Item (NPI-10) Score From Baseline to Week 8 and Week 24|Change in QOL-AD Score From Baseline to Week 24|Change in J-CGIC Score From Baseline and at Week 24|Change in as Modified Crichton Scale Score From Baseline to Week 4, 8, 16 and 24|Formulation Usability Questionnaire Form Score up to Week 24","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","118","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DJP02","May 9, 2016","May 7, 2018","May 7, 2018","March 9, 2016","September 12, 2019","September 12, 2019","Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Aizuwakamatsu, Fukushima, Japan|Novartis Investigative Site, Tsukuba-city, Ibaraki, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, Japan|Novartis Investigative Site, Kochi-city, Kochi, Japan|Novartis Investigative Site, Sanjo-city, Niigata, Japan|Novartis Investigative Site, Kurashiki-city, Okayama, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Kasukabe-city, Saitama, Japan|Novartis Investigative Site, Koshigaya-city, Saitama, Japan|Novartis Investigative Site, Fuji city, Shizuoka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Suginami Ku, Tokyo, Japan|Novartis Investigative Site, Okayama, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02703636/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02703636/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02703636"
802,"NCT00459355","Home Safety Clinical Trial for Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease|Dementia","Behavioral: Home Safety Toolkit","Caregiver Strain|Caregiver Self-efficacy|Care Recipient Risky Behaviors and Accidents","US Department of Veterans Affairs|Boston Medical Center|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 1","254","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","NRH 05-056","July 2007","May 2010","December 2011","April 11, 2007","September 29, 2014","April 28, 2015","Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00459355"
803,"NCT01409694","Alzheimer's Disease - Input of Vitamin D With mEmantine Assay","AD-IDEA","Completed","No Results Available","Alzheimer Disease","Drug: Memantine|Drug: Vitamin D|Drug: Vitamin D placebo","Change in cognitive performance|Change in other cognitive scores|Change in functional performance|Change in posture and gait|Between-group comparison of compliance to treatment and tolerance","University Hospital, Angers","All","60 Years and older   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-024506-35","September 2011","January 2016","January 2016","August 4, 2011",,"September 22, 2016","University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT01409694"
804,"NCT01320527","A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Dietary Supplement: Nutriceutical formulation|Other: Placebo","cognitive improvement or maintenance of cognitive performance|behavioral/psychotic symptoms","University of Massachusetts, Worcester|University of Massachusetts, Lowell|Alzheimer's Association","All","40 Years and older   (Adult, Older Adult)","Phase 2","135","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-1350|IIRG-08-91737","August 2008","April 2012","April 2012","March 22, 2011",,"March 3, 2016","Naples Medical Center, Naples, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Rivercourt Residences, Groton, Massachusetts, United States|Mary Immaculate Residential, Lawrence, Massachusetts, United States|D'Youville Senior Care, Lowell, Massachusetts, United States|Neurocognitive Institute, Mt. Arlington, New Jersey, United States|Advanced Memory Dynamics, Layton, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01320527"
805,"NCT01819545","The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease",,"plasma and CSF press of miRNA 107 and BACE1 mRNA","Shanghai Mental Health Center|Shanghai Municipal Science and Technology Commission|National Natural Science Foundation of China","All","60 Years to 90 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","10ZR1425800","January 2012","July 2014","December 2015","March 27, 2013",,"February 19, 2014","Department of Psychogeriatrics，Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01819545"
806,"NCT03089827","Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease",,"Enrolling by invitation","No Results Available","Alzheimer Disease|Mild Cognitive Impairment",,"Amyloid deposition","Wake Forest University Health Sciences","All","55 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00027675","May 21, 2014","April 2022","January 2025","March 24, 2017",,"May 10, 2019","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03089827"
807,"NCT02284906","AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease",,"Terminated","Has Results","Mild Cognitive Impairment Due to Alzheimer's Disease","Drug: Pioglitazone|Drug: Placebo","Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24|Time to Diagnosis of Alzheimer's Disease (AD) Dementia","Takeda","All","65 Years and older   (Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AD-4833/TOMM40_303|U1111-1154-9637|2013-004984-30","February 12, 2015","January 31, 2018","May 8, 2018","November 6, 2014","July 2, 2019","July 2, 2019","Phoenix, Arizona, United States|Sun City, Arizona, United States|San Diego, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Merritt Island, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|Basel, Switzerland|Bristol, Avon, United Kingdom|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Perth, Tayside Region, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02284906/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02284906/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02284906"
808,"NCT01463384","Minocycline in Patients With Alzheimer's Disease",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease","Drug: Minocycline","Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).|Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)","Huntington Medical Research Institutes","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LKW-AB34","September 2011","October 2012","October 2012","November 1, 2011","September 25, 2014","September 25, 2014","Huntington Medical Research Institutes, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT01463384"
809,"NCT02918539","Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials","RAmP","Completed","No Results Available","Alzheimer Disease|Cognition Disorders","Drug: florbetapir F 18 PET scan","Patient Registry Participation","Avid Radiopharmaceuticals|Eli Lilly and Company|PRA Health Sciences","All","50 Years and older   (Adult, Older Adult)",,"317","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","18F-AV-45-A25|PRA Study Code: 446601","October 2016","October 18, 2017","October 18, 2017","September 29, 2016",,"October 24, 2018","Arrowhead Internal Medicine, PC, Glendale, Arizona, United States|Center for Neuro and Spine Inc. (CNS) - Main Office, Phoenix, Arizona, United States|Imaging Endpoints, Scottsdale, Arizona, United States|Center for Neurology and Spine, Sun City, Arizona, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Neurology Center of North Orange County, Fullerton, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Pacific Research Network, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|North Bay Neuroscience Institute, Sebastopol, California, United States|Mile High Research Center, Denver, Colorado, United States|Coastal Conneticut Research, New London, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Ptak Alzheimer Research Center, Clearwater, Florida, United States|Wisdom Clinical Research Institute, Coral Gables, Florida, United States|Direct Helpers Research, Hialeah, Florida, United States|Healing Touch C&C Research Inc, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Precision Clinical Research, Lauderdale Lakes, Florida, United States|Neurology Associates, PA, Maitland, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Advance Research Development Solutions, Miami Lakes, Florida, United States|Homestead Associates in Research, Miami, Florida, United States|Dade Research Center, Miami, Florida, United States|United Clinical Research, Corp., Miami, Florida, United States|Advanced Medical Research Institute (AMRI), Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Bravo Health Care Center, North Bay Village, Florida, United States|Laszlo J. Mate, MD, North Palm Beach, Florida, United States|Pines Care Research Center, Pembroke Pines, Florida, United States|Neurostudies.net, LLC, Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Olympian Clinical Research - South Tampa Office, Tampa, Florida, United States|Tampa Neurology Associates, Tampa, Florida, United States|University of South Florida Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Lovelance Scientific Resources, Inc., Venice, Florida, United States|Sand Lake Imaging, MRI Facility, Winter Park, Florida, United States|Doctors Clinical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Community Hospital of Anderson and Madison Country, Anderson, Indiana, United States|American Health Network of Indiana, Avon, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Spectrum Clinical Research, Baltimore, Maryland, United States|Boston Center for Memory, Brookline, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millenium Psychiatric Associates, Creve Coeur, Missouri, United States|Las Vegas Medical Center, Las Vegas, Nevada, United States|Amici Clinical Research, Martinsville, New Jersey, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, PA, West Long Branch, New Jersey, United States|Integrative Clinical Trials, Brooklyn, New York, United States|Adirondack Medical Research, Glens Falls, New York, United States|Neurological Associates of Long Island, Lake Success, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Dayton Center for Neurological Disorders, Dayton, Ohio, United States|Clinical Inquest Center, Dublin, Ohio, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Legacy Research Institute, Portland, Oregon, United States|Adler Institute for Advanced Imaging, Jenkintown, Pennsylvania, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Heights Doctors Clinic, Houston, Texas, United States|Yvonne Kew MD PLLC Neuro-Oncology Clinic, Houston, Texas, United States|FMC Science, Lampasas, Texas, United States|The Clinical Research Group, Inc., Lewisville, Texas, United States|Texas Medical Research Associates, LLC, San Antonio, Texas, United States|National Clinical Research-Richmond, Inc., Richmond, Virginia, United States|Dean Foundation for Health, Research and Education, Inc., Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02918539"
810,"NCT00954616","Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly","MIDA","Completed","No Results Available","Alzheimer's Disease",,"To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine|To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence.","University Hospital, Limoges","All","75 Years and older   (Older Adult)",,"636","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","I07033","January 2009","July 2011","January 2012","August 7, 2009",,"March 20, 2014","CHU Rouen, Rouen, Bois guillaume, France|CHU Bordeaux, Pessac, Bordeaux, France|CH Le Mans, Le Mans, Le Mans Cedex 1, France|CHU Montpellier, Montpellier, Montpellier Cedex 5, France|APHP Charles Foix, Ivry sur Seine, Paris, France|CHU Saint Etienne, Saint Etienne, France",,"https://ClinicalTrials.gov/show/NCT00954616"
811,"NCT03806478","Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease",,"Not yet recruiting","No Results Available","Dementia|Alzheimer Disease 1|Alzheimer Disease 2|Alzheimer Disease 3","Drug: APH-1105|Other: Placebo","Safety: Incidence of Treatment-emergent Adverse Events|Efficacy: Cognition Change|Efficacy: Change in Cognitive Functioning|Tolerability: [Pharmacokinetics] Cmax|Tolerability: [Pharmacokinetics] Tmax|Tolerability: [Pharmacokinetics] serum elimination half life|Tolerability: [Pharmacodynamics] protein kinase C activity|Change in Behavioral Functioning|Change in Behavioral Disturbance|Change in Dementia Symptom Severity|Evaluate the Quality of Life Status|Risk of Suicide","Aphios","All","50 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","APH-1105","June 2021","September 2022","December 2022","January 16, 2019",,"January 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03806478"
812,"NCT00544453","Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC",,"Terminated","No Results Available","Alzheimer Disease","Drug: [123I] MNI-308",,"Molecular NeuroImaging","All","50 Years and older   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","MNI-308-01","October 2007","October 2007","July 2008","October 16, 2007",,"August 21, 2009","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00544453"
813,"NCT02500784","Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease",,"Suspended","No Results Available","Alzheimer's Disease|Cognitive Dysfunction","Drug: Formoterol A|Other: Formoterol B (placebo)","Cognition Evaluation|Brain-derived neurotrophic factor (BDNF) Evaluation|Amyloid accumulation","Palo Alto Veterans Institute for Research|Alzheimer's Association|Mylan Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASJ0015","January 2023","April 2025","July 2025","July 17, 2015",,"April 3, 2019","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02500784"
814,"NCT00488007","Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids",,"Completed","No Results Available","Alzheimer Disease|Presbycusis","Device: Hearing aids used : PHONAK Savia and Valeo","Cognitive benefit evaluated thanks to the ADAS-Cog scale|Cognitive scales: MMSE, Grober and Buschke, Digit symbol test|Behavioural scales: IADL, NPI|Quality of life scales: Zarit scale and ADRQL|Consumption questionnaire","Hospices Civils de Lyon","All","65 Years and older   (Older Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2006.414","May 2007","June 2013","September 2013","June 19, 2007",,"August 30, 2016","Xavier PERROT, Lyon, France",,"https://ClinicalTrials.gov/show/NCT00488007"
815,"NCT01329536","The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Agitation",,"Apolipoprotein E4 Allele","Avera McKennan Hospital & University Health Center","All","65 Years and older   (Older Adult)",,"50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","AIHBG-1380-Agitation","December 2010","October 2011","October 2011","April 6, 2011",,"October 6, 2011","Avera Research Institute, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01329536"
816,"NCT03487380","Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease","MiDCR","Recruiting","No Results Available","Alzheimer Disease|Intestinal Microbiota","Procedure: Fecal sample collection","analysis of the taxonomic and functional composition of the microbiome|to determine if there is a specific modification of the composition of the intestinal microbiota of patients with Alzheimer's disease, compared to control group.|create a prognostic score of DCR based on clinical data, including the responses to the MMSE, BREF and MNA questionnaires, and taking into account the microbiota analysis","Nantes University Hospital","All","70 Years to 90 Years   (Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC17_0162|2017-A02246-47","September 4, 2017","September 2020","September 2020","April 4, 2018",,"May 1, 2019","CHU de Angers, Angers, France|CHU de Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT03487380"
817,"NCT04122001","Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease, Early Onset|Atypical Alzheimer's Disease|Logopenic Progressive Aphasia","Device: Anodal tDCS|Device: Sham|Other: Word list learning therapy","Change in auditory recall accuracy of word lists (trained words)|Change in written recall accuracy of word lists (trained words)|Change in auditory recall accuracy of word lists (untrained words)|Change in written recall accuracy of word lists (untrained words)|Change in Rey Auditory-Verbal Learning Test (RAVLT) score|Change in Mini Mental State Examination (MMSE) score|Change in Mnemonic Similarity Task (MST) score|Change in word repetition score|Change in non-word repetition score|Change in sentence repetition score|Change in oral naming Boston Naming Test score|Change in oral naming Philadelphia Naming Test score|Change in written naming as assessed by Boston Naming Test|Change in written naming as assessed by Philadelphia Naming Test|Change in Syntactic production as assessed by Northwestern Assessment of Verbs and Sentences (NAVS)|Change in Syntactic comprehension as assessed by Subject-relative, Object-relative, Active, Passive (S.O.A.P.) Syntactic Battery|Change in Verbal fluency task score|Change in spelling as assessed by the Johns Hopkins Dysgraphia battery|Change in digit span forward score|Change in digit span backward score|Change in spatial span forward score|Change in spatial span backward score|Change in GABA concentration|Change in volumetric measurements of select brain regions|Change in functional connectivity of select brain regions (z-correlations)|Change in location of white matter tracts of select brain regions|Change in orientation of white matter tracts of select brain regions|Change in anisotropy of white matter tracts of select brain regions","Johns Hopkins University","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00229164","August 1, 2020","July 31, 2025","July 31, 2025","October 10, 2019",,"October 11, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04122001"
818,"NCT01315639","New Biomarker for Alzheimer's Disease Diagnostic","BALTAZAR","Active, not recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Biological: biomarkers, MRI and CSF","Mean concentration of plasma AB peptides|plasma levels of Tau protein|Mean concentration of biomarker|MRI|Transcriptomics biomarkers|Bace peptide|TACE/ADAM17|Cathepsin|sAPPβ|Ratio of CSF sAPPβ and CSF sAPPα|Ratio of plasma Aβ and plasma Tau|Plasma Tau|MRI biomarkers","Assistance Publique - Hôpitaux de Paris","All","45 Years and older   (Adult, Older Adult)","Not Applicable","1067","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P081205","September 3, 2010","September 2018","February 2019","March 15, 2011",,"March 19, 2018","APHP, Hôpital Broca, Paris, France",,"https://ClinicalTrials.gov/show/NCT01315639"
819,"NCT02989402","A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Rivastigmine","Number of participants with Adverse events as a measure of Safety and tolerability|Change from baseline in Mini-Mental State Examination (MMSE|Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory - Severe Impairment Version (ADCS-ADL SIV) score|Mean Caregiver Medication Questionnaire (CMQ) score|Number of participants with a skin irritation|Number of participants with a urinary tract infection (UTI)|Change from baseline in patch adhesion score","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","Phase 4","102","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DIN01","December 31, 2018","February 3, 2020","February 3, 2020","December 12, 2016",,"September 2, 2019","Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT02989402"
820,"NCT01515982","Physical Exercise as an Additional Treatment for Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Behavioral: Aerobic Exercise|Behavioral: Control Group","Change from baseline in CAMCOG scale at 16 weeks|Change from baseline in Time to Up and Go Test at 16 weeks|Change from baseline in Sit-to-Stand test at 16 weeks|Change from baseline in Berg Balance Scale at 16 weeks|Change from baseline in Trail Making Test at 16 weeks","Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Conselho Nacional de Desenvolvimento Científico e Tecnológico","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","60liv02-09B","February 2010","June 2013","December 2013","January 24, 2012",,"December 3, 2014","Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT01515982"
821,"NCT02000583","Alzheimer's Prevention Through Exercise","APEx","Active, not recruiting","No Results Available","Alzheimer's Disease","Other: Aerobic Exercise|Other: Standard of Care","Change in amyloid burden|Amount of reduction in structural brain changes in preclinical AD|Change in cognitive function","University of Kansas Medical Center|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","13376|R01AG043962-01","November 2013","December 2019","December 2019","December 4, 2013",,"November 21, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02000583"
822,"NCT03136679","Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease","BVB","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease",,"Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.","Baylor Research Institute","All","40 Years and older   (Adult, Older Adult)",,"220","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","017-039","March 22, 2017","April 30, 2022","December 31, 2022","May 2, 2017",,"October 7, 2019","Baylor AT&T Memory Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03136679"
823,"NCT02227953","A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Device: Yband (YDT-201N)|Device: sham-Yband (YDT-201N)","Change in cognitive function|Change in questionnaire|Change in Korean version of Geriatric Depression Scale (K-GDS)|Change in activities of daily living|Change in behavioral symptoms|Change in Clinician's Interview-Based Impression of Change Plus (CIBIC plus)|Change in tDCS feedback","Samsung Medical Center|Ybrain Inc.","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMC 2014-04-025","August 2014","December 2014","December 2014","August 28, 2014",,"September 3, 2014","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02227953"
824,"NCT01931566","Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","TOMMORROW","Terminated","Has Results","Mild Cognitive Impairment Due to Alzheimer's Disease","Drug: Pioglitazone|Drug: Pioglitazone placebo","Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants|Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants|Change From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum|Change From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum","Takeda|Zinfandel Pharmaceuticals Inc.","All","65 Years to 83 Years   (Older Adult)","Phase 3","3494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AD-4833/TOMM40_301|2012-003111-58|U1111-1139-0355","August 1, 2013","July 24, 2018","September 6, 2018","August 29, 2013","August 14, 2019","September 16, 2019","Phoenix, Arizona, United States|Sun City, Arizona, United States|Long Beach, California, United States|San Diego, California, United States|San Francisco, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lady Lake, Florida, United States|Lake Worth, Florida, United States|Merritt Island, Florida, United States|Orlando, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Farmington Hills, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Portland, Oregon, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|West Heidelberg, Victoria, Australia|Nedlands, Western Australia, Australia|Stuttgart, Baden Wuerttemberg, Germany|Siegen, Nordrhein Westfalen, Germany|Halle, Sachsen Anhalt, Germany|Berlin, Germany|Basel, Switzerland|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Salford, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Dundee, Tayside Region, United Kingdom|Perth, Tayside Region, United Kingdom|Bristol, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01931566/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01931566/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01931566"
825,"NCT01403519","Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized",,"Unknown status","No Results Available","Alzheimer's Disease",,,"Rambam Health Care Campus","All","45 Years to 80 Years   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","437-10CTIL","July 2011","January 2014","January 2014","July 27, 2011",,"July 27, 2011","Rambam Hospital, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT01403519"
826,"NCT01023867","Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: donepezil","Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)|Seoul Activities of Daily Living (S-ADL)|Seoul-Instrumental Activities of Daily Living (S-IADL)|Korean Neuropsychiatric Inventory (K-NPI)","Samsung Medical Center|Eisai Korea Inc.","All","Child, Adult, Older Adult","Not Applicable","88","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-03-039","March 2007","June 2010","June 2010","December 2, 2009",,"January 6, 2016","Samsung Medical Center, Seoul City, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01023867"
827,"NCT03118947","A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease",,"Completed","No Results Available","Agitation and Aggression in Alzheimer's Disease","Drug: Pimavanserin","Treatment emergent adverse events (TEAEs)","ACADIA Pharmaceuticals Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACP-103-033|2016-001128-78","February 23, 2017","February 25, 2019","February 25, 2019","April 18, 2017",,"May 31, 2019","ATP Clinical Research, Inc., Costa Mesa, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Clinical Research Network, San Diego, California, United States|Clinical Research Unit, Washington, District of Columbia, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Quantum Laboratories Inc., Deerfield Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists LLC, Naples, Florida, United States|Acadia Hospital, Bangor, Maine, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Abington Neurological Associates, Ltd., Willow Grove, Pennsylvania, United States|Insite Clinical Research, LLC, DeSoto, Texas, United States|Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States|Psicomed Estudios Médicos, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Medicas L y S, Santiago, Chile|CHU de Toulouse - Cite de la sante - Gerontople, Toulouse, Cedex 9, France|Centro de Atencion Especializada Oroitu, Algorta, Viscaya, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|RICE-The Research Institute for the Care of Older People, The RICE Centre, The Royal United Hospital, Bath, United Kingdom|West London Cognitive Disorders Treatment & Research Unit, Lakeside Mental Health Unit, West Middlesex University Hosp. Site, Isleworth, United Kingdom|Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03118947"
828,"NCT02951598","A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)","GERAS-US","Active, not recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: Florbetapir F 18 PET Scan","Mean Economic Cost Associated with Amyloid Positive AD|Healthcare Resource Use by AD Cohort|Mean Economic Cost by AD Cohort|Bath Assessment of Subjective Quality of Life in Dementia (BASQID)|Mini-Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)|Neuropsychiatric Inventory (NPI)|Functional Activities Questionnaire (FAQ)|Cognitive Function Inventory (CFI)|Zarit Burden Interview (ZBI)|Percentage of Participants with a Change in Living Situation|Time to Transition Across Stages of AD|Desire to Institutionalize Scale (DTI)","Eli Lilly and Company","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","1400","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","16466|H8A-US-B004","October 29, 2016","October 28, 2020","October 28, 2020","November 1, 2016",,"December 4, 2018","California Pharmaceutical Research Institute, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Sun Valley Research Center, Imperial, California, United States|Global Clinical Trials, Irvine, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Pacific Clinical Studies, Inc, Los Alamitos, California, United States|California Neurological Services, Inc., Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Clinical Innovations, Inc., Riverside, California, United States|Breakthrough Clinical Trials, San Bernardino, California, United States|HB Clinical Trials, Santa Ana, California, United States|Ventura Clinical Trials, Ventura, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Visionary Investigators Network, Aventura, Florida, United States|Research Alliance, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC., Doral, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|South Florida Clinical Trials, Hialeah, Florida, United States|Van Buren Medical, Hollywood, Florida, United States|Clinical Research of Homestead, Homestead, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Universal Neurological Care, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|Empire Clinical Research, Miami Lakes, Florida, United States|Biomed Research Institute, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Florida International Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Genoma Research Group, Inc., Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Combined Research Orlando Phase I-IV LLC, Orlando, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Asclepes Research Centers Florida, Weeki Wachee, Florida, United States|Doctors Clinical Research, Atlanta, Georgia, United States|American Health Network, Franklin, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Heartland Research Associates, Newton, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, United States|St. Agnes Medical Group, Catonsville, Maryland, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Healthwise Medical Associates, PC, Brooklyn, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Adirondack Medical Center, Lake Placid, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Coastal Carolina Healthcare, P.A., New Bern, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Family Practice Center of Wooster, Wooster, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Clinical Research Solutions, P.C., Knoxville, Tennessee, United States|Lakeside Life Center, Carrollton, Texas, United States|Univ Of Texas Southwestern at Dallas Childrens Med Ctr, Dallas, Texas, United States|The Clinical Research Group, Frisco, Texas, United States|Dallas Clinical Research, Greenville, Texas, United States|Highlands Medical Associates, P.A., Highlands, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|North Pointe Psychiatry, Lewisville, Texas, United States|Premier Clinical Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02951598"
829,"NCT01099332","Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Other: Gastro-retentive zinc cysteine tablet|Other: Tablet identical physically to active comparator containing some lactose","Biometal levels will be measured in serum by atomic absorption spectrometry|Serum zinc levels after oral administration of two different zinc-containing compounds and placebo will be determined by atomic absorption spectrometry|Comparison of mental status functions at baseline, 3 and 6 months in active comparator versus placebo groups.","Adeona Pharmaceuticals","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CopperProof-2","November 2009","January 2011","January 2011","April 7, 2010",,"January 28, 2011","Neuroscience Research Unit, Clearwater, Florida, United States|ATIT Neurology, Holiday, Florida, United States|The Cottages, Port Richey, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01099332"
830,"NCT01874418","Biomarker Study to Diagnose Alzheimer's Disease","ADAM","Unknown status","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Other: Biomarker","Oligomeric beta-amyloid 42 in serum|Total tau concentration in CSF|Phosphorylated tau concentration in CSF|Monomeric beta-amyloid 42 in CSF","Seoul National University Hospital","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ADAM","March 2012","February 2015","February 2015","June 11, 2013",,"June 11, 2013","Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01874418"
831,"NCT00874939","A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)",,"Terminated","Has Results","Alzheimer's Disease|Dementia","Drug: MK-0249 7.5 mg|Drug: MK-0249 25 mg|Drug: Donepezil 5mg|Drug: Placebo to MK-0249|Drug: Placebo to Donepezil","Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Participants With Alzheimer's Disease|Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Healthy Participants|Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Participants With Alzheimer's Disease.|Time Weighted Average of the Change From Baseline After Single Dose Administration of MK-0249, Measured by GMLT in Healthy Participants.","Merck Sharp & Dohme Corp.","All","65 Years and older   (Older Adult)","Phase 1","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0249-023|MK-0249-023|2009_572","April 6, 2009","April 20, 2009","April 20, 2009","April 3, 2009","June 8, 2015","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00874939"
832,"NCT00112073","AAB-001 in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: bapineuzumab|Other: placebo","safety assessments|blood levels of administered study drug|cognitive and functional assessments","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","234","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAB-001-201","April 2005","November 2008","December 2008","May 30, 2005",,"March 14, 2012","Cleo Roberts Center for Clinical Research / Sun Health Research Institute, Sun City, Arizona, United States|UC Irvine, Irvine, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Northridge, California, United States|UCSD Shiley-Marcos Alzheimer's Disease Research Center, San Diego, California, United States|Memory & Aging Center, UCSF, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Mayo Clinic - Department of Neurology, Jacksonville, Florida, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Department of Neurology - Indiana University Medical Center, Indianapolis, Indiana, United States|Behavioral Neurology, Boston, Massachusetts, United States|University of Michigan Health System, Department of Neurology, Ann Arbor, Michigan, United States|Mayo Clinic Department of Neurology - Alzheimer's Disease Research Center, Rochester, Minnesota, United States|The Memory Enhancement Center, Long Branch, New Jersey, United States|Sergievsky Center, Columbia University, New York City, New York, United States|University of Rochester / Monroe Community Hospital, Rochester, New York, United States|Department of Psychiatry and Behavioral Sciences, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memory and Aging Program, Butler Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00112073"
833,"NCT00216515","The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type",,"Completed","No Results Available","Alzheimer Disease","Drug: galantamine hydrobromide","Attention and Executive function: Visual CPT, Visual Span, Color Trail Making test, Stroop test|Cognition: Mini-Mental Sate Examination-Korean version (MMSE-K);Activities of Daily living: Seoul- Instrumental Activities of daily livings (S-IADL);Behavior: NPI-Q;Global Change: Global Deterioration Scale (GDS)","Janssen Korea, Ltd., Korea","All","50 Years and older   (Adult, Older Adult)","Phase 4","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005047","March 2004",,"November 2005","September 22, 2005",,"January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00216515"
834,"NCT01436045","Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.",,"Completed","Has Results","Alzheimer's Disease","Drug: Insulin glulisine|Drug: Saline","Cognitive Performance|Trails B - Seconds|Trails B - Errors|Olfactory Function","HealthPartners Institute","All","65 Years to 85 Years   (Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-111","September 2011","June 2013","June 2013","September 19, 2011","October 19, 2015","October 19, 2015","HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care, St. Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01436045"
835,"NCT00467766","Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease",,"Completed","No Results Available","Alzheimer Disease|Caregivers","Behavioral: Psychosocial information, counseling, and support|Drug: Donepezil (Aricept)","Caregiver: Changes in depression, measured with the Beck Depression Inventory|Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale|Patient: Changes in cognition measured by ADAS-cog|Patient: Changes in abilities with activities of daily living measured by ADCS-ADL|Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery|Patient: Time to nursing home placement","Pfizer|National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","IA0114","July 1999",,"June 2003","May 1, 2007",,"May 7, 2007","Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|University of Manchester, Division of Psychiatry, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00467766"
836,"NCT02868905","Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women","Oba","Unknown status","No Results Available","Obesity|Alzheimer's Disease","Procedure: Blood sample","Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects|body mass index|visceral fat mass level|leptinemia by ELISA|insulinemia by ELISA|glycemia|triglyceridemia|HDL cholesterol level in blood|Reactive C protein level in blood","Central Hospital, Nancy, France","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-A01686-43","September 2016","September 2018","September 2018","August 16, 2016",,"August 16, 2016","CHRU de Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT02868905"
837,"NCT02224326","Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia","Vogel","Active, not recruiting","No Results Available","Alzheimer´s Disease",,"Mini Mental State Examination (MMSE)|Dementia detection test","University of Wuerzburg","All","70 Years to 78 Years   (Older Adult)",,"604","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Vogel-1","June 2011","December 2020","December 2021","August 25, 2014",,"June 19, 2017","University Clinic Wuerzburg, Wuerzburg, Germany",,"https://ClinicalTrials.gov/show/NCT02224326"
838,"NCT01078636","Alzheimer's Disease Neuroimaging Initiative Grand Opportunity","ADNI-GO","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease",,"Rate of Decline as measured by: Cognitive tests, Activities of Daily Living, and CDR Sum of Boxes|Rate of conversion will be evaluated among all four groups|Rate of volume change of whole brain, hippocampus, and other structural MRI measures|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV-45|Group differences for each imaging and biomarker measurement|Correlations among biomarkers and biomarker change|Subgroups analyses: APOE genotype, low CSF Aβ42, positive amyloid imaging with 18F-AV-45","Alzheimer's Disease Cooperative Study (ADCS)|Northern California Institute of Research and Education|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)",,"342","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IA0175|1RC2AG036535-01","April 2010","October 2012","October 2012","March 2, 2010",,"September 16, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, Irvine - BIC, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Martinez, California, United States|Stanford University, Palo Alto, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, St. Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRBC), Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Group, Amherst, New York, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory & Aging Program, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas SWMC, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Vancouver, British Columbia, Canada|Saint Joseph's Hospital, Hamilton, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01078636"
839,"NCT00246896","Care Management for Patients With Alzheimer Disease and Their Family Caregivers",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Behavioral: care management","Neuropsychiatric Inventory|Cornell Depression in Dementia Scale|Activities of Daily Living|Nursing home placement|hospitalization","Agency for Healthcare Research and Quality (AHRQ)","All","65 Years and older   (Older Adult)","Not Applicable","220","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","R01HS010884","August 2001",,"August 2005","November 1, 2005",,"July 27, 2006","Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00246896"
840,"NCT03901261","Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)",,"Recruiting","No Results Available","Down Syndrome|Alzheimer Disease","Procedure: Neuro-imaging, Lumbar puncture","Age of onset of Alzheimer's disease|Gender that could influence the age of onset of the disease as determined by medical record review|Level of intellectual diasability that could influence the age of onset of the disease as determined by medical record review|Family history of Alzheimer's disease that could influence the age of onset of the disease as determined by medical record review|Cardio-vascular risk factors that could influence the age of onset of the disease as determined by medical record review|Down syndrome comorbidies that could influence the age of onset of the disease as determined by medical record review|Genetic's factor other than APP that could influence the age of onset of the disease as determined by medical record review|Head trauma that could influence the age of onset of the disease as determined by medical record review|Age of menopause that could influence the age of onset of the disease as determined by medical record review|Evaluation of neuropsychological evolution using Katz Index of Independence in Activities of Daily Living (Katz ADL) score|Evaluation of neuropsychological evolution using Lawton-Brody Instrumental Activities of Daily Living scale ( IADL)|Evaluation of neuropsychological evolution using Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) score|Evaluation of neuropsychological evolution using Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities score|Evaluation of neuropsychological evolution using Cambridge Cognition Examination score|Evaluation of neuropsychological evolution using Cued Recall test score|Evaluation of neuropsychological evolution using Cancellation task|Evaluation of neuropsychological evolution using Leiter III assessment score|Identification of prodromal Alzheimer's disease markers using brain imaging|Identification of prodromal Alzheimer's disease markers using dosage (pg/mL) of biomarkers in cerebrospinal fluid|Number of adverse event and serious adverse events related to trial procedures|Evaluation of survival assessed by vital status","Institut Jerome Lejeune","All","35 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TriAL21","April 26, 2019","March 31, 2023","March 31, 2023","April 3, 2019",,"July 26, 2019","Institut Jérôme Lejeune, Paris, France",,"https://ClinicalTrials.gov/show/NCT03901261"
841,"NCT01055392","Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease",,"Unknown status","No Results Available","Cognitive Impairment|Alzheimer Disease","Drug: Lithium Carbonate|Drug: Placebo","effect of lithium to delay progression of cognitive deficits in patients with amnestic MCI|effect of lithium on CSF levels of Total Tau, Phosphorylated Tau and Amyloid-beta42|the effect of lithium on the activity of GSK3β in platelets and leukocytes drawn from peripheral blood.","University of Sao Paulo","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","OVForlenza-Lithium|554535/2005-0","March 2007","March 2009",,"January 25, 2010",,"January 25, 2010","Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01055392"
842,"NCT00470418","Development of NIC5-15 in the Treatment of Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease|Dementia","Drug: NIC5-15|Drug: Placebo","Safety Assessments: Number of Participants With Adverse Events|Changes From Baseline in Clinical Measures of Cognition at Terminal Visit","VA Office of Research and Development|National Center for Complementary and Integrative Health (NCCIH)|Humanetics Corporation","All","Child, Adult, Older Adult","Phase 2","15","U.S. Fed|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MHBB-009-06S|R21AT003302-01A1","January 2007","August 2008","March 2010","May 7, 2007","January 9, 2017","January 9, 2017","VA Medical Center, Bronx, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00470418"
843,"NCT02249403","Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type",,"Completed","No Results Available","Alzheimer Disease","Drug: Talsaclidine 6 mg|Drug: Talsaclidine 12 mg|Drug: Talsaclidine 24 mg|Drug: Talsaclidine 36 mg|Drug: Placebo","Change in Alzheimer's Disease Assessment Scale cognitive part (ADAScog)|Change in ADAScog (extension)|Change in ADAScog (Total)|Change in mini mental state (MMS)|Change in neuropsychiatric inventory (NPI)|Change in Hamilton Depression Rating Scale|Change in instrumental activity of daily living (IADL)|Change in living status rated on a 6-point verbal rating scale|Change in clinician's global impression rated with Alzheimer's Disease cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Number of patients with adverse events","Boehringer Ingelheim","All","40 Years and older   (Adult, Older Adult)","Phase 2","362","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","506.203","January 1999","January 2000",,"September 25, 2014",,"September 26, 2014",,,"https://ClinicalTrials.gov/show/NCT02249403"
844,"NCT00940589","Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor",,"Completed","Has Results","Alzheimer's Disease|Sleep Disorder","Drug: Circadin|Drug: Placebo","Change From Baseline to 24 Weeks in ADAS-cog|Change From Baseline to 24 Weeks in iADL|Change From Baseline to 24 Weeks in MMSE","Neurim Pharmaceuticals Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEU AZ1","September 2009","February 2013","May 2013","July 16, 2009","June 1, 2018","June 1, 2018","Meridien Research, Brooksville, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Exodon LLC, Mount Arlington, New Jersey, United States|Scranton Medical Institute, Scranton, Pennsylvania, United States|Merchav clinics, Tel-Aviv, Israel|CPS Research, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00940589"
845,"NCT02992132","Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)",,"Terminated","Has Results","Agitation and Aggression in Alzheimer's Disease","Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg|Other: Placebo","Cohen-Mansfield Agitation Inventory (CMAI)|Zarit Burden Interview","ACADIA Pharmaceuticals Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-032|2016-001127-32","November 2016","January 25, 2018","February 16, 2018","December 14, 2016","March 28, 2019","March 28, 2019","Costa Mesa, California, United States|Fresno, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Pasadena, California, United States|San Diego, California, United States|Danbury, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Deerfield Beach, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Bangor, Maine, United States|Quincy, Massachusetts, United States|Clinton Township, Michigan, United States|Flowood, Mississippi, United States|Jackson, Mississippi, United States|Eatontown, New Jersey, United States|Marlton, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Willow Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|DeSoto, Texas, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Valdivia, Los Rios, Chile|Antofagasta, Chile|Santiago, Chile|Santiago, Chile|Toulouse, Cedex 9, France|Paris, France|Saint-Herblain, France|Strasbourg, France|Villeurbanne, France|Algorta, Vizcaya, Spain|Córdoba, Spain|Elche, Spain|Madrid, Spain|Palma de Mallorca, Spain|Pamplona, Spain|Santa Coloma De Gramenet, Spain|Terrassa, Spain|Zaragoza, Spain|Swindon, Wiltshire, United Kingdom|Bath, United Kingdom|Isleworth, United Kingdom|Manchester, United Kingdom|Northampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02992132/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02992132/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02992132"
846,"NCT02246075","Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine",,"Withdrawn","No Results Available","Alzheimer's Disease|Dementia|Cognition","Drug: EVP-6124","Safety/Tolerability of EVP-6124 with concurrent memantine|Change from Baseline in the Mini-Mental State Examination (MMSE)","FORUM Pharmaceuticals Inc|Quintiles, Inc.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-027","July 2015","October 2016",,"September 22, 2014",,"October 15, 2015","Delray Beach, Florida, United States|Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT02246075"
847,"NCT02249351","Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type",,"Terminated","No Results Available","Alzheimer Disease","Drug: Talsaclidine|Drug: Placebo","Change in Alzheimer's Disease Assessment Scale cognitive part (ADAScog)|Change in ADAScog (extension)|Change in ADAScog (Total)|Change in mini mental state (MMS)|Change in neuropsychiatric inventory (NP)|Change in Hamilton Depression Rating Scale (HAMD 17 item scale)|Change in instrumental activity of daily living (IADL)|Change in living status rated on a 6-point scale|Change in clinician's global impression rated with Alzheimer's Disease cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Number of patients with adverse events","Boehringer Ingelheim","All","40 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","506.209","December 1999","May 2000",,"September 25, 2014",,"September 26, 2014",,,"https://ClinicalTrials.gov/show/NCT02249351"
848,"NCT02248116","Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type",,"Terminated","No Results Available","Alzheimer Disease","Drug: Talsaclidine","Number of patients with adverse events|Number of patients with abnormal changes in laboratory tests|Changes in neuropsychiatric inventory scores|Changes in clinical global impression (CGI)/ clinical global impression of change scores|Changes in mini mental state scores|Changes in quality of life by EuroQol (EQ-5D) score|Assessment of healthy economic impact by healthy resource utilisation, living and employment status changes|Changes in Alzheimer carer quality of life instrument (ACQLI) scores","Boehringer Ingelheim","All","Child, Adult, Older Adult","Phase 2|Phase 3","198","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","506.208","May 1999","September 2000",,"September 25, 2014",,"September 25, 2014",,,"https://ClinicalTrials.gov/show/NCT02248116"
849,"NCT03287765","Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans","ADRC proj 1","Recruiting","No Results Available","Alzheimer Disease","Drug: 18F-AV-1451","Examine the association among T807-PET measures of PHF-tau.|Characterize the amount and spatial distribution of T807-PET measures in healthy aging. preclinical AD, and early symptomatic AD.|Characterize the amount and spatial distribution of T807-PET measures in preclinical AD.|Characterize the amount and spatial distribution of T807-PET measures in early symptomatic AD.|Examine the association among T807-PET measures of concentrations of CSF biomarkers. and cognitive performance.|Examine the association among T807-PET measures of cognitive performance.|Evaluate the change in T807-PET measures over time in asymptomatic amyloid-positive individuals and its association with changes in concentrations of CSF biomarkers.","Washington University School of Medicine","All","65 Years and older   (Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND123119,Protocol F","May 2016","May 2021","November 2021","September 19, 2017",,"January 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03287765"
850,"NCT00287248","Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain",,"Completed","No Results Available","Alzheimer Disease","Drug: [123I] IMPY & SPECT Imaging","Does 123-I IMPY demonstrate qualitatively increased radiotracer uptake in cortical regions consistent with β-amyloid deposition in AD patients relative to controls|Can 123-I IMPY and SPECT provide a quantitative and reproducible measure of amyloid deposition","Institute for Neurodegenerative Disorders|Alzheimer's Association|Molecular NeuroImaging","All","50 Years and older   (Adult, Older Adult)","Phase 1","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AMYLOID001","February 2006","February 2008","March 2008","February 6, 2006",,"March 7, 2014","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00287248"
851,"NCT02036645","SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",,"Completed","Has Results","Mild-Moderate Alzheimer's Disease|Healthy Elderly","Biological: MEDI1814 for IV injection|Biological: MEDI1814 for Subcutaneous Injection|Biological: IV Placebo|Biological: Placebo for Subcutaneous Injection","Tolerability as Measured by Participant Withdrawal for an Adverse Event|Area Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)|Maximum Plasma Concentration (Cmax) of Medi1814|Mean Termination Half Life (t 1/2) of Medi1814|Biomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)|Biomarker: Total Amyloid-beta 1-42 in Plasma|Medi1814 Concentration in CSF Samples|Immunogenicity: Anti-drug Antibody Titer","AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","D4750C00001","February 4, 2014","September 15, 2016","September 15, 2016","January 15, 2014","June 3, 2019","June 3, 2019","Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Panorama City, California, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02036645"
852,"NCT00064870","Alzheimer's Disease Genetics Study","NCRAD","Recruiting","No Results Available","Alzheimer Disease|Late Onset Alzheimer Disease|Dementia",,"Distribute biological specimens to qualified investigators for use in their research studies.","Indiana University|National Institute on Aging (NIA)","All","Child, Adult, Older Adult",,"3000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IA0042|U24AG021886|NIH grant U24 AG21886","June 2002","July 2021","July 2021","July 16, 2003",,"February 28, 2019","Participants are being recruited from all over the United States, Multiple Locations, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00064870"
853,"NCT00104273","Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)",,"Completed","No Results Available","Dementia|Alzheimer's Disease","Drug: Rasagiline","Cognitive Function|Other Cognitive Assessments; Activities of Daily Living (ADLs); Functional Assessments; Safety; Tolerability.","Teva Pharmaceutical Industries|Eisai Inc.","All","45 Years to 90 Years   (Adult, Older Adult)","Phase 2","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TVP-1012-A001-201","August 2004","March 2007",,"February 25, 2005",,"July 15, 2009","Collaborative Neuroscience Network, Huntsville, Alabama, United States|North Alabama Neuroscience Research, Huntsville, Alabama, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|Clinical Study Centers, LLC, Little Rock, Arkansas, United States|East Bay Region Associates in Neurology, Berkeley, California, United States|Margolin Brain Institute, Fresno, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Premiere Research Institute, West Palm Beach, Florida, United States|North Broward Medical Center/Memory Disorder Center, West Palm Beach, Florida, United States|Emory University Wesley Woods Health Center, Altanta, Georgia, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, United States|Radiant Research, Chicago, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Tulane University Health Sciences Center, Dept of Psychiatry and Neurology, New Orleans, Louisiana, United States|Department of Neurology - Brigham and Women's Hospital, Boston, Massachusetts, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|University Behavioral Healthcare Centre Department of Psychiatry, Piscataway, New Jersey, United States|Odyssey Research, Fargo, North Dakota, United States|Ohio State University, Department of Neurology, Columbus, Ohio, United States|Pahl Brain Associates, Oklahoma City, Oklahoma, United States|Medical University of South Carolina Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, United States|Department of Neurology Baylor College of Medicine, Houston, Texas, United States|Premiere Research Institute, Houston, Texas, United States|University of Texas Mental Sciences Institute, Houston, Texas, United States|Peninsula Internal Medicine Associates, Gig Harbor, Washington, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Ballarat Health Service - Queen Elizabeth Center, Ballarat, Australia|Aged Mental Health Research Unit - Kingston Centre, Cheltenham, Australia|Prince Charles Hospital - Dept. of Geriatrics, Chermside, Australia|Central Coast Neuroscience Research, East Gosford, Australia|Heidelberg Repatriation Hospital, Heidelberg West, Australia|Hornsby Kur-ing-gai Hospital, Rehabilitation and Aged Care Service, Hornsby, Australia|St. George's Hospital, Kew, Australia|McCusker Foundation for Alzheimer's Disease Research, Nedlands, Australia|The Queen Elizabeth Hospital, Woodville, Australia|Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada|Memory Disorder Clinic/Winnipeg Clinic, Winnipeg, Manitoba, Canada|Dept. of Clinical Neurological Sciences - University of Western Ontario, London, Ontario, Canada|155974 Ont. Inc., Peterborough, Ontario, Canada|Neurology Research Inc., Toronto, Ontario, Canada|Bloemfontein Medi Clinic, Westdene, Bloemfontein, South Africa|Westdene Research Centre, Westdene, Bloemfontein, South Africa|Suite C, Black C, Sandton, Gauteng, South Africa|St. Augustine's Medical Mews., Durban, South Africa|The Memory Centre, Johannesburg, South Africa|Dr. Felix Potocnik, Oakdale, South Africa|Panorama Medical Centre, Panorama, South Africa|Milpark Hospital, Parktown, South Africa|Crompton Medical Centre West, Pinetown, South Africa|Constantiaberg Medi Clinic, Plumstead, South Africa|Willows Medical Center, Pretoria, South Africa|Little Company of Mary Hospital, Pretoria, South Africa|Richard's Bay Trial Centre, Richard's Bay, South Africa",,"https://ClinicalTrials.gov/show/NCT00104273"
854,"NCT03462121","A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease",,"Recruiting","No Results Available","Mild to Moderate Dementia Due to Alzheimer's Disease|With or Without Coexisting Cerebrovascular Disease","Drug: RPh201|Other: Placebo","Change in (Alzheimer disease assessment scale) ADAS-Cog score between Baseline and Month 6|Change in CDR-SB score between Baseline and Month 6|AEs at Month 6|12-lead ECG at Month 6|Clinical Laboratory Assessments - (blood and urine) at at Month 6|Vital Signs|Change from Baseline on ADAS-Cog total scores at Month 3|Change from Baseline on ADAS-Cog total scores at Month 5|Change from Baseline on ADAS-Cog total scores at Month 12|Change from Baseline on CDR-SB total scores at Month 3|Change from Baseline on CDR-SB total scores at Month 5|Change from Baseline on CDR-SB total scores at Month 12|Change from Baseline in ADCS-ADL total score at Month 3|Change from Baseline in ADCS-ADL total score at Months 12|Change from Baseline in NPI total score at Month 3|Change from Baseline in NPI total score at Month 6|Change from Baseline in NPI total score at Month 12|Change from Baseline in the MMSE at Month 3|Change from Baseline in the MMSE at Month 6|Change from Baseline in the MMSE at Month 12|AEs at Month 12|Clinically significant changes in vital signs at Month 12|12-lead ECG at Month 12|Clinical Laboratory Assessments - (blood and urine) at Month 12","Regenera Pharma Ltd","All","65 Years and older   (Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RGN-ADC-002","March 1, 2018","December 28, 2019","July 30, 2020","March 12, 2018",,"June 14, 2019","Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Gerontion Research Inc., The Center for Memory & Aging, Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03462121"
855,"NCT01028053","Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease","Drug: Flutemetamol (18F) Injection","Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.|The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.","GE Healthcare|Medpace, Inc.|i3 Statprobe|i3 Research|Quintiles, Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-067-005","December 2009","January 2014","January 2014","December 9, 2009","September 11, 2014","September 11, 2014","GE Healthcare, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01028053"
856,"NCT01696123","Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine",,"Completed","No Results Available","Alzheimer Disease","Drug: MLC601","changes in the Mini-Mental State Examination (MMSE) relative to baseline measurements|changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements|to measure included adverse events (AEs)|measuring withdrawal rate","Shahid Beheshti University of Medical Sciences","All","50 Years and older   (Adult, Older Adult)","Phase 2","125","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBMU-1391","January 2011","January 2012","August 2012","September 28, 2012",,"September 28, 2012","Loghman Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01696123"
857,"NCT00001917","Brain Imaging in Elderly People and Individuals With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Healthy","Drug: O15|Drug: [F-18] FP-TZTP",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"150","NIH","Observational",,"990073|99-M-0073","April 1999",,"April 2005","November 4, 1999",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001917"
858,"NCT00829816","Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",,"Completed","No Results Available","Alzheimer's Disease","Drug: Dimebon|Drug: Placebo","To assess the safety and tolerability of orally administered dimebon in patients with Alzheimer's disease (AD) on a stable dose and regimen of memantine, or memantine plus donepezil.|To assess the steady-state pharmacokinetics (PK) of orally-administered dimebon in patients with AD on a stable dose and regimen of memantine, or memantine plus donepezil.","Medivation, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DIM17","December 2008","April 2009","August 2010","January 27, 2009",,"November 10, 2015","Los Alamitos, California, United States|National City, California, United States|Delray Beach, Florida, United States|Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00829816"
859,"NCT01436188","A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease",,"Completed","No Results Available","Healthy|Alzheimer Disease","Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure","Measurement of CSF proteins|The number of volunteers with adverse events","Janssen Research & Development, LLC","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","CR100658|NOCOMPOUNDEDI0001|2011-003525-94","September 2011",,"June 2013","September 19, 2011",,"March 18, 2014","Antwerp, Belgium|Groningen, Netherlands|Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01436188"
860,"NCT01125683","To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer´s Disease","Drug: AZD1446|Drug: Donepezil|Drug: Placebo","To evaluate the effect of single and multiple dosing of AZD1446 and a single dose of donepezil on Quantified electroencephalography (qEEG) and Event-related potentials (ERP) in patients with mild-to-moderate AD.|To measure the relationship between plasma concentration of AZD1446/donepezil and qEEG and ERP.|To evaluate the correlation between changes in qEEG/ERP and changes in cognition, if applicable|Safety as measured by Adverse Events, Vital Signs, ECGs, Clinical Chemistry, Haematology, Urinalysis and Physical Examination.","AstraZeneca","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D1950C00011|2010-018273-38","June 2010","March 2011","March 2011","May 18, 2010",,"May 13, 2011","Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01125683"
861,"NCT01638884","Prospective Memory Imaging","IMPRO","Unknown status","No Results Available","Alzheimer Disease","Behavioral: Memory assessment|Other: Structural MRI|Other: Functional MRI|Other: Virtual reality / Memory assessment","Rate of volume change of whole brain and other structural MRI measures|Cerebral regions implicated in prospective memory observed by functional MRI|Episodic memory as measured by Cognitive Tests|Virtual reality evaluation of prospective memory|Group differences for each imaging and neuropsychological measurement","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","118","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2010-A00031-38","September 2010","June 2015","June 2015","July 12, 2012",,"April 9, 2014","GIP Cyceron, Caen, Calvados, France|MRSH - University of Caen, Caen, Calvados, France|University Hospital Côte de Nacre, Caen, France",,"https://ClinicalTrials.gov/show/NCT01638884"
862,"NCT02294513","Hearing Instruments in Alzheimer's Disease","HIAD","Completed","No Results Available","Alzheimer Disease|Hearing Loss","Device: Standard audiologic rehabilitation (incl. HI)","Client Oriented Scale of Improvement (COSI): Change over 3months|Hearing Handicap Inventory of the Elderly (HHIE): Change over 3months|International Outcome Inventory for Hearing Aids (IOI-HA): Change over 2months|Self-Assessment of Communication (SAC): Change over 3months|Satisfaction with Amplification in Daily Life (SADL): Change over 2months|Significant Other Assessment of Communication (SOAC): Change over 3months|Significant Other Scale for Hearing Disability (SOS-Hear): Change over 3months|Words-in-noise test (WIN): Change over 3months|Dichotic digits test (DDT): Change over 3months|Montreal Cognitive Assessment (MoCA): Change over 3months|Hopkins Verbal-Learning Test (HVLT): Change over 3months|Brief Visuospatial Memory Test-R (BVMT): Change over 3months|Behavioural Pathology in Alzheimer's disease (BEHAVE-AD): Change over 3months|Neuropsychiatric Inventory Brief (NPI-Q): Change over 3months|Positive and Negative Affect Schedule (PANAS): Change over 3months|Geriatric Depression Scale- Short Form (GDS-S): Change over 3months|Bristol Activities of Daily Living Scale: Change over 3months|Activity and Social Participation Assessment: Change over 3months|Quality of Life in Alzheimer's disease: Change over 3months|Practical Hearing Test- Revised: Change over 2months|Measure of Audiologic Rehabilitation Self‐Efficacy for Hearing Aids: Change over 3months|Perception of Conversation Index- Dementia of the Alzheimer Type: Change over 3months|Relationship Satisfaction Questionnaire (RAS): Change over 3months|Social Support Questionnaire: Change over 3months|Zarit Burden Interview- Short Form: Change over 3months|Short-Form Health Survey-12 items: Change over 3months|Hours of hearing aid use: Change over 3months","Phonak AG, Switzerland|University of Toronto|Baycrest Centre for Geriatric Care","All","60 Years and older   (Adult, Older Adult)",,"25","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHPHST101659-03HIAD","October 2014","February 2017","February 2017","November 19, 2014",,"April 11, 2017","Baycrest Center of Geriatric Care, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02294513"
863,"NCT00183378","Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Sleep Initiation and Maintenance Disorders","Behavioral: Walking Program|Behavioral: Light Exposure Program|Behavioral: Combined Education, Walking and Light Exposure Program|Behavioral: Routine Medical Care with Education","Patient total wake time (actigraphy)|Caregiver reports of patient behavioral disturbances at night (Sleep Disorders Inventory)|Additional patient actigraphy outcomes|Patient daytime sleepiness, behavioral problems, and residential status|Caregiver sleep","University of Washington|National Institute of Mental Health (NIMH)","All","55 Years and older   (Adult, Older Adult)","Not Applicable","132","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH072736|DATR A4-GPS","September 2005","September 2009","March 2011","September 16, 2005",,"January 13, 2012","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00183378"
864,"NCT02750306","Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)",,"Completed","No Results Available","Insomnia|Alzheimer's Disease","Drug: Suvorexant 10 mg|Drug: Suvorexant 20 mg|Drug: Placebo","Change from Baseline in PSG-derived TST at Week 4|Percentage of Participants Who Experienced One or More Adverse Events (AEs)|Percentage of Participants Who Discontinued Study Drug Due to an AE|Change from Baseline in PSG-derived Wakefulness After Persistent Sleep Onset (WASO) at Week 4","Merck Sharp & Dohme Corp.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","4305-061|2015-003154-40|MK-4305-061","May 23, 2016","September 30, 2018","September 30, 2018","April 25, 2016",,"October 10, 2018",,,"https://ClinicalTrials.gov/show/NCT02750306"
865,"NCT03752294","A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Mild Alzheimer's Disease","Drug: Dabigatran|Drug: Placebo - Cap","Evaluate dabigatran efficacy in MCI and mild AD population using changes in targeted plasma and CSF biomarker levels at 9 and 21 months|Demonstrate a reduction in decline of cognitive function related to physical functioning in placebo arm after crossing over to 12-months of active treatment|Changes in cognitive performance in placebo arm after cross-over to open-label treatment phase|Safety and tolerability of dabigatran in experimental population (MCI and mild AD populations) based on reported serious and adverse events|Evaluation of cognitive performance in placebo arm after cross-over to open-label treatment phase","University of Rhode Island|Alzheimer’s Drug Discovery Foundation|Boehringer Ingelheim","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIN001-001","November 2018","November 2021","December 2021","November 23, 2018",,"November 23, 2018",,,"https://ClinicalTrials.gov/show/NCT03752294"
866,"NCT02817906","ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",,"Terminated","No Results Available","Agitation in Dementia, Including Alzheimer's Disease","Drug: ITI-007|Drug: Placebo","Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)|Clinical Global Impression Scale for Severity of Illness (CGI-S)","Intra-Cellular Therapies, Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 3","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-201","June 2016","December 2018","December 2018","June 29, 2016",,"December 20, 2018","Sun City, Arizona, United States|Little Rock, Arkansas, United States|Rogers, Arkansas, United States|Costa Mesa, California, United States|Glendale, California, United States|Irvine, California, United States|Lemon Grove, California, United States|Long Beach, California, United States|Oceanside, California, United States|Riverside, California, United States|Santa Ana, California, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Suwanee, Georgia, United States|Honolulu, Hawaii, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Marlton, New Jersey, United States|Toms River, New Jersey, United States|Brooklyn, New York, United States|Staten Island, New York, United States|Centerville, Ohio, United States|Dayton, Ohio, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02817906"
867,"NCT02769065","Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants",,"Terminated","Has Results","Alzheimer Disease|Healthy Volunteers","Drug: TAK-071|Drug: Donepezil|Drug: TAK-071 Placebo|Drug: Donepezil Placebo","Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose|Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]|Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect|Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]|Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect|Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil|Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants|Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants|Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants|Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants|CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants|CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants|CLR: Renal Clearance for TAK-071 MRD Japanese Participants|CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071|CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071|CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071|Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071|Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants|Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil|Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071|Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071","Takeda","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-071-1001|U1111-1176-7435","May 5, 2016","June 8, 2017","June 8, 2017","May 11, 2016","June 10, 2019","June 10, 2019","Glendale, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02769065"
868,"NCT01730430","Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias",,"Completed","No Results Available","Alzheimer's Disease|Dementias",,"Ratio of CSF tau to Aβ42 (tau/Aβ42)","Duke University|Merck Sharp & Dohme Corp.","All","55 Years to 85 Years   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","Pro00033660","July 2012","December 2013","December 2013","November 21, 2012",,"April 22, 2014","Duke Health Center at Morreene Road, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01730430"
869,"NCT03710642","Prazosin for Agitation in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Disruptive Behavior","Drug: Prazosin|Drug: Placebo oral capsule","ADAS-Clinical Global Impression of Change in Agitation (CGIC)|Neuropsychiatric Inventory-Nursing Home version (NPI-NH)","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|VA Puget Sound Health Care System","All","Child, Adult, Older Adult","Phase 2","186","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADC-042-PRAZ|5U19AG010483","July 30, 2019","December 31, 2021","December 31, 2022","October 18, 2018",,"June 26, 2019","University of Southern California, Los Angeles, California, United States|University of California, San Diego (UCSD), San Diego, California, United States|Stanford University, Stanford, California, United States|University of Kentucky, Lexington, Kentucky, United States|Roper St. Francis, Charleston, South Carolina, United States|University of Texas, Southwestern MC at Dallas, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03710642"
870,"NCT01798199","Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project","VERVE","Completed","No Results Available","Alzheimer's Disease","Other: The training by Verve System","the participants and careers acceptability|To assess the impact of behavioral disturbances over the use of the VR using the NPI and the Apathy Inventory|To describe the parameters those facilitate engagement within the designs of VERVE VR setting using the engagement scale OME|To assess the potential acceptability and preventive effectiveness of such setting in home setting using visual analogic scale and EQ-D6|To assess cognitive impact of the light VERVE setting. Using Stroop, TMT, VAT and functional task (IADL)","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","12-PP-04","May 2013","September 2014","September 2014","February 25, 2013",,"September 1, 2015","CHU de Nice, Nice, France|EHPAD Valrose, Nice, France|EHPAD Villa Hélios Saint Jean, Nice, France",,"https://ClinicalTrials.gov/show/NCT01798199"
871,"NCT00392912","Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone",,"Completed","No Results Available","Alzheimer's Disease|Hypogonadism","Drug: AndroGel (Solvay Pharmaceuticals)","Calculated difference image of pre-treatment and on-treatment PET scans.|Change in cognitive function at 8-week intervals over a 6-month period.","VA Medical Center, Houston|Solvay Pharmaceuticals","Male","55 Years and older   (Adult, Older Adult)","Not Applicable","10","U.S. Fed|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GR-294","April 2007","November 2009","July 2010","October 26, 2006",,"August 19, 2010","Michael E. DeBakey VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00392912"
872,"NCT02719327","Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid","BRAVE-EPA","Recruiting","No Results Available","Alzheimer's Disease","Drug: icosapent ethyl (IPE)|Other: gel cap placebo","Regional cerebral blood flow using arterial spin-labeling MRI|Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease|cognitive performance","VA Office of Research and Development|University of Wisconsin, Madison","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CLNA-001-15S|CX001261","June 8, 2017","November 30, 2021","November 30, 2021","March 25, 2016",,"April 17, 2019","William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02719327"
873,"NCT01962779","Sleep, Aging and Risk for Alzheimer's Disease","SARA","Active, not recruiting","No Results Available","Sleep Disordered Breathing|Alzheimer's Disease","Other: Continuous positive airway pressure (CPAP)","Observational. Cerebrospinal fluid (CSF) biomarkers of risk for Alzheimer's disease (AD) in sleep disordered breathing (SDB) subjects.|Observational. Structural MRI hippocampal volume in SDB subjects.|Observational. MRI-ASL vasoreactivity response to CO2 challenge in subjects with SDB|Interventional CPAP Clinical Trial, memory changes after CPAP treatment|Interventional CPAP Clinical Trial, CSF biomarker changes after CPAP treatment|Interventional CPAP Clinical Trial, MRI biomarker changes","NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","224","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-03068|R01HL118624","July 31, 2013","April 30, 2017","December 30, 2019","October 14, 2013",,"June 27, 2019","NYU Sleep Disorders Center, New York, New York, United States|NYU Center for Brain Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01962779"
874,"NCT01867346","Early Markers of Cognitive Change and Alzheimer s Disease",,"Completed","No Results Available","Alzheimer's Disease",,"Identifying early makers of cognitive and Alzheimer s disease|Characterizing risk factors which modify progression to these states|Cognitive changes associated with other health factors","National Institute on Aging (NIA)|Johns Hopkins University|National Institutes of Health Clinical Center (CC)","All","60 Years and older   (Adult, Older Adult)",,"2850","NIH|Other","Observational","Time Perspective: Prospective","999903323|03-AG-N323","March 19, 2003","June 16, 2014","January 2, 2015","June 4, 2013",,"April 5, 2018","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01867346"
875,"NCT02503501","Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease",,"Active, not recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease (AD)","Drug: Insulin glulisine|Drug: Placebo","Change in cognition as measured by the Alzheimer's Disease Assessment Scale - Cognitive 13 (ADAS-Cog 13)|Change in functional performance as measured by the Clinical Dementia Rating (CDR) Scale|Change in functional performance as measured by the Functional Activities Questionnaire (FAQ)|Change in auditory working memory as measured by the Digit Span subtest from the Wechsler Adult Intelligence Scale - 4th Edition (WAIS-IV)|Change in mental flexibility as measured by the Trail Making Test, Parts A and B|Change in executive functioning as measured by the Controlled Oral Word Association Test (COWAT)|Change in executive functioning as measured by the Animal Naming test|Change in memory functions as measured by the Weschler Memory Scale Logical Memory (WMS-LM)|Change in feelings of depression as measured by the Geriatric Depression Scale-15 (GDS)","HealthPartners Institute","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IN-INSUL-MCI-AD","August 2015","November 2019","November 2019","July 21, 2015",,"October 4, 2019","HealthPartners Riverside, Minneapolis, Minnesota, United States|HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02503501"
876,"NCT00190372","AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Controlled diet|Behavioral: Self-hypnotic relaxation","DAD scale (Disability Assessment for Dementia)|cardiovascular mortality|functional status|for the patient: NPI and ADAS-Cog|for the caregiver: ZARIT scale, questionnaire of feeling of competency, Montgomery and Asberg Depression Rating Scale (MADRS), Geriatric Depression Scale (GDS)|all cause mortality|score on a depression rating scale","Assistance Publique - Hôpitaux de Paris","All","60 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research","P030437","October 2004","May 2008","May 2008","September 19, 2005",,"February 17, 2011","Assistance Publique-Hôpitaux de Paris, Paris, Ile de France, France",,"https://ClinicalTrials.gov/show/NCT00190372"
877,"NCT00192816","Pain Perception in Alzheimer's Disease",,"Unknown status","No Results Available","Dementia Alzheimer Type","Behavioral: reaction to pain",,"Rambam Health Care Campus","All","55 Years to 95 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Prospective","2038CTIL","June 2005",,,"September 19, 2005",,"September 19, 2005","Neurocognitive unit,Neurophysiology laborator Rambam Health Care Campus, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT00192816"
878,"NCT03486938","Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease","HOPE4MCI","Recruiting","No Results Available","Mild Cognitive Impairment|Prodromal Alzheimer's Disease","Drug: Placebo Oral Tablet|Drug: AGB101 220 mg tablet","CDR-SB|MMSE|FAQ","AgeneBio|National Institute on Aging (NIA)","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","830","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AGB101 MCD|R56AG055416|R01AG048349|R01AG061091","January 15, 2019","November 2021","November 2022","April 3, 2018",,"July 2, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Excell Research Inc, Oceanside, California, United States|Care Access Research, Santa Clarita, Santa Clarita, California, United States|The Mile High Research Center, Denver, Colorado, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Bioclinica Research, Melbourne, Florida, United States|Miami Jewish Health, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|IMIC Research, Palmetto Bay, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|University of South Florida Psychiatry and Behavioral Neurosciences, Tampa, Florida, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Global Medical Institutes LLC; Princeton Medical Institute, Princeton, New Jersey, United States|Neurology Specialist of Monmouth County, PA, West Long Branch, New Jersey, United States|Neurological Associates of Albany PC, Albany, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Toronto Memory Program, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03486938"
879,"NCT02322021","Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease|Dementia, Alzheimer Type","Drug: Elenbecestat (E2609)|Drug: Placebo","Number of treatment emergent adverse event (TEAEs) and serious adverse events (SAEs)|Percentage change from baseline in cerebrospinal fluid (CSF) Abeta(1-x) and Abeta(1-42) after 4 weeks and 18 months of treatment in MCI/Prodromal participants and mild to moderate AD participants|Mean plasma concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]|Mean CSF concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]","Eisai Inc.|Biogen","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2609-G000-202","November 26, 2014","March 27, 2018","July 31, 2022","December 22, 2014",,"June 10, 2019","CITrials, Bellflower, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Behavioral Research Specialists, Glendale, California, United States|Nervepro Research, Irvine, California, United States|JEM Research Institute, Atlantis, Florida, United States|Aventura Neurologic Associates, Aventura, Florida, United States|Elite Research and Clinical Trials LLC, Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton, Florida, United States|Bradenton Research Center Inc, Bradenton, Florida, United States|Quantum Labs Inc, Deerfield Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Alzheimers Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, LLC, Melbourne, Florida, United States|Miami Jewish Health Systems Inc, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Neurology Clinical Research, Inc., Sunrise, Florida, United States|Infinity Clinical Research, Sunrise, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Neurostudies Inc, Decatur, Georgia, United States|RTR Medical Group LLC, Savannah, Georgia, United States|Southeastern Georgia Geriatrics, Savannah, Georgia, United States|Georgia Neurology and Sleep Medicine Associates, Suwanee, Georgia, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Ohio Clinical Research Partners LLC, Canton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Alzheimers Research and Treatment Center, Willow Grove, Pennsylvania, United States|Abington Neurologic Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Coastal Neurology, Port Royal, South Carolina, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Clinical Trials of Texas Incorporated, San Antonio, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Quorum Review, Inc., Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02322021"
880,"NCT00691340","Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease|Glaucoma",,,"University Hospital, Basel, Switzerland|University Hospital, Bonn","All","18 Years to 75 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","075-WUK-2008-002","June 2008","August 2011","August 2011","June 5, 2008",,"March 10, 2015",,,"https://ClinicalTrials.gov/show/NCT00691340"
881,"NCT00880347","Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Device: Blood sampling","To define the test performance of the blood expression signatures in the intended use population of demented patients to differentiate AD patients from non-AD demented patients.|Performance of blood signatures (AD versus control, AD vs each individual type of non-AD dementia,...). Specificity of the blood signatures versus NINCDS-ADRDA criteria. Exploratory assessment of clinical parameters that may influence blood signature.","Exonhit","All","40 Years and older   (Adult, Older Adult)","Not Applicable","550","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","EHTAD/002","February 2008","February 2011","February 2011","April 13, 2009",,"March 31, 2011","Hôpital Privé Les Magnolias, Ballainvilliers, France|Cabinet Médical, Bergerac, France|Centre Médical, Dijon, France|Cabinet Médical, La Seyne sur Mer, France|Cabinet Médical, Le Vesinet, France|Clinique Léopold Bellan, Magnanville, France|Cabinet Médical, Marseille, France|Centre Médical, Montpellier, France|Cabinet Médical, Montpellier, France|CMRR Gui de Chauliac Hospital, Montpellier, France|CHU Nantes Hôpital Laennec, Nantes, France|ClinOuest network, Nantes, France|Cabinet Médical 2, Nice, France|Cabinet Médical, Nice, France|Cabinet Médical, Paris, France|Centre Médical, Rambouillet, France|Cabinet Médical, Rodez, France|Cabinet Médical, Rueil Malmaison, France|Cabinet Médical, Saint Brieuc, France|Purpan-Casselardit Hospital - University of Toulouse, Toulouse, France|CDPRV Le Capitole, Valence, France",,"https://ClinicalTrials.gov/show/NCT00880347"
882,"NCT02249468","An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population",,"Terminated","No Results Available","Mild and Moderate Alzheimer's Disease|Cognitively Healthy People",,"Uridine|Serum Phospholipids and Fatty Acid Profile|Red Blood Cell Phospholipids and fatty acid profile|Plasma polar lipid profile|Choline|Homocysteine|Vitamin B6|Folate|Vitamin B12|Selenium|Vitamin E|Vitamin D|HbA1C (haemoglobin A1C )|Liver Function - Alanine Aminotransferase and Aspartate Aminotransferase|Kidney function - Creatinine|Inflammatory marker","Danone Nutricia Research","All","50 Years and older   (Adult, Older Adult)",,"191","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Alz.1.C/O/0","October 2014","November 2016","November 2016","September 25, 2014",,"March 3, 2017","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02249468"
883,"NCT00380302","Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.",,"Completed","No Results Available","Alzheimer Disease","Drug: AVE1625","Safety and tolerability throughout the study:adverse events collected by spontaneous report|physical examination and neurological assessment|vital sign monitoring, clinical laboratories, and ECGs.|Efficacy variables:measures of change in cognition, global functioning and behavior at week 12.|Pharmacokinetic parameters will be assessed throughout the 12-week treatment period.","Sanofi","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT10019|EUDRACT: 2006-002317-12","September 2006","July 2007","July 2007","September 25, 2006",,"December 19, 2008","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Bromma, Sweden",,"https://ClinicalTrials.gov/show/NCT00380302"
884,"NCT01325259","FluoroAv45 Imaging Research-in Alzheimer's Disease","FAIR-AD","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Other: neuropsychologic assessment|Radiation: [18F]AV-45 PET|Radiation: 18-FDG PET|Other: MRI","Standard Uptake Value Ratios (SUVr)","University Hospital, Tours","All","60 Years and older   (Adult, Older Adult)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","PHRN08-VC / FAIR AD","April 2009","December 2011","December 2013","March 29, 2011",,"February 8, 2016","university hospital of CAEN, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Toulouse, Toulouse, France|University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01325259"
885,"NCT03999879","PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION","PREPARE","Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: Measure of OxPhos upregulation|Diagnostic Test: lactate (measured with 1H-MRSI)","(PCr)-to-ATP ratio levels","NYU Langone Health","All","70 Years to 85 Years   (Older Adult)",,"45","Other","Observational","Observational Model: Other|Time Perspective: Prospective","18-01919","May 1, 2019","July 1, 2020","December 1, 2020","June 27, 2019",,"June 27, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03999879"
886,"NCT02392468","Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",,"Completed","No Results Available","Schizophrenia|Alzheimer Disease","Drug: BI 409306 matching placebo|Drug: BI 409306","The percentage of subjects with Adverse Events (AE), coded to the Medical Dictionary for Regulatory Activities, System Organ Class Eye disorders, as determined by the investigator at End of Study|The percentage of subjects with drug-related AEs as determined by the investigator at End of Study|Cmax,ss - maximum measured concentration of the analyte in plasma at steady-state|tmax,ss - time from dosing to maximum measured concentration of the analyte in plasma at steady-state.","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1289.27","April 15, 2015","August 10, 2017","August 10, 2017","March 19, 2015",,"December 20, 2017","Altman Clinical and Translational Research Institute, La Jolla, California, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Community Clinical Research, Inc., Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02392468"
887,"NCT02351388","Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research","ADAPT","Unknown status","No Results Available","Alzheimer Disease|Depression","Device: Transcranial Direct Current Stimulation|Other: Sham Stimulation","Attrition rate due to any adverse event|Rate of adverse events related to tDCS procedure|Geriatric Depression Scale|Cornell Scale for Depression in Dementia|Neuropsychiatric Inventory|Zarit Burden Interview|Clinical Global Impression of Improvement|Starkstein Apathy Scale","National Center of Neurology and Psychiatry, Japan","All","65 Years to 90 Years   (Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A2014-086","December 2014","December 2017",,"January 30, 2015",,"January 4, 2017","National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02351388"
888,"NCT02361424","Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)","PLEODIAL-I","Completed","No Results Available","Alzheimer Disease","Drug: PXT00864|Drug: placebo","Change From Baseline in the total score of the 11-item Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Number of Treatment Emergent Adverse Events (TEAEs)|Change From Baseline in the score of the Digit Symbol Substitution Test (DSST)|Change From Baseline in the speed to perform the Zazzo's Cancellation Test|Change From Baseline in the score of the Zazzo's Cancellation Test|Change From Baseline in the score of the 15-second Isaacs Set Test|Change From Baseline in the time score of the Trail Making Test - part A|Change From Baseline in the time score of the Trail Making Test - part B|Change From Baseline in the score of the Free and Cued Selective Reminding Test (FCSRT)|Change From Baseline in the score of the 4-item Instrumental Activities of Daily Living scale (IADL-PAQUID)|Change From Baseline in the score of the Clinical Dementia Rating (CDR) scale|Change From Baseline in the score of the Apathy Inventory (AI) scale","Pharnext SA|Ascopharm Groupe Novasco","All","60 Years and older   (Adult, Older Adult)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CLN-PXT00864-03","February 2013","June 2015","June 2015","February 11, 2015",,"February 15, 2016","CMRR, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT02361424"
889,"NCT02802371","Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program","PHARMAID","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Psychosocial intervention|Other: Pharmaceutical care and psychosocial support","caregiver's burden|caregiver's quality of life|caregiver's anxiety|caregiver's depression|patient's quality of life|patient's behavioral disorders|patient's functional autonomy|Occurrence of medical consultation|Occurrence of recourse to emergency service|Occurrence of hospitalizations|Occurrence of admission in institution","Hospices Civils de Lyon","All","65 Years and older   (Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","69HCL14_0450","August 2016","February 2020","February 2020","June 16, 2016",,"January 10, 2019","Pharmacy unit and Clinical Research Center VCF ("" Aging Brain Frailty "") University hospital of Lyon, Charpennes Hospital / University Lyon / INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02802371"
890,"NCT01764243","Safety and Efficacy of MT-4666",,"Completed","No Results Available","Alzheimer's Disease","Drug: MT-4666|Drug: Placebo","Change from baseline in ADAS-cog-13|Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change from baseline in Alzheimers Disease Assessment Scale-cognitive subscale 11-item (ADAS-cog-11)|Change from baseline in Mini-Mental State Examination (MMSE)|Change from baseline in Neuropsychiatric Inventory (NPI)|Change from baseline in Modified Crichton Scale","Mitsubishi Tanabe Pharma Corporation","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P211-03","November 2012","June 2015","July 2015","January 9, 2013",,"September 28, 2015","Kanto, Japan",,"https://ClinicalTrials.gov/show/NCT01764243"
891,"NCT01453569","Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease|Cognitive Impairment","Drug: Sodium oligo-mannurarate 600mg|Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo","Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule","Shanghai Greenvalley Pharmaceutical Co., Ltd.|Shanghai Mental Health Center","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","255","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","9712011-1","October 2011","August 2013","August 2013","October 18, 2011","January 27, 2015","January 27, 2015","Beijing Hospital, Beijing, Beijing, China|Chongqing Medical University Second Affiliated Hospital, Chongqing, Chongqing, China|The First Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|The Third Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangzhou Brain Hospital, Guangzho, Guangdong, China|The 251 Hospital of People's Liberation Army, Zhangjiakou, Hebei, China|The First Affliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Wuhan General Hospital of Guangzhou Military of People's Military Army, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Central Hospital of Baotou, Baotou, Inner Mongolia, China|The Affliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|The First Affliated Hospital of Chinese Medical University, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Ninth Hospital, Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Shanghai Mental Health Center , Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Tangdu Hospital of The Forth Military Medical University of PLA, Xi'an, Shanxi, China|West China Hospital, West China School of Medicine Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital, Medical college of Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01453569"
892,"NCT03777722","Light and the Effect on Metabolic Syndrome and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Diabetes Mellitus, Type 2","Device: Tailored Lighting Intervention","Change in Glucose tolerance|Change in sleep disturbance|Change in depression|Sleep Efficiency using actigraphy|Light exposure using the Daysimeter","Rensselaer Polytechnic Institute|Icahn School of Medicine at Mount Sinai","All","55 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","1R01AG060716-01-NOA|1R01AG060716-01","November 1, 2018","December 31, 2022","October 31, 2023","December 17, 2018",,"May 13, 2019","Rensselaer Polytechnic Institute, Troy, New York, United States",,"https://ClinicalTrials.gov/show/NCT03777722"
893,"NCT00253214","Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: galantamine hydrobromide","Change from baseline to end of treatment for controlled release group in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline in ADAS-cog/13, /10, /mem scores, NPI, and ADCS/ADL; safety and tolerability of controlled-release formulation; difference in effects between the controlled-release and immediate-release formulations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","40 Years and older   (Adult, Older Adult)","Phase 3","973","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006037","March 2001",,"July 2002","November 15, 2005",,"May 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00253214"
894,"NCT01839422","Imaging of New Learning in Severe Alzheimer's Disease Patients","INCAS","Unknown status","No Results Available","Alzheimer Disease","Behavioral: Memory assessment|Other: Brain imaging examination MRI","Succesful learning of new songs and paintings, succesful MRI acquisitions.","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France","All","60 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2011-A00351-40","January 2012","December 2015",,"April 24, 2013",,"April 9, 2014","GIP Cyceron, Caen, France",,"https://ClinicalTrials.gov/show/NCT01839422"
895,"NCT03824197","Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)","(AU-ROOAD)","Recruiting","No Results Available","Alzheimer Disease|Cerebral Amyloid Angiopathy","Other: EVOO|Other: OO","Effect of olive oil on the BBB intactness|Effect of olive oil on the brain activity|Cognitive function","Auburn University","All","55 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","18-446 MR 1901","May 7, 2019","December 8, 2020","December 31, 2020","January 31, 2019",,"June 24, 2019","Auburn University, Auburn, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03824197"
896,"NCT01743534","Conservation of Praxis in the Food and Alzheimer Disease","PRAXALIM","Completed","No Results Available","Alzheimer Disease",,"Score of Blandford Scale|Score of Blandford scale","University Hospital, Limoges","All","75 Years and older   (Older Adult)",,"32","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","I09023","July 2011","February 2016","July 2016","December 6, 2012",,"August 22, 2016","Limoges University hospital, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01743534"
897,"NCT04104659","Study of Tau Imaging With the Use of [18F]MK-6240 Tracer","MKADAD","Recruiting","No Results Available","Alzheimer Disease","Drug: MK 6240","Study the temporal dynamics of tau deposition (using [18F]MK-6240).|Study the spatial (both local and distributed) changes of tau deposition (using [18F]MK-6240).|Study the relationship between in vivo tau deposition and neuropathology.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB #201901045","April 11, 2019","April 1, 2024","June 1, 2024","September 26, 2019",,"September 26, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04104659"
898,"NCT04103580","Caregiver Speaks: A Technologically Mediated Storytelling Intervention",,"Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Photo elicitation","Change in Public Health Questionaire- 9 depression score|Change in General Anxiety Disorder -7 anxiety score","University of Missouri-Columbia","All","Child, Adult, Older Adult","Not Applicable","468","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","R01AG59818-01A1","November 1, 2019","December 31, 2025","December 31, 2025","September 25, 2019",,"October 4, 2019",,,"https://ClinicalTrials.gov/show/NCT04103580"
899,"NCT01700556","A Trial to Support Caregivers of Patients With Dementia in Italy: the UP-TECH Project","UP-TECH","Unknown status","No Results Available","Alzheimer Disease","Other: Case Manager|Other: Assistive Technologies|Other: light support|Other: 3 preventive home visits by a nurse","Caregiver Burden Inventory|Proportion of days spent at home by the AD patient in the past year|Quality of Life Questionnaire, SF12|Analysis of resource consumption","Istituto Nazionale di Ricovero e Cura per Anziani|Regione Marche|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 5 (ASUR Marche, Area Vasta 5, Distretto Sanitario San Benedetto), Italy","All","18 Years and older   (Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","INRCA-01-2012","November 2012","January 2014","January 2015","October 4, 2012",,"January 29, 2013","REGIONAL HEALTH UNIT - MARCHE REGION - AREA 2 (ASUR Marche, Area Vasta 2, Distretto Sanitario Centro Ancona), Italy, Ancona, Italy|REGIONAL HEALTH UNIT-MARCHE REGION-AREA 3 (ASUR Marche, Area Vasta 3, Distretto Sanitario Macerata), Italy, Macerata, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 1 (ASUR Marche, Area Vasta 1, Distretto Sanitario Pesaro), Italy, Pesaro, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 4 (ASUR Marche, Area Vasta 4, Distretto Sanitario Fermo), Italy, Porto San Giorgio, Italy|REGIONAL HEALTH UNIT - MARCHE REGION - AREA 5 (ASUR Marche, Area Vasta 5, Distretto Sanitario San Benedetto), Italy, San Benedetto del Tronto, Italy",,"https://ClinicalTrials.gov/show/NCT01700556"
900,"NCT03943264","A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's",,"Recruiting","No Results Available","Alzheimer Disease","Drug: XPro1595","The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595|The percentage of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595|Changes from baseline in high sensitivity C-reactive protein in the blood and cerebral spinal fluid following 12 weeks of treatment with XPro1595|Changes from baseline in inflammatory cytokines in the blood and cerebral following 12 weeks of treatment with XPro1595 spinal fluid|Changes from baseline in blood and cerebral spinal fluid levels of amyloid beta following 12 weeks of treatment with XPro1595|Changes from baseline in cerebral spinal fluid levels of tau following 12 weeks of treatment with XPro1595|Change from baseline in FreeWater content (edema) using magnetic resonance imaging following 12 weeks of treatment with XPro1595|Change from baseline in the Mini-Mental State Examination (MMSE) following 12 weeks of treatment with XPro1595|Change from baseline in the Digit Symbol Substitution Test (DSST) following 12 weeks of treatment with XPro1595|Change from baseline in the Verbal Fluency Test following 12 weeks of treatment with XPro1595|Change from baseline in the Neuropsychiatric Inventory (NPI) following 12 weeks of treatment with XPro1595|Change from baseline in the Bristol Activities of Daily Living Scale (BALDS) following 12 weeks of treatment with XPro1595|Change from baseline in the Memory-Enhanced Retrospective Evaluation of Treatment Observer Reported Global Impression of Improvement (MERET OBSRO-C) following 12 weeks of treatment with XPro1595|Evaluate changes in the Memory-Enhanced Retrospective Evaluation of Change from baseline Global Impression of Improvement (MERET PGI-C) following 12 weeks of treatment with XPro1595","Inmune Bio, Inc.|Alzheimer's Association","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XPRO1595-AD|18PTC-R-592167","June 2019","June 2020","December 2020","May 9, 2019",,"June 13, 2019","KaRa MINDS, Macquarie Park, New South Wales, Australia|Central Adelaide Local Health Network, Woodville, South Australia, Australia|Austin Health, Heidelberg Heights, Victoria, Australia|Alfred Heath, Melbourne, Victoria, Australia|The Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03943264"
901,"NCT00898807","Citalopram for Agitation in Alzheimer's Disease","CitAD","Completed","Has Results","Alzheimer's Disease|Agitation","Drug: citalopram|Drug: placebo","NeuroBehavior Rating Scale-- Agitation|Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)|Cohen-Mansfield Agitation Inventory (CMAI)|Neuropsychiatric Inventory (NPI)-- Agitation Subscore","JHSPH Center for Clinical Trials|National Institute on Aging (NIA)|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Phase 3","186","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0155|R01AG031348","July 2009","September 2013","September 2013","May 12, 2009","June 27, 2014","June 27, 2014","University of Southern California Keck School of Medicine Memory and Aging Center, Los Angeles, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|Monroe Community Hospital, Rochester, New York, United States|University of Pennsylvania, Section of Geriatric Psychiatry, Ralston House, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Alzheimer's Research and Clinical Programs, Charleston, South Carolina, United States|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00898807"
902,"NCT00253227","A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: galantamine hydrobromide","Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline in ADAS-cog/13, DAD and NPI scores to the end of treatment; Incidence of adverse events; Pittsburgh Sleep Scale score; Changes in laboratory tests, ECGs and physical examinations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","387","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006028","July 1997",,"December 1998","November 15, 2005",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00253227"
903,"NCT03865017","A Safety and Tolerability Study of GB301",,"Not yet recruiting","No Results Available","Alzheimer Disease","Biological: Regulatory T cells|Other: Saline","Number of subjects With Clinically Significant Abnormalities in 12-lead Electrocardiogram|Number of subjects with abnormal clinical chemistry parameters|Number of subjects with abnormal Hematology parameters|Number of subjects with abnormal Coagulation parameters|Number of subjects with abnormal Urinalysis parameters|Number of subjects with abnormal vital signs|Number of subjects with adverse events (AEs)|Number of subjects with abnormal physical examination|Columbia Suicide Severity Rating Scale (C-SSRS)|Change from Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog-13) Score|Change from baseline in MMSE score","GMP BIO Co., LTD.|BHT Lifescience Austrailia Pty Ltd.","All","40 Years to 72 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GB301-A01","December 1, 2019","December 1, 2020","December 1, 2021","March 6, 2019",,"August 5, 2019","Bht Lifescience Australia Pty Ltd, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT03865017"
904,"NCT02522091","Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI","IMPRO","Unknown status","No Results Available","Alzheimer's Disease","Device: functional brain MRI|Other: Neuropsychology tests","measuring the amplitude of the BOLD signal (Blood Oxygen Level Dependent)","University Hospital, Caen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","178","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-002","November 2010","December 2015",,"August 13, 2015",,"August 13, 2015","Service de neurologie, Caen, CHU, France",,"https://ClinicalTrials.gov/show/NCT02522091"
905,"NCT03778151","Repetitive TMS of the Default Mode Network in AD","TMS-AD","Recruiting","No Results Available","Alzheimer Disease","Device: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION","Clinical Dementia Rating scale (CDR) sum of boxes|Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Frontal Assessment Battery (FAB)|Immediate and delayed total recall score from the Rey Auditory Verbal Learning test (RAVLT)|Cortical activity (TMS-EEG)","I.R.C.C.S. Fondazione Santa Lucia","All","30 Years to 85 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RC-2018","February 1, 2018","September 30, 2019","February 1, 2020","December 18, 2018",,"December 18, 2018","Giacomo Koch, Rome, Italy|Santa Lucia Foundation, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT03778151"
906,"NCT00216593","Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study",,"Completed","No Results Available","Dementia|Alzheimer Disease","Drug: galantamine hydrobromide","Change in scores from baseline to week 26 on measuring cognition Severe Impairment Battery test and the Minimum Data Set Activities of Daily Living test.|Results from Neuro Psychiatric Inventory-nursing home version test. Safety assessments include reports of adverse events, physical exam, vital signs, electrocardiograms, and laboratory test results.","Janssen Pharmaceutica N.V., Belgium","All","40 Years and older   (Adult, Older Adult)","Phase 3","415","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR003940","December 2003","September 2007","March 2008","September 22, 2005",,"June 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00216593"
907,"NCT02833792","Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Dementia","Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo","Safety of aMBMC administration|Efficacy of aMBMC administration","Stemedica Cell Technologies, Inc.|Stemedica International SA","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM105-M-AD","June 2016","December 2019","June 2020","July 14, 2016",,"April 9, 2019","John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT02833792"
908,"NCT03531684","Efficacy and Safety of MMFS in Early AD",,"Recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: MMFS-205-SR|Dietary Supplement: Placebo","Neuropsychological Test Battery (NTB) standardized composite score|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) score|Modified Mini-Mental State Examination (mMMSE) total score|Alzheimer's Disease Cooperative Scale-Activities of Daily Living-Mild Cognitive Impairment 24 questions (ADCS-ADL-MCI24)|Alzheimer's Disease Cooperative Scale - Clinical Global Impression of Change (ADCS-MCI-CGIC) score|Neuropsychiatric Inventory (NPI) sub score","Neurocentria, Inc.|Ohio State University","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","12","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","NC007","March 20, 2018","March 30, 2020","March 30, 2020","May 22, 2018",,"May 22, 2019","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03531684"
909,"NCT03959124","Deep Brain Stimulation for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Dementia, Alzheimer Type|Deep Brain Stimulation","Device: Deep brain stimulation|Drug: Best medical treatment for Alzheimer's disease","Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)","Buddhist Tzu Chi General Hospital|Beijing Tiantan Hospital","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB106-68-A","July 15, 2019","September 30, 2020","September 30, 2021","May 22, 2019",,"May 22, 2019","Buddhist Tzu Chi General Hospital, Hualien City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03959124"
910,"NCT01565434","Erythrocyte Complement Receptor 1 and Alzheimer Disease",,"Completed","No Results Available","Alzheimer Disease","Other: CR1 impact",,"CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Primary Purpose: Screening","PA11014","February 2012",,"April 2015","March 28, 2012",,"June 9, 2016","CHU de REIMS, Reims, France",,"https://ClinicalTrials.gov/show/NCT01565434"
911,"NCT01566071","Ability to Drive of Early Stage Alzheimer Disease","DRIVE COG","Completed","No Results Available","Alzheimer Disease","Other: Assessment of drive abilities",,"CHU de Reims","All","70 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic","PN11009","July 2012",,"July 2015","March 29, 2012",,"June 9, 2016","CHU de REIMS, Reims, France",,"https://ClinicalTrials.gov/show/NCT01566071"
912,"NCT03389698","Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD",,"Recruiting","No Results Available","Alzheimer Disease","Device: GRASP DCE-MRI|Device: 3T Brain Scan","Permeability Surface Area (PS) estimates derived from 9 min GRASP DCE reconstruction","NYU Langone Health","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17-01336","December 18, 2018","February 2019","February 2021","January 3, 2018",,"January 25, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03389698"
913,"NCT03817684","Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: BPN14770|Drug: Placebo","Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI)|Repeatable Battery for the Assessment of Neurological Status (RBANS) total score|Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)|Mini-Mental State Exam (MMSE) Score|Clinical Dementia Rating Sum of Boxes Score (CDR-SB)|Clinical Global Impression - Improvement (CGI-I) Score|Pharmacokinetics: Maximum Drug Plasma Levels","Tetra Discovery Partners","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BPN14770-CNS-201","April 30, 2019","June 2020","June 2020","January 25, 2019",,"September 19, 2019","Generations at Agritopia/CCT Research, Gilbert, Arizona, United States|CiTrials, Inc., Bellflower, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Alliance for Research, Long Beach, California, United States|Pacific Research Network Inc., San Diego, California, United States|HB Clinical Trials, Inc., Santa Ana, California, United States|Mile High Research Center, Denver, Colorado, United States|JEM Research Insitute, Atlantis, Florida, United States|Linfritz Research Group, Coral Gables, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Hialeah, Florida, United States|Alzheimer's Research and Treatement Center, Lake Worth, Florida, United States|Optimus Clinical Research, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Vitae Research Center, LLC, Miami, Florida, United States|Arocha Research Center, Miami, Florida, United States|Allied Biomedical Research Institute Inc., Miami, Florida, United States|Advanced Clinical Research Network, Miami, Florida, United States|Gutierrez Medical Center LLD, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Palm Beach Neurological Center, Palm Beach, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Synergy Clinical Research, Pensacola, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Neurosciences Research, Elk Grove Village, Illinois, United States|Hassman Research Institute, Berlin, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Integrative Clinical Trials, Brooklyn, New York, United States|Neurological Associates of Long Island, Lake Success, New York, United States|Manhattan Behavioral Medicine PLLC, New York, New York, United States|Alzheimers Memory Center, Charlotte, North Carolina, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|MDH Research, Westerville, Ohio, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Aspen Clinical Research, Orem, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03817684"
914,"NCT03352024","Impact of Hypno-analgesia on Pain During a Lumbar Puncture for Diagnosis of Alzheimer's Disease","PLHYMANEDE","Not yet recruiting","No Results Available","Cognitive Impairment|Alzheimer Disease","Other: Relational care|Other: Hypno-analgesia","Algoplus score of pain during the LP procedure|Rate of failure of the Lumbar Ponction|Evaluation of the anxiety|Evaluation of the pain|Evaluation of the pain by the patient","University Hospital, Montpellier","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","9731","January 2018","January 2020","January 2020","November 24, 2017",,"November 24, 2017",,,"https://ClinicalTrials.gov/show/NCT03352024"
915,"NCT01574456","Blood-brain Barrier Permeability in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease",,"The main study measures are blood brain barrier permeability as measured by T1-weighted dynamic contrast MRI","Maastricht University Medical Center","All","Child, Adult, Older Adult",,"39","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","NL36156.068.11","March 2012","December 2013","December 2013","April 10, 2012",,"December 10, 2013","Leids University Medical Center, Leiden, Netherlands|Maastricht University Hospital, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01574456"
916,"NCT01570322","Determinants of Quality of Life Related to Health in Alzheimer Disease",,"Unknown status","No Results Available","Alzheimer Disease",,"Health-Related Quality of Life (HRQOL) Assessment","CHU de Reims","All","75 Years and older   (Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PN09004",,,,"April 4, 2012",,"June 9, 2016","CHU de REIMS, Reims, France",,"https://ClinicalTrials.gov/show/NCT01570322"
917,"NCT03016702","The Cognitive Resilience Study","CogRes","Completed","No Results Available","Alzheimer Disease","Other: Cognitive stress tests during functional MRI|Other: Cognitive stress tests during gait task","Change in reaction time during memory testing during fMRI|Change in reaction time during executive function testing during fMRI|Change in accuracy during memory testing during gait task|Change in reaction time during executive function testing during gait task|Change in accuracy during memory testing during fMRI|Change in accuracy during executive function testing during fMRI|Brain activation during memory testing during fMRI|Brain activation during executive function testing during fMRI|Change in gait performance provoked by memory dual tasking|Change in gait performance provoked by executive function dual tasking","Duke University|National Institute on Aging (NIA)|Bryan Alzheimer's Disease Research Center|Duke University Center for the Study of Aging and Human Development","All","58 Years to 70 Years   (Adult, Older Adult)","Not Applicable","29","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Pro00078117|P30AG028716-11S1|SPS # 224571","February 27, 2017","August 9, 2017","August 9, 2017","January 10, 2017",,"August 14, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03016702"
918,"NCT01313806","Study of Magnetic Fields to Treat Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Device: Resonator|Device: Placebo","Alzheimer's Disease Assessment Scale-Cog (ADAS-cog)|Mini-Mental Status Exam (MMSE), Neuropsychiatric Inventory Questionnaire (NPI-Q), Clinical Dementia Scale","pico-tesla Magnetic Therapies, LLC","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WIRB 1123661","September 2011","September 2012","September 2012","March 14, 2011",,"May 30, 2011","Mile High Research Center, Denver, Colorado, United States|Innovative Research of West Florida, Clearwater, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01313806"
919,"NCT00001662","Treatment of Alzheimer's Disease With CX516 (Ampalex)",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: CX516 (Ampalex)",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","40","NIH","Interventional","Primary Purpose: Treatment","970049|97-N-0049","December 1996",,"November 2005","November 4, 1999",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001662"
920,"NCT00253201","A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: galantamine hydrobromide","Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline to the end of treatment in ADAS-cog/13 and DAD scores; Concentration of drug in blood; PGWB; Health/social care resource use; Incidence of adverse events; Changes in laboratory tests, ECGs and physical examinations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","636","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006025",,,"October 1997","November 15, 2005",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00253201"
921,"NCT00253188","A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: galantamine hydrobromide","Change from baseline to the end of treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline in ADAS-cog/13 and DAD scores to the end of treatment; concentration of drug in blood; PGWB; Health/social care resource use; Incidence of adverse events; Changes in laboratory tests, ECGs and physical examinations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","653","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006031","February 1997",,"December 1998","November 15, 2005",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00253188"
922,"NCT03814603","The Sleep Amyloid, Slow WAve Race and Ethnicity Study","Sleep AWARE","Recruiting","No Results Available","Alzheimer Disease","Procedure: PET-MR Scan|Drug: PiB","Association between Percentage of African Ancestry (%AF) and Slow Wave Sleep (SWS) duration and activity (SWA).|Examine association between SWS duration and poor SWA with longitudinal change in amyloid burden.|Examine the association between race, SWS duration and poor SWA and cognition using both standardized and sleep-dependent cognitive tests at baseline and follow-up.","NYU Langone Health|Icahn School of Medicine at Mount Sinai","All","60 Years to 75 Years   (Adult, Older Adult)",,"210","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","s18-01302","November 21, 2018","June 2022","June 2023","January 24, 2019",,"March 14, 2019","NYU Center for Brain Health, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03814603/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03814603"
923,"NCT01681602","Effect of Physical Exercise in Alzheimer Patients","ADEX","Completed","No Results Available","Alzheimer Disease","Other: Aerobic exercise","Symbol Digit Modalities Test|NPI (psychological symptoms.)|Astrand submaximal bicycle test for estimating VO2 max|Euro-qol-5D-5L (health related quality of life)|Alzheimer's disease Assessment Scale - Cognitive section (ADAS-cog).|Changes in physical fitness|Self-efficacy scale|Verbal fluency|Stroop|MMSE (Mini Mental State Examination)","Rigshospitalet, Denmark","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-3-2011-128","January 2012","January 2014","June 2014","September 10, 2012",,"December 2, 2014","Danish Dementia Research Centre, Department of Neurology, Rigshospitalet., Copenhagen, Copenhagen Ø, Denmark",,"https://ClinicalTrials.gov/show/NCT01681602"
924,"NCT04048759","The Promotion of Physical Activity for the Prevention of Alzheimer's Disease in Adults With Down Syndrome",,"Not yet recruiting","No Results Available","Down Syndrome|Alzheimer Disease","Behavioral: Remote Low|Behavioral: Remote High|Behavioral: Personal Coach","Moderate to Vigorous Physical Activity (MVPA)|Cognitive Function|Cardiovascular fitness|Change in Quality of Life|Brain volume|Functional connectivity|Cerebral blood flow|Retention|Session attendance|Use of recorded exercise sessions|Reported Serious adverse event","University of Kansas Medical Center|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STUDY00143836|R01AG063909","January 1, 2020","January 1, 2024","January 1, 2024","August 7, 2019",,"August 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04048759"
925,"NCT01430286","Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients","DIAPASON","Completed","No Results Available","Alzheimer Disease","Behavioral: psycho-social intervention based on a web-based psycho-educational program, called Diapason.|Behavioral: Consultation in memory clinic","Perceived stress|Nottingham Health Profile (NPH)|ZARIT Burden Interview (BI)|Revised Memory and Behavior Problems Checklist (RMBPC)|Beck Depression Inventory (BDI-2)|Revised Scale for Caregiving Self-Efficacy (RCSE)","Assistance Publique - Hôpitaux de Paris|Direction de l’Hospitalisation et de l’Organisation des Soins (PREQHOS)|Fondation Médéric Alzheimer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","P081002","October 2011","May 2014","July 2014","September 8, 2011",,"March 19, 2018","Hôpital Broca - la Collégiale, Geriatric Unit, Memory Clinic, Paris, France",,"https://ClinicalTrials.gov/show/NCT01430286"
926,"NCT00838877","Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid","PET","Completed","No Results Available","Alzheimer's Disease","Drug: radioligand [18F]AZD4694|Drug: radioligand [11C]AZD2184","Positron emission tomography using the radioligand [18F]AZD4694 and/or [11C]AZD2184|To assess safety and tolerability of [18F]AZD4694 and the study procedures, by assessment of adverse events, vital signs, and laboratory variables.","AstraZeneca","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D2750C00001|2008-006747-39","January 2009",,"October 2009","February 9, 2009",,"October 23, 2009","Research Site, Huddinge, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00838877"
927,"NCT01662882","A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: florbetapir (18F)","Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR","Avid Radiopharmaceuticals|Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-J05|I6E-AV-AVBB","October 2012","February 2013","February 2013","August 13, 2012","September 19, 2013","September 19, 2013","Research Site, Kobe, Japan|Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01662882"
928,"NCT00071721","Valproate in Dementia (VALID)",,"Completed","Has Results","Alzheimer Disease","Drug: Valproate|Drug: Placebo","Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician|Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog)|Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory|Global Severity of Dementia Using the CDR Sum of Boxes|Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version|Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC)","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","313","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0043|1RC2AG036535|IND 67,222|ADCS Protocol ADC-022-VN","October 2003","February 2009","December 2009","October 31, 2003","October 20, 2010","September 25, 2014","Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, ADRC, San Diego, La Jolla, California, United States|VA Healthcare System Long Beach, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California ADRC, Los Angeles, California, United States|University of California, LA (Olive View), Los Angeles, California, United States|Pacific Research Network, San Diego, California, United States|Stanford University, VA Aging Clinical Research Center, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, DC, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Wein Center, Mount Sinai Medical Center, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Byrd Institute, Tampa, Florida, United States|Premier Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|Lahey Clinic, Research Neurology, Burlington, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|St. Louis University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Albany Medical Center, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|University of Rochester, Rochester, New York, United States|Syracuse VA Medical Center, Syracuse, New York, United States|North East Ohio Health Services, Beachwood, Ohio, United States|Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Memorial Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina-Columbia, Columbia, South Carolina, United States|Medical University of South Carolina-Florence, Florence, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Psychiatric Consultants, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00071721"
929,"NCT01459016","A Non-drug Methods Study in Participants With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Other: PET scan using florbetapir|Other: MRI Scan","Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)|Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)|Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir|Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)|Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T|Change From Baseline in the Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score|Change From Baseline in the Clinical Dementia Rating (CDR) Total Score","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14162|I4O-MC-BACH","December 2011","December 2014","December 2014","October 25, 2011","February 13, 2017","June 28, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cahors, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castres, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Foix Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lavaur, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Limoges, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Léon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montauban Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vic-En-Bigorre, France",,"https://ClinicalTrials.gov/show/NCT01459016"
930,"NCT03418688","A Multiple Ascending Dose Study of COR388",,"Completed","No Results Available","Alzheimer Disease","Drug: COR388|Drug: Placebo","AUC|Cmax|Tmax","Cortexyme Inc.","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COR388-002","March 6, 2018","October 15, 2018","October 15, 2018","February 1, 2018",,"November 7, 2018","Pacific Research Network, San Diego, California, United States|Bioclinica Research, Orlando, Florida, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03418688"
931,"NCT01639586","Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care","COMPARSE","Unknown status","No Results Available","Alzheimer Disease","Behavioral: respite platform|Behavioral: Day care|Behavioral: No access to a respite structure","Analysis of the perceived and diagnosed health evolution of the patient|Efficacity of the different structures","Department of Clinical Research and Innovation|Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2011-A00167-34","August 2011","October 2012","April 2013","July 12, 2012",,"July 12, 2012","Le Duff, Nice, France",,"https://ClinicalTrials.gov/show/NCT01639586"
932,"NCT03594123","A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Brexpiprazole","Adverse Events (AEs)","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","55 Years to 91 Years   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-201-00182","October 12, 2018","August 2021","August 2021","July 20, 2018",,"July 17, 2019","Shreenath Clinical Service, Lakewood, California, United States|Advanced Clinical Research, Coral Gables, Florida, United States|Research in Miami, Inc., Hialeah, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|SIH Research, Kissimmee, Florida, United States|Arocha Research Center, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Alzheimer Disease Center, Winchester, Massachusetts, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Mental Health Center Prof. Dr Ivan Temkov - Burgas EOOD, Burgas, Bulgaria|Mental Health Centre-Ruse EOOD, Daily Unit, Ruse, Bulgaria|Medical Center Intermedica OOD, Sofia, Bulgaria|Diagnostic and Consultative Centre Mladost - M Varna OOD, Varna, Bulgaria|Diagnostic and Consultative Centre Mladost - M Varna OOD, Varna, Bulgaria|Mental Health Center - Vratsa EOOD, Vratsa, Bulgaria|Clinical Hospital Center ""Dr. Dragisa Misovic - Dedinje"", Belgrade, Serbia|Special Hospital for Psychiatric Diseases ""Kovin"", Kovin, Serbia|Centro de Salud San Juan, Salamanca, Spain|Complejo Asistencial de Zamora. Servicio de Psiquiatria, Zamora, Spain|Public Non-profit Enterprise within Kharkiv Regional Council ""Regional Clinical Psychiatric Hospital No. 3, #14 psychiatric department for adults, Kharkiv, Ukraine|Public Non-profit Enterprise within Kharkiv Regional Council ""Regional Clinical Psychiatric Hospital No. 3, #23 psychiatric department for war veterans, Kharkiv, Ukraine|Public Institution: Kherson Regional Psychiatric Hospital within Kherson Regional Council, Male Psychiatric Department #3 and Female Psychiatric Department #10, Kherson, Ukraine|Kyiv Regional Medical Incorporation ""Psychiatry"", Center for Novel Treatment and Rehabilitation of Phychotic disorders, Department 29 (Men's), Department 30 (Women's), Outpatient Clinic Office of Department 30, Kyiv, Ukraine|Communal Institution of Lviv Regional Council ""Lviv Regional Clinical Psychiatric Hospital"", Department #20, Lviv, Ukraine|Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev,7 department (gerontopsychiatric, palliative care), Higher State Educational Establishment of Ukraine ""Ukrainian Medical and Dental Academy"", Chair of Psychiatry, Narcology and Medica, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT03594123"
933,"NCT03493282","Effect of CT1812 Treatment on Brain Synaptic Density",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Active Treatment- CT1812 100 mg|Drug: Placebo|Drug: Active Treatment- CT1812 300 mg","Number of study participants with treatment related adverse events and serious adverse events.|Changes in brain synaptic density over a six month period using the SV2A PET ligand 11C-UCB-J.","Cognition Therapeutics","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COG0105","April 20, 2018","January 31, 2020","July 30, 2020","April 10, 2018",,"April 2, 2019","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03493282"
934,"NCT00001235","Genetic Studies in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Nervous System Disease",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"1500","NIH","Observational",,"880029|88-N-0029","February 1988",,"February 2004","November 4, 1999",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001235"
935,"NCT01351142","Cytokines and Cognitive Decline in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Other: blood test and cognitive tests",,"Poitiers University Hospital","All","Child, Adult, Older Adult","Not Applicable","133","Other","Interventional","Intervention Model: Single Group Assignment","CYTOCOGMA","November 2009","November 2013",,"May 10, 2011",,"October 11, 2016","CHU Angers - service Gérontologie clinique, Angers, France|Hôpital Dupuytren - CHU de Limoges, Limoges, France|CHU de NANTES - service Gériatrie, Nantes, France|CHU DE NANTES - Centre ambulatoire de Gérontologie clinique, Nantes, France|Hôpital Broca - service de Gériatrie, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Chu de Poitiers -, Poitiers, France|Chu Strasbourg, Strasbourg, France|CHU de TOURS - service de Gériatrie, Tours, France|Hôpital gériatrique des Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT01351142"
936,"NCT00766363","Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease|Central Nervous System Diseases","Drug: EVP-6124 (0.1 mg/day)|Drug: EVP-6124 (0.3 mg/day)|Drug: EVP-6124 (1.0 mg/day)|Drug: Comparator: Placebo|Drug: Donepezil|Drug: Rivastigmine","Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease|EVP-6124 PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|EVP-6124 PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|EVP-6124 PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])|Donepezil PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|Donepezil PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|Donepezil PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])|Rivastigmine PK Data Following the First Dose of EVP-6124 - Maximum Concentration (Cmax)|Rivastigmine PK Data Following the First Dose of EVP-6124 - Time to Maximum Concentration (Tmax)|Rivastigmine PK Data Following the First Dose of EVP-6124 - Area Under the Curve (AUC[0-24 h])","FORUM Pharmaceuticals Inc|Syneos Health","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","49","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-007","October 2008","March 2009","March 2009","October 3, 2008","July 14, 2011","April 20, 2012","Pacific Research Network, Inc., San Diego, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Global Medical Institutes, LLC, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00766363"
937,"NCT03116126","Noradrenergic Add-on Therapy With Guanfacine","NorAD","Recruiting","No Results Available","Alzheimer Disease","Drug: Guanfacine|Drug: Placebo","Cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)|Tests of Attention: Trails A and B|Digit-symbol substitution|Test of Everyday attention|CANTAB-RVP|Neuropsychiatric Inventory (NPI)|Zarit Burden Interview (22 Item)|Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory (ADCS-ADL)|Blood pressure|Epworth Sleepiness Scale","Imperial College London","All","45 Years and older   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRAS 171996","January 4, 2019","March 31, 2021","March 31, 2021","April 14, 2017",,"June 12, 2019","Imperial Memory Unit, Charing Cross Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03116126"
938,"NCT03328195","Vielight Neuro RX Gamma - Feasibility Pilot",,"Recruiting","No Results Available","Alzheimer Disease","Device: Neuro RX Gamma synchronous|Device: Sham|Device: Neuro RX Gamma asynchronous","Change in the Severe Impairment Battery (SIB) score - An assessment of Severe Dementia in the elderly.|Device safety according to the number of device-related adverse events|Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly.|Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score|Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview.|Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score.|Change in the Electroencephalogram's (EEG) overall power spectral density","Vielight Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P17.02","December 4, 2017","October 2019","November 2019","November 1, 2017",,"July 11, 2019","Chatham Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03328195"
939,"NCT01266525","Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil",,"Completed","No Results Available","Dementia Alzheimer's Type","Drug: SAR110894|Drug: placebo (for SAR110894)|Drug: Donepezil","Change from baseline to Week 24 in the standard 11-item total score from the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog).|Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) global score|Change from baseline in each of the two remaining items of the ADAS-Cog (namely ""delayed word recall"" and ""concentration/distractibility"")|Change from baseline in each of the five factors from the Cognitive Drug Research System (CDR-S) computerized assessment|Change from baseline in the Mini Mental State Examination (MMSE) total score","Sanofi","All","55 Years and older   (Adult, Older Adult)","Phase 2","291","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRI10734|2010-022596-64|U1111-1115-7535","February 2011","January 2013","January 2013","December 24, 2010",,"March 14, 2016","Investigational Site Number 840041, Gilbert, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840024, Costa Mesa, California, United States|Investigational Site Number 840013, Fresno, California, United States|Investigational Site Number 840030, La Jolla, California, United States|Investigational Site Number 840001, Redlands, California, United States|Investigational Site Number 840002, Santa Ana, California, United States|Investigational Site Number 840026, Sherman Oaks, California, United States|Investigational Site Number 840034, Darien, Connecticut, United States|Investigational Site Number 840003, Delray Beach, Florida, United States|Investigational Site Number 840015, Hialeah, Florida, United States|Investigational Site Number 840004, Jacksonville, Florida, United States|Investigational Site Number 840006, Miami, Florida, United States|Investigational Site Number 840012, Orlando, Florida, United States|Investigational Site Number 840011, Tampa, Florida, United States|Investigational Site Number 840005, W Palm Beach, Florida, United States|Investigational Site Number 840008, Baton Rouge, Louisiana, United States|Investigational Site Number 840025, Quincy, Massachusetts, United States|Investigational Site Number 840009, Hattiesburg, Mississippi, United States|Investigational Site Number 840040, Eatontown, New Jersey, United States|Investigational Site Number 840018, Cedarhurst, New York, United States|Investigational Site Number 840039, Charlotte, North Carolina, United States|Investigational Site Number 840037, Tulsa, Oklahoma, United States|Investigational Site Number 840014, Franklin, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840021, Bennington, Vermont, United States|Investigational Site Number 840031, Williamsburg, Virginia, United States|Investigational Site Number 036002, Adelaide, Australia|Investigational Site Number 036007, Chermside, Australia|Investigational Site Number 036008, Heidelberg West, Australia|Investigational Site Number 036006, Herston, Australia|Investigational Site Number 036001, Nedlands, Australia|Investigational Site Number 036004, Randwick, Australia|Investigational Site Number 036009, Toowoomba, Australia|Investigational Site Number 036005, Waratah, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 124010, Calgary, Canada|Investigational Site Number 124015, Gatineau, Canada|Investigational Site Number 124009, Greenfield Park, Canada|Investigational Site Number 124014, Halifax, Canada|Investigational Site Number 124001, London, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124008, Ottawa, Canada|Investigational Site Number 124013, Regina, Canada|Investigational Site Number 124003, Sherbrooke, Canada|Investigational Site Number 124006, St. John, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124004, Toronto, Canada|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250001, Lille Cedex, France|Investigational Site Number 250009, Limoges, France|Investigational Site Number 250007, Marseille, France|Investigational Site Number 250003, Nantes, France|Investigational Site Number 250005, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Strasbourg Cedex, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 276011, Berlin, Germany|Investigational Site Number 276012, Dresden, Germany|Investigational Site Number 276007, München, Germany|Investigational Site Number 276008, München, Germany|Investigational Site Number 276001, Schwerin, Germany|Investigational Site Number 276009, Würzburg, Germany|Investigational Site Number 380006, Ancona, Italy|Investigational Site Number 380004, Castellanza, Italy|Investigational Site Number 380005, Cefalù, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 616004, Bydgoszcz, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616006, Szczecin, Poland|Investigational Site Number 616005, Warszawa, Poland|Investigational Site Number 620002, Amadora, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 724002, Algorta, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 724003, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT01266525"
940,"NCT00096473","Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Donepezil hydrochloride","Assessments of global and cognitive function of Severe AD patients|Assessment of behavior and performance on Activity of Daily Living in severe AD patients|Assessment of caregiver burden","Eisai Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","E2020-A001-315","January 2001","June 2005","September 2005","November 10, 2004",,"April 1, 2011","Northport, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|San Francisco, California, United States|Santa Monica, California, United States|Torrance, California, United States|Denver, Colorado, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|North Miami, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Springfield, Massachusetts, United States|Long Branch, New Jersey, United States|Piscataway, New Jersey, United States|New Hyde Park, New York, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Centerville, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Austin, Texas, United States|Houston, Texas, United States|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Woodville South, South Australia, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|Toronto, Ontario, Canada|Hôpital Broca-La Rochefoucauld, Paris, France|Belfast, Ireland|St. Leonards on Sea, East Sussex, United Kingdom|West End, Southampton, United Kingdom|Swindon, Wilshire, United Kingdom|Bath, United Kingdom|Blackpool, United Kingdom|Bradford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00096473"
941,"NCT03531710","An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Biological: UB-311|Drug: Placebo","The incidence of adverse event (AE)/serious adverse event (SAE) [Safety and Tolerability]).|Change from baseline and through to the end of the study in anti-Aβ antibody titers [The immunogenicity of UB-311]|Change from baseline in cognitive: Alzheimer´s Disease Assessment Scale- Cognitive|Change from baseline in cognition: Mini-Mental State Examination|Change from baseline in global assessment: Clinical Dementia Rating-Sum of Boxes|Change from baseline in global assessment: Computerized cognitive test (Cogstate test battery)|Change of amyloid deposition from baseline in 18F-AV-45 PET imaging in selected brain areas|Change from baseline of brain volume assessed by vMRI|The change from baseline of neurodegenerative biomarkers in blood|To evaluate the correlation between changes in qEEG and changes in cognition, if applicable","United Neuroscience Ltd.","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","V203-AD-EXT","August 10, 2018","October 31, 2019","April 2020","May 22, 2018",,"September 13, 2019","Kaohsiung Chang Gung Memorial Hospital (KS-CGMH), Kaohsiung, Taiwan|National Taiwan University Hospital (NTUH), Taipei, Taiwan|Taipei Veterans General Hospital (TVGH), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital (LK-CGMH), Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03531710"
942,"NCT01760005","Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.","DIAN-TU","Recruiting","No Results Available","Alzheimers Disease|Dementia|Alzheimers Disease, Familial","Drug: Gantenerumab|Drug: Solanezumab|Drug: Matching Placebo (Gantenerumab)|Drug: Matching Placebo (Solanezumab)","Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by change in the DIAN-TU cognitive composite score.|Gantenerumab: Cerebral amyloid imaging using [11C]PiB-PET.|Solanezumab: Total Abeta 1-42 (Aβ42) in CSF.|Change from Baseline in Clinical Measures|Change from Baseline in Cognitive Measures","Washington University School of Medicine|Eli Lilly and Company|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Avid Radiopharmaceuticals|Accelerating Medicines Partnership (AMP)|Janssen, LP","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","490","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DIAN-TU-001|The Alzheimer's Association|U01AG042791|2013-000307-17|R01AG046179|REec-2014-0817|R56AG053267|GHR Foundation|Alzheimer's Association|U01AG059798|R01AG053267","December 2012","December 2020","March 2021","January 3, 2013",,"October 3, 2019","University of Alabama in Birmingham, Birmingham, Alabama, United States|University of California San Diego Medical Center, La Jolla, California, United States|USC Keck School of Medicine, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Health Hospital, Arlington, Texas, United States|University of Washington, Seattle, Washington, United States|Instituto de Investigaciones Neurologicas Raul Carrea, FLENI, Ciudad Autonoma de Buenos Aire, Argentina|Neuroscience Research Australia, Randwick, New South Wales, Australia|Mental Health Research Institute, Melbourne, Victoria, Australia|The McCuster Foundation of Alzheimer's Disease Research, Nedlands, Western Australia, Australia|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil|UBC Hospital, Vancouver, British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill Center for Studies in Aging, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Québec, Canada|Beijing Xuan Wu Hospital Affiliated Capital Medical University, Beijing, Beining, China|Ruijin Hospital, Shanghai Jiaotong Uni. School of Med., Shanghai, Shanghai, China|Grupo de Neurociencias Sede de la Universidad de Antioquia, Medellín, Medellin, Colombia|CHU de Toulouse - Hôpital Purpan, Toulouse, Haute Garonne, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France|Hopital Neurologique Pierre Wertheimer, Bron cedex, Rhone, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France|Universitaetsklinikum Tubingen, Tübingen, Baden Wuerttemberg, Germany|LMU-Campus Grosshadern, Muenchen, Bayern, Germany|St Vincent's University Hospital, Dublin, Ireland|IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|University of Tokyo Hospital, Bunkyō-Ku, Tokyo-To, Japan|Osaka City University Hospital, Osaka-Fu, Japan|Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico, Distrito Federal, Mexico|Brain Research Center, Amsterdam, Netherlands|University of Puerto Rico, School of Medicine, San Juan, Puerto Rico|Hospital Clínic I Provincial de Barcelona, Barcelona, Spain|The National Hospital for Neurology and Neurosurgery, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01760005"
943,"NCT00692705","Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid","PET","Completed","No Results Available","Alzheimer´s Disease","Drug: Radioligand (11C)AZD2995|Drug: Radioligand (11C)AZD2184","Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184|To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables.","AstraZeneca","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D0180C00018|Eudract No. 2007-004842-33","January 2008","December 2008","December 2008","June 6, 2008",,"January 23, 2009","Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00692705"
944,"NCT01211782","AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)","ALERT","Withdrawn","No Results Available","Alzheimer's Disease","Drug: caprylic triglyceride|Drug: long-chain triglyceride","Alzheimer's disease assessment scale - cognitive subscale (ADAS-cog)|Clinicians Interview Based Impression of Change with Caregiver Input (CIBIC+)","Cerecin","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-10-006",,,,"September 30, 2010",,"December 4, 2012","Meridien Research, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01211782"
945,"NCT01661673","Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Drug: EVP-0962|Drug: Placebo","The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis)|To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects|To measure the concentration of Amyloid Beta in cerebral spinal fluid|To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients|To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma","FORUM Pharmaceuticals Inc|Parexel","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-0962-002","November 2012","October 2013",,"August 9, 2012",,"January 13, 2014","Glendale Adventist Medical Center, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01661673"
946,"NCT01565382","Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Inter-reader Agreement - Median Kappa Statistic|Overall Inter-reader Agreement - Fleiss' Kappa","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A09","February 2011","February 2011","February 2011","March 28, 2012","June 27, 2012","June 27, 2012",,,"https://ClinicalTrials.gov/show/NCT01565382"
947,"NCT01249196","A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: SK-PC-B70M","ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|CIBIC-Plus (Clinician's Interview-Based Impression of Change-Plus caregiver input)|MMSE (Mini Mental State Examination)|CDR-SB (Clinical Dementia Rating Sum of Box)","SK Chemicals Co., Ltd.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SMART_AD_III_2009","May 2010","August 2013",,"November 29, 2010",,"November 26, 2013","SKChemicals invetigational site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01249196"
948,"NCT02973971","ADDIA Chronobiological Study",,"Completed","No Results Available","Alzheimer Disease",,"Blood cell biomarker level|Circulating biomarker level","Amoneta Diagnostics SAS","All","55 Years to 85 Years   (Adult, Older Adult)",,"24","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ST0055","November 2016","March 29, 2018","March 29, 2018","November 28, 2016",,"April 20, 2018","Hopitaux Universitaires de Strasbourg, Strasbourg, Alsace, France",,"https://ClinicalTrials.gov/show/NCT02973971"
949,"NCT01350362","Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients","ARGO","Completed","No Results Available","Alzheimer's Disease","Drug: tideglusib|Drug: Placebo","ADAS-Cog+|Adverse events (AEs): Number of AEs and patients with an incidence rate of ≥ 5% AEs|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Alzheimer's Disease Cooperative Study Unit Activities of Daily Living (ADCS-ADL).|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Mini Mental State Examination (MMSE)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Word Fluency test|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Neuropsychiatric Inventory (NPI)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Geriatric Depression Scale (GDS)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Clinical Global Impression of Change (CGIC)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the European Quality of life Instrument (EQ-5D)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Caregiver time (RUD Lite)|Change from Baseline of the 3 active study medication groups will be compared with the placebo group in the Questionnaire on urinary incontinence|Exploratory Endpoints (only in a subgroup of patients at predefined sites): Change from Baseline of the 3 active study medication groups will be compared with the placebo group in levels of τ, phospho-τ, and β−amyloid in CSF and change in MRI measures.","Noscira SA|ICON Clinical Research","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NP031112-10B04","April 2011","July 2012","October 2012","May 9, 2011",,"October 2, 2012","Leuven and 4 additional cities, Belgium|Turku and 3 additional cities, Finland|Paris and 10 additional cities, France|Freiburg and 5 additional cities, Germany|Madrid and 7 additional cities, Spain|London and 11 additional cities, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01350362"
950,"NCT00546767","Home-Based Assessment for Alzheimer Disease Prevention","HBA","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Behavioral: Mail and Live Phone|Behavioral: Interactive Voice Response (IVR)|Behavioral: Home-based Computer Kiosk|Behavioral: Traditional Evaluation Instruments","Feasibility Data -- the number of subjects recruited, screened, enrolled, and retained|Efficiency Data -- staff time required to successfully complete data collection|Transition from cognitive health to impairment|Method-Specific Adherence, including medication adherence|Rate of change in domains of assessment|Research blood samples|Safety Assessments: symptom checklist and adverse event checklist","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)","All","75 Years and older   (Older Adult)","Not Applicable","640","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IA0123|1RC2AG036535|ADC-030-HBA","September 2007","June 2013","June 2013","October 19, 2007",,"September 16, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Sun Health Reseach Institute, Sun City, Arizona, United States|University of California, Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of California-San Diego ADRC/Neurosciences, La Jolla, California, United States|University of California, Davis, Martinez, California, United States|Stanford University / PAIRE, Palo Alto, California, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Mayo Clinic Jacksonville Neurology, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|University of South Florida, Suncoast Alzheimer's & Gerontology Center, Tampa, Florida, United States|Northwestern University Cognitive Neurology & Alzheimer's Disease, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University Alzheimer's Disease Clinical and Research Program, Boston, Massachusetts, United States|University of Michigan Psychiatry - Neuropsychology, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|New York University Aging and Dementia Research Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Wake Forest University Gerontology and Geriatric Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Geriatrics, Philadelphia, Pennsylvania, United States|University of Utah Center for Alzheimer's Care, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00546767"
951,"NCT01143350","Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders",,"Terminated","No Results Available","Alzheimer's Disease","Other: Bras A (EHPAD Training and stimulation)|Other: EHPAD Control","Identification of yet unknown enzymes involved in the processing of Ab, especially on those responsible for the exoproteasic truncation of Ab at its N-terminus.|Secondary efficacy criteria: Apathy Inventory patient and caregiver version changes, Observation scale changes, frequency and severity of the other BPSD using the NPI, qualitative analysis of the nursing home staff behavioural changes","Centre Hospitalier Universitaire de Nice","All","65 Years and older   (Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","09-PP-09","March 2010","March 2010","March 2011","June 14, 2010",,"June 1, 2011","Robert, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT01143350"
952,"NCT02874820","I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD","I2PETPG","Completed","No Results Available","Alzheimer Disease","Radiation: [11C]BU99008|Drug: Idazoxan","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16HH3243|MR/L01307X/1","July 2016","March 2017","July 2017","August 22, 2016",,"March 7, 2018","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02874820"
953,"NCT01089582","Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets","QUEST","Completed","Has Results","Alzheimer Disease","Other: No intervention","Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12|Number of Participants for Change From Baseline for the Caregiver's Assessment of Improvement at Week 12|Change From Baseline in the Participant's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12|Change From Baseline in the Caregiver's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12|Change in ARICEPT Dosing: Number of Participants for Time to First ARICEPT Dose Escalation|Change in ARICEPT Dosing: Number of Participants at Each Final Dose of ARICEPT|Number of Participants for the Physician's Assessment of Tolerance to ARICEPT at Week 12","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"628","Industry","Observational","Time Perspective: Prospective","A2501054","November 2007","July 2009","July 2009","March 18, 2010","August 3, 2010","April 28, 2011","University Hospital of Alexandroupolis Dimokritio, Alexandroupolis, Thrace, Greece|General Hospital of Arta, Arta, Greece|NIMITS (Geriatric Department), Athens, Greece|NIMITS Geriatric Department, Athens, Greece|General Hospital of Athens Laikon Dementia Department, Athens, Greece|Naval Hospital, Dementia Department, Athens, Greece|General State Hospital ""G. Genimatas"", Neurology Department, Athens, Greece|ATTIKON University General Hospital (Dementia Department), Athens, Greece|Psychiatric Hospital of Attica Dromokaiteio, Psychiatric Department, Athens, Greece|1st IKA Hospital Neurology Clinic, Athens, Greece|Sismanogleio Psychiatric Clinic, Athens, Greece|HYGEIA Diagnostic & Therapeutic Center of Athens Internal Medicine Department, Athens, Greece|251 General air force hospital, Athens, Greece|Psychiatric Hospital, Psychogeriatric Clinic, Chaidari, Greece|Venizeleio General Hospital, Crete, Greece|Hospital of Chania, Crete, Greece|Hospital of Giannitsa, Giannitsa, Greece|University General Hospital, Ioannina, Greece|General Hospital of Ioannina, Ioannina, Greece|Center of Psychiatric Health of Katerini, Katerini, Greece|General Hospital Neurological Clinic, Kavala, Greece|Ag. Andreas, Patra, Greece|A.H.E.P.A University General Hospital of Thessaloniki, Thessaloniki, Greece|B´ IKA Panagia Hospital, Dementia Departments, Thessaloniki, Greece|Papageorgiou hospital, Thessaloniki, Greece|Psychiatric hospital, 1st Psychogeriatric Department, Thessaloniki, Greece|Psychiatric Hospital of Thessaloniki, Psychiatric Department, Thessaloniki, Greece|G. Papanikolaou Hospital 3rd Neurology Clinic, Thessaloniki, Greece|Centre of Psychiatric Health, Tripoli, Greece",,"https://ClinicalTrials.gov/show/NCT01089582"
954,"NCT02485730","Early Identification of Markers in Alzheimer's Families / ALFA","ALFA Cohort","Recruiting","No Results Available","Alzheimer's Disease",,"Change from preclinical phase of AD to Mild Cognitive Impairment.","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Obra Social La Caixa, Spain","All","45 Years to 64 Years   (Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALFA-FPM-0311","October 25, 2016","May 31, 2019","January 2024","June 30, 2015",,"February 19, 2019","Barcelonabeta Brain Research Center, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02485730"
955,"NCT02501876","Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease","DIACEA","Completed","No Results Available","Alzheimer´s Disease|Diabetes Mellitus Type 2","Other: There is a retrospectiv observational study. No intervention","The rate of conversion to Alzheimer's disease (AD)|The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2","Hospital Universitari Vall d'Hebron Research Institute","All","65 Years to 90 Years   (Older Adult)",,"202","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","PR(AG)32/2015","May 2015","September 2015","May 2016","July 17, 2015",,"April 12, 2017","Vall d´Hebron University Hospital, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02501876"
956,"NCT00000179","Agitation in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Trazodone|Drug: Haloperidol",,"National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0003|3U01AG010483-08S2",,,,"November 1, 1999",,"June 24, 2005","University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Southern Illinois University, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|New York University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00000179"
957,"NCT02502045","Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's",,"Completed","No Results Available","Alzheimer's Disease","Device: Morning Simulated Sunlight|Device: Non-therapeutic Red Light","Change in sleep characteristics","Yale University","Female","65 Years and older   (Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","1310012895","May 2012","January 2016","January 2016","July 17, 2015",,"February 20, 2017","Botsford Continuing Care, Farmington Hills, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02502045"
958,"NCT00232570","Quetiapine for the Treatment of Insomnia in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Insomnia","Drug: quetiapine","The primary objective is to determine whether quetiapine can increase total sleep time and reduce time awake in patients with AD and sleep disturbance.|Dose-response relationship of quetiapine and sleep in AD patients?|Are there sleep architecture changes from quetiapine?|Do the primary sleep variables change relative to placebo at any weekly time or dose point?|Are caregivers, blind to treatment status, able to detect changes in sleep quality in the patients for quetiapine relative to placebo?|Does quetiapine used at single bedtime dosing for potential nighttime soporific effect have a measurable impact on neuropsychiatric symptoms other than insomnia?","University of Vermont|AstraZeneca|National Center for Research Resources (NCRR)","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","18","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","05-234","November 2005","December 2009","January 2010","October 4, 2005",,"May 5, 2009","Fletcher Allen Health Care-Clinical Neuroscience Research Unit, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00232570"
959,"NCT01482013","Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease",,"Terminated","No Results Available","Mild Alzheimer's Disease|Mild Cognitive Impairment","Drug: HPP854|Drug: Placebo","Number of Participant Adverse Events|Evaluation of participant plasma HPP854 concentrations|Change in cerebrospinal fluid concentration of Amyloid-Beta","High Point Pharmaceuticals, LLC.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HPP854-104","October 2011","March 2012","March 2012","November 30, 2011",,"August 30, 2012","Elite Research Institute, Miami, Florida, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01482013"
960,"NCT02361242","24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion","PLEODIAL-II","Completed","No Results Available","Alzheimer Disease","Drug: PXT00864","Change from Baseline in the total score of the 11-items Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Number of Treatment Emergent Adverse Events (TEAEs)","Pharnext SA|Ascopharm Groupe Novasco","All","60 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLN-PXT00864-04","June 2013","December 2015","December 2015","February 11, 2015",,"February 15, 2016","CMRR, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT02361242"
961,"NCT01404169","A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Type Dementia","Drug: E2020|Drug: Placebo","The change in the total Severe Impairment Battery (SIB) score at Week 24|Clinician Interview-Based Impression of Severity (CIBIC)+ overall score at Week 24","Eisai Limited|Eisai Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2020-C086-339","September 2011","July 2014","September 2014","July 27, 2011",,"March 8, 2017","Beijing Anding Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Beijing Huilongguan Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China|Union Hospital, Tongji Medical college Huazhong University of Science and Technology, Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|The First People's Hospital of YueYang, Yueyang, Hunan, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China|Hushan Hospital affliated to Fudan University, Shanghai, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China|Tangdu Hospital, The Fourth Military Medical University, Xi'An, Shanxi, China|Xi'An Mental Health Center, Xi'An, Shanxi, China|Xijing Hospital, The Fourth Military Medical University, Xi'An, Shanxi, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Nanjing Brain Hospital, Nanjing Jiangsu, China|Tianjin Anding Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT01404169"
962,"NCT00663026","Study Evaluating Bapineuzumab In Alzheimer Disease Subjects",,"Completed","Has Results","Alzheimer Disease","Drug: bapineuzumab|Drug: placebo","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Maximum Observed Serum Concentration (Cmax)|Average Serum Concentration at Steady State (Cavg,ss)|Serum Decay Half-Life (t1/2)|Time to Reach Maximum Observed Serum Concentration (Tmax)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Apparent Systemic Clearance (CL/F)","Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3133L1-2203|B2521008","November 2008","October 2010","October 2010","April 21, 2008","November 15, 2013","November 15, 2013","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Delray Beach, Florida, United States|Pfizer Investigational Site, Hallandale, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Lawrenceville, Georgia, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Bennington, Vermont, United States|Pfizer Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00663026"
963,"NCT01128725","Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers",,"Unknown status","No Results Available","Alzheimer Disease","Other: Alzhamyd","Identification of yet unknown enzymes involved in the processing of Ab, especially on those responsible for the exoproteasic truncation of Ab at its N-terminus.|The availability of truncated fragments designed to set up monoclonal antibodies will allow us to estimate their associated toxicity in various cellular models.","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-PP-01","September 2010","September 2010","December 2012","May 24, 2010",,"March 26, 2012","Robert, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT01128725"
964,"NCT01023685","To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients",,"Completed","No Results Available","Alzheimer Disease","Biological: CAD106","Safety/tolerability assessments at multiple time points including but not limited to screening, and through to the end of the study to week 66.|Collect long-term safety information through SAE's collection for two years after completion of the extension study.|Immune response, cognitive and functional assessments at multiple time points including but not limited to baseline, and through to the end of the study to week 66.|Evaluate the antibody response after 4 additional injections in the Extension study, in patients initially treated with CAD106 in the Core study.","Novartis","All","Child, Adult, Older Adult","Phase 2","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCAD106A2202E1","December 2009","February 2012","February 2012","December 2, 2009",,"June 26, 2013","ATP Clinical Research, Inc., Costa Mesa, California, United States|Alpin Research Center, Boulder, Colorado, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Volunteer Research Group, Knoxville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01023685"
965,"NCT01539031","Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Type Dementia","Drug: E2020","The Severe Impairment Battery (SIB)|The Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC+)","Eisai Co., Ltd.|Eisai Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 3","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2020-J081-343","March 2012","January 2015","March 2015","February 27, 2012",,"September 17, 2015","Anjo, Aichi, Japan|Obu, Aichi, Japan|Toyoake, Aichi, Japan|Chikushi, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Fukuoka, Gunma, Japan|Miyoshi, Hiroshima, Japan|Otake, Hiroshima, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Morioka, Iwate, Japan|Kida, Kagawa, Japan|Takamatsu, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Maizuru, Kyoto, Japan|Nagasaki, Kyushu, Japan|Sendai, Miyagi, Japan|Kitamorokata, Miyazaki, Japan|Ina, Nagano, Japan|Nagaoka, Niigata, Japan|Kurashiki, Okayama, Japan|Ibaraki, Osaka, Japan|Ikeda, Osaka, Japan|Sakai, Osaka, Japan|Sennan, Osaka, Japan|Takatsuki, Osaka, Japan|Age, Saitama, Japan|Iruma, Saitama, Japan|Kasukabe, Saitama, Japan|Tokorozawa, Saitama, Japan|Fuji, Shizuoka, Japan|Izunokuni, Shizuoka, Japan|Anan, Tokushima, Japan|Bunkyo-ku, Tokyo, Japan|Kodaira, Tokyo, Japan|Koto, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya, Tokyo, Japan|Suginami, Tokyo, Japan|Akita, Japan|Chiba, Japan|Fukuoka, Japan|Hiroshima, Japan|Iwate, Japan|Kagoshima, Japan|Kochi, Japan|Kyoto, Japan|Nara, Japan|Osaka, Japan|Saitama, Japan|Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT01539031"
966,"NCT03132272","Immunoadsorption for Treatment of Alzheimer's Disease","IMAD","Recruiting","No Results Available","Alzheimer Dementia","Device: Immunoadsorption with Globaffin","Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI|Cognition (changes/improvement/impairment)|Vascular effects|Renal function|Laboratory parameters in liquor associated with Alzheimer's disease","University Medicine Greifswald","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201503IMAD|CIV-16-02-014668","July 2016","March 31, 2019","December 31, 2019","April 27, 2017",,"October 31, 2018","University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany",,"https://ClinicalTrials.gov/show/NCT03132272"
967,"NCT01775696","Central and Systemic Inflammation in Alzheimer's Disease","IMABio3","Completed","No Results Available","Alzheimer's Disease",,"evolution of blood markers|Patient's blood cell modification assessment|[F18] DPA-714 PET examination","Assistance Publique - Hôpitaux de Paris","All","30 Years and older   (Adult, Older Adult)",,"125","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P100145","December 8, 2011","April 4, 2017","April 4, 2017","January 25, 2013",,"November 6, 2017","APHP - Pitié Salpetriere Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT01775696"
968,"NCT01707719","Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Oxidative Stress|Adrenocortical Hyperfunction",,"Malondialdehyde assay|Relationship between urinary excretion of cortisol and levels of malondialdehyde","Raffaele Antonelli Incalzi|Campus Bio-Medico University","All","50 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ERASE","June 2015","May 2018","September 2018","October 16, 2012",,"March 15, 2018","Policlinico Universitario Campus Bio-Medico, Rome, RM, Italy",,"https://ClinicalTrials.gov/show/NCT01707719"
969,"NCT00480701","Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease","IBVM001","Completed","No Results Available","Alzheimer Disease|Parkinson Disease","Drug: [123I]-IBVM","Does 123-I IBVM SPECT provide a quantitative measure of acetylcholinergic transporters in Healthy controls and AD patients?|Does 123-I IBVM SPECT demonstrate reduced acetylcholinergic transporter binding in AD compared to healthy controls?|Does 123-I IBVM SPECT provide a reliable measure of acetylcholinergic transporters in healthy controls and AD patients?","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","IBVM001","February 2007","October 2011","October 2011","May 31, 2007",,"May 7, 2014","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00480701"
970,"NCT00956410","To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients",,"Completed","No Results Available","Alzheimer Disease","Biological: CAD106","Safety/tolerability assessments at multiple timepoints including but not limited to screening, and through to the end of the study to week 66.|Immune response, cognitive and functional assessments at multiple timepoints including but not limited to baseline and through to the end of the study to week 66.|Evaluate the antibody response after 4 additional injections in the Extension study in patients initially treated with CAD106 in the Core study.|Collect long-term safety information through SAEs collection for two years after completion of the core study, CAD106A2201, or extension study, CAD106A2201E1.","Novartis","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCAD106A2201E1","September 2009","June 2011","June 2011","August 11, 2009",,"November 17, 2011","Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00956410"
971,"NCT00153010","An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type",,"Completed","No Results Available","Alzheimer Disease","Drug: NS 2330 (Tesofensine)","Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change|Alzheimer's Disease Cooperative Study-Activities of Daily Living|Neuropsychiatric Inventory|Mini-Mental State Examination|ADAS-Cog Extension|ADAS-Cog total score including Extension|types and frequencies of adverse events|proportion of patients discontinued from the trial because of adverse events|changes from baseline in vital signs|changes from baseline in laboratory measurements|changes from baseline in ECG readings|comparison of study groups for drug plasma concentrations|population PK parameters","Boehringer Ingelheim","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","430","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1198.52","February 2003","March 2005",,"September 12, 2005",,"October 29, 2013","Pivotal Research Center, Mesa, Arizona, United States|Pivotal Research Center, Peoria, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Boehringer Ingelheim Investigational Site, Berkeley, California, United States|California Clinical Trials Medical Group, Culver City, California, United States|Margolin Brain Institute, Fresno, California, United States|Care@ Granada Hills Community Hospital, Granada Hills, California, United States|Optimum Health Services, LaMesa, California, United States|Optimum Health Services, Oceanside, California, United States|Southwest Institute for Clinical Research, Rancho Mirage, California, United States|Health Quest Clinical Trials, San Diego, California, United States|Institute on Aging Research Center, San Francisco, California, United States|Torrance Clinical Research, Torrance, California, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Center for Geriatric & Adult Psychiatry, Hamden, Connecticut, United States|Neurology Associates PA, Wilmington, Delaware, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Fort Lauderdale, Florida, United States|Neurologic Consulting/PA, Fort Lauderdale, Florida, United States|Clinical Physiology Associates Study Center, Fort Meyers, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Miami Jewish Home and Hospital for the Aged, Miami, Florida, United States|Segal Institute for Clinical Research, N. Miami, Florida, United States|Magnolia Research Group, Ocala, Florida, United States|Memory Disorder Clinic, Pompano Beach, Florida, United States|Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|USF Suncoast Gerontology Center, Tampa, Florida, United States|Palm Beach Neurology/Premier Research Institute, W. Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Peryam and Kroll Healthcare Research, Chicago, Illinois, United States|LaGrange Hospital, LaGrange, Illinois, United States|Agewell, Ltd., Indianapolis, Indiana, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Hartford Research Group, Florence, Kentucky, United States|Associates in Neurology-Research, Lexington, Kentucky, United States|Louisiana State University Medical Center, New Orleans, Louisiana, United States|Attn: M. Lannom, RN, MS, Sharon, Massachusetts, United States|Future Care Studies, Springfield, Massachusetts, United States|Saginaw Cooperative Hosp. Inc./ Internal medicine, Saginaw, Michigan, United States|North Michigan Neurology, Traverse City, Michigan, United States|University of Missouri, Columbia, Missouri, United States|St. Louis University, St. Louis, Missouri, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Atlantic Coast Research, Tom's River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates of Albany, Albany, New York, United States|Upstate Clinical Research, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|The Jewish Home and Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Triangle Medical Research, Lexington Road, North Carolina, United States|Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|North Coast Clinical Trials, Inc., Beachwood, Ohio, United States|Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology Center of Ohio, Toledo, Ohio, United States|Linden Research Consultants, Oklahoma City, Oklahoma, United States|Pahl Brain Associates, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigators, Inc., Eugene, Oregon, United States|PRO Research, Eugene, Oregon, United States|Attn: Valerie MacDonald, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Crosswords Counseling and Consulting Associates, Moon Township, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, E. Providence, Rhode Island, United States|Butler Hospital Dept. of Neurology, Providence, Rhode Island, United States|Medical Univ. of South Carolina, Alzheimer's Research, N Charleston., South Carolina, United States|Psychiatric Consultants, Nashville, Tennessee, United States|Baylor College of Medicine VA Medical Center, Houston, Texas, United States|University of Texas Medical Science Institute, Houston, Texas, United States|Caprock Clinical Trials Center, Lubbock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic/Southwestern Vermont Medical Center, Bennington, Vermont, United States|UVA Dept. of Neurology, Charlottesville, Virginia, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|Infectious Disease, Moncton, New Brunswick, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Clinical Research Consultant Group, Beaconsfield, Quebec, Canada|Boehringer Ingelheim Investigational Site, Greenfield Park, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00153010"
972,"NCT00726726","Drug Interaction Study With a Potential Alzheimer's Disease Compound",,"Completed","No Results Available","Alzheimer Disease","Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Drug: BMS-708163|Drug: BMS-708163 + Cooperstown Cocktail","Pharmacokinetic effects of BMS-708163 on interacting drugs (midazolam, warfarin, caffeine, omeprazole, and dextromethorphan)|Safety variables (adverse events, vital signs, safety labs)","Bristol-Myers Squibb","Male","18 Years to 45 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN156-005","August 2008","October 2008","October 2008","August 1, 2008",,"November 5, 2008","Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00726726"
973,"NCT00939822","Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease","SHARP","Completed","Has Results","Alzheimer's Disease","Drug: Simvastatin|Drug: Placebo","Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP|Changes in CSF Beta-amyloid-40 Levels as Measured by xMAP (Multi-Analyte Profiling) )|Changes in CSF Soluble Alpha Precursor Proteins (sAPP-alpha) and Soluble Beta Precursor Proteins (sAPP-beta) as Measured by Duplex|Changes in CSF Total Tau (T-tau) and Phosphorylated Tau (P-tau) as Measured by xMAP","University of Wisconsin, Madison|National Institute on Aging (NIA)","All","40 Years to 72 Years   (Adult, Older Adult)","Phase 2","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015-0038|R01AG031790-01A1|H-2009-0030|H-2008-0275","March 2009","September 2013","September 2013","July 15, 2009","August 9, 2019","August 9, 2019","Karen Lazar, Fitchburg, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00939822"
974,"NCT00368459","Raloxifene for Women With Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: raloxifene|Drug: Placebo","Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)|Global Rating, Clinical Dementia Rating (CDR) Sum of Boxes|Function, Activities of Daily Living (ADL)|Behavior|Cognitive (Neuropsychological)|ADAS-cog|Clinical Dementia Rating, Sum of Boxes|Function, Activities of Daily Living|Cognition (Neuropsychological)","Stanford University|Kaiser Permanente|Indiana University|Southern Illinois University","Female","60 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0096","August 2006","March 2011","January 2012","August 24, 2006","April 2, 2015","April 2, 2015","Kaiser Permanente Santa Rosa, Santa Rosa, California, United States|Stanford University School of Medicine, Stanford, California, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00368459"
975,"NCT00104013","Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",,"Completed","No Results Available","Alzheimer Disease","Drug: xaliproden (SR57746A)","Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.|Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.","Sanofi","All","50 Years and older   (Adult, Older Adult)","Phase 3","1455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","EFC2724|SR57746A","November 2003","November 2007","November 2007","February 21, 2005",,"August 21, 2008","Neurological Physicians of Arizona, Inc., Mesa, Arizona, United States|Pivotal Research Centers, Mesa, Arizona, United States|Pivotal Research Centers, Peoria, Arizona, United States|Northwest NeuroSpecialists, Tucson, Arizona, United States|Optimum Health Services, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|Univ. of CT Health Center, Farmington, Connecticut, United States|CNS Healthcare, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Memory Disorder Center, Pompano Beach, Florida, United States|Neurological Center, Fort Wayne, Indiana, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Hartford Research Group, Florence, Kentucky, United States|Lexington Clinic, Lexington, Kentucky, United States|LSUHSC Geriatric Psychiatry, New Orleans, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Synergy Medical, Saginaw, Michigan, United States|University Medical Center, Dept. of Psychiatry Clinical Trials, Jackson, Mississippi, United States|Radiant Research, Inc., St. Louis, Missouri, United States|Center For Emotional Fitness, Moorestown, New Jersey, United States|Ubhc/Umdnj667, Piscataway, New Jersey, United States|The Ohio State University, Columbus, Ohio, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|Radiant Research, Greer, South Carolina, United States|Alzheimer's Research & Clinical Programs, North Charleston, South Carolina, United States|Harmony Research, Inc, Johnson City, Tennessee, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Grayline Clinical Drug Trial, Wichita Falls, Texas, United States|The Innovative Clinical Research Center, Alexandria, Virginia, United States|Eastern Virginia Medical School - The Glennan Center For Geriatrics ""Gerontology"", Norfolk, Virginia, United States|National Clinical Research, Inc, Richmond, Virginia, United States|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanfoi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00104013"
976,"NCT02293915","An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease",,"Completed","No Results Available","Mild to Moderate Alzheimer Disease|Cognitive Impairment","Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo","Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule|Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule|Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule|Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule|Glucose metabolism of bilateral temporoparietal cortex","Shanghai Greenvalley Pharmaceutical Co., Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","818","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","971-III","April 1, 2014","June 29, 2018","September 28, 2018","November 19, 2014",,"October 10, 2018","Beijing, Beijing, Beijing, China|Chongqing, Chongqing, Chongqing, China|Fujian, Fuzhou, Fujian, China|Guangzhou, Guangzhou, Guangdong, China|Wuhan, Wuhan, Hubei, China|Changsha, Changsha, Hunan, China|Nanjing, Nanjing, Jiangsu, China|Suzhou, Suzhou, Jiangsu, China|Yangzhou, Yangzhou, Jiangsu, China|Jinan, Jinan, Shandong, China|Shanghai, Shanghai, Shanghai, China|Xi'an, Xi'an, Shanxi, China|Sichuan, Chengdu, Sichuan, China|Tianjin, Tianjin, Tianjin, China|Hangzhou, Hangzhou, Zhejiang, China|Wenzhou, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02293915"
977,"NCT01953601","Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","APECS","Terminated","Has Results","Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease","Drug: Verubecestat 12 mg (Parts 1 and 2)|Drug: Verubecestat 40 mg (Parts 1 and 2)|Other: Placebo (Part 1)","Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104|Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130|Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia|Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment|Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104|Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104|Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104","Merck Sharp & Dohme Corp.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","1454","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8931-019|2012-005542-38|142502|MK-8931-019","November 5, 2013","April 17, 2018","April 17, 2018","October 1, 2013","May 17, 2019","May 17, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01953601/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01953601"
978,"NCT02667496","Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease",,"Withdrawn","No Results Available","Dementia Alzheimer's Type","Drug: Sargramostim GZ402664|Drug: Placebo|Drug: Florbetapir F18","Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 (Amyvid)|Number of patients experiencing treatment-emergent adverse events (TEAEs)|Change from baseline in CSF analysis|MRI to assess for emergence of amyloid related imaging abnormalities (ARIA)|Measurement of antidrug antibody levels","Sanofi|National Institute on Aging (NIA)","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","0","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14019|U1111-1163-0793|1UF1AG046143","November 2016","March 31, 2017","March 31, 2017","January 29, 2016",,"April 7, 2017","Investigational Site Number 840001, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02667496"
979,"NCT00621010","Safety Study of CTS21166 to Treat Alzheimer Disease","CTS","Completed","No Results Available","Alzheimer's Disease","Drug: CTS21166 (ZPQ-21166)","To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration|To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma","CoMentis","Male","22 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Primary Purpose: Treatment","CTS21166-101","June 2007","February 2008","February 2008","February 22, 2008",,"July 9, 2008","Lifetree Clinical Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00621010"
980,"NCT00103649","18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",,"Completed","No Results Available","Alzheimer Disease","Drug: xaliproden (SR57746A)","Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.|Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.","Sanofi","All","50 Years and older   (Adult, Older Adult)","Phase 3","1306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","EFC2946|SR57746","November 2003","October 2007","October 2007","February 14, 2005",,"August 21, 2008","UAB Memory Disorders Clinic, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States|Radiant Research, Scottsdale, Arizona, United States|Anaheim Research Center, Anaheim, California, United States|Margolin Brain Institute, Fresno, California, United States|Coordinated Clinical Research, La Jolla, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|Pharmacology Research Institute, Riverside, California, United States|Pacific Research Network, San Diego,, California, United States|California Neuroscience Research Medical Group, Sherman Oaks, California, United States|Pacific Research Network, Vista,, California, United States|Radiant Research, Denver, Colorado, United States|Associated Neurologist, Danbury,, Connecticut, United States|Geriatric and Adult Psychiatry, LLC, Hamden, Connecticut, United States|Yale University School of Medicine AD Research Unit, New Haven, Connecticut, United States|Healthcore, Newark, Delaware, United States|Neurology Associates, PA, Wilmington, Delaware, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Miami Research Associates, Miami, Florida, United States|Baumel-Eisner Neuromedical Institute in Miami Beach, Miami, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens,, Florida, United States|Neurology Clinical Research, Inc., Plantation, Florida, United States|CNS Clinical Trials, St Petersburg, Florida, United States|Baumel-Eisner Neuromedical Institute in Miami Beach, Tamarac, Florida, United States|Meridien Research, Tampa, Florida, United States|Suncoast Gerontology Center USF, Tampa, Florida, United States|Radiant Research, Marietta, Georgia, United States|Southeastern Geriatric Healthcare, Snellville, Georgia, United States|Chicago Center for Clinical Research, Chicago, Illinois, United States|Radiant Research Center, Hoffman Estates, Illinois, United States|Elkhart Clinic, LLC, Elkhart,, Indiana, United States|Ruan Neurology, Des Moines, Iowa, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|J. Gary Booker MD, Shreveport,, Louisiana, United States|Clinical Insights, Glen Burnie, Maryland, United States|Summit Research Network Michigan, Inc., Okemos, Michigan, United States|Pivotal Research Centers, Detroit Office, Royal Oak,, Michigan, United States|Minneapolis VA Medical Center, Minneapolis, Minnesota, United States|Radiant Research, Las Vegas, Nevada, United States|ClinSearch, Inc., Kenilworth,, New Jersey, United States|The Neuroscience Center of Northern New Jersey, Morristown, New Jersey, United States|Princeton Medical Institute, Princeton,, New Jersey, United States|Neurology Group of Bergen County, Ridgewood, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Neurological Association of Albany P.C., Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn,, New York, United States|Parker Jewish Institute for Healthcare and Rehabilitation, Hyde Park,, New York, United States|Neurobehavioral Research, Inc., Lawrence, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Behavioral Medical Research of Staten Island, New York, New York, United States|Global Research and Consulting, Olean, New York, United States|Duke University Medical Center (DUMC) - Dept. of Psychiatry, Durham, North Carolina, United States|MedARK Clinical Research, Morganton, North Carolina, United States|Piedmont Medical Research Assoc, Inc., Winston-Salem, North Carolina, United States|DayStar Clinical Research, Inc., Akron, Ohio, United States|North East Ohio Health Services, Beachwood, Ohio, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|TriPhase Research, Franklin,, Ohio, United States|Triphase Research, Ltd., Franklin, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Radiant Research Eugene, Eugene, Oregon, United States|Clinical Research Institute of Southern Oregon, Medford, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Coatesville VA Medical Center, Coatesville, Pennsylvania, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Memory Disorders Clinic, Philadelphia, Pennsylvania, United States|Radiant Research, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States|JRMC Clinical Trials Center, Pittsburgh, Pennsylvania, United States|RI Mood and Memory, East Providence, Rhode Island, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|CNS Healthcare, Memphis, Tennessee, United States|Vanderbilt University Medical Center - Geriatric Psychiatry, Nashville, Tennessee, United States|University of Texas - Southwestern Medical Center at Dallas, Dallas,, Texas, United States|Houston Sleep Center, Houston, Texas, United States|AD Research Center, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|North Texas Neurology Research, Wichita Falls, Texas, United States|Radiant Research SLC, Salt Lake City, Utah, United States|The Memory Clinic, Bennington,, Vermont, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Internal Medicine Northwest, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Dean Foundation, Middleton, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|IPC Research, Waukesha, Wisconsin, United States|Glenrose Rehabilitation Hospital, Edmonton,, Alberta, Canada|Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|Can-Med Clinical Research Inc., Victoria, British Columbia, Canada|Winnipeg Clinic, Winnipeg,, Manitoba, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Davidson Memory Clinic, Moncton,, New Brunswick, Canada|St. Joseph's Hospital, Saint John,, New Brunswick, Canada|St. Joseph's Healthcare Hamilton, Hamilton,, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|St. Joseph's Health Care, London, Ontario, Canada|Parkwood Hospital - Geriatric Medicine, London, Ontario, Canada|S.C.O. Health Centre, Ottawa,, Ontario, Canada|Parkinson's & Neurodegenerative Disorders, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto,, Ontario, Canada|University Health Network - The Toronto, Toronto, Ontario, Canada|NeuroSearch Developments Inc, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Quebec Memory & Motor Skills Disorders, Quebec City, Quebec, Canada|Institut Universitaire de Geriatrie de Sherbrooke, Sherbrooke, Quebec, Canada|Douglas Hospital Research Centre, Verdun, Quebec, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|Centre de Hospitalier Affilie, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00103649"
981,"NCT02149017","Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)",,"Terminated","No Results Available","Alzheimer Disease","Radiation: SNUBH-NM-333(18F)","Distribution volume ratio (DVR)|Standardized uptake value ratio (SUVr)","Seoul National University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SNUBH-NM-333(18F)","December 2010","May 2011","December 2012","May 29, 2014",,"May 29, 2014","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02149017"
982,"NCT00702143","A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: florbetapir F 18","Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR|Proportion of Positive Florbetapir-PET Scans","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A05","June 2008","December 2008","December 2008","June 20, 2008","May 3, 2012","May 10, 2012","Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00702143"
983,"NCT00733863","Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.",,"Completed","No Results Available","Alzheimer Disease","Biological: Placebo|Biological: CAD106","Safety/tolerability assessments at multiple timepoints including but not limited to screening, baseline, and through the end of the study to Week 52.|Immune response, cognitive and functional assessments at multiple timepoints including but not limited to baseline and through the end of the study to Week 52.","Novartis","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCAD106A2201","July 2008","February 2010",,"August 13, 2008",,"May 12, 2010","Centre Hospitalier Universitaire Pellegrin, Bordeaux, France|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|NeuroPsychologieZentrum, Basel, Switzerland|Moorgreen Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00733863"
984,"NCT01867775","Mirtazapine for Sleep Disorders in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Sleep Disorders","Drug: Mirtazapine","Change From Baseline in Nighttime Total Sleep Time|Change From Baseline in Nighttime Number Of Awakenings|Change From Baseline in Nighttime Wake After Sleep Onset|Change From Baseline in in Daytime Total Sleep Time|Change From Baseline in Number of Daytime Naps|Change in Cognitive Function (as Measured by the Mini-Mental State Examination)|Change in Activities of Daily Living (The Index of ADL - Katz)|Change of Baseline in Behavioral Variables (BAHAVE-AD Scale)|Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)","Brasilia University Hospital","All","55 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","052/2012","May 2012","December 2013","May 2014","June 4, 2013",,"June 4, 2013","Brasilia University, Brasilia, Distrito Federal, Brazil",,"https://ClinicalTrials.gov/show/NCT01867775"
985,"NCT01894620","The Effect of rTMS Treatment on Alzheimer's and Sleep Quality","rTMS","Completed","Has Results","Alzheimer's Disease","Device: rTMS real-sham|Device: rTMS sham-real","Cognitive Improvement Measured Using Montreal Cognitive Assessment (MoCA)|Improvement in Sleep Quality","Dr. Zahra Kazem-Moussavi|University of Manitoba","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","B2012:76","May 2013","May 2014","October 2014","July 10, 2013","February 12, 2018","February 12, 2018","Misericordia Health Center, Winnipeg, Manitoba, Canada|Riverview Health Center, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01894620"
986,"NCT00795418","Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients",,"Completed","No Results Available","Alzheimer's Disease","Biological: Placebo|Biological: CAD106","Safety/tolerability of repeated injection of CAD106 at multiple timepoints including but not limited to screening, baseline and through the end of the study (adverse events, physical/neurologic exams, vital signs, 12- lead ECGs, clinical labs, brain MRI)|Immune response at multiple timepoints including but not limited to screening, baseline and through the end of the study.|Cognitive assessments at multiple timepoints including but not limited to screening, baseline and through the end of the study.|Functional assessments at multiple timepoints including but not limited to screening, baseline and through the end of the study.","Novartis","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCAD106A2202","October 2008","November 2010",,"November 21, 2008",,"May 4, 2012","ATP Clinical Research, Costa Mesa, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|MidAmerica NeuroScience Research Foundation, Lenexa, Kansas, United States|Columbia University Medical Center, New York, New York, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|NOCCR Knoxville, Knoxville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00795418"
987,"NCT01245530","An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia",,"Completed","No Results Available","Alzheimer Type Dementia","Drug: Aricept|Drug: INM-176","Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score|Change from baseline to endpoint in Mini-Mental State Examination (MMSE)|Change from baseline to endpoint in Clinical Dementia Rating|Change from baseline to endpoint in Global Deterioration Scale(GDS)|Change from baseline to endpoint in Korean Activity of Living(K-IADL)|Change from baseline to endpoint in Korean Neuropsychiatric Inventory (NPI)","Whanin Pharmaceutical Company","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INM-176","June 2008","February 2011","March 2011","November 22, 2010",,"June 13, 2011","Whanin Pharm.Co.,Ltd., Seoul, Moonjung, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01245530"
988,"NCT02649985","Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease",,"Recruiting","No Results Available","Multiple Sclerosis|Alzheimer's Disease","Drug: [F-18]PBR06","Tissue Volume of Distribution","Brigham and Women's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015P002329","January 2016","June 30, 2019","June 30, 2019","January 8, 2016",,"May 22, 2018","Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02649985"
989,"NCT01334450","Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients",,"Unknown status","No Results Available","Alzheimer Disease","Device: TMS , H2-coil","cognitive functioning score by ADAS-COG","Hadassah Medical Organization","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","0316","June 2011","June 2012","June 2013","April 13, 2011",,"April 28, 2011","Hadassah Medical Center, Jerusalem District, Israel",,"https://ClinicalTrials.gov/show/NCT01334450"
990,"NCT00322153","A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease",,"Completed","Has Results","Dementia of the Alzheimer's Type","Drug: memantine ER|Drug: Placebo","Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)|Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)|Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)","Forest Laboratories","All","50 Years and older   (Adult, Older Adult)","Phase 3","677","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MEM-MD-50","June 2005","October 2007","January 2008","May 5, 2006","September 16, 2010","September 16, 2010","Forest Investigative Site 010, Phoenix, Arizona, United States|Forest Investigative Site 062, Costa Mesa, California, United States|Forest Investigative Site 050, Fresno, California, United States|Forest Investigative Site 024, San Francisco, California, United States|Forest Investigative Site 071, Santa Ana, California, United States|Forest Investigative Site 002, Denver, Colorado, United States|Forest Investigative Site 021, Boca Raton, Florida, United States|Forest Investigative Site 052, Boynton Beach, Florida, United States|Forest Investigative Site 070, Delray Beach, Florida, United States|Forest Investigative Site 065, Fort Myers, Florida, United States|Forest Investigative Site 043, Hallandale Beach, Florida, United States|Forest Investigative Site 044, Hallandale Beach, Florida, United States|Forest Investigative Site 001, Miami, Florida, United States|Forest Investigative Site 034, North Miami, Florida, United States|Forest Investigative Site 068, Orlando, Florida, United States|Forest Investigative Site 038, Palm Beach Gardens, Florida, United States|Forest Investigative Site 008, Saint Petersburg, Florida, United States|Forest Investigative Site 028, Tampa, Florida, United States|Forest Investigative Site 009, Snellville, Georgia, United States|Forest Investigative Site 069, Joliet, Illinois, United States|Forest Investigative Site 045, Kalamazoo, Michigan, United States|Forest Investigative Site 014, Saint Loius, Missouri, United States|Forest Investigative Site 064, Long Branch, New Jersey, United States|Forest Investigative Site 011, Morristown, New Jersey, United States|Forest Investigative Site 003, New Brunswick, New Jersey, United States|Forest Investigative Site 048, Albany, New York, United States|Forest Investigative Site 006, Buffalo, New York, United States|Forest Investigative Site 004, White Plains, New York, United States|Forest Investigative Site 027, Centerville, Ohio, United States|Forest Investigative Site 012, Toledo, Ohio, United States|Forest Investigative Site 020, Portland, Oregon, United States|Forest Investigative Site 032, Greensburg, Pennsylvania, United States|Forest Investigative Site 018, Jenkintown, Pennsylvania, United States|Forest Investigative Site 067, East Providence, Rhode Island, United States|Forest Investigative Site 041, Austin, Texas, United States|Forest Investigative Site 017, San Antonio, Texas, United States|Forest Investigative Site 013, Richmond, Virginia, United States|Forest Investigative Site 026, Tacoma, Washington, United States|Forest Investigative Site 103, Banfield, Buenos Aires, Argentina|Forest Investigative Site 105, La Plata, Buenos Aires, Argentina|Forest Investigative Site 123, Lanus, Buenos Aires, Argentina|Forest Investigative Site 113, Rosario, Santa Fe, Argentina|Forest Investigative Site 102, Buenos Aires, Argentina|Forest Investigative Site 118, Buenos Aires, Argentina|Forest Investigative Site 109, Buenos Aires, Argentina|Forest Investigative Site 104, Buenos Aires, Argentina|Forest Investigative Site 108, Buenos Aires, Argentina|Forest Investigative Site 114, Buenos Aires, Argentina|Forest Investigative Site 106, Buenos Aires, Argentina|Forest Investigative Site 119, Buenos Aires, Argentina|Forest Investigative Site 122, Buenos Aires, Argentina|Forest Investigative Site 107, Buenos Aires, Argentina|Forest Investigative Site 111, Buenos Aires, Argentina|Forest Investigative Site 121, Buenos Aires, Argentina|Forest Investigative Site 115, Buenos Aires, Argentina|Forest Investigative Site 116, Buenos Aires, Argentina|Forest Investigative Site 112, Cordoba, Argentina|Forest Investigative Site 124, Cordoba, Argentina|Forest Investigative Site 110, Mendoza, Argentina|Forest Investigative Site 125, Mendoza, Argentina|Forest Investigative Site 120, Santa Fe, Argentina|Forest Investigative Site 308, Coquimbo, Elqui, Chile|Forest Investigative Site 301, Las Condes, Santiago, Chile|Forest Investigative Site 309, Las Condes, Santiago, Chile|Forest Investigative Site 303, Providencia, Santiago, Chile|Forest Investigative Site 310, Providencia, Santiago, Chile|Forest Investigative Site 313, Recoleta, Santiago, Chile|Forest Investigative Site 305, San Ramon, Santiago, Chile|Forest Investigative Site 302, Antofagasta, Chile|Forest Investigative Site 304, Santiago, Chile|Forest Investigative Site 312, Santiago, Chile|Forest Investigative Site 306, Valdivia, Chile|Forest Investigative Site 212, Saltillo, Coahuila, Mexico|Forest Investigative Site 202, Mexico City, Federal District, Mexico|Forest Investigative Site 207, Mexico City, Federal District, Mexico|Forest Investigative Site 211, Leon, Guanajuato, Mexico|Forest Investigative Site 205, Guadalajara, Jalisco, Mexico|Forest Investigative Site 203, Zapopan, Jalisco, Mexico|Forest Investigative Site 208, Monterrey, Nuevo Leon, Mexico|Forest Investigative Site 204, Monterrey, Nuevo Leon, Mexico|Forest Investigative Site 213, Culiacan, Sinaloa, Mexico|Forest Investigative Site 206, Aguascalientes, Mexico|Forest Investigative Site 210, San Luis Potosi, Mexico",,"https://ClinicalTrials.gov/show/NCT00322153"
991,"NCT02063269","Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Rivastigmine","the mean changes of Standardized Uptake Values (SUVmean) in PET imaging|the mean changes of serum BuChE activity between BuChE wild type and K-variant type|the mean changes of cortical thickness in brain MRI|the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|the cognitive changes in Mini-Mental State Exam (MMSE)|the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI)|the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type","Seoul National University Hospital|Novartis Korea Ltd.","All","55 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CENA713DKR15T","February 2014","June 2017","June 2017","February 14, 2014",,"May 14, 2015","Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02063269"
992,"NCT01097096","Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",,"Completed","No Results Available","Alzheimer's Disease","Biological: CAD106","Safety and tolerability assessments (physical/neurological examinations, electrocardiogram (ECG), vital signs, standard and special laboratory evaluations, Magnetic Resonance Imaging (MRIs), Adverse events / Serious adverse events (AE/SAE) monitoring).|Amyloid beta (Aβ)-specific and Qβ carrier-specific antibody response to CAD106 (with either adjuvant) in serum and cerebrospinal fluid (CSF)|Amyloid beta (Aβ)-specific and Qβ carrier-specific T-cell response to CAD106 (with either adjuvant) using peripheral blood mononuclear cells (PBMCs)|Changes over time of the concentrations of disease related markers (Aβ1-40 and Aβ1-42 in plasma; Aβ1-40, Aβ1-42, total-tau, phospho-tau in CSF, or other markers) in patients with mild AD receiving CAD106 (with either adjuvant) compared to placebo","Novartis Pharmaceuticals|Novartis","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 2","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCAD106A2203|2009-012394-35","March 2010","December 2012","December 2012","April 1, 2010",,"April 25, 2016","Novartis Investigative Site, Costa Mesa, California, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Eatontown, New Jersey, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Sant Cugat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barakaldo, País Vasco, Spain|Novartis Investigative Site, Mölndal, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Biel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01097096"
993,"NCT03919162","A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD",,"Not yet recruiting","No Results Available","Early Alzheimer's Disease","Drug: PQ912|Other: Placebo","2A Primary safety: proportion of participants who experience any drug-related adverse event of interest (DAE-I).|2A Primary PK|2B Primary efficacy: CDR-SoB scale, a measure of cognition and function|Key secondary efficacy: CFC2, a cognitive-functional composite","Probiodrug AG|Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","462","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PBD-01187|1R01AG061146-01","January 2020","December 2022","April 2023","April 18, 2019",,"April 18, 2019",,,"https://ClinicalTrials.gov/show/NCT03919162"
994,"NCT01826110","PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers",,"Completed","No Results Available","Alzheimer's Disease","Drug: [11C]PIB","Distribution Volumes of 11C-PIB","Johns Hopkins University|National Institute on Aging (NIA)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NA_00033154|1R21AG056142-01","September 2013","July 2018","July 2018","April 8, 2013",,"March 5, 2019","Johns Hopkins Medical Institution- Dept of Radiology , Division of Nuclear Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01826110"
995,"NCT00809510","A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-089","Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)|ADAS-Cog, CIBIC-plus, MMSE, QoL-AD","Abbott","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-745","January 2009","June 2009",,"December 17, 2008",,"September 2, 2011","Site Reference ID/Investigator# 16543, Phoenix, Arizona, United States|Site Reference ID/Investigator# 16528, Sun City, Arizona, United States|Site Reference ID/Investigator# 16524, Fresno, California, United States|Site Reference ID/Investigator# 16520, San Diego, California, United States|Site Reference ID/Investigator# 16521, Santa Monica, California, United States|Site Reference ID/Investigator# 16533, Hamden, Connecticut, United States|Site Reference ID/Investigator# 16516, Brooksville, Florida, United States|Site Reference ID/Investigator# 16510, Deerfield Beach, Florida, United States|Site Reference ID/Investigator# 16508, Delray Beach, Florida, United States|Site Reference ID/Investigator# 16515, Miami, Florida, United States|Site Reference ID/Investigator# 16545, Palm Beach Gardens, Florida, United States|Site Reference ID/Investigator# 16541, Sunrise, Florida, United States|Site Reference ID/Investigator# 16542, Tampa, Florida, United States|Site Reference ID/Investigator# 16529, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 16526, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 16527, Eatontown, New Jersey, United States|Site Reference ID/Investigator# 16523, Ridgewood, New Jersey, United States|Site Reference ID/Investigator# 16532, New York, New York, United States|Site Reference ID/Investigator# 16519, Winston Salem, North Carolina, United States|Site Reference ID/Investigator# 16525, Centerville, Ohio, United States|Site Reference ID/Investigator# 16507, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 16509, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00809510"
996,"NCT00608946","Treatment With Copper in Patients With Mild Alzheimer´s Dementia",,"Completed","No Results Available","Alzheimer´s Disease","Dietary Supplement: copper|Dietary Supplement: placebo","change of cognitive function, measured by ADAS-cog|change of beta amyloid in the CSF and volumetric changes in the brain","University Hospital, Saarland|University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UKS-PSY-DEM-01","March 2004","August 2007",,"February 6, 2008",,"February 6, 2008",,,"https://ClinicalTrials.gov/show/NCT00608946"
997,"NCT00531804","A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.",,"Completed","No Results Available","Alzheimer's Disease","Drug: gantenerumab","AEs, laboratory parameters, vital signs.|Pharmacokinetic parameters of R1450 in plasma|CSF biomarkers, clinical efficacy parameters.","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN19866","December 2006","September 2010","September 2010","September 19, 2007",,"November 2, 2016","København, Denmark|Ramat Gan, Israel|Amsterdam, Netherlands|Malmoe, Sweden|Stockholm, Sweden|Blackpool, United Kingdom|Glasgow, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00531804"
998,"NCT00777608","A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)",,"Completed","Has Results","Alzheimer's Disease","Drug: Comparator: Placebo 5mg (run in)|Drug: Donepezil 5 - 10 mg|Drug: Comparator: Placebo 5-10 mg|Drug: Donepezil 10 mg","Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4|Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12|Evaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12","Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 1","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0000-086|2008_573","December 2008","October 2009","April 2010","October 22, 2008","February 24, 2011","August 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00777608"
999,"NCT02016560","Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: florbetapir F 18|Drug: 18F-AV-1451","Cross-sectional 18F-AV-1451 Imaging Results|Change in tau deposition over time|18F-AV-1451 imaging in healthy individuals","Avid Radiopharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","383","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-1451-A05","December 2013","July 28, 2017","July 28, 2017","December 20, 2013",,"October 25, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Four Peaks Neurology, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Irvine, Irvine, California, United States|Hoag Memorial, Newport Beach, California, United States|Norther California PET Imaging Center, Sacramento, California, United States|UC Davis, Sacramento, California, United States|UC San Francisco, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|21st Century Oncology, Fort Myers, Florida, United States|Sandlake Imaging, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|USF Health Byrd Alzheimer's Center, Tampa, Florida, United States|Independent Imaging, West Palm Beach, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Center for Clinical Imaging Research, Saint Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Center for Brain Health - NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02016560"
1000,"NCT03639987","A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities","EVOLVE","Active, not recruiting","No Results Available","Cognitive Dysfunction|Alzheimer's Disease","Drug: Aducanumab|Drug: Placebo","Number of Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)|Number of Participants With ARIA by Severity as Obtained on Magnetic Resonance Imaging (MRI)|Time to Onset of ARIA as Obtained on MRI|Time to Resolution of ARIA as Obtained on MRI|Number of Participants With Symptomatic ARIA by Severity|Time to Onset of Symptomatic ARIA|Time to Resolution of Symptomatic ARIA|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in the Montreal Cognitive Assessment (MoCA) at Week 54|Aducanumab Concentration in Serum|Number of Participants With Antiaducanumab Antibodies in Serum","Biogen","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","221AD205|2018-002102-31","December 20, 2018","July 9, 2021","November 13, 2023","August 21, 2018",,"April 16, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Pacific Research Network, Inc, San Diego, California, United States|California Neuroscience Research Medical Group Inc., Sherman Oaks, California, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Bioclinica Orlando, Orlando, Florida, United States|Bioclinica Orlando, The Villages, Florida, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|Josephson, Wallack, Munshower Neurology, P.C., Indianapolis, Indiana, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Senior Adult Specialty Research, Austin, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States|Australian Alzheimer's Research Foundation Incorporated, Nedlands, Western Australia, Australia|Health Research., Kamloops, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Ospedale San Raffaele, Milano, Italy|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain|Hospital Universitario Reina Sofia, Cordoba, Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT03639987"
1001,"NCT00556660","Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: [123I] AV-151","To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","AV51 001","September 2007","July 2008","July 2008","November 12, 2007",,"March 14, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00556660"
1002,"NCT00018291","Specific Interventions for Agitation in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Risperidone|Drug: Gabapentin",,"US Department of Veterans Affairs|VA Office of Research and Development","All","50 Years and older   (Adult, Older Adult)","Not Applicable",,"U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","AGCG-005-00S","January 2001",,"January 2005","July 5, 2001",,"January 21, 2009","Palo Alto VA Health Care System, Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00018291"
1003,"NCT01297140","The PACO Study (""Personnalité Alzheimer COmportement"")","PACO","Unknown status","No Results Available","Alzheimer Disease","Behavioral: questioning","Behavioural and psychological symptoms of dementia (BPSD)|social cognition tests|connection between social cognitive tests and BPSD|connection between cerebral atrophy and BPSD","Hospices Civils de Lyon","All","50 Years and older   (Adult, Older Adult)","Not Applicable","252","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","2008.508","January 2009","July 2015","November 2015","February 16, 2011",,"October 3, 2014","Service de Gériatrie - Hôpital des Charpennes - Hospices Civils de Lyon, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT01297140"
1004,"NCT01729598","Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study","VPA","Completed","Has Results","Alzheimer's Disease","Drug: Valproic Acid|Drug: Placebo","Frequency of Adverse Events Over the Duration of the Study by Study Arm|Change in Cerebrospinal Fluid Amyloid Levels (pg/ml) Over 28 Day Intervention Period by Study Arm|Change in Cerebrospinal Fluid P-tau Levels (pg/ml)|Change in Free & Cued Selective Reminding Test- Free Recall (Number of Items Correct)|Change in Cerebrospinal Fluid Clusterin Levels (pg/ml)","Gregory Jicha, 323-5550|University of Kentucky|Kentucky Alzheimer's Center","All","65 Years to 90 Years   (Older Adult)","Early Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","12-0068-F6A","April 2012","October 2014","October 2014","November 20, 2012","October 9, 2019","October 9, 2019","Sander's Brown Center on Aging, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01729598"
1005,"NCT00203359","TNF-Alpha Inhibition for Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: etanercept given by perispinal administration","ADAS-Cog|SIB|MMSE|Category fluency|other neuropsychological tests","Tobinick, Edward Lewis, M.D.","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10005","September 2004",,"April 2006","September 20, 2005",,"April 24, 2006","Edward Tobinick, MD (private medical office), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00203359"
1006,"NCT00203320","TNF-Alpha Inhibition for Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: etanercept given by perispinal administration","ADAS-Cog|SIB|MMSE|ADCS-ADLsev|Category fluency","Tobinick, Edward Lewis, M.D.","All","Child, Adult, Older Adult","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10007","April 2005",,"January 2006","September 20, 2005",,"April 24, 2006","100 UCLA Medical Plaza, Suites 205-210, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00203320"
1007,"NCT03799991","Vestibular Therapy in Alzheimer's Disease",,"Not yet recruiting","No Results Available","Vestibular Diseases|Vestibular Disorder|Alzheimer Disease","Behavioral: Vestibular physical therapy|Behavioral: Active control","Change in Berg Balance Scale score","Johns Hopkins University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01082019","July 1, 2020","June 30, 2024","June 30, 2024","January 10, 2019",,"September 30, 2019",,,"https://ClinicalTrials.gov/show/NCT03799991"
1008,"NCT03070821","Therapy of Alzheimer's Disease With Neurofeedback",,"Completed","No Results Available","Alzheimer Dementia (AD)|Elderly","Other: rtfMRI neurofeedback training|Device: 3T MRI","Visual and Verbal Memory Test (VVM)|Montreal Cognitive Assessment (MoCA)|Wechsler Memory Scale Revised (WMS-R)|Trail Making Test (TMT)|Visual Patterns Test (VPT)|Parahippocampal activation|Memory-related functional connectivity using Granger Causality Analysis (GCA)|Change of brain structure|Change of brain function","University Hospital, Aachen|Alzheimer Forschung Initiative e.V.","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AFI 13812","January 30, 2013","June 30, 2016","June 30, 2016","March 6, 2017",,"March 6, 2017",,,"https://ClinicalTrials.gov/show/NCT03070821"
1009,"NCT00046358","The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease","Drug: Lovostatin|Drug: Ibuprofen",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 4","50","NIH","Interventional","Primary Purpose: Treatment","020305|02-M-0305","September 2002",,"August 2005","September 27, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00046358"
1010,"NCT01565356","Evaluation of PET Scan Timing Relative to AV-45 Injection Time",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Percent Agreement of Interpretation Between 30-40 and 50-60 Min Reads - Qualitative Evaluation|Agreement of Interpretation Between 30-40 and 50-60 Min Reads - Semi-quantitative Evaluation","Avid Radiopharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Not Applicable","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A06","March 2010","May 2010","May 2010","March 28, 2012","June 7, 2012","June 7, 2012",,,"https://ClinicalTrials.gov/show/NCT01565356"
1011,"NCT00550420","Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers",,"Terminated","Has Results","Alzheimer's Disease","Drug: Rosiglitazone XR","Number of Participants With Any Adverse Events (AEs) and Severity of AEs|Number of Participants With Serious AEs and Deaths|Percentage of Participants With AEs of Edema|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Heart Rate (HR)|Number of Participants With Abnormal SBP and DBP at Any Time During Treatment Period|Number of Participants With Abnormal HR at Any Time During Treatment Period|Change From Baseline in Body Weight (BW)|Number of Participants With Abnormal BW at Any Time During Treatment Period|Change From Baseline in Non-fasting Measures of Lipid Metabolism Including Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein and Triglycerides at Indicated Timepoints.|Number of Participants With Hematological Parameters of Potential Clinical Concern|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) Total Score as a Function of Apolipoprotein E (APOE) 4 Status at W24 and W52|Mean Clinician Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) Score as a Function of APOE 4 Status|Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE 4 Status at W24 and W52|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOEe 4 Status|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE 4 Status at W24 and W52|Change From Baseline in Glycosylated Haemoglobin (HbA1c)","GlaxoSmithKline","All","51 Years to 91 Years   (Adult, Older Adult)","Phase 3","331","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVA102677","October 1, 2007","February 12, 2009","February 12, 2009","October 29, 2007","November 8, 2017","November 8, 2017","GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Melbourne, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Centerville, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Graz-Eggenberg, Austria|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Guenzburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Saltillo, Coahuila, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St.-Petersburg, Russian Federation|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00550420"
1012,"NCT01195389","Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Dementia","Device: Resonator","Alzheimer's Disease Assessment Scale-Cog (ADAS-cog)","pico-tesla Magnetic Therapies, LLC","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","USF #6178-P67865","December 2010","October 2011","October 2011","September 6, 2010",,"July 8, 2011","USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01195389"
1013,"NCT01741194","AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext","NOURISH-AD","Completed","No Results Available","Alzheimer's Disease","Drug: AC-1204|Drug: Placebo","Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Clock Draw Interpretation Scale (CDIS)|Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)|Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)|Quality of Life - Alzheimer's Disease (QoL-AD)|Resource Utilization in Dementia (RUD-Lite)|Incidence of treatment-emergent adverse events","Cerecin","All","66 Years to 90 Years   (Older Adult)","Phase 2|Phase 3","418","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","AC-12-010","March 2013","October 24, 2016","April 14, 2017","December 4, 2012",,"May 17, 2017","University of Alabama at Birmingham, Department of Neurology, Memory Disorders Division, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Principals Research Group, Hot Springs, Arkansas, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|CITrials, Inc., Bellflower, California, United States|Southern Research LLC, Beverly Hills, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Diligent Clinical Trials, Downey, California, United States|UCSD Comprehensive Alzheimer's Program, La Jolla, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Alliance for Research, Long Beach, California, United States|Renew Behavioral Health, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Research Across America, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Redwood Research Medical Group, Santa Rosa, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Chase Medical Research of Greater New Haven, Hamden, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Meridian Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|The Roskamp Institute, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Inc, Atlanta, Georgia, United States|IU Health Partners Adult Neurology Clinic, Indianapolis, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Alzheimers Disease Center, Quincy Medical Center, Somerville, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Saint Louis University Medical School /Department of Neurology & Psychiatry, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Alzheimer's Research Corporation, Manchester Township, New Jersey, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|The Litwin-Zucker Research Center, Manhasset, New York, United States|Parker Jewish Institute For Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU Langone Medical Center Comprehensive Center on Brain Aging, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute Geriatric Psychiatry Program, Orangeburg, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Ani Neurology, PLLC dba Alzheimer's Memory Ctr, Charlotte, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Drexel Neurological Associates, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc, Austin, Texas, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|VA Puget Sound-Alzhemier's Disease Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01741194"
1014,"NCT01658722","Retrieval of Patient Information After Discontinuation","RAPID","Terminated","No Results Available","Alzheimer's Disease","Drug: Bapineuzumab","Dependence Scale","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","55 Years and older   (Adult, Older Adult)",,"169","Industry","Observational","Time Perspective: Prospective","AAB-001-ALZ-3300","December 2011","August 2012","August 2012","August 7, 2012",,"September 2, 2015",,,"https://ClinicalTrials.gov/show/NCT01658722"
1015,"NCT01194713","Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics","AWAKE","Completed","No Results Available","Alzheimer Disease","Behavioral: Sleep deprivation","Amyloid beta","University Medical Center Nijmegen","Male","40 Years to 60 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AWAKE32920","March 2011","September 2013","September 2013","September 3, 2010",,"May 13, 2014","Clinical Research Centre Nijmegen, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01194713"
1016,"NCT00490568","Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers",,"Terminated","Has Results","Alzheimer's Disease","Drug: Rosiglitazone XR","Number of Participants With Any Adverse Events (AEs) and Severity of AEs|Number Participants With Serious Adverse Events (SAEs) and Deaths|Number of Participants With Adverse Event of Oedema|Change From Baseline in Vital Sign Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Vital Sign Heart Rate (HR)|Change From Baseline in Vital Sign Body Weight (BW)|Change From Baseline in Non-fasting Measures of Lipid Metabolism Namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides|Number of Participants With SBP and DBP Values of Potential Clinical Concern (PCC)|Number of Participants With HR Values of PCC ATOT|Number of Participants With BW Values of PCC ATOT|Number of Participants With Hematology Parameters of PCC ATOT|Number of Participants With Clinical Chemistry Parameters (Including Lipids) of PCC ATOT|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score as a Function of Apolipoprotein E (APOE) ε4 Status.|Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score as a Function of APOE ε4 Status.|Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE ε4 Status.|Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOE ε4 Status.|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE ε4 Status.","GlaxoSmithKline","All","51 Years to 91 Years   (Adult, Older Adult)","Phase 3","1461","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVA102675","August 8, 2007","June 1, 2009","June 1, 2009","June 22, 2007","November 13, 2017","November 13, 2017","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Sherman Oaks, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Delray Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Fort Wayne, Indiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, West Yarmouth, Massachusetts, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Stratford, New Jersey, United States|GSK Investigational Site, Toms River, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, South Ogden, Utah, United States|GSK Investigational Site, Bennington, Vermont, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Godoy Cruz, Mendoza, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Hornsby, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Auchenflower, Queensland, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Cheltenham, Victoria, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Kew, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Hall in Tirol, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Woluwe-Saint-Lambert, Belgium|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Kentville, Nova Scotia, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Peterborough, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Whitby, Ontario, Canada|GSK Investigational Site, Charlottetown, Prince Edward Island, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 7, Czechia|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Trutnov, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Bourg en Bresse, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Ivry, France|GSK Investigational Site, La Seyne sur Mer, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Limoges, France|GSK Investigational Site, Luynes, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pau, France|GSK Investigational Site, Rodez, France|GSK Investigational Site, Saint Ouen la Rouerie, France|GSK Investigational Site, Saint-Etienne, France|GSK Investigational Site, Sautron, France|GSK Investigational Site, Tinteniac, France|GSK Investigational Site, Toulon, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Tours, France|GSK Investigational Site, Vichy, France|GSK Investigational Site, Aalen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ludwigsburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Alzenau, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Erbach, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Bockhorn, Niedersachsen, Germany|GSK Investigational Site, Ganderkesee, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Lueneburg, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bad Honnef, Nordrhein-Westfalen, Germany|GSK Investigational Site, Baesweiler, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Melissia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Varanasi, India|GSK Investigational Site, Chieti Scalo, Abruzzo, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, San Felice a Cancello Caserta, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Brescia, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Rho, Lombardia, Italy|GSK Investigational Site, Torrette (AN), Marche, Italy|GSK Investigational Site, Arezzo, Toscana, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Seongnam-si,, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Blaricum, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hilversum, Netherlands|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Mosina, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warsaw, Poland|GSK Investigational Site, Coimbra, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Ljubljana, Slovenia|GSK Investigational Site, Šempeter, Slovenia|GSK Investigational Site, Loeventstein, South Africa|GSK Investigational Site, Oakdale, South Africa|GSK Investigational Site, Richards Bay, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Waverley, Bloemfontein, South Africa|GSK Investigational Site, Willows, X14, Pretoria, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Castellón, Spain|GSK Investigational Site, Elche (Alicante), Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Jönköping, Sweden|GSK Investigational Site, Kalix, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Sundsvall, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Blackpool, Lancashire, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00490568"
1017,"NCT00110552","Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients",,"Completed","No Results Available","Alzheimer Disease","Drug: Salvia officinalis (sage)","Cognitive function|Stress|cognitive electrophysiology","Oregon Health and Science University|National Center for Complementary and Integrative Health (NCCIH)","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","111","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","U19AT002656-03","July 2005","December 2012","October 2014","May 11, 2005",,"October 29, 2014","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00110552"
1018,"NCT00041678","Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Alzheimer Disease","Drug: aripiprazole",,"Otsuka Pharmaceutical Development & Commercialization, Inc.","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Primary Purpose: Treatment","CN138-005","January 2000","March 2003","March 2003","July 15, 2002",,"November 11, 2013","Local Institution, Rosemead, California, United States|Local Institution, Miami, Florida, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Bennington, Vermont, United States|Local Institution, Burlington, Vermont, United States|Local Institution, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00041678"
1019,"NCT00036114","Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Alzheimer Disease","Drug: aripiprazole",,"Otsuka Pharmaceutical Development & Commercialization, Inc.","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Primary Purpose: Treatment","CN138-004","March 2000","August 2003","August 2003","May 9, 2002",,"November 11, 2013","Local Institution, Tuscaloosa, Alabama, United States|Local Institution, Scottsdale, Arizona, United States|Local Institution, Cerritos, California, United States|Local Institution, Granada Hills, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, San Diego, California, United States|Local Institution, Torrance, California, United States|Local Institution, Denver, Colorado, United States|Local Institution, Hamden, Connecticut, United States|Local Institution, Miami, Florida, United States|Local Institution, North Miami Beach, Florida, United States|Local Institution, West Palm Beach, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Augusta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Honolulu, Hawaii, United States|Local Institution, North Chicago, Illinois, United States|Local Institution, Springfield, Illinois, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Newton Center, Massachusetts, United States|Local Institution, Springfield, Massachusetts, United States|Local Institution, Wellesley Hills, Massachusetts, United States|Local Institution, Lyons, New Jersey, United States|Local Institution, Albany, New York, United States|Local Institution, Lawrence, New York, United States|Local Institution, Montrose, New York, United States|Local Institution, Northport, New York, United States|Local Institution, White Plains, New York, United States|Local Institution, Raleigh, North Carolina, United States|Local Institution, Beachwood, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Hershey, Pennsylvania, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Wichita Falls, Texas, United States|Local Institution, Bennington, Vermont, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00036114"
1020,"NCT01209156","Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions","PBR111","Completed","No Results Available","Alzheimer Disease","Drug: [18F] PBR111","To evaluate the cerebral distribution of [18F]PBR-111 positron emission tomography (PET) for detection/exclusion of microglial activation in patients with Alzheimer Disease compared to healthy volunteers.|To assess the dynamic uptake and washout of [18F]PBR-111, a potential imaging biomarker for inflammatory changes in brain, using positron emission tomography (PET) in Alzheimer disease subjects compared to healthy volunteers.|To perform blood metabolite characterization of [18F]PBR-111 in AD subjects compared to Healthy volunteers to determine the nature of metabolites in assessment of [18F]PBR-111 as a single positron computed tomography (PET) brain imaging agent.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PBR111 001","March 2010","June 2013","June 2013","September 27, 2010",,"November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01209156"
1021,"NCT01385033","[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)",,"Terminated","Has Results","Alzheimer's Disease","Drug: [18F]MK-3328","Area Under the Receiver Operating Curve (AUC of ROC) for Distinguishing Between AD and HE Participants Based on Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)|Brain Cortical [18F]MK-3328 SUVR in AD Participants and HE Participants|Amyloid Plaque Burden Threshold Determined by the Trimmed HE Sample Mean and SD Brain Cortical [18F]MK-3328 SUVR","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3328-002","August 19, 2011","May 15, 2012","May 15, 2012","June 29, 2011","February 20, 2014","November 8, 2018",,,"https://ClinicalTrials.gov/show/NCT01385033"
1022,"NCT01152216","An Extension of the CONCERT Protocol (DIM18)","CONCERT PLUS","Terminated","No Results Available","Alzheimer's Disease","Drug: Dimebon","Safety","Medivation, Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","672","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIM18EXT","April 2010","May 2012",,"June 29, 2010",,"September 27, 2016",,,"https://ClinicalTrials.gov/show/NCT01152216"
1023,"NCT00391833","Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease",,"Completed","No Results Available","Alzheimer's Disease|Memory Decline","Drug: Panax Ginseng","Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.|Biomarkers including hematopoietic progenitor cell count.","Seoul National University Hospital","Female","40 Years to 83 Years   (Adult, Older Adult)","Phase 1|Phase 2",,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ginseng-AD","April 2004",,"October 2005","October 24, 2006",,"October 24, 2006",,,"https://ClinicalTrials.gov/show/NCT00391833"
1024,"NCT01255046","Study of STA-1 as an Add-on Treatment to Donepezil",,"Unknown status","No Results Available","Alzheimer Disease","Drug: Donepezil,|Drug: STA-1|Drug: placebo","Change from baseline in ADAS-cog at Week 72|Change from baseline in Mini-Mental State Examination Scale Score (MMSE) at 72 week","Sinphar Pharmaceutical Co., Ltd","All","50 Years and older   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCCD09009A","December 2015","December 2018",,"December 7, 2010",,"August 20, 2014","Tri-Service General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01255046"
1025,"NCT01035138","A Study of Semagacestat for Alzheimer's Patients","Identity XT","Completed","Has Results","Alzheimer's Disease","Drug: semagacestat","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at Week 16 After Cessation of Study Drug|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at Week 12|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) at Week 12|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45-PET) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) at Week 12|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14) at Week 12|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at Week 12|Mean Concentration of LY450139|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) at Week 16 After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14) at Week 16 After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating Scale (Sum of Boxes) (CDR-SB) at Week 24|Change From Baseline in Mini-Mental State Examination (MMSE) at Week 24|Change From Baseline in Neuropsychiatric Inventory (NPI) at Week 24|Change From Baseline in EuroQol-5D (EQ-5D) at Week 24|Change From Baseline in Resource Utilization in Dementia-Lite Questionnaire (RUD-Lite) at Week 12","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 3","180","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5930|H6L-MC-LFBF","December 2009","April 2011","April 2011","December 18, 2009","September 25, 2014","September 25, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooksville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deerfield Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyannis, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenkintown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg West, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valdivia, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukui, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01035138"
1026,"NCT03875638","Treating Hyperexcitability in AD With Levetiracetam",,"Recruiting","No Results Available","Alzheimer Disease, Early Onset","Drug: Levetiracetam|Drug: Placebo oral capsule","Neuropsychological Test Battery (NTB)|Transcranial magnetic stimulation (TMS) resting motor threshold|Transcranial magnetic stimulation (TMS)-evoked electroencephalogram (EEG) hypersynchrony|Resting-state electroencephalogram (EEG) beta band power|Resting-state electroencephalogram (EEG) beta band connectivity|Default-mode network resting-state functional magnetic resonance imaging (fMRI) functional connectivity|Change in motor evoked potential (MEP) amplitude|Change in beta power after theta-burst stimulation","Beth Israel Deaconess Medical Center","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","85","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019P000091","August 22, 2019","August 2023","November 2023","March 15, 2019",,"September 10, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03875638"
1027,"NCT01309763","Safety and Tolerability of AFFITOPE AD03","MimoVax","Completed","No Results Available","Alzheimer's Disease","Biological: AFFITOPE AD03|Biological: AFFITOPE AD03 + Alum","change in ADAS-Cog score as a measure of cognition","Affiris AG","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AFF005A","October 2010","September 2011","November 2011","March 7, 2011",,"December 20, 2011","MUW Wien, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01309763"
1028,"NCT01217021","Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558","MNI-558","Completed","No Results Available","Alzheimer Disease","Drug: [18F] MNI-558","To evaluate the efficacy safety of MNI-558 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer disease (AD) compared to healthy volunteers (HV)|To assess the dynamic uptake of MNI-558, a potential imaging biomarker for B-amyloid burden in brain, using positron emission tomography (PET) in similarly aged Alzheimer (AD) subjects and healthy volunteers (HV|To determine pharmacokinetics pattern of MNI-558 in venous plasma of healthy and AD subjects.|To determine metabolite pattern of MNI-558 in venous plasma of healthy and AD subjects.","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-558-01","September 2010","March 2011","March 2011","October 8, 2010",,"July 25, 2011","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01217021"
1029,"NCT03282916","Anti-viral Therapy in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Herpes Simplex 1|Herpes Simplex 2","Drug: Valacyclovir|Drug: Placebo","Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, modified version) scores from baseline to 78 weeks.|Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scores from baseline to 78 weeks.|Change in total 18F-Florbetapir brain uptake from baseline to 78 weeks.|Change in total 18F-MK-6240 brain uptake from baseline to 78 weeks.","New York State Psychiatric Institute|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","18 Years to 105 Years   (Adult, Older Adult)","Phase 2","130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","7537|R01AG055422","February 12, 2018","August 2022","August 2022","September 14, 2017",,"April 11, 2019","New York University School of Medicine, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03282916"
1030,"NCT01225809","AD01 Follow up Extension Visit",,"Completed","No Results Available","Alzheimer´s Disease",,"Long term tolerability and safety of AFFITOPE AD01","Affiris AG","All","Child, Adult, Older Adult",,"17","Industry","Observational","Time Perspective: Retrospective","AFF003E","September 2010","December 2010","January 2011","October 21, 2010",,"January 26, 2011","Univ. Klinik für Neurologie, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01225809"
1031,"NCT03706885","Efavirenz for Patients With Mild Cognitive Impairment",,"Recruiting","No Results Available","Alzheimer Disease, Early Onset","Drug: Sustiva Pill","Serum levels of 24-hydroxycholesterol|Serum levels of deuterated 24-hydroxycholesterol|APOE isoform status (E2, E3, or E4) and presence of the SNPs rs754203 and rs3745274 in CYP46A1 and CYP2B6, respectively.","Case Western Reserve University|University Hospitals Cleveland Medical Center|Massachusetts General Hospital","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","ADDF 20160601","December 21, 2018","October 2019","May 2020","October 16, 2018",,"February 15, 2019","Case Western Reserve University, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03706885"
1032,"NCT00486044","Evaluating Simvastatin's Potential Role in Therapy","ESPRIT","Completed","Has Results","Alzheimer Disease","Drug: Simvastatin|Drug: Placebo","Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42|Changes in Regional Cerebral Blood Flow on MRI|Change in Inflammatory Markers|Changes in Cognitive Performance","University of Wisconsin, Madison|National Institute on Aging (NIA)|Paul Beeson Faculty Scholars Program|The John A. Hartford Foundation|The Atlantic Philanthropies|Starr Foundation|American Federation for Aging Research|Merck Sharp & Dohme Corp.","All","35 Years to 69 Years   (Adult, Older Adult)","Phase 2","103","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IA0116|1K23AG026752-01","February 2005","June 2009","June 2009","June 13, 2007","November 5, 2015","March 5, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00486044"
1033,"NCT00750529","Alzheimer and Sleep",,"Completed","No Results Available","Alzheimer's Disease","Drug: Galantamine and Donepezil","Comparison of the percentage of paradoxical sleep recorded with polysomonography in 65 years old patients with administration of Galantamine or Donépézil|Describe the iatrogenic modifications of rhythm and architecture of sleep. describe the iatrogenic modifications of rythm and architecture of sleep","University Hospital, Clermont-Ferrand|Janssen-Cilag Farmaceutica Ltda.","All","65 Years and older   (Older Adult)","Phase 1","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0038","November 2008","September 2013","September 2013","September 10, 2008",,"July 8, 2014","CHU Clermont-Ferrand, Clermont-Ferrand, France|CPC-CIC, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT00750529"
1034,"NCT01025466","Exelon Patch and Combination With Memantine Comparative Trial","EXPECT","Completed","No Results Available","Alzheimer's Disease","Drug: Rivastigmine transdermal patch (Exelon patch), memantine|Drug: Rivastigmine transdermal patch","Retention rate at week 16 after randomization|Change from baseline at week 16 in Alzheimer's Disease Assessment Scale-Cognitive subscale|Change from baseline at week 16 in Mini-Mental State Examination|Change from baseline at week 16 in Frontal Assessment Battery|Change from baseline at week 16 in Alzheimer's Disease Cooperative Study - Activities of Daily Living|Change from baseline at week 16 in Caregiver-Administered Neuropsychiatric Inventory|Change from baseline at week 16 in Cohen Mansfield Agitation Inventory|Change from baseline at week 16 in Clinical Dementia Rating Scale-Sum of Boxes|Safety","Inha University Hospital","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EXPECT","December 2008","November 2009","April 2010","December 3, 2009",,"May 19, 2010","Soonchunhyang University Hospital, Bucheon, Korea, Republic of|The Catholic University of Korea Hospital, Bucheon, Korea, Republic of|Donga University Hospital, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Daejun Eulji University Hopistal, Daejun, Korea, Republic of|Dongguk University Medical Center, Goyang, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|Inha Univeristy Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Maryknoll Hospital, Pusan, Korea, Republic of|Bobath Memorial Hospital, Seongnam, Korea, Republic of|Kyughee University Medical Center, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Sungkyunkwan University, Samsung Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Hallym University Hospital, Seoul, Korea, Republic of|Ewha Womans University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul Eulji Hospital, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01025466"
1035,"NCT03548883","Examining Neuroinflammation in AlzHeimer's","ENHANCE","Enrolling by invitation","No Results Available","Alzheimer Disease, Early-Onset",,"Compare the Blood Brain Barrier leaking between AD, T2D and healthy control subjects.|Age|Gender|Body composition|Weight|Height|BMI|Race|Cognitive data|Lipid profile|Insulin|Adiponectin|Free Fatty Acid|Transcriptomic profiles of the cells isolated from the blood|Activity monitoring - energy cost of free-living activity|Epigenetic|Metabolic of the cells isolated from the blood|Proteomic of the cells isolated from the blood|Activity monitoring - lying down time|Activity monitoring - sleeping time","Florida Hospital","All","60 Years and older   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","864676","June 2016","December 2018","December 2018","June 7, 2018",,"June 21, 2018",,,"https://ClinicalTrials.gov/show/NCT03548883"
1036,"NCT01000870","Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513",,"Terminated","No Results Available","Alzheimer Disease","Drug: MNI-513-01","To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers","Institute for Neurodegenerative Disorders","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-513-01","October 2009","September 2010","September 2010","October 23, 2009",,"October 6, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01000870"
1037,"NCT01222351","Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172",,"Active, not recruiting","No Results Available","Late Onset Alzheimer Disease","Drug: BAY 94-9172 (Florbetaben)","Changes in amyloid plaque load in the brain of the course of 3 years","New York State Psychiatric Institute|Bayer|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","161","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6045/7130R (Bayer)|IND 78868|R01AG037212-01","December 2010","January 2020","January 2029","October 18, 2010",,"May 22, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01222351"
1038,"NCT00443014","The Dementia Study in Northern Norway",,"Completed","No Results Available","Alzheimer Disease","Device: Cognitive, physical and social stimulation","The cognitive function is measured with the Alzheimer's Disease Assessment|Changes in Activity of Daily Living (ADL) measured by standardized tests.","University Hospital of North Norway|County Officer of Nordland, Moloveien 2, 8006 Bodø, Norway|Norwegian Foundation for Health and Rehabilitation|Norwegian Department of Health and Social Affairs","All","65 Years and older   (Older Adult)","Phase 4","187","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200201054-12/12BMA2/400","June 2003","June 2009","June 2009","March 5, 2007",,"November 10, 2011","Arran Lulesami Centre, Drag, Nordland, Norway",,"https://ClinicalTrials.gov/show/NCT00443014"
1039,"NCT02256306","The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study","PLASMA","Completed","No Results Available","Mild-To-Moderate Alzheimer's Disease|Alzheimer's Disease","Other: Plasma","Number of participants with adverse events as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility.|Change on the 13-item ADAS-Cog|Change on the Trail-Making Test|Change on the Clinical Dementia Rating scale Sum of Boxes (CDR-SB)|Change on the Functional Activities Questionnaire (FAQ)|Change on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)|Change on the Geriatric Depression Scale|Change on the Neuropsychiatric Inventory Questionnaire (NPI-Q)","Stanford University|Alkahest, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30350","September 2014","February 2017","February 2017","October 3, 2014",,"October 10, 2017","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02256306"
1040,"NCT00916617","Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab",,"Terminated","Has Results","Alzheimer Disease","Drug: bapineuzumab","Number of Participants Reporting Clinically Significant Magnetic Resonance Imaging (MRI) Findings|Pharmacokinetic Parameters Including Maximal Serum Drug Concentration, Time to Maximal Serum Drug Concentration, and Terminal Half-life of Elimination","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3133L1-2204|B2521009","June 2009","September 2012","September 2012","June 9, 2009","June 1, 2017","June 1, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Pharmacology Research Institute, Encino, California, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Palm Beach Neurology - Premiere Research Institute, West Palm Beach, Florida, United States|Neurostudies.net, Decatur, Georgia, United States|Dekalb Neurology Associates, LLC, Lawrenceville, Georgia, United States|NeuroStudies.net, Lawrenceville, Georgia, United States|Clinical Research Institute, Wichita, Kansas, United States|Monroe Community Hospital, Rochester, New York, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Texas Neurology, P.A., Dallas, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|University of Wisconsin, Department of Surgery, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00916617"
1041,"NCT00605046","Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects","AV151","Terminated","No Results Available","Alzheimer Disease","Drug: SPECT scan","AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects","Institute for Neurodegenerative Disorders","All","50 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","AV151","August 2007","June 2008","June 2008","January 30, 2008",,"October 6, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00605046"
1042,"NCT00315575","Memory Imaging of Normal Aging",,"Completed","No Results Available","Alzheimer's Disease","Procedure: BOLD and Perfusion brain MRI","identification of consistent patterns of variance in brain function in subjects at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk","National Institute on Aging (NIA)","All","25 Years to 65 Years   (Adult, Older Adult)",,"90","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IA0092|5K23AG024062-02","August 2005","July 2008","July 2008","April 18, 2006",,"January 26, 2009","Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT00315575"
1043,"NCT00657813","Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition",,"Terminated","No Results Available","Alzheimer Disease","Drug: MNI-330 as a brain SPECT tracer of Beta-Amyloid","The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-330.","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","All","50 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-330-01","March 2008","September 30, 2008","September 30, 2008","April 14, 2008",,"April 3, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00657813"
1044,"NCT00582127","Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.",,"Completed","No Results Available","Alzheimer's Disease",,"Signal to noise ratio (SNR) of ERPs|Patient tolerance of the COGNISION(TM) system.","Neuronetrix, Inc.|University of Kentucky","All","60 Years to 85 Years   (Adult, Older Adult)",,"50","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","VAL-UK-01","January 2008","November 2010","November 2010","December 28, 2007",,"December 24, 2010","Sanders Brown Center for Aging, Neurology Dept., Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00582127"
1045,"NCT00480870","The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients","ACHALZSLEEP","Completed","No Results Available","Alzheimer Disease|Sleep Apnea, Obstructive","Drug: donepezil|Drug: Placebo","Polysomnography parameters: sleep structure, respiratory, limb movements|Brain magnetic resonance imaging|laboratory tests: hematological evaluation, creatinine, vitamin B12-folic acid, thyroid hormones, GOT, GPT, GGT, bilirubin, fasting glycemia, venereal disease research test and urine sediment|electroencephalogram|Mini-mental state examination|IDATE|Frequency bands of scalp EEG areas: overall (average of all electrodes), frontal (F3, F4, F7, F8, Fz), temporal (T3, T4, T5, T6), parietal (P3, P4, Pz), central (C3, C4, Cz), and occipital (O1, O2, Oz).|ADAS-cog scores|Clinical Dementia Rating|EEG slowing ratio","Associacao Fundo de Incentivo a Psicofarmcologia|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","CEP nº051/99","April 1999",,"January 2005","May 31, 2007",,"December 4, 2007","Instituto do Sono, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT00480870"
1046,"NCT01993628","Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))",,"Unknown status","No Results Available","Alzheimer's Disease|Lewy Body's Dementia","Other: Rey figure test|Other: MRI","Score obtained at the Rey figure test with a planning strategy help by LBD patients compared to the score obtained by AD patients.","University Hospital, Strasbourg, France","All","45 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","5565","October 2013","November 2016","November 2016","November 25, 2013",,"November 25, 2013","Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT01993628"
1047,"NCT00438724","Couples Coping With Alzheimer's Disease",,"Unknown status","No Results Available","Aging|Alzheimer Disease|Dementia","Behavioral: Information, counseling and support","Changes in dyadic (couple) adjustment|depression|Level of anxiety|satisfaction with social support","Alzheimer's Association|National Institute on Aging (NIA)","All","21 Years to 90 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IA0103|ZEN-04-1011","November 2004",,"November 2007","February 22, 2007",,"September 20, 2007","Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00438724"
1048,"NCT03046121","A Family-centered Intervention for Acutely-ill Persons With Dementia",,"Recruiting","No Results Available","Alzheimer Disease","Behavioral: Family-centered Function-focused Care (Fam-FFC)","physical function|functional performance|Physical activity|Delirium occurrence|Delirium severity|Behavior|Mood|Preparedness for caregiving|Caregiver Strain|Caregiver Burden|Desire to Institutionalize","Penn State University|National Institutes of Health (NIH)","All","65 Years and older   (Older Adult)","Not Applicable","438","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","1R01AG054425-01A1","November 6, 2017","July 31, 2021","February 28, 2022","February 8, 2017",,"January 17, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03046121"
1049,"NCT00034567","Healthy Aging and Memory Study",,"Completed","No Results Available","Alzheimer Disease",,,"National Institute on Aging (NIA)","All","75 Years and older   (Older Adult)",,"650","NIH","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","IA0032",,,,"May 1, 2002",,"September 18, 2007","University of Alabama, Birmingham, Birmingham, Alabama, United States|Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford/Va Aging Clinical Research Center, Palo Alto, California, United States|University of California, Davis, Sacramento, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Boca Raton, Florida, United States|Baumel-Eisner Ft Lauderdale, Ft Lauderdale, Florida, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Memory Disorders, Miami Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, Miami Beach, Miami Beach, Florida, United States|University of South Florida, Tampa, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Michigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, United States|Mayo Alzheimer's Disease Center, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Las Vegas, Nevada, United States|New York University School of Medicine, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Memorial Hospital of Rhode Island (Brown University), Pawtucket, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00034567"
1050,"NCT00021723","Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Biological: AN-1792 also known as AIP-001",,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Wyeth is now a wholly owned subsidiary of Pfizer","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AN-1792-201","September 2001",,"September 2003","August 6, 2001",,"September 24, 2009","Pivotal Research Centers, Peoria, Arizona, United States|21st Century Neurology, Phoenix, Arizona, United States|California Clinical Trials, Beverly Hills, California, United States|UCSD Medical Center, La Jolla, California, United States|Pharmacology Research Institute, Northridge, California, United States|Baumel-Eisner Neuromedical Institute, Bay Harbor Islands, Florida, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00021723"
1051,"NCT00172900","MRS and DTI of White Matter in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease|Vascular Dementia",,,"National Taiwan University Hospital","All","55 Years to 95 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","9461700320","June 2005",,,"September 15, 2005",,"December 21, 2005","Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00172900"
1052,"NCT00479219","Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients",,"Completed","No Results Available","Alzheimer Disease","Drug: GSI-953|Other: Placebo","We will assess the pharmacodynamics (PD) of biomarkers amyloid beta 40 and 42 in CSF, following single oral doses of GSI-953 in healthy young and Alzheimer's Patients.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3183A1-103","May 2007","October 2007","October 2007","May 28, 2007",,"July 10, 2008","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00479219"
1053,"NCT04118985","Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease",,"Enrolling by invitation","No Results Available","Cognitive Symptom|Pre Senile Dementia|Alzheimer Disease","Behavioral: Cognitive rehabilitation and health behavior change intervention|Behavioral: Self-implementation","Everyday Compensation Questionnaire|Lifestyle Activities Questionnaire|BrainHQ|Physical Activities Questionnaire|Mindful Attention Awareness Scale|Everyday Cognition|Quality of Life (in aging and cognitive health)|Psychological well-being|Centers for Epidemiological Studies - Depression|Cognitive measure of memory|cognitive measure of executive functioning|cognitive measure of verbal fluency|cognitive measure of visual scanning speed|cognitive measure of response inhibition","Mayo Clinic","All","50 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","19-006676","October 10, 2019","October 30, 2020","October 30, 2020","October 8, 2019",,"October 8, 2019","Mayo Clinic, Scottsdale, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04118985/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04118985"
1054,"NCT00239759","MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology",,"Completed","No Results Available","Alzheimer's Disease",,,"National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)",,"2000","NIH","Observational",,"IA0085|2R01AG0902911-A2","September 2002",,"June 2008","October 17, 2005",,"February 25, 2009","University of Alabama, Birmingham, Alabama, United States|Sun Health Research Institute, Sun City, Arizona, United States|Rancho Los Amigos National Rehabilitation Center/University of Southern California, Downey, California, United States|University of California, Davis, Sacramento, California, United States|Howard University, Washington, District of Columbia, United States|University of Miami School of Medicine, Miami Beach, Florida, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Pacific Health Research Institute, Honolulu, Hawaii, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Cornell Medical University, New York City, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|University of British Columbia, Vancouver, British Columbia, Canada|Technical University of Munich, Munich, Germany|G. Papanicolaou Hospital, Exholi Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT00239759"
1055,"NCT00006187","The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer Disease","Drug: Investigational drug",,"Merck Sharp & Dohme Corp.|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0025",,"June 2005","June 2005","August 28, 2000",,"December 11, 2009","Pivotal Research Centers, Peoria, Arizona, United States|California Clinical Trials, Beverly Hills, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Daniel Grosz MD, Northridge, California, United States|Pharmacology Research Institute, Riverside, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Headache Clinic, San Francisco, California, United States|Yale University, Alzheimer's Disease ResearchUnit, New Haven, Connecticut, United States|New England Center for Headache, Stamford, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Florida, United States|ICSL Clinical Studies, Fort Myers, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft Lauderdale, Florida, United States|ICSL Clinical Studies, Melbourne, Florida, United States|ICSL Clinical Studies, Sarasota, Florida, United States|ICSL Clinical Studies, St Petersburg, Florida, United States|Meridien Research, St Petersburg, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Palm Beach Neurological Center, West Palm Beach, Florida, United States|Chicago Center for Clinical Research, Chicago, Illinois, United States|ICSL Clinical Studies, South Yarmouth, Massachusetts, United States|Las Vegas Center for Clinical Research, Las Vegas, Nevada, United States|Nathan Klein Institute, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Pahl Brain Associates, P.C., Oklahoma City, Oklahoma, United States|Clinical Pharmaceutical Trials, Tulsa, Oklahoma, United States|Pacific NW Clinical Research Center, Portland, Oregon, United States|Institute for Advanced Clinical Research, Elkins Park, Pennsylvania, United States|ICSL Clinical Studies, Philadelphia, Pennsylvania, United States|ICSL Clinical Studies, East Providence, Rhode Island, United States|Pharmacology Research Clinic, Salt Lake City, Utah, United States|Seattle Clinical Research Center, Seattle, Washington, United States|Froedtert Lutheran Memorial Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00006187"
1056,"NCT00380276","Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol",,"Terminated","No Results Available","Alzheimer's Disease","Drug: MPC-7869","Primary Safety","Myrexis Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MPC-7869-05-009","September 2006",,"December 2008","September 25, 2006",,"August 5, 2008","Alabaster, Alabama, United States|Huntsville, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Irvine, California, United States|Lafayette, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Rancho Mirage, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Vista, California, United States|Danbury, Connecticut, United States|Darien, Connecticut, United States|New Haven, Connecticut, United States|Washington D.C, District of Columbia, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Ft Meyers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Glen Burnie, Maryland, United States|Boston, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Grand Rapids, Michigan, United States|Rochester, Minnesota, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Kenilworth, New Jersey, United States|Morristown, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Elmsford, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Centerville, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburg, Pennsylvania, United States|Scotland, Pennsylvania, United States|East Providence, Rhode Island, United States|Beaufort, South Carolina, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Virginia Beach, Virginia, United States|Middleton, Wisconsin, United States|Milwaukee, Wisconsin, United States|Winnepeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00380276"
1057,"NCT02245568","Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)",,"Terminated","No Results Available","Alzheimer's Disease|Behavioral Variant Frontotemporal Dementia","Drug: TRx0237","Number of participants with serious and non-serious adverse events|Change from Baseline in laboratory test values|Change from Baseline in vital signs|Change from Baseline in electrocardiograms","TauRx Therapeutics Ltd","All","Child, Adult, Older Adult","Phase 3","913","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRx-237-020","August 2014","May 2017","May 2017","September 19, 2014",,"May 18, 2018","Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States|Southern California Research, LLC, Fountain Valley, California, United States|Feldman, Robert MD, Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|The Shankle Clinic, Newport Beach, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Memory and Aging Centre, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Mile High Research Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|CNS Healthcare, Inc, Jacksonville, Florida, United States|Miami Research Associates, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research, LLC - North Clinic, The Villages, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Mayo Clinic, Alzheimer's Disease Research Center, Rochester, Minnesota, United States|Neurological Research Center - Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Memory Enhancement Center of America, Inc, Eatontown, New Jersey, United States|The Atlantic Neuroscience Institute, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|SPRI, Brooklyn, New York, United States|Columbia University Taub Institute, New York, New York, United States|Research Foundation for Mental Hygiene, Inc., Orangeburg, New York, United States|UNC Department of Neurology, Physicians Office Building, Chapel Hill, North Carolina, United States|Clinical Trials of America, Inc, Winston-Salem, North Carolina, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|University Hospitals Case Medical Center, Neurology Clinical Trials Unit, Cleveland, Ohio, United States|Rivers Wellness and Research Institute, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, United States|RI Hospital, Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Division of Rehabilitation and Aged Care, Hornsby, New South Wales, Australia|Southern Neurology Pty Limited, Kogarah, New South Wales, Australia|Neuroscience Research Australia, Randwick, New South Wales, Australia|Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia|Royal Adelaide Hospital Memory Trials Centre, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|McCusker Alzheimer's Research Foundation Inc, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research Pty Ltd, Subiaco, Western Australia, Australia|Hospital Brussels Department of Neurology, Bruxelles, Belgium|University Hospital Ghent Department of Neurology, Ghent, Belgium|Jessa Hospital, Hasselt, Belgium|GZA Sint-Augustinus, Wilrijk, Belgium|Heritage Medical Research Clinic, Calgary, Alberta, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville Inc, Kentville, Nova Scotia, Canada|Geriatric Clinical Trials Group, St. Joseph's Health Care, Parkwood Hospital Site, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Alzheimer Disease Research Unit, Verdun, Quebec, Canada|University Hospital Centre Zagreb, Department of Neurology, Zagreb, Croatia|University Psychiatric Hospital Vrapče, Zagreb, Croatia|University of Eastern Finland, Brain Research Unit Mediteknia, Kuopio, Finland|Clinical Research Services Turku (CRST), Turku, Finland|Hôpitaux Civils de Colmar, Colmar Cedex, France|Hôpital La Grave, Toulouse, France|Hôpital de Charpennes, Villeurbanne, France|Charité, University Medicine Berlin, CBF, Neurology, Berlin, Germany|Arzeneimittelforschung Leipzig GmbH, Leipzig, Germany|Dong-A Medical Center, Busan, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University Kuala Lumpur Royal College of Medicine, Ipoh, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Alzheimer Research Center Amsterdam, Amsterdam, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|State Budgetary Healthcare Institution of Sverdlovsk region ""Sverdlovsk Regional Clinical Psychiatric Hospital"", Ekaterinburg, Russian Federation|Non-governmental Healthcare Institution ""Central Clinical Hospital #6 of the JSC ""Russian Railways"", Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Gerontopsychiatry department, Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|City Clinical Hospital #34, City Scientific Practical Neurological Center, Novosibirsk, Russian Federation|City Geriatric Medical and Social Center, Saint Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n. a. V.M. Bekhterev, Saint Petersburg, Russian Federation|National University Hospital (NUH), Singapore, Singapore|National Neuroscience Institute (NNI), Singapore, Singapore|Fundació ACE, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|NHS Grampian, OAP Directorate, Aberdeen, United Kingdom|RICE - The Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust (BHSCT), Belfast, United Kingdom|The Barberry Centre, Birmingham, United Kingdom|MAC Clinical Research Ltd, Blackpool, United Kingdom|MAC Clinical Research Ltd, Cannock, United Kingdom|Sussex Partnership NHS Foundation Trust, Cognitive Treatment and Research Unit, Crowborough, United Kingdom|St Margaret's Hospital Mental Health Unit, Epping, United Kingdom|Cognition Health Ltd, Guildford, United Kingdom|MAC Clinical Research Ltd, Leeds, United Kingdom|Cognition Health Ltd., London, United Kingdom|Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, United Kingdom|Leonard Watson Experimental Neurology Centre, London, United Kingdom|MAC Clinical Research Ltd, Manchester, United Kingdom|Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom|Redwoods Centre, Shrewsbury, United Kingdom|Wessex Neurological Centre, Southampton General Hospital, Southampton, United Kingdom|Memory Assessment and Research Centre (MARC), Southampton, United Kingdom|Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02245568"
1058,"NCT00499200","Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy",,"Completed","No Results Available","Alzheimer's Disease","Drug: SRA-444","To assess the safety and tolerability of ascending single oral doses of SRA-444 in healthy elderly subjects and subjects with Alzheimer's disease|To obtain PK profiles and determine the level and duration of 5-HT1A RO of SRA-444 by PET","Wyeth is now a wholly owned subsidiary of Pfizer","All","60 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3197A1-1104","October 2007","June 2008","June 2008","July 11, 2007",,"July 9, 2008","Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00499200"
1059,"NCT01481558","Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease",,"Completed","Has Results","Apathy|Alzheimer's Disease","Device: Transcranial direct current stimulation","Apathy Symptoms","University of Sao Paulo","All","50 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","0679/11","January 2012","May 2012","May 2012","November 29, 2011","January 9, 2014","January 9, 2014","University of São Paulo Medical School, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01481558"
1060,"NCT03412604","Effect of Modulating Gamma Oscillations Using tACS",,"Recruiting","No Results Available","Alzheimer Disease","Device: Transcranial Alternating Current Stimulation (tACS)","Incidence of Treatment-Emergent Adverse Events|PET amyloid burden|PET tau deposition|PET Microglia activation","Beth Israel Deaconess Medical Center|Defense Advanced Research Projects Agency|Massachusetts General Hospital","All","45 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P000648","August 2, 2018","May 15, 2019","May 15, 2019","January 26, 2018",,"September 11, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03412604"
1061,"NCT01585272","Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia",,"Completed","Has Results","Alzheimer's Dementia","Drug: ENA713","Number of Patients With Adverse Events, Serious Adverse Events, and Death|Change From Baseline in Mini-Mental Status Examination (MMSE)|Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|The Discontinuation Rate Due to the Treatment Switching From Oral Capsule to Rivastigmine Patch Treatment|Percentage of Patients Successfully Titrated to Rivastigmine Patch 10 cm^2","Novartis Pharmaceuticals|Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","121","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CENA713DTW04","August 2012","June 2015","June 2015","April 25, 2012","November 10, 2016","April 18, 2018","Novartis Investigative Site, Taichung, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01585272"
1062,"NCT03422250","Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia","NetCogBs","Completed","No Results Available","Alzheimer Disease|Frontotemporal Dementia, Behavioral Variant","Device: transcranial direct current stimulation (tDCS)","Change from baseline in clinical disease severity|Change from baseline in behavioral symptom severity|Change from baseline in functional connectivity|Change from baseline in perfusion|Change from baseline in cognition: memory|Change from baseline in cognition: language|Change from baseline in cognition: executive function|Change from baseline in cognition: visuospatial function|Change from baseline in cognition: emotion recognition|Change from baseline in structural connectivity","IRCCS Centro San Giovanni di Dio Fatebenefratelli","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","GR-2011-02349787","June 8, 2015","November 3, 2018","November 3, 2018","February 5, 2018",,"November 20, 2018","IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT03422250"
1063,"NCT03564964","Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease","SUVN-502","Available","No Results Available","Alzheimer Disease|Dementia|Cognition Disorders","Drug: SUVN-502",,"Suven Life Sciences Limited","All","50 Years to 85 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"EAP1502HT6",,,,"June 21, 2018",,"September 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03564964"
1064,"NCT02109705","Porphyromonas Gingivalis and Alzheimer`s Disease","PGNEURO","Unknown status","No Results Available","Alzheimer`s Disease|Dementia|Periodontitis",,"Cmax Antibody Levels against Gingipains|Cmax Beta-Amyloid","University Hospital Muenster|University of Bern","All","40 Years to 70 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","PG001","March 2014","February 2015",,"April 10, 2014",,"December 9, 2014","Department of Periodontology, Muenster, Germany",,"https://ClinicalTrials.gov/show/NCT02109705"
1065,"NCT00287742","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease|Dementia","Drug: risperidone","Change in Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) psychotic symptom cluster score from baseline and intermediate visits to study end (Week 9) compared with placebo.|Changes in BEHAVE-AD total, subscales and items scores, changes in CMAI aggressiveness and non-aggressiveness item scores and changes in CGI-C from baseline and intermediate visits to study end (Week 9) compared with placebo. Safety evaluations.","Janssen Pharmaceutical K.K.","All","Child, Adult, Older Adult","Phase 3","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR003172","March 2002",,"March 2003","February 7, 2006",,"May 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00287742"
1066,"NCT02997982","Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease","VALZ-Pilot","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex","Drug: Valaciclovir 500Mg Tablet","Cerebrospinal fluid (CSF) Total Tau|Cerebrospinal fluid (CSF) Neurofilament light chain (NFL)|Cerebrospinal fluid (CSF) phosphorylated Tau (p-Tau)|Cerebrospinal fluid (CSF) Amyloid beta 1-42|PET/CT: [18F]-FHBG accumulation within the central nervous system (CNS)|PET/CT: Location of [18F]-FHBG accumulation|PET/CT: [18F]-FHBG accumulation|Mini Mental State Examination - Swedish Revision (MMSE-SR)|Cerebrospinal fluid (CSF) acyclovir concentration|Cerebrospinal fluid (CSF) 9-carboxymethoxymethylguanine (CMMG) concentration|Serum acyclovir concentration|Serum 9-carboxymethoxymethylguanine (CMMG) concentration|Proportion completing the [18F]-FHBG-PET/CT investigations|Proportion completing the 28 days treatment with valaciclovir at specified doses","Hugo Lovheim|Umeå University","All","65 Years and older   (Older Adult)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UmU-2016-390-31M|2016-002317-22","December 2016","April 2019","April 2019","December 20, 2016",,"May 2, 2018","Geriatric Centre, University Hospital in Umeå, Umeå, Västerbotten, Sweden",,"https://ClinicalTrials.gov/show/NCT02997982"
1067,"NCT03384043","Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment, Mild|Dementia, Mild","Behavioral: Smartphone Personal Assistant|Behavioral: Implementation Intention","Objective Prospective Memory Performance|Quality of Life - Positive Affect and Well-Being|Quality of Life - Ability to Participate in Social Roles and Activities|Quality of Life - Satisfaction with Social Roles and Activities|Quality of Life - Cognitive Function|Subjective Memory Performance Questionnaire|Perceived Memory Structured Interview|Use of Technology/Strategy|Instrumental Activities of Daily Living|Smartphone Acceptability/Usability Scale|Training Duration","Baylor University|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","52","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","017-327|1R21AG053161-01A1","January 8, 2018","December 2019","December 2019","December 27, 2017",,"November 12, 2018","Baylor Scott & White Medical Center, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03384043"
1068,"NCT00151502","To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.",,"Completed","No Results Available","Alzheimer's Disease","Drug: Atorvastatin","If the results of this study demonstrate efficacy and lead to the approval by the FDA of atorvastatin for use in humans for the treatment of Alzheimer's disease, this would be available as an additional treatment option for patients.|If the results of this study demonstrate efficacy and lead to the approval by the Food and Drug Administration of atorvastatin for use in humans, subject activities of daily living are being assessed.","Pfizer","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A2581078","November 2002",,"July 2007","September 9, 2005",,"July 11, 2008","Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Laguna Hills, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Fort Meyers, Florida, United States|Pfizer Investigational Site, Miami Beach, Florida, United States|Pfizer Investigational Site, Pompano Beach, Florida, United States|Pfizer Investigational Site, St Petersburg, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Fort Wayne, Indiana, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Dartmouth, Massachusetts, United States|Pfizer Investigational Site, W Yarmouth, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Jamesburg, New Jersey, United States|Pfizer Investigational Site, Princeton, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Troy, New York, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Jenkintown, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Madison, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Wichita Falls, Texas, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, East Gosford, New South Wales, Australia|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, Daw Park, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Ballarat, Victoria, Australia|Pfizer Investigational Site, West Heidelberg, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Wein, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Verdun, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Aarhus, Denmark|Pfizer Investigational Site, Copenhagen, Denmark|Pfizer Investigational Site, Hillerod, Denmark|Pfizer Investigational Site, Rudkobing, Denmark|Pfizer Investigational Site, Svendborg, Denmark|Pfizer Investigational Site, Bad Honnef, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Rosebank, Gauteng, South Africa|Pfizer Investigational Site, Willows, Gauteng, South Africa|Pfizer Investigational Site, Pinetown, Kwazulu Natal, South Africa|Pfizer Investigational Site, Belleville, South Africa|Pfizer Investigational Site, Westville, South Africa|Pfizer Investigational Site, Terrassa, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Linkoeping, Sweden|Pfizer Investigational Site, Malmoe, Sweden|Pfizer Investigational Site, Moelndal, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uddevalla, Sweden|Pfizer Investigational Site, Bradford, England, United Kingdom|Pfizer Investigational Site, Stirling, Stirlingshire, United Kingdom|Pfizer Investigational Site, Swindon, Wiltshire, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Penarth, United Kingdom|Pfizer Investigational Site, Southhampton, United Kingdom|Pfizer Investigational Site, Stirling, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00151502"
1069,"NCT03313518","Therapeutic Role of Transcranial DCS in Alzheimer",,"Completed","No Results Available","Alzheimer Disease","Device: tDCS|Device: Sham tDCS","Change in measurement of improvement in cognitive function by using MMSE|Change in measurement of improvement in cognitive function by cornell Scale|The change of measurement of brain damage biomarkers modulation in plasma (i.e. Tau, Beta-Amyloid, Lipid Peroxidation) cornell Scale","Assiut University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","tDCS in Alzheimer","August 12, 2016","October 10, 2017","October 10, 2017","October 18, 2017",,"October 18, 2017",,,"https://ClinicalTrials.gov/show/NCT03313518"
1070,"NCT01920672","Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Timed Planned Activity|Behavioral: Home Safety and Education Program","total sleep time|Wake after sleep onset","Johns Hopkins University|National Institute of Nursing Research (NINR)","All","60 Years to 100 Years   (Adult, Older Adult)","Not Applicable","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","NA_00088139|P30NR014131","September 2013","June 2015","June 2015","August 12, 2013",,"December 12, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01920672"
1071,"NCT03851523","Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.",,"Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Subjective Cognitive Decline","Other: No intervention","Subjective Cognitive Decline Questionnaire (my-Cog)|Subjective Cognitive Decline Questionnaire (their-Cog)","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","45 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ALFAcognition/BBRC2017","February 12, 2018","December 31, 2020","December 31, 2021","February 22, 2019",,"February 22, 2019","Barcelonabeta Brain Research Center, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT03851523"
1072,"NCT00795730","Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789",,"Terminated","No Results Available","Alzheimer Disease|Healthy Subjects","Drug: NSA-789|Other: placebo","Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability|Pharmacokinetic and pharmcodynamic parameters","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3230A1-1002","January 2009","June 2009","June 2009","November 21, 2008",,"July 21, 2009","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00795730"
1073,"NCT00338117","Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Galantamine hydrobromide","The primary outcomes included evaluations by EURO-ADAS cognitive score, CIBIC Plus, and NOSGER at 6 months.|EURO-ADAS non-cognitive score; MMSE; Short Cognitive Performance Test (SKT) sub-set 6; Neuropsychological Assessment Battery (NAB); incidence of adverse events, changes in laboratory measures, results of physical exams, and results of 12-lead ECG.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Shire","All","45 Years and older   (Adult, Older Adult)","Phase 3","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR005884","August 1995",,"May 1997","June 20, 2006",,"April 28, 2010",,,"https://ClinicalTrials.gov/show/NCT00338117"
1074,"NCT03928405","Effect of Virtual Reality on Balance and Gait Speed With Alzheimer's Dementia",,"Completed","No Results Available","Alzheimer's Dementia","Other: Exercises with Nintendo Wii virtual reality device","The Tinetti Gait and Balance Test (TGBT)|The 5-times Sit to Stand Test|The Gait Speed Measurement Test (GSMT)|Mini Mental State Test","Kırıkkale University","All","65 Years to 80 Years   (Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Alzheimer,Virtual Reality","January 1, 2018","April 30, 2018","June 6, 2018","April 26, 2019",,"April 26, 2019","Kirikkale University, Kirikkale, Fabrikalar Street, Turkey|Kirikkale Universtiy, Kırıkkale, Fabrikalar Street, Turkey",,"https://ClinicalTrials.gov/show/NCT03928405"
1075,"NCT03814382","Acupuncture to Reduce Anxiety in Alzheimer's Disease (AD) and AD Related Dementias",,"Recruiting","No Results Available","Alzheimer's Dementia With Behavioral Disturbance","Device: Acupuncture needle","Heart Rate Variability as measured by BioStamp|Galvanic Skin Response","Massachusetts General Hospital","All","55 Years to 95 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018P002480","March 11, 2019","June 30, 2020","June 30, 2020","January 24, 2019",,"April 18, 2019","Clinical Translational Research Unit, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03814382"
1076,"NCT00965835","Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome",,"Unknown status","No Results Available","Down Syndrome|Alzheimer's Disease",,,"National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)",,"40","NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IA0166|1R21AG030681-01A2","August 2009","May 2011","May 2011","August 26, 2009",,"December 29, 2009","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00965835"
1077,"NCT03903211","Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease",,"Recruiting","No Results Available","Cognitively Normal|Mild Cognitive Impairment|Alzheimer Disease","Drug: [18F]PI-2620","Cross-sectional PI-2620 uptake measured by standard uptake value ratio (SUVR)|Changes of PI-2620 uptake over time measured by standard uptake value ratios (SUVR)|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and indices of structural MRI","Jae Seung Kim|Asan Medical Center","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI-18002","April 9, 2019","February 28, 2021","February 28, 2021","April 4, 2019",,"May 31, 2019","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03903211"
1078,"NCT00031018","Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha",,"Unknown status","No Results Available","Memory Disorders|Alzheimer's Disease","Drug: Aricept|Drug: IFN-alpha2A",,"National Center for Research Resources (NCRR)|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2",,"NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","NCRR-M01RR02558-0120",,,,"February 22, 2002",,"February 5, 2008","University of Texas - Houston, Gerontology Center of the UTMSI, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00031018"
1079,"NCT01073228","Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Central Nervous System Diseases|Cognition","Drug: EVP-6124|Drug: Placebo","Alzheimer's Disease Assessment Scale-Cognitive subscale-13 (ADAS-cog-13)|Alzheimer's Disease Assessment Scale-Cognitive subscale-11|Controlled Oral Word Association Test|Category Fluency Test|Clinical Dementia Rating Scale Sum of Boxes|Alzheimer's Disease Cooperative Study-Activities of Daily Living|Neuropsychiatric Inventory|Mini-Mental State Exam","FORUM Pharmaceuticals Inc|INC Research Limited","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EVP-6124-010","April 2010","November 2011","February 2012","February 23, 2010",,"April 25, 2014","HOPE Research Institute, Phoenix, Arizona, United States|Catalina Research Institute, Chino, California, United States|ATP Clinical Research, Costa Mesa, California, United States|University of California, Irvine, Orange, California, United States|Radiant Research, Santa Rosa, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Advanced Bio Behavioral Sciences Inc., Elmsford, New York, United States|University of Rochester Medical Center at MCH, Rochester, New York, United States|Columbus Research and Wellness Institute, Columbus, Ohio, United States|Summit Research Network, Portland, Oregon, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Clinical Site 1, Bucharest, Romania|Clinical Site 2, Bucharest, Romania|Clinical Site 3, Bucharest, Romania|Clinical Site 4, Bucharest, Romania|Clinical Site 5, Bucharest, Romania|Iasi, Romania|Oradea, Romania|Tirgu Mures, Romania|Kazan, Russian Federation|Clinical Site 1, Moscow, Russian Federation|Clinical Site 2, Moscow, Russian Federation|Saratov, Russian Federation|Clinical Site 3, St Petersburg, Russian Federation|Clinical Site 4, St Petersburg, Russian Federation|Clinical Site 1, St. Petersburg, Russian Federation|Clinical Site 2, St. Petersburg, Russian Federation|Voronezh, Russian Federation|Yekaterinburg, Russian Federation|Clinical site 1, Belgrade, Serbia|Clinical Site 2, Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Dnipropetrovs'k, Ukraine|Donets'k, Ukraine|(1), Kyiv, Ukraine|(2), Kyiv, Ukraine|Odesa, Ukraine|Simferopol, Ukraine|Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01073228"
1080,"NCT02667665","Verification Study and Reactivity Study for the Validity of QuQu Scale","QuQu","Completed","No Results Available","Alzheimer's Disease Dementia|Cognitive Concern Without Dementia",,"QuQu scale candidate|Mini-Mental State Examination (MMSE)|NPI-Caregiver Distress. Scale(NPI-D)|Disability Assessment for Dementia (DAD)|Clinical Dementia Rating","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Daiichi Sankyo Co., Ltd.","All","Child, Adult, Older Adult",,"240","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","TRIAD1412","February 19, 2016","November 15, 2016","November 15, 2016","January 29, 2016",,"June 2, 2017","Kagawa University School of Medicine, Kitagun, Kagawa Prefecture, Japan",,"https://ClinicalTrials.gov/show/NCT02667665"
1081,"NCT02814045","Role of Hypoxia Ans Sleep Fragmentation in Alzheimer's Disease. and Sleep Fragmentation.",,"Recruiting","No Results Available","Alzheimer's Disease|Obstructive Sleep Apnea",,"Change from baseline in cognitive scores on the Disease Assessment Scale-cognitive at 12 months in patients with mild AD with and without OSA.|Differential pattern of biomarkers at baseline in in patients with mild AD with and without OSA.","Sociedad Española de Neumología y Cirugía Torácica","All","50 Years to 90 Years   (Adult, Older Adult)",,"144","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","464/C/2014","November 2015","June 2019","June 2019","June 27, 2016",,"April 11, 2019","Hospital santa Maria, Lleida, Catalonia, Spain|Hospital Santa Maria Lleida, Lleida, Spain",,"https://ClinicalTrials.gov/show/NCT02814045"
1082,"NCT01421420","Alzheimer's Disease Core Center","ADCC","Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Memory Disorders",,"Neuropsychological Test Scores|Neurological Exam|Brain Tissue","University of Arizona|Banner Health|Barrow Neurological Foundation|Mayo Clinic|National Institute on Aging (NIA)|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)",,"900","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P30AG019610","July 2001","December 2024","July 2025","August 22, 2011",,"June 12, 2015","University of Arizona, University Medical Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01421420"
1083,"NCT03140865","Wake Forest Alzheimer's Disease Clinical Core","ADCC","Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Prediabetic State",,"Change in performance on cognitive measures.|Change in biomarker levels in cerebrospinal fluid (CSF).|Change in brain volumes on magnetic resonance imaging (MRI).","Wake Forest University Health Sciences","All","55 Years and older   (Adult, Older Adult)",,"850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00025540","January 2014","January 2021","June 2021","May 4, 2017",,"August 26, 2019","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03140865"
1084,"NCT01400542","Sleep Apnea in Early to Mid-Stage Alzheimer's Disease","AZAP","Terminated","No Results Available","Early Onset Alzheimer Disease|Alzheimer Disease|Obstructive Sleep Apnea Syndromes","Device: CPAP Treatment|Device: No treatment","Impact of the CPAP treatment on cognitive functions|Rate of apnea/hypopnea events per hour (AHI/h)|Impact of CPAP treatment on neuropsychological evaluation parameters|Impact of the CPAP treatment on Quality of Life","Centre Hospitalier Universitaire de Saint Etienne|Association Lyonnaise de Logistique Posthospitalière","All","65 Years and older   (Older Adult)",,"22","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1002050|2010-A01003-36","December 2010","June 2014","June 2014","July 22, 2011",,"August 11, 2016","CHU de Saint-Etienne, Saint-etienne, France",,"https://ClinicalTrials.gov/show/NCT01400542"
1085,"NCT02052947","Co-LEsions in Alzheimer Disease and Related Disorders","CLEM","Recruiting","No Results Available","Alzheimer's Disease|Cerebrovascular Disease|Lewy Body Disease","Radiation: SPECT-DaTscan","Disability progression|Neuropsychological inventory|NeuroPsychiatric inventory|Clinical/serum markers","Hospices Civils de Lyon","All","70 Years and older   (Older Adult)","Not Applicable","214","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2013.795","January 2014","July 2018","October 2020","February 3, 2014",,"August 23, 2017","Hopital Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02052947"
1086,"NCT03069014","Study of LM11A-31-BHS in Mild-moderate AD Patients",,"Recruiting","No Results Available","Mild to Moderate Alzheimer's Disease","Drug: 400mg LM11A-31-BHS|Drug: 800mg LM11A-31-BHS|Drug: Placebos","Number of AEs/SAEs within the 26-week study period|Statistically relevant changes in CSF-Biomarkers between baseline and final visit|Statistically relevant changes in working memory ability between baseline and final visit assessed with the Controlled Oral Word Association Test (COWAT)|Statistically relevant changes in word fluency between baseline and final visit assessed with the Category Fluency Test (CFT)|Statistically relevant changes in processing speed between baseline and final visit assessed with the Coding Test (Subtest of the Wechsler Adult Intelligence Scale)|Statistically relevant changes in executive functions between baseline and final visit assessed with the Digit Span test (Subtest of the Wechsler Adult Intelligence Scale)","PharmatrophiX Inc.|National Institute on Aging (NIA)","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","190","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NSC15001|2015-005263-16|1R01AG051596-01A1","February 15, 2017","October 10, 2019","October 31, 2019","March 3, 2017",,"April 17, 2019","University Hospital Graz, Graz, Styria, Austria|Landeskrankenhaus Hall, Hall in Tirol, Tirol, Austria|Charles University, Praha, Hlavni Mesto Praha, Czechia|Neurology Clinic of Martin Urbanek, Brno, Jihomoravsky Kraj, Czechia|Vestra clinics s.r.o, Rychnov nad Kneznou, Kralovehadrecky Kraj, Czechia|NEUROHK s.r.o, Chocen, Pardubicky Kraj, Czechia|Nordwestkrankenhaus Sanderbusch, Sande, Friesland, Germany|Zentrum für klinische Forschung, Bad Homburg, Hesse, Germany|Studienzentrum Nordwest, Westerstede, Niedersachsen, Germany|Universitätsklinik Magdeburg, Klinik für Neurologie, Magdeburg, Sachsen Anthal, Germany|Sächsisches Krankenhaus Arnsdorf, Arnsdorf, Sachsen, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Chemnitz, Sachsen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Neurologie Sendlinger Strasse Studien- und Gedächtniszentrum München, München, Germany|LMU München Klinik für Psychiatrie und Psychotherapie, München, Germany|Fundació ACE, Barcelona, Catalonia, Spain|Fundación de Gestión Sanitaria del Hospital de la Santa Creu I Sant Pau, C, Barcelona, Catalonia, Spain|Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain|Hospital la Paz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Karolinska University, Stockholm, Stockholms Iän, Sweden",,"https://ClinicalTrials.gov/show/NCT03069014"
1087,"NCT01273272","Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers","CBTAC","Completed","No Results Available","Alzheimer Disease","Behavioral: Comprehensive, CBT-based, multi-component treatment|Behavioral: Treatment as usual","Change from baseline in Geriatric Depression Scale (GDS)|Change from baseline in Neuropsychiatric Inventory (NPI)|Change from baseline in Bayer-Activities of Daily Living (B-ADL)|Change from baseline in Stress Coping Inventory (SCI)|Change from baseline in Apathy Evaluation Scale (AES)|Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)|Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)|Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)|Caregiver: Change from baseline in Short-Form Health Survey (SF-12)|Caregiver: Change from baseline in Zarit Burden Interview (ZBI)|Caregiver: Change from baseline in Stress Coping Inventory (SCI)","University of Zurich|Psychiatric University Hospital, Zurich","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10-130034/1a","February 2011","September 2017","September 2017","January 10, 2011",,"November 6, 2017","Psychiatric University Hospital, Clinic for Geriatric Medicine, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01273272"
1088,"NCT02778581","Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment",,"Unknown status","No Results Available","Cognitive Impairments|Alzheimer Disease","Dietary Supplement: Lipidic Blend 1|Dietary Supplement: Lipidic Blend 2|Dietary Supplement: Placebo","Changes in Mini-Mental State Examination (MMSE) score|Changes in Global Clinical Dementia Rating (CDR) score|Changes in systemic oxidative parameters in periferic blood samples (Nitric Oxyde)|Changes in systemic oxidative parameters in periferic blood samples (Malondialdehyde (MDA))|Changes in beta-amyloid protein concentration|Changes in TAU-Protein concentration|Changes in regular treatment for the cognitive impairment|Changes in dietetic habits|Changes in Barthel score|Changes in Morisky-Green score|changes in weight|Number of adverse events","Team Foods Colombia S.A.|Biopolis S.L.","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","ALZ-OIL.01","March 2016","April 2017","July 2017","May 20, 2016",,"June 3, 2016","Hospital Universitario Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja,, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT02778581"
1089,"NCT01779310","Clinical Pathway for Alzheimer's Disease in China (CPAD)",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Dementia",,"Rate of cognitive assessment administration|Rate of anti-dementia prescription","Peking University|Beijing Novartis Pharma","All","45 Years and older   (Adult, Older Adult)",,"1024","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CENA731DCN01T","November 2012","April 2013","April 2013","January 30, 2013",,"July 25, 2017","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Union Hospital Tongji Mecial College, Huazhong University of Science and Technology, Wuhan, Hebei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Mental Health Center, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China|General Hospital, Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Huanhu Hospital, Tianjin, Tianjin, China|The First Teaching Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Ningbo Kangning Hospital, Ningbo, Zhejiang, China|The First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01779310"
1090,"NCT04021888","The Effects of Exercise Program in Alzheimer's Patients With Mild to Moderate Stage Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease|Aerobic Exercise|Breathing Exercise|Resistance Training","Other: Exercise","Change in cognition|Change in pulmonary functions|Change in respiratory muscle strength|Change in functional capacity|Change in physical performance|Change in sleepiness|Change in quality of life|Change in activities of daily living|Change in depression|Change in muscle strength","Dokuz Eylul University|Sevgi Ozalevli|Gorsev Yener","All","65 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","KELES","July 16, 2018","October 8, 2018","July 30, 2020","July 16, 2019",,"July 16, 2019","Elvan Keleş, İzmi̇r, Turkey",,"https://ClinicalTrials.gov/show/NCT04021888"
1091,"NCT01890343","Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",,"Completed","Has Results","Alzheimer's Disease|Frontotemporal Dementia","Drug: florbetapir 18F|Drug: 18F-FDG","Qualitative Amyloid Image Assessment|Quantitative Amyloid Image Assessment","Avid Radiopharmaceuticals","All","45 Years and older   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-010","September 2009","December 2012","April 2013","July 1, 2013","September 17, 2014","September 29, 2014","Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01890343"
1092,"NCT03184467","Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients",,"Unknown status","No Results Available","Alzheimer Disease","Drug: Normal Saline 0.9%|Drug: GV1001 0.56 mg|Drug: GV1001 1.12 mg","SIB (Severe Impairment Battery)|K-MMSE (Korean-Mini-Mental State Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Box)|NPI (Neuropsychiatric Inventory)|GDS (Global Deterioration Scale)|ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe)|CIBIC-plus (Clinician Interview-Based Impression of Change-Plus)","GemVax & Kael","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KG 6/2016","June 2017","June 2019","June 2019","June 12, 2017",,"June 12, 2017","Hanyang University Guri Hospital, Guri-si, Gyunggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03184467"
1093,"NCT01297218","The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease",,"Completed","No Results Available","Dementia of the Alzheimer's Type","Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells","Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose","Medipost Co Ltd.","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CR-007","February 2011","September 2011","December 2011","February 16, 2011",,"April 23, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01297218"
1094,"NCT02614131","A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)",,"Terminated","Has Results","Healthy|Alzheimer's Disease|Mild Cognitive Impairment","Drug: LY2599666|Drug: Solanezumab|Drug: Placebo SC|Drug: Placebo IV","Number of Participants With One or More Serious Adverse Event (SAE) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part A|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part B|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-∞) of LY2599666 Part A|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 168 Hours (AUC 0-168) of LY2599666 Part B|Plasma Amyloid Beta1-40 (Aβ1-40 ) Concentration Part A|Plasma Amyloid Beta (Aβ1-40 and Aβ1-42) Concentration Part B","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15491|I2L-MC-ALCA","December 2015","December 2016","December 2016","November 25, 2015","September 23, 2019","September 23, 2019","Parexel Early Phase Unit at Glendale, Glendale, California, United States|CRI Lifetree, Marlton, New Jersey, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan",,"https://ClinicalTrials.gov/show/NCT02614131"
1095,"NCT01993836","Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care","MADCO-PC","Completed","No Results Available","Alzheimers Disease|Postoperative Delirium|Post Operative Cognitive Dysfunction","Drug: Total intravenous anesthesia with propofol|Drug: General anesthesia with isoflurane","Assess the correlation between perioperative change in CSF Markers of Alzheimers Disease and perioperative cognitive change.|Continuous cognitive index score change|Assess CSF Markers of Alzheimers Disease|Perioperative CSF Tau/Abeta ratio change","Duke University","All","60 Years and older   (Adult, Older Adult)","Phase 4","191","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Pro00045180","November 2013","January 10, 2019","January 10, 2019","November 25, 2013",,"July 15, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01993836"
1096,"NCT01148498","A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's",,"Completed","No Results Available","Alzheimer's Disease","Drug: solanezumab","Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3)|Mean change in plasma levels of Aβ1-42 after solanezumab infusion|Mean change in plasma levels of Aβ1-40 species after solanezumab infusion|Mean change in plasma levels of modified Aβ species after solanezumab infusion","Eli Lilly and Company","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13572|H8A-MC-LZAT","August 2010","August 2012","August 2012","June 22, 2010",,"September 25, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01148498"
1097,"NCT01190800","Capacity Assessment in Persons With Alzheimer's Disease","MACAP","Completed","No Results Available","Alzheimer's Disease|Capacity to Consent to Treatment|Capacity to Vote|Capacity to Design a Proxy",,,"Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","NI 08009","June 2010","September 2014","September 2014","August 30, 2010",,"October 15, 2014","Hôpital Louis Mourier, Colombes, France",,"https://ClinicalTrials.gov/show/NCT01190800"
1098,"NCT03621839","New CSF Biomarkers for Alzheimer's Disease","BioAD","Recruiting","No Results Available","Alzheimer Disease|Dementia|Neurodegenerative Diseases",,"CSF collection constitution to have samples available for assessing new Alzheimer's biomarker","Central Hospital, Nancy, France","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012-PSS/COLL- LCR/ARMAND/MS","July 12, 2013","December 31, 2050","December 31, 2050","August 9, 2018",,"August 9, 2018","CHRU De Nancy, Nancy, Grand Est, France",,"https://ClinicalTrials.gov/show/NCT03621839"
1099,"NCT00742417","Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid",,"Completed","Has Results","Alzheimer's Disease","Biological: Albutein 5%|Other: Control","Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels.|P-Tau and Tau CSF Levels Throughout the Study.|Aβ1−40 Plasma Levels Before and After Each Study Period (The Genetics Company).|Aβ1−42 Plasma Levels Before and After Each Study Period (The Genetics Company).|Aβ1−42 Plasma Levels Before and After Each Study Period (Innotest).|Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (MMSE, ADAS-Cog, NPS Battery and CSDD)|Change From Baseline to Week 44 in Cognitive, Functional and Neuropsychiatric Scores (ADCS-ADL, NPI, CDR-Sb and ADCS-CGIC).|Magnetic Resonance Imaging (MRI) Structural Changes Variations Versus Baseline.|Variations in Hypoperfusion Based on Single Photon Emission Computed Tomography (SPECT)","Instituto Grifols, S.A.|Grifols Biologicals, LLC","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IG0602","July 2007","February 2011","March 2011","August 27, 2008","June 14, 2016","June 14, 2016","Howard University, Washington, District of Columbia, United States|Mid-Atlantic Geriatric/ARC, Manchester Township, New Jersey, United States|Fundació ACE, Barcelona, Catalunya, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00742417"
1100,"NCT03933696","Light, Metabolic Syndrome and Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Type2 Diabetes","Device: Tailored Lighting Intervention","Sleep disturbance|Metabolic control|Depression|Cognition|Sleep disturbance using actigraphy|Light measurements|Melatonin Levels","Rensselaer Polytechnic Institute|Icahn School of Medicine at Mount Sinai","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Aim 2","April 1, 2019","September 1, 2022","September 1, 2022","May 1, 2019",,"May 13, 2019","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03933696"
1101,"NCT00544856","Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Cognitive Impairment","Behavioral: complex cognitive training","cognition: MMSE, ADAS-cog.|quality of life","Ludwig-Maximilians - University of Munich","All","55 Years to 95 Years   (Adult, Older Adult)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","cogT001","October 2007","October 2008","October 2008","October 16, 2007",,"January 29, 2009",,,"https://ClinicalTrials.gov/show/NCT00544856"
1102,"NCT01979419","Korea Alzheimer's Disease Neuroimaging Initiative","K-ADNI","Active, not recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Subcortical Vascular Dementia",,"Rate of dementia conversion or disease severity worsening, evaluated by neuropsychological, MRI, PET, biomarker indices.|Change from baseline in cognitive, neuroimaging, and biomarker assessments","Korean Alzheimers' Disease Neuroimaing Intitiative","All","50 Years to 80 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HI12C0713","November 2012","October 2020","October 2020","November 8, 2013",,"March 8, 2019","Seong Yoon Kim, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01979419"
1103,"NCT03887923","Vestibular Physical Therapy for People With Alzheimer Disease","VPT in AD","Recruiting","No Results Available","Vestibular Diseases|Alzheimer Disease|Cognitive Impairment","Behavioral: Vestibular Physical Therapy","Tolerability of Vestibular Physical Therapy in people with Alzheimer Disease: number of times modifications are needed to be made|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in balance performance for people with Alzheimer Disease; Gait velocity|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in balance performance for people with Alzheimer Disease: Four Square Step Test|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in balance performance for people with Alzheimer Disease: Mini Balance Evaluation Systems Test|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Montreal Cognitive Assessment|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Money Road Map Test|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Trail Making Test A|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Trail Making Test B|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Digit Span Forward & Backward|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Letter Fluency|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Category Fluency|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Digit Symbol Substitution|Preliminary efficacy of an 8-week home-based Vestibular Physical Therapy program on change in cognitive function for people with Alzheimer Disease: Benton Visual Retention Test","University of Pittsburgh|Johns Hopkins University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY18120038","May 10, 2019","December 31, 2019","December 31, 2019","March 25, 2019",,"July 10, 2019","University of Pittsburgh Alzheimer Disease Research Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03887923"
1104,"NCT00299676","An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period",,"Completed","No Results Available","Alzheimer Disease|Dementia|Galantamine","Drug: Galantamine (Reminyl)","Investigate the change in cognitive functioning, clinical and functional improvement, in patients treated with REMINYL in a naturalistic setting.|Development of information regarding treatment expectations that can be used for communicating with patients and supporters.|Gain usage experience in a clinical practice setting that can be used for communicating treatment expectations to patients and carers.","Janssen-Cilag Pty Ltd","All","Child, Adult, Older Adult",,"61","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR004816","May 2005","March 2008","March 2008","March 7, 2006",,"May 23, 2014","Auckland, Australia|Christchurch Nz, Australia|Hamilton, Australia|Porirua, Australia|Tauranga, Australia",,"https://ClinicalTrials.gov/show/NCT00299676"
1105,"NCT00649220","Memantine and Antipsychotics Use","MemAP","Terminated","Has Results","Alzheimer's Disease","Drug: Memantine","Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.|Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.|Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.|Change of ""Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]"" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia|Change of ""Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]"" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression|Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.|Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20|Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.","Merz Pharmaceuticals GmbH","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRZ 90001-0716/1|2007-004489-41","July 2008","May 2009","June 2009","April 1, 2008","September 13, 2011","September 26, 2011","Alexianer Hospital, Krefeld, North-Rhine-Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT00649220"
1106,"NCT00000173","Memory Impairment Study (Mild Cognitive Impairment Study)",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil|Drug: Vitamin E",,"National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3",,"NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0011|3U01AG010483-08S2","March 1999","January 2004","January 2004","November 1, 1999",,"December 11, 2009","Barrow Neurological Group, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|East Bay Institute, Martinez, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Affiliated Research Instiute, San Diego, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Ft. Lauderdale, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, MiamiBeach, Miami Beach, Florida, United States|University of Miami, Port Charlotte, Florida, United States|University of South Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta VA Medical Center, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memory Disorders Institute, Lakehurst, New Jersey, United States|Princeton Biomedical Research, PA, Princeton, New Jersey, United States|ClinSearch, Inc., Summit, New Jersey, United States|Princeton Biomedical - Toms River, Toms River, New Jersey, United States|Alzheimer's Research Corp., West Long Branch, New Jersey, United States|Univ. of New Mexico, Albuquerque, New Mexico, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|MCP Hahnemann, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown University, Pawtucket, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Clinical Neuroscience Research Unit, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Fredericton Medical Clinic, Fredericton, New Brunswick, Canada|Geriatric Medicine Research Group, Halifax, Nova Scotia, Canada|St. Joseph's Health Center, London, Ontario, Canada|Elizabeth Bruyere Centre, Ottawa, Ontario, Canada|Sunnybrook Health Science Center, Toronto, Ontario, Canada|Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Verdun, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00000173"
1107,"NCT02384993","aeRobic Exercise and Cognitive Health","REACH","Completed","No Results Available","Alzheimer's Disease|Aging","Behavioral: Enhanced Physical Activity","Cerebral Glucose Metabolism","University of Wisconsin, Madison|Alzheimer's Association","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014-1434|2014-NIRGD-305257","January 2015","August 2016","August 2016","March 10, 2015",,"December 30, 2016","University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02384993"
1108,"NCT03466177","Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease","RetAD","Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Dementia","Diagnostic Test: Non-invasive, multimodal retinal imaging|Diagnostic Test: Cerebral imaging|Diagnostic Test: Neuropsychiatric testing|Diagnostic Test: Venous blood sampling","Retinal biomarkers for AD: specificity|Retinal biomarkers for AD: sensitivity|Retinal biomarkers for AD: number needed to image|Retinal biomarkers for AD: area under the curve (AUC)|Retinal biomarkers for AD: receiver operating characteristic (ROC)|Retinal biomarkers for AD: quantification of cerebral Aβ load by non-invasive retinal imaging against the cerebral Aβ load measured by cerebral imaging|Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years","Universitaire Ziekenhuizen Leuven","All","50 Years to 85 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","S60932","April 1, 2018","December 31, 2018","December 31, 2020","March 15, 2018",,"March 15, 2018","UZ Leuven, Leuven, Vlaams Brabant, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03466177/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03466177"
1109,"NCT03508024","Patients With Alzheimer's Disease or Related Youth Disease","PARMAAJJ","Recruiting","No Results Available","Alzheimer Disease, Early Onset|Lewy Body Disease|Frontotemporal Lobar Degeneration",,"the delay between the diagnosis and the first symptomsIdentification of factors related with diagnosis delay|Comparison of patient profiles followed at the CMRR-CNR-MAJ Lille and those who are not.|Comparison of patients characteristics followed at the CMRR-CNR-MAJ Lille and those who are not.Impact of the diagnosis on YOD|the percentage of patients who have had a lack of information about the disease and possible aids|the percentage of refusal or delay of treatment of certain medico-social aids by the competent authorities","University Hospital, Lille","All","Child, Adult, Older Adult",,"220","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NI_2016_39|2017-A00486-47","January 5, 2018","January 2019","January 2019","April 25, 2018",,"April 25, 2018","Hôpital Roger Salengro, CHRU, Lille, France",,"https://ClinicalTrials.gov/show/NCT03508024"
1110,"NCT00814697","Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease|Aphasia|Dementia","Device: Repetitive Transcranial Magnetic Coil Stimulation (rTMS)","Cognitive Assessment Task Scores Before, During and After rTMS.","The New York Memory Services","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91913-5","December 2008","December 2011","August 2012","December 25, 2008","January 28, 2014","January 28, 2014","The NY Memory Services, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00814697"
1111,"NCT02769000","Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's",,"Recruiting","No Results Available","Alzheimer's Disease","Radiation: 10 GY in 5 daily fractions|Radiation: 20 GY in 10 daily fractions","Evaluate safety and toxicity/adverse events associated with delivery of low dose fractionated whole brain irradiation in subjects with early Alzheimer's dementia according to NINCDS-ADRDA Criteria.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using neurcognitive testing methods.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using psychological functioning tests.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using Quality of Life indices.","Virginia Commonwealth University","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20004955","May 2016","April 2020","April 2020","May 11, 2016",,"April 2, 2019","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02769000"
1112,"NCT00141661","A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients",,"Completed","No Results Available","Alzheimer Disease","Drug: PF-04494700 - Low Dose Arm|Drug: PF-04494700 - High Dose Arm|Drug: Placebo Comparator","Safety Measures include Adverse Events|Laboratory Tests|12-Lead Electrocardiogram|24-Hour 12-Lead Serial ECGs|Surrogate Efficacy Markers in Plasma: A-Beta, C-Reactive Protein, IL-1, IL-6, Isoprostanes, TNF-alpha, TNF-beta|Cognitive Function Tests: ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL|Pharmacokinetic Profile","Pfizer|Trans Tech Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","67","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B0341008|TTP488-201","October 2005","June 2006","June 2006","September 1, 2005",,"August 20, 2009","Pfizer Investigational Site, Sun City, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Hallandale Beach, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Largo, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, West palm Beach, Florida, United States|Pfizer Investigational Site, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00141661"
1113,"NCT00843115","Observational Study Of Donepezil In Routine Clinical Practice",,"Terminated","Has Results","Alzheimer's Disease","Other: donepezil","All Subjects Improved/Stabilized or Worsened for Cognitive Activation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Attention in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Repetitiveness in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Remembering in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Temporal Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Asphasia in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Spatial Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Judgment in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Insight in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Leisure in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Domestic Activities in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Hygiene in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Dressing in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Telephoning in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Agitation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Mood in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Anxiety in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Delusions in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Apathy in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Caregiver in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|All Subjects Improved/Stabilized or Worsened for Severity in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment|Change From Baseline in Mini-Mental State Examination (MMSE) Total Scores at Week 12|Last Observation Carried Forward (LOCF) Change From Baseline in Mini-Mental State Examination (MMSE) Total Scores at Week 12|Correlation Between Change From Baseline in Mini-Mental State Examination (MMSE) Score and Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Score|Correlation Between LOCF Change From Baseline in Mini-Mental State Examination (MMSE) Score and LOCF Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Score|Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Scores|LOCF Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Scores|Correlation Analysis: Change From Baseline in Combined Patient and Caregiver Quality of Life in Alzheimer's Disease(QoL-AD) Questionnaire Total Score Versus Number of Treatment Emergent Adverse Events (TEAEs)|Correlation Analysis: LOCF Change From Baseline in Combined Patient and Caregiver Quality of Life in Alzheimer's Disease (QoL-AD) Questionnaire Total Score Versus the Number of Treatment Emergent Adverse Events (TEAEs)|Change From Baseline Total Score in EuroQuality of Life-5 Domains (EQoL-5D)|LOCF Change From Baseline Total Score in EuroQuality of Life-5 Domains (EQoL-5D)|Change From Baseline in Visual Analog Scale (VAS) of Subject's Overall Health Included in EuroQuality of Life-5 Domains (EQoL-5D)Questionnaire|LOCF Change From Baseline in Visual Analog Scale (VAS) of Subject's Overall Health Included in EuroQuality of Life-5 Domains (EQoL-5D) Questionnaire|Change From Baseline in Subject's Mobility at Week 12|Change From Baseline in Subject's Mobility at Week 12 LOCF|Change From Baseline in Subject's Self-Care at Week 12|Change From Baseline in Subject's Self-Care at Week 12 LOCF|Change From Baseline in Subject's Usual Activities at Week 12|Change From Baseline in Subject's Usual Activities at Week 12 LOCF|Change From Baseline in Subject's Pain/Discomfort at Week 12|Change From Baseline in Subject's Pain/Discomfort at Week 12 LOCF|Change From Baseline in Subject's Anxiety/Depression at Week 12|Change From Baseline in Subject's Anxiety/Depression at Week 12 LOCF","Pfizer","All","50 Years and older   (Adult, Older Adult)",,"370","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","NRA2500065|ECO STUDY","February 2007","April 2008","April 2008","February 13, 2009","June 2, 2009","March 13, 2014",,,"https://ClinicalTrials.gov/show/NCT00843115"
1114,"NCT02612376","Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study",,"Recruiting","No Results Available","Alzheimer Disease|Down Syndrome|Mild Cognitive Impairment",,"Longitudinal collection of biospecimens and data from participants with MCI, AD, DS, healthy controls, and parents of DS individuals.","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","15-1774","February 2016","December 2030","December 2030","November 23, 2015",,"December 27, 2018","University of Colorado, Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02612376"
1115,"NCT02221622","Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD","Allo","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer Disease","Drug: Allopregnanolone injection (intravenous solution)|Drug: Placebo injection (intravenous solution)","Safety profile: Adverse events|Safety profile: Clinical laboratory measurements|Safety profile: ARIA|Safety profile: Physical and neurological examination|Tolerability - Maximum tolerated dose (MTD)|Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax)|Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax)|Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC)|Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL)|Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss)|Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState)|Brain MRI volumetrics","University of Southern California|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AlloPhase1|1UF1AG046148","August 2014","February 2018","February 2018","August 20, 2014",,"July 4, 2019","University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02221622"
1116,"NCT01702467","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK2647544|Drug: Placebo","Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s|Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values|Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings|Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters|Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs|Safety and tolerability of GSK2647544 as assessed by using the Columbia Suicide Severity Rating Scale (C-SSRS)|Peak plasma concentration (Cmax) of GSK2647544|Time of peak plasma concentration (tmax) of GSK2647544|Area under the time concentration curve (AUC) of GSK2647544|Terminal half-life (t½ ) of GSK2647544|Apparent oral clearance (CL/F) of GSK2647544|Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity","GlaxoSmithKline","Male","18 Years to 55 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","116698","October 19, 2012","May 15, 2013","May 15, 2013","October 8, 2012",,"October 18, 2017","GSK Investigational Site, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01702467"
1117,"NCT01467726","Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: Velusetrag|Drug: Placebo","Tolerability of repeat dosing of velusetrag|Profile of Plasma Pharmacokinetics (PK) of velusetrag and metabolite|Profile of urine PK of velusetrag and metabolite|Pharmacodynamic effects of velusetrag","Theravance Biopharma","All","65 Years to 85 Years   (Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0048","November 2011","January 2012","January 2012","November 9, 2011",,"December 3, 2014","Comprehensive Clinical Development, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01467726"
1118,"NCT03597360","Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia: A Pilot Study","LDIR-CT-AD","Recruiting","No Results Available","Dementia Alzheimers","Radiation: CT scan","Alzheimer Disease Functional Assessment and Change Scale (ADFACS)|Severe Impairment Battery (SIB)|Cohen-Mansfield Agitation Index (CMAI)","Baycrest","All","70 Years to 90 Years   (Older Adult)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Baycrest REB # 18-02","January 2019","April 2019","June 2019","July 24, 2018",,"January 23, 2019","Baycrest Health Sciences, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03597360"
1119,"NCT02804789","European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)","EPAD-LCS","Recruiting","No Results Available","Alzheimer's Dementia",,"Change in RBANS Composite score over time, units on a scale.|Change in other Secondary Cognitive Tests score: Working Memory, over time, units on a scale.|Change in other Secondary Cognitive Tests score: Choice Reaction Time and Set Shifting, over time, units on a scale.|Change in other Secondary Cognitive Tests score: Paired Associate Learning, over time, units on a scale.|Change in cerebrospinal fluid (CSF) AD biomarkers over time|Changes in neuro-imaging assessment of hippocampal and whole brain volume, over time","University of Edinburgh|Innovative Medicines Initiative","All","50 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPAD-UoE-001","May 2016","June 30, 2020","June 30, 2020","June 17, 2016",,"September 30, 2019","Cliniques Universitaires Saint-Luc ASBL, Neurology Department, Brussels, Belgium|UZ Leuven, Campus Gasthuisberg, Leuven, Belgium|CMRR du CHRU de Lille Hôpital Roger Salengro, Lille, France|CHU Gui de Chauliac Département de Neurologie, Montpellier, France|Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal, Paris, France|Hôpital Universitaire de la Pitié Salpêtrière, Paris, France|CMRR- Hôpital Laënnec Nord - CIC Neurologie / CHU de Nantes, Saint-Herblain, France|Toulouse University Hospital / Gérontopôle-Research Clinical Center, Toulouse, France|National and Kapodistran, University of Athens, 1st Department of Neurology, Aeginition Hospital, Athens, Greece|Univerita di Perugia, Centro Disturbi della Memoria, Clinica Neurologica, Perugia, Loc. S Andrea Delle Fratte, Italy|IRCCS San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|VUmc Alzheimer Center and Alzheimer Research Center, Amsterdam, Noord Holland, Netherlands|Unidade Deterioro Cognitivo, Servicio de Neurologia, Hospital Universitario, Santander, Cantabria, Spain|BarcelonaBeta Brain Research Centre, Barcelona, Spain|Fundacion ACE, Institut Catala de Neurocienies Aplicades, Barcelona, Spain|Fundacion CITA-alzheimer Fundazioa, Center for Research and Advanced Therapies, San Sebastián, Spain|Neuropsychiatric Research Unit, Sahlgrenska University Hoospital, Gothenburg, Vastra Gotaland, Sweden|Karolinska Institutet, Stockholm, Sweden|Hôpitaux Universitaires de Genève - HUG, Geneva, Switzerland|Centre Leenaards de la memoire- CHUV, Department of Neurosciences cliniques, Lausanne, Switzerland|Monklands University Hospital, Cumbernauld, Lanarkshire, United Kingdom|University of Edinburgh, Centre for Dementia Prevention, Edinburgh, Midlothian, United Kingdom|NHS Grampian, Aberdeen, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|University of Cambridge; Department of Clinical Neurosciences, Cambridge, United Kingdom|NHS Tayside, Dundee, United Kingdom|Glasgow Clinical Research Facility; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|West London Mental Health NHS Trust, London, United Kingdom|Greater Manchester Clinical Research Network, Manchester, United Kingdom|University of Oxford, Department of Psychiatry, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02804789"
1120,"NCT02323334","A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease",,"Completed","No Results Available","Healthy Volunteers|Alzheimer Disease","Drug: LY3202626|Drug: Placebo (Part A, B, C)|Drug: Itraconazole","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3202626|Pharmacodynamic Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration|Pharmacodynamic Biomarker: Cerebrospinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration|Pharmacokinetics (PK): Cerebrospinal fluid (CSF) Concentration of LY3202626|Pharmacodynamic Biomarker: Change in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 1","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15562|I7X-EW-LLCA","December 2014","February 2016","February 2016","December 23, 2014",,"February 26, 2016","California Clinical Trials Medical Group, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02323334"
1121,"NCT03073876","Detecting an Early Response to Donepezil With Measures of Visual Attention",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: Donepezil Hydrochloride|Drug: Placebo","Change in Foreperiod Effect task from baseline to 6 weeks|Change in Attentional Blink task from baseline to 6 weeks|Change in Corert Orienting task from baseline to 6 weeks|Change of Foreperiod Effect task from baseline to 6 months|Change in Attentional Blink task from baseline to 6 months|Change of Covert Orienting task from baseline to 6 months|Change in Dementia Rating Scale|Change in Mini Mental Status Examination|Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale|Change in Clinical Dementia Rating|Change in Digit Span|Change in Hopkins Verbal Learning Test- Revised|Change in Language function assessed with the Letter and Category Fluency Test|Change in Executive function assessed with the Trail Making Test|Change in Visuospatial function assessed with Visual Form Discrimination","NYU Langone Health|Queens College, The City University of New York","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","WUH 05030","December 1, 2005","October 8, 2009","July 31, 2019","March 8, 2017",,"January 11, 2019","Winthrop-University Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT03073876"
1122,"NCT00721383","Telephone Resources and Assistance for Caregivers (TRAC)","TRAC","Completed","No Results Available","Alzheimer's Disease","Behavioral: Enhancing Physical Activity Intervention|Behavioral: CSBI","self-reported physical activity|caregiving burden|caregiver positive well-being|self-reported physical health|physical function","Rush University Medical Center|Stanford University","All","40 Years and older   (Adult, Older Adult)","Not Applicable","211","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","04092307","May 2007","February 2013","February 2013","July 24, 2008",,"December 31, 2014","Stanford University School of Medicine, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00721383"
1123,"NCT02521558","Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease","CTAD","Recruiting","No Results Available","Memory Disorders|Mild Cognitive Impairment|Alzheimer's Disease","Behavioral: Intervention Group|Behavioral: Control Group","Changes in cognition as measured by the Mini Mental Status Exam|Changes in cognition as measured by the Montreal Cognitive Assessment|Changes in cognition as measured by the Consortium to Establish a Registry in Alzheimer's disease Word List Test|Changes in cognition as measured Letter and Category Fluency|Changes in cognition as measured by the Boston Naming Test (Short Form)|Changes in cognition as measured by the Trail Making Parts A & B|Changes in performance on cognitive rehabilitation tasks (composite measure of memory tasks)","Boston University|Wallace H. Coulter Foundation","Female","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-34203","September 2015","September 2020","September 2020","August 13, 2015",,"October 1, 2019","Boston University School of Medicine, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02521558"
1124,"NCT01479855","Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type","ALZ-vit","Unknown status","No Results Available","Mild Cognitive Impairment|Alzheimers Disease",,"Vitamin A|Vitamin B1|Vitamin B6|Vitamin B12|Vitamin C|Vitamin E|Cognitive function","Oslo University Hospital|South Eastern Area Health Service","All","Child, Adult, Older Adult",,"180","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2011/698 (REK)|Other Identifier","January 2012","December 2013","December 2013","November 28, 2011",,"November 27, 2013","OsloUH, Ullevål, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01479855"
1125,"NCT01095744","Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease","BIOMAGE","Completed","No Results Available","Alzheimer's Disease|Posterior Cortical Atrophy|Logopenic Progressive Aphasia",,"PIB-PET imaging of amyloid load|FDG-PET imaging of glucose metabolism|clinical phenotypic assessment|MRI|ApoE gene sequencing|amyloid and Tau measurements in cerebro-spinal fluid (csf)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","C08-30|2008-A00939-46","March 2009","May 2012","May 2012","March 30, 2010",,"October 10, 2012","Pitie Salpêtrière Hospital, Paris, Ile de France, France",,"https://ClinicalTrials.gov/show/NCT01095744"
1126,"NCT03942341","Sleep in Adults With Down Syndrome and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Obstructive Sleep Apnea|Sleep Disturbances",,"Sleep Efficiency|The apnea/hypopnea index (AHI)","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IIBSP-ASD-2019-15","May 8, 2019","March 2020","December 2020","May 8, 2019",,"May 10, 2019","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03942341"
1127,"NCT02129348","Treatment of Psychosis and Agitation in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Psychosis|Agitation","Drug: Lithium|Drug: Placebo","Change in Neuropsychiatric Inventory (NPI) Score|Clinical Global Impression (CGI) Global|Clinical Global Impression (CGI) Behavior|Young Mania Rating Scale|Treatment Emergent Signs and Symptoms (TESS)|Simpson-Angus Scale|Basic Activities of Daily Living (BADL)|Zarit Caregiver Burden Interview|Clinical Dementia Rating Scale (CDR)","New York State Psychiatric Institute|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","#6915|1R01AG047146-01","June 2014","January 2020","January 2020","May 2, 2014",,"August 20, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|McLean Hospital, Belmont, Massachusetts, United States|New York State Psychiatric Institute, New York, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02129348"
1128,"NCT02740634","Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study",,"Recruiting","No Results Available","Atypical Alzheimer's Disease|Logopenic Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA)","Drug: F-18 AV 1451|Drug: C-11 PiB","Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Rates of change in amyloid-PET burden over time.|Rates of change in tau-PET burden over time.","Mayo Clinic","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-008682","May 2016","March 2021","March 2021","April 15, 2016",,"April 4, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02740634"
1129,"NCT02549196","A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type","CPC-12","Completed","Has Results","Dementia of Alzheimer's Type","Drug: Donepezil|Drug: Solifenacin","Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort|Number of Participants With TEAEs Leading to Study Drug Discontinuation","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CPC-001-12","October 7, 2015","September 28, 2017","September 28, 2017","September 15, 2015","March 5, 2019","March 5, 2019","Quantum Laboratories, Deerfield Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|PMG Research, Winston-Salem, North Carolina, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02549196/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02549196"
1130,"NCT03802162","A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355",,"Not yet recruiting","No Results Available","Alzheimer's Disease (AD)","Drug: CKD-355A (D797/Memantine HCl 20mg)|Drug: CKD-355B (D797/Memantine HCl 20mg)|Drug: D797|Drug: D324 (Memantine HCl 10mg)","Cmax of D324|AUCt of D324|Cmax of D797|AUCt of D797|Cmin of D324|Cmin of D797|Tmax of D324|Tmax of D797|t½ of D324|t½ of D797","Chong Kun Dang Pharmaceutical","All","19 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","179BE18029","February 13, 2019","May 10, 2019","July 31, 2019","January 14, 2019",,"January 17, 2019","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03802162"
1131,"NCT02656498","[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases","Drug: [18F]THK-5351","Cross-sectional [18F]THK-5351 Imaging Results|Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of structural MRI|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of functional MRI|Correlation between standard uptake value ratios (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and amyloid positron emission computed tomography","Jae Seung Kim|Korea Health Industry Development Institute|Samsung Medical Center|Asan Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","THK-15002","January 2016","December 2019","December 2019","January 15, 2016",,"April 19, 2018","Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02656498"
1132,"NCT01276353","A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia",,"Completed","Has Results","Alzheimer's Type Dementia","Drug: E2020","Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3|Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status","Eisai Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2020-J081-221","January 2011","April 2012","April 2012","January 13, 2011","August 1, 2014","August 8, 2014","Kitakyushu, Fukuoka, Japan|Mizunami, Gifu, Japan|Yokosuka, Kanagawa, Japan|Sanjo, Niigata, Japan|Kurashiki, Okayama, Japan|Fuji, Shizuoka, Japan|Hachioji, Tokyo, Japan|Kodaira, Tokyo, Japan|Akita, Japan|Fukuoka, Japan|Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT01276353"
1133,"NCT00403520","Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers",,"Completed","No Results Available","Alzheimer's Disease","Drug: Experimental 1|Drug: Placebo Comparator","Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ).|Evolution of the neuropsychological scores between Day 0 and final visit.","Eisai Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 4","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","E2020-E033-415","November 2006","March 2008","August 2010","November 23, 2006",,"July 14, 2014","CHU Gui de Chauliac, Montpellier cedex, France",,"https://ClinicalTrials.gov/show/NCT00403520"
1134,"NCT03071224","Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein",,"Recruiting","No Results Available","Alzheimer Disease|Healthy Volunteers","Drug: [18F] MNI-946|Drug: [18F]Florbetapir","To determine the longitudinal change in tau burden (including SUVR and tau distribution metrics) compared to baseline in AD subjects and in similarly aged HV subjects.","Invicro","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F] MNI-946","June 2016","June 2020","June 2020","March 6, 2017",,"September 10, 2019","Invicro, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03071224"
1135,"NCT01780519","The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms",,"Completed","No Results Available","Alzheimer's Disease (AD)","Drug: lorazepam","Groton Maze Learning Test (GMLT) score|Auditory Verbal Learning Test (AVLT) Long-term memory score|Two Back Test (TBK)","Mayo Clinic","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","57","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-006469","January 2013","September 2016","September 2016","January 31, 2013",,"November 10, 2016","Mayo Clinic, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01780519"
1136,"NCT01901263","Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units",,"Completed","No Results Available","Alzheimer Disease","Behavioral: patients with alzheimer's disease","Neuropsychiatric Inventory (NPI) score|CBU effectiveness in reducing BPSD|CBU effectiveness on quality of life of patients and caregivers, and on caregivers' burden|Psychotropic drugs (in particular neuroleptic drugs) consumption|rehospitalisation rate for BPSD of the patients in the year following their hospitalisation in CBU","Centre Hospitalier Universitaire de Saint Etienne|Agence Régionale de Santé Rhône-Alpes","All","18 Years and older   (Adult, Older Adult)",,"306","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1208125|13.069bis","October 2012","October 2015","October 2015","July 17, 2013",,"December 2, 2015","CH Saint Jean de Dieu, Lyon, France|CHU de Saint Etienne, Saint Etienne, France|Hospices Civils de Lyon, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT01901263"
1137,"NCT04093882","The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease",,"Recruiting","No Results Available","Blood Brain Barrier|Alzheimer Disease|Cognitive Dysfunction|Dementia","Diagnostic Test: Contrast agent enhanced MRI using Gadovist","Marker of blood-brain dysfunction using MRI|Markers of blood-brain dysfunction using CSF","Charite University, Berlin, Germany|Prof. Dr. med. Jochen Fiebach (Senior Physician)","All","60 Years and older   (Adult, Older Adult)",,"132","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BHSkog","September 12, 2019","December 31, 2019","December 31, 2019","September 18, 2019",,"September 18, 2019","Charité Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04093882"
1138,"NCT03019757","Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Lewy Body Dementia|Parkinson's Disease","Radiation: DaTscan|Radiation: F18-AV-45|Radiation: FDG-PET|Genetic: APOE genotype|Procedure: Polysomnogram|Behavioral: Clinical Assessment","Mini Mental State Examination (MMSE-1)|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Vocabulary|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Digit Span|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Block Design|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Matrix Reasoning|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Reliable Digits (embedded measure)|Wechsler Memory Scale 3rd ed. (WAIS-3) Spatial Span|Wechsler Memory Scale 3rd ed. (WAIS-3) Logical Memory 1 & 2|Trail Making Test A|Trail Making Test B|Boston Naming Test|Controlled Oral Word Association Test (COWAT)- Animal Naming|Judgment of Line Orientation Standardized Test|Brief Visuospatial Memory Test (BVMT)|California Verbal Learning Test (CVLT-2)|Wisconsin Card Sorting Task|California Verbal Learning Test (CVLT-2) Forced Choice (embedded measure)|Self Administered Gerocognitive Examination- A brief cognitive assessment instrument for mild cognitive impairment and early dementia|Apolipoprotein E (APOE) Genotyping of a whole blood sample|Clinical Dementia Rating Scale (CDR)|The Activities of Daily Living (ADL) Standardized Scale|Mayo Fluctuations Scale|Neuropsychiatric Inventory (NPI)|Beck Depression Inventory 2nd ed.|The Modified Somatic Perception Questionnaire|The Epworth Sleepiness Scale|Mayo Sleep Questionnaire-Informant|Functional Outcomes of Sleep Questionnaire-10|Part III and IV of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)|Berg Balance Scale (BBS)|Florbetapir (F18-AV-45) positron emission tomography (amyloid PET)|Single-photon emission computed tomography (SPECT) with the radioligand [123I]FP-CIT|Positron emission tomography with 2-(18F) fluoro-2-deoxy-d-glucose (FDG-PET)|Brain MRI|Polysomnogram","Douglas Scharre|Avid Radiopharmaceuticals|Mangurian Foundation|Ohio State University","All","18 Years and older   (Adult, Older Adult)",,"76","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2014H0415","August 30, 2018","December 2020","December 2020","January 13, 2017",,"August 26, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03019757"
1139,"NCT02414282","F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)","Protocol E","Enrolling by invitation","No Results Available","Alzheimer Disease|Progressive Posterior Cortical Dysfunction (PPCD)","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","45 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol E","March 2015","March 2020","September 2020","April 10, 2015",,"January 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02414282"
1140,"NCT03053908","Orexin and Tau Pathology in Cognitively Normal Elderly",,"Recruiting","No Results Available","Elderly|Alzheimer Disease","Procedure: Actigraphy|Procedure: Nocturnal Polysomnograpahy (NPSG)","Cerebral Spinal Fluid (CSF) P-Tau measured with PET-MR|18MK6240 binding amount measured with PET-MR","NYU Langone Health|NIH/NIA","All","55 Years to 75 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-01529","March 27, 2018","November 2019","November 2019","February 15, 2017",,"March 26, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03053908"
1141,"NCT03822208","First in Human Study for Safety and Tolerability of AL003.",,"Recruiting","No Results Available","Healthy|Alzheimer Disease","Biological: AL003|Other: Saline Solution","Evaluation of safety and tolerability of AL003 measured by number of subjects with adverse events and dose limiting adverse events (DLAE)|Pharmacokinetics (PK) of AL003|Maximum concentration (Cmax) for AL003|Area under the curve concentration (AUC) for AL003","Alector Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AL003-1","March 29, 2019","April 2020","July 2020","January 30, 2019",,"April 19, 2019","Nucleus Network, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT03822208"
1142,"NCT00901498","Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Healthy","Drug: BMS-708163","To assess the bioavailability of 4 experimental formulations relative to the current reference formulation|Safety: Adverse Events|Safety: Vital Signs|Safety: ECGs|Safety: Clinical Lab Tests","Bristol-Myers Squibb","Male","18 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","CN156-004","May 2009","July 2009","July 2009","May 13, 2009",,"January 7, 2011","Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00901498"
1143,"NCT03834402","INTERCEPTOR Project: From MCI to Dementia","INTERCEPTOR","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease",,"MCI converting to AD|PREDICTING BIOMARKERS","Catholic University of the Sacred Heart|Ministry of Health, Italy|Agenzia Italiana del Farmaco","All","50 Years to 85 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2251","May 1, 2019","October 1, 2019","December 31, 2023","February 8, 2019",,"July 17, 2019","Policlinico Agostino Gemelli, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT03834402"
1144,"NCT03095417","Improving the Recovery and Outcome Every Day After the ICU","IMPROVE","Recruiting","No Results Available","Delirium|Alzheimer Disease","Behavioral: Physical Exercise Intervention|Behavioral: Cognitive Training Intervention|Behavioral: Stretching Control|Behavioral: Cognitive Control","Cognitive Status Outcome at 6 months|Cognitive Status Outcome at 3 months|Quality of Life Scores at 3 months|Quality of Life Scores at 6 months","Indiana University","All","50 Years and older   (Adult, Older Adult)","Not Applicable","344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1608126693","September 25, 2017","June 1, 2022","June 1, 2023","March 29, 2017",,"July 17, 2019","Indiana University Health West Hospital, Avon, Indiana, United States|Indiana University Health North Hospital, Carmel, Indiana, United States|Indiana University Health Saxony Hospital, Fishers, Indiana, United States|Eskenazi Health, Indianapolis, Indiana, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03095417"
1145,"NCT01504958","Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients",,"Completed","Has Results","Alzheimer's Disease","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Behavioral: NICE Cognitive Training","Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Clinical Global Impression of Change (CGIC)|Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)","Beth Israel Deaconess Medical Center|Neuronix Ltd","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2010P000325","December 2010","May 2015","May 2015","January 6, 2012","June 5, 2017","July 2, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01504958"
1146,"NCT03732053","The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients","GPR","Completed","No Results Available","Alzheimer's Type Dementia|Cognitive Decline|Postural; Strain","Other: GPR Intervention Research group","Cognitive Abilities Measurement|Quality of Life in Alzheimer's disease (QoL-AD) Questionnaire|Geriatric Depression Scale (GDS) Questionnaire|Barthel Index (BI)|Neuropsychiatric Inventory (NPI)|Tinetti Scale (TS)","Universidad Católica San Antonio de Murcia","All","40 Years to 95 Years   (Adult, Older Adult)","Not Applicable","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BJ8674287","December 5, 2016","March 10, 2017","July 3, 2017","November 6, 2018",,"November 15, 2018",,,"https://ClinicalTrials.gov/show/NCT03732053"
1147,"NCT03635047","A Phase I Study for Safety and Tolerability of AL002.",,"Recruiting","No Results Available","Healthy|Alzheimer Disease","Biological: AL002|Other: Saline Solution","Evaluation of safety and tolerability of AL002 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)|Pharmacokinetics (PK) of AL002|Maximum plasma concentration (Cmax) for AL002|Area under the curve concentration (AUC) for AL002","Alector Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AL002-1","November 12, 2018","December 2019","March 2020","August 17, 2018",,"July 25, 2019","Bioclinica Research - Orlando, Orlando, Florida, United States|Bioclinica Research - The Villages, The Villages, Florida, United States|Alfred Health, Melbourne, Australia|Box Hill Hospital, Melbourne, Australia|Nucleus Network Pty Ltd, Melbourne, Australia|University College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03635047"
1148,"NCT00000171","Study of Melatonin: Sleep Problems in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dyssomnias","Drug: Melatonin",,"National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IA0006|3U01AG010483-08S2",,,,"November 1, 1999",,"June 24, 2005","University of Arizona, Tucson, Arizona, United States|University of California Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Yale University, Alzheimer's Disease ResearchUnit, New Haven, Connecticut, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mount Sinai (Miami), Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta VA Medical Center, Augusta, Georgia, United States|Southern Illinois University, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic at Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown University, Pawtucket, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000171"
1149,"NCT03577262","A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density",,"Completed","No Results Available","Healthy|Alzheimer Disease","Other: [11C]-UCB-J","Measure [11C]-UCB-J plasma radioactivity levels in plasma over time|Measure concentration of radioactivity as a function of time according to pre-defined brain regions","Rodin Therapeutics|QPS Netherlands B.V.|University Medical Center Groningen|VU University Medical Center","All","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","19","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RDN-NI-001","July 23, 2018","August 2, 2019","August 2, 2019","July 4, 2018",,"September 10, 2019","VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands|QPS Netherlands B.V., Groningen, Netherlands|University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03577262"
1150,"NCT02434666","Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07",,"Completed","No Results Available","Dementia of the Alzheimer's Type","Drug: CPC-201","safety and tolerability of the maximum tolerated dose (MTD) of CPC-201 (adverse events)|safety and tolerability of CPC-201 20mg/day (adverse events)","Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-10","January 8, 2015","October 18, 2016","November 22, 2016","May 5, 2015",,"September 20, 2017","Miami Jewish Health Systems, Miami, Florida, United States|Quantum Laboratories, Inc. Memory Disorder Center, Pompano Beach, Florida, United States|Premiere Research Institute Neuroscience, West Palm Beach, Florida, United States|IU School of Medicine IU Health Neuroscience Center, Indianapolis, Indiana, United States|Giles Cromwell, MD, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02434666"
1151,"NCT00838942","Life From Vision in Alzheimer Disease","VIVA","Completed","No Results Available","Alzheimer Disease|Cataract","Behavioral: Questionaries","Improvement score of the NPI (Neuropsychiatric Inventory). The improvement is based on the increase by 1 point on the score of NPI|Improvement score of MMS(Mini mental status), of ADAS-COG(Alzheimer disease Assessment scale for cognitive function), IADL(Instrumental activity on daily) and GDS(Geriatric depression scale).","Assistance Publique - Hôpitaux de Paris","All","50 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P 010110","December 2004","March 2011","April 2011","February 9, 2009",,"October 28, 2011","Hopital Tenon, Service Ophtalmologie, Paris, France",,"https://ClinicalTrials.gov/show/NCT00838942"
1152,"NCT04121208","MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease","MICAD","Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: JNJ-40346527|Other: Placebo","Placebo-controlled change from baseline in cerebrospinal fluid (CSF) protein marker concentration levels.|Placebo-controlled change from baseline in CSF and blood biomarker concentration levels|Placebo-controlled change from baseline in amount of CSF extracellular vesicles and cell population.|Measurement of plasma/CSF JNJ-40346527 levels|Measurement of cerebrospinal fluid (CSF) protein marker concentration levels following different JNJ-40346527 doses|Occurrence of adverse events during the study","University of Oxford|Janssen Pharmaceutica","All","50 Years to 99 Years   (Adult, Older Adult)","Phase 1","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","40346527ALZ1001|2018-004149-17","November 2019","November 2020","November 2021","October 9, 2019",,"October 9, 2019","Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom|South London and Maudsley Hospital NHS Foundation Trust, London, United Kingdom|Oxford Health NHS Trust, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04121208"
1153,"NCT02409082","Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures","ADhipfract","Completed","No Results Available","Alzheimers Disease|Inflammation|Hip Fracture",,"Mortality and morbidity","Sahlgrenska University Hospital, Sweden","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HOFTDEM","September 11, 2013","June 22, 2015","December 20, 2016","April 6, 2015",,"April 26, 2017","Sahlgrenska University Hospital, Molndal, Vastra Gotaland, Sweden",,"https://ClinicalTrials.gov/show/NCT02409082"
1154,"NCT00403507","Exercise Treatment of Mild-Stage Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Memory Disorders|Dementia","Behavioral: Participation in a monitored exercise program|Behavioral: Personalized aerobic and strength training.","For the intervention group: Change in cognitive performance relative to baseline|Group differences in cognitive performance following intervention and relative to wait-list control group|For the intervention group: Change in attitudes, including self-report of well-being and cognitive abilities relative to baseline|Group differences in attitudes, including self-report of well-being, following intervention and relative to wait-list control group|For the intervention group: Change in knowledgeable informant's ratings of function, behavior, and attitudes|Group differences in knowledgeable informant's ratings of function, behavior, and attitudes following intervention and relative to wait-list control group","Intermountain Health Care, Inc.|Deseret Foundation","All","65 Years to 89 Years   (Older Adult)","Phase 2","79","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Kelly Garrett","October 2006","October 2009","October 2009","November 23, 2006",,"May 11, 2011","LDS Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00403507"
1155,"NCT01066481","A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease|Dementia|Dimebon|Investigational Drug","Drug: PF-01913539 5 mg|Drug: Placebo","Mean change in the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) score from baseline.|Distribution of Clinician's Interview-Based Impression of Change plus Caregiver (CIBIC-plus) Input|Mean change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADAS-ADL) score from baseline.|Mean change in Neuropsychiatric Inventory (NPI) score from baseline.|Mean change in Mini-Mental State Examination (MMSE) score from baseline.|Mean change in each item of Resource Utilization In Dementia(RUD) Lite from baseline.|Adverse events, physical examination, vital signs (blood pressure, temperature, and heart rate), 12-lead ECG, and laboratory tests (hematology, blood chemistry and urinalysis).|Population PK parameters (CL/F, V/F, etc.)","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B1451010","April 2010","March 2012","April 2012","February 10, 2010",,"June 29, 2010",,,"https://ClinicalTrials.gov/show/NCT01066481"
1156,"NCT03676881","Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Dementia|Neuropathology|Mild Cognitive Impairment","Device: Computerized cognitive battery: Cognigram (CG)|Device: The NeuroCatch™ Platform (NCP)","CG scores (accuracy and reaction speed)|MoCA scores|ERP´s amplitudes for Auditory sensation (N100)|ERP´s amplitude for Cognitive processing (N400)|ERP´s amplitude for Basic Attention (P300)|ERP´s latency for Auditory sensation (N100)|ERP´s latency for Cognitive processing (N400)|ERP´s latency for Basic Attention (P300)|Longitudinal changes in CG scores|Longitudinal changes in MoCA scores|Longitudinal change in Mini-mental state examination (MMSE)|Longitudinal change in FAQ|Longitudinal change in GPCOG scores|Longitudinal change in Rey-Osterrieth Complex Figure test (RCFT)|Longitudinal change in Hopkins Verbal Learning test (HVLT-R)|Longitudinal change in Trail Making Tests A and B|Longitudinal change in Semantic Verbal Fluency test (animals).|Longitudinal change in ERP´s amplitudes for Auditory sensation (N100)|Longitudinal change in ERP´s amplitudes for Cognitive processing (N400)|Longitudinal change in ERP´s amplitudes for Basic Attention (P300)|Longitudinal change in ERP´s latencies for Auditory sensation (N100)|Longitudinal change in ERP´s latencies for Cognitive processing (N400)|Longitudinal change in ERP´s latencies for Basic Attention (P300)","Bruyere Research Institute","All","60 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M16-17-032)","September 4, 2018","December 2021","December 2021","September 19, 2018",,"September 19, 2018","Bruyere Research Institute, Ottawa, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03676881"
1157,"NCT03565809","Quality of the Management of Diabetes in Elderly People With Dementia in France","DIA-FRADEM","Enrolling by invitation","No Results Available","Alzheimer Disease","Other: Incidence analysis","Diabetes control|Ocular Diabetes complications|Hypoglycemia|ketoacidosis without coma|diabetic coma|diabetic nephropathy|diabetic neuropathy|hospitalization for any of the 5 previous diabetes-related cause|hospitalization for falls and femoral fracture","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","65 Years and older   (Older Adult)",,"87816","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","RC31/16/8256","May 2, 2017","July 2019","December 2019","June 21, 2018",,"December 20, 2018","University Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03565809"
1158,"NCT03472664","Brain Energy for Amyloid Transformation in Alzheimer's Disease Study","BEAT-AD","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Other: low carbohydrate/high fat diet|Other: low fat/high carbohydrate diet","Cerebrospinal Fluid (CSF) Abeta42|CSF abeta42/ptau ratio|Preclinical Alzheimer Cognitive Composite (PACC)|Cerebral Blood Flow Measure with Arterial Spin Labeling (ASL) MRI","Wake Forest University Health Sciences|National Institute on Aging (NIA)","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00049474|1R01AG055122-01","July 16, 2018","April 2023","April 2023","March 21, 2018",,"August 1, 2019","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03472664"
1159,"NCT00065169","Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: Celecoxib",,"University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","40 Years to 90 Years   (Adult, Older Adult)","Not Applicable","138","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","R01MH058156|DSIR AT-GP","November 2000","November 2005","November 2005","July 18, 2003",,"October 16, 2018","UCLA Neuropsychiatric Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00065169"
1160,"NCT01582919","Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study","AMIMAGE 2","Completed","No Results Available","Dementia|Alzheimer Disease","Other: Neuroimaging","Measures of volume and diffusion parameters in the gray matter (hippocampus and cingular posterior cortex)|Performance on neuropsychological and daily life cognitive tests","University Hospital, Bordeaux","All","65 Years and older   (Older Adult)","Not Applicable","304","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHUBX 2011/15","September 2012","June 2015","June 2015","April 23, 2012",,"April 4, 2017","Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT01582919"
1161,"NCT00034762","Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease",,"Completed","No Results Available","Dementia|Alzheimer Disease|Mental Disorders","Drug: risperidone","Change from baseline to end of treatment (Week 8) in Psychosis Cluster Score of Pathology from the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Rating Scale and Clinical Global Impression (CGI).|Change in BEHAVE-AD total score and subscales (other than Psychosis Cluster subscale) from baseline; improvement in CGI scores during treatment; incidence of adverse events throughout study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","55 Years and older   (Adult, Older Adult)","Phase 3","473","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR002764","December 2000",,"January 2003","May 3, 2002",,"February 1, 2011",,,"https://ClinicalTrials.gov/show/NCT00034762"
1162,"NCT02576639","Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age",,"Completed","Has Results","Alzheimer's Disease","Drug: CNP520|Drug: Placebo","Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths|Change From Baseline of Amyloid Beta (Aβ) 1-38 , Aβ 1-40 and Aβ 1-42 Cerebrospinal Fluid (CSF) Concentrations|Summary of Plasma PK Parameter: Cmax|Summary of Plasma PK Parameter: AUCtau|Summary of Plasma PK Parameter: Tmax|Summary of Plasma PK Parameter: Tlag|Summary of Plasma PK Parameter: T1/2|Summary of PK Parameter: CLss/F|Summary of Plasma PK Parameter: Racc|Summary of CSF PK Concentrations|Area-under-plasma Concentration Time Curve up to Infinity (AUCinf)|Apparent Volume of Distribution (Vz/F)","Novartis Pharmaceuticals|Novartis","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CCNP520X2102|2013-005576-18","August 10, 2015","March 11, 2016","March 11, 2016","October 15, 2015","May 25, 2017","August 11, 2017","Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Groningen, GZ, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Mid Glamorgan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02576639"
1163,"NCT01020838","Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology",,"Completed","Has Results","Alzheimer Disease","Drug: Florbetaben (BAY94-9172)","Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).|Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.|Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans","Life Molecular Imaging SA","All","21 Years and older   (Adult, Older Adult)","Phase 3","218","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14595|2009-012569-79","November 2009","September 2011","December 2013","November 26, 2009","March 25, 2015","May 27, 2016","Sun City, Arizona, United States|Stanford, California, United States|Tampa, Florida, United States|Teaneck, New Jersey, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Heidelberg, Victoria, Australia|Lille, France|Strasbourg, France|Jülich, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Isezaki, Gunma, Japan|Hamamatsu, Shizuoka, Japan|Itabashi-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01020838"
1164,"NCT03347084","Deep Brain Stimulation With LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease","LIFUP","Recruiting","No Results Available","Brain Imaging|Mild Cognitive Impairment|Alzheimer Disease|Deep Brain Stimulation","Device: Excitation|Device: Inhibition","Change from baseline in fMRI brain scan to 40 minutes.|Change from baseline in Hopkins Verbal Learning Test-Revised45 (HVLT-R)|Change from baseline in Brief Visual Memory Test-Revised|Change from baseline in Geriatric Anxiety Inventory (GAI)","University of California, Los Angeles","All","55 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Device Feasibility","16-001314","November 10, 2018","March 1, 2020","March 1, 2020","November 20, 2017",,"April 22, 2019","UCLA Longevity Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03347084"
1165,"NCT04064021","Acupuncture Treatment for Improving Alzheimer's Dementia",,"Not yet recruiting","No Results Available","Cognitive Deficits|Alzheimer Disease","Procedure: Acupunture","Improvement on Montreal Cognitive Assessment test of 5 points or more than baseline( total score is out of 30 points)|Improvement of Montreal Cognitive Assessment test by category than raw total score","N & S Neurology Center, A Medical Group, Inc","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NS1","June 30, 2020","December 31, 2020","March 31, 2021","August 21, 2019",,"August 21, 2019",,,"https://ClinicalTrials.gov/show/NCT04064021"
1166,"NCT02462291","New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)","ABCD","Completed","Has Results","Alzheimer Disease|Behavioral Disorders|Cognitive Impairment","Other: Ecological Environmental therapy","Evaluations of Behavioral Disorders|Evaluation of Cognitive Status (Score 0-30)|Body Composition (Kilograms of Fat Free Mass)|Systolic Blood Pressure (mmHg)|Diastolic Blood Pressure (mmHg)|Blood Glucose (mg/dl)|Blood Cholesterol HDL (mg/dl)|Blood Cholesterol LDL (mg/dl)|Daily Energy Expenditure (Kcal/Day)|Evaluation of Activity of Daily Life|Salivary Cortisol (Nmol/l)|Number of Medications|Number of Patients Treated With Quetiapine|Number of Patients Treated With Citalopram|Number of Patients Treated With Donepezil|Number of Patients Treated With Memantine|Number of Patients Treated With Ticlopidin","Universita di Verona|Mons. Mazzali Foundation (Mantua, Italy)","All","65 Years and older   (Older Adult)","Not Applicable","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18201","June 2015","October 2015","December 2015","June 4, 2015","February 29, 2016","October 12, 2018","Mons. Mazzali Foundation, Mantua Italy, Mantua, Italy",,"https://ClinicalTrials.gov/show/NCT02462291"
1167,"NCT00647478","System-IGF-1 Pathway and Alzheimer's Disease","SIGAL","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Cognitive Function 1, Social|Control With Normal Activities of Daily Living",,"Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0).|Circulating IGF-I and IGFBP-3 levels|Genetic polymorphisms in IGF-I / IGFBP-3|Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function.","Assistance Publique - Hôpitaux de Paris","All","65 Years and older   (Older Adult)",,"693","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P060224","October 2007","October 2010","July 2012","March 31, 2008",,"May 1, 2018","Broca Hospital Memory Clinic (CMRR), Paris, France",,"https://ClinicalTrials.gov/show/NCT00647478"
1168,"NCT00991419","To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden",,"Completed","No Results Available","Alzheimer's Disease","Drug: [18F]AZD4694","PET Measurements","AstraZeneca","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","D2750N00006","February 2010","August 2011","August 2011","October 8, 2009",,"January 30, 2013","Research Site, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00991419"
1169,"NCT02859207","A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects",,"Completed","No Results Available","Early Alzheimer's Disease","Drug: E2609","Mean maximum plasma concentration (Cmax) of E2609|Mean area under plasma concentration versus time curve from time zero to time of last quantifiable concentration (AUC(0-t)) of E2609|Mean area under plasma concentration versus time curve from time zero to infinity (AUC(0-inf)) of E2609|Mean time to reach maximum plasma concentration (tmax) of E2609 and its metabolites|Mean terminal phase plasma half-life (t1/2) of E2609 and its metabolites|Mean apparent total body clearance (CL/F) of E2609|Mean apparent volume of distribution (Vz/F) of E2609|Mean ratio of AUC(0-inf) of individual metabolite to AUC(0-inf) of E2609, corrected for molecular weight (AUC metabolite ratio)|Mean plasma protein unbound fraction (fu) of E2609|Mean Cmax values adjusted for unbound fraction in plasma (Cmaxu) of E2609|Mean AUC(0-inf) values adjusted by unbound fraction in plasma (AUCu) of E2609|Mean Apparent clearance relative to the unbound plasma concentration based on AUCu (CLu/F) of E2609|Number of participants with treatment emergent adverse events and serious adverse events","Eisai Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2609-A001-103","August 2016","December 6, 2016","January 25, 2017","August 8, 2016",,"June 8, 2017","Miami, Florida, United States|Orlando, Florida, United States|Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02859207"
1170,"NCT01746498","Therapeutic Effect of Direct Current Stimulation on Cognitive Function of Mild to Moderate Alzheimer Patients",,"Completed","No Results Available","Alzheimer Disease","Procedure: Direct current stimulation using Anodal electrode|Procedure: direct current stimulation using cathodal electrode|Procedure: Sham direct current stimulation","Minimental state Examination|changes in cortical excitability|Wechsler memory scale|Intelligent questant ( IQ)","Assiut University","All","45 Years to 79 Years   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Direct current in Alzheimer's","June 2011","November 2012","November 2012","December 11, 2012",,"December 17, 2012","Eman Khedr, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT01746498"
1171,"NCT03709238","Pain Processing and Pain Reporting in Patients With Alzheimer's Disease",,"Recruiting","No Results Available","Pain","Behavioral: Thermal stimulation","Numerical rating scale (NRS)|Pain Assessment in persons with Impaired Cognition (PAIC)","University of Aarhus","All","50 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UAarhus_Susan","January 3, 2019","August 31, 2021","August 31, 2021","October 17, 2018",,"January 29, 2019","Department of Psychology and Behavioural Sciences, Aarhus, Midtjylland, Denmark",,"https://ClinicalTrials.gov/show/NCT03709238"
1172,"NCT00689559","Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: AZD3480|Drug: Placebo|Drug: Aripiprazole","PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)","AstraZeneca","Male","18 Years to 45 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D3691C00001|EudraCt nr 2008-000310-74","March 2008",,"April 2009","June 3, 2008",,"July 2, 2009","Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00689559"
1173,"NCT04045990","Network Modulation in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Primary Progressive Aphasia|Mild Cognitive Impairment","Device: repetitive transcranial magnetic stimulation (rTMS)","Boston Naming Test|Western Aphasia Battery-repetition|Western Aphasia Battery-reading comprehension|Western Aphasia Battery-spelling|Controlled Oral Word Association Test|Cambridge Semantic Battery|The Northwestern Anagram Test|Picture Description Test|Changes in intrinsic functional connectivity","Brigham and Women's Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018P001362","September 1, 2018","December 2020","December 2021","August 6, 2019",,"August 6, 2019","Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04045990"
1174,"NCT02360527","Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease","DIALRET","Completed","No Results Available","Retinal Neurodegeneration|Alzheimer´s Disease|Type 2 Diabetes",,"Retinal neurodegeneration among three groups of type 2 diabetic patients patients with AD, patients with MCI and patients without AD or MCI.","Hospital Universitari Vall d'Hebron Research Institute","All","65 Years and older   (Older Adult)",,"126","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","PR(IR)15/2014","September 2014","November 2015","December 2015","February 10, 2015",,"April 12, 2017","Vall d´Hebron Research Institute VHIR, Barcelona, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT02360527"
1175,"NCT01231971","Alzheimer's Disease Neuroimaging Initiative 2","ADNI2","Completed","No Results Available","Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)|Significant Memory Concern (SMC)|Early Mild Cognitive Impairment (EMCI)|Late Mild Cognitive Impairment (LMCI)","Drug: Florbetapir|Drug: Flortaucipir","Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rate of conversion will be evaluated among all five groups|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by Florbetapir F 18|Group differences for each imaging and biomarker measurement|Correlations among biomarkers and biomarker change|APOE genotype, low CSF Aβ42, positive amyloid imaging with florbetapir F 18 (AV-45)|Rate of change of tau and extent of tau deposition as measured by flortaucipir (18F-AV-1451)|Rate of cognitive decline using computer based testing as measured by Cogstate Brief Battery (CBB)","University of Southern California|Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute","All","55 Years to 90 Years   (Adult, Older Adult)",,"1185","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADC-039-ADNI2|U01AG024904","January 2011","September 28, 2017","November 29, 2017","November 1, 2010",,"July 12, 2019","University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Martinez, California, United States|University of California, Irvine (Brain Imaging Center), Orange, California, United States|Stanford University / PAIRE, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Dartmouth Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Clinic for Alzheimer's Disease and Related Disorders Program, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|St. Joseph's Health Center - Cognitive Neurology, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University / Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01231971"
1176,"NCT02987842","Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease",,"Unknown status","No Results Available","Mild Cognitive Impairment|Alzheimer Disease","Device: TruScan Neurofeedback","Memory performance|General cognitive performance improvement|qEEG","Beersheva Mental Health Center","All","50 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BeershevaMHC","December 2016","December 2017","December 2017","December 9, 2016",,"December 13, 2016","Beer-Sheva Mental Health Center, Beer-Sheva, Israel",,"https://ClinicalTrials.gov/show/NCT02987842"
1177,"NCT02063308","Oxaloacetate Pharmacokinetics and Safety",,"Completed","No Results Available","Alzheimer's Disease","Dietary Supplement: Oxaloacetate (OAA)","Correlation between oral OAA intake and plasma levels|safety of OAA in study participants","Russell Swerdlow, MD|University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00000581","February 2014","June 2014","June 2014","February 14, 2014",,"July 24, 2014","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02063308"
1178,"NCT00000177","Estrogen Hormone Protocol",,"Completed","No Results Available","Alzheimer Disease","Drug: Estrogen",,"National Institute on Aging (NIA)","Female","60 Years and older   (Adult, Older Adult)","Phase 3","120","NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0001|3U01AG010483-08S2","October 1995","January 1999","January 1999","November 1, 1999",,"December 11, 2009","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia Presbyterian Medical Center, New York, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000177"
1179,"NCT00468897","A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.",,"Completed","No Results Available","Alzheimer's Disease","Drug: RSG XR","PK samples|Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements.","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AXR107453","March 21, 2007","May 2, 2007","May 2, 2007","May 3, 2007",,"August 7, 2017","GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT00468897"
1180,"NCT01119638","Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone","EscBPSD","Completed","No Results Available","Agitation|Psychosis|Alzheimer's Disease","Drug: Escitalopram|Drug: Risperidone","Change in total score on the NPI.|Time from initial treatment to the discontinuation of treatment for any reason.","Abarbanel Mental Health Center","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ABR-BPSD-001|CO01ABR01022008","April 2008","April 2010","May 2010","May 7, 2010",,"June 24, 2015","Abarbanel MHC, Bat-Yam, Israel",,"https://ClinicalTrials.gov/show/NCT01119638"
1181,"NCT03706261","Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults",,"Recruiting","No Results Available","Alzheimer Disease","Drug: 18F-MK-6240|Drug: 18F-Florbetaben","Regional SUVR value for 18F-MK-6240|Amyloid Positivity (Aβ+) for 18F-Florbetaben","Adam Brickman|National Institute on Aging (NIA)|Columbia University","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AAAR8986|1RF1AG058067-01A1","March 22, 2019","June 2023","June 2023","October 15, 2018",,"April 3, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03706261"
1182,"NCT00548145","The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease","PIT-ROAD","Terminated","Has Results","Alzheimer Disease|Hypercholesterolemia","Drug: Pitavastatin|Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)","Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)|MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C)","Osaka University|Kowa Company, Ltd.","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSK-07098","November 2007","October 2011","March 2012","October 23, 2007","June 14, 2012","June 14, 2012","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00548145"
1183,"NCT03718494","The Kronos Early Estrogen Prevention Study (KEEPS)","KEEPS","Enrolling by invitation","No Results Available","Alzheimer Dementia","Combination Product: F-18 AV-1451 PET|Combination Product: F-18 Florbetapir","Aβ PET SUVR|WMH volume|Regional cortical thickness|AV-1451|Global cognitive function","Mayo Clinic|Columbia University|Yale University|Utah State University|Brigham and Women's Hospital|Banner Alzheimer's Institute|University of California, San Francisco|National Institute on Aging (NIA)","Female","Child, Adult, Older Adult","Phase 4","688","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-008697|1RF1AG057547-01","May 22, 2019","June 2022","June 2022","October 24, 2018",,"August 21, 2019","Banner Health, Phoenix, Arizona, United States|University of California San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03718494"
1184,"NCT00814346","Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions",,"Completed","Has Results","Alzheimer's Disease|Cognitive Impairment","Drug: EGb761®|Drug: Placebo","Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)|Change in Brain Glucose Metabolism in the MC and CNE Groups|Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups|Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups|Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups|Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups|Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)|Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups|Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups|Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)|Change in Cognitive Tests-CDR Score in MC and CNE Groups|Change in Cognitive Tests-GDS Score in MC and CNE Groups|Change in Cognitive Tests-MMSE Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT|Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups|Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups|Incidence of Adverse Events (AEs)|Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size","Ipsen","All","65 Years and older   (Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2-39-00240-134|2007-005377-63","October 2008","July 2012","July 2012","December 24, 2008","March 28, 2016","February 8, 2019","Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-Les-Moulineaux, France|Hôpital de Juvisy, Juvisy sur Orge, France|CMPI ""Les Rives de Seine"", Le Vesinet, France|Centre Hospitalier d'Orsay 4 place du Général Leclerc, Orsay, France|Private practice, Paris, France|Hôpital Broca 54-56 rue Pascal, Paris, France|Observatoire de l'âge, Paris, France|Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00814346"
1185,"NCT00009217","Treatment of Behavioral Symptoms in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Psychosis|Agitation","Drug: Haloperidol-Haloperidol|Drug: Haloperidol-Placebo","For the primary hypothesis, the primary endpoint is time to relapse.|Severity of target symptoms at the end of Phase A as a predictor of relapse|Severity of Brief Psychiatric Rating Scale psychosis and hostile suspiciousness factor scores|MMSE and Blessed Functional Activity Scale","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 4","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#4051R|R01MH055735","January 1999","December 2004","December 2004","January 24, 2001",,"May 24, 2016","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00009217"
1186,"NCT03381482","Ectosomes, New Biomarkers of Tau Pathology?","ECTAUSOME","Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: CSF drawing during spinal anaesthesia|Diagnostic Test: Fasting blood sample|Diagnostic Test: Lumbar puncture","Presence of Tau in extracellular vesicles in CSF|The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.|The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.","University Hospital, Lille","All","40 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016_59|2017-A01715-48","December 20, 2017","December 2019","December 2019","December 22, 2017",,"June 26, 2019","Hôpital Roger Salengro, CHRU, Lille, France",,"https://ClinicalTrials.gov/show/NCT03381482"
1187,"NCT04018092","The Revitalize Study",,"Not yet recruiting","No Results Available","Cognitive Aging|Alzheimer Disease, Protection Against","Device: Active NIR-PBM|Device: Sham NIR-PBM","Change in Active group ARENA scores compared to Sham group ARENA scores","University of Florida|University of Arizona|National Institute on Aging (NIA)","All","65 Years to 89 Years   (Older Adult)","Phase 2","168","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB201901780 -N|R01AG064587","January 2020","January 2025","January 2025","July 12, 2019",,"July 16, 2019","University of Arizona, Tucson, Arizona, United States|University of Florida McKnight Brain Institute, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04018092"
1188,"NCT02623764","EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors","Cholindex","Active, not recruiting","No Results Available","Alzheimer´s Disease",,"Change from baseline in Addenbrooke cognitive battery at 3 months and at 6 months|Mini Mental State Examination (MMSE)|CERAD-10 word test","Landspitali University Hospital|Mentis Cura","All","55 Years to 85 Years   (Adult, Older Adult)",,"218","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LSH-15-002","December 2015","May 2019","November 2019","December 8, 2015",,"August 17, 2018",,,"https://ClinicalTrials.gov/show/NCT02623764"
1189,"NCT00283725","Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease","REMIND","Completed","No Results Available","Dementia|Alzheimer's Disease","Other: No intervention","Change from baseline in Mini Mental State Examination (MMSE) scale score at Month 24|Change from baseline in clinical global impression (CGI) scale score at Month 24|Change from baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) at Month 24|Change from baseline in Zarit caregiver burden scale score at Month 24|Change from baseline in Kaplan-Meier estimate at Month 24|Number of patients with adverse events","Ortho-McNeil Neurologics, Inc.","All","Child, Adult, Older Adult",,"573","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","CR004636|GALALZ4004|GAL-OUT-065","June 2003","December 2006","December 2006","January 30, 2006",,"January 25, 2013",,,"https://ClinicalTrials.gov/show/NCT00283725"
1190,"NCT00495820","Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study",,"Completed","Has Results","Alzheimer's Disease|Apathy|Dementia","Drug: Methylphenidate|Other: Placebo","Apathy Evaluation Scale Score at 12 Weeks|Mini-mental State Examination (MMSE) at 12 Weeks|Clinical Global Impression","VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Phase 4","60","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MHBB-011-06F","August 2007","March 2010","June 2010","July 3, 2007","November 20, 2015","November 20, 2015","VA Medical Center, Omaha, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00495820"
1191,"NCT01615666","A Composite MR Neuroimaging Marker for Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Frontotemporal Dementia",,"To determine the sensitivity and specificity of the MRN Index as an AD biomarker.","Medical College of Wisconsin|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)",,"0","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","2R01AG020279-06A2","March 2009","January 2016","January 2016","June 8, 2012",,"January 14, 2016","Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01615666"
1192,"NCT01255163","A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease",,"Terminated","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Exendin-4 SC|Drug: Placebo SC","Number of Participants With Incidence of Nausea|Mini Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70)|Clinical Dementia Rating (CDR) Global Score|Clinical Dementia Rating (CDR) Sum of Boxes|Cerebrospinal Fluid (CSF) Total Tau|Cerebrospinal Fluid phospho181-tau (CSF p181-tau)|Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42)|Body Mass Index (BMI)","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","60 Years and older   (Adult, Older Adult)","Phase 2","57","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","100423|10-AG-0423","November 21, 2010","November 18, 2016","November 18, 2016","December 7, 2010","February 21, 2018","February 21, 2018","National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01255163"
1193,"NCT02520232","Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition","VIAGECO","Completed","No Results Available","Alzheimer's Disease","Behavioral: Combination of aerobic and strength exercises|Behavioral: Stretching and balance exercise program","Executive functions (Mean z score)|Senior Fitness Test score|Body Mass Index|Energy expenditure related to physical activity (Actimetry)|Heart rate variability at rest|Blood pressure|Depression score|Self-efficacy score|Quality of life score|Stage of change score related to physical activity|Score at Verbal working-memory span|Reaction time in a two-choice reaction time task|Error rate in a two-choice reaction time task|Logic memory score|Grey and white matter volumes in regions of interest|Cerebral perfusion in the same regions of interest|Resting State Networks Activity|Brain glucose metabolism","University Hospital, Bordeaux|Poitiers University Hospital|Centre National de la Recherche Scientifique, France|University of Poitiers|University of Bordeaux","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","139","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CHUBX 2013/22","June 2015","February 10, 2017","May 11, 2018","August 11, 2015",,"February 25, 2019","University Hospital Bordeaux, France, Bordeaux, France|University Hospital, Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT02520232"
1194,"NCT00105612","Memory Aid for Informed Consent in Alzheimer's Research",,"Completed","No Results Available","Alzheimer's Disease|Aging","Device: Memory and Organizational Aid|Behavioral: Standard Informed Consent Process","MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR) to quantify decision making abilities|Participant competency","National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","110","NIH","Interventional","Allocation: Randomized","IA0070|1R01AG020627-01A2","September 2004","March 2007","March 2007","March 16, 2005",,"December 29, 2009","University of Pennsylvania, Memory Disorders Clinic, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00105612"
1195,"NCT01202994","Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET",,"Active, not recruiting","Has Results","Alzheimer's Disease","Drug: 18F-Flutemetamol","Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan.|Change in Participant Z-score","University of Utah","All","65 Years and older   (Older Adult)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","43306","May 2011","May 2016","December 2018","September 16, 2010","January 11, 2018","February 7, 2018","University of Utah Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01202994"
1196,"NCT01825330","Effect of NeuroAD on the Cognitive Function of Alzheimer Patients",,"Completed","No Results Available","Alzheimer's Disease","Device: TMS and cognitive stimulation|Device: sham","Efficacy","Neuronix Ltd","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX - US4","October 2013","January 2016","March 2016","April 5, 2013",,"March 31, 2016","Banner Sun Health Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Miami Jewish Health Systems, Miami, Florida, United States|Roskamp Institute Clinic, Sarasota, Florida, United States|Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cleveland Clinic Lou Ruvo Brain Center, Las Vegas, Nevada, United States|NYU Langone Medical Center, New York, New York, United States|Cleveland Clinic Center for Brain Health Lakewood Hospital, Cleveland, Ohio, United States|Assaf Harofe Medical Center, Beer Yaakov, Israel",,"https://ClinicalTrials.gov/show/NCT01825330"
1197,"NCT01825317","Effect of NeuroAD on Alzheimer Patients",,"Completed","No Results Available","Alzheimer's Disease","Device: NeuroAD|Device: Sham device","ADAS-Cog","Neuronix Ltd|company: K The Power|Chungnam National University Hospital","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NRX-KOR1","March 2013","December 2013","December 2013","April 5, 2013",,"April 21, 2014","Chungnam national university hospital, Daejeon Geriatric Medical Center, Daejeon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01825317"
1198,"NCT00582855","Effect of AQW051 in Patients With Memory Impairment",,"Terminated","No Results Available","Mild Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: AQW051|Drug: Placebo","Validated computerized cognitive assessment scores|Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale","Novartis Pharmaceuticals|Novartis","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAQW051A2104","December 2007","February 2009",,"December 28, 2007",,"April 19, 2016","Novartis Investigator Site, Halifax, Canada|Novartis Investigator Site, Montreal, Canada|Novartis Investigator Site, Toronto, Canada|Novartis Investigator Site, Bloemfontein, South Africa|Novartis Investigator Site, George, South Africa|Novartis Investigator Site, Port Elizabeth, South Africa|Novartis Investigator Site, Blackpool, United Kingdom|Novartis Investigator Site, Epping, United Kingdom|Novartis Investigator Site, Glasgow, United Kingdom|Novartis Investigator Site, Manchester, United Kingdom|Novartis Investigator Site, Southampton, United Kingdom|Novartis Investigator Site, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00582855"
1199,"NCT03298672","Safety, Tolerability, and Pharmacokinetics Study of NDX-1017",,"Completed","No Results Available","Alzheimer Disease","Drug: NDX-1017|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].|Maximum observed plasma concentration (Cmax).|Time to maximum observed plasma concentration (Tmax).|Plasma concentration at the end of the dosing interval (Ctrough).|Area under the plasma concentration time curve (AUC).|Half-life (t1/2).","Athira Pharma|Alzheimer’s Drug Discovery Foundation|Biotrial Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","88","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NDX-1017-0101-01","October 9, 2017","September 5, 2019","September 5, 2019","October 2, 2017",,"September 10, 2019","Biotrial Inc., Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03298672"
1200,"NCT01409564","Cilostazol Augmentation Study in Dementia",,"Completed","Has Results","Alzheimer's Dementia","Drug: Cilostazol|Drug: Placebo","Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)|Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)|Activities of Daily Living (ADCS-ADL)|Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)|Fazekas Scale","Seoul National University Hospital|Korea OIAA","All","60 Years and older   (Adult, Older Adult)","Phase 4","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","06-2009-145","May 2010","June 2012","July 2013","August 4, 2011","May 13, 2014","May 13, 2014","SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01409564"
1201,"NCT00000174","Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)",,"Completed","No Results Available","Alzheimer Disease|Cognition Disorders","Drug: Rivastigmine",,"Novartis|National Institute on Aging (NIA)","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0012",,,,"November 1, 1999",,"December 9, 2005","Medici Research Centers, Peoria, Arizona, United States|University of California, Irvine, Orange, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Neuromedical Research Institute (Offices in Ft. Lauderdale, Miami Beach and Boca Raton), Ft. Lauderdale, Florida, United States|Miami Research Associates, Miami, Florida, United States|Center for Clinical Trials and Research, Venice, Florida, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|St. Louis University, St. Louis, Missouri, United States|Alzheimer's Research Corporation, Lakewood, New Jersey, United States|NYU Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Pahl Brain Associates, P.C., Oklahoma City, Oklahoma, United States|Clinical Studies, Ltd., Philadelphia, Philadelphia, Pennsylvania, United States|St. Paul Medical Center, Dallas, Texas, United States|University of Washington, Seattle, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000174"
1202,"NCT02267486","Exploratory Study for the Validity of QuQu Scale","QuQu","Completed","No Results Available","Alzheimer Dementia","Other: Standard therapy of Alzheimer Dementia (AD)|Other: Observation","Novel Dementia Rating Scale (QUick QUestion Scale)","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Daiichi Sankyo Co., Ltd.","All","Child, Adult, Older Adult",,"972","Other|Industry","Observational","Time Perspective: Prospective","TRIAD1402|UMIN000016394","October 2014","March 2016",,"October 17, 2014",,"July 15, 2016","Kagawa University School of Medicine, Kida-gun, Kagawa, Japan",,"https://ClinicalTrials.gov/show/NCT02267486"
1203,"NCT03617497","Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease","PESAD","Not yet recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Epilepsy|Sleep Wake Disorders","Diagnostic Test: scalp EEG and polysomnography|Diagnostic Test: scalp EEG with foramen ovale electrodes with polysomnography","Epilepsy|Sleep wake disorder","Universitaire Ziekenhuizen Leuven","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S61745","October 1, 2018","September 30, 2021","September 30, 2022","August 6, 2018",,"August 6, 2018","University Hospitals Leuven, department of Neurology, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03617497"
1204,"NCT01548287","A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment",,"Completed","Has Results","Mild Cognitive Impairment|Mild Alzheimer's Disease","Drug: AZD5213|Other: Placebo","Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.","AstraZeneca","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3030C00005","April 2012","January 2013","January 2013","March 8, 2012","December 5, 2016","February 7, 2017","Research Site, Phoenix, Arizona, United States|Research Site, Indio, California, United States|Research Site, Lomita, California, United States|Research Site, San Francisco, California, United States|Research Site, Delray Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01548287"
1205,"NCT01777789","The Role of Mid-Life Adiposity in Functional Brain Connectivity",,"Terminated","No Results Available","Alzheimer's Disease",,"Brain connectivity measured by fMRI","Medical College of Wisconsin","All","45 Years to 65 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","PRO16109","December 2012","February 2016","February 2016","January 29, 2013",,"February 9, 2016","Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01777789"
1206,"NCT00322036","Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's",,"Terminated","No Results Available","Alzheimer Disease|Dementia","Drug: MPC-7869","Cognition and activities of daily living|Global function and cognition","Myrexis Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MPC-7869-05-010.01","May 2006",,"December 2008","May 4, 2006",,"August 5, 2008","Phoenix, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Deerfield Beach, Florida, United States|DelRay Beach, Florida, United States|Gainsville, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Aalst, Belgium|Antwerpen, Belgium|Edegem, Belgium|Hasselt, Belgium|Leuven, Belgium|Sint-truiden, Belgium|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Verdun, Quebec, Canada|Regina, Saskatchewan, Canada|Odense C, Denmark|Odense, Denmark|Bordeaux, France|Dijon, France|Marseille, France|Montpellier, France|Nice, France|Reims, France|Rennes, France|Saint Herblain, France|Toulouse, France|Tours, France|Berlin, Germany|Bochum, Germany|Bonn, Germany|Darmstadt, Germany|Dusseldorf, Germany|Freiburg, Germany|Hamburg, Germany|Heidelberg, Germany|Leipzig, Germany|Mannheim, Germany|Munchen, Germany|Schwerin, Germany|Brescia, Italy|Milano, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Amsterdam, Netherlands|Blaricum, Netherlands|Hertogenbosch, Netherlands|Barcelona, Spain|Bilbao, Spain|Getafe. Madrid, Spain|Madrid, Spain|Lund, Sweden|Basel, Switzerland|Bath, England, United Kingdom|London, England, United Kingdom|Oxford, England, United Kingdom|Sheffield, England, United Kingdom|Swindon, England, United Kingdom|Belfast, N. Ireland, United Kingdom|Glasgow, Scotland, United Kingdom|Penarth, Wales, United Kingdom|Southhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00322036"
1207,"NCT03548584","A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Agitaton Associated With Alzheimer's Dementia|Alzheimer Dementia","Drug: Brexpiprazole|Other: Placebo","Cohen-Mansfield Agitation Inventory (CMAI) total score|Clinical Global Impression Severity of Illness (CGI-S) score","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-14-213","May 16, 2018","November 2020","December 2020","June 7, 2018",,"July 12, 2019","MD First Research, LLC, Chandler, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|Global Clinical Trials, Costa Mesa, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Irvine Clinical Research, Irvine, California, United States|Shreenath Clinical Services, Lakewood, California, United States|Axis Clinical Trials, Los Angeles, California, United States|Califnoria Neurological Services, Panorama City, California, United States|SC3 Research, Pasadena, California, United States|Nova Clinical Research, Bradenton, Florida, United States|Advanced Clinical Research, Coral Gables, Florida, United States|Arocha Research Center, Coral Gables, Florida, United States|ICR Sites, LLC, Doral, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Research in Miami Inc., Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|MaxBlue Institute, Hialeah, Florida, United States|SIH Research, Kissimmee, Florida, United States|Ocean Blue Medical Research, Miami Springs, Florida, United States|Premier Clinical Research, Miami, Florida, United States|Central Miami Medical Institute, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Janus Clinical Research, Miami, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|Health Care Family Research 2, Pembroke Pines, Florida, United States|University of West Florida (UWF) Clinical Trials, Pensacola, Florida, United States|Clinovation Research, LLC, Weston, Florida, United States|Georgia Neurology and Sleep Medicine Associates, Suwanee, Georgia, United States|Alzheimer Disease Center, Winchester, Massachusetts, United States|Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Arch Clinical Trials, Saint Louis, Missouri, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Neurological Associates of Albany ,PC, Albany, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Five Towns Neurology PC/Villiage, Woodmere, New York, United States|Richard H. Weisler, MD PA Associates, Raleigh, North Carolina, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Centex Studies Inc., Houston, Texas, United States|Bio Pharma Informatic Inc., Houston, Texas, United States|Northpointe Psychiatry, Lewisville, Texas, United States|Mental Health Center Prof. Dr Ivan Temkov - Burgas EOOD, Burgas, Bulgaria|State Psychiatry Hospital - Kardzhali, Kardzhali, Bulgaria|Mental Health Centre-Ruse EOOD, Daily Unit, Ruse, Bulgaria|Medical Center Sveti Naum EOOD, Sofia, Bulgaria|Medical Center Intermedica OOD, Sofia, Bulgaria|Diagnostic and Consultative Centre Mladost - M Varna OOD, Varna, Bulgaria|Diagnostic and Consultative Centre Mladost - M Varna OOD, Varna, Bulgaria|Mental Health Center - Vratsa EOOD, Vratsa, Bulgaria|Clinical Hospital Center ""Dr. Dragisa Misovic - Dedinje"", Belgrade, Serbia|Special Hospital for Psychiatric Diseases ""Kovin"", Kovin, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina, Novi Sad, Serbia|Centro de Salud San Juan, Salamanca, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital Universitario Rio Hortega, Valladolid, Spain|Complejo Asistencial de Zamora, Zamora, Spain|I.I. Mechnikov - Dnipropetrovsk Regional Clinical Hospital, Dnipro, Ukraine|Kiev City Psychoneurological hospital # 3, Hlevakha, Ukraine|Kharkiv Regional Clinical Psychiatric Hospital No. 3, #23, Kharkiv, Ukraine|Kharkiv Regional Council ""Regional Clinical Psychiatric Hospital No. 3, #14, Kharkiv, Ukraine|Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine|Kherson Regional Psychiatric Hospital, Kherson, Ukraine|Kyiv Center for Novel Treatment and Rehabilitation of Phychotic disorders, Kyiv, Ukraine|Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, Poltava, Ukraine|Acad. O. I. Iushchenko - Vinnitsia Regional Psychoneurologic Hospital, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03548584"
1208,"NCT02164643","Longitudinal Study of Brain Amyloid imaGing in MEMENTO","MEMENTOAmyGing","Active, not recruiting","No Results Available","Alzheimer's Disease (AD) and Related Disorders","Drug: Flutemetamol (18F)|Drug: Florbetapir (18F)","Progression to clinical dementia stage according to standardized classifications (DSM-IV and NINCDS-ADRDA) as described in the MEMENTO protocol.|Longitudinal evolution of amyloid load measured through either Florbetapir (18F) or Flutemetamol (18F)|Speed of cognitive decline based on change in cognitive performances|Longitudinal evolution of biomarkers measured from blood, CSF, structural neuroimaging (MRI) and glucose metabolism molecular neuroimaging (18F-FDG PET).|Mortality|Loss of autonomy based on functional activity assessment|Institutionalization|Cardiovascular event (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Etiology of dementia, when converted","University Hospital, Bordeaux|Fondation Plan Alzheimer|GE Healthcare|Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","448","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHUBX 2010/47 A","June 10, 2014","December 2019","December 2019","June 16, 2014",,"January 21, 2019","CHU d'Angers, Angers, France|CHU de Besançon, Besancon, France|APHP - Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Bordeaux - Hôpital Xavier-Arnozan, Bordeaux, France|CHU de Brest, Brest, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02164643"
1209,"NCT03919669","A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking",,"Enrolling by invitation","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: All Subjects","Change in [18F]MK-6240 uptake|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Mini-Mental Status Exam (MMSE)|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Clinical Dementia Rating Scale (CDR).|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Change in the Cross-sectional comparison of [18F]MK-6240 uptake","University of Wisconsin, Madison|Cerveau Technologies, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018-1348","April 1, 2019","January 2022","September 2022","April 18, 2019",,"May 24, 2019","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03919669"
1210,"NCT00586430","The Impact of Lorazepam on Cognition in APOE e4 Carriers",,"Completed","No Results Available","Alzheimer's Disease","Drug: lorazepam|Drug: placebo","Groton Maze Learning Task|Auditory Verbal Learning Test|1-back test","Mayo Clinic|National Institute of Mental Health (NIMH)","All","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Screening","929-05","December 2005","July 2007","July 2007","January 4, 2008",,"January 4, 2008","Mayo Clinic, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00586430"
1211,"NCT02681172","Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD",,"Completed","Has Results","Alzheimer's Disease (AD)","Drug: Neuraceq (florbetaben 18F)|Procedure: PET","Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes|Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3|Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes|Number of Subjects With Positive FBB PET Scan|Number of Subjects With Negative FBB PET Scans|Number of Subjects With Contraindicated or Failed Lumbar Puncture|Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician|Number of Subjects Who Refused Lumbar Puncture.","Piramal Imaging Limited","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","218","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","FBB_01_02_2015|2015-002606-37","October 2015","September 2016","November 2016","February 12, 2016","November 2, 2018","November 2, 2018","Coordinating center (Hôpital de La Timone) and 18 associated centers in France, Marseille, France",,"https://ClinicalTrials.gov/show/NCT02681172"
1212,"NCT00628017","Preliminary Study of Fish Oil and Dementia",,"Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Dietary Supplement: omega-3 polyunsaturated fatty acids ( EPA+DHA)","the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus)|the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog)|Mini Mental Status Examination (MMSE) scores|17-item Hamilton Depression Scale (HDRS)|adverse events","Taipei City Psychiatric Center, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DOH-92-TD-1095","January 2003","March 2005","March 2005","March 4, 2008",,"March 4, 2008","Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00628017"
1213,"NCT01767909","The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)",,"Completed","No Results Available","Amnestic Mild Cognitive Impairment|Alzheimer's Disease","Drug: Insulin (Humulin® R U-100)|Drug: Placebo","Change in global measure of cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12)|Change in Memory Composite as measured by Story Recall and Buschke Selective Reminding Test|Change in daily functioning as measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI)|Change from screen in magnetic resonance imaging (MRI)|Rate of change over time on CSF Abeta|Rate of change over time on CSF Abeta/tau ratio|Comparison of the response to treatment of INI based on baseline AD biomarker profile|Comparison of the response to treatment of INI based on gender|Comparison of the response to treatment of INI based on APOE-ε4 genotype|Examine whether further improvement occurs after 18 months of treatment","University of Southern California|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute|Wake Forest University Health Sciences","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","239","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADC-046-INI|RF1AG041845","January 8, 2014","December 11, 2018","December 11, 2018","January 15, 2013",,"January 18, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01767909"
1214,"NCT00478491","fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease","ALZ","Completed","No Results Available","Magnetic Resonance Imaging|Alzheimer's Disease|Dementia|Adult Children|Risk",,,"University of Wisconsin, Madison|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","40 Years to 85 Years   (Adult, Older Adult)",,"390","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","2002-515|NIH RO1 AG021155A","January 2003","June 2011","July 2011","May 24, 2007",,"October 27, 2016","University of Wisconsin - Wisconsin Comprehensive Memory Program, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00478491"
1215,"NCT02130661","Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: Rilapladib 25 mg|Drug: Rilapladib 250 mg|Drug: Itraconazole","Maximum observed concentration (Cmax), time of occurrence of Cmax (Tmax), area under the concentration-time curve over the dosing interval (AUC(0-Tau)) of rilapladib parent compound after single and repeat dosing, in part A of the study.|Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)), and terminal phase half-life (T1/2) of rilapladib after repeat dosing, in part A of the study|Cmax, Tmax, AUC(0-tau), and area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC(0-t)) of SB-664601 and GSK1174379 after single and repeat dosing, in part A of the study|AUC(0-infinity) and T1/2 of SB-664601 and GSK1174379 after repeat dosing, as data permit, in part A of the study.|AUC(0 infinity), AUC(0 t), and Cmax of rilapladib alone and in the presence of itraconazole in part B of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by adverse events (AEs), in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by 12-lead electrocardiogram (ECG) parameters, in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by measuring vital signs, in part A of the study.|Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by laboratory tests, in part A of the study.|Tmax and T1/2 of rilapladib alone and in the presence of itraconazole, in part B of the study.|AUC(0-infinity), AUC(0-t), Cmax, Tmax and T1/2 of rilapladib metabolites, SB-664601 and GSK1174379, alone and in the presence of itraconazole, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by AEs, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed using ECG parameters, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed as vital signs, in part B of the study.|Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by laboratory tests, in part B of the study.","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201274","October 2017","January 2018","January 2018","May 5, 2014",,"December 13, 2016",,,"https://ClinicalTrials.gov/show/NCT02130661"
1216,"NCT01978327","GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers",,"Terminated","No Results Available","Alzheimer's Disease","Drug: GSK2647544|Drug: drug-drug interaction","Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s|Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values|Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings|Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters|Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs|Safety and tolerability of GSK2647544 as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)|Peak plasma concentration (Cmax) of GSK2647544|Time of peak plasma concentration (tmax) of GSK2647544|Area under the time concentration curve (AUC) of GSK2647544|Terminal half-life (t½ ) of GSK2647544|Time of peak plasma concentration (tmax) of simvastatin|Area under the time concentration curve (AUC) of simvastatin|Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","200592","November 22, 2013","March 3, 2014","March 3, 2014","November 7, 2013",,"June 8, 2017","GSK Investigational Site, Harrow, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01978327"
1217,"NCT00478166","Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease","PC","Completed","No Results Available","Magnetic Resonance Imaging|Alzheimer's Disease|Dementia|Adult Children|Risk",,,"University of Wisconsin, Madison|VA Office of Research and Development","All","55 Years to 65 Years   (Adult, Older Adult)",,"206","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2004-174","July 2005",,"October 2007","May 24, 2007",,"October 5, 2015","University of Wisconsin - Wisconsin Comprehensive Memory Program, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00478166"
1218,"NCT03130036","Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning",,"Completed","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Other: Low-Carbohydrate Diet|Other: Low-Fat Diet","Brain biodistribution of [11C]AcAc/[18F]FDG","Wake Forest University Health Sciences","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","IRB00033365","June 9, 2015","June 2017","June 2017","April 26, 2017",,"August 1, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03130036"
1219,"NCT01924858","A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.",,"Terminated","No Results Available","Alzheimer's Disease","Drug: GSK2647544 oral|Drug: [18F]GSK2647544 IV bolus","Whole brain PET VT of [18F]-GSK2647544|Safety and tolerability assessment following oral administration of GSK2647544|GSK2647544 PK assessment","GlaxoSmithKline","Male","30 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117155","August 19, 2013","March 3, 2014","March 3, 2014","August 19, 2013",,"October 19, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01924858"
1220,"NCT03030365","Orientation in AD Patients: PET-MR Study",,"Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Device: Siemens ""Biograph mMR"" PET-MR (3T)","Orientation performance|Cortical atrophy|Functional connectivity analysis|Mental-orientation evoked fMRI activity|[18]F-fluorodeoxyglucose (FDG) uptake","Assuta Medical Center|Hadassah Medical Organization","All","50 Years to 79 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","AssutaMC","February 15, 2017","February 15, 2019","February 15, 2020","January 25, 2017",,"January 25, 2017",,,"https://ClinicalTrials.gov/show/NCT03030365"
1221,"NCT01142336","Effects of Simvastatin on Biomarkers","SimBio","Completed","Has Results","Alzheimer's Disease","Drug: Simvastatin|Drug: Placebo","Change From Baseline in Aβ42 in Cerebrospinal Fluid (CSF) at 1 Year|Change From Baseline in CSF Total Tau at 1 Year|Change From Baseline in CSF ptau181 at 1 Year","University of Washington|Seattle Institute for Biomedical and Clinical Research|VA Puget Sound Health Care System","All","45 Years to 64 Years   (Adult)","Phase 4","49","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","37373|00183","June 2010","October 2015","October 2015","June 11, 2010","July 28, 2017","July 28, 2017","VA Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01142336"
1222,"NCT01972204","Intensive Instruction on the Use of Aricept",,"Completed","Has Results","Alzheimer's Type Dementia","Behavioral: Intensive adherence instruction|Behavioral: Control","Number of Participants With Medication Continuation|Reasons for Discontinuation|Number of Participants With Medication Discontinuation Due to Change to Alicept or Generics|Adverse Events","Mirai Iryo Research Center, Inc.","All","Child, Adult, Older Adult","Not Applicable","125","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ART-2013-01","September 2013","August 2017","August 2017","October 30, 2013","June 3, 2019","June 3, 2019","Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01972204/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01972204"
1223,"NCT00869817","Dominantly Inherited Alzheimer Network (DIAN)","DIAN","Recruiting","No Results Available","Alzheimer's Disease",,"Positive predictive power of a biomarker or group of biomarkers|Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging|Clinical markers also examined from clinical interview and cognitive testing","Washington University School of Medicine|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)",,"700","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IA0147|U19AG032438","January 2009","July 2024","July 2024","March 26, 2009",,"July 16, 2019","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Indiana University-Indiana Alzheimer Disease Center, Indianapolis, Indiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia"" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa, Buenos Aires, Argentina|Neuroscience Research Australia, Sydney, New South Wales, Australia|Mental Health Research Institute, University of Melbourne, Melbourne, Victoria, Australia|Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University, Perth, Western Australia, Australia|German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich, Munich, Germany|German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany|Osaka City University, Osaka City, Japan|Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of|Institute of Neurology, Queen Square, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00869817"
1224,"NCT03994237","Accompanying ALZHEIMER CAREGIVER","ACCAIDANT","Completed","No Results Available","Alzheimer Disease","Other: semi-structured interview","score of the grid ""MiniZarit""|score of the EuroQuol scale|Number of days between pre-clinical consultation and consultation MEMORY|Questionnary for caregivers' organization","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2016/48","December 12, 2018","June 7, 2019","June 7, 2019","June 21, 2019",,"July 1, 2019","CHU de Bordeaux, Pessac, France",,"https://ClinicalTrials.gov/show/NCT03994237"
1225,"NCT00178165","Coordinating Center for Enhancing ADRD Caregiving",,"Completed","No Results Available","Dementia|Alzheimer Disease","Procedure: Skill Training Condition – problem solving training|Procedure: REACH for TLC (Telephone Linked Computer) system","The outcomes were assessed 6 months after randomization and included a measure of burden and a measure of depression. Caregiver burden was assessed using the Revised Memory and Behavior Problem Checklist (RMBPC).|Emotional distress was determined by the Center for Epidemiological Studies Depression Scale (CES-D) a global measure of depression.|Long-term care placement of dementia patients and caregiver health and well-being|Use of cognitive enhancement medication|Clinical significance of caregiver interventions in diverse populations","University of Pittsburgh|National Institute on Aging (NIA)|National Institute of Nursing Research (NINR)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG13305-01|NR13269|AG13313|AG13297|AG13289|AG13265|AG13255|AG13305","September 1996",,"November 2001","September 15, 2005",,"September 15, 2005","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University and Veterans Affairs, Menlo Park, California, United States|University of Miami at Miami, Center on Adult Development and Aging, Miami, Florida, United States|Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health, Philadelphia, Pennsylvania, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00178165"
1226,"NCT03977025","Alzheimer Biomarkers on CSF of Elderly Patients Undergoing Surgery",,"Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: Lumbar punction","Montreal Cognitive Assessment","University of Chile","All","65 Years to 99 Years   (Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Saval 018","June 11, 2019","September 2019","March 2020","June 6, 2019",,"June 13, 2019","University of Chile Clinical Hospital, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT03977025"
1227,"NCT03981159","Effect of Exercise Training in Alzheimer's Patients","ExCiTE-A","Completed","No Results Available","Alzheimer Disease","Other: Physical training","Tinetti test|Berg Balance Scale|6-minute walking test|Timed up and go test|""Walking While Talking"" test|Red blood cell count|White blood cell count|Hemoglobin|Platelet count|Hematocrit|Triglycerides|Cholesterol|Total bilirubin|AST (aspartate aminotransferase)|ALT (alanine aminotransferase)|Blood pressure|Creatinine|Urea|Glucose|Sodium|Calcium|Potassium","University of Genova","All","80 Years to 90 Years   (Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","ExCiTE-A-17-0020","March 1, 2017","July 1, 2017","November 15, 2017","June 10, 2019",,"June 10, 2019","University of Genova, Genoa, Italy",,"https://ClinicalTrials.gov/show/NCT03981159"
1228,"NCT01434940","Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression","MOMAD","Unknown status","No Results Available","Alzheimer Disease|Depression","Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam","pro-saccade task|anti-saccade task|predictive saccade task|scan of images pair with emotional connotation|portrait analysis","Centre Hospitalier Universitaire de Besancon|Laboratoire de psychologie EA 3188|Centre Hospitalier Universitaire Dijon|Centre Hospitalier de Novillars","All","60 Years and older   (Adult, Older Adult)","Not Applicable","288","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","N/2009/55","April 2010","January 2018","July 2018","September 15, 2011",,"July 31, 2017","Univserity Hospital of Besançon - Psychiatry Department, Besançon, France",,"https://ClinicalTrials.gov/show/NCT01434940"
1229,"NCT02008513","Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006",,"Terminated","No Results Available","Alzheimer´s Disease","Biological: AFFITOPE® AD02|Biological: Placebo","Composite Measures of Primary Safety and Tolerability Endpoints|Composite Measures of Secondary Efficacy Endpoints","Affiris AG","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AFF006A|2012-005280-27","June 2013","September 2014","September 2014","December 11, 2013",,"June 24, 2015","Landeskrankenhaus Hall Gedächtnisambulanz, Hall in Tirol, Austria|LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria|Christian Doppler Klinik, Univ. Klinik f. Neurologie, Salzburg, Austria|MUW Klin. Pharmakologie und Klinik für Neurologie, Vienna, Austria|MUW, Klin.Abt.f. Biolog. Psychiatrie, Vienna, Austria|SMZ-Ost, Psychiatric Dep., Vienna, Austria|Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju, Rijeka, Croatia|Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia|""BONIFARM"" Poliklinika za kliničku farmakologiju i toksikologiju, Zagreb, Croatia|Psihijatrijska Bolnica Vrapče, Zagreb, Croatia|University Thomayer Hospital, Praha, Czech Republic|University Hospital Motol, Clinic of Neurology, Praha, Czech Republic|CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard, Bordeaux Cedex, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France|Centre Mémoire de Ressources et de Recherche, Service de Neurologie, Montpellier Cedex, France|Hôpital de la Pitié-Salpêtrière, Paris, France|CHU de Rennes Site Hôtel Dieu, Rennes Cedex, France|Hopital La Grave, Toulouse, France|Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie, Berlin, Germany|Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie, Hamburg, Germany|Arzneimittelforschung Leipzig GmbH, Studienzentrum, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie, Mannheim, Germany|Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München, Munich, Germany|Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany|NeuroPoint GmbH, Ulm/Donau, Germany|EPAMED, s.r.o., Kosice, Slovakia",,"https://ClinicalTrials.gov/show/NCT02008513"
1230,"NCT03687112","National Bank Alzheimer","BNA","Recruiting","No Results Available","Alzheimer Disease","Other: non ontervention / observational study","Evolution of the morbi-mortality|number of the miscellaneous determiners of Access to healthcare or diagnosis","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult",,,"Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-DSP-03","January 1, 2009","January 1, 2009","December 31, 2025","September 27, 2018",,"September 27, 2018","Nice University Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT03687112"
1231,"NCT03649724","The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's","LUCINDA","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: Placebo|Drug: LUPRON DEPOT 22.5 mg","Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale","Weill Medical College of Cornell University|National Institute on Aging (NIA)","All","65 Years to 90 Years   (Older Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","057681|R01AG057681-01A1","February 2020","February 2025","February 2026","August 28, 2018",,"September 30, 2019","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03649724"
1232,"NCT04102514","A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers",,"Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Real-time Group Video|Behavioral: Enhanced Usual Care","Moderate Physical Activity|Sedentary time|Functional Fitness|Activities of Daily Living|Change in Quality of Life|Residential Transitions|Neuropsychiatric Symptoms|Cognitive Function|Caregiver Sedentary Time|Caregiver Functional Fitness|Caregiver Quality of Life|Caregiver Burden","University of Kansas|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STUDY00144595","April 2020","April 2024","April 2024","September 25, 2019",,"September 26, 2019",,,"https://ClinicalTrials.gov/show/NCT04102514"
1233,"NCT04074837","Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers",,"Recruiting","No Results Available","Alzheimer Disease","Drug: NNI-362|Drug: Placebo","Measure number of treatment related adverse events following single and multiple dosing of NNI-362.|Measure Maximum Plasma Concentration with single or multiple dosing of NNI-362.|Measure Area Under the Curve with single and multiple dosing of NNI-362","Neuronascent, Inc.|National Institute on Aging (NIA)","All","50 Years to 72 Years   (Adult, Older Adult)","Phase 1","56","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NNI-001|1R01AG056561-01A1","August 1, 2019","March 1, 2020","April 1, 2020","August 30, 2019",,"August 30, 2019","Parexel, International, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT04074837"
1234,"NCT03256539","Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Sleep|Alzheimer Disease|Cognitive Impairment|Aging|CBT","Behavioral: Sleep intervention|Behavioral: Placebo intervention","Number of participants enrolled to the study|Number of participants that complete the study|Sleep as assessed by actigraphy|Cognitive function assessed by standard neurocognitive battery","University of California, San Francisco","All","65 Years and older   (Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","1K99AG056598-01","September 2019","August 2021","May 2022","August 22, 2017",,"December 3, 2018",,,"https://ClinicalTrials.gov/show/NCT03256539"
1235,"NCT02752750","Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease",,"Enrolling by invitation","No Results Available","Alzheimer's Disease","Other: MRI","Quantitative magnetic susceptibility (QSM) in the human brain","Medical University of Graz","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","QSM AD","May 2016","May 2020","May 2020","April 27, 2016",,"August 14, 2019",,,"https://ClinicalTrials.gov/show/NCT02752750"
1236,"NCT04100889","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease|Alzheimer Disease 1|Alzheimer Disease 2|Alzheimer Disease 3|Alzheimer Disease 4|Alzheimer Disease 5|Alzheimer Disease 6|Alzheimer Disease 7|Alzheimer Disease 8|Alzheimer Disease 9, Late-Onset|Alzheimer Disease 10|Alzheimer Disease 11|Alzheimer Disease 12|Alzheimer Disease 13|Alzheimer Disease 14|Alzheimer Disease 15|Alzheimer Disease 16|Alzheimer Disease 17|Alzheimer Disease 18|Alzheimer Disease 19|Alzheimer Disease, Early Onset|Alzheimer Disease, Late Onset|Alzheimer Disease Focal","Other: No Intervention","Correlation of Microbiome to Alzheimer's Disease via Relative Abundance Found in Microbiome Sequencing","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ProgenaBiome-007","September 2019","September 2020","December 2020","September 24, 2019",,"September 24, 2019","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04100889"
1237,"NCT03971123","Study to Compare the Pharmacokinetics of Two Formulations of Tricaprilin and a Placebo on Ketone Body Production",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Tricaprilin|Drug: Placebo","Safety and tolerability of single-dose administration of each of 2 tricaprilin formulations (AC-SD-03 and AC-LMP-01) and the placebo formulation, AC-SD-03P, in healthy, male volunteers|Pharmacokinetics (PK) parameters of Total Ketones, Tricaprilin and Octanoic acid levels after single dose of AC-SD-03, AC-LMP-01 and AC-SD-03P using AUC(0-t).|Pharmacokinetics (PK) parameters of Total Ketones, Tricaprilin and Octanoic acid levels after single dose of AC-SD-03, AC-LMP-01 and AC-SD-03P using Cmax.|Pharmacokinetics (PK) parameters of Total Ketones, Tricaprilin and Octanoic acid levels after single dose of AC-SD-03, AC-LMP-01 and AC-SD-03P using Tmax.|ApoE4 Genotyping","Cerecin","Male","18 Years to 50 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AC-19-017","August 30, 2019","October 23, 2019","March 31, 2020","June 3, 2019",,"September 13, 2019","Nucleus Network, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03971123"
1238,"NCT04096261","The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease",,"Recruiting","No Results Available","Blood Brain Barrier Defect|Sleep Deprivation|Sleep Apnea|Alzheimer Disease","Diagnostic Test: Diagnostic Test","Marker of blood-brain dysfunction using MRI|Markers of blood-brain dysfunction using CSF|Sleep quality measurement","Charite University, Berlin, Germany|Arda Can Cetindag|Lukas Preis","All","60 Years and older   (Adult, Older Adult)",,"132","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BBB-Sleep","September 12, 2019","December 31, 2019","December 31, 2019","September 19, 2019",,"September 19, 2019","Charité Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04096261"
1239,"NCT03816228","Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.","Protocol Z","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: F 18 T807 Flortaucipir","F 18 T807 Standard Uptake Value Ratios","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol Z","October 14, 2019","December 2024","June 2025","January 25, 2019",,"September 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03816228"
1240,"NCT02562989","[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)",,"Completed","Has Results","Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: [18F]MK-6240, ~185 MBq|Drug: [18F]MK-6240, ~160 MBq","Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-6240|Organ Effective Dose of [18F]MK-6240|Standardized Uptake Value Ratio (SUVR) of [18F]MK-6240 in Brain Regions of Interest|Intra-subject Test-Retest (T-RT) Variability of Standardized Uptake Value Ratio (SUVR) in Brain Regions of Interest","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6240-001|2015-001659-58|MK-6240-001","October 19, 2015","December 27, 2016","December 27, 2016","September 29, 2015","July 23, 2018","September 18, 2018",,,"https://ClinicalTrials.gov/show/NCT02562989"
1241,"NCT02444637","Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD",,"Unknown status","No Results Available","Alzheimer Disease|CVA (Cerebrovascular Accident)","Drug: Rivastigmine","Number of Participants with Demonstrated Benefit in Global and Cognitive Measures|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","National Neuroscience Institute","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RACE_1.0","April 2015","April 2017",,"May 14, 2015",,"May 14, 2015","National Neuroscience Institute, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02444637"
1242,"NCT02089555","African American Alzheimer's Progression Markers - CSF and Neuro-Imaging","A3PM","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Procedure: Lumbar puncture|Procedure: Blood draw|Procedure: Magnetic Resonance Imaging (MRI)","CSF endothelial marker levels|CSF Alzheimer's biomarker levels|MRI evidence of small vessel disease|MRI evidence of brain atrophy","Emory University|National Institute on Aging (NIA)","All","60 Years to 85 Years   (Adult, Older Adult)",,"135","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00066145|R21AG043885","September 2013","June 2016","June 2016","March 18, 2014",,"June 23, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02089555"
1243,"NCT03420807","Retinal Metabolic Imaging of Alzheimer Patient",,"Recruiting","No Results Available","Alzheimer Disease","Device: MHRC","Retinal beta-amyloid detection","Optina Diagnostics Inc.|McGill University|Polytechnique Montreal|Sunnybrook Health Sciences Centre","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","50","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","071317","December 4, 2017","September 26, 2020","September 26, 2020","February 2, 2018",,"September 27, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03420807"
1244,"NCT03901092","A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation",,"Completed","No Results Available","Alzheimer Disease","Drug: flortaucipir F 18","Sensitivity and specificity of reader interpretation of Flortaucipir-PET images read as τAD+/τAD++, to detect NFT (neurofibrillary tangles) score of B3.|Sensitivity and specificity of reader interpretation of Flortaucipir-PET images read as τAD+/τAD++, to detect high AD neuropathological change.|Inter-reader reliability of reader interpretation of Flortaucipir-PET imaging|Sensitivity and specificity of reader interpretation of Flortaucipir-PET images read as τAD++, to detect NFT (neurofibrillary tangles) score of B3 (Hyman, et al 2012).|Sensitivity and specificity of reader interpretation of Flortaucipir-PET images read as τAD++, to detect high AD neuropathological change (Hyman, et al 2012).|Intra-reader reliability of reader interpretation of Flortaucipir-PET imaging","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 3","262","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-FR01","March 26, 2019","April 26, 2019","April 26, 2019","April 3, 2019",,"May 29, 2019","American College of Radiology, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03901092"
1245,"NCT04023994","A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",,"Recruiting","No Results Available","Alzheimers Disease","Drug: RO7126209|Drug: Placebo","Incidence of Adverse Events|Incidence of Abnormal Laboratory Findings|Incidence of Abnormal Vital Signs and Electrocardiogram (ECG) Parameters|Concentration at the End of Infusion (Cend) of RO7126209|Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209|Area Under the Plasma Concentration Versus Time Curve From Zero to 168h (AUC0-168h) of RO7126209|Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209|Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)|Terminal Rate Constant of RO7126209|Apparent Terminal Half-Life (T1/2) of RO7126209|Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209|Volume of Distribution at Steady-State (V) of RO7126209|CSF Concentration of RO7126209|Incidence of Anti-RO7126209 Antibodies (ADAs)","Hoffmann-La Roche","Male","18 Years to 40 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP41192","August 3, 2019","April 24, 2020","April 24, 2020","July 18, 2019",,"October 2, 2019","PRA Health Sciences, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04023994"
1246,"NCT03838185","Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: J147|Drug: Placebo","Incidence of treatment-emergent adverse events|Number of subjects with abnormal electrocardiogram|Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel|Incidence of clinically significant changes in hematological biomarker levels in a standard hematology panel|Incidence of clinically significant changes in urine biomarker levels in a standard urinalysis panel|Number of patients exhibiting changes in standard Physical Examination results|Number of patients exhibiting changes in standard Neurological Examination results|Maximum plasma concentration (Cmax)|Time to Cmax (Tmax)|Area under the plasma concentration vs. time curve (AUC)|Terminal rate constant|Terminal half-life (t1/2)|Apparent plasma clearance (CL/F)|Renal clearance (CLr)","Abrexa Pharmaceuticals, Inc.|Iqvia Pty Ltd","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ABRJ147001","January 22, 2019","October 2019","January 2020","February 12, 2019",,"February 12, 2019","Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03838185"
1247,"NCT03770182","Brain Stimulation for Neurological Patients",,"Recruiting","No Results Available","Alzheimer Disease","Device: NEUROLITH","Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Corrected Total Score|Alzheimer's Disease Assessment Scale (ADAS)|Neuropsychological Test Battery Vienna (NTBV)|CERAD|Clock drawing test|Forgetfulness assessment inventory (FAI)|Instrumental Activities of Daily Living Scale (IADL) - Patient|IADL- Patient|Beck Depression Inventory (BDI)|Prosopagnosia index (PI20)|Neuropsychiatric Inventory (NPI) (Care Taker)|IADL (Care Taker)|anatomical Magnetic Resonance Imaging (MRI)|functional Magnetic Resonance Imaging (fMRI)","Storz Medical AG|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TPS-AD-Vienna","January 24, 2017","January 1, 2020","January 1, 2020","December 10, 2018",,"December 13, 2018","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03770182"
1248,"NCT01795339","A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients",,"Completed","No Results Available","Healthy Elderly Volunteers|Mild-to-moderate Alzheimer's Disease Patients","Drug: AZD3293|Drug: Placebo","Adverse event monitoring|Assessment of vital signs (blood pressure, pulse and body temperature) and physical exams|Clinical laboratory tests (chemistry, hematology, urinalysis, renal safety)|Assessment of 12-lead digital electrocardiograms to measure rhythm, rate, morphology, QT/QTc interval|Assessment of telemetry, as reported by Investigator Columbia-Suicide Severity Rating Scale (C-SSRS)|Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD)|Investigation of the effect of AZD3293 on plasma and cerebrospinal fluid (CSF) biomarkers relevant for Alzheimer Disease (AD) in mild-moderate AD patients in comparison to elderly healthy volunteers|Investigation of the multiple dose Pharmacokinetics for AZD3293 and its metabolite AZ13569724, including dose proportionality for AZD3293 following oral administration|Investigation of the Pharmacokinetics/Pharmacodynamics relationship of the effect of AZD3293 on biomarkers relevant for Alzheimer Disease (AD) in plasma","AstraZeneca","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D5010C00002","March 2013","March 2014","March 2014","February 20, 2013",,"April 3, 2014","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01795339"
1249,"NCT03757910","Brain Imaging in the Diabetes Prevention Program Outcomes Study","DPPOS-Brain","Enrolling by invitation","No Results Available","Alzheimer Disease","Drug: 18F-MK-6240|Drug: 11C-PIB","Brain Amyloid SUVR|Brain Tau SUVR|Hippocampal Cortical Thickness|White Matter Hyper Intensity Volume","José A. Luchsinger|Albert Einstein College of Medicine|George Washington University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAS1176|3U01DK048404-25S1","October 1, 2019","January 31, 2020","January 31, 2020","November 29, 2018",,"September 23, 2019","Columbia University Medical Center, New York, New York, United States|Albert Einstein College of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03757910"
1250,"NCT03461276","Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease","Biological: ABvac40|Biological: Placebo","Incidence of treatment-emergent adverse events [safety and tolerability]|Immune response","Araclon Biotech S.L.","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AB1601","February 8, 2018","February 2022","February 2022","March 12, 2018",,"July 4, 2019","CHU de Montpellier, Montpellier, France|Centre de Recherche Clinique du Gérontopôle, Toulouse, France|San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Hospital Mutua de Terrasa, Terrassa, Barcelona, Spain|Hospital Universitario Donosti, San Sebastian, Guipuzcoa, Spain|Hospital Ramón y Cajal, Colmenar Viejo, Madrid, Spain|CUN - Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Cae Oroitu, Algorta, Vizcaya, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Fundació ACE, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital U. de Burgos, Burgos, Spain|Hospital Santa Maria de Lleida, Lleida, Spain|Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Karolinska Universitetssjukhuset, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03461276"
1251,"NCT03688126","U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk","POINTER","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Self-Guided Lifestyle Intervention|Behavioral: Structured Lifestyle Intervention","Global cognitive function|Episodic Memory|Executive Function|Processing Speed|Clinical Dementia Rating—Sum of Boxes|Instrumental Activities of Daily Living (IADL)|Everyday Cognition (ECog)|Digital Clock Drawing Test (DCTClock)|Lifestyle Composite","Wake Forest University Health Sciences|Alzheimer's Association","All","60 Years to 79 Years   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00052881","January 8, 2019","November 2023","November 2023","September 28, 2018",,"October 2, 2019","U.C. Davis, Sacramento, California, United States|Chicagoland (Rush University/Advocate Health Care), Chicago, Illinois, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03688126"
1252,"NCT03935568","A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: PU-AD|Drug: Placebo","To evaluate the safety and tolerability of single and multiple doses of PU-AD in healthy subjects|To determine the pharmacokinetics (PK) PU-AD in healthy subjects","Samus Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PU-AD-01-001","June 24, 2019","December 2019","December 31, 2019","May 2, 2019",,"September 25, 2019","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03935568"
1253,"NCT03108846","Escitalopram for Agitation in Alzheimer's Disease","S-CitAD","Recruiting","No Results Available","Dementia","Drug: Escitalopram|Drug: Placebo","modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)","JHSPH Center for Clinical Trials|National Institute on Aging (NIA)","All","18 Years to 109 Years   (Adult, Older Adult)","Phase 3","392","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S-CitAD|R01AG052510","January 3, 2018","December 2021","August 2022","April 11, 2017",,"January 17, 2019","Biomedical Research Foundation, Little Rock, Arkansas, United States|Irvine Clinical Research, Irvine, California, United States|University of California Los Angeles/VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of Southern California Keck School of Medicine Memory and Aging Center, Los Angeles, California, United States|Miami Jewish Health Systems, Miami, Florida, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Maryland VA Health Care System, Baltimore, Maryland, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Bayview Medical Center, Baltimore, Maryland, United States|Clinical Insights, Glen Burnie, Maryland, United States|Alzheimer Disease Center, Quincy, Massachusetts, United States|University of Michigan Program for Positive Aging, Ann Arbor, Michigan, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|Alzheimer Disease Research Center; University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Ltd, Willow Grove, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|University of Calgary and Foothills Medical Centre, Calgary, Alberta, Canada|Lawson Health Research Institute/Parkwood Institute, London, Ontario, Canada|Neuropsychopharmacology Research Group, Sunnybrook, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03108846"
1254,"NCT03635879","Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides",,"Withdrawn","No Results Available","Alzheimer Disease","Other: MCTprocal medical food|Other: Milk/tricaprilin oil blend|Other: AC-1207|Other: AC-1205|Other: AC-1206|Drug: AC-1202","Total ketones|B-hydroxybutyrate|Acetoacetate","Cerecin","Male","18 Years to 55 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","AX-18-018_PK","February 13, 2019","April 16, 2019","April 16, 2019","August 17, 2018",,"September 27, 2018",,,"https://ClinicalTrials.gov/show/NCT03635879"
1255,"NCT03587376","Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)",,"Completed","No Results Available","Alzheimer Disease","Drug: Atabecestat","Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response|Participants T-cell Receptor (TCR) Sequencing","Janssen Research & Development, LLC","All","50 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR108462|54861911ALZ0002|2018-000403-17","May 30, 2018","August 23, 2018","August 23, 2018","July 16, 2018",,"October 7, 2019","Ziekenhuis Hoge Beuken, Hoboken, Belgium|Hôpital Fernand Widal, Paris, France|CTC North GmbH & Co. KGim Spectrum am UKE, Hamburg, Germany|Fundacion Ace, Barcelona, Spain|Minnesmottagningen, M51, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03587376"
1256,"NCT03393520","Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Agitation in Patients With Dementia of the Alzheimer's Type","Drug: Placebo|Drug: AVP-786","Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change for Agitation (mADCS-CGIC-Agitation) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the ADCS-CGIC for Overall Clinical Status Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Scale Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Scale Score|Change from Baseline to Week 12 in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Dimension Scores|Change from Baseline to Week 12 in the Resource Utilization in Dementia (RUD) Scale Score","Avanir Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-AVP-786-305|2017-001339-38","October 13, 2017","June 2021","June 2021","January 8, 2018",,"October 11, 2019","Clinical Trials Inc., Little Rock, Arkansas, United States|SFM Clinical Research, LLC, Boca Raton, Florida, United States|Helix Biomedics LLC, Boynton Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Meridien Research - Lakeland Site, Lakeland, Florida, United States|Zynak Clinical Services, Lauderdale Lakes, Florida, United States|Crystal Biomedical Research, LLC, Miami Lakes, Florida, United States|City Medical Group RC, Miami, Florida, United States|Finlay Medical Research Corp, Miami, Florida, United States|Clinical Research Associates of South Florida, Miami, Florida, United States|Research Institute of West Kendall, Miami, Florida, United States|Bayside Clinical Research, New Port Richey, Florida, United States|Onyx Clinical Research, LLC, Caro, Michigan, United States|Galen Research, Chesterfield, Missouri, United States|Newton Clinical Research, Oklahoma City, Oklahoma, United States|Australian Alzheimer's Research Foundation, Nedlands, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|The Alfred Hospital, Parkville, Australia|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Bulgaria|Center for Mental Health - Ruse, Ruse, Bulgaria|First Multiprofile Hospital for Active Treatment Sofia, Sofia, Bulgaria|Medical Center Stimul, Sofia, Bulgaria|Medical Center Sveti Naum, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Alexandrovska, Sofia, Bulgaria|Medica Plus Medical Center, Veliko Tarnovo, Bulgaria|Fakultni Nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultní Nemocnice Hradec Králové, Hradec Kralové, Czechia|Brain-Soultherapy, Kladno, Czechia|Supervize, Kutná Hora, Czechia|AD71, Praha, Czechia|Clintrial, Praha, Czechia|Neurologicka Ambulance - Forbeli, Praha, Czechia|Neuropsychiatrie, Praha, Czechia|Vestra Clinics, Rychnov nad Kněžnou, Czechia|Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre, Caen cedex 9, France|Centre Hospitalier de Calais, Calais, France|Centre Hospitalier Universitaire Dijon Bourgogn, Dijon Cedex, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Centre Hospitalier Universitaire de Saint-Étienne - Hôpital Nord, Saint-Etienne, France|Centre Hospitalier Universitaire Toulouse - Casselardit Ancely, Toulouse, France|Centre Hospitalier Universitaire de Nancy - Hôpital de Brabois, Vandoeuvre les Nancy, France|Dr. Kenessey Albert Kórház-Rendelőintézet, Balassagyarmat, Hungary|Semmelweis Egyetem, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|Valeomed Egeszsegugyi es Szolgaltato Kft, Esztergom, Hungary|CRU Hungary Egészségügyi és Szolgáltató Korlátolt Felelősségű Társaság, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|PsychoTech, Pecs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Fejér Megyei Szent György Egyetemi Oktató Kórház, Székesfehérvár, Hungary|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy|Centro San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Università degli studi G.D'Annunzio Chieti Pescara, Chieti, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Italy|Fondazione Santa Lucia - Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy|Śródmieście Przychodnia - Bydgoszcz, Bydgoszcz, Poland|Centrum Medyczne Sensemed, Chorzów, Poland|Care Clinic, Katowice, Poland|Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland|Krakowska Akademia Neurologii, Kraków, Poland|Pratia MCM Kraków, Kraków, Poland|Medycyna Milorzab, Lodz, Poland|Neurologiczny Niepubliczny Zakład Opieki Zdrowotnej, Plewiska, Poland|Centrum Medyczne HCP, Poznań, Poland|Solumed Centrum Medyczne, Poznań, Poland|Centrum Medyczne Euromedis, Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|ACF Neurological Services, Cape Town, South Africa|Cape Trial Centre, Cape Town, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Apollo Clinical Research, Johannesburg, South Africa|Medical and Dental Centre, Rosebank, South Africa|Dr. Chisto Carel Coetzee, Umhlanga, South Africa|Fundació ACE, Barcelona, Spain|Fundació Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital Universitari de Santa Maria, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario y Politécnico de La Fe, Valencia, Spain|Complejo Asistencial de Zamora Hospital Virgen de la Concha, Zamora, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|MAC Clinical Research - Barnsley, Barnsley, United Kingdom|Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust, Belfast, United Kingdom|MAC Clinical Research - Blackpool, Blackpool, United Kingdom|MAC Clinical Research - Cannock, Cannock, United Kingdom|MAC Clinical Research - Leeds, Leeds, United Kingdom|Re:Cognition Health - London, London, United Kingdom|South London and Maudsley NHS Foundation Trust, London, United Kingdom|MAC Clinical Research - Manchester, Manchester, United Kingdom|Northamptonshire Healthcare NHS Foundation Trust, Northampton, United Kingdom|MAC Clinical Research - Liverpool, Prescot, United Kingdom|Southern Health NHS Foundation Trust, Southampton, United Kingdom|Avon and Wiltshire Mental Health Partnership NHS Trust, Swindon, United Kingdom|North West Boroughs Healthcare NHS Foundation Trust, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03393520"
1257,"NCT03551769","Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production",,"Completed","No Results Available","Alzheimer Disease","Drug: tricaprilin|Other: standard meal|Other: high-fat meal|Other: overnight fast","Total ketones|B-hydrodxybutyrate|B-hydroxybutyrate|Acetoacetate|tricaprilin|octanoic acid|Computerized Cognitive Battery - Attention|Computerized Cognitive Battery - Episodic Memory|Computerized Cognitive Battery - Working Memory|Computerized Cognitive Battery - Psychomotor Function","Cerecin","Male","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AC-18-016_FE","August 5, 2018","August 16, 2018","August 27, 2018","June 11, 2018",,"May 29, 2019","Nucleus Network, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03551769"
1258,"NCT03543878","Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials","FLICKER","Recruiting","No Results Available","Alzheimer Disease","Device: Flicker","Feasibility: amount of time of device use per day.|Tolerability: participant report","Emory University|Georgia Institute of Technology","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00101694","November 16, 2018","December 2019","December 2019","June 1, 2018",,"November 20, 2018","12 Executive Park Drive, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03543878"
1259,"NCT03467477","Tau Screening Study in Subjects With Early Symptomatic AD",,"Completed","No Results Available","Alzheimer Disease","Drug: 18F-AV-1451","Completion of a flortaucipir F18 PET scan","Avid Radiopharmaceuticals","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","161","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A24","March 8, 2018","November 15, 2018","November 15, 2018","March 16, 2018",,"December 6, 2018","Irvine Center for Clinical Research, Irvine, California, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|BioClinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Cotton O'neil Clinical Research Center, Topeka, Kansas, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT03467477"
1260,"NCT03447613","Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau",,"Completed","No Results Available","Alzheimer Disease","Procedure: surgery","Specific cognitive function|retinal nerve fiber layer (RNFL) thickness|Cerebrospinal fluid (CSF) Aβ concentration|Cerebrospinal fluid (CSF) Tau concentration|Global cognitive state","Shanghai 10th People's Hospital|Massachusetts General Hospital","All","50 Years and older   (Adult, Older Adult)",,"86","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","dsyy001","August 1, 2013","December 31, 2014","December 31, 2014","February 27, 2018",,"November 30, 2018","Shanghai 10th People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03447613"
1261,"NCT01198093","Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)","CREDOS","Unknown status","No Results Available","Alzheimer's Disease",,,"Samsung Medical Center|Ministry of Health & Welfare, Korea","All","Child, Adult, Older Adult",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2005-02-008","November 2005","August 2015","August 2015","September 9, 2010",,"September 28, 2012","Samsung Medical Center, Seoul, Kangnam-Ku, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01198093"
1262,"NCT02351882","Safety and Efficacy of Nabilone in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Agitation|Weight Loss|Pain|Oxidative Stress","Drug: Nabilone|Drug: Placebo","Change in agitation; Cohen-Mansfield Agitation Inventory (CMAI)|Change in neuropsychiatric symptoms; Neuropsychiatric Inventory (NPI)|Change in cognition; Standardized Mini-mental State Examination (sMMSE)|Change in cognition; Severe Impairment Battery (SIB)|Change in cognition; Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Change in clinical representation; Alzheimer's Disease Cooperative Study - The Clinician Global Impression (ADCS - CGIC)","Sunnybrook Health Sciences Centre","All","55 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","318-2013","January 2015","January 2018","March 2019","January 30, 2015",,"April 10, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02351882"
1263,"NCT03322462","Tau Screening Study in Patients With Early Symptomatic AD",,"Completed","No Results Available","Alzheimer Disease","Drug: 18F-AV-1451","Completion of a flortaucipir F18 PET scan","Avid Radiopharmaceuticals","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","153","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A23","October 26, 2017","August 31, 2018","August 31, 2018","October 26, 2017",,"September 10, 2019","Pacific Research Network, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Brain Matters Research, Delray Beach, Florida, United States|Bioclinica (Compass Research), Orlando, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Boston Center for Memory, Newton, Massachusetts, United States|PMG Research, Winston-Salem, North Carolina, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|The Memory Clinic, Bennington, Vermont, United States|Toronto Memory Program, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03322462"
1264,"NCT02835716","Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO","PCD=OOALZ","Recruiting","No Results Available","Alzheimer Disease","Drug: roflumilast|Biological: ustekinumab","Number of Participants who Develop Cognitive Decline","Millennium Magnetic Technologies, LLC","All","50 Years to 75 Years   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PCD=OO ALZ","September 2016","September 2019","September 2020","July 18, 2016",,"September 13, 2016","Millennium Magnetic Technologies, LLC, Westport, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02835716"
1265,"NCT03411291","Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study",,"Completed","No Results Available","Alzheimer's Disease","Device: MRI, MR Spectroscopy, MR Perfusion","MRI Spectroscopy|MRI Perfusion","Cedars-Sinai Medical Center","All","45 Years to 65 Years   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CSMC IRB Pro00011194","April 2007","September 2010","September 2010","January 26, 2018",,"February 19, 2018","Cedars-Sinai Medical Center, S. Mark Taper Foundation Imaging Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03411291"
1266,"NCT03204604","The Brain Ketone Body Challenge Imaging Study",,"Withdrawn","No Results Available","Alzheimer Disease","Dietary Supplement: Challenge A - low calorie Ensure®|Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)|Procedure: PET Scan|Behavioral: Cognitive Testing - FCSRT|Behavioral: Story Recall|Behavioral: BVRT|Behavioral: CogState One Card Learning","Primary Outcome - Brain Ketone Utilization|Secondary Outcome - Memory Composite Score","Wake Forest University Health Sciences","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","IRB00036958","August 8, 2016","March 2019","March 2019","July 2, 2017",,"March 19, 2019","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03204604"
1267,"NCT02928211","Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Device: Sapphire II|Drug: Aftobetin-HCl|Radiation: Positron Emission Tomography","Paired pre-ligand and post ligand fluorescent uptake values (FUV)|Determination of success (yes or no)|The overall diagnostic precision for each combination of Aftobetin-HCl administrations and Fluorescent Uptake Value (FUV)|Estimates of sensitivity and specificity of MCI and mild AD subjects compared to cognitively normal subjects|Safety of Sapphire II procedure as determined by instances of Adverse Events|Characterization of maximal fluorescence after 1, or potentially 3, ointment administrations|Intra-class correlation of the repeatability of the Sapphire II measurements to verify the system's reliability for reproducible results|Correlation of FUV to PET amyloid status","Cognoptix, Inc.","All","25 Years to 90 Years   (Adult, Older Adult)","Phase 1","105","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PRT-0036","July 2016","December 2018","January 2019","October 10, 2016",,"August 22, 2018","Neurology Research Institute, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02928211"
1268,"NCT03438604","A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil TDS","Pharmacokinetics, Cmax|Pharmacokinetics, AUC|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Summary Listing of Skin Irritation Score of Donepezil TDS by post-removal time point|Application Site Mean Adhesion Scores of Donepezil TDS","Corium International Inc.","All","30 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-16039","February 13, 2018","June 19, 2018","June 30, 2018","February 19, 2018",,"September 14, 2018","Celerion, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03438604"
1269,"NCT03432195","A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil TDS","Pharmacokinetics, AUC|Pharmacokinetics, CMAX|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Summary Listing of Skin Irritation Score of Donepezil Corplex TDS by post-removal time point|Application Site Mean Adhesion Scores of Donepezil Corplex TDS","Corium International Inc.","All","30 Years and older   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P16012","January 31, 2018","June 28, 2018","June 28, 2018","February 14, 2018",,"August 7, 2018","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03432195"
1270,"NCT03089918","A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain",,"Completed","No Results Available","Alzheimer Disease","Drug: 11C-JNJ-63779586","Effective Radiation Dose Following Injection of 11C-JNJ-63779586 (Part A)|Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 (Part B)|Percent Intact Tracer of 11C-JNJ-63779586 in Blood Samples (Part B)|Radiometabolite Fraction of 11C-JNJ-63779586 in Blood Samples (Part B)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Part A and Part B)","Janssen Research & Development, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR108288|63779586NAP1001|2016-001756-21","May 17, 2017","August 24, 2018","August 24, 2018","March 24, 2017",,"January 23, 2019","UZ Leuven, Leuven, Belgium|University of Antwerpen, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT03089918"
1271,"NCT02564692","GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype",,"Active, not recruiting","No Results Available","Alzheimer Disease",,"Number of individuals who enroll in GeneMatch|Number of individuals referred to research studies|Number of individuals who enroll in research studies","Banner Health","All","55 Years to 75 Years   (Adult, Older Adult)",,"500000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APR-001","November 2015","December 2030","December 2030","October 1, 2015",,"August 28, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Roaring Fork Neurology, Basalt, Colorado, United States|Colorado Springs Neurological Clinic, Colorado Springs, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|University of Miami Center on Aging, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Compass Research, LLC, The Villages, Florida, United States|Medical Research Health Education Foundation,, Columbus, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Advanced Clinical Research, Meridian, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|AMITA Health Alexian Brothers Neurosciences Research Institute, Elk Grove Village, Illinois, United States|University of Kansas Medical center - Alzheimer's Disease Center, Fairway, Kansas, United States|Boston University School of Medicine Alzheimer's Disease Center, Boston, Massachusetts, United States|Memory Center / Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Empire Neurology, Latham, New York, United States|University of Rochester Medical Center, AD-CARE, Rochester, New York, United States|Clarity Clinical Research, Syracuse, New York, United States|ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|University Hospitals Cleveland Medical Center, Beachwood, Ohio, United States|Abington Neurological Associates Ltd.,, Willow Grove, Pennsylvania, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinical Neuroscience Research Assoc. dba. The Memory Clinic, Bennington, Vermont, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02564692"
1272,"NCT03259958","A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®",,"Completed","No Results Available","Alzheimer's Disease","Drug: Donepezil TDS|Drug: Aricept","PK, AUC|PK, Cmax|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|PI assessment of local skin irritation response to TDS|PI assessment of TDS Adhesion","Corium International Inc.","All","30 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-16010","October 30, 2017","March 13, 2018","March 14, 2018","August 24, 2017",,"August 1, 2018","Celerion Inc., Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03259958"
1273,"NCT00733785","PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers","Rosi XR","Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone XR","•For the single dose period: AUC(0-inf) and Cmax of RSG XR.•For repeat dose period on Day 1 and 6:, AUC(0-24) and Cmax of RSG XR.|For single dose period: AUC(0-t), Tmax, lz, and t1/2 of RSG XR as data permit|For repeat dose period: Tmax, concentration at the end of the dosing interval (Ct), minimum observed concentration (Cmin),|Average concentration during a dosing interval (Cav), t1/2, , accumulation ratio(Rs) Rs= (AUC(0-t) last day)/(AUC(0-t) first day) and degree of fluctuation DF= (Cmax-Cmin)/Cave.|• Safety reporting (adverse events, laboratory testing, ECG, vital signs)","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVA109939","August 13, 2008","November 28, 2008","November 28, 2008","August 13, 2008",,"July 21, 2017","GSK Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00733785"
1274,"NCT02968719","A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil TDS Version A|Drug: Donepezil TDS Version B|Drug: Aricept|Drug: Donepezil TDS Version D|Drug: Donepezil TDS Version E","Steady-state PK|PK (Part B)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (Part A and B)|PI assessment of local skin irritation response to TDS (Part A and B)|PI assessment of TDS Adhesion per FDA UCM504157","Corium International Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-15086","November 2016","July 11, 2017","July 11, 2017","November 21, 2016",,"August 1, 2018","Celerion, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02968719"
1275,"NCT02414178","F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)","AV ADAD","Recruiting","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol D","March 20, 2019","February 2020","September 2020","April 10, 2015",,"June 20, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02414178"
1276,"NCT03172117","Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.",,"Recruiting","No Results Available","Alzheimer's Disease","Biological: human umbilical cord blood derived mesenchymal stem cells|Other: Normal saline 2mL","Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in CIBIC-plus|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers","Medipost Co Ltd.","All","50 Years to 86 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-CR-010-F/U","May 19, 2017","December 31, 2021","December 31, 2021","June 1, 2017",,"August 17, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03172117"
1277,"NCT02648906","A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients",,"Unknown status","No Results Available","Alzheimer Disease","Drug: Choline alfoscerate|Drug: Placebo","change of ADAS-cog score compared with Baseline","Daewoong Pharmaceutical Co. LTD.","All","56 Years to 90 Years   (Adult, Older Adult)","Phase 4","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DWB_GTM001","July 2015","November 2018",,"January 7, 2016",,"November 2, 2016","Seoul National University Bundang Hospital, Sungnam, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02648906"
1278,"NCT01138111","Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients",,"Completed","Has Results","Alzheimer Disease|Amyloid Beta-Protein","Drug: Florbetaben (BAY94-9172)","Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake|Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4|Number and Proportion of Normal and Abnormal Scans Based on Brain ß-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress|Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ß-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress","Life Molecular Imaging SA","All","60 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","312043","June 2008","December 2011","December 2011","June 7, 2010","June 25, 2014","June 25, 2014","Heidelberg, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01138111"
1279,"NCT00626613","The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)",,"Unknown status","No Results Available","Dementia|Alzheimer's Disease","Drug: Risperdal,reminyl","Neoropsychiatric Inventory (NPI)Cognitive Abilities Screening Instrument (CASI) SF-36abnormal involuntary movement scale (AIMS), Barnes akathisia rating scale (BARS), and Simpson angus scale (SAS)","Jinan Mental Hospital|Johnson & Johnson","All","60 Years and older   (Adult, Older Adult)","Phase 4",,"Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","REM-TWN-MA5",,,,"February 29, 2008",,"March 5, 2008","Department of Psychiatry Jinan Mental Hospital, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00626613"
1280,"NCT00759863","LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia","Lifezig","Completed","Has Results","Alzheimer's Disease|Dementia","Behavioral: Lifezig","Multidimensional Observation Scale for Elderly Subject|Revised Memory and Behavior Problems Checklist|Center for Epidemiologic Studies Depression Scale","Photozig, Inc.","All","21 Years and older   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pz-A102b|R44AG022261","August 2006","April 2009","April 2009","September 25, 2008","February 23, 2010","March 2, 2010","Photozig, Inc., Moffett Field, California, United States",,"https://ClinicalTrials.gov/show/NCT00759863"
1281,"NCT01640275","Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia","MAD-PIA","Completed","No Results Available","General Anesthesia","Drug: Propofol|Drug: Isoflurane","Ratio of cerebrospinal fluid tau to amyloid beta|the relationship between anesthetic exposure and CSF biomarker changes|the relationship between anesthetic exposure and CSF biomarker changes, and demographics (age, gender, and race)|the relationship between CSF biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and neuroimaging results obtained as dictated by routine standard of care|the relationship between anesthetic exposure and biomarker changes and depth of anesthesia, based on average BIS (bispectral index) monitoring signal|the relationship between anesthetic exposure and biomarker changes and the time of day that surgery is performed|the relationship between anesthetic exposure and biomarker changes with genetic polymorphisms in ApoE (apolipoprotein E) and other genes related to inflammation, metabolism, brain function and/or Alzheimer's disease","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","Pro00030861","March 2012","March 2015","March 2015","July 13, 2012",,"August 4, 2015","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01640275"
1282,"NCT02506374","Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads","BEST-Sleep","Withdrawn","No Results Available","Alzheimer's Disease",,"Qualitative Output from Focus Groups","Yale University","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort","1412015088","November 2014","January 2016","January 2016","July 23, 2015",,"January 12, 2016","Jewish Senior Services, Fairfield, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02506374"
1283,"NCT00954369","Exploratory and Safety Study of [F-18]W372",,"Completed","No Results Available","Alzheimer's Disease","Drug: [F-18]W372","Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.","Siemens Molecular Imaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","W372000","August 2009","February 2010","February 2010","August 7, 2009",,"August 22, 2012","University of California, Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT00954369"
1284,"NCT02840279","A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: BPN14770|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero to Twelve Hours [AUC0-12]|Area Under the Concentration Time Curve from Zero to 12 Hours, Corrected for Dose [AUC12/D]","Tetra Discovery Partners","All","25 Years to 90 Years   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-102","June 2016","November 2016","December 2016","July 21, 2016",,"January 18, 2017","Jasper Clinic, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02840279"
1285,"NCT02204969","LIWA for Treatment of Alzheimer Patients","LIWA","Unknown status","No Results Available","Alzheimer Disease","Dietary Supplement: Lithia water|Device: Transcranial Magnetic stimulation","Cognitive functioning score by ADAS-COG","American Society Of Thermalism And Climatology Inc","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","822429989","January 2015","June 2015","December 2015","July 31, 2014",,"January 6, 2015","Gaviota Clinic, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02204969"
1286,"NCT02795780","Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Change in tau deposition over time","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A18","August 2016","August 28, 2017","August 28, 2017","June 10, 2016",,"October 25, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Imaging Endpoints, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Brain Aging and Dementia, UC Irvine, Irvine, California, United States|21st Century Oncology, Newport Beach, California, United States|Alzheimer's Disease Center, UC Davis, Sacramento, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|University of South Florida Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|New York University Center for Brain Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02795780"
1287,"NCT02782975","Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants",,"Completed","No Results Available","Alzheimer's Disease","Drug: aducanumab","PK parameter of SC dose of aducanumab: Absolute Bioavailability|PK parameter of IV dose of aducanumab: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of SC dose of aducanumab: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of aducanumab: Maximum observed concentration (Cmax)|PK parameter of SC route of aducanumab: Time to reach maximum observed concentration (Tmax)|Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant laboratory assessment abnormalities|Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities|PK parameter of aducanumab: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)|PK parameter of aducanumab: Terminal elimination half-life (t1/2)|PK parameter of aducanumab: Volume of distribution (Vd)|PK parameter of aducanumab: Apparent total body clearance (CL/F)","Biogen","All","18 Years to 55 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","221HV102","May 2016","November 2016","November 2016","May 26, 2016",,"January 13, 2017","Research Site, Evansville, Indiana, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02782975"
1288,"NCT02710188","Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation",,"Completed","No Results Available","Alzheimer's Disease","Drug: HTL0009936 modified release|Drug: HTL0009936 immediate release","Tlag|Frel|Tmax|Cmax|Concentration of HTL0009936 at 6 hours post dose (C6)|AUC (0-last)|AUC (0-inf)|AUC%extrap|Lambda-z|T1/2|Dose normalized AUC|Dose normalized Cmax|Concentration of HTL0009936 at 12 hours post dose (C12)|Concentration of HTL0009936 at 24 hours post dose (C24)","Heptares Therapeutics Limited|Quotient Clinical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9936-104|2015-004921-16","February 2016","July 2016","August 2016","March 16, 2016",,"October 18, 2016","Quotient Clinical, Ruddington, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02710188"
1289,"NCT02695004","Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: DKF-310|Drug: Placebo","AUC|Cmax","Dongkook Pharmaceutical Co., Ltd.","Male","19 Years to 50 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","DKF-310-P1","February 2016","December 2017","December 2017","March 1, 2016",,"March 1, 2016","Seoul National Univ. Bundang Hospital, Seongnam, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02695004"
1290,"NCT02685969","Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants",,"Recruiting","No Results Available","Alzheimer's Disease","Procedure: 18F-Flutemetamol & 18F-FDG","Prevalence of a positive 18F-Flutemetamol scan|Prevalence of the different stages of preclinical AD according to the NIA-AA criteria","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Hospital Clinic of Barcelona|General Electric","All","45 Years to 75 Years   (Adult, Older Adult)",,"440","Other|Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","PET FLUTEMETAMOL-FDG/BBRC2015","March 1, 2017","March 1, 2019","March 1, 2020","February 19, 2016",,"April 4, 2018","BarcelonaBeta Brain Research Center, Barcelona, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT02685969"
1291,"NCT03319810","Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease",,"Completed","Has Results","Mild Cognitive Impairment","Biological: Octagam 10%","Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months|Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months","Sutter Health","All","50 Years to 84 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIMR_Kile_IVIG POC","January 4, 2018","July 19, 2018","July 19, 2018","October 24, 2017","April 16, 2019","June 25, 2019","Sutter Neuroscience Medical Group, Sacramento, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03319810/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03319810"
1292,"NCT02648672","BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: BPN14770|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero Extrapolated to Infinity [AUC0-∞]|Maximum Concentration [Cmax]","Tetra Discovery Partners","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-101","December 2015","February 2016","July 2016","January 7, 2016",,"January 18, 2017","Jasper Clinic, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02648672"
1293,"NCT02621606","[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)",,"Completed","Has Results","Alzheimer's Disease","Drug: [11C]MK-6884","Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing the Study Due to an Adverse Event (AE)|[Part 1] Mean Effective Dose of [11C]MK-6884|[Part 1] Mean Organ Effective Dose of [11C]MK-6884|[Part 2] Mean Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)|[Part 2] Intra-subject Test-Retest (T-RT) Variability of Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)|[Part 3] Mean Regional Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","6884-001|2015-001631-20|MK-6884-001","January 8, 2016","December 28, 2017","December 28, 2017","December 3, 2015","February 28, 2019","February 28, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02621606/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02621606"
1294,"NCT02141971","Down Syndrome Biomarker Initiative (DSBI)","DSBI","Completed","No Results Available","Down Syndrome|Alzheimer's Disease",,"Rate of decline as measured by cognitive, functional and behavioral tests|Rate of conversion will be evaluated among all age groups|Rate of volume change of whole brain, hippocampus, and other structural Magnetic resonance imaging (MRI) measures.|Rates of change on each specified biochemical biomarkers|Rates of change of glucose metabolism as measured by fluorodeoxyglucose positron emission tomography (FDG-PET) imaging|Extent of amyloid deposition as measured amyloid PET imaging|Rates of change on retinal amyloid measures.|Correlations among biomarkers and cognitive change.|Correlations of Tau deposition as measured by 18F-AV-1451 PET (Tau) imaging with other biomarkers","Michael Rafii|Janssen Research & Development, LLC|University of California, San Diego","All","30 Years to 60 Years   (Adult)",,"12","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DSBI","June 1, 2013","April 15, 2017","April 15, 2017","May 20, 2014",,"May 2, 2017","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02141971"
1295,"NCT02340195","Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function",,"Completed","No Results Available","Alzheimer Disease","Drug: Idalopirdine (Lu AE58054) 60 mg","Area under the LuAE58054 plasma concentration-time curve from time zero to 24h(AUC0-24)|Maximum observed concentration (Cmax) of Lu AE58054","H. Lundbeck A/S","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14916A|2012-005647-25","January 2015","September 2015",,"January 16, 2015",,"November 9, 2015","DE801, Munchen, Germany",,"https://ClinicalTrials.gov/show/NCT02340195"
1296,"NCT02546310","Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: HTL0009936|Drug: HTL0009936 matching placebo","Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks|BOLD signal in fMRI in other brain regions involved in the regulation of cognitive processes during cognitive tasks|cerebral blood flow, assessed using Arterial Spin Labelling (ASL)|adverse events|blood pressure|12-lead electrocardiogram","Heptares Therapeutics Limited|P1vital Limited","All","65 Years to 80 Years   (Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","9936-103","October 2015","February 2017","February 2017","September 10, 2015",,"February 3, 2017","Neuroscience and Psychiatry Unit, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02546310"
1297,"NCT02537938","Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)",,"Completed","No Results Available","Alzheimer's Disease","Drug: NGP 555","Number of adverse events or safety outcomes","NeuroGenetic Pharmaceuticals Inc|WCCT Global","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NGP 555-002","January 2016","December 2016","December 2016","September 2, 2015",,"March 29, 2017","WCCT Global, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT02537938"
1298,"NCT02534480","Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)",,"Completed","No Results Available","Alzheimer's Disease","Drug: NGP 555","Number of subjects with adverse events as a measure of safety and tolerability","NeuroGenetic Pharmaceuticals Inc","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NGP 555-001","March 2015","October 2015","November 2015","August 27, 2015",,"January 13, 2016","WCCT, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT02534480"
1299,"NCT02516046","18F-AV-1451 Autopsy Study",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Diagnostic Performance Individual Readers (NFT Score)|Diagnostic Performance Individual Readers (NIA-AA Autopsy Diagnosis)|Diagnostic Performance (NFT Score)|Diagnostic Performance (NIA-AA Autopsy Diagnosis)|Inter-Reader Agreement (NFT Score)|Inter-Reader Agreement (NIA-AA Autopsy Diagnosis)","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","156","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A16","September 2015","June 13, 2018","July 15, 2018","August 5, 2015",,"September 10, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Cherlin Research, Los Gatos, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|California Research Foundation, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|Ray Dolby Brain Health Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Galiz Research, Hialeah, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|D de la Vega MD Research Group, Miami, Florida, United States|Bioclinica, Orlando, Florida, United States|Emory University Brain Health Center, Atlanta, Georgia, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Steinberg Diagnostics, Henderson, Nevada, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Clarity Clinical Research, LLC, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Hospice of the Western Reserve, Cleveland, Ohio, United States|American Clinical Trials, LLC (Site 1216), Oklahoma City, Oklahoma, United States|Oklahoma Behavioral Health, Oklahoma City, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Houston Methodist Research Institute, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Overlake Internal Medicine Associates, PS, Bellevue, Washington, United States|University of Washington Medicine, Seattle, Washington, United States|University of Melbourne, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02516046"
1300,"NCT00366483","Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: Lecozotan SR","The incidence of adverse events and adverse reactions will be calculated. The safety variables (vital signs, ECG parameters, and routine laboratory tests) and PK parameters will be measured throughout study period.|Pharmacokinetic analysis after single and multiple dosing","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3098B1-130","May 2006",,,"August 21, 2006",,"March 16, 2007","Paris, France",,"https://ClinicalTrials.gov/show/NCT00366483"
1301,"NCT02471833","Health Evaluation in African Americans Using RAS Therapy","HEART","Recruiting","No Results Available","Alzheimer's Disease","Drug: Telmisartan 20mg|Drug: Telmisartan 40mg|Drug: Placebo","Change in concentration of cerebrospinal fluid angiotensin metabolites|Change in levels of plasma angiotensinogen|Change in levels of plasma renin|Change in levels of plasma angiotensin converting enzyme|Change in levels of plasma aldosterone|Change in levels of cerebrospinal fluid amyloid β42|Change in levels of cerebrospinal fluid T-tau|Change in levels of cerebrospinal fluid P-tau|Change in arterial function|Flanker Inhibitory Control and Attention Test|Set-shifting Test|Spatial 1-Back Test|Montreal Cognitive Assessment|Mini Mental State Examination (MMSE)|Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests|Wechsler Memory Scale-III Faces Test|Wechsler Memory Scale-Revised Logical Memory Test|Rey Auditory Verbal Learning Test|Arterial Spin Labeling-Magnetic Resonance Imaging|Structural Magnetic Resonance Imaging and White Matter Hyperintensities","Emory University","All","30 Years and older   (Adult, Older Adult)","Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00080192","April 2015","June 30, 2020","June 30, 2020","June 15, 2015",,"June 3, 2019","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02471833"
1302,"NCT04111211","Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits","Memento-Plus","Not yet recruiting","No Results Available","Alzheimer Disease",,"Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)|Mortality|Loss of autonomy based on functional activity assessment|Rate of cognitive decline based on change in cognitive performances|Neurovascular and cardiovascular events (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Institutionalization","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2019/16","October 2019","October 2024","October 2024","October 1, 2019",,"October 1, 2019","CHU d'Amiens, Amiens, France|AP-HP - CHU Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHRU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal, Paris, France|CHU de Bordeaux, Pessac, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France|Hospice Civil de Lyon, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT04111211"
1303,"NCT02178124","A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil|Drug: placebo","safety and tolerability evaluation|pharmacokinetics characteristic evaluation","Icure Pharmaceutical Inc.","Male","20 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IPI-002","July 2014","December 2014","December 2014","June 30, 2014",,"March 25, 2015","ASAN Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02178124"
1304,"NCT02172612","A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly",,"Completed","No Results Available","Alzheimer Disease","Other: Arm 1 Education Session","Change in appropriateness of anticholinergic medication prescribing practices.|Change in Anticholinergic Burden","Daniela Moga|University of Kentucky","All","65 Years and older   (Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","14-0461-F3R","September 2014","November 20, 2015","November 20, 2015","June 24, 2014",,"March 29, 2019","Sander's BrownCenter on Aging, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02172612"
1305,"NCT02363504","The Locus Coeruleus and Memory","LOCUS","Recruiting","No Results Available","Alzheimer's Disease","Other: 7 Tesla MRI with memory task and non-invasive neurostimulation","Blood Oxygen Level Dependent (BOLD) response during a memory task|Performance on the memory task|Noradrenalin levels during the memory task|Grey matter volume of the locus coeruleus|shape properties of the locus coeruleus|Performance on neuropsychological tests","Maastricht University Medical Center|Netherlands Organisation for Scientific Research","All","60 Years to 85 Years   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","NL51297.068.14","February 1, 2017","August 2019","August 2019","February 16, 2015",,"April 27, 2018","Maastricht University, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02363504"
1306,"NCT02264899","MEMENTO-VAScular COmponents of Dementia","VASCOD","Active, not recruiting","No Results Available","Alzheimer's Disease (AD)|Alzheimer's Disease (AD) Related Disorders","Other: in Memento-VASCOD","Change in cognitive performances over|Progression to clinical dementia of Alzheimer's type according to standardized criteria|Change in CSF and blood amyloid biomarkers of AD|Change in brain atrophy and hippocampal volumes|Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)","University Hospital, Bordeaux|Ministry for Health and Solidarity, France","All","50 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2012/32","November 4, 2014","December 2020","December 2020","October 15, 2014",,"July 31, 2019","CHU d'Amiens, Amiens, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|CHU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT02264899"
1307,"NCT02350634","18F-AV-1451 High Resolution Autopsy Study",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Relationship of 18F-AV-1451 scan and pathology","Avid Radiopharmaceuticals","All","60 Years to 89 Years   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A13","June 2015","May 18, 2018","May 18, 2018","January 30, 2015",,"October 24, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02350634"
1308,"NCT02336360","Augmenting 18F-AV-1451 Dosimetry Estimates",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Urine Analysis - Total integrated radioactivity excreted in urine","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A15","January 2015","June 2015","June 2015","January 13, 2015",,"January 25, 2016","Molecular NeuroImaging, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02336360"
1309,"NCT02198586","Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old",,"Completed","No Results Available","Alzheimer's Disease",,"Hippocampal atrophy","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","45 Years to 75 Years   (Adult, Older Adult)",,"575","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MRI/FBB 2014","April 2014","July 2015","September 2015","July 23, 2014",,"March 3, 2017","Barcelonabeta Brain Research Center, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02198586"
1310,"NCT02291783","Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment",,"Completed","No Results Available","Alzheimer's Disease","Drug: HTL0009936|Drug: HTL0009936 placebo","Number of participants with Adverse Events, as a measure of safety and tolerability|Changes in Safety Lab parameters as a measure of safety and tolerability|Changes in vital signs as a measure of safety and tolerability|Changes in 12-lead electrocardiograms as a measure of safety and tolerability|Pharmacokinetic measures in plasma as measured by Peak plasma concentration (Cmax)|Pharmacokinetic measures in cerebro spinal fluid (CSF) in young males as measured by max observed CSF (Cmax CSF)|Pharmacokinetic measures to assess the food effect as measured by ANOVA|Pharmacodynamic response as measured by pupillometry|Pharmacokinetic measures in urine in young males and elderly male and female subjects as measured by amount of urine excreted at collection intervals|Pharmacodynamic response as measured by Bond and Lader visual analogue scale|Pharmacodynamic response as measured by changes in qEEG and Event Related Potentials (ERP)","Heptares Therapeutics Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9936-101|2013-002307-34","November 2013","July 2014","July 2014","November 14, 2014",,"June 20, 2017","Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02291783"
1311,"NCT02278354","Tau Imaging in Professional Fighters",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","18F-AV-1451 Uptake","Avid Radiopharmaceuticals|The Cleveland Clinic","Male","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A11","December 2014","February 3, 2017","February 3, 2017","October 30, 2014",,"April 14, 2017","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT02278354"
1312,"NCT01009476","Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine",,"Completed","No Results Available","Dementia|Alzheimer Disease|Dementia, Vascular","Drug: Galantamine|Drug: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)","documentation of the long-term use of galantamine and nootropics over a 1 year period under conditions of daily routine in patients with Alzheimer's disease (with or without vascular pathology)","Janssen-Cilag G.m.b.H","All","50 Years and older   (Adult, Older Adult)",,"1134","Industry","Observational","Time Perspective: Prospective","CR011689","March 2006","August 2008","August 2008","November 6, 2009",,"June 18, 2014",,,"https://ClinicalTrials.gov/show/NCT01009476"
1313,"NCT01656525","A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients",,"Completed","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Number of participants with Adverse Events|Pharmacokinetic parameters of Gantenerumab in plasma|CSF/plasma ratios of Gantenerumab.|Change from baseline in plasma Abeta|Change from baseline in plasma and CSF tau|Change from baseline in Mini-Mental State Examination (MMSE) and Alzheimer's disease assessment scale cognitive behaviors (ADAS-Cog).","Chugai Pharmaceutical","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","JP22431|JapicCTI-121849","June 2012","March 2014","June 2014","August 3, 2012",,"September 19, 2014","Kansai region, Kansai, Japan|Kanto region,, Kanto, Japan|Kyushu region, Kyushu, Japan|Tokai region, Toakai, Japan|Tohoku region, Tohoku, Japan",,"https://ClinicalTrials.gov/show/NCT01656525"
1314,"NCT03613844","DHA Brain Delivery Trial","PreventE4","Recruiting","No Results Available","Brain DHA Delivery and Alzheimer's Disease Risk","Drug: DHA|Drug: Placebo","change in cerebrospinal fluid fatty acid levels after the intervention in 160 subjects","University of Southern California|Huntington Medical Research Institutes|National Institute on Aging (NIA)|Alzheimer’s Drug Discovery Foundation","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","HS-18-00291/00984|R01AG054434|GC-201711-2014197","July 1, 2018","September 30, 2023","September 30, 2024","August 3, 2018",,"July 19, 2019","USC Keck School of Medicine, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03613844"
1315,"NCT02190084","Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia",,"Completed","No Results Available","Apathy|Alzheimer's Dementia","Device: Neurostar repetitive transcranial magnetic stimulator","Apathy Evaluation Scale (AES)|Trials making test","Central Arkansas Veterans Healthcare System","All","55 Years to 91 Years   (Adult, Older Adult)","Phase 4","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547461","May 2014","May 2019","July 2019","July 15, 2014",,"August 21, 2019","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02190084"
1316,"NCT02120664","Florbetapir Calibration to the Centiloid Scale",,"Completed","Has Results","Alzheimer's Disease","Drug: Florbetapir (18F)|Drug: 11C-PiB","Florbetapir SUVr Conversion to Centiloid Units|Correlation of Florbetapir (18F) Centiloid and 11C-PiB Centiloid|Variability of PET Images in Young Healthy Control Subjects.","Avid Radiopharmaceuticals","All","21 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A22","April 2014","September 2015","September 2015","April 23, 2014","March 9, 2017","March 9, 2017","Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Heidelberg, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02120664"
1317,"NCT02107599","The Feasibility of Florbetapir Quantitation in Europe",,"Completed","Has Results","Alzheimer's Disease","Drug: Florbetapir (18F)","Change in Reader Accuracy After Application of Quantitation Software|Change in Scan Interpretation Reliability After Application of Quantitation Software","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 4","96","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-QP02","March 2014","May 2014","May 2014","April 8, 2014","July 9, 2015","July 9, 2015","Research Site, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02107599"
1318,"NCT01584440","Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients",,"Completed","No Results Available","Agitation|Alzheimer's Disease","Drug: AVP-923 (dextromethorphan/quinidine)|Drug: Placebo","Neuropsychiatric Inventory (NPI)|Safety and Tolerability|ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating)|PGIC Patient Global Impression of Change (PGI-C)|QoL-AD (Quality of Life - Alzheimer's Disease measure)|ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory)|CSI (Caregiver Strain Index)|CSDD (Cornell Scale for Depression in Dementia)|(MMSE) Mini-Mental State Examination","Avanir Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-AVR-131","June 2012","July 2014","September 2014","April 25, 2012",,"January 11, 2018","Phoenix, Arizona, United States|Sun City, Arizona, United States|Fresno, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Sherman Oaks, California, United States|Temecula, California, United States|Boynton Beach, Florida, United States|Deerfield Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|West Palm Beach, Florida, United States|Weston, Florida, United States|Elk Grove Village, Illinois, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Summit, New Jersey, United States|Toms River, New Jersey, United States|Orangeburg, New York, United States|Rochester, New York, United States|White Plains, New York, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Lakewood, Ohio, United States|Allentown, Pennsylvania, United States|Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01584440"
1319,"NCT02061878","A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: Bexarotene|Drug: Placebo","Area under the effect curve for newly generated beta-Amyloid (clearance phase),|Fractional clearance rate of beta-Amyloid peptide in CNS","ReXceptor, Inc.","All","21 Years to 50 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","REXCEPTOR-101","August 2014","November 2014","November 2014","February 13, 2014",,"August 13, 2015","Compass Research, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02061878"
1320,"NCT01860625","A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil patch|Drug: placebo","safety and tolerability evaluation|pharmacokinetics characteristic evaluation","Icure Pharmaceutical Inc.","Male","20 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IPI-001","April 2013","December 2013","February 2014","May 23, 2013",,"June 30, 2014","ASAN Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01860625"
1321,"NCT02051790","Evaluation of Reader Training Processes",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Agreement Between Expert Panel and Clinical Practice Reads","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 4","241","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-RTP01","March 2014","August 2014","August 2014","January 31, 2014","September 28, 2015","September 28, 2015","Research Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02051790"
1322,"NCT02051764","Imaging Characteristics of a Follow-up 18F-AV-1451 Scan",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451|Drug: Florbetapir F 18","Change in Tau deposition","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A04","May 2014","December 2016","December 2016","January 31, 2014",,"February 9, 2017","Hoag Memorial Hospital, Newport Beach, California, United States|UC Irvine Medical Center, Orange, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Center for Clinical Imaging Research, Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02051764"
1323,"NCT01946243","The Feasibility of Florbetapir Quantitation",,"Completed","Has Results","Alzheimers Disease","Drug: Florbetapir F18","Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)|Change in Total Accuracy (MIMNeuro Software, All Readers)|Change in Reliability (MIMNeuro Software)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)|Change in Reliability (Siemens Syngo.PET Software)","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 4","96","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-QP01","August 2013","April 2014","April 2014","September 19, 2013","June 1, 2015","June 29, 2015","Research Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01946243"
1324,"NCT02041728","The Detection of Early Dementia With the Digital Game Memory",,"Completed","No Results Available","Alzheimer's Disease",,"Association of cognitive status with failures in a computerised memory game","Universitaire Ziekenhuizen Leuven","All","75 Years and older   (Older Adult)",,"20","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","S54845","January 2013","March 2013","April 2013","January 22, 2014",,"January 22, 2014","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT02041728"
1325,"NCT02040987","AZD3293 Thorough QT Study in Healthy Male Volunteers","AZD3293TQT","Completed","No Results Available","Alzheimer's Disease","Drug: AZD3293|Drug: Placebo|Drug: Moxifloxacin","The effect of a single dose of AZD3293 low dose and high dose on the change in time-matched QTcF intervals compared with placebo.|The effect of a single oral dose of moxifloxacin on the changes in time-matched QTcF intervals compared with placebo.|The safety and tolerability of AZD3293 in healthy male subjects by assessing a panel of adverse events measures|Plasma concentrations, AUC, Cmax and tmax of single dose AZD3293 and moxifloxacin in healthy male subjects|The effect of AZD3293 on additional electrocardiogram (ECG) variables (heart rate, RR, PR, QRS, QT and QTcB)","AstraZeneca|Parexel","Male","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D5010C00008","January 2014","May 2014","May 2014","January 20, 2014",,"July 3, 2014","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02040987"
1326,"NCT02423122","A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: VX-745","Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET|Number of 11C-PiB Responders|Wechsler Memory Scale (WMS) Immediate Recall Composite|Wechsler Memory Scale (WMS) Delayed Recall Composite","EIP Pharma Inc","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EIP-VX00-745-302","April 2015","July 2016","September 2016","April 22, 2015","June 14, 2019","June 14, 2019","Alzheimer Research Center, VU Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02423122"
1327,"NCT02029547","Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: Florbetapir (18F)","Inter Rater Reliability|Percent Agreement with Expert Panel|Change in inter reader reliability after application of quantitation software|Change in agreement with expert panel","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Not Applicable","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-JPT01","October 2014","May 2015","May 2015","January 8, 2014",,"October 23, 2014","Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02029547"
1328,"NCT01992380","A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Test-Retest Reproducibility","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-1451-A03","November 2013","May 2014","May 2014","November 25, 2013",,"June 9, 2014","Research Site, Newport Beach, California, United States|Research Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01992380"
1329,"NCT02380573","Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","MB2","Suspended","No Results Available","Mild Cognitive Impairment|MCI|Aging|Alzheimer's Disease|AD","Drug: Methylene Blue|Drug: FD&C Blue # 2|Drug: Phenazopyridine hydrochloride","Working memory task|Working memory task response|Episodic memory task|Episodic memory task response|Sustained attention task|Sustained attention task reaction time|Neuropsychological battery composite score|Cerebral blood flow measures","The University of Texas Health Science Center at San Antonio|Texas Alzheimer’s Research and Care Consortium (TARCC)","All","45 Years to 89 Years   (Adult, Older Adult)","Phase 2","117","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC20150410H","July 2015","July 2022","July 2023","March 5, 2015",,"May 8, 2019","Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02380573"
1330,"NCT03075241","Z-Drugs for Sleep Disorders in Alzheimer's Disease",,"Recruiting","No Results Available","Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease","Drug: Zolpidem|Drug: Zoplicone|Drug: Placebo","Nighttime Total Sleep Time|Daytime Total Sleep Time|Ratio of daytime to nighttime sleep|Nighttime Wake after Sleep Onset|Proportion of sleep time at nighttime|Proportion of patients with gain of at least 30 minutes in Total Sleep Time|Differences between sleep efficiency between the two treatments.|Nighttime Number of Awakenings","Brasilia University Hospital","All","55 Years and older   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ZOLP-001","October 2016","January 2020","December 2020","March 9, 2017",,"July 9, 2019","Geriatric Medical Centre, Brasilia, Distrito Federal, Brazil",,"https://ClinicalTrials.gov/show/NCT03075241"
1331,"NCT01609335","Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults",,"Completed","No Results Available","Alzheimer's Disease","Drug: F-18 FDG|Drug: C-11 PiB","Normal values for amyloid PET, FDG and Magnetic Resonance Imaging","Mayo Clinic","All","30 Years to 49 Years   (Adult)","Phase 1","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11-006972","July 2012","August 2013","August 2013","May 31, 2012",,"August 8, 2014","Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01609335"
1332,"NCT02530255","Telomerase Activator and Retinal Amyloid",,"Completed","No Results Available","Alzheimer Disease","Dietary Supplement: cycloastragenol|Dietary Supplement: placebo (for cycloastragenol)","Retinal Amyloid Index (RAI)|Telomere length (kilobases)","Chippewa Valley Eye Clinic|TA-Sciences","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAS-003-AD","December 1, 2016","October 31, 2018","December 31, 2018","August 21, 2015",,"July 3, 2019","Chippewa Valley Eye Clinic, Eau Claire, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02530255"
1333,"NCT01723488","A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808","T808","Terminated","No Results Available","Alzheimers Disease","Radiation: [F18] T808","To monitor and assess the safety of IV administration of [F-18]T808|To begin collection of baseline [F-18]T808 PET/CT imaging data","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T808000","July 2012","March 2013","March 2013","November 8, 2012",,"July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01723488"
1334,"NCT02303158","Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression","LIDEAL","Terminated","No Results Available","Alzheimer's Disease",,"Analysis of cerebrospinal fluid|Conversion to dementia|Depression subtypes","Institut Investigacio Sanitaria Pere Virgili","All","18 Years to 60 Years   (Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IISPV-LIDEAL-HTVC","January 2014","February 2016","October 2018","November 27, 2014",,"October 9, 2018","Hospital de Tortosa, Verge de la Cinta, Tortosa, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT02303158"
1335,"NCT03724942","Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Agitation Associated With Dementia of the Alzheimer's Type","Drug: Brexpiprazole","The frequency of Adverse events|Mean change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) score at 14 weeks after dosing|Mean change from baseline in Clinical Global Impression of Severity (CGI-S) score at 14 weeks after dosing|Mean change from baseline in Clinical Global Impression of Improvement (CGI-I) score at 14 weeks after dosing","Otsuka Pharmaceutical Co., Ltd.","All","55 Years to 89 Years   (Adult, Older Adult)","Phase 3","157","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-102-00184","November 9, 2018","May 2021","May 2021","October 30, 2018",,"December 27, 2018","Jisenkai Nanko Psychiatric Institute, Shirakawa, Japan",,"https://ClinicalTrials.gov/show/NCT03724942"
1336,"NCT01564706","A Study of 18F-AV-45 in Healthy Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Whole Body Radiation Dosimetry","Avid Radiopharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A02","October 2007","January 2008","January 2008","March 28, 2012","April 30, 2012","May 18, 2012","Research Site, Jenkintown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01564706"
1337,"NCT01716897","An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption",,"Completed","No Results Available","Alzheimer's Disease","Drug: E2609","AUC(0-inf) ratio, new tablet vs. capsule|AUC(0-inf) ratio, fed state vs. fasted state, both after administration of new tablet|Cmax ratio, new tablet vs. capsule|Cmax ratio, fed state vs. fasted state, both after administration of new tablet|incidence of Adverse events","Eisai Inc.","Male","30 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2609-A001-007","October 2012","December 2012","February 2013","October 30, 2012",,"May 22, 2013","California Clinical Trials/Parexel, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01716897"
1338,"NCT01702480","Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK2981710|Drug: Placebo","Part 1: Plasma BHB elevation time course of GSK2981710|Part 1: Area under the time concentration curve (AUC) of GSK2981710|Part 1: Maximum concentration (Cmax) of GSK2981710|Part 2: Change from Baseline in performance on CANTAB Paired Associates Learning task|Part 2: Change from Baseline in performance on CANTAB Verbal Recognition Memory task|Part 2: Change from Baseline in performance on CANTAB Spatial Working Memory (SWM) task|Part 2: Change from Baseline in performance on CANTAB Rapid Visual Processing task|Part 2: Change from Baseline in performance on CANTAB Reaction Time task|Part 2: Change from Baseline in performance on Source Memory Task|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by number of subjects with adverse events (AE)s|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in ECG readings|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in laboratory values|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in vital signs|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Gastrointestinal (GI) Symptom and stool diary|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Liking Assessment|Part 2: Change from Baseline in P300 EEG measurement|Part 2: Resting EEG measurement|Part 2: EEG measurement during Source Memory Task|Part 2: Correlation between systemic exposure of BHB and selected PD measurements","GlaxoSmithKline","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","116713","November 5, 2012","July 3, 2015","July 3, 2015","October 8, 2012",,"May 9, 2017","GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01702480"
1339,"NCT03657745","Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy","AlzLife","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Dementia|Cognition Disorders in Old Age|Cognitive Decline|Cognitive Deterioration","Device: Combination of 40Hz light and cognitive therapy (ALZLIFE)","In-app cognitive test|Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL)","Alzheimer's Light LLC","All","50 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AlzLife001","January 1, 2018","December 31, 2023","December 31, 2023","September 5, 2018",,"September 5, 2018","Andrey Vyshedskiy, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03657745"
1340,"NCT01660815","A Study of Florbetapir (18F) in Japanese Healthy Volunteers",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir (18F)","Whole Body Radiation Dosimetry","Avid Radiopharmaceuticals|Eli Lilly and Company","All","45 Years and older   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-J02|I6E-AV-AVBA","August 2012","January 2013","January 2013","August 9, 2012","September 19, 2013","September 19, 2013","Research Site, Kobe, Japan",,"https://ClinicalTrials.gov/show/NCT01660815"
1341,"NCT01230853","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study",,"Completed","No Results Available","Alzheimer's Disease","Drug: Active Comparator: A|Drug: Placebo Comparator B|Drug: Active Comparator B|Drug: Placebo Comparator A","Single Ascending Dose (SAD)|Multiple Ascending Dose(MAD)","Eisai Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BAN2401-A001-101","August 2010","October 2012","February 2013","October 29, 2010",,"May 22, 2013","Garden Grove, California, United States|San Francisco, California, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Eatontown, New Jersey, United States|Princeton, New Jersey, United States|Salt Lake City, UT, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01230853"
1342,"NCT01329484","Computerized Personal Interventions for Alzheimer's Patients",,"Unknown status","No Results Available","Alzheimer's Disease","Behavioral: Reminiscence therapy|Behavioral: Cognitive training|Other: No treatment","Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.","Shaare Zedek Medical Center","All","60 Years and older   (Adult, Older Adult)","Not Applicable","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPI-AD-TD-CTIL","March 2011","September 2012","September 2012","April 6, 2011",,"April 6, 2011","Mental Health Center, Beer Sheva, Israel|Memory Clinic, Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01329484"
1343,"NCT01607476","Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)",,"Completed","Has Results","Alzheimer's Disease","Drug: C11 PiB|Drug: F18 Flutametamol","Global Distribution of C11 PiB in the Brain|Global Distribution of F18 Flutemetamol in the Brain","Mayo Clinic","All","30 Years and older   (Adult, Older Adult)","Phase 2","89","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-000118","July 2012","December 2014","March 2016","May 30, 2012","November 1, 2016","April 18, 2017","Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01607476"
1344,"NCT03620981","Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Agitation Associated With Dementia of the Alzheimer's Type","Drug: Brexpiprazole|Drug: Placebo","Mean change from baseline in Cohen-Manfield Agitation Incentory(CMAI) score at 10 weeks|Mean change from baseline in CMAI score at 10 weeks|Mean change from baseline in Clinical Global Impression of Severity (CGI-S) score at 10 weeks","Otsuka Pharmaceutical Co., Ltd.","All","55 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-102-00088","August 20, 2018","November 2021","November 2021","August 8, 2018",,"July 11, 2019","Jisenkai Nanko Psychiatric Institute, Shirakawa, Japan",,"https://ClinicalTrials.gov/show/NCT03620981"
1345,"NCT01568086","Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A",,"Terminated","No Results Available","Alzheimer's Disease",,"Safety/Tolerability|Clinical Efficacy|Immunological","Affiris AG","All","50 Years to 80 Years   (Adult, Older Adult)",,"16","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AFF005B","December 2011","June 2013","October 2013","April 2, 2012",,"November 6, 2013","Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt, Vienna, Austria|Medical University of Vienna, Department for Psychiatry and Psychotherapy, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT01568086"
1346,"NCT01565369","Evaluation of Physician Training Methods to Read Florbetapir-PET Scans",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Inter-reader Agreement","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A08","January 2011","January 2011","January 2011","March 28, 2012","June 7, 2012","June 7, 2012",,,"https://ClinicalTrials.gov/show/NCT01565369"
1347,"NCT00857506","Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: florbetapir F 18","Change in ADAS-Cog for MCI Subjects|Cognitive Decline in MCI Subjects|Change in ADAS-Cog in CN and AD Subjects|Cognitive Decline in CN and AD Subjects|Covariate Adjusted Psychometric Score Change|Correlation of Change in ADAS-Cog and SUVR","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A11","January 2009","December 2011","December 2011","March 6, 2009","March 28, 2013","March 28, 2013","Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, Brooksville, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00857506"
1348,"NCT01268020","Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC","FMH3","Completed","No Results Available","Alzheimer Disease","Drug: [18F]-FMH3","To assess the dynamic uptake and washout of 18F-FMH3","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FMH3-01","December 2010","October 2012","October 2012","December 29, 2010",,"November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01268020"
1349,"NCT02832921","Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk",,"Recruiting","No Results Available","Alzheimer's Disease (AD)","Behavioral: cognitive training by virtual reality|Behavioral: watching a scientific TV documentary|Device: treadmill","change in overall cognition- measured by averaging z-scores from 14 paper and pencil neuropsychological tests covering episodic memory and executive functions cognitive domains.|change in cerebral blood flow from arterial spin labeling (ASL)|specific cognitive domains- average of z-scores of paper and pencil memory tests and of executive functions tests|blood oxygenation level dependent (BOLD) functional MRI (fMRI) signal in the fronto-parietal network associated with working memory|brain resting state functional connectivity by resting state network fMRI BOLD signal correlations|hippocampal volume|frontal inferior cortex volume|white matter hyperintensity (WMH) burden|diffusion-tensor imaging (DTI) measures","Sheba Medical Center","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","SHEBA-16-2988-MSB-CTIL","July 2016","July 2019","August 2019","July 14, 2016",,"January 26, 2018","Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT02832921"
1350,"NCT01297036","Pharmacokinetic Comparisons of Two Donepezil Formulations",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil, ODT 10 mg|Drug: Donepezil, 10 mg tablet","donepezil pharmacokinetics: peak plasma concentrations (Cmax)|donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to 240 hr(AUCall)|donepezil pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to infinity(AUCinf)","Korea University Anam Hospital|Chong Kun Dang Pharmaceutical Corp.","Male","20 Years to 45 Years   (Adult)","Phase 1","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","121HPS07D_03","January 2008","March 2008","May 2008","February 16, 2011",,"February 16, 2011","Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01297036"
1351,"NCT01454115","Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163",,"Completed","No Results Available","Alzheimer's Disease","Drug: BMS-708163 (Gamma-Secretase Inhibitor)|Drug: Placebo matching BMS-708163","Safety and tolerability of Single doses of BMS-708163 in the range of 0.3 to 800 mg in the healthy subjects|Effects of BMS-708163 on cortisol and QT interval corrected for heart rate|Effect of BMS-708163 on thyroid stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), and lymphocyte subsets|Bioavailability of BMS-708163 from a capsule formulation relative to a solution formulation|Effect of food on the PK of BMS-708163 administered as a capsule formulation|Maximum observed plasma concentration (Cmax) of BMS-708163|Time of maximum observed plasma concentration (Tmax) of BMS-708163|Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-708163|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-708163|Plasma half-life (T-HALF) of BMS-708163","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CN156-001","June 2007","March 2009","March 2009","October 18, 2011",,"November 21, 2011",,,"https://ClinicalTrials.gov/show/NCT01454115"
1352,"NCT01447719","Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Sensitivity Analysis in All Autopsy Population|Specificity Analysis in All Autopsy Population|Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Sensitivity Analysis in Subjects With Autopsy Within 1 Year of Scan|Specificity Analysis in Subjects With Autopsy Within 1 Year of Scan","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A16","March 2010","March 2011","July 2011","October 6, 2011","May 7, 2012","May 22, 2012","Research Site, Phoeniz, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01447719"
1353,"NCT01577394","Oculomotor Testing in the Differential Diagnosis of Dementia","OculoMacl","Completed","No Results Available","Lewy Body Disease|Alzheimer's Disease","Other: oculomotor measurements","Variability of reflexive saccades latencies|Correlations between oculomotor records and neuropsychological examination assessing attention abilities and their fluctuations|Potential correlations between hippocampal volume and neuropsychological examination in DLB cases|Cerebral atrophy differences between DLB and AD using SVM (Support Vector Machine) method|Percentage of alpha synuclein in CSF to discriminate DLB from AD|Variations at one year in oculomotor test scores and neuropsychological test scores|Mean reflexive saccades latency|Percentage of express saccades|Correlations between neuropsychological tests scores assessing attention abilities and variability of reflexive saccades latencies","Assistance Publique - Hôpitaux de Paris","All","65 Years and older   (Older Adult)","Phase 3","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AOM 09158","June 2011","February 2016","April 2016","April 13, 2012",,"May 23, 2016","Assistance Publique Hôpitaux de Paris - Pitié-Salpetriere hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT01577394"
1354,"NCT02013518","Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia",,"Unknown status","No Results Available","Alzheimers' Disease","Behavioral: Cognitive Behavioural Therapy","Number of participants reporting decrease in depression scores|Number of participants reporting increased Self-efficacy|Number of participants reporting increased Quality of Life|Number of participants reporting change in cognitive function|Number of participating caregivers reporting decreased burden of care","Oslo University Hospital|Sykehuset i Vestfold HF|Sykehuset Innlandet HF","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2012/1943|12345","September 2013","December 2015","December 2016","December 17, 2013",,"December 17, 2013","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02013518"
1355,"NCT01325662","A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211)",,"Completed","No Results Available","Alzheimer's Disease",,"Increase in CSF Aβ40 levels as measured by the new low flow continuous drip sampling method|Increase in CSF Aβ40 levels as measured by the current intermittent drip sampling method","Merck Sharp & Dohme Corp.","All","18 Years to 40 Years   (Adult)",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","0000-211","March 2011","September 2011","September 2011","March 30, 2011",,"July 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01325662"
1356,"NCT01314131","Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home",,"Unknown status","No Results Available","Alzheimer's Disease","Behavioral: Stimulation group","The primary outcome is the engagement duration for an activity, measured by the OME (Observational Measurement of Engagement) scale.","Association Recherche Méthodologie Evaluation Psychiatrique","All","60 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","ARMEP-01","March 2011","September 2011","June 2012","March 14, 2011",,"April 29, 2011","Centre Mémoire de Ressources et de Recherche, Nice, France",,"https://ClinicalTrials.gov/show/NCT01314131"
1357,"NCT01303744","Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074","CT04","Completed","Has Results","Alzheimer's Disease","Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo","Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point|Measurement of Trough CHF 5074 Plasma Levels|Changes in Plasma ΔTNFα Concentrations","CERESPIR","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCD-1014-PR-0053|2010-024270-19","March 2011","April 2012","April 2012","February 25, 2011","January 11, 2016","January 11, 2016","Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Maggiore Policlinico, Clin. Neurol, Milano, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy|Nuovo Osp Civ S. Agostino Estense, Dip di Neuroscienze, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT01303744"
1358,"NCT01297114","Imaging of Cognition, Learning, and Memory in Aging",,"Completed","No Results Available","Alzheimer's Disease","Drug: Florbetaben","Cognition as measured with cognitive evaluations","Yaakov Stern|National Institute on Aging (NIA)|Columbia University","All","20 Years to 70 Years   (Adult, Older Adult)",,"294","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AAAB0596|R01AG026158","March 2011","October 1, 2017","October 1, 2017","February 16, 2011",,"November 1, 2017","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01297114"
1359,"NCT01294540","Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort",,"Completed","No Results Available","Alzheimer's Disease","Drug: Drug: E2609|Drug: Placebo","Safety and tolerability as evidenced by the number of subjects with adverse events|To assess the pharmacokinetics (PK) of E2609 in plasma and urine following administration of single oral doses","Eisai Inc.","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 1","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2609-A001-001","December 2010","October 2011","December 2011","February 11, 2011",,"August 29, 2013","Glendale Adventist Medical Center, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01294540"
1360,"NCT01258452","Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects","CT03","Completed","No Results Available","Alzheimer's Disease","Drug: CHF 5074|Drug: CHF 5974","area under the curve of plasma CHF 5074 levels from 0 to 96 hours (AUC 0-96)|peak CHF 5074 plasma concentration (Cmax)|the time of occurrence of Cmax (Tmax)","CERESPIR","Male","18 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCD-1013-PR-0052","February 2011","March 2011","March 2011","December 13, 2010",,"February 10, 2015","Iberica Clinical Research Center, Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01258452"
1361,"NCT01253499","Multiple Dose Study of TRx0037",,"Completed","No Results Available","Alzheimer's Disease","Drug: TRx0037","Bioavailability|Pharmacokinetics|Safety and tolerability","TauRx Therapeutics Ltd|Quotient Clinical","All","55 Years and older   (Adult, Older Adult)","Phase 1","31","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TRx-037-003","March 2010","May 2010","May 2010","December 3, 2010",,"December 17, 2010",,,"https://ClinicalTrials.gov/show/NCT01253499"
1362,"NCT01253122","Comparative Bioavailability in Healthy Elderly Volunteers",,"Completed","No Results Available","Alzheimer's Disease","Drug: TRx0037","Relative bioavailability|Safety, tolerability and pharmacokinetics","TauRx Therapeutics Ltd|Quotient Clinical","All","55 Years and older   (Adult, Older Adult)","Phase 1","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","TRx-037-002","February 2010","April 2010","April 2010","December 3, 2010",,"December 3, 2010",,,"https://ClinicalTrials.gov/show/NCT01253122"
1363,"NCT01093664","Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02",,"Completed","No Results Available","Alzheimer's Disease","Biological: AFFITOPE AD02","Safety and Tolerability|Immunological and clinical activity","Affiris AG","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFF004A","October 2009","July 2010","July 2010","March 26, 2010",,"October 19, 2010","Ordination Schmitz, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01093664"
1364,"NCT01227252","A Safety Study of LY2886721 Multiple Doses in Healthy Subjects",,"Completed","Has Results","Alzheimer's Disease","Drug: LY2886721|Drug: Placebo","Number of Participants With Clinically Significant Effects|Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721|Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721|Plasma Amyloid Beta (Aβ) 1-40 Concentration|Cerebrospinal Fluid (CSF) Concentration of LY2886721|Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13734|I4O-MC-BACB","December 2010","April 2011","April 2011","October 25, 2010","July 19, 2019","July 19, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01227252"
1365,"NCT01221259","A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: E2212|Drug: placebo","To evaluate the safety and tolerability of single ascending oral doses of E2212 in healthy subjects.","Eisai Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2212-A001-001","January 2010","October 2011","November 2012","October 14, 2010",,"May 22, 2013","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01221259"
1366,"NCT01057030","Multiple Dose Japanese Bridging Study",,"Completed","No Results Available","Alzheimer Disease","Drug: BMS-708163|Drug: Placebo","BMS-708163 or placebo in Japanese and non-Japanese: Safety and tolerability (AE's, ECG, vital signs, safety labs)|BMS-708163 pharmacokinetic parameters (Cmax, Cmin, Ctrough, Tmax, AUC(TAU), AI, and CLT/F and T-HALF (only following Day 14 dose))","Bristol-Myers Squibb","Male","20 Years to 45 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CN156-038","March 2010","June 2010","June 2010","January 27, 2010",,"January 25, 2011","California Clinical Trials Medical Group, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01057030"
1367,"NCT02848404","Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application",,"Enrolling by invitation","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Device: Categorical Language Fluency Smartphone Application","Application usage log|Subjective Memory Complaint Questionnaire|Geriatric Depression Scale|Korean version of MMSE for dementia screening","Seoul National University Bundang Hospital|Seoul National University|Ministry of Science, ICT and Future Planning","All","55 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0028631","June 2016","December 2019","March 2020","July 28, 2016",,"April 4, 2019",,,"https://ClinicalTrials.gov/show/NCT02848404"
1368,"NCT01203384","Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","CT02","Completed","No Results Available","Alzheimer's Disease","Drug: CHF5074 1x|Drug: CHF5074 2x|Drug: CHF5074 3x|Drug: Placebo","Adverse Events|Dose linearity of CHF5074 plasma levels (Cmax)|Dose linearity of CHF5074 plasma levels (AUC 0-t)","CERESPIR","Male","18 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCD-0913-PR-0038","September 2010","December 2010","December 2010","September 16, 2010",,"February 10, 2015","Iberica Clinical Research Center, Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01203384"
1369,"NCT01042314","Drug-Drug Interaction Study With Aricept® (Donepezil)",,"Completed","No Results Available","Alzheimer Disease","Drug: Donepezil|Drug: BMS-708163","Aricept® alone and with BMS-708163: Aricept® Multiple-dose pharmacokinetic parameters (Cmax, Tmax, AUC (TAU), and Ctrough) will be assessed without BMS-708163 on Day 14 and with BMS-708163 (Ctrough) on Day 28|Aricept® alone and with BMS-708163: Safety and tolerability based on adverse events, ECG, vital signs and safety labs","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CN156-008","January 2010","April 2010","April 2010","January 5, 2010",,"January 25, 2011","Parexel International - Baltimore Epcu, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01042314"
1370,"NCT01039194","Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)",,"Completed","No Results Available","Alzheimer Disease","Drug: galantamine|Drug: BMS-708163","Galantamine alone and with BMS-708163: Galantamine PK parameters (Cmax, Tmax, AUC(TAU) and Ctrough rations will be assessed without BMS-708163 Day 14) and with BMS708-163 (Ctrough Day 24)|Galantamine alone and with BMS 708163: Safety and tolerability (AE's, ECG, vital signs, safety labs)","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CN156-009","January 2010","April 2010","April 2010","December 24, 2009",,"January 25, 2011","Parexel International - Baltimore Epcu, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01039194"
1371,"NCT01002079","Drug-Drug Interaction Study With Rifampin",,"Completed","No Results Available","Alzheimer Disease","Drug: BMS-708163|Drug: Rifampin","BMS-708163 alone and with rifampin: BMS-708163 single dose PK parameters (Cmax, Tmax, T-HALF, AUC(0-T), AUC(INF), CLT/F and molar AUCmet/AUCparent ratios will be assessed without rifampin (Day 1) and with rifampin (Day 13)|BMS-708163 alone and with rifampin: Safety and tolerability (AE's, ECG, vital signs, safety labs)","Bristol-Myers Squibb|PRA Health Sciences","All","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CN156-028","August 2010","October 2010","October 2010","October 27, 2009",,"January 25, 2011","Local Institution, Bangalore, India",,"https://ClinicalTrials.gov/show/NCT01002079"
1372,"NCT02759887","Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Down Syndrome|Alzheimer's Dementia","Procedure: biospecimen collection|Other: cognitive assessments|Other: caregiver questionnaire|Procedure: Florbetapir F18 imaging|Procedure: MRI|Procedure: Fludeoxyglucose F18 (FDG)|Procedure: Tau Pet|Procedure: Actigraphy","Florbetapir PET - change between timeframes|tau PET - change between timeframes|FDG PET - change between timeframes|MRI - change between timeframes|dried blood spot collection (DBSC) analysis - change between timeframes","St. Joseph's Hospital and Medical Center, Phoenix|Banner Alzheimer's Institute, Phoenix|Translational Genomics Research Institute (TGEN), Phoenix","All","21 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHX-16-0028-70-03","November 2016","March 2019","June 2019","May 3, 2016",,"November 3, 2016","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02759887"
1373,"NCT01133405","A Safety Study of LY2886721 Single Doses in Healthy Subjects",,"Completed","Has Results","Alzheimer's Disease","Drug: LY2886721|Drug: Placebo","Number of Participants With Clinically Significant Effects (Adverse Events)|Maximum Observed Plasma Concentration (Cmax) of LY2886721|Plasma Concentration of LY2886721: Area Under the Concentration Versus Time Curve (AUC)|Pharmacodynamic Biomarker: Plasma Amyloid Beta (Aβ) 1-40 Concentration (Part 1 Only)|Cerebrospinal Fluid (CSF) Maximum Observed Drug Concentration (Cmax) of LY2886721 (Part 2 Only)|Cerebrospinal Fluid (CSF) Pharmacodynamic Biomarker Amyloid Beta (Aβ) 1-40 Concentration (Part 2 Only)|Cerebrospinal Fluid (CSF) Area Under the Concentration Versus Time Curve (AUC) of LY2886721 (Part 2 Only)","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13733|I4O-MC-BACA","June 2010","October 2010","October 2010","May 28, 2010","September 16, 2019","September 16, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT01133405"
1374,"NCT00979316","Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: BMS-708163|Drug: Placebo|Drug: Moxifloxacin","Effect on the electrocardiographic QT interval corrected for heart rate (QTc) in healthy subjects|To assess the effects of BMS-708163 on other ECG endpoints (heart rate [HR], QRS and PR intervals), and changes in waveform morphology","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CN156-020","September 2009","February 2010","February 2010","September 18, 2009",,"January 7, 2011","Mds Pharma Services (Us), Inc, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00979316"
1375,"NCT01129115","Dose Response Study of Aerobic Exercise in Older Adults",,"Completed","Has Results","Alzheimer's Disease","Behavioral: Nonexercise control group|Behavioral: Aerobic Exercise Group 1|Behavioral: Aerobic Exercise Group 2|Behavioral: Aerobic Exercise Group 3","Visuospatial Processing|Change in Maximal Oxygen Consumption|Change in Physical Performance Test|Verbal Memory|Simple Attention|Set Maintenance & Shifting|Reasoning","Jeff Burns, MD|University of Kansas Medical Center","All","65 Years and older   (Older Adult)","Early Phase 1","101","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11883","May 2010","February 2014","April 2014","May 24, 2010","February 15, 2016","February 15, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01129115"
1376,"NCT00824967","Non Pharmacological Management of Behavioural Symptoms in Nursing Home",,"Terminated","No Results Available","ALZHEIMER Disease","Other: Training and valuation of the treating personnel","Changes at the behavioural assessment (CMAI, OS, NPI) after 8 weeks of intervention|Changes at the behavioural assessment (CMAI, OS, NPI) 16 weeks after the end of the intervention","Centre Hospitalier Universitaire de Nice","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","07-PP-03","October 2007","October 2009","October 2009","January 19, 2009",,"March 26, 2012","CHU de Nice - 4 avenue Reine Victoria, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT00824967"
1377,"NCT01079819","Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163",,"Completed","No Results Available","Alzheimer's Disease","Drug: BMS-708163|Drug: Placebo","Safety assessments will be based on adverse event reports and the results of vital sign measurements, ECGs, physical exams and clinical laboratory tests. Adverse events will be tabulated and reviewed for potential significance and clinical importance|Single-dose pharmacokinetic parameters (Cmax, Tmax, AUC(0-T), AUC(INF), T-HALF and multiple-dose pk parameters (Cmax, Tmax, Cmin, AUC(TAU), T-HALF, and accumulation index will be derived from plasma concentration versus time data","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CN156-029","April 2010","December 2010","December 2010","March 3, 2010",,"February 7, 2011","West Coast Clinical Trials, Llc, Cypress, California, United States|California Clinical Trials Medical Group, Glendale, California, United States|Iberica Clinical Research Center, Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01079819"
1378,"NCT00719394","Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males",,"Completed","No Results Available","Alzheimer Disease|Healthy","Drug: GSI 136|Drug: placebo","Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.|Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3225A1-1001","March 2008","August 2008","August 2008","July 21, 2008",,"July 10, 2009","Tokyo Heat Center, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00719394"
1379,"NCT00718731","Study GSI-136 in Healthy Young and Healthy Elderly Subjects",,"Completed","No Results Available","Alzheimer Disease|Healthy","Drug: GSI-136|Other: Placebo","Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.|Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3225A1-1000","March 2008","August 2008","August 2008","July 21, 2008",,"April 2, 2010","New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00718731"
1380,"NCT00906191","Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","Radioactivity measurements in blood, urine and feces and pharmacokinetic parameters (Cmax, AUC, terminal elimination half life, total clearance and volume of distribution in the plasma ; urine clearance ; metabolite profiling in plasma, urine and feces.)","Wyeth is now a wholly owned subsidiary of Pfizer","Male","18 Years to 50 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","3193A1-1114","May 2009","August 2009","August 2009","May 21, 2009",,"August 26, 2009","Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT00906191"
1381,"NCT00684710","Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects",,"Completed","No Results Available","Alzheimer Disease|Healthy","Drug: PAZ-417|Drug: Placebo","Safety and Tolerability|Pharmacokinetics","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3186A1-101","April 2008","August 2008","August 2008","May 28, 2008",,"January 30, 2009","Kitashinagawa, Shinagawa-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00684710"
1382,"NCT00860275","Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole",,"Completed","No Results Available","Alzheimer Disease","Drug: BMS-708163|Drug: BMS-708163 + Ketoconazole|Drug: Ketoconazole|Drug: Fluconazole|Drug: BMS-708163 + Fluconazole","PK profile of BMS-708163|Safety and tolerability of BMS-708163 when administered alone and with either ketoconazole or fluconazole","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CN156-019","April 2009","June 2009","June 2009","March 12, 2009",,"January 25, 2011","Ppd Development, Lp, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00860275"
1383,"NCT00947934","Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer Disease",,"Unknown status","No Results Available","Memory Disorders","Device: Deep brain stimulation","Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event.|- Efficacy : evaluated using cognitive and memory testing. - Global improvement : CGI and IADL - Neuro-imaging : MRI and functional imaging - Safety/tolerance : Changes in behavioral,in hypothalamic functions and assessment of adverse events","Centre Hospitalier Universitaire de Nice","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09 - APN - 04|AFSSAPS2009-A00318-49","August 2009","August 2010","August 2012","July 28, 2009",,"December 8, 2011","CMR2 Hôpital de Cimiez, Nice, France|Service de Neurochirurgie Hôpital Universitaire de Pasteur, Nice, France",,"https://ClinicalTrials.gov/show/NCT00947934"
1384,"NCT00954538","Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",,"Completed","Has Results","Alzheimer's Disease","Drug: [18F]MK-3328","Number of Participants With an Adverse Event (AE)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-3328|Organ Effective Dose of [18F]MK-3328|Mean Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR) in AD Participants and HE Participants|Least Squares (LS) Mean [18F]MK-3328 SUVR in Brain Posterior Cingulate Gyrus in AD Participants and HE Participants","Merck Sharp & Dohme Corp.","All","50 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3328-001|2009_630","August 2009","May 2011","May 2011","August 7, 2009","February 5, 2014","November 3, 2015",,,"https://ClinicalTrials.gov/show/NCT00954538"
1385,"NCT00954252","Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects","CT01","Completed","No Results Available","Alzheimer's Disease","Drug: CHF 5074|Drug: placebo","Adverse Events|Dose linearity of CHF5074 plasma levels (Cmax and AUC0-t)","CERESPIR","Male","18 Years to 45 Years   (Adult)","Phase 1","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CCD-0814-PR-0008","October 2009","May 2010","May 2010","August 7, 2009",,"February 10, 2015","Iberica Clinical Research Center, Eatontown, NJ 07724, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00954252"
1386,"NCT01348061","Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls",,"Completed","No Results Available","Alzheimer Disease|Progressive Supranuclear Palsy",,"Biomarker Measures","KineMed|Bristol-Myers Squibb","All","50 Years to 85 Years   (Adult, Older Adult)",,"16","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","CN167001","July 2011","July 2013","July 2013","May 5, 2011",,"October 24, 2014","Parexel, Glendale, California, United States|Memory Enhancement Centers of America Inc., Eatontown, New Jersey, United States|Worldwide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01348061"
1387,"NCT00765115","A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.",,"Completed","No Results Available","Alzheimer Disease","Drug: LY450139|Drug: placebo","To test hypothesis that LY450139, a gamma-secretase inhibitor, will reduce the rate of synthesis of 13C6-leucine-labeled Aβ (newly synthesized) in lumbar cerebrospinal fluid (CSF).|To test the hypothesis that LY450139 has an effect on fractional clearance rate of Amyloid Beta assayed from CSF samples in LY450139-treated subjects compared to placebo-treated subjects.|To study and evaluate other biomarkers, such as sAPPB and sAPPA that may enable drug effectiveness to be predicted.|To measure concentrations of Amyloid Beta(1-40), Amyloid Beta(1-42), and leucine in CSF by mass spectrometry.|To explore the relationship between Amyloid Beta plasma decrease and Amyloid Beta synthesis rate as determined by CSF measurements.","Eli Lilly and Company","Male","21 Years to 50 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","9384|H6L-MC-LFAM","July 2006","September 2007","September 2007","October 2, 2008",,"October 2, 2008","For additional information regarding investigtive sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00765115"
1388,"NCT00900770","Implications of Amyloid Pathology",,"Unknown status","No Results Available","Alzheimer's Disease",,"Pittsburgh Compound B (PiB) and F-18 fluorodeoxyglucose (FDG) PET Scan|Cognitive and functional assessments|Lumbar Puncture (optional)","National Institute on Aging (NIA)","All","60 Years to 90 Years   (Adult, Older Adult)",,"100","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IA0158|2P50AG005134-268381|2P50AG005134","November 2008","March 2014","March 2014","May 13, 2009",,"December 29, 2009","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00900770"
1389,"NCT00745576","Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","blood samples|Safety based on supine vital signs evaluations, 12-lead ECGs and routine lab tests","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3193A1-1112","October 2008","December 2008","December 2008","September 3, 2008",,"February 8, 2010","Gieres, France",,"https://ClinicalTrials.gov/show/NCT00745576"
1390,"NCT04123314","Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease",,"Not yet recruiting","No Results Available","Depressive Symptoms|Depression|Alzheimer Disease|Mild Cognitive Impairment","Drug: Psilocybin","Change in Cornell Scale for Depression in Dementia (CSDD) score|Change in Quality of Life Alzheimer's Disease (QOL-AD) scale score","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00175915","October 15, 2019","March 1, 2022","September 1, 2022","October 10, 2019",,"October 10, 2019","Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04123314"
1391,"NCT00884533","QTc Study of Rosi XR in Healthy Volunteers","Rosi XR","Withdrawn","No Results Available","Alzheimer's Disease","Drug: Rosi XR|Other: Placebo|Drug: Moxifloxacin","Day 20 time-matched change from baseline in QTcI for RSG- XR 8mg and placebo|Day 21 time-matched change from baseline in QTcI for RSG- XR 20mg, placebo and moxifloxacin 400mg|Day 20 time-matched change from baseline in QTcF and QTcB for RSG XR 8mg and placebo.|Day 21 time-matched change from baseline in QTcF and QTcB for RSG XR 20mg, placebo and moxifloxacin 400mg|Tolerability of repeat doses of RSG- XR at 8 mg and a single oral dose of RSG- XR at 20 mg as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","111802","June 2009","August 2009","August 2009","April 20, 2009",,"April 17, 2015","GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00884533"
1392,"NCT00880451","Development and Decline of Brain and Cognition Through the Life Span",,"Completed","No Results Available","Alzheimer's Disease",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,,"NIH","Observational","Time Perspective: Retrospective","999909027|09-M-N027","March 2009",,,"April 13, 2009",,"April 13, 2009","National Institute of Mental Health (NIMH), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00880451"
1393,"NCT00726115","Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531|Drug: placebo","Pharmacokinetics, routine Lab tests, Vital signs, ECG","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3193A1-1111","August 2008","February 2009","February 2009","July 31, 2008",,"July 30, 2009","Rueil Malmaison, France",,"https://ClinicalTrials.gov/show/NCT00726115"
1394,"NCT00867399","A Safety and Tolerability Study of ABT-126 in Elderly",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-126","Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)|Assess the Pharmacokinetics","Abbott","All","65 Years and older   (Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-717","March 2009","May 2009",,"March 23, 2009",,"November 2, 2010","Site Reference ID/Investigator# 17283, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00867399"
1395,"NCT00453544","Enhancing Consent for Alzheimer's Research","BWP-AD","Completed","No Results Available","Alzheimer Disease","Other: Enhanced Consent Procedure|Other: Routine Consent Procedure","Level of Understanding|Appreciation|Reasoning|Expression of a Choice regarding hypothetical protocol|Level of Satisfaction with consent process|Expressed willingness to participate in the hypothetical protocol","University of California, San Diego|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","252","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","IA0110|1R01AG028827","April 2006","September 2012","September 2012","March 29, 2007",,"October 28, 2016","Veterans Affairs San Diego Healthcare System, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00453544"
1396,"NCT00838084","A Safety Study of LY2811376 Single Doses in Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: LY2811376|Drug: Placebo","Clinical Effects|Plasma concentration of LY2811376 (Cmax)|Plasma concentration of LY2811376 (AUC)|Amyloid beta 1-40 plasma concentrations|Cerebrospinal fluid (CSF) concentration of LY2811376 (Cmax) (Part 2 only)|Cerebrospinal fluid (CSF) concentration of LY2811376 (AUC) (Part 2 only)|Amyloid beta 1-40 cerebrospinal fluid CSF concentrations (Part 2 only)","Eli Lilly and Company","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","12852|I3J-MC-LACE","December 2008","June 2009","June 2009","February 6, 2009",,"July 15, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00838084"
1397,"NCT00105547","Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: MPC-7869","Cognition and activities of daily living|Global function and behavior","Myrexis Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 3","1600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MPC-7869-04-005.02","February 2005",,"May 2008","March 16, 2005",,"May 5, 2009","Alabaster, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Peoria, Arizona, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Fresno, California, United States|Irvine, California, United States|La Jolla, California, United States|Lafayette, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Newport Beach, California, United States|Oceanside, California, United States|Rancho Mirage, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|Vista, California, United States|Denver, Colorado, United States|Danbury, Connecticut, United States|Darien, Connecticut, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Bay Harbor, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Derrfield Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|North Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Plantation, Florida, United States|Pompano Beach, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Ft. Wayne, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore,, Maryland, United States|Glen Burnie, Maryland, United States|Boston, Massachusetts, United States|Brockton, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Farmington Hills, Michigan, United States|Grand Rapids, Michigan, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|Kenilworth, New Jersey, United States|Morristown, New Jersey, United States|Piscataway, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Brooklyn, New York, United States|Elmsford, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburg, Pennsylvania, United States|Scotland, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Providence, Rhode Island, United States|Beaufort, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Johnson City, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Virginia Beach, Virginia, United States|Middleton, Wisconsin, United States|Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00105547"
1398,"NCT00777361","Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers","MB","Terminated","No Results Available","Alzheimer's Disease","Drug: AZD3480","Recovery (% dose) of radioactivity retrieved in urine and faeces Total radioactivity in blood and plasma, AUC, Cmax , tmax, t1/2 and blood/plasma ratio.|Plasma and urine concentration (AUC, Cmax, tmax, t1/2, F, CL, CLR, fe, Ae, and Vss)|identity of major metabolites in plasma and excreta|Adverse Events, vital signs (supine blood pressure and pulse rate), ECG, hematology, clinical chemistry and urinalysis.","AstraZeneca","Male","35 Years to 65 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D3690C00017|EudraCT No.: 2007-005903-16","October 2008","October 2009","October 2009","October 22, 2008",,"November 18, 2010","Research site, Macclesfield, Cheshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00777361"
1399,"NCT00711321","Long-term Safety and Tolerability of AFFITOPE AD02",,"Completed","No Results Available","Alzheimer's Disease",,"Long-term tolerability|Clinical and immunological efficacy (evaluated in an explorative manner only)","Affiris AG","All","50 Years and older   (Adult, Older Adult)",,"23","Industry","Observational","Time Perspective: Prospective","Affiris 004|EudraCT 2008-002764-33","November 2008","April 2010","April 2010","July 8, 2008",,"May 27, 2010","Ordination Schmitz, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00711321"
1400,"NCT00751907","Cerebral and Peripheral Perfusion Pilot Study","CAPP","Completed","No Results Available","Alzheimer's Disease","Drug: atorvastatin|Drug: Placebo","Change in regional cerebral blood flow (rCBF)|Change in Endothelial function","University of Wisconsin, Madison|National Institute on Aging (NIA)","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IA0138|K23AG026752|Pilot Award","June 2006","April 2007","April 2007","September 12, 2008",,"September 9, 2019","Karen Lazar, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00751907"
1401,"NCT02168920","Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",,"Terminated","No Results Available","Agitation Associated With Dementia of the Alzheimer's Type","Drug: 2 mg/day|Drug: 3 mg/day|Drug: 6 mg/day|Drug: Placebo (0 mg/day)","CMAI|Clinical Global Impression of Severity （CGI-S）|Clinical Global Impression-Improvement (CGI-I)","Otsuka Pharmaceutical Co., Ltd.","All","55 Years to 89 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","031-13-001","June 11, 2014","March 18, 2016","March 18, 2016","June 20, 2014",,"October 16, 2017","Kanto Region, Japan",,"https://ClinicalTrials.gov/show/NCT02168920"
1402,"NCT00711139","Long-term Safety and Tolerability of AFFITOPE AD01",,"Completed","No Results Available","Alzheimer's Disease",,"Tolerability|Immunological and clinical efficacy (evaluated in an explorative manner only)","Affiris AG","All","50 Years and older   (Adult, Older Adult)",,"22","Industry","Observational","Time Perspective: Prospective","Affiris 003|EudraCT 2008-001455-22","June 2008","November 2009","November 2009","July 8, 2008",,"May 27, 2010","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00711139"
1403,"NCT00563732","Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin",,"Completed","No Results Available","Alzheimer Disease","Drug: Lecozotan","Evaluation of the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3098B1-1142","December 2007","September 2008","September 2008","November 26, 2007",,"September 9, 2008",,,"https://ClinicalTrials.gov/show/NCT00563732"
1404,"NCT00713765","Pharmacokinetic Interaction Between AZD3480 and Donepezil",,"Terminated","No Results Available","Alzheimer's Disease","Drug: AZD3480|Drug: Donepezil","PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)","AstraZeneca","All","20 Years to 60 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","D3690C00005|EudraCt No.2008-002847-17","December 2008","December 2008","December 2008","July 11, 2008",,"August 15, 2014","Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00713765"
1405,"NCT00689637","Drug Interaction Study Between AZD3480 and Warfarin","DDI","Completed","No Results Available","Alzheimer's Disease","Drug: AZD3480|Drug: Placebo|Drug: Warfarin","PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)","AstraZeneca","Male","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D3690C00014|EudraCt nr 2007-004756-37","September 2007",,"February 2009","June 3, 2008",,"July 2, 2009","Research SIte, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00689637"
1406,"NCT00687141","Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: AZD0328|Drug: Placebo","Safety and tolerability of AZD0328 by assessment of vital signs, laboratory variables and ECG|Safety and tolerability of AZD0328 by assessment of adverse events|Determine the single and multiple dose pharmacokinetics (PK) of AZD0328|Evaluate the cognitive dose response relationship for AZD0328","AstraZeneca","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D0190C00006|EudractCT 2007-004598-25","November 2007","June 2008","June 2008","May 30, 2008",,"December 10, 2010","Research Site, Linkoping, Sweden|Research Site, Lulea, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00687141"
1407,"NCT00660088","Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly",,"Completed","No Results Available","Alzheimer's Disease","Other: Ketasyn","Plasma peak concentration levels and AUC|Incidence and severity of adverse events","Cerecin","All","55 Years to 85 Years   (Adult, Older Adult)",,"60","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","KET-08-004","April 2008","June 2008","August 2008","April 17, 2008",,"October 8, 2008","Meridien Research Center, St. Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00660088"
1408,"NCT01061489","Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment (MCI)|Mild Alzheimer's Disease","Other: auditory discrimination training|Other: physical movement training","Change in global cognition|electrophysiological, MRI, blood and liquor correlates","University of Konstanz|University of Ulm","All","55 Years and older   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","WIN-Kol-09","August 2009","March 2013","March 2013","February 3, 2010",,"July 14, 2016","University of Konstanz, Konstanz, Germany|University of Ulm, Memory Clinic, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT01061489"
1409,"NCT00494962","Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: lecozotan SR","Pharmacokinetic (PK) analyses","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 50 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","3098B1-1147","June 2007",,"June 2007","July 2, 2007",,"December 5, 2007","Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT00494962"
1410,"NCT00624026","Memantine - Communication Study",,"Completed","No Results Available","Alzheimer's Disease","Drug: Memantine-HCl","To assess the efficacy of the memantine OD IR treatment using the Consortium to establish a registry for Alzheimer's Disease (CERAD-NP) total score","Merz Pharmaceuticals GmbH","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRZ 90001-0608/1","November 2007","December 2008","December 2008","February 26, 2008",,"November 1, 2011","Central Medical Affairs, Frankfurt/Main, Germany",,"https://ClinicalTrials.gov/show/NCT00624026"
1411,"NCT00480818","Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3193A1-102","September 2006",,"July 2007","May 31, 2007",,"December 11, 2007","Rennes, France",,"https://ClinicalTrials.gov/show/NCT00480818"
1412,"NCT00480467","Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-315","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3182A1-102","September 2006",,"August 2007","May 31, 2007",,"December 5, 2007","Ibaraki Pref, Japan",,"https://ClinicalTrials.gov/show/NCT00480467"
1413,"NCT00479700","Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 45 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3193A1-100","May 2006",,"July 2006","May 28, 2007",,"December 10, 2007",,,"https://ClinicalTrials.gov/show/NCT00479700"
1414,"NCT00479440","Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-315","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 45 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3182A1-100","August 2006",,"March 2007","May 28, 2007",,"December 5, 2007",,,"https://ClinicalTrials.gov/show/NCT00479440"
1415,"NCT00479349","Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3193A1-1104","May 2007","January 2008","January 2008","May 28, 2007",,"July 7, 2009","Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00479349"
1416,"NCT00479297","Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males",,"Completed","No Results Available","Alzheimer Disease","Drug: SAM-531","Safety and tolerability|Pharmacokinetics and pharmacodynamics","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years to 45 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3193A1-101","May 2006","February 2007","February 2007","May 28, 2007",,"August 7, 2009",,,"https://ClinicalTrials.gov/show/NCT00479297"
1417,"NCT00474552","Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315",,"Terminated","No Results Available","Alzheimer Disease","Drug: SAM-315","safety, tolerability and PK","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3182A1-101","June 2007","October 2007","October 2007","May 17, 2007",,"February 18, 2008","Paris, France",,"https://ClinicalTrials.gov/show/NCT00474552"
1418,"NCT00236431","A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment",,"Completed","No Results Available","Dementia|Alzheimer Disease","Drug: Galantamine hydrobromide","Memory and cognition (ADAS-COG/MCI and CDR-SB scores), global functional skills and overall severity of dementia (the CDR-SB and the overall Clinical Dementia Rating) measured at 12 and 24 months.|Digit Symbol Coding and Alzheimer's Disease Cooperative Study-ADL scale (MCI version) at 12 and 24 months. Safety assessment (reports of adverse events, laboratory values, results of physical examinations, and electrocardiograms) throughout the study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","50 Years and older   (Adult, Older Adult)","Phase 3","1063","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR002014","May 2001",,"December 2003","October 12, 2005",,"June 8, 2011",,,"https://ClinicalTrials.gov/show/NCT00236431"
1419,"NCT00452504","Single Ascending Dose Study of SRA-444 in Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: SRA-444","Assessment of the safety and tolerability of SRA-444","Wyeth is now a wholly owned subsidiary of Pfizer","Male","18 Years to 50 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3197A1-100","February 2007",,"June 2007","March 27, 2007",,"December 5, 2007","Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT00452504"
1420,"NCT02963415","Concurrent Aerobic Exercise and Virtual Reality Cognitive Training","VRCT","Not yet recruiting","No Results Available","Preclinical Alzheimer's Disease","Behavioral: Exergame","Feasibility of the exergame development|Cycling adherence rate|VCRT adherence rate|Usability and satisfaction with the exergame","University of Minnesota - Clinical and Translational Science Institute","All","65 Years to 99 Years   (Older Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1610M98324","September 30, 2019","March 2021","March 2021","November 15, 2016",,"April 19, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02963415"
1421,"NCT00551772","A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.",,"Completed","No Results Available","Alzheimer's Disease","Drug: SB-742457","To characterise pharmacokinetics ( AUC(0-inf) and Cmax ) of SB-742457 from pre-dose to 96 hours following single doses formulated as a capsule and a tablet.|To assess safety and tolerability (adverse events, blood pressure, heart rate, 12-lead ECG, blood haematology/clinical chemistry and urinalysis) of SB-742457 following single doses formulated as a capsule and a tablet over the 6 week study period.","GlaxoSmithKline","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZ3110291","August 2007",,,"October 31, 2007",,"December 25, 2008","GSK Investigational Site, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00551772"
1422,"NCT00416078","Online Caregiver Psychoeducation and Support for Alzheimer's",,"Completed","Has Results","Alzheimer's Disease","Behavioral: caregiver website support|Behavioral: caregiver brief supportive phone calls","Change in Caregiver Burden From Baseline|Change in Frequency of Patient Problematic Behavioral Patterns From Baseline|Change in Caregiver Negative Reactions to Problematic Behavioral Patterns From Baseline|Change in Caregiver Depression From Baseline|Change in Caregiver Report of Patient Medication Adherence From Baseline","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2|Phase 3","53","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIR 05-107","August 2007","June 2012","December 2012","December 27, 2006","April 29, 2015","April 29, 2015","VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00416078"
1423,"NCT00889603","Non-Interventional Study With Aricept® Evess",,"Completed","Has Results","Alzheimer's Disease|Vascular Dementia","Drug: Aricept® Evess","Change From Baseline in Mini Mental State Examination (MMSE) Total at Week 24 Last Observation Carried Forward (LOCF)|Change From Baseline in MMSE Total|Change From Baseline in Functional Activity Questionnaire (FAQ)|Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) at Week 8|Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) at Week 16|Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) at Week 24|Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) at Week 24 LOCF|Number of Participants in Each Patient Domain of Benefit","Pfizer","All","50 Years and older   (Adult, Older Adult)",,"370","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A2501065","May 2009","March 2010","March 2010","April 29, 2009","March 31, 2011","March 31, 2011","Pfizer Investigational Site, Bacau, Jud. Bacau, Romania|Pfizer Investigational Site, Cluj-Napoca, Jud. Cluj, Romania|Pfizer Investigational Site, Cluj-Napoca, Jud. Cluj, Romania|Pfizer Investigational Site, Constanta, Jud. Constanta, Romania|Pfizer Investigational Site, Craiova, Jud. Dolj, Romania|Pfizer Investigational Site, Iasi, Jud. Iasi, Romania|Pfizer Investigational Site, Ploiesti, Jud. Prahova, Romania|Pfizer Investigational Site, Timisoara, Jud. Timis, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Iasi, Romania",,"https://ClinicalTrials.gov/show/NCT00889603"
1424,"NCT01745198","Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Alzheimer's Disease Related Disorders",,"Change in rate of cognitive decline as measured by the Memory Performance Index (MPI)|Change in rate of cognitive decline as measured by the MCI Screen|Change in rate of cognitive decline as measured by The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Drawings|Change in rate of cognitive decline as measured by Trails A & B|Rate of atrophy of hippocampal volume|Rate of atrophy in cortical volume|Rate of atrophy in ventricular volume|Change in rate of cognitive decline as measured by Functional Assessment Staging Test (FAST)","Pamlab, Inc.|The Shankle Clinic|Hoag Memorial Hospital Presbyterian","All","18 Years and older   (Adult, Older Adult)",,"121","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","NAC-002c","December 2012","March 2014","June 2014","December 10, 2012",,"April 28, 2015","Hoag Memorial Hospital, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01745198"
1425,"NCT00483028","A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",,"Completed","No Results Available","Alzheimer's Disease","Drug: donezepil (Aricept)","Neuropsychologic test scores: GMLT, DSST, Cog State TM including PAL test, RAVLT, ADAS-cog at baseline (pre-dose) 5 and 8 hours after the first dose and 2 and 6 weeks. (Continues in next bullet.)|MRS (Magnetic Resonance Spectroscopy) profile including but not limited to NAA (N-acetyl-aspartate), NAA/Cr (N-acetyl-aspartate/creatinine ratio), MI (Myoinositol) and MI/Cr (Myoinositol/creatinine ratio).","Pfizer","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A9001134","June 2004",,"January 2007","June 6, 2007",,"February 5, 2008","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT00483028"
1426,"NCT00154635","Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease",,"Unknown status","No Results Available","Dementia, Alzheimer Type","Drug: DCB-AD1","ADAS-Cog|CIBIC-PLUS|IADL|Behav-AD|MMSE|CDR","National Taiwan University Hospital|Development Center for Biotechnology, Taiwan|Taipei Veterans General Hospital, Taiwan|Program Office, National Science & Technology, Biotechnology & Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","931006|NTUH IRB 931006|VGH IRB 93-11-06|DCB-AD1-01-01","September 2005",,,"September 12, 2005",,"September 12, 2005","NTUH, Taipei, Taiwan|VGH, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00154635"
1427,"NCT00366288","Study Evaluating PAZ-417 in Healthy Young/Elderly",,"Completed","No Results Available","Alzheimer Disease","Drug: PAZ-417",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)",,"56","Industry","Observational","Observational Model: Cohort","3186A1-100","July 2006","March 2008","March 2008","August 21, 2006",,"July 10, 2009","Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00366288"
1428,"NCT01142258","Trazodone for Sleep Disorders in Alzheimer's Disease",,"Completed","No Results Available","Sleep|Sleep Disorders|Insomnia|Alzheimer's Disease","Drug: Trazodone|Drug: Placebo","Change from Baseline in Nighttime Total Sleep Time|Change from Baseline in Nighttime Wake After Sleep Onset|Change from Baseline in Nighttime Number Of Awakenings|Change from Baseline in Daytime Total Sleep Time|Change from Baseline in Number of Daytime Naps|change in cognitive function (as measured by the Mini-Mental State Examination)|Change in activities of daily living (The index of ADL - Katz)|Change of baseline in behavioral variables (BAHAVE-AD scale)|Proportion of subjects who gained at least 30 minutes in total nighttime sleep|Change from Baseline in Clinical Dementia Rating|Change from Baseline in cognitive function (Digit Symbol Substitution Test)","Brasilia University Hospital|Universidade Federal do Paraná","All","55 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TZD-001","March 2010","April 2012","August 2012","June 11, 2010",,"October 15, 2012","Geriatric Medical Centre, Brasilia, Distrito Federal, Brazil",,"https://ClinicalTrials.gov/show/NCT01142258"
1429,"NCT03900273","Development of Novel Measures for Alzheimer's Disease Prevention Trials","NoMAD","Recruiting","No Results Available","Healthy Participants","Other: No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Other: Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)","Computerized Functional Assessment Scale (CFAS).|No Practice Effect (NPE) Cognitive Battery.","New York State Psychiatric Institute|Columbia University|University of Southern California|Feinstein Institute for Medical Research|University of Miami","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Novel Measures","February 25, 2019","March 31, 2023","March 31, 2023","April 3, 2019",,"April 3, 2019","University of Southern California, Los Angeles, California, United States|University of Miami, Miami, Florida, United States|The Feinstein Institute for Medical Research, Manhasset, New York, United States|New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03900273"
1430,"NCT03070535","APOE Genotype and Diet Influences on Alzheimer's Biomarkers",,"Recruiting","No Results Available","Alzheimer's Disease; Dementia","Other: HIGH and LOW meal ingestion","Lipid biomarkers|APOE lipidation|Insulin","University of Washington","All","55 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STUDY00001483","September 2016","May 31, 2020","May 31, 2020","March 3, 2017",,"October 27, 2017","University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03070535"
1431,"NCT00182988","Alzheimer's Caregiver Communication Study",,"Completed","No Results Available","Alzheimer's Disease",,,"National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)",,"140","NIH","Observational","Time Perspective: Prospective","IA0082|1R03AG022627","October 2004",,"December 2007","September 16, 2005",,"November 25, 2009","Georgetown University Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00182988"
1432,"NCT00388544","Enhancing Quality of Life for Nursing Home Residents",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Activity matched to interest|Behavioral: Activity matched to function|Behavioral: Activity matched to both interest and function","Agitation|Passivity|Mood|Affect|Engagement","Penn State University|National Institute of Nursing Research (NINR)","All","65 Years and older   (Older Adult)","Phase 2","128","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","19150|R01NR008910|R01NR008910-01A1","May 2005","February 2010","February 2010","October 17, 2006",,"May 9, 2012","Nursing homes in Central and Northeast Pennsylvania, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00388544"
1433,"NCT02646982","Candesartan's Effects on Alzheimer's Disease And Related Biomarkers","CEDAR","Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Placebo|Drug: Candesartan","Change in the number hypotensive episodes|Change in the number of subjects with symptoms of hypotension|Changes in the levels of serum creatinine|Change in the levels of serum potassium|Number of subjects discontinuations of candesartan|Changes in cerebrospinal fluid (CSF) phospho-tau181P levels|Changes in cerebrospinal fluid (CSF) amyloid β1-42 levels|Changes in levels of cerebrospinal fluid cytokines|Change in arterial stiffness, assessed by Pulse Wave Velocity (PWV)|Changes in aortic stiffness, assessed by Augmentation Index|Changes in levels of circulating Endothelial Progenitor Cells (EPCs)|Change in Alzheimer's Disease Assessment Scale (ADAS-cog) scores|Change in Clinical Dementia Rating (CDR) scores|Change in executive function, assessed by the EXAMINER score|Change in executive function, assessed by the Spatial 1-Back test|Change in cerebral vasoreactivity, assessed by MRI|Change in white matter hyperintensities (WMH), assessed by structural MRI|Change in functional connectivity, assessed by rs-fMRI","Emory University","All","50 Years and older   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00084574","June 2016","September 2021","September 2021","January 6, 2016",,"February 18, 2019","Emory University, Atlanta, Georgia, United States|Wesley Woods Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02646982"
1434,"NCT02959489","Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)","REVEAL-SCAN","Recruiting","No Results Available","Alzheimer Disease|Amyloid Beta-Peptides|Risk Assessment|Education|Neuropsychological Tests|Neuroimaging","Behavioral: Alzheimer's Disease Risk Disclosure|Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure","Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure|Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.|Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.","Brigham and Women's Hospital|University of Pennsylvania|University of Michigan|Duke University|Boston University|National Institute on Aging (NIA)","All","65 Years to 80 Years   (Older Adult)","Not Applicable","270","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","RF1AG047866|1RF1AG047866-01A1","November 2016","July 2019","December 2019","November 9, 2016",,"August 31, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Duke University, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02959489"
1435,"NCT02446132","Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Agitation in Patients With Dementia of the Alzheimer's Type","Drug: AVP-786","Number of Participants with any Treatment-Emergent Adverse Event|Number of Participants with any Treatment-Emergent Serious Adverse Event|Number of Participants with any abnormal, clinically significant Clinical Laboratory Value|Number of Participants with any abnormal, clinically significant 12-lead Electrocardiogram (ECG) value|Number of Participants with any abnormal, clinically significant Physical and Neurological Examination finding|Number of participants with any abnormal, clinically significant vital sign value|Change from Baseline to Week 64 in the Sheehan Suicidality Tracking Scale (S-STS) Score|Change from Baseline to Week 52 in the Mini-Mental State Examination (MMSE) Score|Change from Baseline to Week 52 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score|Change from Baseline to Week 52 in the Timed Up and Go (TUG) Test Score|Change from Baseline to Week 52 in the Epworth Sleepiness Scale (ESS) Score|Change from Baseline to Week 52 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 52 in the Neuropsychiatric Inventory (NPI) Total Score|Change from Baseline to Week 52 in the modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change-Agitation (mADCS-CGIC-Agitation) Score|Change from Baseline to Week 22 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 52 in the ADCS-CGIC Overall Score|Change from Baseline to Week 52 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 52 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 52 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline to Week 52 in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 52 in the Resource Utilization in Dementia (RUD) Score|Change from Baseline to Week 52 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 52 in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score","Avanir Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-AVP-786-303","December 2015","June 2022","June 2022","May 18, 2015",,"October 11, 2019","Brain and Spine Center, Chandler, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|NoesisPharma, LLC, Phoenix, Arizona, United States|Perseverance Research Center, LLC, Scottsdale, Arizona, United States|Health Initiatives Research, Fayetteville, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|University of California, Irvine, Irvine, California, United States|Omega Clinical Trials, LLC, La Habra, California, United States|Collaborative Neuroscience Network, LLC., Long Beach, California, United States|Shankle Clinic, Newport Beach, California, United States|NRC Research Institute, Orange, California, United States|California Neurological Services, Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Pacific Research Network, Inc. #1, San Diego, California, United States|Pacific Research Network, Inc. #2, San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|HB Clinical Trials Inc., Santa Ana, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|New Foundation Medical Group Clinical Trials, Tustin, California, United States|Lytle and Weiss, PLLC dba Clinical Trials of the Rockies, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Geriatric and Adult Psychiatry LLC, Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Science Connections, LLC, Doral, Florida, United States|University of Florida, Gainesville, Florida, United States|Finlay Medical Research Corp, Green Acres, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research,LLC, Hialeah, Florida, United States|Research in Miami, Inc, Hialeah, Florida, United States|The Research Center, Inc, Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Maxblue Institute, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Alzheimer's Research and Treatment Center Clinical Trial Site 1, Lake Worth, Florida, United States|Alzheimer's Research and Treatment Center Clinical Trial Site 2, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc. Clinical Trial Site 1, Miami, Florida, United States|Premier Clinical Research Institute, Inc. Clinical Trial Site 2, Miami, Florida, United States|Global Medical Institutes, LLC, Miami, Florida, United States|Project 4 Research Clinical Trial Site 1, Miami, Florida, United States|Project 4 Research Clinical Trial Site 2, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Advance Medical Research Center #1, Miami, Florida, United States|Advance Medical Research Center #2, Miami, Florida, United States|Dade Research Center Llc, Miami, Florida, United States|Vitae Researrch Center LLC, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Inc., Miami, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|United Health Research Corp. Clinical Trial Site 1, Miami, Florida, United States|United Health Research Corp. Clinical Trial Site 2, Miami, Florida, United States|Advanced Medical Center Group, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|Clinical Research Associates of South Florida, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|P&S Research, Llc., Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Kendall Research Institute, Miami, Florida, United States|Nuovida Research Center Corp., Miami, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Naples Research, Inc, Naples, Florida, United States|Lazlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Innovation Medical Research Center, Palmetto Bay, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|University of West Florida, Pensacola, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research North, LLC, The Villages, Florida, United States|Neurology Research Institute Palm Beach, LLC #1, West Palm Beach, Florida, United States|Neurology Research Institute Palm Beach, LLC #2, West Palm Beach, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Emory Brain Health Center, Atlanta, Georgia, United States|NeuroTrials Research Inc, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, INC, Columbus, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|The Samuel & Alexia Bratton Memory Clinic, Easton, Maryland, United States|Mir Neurology, Hagerstown, Maryland, United States|Bedford VA Hospital, Bedford, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Onyx Clinical Research, LLC, Caro, Michigan, United States|Michigan State University Department of Neurology, East Lansing, Michigan, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Galen Research, Chesterfield, Missouri, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Geriatric Solutions, LLC, Las Vegas, Nevada, United States|Flora Baker Center for Alzheimer's Disease and Related Disorders, Marmora, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Integrative Clinical Trials LLC Clinical Trial Site 1, Brooklyn, New York, United States|Integrative Clinical Trials LLC Clinical Trial Site 2, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Psychiatry and Alzheimer's Care of Rochester, PLLC, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Herbert Harris, Md, Phd, Pa, Chapel Hill, North Carolina, United States|ANI Neurology PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Daystar Clinical Research Inc, Akron, Ohio, United States|Neurology and Neuroscience Associates, Inc., Akron, Ohio, United States|Insight Neuroscience, LLC, Bellevue, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|The Birches at Newton / Family Medical Associates, Levittown, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, LTD, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|RH Johnson VA Medical Center, Charleston, South Carolina, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Coastal Neurology, PA, Port Royal, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Texas Neurology, P.A., Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|University Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Neurology Associates of Arlington, Mansfield, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Pharmaceuticals Research Associates, Inc., Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic, Bennington, Vermont, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|Sentara Neurosciences Institute, Norfolk, Virginia, United States|Veteran Affairs Medical Center, Salem Virginia, Salem, Virginia, United States|Frontier Institute, Spokane, Washington, United States|IPC Research, Waukesha, Wisconsin, United States|Center for Mental Health - Ruse, Ruse, Bulgaria|University Multiprofile Hospital for Active Treatment Alexandrovska, Sofia, Bulgaria|Medica Plus Medical Center, Veliko Tarnovo, Bulgaria|Dr. Alexander McIntyre Inc., Penticton, Canada|Fakultni Nemocnice u sv. Anny v Brne, Brno, Czechia|AD71, Praha, Czechia|Clintrial, Praha, Czechia|Neurologicka Ambulance - Forbeli, Praha, Czechia|Neuropsychiatrie, Praha, Czechia|Vestra Clinics, Rychnov nad Kněžnou, Czechia|Centre Hospitalier Universitaire Dijon Bourgogn, Dijon Cedex, France|Centre Hospitalier Universitaire Toulouse - Casselardit Ancely, Toulouse, France|Dr. Kenessey Albert Kórház-Rendelőintézet, Balassagyarmat, Hungary|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|PsychoTech, Pécs, Hungary|Fondazione Santa Lucia - Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy|Care Clinic, Katowice, Poland|Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland|Krakowska Akademia Neurologii, Kraków, Poland|Solumed Centrum Medyczne, Poznań, Poland|Centrum Medyczne Euromedis, Szczecin, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|ACF Neurological Services, Cape Town, South Africa|Cape Trial Centre, Cape Town, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Apollo Clinical Research, Johannesburg, South Africa|Fundació ACE, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Viamed Montecanal, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02446132"
1436,"NCT02442765","Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Agitation in Patients With Dementia of the Alzheimer's Type","Drug: AVP-786|Drug: Placebo","Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation (Global Clinical Status of Agitation on mADCS-CGIC Scale) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline to Week 12 in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 12 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Change from Baseline to Week 12 in the Resource Utilization in Dementia (RUD) Score","Avanir Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-AVP-786-301","September 2015","January 30, 2019","February 27, 2019","May 13, 2015",,"March 6, 2019","NoesisPharma, LLC, Phoenix, Arizona, United States|Perseverance Research Center, LLC, Scottsdale, Arizona, United States|University of California, Irvine, Irvine, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|NRC Research Institute, Orange, California, United States|Pacific Research Network, Inc., San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|HB Clinical Trials Inc., Santa Ana, California, United States|New Foundation Medical Group Clinical Trials, Tustin, California, United States|Lytle and Weiss, PLLC dba Clinical Trials of the Rockies, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Coral Gables Clinical Research, Inc, Coral Gables, Florida, United States|Optimus U Corp, Coral Gables, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|Care Research Center, Inc., Kendall, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Global Medical Institutes, LLC, Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Vitae Researrch Center LLC, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Inc., Miami, Florida, United States|United Health Research Corp., Miami, Florida, United States|Advanced Medical Center Group, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Naples Research, Inc., Naples, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Innovation Medical Research Center, Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Compass Research North, LLC, The Villages, Florida, United States|Neurology Research Institute Palm Beach, LLC, West Palm Beach, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|NeuroTrials Research Inc., Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|MidAmerica Neuroscience Research Foundation, Lenexa, Kansas, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Bedford VA Hospital, Bedford, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurologic Institute, Amherst, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Neurology and Neuroscience Associates, Inc., Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Abington Neurological Associates, LTD, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|University Texas Southwestern Medical Center, Dallas, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Neurology Associates of Arlington, Mansfield, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02442765"
1437,"NCT02442778","Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Agitation in Patients With Dementia of the Alzheimer's Type","Drug: AVP-786|Drug: Placebo","Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Change from Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation (Global Clinical Status of Agitation on mADCS-CGIC Scale) Score|Change from Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change from Baseline to Week 12 in the NPI Caregiver Distress Score|Change from Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change from Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score|Change from Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change from Baseline to Week 12 in the NPI Total Score|Change from Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change from Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating|Change from Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score|Change from Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score|Change from Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score|Change from Baseline to Week 12 in the General Medical Health Rating (GMHR) Score|Change from Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Change from Baseline in the Resource Utilization in Dementia (RUD) Score","Avanir Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","522","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-AVP-786-302","September 2015","August 14, 2019","September 9, 2019","May 13, 2015",,"September 16, 2019","Brain and Spine Center, Chandler, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Health Initiatives Research, Fayetteville, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|California Neurological Services, Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|Denver Neurological Research, LLC, Denver, Colorado, United States|JEM Research Institute, Atlantis, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Science Connections, LLC, Doral, Florida, United States|Finlay Medical Research Corp, Green Acres, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research,LLC, Hialeah, Florida, United States|Research in Miami, Inc, Hialeah, Florida, United States|The Research Center, Inc, Hialeah, Florida, United States|Maxblue Institute, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|DADE Research Center, LLC, Miami, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|United Health Research Corp, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|P&S Reasearch, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Kendall Research Institute, Miami, Florida, United States|Nuovida Research Center Corp., Miami, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Lazlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|University of West Florida, Pensacola, Florida, United States|Neurology Research Institute Palm Beach, LLC, West Palm Beach, Florida, United States|Emory Brain Health Center, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, INC, Columbus, Georgia, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Baptist Health Medical Group, Richmond, Kentucky, United States|The Samuel & Alexia Bratton Memory Clinic, Easton, Maryland, United States|Mir Neurology, Hagerstown, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|AMAC Research Institute, North Dartmouth, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Herbert Harris, MD, PhD, PA, Chapel Hill, North Carolina, United States|ANI Neurology PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Daystar Clinical Research Inc, Akron, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood, Ohio, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|The Birches at Newton / Family Medical Associates, Levittown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|RH Johnson VA Medical Center, Charleston, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Pharmaceuticals Research Associates, Inc., Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic, Bennington, Vermont, United States|Veteran Affairs Medical Center, Salem Virginia, Salem, Virginia, United States|IPC Research, Waukesha, Wisconsin, United States|Dr. Alexander McIntyre Inc., Calgary, Alberta, Canada|The Medical Art Health Research Group, Kelowna, Bristish Columbia, Canada|The Medical Art Health Research Group, Penticton, Bristish Columbia, Canada|The Medical Art Health Research Group, West Vancouver, Bristish Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02442778"
1438,"NCT00165659","A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020",,"Completed","No Results Available","Alzheimer Disease","Drug: DONEPEZIL HYDROCHLORIDE","Primary Outcomes: Efficacy:|CIBIC plus*, SIB**|(*for overall evalution of clinical symtoms)|(**for cognitive function test)|Safety:|Adverse event, adverse drug reaction, vital sign, clinical laboratory parameter, electrocardiogram|Efficacy|Behave-AD, ADCS-ADL-sev","Eisai Limited|Eisai Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","E2020-J081-231","November 2002","May 2005",,"September 14, 2005",,"January 29, 2010","Chita, Aichi-prefecture, Japan|Nagoya, Aichi-prefecture, Japan|Toyohashi, Aichi-prefecture, Japan|Akita, Akita-prefecture, Japan|Akita, Akita-prefecture, Japan|Daisen, Akita-prefecture, Japan|Kashiwa, Chiba-prefecture, Japan|Fukui, Fukui-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Fukuoka, Fukuoka-prefecture, Japan|Kita-kyusyu, Fukuoka-prefecture, Japan|Fukushima, Fukushima-prefecture, Japan|Koriyama, Fukushima-prefecture, Japan|Fujioka, Gunma-prefecture, Japan|Numata, Gunma-prefecture, Japan|Hiroshima, Hiroshima-prefecture, Japan|Hiroshima, Hiroshima-prefecture, Japan|Otake, Hiroshima-prefecture, Japan|Asahikawa, Hokkaido-prefecture, Japan|Aio, Hyogo-prefecture, Japan|Asago, Hyogo-prefecture, Japan|Kako, Hyogo-prefecture, Japan|Kobe, Hyogo-prefecture, Japan|Kobe, Hyogo-prefecture, Japan|Tsuchiura, Ibaraki-prefecture, Japan|Tsukuba, Ibaraki-prefecture, Japan|Kanazawa, Ishikawa-prefecture, Japan|Kawasaki, Kanagawa-prefecture, Japan|Kawasaki, Kanagawa-prefecture, Japan|Sagamihara, Kanagawa-prefecture, Japan|Kochi, Kochi-prefecture, Japan|Kyoto, Kyoto-prefecture, Japan|Kyoto, Kyoto-prefecture, Japan|Nagasaki, Nagasaki-prefecture, Japan|Nagasaki, Nagasaki-prefecture, Japan|Sasebo, Nagasaki-prefecture, Japan|Kashihara, Nara-prefecture, Japan|Joetsu, Niigata-prefecture, Japan|Kashiwazaki, Niigata-prefecture, Japan|Tsukubo, Okayama-prefecture, Japan|Moriguchi, Osaka-prefecture, Japan|Neyagawa, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Suita, Osaka-prefecture, Japan|Takatsuki, Osaka-prefecture, Japan|Saitama, Saitama-prefecture, Japan|Izumo, Shimane-prefecture, Japan|Shizuoka, Shizuoka-prefecture, Japan|Kawachi, Tochigi-prefecture, Japan|Shimotsuga, Tochigi-prefecture, Japan|Chiyoda-ku, Tokyo-prefecture, Japan|Hachioji, Tokyo-prefecture, Japan|Higashimurayama, Tokyo-prefecture, Japan|Itabashi-ku, Tokyo-prefecture, Japan|Kodaira, Tokyo-prefecture, Japan|Machida, Tokyo-prefecture, Japan|Shinjuku-ku, Tokyo-prefecture, Japan|Nanto, Toyama-prefecture, Japan|Gobo, Wakayama-prefecture, Japan|Wakayama, Wakayama-prefecture, Japan|Hofu, Yamaguchi-prefecture, Japan",,"https://ClinicalTrials.gov/show/NCT00165659"
1439,"NCT03630419","Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer Disease","Dietary Supplement: Mito-Food Plan|Other: Cellular Repair Therapy","Change in inflammation as measured through bioimpedance analysis from baseline to week 12|Change in Mini Mental State Exam (MMSE) from Baseline to Week 12|Change in Montreal Cognitive Assessment (MoCA) from Baseline to Week 12|Change in Quality of Life in Alzheimer's Disease (QOL-AD) from Baseline to Week 12","Perseverance Research Center, LLC|Cerulean Advanced Fitness and Wellness","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mito-01","February 10, 2018","July 28, 2018","July 28, 2018","August 14, 2018",,"October 2, 2018","Perseverance Research Center, LLC, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03630419"
1440,"NCT03611439","Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients",,"Completed","No Results Available","Alzheimer Disease|Alzheimer Dementia","Dietary Supplement: ReBuilder|Dietary Supplement: Placebo","Change From Baseline Mini Mental State Exam (MMSE) Scores|Change From Baseline Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Scores|Change From Baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores","Genescient Corporation","All","Child, Adult, Older Adult","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Genescient","October 1, 2013","December 25, 2015","December 25, 2015","August 2, 2018",,"August 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03611439"
1441,"NCT00267124","Brain Aging Project--Kansas University",,"Completed","No Results Available","Alzheimer's Disease",,,"University of Kansas Medical Center|University of Kansas|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)",,"172","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IA0089|1R03AG026374-01","November 2004","August 2009","August 2009","December 20, 2005",,"April 6, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00267124"
1442,"NCT00259480","Project ACT: Advancing Caregiving Techniques",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Home Based Intervention","Caregiver upset|Care recipient behaviors|Caregiver self-efficacy|Nursing home placement|Caregiver depression","Thomas Jefferson University","All","21 Years and older   (Adult, Older Adult)","Phase 3","272","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)","R01AG022254","August 2001","March 2014","March 2015","November 29, 2005",,"May 13, 2015","Laura N. Gitlin,Ph.D, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00259480"
1443,"NCT00259467","Project TAP: Tailored Activities Project",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: Home-Based Behavorial Intervention","Behavioral occurrence|Care recipient depressive mood|Caregiver upset|Activity engagement and vigilance","Thomas Jefferson University","All","21 Years and older   (Adult, Older Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double","R21MH069425","February 2004",,"January 2007","November 29, 2005",,"August 25, 2010","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00259467"
1444,"NCT03946930","IGF Binding Protein-2 Associated With Cognitive Decline",,"Recruiting","No Results Available","Alzheimer Disease",,"Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG|plasma IGF binding protein -2","Chinese University of Hong Kong","All","65 Years to 90 Years   (Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018.274","December 13, 2018","December 31, 2021","December 31, 2021","May 13, 2019",,"May 13, 2019","The Chinese University of Hong Kon, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03946930"
1445,"NCT00236574","A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment",,"Completed","No Results Available","Dementia|Alzheimer Disease","Drug: Galantamine hydrobromide","Memory and cognition (ADAS-cog/MCI and CDR-SB scores) at 12 months and Global functional skills and the overall severity of dementia (the CDR-SB and the overall CDR) at 24 months.|Brain atrophy assessed by MRI, Digit Symbol Coding, Alzheimer's Disease Cooperative Study-ADL scale(MCI version) at 24 months. Safety evaluations (adverse event reports, vital signs, laboratory tests, physical examination, electrocardiograms) throughout.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","50 Years and older   (Adult, Older Adult)","Phase 3","974","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR003145","May 2001",,"November 2003","October 12, 2005",,"June 8, 2011",,,"https://ClinicalTrials.gov/show/NCT00236574"
1446,"NCT00239746","BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Ibuprofen|Drug: Placebo","Changes in biomarker assays","National Institute on Aging (NIA)","All","59 Years and older   (Adult, Older Adult)","Phase 1","40","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0086|R01AG024010","October 2005","August 2009","August 2009","October 17, 2005",,"April 29, 2009","Layton Aging & Alzheimer's Disease Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00239746"
1447,"NCT00165750","Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients",,"Terminated","No Results Available","Alzheimer's Disease","Drug: DONEPEZIL HYDROCHLORIDE","MRI, ADAS-cog|ADL, BPSD, CDR-SB, ZBI, GHQ, CIBIC plus","Eisai Korea Inc.|Eisai Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AS-019 (EKI-5-003)","March 2005","August 2008","November 2008","September 14, 2005",,"November 20, 2013","Cheonnam University Hospital, Gwangju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00165750"
1448,"NCT00142324","CALM-AD",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Donepezil","Cohen Mansfield Agitation Inventory|Neuropsychiatric Inventory|Standardized Mini-Mental State Examination|Severe Impairment Battery|Clinical Global Impression of Severity/Change","Institute of Psychiatry, London|Medical Research Council|Alzheimer's Society","All","40 Years and older   (Adult, Older Adult)","Phase 4","190","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","ISRCTN62185868","November 2003",,"December 2005","September 2, 2005",,"December 14, 2005","Queen Elizabeth Psychiatric Hospital, Birmingham, United Kingdom|Department of Psychiatry for the Elderly, Leicester General Hospital, Leicester, United Kingdom|Institute of Psychiatry, King's College, London, London, United Kingdom|Old Age Psychiatry, Wythenshawe Hospital, Manchester, Manchester, United Kingdom|Institute for Ageing and Health, Newcastle General Hospital, Newcastle, Newcastle upon Tyne, United Kingdom|Department of Psychiatry, Warneford Hospital, Oxford, Oxford, United Kingdom|MARC, Moorgreen Hospital, Southamptom, Southampton, United Kingdom|Department of Old Age Psychiatry, Victoria Hospital, Swindon, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00142324"
1449,"NCT03461861","Network-Level Mechanisms for Preclinical Alzheimer's Disease Development",,"Recruiting","No Results Available","APOE 4","Drug: AGB101 220 mg|Other: Placebo","Functional connectivity strengths of neural networks|Rey Auditory Verbal Learning Test (AVLT)|Logical memory test (LMT)","Medical College of Wisconsin|National Institute on Aging (NIA)","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO00031146|R21AG056882-01","April 11, 2019","March 31, 2020","March 31, 2020","March 12, 2018",,"May 13, 2019","Froedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03461861"
1450,"NCT00362284","Comprehensive Support for Alzheimer's Disease Caregivers",,"Completed","No Results Available","Caregivers|Stress|Depression","Behavioral: NYUCI-AC","Care recipient nursing home/institutional placement|Caregiver emotional stress|caregiver depression|caregiver social support|Caregiver subjective health|secondary stressors","University of Minnesota - Clinical and Translational Science Institute|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","161","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","IA0095|R01AG022066","September 2005","December 2011","January 2012","August 9, 2006",,"September 27, 2019","University of Minnesota, School of Nursing, 6-150 Weaver-Densford Hall, Minneapolis, Minnesota, United States|Silberstein Institute for Aging and Dementia, Department of Psychiatry, NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00362284"
1451,"NCT03333252","A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program)","CPProgram","Recruiting","No Results Available","Caregiver","Behavioral: Intervention Condition|Behavioral: Control Condition","Decrease in depression score for caregiver as measured by CES-D|Decrease in caregiving burden score for caregiver as measured by Burden Inventory","Weill Medical College of Cornell University|National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","246","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1803019068|5R01AG054009","January 29, 2018","April 30, 2020","April 30, 2021","November 6, 2017",,"May 30, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03333252"
1452,"NCT03926520","Electroconvulsive Therapy (ECT) for Agitation in Alzheimer's Dementia (AD)",,"Not yet recruiting","No Results Available","Alzheimer Dementia|Agitation,Psychomotor","Device: Electroconvulsive Therapy (ECT)|Other: Simulated Electroconvulsive Therapy (S-ECT)","CMAI total score|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale (ADCS-CGIC)|Neuropsychiatric Inventory (NPI)|Pittsburgh Agitation Scale (PAS)","Brent Forester|Mayo Clinic|Pine Rest Christian Mental Health Services|Emory University|The Zucker Hillside Hospital|Medical University of South Carolina|Mclean Hospital","All","55 Years to 89 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","2018P003142","September 30, 2019","March 2023","March 2023","April 24, 2019",,"July 31, 2019",,,"https://ClinicalTrials.gov/show/NCT03926520"
1453,"NCT03786510","A Study on the Effectiveness of Multidomain Intervention Program for Reducing Risks of Dementia",,"Completed","No Results Available","Alzheimer Disease","Behavioral: Active control|Behavioral: Intensive + Maintenance program|Behavioral: Intensive program only","Changes from baseline Australian National University Alzheimer's Disease Index (ANU-ADRI) at 4 weeks and 24 week|Changes from baseline Short Physical Performance Battery (SPPB) at 4 weeks and 24 week|Changes from baseline total score in the CERAD neuropsychological battery at 4 weeks and 24 week|Changes from baseline Color Word Stroop Test (CWST) at 4 weeks and 24 week|Changes from baseline Seoul-Instrumental Activities of Daily Living (S-IADL) at 4 weeks and 24 week|Changes from baseline EuroQol Five-Dimensional Questionnaire (EQ-5D) at 4 weeks and 24 week|Changes from baseline Motivation to Change Lifestyle and Health Behaviors for Dementia Risk Reduction Scale (MCLHB-DRR) scale at 4 weeks and 24 week","Seoul National University Hospital|Seoul Metropolitan Government","All","60 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","MDP_AD","November 1, 2016","July 31, 2017","July 31, 2017","December 25, 2018",,"December 25, 2018","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03786510"
1454,"NCT00009191","The Depression in Alzheimer's Disease Study (DIADS)",,"Completed","No Results Available","Alzheimer Disease|Depression","Drug: Sertraline [Zoloft]",,"Johns Hopkins University|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Phase 4",,"Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","R01MH056511|IA0010|DSIR AT-GP","November 2005","November 2006","November 2007","January 24, 2001",,"August 20, 2018","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00009191"
1455,"NCT03691519","Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells","LO-MAPT","Recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: Omega-3 treatment|Dietary Supplement: Placebo","Change from Baseline of Composite Z-score which evaluate cognitive performance|FCSRT Test|MMSE total score|Category Naming Test (CNT)","University Hospital, Toulouse","All","70 Years and older   (Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RC31/16/8752|2016-A01450-51","April 17, 2018","April 2020","April 2022","October 1, 2018",,"October 1, 2018","University Hospital Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03691519"
1456,"NCT03955380","MAD Phase I Study to Investigate Contraloid Acetate",,"Completed","No Results Available","Alzheimer Dementia|Alzheimer Disease","Drug: Contraloid","Assessment of safety and tolerability of Contraloid by monitoring vital signs, ECG and lab values|Assessment of pharmacokinetics of Contraloid: Area under curve (AUC) in plasma|Assessment of pharmacokinetics of Contraloid: Cmax in plasma|Assessment of pharmacokinetics of Contraloid: Tmax in plasma|Assessment of pharmacokinetics of Contraloid: Terminal elimination half-life (t1/2) in plasma|Assessment of pharmacokinetics of Contraloid: distributive half-life (t1/2alpha) in plasma|Assessment of pharmacokinetics of Contraloid: terminal elimination half-life (t1/2beta) in plasma|Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel alpha) in plasma|Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel beta) in plasma|AUC0-24 of Contraloid does not exceed of 2.3 µg·h/mL","Prof. Dr. Dieter Willbold|Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany|Medical University of Vienna|NeuroScios, Austria|Nuvisan, Germany|Fundación Teófilo Hernando, Spain|Alzheimer's Association|Forschungszentrum Juelich","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EUDRA-CT: 2018-002500-14","December 12, 2018","April 3, 2019","April 3, 2019","May 20, 2019",,"May 20, 2019","Forschungszentrum Jülich, Jülich, Germany",,"https://ClinicalTrials.gov/show/NCT03955380"
1457,"NCT03944460","SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate",,"Completed","No Results Available","Alzheimer Dementia|Alzheimer Disease","Drug: Contraloid","Assessment of safety and tolerability of Contraloid by monitoring vital signs, ECG, EEG, and lab values|Assessment of pharmacokinetics of Contraloid: Area under curve (AUC) in plasma|Assessment of pharmacokinetics of Contraloid: Cmax in plasma|Assessment of pharmacokinetics of Contraloid: Tmax in plasma|Assessment of pharmacokinetics of Contraloid: Terminal elimination half-life (t1/2) in plasma|Assessment of pharmacokinetics of Contraloid: Apparent total clearance (Cl/F) in plasma|Assessment of pharmacokinetics of Contraloid: Volume of distribution (Vd) in plasma|AUC0-24 of Contraloid does not exceed of 2.3 µg·h/mL","Prof. Dr. Dieter Willbold|Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany|Medical University of Vienna|NeuroScios, Austria|Triskelion, The Netherlands|Fundación Teófilo Hernando, Spain|Forschungszentrum Juelich","Male","18 Years to 45 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EUDRA-CT: 2017-000396-93","April 9, 2018","July 27, 2018","July 27, 2018","May 9, 2019",,"May 9, 2019","Forschungszentrum Jülich, Jülich, Germany",,"https://ClinicalTrials.gov/show/NCT03944460"
1458,"NCT03615027","Dementia-specific Intervention of Advance Care Planning","ADIA","Recruiting","No Results Available","Alzheimer Disease","Behavioral: Dementia-specific advance care planning","Change in participants' anxiety and depression levels|Change in participants' decisional conflict level|Change in proxies' perception of the burden|Changes in patients' psychological autonomy and perceived control|Participants' satisfaction with the intervention","University of Lausanne Hospitals","All","65 Years to 100 Years   (Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018-00785","August 3, 2018","September 30, 2019","December 31, 2019","August 3, 2018",,"August 7, 2018","Lausanne University Hospital, Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT03615027"
1459,"NCT01819714","Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease","SensiCare","Completed","No Results Available","Alzheimer Disease","Other: Multi-sensory supportive care","Change from baseline in NPI-Q scores|Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD)|Change from baseline in the ""aggressive behavior"" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire|Change in drug consumption from baseline","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PHRIP/2012/JD|2013-A00005-40","June 2013","May 2014","February 2015","March 28, 2013",,"April 29, 2015","CHU de Nîmes - Centre de Gérontologie de Serre Cavalier, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT01819714"
1460,"NCT03442322","Optimizing Care for Patients With Dementia",,"Recruiting","No Results Available","Alzheimer Disease","Other: transdisciplinary approach|Other: multidisciplinary approach","Dispensing of psychotropic medications","University of Pittsburgh|Patient-Centered Outcomes Research Institute","All","Child, Adult, Older Adult","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","PRO17100544","March 15, 2018","July 2021","December 2021","February 22, 2018",,"February 5, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03442322"
1461,"NCT03384069","CBT for African Americans With Cognitive Impairment",,"Recruiting","No Results Available","Alzheimer Disease","Behavioral: Group-based Cognitive Behavioral Therapy (CBT)|Behavioral: Phone-based Cognitive Behavioral Therapy (CBT)","Number of participants attending CBT sessions (participants retention)|Percentage of patients enrolled as per target (feasibility)|Change in attitudes of patients regarding a CBT intervention for Mild Cognitive Impairment (MCI)|Change in C-reactive protein level|Change in the Center for Epidemiological Studies-Depression (CESD-R) score|Change in Perceived Stress Scale (PSS) score|Change in the quality of life scale (36-Item Short-Form Health Survey (SF-36)) score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) score|Change in activities of daily living (ADL)|Change in Instrumental activities of daily living (IADL)","Emory University|Alzheimer's Association","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00099440","January 10, 2018","March 31, 2020","March 31, 2020","December 27, 2017",,"April 4, 2019","Emory Clinic, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03384069"
1462,"NCT03349320","Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms",,"Completed","No Results Available","Late Onset Alzheimer Disease",,"Association among donepezil serum concentration after 3, 6, and 12 months of treatment onset and clinical response.|Evaluation of baseline cognitive performance|Evaluation of CYP2D6 and APOE polymorphisms|Evaluate donepezil serum concentration after 3 months of treatment onset.|Evaluate donepezil serum concentration after 6 months of treatment onset.|Evaluate donepezil serum concentration after 12 months of treatment onset.","Federal University of Minas Gerais","All","Child, Adult, Older Adult",,"37","Other","Observational","Observational Model: Other|Time Perspective: Prospective","0172 /2010","June 2009","March 2013","March 2013","November 21, 2017",,"December 18, 2017",,,"https://ClinicalTrials.gov/show/NCT03349320"
1463,"NCT03030105","Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",,"Completed","No Results Available","Alzheimer Disease","Drug: BPN14770|Drug: BPN14770 placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine 0.6 MG/ML|Drug: Scopolamine placebo","Groton Maze Learning Test (GMLT)","Tetra Discovery Partners","All","18 Years to 55 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-103","January 2017","May 2017","June 2017","January 24, 2017",,"October 16, 2018","ICON Early Phase Services, LLC, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03030105"
1464,"NCT03435705","Maintenance of Occupational Therapy for Patients With Alzheimer","MaTheoAlz","Recruiting","No Results Available","Alzheimer's Disease or Related Disorder","Behavioral: maintaining of occupational therapy","Neuropsychiatric inventory (NPI) score|The functional autonomy measured by the Disability Assessment in Dementia (DAD scale).|Quality of life measured by the Quality of Life in Alzheimer's Disease scale.|Depression of the patient via the Montgomery-Asberg Depression Rating Scale (MADRS).|Apathy of the patient via the Apathy inventory.|Mortality and institutionalization of patients.|The care processes.|The caregiver burden via the Burden Interview with Zarit|The sense of competence of the caregivers|Patient care consumption measured by the RUD Lite scale|The total cost (health and social) of patient care in each of the groups|The cost per disorder behavior avoided|The cost related to the consequences in terms of quality of life of the patient","University Hospital, Bordeaux","All","Child, Adult, Older Adult","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","CHUBX 2016/29","January 17, 2018","November 17, 2020","November 17, 2020","February 16, 2018",,"February 16, 2018","Aapam-Ssiad, Blaignan, France|SESAME, Bordeaux, France|Castelsanté, Casteljaloux, France|SSIAD Hauts de garonne, Cenon, France|SSIAD du bassin d'Arcachon, La Teste-de-Buch, France|Vie Santé Merignac, Mérignac, France|AMSADHG, Saint Savin, France|Equipe Espard, Talence, France",,"https://ClinicalTrials.gov/show/NCT03435705"
1465,"NCT02957227","Diagnosis of Alzheimer's Disease Using Event Related Potentials",,"Recruiting","No Results Available","Mild Cognitive Impairment","Device: No intervention is part of this study but patients use an EEG device during observational data collection.","Change in memory disorder diagnosis|EEG peak amplitude and latency|Cortical, quantitative MRI volume measurements|Amyloid PET tracer uptake, Standardardized Uptake Value ratios (SUVRs)|Mini mental status exam scores|Test of Memory and Malingering (TOMM) scores","VA Boston Healthcare System","All","50 Years to 100 Years   (Adult, Older Adult)",,"170","U.S. Fed","Observational","Observational Model: Case-Control|Time Perspective: Prospective","5I01CX000736-02-COG|5I01CX000736-02","July 2016","January 2019","January 2019","November 7, 2016",,"November 6, 2017","VA Boston Healthcare, Jamaica Plain, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02957227"
1466,"NCT00417482","Antipsychotic Discontinuation in Alzheimer's Disease","ADAD","Completed","Has Results","Alzheimer Disease|Psychotic Disorders|Agitation|Aggression","Drug: risperidone","Relapse by Study Week 32|Relapse by Study Week 48|Mini Mental State Exam (MMSE)|Treatment Emergent Symptoms Scale (TESS)|Extrapyramidal Signs (EPS)|AIMS|Physical Self-Maintenance Scale (PSMS)|Weight","New York State Psychiatric Institute|National Institute on Aging (NIA)|Columbia University","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 4","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#5598R|5R01AG021488","August 2004","April 2011","April 2011","January 1, 2007","April 24, 2013","April 24, 2013","Tuscaloosa VA Medical Center, Department of Psychiatry, Tuscaloosa, Alabama, United States|WLA VA Medical Center/UCLA, Psychiatry, Los Angeles, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, New York, United States|New York State Psychiatric Institute, Columbia University, New York, New York, United States|Medical University of South Carolina, North Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00417482"
1467,"NCT03430648","Is Tau Protein Linked to Mobility Function?","SYNERGY","Enrolling by invitation","No Results Available","Alzheimer Disease|Physical Activity",,"Association between CSF total and phosphorylated tau levels and gait speed|Association between CSF total and phosphorylated tau levels and gait variability|Association between CSF total and phosphorylated tau levels and standing balance.|Examine the association between Digit Symbol Substitution Test and gait speed","Wake Forest University Health Sciences|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)",,"60","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00042050|P30AG021332","September 7, 2017","June 2020","June 2020","February 13, 2018",,"February 18, 2019","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03430648"
1468,"NCT03890861","Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)""","RAATE","Not yet recruiting","No Results Available","Dementia, Alzheimer Type","Behavioral: Physical activity|Behavioral: Successful Aging","Change in episodic memory|Change in executive function|Change in cognitive status|Change in glucose|Change in time spent in physical activity|Change in cardiorespiratory fitness|Change in physical function-NIH Toolbox|Change in telomere length|Change in weight|Change in brain structure|Changes in brain function|Change in lipoproteins|APOE genotype|Change in physical activity|Change in blood pressure|Change in mood|Change in height|Change in physical function-SPPB","Pennington Biomedical Research Center|National Institute on Aging (NIA)","All","65 Years to 85 Years   (Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PBRC2019-002|R01AG062200-01","August 2019","February 2022","November 30, 2023","March 26, 2019",,"March 26, 2019","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03890861"
1469,"NCT01325402","An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease",,"Completed","No Results Available","Maximum Diagnostic Mass of [18Fluor]AZD4694","Other: [18Fluor]AZD4694","The Maximum Diagnostic Mass by assessing the visual read out of amyloid status according to and quantification of an [18F]AZD4694 PET image in a high mass experiment compared to the image in a low mass experiment in the same subject.|Number of Adverse Events as a measure of Safety and tolerability of [18F]AZD4694|Correlation between early uptake of [18F]AZD4694 images and cerebral blood flow images as measured by Arterial Spin Labeling Magnetic resonance imaging|Correlation between estimates of β-amyloid load in brain obtained using [18F]AZD4694 Position Emission Tomography imaging and concentrations of β-amyloid in Cerebrospinal fluid","AstraZeneca","Male","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D2750C00002|EudraCT # 2011-000095-34","August 2011","November 2012","November 2012","March 29, 2011",,"December 10, 2012","Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01325402"
1470,"NCT01147679","Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls",,"Unknown status","No Results Available","Frontotemporal Dementia|Frontotemporal Degeneration|Alzheimer's Disease|Social Behavior",,"Psychophysiological Reactivity|Behavioral Reports and Observations|MRI Brain-Mapping","University of California, Los Angeles|National Institute on Aging (NIA)","All","40 Years to 75 Years   (Adult, Older Adult)",,"99","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","1R01AG034499|UCLA IRB#10-001097|R01AG034499","January 2010","September 2013","July 2014","June 22, 2010",,"October 28, 2011","UCLA Department of Neurology, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01147679"
1471,"NCT02741505","Brain Sleep Deprivation MRI Effects (BEDTIME)","BEDTIME","Not yet recruiting","No Results Available","Alzheimer's Disease","Device: Actigraph","Measure of Interstitial Space Volume during sleep using MRI imaging|Changes in Cerebral Spinal Fluid volume measured by increases in the power of slow wave activity (SWA)","NYU Langone Health","All","21 Years to 30 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-00971","June 2019","December 2019","December 2019","April 18, 2016",,"April 19, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02741505"
1472,"NCT01354691","Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment","Drug: ladostigil hemitartrate","ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale|Safety Evaluation|Neuropsychiatric Inventory (NPI)|Cornell Scale for Depression in Dementia (CSDD)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini-Mental State Examination (MMSE)|ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive Subscale","Avraham Pharmaceuticals Ltd","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR100101/CO15570","February 2011","September 2012","March 2013","May 17, 2011",,"July 23, 2013","Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22, Graz, Austria|Privatordination Horn, HamerlingstraBe 15, Horn, Austria|Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9, Linz, Austria|Privatordination, Lainzerstrasse 20, Wein, Austria|General Hospital Pula, Negrijeva 6, Pula, Croatia|General Hospital Zabok, Bracak 8, Zabok, Croatia|Clinical Hospital Center Zagreb, Kispaticeva 12, Zagreb, Croatia|Clinical Hospital Dubrava, Avenija Gojka Suska 6, Zagreb, Croatia|Polyclinic Neuron, Salata 12, Zagreb, Croatia|Psychiatric Hospital Vrapce, Bolnicka cesta 32, Zagreb, Croatia|Klinische Forschung Hamburg GmbH, Hoheluftaussee 18, Hanburg, Germany|Klinische Forschung Schwerin GmbH, FriedrichstraBe 1, Schwerin, Germany|Studienzentrum Nordwest, Lange StraBe 23-25, Westerstede, Germany|Clinical Centre of Serbia, Dr. Subotica 6, Beograd, Serbia|Military Medical Academy, Crnotravska 17, Beograd, Serbia|CAE Oroitu Centro Atencion Especializada C/Jata, 9, Algorta (Vizcaya), Spain|Centro Geroinnova Barcelona, Calle Mandoni n 17, Barcelona, Spain|Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37, Barcelona, Spain|Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n, SALT (Girona), Spain",,"https://ClinicalTrials.gov/show/NCT01354691"
1473,"NCT02578303","Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations","VAAPS","Recruiting","No Results Available","Alzheimer Disease","Other: Vascular flow measurement by PC-MRI","Total arterial flowrate (measured by PC-MRI debit ml/Mn)|sleep apnea measured by elderly polygraphy (Number of apneas / night)","Central Hospital Saint Quentin","All","75 Years to 120 Years   (Older Adult)","Not Applicable","139","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RCB / N° 2014-A01617-40","May 2015","January 1, 2020","January 1, 2020","October 16, 2015",,"July 26, 2019","CH Saint-Quentin, Saint-Quentin, France",,"https://ClinicalTrials.gov/show/NCT02578303"
1474,"NCT01153607","Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers",,"Completed","No Results Available","Diagnostic Imaging","Drug: BAY1006578","Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by different quantification approaches|Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by visual analysis and by standard parameters (e.g. Standardized Uptake Values=SUV)|Electrocardiogram (ECG)|Blood pressure|Adverse events collection","Life Molecular Imaging SA","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14708|2009-017166-24","June 2010","October 2011","October 2011","June 30, 2010",,"January 21, 2013","Turku, Finland|Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01153607"
1475,"NCT02078310","Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia",,"Completed","No Results Available","Alzheimer's Disease","Drug: ITI-007|Drug: Placebo","Number of participants with adverse events|Area under the concentration-time curve (AUC)","Intra-Cellular Therapies, Inc.","All","65 Years and older   (Older Adult)","Phase 1|Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","ITI-007-200","February 2014","August 2014","November 2014","March 5, 2014",,"November 17, 2017","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02078310"
1476,"NCT01435551","Using Hypnotherapy For Dementia & Alzheimer's",,"No longer available","No Results Available","Alzheimer Disease","Other: Hypnotherapy",,"Families To The Rescue","All","Child, Adult, Older Adult",,,"Other","Expanded Access",,"ALZ2012JB",,,,"September 16, 2011",,"February 4, 2016",,,"https://ClinicalTrials.gov/show/NCT01435551"
1477,"NCT01009359","Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",,"Completed","No Results Available","Diagnostic Imaging","Drug: F-18 DPA-714 (BAY85-8102)","Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches|Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV)|Electrocardiogram (ECG)|Blood pressure|Serum protein|Serum creatinine|Serum GOT (Glutamat-Oxalacetate-Transaminase)|Adverse events collection","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13150|2009-009358-26","October 2009","July 2010","October 2010","November 6, 2009",,"July 31, 2013","Turku, Finland|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01009359"
1478,"NCT03727360","Exercise for Brain Health in the Fight Against Alzheimer's Disease",,"Recruiting","No Results Available","Healthy Cognition","Other: Exercise Training|Other: Flexibility Control","Change from Baseline to 6 months in Rey Auditory Verbal Learning Test Sum of Trials 1-5|Change from Baseline to 6 months in Resting Cerebral Blood Flow|Change from Baseline to 6 months in VO2peak|Change from Baseline to 6 months in 6 Minute Walk Test","University of Maryland, College Park|National Institute on Aging (NIA)|Johns Hopkins University|Marquette University","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","152","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other","1115946|1R01AG057552","October 8, 2018","April 2023","April 2023","November 1, 2018",,"November 1, 2018","University of Maryland, Department of Kinesiology, College Park, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03727360"
1479,"NCT00190021","Donepezil Treatment of Psychotic Symptoms in Dementia Patients",,"Unknown status","No Results Available","Dementia of Alzheimer Type","Drug: donepezil","Possitive and Negative Syndrome Scale|Clinical Global Impression","Beersheva Mental Health Center","All","65 Years to 90 Years   (Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BMHC-3495CTIL",,,,"September 19, 2005",,"September 8, 2010","Beersheva Mental Health Center, Beersheva, Israel",,"https://ClinicalTrials.gov/show/NCT00190021"
1480,"NCT04113967","Efficacy of a Biodanza Program in People With Alzheimer's Disease.",,"Completed","No Results Available","Alzheimer Dementia (AD)|Mental Disorder|Mood Disorders|Physically Disabled","Other: Biodanza program","6-minute walk test|Tinetti test|Mini Mental State Examination (MMSE)|Daily Living Activities Index (Barthel Scale/Index)|Pfeiffer Short Portable Mental Status Questionnaire|Hamilton Depression Rating Scale|Pittsburg Sleep Quality Index.","Universidad de Almeria","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Universidad de Almería","March 1, 2018","July 1, 2018","October 1, 2018","October 3, 2019",,"October 3, 2019","Universidad de Almería, Almería, Spain",,"https://ClinicalTrials.gov/show/NCT04113967"
1481,"NCT01703702","Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir (18F)","Clinical and Diagnostic Change in Patient Management|Change in ADAS-Cog 11 Total Score|Change in Patient's Clinical Diagnosis|Change in Diagnostic Confidence|Change in Patient Management: Advice/Counseling|Change in Caregiver Self-efficacy|Change in Patient Management: Individual Categories","Avid Radiopharmaceuticals|Eli Lilly and Company","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","641","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A18","October 2012","April 2015","April 2015","October 10, 2012","August 17, 2016","August 17, 2016","Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Clearwater, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Chestnut Hill, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Patchogue, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bennington, Vermont, United States|Research Site, Amiens, France|Research Site, Bordeaux, France|Research Site, Bron, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Reims, France|Research Site, Rouen, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Villeurbanne, France|Research Site, Bergamo, Italy|Research Site, Brescia, Italy|Research Site, Brescia, Italy|Research Site, Florence, Italy|Research Site, Genoa, Italy|Research Site, Genoa, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Modena, Italy|Research Site, Monza, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Rome, Italy|Research Site, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT01703702"
1482,"NCT01602393","Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase","CT04 POLEP","Completed","No Results Available","Alzheimer's Disease","Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x","Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment","Chiesi Farmaceutici S.p.A.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCD-1014-PR-0053 POLEP|2010-024270-19","May 2012","October 2013","October 2013","May 21, 2012",,"February 6, 2014","Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01602393"
1483,"NCT00833274","Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases",,"Completed","No Results Available","Alzheimer Disease","Behavioral: computerized test","Reaction times (ms), using a computerized test|Apathy severity, using a specific apathy scale (Apathy Inventory)","Centre Hospitalier Universitaire de Nice","All","65 Years to 75 Years   (Older Adult)","Not Applicable","70","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","06-CIR-01","February 2009","October 2011","October 2011","February 2, 2009",,"December 9, 2011","CM2R, Nice University Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT00833274"
1484,"NCT00505167","Memantine Versus Donepezil in Early Stages of Alzheimer's Disease",,"Completed","No Results Available","Dementia, Alzheimer Type","Drug: Memantine|Drug: Donepezil","Changes in the Levels of the metabolite N-acetyl-aspartate in several areas of the brain.|Changes in the clinical scales observed after treatment","Hospital Miguel Servet|Clinica Quiron de Zaragoza|Universidad de Zaragoza|Hospital de Barbastro|Hospital Royo Villanova","All","Child, Adult, Older Adult","Phase 4","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","0910-0459","July 2007","July 2008","December 2008","July 23, 2007",,"December 29, 2008","Hospital de Barbastro, Barbastro, Huesca, Spain|Cenro de especialidades San José. Hospital Miguel Servet, Zaragoza, Spain|Hospital Royo Villanova, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00505167"
1485,"NCT01537757","A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])",,"Completed","No Results Available","Alzheimer's Disease","Drug: MK-8931","Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of MK-8931|Renal clearance (CLr) of MK-8931|Fraction of MK-8931 dose excreted in urine (fe)","Merck Sharp & Dohme Corp.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P08535|MK-8931-009","March 2012","May 2012","May 2012","February 23, 2012",,"January 26, 2015",,,"https://ClinicalTrials.gov/show/NCT01537757"
1486,"NCT03821844","Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease","METRIcAL","Not yet recruiting","No Results Available","Dementia","Behavioral: Music and Memory","Frequency of agitated and aggressive behaviors (staff report)|Frequency of agitated and aggressive behaviors (direct observation)|Frequency of agitated and aggressive behaviors (administrative data)|Antipsychotic use|Antianxietal use|Antidepressant use|Hypnotic use|Observed emotion|Depression","Brown University|Westat|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","1620","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","R33AG057451","May 1, 2019","August 1, 2021","December 31, 2021","January 30, 2019",,"March 19, 2019","PruittHealth, Norcross, Georgia, United States|Vetter Senior Living, Elkhorn, Nebraska, United States|CommuniCare Terrapins Division, Blue Ash, Ohio, United States|Good Samaritan Society, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT03821844"
1487,"NCT04077450","HRVB on Alzheimer's Disease Caregivers",,"Recruiting","No Results Available","Burnout, Caregiver|Quality of Life","Behavioral: Heart Rate Variability Biofeedback Training","Caregiver Burden|Life Quality|Perceived Stress","Arizona State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00009353","January 28, 2019","January 27, 2020","January 27, 2020","September 4, 2019",,"September 4, 2019","Arizona State University, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04077450"
1488,"NCT01421056","Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)",,"Completed","No Results Available","Alzheimer's Disease","Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x","Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment","Chiesi Farmaceutici S.p.A.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCD-1014-PR-0053 OLEP|2010-024270-19","July 2011","November 2012","November 2012","August 22, 2011",,"February 6, 2014","Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01421056"
1489,"NCT04075435","Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia","CBD","Not yet recruiting","No Results Available","Alzheimer Disease|Anxiety|Agitation,Psychomotor","Drug: high CBD/low THC sublingual solution","Anxiety Domain on the Neuropsychiatric Inventory-Clinician scale|Total score on the Generalized Anxiety Disorder 7 scale|Safety defined by absence of serious adverse events|Safety as defined by lack of treatment emergent cognitive impairment as measured by the Mini Mental Status Exam (MMSE)|Safety defined as absence of treatment emergent delirium as measured by the Confusion Assessment Method (CAM)","Mclean Hospital|Spier Family Foundation","All","60 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019P002466","November 1, 2019","November 1, 2021","November 1, 2021","August 30, 2019",,"September 27, 2019",,,"https://ClinicalTrials.gov/show/NCT04075435"
1490,"NCT00909285","Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients",,"Completed","No Results Available","Alzheimer Disease, Early Onset","Device: TMS stimulation|Device: Sham comparator|Behavioral: Cognitive training","Evaluation of the efficacy of the TMS stimulation with cognitive training in treatment of early- to mid- stage Alzheimer's patients will be established by improvement of at least 4 points on ADAS-COG.|Safety will be established by paucity of related adverse events.","Assaf-Harofeh Medical Center","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NRX -NC-01","July 2009","July 2010","July 2010","May 27, 2009",,"July 13, 2010","Assaf-Harofeh MC, Beer-Yaakov, Israel",,"https://ClinicalTrials.gov/show/NCT00909285"
1491,"NCT02263287","LESCOD: ""Lewy Body Screening in Cognitive Disorders""","LESCOD","Terminated","No Results Available","Alzheimer Disease|Lewy Body Disease","Other: LeSCoD scale","Construct validity of the LeSCoD scale with a factorial analysis|Diagnostic validity of the Lescod scale by measuring the sensitivity and the specificity|Intergroup variance will be used to assess the quality of the patient denomination|Concurrent validity will be assessed by the measurement of the striatal dopaminergic depletion and its correlation with the Lescod score","Nantes University Hospital","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","133","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC14_0007","October 2014","August 2017","August 2017","October 13, 2014",,"December 7, 2017","Nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT02263287"
1492,"NCT03090516","Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's","Drug: Ginkgo biloba dispersible tablets|Drug: Donepezil|Drug: Ginkgo biloba dispersible tablets and Donepezil","Scales to assess|Electroencephalography P300|liver function (blood)|1.5T MRI changes|Alzheimer disease assessment scale (ADAS-cog)|activities of daily living scale (ADL)|Change in neuropsychiatrc interventory (NPI)|Change in geriatric depression scale (GDS)|renal function|ECG","The First Affiliated Hospital with Nanjing Medical University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ginkgo biloba","August 10, 2016","March 10, 2020","March 10, 2020","March 24, 2017",,"August 7, 2019","Ting Wu, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03090516"
1493,"NCT01021644","Genes, Exercise, Memory and Neurodegeneration",,"Completed","No Results Available","Alzheimer's Disease","Behavioral: aerobic exercise-training|Behavioral: stretch exercise","AD Assessment Scale-Cognitive (ADAS-COG)|Mini-Mental State Exam (MMSE)|CDR (Clinical Dementia Rating) Scale|Logical Memory Test (Delayed Paragraph Recall)|Visuospatial and Visuographic: Clock Drawing Test|American National Adult Reading Test (ANART)|Neuropsychiatric Inventory Q (NPIQ)|Geriatric Depression Scale|Activities of Daily Living (ADCS-ADL)|PET imaging to measure cerebral glucose homeostasis/metabolism","Howard University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IA0172|1R01AG031517-01A209|1R01AG031517-01","October 2009","December 2013","December 2013","November 30, 2009",,"February 14, 2014","Howard University General Clinical Research Center (GCRC), Washington, District of Columbia, United States|Temple University Exercise Physiology Laboratory, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01021644"
1494,"NCT00090402","Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease|Oxidative Stress|Dementia|Hyperlipidemia|Inflammation","Dietary Supplement: Fish Oil|Dietary Supplement: Lipoic Acid|Other: Fish Oil Placebo|Other: Lipoic Acid Placebo","F2-isoprostane Level Urine F2-Isoprostanes|Change in Mini-Mental State Exam (MMSE) Score From Baseline to 12 Months|Change in Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) Scores From Baseline to 12 Months","Oregon Health and Science University|National Institute on Aging (NIA)|National Center for Research Resources (NCRR)","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IA0062|1R21AG023805-01|5R21AG023805-02|AG08017|M01RR000334","April 2004","January 3, 2006","August 2007","August 26, 2004","February 26, 2010","July 21, 2017","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00090402"
1495,"NCT02331784","Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease","PACR-AD","Completed","No Results Available","Older Adults, Aging Brain","Behavioral: Computerized Plasticity-based Software|Behavioral: Commercially available Video Game","Changes in performance on global cognitive composite score|Changes in brain function|Changes in brain structure|Changes in task-related brain activation|Changes in performance on memory composite score|Changes in performance on executive function composite score|Changes in performance on processing speed composite score","Posit Science Corporation|University of Iowa","All","65 Years to 79 Years   (Older Adult)","Not Applicable","68","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","PSC-PACR-AD-01","April 2015","April 20, 2017","April 20, 2017","January 6, 2015",,"April 19, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02331784"
1496,"NCT02273895","The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study",,"Completed","No Results Available","AD","Drug: Scopolamine","Changes in EEG as a result of scopolamine administration","Mentis Cura|Landspitali University Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","29","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC-CT-001","April 2004","October 2004","January 2010","October 24, 2014",,"October 24, 2014",,,"https://ClinicalTrials.gov/show/NCT02273895"
1497,"NCT00857415","Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Specificity Analysis|Regional Correlation Analysis","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A07","December 2008","March 2010","May 2010","March 6, 2009","May 7, 2012","May 22, 2012","Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, San Francisco, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00857415"
1498,"NCT00375557","Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients",,"Withdrawn","No Results Available","Alzheimer's Disease|Dementia|Behavioral Symptoms","Drug: Divalproex ER|Drug: Quetiapine","The change from the Baseline to the End of the Study/Early Termination visit in the CMAI & Quality of life scale scores.","University of Cincinnati|Abbott","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-08-25-06","October 2006",,"September 2007","September 13, 2006",,"May 27, 2015","Cincinnati VA Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00375557"
1499,"NCT02563483","Yoga for Family Caregivers of Alzheimers Disease Patient",,"Completed","No Results Available","Stress|Anxiety|Compassion","Behavioral: yoga and compassion meditation program","change in cortisol|change in stress|change in depression|change in anxiety|change in quality of life|change in vitality|change in attention|change in self-compassion","Federal University of São Paulo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","yoga caregivers","September 2007","February 2008","November 2009","September 30, 2015",,"September 30, 2015",,,"https://ClinicalTrials.gov/show/NCT02563483"
1500,"NCT02838563","Validation of a Scale of Well-Being Assessment (SIWA) in Patients With Alzheimer's Disease or a Related Disease.","SIWA","Terminated","No Results Available","Well-Being","Other: SIWA","Correlation between SIWA and an other quality of life scale (Qol-AD)|Stability over time of SIWA|Correlation between SIWA and an health scale (EQ-5D)|Correlation between SIWA and behavioral and psychological symptom of dementia (BPSD) (NPI)","Hospices Civils de Lyon","All","60 Years and older   (Adult, Older Adult)",,"135","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0441","January 13, 2016","April 27, 2017","April 27, 2017","July 20, 2016",,"July 13, 2017","Centre de Recherche Clinique "" Vieillissement-Cerveau-Fragilité "", Hôpital des Charpennes, Hospices Civils de Lyon, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02838563"
1501,"NCT02305836","Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease",,"Recruiting","No Results Available","Cognitive Impairment","Procedure: acupuncture|Drug: donepezil","change of total ADAS-cog score from baseline|change of total MMSE score from baseline|change of total ADCS-ADL score score from baseline|change of total QoL-AD score score from baseline","Guang'anmen Hospital of China Academy of Chinese Medical Sciences","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","334","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014S291","June 2017","June 2019","December 2019","December 3, 2014",,"May 16, 2017","Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02305836"
1502,"NCT03721705","Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type",,"Recruiting","No Results Available","Alzheimer Disease|Cognitive Dysfunction|Mild Cognitive Impairment|Mild Dementia|Cognitive Decline|Dementia, Alzheimer Type","Device: Renew NCP-5","Mean change from baseline to 24 weeks in Vascular Dementia Assessment Scale Coginitive subscale (vADAS-cog) using the average of scores at 12, 18 and 24 weeks.|Number of participants with treatment related adverse events as assessed by MedDRA.|Number of participants with treatment related serious adverse events as assessed by MedDRA.","Renew Research, LLC|KAI Research","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RenewTM NCP-5-1001","November 12, 2018","November 12, 2019","January 31, 2020","October 26, 2018",,"June 6, 2019","Xenoscience, Phoenix, Arizona, United States|Irvine Clinical Research, Irvine, California, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|iResearch Atlanta, Atlanta, Georgia, United States|iResearch Savannah, Savannah, Georgia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cardiovascular Advantages, LLC, Baton Rouge, Louisiana, United States|Neuro-Behavioral Clinical Research, Canton, Ohio, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03721705"
1503,"NCT02007291","Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment","NINDS-AIREN","Completed","Has Results","Late Onset Alzheimer",,"Cognitive Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease|Independence for Daily Activities Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease","Federal University of Minas Gerais","All","59 Years to 93 Years   (Adult, Older Adult)",,"71","Other","Observational","Observational Model: Other|Time Perspective: Prospective","0172 / 2010","June 2009","October 2011","March 2013","December 10, 2013","June 12, 2018","June 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02007291"
1504,"NCT02654574","Comparison of Two Modes of Administration of the IADL Questionnaire, Assessing the Level of Functional Autonomy of Patients to Carry Out the Tasks of Daily Living: Randomized Controlled Trial Among Patients of a Memory Clinic","IADL","Completed","No Results Available","Alzheimer's Disease|Dementia Disorders","Other: IADL administration by phone","Degree of agreement (concordance) of the overall level of functional autonomy measured with two ways (face-to-face interview and by phone)|Consistency of the answers to each question of the IADL questionnaires between the two methods of administration","Hospices Civils de Lyon","All","50 Years and older   (Adult, Older Adult)","Not Applicable","299","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014-867|2014-A00446-41","June 2014","April 2016","April 2016","January 13, 2016",,"May 20, 2016","Hospices Civils de Lyon - Hôpital Charpennes - Memory Research Centre Lyon, Clinical Research Centre (CVF), Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02654574"
1505,"NCT00441987","Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953",,"Completed","No Results Available","Alzheimer Disease|Healthy","Drug: GSI-953","Safety","Wyeth is now a wholly owned subsidiary of Pfizer","Male","20 Years and older   (Adult, Older Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3183A1-101","February 2007","July 2009","July 2009","March 1, 2007",,"June 22, 2010","5-4-12, Kitashinagawa, Shinagawa-ku, Japan",,"https://ClinicalTrials.gov/show/NCT00441987"
1506,"NCT00988624","A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)",,"Completed","No Results Available","Alzheimer's Disease|Huntington Disease","Drug: Dimebon IR Tablet|Drug: Dimebon MR1|Drug: Dimebon MR2|Drug: Dimebon MR3|Drug: Dimebon MR4","PK endpoints for dimebon and M7 (where appropriate) for each formulation: AUC0-24, AUC0-24(dn), AUCinf (as data permit) AUCinf(dn), AUClast, AUClast(dn), Tlag, Cmax, Tmax, and t1/2 (as data permit).|Safety and tolerability for each formulation (AEs, ECG, vital signs, safety labs)","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","B1451023","October 2009","December 2009","December 2009","October 2, 2009",,"January 12, 2010","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00988624"
1507,"NCT00303277","Do HMG CoA Reductase Inhibitors Affect Abeta Levels?",,"Completed","No Results Available","Alzheimer's Disease|Aging","Drug: simvastatin|Drug: pravastatin","CSF abeta levels|CSF biomarkers","Seattle Institute for Biomedical and Clinical Research","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","21974","August 2002","April 2005","April 2005","March 16, 2006",,"April 13, 2010","VA Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00303277"
1508,"NCT03848312","Preventing Alzheimer's Disease With Cognitive Training","PACT","Recruiting","No Results Available","Age-related Cognitive Decline","Behavioral: Cognitive Training|Behavioral: Computerized Cognitive Stimulation","Number of participants enrolled|Adherence, which will be quantified as percent of participants who completed 20 or more sessions of assigned exercises.","University of South Florida|Michigan State University|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","1600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","WIRB® Protocol #20182630|1R56AG058234-01A1","February 19, 2019","March 30, 2020","June 30, 2020","February 20, 2019",,"September 6, 2019","University of South Florida, Tampa, Florida, United States|Michigan State University, Grand Rapids, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03848312"
1509,"NCT03899844","Study to Evaluate Amyloid in Blood and Imaging Related to Dementia","SEABIRD","Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia","Other: Blood collection, PiB PET/MRI, and cognitive testing","Plasma amyloid-beta 42/40 ratio|Area under the curve (AUC) of the blood test (plasma amyloid-beta 42/40 ratio) in predicting amyloid PET status|Coefficient of variation for the initial and confirmatory blood amyloid-beta test results","Washington University School of Medicine","All","60 Years and older   (Adult, Older Adult)",,"1120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","201902081","April 9, 2019","August 2023","August 2023","April 2, 2019",,"April 26, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03899844"
1510,"NCT03049501","Caring for the Caregiver Network",,"Completed","Has Results","Caregivers of Alzheimer's Disease or Memory Problem Patients","Behavioral: Caregiving condition|Behavioral: Nutrition condition","Depression as Measured by Center for Epidemiologic Studies Depression Scale (CES-D)|Caregiving Burden as Measured by Burden Inventory|Caregiver's Self Report of Self-care|Caregiver's Self-report of Physical Health|Caregiver's Self-efficacy|Positive Aspects of Caregiving","University of Miami|National Institute of Nursing Research (NINR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","244","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20130460|R01NR014434","July 2013","April 20, 2018","April 20, 2018","February 10, 2017","June 25, 2019","June 25, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03049501/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03049501"
1511,"NCT03900936","Detecting Dementia Earlier","DDE","Recruiting","No Results Available","Alzheimer Disease|MCI|Aging","Diagnostic Test: Neuropsychological tests","Predicting progression|Social Characteristics and questionnaires","South Tees Hospitals NHS Foundation Trust","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","207985","January 19, 2017","June 20, 2019","August 30, 2021","April 3, 2019",,"April 3, 2019","South Tees Hospitals NHS FT, Middlesbrough, Teesside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03900936"
1512,"NCT01450891","Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease",,"Completed","No Results Available","Neurodegenerative Diseases|Memory Disturbances",,"Diagnostic accuracy of Magnetic Resonance Imaging (MRI)|Change in cognition at 2 years|Change in dementia severity at 2 years|Change in quality of life at 2 years|Health care resource use during 2 years|Change in productivity at 2 years|Diagnostic accuracy of cerebrospinal fluid (CSF)|Demographic changes at 2 years|General clinical changes at 2 years|Change in behavioural and psychological problems at 2 years|Change in basic and instrumental activities in daily activities at 2 years|Change in depression at 2 years|Change in cognitive functioning at 2 years|Change in sense of competence at 2 years|Change in Care-related quality of life","Maastricht University Medical Center|Center for Translational Molecular Medicine|Leiden University Medical Center|Radboud University|VU University Medical Center","All","18 Years and older   (Adult, Older Adult)",,"304","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-3-038|02N-101","September 2009","July 2013","July 2013","October 12, 2011",,"May 28, 2015","VU University Medical Center, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01450891"
1513,"NCT03644043","Evidence Amyloid Scan EEG Study","EASES","Recruiting","No Results Available","Alzheimer Disease|Dementia Frontal|Mild Cognitive Impairment","Device: EEG scan","Patient meeting Appropriate Use Criteria (AUC) with EEG brain scan - P300 and P50 will be measured for correlation between P300 and P50 with amyloid deposition.","Metabolic Therapy Inc.|Institute of Asian American Adult Development","All","60 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1R02TCR0072518","July 20, 2018","November 15, 2020","November 30, 2020","August 23, 2018",,"August 23, 2018","Translational Cognitive Research, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03644043"
1514,"NCT01622894","Genetics of Mendelian Forms of Young Onset Alzheimer Disease","GMAJ","Unknown status","No Results Available","Autosomal Dominant Cases of Alzheimer 's Disease",,,"University Hospital, Rouen","All","18 Years to 75 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2008/067/HP|2009-010884-18","November 2009","December 2018","December 2018","June 19, 2012",,"June 14, 2017","CMRR Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT01622894"
1515,"NCT00980785","Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's","SEAIRA","Completed","No Results Available","Alzheimer's Disease|Hypertension","Drug: Ramipril|Drug: Placebo","To determine the effects of 4 months of ramipril therapy on CSF Aβ levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To evaluate the effects of 4 months of ramipril on CSF ACE levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To determine the effects of 4 months of ramipril therapy on the cardiovascular outcome variables of brachial reactivity and aortic augmentation index in non-demented adult children of persons with AD when compared to subjects taking placebo.","University of Wisconsin, Madison","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H-2014-1353|H-2009-0036","April 2009","July 2011","July 2011","September 21, 2009",,"March 29, 2017","Wisconisn Alzheimer's Disease Research Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00980785"
1516,"NCT03587649","Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss",,"Recruiting","No Results Available","Alzheimer Disease|Parkinson Disease|Healthy Volunteers","Drug: [18F]MNI-1126","Regions in the VOI template will be used to quantify the regional tracer uptake and used for comparison of potential uptake differences across the different groups.","Invicro","All","18 Years to 55 Years   (Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-1126","May 7, 2018","May 7, 2020","May 7, 2020","July 16, 2018",,"September 10, 2019","Invicro, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03587649"
1517,"NCT00743418","Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease","SenTra","Unknown status","No Results Available","Dementia","Device: GPS modem and RFID","Evaluation tools include: Geriatric Depression Scale, functional health questionnaire (SF-36), Emotional well-being questionnaire (Positive and Negative Affect Schedule; PANAS), single Life Satisfaction question and the Zarit Burden Interview","Tel-Aviv Sourasky Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DIP-K.3.1.","June 2007","December 2012",,"August 28, 2008",,"August 28, 2008","Psychogeriatric clinic, Sourasky Medical Center, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00743418"
1518,"NCT03545789","Phase 1 Test-retest Evaluation of [18F]MNI-958 PET",,"Recruiting","No Results Available","Healthy Volunteers|Alzheimer Disease|Progressive Supranuclear Palsy","Drug: [18F]MNI-958","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 4 AD, 7 PSP, and 3 HV subjects.","Invicro","All","18 Years to 55 Years   (Adult)","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-958 Test-Retest","March 12, 2018","March 12, 2020","March 12, 2020","June 4, 2018",,"March 21, 2019","Invicro, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03545789"
1519,"NCT03058965","Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Completed","No Results Available","Alzheimer Disease|Healthy Volunteers|Progressive Supranuclear Palsy","Drug: [18F]MNI-958|Drug: [18F]Florbetapir|Drug: DaTscan","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.","Molecular NeuroImaging","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-958","November 29, 2016","May 11, 2018","May 11, 2018","February 23, 2017",,"March 25, 2019","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03058965"
1520,"NCT01002586","Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia",,"Completed","No Results Available","Alzheimer's Dementia|Falls|Gait Impairment|Balance Impairment","Other: Wii-Fit intervention|Other: Walking exercise program","Berg Balance Test|Biomechanical assessment of balance, gait and dual tasking|Activities of daily living (ADL)|Instrumental activities of daily living (IADL)|Quality Of Life-AD (QOL-AD)|Mini mental state exam (MMSE)|Falls Efficacy Scale (FES)|Activities-specific Balance Confidence Scale (ABC)|Exit-25","University of Nebraska","All","60 Years and older   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","361-09-EP","November 2009","October 2012","October 2012","October 27, 2009",,"September 6, 2017","University of Nebrasaka Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01002586"
1521,"NCT01571427","Conversations as a Means to Delay the Onset of Alzheimer's Disease","conversation","Completed","Has Results","Mild Cognitive Impairment|Cognitive Change","Behavioral: Active social engagement group|Behavioral: Control group","Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score)|Changes in Category Fluency (Animals) Test Scores (Post-study Test Score - Baseline Test Score)|Changes in Verbal Fluency Letter Test Scores (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Immediate Recall (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Delayed Recall (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test A Scores (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test B Scores (Post-study Test Score - Baseline Test Score)|Changes in the Stroop Color and Word Test (Stroop Test C) Scores (Post-study Test Scores - Baseline Test Scores)|Changes in Cogstate Computerized Test: Detection Test (Post-study Test Score - Baseline Test Score)|Changes in Cogstate One Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in Cogstate Two Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in CAMCI Total Score (Post-study Test Score - Baseline Test Score)","Oregon Health and Science University|National Institute on Aging (NIA)","All","70 Years and older   (Older Adult)","Early Phase 1","83","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","socialengagementR01|R01AG033581","February 2012","September 2013","September 2013","April 5, 2012","April 24, 2019","May 7, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01571427"
1522,"NCT03153371","Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks","EOAD-Subtype","Recruiting","No Results Available","Alzheimer Disease, Early Onset|Alzheimer Disease|Alzheimer Disease, Late Onset|Dementia, Alzheimer Type|Logopenic Progressive Aphasia|Primary Progressive Aphasia|Visuospatial/Perceptual Abilities|Posterior Cortical Atrophy|Executive Dysfunction|Corticobasal Degeneration|Ideomotor Apraxia",,"Alzheimer's disease Subtype|Change in overall Neurological profile|Brain atrophy in MRI - Magnetic Resonance Imaging of the brain|Change in overall Neuropsychological profile","University of California, Los Angeles|National Institute on Aging (NIA)|University of Southern California","All","40 Years to 85 Years   (Adult, Older Adult)",,"180","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1RF1AG050967|UCLA IRB#16-000496|1RF1AG050967-01A1","April 4, 2016","March 31, 2021","March 31, 2022","May 15, 2017",,"October 16, 2018","UCLA Department of Neurology, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03153371"
1523,"NCT03080051","Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Completed","No Results Available","Progressive Supranuclear Palsy|Alzheimer Disease|Healthy Volunteers","Drug: [18F]MNI-952|Drug: [18F]Florbetapir","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.","Molecular NeuroImaging","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-952","August 2016","March 6, 2017","March 6, 2017","March 15, 2017",,"October 6, 2017","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03080051"
1524,"NCT03641768","Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics",,"Withdrawn","No Results Available","Alzheimer Dementia|Posttraumatic Stress Disorder|Traumatic Brain Injury","Device: MRI|Device: PET|Device: 18F-Florbetapir|Device: Radioligand 18F-AV-1451","Cortical thickness as measured by MRI scans|Beta amyloid plaques as measured by PET scans|Tau proteins as measured by PET scans","Duke University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00100030","January 1, 2019","January 1, 2021","January 1, 2021","August 22, 2018",,"October 16, 2018","Durham VA, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03641768"
1525,"NCT01000038","Wii-fit for Activity, Balance and Gait in Assisted Living",,"Completed","No Results Available","Falls|Alzheimer's Disease","Other: Wii-Fit intervention|Other: Walking","Berg Balance Scale|Activities of Daily Living|Instrumental Activities of Daily Living|Timed Up and Go|Quality of Life-AD|Mini Mental State Exam|Actigraphy|Trails A and B","University of Nebraska","All","60 Years and older   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","085-09-FB","March 2009","July 2011","July 2011","October 22, 2009",,"August 27, 2018","Parson's House Assisted Living, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01000038"
1526,"NCT00325728","Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Chronic Insomnia","Drug: Ramelteon|Drug: Placebo","Mean Nighttime Total Sleep Time as determined by actigraphy.|Change from Baseline in Nighttime Total Sleep Time|Change from Baseline in Nighttime Wake After Sleep Onset per Actigraphy|Change from Baseline in Nighttime Number Of Awakenings per Actigraphy|Change from Baseline in Daytime Total Sleep Time|Change from Baseline in the ratio of Daytime Total Sleep Time to Nighttime Total Sleep Time.|Change from Baseline in Sleep Efficiency.|Percentage of subjects who experience Increase in Nighttime Total Sleep Time of 30 minutes.|Number of Daytime Naps.","Takeda","All","55 Years and older   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-05-TL-375-061|U1111-1115-1644","March 21, 2006","August 1, 2007","August 20, 2007","May 15, 2006",,"August 14, 2017","Alabaster, Alabama, United States|Huntsville, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Fresno, California, United States|Irvine, California, United States|Los Angeles, California, United States|National City, California, United States|Oxnard, California, United States|San Diego, California, United States|San Francisco, California, United States|Darien, Connecticut, United States|Waterbury, Connecticut, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Brooksville, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|Orange City, Florida, United States|Pompano Beach, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Grand Rapids, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Dover, New Hampshire, United States|Manchester Township, New Jersey, United States|Piscataway, New Jersey, United States|Princeton, New Jersey, United States|Stratford, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Havertown, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Moon, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Beaufort, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Bellaire, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Burlington, Vermont, United States|Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00325728"
1527,"NCT01434667","Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV",,"Completed","Has Results","Mild Cognitive Impairment","Behavioral: APOE genotype and Alzheimer's disease risk disclosure|Behavioral: Alzheimer's disease risk disclosure","Geriatric Depression Scale|Mini State Trait Anxiety Inventory|Impact of Event Scale (IES)|Psychological Impact of Test Disclosure (IGT-AD)|Recall and Comprehension of Risk Information|Participant Satisfaction|User Ratings of Risk Assessment Experience|Health Behavior and Insurance Changes|Insurance and Advance Planning Changes|Participation in Alzheimer's Disease-related Research After Receiving the Alzheimer's Disease Risk Estimate.","Brigham and Women's Hospital|National Human Genome Research Institute (NHGRI)|University of Michigan|University of Pennsylvania|Howard University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","146","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01HG002213","January 2010","July 2014","July 2014","September 15, 2011","October 23, 2018","October 23, 2018","Howard University, Washington, District of Columbia, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01434667"
1528,"NCT02813070","Comparison of PET Amyloid Imaging in Japanese and Western Subjects",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease|Healthy","Drug: [18F] Flutemetamol","Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers|Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese Readers","GE Healthcare","All","25 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE067-017","October 2012","May 2013","May 2013","June 24, 2016","June 5, 2017","June 5, 2017",,,"https://ClinicalTrials.gov/show/NCT02813070"
1529,"NCT03984396","Optimal Medication Management in Alzheimer's Disease and Dementia","Optimize","Recruiting","No Results Available","Dementia","Other: Educational Materials - Patient & Clinician","Number of chronic medications|Number of potentially inappropriate medications|Treatment change|Selected adverse drug event (ADE) rates|Hospitalization Rate, Skilled Nursing Facility Admissions Rate, Emergency Department Visit Rate|Activities of daily living as reported in the Medicare Health Risk Assessment (MHRA)","Kaiser Permanente|Johns Hopkins University|Duke University|University of South Australia","All","65 Years and older   (Older Adult)","Not Applicable","3671","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R33AG057289","March 6, 2019","May 2021","August 2022","June 13, 2019",,"June 13, 2019","Kaiser Permanente, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03984396"
1530,"NCT01723670","Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment","CT05","Withdrawn","No Results Available","Alzheimer's Disease","Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: Placebo","To determine the effects on change from baseline on brain atrophy|To determine the presence of other biomarkers of neuronal degeneration","CERESPIR","All","45 Years to 64 Years   (Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CCD-1109-PR-0072","December 2012","March 2016","March 2016","November 8, 2012",,"February 10, 2015",,,"https://ClinicalTrials.gov/show/NCT01723670"
1531,"NCT03001557","Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia",,"Active, not recruiting","No Results Available","Irregular Sleep-Wake Rhythm Disorder","Drug: Lemborexant 2.5 mg|Drug: Lemborexant 5 mg|Drug: Lemborexant 10 mg|Drug: Lemborexant 15 mg|Drug: Lemborexant-matched placebo","Change From Baseline of Mean Sleep Fragmentation Index (SFI) During Week 1 of Treatment|Change From Baseline of Mean SFI During Week 2 of Treatment|Change From Baseline of Mean SFI During Week 3 of Treatment|Change From Baseline of Mean SFI During Week 4 of Treatment|Change From Baseline of Mean Wake Fragmentation Index (WFI) During Week 1 of Treatment|Change From Baseline of Mean WFI During Week 2 of Treatment|Change From Baseline of Mean WFI During Week 3 of Treatment|Change From Baseline of Mean WFI During Week 4 of Treatment|Change From Baseline in the Mean Duration of Sleep Bouts (aMeanDurSB) During Week 1 of Treatment|Change From Baseline in the aMeanDurSB During Week 2 of Treatment|Change From Baseline in the aMeanDurSB During Week 3 of Treatment|Change From Baseline in the aMeanDurSB During Week 4 of Treatment|Change From Baseline in the Mean Duration of Wake Bouts (aMeanDurWB) During Week 1 of Treatment|Change From Baseline in the aMeanDurWB During Week 2 of Treatment|Change From Baseline in the aMeanDurWB During Week 3 of Treatment|Change From Baseline in the aMeanDurWB During Week 4 of Treatment|Change From Baseline of Mean Actigraphy Sleep Efficiency (aSE) During Week 1 of Treatment|Change From Baseline of Mean aSE During Week 2 of Treatment|Change From Baseline of Mean aSE During Week 3 of Treatment|Change From Baseline of Mean aSE During Week 4 of Treatment|Change From Baseline of Mean Actigraphy Wake Efficiency (aWE) During Week 1 of Treatment|Change From Baseline of Mean aWE During Week 2 of Treatment|Change From Baseline of Mean aWE During Week 3 of Treatment|Change From Baseline of Mean aWE During Week 4 of Treatment|Change From Baseline in Intradaily Variability (IV) Over Week 1 of Treatment|Change From Baseline in IV Over Week 2 of Treatment|Change From Baseline in IV Over Week 3 of Treatment|Change From Baseline in IV Over Week 4 of Treatment|Change From Baseline in Interdaily Stability (IS) Over Week 1 of Treatment|Change From Baseline in IS Over Week 2 of Treatment|Change From Baseline in IS Over Week 3 of Treatment|Change From Baseline in IS Over Week 4 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 1 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 2 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 3 of Treatment|Change From Baseline in the Activity Across the Least Active 5-hour Period per 24-hour Period (L5) Over Week 4 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 1 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 2 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 3 of Treatment|Change From Baseline in the Activity During the Most Active 10-hour Period per 24-hour Period (Mean M10) Over Week 4 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 1 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 2 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 3 of Treatment|Change From Baseline in the Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 (AMP) Over Week 4 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 1 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 2 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 3 of Treatment|Change From Baseline in the Relative Amplitude of the Rest-activity Rhythm Calculated as the Difference Between M10 and L5 Divided by M10 Plus L5 (RA) Over Week 4 of Treatment|Change From Baseline in the Neuropsychiatric Inventory (NPI-10) Total Score at Day 29|Change From Baseline in the Sleep Disorders Inventory (SDI) Score at Day 29|Number of Participants in Each Category of the Clinician's Global Impression of Change Irregular Sleep-Wake Rhythm Disorder (CGIC-ISWRD) Scale Overall Score at Day 29|Number of Participants With any Non-serious Adverse Event or any Serious Adverse Event","Eisai Inc.|Purdue Pharma LP","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2006-G000-202|2017-003306-40","December 20, 2016","July 26, 2018","April 9, 2020","December 23, 2016",,"July 29, 2019","Facility #1, Little Rock, Arkansas, United States|Facility #1, Rogers, Arkansas, United States|Facility #1, Springdale, Arkansas, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Glendale, California, United States|Facility #1, La Jolla, California, United States|Facility #1, San Diego, California, United States|Facility #1, Bradenton, Florida, United States|Facility #1, Brandon, Florida, United States|Facility #1, Brooksville, Florida, United States|Facility #1, Hallandale Beach, Florida, United States|Facility #1, Hialeah, Florida, United States|Meridien Research, Lakeland, Florida, United States|Facility #1, Miami Lakes, Florida, United States|Facility #1, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #1, Sunrise, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Macon, Georgia, United States|Facility #1, Wichita, Kansas, United States|Facility #1, Belmont, Massachusetts, United States|Nevada Senior Services (NSS) Adult Day Care Center, Henderson, Nevada, United States|Facility #1, Las Vegas, Nevada, United States|Facility #1, Toms River, New Jersey, United States|Facility #2, Toms River, New Jersey, United States|Facility #1, Charlotte, North Carolina, United States|Facility #1, Raleigh, North Carolina, United States|Facility #1, Norristown, Pennsylvania, United States|Facility #1, Willow Grove, Pennsylvania, United States|Facility #1, Columbia, South Carolina, United States|Eisai Trial Site #1, Fujisawa, Kanagawa, Japan|Eisai Trial Site #1, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site #1, Wako, Saitama, Japan|Eisai Trial Site #1, Bunkyō-Ku, Tokyo, Japan|Eisai Trial Site #1, Kodaira, Tokyo, Japan|Eisai Trial Site #1, Setagaya, Tokyo, Japan|Eisai Trial Site #1, Shinjuku, Tokyo, Japan|Eisai Trial Site #1, Tachikawa-shi, Tokyo, Japan|Cognitive Treatment and Research Unit, Crowborough, East Sussex, United Kingdom|West London Cognitive Disorders Treatment and Research Unit, Isleworth, Hounslow, United Kingdom|University of Edinburgh - PPDS, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03001557"
1532,"NCT03282097","Decisions About Cancer Screening in Alzheimer's Disease","DECAD","Recruiting","No Results Available","Cancer, Breast","Behavioral: DECAD decision aid|Other: Home safety guide","Decisional conflict Scale|Change in Decision-making self-efficacy|Record of mammogram","Indiana University","Female","75 Years and older   (Older Adult)","Not Applicable","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1501278953","November 17, 2017","October 2021","October 2022","September 13, 2017",,"June 27, 2019","Alzheimer's Association, Indianapolis, Indiana, United States|Eskenazi Health, Indianapolis, Indiana, United States|IU Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03282097"
1533,"NCT00954590","A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease","CONTACT","Terminated","No Results Available","Moderate to Severe Alzheimer","Drug: Dimebon (latrepirdine)|Drug: Placebo","Neuropsychiatric Inventory (NPI)|Activities of Daily Living (severe) (ADCS ADLsev)","Medivation, Inc.|Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DIM19","October 2009","August 2010",,"August 7, 2009",,"September 27, 2016","Santiago, Chile|Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00954590"
1534,"NCT03663387","PET Measures of CSF Clearance in Preclinical Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment","Device: 18F--MK6240 PET-MRI","Measure of ventricular clearance measured by Aβ load|Measure of ventricular clearance measured by decreased cortical ribbon thickness|Measure of Cognition as indicator of reduced ventricular clearance","NYU Langone Health|NIH/NIA","All","40 Years to 85 Years   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","17-01314","July 30, 2018","June 2022","June 2022","September 10, 2018",,"September 30, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03663387"
1535,"NCT02553928","Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer",,"Completed","Has Results","Alzheimer Dementia (AD)","Drug: Memantine (once daily)|Drug: Memantine (twice daily)","Adverse Events|ADCS - CGIC Score at Week 12","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 4","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14603A","October 2015","July 2016","July 2016","September 18, 2015","March 14, 2019","March 14, 2019","CN001, Beijing, China|CN006, Fujian, China|CN004, Shandong, China|CN002, Tianjin, China|CN007, Xi'an, China|CN003, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02553928"
1536,"NCT03138018","Aging Stereotypes and Prodromal Alzheimer's Disease","AGING","Recruiting","No Results Available","Mild Cognitive Impairment (MCI)","Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)","Neuropsychological tests|Neuroimaging biomarkers of neurodegeneration|Physiological stress|Self-report questionnaires|Heart rate variability (thin elasticized heart rate transmitter belt),|Skin conductance (wristwatch)|Salivary biomarkers","Assistance Publique Hopitaux De Marseille","All","50 Years and older   (Adult, Older Adult)","Not Applicable","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","2016-45|IDRCB Number","July 6, 2018","July 1, 2023","July 1, 2023","May 3, 2017",,"July 25, 2018","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03138018"
1537,"NCT01772095","ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE","ADVANCE","Completed","No Results Available","Alzheimer Disease|Dementia|Cognitive Disorders",,"Change in Alzheimer Disease Evaluation Scales (MMSE, Clock test, IADL)from baseline until the end of the study|Number of Adverse Events occured during study duration","Elpen Pharmaceutical Co. Inc.","All","50 Years to 95 Years   (Adult, Older Adult)",,"389","Industry","Observational","Time Perspective: Prospective","2012-DON-EL-33","February 2013","November 2013","November 2013","January 21, 2013",,"August 19, 2014","Aiginition University Hospital, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT01772095"
1538,"NCT03284112","Old SCHOOL Hip-Hop: Improve Alzheimer's Disease Knowledge",,"Recruiting","No Results Available","Dementia","Behavioral: Old SCHOOL Hip-Hop|Behavioral: My Plate","Change in Dementia Symptom and Response Knowledge Assessment Score","Columbia University","All","9 Years and older   (Child, Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAAR5473","September 18, 2018","July 2022","July 2022","September 15, 2017",,"February 1, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03284112"
1539,"NCT03388242","Protein and microRNA Markers for Early Detection of Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment","Other: No intervention","Fold changes of microRNAs in the blood of Patients with MCI over control people.|Fold changes of proteins in the blood of Patients with MCI over control people.","Sun Yat-sen University","All","30 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYSEC-KY-060","December 7, 2017","March 30, 2020","March 30, 2020","January 2, 2018",,"January 3, 2019","Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03388242"
1540,"NCT02403752","Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)","PairedPLIE","Completed","No Results Available","Dementia|Alzheimer's Disease","Behavioral: Paired PLIE Program","Change in Short Physical Performance Battery (SPPB) from Baseline to 4 months|Change in Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) from baseline to 4 months|Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD) from baseline to 4 months|Change in Caregiver Burden Inventory (CBI) from baseline to 4 months","University of California, San Francisco|Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-14943","March 2015","July 2018","July 2018","March 31, 2015",,"December 18, 2018","UCaliforniaSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02403752"
1541,"NCT03538574","Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers","CARES","Recruiting","No Results Available","Insomnia Chronic","Behavioral: CBT-I|Behavioral: MAP-I","Insomnia clinical response|Daytime dysfunction|Inflammation|Cellular aging","University of California, Los Angeles","All","45 Years to 95 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","16-001256","July 1, 2018","May 30, 2023","May 30, 2024","May 28, 2018",,"September 6, 2018","Cousins Center for Psychoneuroimmunology, UCLA Neuropsychiatric Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03538574"
1542,"NCT01168245","TMS Stimulation and Cognitive Training in Alzheimer Patients",,"Completed","No Results Available","Alzheimer Disease|Mild to Moderate","Device: Sham-NICE-System|Device: NICE-System","A significant improvement and/or improvement of at least 2 points on ADAS-COG of the Treatment Group in comparison with the Placebo Group after 6 weeks of treatment.|Safety profile: rate of device and/or procedure related adverse events.","Neuronix Ltd|Assaf-Harofeh Medical Center","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","15","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX-NICE-PLA02","January 2010","September 2011","September 2011","July 23, 2010",,"March 28, 2013","Assaf-Harofeh Medical Center, Beer Yaakov, Israel",,"https://ClinicalTrials.gov/show/NCT01168245"
1543,"NCT01547169","Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days","SNIFF-LONG 21","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Placebo Comparator|Drug: insulin detemir","Verbal Memory Composite|Neuropsychological Test of Executive Function 1|Glucose Tolerance|Functional Ability|Plasma biomarkers of AD|Neuropsychological Test of Executive Functioning 2|Neuropsychological Tests of Visual Working Memory","University of Washington|National Institute on Aging (NIA)","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","39683-A|2P50AG005136-27","March 2011","December 2012","December 2012","March 7, 2012",,"December 18, 2012","VA Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01547169"
1544,"NCT01747213","Bisnorcymserine in Healthy Adult Volunteers",,"Completed","No Results Available","Alzheimer's Disease|Healthy Volunteers","Drug: BNC|Other: Placebo","Safety and tolerability|AUC, Tmax, Cmax, elimination rate constant, T1/2, clearance and volume of distribution of BNC","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","55 Years and older   (Adult, Older Adult)","Phase 1","75","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","130034|13-AG-0034","January 1, 2013","January 8, 2019","January 8, 2019","December 11, 2012",,"May 16, 2019","National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01747213"
1545,"NCT03883633","Reversal of Cognitive Decline (ReCODE) Study","RECODE","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Behavioral: ReCODE Protocol","Changes in short-time memory function|Changes in cognitive function|Perceived changes in capability assessed by input from care giver or family member","QuesGen Systems Inc","All","45 Years to 76 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RECODE-1018","June 30, 2019","April 30, 2020","November 30, 2020","March 21, 2019",,"June 26, 2019","Ann Hathaway MD, San Rafael, California, United States|Bay Area Wellness, Walnut Creek, California, United States|Northwest Memory Center, Ashland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03883633"
1546,"NCT03653871","Caregiver Study Dr. Phillips",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Performing Arts Instruction","Change caregiver burden as measured by Zarit Burden Interview|Change caregiver resiliency as measured by Brief Resiliency Scale|Determine if intervention helps recovery from agitation and disruptive behavior for caregivers as measured by salivary cortisol levels|Determine if intervention improves caregiver's perception of care recipient's quality of life as measured by Quality of Life - Alzheimer's Disease","Florida Hospital|Dr. Phillips Center for the Performing Arts","All","18 Years to 115 Years   (Adult, Older Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1236971","September 11, 2018","December 31, 2019","December 31, 2019","August 31, 2018",,"September 17, 2018","Dr. Phillips Center for the Performing Arts, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03653871"
1547,"NCT03081546","Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease",,"Enrolling by invitation","No Results Available","Mild Cognitive Impairment|Healthy Controls",,"University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA)|Medication Management Ability Assessment|Lawton iADL (instrumental activities of daily living) scale","University of Colorado, Denver|Alzheimer's Association","All","55 Years to 85 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","16-1954","May 4, 2017","October 2019","October 2019","March 16, 2017",,"June 24, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03081546"
1548,"NCT01886820","A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology",,"Unknown status","No Results Available","Dementia|Alzheimer's Disease","Drug: [18F]NAV4694","Incidence of [18F]NAV4694 Brain PET scan positivity compared to histopathology|Quantification of [18F]NAV4694 brain PET Scan positivity compared to histopathology|Incidence of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Quantification of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Incidence of adverse events","Navidea Biopharmaceuticals","All","21 Years and older   (Adult, Older Adult)","Phase 3","290","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAV4-02","June 2013","June 2018","September 2018","June 26, 2013",,"July 26, 2017","Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Diego, La Jolla, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Mount Sinai Medical Center of Florida, Miami Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Compass Research, Orlando, Florida, United States|Physicians Care Clinical Research, Sarasota, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Biomedical Research Foundation, Shreveport, Louisiana, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health-Gerontology, Winston-Salem, North Carolina, United States|Valley Medical Center, Centerville, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01886820"
1549,"NCT03638583","Alzheimer Prevention Trials Webstudy",,"Recruiting","No Results Available","Alzheimer Disease|Dementia",,"Enrollment into Alzheimer's prevention research studies|Referral into prevention research studies|Number of individuals enrolled into Alzheimer's prevention studies","University of Southern California|National Institute on Aging (NIA)|Brigham and Women's Hospital|The Cleveland Clinic","All","50 Years to 85 Years   (Adult, Older Adult)",,"200000","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","HS-17-00746|R01AG053798","December 20, 2017","April 30, 2022","April 30, 2022","August 20, 2018",,"August 20, 2018","Https://Www.Aptwebstudy.Org, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03638583"
1550,"NCT01937221","Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease",,"Completed","No Results Available","Mild Cognitive Impairment|Mild to Moderate Cognitive Impairment","Other: spectral-domain optical coherence tomography (SD-OCT)","Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score|NFL/GCL abnormality score|Drusen/plaque score|Total drusen area","Duke University|Duke Institute for Brain Sciences|Alzheimer's Association|Duke-NUS Graduate Medical School","All","55 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00047227","September 2013","July 2017","July 2017","September 9, 2013",,"January 31, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01937221"
1551,"NCT03278119","Sleep Aging and Risk for Alzheimer's 2.0","SARA","Recruiting","No Results Available","Alzheimer Disease|Sleep Apnea","Diagnostic Test: PET Scan and nocturnal polysomnography","Establishing how mild-to-moderate OSA increases AD risk will inform novel preventive therapies for AD.|Establishing that SWS quality is associated with longitudinal amyloid deposition will identify a key mechanism by which age increases AD risk.","NYU Langone Health|National Institute on Aging (NIA)","All","55 Years to 75 Years   (Adult, Older Adult)",,"124","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-01005|R01AG056031","May 1, 2018","May 30, 2023","May 30, 2023","September 11, 2017",,"March 19, 2019","NYU Center for Brain Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03278119"
1552,"NCT00407576","PET Imaging of Brain Amyloid Using [11C]MeS-IMPY",,"Completed","No Results Available","Alzheimer's Disease|Healthy","Drug: [11C]MeS-IMPY",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","NIH","Interventional","Primary Purpose: Treatment","070036|07-M-0036","December 1, 2006","November 7, 2008",,"December 5, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00407576"
1553,"NCT02861846","Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy","BIOMALEPSIE","Recruiting","No Results Available","Epilepsy","Biological: profile of CSF biomarkers of AD","The primary endpoint was the number of patients in a population of subjects older than 60 years with new-onset epilepsy but without cognitive impairment whose profile of the CSF biomarkers of the AD is suggestive of an AD.|changes in episodic verbal memory at 2 years|changes in visual recognition memory at 2 years|Evolution of DO 80 score|Evolution of categorical influences|Evolution of TOP 10 score|Changes in monthly frequency of seizures at 2 years","Hospices Civils de Lyon","All","60 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL16-0041|2016-A00563-48","March 1, 2017","March 1, 2022","March 1, 2022","August 10, 2016",,"January 30, 2019","Hospices Civils de Lyon, Bron, France|CHU Gabriel- Montpied, Clermont-Ferrand, France|CHU des Alpes, Grenoble, France|CHU Hôpital Nord, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT02861846"
1554,"NCT04012346","Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease","LUSTR","Recruiting","No Results Available","Mild Cognitive Impairment","Device: Transcranial magnetic stimulation","Visual-attention task accuracy and reaction times|Resting state measurement","Masaryk University|St. Anne's University Hospital Brno, Czech Republic","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","NV16-31868A","April 30, 2018","December 2019","December 2019","July 9, 2019",,"July 9, 2019","Ceitec Masaryk University, Brno, Czechia",,"https://ClinicalTrials.gov/show/NCT04012346"
1555,"NCT01811381","Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Curcumin|Behavioral: aerobic yoga|Behavioral: non aerobic yoga|Dietary Supplement: Placebo","Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events","VA Office of Research and Development","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","E0669-I|VA_RX00069","January 20, 2014","September 1, 2019","December 31, 2019","March 14, 2013",,"July 12, 2019","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01811381"
1556,"NCT02913664","Risk Reduction for Alzheimer's Disease","rrAD","Recruiting","No Results Available","Cognitively Normal Older Adults|Hypertension|Subjective Cognitive Decline|Family History of Alzheimer's Disease","Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|Behavioral: Aerobic Exercise Training|Other: Usual Care|Behavioral: Stretching Exercise|Drug: Atorvastatin","Change in global neurocognitive function|Domain-specific neurocognitive function assessed by using the tests included in the ADCS-PACC and NIH-TB Cognition.|Whole brain and hippocampal volume assessed via Magnetic Resonance Imaging (MRI).|Global and regional brain perfusion assessed via Magnetic Resonance Imaging (MRI).|Brain white matter hyperintensity (WMH) assessed via Magnetic Resonance Imaging (MRI).|Brain white matter microstructural integrity assessed via Magnetic Resonance Imaging (MRI).|Brain neural network functional connectivity assessed via functional Magnetic Resonance Imaging (MRI).|Patient-reported outcomes (PRO) of mental and physical health and health-related quality of life assessed by using NIH PROMIS.|Physical function assessed via the Short Physical Performance Battery (SPPB).|Dual task performance assessed via distracted and non-distracted 10 meter walk.","University of Texas Southwestern Medical Center|Texas Health Resources|University of Kansas Medical Center|Washington University School of Medicine|Pennington Biomedical Research Center|Michigan State University","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","RZNIA60","September 2016","September 2021","September 2022","September 26, 2016",,"February 15, 2019","University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02913664"
1557,"NCT00160147","Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type",,"Terminated","No Results Available","Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type","Drug: bifeprunox|Drug: Placebo","Brief Psychiatric Rating Scale (BPRS) Total Score|Adverse events","Solvay Pharmaceuticals","All","65 Years to 90 Years   (Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S154.3.016|2005-003475-20","December 2005","January 2008","January 2008","September 12, 2005",,"February 9, 2015","Site 912, Phoenix, Arizona, United States|Site 902, Carson, California, United States|Site 903, Long Beach, California, United States|Site 911, Pasadena, California, United States|Site 922, San Marino, California, United States|Site 910, Santa Ana, California, United States|Site 929, Hamden, Connecticut, United States|Site 914, New Britain, Connecticut, United States|Site 931, Norwalk, Connecticut, United States|Site 901, Miami, Florida, United States|Site 907, North Miami, Florida, United States|Site 933, Orange City, Florida, United States|Site 934, Atlanta, Georgia, United States|Site 917, Blue Ridge, Georgia, United States|Site 925, Newnan, Georgia, United States|Site 904, New Orleans, Louisiana, United States|Site 905, Shreveport, Louisiana, United States|Site 906, Shreveport, Louisiana, United States|Site 919, Bedford, Massachusetts, United States|Site 923, Boston, Massachusetts, United States|Site 942, Flowood, Mississippi, United States|Site 927, St. Louis, Missouri, United States|Site 930, St. Louis, Missouri, United States|Site 940, St. Louis, Missouri, United States|Site 941, Olean, New York, United States|Site 921, Staten Island, New York, United States|Site 909, Cincinnati, Ohio, United States|Site 908, Oklahoma City, Oklahoma, United States|Site 916, Oklahoma City, Oklahoma, United States|Site 935, Philadelphia, Pennsylvania, United States|Site 932, Humboldt, Tennessee, United States|Site 936, Austin, Texas, United States|Site 928, Dallas, Texas, United States|Site 913, Williamsburg, Virginia, United States|Site 918, Waukesha, Wisconsin, United States|Site 803, Litomerice, Czech Republic|Site 802, Lnare, Czech Republic|Site 804, Praha, Czech Republic|Site 805, Skvorec, Czech Republic|Site 801, Tabor, Czech Republic|Site 807, Viljandimaa, Estonia|Site 806, Voru Maakond, Estonia|Site 812, Bat Yam, Israel|Site 808, Beer Yaakov, Israel|Site 811, Hadera, Israel|Site 816, Pardes Hana, Israel|Site 810, Rehovot, Israel|Site 809, Tirat HaCarmel, Israel|Site 814, Choroszcz, Poland|Site 813, Gdansk, Poland|Site 815, Torun, Poland",,"https://ClinicalTrials.gov/show/NCT00160147"
1558,"NCT02840045","Development of a New Neuroimaging Method Aimed to Differentiate Mnesic Abilities of Alzheimer and Depressed Patients","RIHANNA","Unknown status","No Results Available","Alzheimer Disease|Depression","Device: high-density electroencephalography","Amplitude of event-related potentials|Spectral power","Centre Hospitalier Universitaire de Besancon","All","60 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","API/2014/51","February 20, 2015","August 20, 2018","August 20, 2018","July 21, 2016",,"August 9, 2017","CHRU Besançon, Besancon, Franche-Comte, France",,"https://ClinicalTrials.gov/show/NCT02840045"
1559,"NCT03454646","Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)",,"Not yet recruiting","No Results Available","Alzheimer Disease|Cholinesterase Inhibitors","Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)","The primary outcome is a combination of complete BADL dependency in bathing and dressing and/or institutionalization or death at 2 years after randomization.|BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].|Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death|Institutionalization with date of entry|Death and date of death|the ADL scale|the MMSE score|the number of hospitalizations|Pharmacologie treatments consumed by the patient","University Hospital, Bordeaux","All","50 Years and older   (Adult, Older Adult)","Phase 4","1205","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2016/27","March 15, 2018","March 15, 2018","September 15, 2021","March 6, 2018",,"March 6, 2018","CHU d'Amiens Centre Mémoire Ressources Recherche, Amiens, France|CHU d'Angers Centre Mémoire Ressources Recherche, Angers, France|CHU de Bastia Centre Mémoire Ressources Recherche, Bastia, France|CHU de Besançon Centre Mémoire Ressources Recherche, Besançon, France|CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche -, Bordeaux, France|CHRU Cavale Blanche Service de Gériatrie, Brest, France|Service de Neuropsychologie Hôpital Neurologique Pierre Wertheimer, Bron, France|CHU Côte de Nacre Service de neurologie et CMRR, Caen, France|CHU de Clermont Ferrand Centre Mémoire Ressources Recherche, Clermont-Ferrand, France|Hôpital Pasteur Service de Neurologie, Colmar, France|CHU de Dijon- CMRR, Dijon, France|Chu de Grenoble CMRR, Neurologie, Grenoble, France|Hôpital Roger Salengro CMRR, Lille, France|CHU Limoges Service de neurologie et CMRR, Limoges, France|AP-HM, Marseille, France|CHU Montpellier Hôpital Gui de Chauliac CMRR, Montpellier, France|CHU de Nantes Clinique Neurologique Hôpital GR Laennec, Nantes, France|Institut Claude Pompidou Centre Mémoire de Ressources et de Recherche, Nice, France|APHP Hôpital Broca, Paris, France|Hôpital Universitaire de la Pitié Salpêtrière Pavillon François Lhermitte, Paris, France|APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal CMRR, Paris, France|CHU La Milétrie Pôle de Gériatrie, Poitiers, France|CHU Reims Hôpital Maison Blanche Court Séjour Gériatrique, Reims, France|CHU de Rennes - Hôpital Pontchaillou / Service de Neurologie, Rennes, France|CHU de Rouen Hôpital Charles Nicolle Service Neurologie, Rouen, France|Chu de Saint-Etienne, CMRR, Saint-Étienne, France|Chu de Strasbourg Hôpital Ka Robertsau Pôle de Gériatrie - CMRR, Strasbourg, France|Centre de Recherche Clinique du Gérontopôle Cité de la Santé, Toulouse, France|CHRU de Bretonneau Unité de gérontopsychiatrie, Tours, France|CHU Nancy Service de Gériatrie-CMRR, Vandoeuvre les nancy, France|Hospice Civil de Lyon Hôpital des Charpennes, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT03454646"
1560,"NCT03279523","F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected",,"Recruiting","No Results Available","Alzheimer Disease|HIV","Drug: F 18 T807","Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 40 years old) HIV+ participants and 30 HIV- controls.|: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.","Washington University School of Medicine","All","40 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol G","May 2016","May 2021","November 2021","September 12, 2017",,"January 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03279523"
1561,"NCT03683394","Systematic Multi-domain Alzheimer's Risk Reduction Trial","SMARRT","Enrolling by invitation","No Results Available","Dementia|Alzheimer Disease","Behavioral: SMARRT Intervention|Behavioral: Health Education Intervention","Cognitive Change|Improvement in Targeted Risk Factors|Physical Performance|Functional Ability|Quality of Life Measure|Incidence of Mild Cognitive Impairment, Alzheimer's Disease, and Dementia","Kaiser Permanente|University of California, San Francisco","All","70 Years to 89 Years   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1R01AG057508","August 30, 2018","January 31, 2021","January 31, 2021","September 25, 2018",,"September 25, 2018","Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03683394"
1562,"NCT01192529","Evaluation of a Diet in Patients With Senile Dementia","SUPRESSI","Unknown status","No Results Available","Alzheimer's Disease|Parkinson's Disease|Senile Dementia","Dietary Supplement: Supressi. T-Diet plus Range|Dietary Supplement: High Protein. T-Diet plus Range","Nutritional and cognitive status in elderly people|Biochemical parameters measure","Vegenat, S.A.","All","70 Years and older   (Older Adult)","Not Applicable","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","VEGENAT-SUPR|SUPRESSI2010-PROYECTO CDTI","October 2010","September 2012","December 2012","September 1, 2010",,"June 22, 2012","Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves, Granada, Spain|Department of Biochemistry and Molecular Biology II. University of Granada, Granada, Spain|Neurological Unit, Complejo Asistencial de León, León, Spain",,"https://ClinicalTrials.gov/show/NCT01192529"
1563,"NCT01316562","Predictive Value of Cognitive Tests Performed for the Diagnosis of Alzheimer's Disease and Related Disorders","EVATEM","Unknown status","No Results Available","Alzheimer's Disease|Impaired Cognition|Memory Disorders",,"Score of episodic memory and executive psychometric tests","University Hospital, Angers","All","65 Years and older   (Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2009-025B","July 2009","July 2011","July 2012","March 16, 2011",,"March 9, 2012","CES Baraban, Lyon, France",,"https://ClinicalTrials.gov/show/NCT01316562"
1564,"NCT03289377","NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers","RDAD&APNs","Recruiting","No Results Available","Alzheimer Disease|Nurse Training","Behavioral: RDAD Training","Physician Confidence in Dementia Care Skills|Sense of Competence in Dementia|Dementia Attitudes Scale|Focus Group Questions|Implementation Questions","University of Washington","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","STUDY00003731","February 1, 2018","October 2018","October 2018","September 21, 2017",,"May 15, 2018","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03289377"
1565,"NCT02849639","The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression","INCREASE","Recruiting","No Results Available","Alzheimer's Disease|Dementia","Other: Placebo|Other: Medication Therapy Management (MTM)|Drug: Scopolamine patch","Medication Appropriateness Index scale|Cognitive Reserve: Trail Making Test B with and without the scopolamine patch|Cognitive Reserve: Montreal Cognitive Assessment|Cognitive Reserve: California Verbal Learning test|Perceived Health Status","Daniela Moga|National Institute on Aging (NIA)|University of Kentucky","All","65 Years to 101 Years   (Older Adult)","Early Phase 1","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16-0375-F2L INCREASE|1R01AG054130-01","April 4, 2017","March 2021","March 2021","July 29, 2016",,"March 28, 2019","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02849639"
1566,"NCT03378453","Narcolepsy Protect Against Alzheimer's Disease?","PROTECMAN","Completed","No Results Available","Narcolepsy|Amyloid Pathology","Device: PET-scan18F-AV-45","Mean of cortical SuVr based of the PET-scan18F-AV-45 imaging|Mean regional SuVr with PET-scan AV45|CSF Amyloid Aβ42|CSF Amyloid Aβ40|CSF Tau protein|CSF Orexin concentration|Night-time sleep duration|Day-time sleep duration|Cataplexy|Epworth sleepiness scale (ESS)|Beck Depression Inventory (BDI)|European Quality of Life Dimension (EQL-5)","University Hospital, Montpellier","All","65 Years to 85 Years   (Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","9636","April 7, 2016","November 2017","November 2017","December 19, 2017",,"December 19, 2017","Montpellier University Hospital, Gui de Chauliac, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03378453"
1567,"NCT03625128","18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls",,"Completed","No Results Available","Alzheimer's Disease|Cortical Basal Syndrome|Frontotemporal Dementia|Progressive Supranuclear Palsy|Vascular Cognitive Impairment","Drug: F-18","The primary outcome measures are to evaluate the dosimetry of novel radiotracer 18F-PM-PBB3 in human.|Optimal scanning time for brain imaging using 18F-PM-PBB3 .","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201700982A0","January 2, 2018","August 3, 2018","December 3, 2018","August 10, 2018",,"October 3, 2019","Chang Gung Memorial Hospital,Linkou, Taoyuan City, Guishan Dist, Taiwan",,"https://ClinicalTrials.gov/show/NCT03625128"
1568,"NCT00946530","Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease",,"Completed","Has Results","Sleep Initiation and Maintenance Disorders","Device: Bright light|Device: Control","Total Sleep Time|WASO (Wake After Sleep Onset)","Stanford University|Palo Alto Veterans Institute for Research","All","55 Years to 100 Years   (Adult, Older Adult)","Not Applicable","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SU-06302009-2840|1677","September 2004","December 2010","December 2010","July 27, 2009","March 29, 2017","October 3, 2018","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00946530"
1569,"NCT02899403","Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003","PharmacogWP3","Recruiting","No Results Available","Alzheimer Disease|ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)","Other: Rapid Visual Information Processing (RVIP) test","EEG spectral power during RVIP task as compared to resting state|EEG spectral power during PRM task as compared to resting state|RVIP latency of responses|PRM number of errors|PRM latency of responses|difference between session 2 and session 1 EEG Spectral power during RVIP task","University Hospital, Lille","Male","18 Years to 30 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2013_45|2015-A00046-43","May 19, 2017","December 2020","December 2020","September 14, 2016",,"June 26, 2019","Hôpital Cardiologique, CIC, Lille, France",,"https://ClinicalTrials.gov/show/NCT02899403"
1570,"NCT02309723","Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Device: Beta amyloid imaging","Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss|Likelihood of Recommending a Medication Indicated for Alzheimer's Disease|Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures","Tufts Medical Center|GE Healthcare","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","315","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CEVR-2013-001","September 2013","September 2013","November 2013","December 5, 2014","April 10, 2017","April 10, 2017","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02309723"
1571,"NCT02114372","Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study","CHARIOT:PRO","Active, not recruiting","No Results Available","Alzheimer's Disease|Plaque, Amyloid",,"Main Study: Change From Baseline Cognition|SubStudy: Change From Baseline on Preclinical Alzheimer Cognitive Composite (PACC) Component Score|SubStudy: Change From Baseline in RBANS Index Scores|Ancillary Study: Correlation Between the Change in Beta-amyloid Protein (A beta) Plaque Identified by Fluorescence in the Retina With Amyloid PET SUVR and CSF Amyloid Beta 42|SubStudy: Change From Baseline on the RBANS Total Scale|SubStudy: Change From Baseline on the PACC Composite Score","Janssen Research & Development, LLC","All","60 Years to 85 Years   (Adult, Older Adult)",,"1146","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CR104383|REGISTRYALZ0001|RRA-11823","February 5, 2014","April 3, 2023","April 3, 2023","April 15, 2014",,"July 29, 2019","Edinburgh, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02114372"
1572,"NCT02288000","Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases","WP3_P002","Recruiting","No Results Available","Alzheimer Disease|Battery","Drug: Memantine|Drug: Placebo","Pharmacog battery","University Hospital, Lille","Male","18 Years to 30 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012_55|2013-001671-21","September 14, 2016","September 2020","September 2020","November 11, 2014",,"June 27, 2019","CHRU de Lille/ Centre d'investigation Clinique, Lille, France|CIC Marseille, Marseille, France|CIC Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02288000"
1573,"NCT02556502","18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study","MAF","Completed","No Results Available","Amyloid PET Imaging","Device: 18F-Florbetaben PET","number of positive or negative amyloid PET","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-A01149-40","November 2015","November 2017","November 2017","September 22, 2015",,"May 7, 2019","CHRU Nancy, Vandoeuvre les Nancy, France",,"https://ClinicalTrials.gov/show/NCT02556502"
1574,"NCT03638323","Age-related Hearing Loss and Lexical Disorders","LOOP","Completed","Has Results","Alzheimer Disease|Presbycusis|Lexical Syntactic Disorder","Other: Speech therapy","Link Between Lack of Word and Presbycusis|Association Between Age and Lack of Word|Association Between Gender and Lack of Word|Association Between Study Level and Lack of Word|Association Between Accommodation Type and Lack of Word|Association Between Laterality and Lack of Word|Association Between Main Diagnosis and Lack of Word|Association Between Hearing Aid and Lack of Word|Association Between Speech Therapy and Lack of Word","Groupe Hospitalier de la Rochelle Ré Aunis","All","65 Years and older   (Older Adult)",,"46","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2018/P08/256","August 27, 2018","January 31, 2019","January 31, 2019","August 20, 2018","September 11, 2019","September 11, 2019","Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03638323/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03638323"
1575,"NCT02022943","Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies","APR","Recruiting","No Results Available","Alzheimer's Disease|Dementia",,"Number of individuals enrolled into Alzheimer's prevention studies|Number of individuals referred to Alzheimer's prevention research studies / sites","Banner Health","All","18 Years to 110 Years   (Adult, Older Adult)",,"500000","Other","Observational","Observational Model: Other|Time Perspective: Other","APR","May 2012","January 2030","January 2030","December 30, 2013",,"September 19, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02022943"
1576,"NCT03308032","Self-Directed Online Training for Chinese Caregivers",,"Unknown status","No Results Available","Dementia|Alzheimer Disease","Behavioral: Intervention|Behavioral: Control","Change in Stress Level","Environment and Health Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NIH 1R43HL115924-01","September 1, 2016","March 5, 2018","July 30, 2018","October 12, 2017",,"October 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03308032"
1577,"NCT01315704","Alzheimer's Disease and Related Disorders","MERE","Unknown status","No Results Available","Alzheimer's Disease|Gait Apraxia|Impaired Cognition","Drug: Drug intervention","Spatiotemporal gait parameters","University Hospital, Angers","All","Child, Adult, Older Adult",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2009-15","November 2009","November 2017","November 2017","March 15, 2011",,"March 15, 2011","Cédric ANNWEILER , MD, Angers, France",,"https://ClinicalTrials.gov/show/NCT01315704"
1578,"NCT03938870","CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease|Brain Diseases|Central Nervous System Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Dementia|Mental Disorders|Nervous System Diseases|Neurodegenerative Diseases|Tauopathies","Other: L-Leucine 13C6","Tau kinetics in cerebrospinal fluid [half-life of tau], as assessed by tau stable isotope labeling kinetics (SILK) method|Age|Tau aggregation measured by PET Imaging|Amyloid aggregation measured by PET Imaging","Washington University School of Medicine|BrightFocus Foundation|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"100","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","201502091","August 2015","September 2019","September 2021","May 6, 2019",,"May 6, 2019","Washington University in Saint Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03938870"
1579,"NCT01672827","Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: [18F]Flutemetamol","Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.|Summary of Specificity of Blinded Visual PET Image Interpretations Without Anatomic Images.|Inter-Reader Agreement of PET Images Without Anatomic Images","GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 3","276","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","GE-067-021","July 2012","August 2012","August 2012","August 27, 2012","December 19, 2013","January 24, 2014",,,"https://ClinicalTrials.gov/show/NCT01672827"
1580,"NCT02347202","Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention",,"Recruiting","No Results Available","Alzheimer's Disease|Dementia","Other: Online counseling via Zoom teleconferencing|Other: Telephone support as needed","Differences in depressive symptoms between groups (One-way analysis of variance, questionnaire)|Differences in reactions to problem behaviors between groups (questionnaire)|Differences in satisfaction with social support between groups (questionnaire)","NYU Langone Health","All","21 Years to 125 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","14-01185","October 2015","September 2019","September 2019","January 27, 2015",,"January 29, 2019","NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02347202"
1581,"NCT04004767","TRC-PAD Program: In-Clinic Trial-Ready Cohort","TRC-PAD","Enrolling by invitation","No Results Available","Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer Disease|Dementia",,"Enrollment into preclinical and prodromal AD clinical trials|Optimization of adaptive risk algorithm to predict risk of amyloid positivity","University of Southern California|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute|Alzheimer's Clinical Trials Consortium|Brigham and Women's Hospital|Cleveland Clinic Lou Ruvo Center for Brain Health","All","50 Years to 85 Years   (Adult, Older Adult)",,"2000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATRI-004|R01AG053798","June 4, 2019","April 30, 2023","April 30, 2023","July 2, 2019",,"October 10, 2019","University of California, Irvine, Irvine, California, United States|Georgetown University, Washington, District of Columbia, United States|University of Kentucky, Lexington, Kentucky, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Case Western Reserve University, Beachwood, Ohio, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04004767"
1582,"NCT01595646","Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)","SL120","Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Saline|Drug: Insulin detemir|Drug: Insulin","Verbal Memory Composite|Cerebral Spinal Fluid (CSF) Biomarkers of AD|Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio|Functional Ability|The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision","Wake Forest University Health Sciences|Alzheimer's Association","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00023230|ZEN-10-173646US","November 2011","March 12, 2015","March 12, 2015","May 10, 2012","February 1, 2018","May 22, 2018","Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States|VA Puget Sound Health Care System - American Lake Division, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01595646"
1583,"NCT02964611","Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration",,"Recruiting","No Results Available","Alzheimer's Disease|Parkinson's Disease|Frontotemporal Lobar Degeneration","Behavioral: Observational Study","Personality via the Interpersonal Adjectives Scales and differences between AD, PD, and FTLD|Personality via the Behaviour Inhibition/Approach Scale (BIS/BAS) and differences between AD, PD, and FTLD|Personality via the Big Five Inventory (BFI) and differences between AD, PD, and FTLD|Social cognition via Social Norms Questionnaire and differences between AD, PD, and FTLD|Social cognition via Interpersonal Reactivity Index (IRI) and differences between AD, PD, and FTLD|Social cognition via Revised Self-Monitoring Scale (RSMS) and differences between AD, PD, and FTLD|Social cognition via Social Behaviour Observer Checklist and differences between AD, PD, and FTLD|Neuropsychiatric Inventory (NPI) and differences between AD, PD, and FTLD|Clinical Dementia Rating Scale (CDR) and differences between AD, PD, and FTLD|Functional Activities Questionnaire (FAQ) and differences between AD, PD, and FTLD|Behavioural Tests composite score and differences between AD, PD, and FTLD|Emotion Evaluation Task (EET) portion of The Awareness of Social Inference Test and differences between AD, PD, and FTLD|Geriatric Depression Scale (GDS) and differences between AD, PD, and FTLD|Neuroimaging and differences between AD, PD, and FTLD","University Health Network, Toronto","All","50 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","12-0451-BE","January 2013","December 2019","December 2019","November 16, 2016",,"April 16, 2019","Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02964611"
1584,"NCT01487395","Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development","PharmacogWP3","Completed","No Results Available","Alzheimer Disease|Battery","Drug: Donepezil .|Drug: Placebo","Pharmacog battery","University Hospital, Lille|Innovative Medicines Initiative","Male","18 Years to 30 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010_41|2010-023989-51","December 2011","December 2012","December 2013","December 7, 2011",,"April 9, 2015","CHRU de Lille/ Centre d'investigation Clinique, Lille, France|CIC Marseille, Marseille, France|CIC Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01487395"
1585,"NCT00908999","Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)",,"Completed","No Results Available","Anosognosia|Alzheimer's Disease|Mild Cognitive Impairment",,,"University of Wisconsin, Madison","All","60 Years to 90 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HSC-2008-0090","April 2008","September 2011","September 2011","May 27, 2009",,"September 29, 2011","William S Middleton VA Hospital GRECC, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00908999"
1586,"NCT01733355","A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807",,"Terminated","No Results Available","Alzheimers Disease|AD","Radiation: [F18] T807","To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging|To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration|To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD|To assess the safety of IV administration of [F-18]T807|To begin collection of baseline [F-18]T807 PET/CT imaging data|To gain information to improve the study design for the conduct of future trials","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T807000","July 2012","March 2013","March 2013","November 27, 2012",,"July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01733355"
1587,"NCT03670615","Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia","EXPRESS","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease","Other: tDCS|Other: Exercise|Other: Exercise Education|Other: Sham tDCS","Change in global cognitive function: The Montreal Cognitive Assessment (MoCA) Total Scores|Changes in concentration of blood biomarkers of brain plasticity","Sunnybrook Health Sciences Centre","All","50 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","075-2018","November 28, 2018","January 2021","August 2021","September 13, 2018",,"December 14, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03670615"
1588,"NCT02271685","Sound Estimation and Accuracy Task",,"Completed","No Results Available","Parkinson's|Alzheimer Disease","Other: Instructions about Overestimates|Other: Instructions about Parkinson's|Other: Instructions about Underestimates|Other: Instructions about Alzheimers","Time Estimate|Time Generation|Perceived Risk of Disease","Carnegie Mellon University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Screening","HS14-553","February 2015","May 2015","May 2015","October 22, 2014",,"May 21, 2015","Carnegie Mellon University, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02271685"
1589,"NCT02365051","Translation of COPE for Publicly-Funded Home Care Clients and Their Families","COPECT","Active, not recruiting","No Results Available","Dementia|Alzheimer's Disease","Behavioral: Care of Persons with Dementia in their Environments","Functional dependence","UConn Health","All","65 Years and older   (Older Adult)","Not Applicable","582","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","15-014-3","May 2015","March 1, 2019","March 31, 2020","February 18, 2015",,"October 7, 2019","UConn Center on Aging, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02365051"
1590,"NCT00001977","The Effect of Acetylcholine on Memory and Attention",,"Completed","No Results Available","Alzheimer's Disease|Healthy",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"70","NIH","Observational",,"000056|00-M-0056","January 2000",,"April 2001","December 10, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001977"
1591,"NCT01812213","Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)","NAV4-04","Unknown status","No Results Available","Mild Cognitive Impairment","Drug: [18F]NAV4694","Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease|Incidence of [18F]NAV4694 PET Positive scans at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 6 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 12 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 24 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 30 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 36 months compared to baseline|Change in SUVR scores at 18 months compared to baseline|Incidence of Adverse Events post baseline","Navidea Biopharmaceuticals","All","55 Years to 99 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAV4-04","March 2013","June 2018","August 2018","March 18, 2013",,"July 26, 2017","Banner Sun Health Research Institute, Sun City, Arizona, United States|Galiz Research, Hialeah, Florida, United States|Mt. Sinai Wien Center for Alzheimer's Disease, Miami Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|McLean Hospital, Belmont, Massachusetts, United States|Qunicy Medical Center, Alzheimer's Disease Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01812213"
1592,"NCT03218982","Vietnamese Caregiver Intervention Study",,"Recruiting","No Results Available","Alzheimer's Disease (Incl Subtypes)|Cognitive Impairment","Behavioral: Enhanced psycho-education about dementia and caregiving","randomization|retention|caregiver intervention adherence|treatment fidelity|administration of study measures|Acceptability|Alzheimer's Disease Knowledge Scale (ADKS)|Caregiver Self-Efficacy|Center for Epidemiological Studies Depression (CES-D) scale|Zarit Burden Inventory (ZBI)|Quality of Life - Alzheimer's Disease (QoL-AD)|Perceived Stress Scale","University of California, Davis|National Institute on Aging (NIA)|Alzheimer's Association","All","21 Years and older   (Adult, Older Adult)","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","823071|K01AG052646","May 22, 2017","June 30, 2020","June 30, 2020","July 17, 2017",,"May 1, 2019","University of California, Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03218982"
1593,"NCT02051335","Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults",,"Completed","Has Results","Memory Impairment|Alzheimer's Disease","Drug: Roflumilast|Drug: Roflumilast placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine","Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate and Delayed Recall at 2 and 4 Hours After Scopolamine Administration|Change From Baseline in the Paired Associates Learning (PAL) Total Number of Errors Adjusted at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) A Prime Signal Detection at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) Median Latency at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Spatial Working Memory (SWM) Total Number of Between Errors at the 10-Box Stage and the 12-Box Stage at All Time-points Assessed After Scopolamine Administration|Percentage of Participants Who Experience at Least 1 Treatment Emergent Adverse Event (TEAE)|Percentage of Participants With Markedly Abnormal Safety Laboratory Tests|Percentage of Participants With Markedly Abnormal Vital Sign Measurements at Least Once Post-dose|Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-Dose","AstraZeneca","Male","18 Years to 45 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ROF-ALZ_102|2012-002089-11|U1111-1151-7178","January 2014","May 2014","May 2014","January 31, 2014","August 17, 2015","February 1, 2017","London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02051335"
1594,"NCT03226522","Addressing Dementia Via Agitation-Centered Evaluation","ADVANCE","Recruiting","No Results Available","Agitation in Patients With Dementia of the Alzheimer's Type|Alzheimer Disease|Agitation,Psychomotor","Drug: AXS-05|Drug: Bupropion|Drug: Placebo","Cohen-Mansfield Agitation Inventory (CMAI)","Axsome Therapeutics, Inc.","All","65 Years to 90 Years   (Older Adult)","Phase 2|Phase 3","435","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AXS-05-AD-301","July 13, 2017","August 2019","September 2019","July 21, 2017",,"March 28, 2019","Axsome Study Site, Phoenix, Arizona, United States|Axsome study site, Scottsdale, Arizona, United States|Axsome study site, Scottsdale, Arizona, United States|Axsome Study Site, Tucson, Arizona, United States|Axsome Study Site, Little Rock, Arkansas, United States|Axsome study site, Canoga Park, California, United States|Axsome study site, Costa Mesa, California, United States|Axsome study site, Fresno, California, United States|Axsome study site, Long Beach, California, United States|Axsome study site, Long Beach, California, United States|Axsome study site, Riverside, California, United States|Axsome study site, Sacramento, California, United States|Axsome study site, Santa Ana, California, United States|Axsome study site, Sherman Oaks, California, United States|Axsome study site, Simi Valley, California, United States|Axsome study site, Temecula, California, United States|Axsome study site, Ventura, California, United States|Axsome Study Site, Colorado Springs, Colorado, United States|Axsome study site, Cromwell, Connecticut, United States|Axsome study site, New London, Connecticut, United States|Axsome study site, Boca Raton, Florida, United States|Axsome study site, Boynton Beach, Florida, United States|Meridian Research, Brooksville, Florida, United States|Axsome Study Site, Coconut Creek, Florida, United States|Axsome study site, Hallandale Beach, Florida, United States|Axsome study site, Hialeah, Florida, United States|Axsome Study Site, Lake City, Florida, United States|Axsome study site, Miami, Florida, United States|Axsome study site, Miami, Florida, United States|Axsome study site, Pensacola, Florida, United States|Axsome study site, Spring Hill, Florida, United States|Axsome study site, Tampa, Florida, United States|Axsome study site, Tampa, Florida, United States|Axsome study site, Atlanta, Georgia, United States|Axsome study site, Decatur, Georgia, United States|Axsome Study Site, Honolulu, Hawaii, United States|Axsome study site, Boise, Idaho, United States|Axsome Study Site, Flossmoor, Illinois, United States|Axsome study site, Avon, Indiana, United States|Axsome Study Site, Overland Park, Kansas, United States|Axsome Study Site, Topeka, Kansas, United States|Axsome study site, Baton Rouge, Louisiana, United States|Axsome Study Site, Lake Charles, Louisiana, United States|Axsome study site, Chesterfield, Missouri, United States|Axsome study site, Las Vegas, Nevada, United States|Axsome Study Site, Princeton, New Jersey, United States|Axsome study site, Toms River, New Jersey, United States|Axsome study site, Brooklyn, New York, United States|Axsome study site, New York, New York, United States|Axsome study site, New York, New York, United States|Axsome study site, Staten Island, New York, United States|Axsome study site, Charlotte, North Carolina, United States|Axsome Study Site, Winston-Salem, North Carolina, United States|Axsome study site, Cincinnati, Ohio, United States|Axsome study site, Shaker Heights, Ohio, United States|Axsome study site, DeSoto, Texas, United States|Axsome study site, Wichita Falls, Texas, United States|Axsome study site, Orem, Utah, United States|Axsome Study Site, Charlottesville, Virginia, United States|Axsome study site, Bellevue, Washington, United States|Axsome study site, Spokane, Washington, United States|Axsome study site, Caulfield, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03226522"
1595,"NCT04082611","The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition","PREVENTION","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Behavioral: Data-Driven Clinical Recommendations|Behavioral: Coached Data-Driven Clinical Recommendations","NIH ToolBox Cognition Function Battery - Cognitive Function Composite Score|RAVLT (Rey's Auditory Verbal Learning Test) score|Hippocampal Volume|Blood Urine Nitrogen","John Wayne Cancer Institute|Institute for Systems Biology|St. Joseph's Healthcare Foundation","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","20190583","July 12, 2019","May 2022","May 2022","September 9, 2019",,"September 9, 2019","Pacific Brain Health Center, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04082611"
1596,"NCT01023425","Clinical Trial of Donepezil Between the Naive Group and the Switching Group",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: donepezil","Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)|Seoul Activities of Daily Living (S-ADL)|Seoul-Instrumental Activities of Daily Living (S-IADL)|Korean Neuropsychiatric Inventory (K-NPI)","Samsung Medical Center|Eisai Korea Inc.","All","Child, Adult, Older Adult","Not Applicable","72","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-02-072","February 2008","April 2009","April 2009","December 2, 2009",,"January 6, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01023425"
1597,"NCT00987220","Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Drug: Placebo|Drug: donepezil (Aricept)","Mean post-dose vs predose change in CSF acetycholine levels in donepezil compared to placebo control group.|Mean post-dose vs predose change in CSF histamine metabolites, sAPPalpha and inflammatory endpoints","Pfizer","All","18 Years to 55 Years   (Adult)",,"12","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","A9001428","October 2009","February 2010","February 2010","September 30, 2009",,"February 14, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00987220"
1598,"NCT01903421","Inhalational Anesthesia and Precipitation of Dementia: is There a Link?",,"Active, not recruiting","No Results Available","Alzheimer's Disease|Dementia","Drug: Spinal anesthesia group: bupivacaine 10-15mg|Drug: General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|Genetic: Blood test|Other: Lumbar spinal tap|Behavioral: Montreal Cognitive Assessment (MOCA) and MMSE","Assessing the incidence of early dementia","University Health Network, Toronto","All","65 Years and older   (Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13-6122-A","March 2014","December 2018","December 2019","July 19, 2013",,"May 20, 2019","Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|William Osler Health Centre, Toronto, Ontario, Canada|Pauls Stradins Clinical University Hospital, Riga, Latvia",,"https://ClinicalTrials.gov/show/NCT01903421"
1599,"NCT03323502","Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support","APPROACHES","Not yet recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: ACP Specialist Program","Hospital Transfers|ACP preferences documentation|hospice enrollment|death in hospital|family satisfaction","Indiana University|National Institute on Aging (NIA)|Hebrew SeniorLife|Regenstrief Institute, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","22650","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","00481769|R21AG057463-01","September 1, 2019","August 31, 2020","September 29, 2022","October 27, 2017",,"February 27, 2019",,,"https://ClinicalTrials.gov/show/NCT03323502"
1600,"NCT00938665","Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.","COGNISION™","Completed","No Results Available","Memory Disorders|Alzheimer Disease|Dementia|Cognitive Impairment|Frontotemporal Dementia","Device: COGNISION™ System","Electrophysiological markers of cognitive status","Neuronetrix, Inc.","All","60 Years to 90 Years   (Adult, Older Adult)",,"204","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","SRP-1418","December 2010","February 2014","February 2014","July 14, 2009",,"March 10, 2014","Premiere Research Institute, West Palm Beach, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Center for Memory, Brookline, Massachusetts, United States|Duke University, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Memory Clinic, Bennington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00938665"
1601,"NCT00192998","The Serotonergic Transmitter System in Dementia and Affective Disorders",,"Unknown status","No Results Available","Mood Disorders|Alzheimer Disease",,,"Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","SERT-AD","October 2003",,,"September 19, 2005",,"September 27, 2007","Neurobiological Research Unit, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00192998"
1602,"NCT02910102","Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia",,"Completed","No Results Available","Alzheimer's Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia","Drug: RVT-101 35 mg|Drug: Placebo","Change in quantitative gait measurements from baseline to the end of each double-blind treatment period based on computerized gait assessment tools.|Incidence of adverse events, and reported changes in physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments from baseline to the end of each double-blind treatment period.","Axovant Sciences Ltd.","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVT-101-2003","October 2016","November 2017","November 2017","September 21, 2016",,"December 27, 2017","US101, Phoenix, Arizona, United States|US118, Simi Valley, California, United States|US117, Temecula, California, United States|US115, Boca Raton, Florida, United States|US109, Hallandale Beach, Florida, United States|US116, Miami, Florida, United States|US108, Pensacola, Florida, United States|US106, Columbus, Georgia, United States|US107, Indianapolis, Indiana, United States|US102, Ann Arbor, Michigan, United States|US111, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02910102"
1603,"NCT00499642","Study Evaluating the Effect of Lecozotan SR on the QTc Interval",,"Completed","No Results Available","Alzheimer Disease|Healthy","Drug: Lecozotan SR|Drug: Moxifloxacin","To assess the effect of drug administration on QTc interval.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","3098B1-133","June 2007",,"August 2007","July 11, 2007",,"December 28, 2007","Rennes, France|Rueil-Malmaison, France",,"https://ClinicalTrials.gov/show/NCT00499642"
1604,"NCT02444078","Effects of Exercise on Functional Ability in People With Dementia in Nursing Homes:a Cluster Randomised Controlled Trial","LEDEN","Completed","No Results Available","Alzheimer Disease|Dementia","Other: Exercise|Other: Social Activity","Functional ability|Change of Functional ability|Physical function|Cost-effectiveness of the interventions|Falls and fractures|Cognitive function|Behavioural and psychological symptoms of dementia (BPSD)|Pain|Nutritional status","University Hospital, Toulouse","All","65 Years and older   (Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RC31/14/7292|2014-A01713-44","August 2015","September 2016","September 2017","May 14, 2015",,"June 1, 2018","Résidence d'Automne de Bruay sur Escaut, Bruay-sur-l'escaut, France|Korian Le Castelli, L'huisserie, France|Korian Pontlieue, Le Mans, France|Résidence Les Lauriers de Plaisance, Neuilly Plaisance, France|Korian Croix Périgourd, Saint Cyr Sur Loire, France|Résidence d'Automne de Notre Dame de Sanhilac, Sanilhac, France|Résidence Les Jardins de Sermaize, Sermaize-les-bains, France|Korian Vill'Alizé, Thise, France",,"https://ClinicalTrials.gov/show/NCT02444078"
1605,"NCT01998711","Impact of a Memory Group for Older Adults Reporting Memory Difficulties",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Behavioral: Memory group","Neuropsychological measures of memory and attention|Self-report on memory performance in everyday activities|Self-report on use of memory strategies|Informant report on memory performance in everyday activities|Informant report on use of strategies|Assessment of psychological wellbeing","Bayside Health","All","Child, Adult, Older Adult","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","156/04","October 2004","November 2007","November 2007","December 2, 2013",,"December 2, 2013","Caulfield General Medical Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01998711"
1606,"NCT02210286","Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia",,"Completed","No Results Available","Dementia|Alzheimer's Disease","Dietary Supplement: Magtein","Cognitive Function|FDG-PET|RBC Magnesium chemistry","Stanford University|Magceutics, Inc.","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29329","July 2014","April 2016","July 2016","August 6, 2014",,"September 19, 2019","Stanford University School of Medicine, Department of Psychiatry & Behavioral Sciences, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02210286"
1607,"NCT02707978","F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)",,"Withdrawn","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol C","September 30, 2017","September 2020","December 2020","March 14, 2016",,"January 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02707978"
1608,"NCT01038726","Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults",,"Completed","No Results Available","Aging|Alzheimer's Disease","Other: Exercise Training|Other: Cognitive Training|Other: Flexibility Training|Other: Educational Sessions","Brain activation patterns measured by functional MRI|Neuropsychological Testing|Exercise assessment","The Cleveland Clinic|National Institutes of Health (NIH)","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","NIH AG035775-01","December 2009","September 2012","September 2012","December 24, 2009",,"September 18, 2013","The Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01038726"
1609,"NCT00182897","PACT: Providers and Alzheimer's Caregivers Together",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Behavioral: Skills Building for Caregiver Health and Care-recipient","General well-being, measured with the revised Rand General Well-Being Scale|caregiver’s level of distress with care recipient behaviors, measured with the Revised Memory and Behavior Problems Checklist at Baseline, within 2 weeks of home care ending and six months.|Determine the cost-effectiveness of home-based intervention; data will be collected at Baseline, within 2 weeks of home care ending and six months.","National Institute on Aging (NIA)|National Institute of Nursing Research (NINR)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IA0081|5R01AG016328","October 2000",,"November 2005","September 16, 2005",,"November 14, 2006","University of Tennessee Health Science Center, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00182897"
1610,"NCT00558402","Meditation or Education for Alzheimer Caregivers",,"Completed","No Results Available","Caregivers|Alzheimer's Disease","Behavioral: Meditation|Behavioral: Education|Behavioral: Respite only","Caregiver stress (Revised Memory and Behavior Problems Checklist)|5-Facet Mindfulness Questionnaire|Perceived Self-Efficacy|EEG measuring reaction time","Oregon Health and Science University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00002226","November 2007","July 2011","July 2011","November 15, 2007",,"October 29, 2014","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00558402"
1611,"NCT02836054","Study of Degenerescence CSF Hallmarks in Older Bipolar Patients","BPL-1318","Recruiting","No Results Available","Bipolar Disorder|Alzheimer's Disease","Procedure: lumbar puncture (LP)|Procedure: brain MRI","Profile 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in cerebrospinal fluid of aged subjects with bipolar disorder : Total Tau proteins, phosphorylated Tau proteins, Aß40 and Aß1-42 concentration","University Hospital, Grenoble","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","38RC13.408|2013-A00930-45","November 2013","December 2019","December 2019","July 18, 2016",,"January 7, 2019","University Hospital, Grenoble, Grenoble, Isère, France",,"https://ClinicalTrials.gov/show/NCT02836054"
1612,"NCT01708304","Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)","RDAD","Completed","No Results Available","Alzheimer's Disease|Dementia|Memory Impairment|Cognitive Impairment","Behavioral: RDAD","Minutes of exercise per week|Restricted Activity Days|Restricted Days of Activity|Independence/Residential Status|Revised Memory and Behavior Problem Checklist (RMBPC)|Quality of Life-AD|CES-D","University of Washington","All","65 Years and older   (Older Adult)","Not Applicable","510","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","41906","November 2012","June 2017","June 2017","October 16, 2012",,"September 15, 2017","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01708304"
1613,"NCT00880555","Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)","CASL","Completed","Has Results","Alzheimer Disease|Dementia",,"FCI Score at Follow-up","VA Office of Research and Development|University of Alabama at Birmingham","All","50 Years to 89 Years   (Adult, Older Adult)",,"78","U.S. Fed|Other","Observational","Time Perspective: Prospective","E6553-W","April 2009","May 2014","May 2014","April 13, 2009","March 24, 2016","March 24, 2016","Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00880555"
1614,"NCT00692510","Drug Interaction Study Between AZD3480 and Cytochrome P450","Cocktail","Completed","No Results Available","Metabolism|Alzheimer's Disease","Drug: AZD3480|Drug: Placebo|Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)","PK variables|Safety variables (adverse events, blood pressure, pulse, safety lab)","AstraZeneca","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D3690C00016|EudraCt nr 2007-002456-10","November 2007","September 2008","September 2008","June 6, 2008",,"November 26, 2008","Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00692510"
1615,"NCT03286608","Polyphenols and Risk of Dementia",,"Completed","No Results Available","Diet, Polyphenols, Flavonoids, Stilbenes, Aged, Dementia, Alzheimer's Disease, Epidemiology","Other: observational study (no intervention)","incidence of dementia|incidence of Alzheimer's disease","Jean-François Dartigues|University of Bordeaux","All","65 Years and older   (Older Adult)",,"1329","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Three-City study Bordeaux","January 1, 1999","December 31, 2015","December 31, 2015","September 18, 2017",,"September 18, 2017",,,"https://ClinicalTrials.gov/show/NCT03286608"
1616,"NCT02489110","Webnovela for Hispanic Dementia Family Caregivers",,"Completed","Has Results","Alzheimer's Disease|Dementia","Behavioral: Webnovela|Behavioral: Information","Stress on the Perceived Stress Scale|Caregiver Burden on the Revised Memory and Behavior Problems Checklist","Photozig, Inc.|National Institute on Aging (NIA)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pz-A104a|R44AG041552","June 2015","May 2016","September 2016","July 2, 2015","September 13, 2018","September 13, 2018","Photozig, Inc., Moffett Field, California, United States",,"https://ClinicalTrials.gov/show/NCT02489110"
1617,"NCT03682081","Interventions for Patients With Alzheimer's Disease and Dysphagia",,"Not yet recruiting","No Results Available","Dementia|Dysphagia","Device: Isometric tongue strengthening|Drug: Biotene","Change in Lingual Pressures at the Anterior and Posterior Tongue Locations|Change in Perceived Swallow Effort|Change in Penetration-Aspiration Scale scores|Change in Functional Oral Intake Scale (FOIS) scores|Change in Swallowing Quality of Life (Swal-QOL) scale|Change in Amount of saliva produced|Change in number of hospital admissions and readmissions as well as pneumonia incidence|Change in Caregiver Burden Scale|Change in 6-item Caregiver Activity Survey (CAS)","University of Wisconsin, Madison","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0835","November 1, 2019","February 1, 2023","February 1, 2023","September 24, 2018",,"October 4, 2019","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03682081"
1618,"NCT00255866","Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers",,"Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: Skills training for the care of dementia patients","Skills to effectively deal with resident behavioral problems|Resident depression, anxiety, behavioral problems, and quality of life","University of Washington|National Institute of Mental Health (NIMH)","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","26082-ED|R21MH069651|DSIR 82-SEDR","January 2004","December 2006","December 2006","November 21, 2005",,"December 2, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Rush University School of Nursing, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00255866"
1619,"NCT02984540","Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease","BEAM","Completed","No Results Available","Mild Cognitive Impairment|Insulin Resistance","Other: Low-Carbohydrate Diet|Other: Low-Fat Diet","Change in spinal fluid levels of biomarkers associated with Alzheimer's disease|Change in memory composite score|Change in insulin sensitivity|change in 11C acetoacetate PET uptake","Wake Forest University Health Sciences","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00029992","February 2015","April 3, 2017","April 3, 2017","December 7, 2016",,"December 21, 2018","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02984540"
1620,"NCT03100617","Alzheimer's Family Caregiver Intervention in Vietnam",,"Recruiting","No Results Available","Dementia Alzheimers","Behavioral: Psychosocial caregiver intervention","Caregiver burden","University of California, Davis|University of South Carolina","All","21 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1084736","August 26, 2017","June 18, 2018","June 18, 2019","April 4, 2017",,"July 4, 2018","Vietnam National Geriatric Hospital, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03100617"
1621,"NCT00241293","Influence of Age on Hemispheric Lateralization of Language : a Longitudinal Study",,"Completed","No Results Available","Aging|Alzheimer's Disease",,,"University Hospital, Tours","All","76 Years and older   (Older Adult)",,,"Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","HOP-PROMO2003",,,,"October 18, 2005",,"October 18, 2005","University Hospital, Tours, France",,"https://ClinicalTrials.gov/show/NCT00241293"
1622,"NCT03234686","Deferiprone to Delay Dementia (The 3D Study)",,"Recruiting","No Results Available","Mild Cognitive Impairment|Prodromal Alzheimer's Disease|Mild Alzheimer's Disease","Drug: Deferiprone 600mg delayed release tablets|Drug: Placebo Oral Tablet","Efficacy of Deferiprone|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Brain Iron Levels","Neuroscience Trials Australia","All","65 Years and older   (Older Adult)","Phase 2","171","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","DEF001","January 19, 2018","July 2021","December 2021","July 31, 2017",,"January 24, 2018","Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03234686"
1623,"NCT03233646","OCTA in Mild Cognitive Impairment and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Retinal Vascular|Parkinson Disease|Multiple Sclerosis|Huntington Disease|Neuro-Degenerative Disease","Device: Retinal Imaging","Foveal avascular zone|Vessel Density|Choroidal Thickness","Duke University|Alzheimer’s Drug Discovery Foundation|University of Edinburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Pro00082598","July 20, 2017","April 1, 2021","April 1, 2021","July 28, 2017",,"September 10, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03233646"
1624,"NCT00677885","P-glycoprotein Function in Brain Diseases",,"Completed","No Results Available","Alzheimer Disease|Parkinson Disease|Frontotemporal Lobar Degeneration",,"P-gp function in AD, PD, and FTD patients and in healthy volunteers. P-gp function will be determined by calculating the brain uptake of [11C]dLop|Comparing P-gp function with the severity of disease","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","35 Years and older   (Adult, Older Adult)",,"20","NIH","Observational","Time Perspective: Prospective","080124|08-M-0124","May 9, 2008",,"August 25, 2014","May 15, 2008",,"September 10, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00677885"
1625,"NCT02931136","Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Biomarker|Diagnosis|Treatment","Drug: Huperzine A|Drug: Placebo","The average annual conversion rate in patients of MCI due to AD convert to the AD.","Shanghai Mental Health Center","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Shanghai Mental Health Center","November 2019","December 2024","December 2025","October 12, 2016",,"April 16, 2019","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02931136"
1626,"NCT00094939","Predictors of Cognitive Decline in Normal Aging",,"Unknown status","No Results Available","Alzheimer Disease|Dementia",,,"National Institute on Aging (NIA)","All","60 Years to 80 Years   (Adult, Older Adult)",,"170","NIH","Observational","Time Perspective: Prospective","IA0056|R01AG012101","September 2003",,"August 2008","October 29, 2004",,"December 14, 2009","Center for Brain Health, Silberstein Institute, New York University School of Medicine, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00094939"
1627,"NCT03794141","Genetic Information as a Life Style Change Motivator","APOE4MOT","Active, not recruiting","No Results Available","Health Behavior|Alzheimer Disease, Protection Against","Behavioral: information on the risk gene status|Behavioral: life style advise","Number of participants with good quality of dietary fat|Dietary habits, number of participants|Food choice questionnaire, health and taste attitude|Food involvement and Food mavenism, scale 1-5|Health concern, scale 1-9|Life-orientation test, scale 1-5|Locus of Control, state-trait anxiety inventory, Three-Factor Eating Questionnaire (TFEQ) scale 1-4|weight kg|height m|Waist circumference, cm|Visceral fat level (1-30)|blood pressure, mmHg|Serum lipid levels mmol/L|Blood glucose levels, mmol/L|Serum lipid peroxidation, MDA/µM|Serum Sensitive C reactive protein, mg/L|Serum Hemoglobin, g/L|Serum Alkaline phosphatase, U/L|Serum Alanine aminotransferase, U/L|Serum haptoglobin, g/L|Plasma thyrotropin, mU/L|serum APOE protein, mg/L|serum brain-derived neurotrophic factor, ng/ml|serum Fatty acids, g/100g fatty acids|serum Carotenoids, retinol and α-tocopherol, Plasma total phenolics ng/µl|Blood cell count|APOE and BDNF genotype|Body mass index","Natural Resources Institute Finland|University of Turku|University of Eastern Finland|Academy of Finland","All","40 Years to 60 Years   (Adult)","Not Applicable","333","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","41007-00040400","January 2, 2017","March 30, 2019","July 31, 2019","January 4, 2019",,"January 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03794141"
1628,"NCT04019665","Self-screening of Cognitive Impairment in Primary Care","OCEANE","Not yet recruiting","No Results Available","Cognition Disorder|Alzheimer Disease","Other: MMSE (mini mental state examination)|Other: SAGE (Self-Administered Gerocognitive Exam)","MMSE Score at general or post emergency geriatric consultation|Sage test done at home|Concordance between the MMSE test score done at consultation and the sage test core done at home","Centre Hospitalier Universitaire, Amiens","All","60 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PI2018_843_0024","July 2019","December 2019","January 2020","July 15, 2019",,"July 15, 2019",,,"https://ClinicalTrials.gov/show/NCT04019665"
1629,"NCT01378195","iCare Stress Management e-Training for Dementia Family Caregivers","iCare","Completed","Has Results","Alzheimer's Disease|Dementia","Behavioral: CBT-based program for dementia caregivers|Behavioral: Educational/Resources program","Perceived Stress Scale|Revised Memory and Behavior Problems Checklist|Perceived Quality of Life","Photozig, Inc.|Stanford University|National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","Phase 2","150","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pz-A103a|R44AG032762","May 2011","July 2012","July 2012","June 22, 2011","January 8, 2013","February 28, 2013","Photozig, Inc., Moffett Field, California, United States",,"https://ClinicalTrials.gov/show/NCT01378195"
1630,"NCT03124550","Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias",,"Recruiting","No Results Available","Sedentary Lifestyle|Stress, Psychological","Behavioral: Exergame Experience","Number of steps|Exercise Intensity|Exercise self-efficacy|Number of social contacts","Brandeis University|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Exergame #17065|5P30AG048785","May 11, 2017","July 2019","July 2020","April 24, 2017",,"January 11, 2019","Northeastern University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03124550"
1631,"NCT02155946","Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Device: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit","Functional MRI|Face-name memory test performance|Object Location Association memory test performance|fMRI|Objective memory test performance|Subjective memory test performance on the MMQ","VA Office of Research and Development","All","50 Years to 88 Years   (Adult, Older Adult)","Not Applicable","100","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","N1534-R","December 1, 2014","December 31, 2020","December 31, 2020","June 4, 2014",,"August 8, 2019","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02155946"
1632,"NCT01548053","The Primary Care - Dementia Assessment and Treatment Algorithm","PC-DATA","Completed","No Results Available","Dementia|Alzheimer's Disease","Other: PC-DATA tool","Change in number of dementia care process quality indicators achieved.|Impact on learning and knowledge application|Client-centred care","Queen's University|Canadian Institutes of Health Research (CIHR)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","PC-DATA1","March 2012","December 2015","May 2016","March 8, 2012",,"April 14, 2017","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01548053"
1633,"NCT01762618","Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients","EMOCUIDA","Completed","No Results Available","Psychological Support to Caregivers of Azlheimer's Patients","Behavioral: Cognitive Behavioral Therapy Group","Change from baseline in POMS Scale (""Profile of Mood States"")|Change from baseline compared to the control and active arms using the Martin and cols. scale to assess the overload level of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia.","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","EMOCUIDA/FPM-0211","January 2012","April 2013","July 2013","January 8, 2013",,"July 9, 2014","Hospital del Carme, Badalona, Barcelona, Spain|Primary Assistant Center Les Corts, Barcelona, Catalonia, Spain|Primary Assistant Center Sarrià, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT01762618"
1634,"NCT03866018","Contribution of Physical Activity to Self-esteem and Motivation in Older Adults With Minor to Major Cognitive Disorders Such as Alzheimer's Disease or Related Disorders","APAMA","Not yet recruiting","No Results Available","Cognitive Disorders","Other: Adapted physical activity","Improvement of patient self-esteem|Improvement of patient motivation|Improvement of patient apathy|Quantitative assessment of physical activity|Patient satisfaction","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-AOI-01","March 1, 2019","August 31, 2019","August 31, 2019","March 7, 2019",,"March 7, 2019","Institut Claude Pompidou - Centre Mémoire de Ressources et de Recherche du CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT03866018"
1635,"NCT01958437","Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease","Device: Transcranial direct current stimulation (tDCS)","Accuracy in Centimeters From Target Location for Allocentric|Hippocampal BOLD Signal During Task-based fMRI|Dorsal Attention Network Connectivity During Resting-state fMRI|Egocentric","VA Office of Research and Development","All","50 Years to 88 Years   (Adult, Older Adult)","Not Applicable","44","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C1381-P","October 1, 2013","March 23, 2017","March 24, 2017","October 9, 2013","August 31, 2018","August 31, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT01958437/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01958437"
1636,"NCT03299062","Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders",,"Recruiting","No Results Available","Alzheimer Disease|Neurodegenerative Diseases","Diagnostic Test: Cytology and Immunohistochemistry","Alpha-synuclein levels from nasal swabs","University of Arkansas","All","19 Years to 89 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","206829","November 14, 2017","June 1, 2020","August 1, 2020","October 2, 2017",,"June 25, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT03299062"
1637,"NCT03244917","Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias","TRAIN-AD","Recruiting","No Results Available","Dementia|Infection, Bacterial","Behavioral: TRAIN-AD","Total antimicrobial use for LRI and UTIs|Antimicrobial use when minimal criteria are absent for LRI and UTIs|Burdensome interventions|Advance care planning|Total antimicrobial use","Hebrew Rehabilitation Center, Boston","All","21 Years and older   (Adult, Older Adult)","Not Applicable","410","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","TRAIN-AD","October 15, 2017","August 2020","March 2021","August 10, 2017",,"July 24, 2019","Hebrew SeniorLife, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03244917"
1638,"NCT03654911","Sustainable Method for Alzheimer's Prediction",,"Not yet recruiting","No Results Available","Alzheimer Disease|Amnestic-Mild Cognitive Impairment","Diagnostic Test: EEG|Genetic: ApoE","Biomarkers: EEG|Biomarker: ApoE4|Biomarker: Accuracy of digital classifier","Catholic University of the Sacred Heart","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ROSSINI_MSD_ID1764","September 3, 2018","September 3, 2020","September 3, 2020","August 31, 2018",,"August 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03654911"
1639,"NCT01117181","Apathy in Dementia Methylphenidate Trial (ADMET)","ADMET","Completed","Has Results","Apathy|Alzheimer's Disease","Drug: Methylphenidate|Drug: placebo|Other: Psychosocial intervention","Apathy Evaluation Scale (AES)|Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change|Digit Span|Mini-Mental State Exam (MMSE)|Neuropsychiatric Inventory (NPI): Apathy Subscale|Vital Status|Electrolytes|Electrocardiogram (ECG)","Johns Hopkins Bloomberg School of Public Health|National Institute on Aging (NIA)|Medical University of South Carolina|Johns Hopkins University|University of Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01AG033032-01","June 2010","August 2012","August 2012","May 5, 2010","May 10, 2013","June 12, 2018","Johns Hopkins University, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01117181"
1640,"NCT00177489","Coordinating Center for Caregiver Intervention Trial","REACH","Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: multicomponent psychosocial intervention|Other: Control arm","multivariate quality of life indicator- assessed caregiver burden, depressive symptoms, self-care, social support and patient problem behaviors. Assessed at six months post-randomization.|Caregiver clinical depression and patient institutional placement-six months post-randomization.","University of Pittsburgh|National Institute on Aging (NIA)|National Institute of Nursing Research (NINR)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","613","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AG13305","June 2002","September 2005","September 2005","September 15, 2005",,"January 5, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University and Veterans Affairs, Menlo Park, California, United States|University of Miami at Miami, Center on Adult Development and Aging, Miami, Florida, United States|Thomas Jefferson University at Philadelphia, Center for Applied Research on Aging and Health, Philadelphia, Pennsylvania, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00177489"
1641,"NCT00119561","Testing the Effectiveness of Telephone Support for Dementia Caregivers","CONNECT","Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: Telephone Support","General well-being (revised Rand General Well-Being Scale); and caregiver's level of distress with care recipient behaviors (Revised Memory and Behavior Problems Checklist). Data is collected at baseline, 6 and 12 months in a face to face interview.|Cost-Effectiveness|Time spent providing care","US Department of Veterans Affairs|VA Office of Research and Development","All","21 Years and older   (Adult, Older Adult)","Not Applicable","154","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIR 03-287","February 2005","June 2007","January 2014","July 13, 2005",,"April 7, 2015","Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00119561"
1642,"NCT03034746","Impact of Physical Activity on Successful Aging",,"Completed","No Results Available","Alzheimer Disease|Cognitive Impairment|Physical Activity","Other: Physical activity (PA)|Other: cognitive treatment (CT)","Mini Mental State Examination|Trail Making Test|Rivermead Behavioral Memory Test|Tower of London|Dual Task|Frontal Assessment Battery|Attention Matrix|Alzheimer's Disease Assessment Scale|6-Minute Walking Test|gait analysis by GAITRite® System|stabilometric assessments with Stability Line|Instrumental Activity in Daily Living Scale (IADL)|Neuropsychiatric Inventory Scale (NPI)|cerebral circulation|peripheral vascular function","Universita di Verona","All","65 Years to 90 Years   (Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PRIN_2010","September 2013","May 2016","October 2016","January 27, 2017",,"January 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03034746"
1643,"NCT03424200","Coaching for Cognition in Alzheimer's (COCOA)",,"Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment","Behavioral: Routine care|Other: Coaching plus routine care","Coaching for Cognitive Decline|Diagnosis of Alzheimer's Disease|Memory Performance Index|FAST Stage","Hoag Memorial Hospital Presbyterian|Institute for Systems Biology|Arivale","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","COCOA","November 1, 2017","November 1, 2022","November 1, 2022","February 6, 2018",,"February 7, 2019","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03424200"
1644,"NCT03740178","Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)",,"Not yet recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: MK-4334|Drug: Placebo to MK-4334|Drug: Donepepzil","Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing Study Treatment due to an Adverse Event|Plasma Steady State Concentration at 24 Hours (C24) of MK-4334|Plasma Steady State Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-4334|Plasma Steady State Maximum Concentration (Cmax) of MK-4334|Plasma Steady State Apparent Half-Life (t1/2) of MK-4334|Plasma Steady State Time to Maximum Concentration (Tmax) of MK-4334|Plasma Steady State Apparent Clearance (CL/F) of MK-4334|Plasma Steady State Apparent Volume of Distribution (Vz/F) of MK-4334","Merck Sharp & Dohme Corp.","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4334-005|MK-4334-005","September 27, 2019","February 28, 2020","February 28, 2020","November 14, 2018",,"May 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03740178"
1645,"NCT00479843","Nutritional Programme for Dementia Elderly Patient",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Behavioral: Nutritional programme","Evaluation of the effectiveness of the intervention -The main evaluation criteria which will allow the effectiveness of this intervention to be evaluated are the reduction in the loss of autonomy measured by the DA/IDA scale.|-Improvement in the patient's state of nutrition -Reducing the burden on carers with the Zarit scale. -Evaluation of the use of healthcare and social resources with the RUD scale. -Improvement of medical practice regarding nutrition.","Nestlé|Institut Català de l'envelliment, Barcelona, Spain|Hospital Purpan|NESTEC R&D, Switzerland|Group MAPI-NAXIS, CRO, Lyon, France","All","50 Years and older   (Adult, Older Adult)","Not Applicable","946","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","05.19.CLI","July 2005","July 2007","July 2007","May 28, 2007",,"January 24, 2014","Institut Català de l'envelliment, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00479843"
1646,"NCT00010803","Ginkgo Biloba Prevention Trial in Older Individuals",,"Completed","Has Results","Dementia|Alzheimer's Disease","Drug: Ginkgo biloba|Drug: Placebo","Number of Participants With Incident Dementia|Number of Participants With the Indicated Cardiovascular Disease or Mortality|Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.","National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institute on Aging (NIA)|National Heart, Lung, and Blood Institute (NHLBI)","All","75 Years and older   (Older Adult)","Phase 3","3069","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","U01 AT000162-01M","October 2000","April 2008","July 2011","February 5, 2001","September 16, 2010","March 14, 2013","University of California, Davis, Sacramento, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh/University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00010803"
1647,"NCT03960476","Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults",,"Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Behavioral: PlanYourLifespan.org","Change in long-term care plan decision-making|Participant utilization of long-term care services|Number of participants that implement any of their long-term care plans|Participant long-term care goal concordance","Northwestern University|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Not Applicable","700","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01AG058777|1R01AG058777-01A1","September 1, 2019","August 30, 2023","February 29, 2024","May 23, 2019",,"May 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03960476"
1648,"NCT03896711","MEMORI Corps: Activity-based Companion Care for Dementia","MEMORI Corps","Not yet recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: MEMORI Corps program|Other: Augmented Waitlist Control","Change in neuropsychiatric symptoms as assessed by Neuropsychiatric Inventory (NPI) score|Change in quality of life as assessed by the Quality of life in Alzheimer's Disease (QOL-AD) tool|Change in subjective caregiver burden as assessed by the Zarit Burden Inventory-Short Form|Change in depressive symptoms in caregivers as assessed by The Patient Health Questionnaire (PHQ) - 9|Change in speed of processing as assessed by the Pattern Comparison test|Change in Gait speed|Change in executive functioning as assessed by Trail Making Test B|Change in activity engagement as assessed by the Community Healthy Activities Model Program for Seniors activity questionnaire|Change in outpatient health services use as assessed by the Resource Utilization in Dementia/Services Utilization and Resources Survey|Change in home and community-based long term services and supports use health services use as assessed by the Resource Utilization in Dementia/Services Utilization and Resources Survey|Change in objective caregiver burden as assessed by time estimates in performing tasks|Change in stress as assessed by the Elders Life Stress Inventory|Time to transition from home|Change in depressive symptoms in senior companion volunteers as assessed by The Patient Health Questionnaire (PHQ) - 9","Johns Hopkins University|Alzheimer's Association|National Institute on Aging (NIA)","All","18 Years to 115 Years   (Adult, Older Adult)","Not Applicable","560","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00197899|R01AG058586","December 15, 2019","September 29, 2024","September 29, 2024","April 1, 2019",,"April 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03896711"
1649,"NCT02873546","tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia","ALSTICO","Unknown status","No Results Available","Alzheimer's Disease|Progressive Primary Aphasia|Early or Mild State","Device: transcranial Direct Current Stimulation (tDCS)","change from baseline cognitive functions at 3 weeks","Centre Hospitalier Universitaire de Besancon|Centre Hospitalier Universitaire Dijon|Assistance Publique - Hôpitaux de Paris","All","60 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","API/2011/24","July 19, 2013","January 31, 2018","July 31, 2018","August 19, 2016",,"October 13, 2017","CHU Besancon - Clinical Psychiatric Department, Besancon, France|Hopital Universitaire Dijon, Dijon, France|Assistance Publique - Hôpitaux Paris, Paris, France",,"https://ClinicalTrials.gov/show/NCT02873546"
1650,"NCT03667924","Utilizing Senior Companions to Enhance Dementia Care",,"Enrolling by invitation","No Results Available","Alzheimer Disease|Dementia","Behavioral: PorchLight Project","Utilization of LTSS by PWML|Quality of primary care interactions|Caregiver Distress: Burden|Caregiver Distress: Depressive symptoms|PWML Well-being|PWML Depression|PWML Quality of Life|Caregiver self-efficacy","University of Minnesota - Clinical and Translational Science Institute|Lutheran Social Services of Minnesota|Johns Hopkins University|Brown University|University of Texas-Arlington","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","R61AG061903","May 1, 2019","October 2020","October 2020","September 12, 2018",,"September 19, 2019","School of Public Health, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03667924"
1651,"NCT03666624","Socially Isolated Older Adults Living With Dementia",,"Not yet recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Personalized care network","Change in Physical Activity of Care Recipient|Change in Physical Functioning of Care Recipient|Change in Quality of Life of Care Recipient|Change in Rate of Care-Recipient Behavioral Disturbances","University of Washington","All","50 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00005149","May 30, 2019","September 1, 2019","September 1, 2019","September 12, 2018",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03666624"
1652,"NCT03585907","Feasibility and Efficacy of Dietary Interventions for Older Adults With Subjective Cognitive Decline",,"Withdrawn","No Results Available","Alzheimer Disease|Cognitive Impairment","Dietary Supplement: MAD|Dietary Supplement: MIND","Change in Memory Functioning Questionnaire (MFQ)|Change in Loewenstein-Acevedo Scales of Semantic Interference and Learning (LASSI-L)|Change in Para-Rodriguez Short-term Visual Memory Binding Test (SVMBT)|Change in Ketone levels|MIND Diet Score|ApoE epsilon 4 status|Change in Trail Making Test|Change in Prospective Memory Test|Change in Geriatric Anxiety Scale|Change in Geriatric Depression Scale","Johns Hopkins University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00175761","September 2, 2019","September 1, 2021","September 1, 2021","July 13, 2018",,"October 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03585907"
1653,"NCT03550131","Innovations in Dementia Empowerment and Action","IDEA","Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Innovations in Dementia Empowerment and Action (IDEA)|Behavioral: Reducing Disabilities in Alzheimer's Disease (RDAD)","Change in Physical Activity of Care Recipient|Change in Physical Activity of Caregiver|Change in Physical Functioning of Care Recipient|Change in Physical Functioning of Caregiver|Change in Perceived Stress (PSS) of Caregiver|Change in Health-Related Quality of Life (HRQOL) of Care Recipient|Change in Health-Related Quality of Life (HRQOL) of Caregiver|Change in Quality of Life (QOL-AD) of Care Recipient|Change in Health-Related Quality of Life (QOL-AD) of Caregiver|Change in Rate of Care-Recipient Behavioral Disturbances","University of Washington","All","50 Years and older   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00003076","December 5, 2018","December 31, 2020","May 31, 2022","June 8, 2018",,"April 17, 2019","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03550131"
1654,"NCT02162251","Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Desease","Drug: Donepezil Hydrochloride","Investigations on adverse events and adverse drug reactions|Severity of dementia based on the Functional Assessment Staging Test (FAST)|Change From Baseline in the Mini-Mental State Examination (MMSE) Score","Eisai Co., Ltd.|Eisai Inc.","All","Child, Adult, Older Adult",,"3482","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ART07T","June 1, 2013","May 1, 2015","April 15, 2016","June 12, 2014",,"September 7, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02162251"
1655,"NCT03578991","Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease","DIALCAT","Recruiting","No Results Available","Patients Aged 65-85 (Both Included)|Diagnosed of Mild Cognitive Impairment|Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years","Device: Smart pillbox|Other: Interactive digital platform","Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).|Cardiovascular risk factor: Hypertension.|Cardiovascular risk factor: Obesity.|Cardiovascular risk factor: Dyslipidemia.|Degree of diabetes control.|Usal medication.|Presence of micro and macrovascular complications.|Presence and severity of hypoglycemia.|Lipid profile and renal and hepatic function.|Biomarkers (serum and DNA).|Short Physical Performance Battery test (SPPB).|Hachinski Scale (HS).|Blessed Dementia Rating Scale (BDRS).|Geriatric Depression Scale (GDS; 15-item short form).|Schwab and England Activities of Daily Living Scale (SE-ADL).|Montreal Cognitive Assessment (MOCA).|Mini-Mental State Examination (MMSE).|Memory failure in everyday life questionnaire (MFE).|The Morisky Medication Adherence Scale (MMAS-8).|The Functional Social Support Questionnaire (DUKE-UNC-11).|The Resource Utilization in Dementia (RUD).","Parc Sanitari Pere Virgili|Hospital Vall d'Hebron|Consorci Sanitari de Terrassa|Fundació Recerca Mútua Terrassa (FMT)|Clínica Universitària de la Fundació Universitària del Bages (FUB)|Althaia Xarxa Assistencial Universitària de Manresa|Fundació Privada Hospital Asil de Granollers (HAG)|Consorci Hospitalari de Vic|LambdaLoopers|Universitat Politècnica de Catalunya|Leitat|Mixestat|Meditecnologia","All","65 Years to 85 Years   (Older Adult)","Not Applicable","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DIALCAT COMRDI-B64574221423350|COMRDI B64574221423350","July 1, 2019","May 2020","May 2020","July 6, 2018",,"August 29, 2019","Fundació Privada Hospital Asil de Granollers (HAG), Granollers, Barcelona, Spain|Clínica Universitària de la Fundació Universitària del Bages (FUB), Manresa, Barcelona, Spain|Fundació Althaia (FA), Manresa, Barcelona, Spain|Fundació Recerca Mútua Terrassa (FMT), Terrassa, Barcelona, Spain|Consorci Sanitari de Terrassa (CST), Terrassa, Barcelona, Spain|Consorci Hospitalari de Vic (CHV), Vic, Barcelona, Spain|Parc Sanitari Pere Virgili, Barcelona, Spain|LambdaLoopers, Barcelona, Spain|University Hospital Vall d'Hebron - Vall d'Hebron Institute of Research, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03578991"
1656,"NCT03466736","Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects","APPE","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Diagnostic Test: [18F]flutemetamol PET scan","short-term practice effects","University of Utah|National Institutes of Health (NIH)","All","65 Years and older   (Older Adult)",,"210","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01AG055428","September 1, 2018","April 30, 2022","April 30, 2022","March 15, 2018",,"December 11, 2018","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03466736"
1657,"NCT00260624","Escitalopram Treatment of Patients With Agitated Dementia",,"Completed","No Results Available","Alzheimer's Disease|Psychomotor Agitation","Drug: Escitalopram (Lexapro)","Agitation factor on the Neurobehavioral Rating Scale (NBRS)|Total NBRS scores|Cohen-Mansfield Agitation Inventory|Neuropsychiatric Inventory|Global Clinical Impression of Change","University of Rochester|Forest Laboratories","All","61 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LXP MD 43","February 2003","December 2006","December 2006","December 1, 2005",,"February 24, 2012","Fairport Baptist Home, Fairport, New York, United States|The Highlands at Brighton, Rochester, New York, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00260624"
1658,"NCT00951197","Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects","AMIMAGE","Completed","No Results Available","Dementia|Alzheimer Disease","Other: Neuroimaging","FA (Fractional Anisotropy), MTR (magnetization transfer ratio) and T2 (Transverse relaxation time) measures in patients with dementia compared to controls, in left and right hippocampus, and posterior cingulum|FA, MTR and T2 measures in subjects with mild cognitive impairment no dementia|Performances in the 7 neuropsychological tests available in the AMI cohort|FA measures for the connexion Hippocampus-cingulum posterior","University Hospital, Bordeaux","All","65 Years and older   (Older Adult)",,"318","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CHUBX2008/13","April 2009","March 2011","March 2011","August 4, 2009",,"April 30, 2012","Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT00951197"
1659,"NCT02844855","Memory for Action in Neurological Patients","EMBODIMENT","Recruiting","No Results Available","Alzheimer Disease|Parkinson Disease","Behavioral: Cognitive tests","Number of correct answers","Centre Hospitalier Universitaire de Saint Etienne","All","55 Years to 80 Years   (Adult, Older Adult)","Not Applicable","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1608068|2016-A00891-50","December 26, 2016","August 31, 2021","August 31, 2021","July 26, 2016",,"July 17, 2019","CHU de Saint-Etienne, Saint-Etienne, France|Hcl - Cm2R, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02844855"
1660,"NCT03033875","Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Tele-Savvy|Behavioral: Healthy Living Education Program","Change in Zarit Burden Inventory (ZBI) Score|Change in State-Trait Anxiety Inventory (STAI) Score|Change in Center for Epidemiological Studies Depression Scale - Revised (CESD-R) Score|Change in Perceived Stress Scale (PSS) Score|Change in Dyadic Relationship Scale Score|Change in Ways of Coping Scale Score|Change in Revised Memory and Behavior Problem Checklist (RMBPC) Score|Change in Self-Rated Health Score|Change in the Caregiver Assessment of Behavioral Skill - Self Report (CAB-SR) Measure Score|Change in the Pearlin Measure Score|Change in Alzheimer's Disease Related Quality of Life (ADRQL) Score|Change in Positive Appraisal of Care Scale: Consequential Gain Score|Change in Mindful Self-Care Scale Score|Change in Neuropsychological Inventory Questionnaire Score","Emory University|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","270","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00092812|1R01AG054079-01","May 18, 2017","November 30, 2020","November 30, 2020","January 27, 2017",,"July 19, 2019","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03033875"
1661,"NCT04099823","MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics",,"Recruiting","No Results Available","Hydrocephalus|Alzheimer Disease","Other: MRI screening form|Diagnostic Test: Urine pregnancy test|Diagnostic Test: MR brain","CSF flow measurement|Volume of CSF spaces|White matter disease","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19-005910","October 2019","October 2020","October 2020","September 23, 2019",,"September 23, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04099823"
1662,"NCT02915939","The Residential Care Transition Module","RCTM","Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: The Residential Care Transition Module","Change in care-related strain|Change in burden: Zarit Burden Interview|Change in stress: Perceived Stress Scale","University of Minnesota - Clinical and Translational Science Institute|Johns Hopkins University|NYU Langone Health|Benjamin Rose Institute|Emory University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","R01AG048931","December 2016","May 2021","May 2021","September 27, 2016",,"May 3, 2019","University of Minnesota, School of Nursing, 6-153 Weaver-Densford Hall, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02915939"
1663,"NCT02569398","An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia","EARLY","Completed","No Results Available","Asymptomatic Amyloid-positive","Drug: Atabecestat, 5 mg|Drug: Atabecestat, 25 mg|Drug: Placebo","Change from Baseline in Preclinical Alzheimer Cognitive Composite (PACC) to Month 54|Change from Baseline in Cognitive Function Index (CFI) to Month 54|Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Prevention Instrument (ADCS-ADLPI) Total Score to Month 54|Change from Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Score to Month 51|Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score to Month 54|Change from Baseline in Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score to Month 54|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Trough Plasma Concentration (Ctrough) of Atabecestat|Area Under the Plasma Concentration-Time Curve From 0 to tau Hours After Dosing (AUCtau)|Change in mean Cerebral Fibrillar Amyloid Accumulation|Change From Baseline of Neurodegeneration by Assessing Changes in Imaging Biomarkers","Janssen Research & Development, LLC","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","596","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107373|2015-000948-42|54861911ALZ2003","October 29, 2015","December 20, 2018","December 20, 2018","October 6, 2015",,"January 21, 2019","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Downey, California, United States|La Jolla, California, United States|Newport Beach, California, United States|Orange, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Ocoee, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Tampa, Florida, United States|The Villages, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Decatur, Georgia, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elkhart, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Boston, Massachusetts, United States|Plymouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|Hattiesburg, Mississippi, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Amherst, New York, United States|New York, New York, United States|Orangeburg, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Willow Grove, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Brisbane, Australia|Darlinghurst, Australia|East Gosford, Australia|Heidelberg, Australia|Herston, Australia|Subiaco, Australia|Tarren Point, Australia|Waratah, Australia|Antwerpen, Belgium|Baudour, Belgium|Brussel, Belgium|Edegem, Belgium|Liège, Belgium|Mons, Belgium|Gatineau, Canada|Toronto, Canada|Aalborg, Denmark|Ballerup, Denmark|København Ø, Denmark|Rødovre, Denmark|Kuopio N/A, Finland|Turku, Finland|Berlin, Germany|Essen, Germany|Halle, Germany|Homburg, Germany|Kiel, Germany|Mannheim, Germany|Mittweida, Germany|Stuttgart, Germany|Ulm, Germany|Chiba-Shi, Japan|Fukuoka-Shi, Japan|Hachioji-Shi, Japan|Iizuka-Shi, Japan|Osaka-Shi, Japan|Shibuya-Ku, Japan|Shinjuku-Ku, Japan|Shirakawa, Japan|Tokyo, Japan|Chihuahua, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Tlalnepantla De Baz, Mexico|Amsterdam, Netherlands|Breda, Netherlands|S-Hertogenbosch, Netherlands|Utrecht, Netherlands|Barcelona, Spain|Getxo, Spain|Madrid, Spain|Manresa, Spain|San Sebastian, Spain|Terrassa, Spain|Valencia, Spain|Mölndal, Sweden|Birmingham, United Kingdom|Glasgow, United Kingdom|Guildford, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom|Plymouth, United Kingdom|Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02569398"
1664,"NCT03838952","The Efficacy of Traditional Chinese Herbal Medicine for Dementia",,"Not yet recruiting","No Results Available","Dementia|Alzheimer Disease","Drug: Herbal medicine","Changes of Mini-Mental State Examination(MMSE)|Changes of Instrumental Activities of Daily Living (IADL)|Changes of Neuropsychiatric Inventory(NPI-Q)|Changes of Geriatric Depression Scale (GDS)|Blood test (AST/ALT/Serum Creatinine)|Changes of Quality of Life-Alzheimer's Disease (QOL-AD)|Changes of Constitution in Chinese Medicine Questionnaire","Taipei Veterans General Hospital, Taiwan","All","65 Years and older   (Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-07-021B","February 11, 2019","December 31, 2019","December 31, 2020","February 12, 2019",,"February 12, 2019","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03838952"
1665,"NCT03811184","Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen","MemScreen","Recruiting","No Results Available","Cognitive Impairment|Alzheimer Disease","Diagnostic Test: MemScreen","Ability to detect patients with mild cognitive impairment.","MemScreen","All","40 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-A02672-53","January 17, 2019","March 2020","June 2020","January 21, 2019",,"August 15, 2019","Centre Neurologie Cognitive Hôpital Fernand Widal, Paris, France",,"https://ClinicalTrials.gov/show/NCT03811184"
1666,"NCT02719938","Triggered Palliative Care for Advanced Dementia",,"Completed","Has Results","Alzheimer Disease|Dementia","Behavioral: Specialty Palliative Care","Hospital / Emergency Visits Per 60 Days (no. of Events/Follow-up Days)|Patient Comfort End of Life in Dementia (CAD-EOLD)|Caregiver Strain|Percent of Participants With Referral to Hospice or Outpatient Palliative Care From Discharge to 60 Days Follow-Up|Percent of Participants With Physician Orders for Life Sustaining Treatment (POLST)|Number of Palliative Care Domains in Treatment Plan|Number of Participants With Burdensome Treatments","University of North Carolina, Chapel Hill|Icahn School of Medicine at Mount Sinai|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","62","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","15-1350|R21AG052140|Pilot & Exploratory Project","March 2016","October 31, 2017","October 31, 2017","March 25, 2016","January 8, 2019","January 8, 2019","University of North Carolina, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02719938/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02719938"
1667,"NCT04073628","The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Device: Lighting Intervention","Cognition using the Word Pairs Associates (WPA) Task|Cognition using the Working Memory (WM) Task|Cognition using Implicit Priming Task|Cognition using the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)|Sleep Quality in the MCI Participant using the Pittsburgh Sleep Quality Index (PSQI)|Sleep Quality in the Caregiver using the Pittsburgh Sleep Quality Index (PSQI)|Sleep Spindles using Ambulatory Electroencephalography (EEG)|Slow Oscillation Sleep Activity using Ambulatory Electroencephalography (EEG)|Caregiver Burden using the Zarit Burden Interview (ZBI)|Depression using the Geriatric Depression Scale (GDS)|Quality of Life using the Dementia Quality of Life Instrument (DQoL)|Light Exposure measurement in MCI Participants|Light Exposure in Caregivers|Sleep Efficiency in the MCI Participant|Sleep Efficiency in the Caregiver|Quality of Life using the Quality of Life in Alzheimer's Disease D - QOL-AD|Cognition in the Caregiver using the Word Pairs Associates (WPA) Task|Cognition in the Caregiver using the Working Memory (WM) Task|Cognition using the Montreal Cognitive Assessment (MoCA) tool|Cognition using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) tool|Depression using the Center for Epidemiological Studies Depression Scale (CES-D)","Rensselaer Polytechnic Institute","All","65 Years and older   (Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","AG062288","October 1, 2019","October 31, 2024","October 31, 2024","August 29, 2019",,"August 29, 2019",,,"https://ClinicalTrials.gov/show/NCT04073628"
1668,"NCT02921672","Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline",,"Completed","No Results Available","Alzheimer's Disease|Cognitive Impairment","Other: Mediterranean Diet","Number of participants completing the study","University of Kansas Medical Center|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003894|P30AG035982","March 2016","June 22, 2018","December 2018","October 3, 2016",,"February 6, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02921672"
1669,"NCT02260167","Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol","MIND","Unknown status","No Results Available","Alzheimer's Disease|Dementia","Other: A mix of natural treatments and medications","Montreal Cognitive Assessment (MoCA)|Mini Mental Status Exam (MMSE)|Alzheimer's Disease Assessment Scale- Activities of Daily Living (ADAS-ADL)","Practitioners Alliance Network","All","Child, Adult, Older Adult","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAN-ALZ002","September 2014","December 2015",,"October 9, 2014",,"October 15, 2014","PAN, Kailua Kona, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT02260167"
1670,"NCT03698695","A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers",,"Active, not recruiting","No Results Available","Cognitive Impairment|Alzheimer Disease","Drug: THN 201|Drug: Donepezil|Drug: Placebo","Pharmacodynamics: Cognitive function measured with the Cognitive Drug Research (CDR) test battery|Safety Adverse events","Theranexus","Male","18 Years to 40 Years   (Adult)","Phase 1","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","THN201-101","September 27, 2018","October 20, 2019","December 20, 2019","October 8, 2018",,"September 26, 2019","CHU Bordeaux, Bordeaux, France|CHU Clermont Ferrand, Clermont-Ferrand, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Marseille, Marseille, France|Biotrial, Rennes, France|CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03698695"
1671,"NCT03665909","A Proactive Health Monitoring Intervention for Dementia Caregivers",,"Active, not recruiting","No Results Available","Dementia|Alzheimer Disease","Other: Remote activity monitoring system","Nursing home utilization at 18 months for the person with ADRD|Perceptions of change in caregiver self-efficacy|Perceptions of change in caregiver competence|Perceptions of change in caregiver burden|Perceptions of change in caregiver role captivity|Change in caregiver role overload|Change in frequency/perceptions caregiver depressive symptom severity|Perceived acceptability/utility of remote activity monitoring at 6-, 12-, and 18-months","University of Minnesota - Clinical and Translational Science Institute","All","21 Years and older   (Adult, Older Adult)","Phase 3","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","R18HS022836","April 1, 2014","March 3, 2020","March 3, 2020","September 11, 2018",,"September 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03665909"
1672,"NCT00261573","A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia",,"Completed","No Results Available","Alzheimer Disease|Vascular Dementia","Drug: galantamine hydrobromide","Change from baseline to end of double-blind treatment in ADAS-cog/11 (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and CIBIC-plus (Clinician's Interview Based Impression of Change - Plus Caregiver Input) scores|Change from baseline to the end of double-blind treatment in ADAS-cog/13, NPI, and DAD scores; Change in ADAS scores from baseline to end of open-label treatment; Incidence of adverse events; Changes in laboratory tests, ECGs and physical examinations","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","40 Years and older   (Adult, Older Adult)","Phase 3","593","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006034","December 1998",,"December 2000","December 5, 2005",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00261573"
1673,"NCT02462161","Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart","SNIFF-Quick","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Insulin aspart|Drug: Placebo","Change in cognition|Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers|MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions","Wake Forest University Health Sciences|National Institute on Aging (NIA)|General Electric","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 1","24","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00026106|5P50AG005136-30","March 20, 2015","April 16, 2019","April 16, 2019","June 3, 2015",,"September 2, 2019","Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02462161"
1674,"NCT02397980","Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia","I-care","Unknown status","No Results Available","Alzheimer's Disease|Dementia","Behavioral: Behavioral intervention","Changes in Caregiver burden (Zaret's Burden Inventory (ZBI)|Changes in quality of life of caregivers as assessed by Philadelphia Geriatric Center for Moral Scale (PGCMS)|Changes in behavioral problems of patients with dementia as assessed by the Neuropsychiatry inventory|Changes in Depression of caregivers as assessed by the geriatric depression scale","Ewha Womans University Mokdong Hospital","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","EUMC2014-12-028","March 2015","December 2015","December 2016","March 25, 2015",,"March 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02397980"
1675,"NCT02192554","Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo",,"Completed","No Results Available","Agitation Associated With Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases",,"Adverse Events (AEs)|Mini-Mental State Examination (MMSE) score","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","Child, Adult, Older Adult",,"450","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","331-13-211","June 2014","May 2017","May 2017","July 17, 2014",,"April 30, 2018","Tuscaloosa, Alabama, United States|Costa Mesa, California, United States|Lakewood, California, United States|Orange, California, United States|Redlands, California, United States|Bradenton, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Orange City, Florida, United States|Sarasota, Florida, United States|Atlanta, Georgia, United States|Suwanee, Georgia, United States|Quincy, Massachusetts, United States|Saint Louis, Missouri, United States|Toms River, New Jersey, United States|Brooklyn, New York, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Raleigh, North Carolina, United States|Dallas, Texas, United States|Waukesha, Wisconsin, United States|Burgas, Bulgaria|Kardzhali, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tŭrnovo, Bulgaria|Penticton, British Columbia, Canada|Kentville, Nova Scotia, Canada|Zagreb, Croatia|Zagreb, Croatia|Bourg N Bresse, France|Douai, France|Elancourt, France|Toulouse, France|Mittweida, Saxony, Germany|Berlin, Germany|Bochum, Germany|Koln, Germany|Westerstede, Germany|Ekaterinburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tonnelniy, Russian Federation|Belgrade, Serbia|Kovin, Serbia|Kragujevac, Serbia|Niš, Serbia|Novi Knezevac, Serbia|Novi Sad, Serbia|Ljubljana, Slovenia|Maribor, Slovenia|Sempeter pri Gorici, Slovenia|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Zamora, Spain|Kharkiv, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Vinnytsia, Ukraine|Torpoint, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02192554"
1676,"NCT02846415","Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study",,"Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: Play Intervention for Dementia","Changes of Global Cognition measured with Montreal Cognitive Assessment Scale after 2 months of intervention|Changes of Global Cognition measured with Montreal Cognitive Scale after 3 months of intervention|Memory measured with Fuld Object Memory Evaluation|Verbal Fluency measured with Modified Verbal Fluency Test","The Hong Kong Polytechnic University","All","65 Years and older   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","4-ZZFU","August 1, 2016","April 30, 2017","December 31, 2017","July 27, 2016",,"April 12, 2018","School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02846415"
1677,"NCT01782248","Self-consciousness in Dementia",,"Recruiting","No Results Available","Alzheimer Disease|Fronto-temporal Lobar Dementia","Other: Questionnary and IRM","Characterize the deficit in critical components of personal identity in patients with Alzheimer's disease (AD) and fronto-temporal lobar dementia (FTLD), compared to healthy elderly, combining a neuropsychology and multi-podal neuroimaging study.","University Hospital, Strasbourg, France","All","45 Years to 85 Years   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","5289","March 13, 2013","January 12, 2020","March 12, 2020","February 1, 2013",,"July 12, 2019","Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT01782248"
1678,"NCT02299154","Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process :","REMAD","Unknown status","No Results Available","Memory Disorders|Alzheimer Disease","Behavioral: Psychological questionnaires","Memory problems perceptions of patients and next of kin during diagnosis process|Psychometric properties of the french adaptation of the Ilness Perceptions Questionnaire - Memory (IPQ-M, Hurt et al. 2010)|Impact of the memory problems perceptions on mood and well-being|Differences of memory problems perceptions and coping according to level of cognitive disorder at the Mini-Mental State Examination (MMSE)","Central Hospital, Nancy, France|Union des associations France Alzheimer et maladies apparentées, France|Laboratoire APEMAC :Maladies chroniques, santé perçue, processus d adaptation, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014-A00156-41","December 2014","November 2017","November 2017","November 24, 2014",,"March 8, 2016","University Hospital of Nancy ,CHU Brabois, France, Vandoeuvre les Nancy, France",,"https://ClinicalTrials.gov/show/NCT02299154"
1679,"NCT04100057","Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia",,"Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Neuropsychiatric Symptoms|Sleep Disturbance","Behavioral: CBT-I|Behavioral: CCT-I","fronto-limbic function|Neuropsychiatric Symptoms|Insomnia symptoms","Stanford University|National Institute of Mental Health (NIMH)","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB-53039","October 1, 2019","August 30, 2024","August 30, 2024","September 23, 2019",,"September 23, 2019",,,"https://ClinicalTrials.gov/show/NCT04100057"
1680,"NCT00911690","Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders",,"Completed","No Results Available","Dementia|Alzheimers Disease",,"Tissue bank of biological specimens","William Beaumont Hospitals","All","60 Years to 90 Years   (Adult, Older Adult)",,"102","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2008-065","July 2009","March 2016","March 2016","June 2, 2009",,"November 4, 2016","Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00911690"
1681,"NCT02690896","Caregiver Burden and Depression: Caring for Those Who Care for Others",,"Recruiting","No Results Available","Dementia|Alzheimer's Disease","Behavioral: UCF Caregiver Support Group|Behavioral: Community Support Groups","Change in Long-Term Care Utilization based on Caregiver Report|Neuropsychiatric symptoms|Caregiver strain|Caregiver depression|Caregiver preparedness|Satisfaction Survey|Stress hormone level|Daily stress inventory|Subjective stress|Emotional affective state","University of Central Florida|Alzheimer's and Dementia Resource Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBE-15-11548","February 24, 2016","December 2018","August 2020","February 24, 2016",,"October 15, 2018","University of Central Florida, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02690896"
1682,"NCT02432222","Effects of Visual Arts Training on Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: Visual Arts Training|Behavioral: Music Training","Montreal Cognitive Assessment (MOCA, change measure)|Working memory (change measure)|Rey-Osterreith test of long-term memory (change measure)|Trails test of set-shifting (change measure)|Dual task for visual and auditory search (change measure)|Behavioural psychiatric peformance (time-to-event measure)|Quality of Life (change measure)|Visual analog mood scale","York University","All","65 Years and older   (Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","YorkU-AD1","April 2015","December 2015","December 2015","May 4, 2015",,"July 13, 2016",,,"https://ClinicalTrials.gov/show/NCT02432222"
1683,"NCT01652222","Experimental Study to Validate the ""Therapeutic Game"" CONEM-BETA",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Other: CONEM-BETA + socio-educational training|Other: Socio-educational training only","change from baseline compared to the control and active arms using the EBP questionnaire (subjective welfare of family caregivers of patients with possible or probable Alzheimer or other advanced stage dementia)|change from baseline compared to the control and active arms using the Cornell scale and NPI-Q to assess behaviour of the patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the Martin and cols. scale to assess the overload level of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the Goldberg's scale to assess anxiety and depression of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the DUKE-UNC scale to assess the perceived social support of the family caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia|change from baseline compared to the control and active arms using the PANAS scale to assess the changes in positive and negative affect of the caregivers of patients with probable or possible Alzheimer's disease or other advanced stage dementia","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Fundacion SARquavitae","All","18 Years and older   (Adult, Older Adult)","Not Applicable","101","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CONEM-BETA-FPM/SAR-0111","January 2012","July 2012","August 2012","July 27, 2012",,"July 9, 2014","Hospital de Santa Maria, Lleida, Catalonia, Spain|Hospital de Salt, Salt, Catalonia, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT01652222"
1684,"NCT02356055","Mass Practice of Activities of Daily Living in Dementia (STOMP)","STOMP","Completed","No Results Available","Dementia|Alzheimer's Disease","Behavioral: STOMP (Skill-building through Task-Oriented Motor Practice)","5 point Observation of Activities of Daily Living|Frequency of Behavioral Responses during the Trial|10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Change in 10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Retention of 10 point Caregiver Perception of Activity of Daily Living Performance and Satisfaction with Performance|Change in Observation of Activity of Daily Living|Retention of Observed Activity of Daily Living at 90 Days","University of Oklahoma|VA Office of Research and Development|OU Medical Center|Oklahoma Shared Clinical and Translational Resources|Alzheimer's Association","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","32","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","4648","October 2014","November 2016","November 2016","February 5, 2015",,"November 21, 2016",,,"https://ClinicalTrials.gov/show/NCT02356055"
1685,"NCT02353884","Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease",,"the accuracy of a predictable classifier from MCI to AD based on Multi-Modality MRI characteristics of MCI patients.|characteristic changes of brain structure in progressive MCI|characteristic changes of anatomical connectivity in progressing MCI|characteristic changes of functional connectivity in progressing MCI","XuanwuH 2|Xuanwu Hospital, Beijing","All","55 Years to 75 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","hanying3","January 2010","December 2011","December 2012","February 3, 2015",,"February 3, 2015","Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02353884"
1686,"NCT02353845","Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease",,"number of participants correctly classified by the support vector machine (SVM) classifier for the aMCI diagnosis|number of participants correctly predicted by the SVM classifier for predicting conversion from aMCI to AD|regional cerebral metabolism (CMgl) measured by FDG-PET|changed regional cerebral blood flow measured by FDG-PET","XuanwuH 2|Xuanwu Hospital, Beijing","All","Child, Adult, Older Adult",,"297","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","hanying2","November 2013","October 2015","August 2016","February 3, 2015",,"August 23, 2016","Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02353845"
1687,"NCT02350127","Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia","PLIE-VA","Completed","No Results Available","Dementia|Alzheimer's Disease","Behavioral: Preventing Loss of Independence through Exercise (PLIE)|Behavioral: Usual Care Control","Short Physical Performance Battery (SPPB)-modified|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Quality of Life Scale in Alzheimer's Disease (QOL-AD)|Disability Assessment for Dementia (DAD)|Geriatric Depression Scale (GDS)|Falls Efficacy Scale (FES)|Caregiver Burden Inventory (CBI)|Neuropsychiatric Inventory (NPI)|Positive Aspects of Caregiving (PAC)","VA Office of Research and Development|LifeLong Marin Adult Day Health Center|Institute on Aging, San Francisco, CA|Catholic Charities, Santa Rosa, CA|Alzheimer's Services of the East Bay|Bayview Hunters Point Adult Day Health Center|Primrose Alzheimer’s Living, Inc","All","Child, Adult, Older Adult","Phase 2|Phase 3","88","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","D1507-I|5I01RX001507-02","May 4, 2015","December 13, 2018","December 31, 2018","January 29, 2015",,"January 31, 2019","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02350127"
1688,"NCT02346201","Apathy in Dementia Methylphenidate Trial 2","ADMET2","Recruiting","No Results Available","Apathy|Alzheimer's Disease","Drug: Methylphenidate|Drug: Placebo","Neuropsychiatric Inventory (NPI)|Clinical Global Impression of Change (CGIC)","Johns Hopkins Bloomberg School of Public Health|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 3","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADMET2|R01AG046543","January 2016","December 2019","June 2020","January 26, 2015",,"April 1, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Emory, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States|Wake Forest, Winston-Salem, North Carolina, United States|University Hospitals- Case Medical Center, Cleveland, Ohio, United States|Roper-St. Francis Healthcare, Charleston, South Carolina, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02346201"
1689,"NCT01454453","Optimisation of Antipsychotic Drug Use in Older People",,"Terminated","No Results Available","Alzheimer's Disease|Schizophrenia","Drug: Patients- dose titration","dose titration","Institute of Psychiatry, London","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 4","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2167SR","May 2012","July 2015","July 2015","October 19, 2011",,"April 19, 2017","Institute of Psychiatry, Kings College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01454453"
1690,"NCT02474251","Brain Sleep Clearance of Amyloid-Beta Peptides","Brain SCRAPs","Active, not recruiting","No Results Available","Obstructive Sleep Apnea|Alzheimer's Disease","Other: Continuous positive airway pressure device","CSF Aβ42/Aβ40 levels","NYU Langone Health|National Institute on Aging (NIA)","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","38","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-01837|5R21AG049348-02","October 1, 2015","May 31, 2017","July 31, 2019","June 17, 2015",,"June 7, 2019","Bellevue Hospital Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02474251"
1691,"NCT01503944","A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)",,"Completed","No Results Available","Dementia With Lewy Bodies|Alzheimer's Disease|Parkinson's Disease","Drug: 18F-AV-133|Drug: 18F-AV-45","18F-AV-133 striatal to occipital standard uptake value ratio|18F-AV-45 cortical to cerebellar standard uptake value ratio","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-133-B03","March 2010","July 2011","July 2011","January 4, 2012",,"August 14, 2012","Research Site, Sun City, Arizona, United States|Research Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01503944"
1692,"NCT00831506","Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease|Huntington Disease","Drug: digoxin|Drug: dimebon","AUC24 and Cmin of digoxin on Day 14|Cmax, Tmax, Ae, and renal clearance of digoxin on Day 14|Adverse event monitoring through Day 14 including physical/neurological examination findings|Clinical safety assessments through Day 14 including chemistry, hematology, and vital signs|12-lead ECGs through Day 14","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B1451021","February 2009","May 2009","May 2009","January 29, 2009",,"June 12, 2009","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00831506"
1693,"NCT00990613","A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin",,"Completed","No Results Available","Alzheimer's Disease|Huntington's Disease","Drug: Dimebon IR|Drug: Dimebon Transdermal","Pharmacokinetic endpoints include dimebon area under the curve from 0 to the last quantifiable concentration (AUClast) and dimebon area under the curve from 0 to infinity (AUCinf) as permitted by data|Safety endpoints include subjective symptoms/objective findings (including skin irritation), clinical safety laboratory assessments, 12 lead ECGs, and supine vital signs.","Pfizer|Medivation, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","B1451038","October 2009","January 2010","January 2010","October 7, 2009",,"February 3, 2010","Pfizer Investigational Site, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00990613"
1694,"NCT00975481","A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users",,"Completed","Has Results","Alzheimer's Disease|Huntington's Disease","Drug: dimebon|Drug: placebo|Drug: alprazolam","Balance of Effects- Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Overall Drug Liking VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Take Drug Again VAS: Peak Effect (Maximum Effect [Emax])|Balance of Effects- Good and Bad Effects VAS: Peak Effect (Maximum Effect [Emax]) and Minimum Effect (Emin)|Balance of Effects- Subjective Drug Value (SDV): Maximum Effect (Emax)|Positive Effects- Addiction Research Center Inventory (ARCI) Morphine Benzedrine Group (MBG): Maximum Effect (Emax)|Positive Effects- Good Drug Effects: Peak Effect (Maximum Effect [Emax])|Positive Effects- High VAS: Peak Effect (Maximum Effect [Emax])|Negative Effects- Bad Drug Effects: Peak Effect (Maximum Effect [Emax])|Negative Effects- Addiction Research Center Inventory (ARCI) Lysergic Acid Diethylamide (LSD): Maximum Effect (Emax)|Sedative Effects- Addiction Research Center Inventory (ARCI) Pentobarbital Chlorpromazine Group (PCAG): Maximum Effect (Emax)|Sedative Effects- Alertness/Drowsiness: Minimum Effect (Emin)|Other Subjective Effects- Any Drug Effects: Peak Effect (Maximum Effect [Emax])|Other Subjective Effects- Drug Similarity|Other Subjective Effects- Addiction Research Center Inventory (ARCI) Benzedrine Group (BG): Maximum Effect (Emax) and Minimum Effect (Emin)","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","B1451037","October 2009","February 2010","February 2010","September 11, 2009","April 2, 2013","April 2, 2013",,,"https://ClinicalTrials.gov/show/NCT00975481"
1695,"NCT00931073","A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers",,"Completed","No Results Available","Alzheimer's Disease|Huntington's Disease","Drug: Dimebon alone|Drug: Dimebon + Ketoconazole|Drug: Dimebon + Omeprazole","Dimebon alone: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon + keto: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon + omeprazole: Dimebon PK in CYP2D6 EMs and PMs (Cmax, Tmax, AUCinf (as data permit), AUClast, and t1/2 (as data permit), CL/F (as data permit) and V/F (as data permit))|Dimebon alone: Safety and tolerability (AE's, ECG, vital signs, safety labs)|Dimebon + keto: Safety and tolerability (AE's, ECG, vital signs, safety labs)|Dimebon + omeprazole: Safety and tolerability (AE's, ECG, vital signs, safety labs)","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","B1451017","July 2009","October 2009","October 2009","July 2, 2009",,"November 18, 2009","Pfizer Investigational Site, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00931073"
1696,"NCT03912571","Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment",,"Recruiting","No Results Available","Sleep Disorder","Diagnostic Test: Structural 3T MRI|Diagnostic Test: MRI Based Perfusion Imaging|Diagnostic Test: VR-CO2 MRI Scans","Decreased cerebral blood flow (CBF)|Measure of vasoreactivity to CO2 (VRCO2)|Increase in cortical AB plaque burden","NYU Langone Health","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","95","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-00041","November 13, 2011","September 2019","September 2019","April 11, 2019",,"June 17, 2019","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03912571"
1697,"NCT04049643","Hearing Aid and Individuals With Cognitive Disorders",,"Not yet recruiting","No Results Available","Presbycusis, Bilateral|Alzheimer Disease 2 Due to Apoe4 Isoform","Device: Audiologist-based fitting|Device: Service-only Fitting|Device: Device-only fitting","Hearing aid benefit as measured by the International Outcomes Inventory for Hearing Aids - Significant Other (IOI-HA-SO)|Daily activity as measured by the Lawton Instrumental Activities of Daily Living Scale (IADL)|Neuropsychiatric symptom as measured by the Neuropsychiatric Inventory-Questionnaire (NPI-Q)|Caregiver burden as measured by the Zarit Burden Interview (ZBI)|Hearing handicap as measured by Hearing Handicap Inventory for the Elderly - Spouse (HHIE-SP)|Quality of life as measured by the Alzheimer's Disease-Related Quality of Life (ADRQL)|Depression as measured using the Geriatric Depression Scale (GDS)","Yu-Hsiang Wu|Vanderbilt University Medical Center|National Institute on Deafness and Other Communication Disorders (NIDCD)|University of Iowa","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201907763|3R01DC015997-02S1","December 1, 2019","August 31, 2020","December 31, 2020","August 8, 2019",,"September 26, 2019","University of Iowa, Iowa City, Iowa, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04049643"
1698,"NCT01072812","Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment",,"Terminated","No Results Available","Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: Posiphen® tartrate capsules","Pharmacokinetics|Pharmacodynamics|Biomarkers|Safety","QR Pharma Inc.","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QR 12001","February 2010","July 2010","July 2010","February 22, 2010",,"April 22, 2015","CEDRA Clinical Research, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01072812"
1699,"NCT00827034","A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease|Huntington's Disease","Drug: Warfarin|Drug: Dimebon","Single dose pharmacokinetics (Cmax, AUCinf) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.|Single dose pharmacodynamics (INRmax, AUC-INR) of warfarin 25 mg with and without co-administration of steady-state Dimebon 20 mg TID in healthy adult subjects.|Safety and tolerability ( adverse event monitoring, physical examinations, vital signs, ECG's and clinical laboratory tests) of multiple doses of Dimebon 20 mg TID with a single dose of warfarin 25 mg in healthy adult subjects.","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1451020","February 2009","April 2009","April 2009","January 22, 2009",,"October 16, 2018","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00827034"
1700,"NCT00825084","A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease|Huntington's Disease","Drug: Dimebon","plasma drug concentrations|Safety will be including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements and adverse event monitoring","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B1451014","February 2009","May 2009","May 2009","January 19, 2009",,"April 26, 2011","Pfizer Investigational Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00825084"
1701,"NCT00824590","A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",,"Completed","No Results Available","Alzheimer's Disease|Huntington's Disease","Drug: Dimebon","Plasma drug concentrations|Safety assessment including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements, and adverse event monitoring.","Pfizer|Medivation, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1451019","February 2009","October 2009","October 2009","January 19, 2009",,"December 30, 2009","Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, St. Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00824590"
1702,"NCT00646074","Self- Care TALK Study - Promoting Alzheimer's Disease (AD) Spousal Caregiver Health",,"Completed","No Results Available","Caregiving","Behavioral: Self-Care Talk","SF-36v2, PCS (perceived physical health), SF-36v2, MCS (perceived mental health)|M-CSI; modified (caregiver strain), SRAHP (self-efficacy for health), CES-D (depression)","University of Kansas|National Institutes of Health (NIH)|National Institute of Nursing Research (NINR)|University of Kansas Medical Center","All","60 Years and older   (Adult, Older Adult)","Not Applicable","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1R21NR009560","July 2006","March 2008","August 2008","March 28, 2008",,"March 7, 2012",,,"https://ClinicalTrials.gov/show/NCT00646074"
1703,"NCT01727622","Arterial Spin Labeling (ASL) MRI for Cognitive Decline",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Drug: FDG-PET|Other: ASL-MRI|Procedure: Lumbar Puncture","Composite region of interest (ROI) measure of cerebral blood flow (CBF) measured by ASL MRI versus composite ROI measure of cerebral metabolism measured by FDG PET|Prediction of longitudinal change in hippocampal volume|Prediction of longitudinal change in clinical status (i.e. progression to Alzheimer's Disease)","University of Pennsylvania|National Institute on Aging (NIA)","All","55 Years to 89 Years   (Adult, Older Adult)",,"102","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","815471|5R01AG040271","August 2012","May 11, 2018","May 31, 2018","November 16, 2012",,"April 24, 2019","Penn Memory Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01727622"
1704,"NCT01724151","Effects of Exercise Training in Patients With Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease",,"Walking speed of participants","National Taiwan University Hospital","All","45 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","200812152R","April 2009","October 2009","April 2012","November 9, 2012",,"April 22, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01724151"
1705,"NCT00908492","Supporting Caregivers of Persons With Dementia: A Pilot Study",,"Completed","No Results Available","Alzheimer Disease|Dementia","Behavioral: Education Control|Behavioral: Environmental Skill Building","Revised Memory and Behavior Problem Checklist|Disability Assessment for Dementia|Number of caregiving assistance hours|Short Zarit Burden Interview|Task Management Strategy Index|Perceived Change Scale","McMaster University|Alzheimer Society of Canada","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASC1050","November 2009","August 2011","September 2011","May 27, 2009",,"April 7, 2015","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00908492"
1706,"NCT01715181","Volunteers Adding Life in Dementia: VALID","VALID","Completed","No Results Available","Dementia|Alzheimer's Disease","Other: Volunteer visits","Change in neuropsychiatric symptoms (measured by the Cohen-Mansfield Agitation Inventory)|Change in Neuropsychiatric Inventory score|Change in Cornell Depression in Dementia Rating Scale score|Change in Dementia Quality of Life Scale (DEMQoL) score|Change in Clinical Global Impression of Change (CGI-C)score","Queen's University|Alzheimer's Association","All","65 Years and older   (Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","VALIDII|NIRG-12-236827","January 2013","June 2015","March 2016","October 26, 2012",,"April 14, 2017","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01715181"
1707,"NCT01055561","A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia",,"Completed","No Results Available","Alzheimer's Disease|Dementia","Other: Acupuncture","The Questionnaire of Acupuncture Events|Change from baseline on Mini-Mental State-Examination（MMSE）,The Behavioral Pathology in Alzheimer's Disease Rating Scale（BEHAVE-AD）and Activity of Daily Living Scale（ADL）|Treatment Emergent Symptom Scale (TESS)","Chengdu University of Traditional Chinese Medicine","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008SZ0135","January 2010","February 2011","March 2011","January 25, 2010",,"May 30, 2016","Yong Tang, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT01055561"
1708,"NCT02576821","Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease","ShaTau7","Recruiting","No Results Available","Patients With Cognitive Disturbances","Other: Neurological examinations|Other: Neuropsychological examinations|Other: Clinical examinations|Radiation: MRI 3T|Radiation: MRI 7T","7 tesla MRI.|3T MRI|7T MRI|CSF|Neuropsychological assessment|Clinical assessment|Genetic markers of bvFTD|Blood markers|Plasmatic progranulin levels|Regional glucose hypometabolism","Centre Hospitalier St Anne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D14-P010","January 27, 2016","January 2020","October 2020","October 15, 2015",,"October 20, 2017","Neurologie de la mémoire et du langage, Service de Neurologie, Centre Hospitalier Sainte-Anne, Paris, France",,"https://ClinicalTrials.gov/show/NCT02576821"
1709,"NCT01553929","Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient","EPAC-M","Terminated","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Other: Physical Training and cognitive activity (EPC group)|Other: Physical training (EP group)|Other: control group","effectiveness of physical training|Cognitive improvement","Centre Hospitalier Universitaire de Nice","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-AOI-03","March 2012","March 2012","January 2015","March 14, 2012",,"August 14, 2015","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT01553929"
1710,"NCT00902499","Evolution of Memory Related Activity",,"Unknown status","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment",,,"National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)",,"160","NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","IA0159|5R01AG027435-04","May 2006","May 2011","May 2011","May 15, 2009",,"July 26, 2010","Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00902499"
1711,"NCT00515333","TRx0014 in Patients With Mild or Moderate Alzheimer's Disease",,"Completed","No Results Available","Dementia, Alzheimer Type","Drug: TRx0014|Drug: Placebo","Cognitive ability (ADAS-cog)|Behavioural and psychological symptoms (NPI)|Global performance (ADCS-CGIC)|Dementia severity (CDR-sb)|Cognition (MMSE)|Dementia caseness (Short CAMDEX)|Cognitive function (ADAS-cog)|Daily activities of living (BADLS)|Changes in cerebral perfusion pattern (SPECT or PET)","TauRx Therapeutics Ltd","All","Child, Adult, Older Adult","Phase 2","323","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-014-001","August 2004","December 2007","December 2007","August 13, 2007",,"February 20, 2008",,,"https://ClinicalTrials.gov/show/NCT00515333"
1712,"NCT00161473","Alzheimer's in Long-Term Care--Treatment for Agitation",,"Completed","Has Results","Alzheimer Disease|Psychomotor Agitation","Drug: prazosin|Drug: placebo (inert substance)","Mean Clinical Global Impression of Change (CGIC) at Last Observation|Change in Neuropsychiatric Inventory (NPI) Total Score Over the Course of Study Participation|Number of Behavioral Assessment Visits Completed|Change in Brief Psychiatric Rating Scale (BPRS) Total Score Over the Course of Study Participation","University of Washington|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16508-A|5R01AG018644|5P50AG005136","January 2001","September 2009","September 2009","September 12, 2005","August 2, 2012","August 2, 2012","Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00161473"
1713,"NCT00585572","Wisconsin Brain Donor Program","WBDP","Enrolling by invitation","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment",,,"University of Wisconsin, Madison|University of Washington","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Other","H-2010-0037|H-2014-1484|A534255, GERIATRICS AND ADULT","March 2007","October 2019","October 2019","January 3, 2008",,"September 23, 2019","University of Wisconsin Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00585572"
1714,"NCT00788047","A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan",,"Completed","No Results Available","Huntington Disease|Alzheimer Disease","Drug: Dextromethorphan|Drug: Dimebon + Dextromethorphan","Dextromethorphan exposure in combination with Dimebon 20 mg TID relative to Dextromethorphan exposure alone|Safety and Tolerability (Adverse Events, Vital Signs, Clinical Labs, Electrocardiograms)|Dextrorphan (the metabolite of dextromethorphan) exposure","Pfizer|Medivation, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B1451022","November 2008","January 2009","January 2009","November 10, 2008",,"March 9, 2009","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00788047"
1715,"NCT00979446","Passport to Brain Wellness in Sedentary Adults",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Behavioral: Guided|Behavioral: Self-directed","We will use this pilot to determine the feasibility of carrying out a full-scale randomized trial to test the efficacy of our intervention.","HealthPartners Institute","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","03-024S2|3R01AG023410-05S2","June 2008","May 2009","August 2009","September 18, 2009",,"September 18, 2009","HealthPartners Research Foundation, Bloomington, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00979446"
1716,"NCT03859245","Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention",,"Recruiting","No Results Available","Diabetic Retinopathy (DR)|Age-related Macular Degeneration (AMD)|Mid-peripheral Drusen Formation|Diabetic Macular Edema (DME)","Behavioral: Photobiomodulation|Behavioral: Ketogenic diet","Diabetic Retinopathy (DR) pathology|Diabetic Macular Edema (DME) pathology|Dry Age-related Macular Degeneration (AMD) pathology|Hard Drusen in the Mid-periphery pathology|HgA1c|Fasting Insulin|Fasting Glucose|HOMA-IR|Triglycerides/HDL ratio","Bristlecone Health, Inc.|University of Minnesota - Clinical and Translational Science Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bristlecone-002","February 23, 2019","September 30, 2020","September 30, 2020","March 1, 2019",,"March 4, 2019","Yankee Eye Clinic, Eagan, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03859245"
1717,"NCT00291161","Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters","PDC","Completed","Has Results","Dementia|Alzheimer Disease","Behavioral: Partners in Dementia Care","Caregiver Outcomes|Veteran Outcomes","VA Office of Research and Development|Benjamin Rose Institute|Alzheimer's Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","994","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIR 04-238","December 2006","September 2010","February 2011","February 13, 2006","May 19, 2016","May 19, 2016","VA Boston Health Care System, Jamaica Plain, Boston, Massachusetts, United States|VA Boston Healthcare System, Brockton Campus, Brockton, Massachusetts, United States|Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Medical Center, Providence, Providence, Rhode Island, United States|Beaumont VA Outpatient Clinic, Beaumont, Texas, United States|Michael E DeBakey VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00291161"
1718,"NCT03370744","Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD",,"Recruiting","No Results Available","Subjective Cognitive Decline|Preclinical Alzheimer's Disease","Diagnostic Test: Neuropsychological scale","The altered volume pattern in SCD/SCD-plus with progression.|The altered DTI pattern in SCD/SCD-plus with progression.|The altered functional MRI pattern in SCD/SCD-plus with progression.|The altered FDG-PET pattern in SCD/SCD-plus with progression.|The altered AV45-PET pattern in SCD/SCD-plus with progression.|Genotype of SCD/SCD-plus with progression.|AD7c-NTP level of SCD/SCD-plus with progression.","XuanwuH 2|Xuanwu Hospital, Beijing","All","60 Years to 80 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","hanying4","March 15, 2017","December 2019","December 2021","December 12, 2017",,"February 27, 2019","Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03370744"
1719,"NCT00539305","Hormone and Information Processing Study","HIP","Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease","Drug: testosterone gel|Drug: placebo gel","Behavioral & Mood Measure: Profile of Mood States (POMS)|Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test|Geriatric Depression Scale (GDS)|Short-Form Health Survey (SF-36)","University of Washington|National Institute on Aging (NIA)|Solvay Pharmaceuticals","Male","60 Years to 90 Years   (Adult, Older Adult)","Phase 3","22","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","29975-A|R01AG027156|1R01AG027156-01A2","July 2009","July 2011","May 2012","October 4, 2007","July 14, 2014","July 14, 2014","VA Puget Sound Health Care Systems, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00539305"
1720,"NCT00056329","Vitamin E in Aging Persons With Down Syndrome",,"Unknown status","No Results Available","Down Syndrome|Alzheimer Disease","Drug: Vitamin E|Drug: multivitamin|Drug: Placebo","Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements|Fuld Object Memory Test (Modified), New Dot Test, Orientation Test, Vocabulary Test, Behavior & Function Down Syndrome Rating Scale, Clinical Global Impression of Change (CGI-C)","New York State Institute for Basic Research|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH)","All","50 Years and older   (Adult, Older Adult)","Phase 3","350","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0039|R01AG016381|NIA Grant AG16381","April 2002","May 2012","May 2012","March 12, 2003",,"May 4, 2012","University of Connecticut Health Center, Farmington, Connecticut, United States|Roskamp Institute Memory Clinic, Tampa, Florida, United States|Institute for the Study of Disadvantage and Disability, Atlanta, Georgia, United States|May South, Inc., Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Third Age, Inc., Lexington, Kentucky, United States|McLean Hospital, Belmont, Massachusetts, United States|Clinical Research Center of New Jersey, Voorhees, New Jersey, United States|University at Albany, SUNY, Albany, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|George Jervis Clinic, Staten Island, New York, United States|Westchester Institute for Human Development, Valhalla, New York, United States|University Memory and Aging Center, Case Western Reserve University, Cleveland, Ohio, United States|Centre for Developmental Disabilities Studies, Ryde, New South Wales, Australia|Down Syndrome Research Foundation, Port Coquitlam, British Columbia, Canada|Surrey Place Centre, Toronto, Ontario, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada|University of Cambridge, Cambridge, England, United Kingdom|Greenfields Monyhull Hospital, Kings Norton, Birmingham, England, United Kingdom|Kings College: London, London, England, United Kingdom|Mercer Institute for Research on Ageing, St. James Hospital, Dublin, Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00056329"
1721,"NCT00438568","SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)","SNIFF 120","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Drug: Regular Insulin|Drug: Placebo","Changes in cognition|glucose metabolism|plasma biological markers|CSF biological markers|cerebral glucose metabolism","University of Washington|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 2","173","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","30579-B|5R01AG027415|1R01AG027415-01","June 2006","December 2011","December 2011","February 22, 2007",,"September 14, 2012","Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00438568"
1722,"NCT04124029","Contributions of mTBI to Neurodegeneration Due to CTE and Alzheimer's Disease",,"Not yet recruiting","No Results Available","Mild Traumatic Brain Injury|Moderate Traumatic Brain Injury|Mild Cognitive Impairment","Device: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|Procedure: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.","To better understand the contribution of mild Traumatic Brain Injury (mTBI) to neurodegeneration with the intent of detecting early behavioral, physiologic, anatomic, and protein evidence of neurodegeneration due to AD and CTE|Recognition Memory|EEG peak amplitude and latency|Cortical, quantitative MRI volume measurements|CSF Proteinopathy","VA Boston Healthcare System","All","30 Years to 90 Years   (Adult, Older Adult)",,"800","U.S. Fed","Observational","Observational Model: Case-Control|Time Perspective: Prospective","I01-CX-19-008-CDA","March 31, 2020","March 31, 2025","March 31, 2025","October 11, 2019",,"October 11, 2019","VA Boston Healthcare System, Jamaica Plain, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04124029"
1723,"NCT02521818","Dietary Treatments for Cognitive Impairment in Older Adults",,"Completed","No Results Available","Mild Cognitive Impairment|Probable Alzheimer's Disease","Other: Modified Atkins Diet|Other: NIA Diet for Seniors","Feasibility for MAD Group|Feasibility for Control Group|Efficacy for Cognition|Efficacy for Function","Johns Hopkins University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00066092","August 2015","July 1, 2019","July 1, 2019","August 13, 2015",,"September 5, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02521818"
1724,"NCT03444181","ALzheimer and MUsic THerapy: Effects of Music Lessons on Brain Plasticity, Mood, and Quality of Life in Alzheimer Patients","ALMUTH","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|MCI With Increased Risk for Alzheimer Disease","Behavioral: Music lessons|Behavioral: Training intervention","Brain age|Depression symptoms|Living independently at home|Language abilities|Sensori-motor functions|Activities of daily living|Disease progression|Cognitive functioning|Integrity of fibre tracts|Resting-state functional connectivity|Working alliance","University of Bergen|NORCE Norwegian Research Centre AS|Bergen Municipality","All","18 Years and older   (Adult, Older Adult)","Not Applicable","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCN 260576","April 11, 2018","June 30, 2020","June 30, 2020","February 23, 2018",,"November 12, 2018","Bergen Municipality, Bergen, Hordaland, Norway",,"https://ClinicalTrials.gov/show/NCT03444181"
1725,"NCT00105638","Telehealth Education Program for Caregivers of Veterans With Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease","Behavioral: educational program, by telephone","Reduction in veteran agitation and symptoms of depression; increase in caregiver management skills|Veterans will experience fewer hospitalizations and nursing home admissions","US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","160","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","IIR 03-076","September 2005",,"April 2007","March 17, 2005",,"April 7, 2015","Albany VA Medical Center Samuel S. Stratton, Albany, NY, Albany, New York, United States|VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT00105638"
1726,"NCT00013182","Effect of Activity on Sleep of Cognitively-Impaired Veterans",,"Completed","No Results Available","Alzheimer's Disease|Sleep Disorders","Behavioral: social activity",,"US Department of Veterans Affairs|Central Arkansas Veterans Healthcare System|University of Arkansas|VA Office of Research and Development","Male","55 Years and older   (Adult, Older Adult)","Not Applicable","90","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRM 95-184",,,"June 2001","March 16, 2001",,"April 7, 2015","Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, No. Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT00013182"
1727,"NCT00095719","Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia",,"Completed","No Results Available","Dementia|Alzheimer's Disease","Drug: Aripiprazole|Drug: Placebo","tolerability|safety assessments","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-131","December 2003","March 2005","March 2005","November 9, 2004",,"November 11, 2013","Local Institution, Santa Ana, California, United States|Local Institution, Hamden, Connecticut, United States|Local Institution, Hialeah, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, North Miami, Florida, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, New York, New York, United States|Local Institution, Staten Island, New York, United States|Local Institution, Dayton, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Hershey, Pennsylvania, United States|Local Institution, Austin, Texas, United States|Local Institution, Midvale, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00095719"
1728,"NCT03943641","Dementia Risk Prediction Model: Development and Validation",,"Not yet recruiting","No Results Available","Dementia Alzheimers","Other: This is not an intervention study","Dementia|Alzheimer's disease","University of Edinburgh|Keele University","All","60 Years to 79 Years   (Adult, Older Adult)",,"400000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AC19049","May 8, 2019","May 8, 2019","May 1, 2020","May 9, 2019",,"May 10, 2019",,,"https://ClinicalTrials.gov/show/NCT03943641"
1729,"NCT00042172","Treatment for Early Memory Loss",,"Completed","No Results Available","Cognition Disorders|Alzheimer Disease","Drug: Donepezil|Drug: Ginkgo Biloba Extract",,"University of Iowa|National Institute of Mental Health (NIMH)","All","65 Years and older   (Older Adult)","Phase 4","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R21MH061801|DSIR AT-GP","June 2002","September 2004","September 2004","July 26, 2002",,"March 3, 2014","University of Iowa Department of Psychiatry, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT00042172"
1730,"NCT03584568","Reappraising Intergeneration Relationships in Dementia Caregiving",,"Recruiting","No Results Available","Alzheimer Dementia","Behavioral: Perspective Taking Reappraisal|Other: Basic Skill Building","Change in Center for Epidemiological Studies-Depression Search Results Center for Epidemiological Studies Depression|Change in Ryff's Psychological Well-being|Change in Revised Memory and Problem Checklist|Change in MacArther Social Support Scales","The Hong Kong Polytechnic University","All","20 Years to 60 Years   (Adult)","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GRFPTR2018","November 11, 2018","July 8, 2021","July 8, 2021","July 12, 2018",,"December 14, 2018","Applied Social Sciences, Hong Kong Polytechnic University, Hong Kong, Hong Kong|Institute of Active Ageing, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03584568"
1731,"NCT03593941","Ageing Gut Brain Interactions",,"Recruiting","No Results Available","Dementia Alzheimers","Other: Standard Diet","Faecal sample Short chain fatty acid (SCFA) profile|Faecal sample Microbiota DNA profile|Macronutrient composition of care home menu|Frequency of challenging behaviours","University of Aberdeen|NHS Grampian|Tenovus Scotland","All","65 Years and older   (Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2/103/17","August 1, 2018","October 1, 2018","October 1, 2018","July 20, 2018",,"August 1, 2018","University of Aberdeen, Aberdeen, Grampian, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03593941/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03593941"
1732,"NCT01713816","Human Brain Antioxidants During Oxidative Stress",,"Completed","No Results Available","Oxidative Stress|Alzheimer's Disease|Aging",,"Antioxidant in Alzheimers","University of Minnesota - Clinical and Translational Science Institute|National Institute on Aging (NIA)","All","65 Years to 89 Years   (Older Adult)",,"52","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","1208M18321|R01AG039396","June 2013","June 1, 2017","July 24, 2018","October 25, 2012",,"May 3, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01713816"
1733,"NCT03224988","Bilateral Brain Dynamics in Cognition and Aging",,"Recruiting","No Results Available","Alzheimer Disease|Aging|MCI","Device: TMS","Establish the structural basis for bilateral brain interactions in healthy older adults.|Establish the structural basis for bilateral brain interactions in MCI-AD older adults.|Establish the temporal dynamics of cross-hemispheric communication in normal aging using unilateral TMS|Establish the temporal dynamics of cross-hemispheric communication in normal aging using bilateral TMS|Establish the temporal dynamics of cross-hemispheric communication in normal aging using EEG|Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using unilateral TMS|Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using bilateral TMS|Establish the temporal dynamics of cross-hemispheric communication in MCI-AD using EEG","Duke University|National Institute on Aging (NIA)|National Institutes of Health (NIH)","All","60 Years to 75 Years   (Adult, Older Adult)",,"60","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00085432","March 20, 2018","August 2019","August 2020","July 21, 2017",,"January 1, 2019","Duke University Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03224988"
1734,"NCT03581643","Validation of the Montreal Cognitive Assessment in Patients With Mild and Major Neurocognitive Disorder","MoCA-Valid","Completed","No Results Available","Alzheimer Disease|Mild Cognitive Impairment",,"Montreal Cognitive Assessment (MoCA) total score|Mini-Mental State Examination (MMSE) total score|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)","Andreas Monsch|University Hospital, Basel, Switzerland","All","65 Years and older   (Older Adult)",,"430","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MoCA-Valid","March 6, 2017","May 8, 2018","May 8, 2018","July 10, 2018",,"July 10, 2018","Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital Basel, Basel, BS, Switzerland",,"https://ClinicalTrials.gov/show/NCT03581643"
1735,"NCT03687710","The Comparative Effectiveness Dementia & Alzheimer's Registry","CEDAR","Active, not recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Behavioral: Multidomain precision medicine intervention","Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months|Change from Baseline in Cognitive Aging Composite (CAC) every 6 months|Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months|Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months|Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months|Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.|Change from Baseline in Cholesterol Biomarkers at 18 months|Change from Baseline in Inflammatory Biomarkers at 18 months|Change from Baseline in Metabolism Biomarkers at 18 months|Change from Baseline in Homocysteine at 18 months|Change from Baseline in Vitamin D at 18 months","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1408015423","February 16, 2015","June 30, 2026","June 30, 2026","September 27, 2018",,"October 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03687710"
1736,"NCT02463084","Macronutrient Effects on Alzheimer's Disease (MEAL-2)","MEAL-2","Completed","No Results Available","Prediabetic State|Insulin Resistance|Middle Age|Prehypertension|Mild Cognitive Impairment","Other: Low Diet|Other: High Diet","Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42)|Changes in brain structure|Changes in adipose tissue distribution (Change in dual energy x-ray absorptiometry (DEXA) scan and CT measures of central and subcutaneous body fat)|Changes in cognition (Change in delayed memory and executive function composites)|Change in brain function as measured by MRI|Change in brain perfusion","Wake Forest University Health Sciences","All","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","IRB 00022512","March 2013","June 2016","June 2016","June 4, 2015",,"August 9, 2018","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02463084"
1737,"NCT03672201","Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia","StaN","Recruiting","No Results Available","Alzheimer's Disease|Alzheimer Dementia (AD)|Aggression","Behavioral: Non-Pharmacological Intervention|Other: Pharmacological Intervention","Change in Cohen-Mansfield Agitation Inventory - Total Frequency Score (CMAI - Frequency)|The proportion of participants on polypharmacy|The impact of the ICP on falls","Centre for Addiction and Mental Health|University of Calgary|Lawson Health Research Institute|Douglas Mental Health University Institute","All","50 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","1482","November 1, 2018","April 2020","April 2020","September 14, 2018",,"September 18, 2019","University of Calgary, Calgary, Alberta, Canada|LAWSON Health Research Institute, London, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|Douglas Hospital Research Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03672201"
1738,"NCT00216502","A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dementia|Mental Disorders|Brain Diseases","Drug: galantamine hydrobromide","Time to worsening of symptoms, defined as the time from the beginning of the double-blind portion of the study to the time of an increase in ADAS-cog score of > or = to 4 points|Change in ADAS-cog, CIBIC-plus and DAD scores over time; Safety parameters assessed by adverse events; laboratory tests, vital signs, weight and ECGs.","Janssen-Cilag S.p.A.","All","50 Years and older   (Adult, Older Adult)","Phase 3","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR004996","August 2001",,"November 2005","September 22, 2005",,"January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00216502"
1739,"NCT01922258","Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases","Drug: Brexpiprazole, OPC-34712","Change in the Cohen-Mansfield Agitation Inventory (CMAI) total score|Change in the Clinical Global Impression Severity of Illness (CGI-S) score, as related to symptoms of agitation","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-12-284","September 2013","March 2017","March 2017","August 14, 2013",,"May 17, 2018","Imperial, California, United States|Lakewood, California, United States|Long Beach, California, United States|Long Beach, California, United States|Panorama City, California, United States|Universal City, California, United States|Denver, Colorado, United States|Bradenton, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Quincy, Massachusetts, United States|South Dartmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Woodstock, Vermont, United States|Burgas, Bulgaria|Kardzhali, Bulgaria|Pazardzhik, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Penticton, British Columbia, Canada|Kentville, Canada|Kuopio, Finland|Turku, Finland|Bourg en Bresse, France|Douai, France|Elancourt, France|Limoges, France|Nice, France|Toulouse, France|Tonnelniy, Stavropol Region, Russian Federation|Ekaterinburg, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Ljubljana, Slovenia|Maribor, Slovenia|Sempeter pri Gorici, Slovenia|Donetsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Vinnytsia, Ukraine|Crewe, United Kingdom|Manchester, United Kingdom|Margate, United Kingdom|Torpoint, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01922258"
1740,"NCT01862640","Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",,"Completed","No Results Available","Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases","Drug: Brexpiprazole, OPC-34712|Drug: Placebo Oral Tablet","The primary outcome is the change in the Cohen-Mansfield Agitation Inventory (CMAI) total score|The secondary outcome is the change in the Clinical Global Impression-Severity of Illness (CGI-S) score, as related to symptoms of agitation","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-12-283","July 2013","March 2017","March 2017","May 24, 2013",,"March 14, 2019","Tuscaloosa, Alabama, United States|Phoenix, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Downey, California, United States|Orange, California, United States|Redlands, California, United States|Yorba Linda, California, United States|Norwalk, Connecticut, United States|Coconut Creek, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Lauderhill, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Decatur, Georgia, United States|Suwanee, Georgia, United States|Weymouth, Massachusetts, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Manchester, New Jersey, United States|Mount Arlington, New Jersey, United States|Toms River, New Jersey, United States|Hickory, North Carolina, United States|Oklahoma City, Oklahoma, United States|Franklin, Tennessee, United States|Bedford, Texas, United States|Waukesha, Wisconsin, United States|Rijeka, Croatia|Zadar, Croatia|Zagreb, Croatia|Zagreb, Croatia|Mittweida, Saxony, Germany|Achim, Germany|Berlin, Germany|Bielefeld, Germany|Bochum, Germany|Hambrg, Germany|Koln, Germany|Ostfildern, Germany|Westerstede, Germany|Ekaterinburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tonnelniy, Russian Federation|Belgrade, Serbia|Kovin, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Knezevac, Serbia|Novi Sad, Serbia|Vrsac, Serbia|Barcelona, Spain|Getafe, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Zamora, Spain|Kharkiv, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Odessa, Ukraine|Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01862640"
1741,"NCT00029120","Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder",,"Completed","No Results Available","Alzheimer Disease|Dementia|Memory Disorder|Healthy",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)",,"450","NIH","Observational",,"020095|02-M-0095","December 18, 2001",,"April 21, 2008","January 7, 2002",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00029120"
1742,"NCT02978729","Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial","CONNECT4APOE","Enrolling by invitation","No Results Available","Alzheimer Disease|Genetic Predisposition to Disease","Other: Two-way videoconference remote genetic counseling|Other: Telephone remote genetic counseling","Satisfaction with genetic counseling services as measured by the Satisfaction with Genetic Services Scale|Satisfaction with genetic counseling services as measured by the Satisfaction with Remote Counseling Scale|Knowledge of Genetic Disease as measured by the Cancer Genetics Knowledge Scale|Disease-specific distress as measured by the Impact of Events Scale|Perceived risk of Alzheimers Disease as measured by questionnaire items measuring perceived risk in quantitative, qualitative, and relative terms|Responses to Genetic Testing as measured by the Impact of Genetic Testing for Alzheimer's disease (IGT-AD) scale|Depression as measured by the GDS Short Form|Anxiety as measured by the Mini State Trait Anxiety Inventory (mSTAI):|Knowledge of Genetic Disease as measured by the ClinSeq Knowledge Scale","University of Pennsylvania","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","824225","August 2016","August 2021","August 2021","December 1, 2016",,"February 15, 2019",,,"https://ClinicalTrials.gov/show/NCT02978729"
1743,"NCT04009629","Dementia Risk and Dynamic Response to Exercise","DYNAMIC","Enrolling by invitation","No Results Available","Alzheimer Disease 2 Due to Apoe4 Isoform|Healthy Aging","Behavioral: Moderate Intensity Aerobic Exercise","CBF Area Under Curve|Insulin-like Growth Factor-1 Change|Vascular Endothelial Growth Factor Change|Brain Derived Neurotrophic Factor Change","University of Kansas Medical Center|National Institute on Aging (NIA)","All","65 Years to 85 Years   (Older Adult)","Not Applicable","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00142822|R21AG061548","October 1, 2019","August 30, 2020","July 1, 2021","July 4, 2019",,"September 4, 2019","University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04009629"
1744,"NCT02323217","I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers","I2PETHV","Completed","No Results Available","Healthy Volunteers|Alzheimer Disease|Molecular Imaging","Radiation: [11C]BU99008|Drug: Idazoxan|Drug: Isocarboxazid","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)|Intra- and Inter-Subject Variability in brain expression of Imidazoline 2 binding sites, measured using coefficient of variability (%COV), determined from either Total Volume of Distribution (VT) or Binding Potential (BP).|Peripheral distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14HH2250|MR/L01307X/1","January 2015","February 2016","July 2016","December 23, 2014",,"August 18, 2016","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02323217"
1745,"NCT03002142","Auditory Rehabilitation and Cognition in Alzheimer Patients","RACO-MA","Recruiting","No Results Available","Alzheimer's Disease|Hearing Loss","Device: Hearing aids|Device: Placebo","Changing score in Cognitive functions measured with Alzheimer's Disease Assessment Scale-cognitive scale|air and bone auditory thresholds (dB HL) measured at 500, 1000, 2000, 3000 and 4000 Hz|Speech recognition threshold (dB HL) measured by speech audiometry|Speech Discrimination Test (%) measured by speech audiometry|Dichotic test measured with audiometry|Amplification with hearing aids or placebo devices measured by tonal and speech audiometry (dB HL)|Devices tolerance measured with number of hours per day with hearing aids|Objective auditory thresholds measured with auditory brainstem responses (ms)|Objective auditory thresholds measured by Auditory steady state responses (in dB eHL)|Mini Mental State Examination (30 items, total score from 0-30)|Hearing Handicap Inventory for Elderly measured by questionnaire (10 items, total score from 0-40)|Hearing loss impact scale in adults measured by 2 questionnaire (Abbreviated Profile of Hearing Aid Benefit, 24 items) and Impact of hearing loss in adults (20 items, total score from 0-200)|Quality of life-Alzheimer disease scale measured by questionnaire (total score from 13-52)|Assessing caregiver burden measured by Zarit scale (22 items, total score from 0-88)|Depression in the elderly measured by Geriatric depression scale (30 items, total score from 0-30)|Executive functions measured by trail making test|Working memory and processing speed measured by Wechsler Adult Intelligence Scale|Speech comprehension measured by Beauregard tests|Hearing aids tolerance measured by Glagow hearing-aid benefit questionnaire","University Hospital, Tours","All","65 Years and older   (Older Adult)","Not Applicable","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PHRI15-DB/RACO-MA","March 31, 2017","February 2020","February 2020","December 23, 2016",,"August 4, 2017","FRANCE, France, Hopital Bretonneau, France",,"https://ClinicalTrials.gov/show/NCT03002142"
1746,"NCT00243451","Early Detection of Mild Cognitive Impairment in Individual Patients",,"Completed","No Results Available","Mild Cognitive Impairment|Mild Alzheimer's Disease","Other: PET scan & fMRI","Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician.|Determine if sensitivity, specificity, receiver-operator characteristics, and predictive value of our method are appropriate for translation into a clinically useful tool.","Louisiana State University Health Sciences Center Shreveport","All","55 Years to 85 Years   (Adult, Older Adult)",,"34","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","LSUHSC H04-049","September 2003","July 2011","July 2011","October 24, 2005",,"September 7, 2011","Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00243451"
1747,"NCT03507192","Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Dementia","Device: Muscle relaxation using full body massage machine","cortical thickiness in 3D MRI|functional connectivity in functional MRI","Samsung Medical Center","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017-05-135","September 25, 2017","December 31, 2019","December 31, 2019","April 24, 2018",,"March 14, 2019","Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03507192"
1748,"NCT01081743","Effectiveness of Care Management in Alzheimer Patients","AIDALZ","Completed","No Results Available","Alzheimer Disease or Associated Disorder|Mild to Moderately Severe Dementia","Other: Intervention of the social worker","NeuroPsychiatric Inventory (NPI)|Cohen-Mansfield Agitation Inventory (CMAI)|Apathy Inventory|Disablement Assessment for Dementia (DAD)|Mini Mental State Examination (MMSE)|Global Deterioration Scale (GDS)|Montgomery-Asberg Depression Rating Scale (MADRS)|Questionnaire Quality of Life - Alzheimer's Disease (QoL-AD)|Burden Interview of Zarit|Resource utilization in dementia scale (RUD Lite)|Medical Outcome Study Short Form 36-item health survey (MOS SF-36)|Institutionalization|Tiredness scale","Institut de Sante Publique, d'Epidemiologie et de Developpement","All","Child, Adult, Older Adult","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RCB : 2009-A00326-51","November 24, 2009","October 2, 2013","October 2, 2013","March 5, 2010",,"August 28, 2017","ISPED (Institut de Santé Publique, d'Epidémiologie et de Développement), Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT01081743"
1749,"NCT02018913","Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study",,"Unknown status","No Results Available","Alzheimer's Disease|Vascular Dementia",,"Blood brain barrier permeability as measured by T1-weighted dynamic contrast MRI","Maastricht University Medical Center|Netherlands Alzheimer Foundation","All","55 Years and older   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL46089.068.13","April 2014","April 2018","April 2018","December 23, 2013",,"December 23, 2013",,,"https://ClinicalTrials.gov/show/NCT02018913"
1750,"NCT02778438","A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits","REINVENT","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease",,"Change in Mini Mental State Examination|Change in Clinical Dementia Rating Sum of Boxes|Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale|Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version)","Quintiles, Inc.|Biogen","All","50 Years to 85 Years   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","REI-001","February 2016","August 2016","August 2016","May 19, 2016",,"September 27, 2016","Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc, Gilbert, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02778438"
1751,"NCT02531360","Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies",,"Completed","No Results Available","Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD)","Drug: [18F]MNI-815 (MNI-815)","Brain uptake of [18F]MNI-815","Molecular NeuroImaging|Life Molecular Imaging SA","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-815","May 2015","July 2016","August 2016","August 24, 2015",,"December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02531360"
1752,"NCT01594346","Multicenter Vitamin E Trial in Aging Persons With Down Syndrome",,"Completed","No Results Available","Alzheimer's Disease|Down Syndrome","Drug: Alpha-Tocopherol|Drug: Sugar Pill","The Brief Praxis Test|The Fuld Object Memory Test|New Dot Test|Orientation Test|Vocabulary Test|Behavior and Function|Clinical Global Impression|Incident Dementia","New York State Institute for Basic Research|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH)|New York State Psychiatric Institute|University of California, San Diego|Columbia University|Bronx Veterans Medical Research Foundation, Inc","All","50 Years and older   (Adult, Older Adult)","Phase 3","349","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01AG016381","September 2000","April 2010","April 2010","May 9, 2012",,"May 9, 2012",,,"https://ClinicalTrials.gov/show/NCT01594346"
1753,"NCT02147652","Personalized Music Therapy and Agitation in Dementia",,"Enrolling by invitation","No Results Available","Alzheimer's Disease|Vascular Dementia","Other: Personalized music","Changes in agitation","University Health Network, Toronto","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-7490-DE","October 14, 2014","June 2020","June 2020","May 28, 2014",,"September 25, 2019",,,"https://ClinicalTrials.gov/show/NCT02147652"
1754,"NCT03711825","Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults",,"Completed","No Results Available","Alzheimer Disease|Gastric Retention|Healthy","Drug: LYN-057|Procedure: Imaging Assessment (MRI)|Procedure: Imaging Assessment (U/S)","Gastric retention by imaging assessment by MRI|Gastric retention by imaging assessment by abdominal U/S|Safety and tolerability of a single dose of LYN-057 extended release capsule|Memantine HCl pharmacokinetics - Maximum Plasma Concentration (Cmax)|Memantine HCl pharmacokinetics - Time after administration of maximum plasma concentration (Tmax)|Memantine HCl pharmacokinetics - Area Under the Curve (AUC)|Physical features of recovered formulation components","Lyndra Inc.","All","18 Years to 40 Years   (Adult)","Early Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYN-057-C-002|ACTRN12618001426279|CM8718","September 10, 2018","October 1, 2018","November 13, 2018","October 19, 2018",,"February 26, 2019","CMAX, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03711825"
1755,"NCT03324711","Psychometric Validation of the ""Antillanisée"" Version of the Mini Mental State Examination (MMSEa)","MMENSEA","Recruiting","No Results Available","Elderly Patients|Cognitive Disorder|Alzheimer Disease","Diagnostic Test: ""Antillanisée"" Mini Mental State Examination (MMSEa)","Evaluation of the psychometric properties of the questionnaire MMSEa|Evaluation of the psychometric properties of questionnaire SPPB","University Hospital Center of Martinique","All","65 Years and older   (Older Adult)","Not Applicable","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15/B/26","November 2016","November 2018","May 2020","October 30, 2017",,"October 30, 2017","CHU de Martinique, Fort-de-France, Martinique, France",,"https://ClinicalTrials.gov/show/NCT03324711"
1756,"NCT03840759","Short-term Effects of an Inpatient Geriatric Consultation Team on Geriatric Syndrome Patients",,"Completed","No Results Available","Depression|Senile Dementia","Other: inpatient geriatric consultation team","readmission rate|mortality rate","Chang Gung Memorial Hospital","All","65 Years and older   (Older Adult)","Not Applicable","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMRPG8F1571","January 1, 2017","December 31, 2017","December 31, 2017","February 15, 2019",,"February 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03840759"
1757,"NCT03549078","A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia",,"Recruiting","No Results Available","Functional Aging|Subjective Cognitive Concerns|Compensation Strategies|Brain Health Activities","Behavioral: Intervention","Everyday Compensation Questionnaire|Everyday Cognition|Beck Depression Inventory|Beck Anxiety Inventory|List learning task|Executive function task|psychomotor speed task|GRIT","University of California, Davis","All","65 Years and older   (Older Adult)","Not Applicable","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","967764","January 1, 2017","November 2019","November 2019","June 7, 2018",,"June 12, 2019","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03549078"
1758,"NCT02817074","MIND Diet Intervention and Cognitive Decline","MIND","Active, not recruiting","No Results Available","Cognitive Decline|Dementia|Alzheimer Disease|Vascular Dementia","Behavioral: MIND Diet|Behavioral: Mild Weight Loss","Change in global cognitive score|Change in brain MRI total brain /intracranial volume (cubic centimeters) and hippocampal/intracranial volume (cubic centimeters)","Rush University Medical Center|Harvard School of Public Health|Brigham and Women's Hospital|National Institute on Aging (NIA)","All","65 Years to 84 Years   (Older Adult)","Phase 3","604","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R01 AG051641|1R01AG052583-01","January 2017","April 2021","April 2021","June 29, 2016",,"June 26, 2018","Rush University, Chicago, Illinois, United States|Harvard School of Public Health, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02817074"
1759,"NCT00621647","Seroquel- Agitation Associated With Dementia",,"Completed","No Results Available","Alzheimer's Disease|Vascular Dementia","Drug: Quetiapine Fumarate|Drug: Placebo","To assess the efficacy of 2 fixed doses of quetiapine compared with placebo|To assess the efficacy of quetiapine compared with placebo","AstraZeneca","All","55 Years and older   (Adult, Older Adult)","Phase 3","333","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","5077US/0046|D1446L00002","September 2002","November 2003","November 2003","February 22, 2008",,"March 25, 2009",,,"https://ClinicalTrials.gov/show/NCT00621647"
1760,"NCT00229333","Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia",,"Unknown status","No Results Available","Depressive Syndrome","Drug: Escitalopram","Cornell Scale for Depression in Dementia (CSDD) total score|Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989)","Sheba Medical Center|H. Lundbeck A/S","All","60 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SHEBA-03-3124-AS-CTIL","December 2004",,,"September 29, 2005",,"August 29, 2006","Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00229333"
1761,"NCT02196545","Physical Activity Training Program for Patients With Alzheimer's Dementia","MOTODEM","Completed","No Results Available","Dementia","Behavioral: Exercise","activities of daily living|behavioral symptoms of dementia|cognition|executive function and language ability|caregiver burden|Reaction time, hand-eye quickness and attention","Technische Universität Dresden|RECK‑Technik GmbH & Co. KG","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MTDEM-001","August 2011","July 2013","July 2013","July 22, 2014",,"July 22, 2014","Technische Universität Dresden, Dresden, Saxony, Germany",,"https://ClinicalTrials.gov/show/NCT02196545"
1762,"NCT01887899","Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type",,"Unknown status","No Results Available","Dementia of Type Alzheimer","Device: transcranial direct current stimulation|Device: sham stimulation","the anodal transcranial direct current stimulation over the primary motor cortex (M1) in patients with dementia of Alzheimer type (DAT)|tDCS effects on central cholinergic activity in patients with DAT|tDCS effects on learning|MR elastography|genetic polymorphism, ApoE4","Charite University, Berlin, Germany","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Plasticity in Alzheimer's","May 2013","October 2017","December 2017","June 27, 2013",,"December 22, 2016","Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01887899"
1763,"NCT03860857","MRI and PET Biomarkers for Cognitive Decline in Older Adults",,"Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment|Cognitive Decline","Radiation: Amyloid PET scan|Drug: Tau PET scan using MK-6240|Behavioral: Neurocognitive testing|Other: MRI","Change in Clinical Dementia Rating - Sum of Box Score|Change in lure discrimination index - objects|Change in lure discrimination index - spatial|Change in lure discrimination index - temporal|Change in entorhinal cortical thickness|Change in perforant path integrity|Change in tau spatial distribution - advancing Braak stage","University of California, Irvine|National Institute on Aging (NIA)","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 3","200","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2017-3832|R01AG053555-02","May 1, 2018","December 22, 2023","December 22, 2024","March 4, 2019",,"March 11, 2019","University of California, Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03860857"
1764,"NCT03811847","A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.",,"Recruiting","No Results Available","Alzheimer Dementia","Drug: Methylphenidate Extended Release Oral Capsule|Other: Placebo","Cognition as measured by Lumosity Games","Massachusetts General Hospital","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","2018P003099","October 30, 2019","January 30, 2021","January 30, 2021","January 21, 2019",,"October 1, 2019","Clinical Translational Research Unit, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03811847"
1765,"NCT01047254","Bupropion for the Treatment of Apathy in Alzheimer's Dementia","APA-AD","Completed","No Results Available","Apathy in Dementia","Drug: Elontril|Drug: placebo","Change in Apathy Evaluation Scale (AES) score|NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE","University Hospital, Bonn|University of Cologne|Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef|Charite University, Berlin, Germany|Universität Duisburg-Essen|University of Erlangen-Nürnberg|University of Freiburg|University Medical Center Goettingen|Saarland University|Johannes Gutenberg University Mainz|Heidelberg University|Philipps University Marburg Medical Center|Ludwig-Maximilians - University of Munich|University of Rostock|University Hospital Tuebingen|University of Ulm","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-005352-17","January 2010","July 2014","July 2014","January 12, 2010",,"May 9, 2017","Department of Psychiatry, University Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT01047254"
1766,"NCT01438060","Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",,"Completed","Has Results","Dementia, Alzheimer Type","Drug: Aripiprazole (BMS-337039)|Drug: Placebo","Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase|Change From Baseline in NPI Psychosis Subscale Score Through Week 8 in Acute Phase|Change From Baseline in NPI Total Score in Acute Phase|Participants Who Demonstrated a ≥ 50% Decrease From Baseline to Endpoint in the NPI Psychosis Subscale Score in Acute Phase|Participants Who Demonstrated a ≥ 50% Decrease From Baseline in the Total NPI Score in Acute Phase|Change From Baseline in NPI Psychosis Subscale Caregiver Distress Score in Acute Phase|Change From Baseline in NPI Total Caregiver Distress Score in Acute Phase|Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score in Acute Phase|CGI Improvement Score in Acute Phase|Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score in Acute Phase|Change From Baseline in Mini Mental State Examination (MMSE) Total Score in Acute Phase|Change From Baseline in NPI Individual Item Scores in Acute Phase: Delusions|Change From Baseline in NPI Individual Item Scores in Acute Phase: Hallucinations|Change From Baseline in NPI Individual Item Scores in Acute Phase: Agitation/Aggression|Change From Baseline in NPI Individual Item Scores in Acute Phase: Depression/Dysphoria|Change From Baseline in NPI Individual Item Scores in Acute Phase: Anxiety|Change From Baseline in NPI Individual Item Scores in Acute Phase: Apathy/Indifference|Change From Baseline in NPI Individual Item Scores in Acute Phase: Elation/Euphoria|Change From Baseline in NPI Individual Item Scores in Acute Phase: Disinhibition|Change From Baseline in NPI Individual Item Scores in Acute Phase: Irritability/Lability|Change From Baseline in NPI Individual Item Scores in Acute Phase: Aberrant Motor Behavior|Change From Baseline in NPI Individual Item Scores in Acute Phase: Appetite/Eating Behaviors|Change From Baseline in NPI Individual Item Scores in Acute Phase: Sleep|Change From Baseline in Simpson-Angus Scale (SAS) Total Score in Acute Phase|Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score in Acute Phase|Change From Baseline in Barnes Global Clinical Assessment of Akathisia in Acute Phase|Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events in Acute Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs in Acute Phase|Participants With Potentially Clinically Significant Laboratory Abnormalities in Acute Phase|Participants With Potentially Clinically Significant (PCS) Vital Sign Abnormalities in Acute Phase|Participants With Potentially Clinically Significant Electrocardiogram Abnormalities in Acute Phase|Change in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score From Baseline During Extension Phase|Clinical Global Impression (CGI) Improvement Score During Extension Phase|Change in Abnormal Involuntary Movement Scale (AIMS) Total Score During Extension Phase|Change in Simpson-Angus Scale (SAS) Total Score During Extension Phase|Change in Barnes Global Clinical Assessment of Akathisia Score During Extension Phase|Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events During Extension Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Extension Phase|Participants With a Potentially Clinically Significant Vital Sign Abnormality During Extension Phase|Participants With a Potentially Clinically Significant Electrocardiogram Abnormalities During Extension Phase|Participants With Potentially Clinically Significant Laboratory Abnormalities During Extension Phase|Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Treatment Beyond 140 Weeks","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 3","232","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN138-006","August 2000","July 2010","July 2010","September 21, 2011","March 5, 2012","December 2, 2013",,,"https://ClinicalTrials.gov/show/NCT01438060"
1767,"NCT04098666","Metformin in Alzheimer's Dementia Prevention","MAP","Not yet recruiting","No Results Available","Amnestic Mild Cognitive Impairment (aMCI)","Drug: Placebo oral tablet|Drug: extended release metformin","Free and Cued Selective Reminding Test (FCSRT)|Alzheimer's Disease Cooperative Study Preclinical Alzheimer's Cognitive Composite (PACC-ADCS)|Cortical Thickness|White matter hyper intensity volume (WMH)","Columbia University|Johns Hopkins University|National Institute on Aging (NIA)|University of Rochester|University of Iowa|Weill Medical College of Cornell University|Boston University|Wake Forest University|Rush University|Louisiana State University Health Sciences Center in New Orleans|University of Miami|Emory University|Georgetown University","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","370","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAS6912|R01AG062624","April 1, 2020","March 30, 2024","May 31, 2024","September 23, 2019",,"September 23, 2019","Georgetown University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Boston University, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04098666"
1768,"NCT01642420","Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression","DEMPROG","Unknown status","No Results Available","Alzheimers Disease|Mild Cognitive Impairment",,"Conversion from Mild Cognitive Impairment to Alzheimers disease","Zealand University Hospital|Rigshospitalet, Denmark","All","50 Years to 90 Years   (Adult, Older Adult)",,"115","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","DEMPROG 2012","April 2012","February 2017","February 2017","July 17, 2012",,"September 13, 2012","Neurologisk Afd, Roskilde Sygehus, Roskilde, Denmark",,"https://ClinicalTrials.gov/show/NCT01642420"
1769,"NCT02460783","Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function",,"Recruiting","No Results Available","Alzheimer's Disease|Obesity|Diabetes Mellitus","Dietary Supplement: Boost A|Behavioral: Healthy Living Diet","Exosomal p-S312-IRS-1/p-panY-IRS-1 ratio (index of brain insulin resistance)|Hormones (GLP-1, insulin) during a mixed|Anthropometric measures (weight, waist)|Measure: CSF, plasma BDNF|Cognitive performance (Examiner, Memory)|Mood, energy, concentration, etc. symptom|Si and HOMA-IR (indices of peripheral insulin resistance)|Lipid panel, uric acid|MRS metabolites|fMRI activation to food preference task|fMRI activation to Stroop|CSF, plasma AD biomarkers (A(SqrRoot) <=42,p181Tau)|Cytokines: IL-6, IL-8, IL-12, IL-23|Physical activity (Accelerometry)|DNA methylation|Measure: Exosomal proteins and mRNA|ROS, AGES|Resting fMRI|Gene expression","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","55 Years to 70 Years   (Adult, Older Adult)","Phase 2","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","150123|15-AG-0123","June 22, 2015","July 1, 2020","July 1, 2020","June 2, 2015",,"July 16, 2019","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02460783"
1770,"NCT03475316","Movement Intervention for Memory Enhancement","MIME","Recruiting","No Results Available","Alzheimer Disease|Dementia|Cognitive Decline|Cognitive Impairment|Dementia, Alzheimer Type","Behavioral: Social Dancing|Behavioral: Treadmill Walking","Executive Function (EF).|Neuroplasticity.","Albert Einstein College of Medicine|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2018-8942|1R21AG057586-01A1","March 28, 2019","August 31, 2020","August 31, 2020","March 23, 2018",,"May 7, 2019","Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03475316"
1771,"NCT02664571","Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis","FBB ACC","Not yet recruiting","No Results Available","Amyloid Cerebral Angiopathy|Alzheimer Disease","Device: Pet scan with FBB|Device: MRI scan|Biological: APO E genotyping","PET scan with Florbetaben: Standardized Uptake Value Ratio|On the reference MRI: the number of lobar hemorrhages|On the reference MRI: the locations of lobar hemorrhages|On the reference MRI: The presence/absence classification for superficial siderosis|On the reference MRI: the locations of superficial siderosis|On the reference MRI: the absolute quantitative count of microbleeds|On the reference MRI: microbleed count category|On the reference MRI: The predominant location of microbleeds|On the reference MRI: a measure of leukoencephalopathy using the ARWMC scale|Apolipoprotein E genotype","Centre Hospitalier Universitaire de Nīmes","All","60 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LOCAL/2015/DM-01|2015-004583-11","January 2020","January 2021","January 2021","January 27, 2016",,"January 14, 2019","CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France|CH de Perpignan - Hôpital Saint Jean, Perpignan, France",,"https://ClinicalTrials.gov/show/NCT02664571"
1772,"NCT03283449","Tau PET Imaging in Atypical Dementias",,"Recruiting","No Results Available","Primary Progressive Aphasia With Suspected Alzheimer's Disease","Drug: 18F-AV-1451|Device: PET","Tau levels in PPA participants","Northwestern University|National Institute on Aging (NIA)","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 1","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU00200893|R01AG056258","February 2016","February 2022","February 1, 2023","September 14, 2017",,"August 14, 2019","Cognitive Neurology and Alzheimer's Disease Center - Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03283449"
1773,"NCT00612872","Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects","CLINDE","Terminated","No Results Available","Parkinson Disease|Alzheimer Disease|Healthy Controls|Multiple Sclerosis","Drug: [123I]CLINDE","To assess the dynamic uptake and washout of 123-I CLINDE, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).","Institute for Neurodegenerative Disorders","All","30 Years to 50 Years   (Adult)","Phase 1","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CLINDE 001|IND 100,863","January 2008","November 1, 2009","November 1, 2009","February 12, 2008",,"April 3, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00612872"
1774,"NCT02697721","Powerful Tools for Caregivers of Dementia Patients","PTC-dementia","Completed","No Results Available","Caregivers|Dementia|Alzheimer Disease","Behavioral: Powerful Tools for Caregivers|Other: Control with delayed intervention","Caregiver Burden|Frequency and reaction to care recipient behavioral and psychological symptoms of dementia|Frequency of care recipient agitated behaviors|Activity parameters as assessed by FitBit|Depressive symptoms|Caregiving Self-Efficacy|Self-rated health|Life satisfaction|Perceived change|Neuropsychiatric symptoms in care recipients","Florida State University|Florida Department of Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6AZ09","February 2016","May 30, 2018","February 2019","March 3, 2016",,"June 3, 2019","Florida State University College of Medicine, Tallahassee, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02697721"
1775,"NCT03858283","Mindfulness for Alzheimer Caregivers",,"Recruiting","No Results Available","Alzheimer Disease|Neurodegenerative Diseases|Dementia","Behavioral: Mindfulness Based Health Care (MBHC) Program","Changes in Neuropsychiatric disorders of Alzheimer patients measured with Neuropsychiatric inventory|Changes in Anxiety and depression symptoms in Caregivers of Alzheimer patients measured with Hospital Anxiety and Depression scale|Changes in Cognitive Function of Alzheimer patients with Mini Mental State Examination|Changes in Executive Function of Alzheimer patients with Frontal Assessment Battery|Changes in Functional Capacity of Alzheimer patients with Disability Assessment for Dementia|Changes in Quality of Life of Alzheimer patients with Quality of Life in Alzheimer's Disease scale|Change in Caregiver Burden of Caregivers of Alzheimer patients measured with Zarit Burden Interview|Change in Occupational Balance of Caregivers of Alzheimer patients measured with Occupational Balance Questionnaire.|Change in Executive Function of Caregivers of Alzheimer patients measured with Frontal Assessment Battery|Change in Quality of Life of Caregivers of Alzheimer patients measured with Study Questionnaire Short Form 36 Health Survey|Change in self-compassion of Caregivers of Alzheimer patients measured with Self-Compassion Scale|Change in well-being of Caregivers of Alzheimer patients measured with Ryff's Well-being Scale","Universidad Miguel Hernandez de Elche","All","18 Years and older   (Adult, Older Adult)","Not Applicable","145","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Mind01UMH","February 2, 2019","October 31, 2021","October 31, 2021","February 28, 2019",,"March 1, 2019","Alicia Sánchez Pérez, San Juan De Alicante, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT03858283"
1776,"NCT02707458","Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration","DEPEND","Completed","No Results Available","Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease","Drug: Probucol","Plasma concentration of probucol following test dose|Apolipoprotein concentration in CSF before and after treatment with probucol at individualized dose","Douglas Mental Health University Institute|Weston Brain Institute|McGill University","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DEPEND","April 2016","March 2017","March 2017","March 14, 2016",,"January 31, 2018","Douglas Hospital Research Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02707458"
1777,"NCT02134041","Amyloid Accumulation After Mild Traumatic Brain Injury","TBI","Recruiting","No Results Available","Traumatic Brain Injury|Dementia|Alzheimer Disease","Other: traumatic brain injury","amyloid accumulation by amyloid PET|mini-mental status examination (MMSE) for cognitive function","Taipei Medical University Shuang Ho Hospital|Chang Gung Memorial Hospital","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DOH101-TD-PB-111-NSC017","October 2012","August 2019","September 18, 2019","May 8, 2014",,"September 19, 2019","Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02134041"
1778,"NCT00966017","Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia",,"Unknown status","No Results Available","Down Syndrome|Alzheimer's Disease",,,"National Institute on Aging (NIA)","All","45 Years and older   (Adult, Older Adult)",,"108","NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","IA0167|1R01AG033015-01","July 2009","February 2014","February 2014","August 26, 2009",,"December 29, 2009","UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00966017"
1779,"NCT00355498","Amyloid Plaque and Tangle Imaging in Aging and Dementia",,"Completed","No Results Available","Memory Disorders|Alzheimer's Disease",,,"University of California, Los Angeles|National Institute on Aging (NIA)","All","30 Years and older   (Adult, Older Adult)",,"194","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IA0093|P01AG025831-01|P01-AG024831-01","September 2005","May 2010","May 2010","July 24, 2006",,"October 16, 2018","Jane & Terry Semel Institute for Neuroscience & Human Behavior, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00355498"
1780,"NCT02055092","Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family",,"Unknown status","No Results Available","Frontotemporal Dementia|Alzheimer's Disease.",,"Quality of life|Change from baseline in quality of life at 12 months|Change from baseline in quality of life at 24 months|Specific needs|Use of healthcare resources|Cognition|Neuropsychiatric symptoms|Activities of Daily Living (ADL)|Relative's stress","Norwegian Centre for Ageing and Health|The Research Council of Norway|The Hospital of Vestfold|Oslo University Hospital|Sykehuset Innlandet HF|Haraldsplass Deaconess Hospital|Karolinska University Hospital|Copenhagen University Hospital, Denmark|Zealand University Hospital|Landspitali University Hospital|Sykehuset Telemark","All","up to 69 Years   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","229002","February 2014","December 2016","December 2016","February 4, 2014",,"October 7, 2015","Norwegian Centre for Ageing and Health, Tønsberg, Vestfold, Norway",,"https://ClinicalTrials.gov/show/NCT02055092"
1781,"NCT02333942","Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia",,"Completed","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Frontotemporal Lobar Degeneration|Memory Disorders","Device: Nautilus NeuroWaveTM System","Sensitivity as a diagnostic aid in detecting Dementia (identified signatures as compared with the clinical assessment made by the PI)|Specificity as a diagnostic aid in detecting Dementia (Rate of false positives as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures for MCI and Alzheimer's disease (Efficacy and rate of false positives as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures between MCI and FTDL. (distinguish between MCI and FTDL using efficacy and rate of false positives from the identified signatures as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures between FTDL and Alzheimer's disease (distinguish between FTLD and Alzheimer's disease using efficacy and rate of false positives from the identified signatures as compared with the clinical assessment made by the PI)","Jan Medical, Inc.|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)",,"41","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","082189","May 2014","February 2015","February 2015","January 8, 2015",,"September 13, 2019","University of Californa San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02333942"
1782,"NCT01687153","A Study of Brain Aging in Vietnam War Veterans","DOD-ADNI","Recruiting","No Results Available","Traumatic Brain Injury|Post Traumatic Stress Disorder|Alzheimer's Disease|Mild Cognitive Impairment",,"Rates of change in brain regions based on neuroimaging|Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers|Rates of change in neuropsychological measures of memory and general cognitive performance|Correlations within each group (TBI and PTSD) to assess whether baseline levels or rates of atrophy or cognitive decline are associated with severity of TBI or PTSD|Group differences in the patterns of amyloid deposition (from Florbetapir F 18) and brain atrophy|Group differences in white matter integrity as assessed with Diffusion Tension Imaging (DTI)|Rate of change of tau deposition as measured by 18F-AV-1451","University of Southern California|United States Department of Defense|Telemedicine & Advanced Technology Research Center|Northern California Institute of Research and Education|San Francisco Veterans Affairs Medical Center|Alzheimer's Therapeutic Research Institute","All","50 Years to 90 Years   (Adult, Older Adult)",,"420","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADC-044|W81XWH-12-2-0012|W81XWH-13-1-0259|W81XWH-14-1-0462","October 2012","September 2019","September 2019","September 18, 2012",,"February 19, 2019","Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cornell Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Roper St Francis Healthcare, Charleston, South Carolina, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01687153"
1783,"NCT02317523","Alzheimer's Caregiver Coping: Mental and Physical Health",,"Completed","No Results Available","Alzheimer Disease|Alzheimer Dementia|Alzheimer's Disease|Dementia","Behavioral: Behavioral Activation|Behavioral: Information and Support","Endothelium-dependent Flow Mediated Dilation (FMD)|Center for Epidemiologic Studies - Depression (CES-D) scale|Interleukin-6|Baroreflex Sensitivity (BRS)|Arterial Compliance (AC)|Carotid Intima Media Thickness (IMT)|D-dimer|C-reactive Protein (CRP)|Tumor Necrosis Factor (TNF)- alpha|Plasminogen Activator Inhibitor (PAI)-1|von Willebrand Factor (vWF)","University of California, San Diego|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Not Applicable","151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BMausbach|RF1AG015301","September 2014","June 30, 2019","June 30, 2019","December 16, 2014",,"September 26, 2019","University of California San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02317523"
1784,"NCT02330510","Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease","MITNEC C6","Recruiting","No Results Available","Alzheimer's Disease|Small Vessel Disease White Matter Hyperintensities Subtype|Vascular Cognitive Impairment",,"Change in F18 florbetapir SUVR over 2 years in patients with moderate-severe White Matter Hyperintensities, at baseline and 1 year follow-up brain uptake of Florbetapir F 18|Florbetapir F18 SUVR brain uptake, regional FDG metabolic measures and regional volutmetrics on MRI based volume including grey and white matter, small vessel disease, as well as regional cortical thickness measures.|F18 florbetapir SUVR brain uptake, with Periventricular White Matter Hyperintensity volumes and cognitive scores.|F18 florbetapir brain SUVR uptake, Periventricular White Matter Hyperintensity volumes and cognitive scores in an age-matched group of normal controls, MCI and AD subjects with minimal or mild degrees of pvWMH.|F18 florbetapir SUVR brain uptake, ApoE e4 genotype status, and White Matter Hyperintensity volumes in patients with a high burden of pvWMH.|Baseline F18 florbetapir SUVR brain uptake, cognitive score decline and increase in White Matter Hyperintensity volume at 2 year follow up.|Assess any adverse events or serious adverse events occurring with a a single intravenous dose of F18 florbetapir Injection (370 MBq +/- 10%) in subjects with significant pvWM","Dr. Sandra E Black|Sunnybrook Health Sciences Centre","All","60 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Ml1-112246","August 2014","February 2020","February 2020","January 5, 2015",,"September 30, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02330510"
1785,"NCT03978052","Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention","(PENSA)","Not yet recruiting","No Results Available","Alzheimer Disease|Nutritional Intervention|Cognitive Function","Dietary Supplement: EGCG|Dietary Supplement: Placebo EGCG|Other: Personalized intervention|Other: Lifestyle recommendations","Preclinical Alzheimer Cognitive Composite- Plus-exe like score (ADCS-PACC-like)|Changes in Functional neuronal connectivity (assessed by a functional magnetic resonance imaging)|Changes in structural connectivity networks known to be affected in Alzheimer Disease","Parc de Salut Mar|Fundacion IMIM|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IMIM/PENSA","September 2019","December 2020","September 2021","June 6, 2019",,"June 11, 2019","Barcelonabeta Brain Research Center, Barcelona, Barcelona, Spain, Spain|IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03978052"
1786,"NCT01208675","The Swedish BioFINDER Study",,"Active, not recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Dementia With Lewy Bodies|Vascular Dementia",,"To compare the time to conversion to clinically probable AD in MCI subjects or healthy elderly subjects with normal and abnormal biomarkers (CSF, blood, MRI, PET)|Rate of cognitive decline as measured by various cognitive tests, Activities of Daily Living (FAQ) and Global Deterioration Scale.|Group differences for imaging and wet biomarker measurements.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on each specified biochemical biomarker|Correlations between biomarkers and biomarker change|Subgroups analyses: Abnormal CSF biomarkers, positive amyloid imaging, APOE genotype.","Skane University Hospital|Lund University","All","60 Years to 80 Years   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TiDiS-2010","September 2010","December 2022","December 2022","September 24, 2010",,"April 17, 2018","Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01208675"
1787,"NCT03024944","TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind","TAUPET","Withdrawn","No Results Available","Diabetes Mellitus|Alzheimer Dementia","Drug: 18F-THK-5351","Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR)","Columbia University|National Institute on Aging (NIA)","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR1419|3R01AG050440","December 2017","January 2019","January 2020","January 19, 2017",,"December 29, 2017","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03024944"
1788,"NCT01699503","Indiana University Dementia Screening Trial","IU-CHOICE","Completed","Has Results","Dementia|Alzheimer's Disease|Mild Cognitive Impairment","Behavioral: Collaborative Dementia Care Program","Health Related Quality of Life (HRQOL)|Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder Scale (GAD-7)|Number of Participants With Health Care Utilization|Number of Participants With an Advance Directive at 12 Months","Indiana University|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","4005","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","R01AG040220-01A1|1R01AG040220-01A1","October 2012","November 22, 2017","November 22, 2017","October 3, 2012","January 23, 2019","January 23, 2019","IU Health-Primary Care Clinics, Indianapolis, Indiana, United States|Wishard Health Services-Primary Care Clinics, Indianapolis, Indiana, United States|IU Health Arnett Primary Care Clinics, West Lafayette, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01699503/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01699503"
1789,"NCT03330587","Living Alone in Old Age With Cognitive Impairment",,"Recruiting","No Results Available","Living Alone|Alzheimer Disease|Mild Cognitive Impairment",,"Ethnographic interviews","University of California, San Francisco","All","55 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","K01AG049102","March 1, 2016","May 20, 2020","September 1, 2020","November 6, 2017",,"September 25, 2019","Institute for Health & Aging, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03330587"
1790,"NCT03378245","Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations","TeleNH","Suspended","No Results Available","Dementia Alzheimers|Disruptive Behavior","Behavioral: Behavioral modification and education on pharmacologic treatments.","Change in the Neuropsychiatric Inventory (NPI) total score|Change in the Resource Utilization in Dementia - Formal Care (RUD-FOCA)|Change in Quality of Life in Alzheimers Dementia (QoL-AD)","Richard Ronan Murphy|University of Kentucky","All","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care","13-0664-P3H","September 2013","August 2022","August 2022","December 19, 2017",,"August 20, 2019","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03378245"
1791,"NCT00291421","A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer Disease|Dementia|Nervous System Diseases|Mental Disorders|Brain Diseases",,,"Janssen Pharmaceutica N.V., Belgium","All","Child, Adult, Older Adult",,"2360","Industry","Observational","Time Perspective: Prospective","CR003937","July 2002",,"May 2006","February 14, 2006",,"April 16, 2013",,,"https://ClinicalTrials.gov/show/NCT00291421"
1792,"NCT02502253","BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)","BDPP","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Drug: grape seed polyphenolic extract, resveratrol","Assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Confirm brain penetrance of BDPP by measuring levels of BDPP constituents in cerebrospinal fluid (CSF).|Evaluate BDPP effect on mood with Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia.|Evaluate BDPP effect on cognition with a composite battery of memory, executive function, and attention measures (composite)","Johns Hopkins University|Icahn School of Medicine at Mount Sinai","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00062802","June 2015","June 2019","October 2019","July 20, 2015",,"July 3, 2019","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02502253"
1793,"NCT02910739","An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)",,"Completed","Has Results","Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease","Drug: MK-8931","Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞)|Maximum Observed Plasma Concentration of MK-8931 (Cmax)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to the Time of the Last Quantifiable (Above LLOQ) Sample (AUC0-last)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to 24 Hours (AUC0-24hr)|Plasma Concentration of MK-8931 at 24 Hours (C24hr)|Apparent Clearance of MK-8931 After Extravascular Administration (CL/F)|Time to Maximum Observed MK-8931 Plasma Drug Concentration (Tmax)|Apparent Terminal Half-Life of MK-8931 (t1/2)|Apparent Volume of Distribution of MK-8931 During the Terminal Phase After Extravascular Administration (Vz/F)|Number of Participants Experiencing an Adverse Event|Number of Participants Discontinuing Study Due to an Adverse Event","Merck Sharp & Dohme Corp.","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P08593|Celerion Project Number|Merck Protocol Number","October 11, 2016","April 3, 2017","April 12, 2017","September 22, 2016","October 1, 2018","October 1, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02910739/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02910739"
1794,"NCT03351452","tES Effects on Associative Memory Performance",,"Enrolling by invitation","No Results Available","Healthy|Mild Cognitive Impairment|Alzheimer Disease","Device: real anodal transcranial direct current stimulation|Device: real transcranial alternating current stimulation|Device: sham transcranial electric current stimulation","Performance on immediate cued recall task|Performance on delayed cued recall task|task-dependent BOLD activity|resting-state BOLD activity","University of Bern","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2017-01197","April 9, 2018","March 1, 2020","September 1, 2020","November 22, 2017",,"May 9, 2019","University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03351452"
1795,"NCT03227185","Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients",,"Recruiting","No Results Available","Healthy|Mild Cognitive Impairment|Alzheimer Disease","Device: real anodal transcranial direct current stimulation (tDCS)|Device: sham transcranial direct current stimulation (tDCS)","Episodic memory performance - learning curve|Episodic memory performance - delayed recall 1|Episodic memory performance - delayed recall 2|Neurotransmitter levels","University of Bern","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","3351|2016-02175","October 1, 2017","October 31, 2019","February 29, 2020","July 24, 2017",,"February 15, 2019","University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03227185"
1796,"NCT02353949","Investigating the Clinical Consequences of Flutemetamol-PET-scanning",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Dementia","Drug: Flutemetamol (Vizamyl)","Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-ADL score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-CGIC score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of MMSE score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.","University of Zurich","All","Child, Adult, Older Adult","Phase 3","110","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Flutemetamol 2","May 2015","July 31, 2020","December 31, 2020","February 3, 2015",,"June 21, 2019","University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy, Schlieren, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02353949"
1797,"NCT02103673","DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia",,"Completed","No Results Available","Behavioral and Psychological Symptoms in Alzheimer's Disease|Behavioral and Psychological Symptoms in Vascular Dementia","Drug: DAOIB|Drug: Placebo","Behavioral Pathology in Alzheimer's Disease Rating Scale|Alzheimer's Disease Assessment Scale - cognitive subscale|Neuropsychiatirc Inventory|Instrumental Activities of Daily Living|Zarit Caregiver Burden Interview|Geriatric Geriatric Depression Scale|Mini-Mental Status Examination","Chang Gung Memorial Hospital","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","102-0035C","February 2014","November 2017","November 2017","April 4, 2014",,"January 24, 2018","Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02103673"
1798,"NCT03602391","The Senior Companion Program Plus","SCP Plus","Recruiting","No Results Available","Family|Alzheimer Dementia","Behavioral: SCP Plus","Change in caregiver burden and stress|Change in caregiver coping skills|Change in caregiver level of satisfaction with social support","The University of Texas at Arlington|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-0431","May 16, 2019","April 30, 2021","June 30, 2021","July 26, 2018",,"May 17, 2019","The Senior Source, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03602391"
1799,"NCT02300584","Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program",,"Completed","No Results Available","Dementia|Alzheimer's Disease|Depression","Behavioral: Tele-Savvy|Other: iPad","The number of participants who use at least half of the opportunities (half of the conferences and half of the daily lessons)|Change in Zarit Burden Interview Score|Change in Center for Epidemiological Studies-Depression Scale Score|Change in State Trait Anxiety Index (STAI) Score|Change in Connor Davidson Resilience Scale (CD-RISC)|Change in Perceived Stress Scale|Change in Caregiver Self-Efficacy Score|Change in Personal Mastery scale|Change in Revised Memory and Behavior Problem Checklist|Change in Lawton Activities of Daily Living (ADL) / Instrumental Activities of Daily Living (IADL) Scale","Emory University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00074715","November 2014","October 2015","October 2015","November 25, 2014",,"September 8, 2016","Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02300584"
1800,"NCT02746484","ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program",,"Completed","No Results Available","Cognitive Impairments|Dementia|Alzheimer Disease","Other: Ability platform program|Other: Usual care program","activities of daily living|behavioral symptoms|cognitive domain (long-term memory)|cognitive domain (language)|cognitive domain (frontal-executive functions)|quality of life|coping strategies|global cognitive level|conversion rate MCI versus AD|cognitive domain - long term memory|cognitive domain - language|cognitive domain - frontal executive functions|caregiver quality of life|caregiver coping strategies|caregiver burden|caregiver affect","Fondazione Don Carlo Gnocchi Onlus|University of Milano Bicocca","All","65 Years to 85 Years   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FdG_AD_02","April 2015","October 2016","October 2016","April 21, 2016",,"January 18, 2017",,,"https://ClinicalTrials.gov/show/NCT02746484"
1801,"NCT01646723","Volunteers Adding Life in Dementia","VALID","Completed","No Results Available","Dementia|Alzheimer Disease|Behavior","Behavioral: Volunteers Adding Life in Dementia (VALID) Program","Change in Cohen-Mansfield Agitation Inventory (CMAI) score|Clinically significant reduction in agitation|Remission of neuropsychiatric symptoms|Change in Neuropsychiatric Inventory (NPI) score|Change in depression symptoms (Cornell Depression in Dementia Rating Scale)|Dementia Quality of Life (DemQoL) Scale|Clinical Global Impression of Change (CGI-C)|Use and dose of required medication|Short form health survey|Change in Modified Nursing Care Assessment Scale score","Queen's University","All","65 Years and older   (Older Adult)","Not Applicable","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","VALID1","June 2012","December 2015","March 2016","July 20, 2012",,"April 14, 2017","Extendicare Kingston, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01646723"
1802,"NCT04058886","Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers",,"Not yet recruiting","No Results Available","Alzheimer Dementia|Caregiver|Dementia Alzheimers","Behavioral: Telephone-delivered Mindfulness","Number of telephone sessions attended|Total number of individuals screened for enrollment|Proportion of screened individuals who qualify for enrollment|Number of qualifiers who enroll|Number enrolled who complete the intervention|Total number of Interviews completed with intervention participants|Total number of audio recordings of intervention sessions|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anxiety-Short Form 4a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anger-Short Form 5a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Meaning and Purpose-Short Form 6a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health|Change from baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form|Change from baseline on Intolerance of Uncertainty Scale (IUS-12)|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Support-Short Form 4a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Informational Support-Short Form 4a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Instrumental Support-Short Form 4a|Change from baseline on Self-Compassion Scale-Short Form (SCS-SF)|Change from baseline on Family Satisfaction Scale (FSS)|Change from baseline on Family Conflict Scale (FCS)|Change from baseline on Zarit Burden Interview Short Form (ZBI-12)|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) General Self-Efficacy-Short Form 4a|Change from baseline on Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Emotions-Short Form 4a","University of North Carolina, Chapel Hill|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","19-0053|R21AG061728","September 2019","December 2021","December 2021","August 16, 2019",,"September 6, 2019","UNC Program on Integrative Medicine, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04058886"
1803,"NCT02062099","PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)","NIDeCo","Unknown status","No Results Available","Memory Complaint|Mild Cognitive Impairment|Alzheimer Disease","Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment","Fixation and distribution of [18F]DPA-714 (Binding Potential BP)|[18F]AV-45 Standard Uptake Values ratio|Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline.","University Hospital, Tours","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO13-CH/ NIDeCo","January 2014","January 2016","January 2018","February 13, 2014",,"February 13, 2014","University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02062099"
1804,"NCT02205710","Adaptive Cognitive Training in Healthy Older Adults",,"Completed","No Results Available","Mild Cognitive Impairment|Mild to Moderate Dementia|Alzheimer`s Disease","Other: Computerized cognitive training|Other: Computerized games","Change in ratings on cognitive training survey|Change in neural activity|Change in performance on neuropsychological tests|Change in ratings of psychological wellbeing","Bruyere Research Institute|University of Ottawa","All","60 Years and older   (Adult, Older Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","M16-14-018","August 2016","August 2018","August 2018","July 31, 2014",,"August 2, 2019","Bruyere Continuing Care, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02205710"
1805,"NCT03144921","EPIC: An Intervention for Early-stage AD Dyads",,"Recruiting","No Results Available","Dementia|Alzheimer Disease|Memory Loss","Behavioral: psychoeducational skills training intervention","EP and CP Emotional well-being|EP Quality of Life|Knowledge and Use of Services for People with Dementia and their Care Partners|Communication Skills and Support within the Dyad|EP and CP Care preparedness","Arizona State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00005510","October 9, 2017","May 2021","May 2021","May 9, 2017",,"July 10, 2019","Arizona & Nevada Program Locations (Based at ASU Edson College of Nursing and Health Innovation), Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03144921"
1806,"NCT01823666","Predicting the Conversion From Mild Cognitive Impairment to Dementia","PCMCItoD","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular",,"Rate of conversion to dementia|Mini-Mental State Examination|Immediate and delayed story recall|Clock Drawing Test(CDT)|Boston Naming Test|Verbal Category Fluency Test(animals)|Trail Making Test(TMT)|Hopkins Verbal Learning Test(HVLT)","Dongzhimen Hospital, Beijing","All","40 Years to 85 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Z11107056811043","September 2012","August 2014","September 2014","April 4, 2013",,"June 8, 2016","Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01823666"
1807,"NCT00281749","Telephone Call From Acute Care Physicians to Long Term Care Physicians: Impact on Transitional Care of Elderly Patients",,"Completed","No Results Available","Alzheimer Disease|Parkinson Disease|Dysphagia","Procedure: TELEPHONE CALL",,"Maimonides Medical Center","All","65 Years and older   (Older Adult)","Phase 1",,"Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05/12/VA03",,,"October 2006","January 25, 2006",,"August 18, 2011","Maimonide Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT00281749"
1808,"NCT02205424","Cognition And Neocortical Volume After Stroke","CANVAS","Active, not recruiting","No Results Available","Ischaemic Stroke|Alzheimer's Disease|Vascular Dementia",,"Difference in brain volume between 3 month and 3 year time-points|Difference in cognition between 3 month and 3 year time-points","The Florey Institute of Neuroscience and Mental Health|National Health and Medical Research Council, Australia","All","18 Years and older   (Adult, Older Adult)",,"175","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","APP-1020526","May 2011","December 2020","December 2020","July 31, 2014",,"August 28, 2018","Eastern Health, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Melbourne Health, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02205424"
1809,"NCT03075007","Brain Vascular Disease in Aging and Dementia",,"Completed","No Results Available","Alzheimer Disease|White Matter Hyperintensities|Dementia|Aging","Radiation: Florbetaben F18|Procedure: Transcranial Doppler","PET amyloid Standard Uptake Value ratio (SUVr) values|Transcranial Doppler (TCD) dynamic autoregulatory dysfunction","Columbia University|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)",,"48","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAR1423|2R56AG034189-06A1","May 23, 2017","August 31, 2019","August 31, 2019","March 9, 2017",,"September 12, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03075007"
1810,"NCT00626210","Modafinil Treatment for Sleep/Wake Disturbances in Older Adults",,"Terminated","Has Results","Insomnia|Sleep Initiation and Maintenance Disorders|Alzheimer Disease","Drug: modafinil","Nocturnal Sleep Length at 1 Month|Improvement of Daytime Alertness and Quality of Life.","VA Palo Alto Health Care System","All","50 Years and older   (Adult, Older Adult)","Phase 4","2","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8564","February 2008","April 2011","October 2012","February 29, 2008","October 30, 2014","January 29, 2018","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00626210"
1811,"NCT02263235","In Vivo Alzheimer Proteomics","PROMARA","Unknown status","No Results Available","Probable Alzheimer Disease|Parkinson Disease|Neurological Disease Without Cognitive Degradation|Brain Trauma|Acute Hydrocephaly","Biological: administration of stable isotope-labelled leucine-|Other: collection of CSF, blood, urine, saliva","C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)|C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)","University Hospital, Montpellier|Assistance Publique - Hôpitaux de Paris|University Hospital, Clermont-Ferrand|International Atomic Energy Agency","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","8652","June 2013","June 2017","June 2017","October 13, 2014",,"May 3, 2016","Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02263235"
1812,"NCT01137799","The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients",,"Terminated","No Results Available","Schizophrenia|Alzheimer's Disease|Cognition Disorders","Drug: JNJ-39393406|Drug: placebo","Improvement of deficits (i.e. sensory gating deficits) in event related potentials like Auditory Evoked Potentials P50 and P300 and Mismatch Negativity.|Improvement in continuous performance testing|Plasma concentrations of JNJ-39393406 (PK blood samples)|Number of patients with clinical significant changes in vitals signs|Number of patients with clinical significant changes in ECG parameters|Number of patients with clinical clinical significant changes in clinical laboratory parameters","Janssen Pharmaceutica N.V., Belgium","Male","18 Years to 55 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR016762","August 2009",,"March 2011","June 4, 2010",,"November 8, 2012","Berlin, Germany|Erlangen, Germany|München, Germany|Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01137799"
1813,"NCT00245206","Side Effects of Newer Antipsychotics in Older Adults",,"Completed","No Results Available","Schizophrenia|Alzheimer's Disease|Dementia","Drug: Aripiprazole|Drug: Olanzapine|Drug: Risperidone","Change in Body Mass Index|Change in Fasting Plasma Glucose (FPG)|Change in LDL cholesterol, HDL cholesterol, and triglycerides","Veterans Medical Research Foundation|National Institute of Mental Health (NIMH)","All","40 Years and older   (Adult, Older Adult)","Phase 4","406","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH071536|DATR A5-ETSE","August 2005","October 2010","October 2010","October 27, 2005",,"December 17, 2018","University of California, San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00245206"
1814,"NCT00391794","Efficacy of Early Stage Alzheimer's Support Groups",,"Completed","No Results Available","Memory Loss|Alzheimer's Disease|Dementia","Behavioral: Early Stage Memory Loss Support Group|Behavioral: Educational Seminar","Quality of life|Mood|Social support|Family Relationships","University of Washington|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","154","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29920-J|5R01AG023091|06-1324-G01|5R01AG023091-02|1A0131","September 2006","May 2011","May 2011","October 24, 2006",,"January 10, 2014","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00391794"
1815,"NCT00012831","Nurse Managed Clinic for Dementia Patients and Family Caregivers",,"Completed","No Results Available","Alzheimer's Disease|Caregivers|Dementia",,,"US Department of Veterans Affairs|GRECC|VA Office of Research and Development","Male","Child, Adult, Older Adult",,"120","U.S. Fed|Other","Observational","Time Perspective: Prospective","NRI 95-143",,,"June 2001","March 16, 2001",,"April 7, 2015","Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00012831"
1816,"NCT03923517","RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia","RHAPSODY-plus","Completed","No Results Available","Early Onset Alzheimer Disease|Frontotemporal Dementia","Device: RHAPSODY online program and MEET online sessions","Acceptability and usefulness|Feasibility","Technische Universität München|University of Melbourne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RP123","January 1, 2018","May 30, 2019","May 30, 2019","April 22, 2019",,"September 17, 2019","Zentrum für kognitive Störungen, Psychiatrische Klinik und Poliklinik, Klinikum Rechts der Isar, TU München, München, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT03923517"
1817,"NCT02727699","A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)","XanADu","Completed","No Results Available","Dementia, Alzheimer Type","Drug: Xanamem™|Drug: Placebo (for Xanamem™)","ADAS-Cog v14|AD COMposite Scores|RAVLT|CDR-SOB|MMSE|NPI|NTB - Executive Domain","Actinogen Medical|ICON Clinical Research","All","50 Years and older   (Adult, Older Adult)","Phase 2","186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACW0002","March 23, 2017","March 15, 2019","March 15, 2019","April 5, 2016",,"September 11, 2019","Tucson Neuroscience Research, LLC, Tucson, Arizona, United States|National Research Institute, Los Angeles, California, United States|PCND Neuroscience Research Institute, Poway, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Research Alliance Inc., Clearwater, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Compass Research LLC, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|NeuroStudies.Net, LLC, Decatur, Georgia, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Richmond Behavioral Associates, Staten Island, New York, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|The Clinical Trial Center, Jenkintown, Pennsylvania, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Central Coast Neurosciences Research, Tumbi Umbi, New South Wales, Australia|Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|The Research Institute for the Care of Older People, Bath, Combe Park, United Kingdom|Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital, Manchester, Lancashire, United Kingdom|West London Mental Health Trust, Isleworth, London, United Kingdom|St Pancras Clinical Research, Kings Cross, London, United Kingdom|Institute of Clinical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom|Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02727699"
1818,"NCT02781220","Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial","IMPACT2","Active, not recruiting","No Results Available","Mild Cognitive Impairment|Dementia|Alzheimer's Disease",,"Percentage of change in care practices after amyloid PET scan|Percentage of change in drug management options after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Percentage of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Percentage of change exhibiting increased behavior disturbance when the diagnosis is given|Care partner's sustained confidence in diagnosis received after amyloid PET scan|Care partner's sustained confidence in ability to adhere to management plan received after amyloid PET scan|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan","University of Utah","All","65 Years and older   (Older Adult)",,"69","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IMPACT-2","July 2016","July 2018","July 2019","May 24, 2016",,"October 15, 2018","Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02781220"
1819,"NCT02778971","Implications for Management of PET Amyloid Classification Technology","IMPACT","Recruiting","No Results Available","Mild Cognitive Impairment|Dementia|Alzheimer's Disease","Drug: [18F]Flutemetamol","Proportion of care practices changed after amyloid PET scan|Proportion of drug management options changed after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Proportion of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Proportion exhibiting increased behavior disturbance when the diagnosis is given|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan","University of Utah","All","45 Years to 90 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IMPACT-1","June 2016","June 2019","June 2019","May 20, 2016",,"October 15, 2018","Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02778971"
1820,"NCT03371420","PET Imaging of Subjects Using 124I-PU-AD",,"Completed","No Results Available","Lymphoma|Solid Malignancy|Alzheimer Disease|Myeloma","Drug: PU-AD|Device: PET Scan|Other: Blood Draws","Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC)|Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax)|Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin)|Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2)|Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)|Incidence of adverse events","Samus Therapeutics, Inc.|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|Rockefeller University","All","21 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","5","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PU-AD-00-001","April 2016","June 10, 2019","June 10, 2019","December 13, 2017",,"June 11, 2019","Memorial Sloan Kettering, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03371420"
1821,"NCT03537729","Effects of Visual Cues and Education for People Who Live Within Long Term Care Communities to Assist in Wayfinding",,"Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Age-Related Memory Disorders|Dementia","Behavioral: Salient Cues|Behavioral: Spaced Retrieval Education","Change in Wayfinding Speed at 12 months|Change in wayfinding errors at 12 months|Change in Life Space at 12 months|Change in Spatial Tracking - Life space at 12 months|Change in Spatial Tracking (Time spent at each life space zone) at 12 months","Grand Valley State University|Michigan State University","All","62 Years and older   (Adult, Older Adult)","Not Applicable","137","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","P17203009","April 1, 2019","April 30, 2023","April 30, 2023","May 25, 2018",,"August 2, 2019","Grand Valley State University, Allendale, Michigan, United States|Brush Development, Chardon, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03537729"
1822,"NCT00970333","Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions",,"Completed","No Results Available","Alzheimer Disease|Parkinson Disease|Multiple Sclerosis","Drug: [18F]-FEPPA","The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FEPPA 001","August 2009","October 2010","October 2010","September 2, 2009",,"February 8, 2012","Instiute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00970333"
1823,"NCT00249158","A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease|Vascular Dementia","Drug: Risperidone","Change from baseline to the end of double-blind treatment in total aggression score of the CMAI (Cohen-Mansfield Agitation Inventory).|Change from baseline to end of double-blind treatment in global and total BEHAVE-AD score, BEHAVE-AD cluster scores and in CMAI cluster scores, CGI, and in FAST MMSE; safety evaluations conducted throughout the study.","Janssen-Cilag Pty Ltd","All","55 Years and older   (Adult, Older Adult)","Phase 3","344","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006010","March 1998",,"February 2001","November 7, 2005",,"November 19, 2010",,,"https://ClinicalTrials.gov/show/NCT00249158"
1824,"NCT00927108","Rajavtihi Neuronal Adult Stem Cells Project","RNASc","Unknown status","No Results Available","Alzheimer's Disease|Parkinson's Disease|Multiple Sclerosis","Other: Progenitor Stem Cell Culture",,"Rajavithi Hospital|Rajavithi Biomolecular Research Center","All","20 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RH-CMR-005","July 2009","December 2011",,"June 24, 2009",,"June 24, 2009","Rajavithi Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00927108"
1825,"NCT00012857","Pain Management and Behavioral Outcomes in Patients With Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease, Pain|Behavior, Agitation","Drug: acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN",,"US Department of Veterans Affairs|VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Phase 2","66","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","NRI 95-192",,,"March 2001","March 16, 2001",,"April 7, 2015","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00012857"
1826,"NCT03702816","The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)",,"Enrolling by invitation","No Results Available","Alzheimer Disease|Parkinson Disease|Inflammation","Diagnostic Test: GE180 PET Scan","Linear Regression Model Assessing Cognitive Performance and Regional Microglial Activation|Repeated Measures Analyses to Asses Change in Microglial Activation Over Time|Linear Regression Model Assessing Cognitive Performance and Global Microglial Activation","Aaron Ritter, MD|Jeffrey Cummings, MD|Jessica Caldwell, PhD|The Cleveland Clinic","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-888","December 13, 2018","December 2020","December 2020","October 11, 2018",,"January 18, 2019","Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT03702816"
1827,"NCT03926702","Tau Imaging With JNJ067",,"Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Progressive Supranuclear Palsy","Drug: Radiopharmaceuticals","Positron-emission tomography (PET) scan results","University of California, Berkeley|University of California, San Francisco","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","073H040","June 18, 2019","January 2020","January 2021","April 24, 2019",,"July 11, 2019","University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT03926702"
1828,"NCT03761381","OCT Angiography and NRAI in Dementia",,"Recruiting","No Results Available","Alzheimer Disease|Dementia|Mild Cognitive Impairment","Device: Optical Coherence Tomography Angiography (OCTA) Imaging|Device: Noninvasive Retinal Amyloid Imaging (NRAI)","Retinal amyloid protein detection|Decreased blood flow|Decreased retinal perfusion","Oregon Health and Science University","All","55 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB#00017045","September 14, 2018","December 2020","December 2020","December 3, 2018",,"December 3, 2018","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03761381"
1829,"NCT02663531","Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Healthy","Device: DVA|Device: FDOCT|Device: Pattern ERG|Device: Optical Coherence Tomography","Flicker induced increase in retinal blood flow","Medical University of Vienna","All","50 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OPHT-180515","September 27, 2016","September 2019","September 2019","January 26, 2016",,"April 2, 2019","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02663531"
1830,"NCT04095962","Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia","BB","Recruiting","No Results Available","Dementia|Alzheimer Disease|Vascular Dementia","Other: Exercise","Change From Baseline on the Mini-mental state examination|Change From Baseline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|Change From Baseline on the Trail-making test Assessment|Change From Baseline on the Modified Bruce Treadmill Test|Change From Baseline on the 2 Minute Step test|Change From Baseline on the 30 second sit to stand test|Change From Baseline on the Chair sit and reach test|Change From Baseline on the Flexibility test of the upper limbs flexibility|Change From Baseline on the Flexion forearm Test|Change From Baseline on the 2.44 meters test balance|Change From Baseline on the Timed Up and Go test|Change From Baseline on the Short Physical Performance Battery (SPBB)|Change From Baseline on the Handgrip Dynamometer|Change From Baseline on the Accelerometer-based activity monitors|Change From Baseline on both Systolic and Diastolic Blood Pressure|Change From Baseline on the arterial stiffness|Change From Baseline in the blood triglycerides (TG)|Change From Baseline in the blood total cholesterol (TC).|Change From Baseline in the blood Low-density lipoprotein cholesterol (LDL-C)|Change From Baseline in the blood high-density lipoprotein cholesterol (HDL-C)|Change From Baseline on the circulating level of Glycated Hemoglobin (HbA1c)|Change From Baseline on the circulating level of free brain-derived neurotrophic factor (BDNF)|Change From Baseline on the circulating level of free Vascular Endothelial Growth Factor (VEGF)|Change From Baseline on the circulating level of C-Reactive Protein (CRP)|Change From Baseline on the circulating level of Interleukin-6 (IL-6)|Change From Baseline on the circulating level of Interleukin-8 (IL-8)|Change From Baseline on the circulating level of Interleukin-10 (IL-10)|Change From Baseline on the circulating level of Tumor Necrosis Factor (TNF)|Change From Baseline on the circulating level of insulin-like growth factor-1 (IGF-1)|Change From Baseline on the for total fat free mass|Change From Baseline on the for Fat Mass (FM)|Change From Baseline on the for Bone mineral density (BMD)|Change From Baseline on the Lawton & Brody|Change From Baseline on the Barthel index|Change From Baseline on the neuropsychiatric symptoms (NPI)|Quality of Life in Alzheimer's Disease scale (QOl-AD) - change in health-related quality of life","Universidade do Porto|Fundação para a Ciência e a Tecnologia","All","65 Years and older   (Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","BB01","September 1, 2018","July 2020","July 2020","September 19, 2019",,"September 19, 2019","Faculty of Sports of University of Porto, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT04095962"
1831,"NCT03901456","Care to Plan: a Tailored Resource for Family Members of Persons With Dementia",,"Recruiting","No Results Available","Dementia|Alzheimer Disease|Memory Loss","Behavioral: Care to Plan|Behavioral: Usual Care","Change in caregiver self-efficacy|Change in frequency of CtP-recommended service use|Change in Decisional Conflict|Change in caregiver distress: burden|Change in caregiver distress: role captivity|Change in caregiver distress: role overload|Change in caregiver distress: depressive symptoms|Change in community-based/health service use","University of Minnesota - Clinical and Translational Science Institute","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","1R21AG060419-01A1","September 1, 2019","July 1, 2021","August 1, 2021","April 3, 2019",,"September 25, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03901456"
1832,"NCT03741543","Learning and Coping With Early Stage Dementia",,"Active, not recruiting","No Results Available","Dementia|Alzheimer Disease|Vascular Dementia","Other: A 12-week health promotion course","The users experiences from an educative intervention in early-stage dementia|Change in cognitive function|Change in depressive symptoms|Change in self-rated health|Change in managing personal activities of daily life|Change in managing instrumental activities of daily life|Change in neuropsychiatric symptoms|Change in carer stress/burden","Helse Stavanger HF|Norwegian Extra Foundation for Health and Rehabilitation|Nasjonalforeningen for folkehelsen","All","65 Years and older   (Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","sus2018mk01","March 3, 2014","June 14, 2021","December 31, 2021","November 15, 2018",,"November 15, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03741543/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03741543"
1833,"NCT02420756","Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study","IDEAS","Completed","No Results Available","Alzheimer's Disease|Dementia|Mild Cognitive Impairment","Device: PET Scan","To assess the impact of amyloid PET on the management of patients meeting Appropriate Use Criteria (AUC)|To assess the impact of amyloid PET on hospital admissions and emergency room visits in patients enrolled in the cohort (amyloid PET-known) compared to matched patients not in the cohort (amyloid PET-naïve) over 12 months","American College of Radiology Imaging Network|Alzheimer's Association","All","65 Years and older   (Older Adult)",,"18488","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IDEAS Study","February 2016","December 2017","December 2017","April 20, 2015",,"December 8, 2017","American College of Radiology Imaging Network, Philadelphia, Pennsylvania, United States|Https://Www.Ideas-Study.Org/Site-Locator/, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02420756"
1834,"NCT02108769","Yogic Breathing Changes Salivary Components",,"Completed","No Results Available","Alzheimer Disease|Neurodegenerative Diseases|Cancer","Behavioral: Yogic Breathing|Behavioral: Attention Control","Nerve growth factor quantification|Measuring changes in salivary constituents","Medical University of South Carolina|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00024336","October 2013","November 2013","November 2013","April 9, 2014",,"April 9, 2014","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02108769"
1835,"NCT02278367","Clinical Evaluation of 18F-AV-1451",,"Recruiting","No Results Available","Alzheimer's Disease|Traumatic Brain Injury|Depression","Drug: 18F-AV-1451","Safety Assessment: Adverse event frequency related to 18F-AV-1451 administration|Efficacy Assessment: 18F-AV-1451 standard uptake value ratios (SUVRs)","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A14","December 2014","April 2019","April 2019","October 30, 2014",,"January 9, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Yale University, New Haven, Connecticut, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Center for Vital Longevity at the University of Texas at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02278367"
1836,"NCT01550549","Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans",,"Completed","Has Results","Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases","Drug: florbetapir F 18","Inter-rater Reliability|Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)|Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","151","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-PT01","August 2011","September 2011","September 2011","March 12, 2012","June 7, 2012","June 7, 2012",,,"https://ClinicalTrials.gov/show/NCT01550549"
1837,"NCT01518374","Clinical Evaluation of Florbetapir F 18 (18F-AV-45)",,"Completed","Has Results","Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases","Drug: Florbetapir F 18","Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","1768","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A14","December 2009","May 3, 2017","May 3, 2017","January 26, 2012","June 14, 2018","July 18, 2018","Banner Health, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Davis, Davis, California, United States|UC Irvine, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|UC Irvine, Orange, California, United States|UC San Francisco, San Francisco, California, United States|UC San Francisco Memory Center, San Francisco, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mt. Sinai Medical Center, Miami Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Jefferson, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|University of Tennessee, Knoxville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01518374"
1838,"NCT03723707","Enhanced Quality in Primary Care for Elders With Diabetes and Dementia","EQUIPED-ADRD","Recruiting","No Results Available","Diabetes|Dementia|Alzheimer Disease","Behavioral: EQUIPED-ADRD Intervention|Behavioral: Control (CON)","Proportion of Intervention patients reaching consensus target HbA1c|Proportion of Control patients reaching consensus target HbA1c","NYU Langone Health|National Institutes of Health (NIH)","All","65 Years and older   (Older Adult)","Not Applicable","1000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","s18-01166","December 3, 2018","March 2022","March 2022","October 29, 2018",,"April 17, 2019","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03723707"
1839,"NCT03923712","PhysIcal Exercise ,Cerebral, COgnitive and Metabolome in People at Risk of Mild Cognitive Impairment","EFICCOM","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Dementia","Behavioral: Supervised Exercise Programme","Assessed changes from Baseline Neuroimaging Markers of Brain Structures (thickness in mm; volumes in mm)|Assessed changes from Baseline Neuroimaging Markers of Brain Function (level of activity in percentage)|Assessed changes from Baseline Cognitive Status|Assessed changes from Baseline Metabolome Analysis|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Muscle-skeletal|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Cardiorespiratory fitness|Assessed changes from Baseline Physical Health Parameters on Functional capacity:Agility-motor coordination|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Flexibility|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Handgrip strength|Assessed changes from Baseline Physical Health by the Scale of instrumental activities of the daily life of Lawton and Brody|Assessed changes from Baseline Physical Health of hemodynamic status|Assessed changes from Baseline Physical Health of Body Composition: Weight|Assessed changes from Baseline Physical Health of Body Composition:Height|Assessed changes from Baseline Physical Health of Body Composition: Waist Circumference|Assessed changes from Baseline Physical Health of Body Composition: Body mass index|Assessed changes from Baseline Physical Health of Body Composition: Total body fluids|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: Glucose.|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Total cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:HDL cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: LDL Cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:triglycerides|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Apolipoprotein B|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Insulin|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: HOMA|Assessed changes from Baseline Blood Sample of the Antioxidant Capacity|Assessed changes from Baseline Blood Sample of the Neurotrophic Factor Derived from the Brain (neurotransmitter)|Assessed of Baseline levels for Cerebrospinal fluid:|Assessed changes from Baseline Quality of life as assessed through the quality of life questionnaire related to health (Short-Form Health Survey 36 -SF36)|Assessed changes from Baseline of Depression using the Geriatric Depression Scale (GDS)|Assessed changes from Baseline of Sociodemographic Characteristics: Age.|Assessed changes from Baseline of Sociodemographic Characteristics.Sex.|Assessed changes from Baseline of Sociodemographic Characteristics.Marital Status.|Assessed changes from Baseline of Sociodemographic Characteristics.Educational level and socio-economic status.|Assessed changes from Baseline of Sociodemographic Characteristics.Family history of dementia.|Assessed changes from Baseline of Sociodemographic Characteristics.Medication.|Assessed changes from Baseline of Sociodemographic Characteristics. Other pathologies.","University of Cadiz|Centro de Excelencia en Metabolómica y Bioanálisis (CEMBIO)|Servicio Central de Neuroimagen de la Universidad Pablo de Olavide|Consejería de Salud y Bienestar Social, Andalucía","All","65 Years to 75 Years   (Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","DEP2016-76123-R","January 15, 2018","December 2019","December 2019","April 23, 2019",,"April 23, 2019","University of Cádiz, Cadiz, Spain",,"https://ClinicalTrials.gov/show/NCT03923712"
1840,"NCT03587012","Brain Fitness APP for Cognitive Enhancement",,"Enrolling by invitation","No Results Available","Mild Cognitive Impairment|Alzheimer Dementia","Other: Brain fitness app|Other: Brain fitness app with tACS","Change in Wechsler Memory Scale (WMS IV)|Change in Egocentric Spatial Orientation|Change in MONTGOMERY ASBERG DEPRESSION RATING SCALE (MADRS)","University of Manitoba","All","20 Years to 95 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2018:029GB","June 20, 2018","December 2019","December 2020","July 16, 2018",,"February 6, 2019","Riverview Health Center, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03587012"
1841,"NCT01028209","Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions","PBR06","Terminated","No Results Available","Alzheimer Disease|Parkinson Disease|Multiple Sclerosis","Drug: [18F] PBR06","To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PBR06 001","November 2009","September 22, 2010","September 22, 2010","December 9, 2009",,"April 3, 2019","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01028209"
1842,"NCT03699644","Multimodal Ocular Imaging in Neurodegeneration",,"Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Frontotemporal Dementia","Device: Spectral-Domain Optical Coherence Tomography (SD-OCT)|Device: Magnetic Resonance Imaging (MRI)|Device: Positron Emission Tomography (PET)|Diagnostic Test: Comprehensive Ophthalmic Examination|Device: Fundus Photography","Presence of Retinal Thinning|Presence of Amyloid Plaque|Presence of Brain Pathology|Presence of Brain Metabolism|Presence of Macular Vascular Anomalies","University of Michigan","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00146956","January 4, 2019","December 2020","December 2020","October 8, 2018",,"May 29, 2019","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03699644"
1843,"NCT01345110","A Longitudinal Multidimensional Population Study on Brain Aging","InveCeAb","Completed","No Results Available","Dementia|Alzheimer Disease|Vascular Dementia",,"The proportion of the recruited persons who will develop Dementia syndrome, Alzheimer disease, Vascular dementia, Lewy Body dementia, frontotemporal dementia, Mild Cognitive Impairment, Cognitive Impairment No Dementia|The proportion of persons who will exhibit a performance decrease equal or more than of 1,5 standard deviation of the mean in the reference population in screening cognitive tests or in memory tests (verbal and visual memory) or in executive tests|Neuropsychological baseline features of the persons who will develop dementia or cognitive impairment|Clinical baseline features of the persons who will develop dementia or cognitive impairment|Social baseline features of the persons who will developed dementia or cognitive impairment|Genetic baseline features of the persons who will developed dementia and/or cognitive impairment","Fondazione Golgi Cenci|Alzheimer Federation Italy|Mario Negri Institute for Pharmacological Research|University of Pavia|Camillo Golgi Geriatric Institute","All","70 Years to 75 Years   (Older Adult)",,"1321","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01","November 2009","December 2015","December 2015","April 29, 2011",,"December 11, 2015","Golgi Cenci Foundation, Abbiategrasso, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT01345110"
1844,"NCT00165100","Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer",,"Completed","No Results Available","Malignant Tumors|Subcutaneous Tumors|Lymph Node Tumors","Procedure: Dynamic Area Telethermometry (DAT)","To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","99-331","January 2000","October 2002","October 2002","September 14, 2005",,"December 28, 2007","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00165100"
1845,"NCT00259454","Project COPE:Managing Dementia at Home",,"Completed","No Results Available","Dementia, Alzheimer Type","Behavioral: In-home intervention","ADL/IADL|Caregiver upset|Caregiver confidence|Behaviors","Thomas Jefferson University|Pennsylvania Department of Health","All","21 Years and older   (Adult, Older Adult)","Phase 3","278","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","SAP 4100027298","June 2005","April 2009","July 2009","November 29, 2005",,"March 16, 2010","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00259454"
1846,"NCT03149380","Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior",,"Recruiting","No Results Available","Alzheimer Disease|Alzheimer Disease, Late Onset|Memory Loss|Patient Education as Topic","Behavioral: Web-based education","Knowledge of AD Preventative behaviors|Willingness to Engage in AD Preventative behaviors|Participant Satisfaction|Behavioral Assessments","Weill Medical College of Cornell University","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1311014539","January 2017","December 2020","October 2024","May 11, 2017",,"August 30, 2019","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03149380"
1847,"NCT00249145","A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease|Dementia, Vascular","Drug: risperidone","Change from baseline to end of double-blind treatment on the total BEHAVE-AD score.|Change from baseline to end of double-blind treatment in global rating, total BEHAVE-AD score, total CMAI score, CGI severity, FAST, and MMSE; safety evaluations conducted throughout the study","Janssen Pharmaceutica N.V., Belgium","All","55 Years and older   (Adult, Older Adult)","Phase 3","349","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006046","April 1995",,"December 1996","November 7, 2005",,"January 14, 2011",,,"https://ClinicalTrials.gov/show/NCT00249145"
1848,"NCT00276510","A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints",,"Completed","No Results Available","Memory Disorders, Age-Related|Retention Disorders, Cognitive","Drug: EGb 761® (Tanakan®)|Other: Placebo","EGb 761® efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysis|Efficacy on rate of cognitive abilities decline|Effect on concomitant diseases|Concomitant treatments' reports|Global evaluation of memory complaint by the patient|Clinical safety","Ipsen","All","70 Years and older   (Older Adult)","Phase 4","2878","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2-31-00240-011","February 2002","November 2009","November 2009","January 13, 2006",,"January 15, 2019","1 rue de l'Orient, Agde, France|3 Avenue de Marlioz, Aix les Bains, France|3 rue Auguste Delaune, Ales, France|17 rue du Cardinal Georges d'Amboise, Amboise, France|17 rue Manuel, Amboise, France|83 rue Nicolas et Paul Paquet, Ancerville, France|10 bd De La Republique, Andernos Les Bains, France|107 bd De La Republique, Andernos Les Bains, France|19 rue Jean Saccheti, Andernos, France|128 Rue Bressigny, Angers, France|18 rue Martin Luther King, Angers, France|2 boulevard Jacques Millot, Angers, France|21 bd Roi René, Angers, France|25, rue St Nicolas, Angers, France|59 Boulevard Joseph Bédier, Angers, France|61 Ave Jean XXIII, Angers, France|68A rue d'Orgemont, Angers, France|Residence le Paradis Bat 17, 74-78 rue Volney, Angers, France|Centre Hospitalier Universitaire Hotel Dieu Gerontologie Clinique 4 rue Larrey, Angers, France|111 rue de la Chalouère, Angers, France|4 rue Saint Jacques, Angers, France|4, rue St Jacques, Angers, France|7 rue Thiers, Angers, France|1172 route de Grasse Ste Elisabeth, Antibes, France|20 boulevard Albert 1er, Antibes, France|700 av. Jules Grec, Antibes, France|26 R Pres Wilson, Ars sur Moselle, France|Avenue Joseph Lafont, Aubagne, France|Groupe Piettot Bâtiment 2, Aubagne, France|37-39 boulevard Anatole France, Aubervilliers, France|26 av. Charles de Gaulle, Aubevoye, France|3 Avenue de Verdun, Audenge, France|27 rue Maréchal Foch, Aumetz, France|2 bis route de Miremont, Auterive, France|70 bis rue Etienne Billieres, Auterive, France|17 rue des Ecoles, Avoine, France|17, rue des Ecoles, Avoine, France|10 Allée Des Rochers, Avrille, France|30 Ter Avenue Pierre Mendès, Avrille, France|5 Place Maréchal Juin, Avrille, France|Rd point de Gal de Gaulle, Avrille, France|1 Résidence Marcel Paul, Bachant, France|11 rue du pont Fouchard, Bagneux, France|13, rue Denis Papin, Bagnolet, France|11 rue du Général Cheroutre, Bailleul, France|17 rue de la Croix de Pierre, Bain De Bretagne, France|9 av Pierre Coupeau, Balma, France|43 rue Ducs de Bar, Bar le Duc, France|33 rue Jean Jaures, Bassens, France|21, rue Georges Clémenceau, Bauge, France|24, rue Julien Daillière, Baune, France|Centre Commercial Tertifume 9 rue de Montreuil, Beaucouze, France|42 rue de la Petite Porte, Beaufort en Vallee, France|14 rue Moulin du Roy, Beaulieu sur Layon, France|L'Helvetia 10 rue Paul Doumer, Beaulieu Sur Mer, France|31, rue du Parc, Beaumont en Veron, France|Rue Lapeyrère, Beaumont Sur Leze, France|2 r Des Muriers, Beauzelle, France|Route de Toulouse, Berat, France|24bis, rue de la Motte, Bersee, France|1 Avenue Gambetta, Beziers, France|1, rue du Pinot, Beziers, France|Centre Médical Sémard 39, place Semard, Beziers, France|9 bis Chemin Aussonne, Blagnac, France|208 Cours Saint Louis, Bordeaux, France|28 bd Du President Wilson, Bordeaux, France|8, Boulevard Albert 1er, Bordeaux, France|Centre Hospitalier Pellegrin-Tripode Service de Neurologie Place Amelie Raba-Leon, Bordeaux, France|Résidence Mozart- Apt 56, 2 rue Jean Artus, Bordeaux, France|183 Cours De La Marne, Bordeaux, France|Les Suriaux Rue du Stade, Bouce, France|2 allée Port Larron, Bouchemaine, France|60 Rue Du Moulin, Bouguenais, France|1 Rue Roeckel, Bourg La Reine, France|12 Esplanade du Prado, Bourges, France|121 Avenue du Général de Gaulle, Bourges, France|14 rue Calvin, Bourges, France|16 rue Emile Martin, Bourges, France|24 Boulevard Clémenceau, Bourges, France|86 Avenue Haegelen, Bourges, France|Centre Hospitalier Jacques Coeur Hopital Taillegrain Centre de Gerontologie des Pres Fichaux 6 rue Taillegrain, Bourges, France|Centre Hospitalier Jacques Coeur Hôpital Taillegrain, Bourges, France|9, rue du Lavoir, Brain-sur-Allonnes, France|106, rue du Docteur Lahaye, Breteuil Sur Iton, France|30 rue de Bayeux, Bretteville L'orgueilleuse, France|1 rue mar Leclerc, Broglie, France|Avenue du Gal de Gaulle, Bruges, France|57 impasse des Cades, Cabrieres, France|114, rue Authie, Caen, France|29 rue Lucien Nelle, Caen, France|36, Avenue Du 6 Juin, Caen, France|6 Avenue Du 6 Juin 1944, Caen, France|98 Boulevard du Maréchal Lyautey, Caen, France|Hopital Cote de Nacre Service de Neurologie avenue de la cote de Nacre, Caen, France|Hôpital Côte de Nacre, Caen, France|12 Grand Rue, Calmont, France|16, rue d'Alger, Cambrai, France|Square la Gare, Cande, France|Avenue Buchholz, Cantaleu, France|8 Boulevard Ronceray, Cantenay Epinard, France|3 rue Lucien Cassagne, Carbonne, France|La Chohonniere Im. la Rotonde, Carquefou, France|10 avenue Victor Hugo, Cassis, France|4 route de Toulouse, Castelmaurou, France|311 chemin Draye du Marbre, Castelnau le Lez, France|Avenue A Briand, Castelnau le Lez, France|Villa 54. Résidence le Village, Castelnau le Lez, France|2 rue Clairval, Castelnau-le-Lez, France|Place d'Armes, Cazeres, France|27 rue Emile Landais, Chace, France|15 rue des Sables, Chalonnes sur Loire, France|8 rue Sainte Croix, Chateaugiron, France|16 Bis rue Cherré, Chateauneuf sur Sarthe, France|48 rue Henri Bouriché, Chemellier, France|290 rue du Bocage, Cheux, France|11 rue du 11 Novembre 1945, Chinon, France|Place Pierre Robbe, Chinon, France|14 rue Faidherbe, Cholet, France|16 Av de l'Europe, Cholet, France|18, avenue des Calins, Cholet, France|25 av de Nantes, Cholet, France|43 Bis Rue Nationale, Cholet, France|6 Allée des forgerons, Cholet, France|83 Rue du Paradis, Cholet, France|8 rue Seguin, Château Gontier Bazouges, France|55, rue Eugène Lecoq, Clary, France|7 rue du Docteur Doussain, Clisson, France|5 rue du Couderc, Colomiers, France|7 rue d'Auch, Colomiers, France|13 rue du Docteur Malabouche, Cournonterral, France|4 Bld Jean-Baptiste Oudry, Creteil, France|61 Rue de l'amiral Courbet, Croix, France|9 rue Peyrere, Cubzac les Ponts, France|14 rue du Cezerou, Cugnaux, France|14, rue Cézerou, Cugnaux, France|3 avenue de Toulouse, Cugnaux, France|6 place de Vivier, Cugnaux, France|2 rue Abbé Bernier, Daon, France|116 rue Henri Barbusse, Denain, France|221 rue Villars, Denain, France|25 place de I'Eglise, Deville Les Rouen, France|11 rue Principale, Diebling, France|1 Avenue Edouard VII, Dinard, France|10 rue Mathieu de Dombasle, Dombasle Sur Meurthe, France|La Tour des Charmettes, Domene, France|18, rue Danton, Drancy, France|97, rue Winston Churchill, Dunkerque, France|Résidence Emeraude 71 av Adolphe Geeraert, Dunkerque, France|72 rue Saint Pierre, Durtal, France|2 rue Jean Monnet, Eaunes, France|108 Faubourg Ambrail, Epinal, France|4 rue du Général de Gaulle, Essey les Nancy, France|3 Place de l'Eglise, Etalondes, France|1 rue du Jardin Botanique, Evreux, France|24, rue des Lombards, Evreux, France|41 rue Victor Hugo, Evreux, France|6 Centre Commercial les Peupliers, Evreux, France|Route Nationale 75, Eyguians, France|7 rue Pasteur, Fabregues, France|3 route de Caen, Falaise, France|33 rue du Camp Fermé, Falaise, France|1 rue Renelles, Fecamp, France|2 rue de I'Eglise, Fenouillet, France|126 Route d'Harcourt, Fleury sur Orne, France|11 bis av. Ambroise Croisat, Fontaine, France|3 place Louis Maisonnat, Fontaine, France|1, rue Pierre et Marie Curie, Fontes, France|21 rue Nationale, Forbach, France|2 pl Clemenceau, Fresnes En Woevre, France|34 rue du Marechal Soult, Fresnes, France|10, Rue Du 8 Mai, Fronton, France|10 route des Mares, Frossay, France|74 avenue de la Liberation, Frouard, France|2 avenue des Camelias, Gan, France|2 bis rue Abon, Gap, France|2 bis rue d'Abon, Gap, France|Residence Le Gaughin Bat 1 68 rue Borely, Gardanne, France|Villa Pinede Route St Tropez, Gassin, France|18, avenue de Verdun, Gemenos, France|24, rue de la République, Gemenos, France|12 rue Cohue, Gennes, France|10 rue de la Sèvre, Getigne, France|18 r Stade, Gironde Sur Dropt, France|4 ave de la Gare, Gourdan Polignan, France|Centre Commercial Malartic, Gradignan, France|41, rue Saint-Yves, Grand-Champ, France|12, Place Jean Moulin, Grenoble, France|13 bis rue du General Champon, Grenoble, France|15, chemin Joseph Brun, Grenoble, France|22 av. Leon Blum, Grenoble, France|28 rue Elie Cartan, Grenoble, France|35 Bd Marechal Foch, Grenoble, France|46 boulevard Joseph Vallier, Grenoble, France|6, Boulevard Joseph Vallier, Grenoble, France|9A place Saint-Bruno, Grenoble, France|Centre de Prevention des Alpes 3 place de Metz, Grenoble, France|15, chemin Joseph Brun, Grenoble, France|28 rue Général Ferrié, Grenoble, France|32 rue Gay-Lussac, Grenoble, France|34 avenue de l'Europe Immeuble le Trident A1er etage, Grenoble, France|4 avenue de la Bouexiere, Guerande, France|117 cours de Verdun, Gujan Mestras, France|117, avenue du Maréchal de Lattre de Tassigny, Gujan Mestras, France|6 pl Du Marché - La Hume, Gujan Mestras, France|14 rue de la Liberation, Halluin, France|14 rue Libération, Halluin, France|3, rue Paul Vaillant Couturier, Haulchin, France|12 rue de Maubeuge, Hautmont, France|206 rue Gambetta, Hautmont, France|1 rue Franz Schubert Saint Martin d'Hères, Heres, France|136 av. Ambroise Croizat Saint Martin d'Heres, Heres, France|20 av. Paul Eluard, Heres, France|137 Route de Dax, Hinx, France|2 bis, route de Belin, Hostens, France|5 rue Mairie, Ingrandes Sur Loire, France|10 rue Gaston Monmousseau, Ivry Sur Seine, France|Hopital Charles Foix Service de Gerontologie 37 avenue de la Republique, Ivry Sur Seine, France|119 rue Franchepre, Joeuf, France|6 rue des Ponts, Jort, France|20 avenue de l'Amiral Courbet, Juan Les Pins, France|117 Boulevard du Président Wilson, Juan Les Pins, France|4 Chemin du Tanit, Juan Les Pins, France|Le Tanagra- 10 pl du Pont du Lys, Juan-Les-Pins, France|7 Route de Gagnebert, Juigne sur Loire, France|2 rue Roger Salengro, L'hay Les Roses, France|76, avenue Gabriel Péri, L'Hay les Roses, France|Le Moulin, La Batie-Neuve, France|33 rue Georges Clemenceau, La Bernerie en Retz, France|La buffaie Route du Doreur, La Breille Les Pins, France|Avenue du Général de Gaulle, La Calmette, France|Maison Médicale av. Géneral de Gaulle, La Calmette, France|4 rue Meriadec Laennec, La Chapelle Basse Mer, France|4 rue Mériadec Laënnec, La Chapelle Basse Mer, France|10 rue Aristide Briand, La Chapelle Heulin, France|17 rue de l'Erdre, La Chapelle sur Erdre, France|53 rue Martin Luther King, La chapelle sur Erdre, France|53 rue Martin Luther King, La Chapelle, France|10 , rue Adolphe Abeille, La Ciotat, France|62, ru du Maréchal de Lattre de Tass, La Foret Sur Sevre, France|8 Chemin des Vendéens, La Jubaudiere, France|149 route de Bouguenais, La Montagne, France|9 av. de la Liberation, La Montagne, France|9 rue de la Liberation, La Montagne, France|Village Retraite, La Motte du Caire, France|4 route de Balaruc, La Peyrade, France|11 Place Sainte Anne, La Riche, France|7 route Targon, La Sauve, France|1 rue Joffre, La Teste, France|4 place de la République, La Trinite, France|16 Grand'rue, La Tronche, France|24 boulevard de la Chantourne, La Tronche, France|8 Place Vincent Auriol, Labarthe sur Leze, France|4, chemin Banque, Labastidette, France|34, rue Vacheresse, Lagny-Sur-Marne, France|23 avenue Pasteur, Laragne Monteglin, France|23 rue Louis Pasteur, Laragne Monteglin, France|23 rue Pasteur, Laragne, France|52 Place de la Fontaine, Laragne, France|43 rue Raymond Poincaré, Laxou, France|44 bis rue Paul Bert, Laxou, France|44b rue Paul Bert, Laxou, France|49 r Theophile Gautier, Le Bouscat, France|5 Av. Gauthier Lagardère, Le Bouscat, France|26 Avenue Jean Macé, Le Cailar, France|8 Avenue Louis Blanc, Le Cailar, France|6 rue Colbert, Le Canet, France|1 rue des Orangers, Le Cannet, France|50 Bd Sadi Carnot, Le Cannet, France|69 av. F. Roosevelt, Le Cannet, France|Route de Marignac, Le Fousseret, France|7 place du Commerce, Le Fuilet, France|17 rue du Dr Leveillé, Le Grand Pressigny, France|35 Avenue du Président Kennedy, Le Grand Quevilly, France|60 rue des Moussaillons, Le Grau Du Roi, France|1 Quai de Bretagne, Le Lion D'angers, France|1 rue Pasteur, Le May, France|48 rue des Mauges, Le Mesnil En Vallée, France|111 route de Paris, Le Mesnil Esnard, France|Impasse Mérite, Résidence Lamiot rue L'ecalier, Le Neubourg, France|31 rue Promenade, Le Puy Saint Bonnet, France|21 rue de Nantes, Le Temple de Bretagne, France|364 rue Pasteur, Le Versoud, France|23 rue Jeanne d'Arc, Les Epesses, France|46 rue de Paris, Les Lilas, France|2 rue des Pleiades, Les Mureaux, France|8 Avenue Amiral Chauvin, Les Ponts De Ce, France|68 ter Rue Marjolin, Levallois Perret, France|11 place de l'Eglise, Lherm, France|34 avenue Georges Clémenceau, Libourne, France|46 avenue François Mitterand, Liffre, France|110 BD de la liberté, Lille, France|115 bis rue d'Artois, Lille, France|129 Rue Des Postes, Lille, France|19 Rue Des Postes, Lille, France|236 rue du Faubourg des Postes, Lille, France|24 rue P. Legrand, Lille, France|Hopital Roger Salengro Service de Neurologie C rue Emile Laine, Lille, France|Hôpital Roger Salengro, Lille, France|Parc du Segrais, Lognes, France|928 avenue de Dunkerque, Lomme, France|Place de la Halle, Longages, France|2, Rue Abbée Rappine, Longeville-les-Saint-Avold, France|47, rue Racine, Longue Jumelles, France|126 Avenue des Graves, Lormont, France|126 Avenue des Gravières, Lormont, France|126 rue des Gravieres, Lormont, France|36 avenue de Leuze, Loudun, France|15 ter Bd Clémenceau, Louviers, France|57 rue Dupont de l'Eure, Louviers, France|Chemin des Diligences, Louvigne de Bais, France|70 rue Andre Auguste, Lunel Viel, France|L'ancien Presbytere, Lussan Adeilhac, France|10, avenue Robert Daugey, Luynes, France|1 Place Bellecroix, Manduel, France|1 bis avenue des Coteaux, Marly, France|2 Avenue Long Pré, Marly, France|8 Rue Georges Thiebaux, Mars La Tour, France|1 boulevard Montricher, Marseille, France|134, rue Félix Pyat, Marseille, France|81 rue Jaubert, Marseille, France|81 rue Jaubert, Marseille, France|12 Bld Des Neiges, Marseille, France|325 avenue de Mazargues, Marseille, France|38 bld Rodocanachi, Marseille, France|431 avenue de Marzargues, Marseille, France|63, boulevard Rabateau, Marseille, France|Hopital St Joseph Service de Neurologie 26 boulevard Louvain, Marseille, France|2 Avenue Jean Bouin, Marseille, France|2 chemin de Morgiou, Marseille, France|23 Bd de la Concorde, Marseille, France|250 Bd Romain Rolland, Marseille, France|Groupe Medical de Mazargues 1 av de la Martheline, Marseille, France|13 rue St Eloi, Marseille, France|90 Boulevard de Saint Loup, Marseille, France|Les Camoins 58 Traverse de St Menet, Marseille, France|21 Traverse des Rosiers, Marseille, France|253 ch. de la Madrague-Ville, Marseille, France|Hopital STe Marguerite Unite de Neurologie 270 boulevard de STe Marguerite, Marseille, France|6 av. des martyrs de la Resistance, Martignas, France|5 Avenue du Pdt Allende, Martigues, France|Espace Vénitien 1 av Pres Salvador Allende, Martigues, France|Espace Vénitien, Martigues, France|75 rue Principale, Maze, France|1 Square Chardin, Meaux, France|Centre Commercial La Verriere place Beauval, Meaux, France|11 rue des Tilleuls, Mercy Le Bas, France|206 av de l'Argonne, Merignac, France|Hôpital Felix Marechal 1 rue Xavier Roussel, Metz, France|203 Rue de Vallieres, Metz, France|10 rue de la Republique, Meudon, France|41, Avenue Plaine Fleurie, Meylan, France|7 rue de l'Oisans, Meylan, France|Domus Médica, Meze, France|2 bis Place du Castellas, Milhaud, France|27 rue de la Croix Thomas, Miniac Morvan, France|32 rue Cité, Mire, France|12 Rue Du 8 Mai 1945, Moirans, France|221 R de Pont A Mousson, Montigny les Metz, France|5 rue des Roses, Montigny les Metz, France|2 place de L'Eglise, Montjean-sur-Loire, France|2, rue Delpech, Montpellier, France|25 av de St Lazare - Le Prieure II, Montpellier, France|32 avenue G Clémenceau, Montpellier, France|32, Avenue Georges Clémenceau, Montpellier, France|41 Bld Du Jeu de Paume, Montpellier, France|7 ter rue Rigaud, Montpellier, France|82 avenue d'Assas, Montpellier, France|82, avenue d'ASSAS, Montpellier, France|9 avenue d'Assas, Montpellier, France|9, Avenue d'Assas, Montpellier, France|11 rue Monge, Montpellier, France|11 rue Mongre, Montpellier, France|20 avenue de Toulouse, Montpellier, France|48 rue Robespierre, Montpellier, France|57, route de Lavérune, Montpellier, France|59 av. de Toulouse- Bat B, Montpellier, France|7 rue du Grau, Montpellier, France|12 Faubourg Boutonnet, Montpellier, France|22 Faubourg Boutonnet, Montpellier, France|Hopital Gui de Chauliac 80 rue Augustin Fliche, Montpellier, France|8 rue Pierre Mendès France, Montreuil-Juigne, France|9 rue Sadi Carnot, Montrouge, France|113 Route de Douai, Mouchin, France|11 Rue du Maine, Mouliherne, France|6, route d'Anjou, Mouliherne, France|18 Rue de Metz, Moulin Les Metz, France|Rue du Rieu, Moussac, France|13 rue Clémenceau, Moutiers, France|48, ave Jacques Douzans, Muret, France|48, avenue Jacques Douzans, Muret, France|25 rue Valentin Desormeaux, Murs Erigne, France|34 Rue de Metz, Nancy, France|82 rue Saint Georges, Nancy, France|15 rue Jeanne d'Arc, Nantes, France|181 rue Paul Bellamy, Nantes, France|2 Bd Amiral Courbet, Nantes, France|23 rue Racine, Nantes, France|29 bis rue Pelleterie, Nantes, France|46 bis bd Gabriel Guist'Hau, Nantes, France|59 bld Gaston Serpette, Nantes, France|71 rue du Coudray, Nantes, France|88 rue Gambetta, Nantes, France|Hopital Bellier Service de Geronotologie 41 rue Curie, Nantes, France|42 rue du Roi Baco, Nantes, France|7 rue Blancho, Nantes, France|Cabinet de Neurologie - Consultations, Nantes, France|101 bld de Doulon, Nantes, France|134 rue du Croissant, Nantes, France|142 bld Robert Schuman, Nantes, France|15 rue Guillaume Grootaers, Nantes, France|23 bld Chauviniere, Nantes, France|27 boulevard des Americians, Nantes, France|34 rue de la Gourmette, Nantes, France|46, boulevard Jules Verne, Nantes, France|58 bld Jules Verne, Nantes, France|63 rue de la Bottière, Nantes, France|Route de Morlaas, Navailles Angos, France|12 rue Pasteur, Neuville Sur Escaut, France|12, rue Pasteur, Neuville sur Escaut, France|16 rue Vernier, Nice, France|30, rue Gioffredo, Nice, France|54 bld François Grosso, Nice, France|6, rue Rossini, Nice, France|Hopital de Cimiez Pavillon Mossa 4 avenue de la Reine Victoria, Nice, France|Hôpital Pasteur, Nice, France|32 rue Auguste Gal, Nice, France|47 Bis, Rue Barberis, Nice, France|5 boulevard du General Delfino, Nice, France|5 rue Smolett, Nice, France|L'Esperanza 9 rue de la République, Nice, France|Maison Médical Mutualiste, Nimes, France|Centre Raymond Ruffi 12 rue Alexandre Ducros, Nimes, France|Cabinet Medical place des Goelands, Nimes, France|30 Bd de la Gare, Nort Sur Erdre, France|4 bld de Strasbourg, Nort Sur Erdre, France|8 rue Foch, Noveant Sur Moselle, France|20 Place d'Armes, Nueil, France|2 Allée des Glycines, Orly, France|2 avenue Pesqué, Orthez, France|2, Avenue Pesqué, Orthez, France|3 rue Madame, Orthez, France|125, rue Gambetta, Ouistreham, France|16 rue Aristide Briand, Pacy sur Eure, France|31 rue Jean L'olive, Pantin, France|route de Gizeux, Parcay Les Pins, France|19 boulevard Morland, Paris, France|1 rue Villersexel, Paris, France|6 rue de la Motte-Piquet, Paris, France|88 rue de Sevres, Paris, France|9 Rue de Montessuy, Paris, France|3, Rue Pierre Le Grand, Paris, France|40 rue du Faubourg Montmartre, Paris, France|15 rue de Chabrol, Paris, France|41 rue de la Grange aux Belles, Paris, France|26, rue Picpus, Paris, France|167, boulevard Vincent Auriol, Paris, France|74 rue Dunois, Paris, France|Hôpital Broca - Service de Gérontologie Clinique 54-56 rue Pascal, Paris, France|191 rue d'Alésia, Paris, France|2 rue de la Briqueterie, Paris, France|96 avenue Maine, Paris, France|81, rue de Rome, Paris, France|33, rue Marx Dormoy, Paris, France|34 rue Hermel, Paris, France|13 Villa Curial, Paris, France|20, rue du Télégraphe, Paris, France|7 Rue Saint Blaise, Paris, France|79 rue Boissiere, Paris, France|1 Avenue Mirabelle, Pau, France|28 rue Castelnau, Pau, France|69 rue du 14 Juillet, Pau, France|Centre Hospitalier des Pyrenees Department de Psychogeriatrie 29 av du Marechal Leclerc, Pau, France|Centre Hospitalier des Pyrénées, Pau, France|2, rue de l'Hôtel de Ville, Perols, France|153 Avenue du Général Leclerc, Pessac, France|Le forum, Pignan, France|1 Impasse Pasteur, Pinsaguel, France|83 rue Andorre, Pinsaguel, France|18 place Gambetta, Podensac, France|14 Rue Philippe de Gueldres, Pont A Mousson, France|170 , avenue des Etats-Unis, Pont A Mousson, France|47, boulevard Ney, Pont A Mousson, France|7 rue du Cardinal Mathieu, Pont A Mousson, France|3 bis rue Cacheleux, Pont De L'arche, France|35bis rue du Général de Gaulle, Pont-de-l'Arche, France|1 place Aristide Briand, Pornichet, France|16 av. du Littoral Ste Marguerite, Pornichet, France|26, rue de Tourte, Pornic, France|Immeuble ""Le Roc Rose"", Port De Bouc, France|69 rue du Général Leclerc, Potigny, France|69, rue du Général Leclerc, Potigny, France|169 , rue de l'Avenir, Poulx, France|BP 22-23 rue republique, Preignac, France|24 avenue Charles de Gaulle, Pulnoy, France|7 rue Gambetta, Quarouble, France|Cours Goudouli, Quint Fonsegrives, France|141 rue Roger Salengro, Raimbeaucourt, France|22 avenue de Tolosane, Ramonville Saint Agne, France|22 avenue Tolosane, Ramonville Saint Agne, France|12, rue Louis Braille, Ramonville, France|La Garenne, Rauzan, France|11, rue du Fresne, Renaze, France|Rue Fresnes, Renaze, France|15 rue Emile Souvestre, Rennes, France|Cabinet de Neurologie 4 av Charles Tillon, Rennes, France|Cabinet de Neurologie, Rennes, France|Centre Commercial La Bellangerais, Rennes, France|Centre Espace Performance, Rennes, France|3, Rue de la petite Mairie, Restigne, France|Immeuble Athéna 62 bis rue Aristide Briand, Reze, France|11 rue Sagazan, Rieumes, France|9 Place de la Mairie, Roquemaure, France|Quai le Repos, ZAC St Estève, Roquevaire, France|13 rue de Messan, Rouans, France|91 avenue Jean Lebas, Roubaix, France|106 bis Rampe Bouvreuil, Rouen, France|45 Boulevard de l'Yser, Rouen, France|Hôpital Charles Nicolle Department de Neurologie 1, rue de Germont, Rouen, France|102 rue Méridienne, Rouen, France|6 rue Soye, Sains Orens De Gameville, France|30 Avenue du Général de Gaulle, Saint Avertin, France|4, rue Manet, Saint Barthelemy d'Anjou, France|13 rue du Commandant Thoreux, Saint Briac, France|4 rue Orme, Saint Broladre, France|103 rue Fleurie, Saint Cyr Sur Loire, France|6, rue de Courpouyran, Saint Georges d'Orques, France|15 bis Avenue Marcellin Berthelot, Saint Gilles, France|30 bis avenue Gallieni, Saint Girons, France|2 impasse Dublin, Saint Herblain, France|27 rue d'Aquitaine, Saint Herblain, France|48 avenue Condamine, Saint Just, France|22 avenue du Général Leclerc Les Bougainvillées, Saint Laurent Du Var, France|63 Chaussée du Sillon, Saint Malo, France|Impasse Dr Adrien Gory, Saint Mamert Du Gard, France|3, Rue Du 3 Août 1944, Saint Mars du Désert, France|34 rue Prieuré, Saint martin du Bois, France|9, Résidence Haut Rivage, Rue Jean Xxiii, Saint Max, France|3, rue du Pertuischaud, Saint Nazaire, France|9, Route du Fort de l'Eve, Saint Nazaire, France|1 bis rue Godillot, Saint Ouen, France|1 rue Canot, Saint Privat la Montagne, France|16, Boulevard Darby - Valescure, Saint Raphael, France|7 place Cambronne, Saint Sebastein Sur Loire, France|2, rue Jean Jaurès, Saint Sebastien, France|25, avenue de la Martellière, Saint Sebastien, France|19, Avenue de Verdun, Saint Serin, France|61 rue Anatole France, Saint-Amand Mont-Rond, France|59 Pl. Du 11 Novembre 1918, Saint-Amand, France|Rue des Oratoires, Saint-Anastaise, France|245, avenue Mindin, Saint-Brevin-les-Pins, France|Rue de Clairdouy, Saint-Georges-d-Orques, France|106, Place du Gué des Joncs, Saint-Georges-de-Montaigu, France|2 rue du Prieuré, Saint-Georges-des-Groseilliers, France|60, Impasses des deux moulins, Saint-Georges, France|Boulevard du Général de Gaulle, Saint-Girons, France|22 av. des Thebaudieres, Saint-Herblain, France|ZA la Petite Croix, Saint-Hilaire-de-Chaleons, France|11 Route de La Foret, Saint-Jean-des-Linieres, France|53 Bd du 8 mai 1945, Saint-Macaire-en-Mauges, France|1 Place du 11 Novembre, Saint-Mandrier, France|38 rue Hector Berlioz, Saint-Max, France|112 av Montesquieu, Saint-Medard-en-Jalles, France|69 avenue Montaigne, Saint-Medard, France|4, avenue du Petit Montrevault, Saint-Pierre-Montlimart, France|50 rue Bosq, Saint-Pierre-sur-Dives, France|Avenue du 14 Juillet, Saint-Quentin-la-Poterie, France|1 allee Jean Restout, Saint-Sebastien-de-Morsent, France|Route Lombez, Sainte Foy De Peyrollieres, France|Route Lombez, Sainte-Foy De Peyrollieres, France|146 av de la République, Sainte-Foy-la-Grande, France|3 rue Moulin du Pain, Sainte-Gemmes, France|Quart Thermal, Salies De Bearn, France|6 Allee Du Merlot, Saussan, France|30 rue de la Vallee, Sautron, France|30 rue Vallée, Sautron, France|1, Allée du Mistral, Savigny le Temple, France|21 rue Chatonnay, Savonnieres, France|Place du Port, Segre, France|3 place de la Gare, Sens de Bretagne, France|72, route Châtel, Sercoeur, France|12 rue Jean Boyer, Serifontaine, France|2 route de Sauvagnon, Serres Castets, France|11 rue Football, Sete, France|12 rue Gabriel Péri, Sete, France|41 rue Pierre Sémard, Sete, France|9 rue Alsace Lorraine, Sete, France|Résidence Tarentelle Place E. Herriot, Sete, France|14 rue Boltar, Seysses, France|60 route d'Ox, Seysses, France|22 Place du Docteur Robert, Sisteron, France|41 rue Faidherbe, Somain, France|43, rue Faidherbe, Somain, France|10 rue Benoît Malon, Sotteville les Rouen, France|33 rue Littre, Sotteville les Rouen, France|5 rue Daniel Casanova Le Parc des Amandiers, St Jean De Vedas, France|63 rue Alexandre 1er, St Max, France|15, avenue Montaigne, St Medard en Jalles, France|107 rue de Pornichet, St Nazaire, France|50 rue Bosq, St Pierre Sur Dives, France|27 rue Gaston Chéreau, Thouars, France|1 Ave des Erables, Tierce, France|1 Chemin Courperron, Tilly Sur Seulles, France|1 rue de l'Ecotay, Tinteniac, France|1 Rue des Deportés, Toufflers, France|1, rue des Ecoles, Toufflers, France|60 av Du 8 Mai 1945, Toulenne, France|11 rue De Metz, Toulouse, France|2, rue Paradoux, Toulouse, France|26 av. Jean Rieux, Toulouse, France|35 rue Remusat, Toulouse, France|68 allee Jean Jaures, Toulouse, France|76 allee Jean Jaures, Toulouse, France|Centre Hospitalier de Purpan Service de Neurologie place du Docteur Baylac, Toulouse, France|135 rue Henri Desbals, Toulouse, France|3 rue Vincent Van Gogh, Toulouse, France|3 rue Vincent Van Gough, Toulouse, France|25 Bld des minimes, Toulouse, France|3 rue Saint Famille, Toulouse, France|44 av Etienne Billieres, Toulouse, France|48 all. Charles de Fitte, Toulouse, France|52 av. de Grande Bretagne, Toulouse, France|8 pl. Interieure St Cyprien, Toulouse, France|1 rue Notre Dame, Toulouse, France|14 rue Jean Duplessis, Toulouse, France|2 Boulevard Griffoul Dorval, Toulouse, France|25 av. Marcel Langer, Toulouse, France|28 rue des Arts, Toulouse, France|28, rue des Arts, Toulouse, France|40, bouleard des Récollets, Toulouse, France|7 avenue Frizac, Toulouse, France|12 rue Jean Poncelet, Toulouse, France|150 avenue Jean Chaubet, Toulouse, France|23, rue Limayrac, Toulouse, France|24 av. du Cimetiere, Toulouse, France|44 av. Leon Blum, Toulouse, France|53 r Du Faubourg Bonnefoy, Toulouse, France|7 pl Commerciale Jolimont, Toulouse, France|7 rue Raymond Boulogne Batiment C- apt 23, Toulouse, France|1 et 3 rue Maryse Bastié, Tours, France|1, rue Maryse Bartié, Tours, France|11 rue de Clocheville, Tours, France|15 rue Jacques Marie Rouge, Tours, France|2 rue du Plat d'Etain, Tours, France|26 rue Boisdenier, Tours, France|29 Bis rue Roger Salengro, Tours, France|3 rue Victor Hugo, Tours, France|31, rue Léon Boyer, Tours, France|63 rue Léon Boyer, Tours, France|8 rue de Montbazon, Tours, France|89 rue Jean-Jacques Noirmant, Tours, France|110 rue de Jemmapes, Tours, France|5 rue de la Halle, Treviere, France|26 rue Victor Hugo, Tullins, France|14 Place de l'Eglise, Uchaud, France|Avenue Georges Chauvin, Uzes, France|Batiment Le Sirius place des Cordeliers, Uzes, France|Hotel des Cordeliers, Uzes, France|Hôtel les Cordeliers place des Cordeliers, Uzes, France|Maison de retraite publique Centre de Memoire Route de Nimes, Uzes, France|Hotel les Cordeliers place des Cordeliers, Uzes, France|route de Montpellier, Vailhauques, France|16 rue Anatole France, Valenciennes, France|Res. Saly-2 rue S. Lebourg, Valenciennes, France|11, Boulevard de la République, Valras Plage, France|23 Bd de l'Europe, Vandoeuvre Les Nancy, France|12 Place de la République, Varces, France|Le Mistral II, Vauvert, France|5 avenue de Libourne, Vayres, France|12 lotissement Figeac, Venerque, France|41 rue de la Pomme d'Or, Verneuil sur Avre, France|3 Rue Fontaine, Verny, France|Rue de la Poste, Vers-Pont-du-Gard, France|18 rue de Noailles, Versailles, France|57 rue Charles Lecour, Vertou, France|7 rue Mortaliere, Vertou, France|4 rue du Chapelet, Vezins, France|15 rue du Jard, Vicherey, France|5 rue des Halles, Vieillevigne, France|200 rue Jean Jaures, Vieux, France|4 Rue Beaurepaire, Vihiers, France|145 rue de Chevilly, Villejuif, France|1 bis avenue Outrebon, Villemomble, France|8 Av G. Clémenceau, Villenave D'ornon, France|8 Av. du Gal Clémenceau, Villenave D'ornon, France|Centre Commercial Chamboparc, Villenave D'ornon, France|1 Rue René Cassin, Villeneuve Tolosane, France|164 boulevard des Fontaines, Villeneuve-les-Maguelonne, France|22, rue du Maréchal Foche, Villerupt, France|1, rue des Charmes, Villette D'Anthon, France|10 Chemin Vignes d'Oule, Villeveque, France|88 rue Liverdun, Villey-Saint-Etienne, France|Rue du 8 Mai 1945, Vinay, France|3 avenue Segond, Vincennes, France|56, avenue de Paris, Vincennes, France|11 rue du Faton, Voiron, France|15 route de la Gare, Vourey, France|9, place Sainte Anne, Vue, France|85 rue Jean Jaurès, Vue, France|64 avenue du 14 Juillet, Wattignies, France|Maison Medicale Bichat, Wattrelos, France",,"https://ClinicalTrials.gov/show/NCT00276510"
1849,"NCT00306124","Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment",,"Unknown status","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Healthy","Drug: Levodopa","Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.|Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.|Long-term stability of learning performance after 1 month in healthy subjects.","University Hospital Muenster","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","LL_001 Project on Dementia/MCI","January 2006",,"March 2008","March 22, 2006",,"October 25, 2007","University of Muenster, Department of Neurology, Muenster, North-Rhine Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT00306124"
1850,"NCT00001178","Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders",,"Terminated","No Results Available","Alzheimer's Disease|Dementia|Down's Syndrome",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"597","NIH","Observational",,"810010|81-N-0010","January 19, 1981",,"December 17, 2012","November 4, 1999",,"September 24, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001178"
1851,"NCT01348737","Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers",,"Completed","No Results Available","Alzheimer's Disease|Safety|Tolerability|Blood Concentration|Healthy Volunteers","Drug: AZD3839|Drug: AZD3839 Placebo","Number of Adverse Event as a measure of safety and tolerability of AZD3839 (Part 1)|Number of Adverse Events as a measure of Safety and tolerability of AZD3839 (Part 2)|Time at which maximum concentration occurs in AZD3839 (Part 1)|Maximum observed concentration of AZD3839 in plasma (Part 1)|Time at which maximum concentration occurs in AZD3839 (Part 2)|Maximum observed concentration of AZD3839 in plasma (Part 2)","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","D4080C00001|2011-001337-16","June 2011","November 2011","November 2011","May 5, 2011",,"April 6, 2012","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01348737"
1852,"NCT00208819","A Comparison of Two Standard Therapies in the Management of Dementia With Agitation",,"Completed","No Results Available","Senile Dementia, Alzheimer Type|Dementia, Alzheimer Type|Alzheimer Disease|Dementia","Drug: risperidone|Drug: quetiapine|Drug: olanzapine|Drug: divalproex","Pittsburgh Agitation Scale (PAS)|DiMarco Rating Scale for Extrapyramidal Symptoms|UKU side effect rating scale:autonomic subscale|Behavioral Activity Rating Scale (BARS)|Visual Analog Scale for Nighttime Sleep and Daytime drowsiness (VAS)|Confusion Assessment Method (CAM)|Mini-Mental State Exam (MMSE)|Cohen-Mansfield Agitation Inventory","Emory University|Abbott","All","65 Years and older   (Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0673-2003","September 2003",,"July 2007","September 21, 2005",,"November 13, 2013","Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00208819"
1853,"NCT00253123","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia",,"Completed","No Results Available","Dementia|Alzheimer Disease|Dementia, Vascular","Drug: risperidone","Reduction of >= 30% from baseline to the end of double-blind treatment on the total BEHAVE-AD score.|Change from baseline to the end of double-blind treatment in BEHAVE-AD global rating and total score; total CMAI score; CGI and CGI change from baseline; PSMS; safety evaluations conducted throughout the study.","Janssen, LP","All","55 Years and older   (Adult, Older Adult)","Phase 3","626","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006022",,,"March 1997","November 15, 2005",,"December 3, 2010",,,"https://ClinicalTrials.gov/show/NCT00253123"
1854,"NCT03221296","Fall Prevention - Vestibular Rehabilitation",,"Completed","No Results Available","Alzheimer Dementia (AD)|Vascular Dementia","Behavioral: Vestibular Training (Intervention Group)","Number of falls/near fall experiences through the Falls Video Analysis Questionnaire (FVAQ)|Change in levels of dizziness through the Dizziness Handicap Inventory (DHI)|Change in perceived level of confidence through the Activities Specific Balance Confidence Scale (ABC)|Change in quality of life through The Geriatric Depression Scale (GDS)|Cognitive status through the Montreal Cognitive Assessment (MoCA)|Change in physical functioning through the head impulse test (HIT)|Number of patients who can successfully complete Head Impulse Test (HIT)|Number of patients who can successfully complete Head Shake Test (HST)|Number of patients who can successfully complete Dynamic Gait Index (DGI)|Number of patients who can successfully complete the test of dynamic visual acuity (DVA)|Number of patients who can successfully complete the modified clinical test of sensory interaction on balance (mCTSIB)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Dizziness Handicap Inventory (DHI)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Montreal Cognitive Assessment (MoCA)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Quality of Life in Alzheimer's Disease (QOL-AD)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the World Health Organization Quality of Life - BREF (WHOQOL-BREF)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Activities Specific Balance Confidence scale (ABC)|Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Geriatric Depression Scale (GDS)|Number of patients who successfully adhered to the vestibular rehabilitation program through the Problematic Experiences of Therapy scale (PETs)|Attrition Rate|Number of patients willing to participate|Change in quality of life through The World Health Organization Quality of Life - BREF (WHOQOL-BREF)|Change in quality of life through The Quality of Life in Alzheimer's Disease (QOL-AD)|Change in physical functioning through the head shake test (HST)|Change in physical functioning through the dynamic visual acuity (DVA)|Change in physical functioning through the modified clinical test of sensory interaction on balance (mCTSIB)|Change in physical functioning through the dynamic gait index (DGI)","University Health Network, Toronto","All","65 Years and older   (Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17-5055","June 27, 2017","August 23, 2018","August 23, 2018","July 18, 2017",,"October 11, 2018","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03221296"
1855,"NCT01965756","Effect of Insulin Sensitizer Metformin on AD Biomarkers",,"Completed","Has Results","Alzheimer's Disease|Vascular Dementia|Dementia|Memory Impairment","Drug: Metformin|Drug: Placebos","Word List Memory Total - ADAS-cog|Trails-B","University of Pennsylvania","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UPenn-AHAF_A2012116","January 2013","December 22, 2015","April 2017","October 18, 2013","September 21, 2017","September 21, 2017","University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01965756"
1856,"NCT00149175","Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment",,"Unknown status","No Results Available","Alzheimer's Disease|Dementia|Neurodegenerative Disorders","Other: Blood sampling, skin biopsy",,"Institut National de la Santé Et de la Recherche Médicale, France|Aventis Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)",,"4000","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","02-156|02-346A10","December 2002",,"October 2007","September 8, 2005",,"March 15, 2010","CHU de la Côte de Nacre, Caen, France|Hôpital Sainte-Marguerite, Marseille, France|Hôpital Guillaume et René Laennec, Nantes, France|Hôpital de l'Archet, Nice, France|Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie, Paris, France|Pitié-Salpêtrière Hospital - Fédération de Neurologie, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Hôpital Pontchaillou, Rennes, France|Hôpital Charles Nicolle, Rouen, France|Centre Hospitalier, Saint-Brieuc, France|Hôpital Bellevue, Saint-Etienne, France|Hôpital Civil, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT00149175"
1857,"NCT03863041","Study of Phosphorylated Metabolism Profile as Predictive Biomarker of Cognitive Decline in Memory Complaint.",,"Recruiting","No Results Available","Memory Complaint|Alzheimer Disease|Phosphorylated Metabolism Profile|Magnetic Resonance Spectroscopy","Other: Additional sequence performed during MRI scan","phosphorylated metabolism profile assessment as predictor of cognitive decline in patients with memory complaint.|Correlation between phosphorylated metabolite and final diagnostic of Alzheimer disease or not.|Correlation between phosphoryled metabolite and variability of cerebro spinal fluid biomarkers|Correlation between multinuclear magnetic resonance spectroscopy data and severity of cognitive dysfunction, at the inclusion and at one year.|Evolution of multinuclear magnetic resonance spectroscopy data at one year and cognitive decline at one year.","Poitiers University Hospital","All","up to 90 Years   (Child, Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRMAPHO","April 8, 2019","November 2021","November 2021","March 5, 2019",,"April 16, 2019","CHU of Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT03863041"
1858,"NCT03721042","Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples","OLFADIAG","Not yet recruiting","No Results Available","Alzheimer Disease|Gastric Cancer|Urologic Cancer|Pneumological Cancer","Device: olfactory measuring device","positive predictive value and negative predictive value","Nouvelle Clinique Bonnefon|University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HSM_NCB_2018-1","October 2018","April 2020","October 2020","October 26, 2018",,"October 26, 2018","Nouvelle Clinique Bonnefon, Ales, France",,"https://ClinicalTrials.gov/show/NCT03721042"
1859,"NCT03715855","Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples","OLFADIAG","Not yet recruiting","No Results Available","Alzheimer Disease|Gastric Cancer|Urologic Cancer|Pneumological Cancer","Device: olfactory measuring device","positive predictive value and negative predictive value","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HSM_NCB_2018-1","October 2018","April 2020","October 2020","October 23, 2018",,"October 23, 2018",,,"https://ClinicalTrials.gov/show/NCT03715855"
1860,"NCT02681822","Multi-center Imaging Genetics Studies in China","CHIMGEN","Recruiting","No Results Available","Alzheimer Disease|Schizophrenia|Major Depressive Disorders",,"Brain structure and function measured by MRI scans|Childhood adversities as assessed by Childhood Trauma Questionnaire-Short Form (Chinese Version)","Tianjin Medical University General Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin Medical University Second Hospital|Tianjin First Central Hospital|Pingjin Hospital,Logistics University of Chinese People's Armed Police Forces|School of Medical Imaging, Tianjin Medical University|Tianjin Huanhu Hospital|Beijing Hospital|Chinese PLA General Hospital|Beijing Tongren Hospital|Xuanwu Hospital, Beijing|Peking Union Medical College Hospital|Beijing Normal University|Chinese Academy of Science Institute of Automation|The Second Hospital of Hebei Medical University|The First Affiliated Hospital of Shanxi Medical University|Inner Mongolia Medical College Hospital|First Hospital of Jilin University|The Frist Hospital Of China Medical University|The First Affiliated Hospital of Dalian Medical University|RenJi Hospital|Huashan Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Nanjing PLA General Hospital|The First Affiliated Hospital with Nanjing Medical University|Xuzhou Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Wenzhou Medical University|The First Affiliated Hospital of Anhui Medical University|Shan dong Medical Imaging Research Institute|Qilu Hospital of Shandong University|Yantai Yuhuangding Hospital|Henan Provincial Hospital|The First Affiliated Hospital of Zhengzhou University|Tongji Hospital|Wuhan University|Xiangya Hospital of Central South University|Central South University|Guangdong General Hospital|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|South China Normal University、Hainan General Hospital|First Affiliated Hospital Xi'an Jiaotong University|Xijing Hospital|Tang-Du Hospital|LanZhou University|West China Hospital|Second Affiliated Hospital of Wenzhou Medical University|University of Electronic Science and Technology of China|First Affiliated Hospital of Chongqing Medical University|Southwest Hospital, China|The University of Science and Technology of China|Guangdong No.2 Provincial People's Hospital","All","18 Years to 30 Years   (Adult)",,"10000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","81425013","November 2015","December 2019","December 2020","February 12, 2016",,"April 10, 2019","Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02681822"
1861,"NCT01815112","Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging",,"Terminated","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia","Other: Magnetic resonance imaging|Other: Positron emission tomography","Dynamic FDG (fluoro-deoxyglucose) PET|Aqueductal CSF flow|Follow-up MRI|Follow-up PET","Centre Hospitalier Universitaire, Amiens","All","65 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","PI07-PR-MEYER1|2007-A01009-44","February 2008","April 2013","April 2014","March 20, 2013",,"March 10, 2015","CHU Rouen, Rouen, Haute Normandie, France|CHU Amiens, Amiens, Picardie, France",,"https://ClinicalTrials.gov/show/NCT01815112"
1862,"NCT02228187","Brain-Computer Interface System for Training Memory and Attention in Elderly",,"Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia","Device: Brain-Computer Interface","Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Sum of Scaled Score of the Rivermead Behavioral Memory Test-II|Number of Adverse Events/Serious Adverse Events Reported|Usability Measure of the Brain-Computer Interface training system","Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital|Tan Tock Seng Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B-14-099","July 2015","June 2017","June 2017","August 28, 2014",,"August 2, 2017","Duke-NUS Medical School, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02228187"
1863,"NCT01661894","Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly","3ECog","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia","Device: BrainPalTM","Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Number of Adverse Events reported by participants on the Safety Measurement Form|Usability Measurement","Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital","All","60 Years to 70 Years   (Adult, Older Adult)","Phase 1","82","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-363","April 2012","April 2014","April 2014","August 10, 2012",,"July 25, 2014","Duke-NUS Graduate Medical School, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01661894"
1864,"NCT04073225","Optimizing Cognitive, Environmental, and Neuromotor Stimulation in Traumatic Brain Injury","OCEANS-TBI","Not yet recruiting","No Results Available","Traumatic Brain Injury|Dementia Alzheimers","Device: MindPod Dolphin|Device: Hand Bike","Change in Executive functioning as assessed by the Trail Making Test|Change in Executive functioning as assessed by the Stroop Test|Change in Processing Speed as assessed by the Pattern Comparison Test|Change in Verbal Learning as assessed by the Rey Auditory Verbal Learning Test (RAVLT)|Change in Physical Mobility Outcome as assessed by the Short Physical Performance Battery|Change in brain Magnetic Resonance Imaging (MRI) Volumetrics|Change in Activity as assessed by the Apple Watch Summary Metric Composite Score|Change in Caregiver Burden as assessed by the Zarit Burden Interview|Change in Depressive Symptoms as assessed by the Patient Health Questionnaire - 9 (PHQ-9)|Change in Neuropsychiatric Symptom Burden as assessed by the Neuropsychiatric Inventory Questionnaire Total Score|Change in Brain Diffuse Tensor Imaging (DTI)|Change in Brain Resting State functional MRI (rsfMRI)","Johns Hopkins University|United States Department of Defense","All","40 Years and older   (Adult, Older Adult)","Not Applicable","66","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00218229","October 2019","December 2021","June 2022","August 29, 2019",,"August 29, 2019",,,"https://ClinicalTrials.gov/show/NCT04073225"
1865,"NCT01314638","Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio)","SIELBLEU","Unknown status","No Results Available","Gait Apraxia|Alzheimer Disease|Impaired Cognition","Other: Workshop balances","Adherence to ""Siel Bleu"" balance exercices","University Hospital, Angers","All","65 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009-A01148-49","May 2010","June 2011","June 2011","March 14, 2011",,"March 14, 2011","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT01314638"
1866,"NCT00714571","Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury","Behavioral: Mnemonic strategy training (MST)|Behavioral: Repeated exposure (XP)|Behavioral: Subtracting Cues training","Memory Test Accuracy on Trained Stimuli","VA Office of Research and Development|Emory University","All","18 Years to 88 Years   (Adult, Older Adult)","Phase 1","82","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","B6366-W","July 2008","September 2014","September 2014","July 14, 2008","January 4, 2017","January 4, 2017","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00714571"
1867,"NCT01876823","Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment",,"Completed","Has Results","Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease","Drug: es-citalopram|Drug: Memantine","Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)|Change in Wechsler Memory Scale-III (WMS-III)|Change in Selective Reminding Test - Delayed Recall (SRT-DR)|Change in Trails B|Change in Trails A","New York State Psychiatric Institute","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6277R","April 2006","March 2010","March 2010","June 13, 2013","October 24, 2014","October 24, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01876823"
1868,"NCT02875496","Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain","(BNA™)","Recruiting","No Results Available","Early Onset Alzheimer Disease|Mild Cognitive Impairment|Depression|Aging",,"Developing a BNA database for healthy aging population.","ElMindA Ltd","All","50 Years to 85 Years   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ELM-26","August 2016","August 2022","December 2022","August 23, 2016",,"June 6, 2019","The Villages Health, The Villages, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02875496"
1869,"NCT01465360","Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center",,"Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Vascular Dementia|Fronto-temporal Dementia|Primary Progressive Aphasia|Parkinson' Disease Dementia|Mixed Dementia",,"Sensitivity of AclarusDx™ in AD patients","Exonhit","All","21 Years and older   (Adult, Older Adult)",,"160","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EHTAD/003","November 2011",,,"November 4, 2011",,"July 6, 2012","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Cleveland Clinic Center for Brain Health - Mellen Center, Cleveland, Ohio, United States|Cleveland Clinic Senior Care Assessment - Lakewood Hospital, Lakewood, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01465360"
1870,"NCT00543322","PET Study of the Nicotinic Receptors in Human",,"Terminated","No Results Available","Healthy|Parkinson Disease|Alzheimer Disease|Epilepsy",,,"Commissariat A L'energie Atomique","All","18 Years to 85 Years   (Adult, Older Adult)",,,"Other","Observational","Time Perspective: Prospective","SHFJ-100008","July 2001",,"July 2006","October 12, 2007",,"October 12, 2007","CEA, Service Hospitalier Frederic Joliot, Orsay, France",,"https://ClinicalTrials.gov/show/NCT00543322"
1871,"NCT03030586","ADDIA Proof-of-Performance Clinical Study","ADDIA","Recruiting","No Results Available","Alzheimer Disease (AD)|Frontotemporal Lobar Degeneration|Dementia With Lewy Bodies (DLB)|Parkinson Disease Dementia (PDD)|Progressive Supranuclear Palsy (PSP)|Corticobasal Degeneration (CBD)",,"Blood cell biomarkers for diagnosis of Alzheimer|Biomarkers circulating in body fluids for diagnosis of Alzheimer and/or other dementia type","Amoneta Diagnostics SAS|European Commission|Firalis SA|University Hospital, Strasbourg|Centre Hospitalier Universitaire Vaudois|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Hôpitaux Civils de Colmar|Istanbul University|Assistance Publique - Hôpitaux de Paris|University Hospital, Lille|University Hospital, Geneva|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Erasme University Hospital|University Hospital, Montpellier|Centre Hospitalier Universitaire de Besancon|Centre Hospitalier Universitaire de Nice","All","40 Years to 85 Years   (Adult, Older Adult)",,"800","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ST0056","January 2017","March 2019","March 2019","January 25, 2017",,"December 5, 2018","Cliniques Universitaires Saint-Luc, Brussels, Belgium|ERASME Hospital, Brussels, Belgium|Hopitaux Universitaires de Strasbourg, Strasbourg, Alsace, France|Centre Hospitalier Universitaire de Besançon, Besançon, France|Hôpitaux Civils (Hopital Louis Pasteur) de Colmar, Colmar, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nice, Nice, France|APHP-Hôpitaux Universitaires Pitié Salpêtrière, Paris, France|IRCCS Centro San Giovanni di Dio Fatenenefratelli, Brescia, Italy|Hôpitaux Universitaires de Genève, Genève, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Istanbul University Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT03030586"
1872,"NCT00792662","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",,"Withdrawn","No Results Available","Diabetes Mellitus|Alzheimer's Disease|Apathy|Dementia","Drug: Methylphenidate|Drug: Placebo","Hemoglobin A1C (HbA1c) will be used as marker for glycemic control. It is accepted as the best marker for glycemic control in the previous 120 days. Changes in HbA1c are clinically meaningful.|Apathy Evaluation Scale-Clinician (AES-C): The clinician-rated version will be used for this project. This 18 item scale with scores ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks.|Clinical Global Impression (CGI): This is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment.|Instrumental Activities of Daily Living (IADL): It is a survey assessing eight domains of higher functions necessary to live independently. It is rated from 0-23 based on the independent living of the patient.","University of Nebraska|Alzheimer's Association","All","60 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","470-08-FB","November 2008","December 2011","December 2011","November 18, 2008",,"March 29, 2018","Veterans Affairs Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00792662"
1873,"NCT03862222","Atlas of Retinal Imaging in Alzheimer's Study","ARIAS","Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Mild Dementia|Aging|Cognitive Change","Other: Retinal Imaging|Other: Pupillometry|Other: Contrast Sensitivity|Diagnostic Test: Neuropsychological Evaluation|Genetic: APOE genotyping|Other: blood draw|Other: Gait Assessment|Other: Actigraphy","Structural retinal biomarkers assessed with OCT|Metabolic retinal biomarkers assessed with OCT|vascular retinal biomarkers assessed with OCT-A|general cognition|processing speed, attention|language|memory|physiological","University of Rhode Island|Stuart Sinoff, MD|Peter J Snyder, MD|BayCare Health System","All","55 Years to 80 Years   (Adult, Older Adult)",,"330","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","900-403-2","December 2019","June 2021","November 2024","March 5, 2019",,"October 1, 2019","Morton Plant Hospital, Clearwater, Florida, United States|St. Anthony's Hospital, Saint Petersburg, Florida, United States|University of Rhode Island, Kingston, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT03862222"
1874,"NCT00009204","Serotonergic Pharmacotherapy for Agitation of Dementia","SPAD","Completed","No Results Available","Dementia|Alzheimer Disease|Dementia, Vascular","Drug: Citalopram [Celexa]|Drug: Perphenazine [Trilafon]",,"Bruce Pollock|National Institute of Mental Health (NIMH)|University of Pittsburgh","All","Child, Adult, Older Adult","Phase 3",,"Other|NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","R01MH059666-01|IA0014|DSIR GT-GP","September 1995","April 2000","April 2002","January 24, 2001",,"June 16, 2017","University of Pittsburgh Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00009204"
1875,"NCT03981380","11C-PIB PET Study in MESA at Columbia University",,"Enrolling by invitation","No Results Available","Cognitive Impairment|Vascular Diseases|Alzheimer Disease|Atherosclerosis","Drug: 11C-PIB","Whole Brain 11C-PIB SUVR","José A. Luchsinger|Wake Forest University|National Institute on Aging (NIA)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Phase 2","250","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAS2808|R01AG058969","September 2019","June 2023","June 2023","June 10, 2019",,"September 20, 2019","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03981380"
1876,"NCT03665831","Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults",,"Recruiting","No Results Available","Major Depressive Disorder|Alzheimer Disease|Mild Cognitive Impairment","Device: Brainsway H1-Coil Deep TMS System","Change From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS)|Remission Rates Compared Within Treatment Group|Response Rates Compared Within Treatment Group|Change From Baseline on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Change From Baseline on the Neuropsychological Battery|Change in Functional Connectivity between PFC and Limbic Regions|Change in Perfusion within Prefrontal Cortex (PFC) and Posterior Cingulate Cortex (PCC)|Change in frontal theta power within the Anterior Cingulate Cortex (ACC)","Rotman Research Institute at Baycrest|Brainsway|Centre for Addiction and Mental Health","All","60 Years and older   (Adult, Older Adult)","Not Applicable","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CICP-2-00095","October 23, 2018","January 2020","April 2020","September 11, 2018",,"October 1, 2019","Rotman Research Institute at Baycrest, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03665831"
1877,"NCT02289118","Tau Imaging in Young Onset Dementia",,"Completed","No Results Available","Alzheimer's Disease, Early Onset|Logopenic Progressive Aphasia|Posterior Cortical Atrophy (PCA)","Drug: [18F]-T807 imaging tracer","Determine and compare the similarities and differences in regional brain uptake of [18F]T807 by using standardized uptake value ratio (SUVr) in patients with typical AD, PCA and lvPPA|Correlate patterns of [18F]T807 binding based on standardized uptake value ratio (SUVr) with MRI-based regional volumetric (mm3) and cortical thickness (mm) measures|Correlate CSF markers of amyloid (Aβ1-42) and/or tau (total tau, phospho-tau) pathology (pg/mL) to uptake of [18F]T807 based on standardized uptake value ratio (SUVr).|Correlate [18F]T807 binding based on standardized uptake value ratio (SUVr) with standard cognitive tests.","University of Pennsylvania","All","45 Years to 70 Years   (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","820665","November 2014","December 2018","January 31, 2019","November 13, 2014",,"April 17, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02289118"
1878,"NCT03333837","Improvisational Movement for People With Memory Loss and Their Caregivers","IMOVE","Recruiting","No Results Available","Alzheimer's Disease (Incl Subtypes)|Dementia|Mild Cognitive Impairment","Behavioral: Dance Group|Behavioral: Non-Group Dance|Behavioral: Social Group|Behavioral: No Contact","Change in quality of life in participants with dementia using the QOL-AD|Change in overall mobility using the Expanded Short Physical Performance Battery (eSPPB)|Change in Fullerton Advanced Balance Scale (overall balance)|Change in graph theory-derived measures of network structure calculated on fMRI images.|Change in mood and neuropsychiatric symptoms using the Neuropsychiatric Inventory Questionnaire|Change in depressive and anxiety symptoms of the person with dementia with the Geriatric Depression and Anxiety Scales|Change in apathy of the person with dementia using the Apathy Evaluation Scale|Change in fear of falling using the Falls Efficacy Scale - International (FES)","Wake Forest University Health Sciences|National Center for Complementary and Integrative Health (NCCIH)","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00042460|R01AT009444","February 6, 2018","January 2020","April 2020","November 7, 2017",,"December 13, 2018","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03333837"
1879,"NCT01951118","Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly",,"Completed","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Delirium, Dementia, Amnestic, Cognitive Disorders","Drug: Donepezil","Change over time in Selective Reminding Test (SRT) Scores|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Clinician's Interview Based Impression (CIBIC-plus)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)","New York State Psychiatric Institute|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 4","121","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","6655|1R01AG041795","October 2013","May 2019","May 2019","September 26, 2013",,"August 12, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01951118"
1880,"NCT03828383","In-Home Technology for Dementia Caregivers",,"Recruiting","No Results Available","Dementia|Alzheimer's Disease|Frontotemporal Dementia","Device: In-home technology|Device: Limited in-home technology","Zarit Burden Interview-Short Form|Center for Epidemiological Studies Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Satisfaction with Life Scale|Revised Functional Limitations Battery","University of California, Berkeley|University of California, San Francisco|People Power Company|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","R44AG059458","February 26, 2019","February 2021","February 2021","February 4, 2019",,"April 8, 2019","University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT03828383"
1881,"NCT00385684","Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)","LDOT","Completed","Has Results","Alzheimer Disease|Dementia|Dementia, Vascular|Pain","Drug: hydrocodone/APAP w placebo PRN|Drug: hydrocodone/APAP|Drug: placebo with hydrocodone/APAP PRN","Pain Assessment in Advanced Dementia (PAINAD)","VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Phase 4","11","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F4483-I","October 2007","December 2011","June 2014","October 11, 2006","November 20, 2015","November 20, 2015","Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States|Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa, Alabama, United States|VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00385684"
1882,"NCT00001972","PET Scan of Brain Metabolism in Relation to Age and Disease",,"Completed","No Results Available","Alzheimer's Disease|Brain Neoplasm|Niemann Pick Disease","Drug: 15 O Water",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"123","NIH","Observational",,"940205|94-N-0205","September 1994",,"August 2002","January 19, 2000",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001972"
1883,"NCT01696019","Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders","SCIBHI","Completed","No Results Available","Cognitive Impairment|Dementia|Mild Cognitive Impairment|Alzheimer Disease","Other: Fast walking|Other: Tai Chi|Other: Intellectual stimulation|Other: Contact and testing only","Change in cognitive performance on battery of neuropsychological tests|Change in whole brain volume","University of South Florida|Fudan University","All","60 Years to 79 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Byrd-ARG2007","July 2008","September 2009","September 2009","September 28, 2012",,"September 28, 2012","Huashan Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01696019"
1884,"NCT01264614","Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults",,"Completed","Has Results","Cognitive Decline|Dementia|Alzheimer's Disease|Mild Cognitive Impairment","Behavioral: Strengthening exercise","Stroop Test Performance From Pre- to Post-intervention|Digits Backwards Test Performance From Pre- to Post-intervention|Color Trails Test Performance From Pre- to Post-intervention|Fuld Test Performance From Pre- to Post-intervention|Figure Copy & Delayed Test Performance From Pre- to Post-intervention|Neurophysiological Function Pre- & Post- Intervention","Union College, New York|US Department of Veterans Affairs","All","55 Years and older   (Adult, Older Adult)","Not Applicable","22","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIRB#00663","December 2010","April 2011","April 2011","December 22, 2010","March 11, 2015","March 11, 2015","Stratton VA Medical Center, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT01264614"
1885,"NCT01378026","Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation",,"Unknown status","No Results Available","Amyotrophic Lateral Sclerosis|Alzheimer Disease|Parkinson's Disease",,,"China Medical University Hospital","All","32 Years to 87 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","DMR100-IRB-069","January 2012",,,"June 22, 2011",,"June 22, 2011",,,"https://ClinicalTrials.gov/show/NCT01378026"
1886,"NCT01492322","SPECT Imaging of DAT Genotype","DDAT","Terminated","No Results Available","Nicotine Withdrawal","Radiation: TRODAT","SPECT Imaging of DAT Genotype - Difference in TRODAT binding to DAT","University of Pennsylvania","All","18 Years to 60 Years   (Adult)",,"14","Other","Observational","Observational Model: Cohort","813475","November 2011","July 2013","October 2014","December 14, 2011",,"October 12, 2015","University of Pennsylvania Addiction Treatment Research Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01492322"
1887,"NCT03119259","iCare-AD: A Mobile Health Application for Caregivers of Patients With Dementia.","iCare-AD","Not yet recruiting","No Results Available","Dementia, Alzheimer Type","Behavioral: ABC Clinical Program|Behavioral: HABC 2.0","Behavioral and Psychological Symptoms of Dementia (BPSD) and Caregiver Distress|Health Care Utilization|Caregiver Depression|Caregiver Burden|Caregiver Self-Efficacy","Richard Holden|Indiana University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","448","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","1606267154","July 2019","April 30, 2023","July 1, 2023","April 18, 2017",,"April 18, 2019","Eskenazi Health, Indianapolis, Indiana, United States|IU Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03119259"
1888,"NCT03556280","Multi-Center Study of Sensory Stimulation to Improve Brain Function","Overture","Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment|Mild Cognitive Impairment|Dementia Alzheimers|Dementia, Mild|Dementia, Alzheimer Type|Dementia of Alzheimer Type|Dementia|Cognitive Impairment, Mild|Cognitive Decline","Device: GammaSense Stimulation System (Active Settings)|Device: GammaSense Stimulation System (Sham Settings)","Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Amyloid PET/CT","Cognito Therapeutics, Inc.","All","55 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CA-0005","April 24, 2018","August 2019","October 2019","June 14, 2018",,"February 27, 2019","Brain Matters Research, Delray Beach, Florida, United States|Brain Matters Research, Stuart, Florida, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|ActivMed Practices & Research, Inc, Portsmouth, New Hampshire, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03556280"
1889,"NCT03847038","BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure",,"Recruiting","No Results Available","Alzheimer Disease|Dementia|Mild Cognitive Impairment|Subjective Cognitive Decline","Procedure: Preventive strategies advice and dementia risk estimate disclosure","Risk/benefit of disclosing dementia risk with a PERSONALISED and INDIVIDUALISED approach","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","425","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BBRC-DemPrev-2018","July 16, 2018","July 15, 2021","December 31, 2022","February 20, 2019",,"February 21, 2019","Barcelonabeta Brain Research Center, Barcelona, Please Choose A State, Spain",,"https://ClinicalTrials.gov/show/NCT03847038"
1890,"NCT01723553","Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",,"Completed","No Results Available","Atypical Alzheimers Disease|Logopenic Variant of Primary Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA)","Drug: C-11 PiB","Proportion of subjects with and without microbleeds|Percentage of white matter hyperintensity burden on MRI and ratio of amyloid burden on PiB PET scan|Number of microbleeds per subject","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-007139","November 2012","March 2015","March 2015","November 8, 2012",,"December 21, 2015","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01723553"
1891,"NCT02439099","Retinoic Acid Homeostasis in Neuropsychiatric Diseases","RAHND","Recruiting","No Results Available","Major Depression|Alzheimer's Disease|Alcoholism|Schizophrenia",,"Serum retinoic acid (RA) levels [nM]|For MDD group: MADRS|For MDD group: BDI II|For MDD and schizophrenia Group: Change of serum retinoic acid (RA) levels [nM]|For schizophrenia group: Positive and Negative Syndrome Scale (PANSS) for Schizophrenia|For schizophrenia group: Change of metabolic parametres For schizophrenia group:Positive and Negative Syndrome Scale (PANSS)","Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EA4/002/13","March 2015","December 2019","December 2019","May 8, 2015",,"January 31, 2019","Department of Psychiatry, Charité - Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02439099"
1892,"NCT02612805","The Diabetes and Aquatic Training Study (DATS)","DATS","Completed","No Results Available","Diabetes Mellitus, Type 2","Other: Aerobic training|Other: Combined training|Other: Training placebo","Changes in levels of glycated hemoglobin|Fasting plasma glucose.|Fasting insulin.|Insulin-resistance index (HOMA-IR).|Total cholesterol.|high density lipoprotein.|Low density lipoprotein.|Triglycerides.|Renin|High sensitive C-reactive protein.|Total testosterone.|Cortisol|Testosterone/cortisol ratio.|Peak oxygen uptake.|Oxygen uptake at the second ventilatory threshold.|Percentage of oxygen consumption in the second ventilatory threshold from the peak oxygen uptake.|Systolic blood pressure.|Diastolic blood pressure|Heart rate at rest.|Maximum dynamic muscle strength (1RM) in the knees extension exercise.|Maximum dynamic muscle strength (1RM) in the elbows flexion exercise.|Resistant dynamic muscle strength (maximal repetitions) in the knees extension exercise.|Resistant dynamic muscle strength (maximal repetitions) in the elbows flexion exercise.|Timed up and go test performed at the usual speed.|Timed up and go test performed at the maximal speed.|Sitting-rising test (SRT).|Overall quality of life and in physical, psychological, social relationships and environment domains, evaluated by instrument of World Health Organization (WHOQOL).|Depressive symptoms, evaluated by Depression Inventory Patient Health Questionnarie (PHQ-9)|Sleep quality, evaluated by Pittsburgh Sleep Scale|Levels of sleep Obstructive Apnea, evaluated by Berlin Questionnaire (BQ)|Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.","Hospital de Clinicas de Porto Alegre","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","15-0380","November 2015","December 2015","May 2016","November 24, 2015",,"August 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02612805"
1893,"NCT01552265","Shanghai Mild Cognitive Impairment Cohort Study",,"Completed","No Results Available","Mild Cognitive Impairment",,"Time to Conversion from MCI to ""Probable AD Dementia""|Time to Conversion from MCI to ""Possible AD Dementia"" or ""Probable AD Dementia""|Time to Conversion from MCI to ""All-cause Dementia""|Overall survival|Changes in Neuropsychological examinations|Changes in MRI","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Fudan University","All","up to 90 Years   (Child, Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TRIAD1109","February 2012","February 2017","July 31, 2017","March 13, 2012",,"April 25, 2018","Department of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01552265"
1894,"NCT03682874","Identifying Novel Aging Targets for Treatment of Delirium","INNOVATE","Recruiting","No Results Available","Delirium|Dementia Alzheimers|Respiratory Failure",,"CSF biomarker|Structural/functional MRI dependent measures","Wake Forest University Health Sciences","All","55 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00052417","October 10, 2018","October 2019","October 2020","September 25, 2018",,"April 22, 2019","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03682874"
1895,"NCT03134963","Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Vascular Dementia|Healthy Controls","Other: Transcranial doppler ultrasonography|Other: Blood pressure monitoring|Other: Heart rate monitoring|Other: End tidal CO2 monitoring|Other: Addenbrooke's cognitive examination","Percentage of recruited subjects able to comply with the protocol|Percentage of measurements rejected|Percentage of subjects in which percentage change in CBFv can be derived|Percentage of subjects in which the change in the autoregulation index (ARI) can be derived","University of Leicester","All","18 Years to 100 Years   (Adult, Older Adult)",,"51","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0613","May 5, 2017","December 1, 2017","December 1, 2017","May 1, 2017",,"May 4, 2018","University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|Leicestershire Partnership Trust, Leicester, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03134963"
1896,"NCT03969732","Multimodal Biomarkers for Diagnosis and Prognosis in CAA","CAA","Recruiting","No Results Available","Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease","Drug: 1. amyloid PET；2. T807 PET","PET imaging","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201612094MINB","September 27, 2018","July 31, 2022","July 31, 2022","May 31, 2019",,"May 31, 2019","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03969732"
1897,"NCT02958670","Imaging Tau Deposition in the Brain of Elderly Subjects","Add-Tau","Enrolling by invitation","No Results Available","Mild Cognitive Impairment|Healthy|Alzheimer Disease|Neurocognitive Disorders","Other: 18F-AV-1451 (Tau-PET tracer)","Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal","University of Zurich|Avid Radiopharmaceuticals|Swiss Federal Institute of Technology","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","KEK-ZH_Nr_2016-01079_V5.0","November 2016","June 2021","November 2023","November 8, 2016",,"October 19, 2018","Institute for Regenerative Medicine (IREM), Schlieren, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02958670"
1898,"NCT03542656","Application of Amyloid PET in Cerebral Amyloid Angiopathy","CAA","Completed","No Results Available","Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease","Drug: amyloid PET","PET imaging","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201404065MIND","September 11, 2014","February 17, 2016","March 22, 2018","May 31, 2018",,"May 30, 2019","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03542656"
1899,"NCT02393027","Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999","LBT 999","Terminated","No Results Available","Idiopathic Parkinson Disease","Drug: [18F] LBT-999 PET","Binding potential of [18F] LBT-999|DAT striatal density by estimating the LBT-999 distribution volume|presence of lipophilic metabolites","University Hospital, Tours","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO14-MJR / LBT-999","March 2015","November 2016","May 2017","March 19, 2015",,"May 30, 2017","University Hospital, Tours, France",,"https://ClinicalTrials.gov/show/NCT02393027"
1900,"NCT02253732","Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs","Brain-Muscle","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Parkinson Disease|Healthy Volunteers","Behavioral: 3 months exercise intervention program","muscle microRNAs and myokines|whole body energy metabolism|cognitive function|motoric function|Muscle functional tests","Slovak Academy of Sciences|University Hospital Bratislava","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UEE-SAS","September 2015","September 2017","March 2018","October 1, 2014",,"April 17, 2018","Univeristy Hospital in Bratislava, Bratislava, Slovakia|Inst. Exp. Endocrinology Slovak Acad Sci, Bratislava, Slovakia",,"https://ClinicalTrials.gov/show/NCT02253732"
1901,"NCT02951559","SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies",,"Recruiting","No Results Available","Encephalopathy|HIV-encephalopathy|Alzheimer Dementia","Device: Nasal Brushing","Diagnostic concordance with gold standard diagnostic procedures|Side effects of the nasal brushing|Cytological and immunohistochemistry examination of nasal brushing smear (neuronal abnormalities and expression of specific markers according to the different aetiologies)|OM markers of neuronal damage and amyloid deposition","University of Turin, Italy","All","18 Years and older   (Adult, Older Adult)","Phase 4","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SOLFAMU","March 2016","February 2021","February 2021","November 1, 2016",,"May 3, 2018","University of Torino, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT02951559"
1902,"NCT02675270","Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia",,"Recruiting","No Results Available","Aphasia, Primary Progressive|Anomia|Alzheimer Disease","Behavioral: Phonological|Behavioral: Orthographic|Behavioral: Semantic|Behavioral: Lexical|Behavioral: Untrained","Change in picture naming accuracy for words within each treatment condition during treatment|Change in picture naming accuracy for words within each treatment condition between baseline and first follow-up assessment|Change in picture naming accuracy for words within each treatment condition between baseline and second follow-up assessment","Georgetown University|National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institute on Aging (NIA)|Johns Hopkins University","All","40 Years and older   (Adult, Older Adult)","Not Applicable","85","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01DC011317","November 2011","April 2021","June 2022","February 5, 2016",,"October 24, 2018","Georgetown University Medical Center, Washington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02675270"
1903,"NCT03656107","The Cognition and Flow Study",,"Recruiting","No Results Available","Dementia|Alzheimer Disease|Mild Cognitive Impairment|Aging|Cognitive Impairment","Behavioral: Cognitive Training","Percentage of participants successfully recruited|Percentage of participants able to successfully complete the minimum (15 mins, 3x per week, for 8 weeks) and maximum (30 mins, 5x per week, for 12 weeks) criteria CT program and complete all assessments|Percentage of participants with full bilateral data for CBFv|Percentage of control participants willing to be randomised to waiting list control|Change in cognition score as detected by the Addenbrooke's cognitive examination (ACE-III)|Change in functional status - Lawton Instrumental Activities of Daily Living (IADL)|Change in mood - Geriatric Depression Scale (GDS-15)|Change in quality of life measure - Dementia Quality of Life Measure (DEMQOL)|Percentage increase in cerebral blood flow velocity (CBFv) from baseline","University of Leicester|The Dunhill Medical Trust|University Hospitals, Leicester|Leicestershire Partnership Trust|University of Nottingham|Lumosity","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0677","January 14, 2019","April 1, 2020","April 2, 2020","September 3, 2018",,"May 10, 2019","University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|Leicestershire Partnership Trust, Leicester, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03656107"
1904,"NCT02664584","The Trinity, Ulster and Department of Agriculture Cohort Study","TUDA","Unknown status","No Results Available","Cardiovascular Disease|Osteoporosis|Alzheimer's Disease|Hypertension",,"Blood pressure|Bone health (DXA)|Cognitive function 1 (MMSE)|Cognitive function 2 (FAB)|Cognitive function 3 (RBANS)|Anxiety (HADS)|Depression (CES-D)|Weight|Routine biochemical markers|Vitamin biomarkers|Single nucleotide polymorphisms|Measures of mobility (TUG)|Measures of muscle strength|Bone turnover markers","University of Ulster|University of Dublin, Trinity College|University College Cork|University College Dublin","All","60 Years and older   (Adult, Older Adult)",,"5186","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","08NIR03/113","December 2008","December 2018","December 2018","January 27, 2016",,"January 27, 2016","St James's Hospital, Dublin, Dublin8, Ireland|Human Intervention Studies Unit, Ulster University, Coleraine, Londonderry, United Kingdom|Clinical Translational Research and Innovation Centre (C-TRIC), Altnagelvin Hospital, Londonderry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02664584"
1905,"NCT01217541","Collaboration Between Department of Old Age Psychiatry and Nursing Homes","SAM-AKS","Completed","No Results Available","Dementia|Alzheimer's Disease|Behavioral Symptoms|Agitation","Other: Education and Supervision|Other: Control","Quality of Life in Severe Dementia (QUALID), Person-Centred Care Assessment Tool (P-CAT, 2010)|Neuropsychiatric Inventory - Nursing Home version, Cornell Scale of Depression in Dementia, Registration of Constraints (Kirkevold, 2004)","Sykehuset Innlandet HF|Helse Sor-Ost|Norwegian Department of Health and Social Affairs","All","Child, Adult, Older Adult","Not Applicable","700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","50022","September 2010","March 2012","March 2012","October 8, 2010",,"December 12, 2014","Lillehammer sykehjem, Lillehammer, Oppland, Norway",,"https://ClinicalTrials.gov/show/NCT01217541"
1906,"NCT01153802","An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands",,"Completed","No Results Available","Depressive Disorder","Drug: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin","To estimate the degree of DAT occupancy in brain regions of interest (ROIs)following oral doses of GSK1360707 in healthy male subjects-To estimate the degree of SERT occupancy in brain ROIs following total oral doses of GSK1360707 in healthy male subject|To evaluate the relationship between the plasma concentration and the resultant DAT occupancy by GSK1360707.To evaluate the relationship between the plasma concentration and the resultant SERT occupancy by GSK1360707.|To further assess the safety and tolerability of total oral doses of GSK1360707 including the maximal tolerated dose in the FTIH study (150 mg PO)-To further assess the pharmacokinetics of GSK1360707 in healthy male subjects","GlaxoSmithKline","Male","35 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112773","April 3, 2009","October 12, 2009","October 12, 2009","June 30, 2010",,"June 27, 2017","GSK Investigational Site, Harrow, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01153802"
1907,"NCT02226835","Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198",,"Terminated","No Results Available","Age-Related Macular Degeneration|Alzheiner's Disease|AMD",,"Photographs and images of subjects' eyes|OCT measurement","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","45 Years and older   (Adult, Older Adult)",,"33","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","140173|14-EI-0173","August 13, 2014","January 24, 2017","January 24, 2017","August 27, 2014",,"September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02226835"
1908,"NCT04117178","Monitoring Anti-Dementia Drugs by Serum Levels","MONANTI","Not yet recruiting","No Results Available","Dementia|Dementia With Lewy Bodies|Dementia in Parkinsons Disease|Dementia Alzheimers|Alzheimer Disease","Drug: Donepezil|Drug: Memantine|Diagnostic Test: Measurement of serum level of anti-dementia drug","Change of Mini Mental State Examination (MMSE) test result|Change of Adenbrooke's Cognitive Exam (ACE) test result|Change of Neuropsychiatric Inventory Questionnaire (NPI-Q) score result|Change of Disability Assessment for Dementia (DAD) score result|Change of Clinical Global Impression (CGI) score result|Serum level of donepezil|Serum level of memantine|Level of compliance to treatment|Change in Geriatric Depression Scale (GDS) symptoms score|Change in quantitative electroencephalogram (qEEG)|Cyp2D6 gene test|genetic test for BcHE K variant|genetic test for APOe4 allele status.","Zealand University Hospital|Epilepsihospitalet Filadelfia","All","18 Years and older   (Adult, Older Adult)","Phase 4","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","REG-007-2018|2017-002707-10","November 2019","November 2021","November 2021","October 7, 2019",,"October 7, 2019",,,"https://ClinicalTrials.gov/show/NCT04117178"
1909,"NCT00593138","Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate",,"Completed","No Results Available","Drug Binding to DAT Receptors","Drug: dex-methylphenidate","DAT occupancy from PET scan results","Massachusetts General Hospital","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2006-p-001610","December 2006","December 2007","December 2009","January 14, 2008",,"October 22, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00593138"
1910,"NCT03653156","China Cognition and Aging Study","COAST","Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease, Late Onset|Familial Alzheimer Disease (FAD)|Vascular Cognitive Impairment|APOE Gene Cohort (Cognitive Normal Subjects)",,"The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design|The conversion rate of normal to MCI to AD in Chinese|The biomarkers for normal (pre-MCI), MCI and AD diagnosis|The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels","Capital Medical University|Beijing Tiantan Hospital|Beijing Chao Yang Hospital|Fu Xing Hospital, Capital Medical University|Peking Union Medical College Hospital|Peking University First Hospital|Peking University Third Hospital|Chinese PLA General Hospital|China-Japan Friendship Hospital|Beijing Geriatric Hospital|The First Affiliated Hospital of Dalian Medical University|Fujian Medical University Union Hospital|Guangzhou Psychiatric Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Handan Central Hospital|Hebei General Hospital|First Hospital of Shijiazhuang City|Tangshan Worker's Hospital|Hunan Provincial People's Hospital|Kaifeng Central Hospital|People's Hospital of Zhengzhou University|Wuhan University Zhongnan Hospital|First Affiliated Hospital of Harbin Medical University|Tongji Hospital|People's Hospital Affiliated Hubei Medical University|The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University|First Hospital of Jilin University|China-Japan Union Hospital, Jilin University|Subei People's Hospital of Jiangsu|Nantong University Affiliated Hospital|Mineral General Hospital, Xuzhou|Jiangxi Provincial People's Hopital|Anshan Central Hospital|The Affiliated Zhongshan Hospital of Dalian University|First Hospital of China Medical University|Baotou Central Hospital|General Hospital of Ningxia Medical University|The People's Hospital of Ningxia|The Affiliated Hospital of Qingdao University|The 88th Hospital of PLA|Qilu Hospital of Shandong University|Qilu Hospital of Shandong University (Qingdao)|Shandong Provincial Hospital|Qingdao Municipal Hospital|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi'an Jiaotong University|Ruijin Hospital|RenJi Hospital|Shanghai Changzheng Hospital|Afﬁliated Hospital of North Sichuan Medical College|Tianjin Huanhu Hospital|Tianjin Medical University General Hospital|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region|Ningbo Medical Center Lihuili Hospital|First Affiliated Hospital of Wenzhou Medical University|First Affiliated Hospital of Zhejiang University|Shao Yifu Hospital of Zhejiang Medical University|Zhejiang Provincial People’s Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|The Second Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Anhui Medical University|People's Hospital of Chongqing|Dongfang Hospital Beijing University of Chinese Medicine|Zigong First People's Hospital","All","18 Years and older   (Adult, Older Adult)",,"25000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYXWJ001","January 10, 2008","January 1, 2028","January 1, 2028","August 31, 2018",,"August 31, 2018","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Geriatric Hospital, Changping, Beijing, China|Beijing Chao Yang Hospital, Chaoyang, Beijing, China|China-Japan Friendship Hospital, Chaoyang, Beijing, China|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Fengtai, Beijing, China|Chinese PLA General Hospital, Haidian, Beijing, China|Fu Xing Hospital, Capital Medical University, Haidian, Beijing, China|Peking University Third Hospital, Haidian, Beijing, China|Peking Union Medical College Hospital, Xicheng, Beijing, China|Peking University First Hospital, Xicheng, Beijing, China|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Yuzhong, Chongqing, China|The Second Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China|Fujian Medical University Union Hospital, Fujian, Guangdong, China|Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan, Guangdong, China|First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China|Handan Central Hospital, Handan, Hebei, China|First Hospital of Shijiazhuang City, Shijiazhuang, Hebei, China|Tangshan Worker's Hospital, Tangshan, Hebei, China|Hebei General Hospital, Zhijiazhuang, Hebei, China|First Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|Kaifeng Central Hospital, Kaifeng, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|People's Hospital of Zhengzhou, Zhengzhou, Henan, China|People's Hospital Affiliated Hubei Medical University, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University, Wuhan, Hunan, China|Wuhan University Zhongnan Hospital, Wuhan, Hunan, China|Xiangya Hospital of Central South University, Wuhan, Hunan, China|Nantong University Affiliated Hospital, Nantong, Jiangsu, China|Subei People's Hospital of Jiangsu, Subei, Jiangsu, China|Mineral General Hospital, Xuzhou, Xuzhou, Jiangsu, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|China-Japan friendship Hospital of Jilin university, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|Changda Hospital, Anshan, Anshan, Liaoning, China|Affiliated Zhongshan hospital of Dalian university, Dalian, Liaoning, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|First Hospital of China Medical University, Shenyang, Liaoning, China|Baotou Central Hospital, Baotou, Nei Monggol, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia, Yinchuan, Ningxia, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jining, Shandong, China|Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China|QingDao Municipal Hospital, Qingdao, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|The 88th Hospital of PLA, Tai'an, Shandong, China|Shanghai Changzheng Hospital, Huangpu, Shanghai, China|Ruijin Hospital, Luwan, Shanghai, China|RenJi Hospital, Putong, Shanghai, China|The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shanxi, China|Tang-Du Hospital, Xi'an, Shanxi, China|Afﬁliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China|Zigong First People's Hospital, Zigong, Sichuan, China|Tianjin Medical University General Hospital, Heping, Tianjin, China|Tianjin Huanhu Hospital, Jinnan, Tianjin, China|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Urumqi, Xinjiang, China|First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Shao Yifu Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, Zhejiang, China|First Affiliated Hospital of Wenzhou Medical Univeristy, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03653156"
1911,"NCT00001480","The Evaluation and Follow-up of Individuals With Memory Disorder",,"Completed","No Results Available","Alzheimer's Disease|Dementia|Healthy|Memory Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)",,"750","NIH","Observational",,"950096|95-M-0096","March 21, 1995",,"March 31, 2007","November 4, 1999",,"July 2, 2017","Catholic University of America, Washington, D.C., District of Columbia, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00001480"
1912,"NCT03448445","A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting","CONCORDE","Active, not recruiting","No Results Available","Mild Cognitive Impairment","Other: Usual care setting","Rate of Alzheimer's Disease (AD) conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI|Mean change from Baseline in Seoul Neuropsychological Screening Battery-Dementia Version scores|Mean change from Baseline in Clinical Dementia Rating (CDR) Sum of Boxes scores|Mean change from Baseline in the CDR-Global Score|Mean change from Baseline in Geriatric Depression Scale scores|Mean change from Baseline in the volume of the whole brain according to Baseline demographics|Mean change from Baseline in other structural magnetic resonance imaging (MRI) measures according to Baseline demographics|Mean change from Baseline in the volume of the hippocampus according to Baseline demographics","Eisai Korea Inc.|Eisai Inc.","All","55 Years to 89 Years   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","E0000-M082-603","June 22, 2018","March 2021","March 2021","February 28, 2018",,"May 30, 2019","Eisai Trial site_12, Anyang, Korea, Republic of|Eisai Trial site_11, Busan, Korea, Republic of|Eisai Trial site_15, Busan, Korea, Republic of|Eisai Trial site_08, Changwon, Korea, Republic of|Eisai Trial site_09, Daegu, Korea, Republic of|Eisai Trial site_05, Daejeon, Korea, Republic of|Eisai Trial site_03, Gachon, Korea, Republic of|Eisai Trial site_07, Guri, Korea, Republic of|Eisai Trial site_10, Gwangju, Korea, Republic of|Eisai Trial site_16, Jeju, Korea, Republic of|Eisai Trial site_01, Seoul, Korea, Republic of|Eisai Trial site_02, Seoul, Korea, Republic of|Eisai Trial site_04, Seoul, Korea, Republic of|Eisai Trial site_06, Seoul, Korea, Republic of|Eisai Trial site_13, Seoul, Korea, Republic of|Eisai Trial site_14, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03448445"
1913,"NCT00147693","Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?",,"Completed","No Results Available","Dementia, Vascular|Dementia|Alzheimer Disease|Lewy Body Disease","Behavioral: Diagnosis of caregivers' problems|Behavioral: Professional service: treatment of problems by counseling or practical support","Patients admissions to nursing homes or residential homes. This outcome is the most important input for the estimation of cost differences between the intervention group and controls.|Secondary outcome for cost estimation is patient and caregiver related costs estimated by ""Resource Utilisation in Dementia"" (RUD), including time spent on caregiving, use of health care services by caregivers and patients and additional productivity.","Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development","All","Child, Adult, Older Adult","Not Applicable","304","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","SCAD|ZonMw grant no 945-04-152","June 2005","February 2006","February 2006","September 7, 2005",,"October 1, 2008","Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00147693"
1914,"NCT03846492","Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS","tTED","Recruiting","No Results Available","Alzheimer Disease|Dementia, Mixed|Dementia|Behavior Problem|Dementia, Alzheimer Type","Device: Transcranial Direct Current Stimulation (tDCS)","Long Interval Cortical Inhibition (LICI), a TMS paradigm, will be used to assess the extent of cortical inhibition|Short Interval Cortical Inhibition (SICI), another TMS paradigm, will be used to assess the extent of cortical inhibition|The rate of successful completion of the 2 week tDCS treatment course|Effects of a 2 week course of tDCS on cortical/inhibition balance|Change in clinical symptoms of agitation as assessed by the Clinical Global Impression of Change (CGIC)|Change in clinical symptoms of agitation as assessed by the Neuropsychiatric Inventory (NPI) agitation/aggression subscale score|Change in clinical symptoms of agitation as assessed by the Cohen Mansfield Agitation Inventory scores (CMAI)|Assess brain structure using Magnetic Resonance Imaging (MRI)|Assess resting state connectivity using Functional Magnetic Resonance Imaging (fMRI)|Assess GABA and glutamate levels using Magnetic Resonance Spectroscopy (MRS)","Centre for Addiction and Mental Health|BrightFocus Foundation","All","50 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","093/2018","April 24, 2019","June 2022","June 2022","February 19, 2019",,"August 15, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03846492"
1915,"NCT03031184","Study of Mirtazapine for Agitation in Dementia","SYMBAD","Recruiting","No Results Available","Dementia","Drug: Mirtazapine|Other: Placebo","Cohen Mansfield Agitation Inventory (CMAI) score (Long Form, 29 questions)","University of Sussex|Norwich Clinical Trials Unit|University of East Anglia|University of Cambridge|University College, London|London School of Economics and Political Science|University of Manchester|University of Newcastle Upon-Tyne|Birmingham and Solihull Mental Health NHS Foundation Trust|Alzheimer's Society|The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT","All","18 Years and older   (Adult, Older Adult)","Phase 3","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15/SC/0606","January 2017","January 2020","July 2020","January 25, 2017",,"November 28, 2018","Sube Banerjee, Brighton, Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03031184"
1916,"NCT02843906","Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?","BIPAGE","Unknown status","No Results Available","Senile Plaques|Tau Proteins|Alzheimer Disease|Bipolar Disorders|Mild Cognitive Impairment","Procedure: Lombar Punction|Radiation: Magnetic Resonance Imaging (MRI)|Radiation: Positron-Emission Tomography (TEP) /(FDG)|Other: Psychiatric tests|Other: Neuropsychological Tests|Genetic: Apolipoprotein (ApoE) detection","Functionnal/Cognitive evaluation|Psychatric evaluation|Brain MRI","University Hospital, Grenoble|University Hospital, Tours|Assistance Publique - Hôpitaux de Paris|University Hospital, Marseille|Hospices Civils de Lyon|Centre Hospitalier Universitaire de Besancon|Central Hospital, Nancy, France|University Hospital, Clermont-Ferrand|Versailles Hospital|University Hospital, Montpellier|Reims University Hospital|Centre Hospitalier Princesse Grace","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","38RC13.217","July 2015","July 2018","July 2018","July 26, 2016",,"July 26, 2016","University Hospital, Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02843906"
1917,"NCT01505504","Mirtazapine in Alzheimer-associated Weight Loss",,"Completed","No Results Available","Alzheimer's Disease|Weight Loss|Mixed Dementia|Dementia","Drug: mirtazapine","body weight","Brugmann University Hospital","All","Child, Adult, Older Adult",,"22","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","MIRTA-2012","January 2004","November 2011","December 2011","January 6, 2012",,"January 6, 2012","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT01505504"
1918,"NCT00396825","Video-Based Coping Skills Training for Caregivers",,"Completed","No Results Available","Caregivers","Behavioral: Video-based coping skills training with telephone coaching","Center for Epidemiological Studies Depression scale|Spielberger State-Trait Anger and Anxiety Scales|Perceived Stress Scale|Pittsburgh Sleep Quality Index|Heart rate and blood pressure at rest and during recall of caregiver situation|Salivary cortisol upon awakening, 30 minutes later, and prior to going to bed at night","Williams LifeSkills|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 2","116","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2R44AG025593-04A;|2R44AG025593","January 2007","May 2009","May 2009","November 8, 2006",,"August 13, 2012","Williams LifeSkills, Inc., Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00396825"
1919,"NCT00654563","Memory Disorders Registry",,"Completed","No Results Available","Dementia|Alzheimer's Disease|Parkinson Disease|Huntington Disease",,,"Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB12126","August 2007","March 2012","March 2012","April 8, 2008",,"March 27, 2012","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00654563"
1920,"NCT02767609","Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging",,"Completed","Has Results","Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor","Device: Magnetic Resonance Imaging","Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.","Loma Linda University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5140083","May 2014","March 3, 2017","March 3, 2017","May 10, 2016","April 30, 2019","April 30, 2019",,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02767609"
1921,"NCT03399591","Gait Disorders in Patients With Cognitive Decline",,"Recruiting","No Results Available","Gait Disorders, Neurologic",,"walking test","University Hospital, Strasbourg, France","All","50 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","6963","May 2, 2017","March 2019","March 2019","January 16, 2018",,"July 6, 2018","Service de Gériatrie Hôpital de la Robertsau, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03399591"
1922,"NCT00448318","Evaluating the Effects of Music Interventions on Hospitalised People With Dementia",,"Unknown status","No Results Available","Dementia|Alzheimer's Disease|Dementia, Vascular|Lewy Body Disease","Procedure: Music Therapy","Mini Mental State Examination: baseline cf. post intervention scores.|Hierarchic Dementia Scale: baseline cf. post intervention scores.|Geriatric Depression Scale: baseline cf. post intervention scores.|Note: post intervention measures taken within 24 hours of final therapeutic intervention session|EEG fast/slow ratio: baseline cf. post intervention scores.|EEG Coherence: baseline cf. post intervention scores.|EEG evoked potentials:baseline cf. post intervention scores.","National Ageing Research Institute, Australia","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","WKG_07_BB","March 2007",,"October 2008","March 16, 2007",,"March 16, 2007","National Ageing Research Institute, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00448318"
1923,"NCT00056524","Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)",,"Completed","No Results Available","Alzheimer's Disease|Stroke|Parkinson's Disease|Traumatic Brain Injury","Drug: AVP-923","emotional control","Avanir Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-AVR-107|AVP-923","February 2003","June 2007","June 2007","March 18, 2003",,"July 14, 2016","Barrow Neurological Institute, Phoenix, Arizona, United States|Center for Neurologic Study, La Jolla, California, United States|UCLA School of Medicine, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United States|George Washington University Medical Faculty Assoc., Washington, District of Columbia, United States|Neurological Associates, Ft. Lauderdale, Florida, United States|University of Miami Dept. of Neurology, Miami, Florida, United States|Miami Jewish Home & Hospital for the Aged, Miami, Florida, United States|Allied Clinical Trials, Miami, Florida, United States|Renstar Medical Research, Plantation, Florida, United States|Suncoast Neuroscience Associates Inc., St. Petersburg, Florida, United States|Tampa, Florida, United States|Neurology & Headache Specialist of Atlanta, L.L.C., Decatur, Georgia, United States|Consultants in Neurology LTD, Northbrook, Illinois, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Neurological Associates, P.C., Lincoln, Nebraska, United States|Upstate Clinical Research, Albany, New York, United States|DENT Neurologic Group L.L.P., Amherst, New York, United States|Hospital for Joint Diseases MS Care Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|NeuroCare Center, Inc., Canton, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Memory and Aging Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma, United States|Lehigh Valley Neurosciences and Pain Research Center, Allentown, Pennsylvania, United States|Westmoreland Neurology, Greensburg, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|MCP-Hahnemann University, Philadelphia, Pennsylvania, United States|Penn Neurological Institute, Philadelphia, Pennsylvania, United States|Neurological Associates of Delaware Valley, Upland, Pennsylvania, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Neurology and Neurosurgery Associates of Tacoma, Tacoma, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00056524"
1924,"NCT01370954","NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)",,"Completed","No Results Available","Early Memory Loss|Mild Cognitive Impairment|Alzheimer's Disease|Vascular Dementia","Other: CerefolinNAC®","To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD)|To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale","Pamlab, Inc.|InfoMedics, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)",,"204","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NAC-003","May 2011","November 2012","December 2012","June 10, 2011",,"May 9, 2013","Falls Neurology and Memory Center, Hickory, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01370954"
1925,"NCT00488670","Escitalopram and Depression in Elderly Alzheimer's Patients",,"Terminated","No Results Available","Depressive Disorder","Drug: Escitalopram","Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.|Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study","University of British Columbia","All","50 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H07-00050","December 2010","June 2011","June 2011","June 20, 2007",,"June 6, 2011","Mt. St. Joseph's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00488670"
1926,"NCT03631069","Detecting Dementia in the Retina Using Optical Coherence Tomography",,"Not yet recruiting","No Results Available","Dementia Alzheimers|Dementia|Dementia, Vascular|Dementia Senile",,"Retinal nerve fiber layer thickness|Ganglion cell layer thickness|Macular volume","Moorfields Eye Hospital NHS Foundation Trust","All","40 Years and older   (Adult, Older Adult)",,"200000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KEAP1004","September 2019","August 2022","August 2022","August 15, 2018",,"August 16, 2019","Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03631069"
1927,"NCT03702907","DC Longitudinal Study on Aging and Specimen Bank","(DC LSOA)","Recruiting","No Results Available","Alzheimer Disease|Dementia|Mild Cognitive Impairment|Aging|Aging Disorder",,"CDR","Georgetown University","All","45 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007-249","January 1, 2007","January 2027","January 2027","October 11, 2018",,"October 11, 2018","Georgetown University Memory Disorders Program, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03702907"
1928,"NCT02612688","Pragmatic Trial of Video Education in Nursing Homes","PROVEN","Completed","No Results Available","Alzheimer Disease|Dementia|Heart Failure|Pulmonary Disease, Chronic Obstructive","Behavioral: ACP Video Program","Hospital transfer rate in target cohort|Hospital transfer rate among long-stay residents without advanced illness|Hospital transfer rate among short-stay residents with advanced illness|Hospital transfer rate among short-stay residents without advanced illness|Proportion of target cohort that has an advance directive status|Proportion of long-stay residents without advanced illness that has an advance directive|Proportion of short-stay residents with advanced illness that has an advance directive|Proportion of short-stay residents without advanced illness that has an advance directive|Average time to switch advance directives in target cohort|Average time to switch advance directives among long-stay residents without advanced illness|Average time to switch advance directives among short-stay residents with advanced illness|Average time to switch advance directives among short-stay residents without advanced illness|Proportion of target cohort receiving any burdensome treatment|Proportion of long-stay residents without advanced illness receiving any burdensome treatment|Proportion of short-stay residents with advanced illness receiving any burdensome treatment|Proportion of short-stay residents without advanced illness receiving any burdensome treatment|Proportion of target cohort with any hospice enrollment|Proportion of long-stay residents without advanced illness with any hospice enrollment|Proportion of short-stay residents with advanced illness with any hospice enrollment|Proportion of short-stay residents without advanced illness with any hospice enrollment|Proportion of target cohort that has Medicare ACP billing codes|Proportion of long-stay residents without advanced illness that has Medicare ACP billing codes|Proportion of short-stay residents with advanced illness that has Medicare ACP billing codes|Proportion of short-stay residents without advanced illness that has Medicare ACP billing codes","Brown University|National Institute on Aging (NIA)|Hebrew SeniorLife|Massachusetts General Hospital|Genesis HealthCare|PruittHealth","All","65 Years and older   (Older Adult)","Not Applicable","197692","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","4UH3AG049619-02","March 1, 2016","May 31, 2019","May 31, 2019","November 24, 2015",,"August 9, 2019","PruittHealth, Norcross, Georgia, United States|Genesis HealthCare, Kennett Square, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02612688"
1929,"NCT03403257","Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)","BASIC-C","Enrolling by invitation","No Results Available","Dementia|Dementia Alzheimers|Dementia, Vascular|Dementia, Mixed","Other: No interventions","Prevalence of mild cognitive impairment and dementia in Mexican Americans and non Hispanic whites|Trajectory of cognitive function in Mexican Americans and non Hispanic whites|Caregiver outcomes and changes over time|Needs and community available resources for cognitive impairment","University of Michigan|National Institutes of Health (NIH)","All","65 Years and older   (Older Adult)",,"776","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01NS100687","April 11, 2018","June 30, 2022","September 30, 2022","January 18, 2018",,"April 25, 2019","Corpus Christi Nueces County Health District, Corpus Christi, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03403257"
1930,"NCT03175874","Autophagy and Pathological Aging","AVP","Recruiting","No Results Available","Osteoporosis","Procedure: Hip bone sampling","Quantification of autophagy|Bone mineral density|25 OH vitamin D (ng/ml).","Centre Hospitalier Universitaire de Nice","Female","65 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17-PP-03","December 20, 2017","February 2020","February 2020","June 5, 2017",,"February 7, 2018","BREUIL, Nice, France",,"https://ClinicalTrials.gov/show/NCT03175874"
1931,"NCT02585232","Optimizing Dementia Care","ODeC","Recruiting","No Results Available","Alzheimer's Disease|Dementia|Dementia, Vascular|Caregivers|Veterans","Behavioral: Counseling (C)|Behavioral: Care Consultation (CC)","Change from baseline in caregiver burden scores on the Zarit Caregiver Burden Inventory|Change from baseline in relationship strain on the Dyadic Adjustment Scale|Change from baseline in Quality of Life|Change from baseline depressive symptoms on the Cornell Scale for Depression in Dementia|Rates of placement in long-term care facilities at 12 months","VA Office of Research and Development","All","19 Years and older   (Adult, Older Adult)","Not Applicable","68","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D1824-W","October 1, 2016","December 31, 2019","October 31, 2020","October 23, 2015",,"August 1, 2019","Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02585232"
1932,"NCT01953705","n-3 PUFA for Vascular Cognitive Aging",,"Active, not recruiting","No Results Available","Age Related Cognitive Decline|Alzheimer's Disease|Vascular Dementia|Endothelial Dysfunction|Executive Dysfunction","Drug: Omega 3 PUFA|Drug: Placebo","total cerebral white matter hyperintensity volume|biomarkers of endothelial health|total brain atrophy|medial temporal lobe atrophy|ventricular expansion","Oregon Health and Science University|National Institute on Aging (NIA)","All","75 Years and older   (Older Adult)","Phase 2","102","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01AG043398|R01AG043398-01A1","May 2014","July 2019","August 2019","October 1, 2013",,"June 17, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01953705"
1933,"NCT03643003","Music Therapy for Persons With Dementia",,"Completed","No Results Available","Quality of Life|Social Interaction|Emotions|Mood|Feelings|Alzheimer Disease|Dementia","Behavioral: Music therapy|Behavioral: Non-Music Verbal Interaction (Placebo)","Social Engagement Behavior Score|Emotion Behavior Score|Mood Behavior Score|Self-Reported Feelings Score|Quality of Life Behavior Score","Alaine Hernandez|University of Iowa","All","65 Years and older   (Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201709731","May 25, 2018","September 30, 2018","September 30, 2018","August 22, 2018",,"October 5, 2018","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03643003"
1934,"NCT02050464","Computational Tools for Early Diagnosis of Memory Disorders","ProsKuopio","Completed","No Results Available","Alzheimer Disease|Frontotemporal Dementia|Dementia, Vascular|Mild Cognitive Impairment",,"Sensitivity, specificity and accuracy of models for diagnosis of memory disorders","University of Eastern Finland|University of Sheffield|VTT Technical Research Centre of Finland|Klinik Hirslanden, Zurich|Sheffield Teaching Hospitals NHS Foundation Trust","All","50 Years to 85 Years   (Adult, Older Adult)",,"126","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","207094","December 2013","April 2017","April 2017","January 30, 2014",,"May 4, 2017","Department of Neurology and Brain Research Unit, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland|Kuopio University Hospital, Kuopio, Finland|VTT Technical Research Centre of Finland, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT02050464"
1935,"NCT03360019","Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:",,"Not yet recruiting","No Results Available","Dementia, Vascular|Alzheimer Dementia|Lewy Body Dementia With Behavioral Disturbance","Device: Activlink insole|Other: Activlink Phone Application","Caregiver Activity Survey|Zarit Caregiver Burden scale|AD Quality of Life Scale","University of Florida|National Institute on Aging (NIA)|Aster Labs, Inc","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","187","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB201702352 -N -A|2R44AG046944-02|OCR17448","September 2019","September 2020","January 2021","December 2, 2017",,"August 26, 2019","Oak Hammock Senior Living Center, Gainesville, Florida, United States|Unversity of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03360019"
1936,"NCT00620191","Metformin in Amnestic Mild Cognitive Impairment","MCI","Completed","No Results Available","Amnestic Mild Cognitive Impairment","Drug: metformin|Drug: placebo","Total Recall in the Selective Reminding Test|ADAS-cog|rCMRgl in the posterior cingulate-precuneus.","Columbia University|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAC7231|R0153596","February 2008","February 2012","February 2012","February 21, 2008",,"March 14, 2013","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00620191"
1937,"NCT03510572","Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain",,"Recruiting","No Results Available","Healthy Volunteer|Alzheimer Disease|Frontotemporal Dementia|Parkinson Disease","Drug: [18F]PI-2620","Cross-sectional [18F]PI-2620 Imaging Results|.Assess the rate of change of tau deposition as measured by [18F]PI-2620 uptake (SUVR) over time|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and indices of structural MRI","Asan Medical Center|Korea Health Industry Development Institute","All","40 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI-18001","June 4, 2018","July 2019","July 2019","April 27, 2018",,"October 15, 2018","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03510572"
1938,"NCT01476228","EEG Objectification in Neuropsychiatry",,"Unknown status","No Results Available","Personality Disorder|Depression|Neurodegeneration|Alzheimer's Disease|Epilepsy","Device: EEG recording","percentage of fitting (0-100%) of EEG pattern to a previously identified electrophysiological ""key""","Hadassah Medical Organization","All","15 Years to 90 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0394-11-HMO-CTIL","November 2011","November 2013","December 2015","November 22, 2011",,"November 22, 2011","HMO, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01476228"
1939,"NCT00209456","Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia",,"Completed","No Results Available","Lewy Body Dementia|Non-DLB Dementia|Alzheimer’s|Vascular Dementia","Drug: DatSCAN","Sensitivity and specificity of DaTSCAN SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects.|Accuracy, positive predictive value and negative predictive value of DaTSCAN SPECT|Semi-quantitative analysis of the striatal uptake ratios of DaTSCAN SPECT images.|Impact of DaTSCAN SPECT analysis on the confidence of diagnosis.|Findings in relation to probable, possible and no-DLB.|Efficacy analysis at 12-month follow-up period.|Safety profile","GE Healthcare","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","326","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PDT301","November 2003",,,"September 21, 2005",,"May 16, 2007","Amersham Buchler GmbH Co. KG, Ismaning, Germany",,"https://ClinicalTrials.gov/show/NCT00209456"
1940,"NCT01315717","Gait and Alzheimer Interaction Tracking (GAIT) Study","GAIT","Completed","No Results Available","Gait Apraxia|Alzheimer Disease|Impaired Cognition|Cerebral Atrophy",,"Stride-to-stride variability of stride time","University Hospital, Angers","All","60 Years and older   (Adult, Older Adult)",,"912","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2009-A00533-54","November 2009","May 2016","May 2016","March 15, 2011",,"September 22, 2016","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT01315717"
1941,"NCT00950430","Imaging of Brain Amyloid Plaques in the Aging Population",,"Enrolling by invitation","No Results Available","Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia","Drug: Pittsburgh Compound B (C-11 PiB)|Drug: F-18 FDG|Drug: Tau (18-F-AV-1451)","To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.|Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.|To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.|To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.|To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.","Mayo Clinic|National Institute on Aging (NIA)","All","30 Years to 100 Years   (Adult, Older Adult)","Phase 4","2500","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-005553|U01AG006786|R01AG011378","April 2008","April 2023","April 2023","July 31, 2009",,"September 27, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00950430"
1942,"NCT02386670","Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)","PACt-MD","Recruiting","No Results Available","Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission","Other: tDCS + CR|Other: sham tDCS + sham CR","Change in cognitive scores over time|Percentage of subjects who remain free of MCI or dementia over time","Centre for Addiction and Mental Health|Brain Canada|Applied Health Research Centre|Queen's University|Baycrest Centre for Geriatric Care|St. Michael's Hospital, Toronto|Sunnybrook Health Sciences Centre|University Health Network, Toronto","All","60 Years and older   (Adult, Older Adult)","Not Applicable","375","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","041-2014","January 2015","December 2019","February 2021","March 12, 2015",,"May 15, 2018","Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Heath Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02386670"
1943,"NCT01029132","Characteristics of Treatment Responders to Galantamine",,"Completed","No Results Available","Dementia","Drug: galantamine","Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K)|Seoul-Activities of Daily Living (S-ADL) Seoul-Instrumental Activities of Daily Living (S-IADL) Korean version Neuropsychiatric Inventory (K-NPI)","Samsung Medical Center|Janssen Korea, Ltd., Korea","All","Child, Adult, Older Adult","Not Applicable","66","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-04-021","April 2007","October 2009","October 2009","December 9, 2009",,"January 6, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01029132"
1944,"NCT03661034","Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)",,"Recruiting","No Results Available","Alzheimer Disease, Early Onset|Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Memory Disorders|Memory Loss|Memory Impairment|Memory Disorders, Age Related|Alzheimer Disease, Late Onset|Cognitive Impairment|Dementia, Mild|Dementia, Alzheimer Type|Cognitive Decline","Device: GammaSense Stimulation System (non-invasive, non-significant risk)","Change in Amyloid Positron Emission Tomography (PET) Scan|Adverse Events|Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)","Cognito Therapeutics, Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-0004","May 31, 2018","November 1, 2019","November 1, 2019","September 7, 2018",,"December 17, 2018","Boston Center for Memory, Newton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03661034"
1945,"NCT02518243","Safe & Easy for Alzheimer's Disease and Related Pathologies","SaFEE2","Unknown status","No Results Available","Cognitive Deterioration","Other: Patient's answer with non pharmacological therapeutic","Tolerance of the systems set up and use frequency evaluated using the Caregiver Questionnaire","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-PP-08","June 2015","September 2016",,"August 7, 2015",,"August 7, 2015","Ehpad Valrose, Nice, France",,"https://ClinicalTrials.gov/show/NCT02518243"
1946,"NCT03330353","Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy","PMPSP","Recruiting","No Results Available","PSP - Progressive Supranuclear Palsy|PD - Parkinson's Disease|AD - Alzheimer's Disease|ALS (Amyotrophic Lateral Sclerosis)","Diagnostic Test: Pupillometry","Maximal Pupil Constriction|Post-illumination pupil response (PIPR)","Massachusetts General Hospital|NeurOptics Inc.|University of Toronto","All","55 Years and older   (Adult, Older Adult)",,"56","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017p001603","November 1, 2017","October 1, 2019","October 1, 2019","November 6, 2017",,"November 7, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03330353/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03330353"
1947,"NCT01608217","Delta-THC in Dementia",,"Completed","No Results Available","Behavioural Disturbances|Pain|Dementia|Alzheimer's Dementia|Vascular Dementia","Drug: delta-9-tetrahydrocannabinol (delta-THC)|Drug: Placebo|Drug: Acetaminophen","Neuropsychiatric Inventory (NPI)|Pain Assessment Checklist for Seniors with Limited Ability to Communicate Dutch version (PACSLAC-D)|Caregiver Clinical Global Impression of Change (CCGIC)|Cohen-Mansfield Agitation Inventory (CMAI)|Quality of Life-Alzheimer's Disease Scale (QoL-AD)|Barthel Index|Paired Associates Learning test Wechsler Memory Scale Revised(PAL WMS-R)|Safety assessments|Verbal Rating Scale (VRS)","Radboud University|Health Valley, Netherlands","All","40 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GER001-02-02|2011-005289-39|NL38617.091.12","June 2012","June 2014","June 2014","May 31, 2012",,"June 30, 2014","Radboud university medical center, department of Geriatrics, Nijmegen, Gelderland, Netherlands|Vincent van Gogh Institute for Psychiatry, department of Elderly, Venlo, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT01608217"
1948,"NCT03217396","Biomarkers of Synaptic Damage in Multiple Sclerosis",,"Recruiting","No Results Available","Multiple Sclerosis|Parkinson Disease|Amyotrophic Lateral Sclerosis|Alzheimer Disease","Procedure: lumbar puncture","Identification of predictive biomarkers of SM using an ex vivo chimeric model|Identification of new therapeutic targets in MS.","Neuromed IRCCS|IRCCS Multimedica","All","18 Years to 65 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","IRCCS Neuromed","November 22, 2017","September 1, 2020","September 30, 2020","July 14, 2017",,"March 18, 2019","IRCCS Neuromed, Pozzilli, Isernia, Italy",,"https://ClinicalTrials.gov/show/NCT03217396"
1949,"NCT03397667","The Aging Brain ANSWERS Program","ABC ANSWERS","Recruiting","No Results Available","Traumatic Brain Injury|Alzheimer Disease|Veterans|Family Caregivers|Caregiver Burden|Quality of Life","Other: ABC ANSWERS|Other: Control","Change from baseline Caregivers Quality of Life at 12 months|Change from baseline Veterans Quality of Life at 12 months|Change from baseline Caregiver Burden at 12 months|Change from baseline Veteran depression at 12 months|Change from baseline Caregiver depression at 12 months|Change from baseline Veteran anxiety at 12 months|Change from Caregiver anxiety at 12 months|Change from Caregiver dyadic strain at 12 months","Indiana University|Richard L. Roudebush VA Medical Center|Cleveland State University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","400","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","#1706902669","August 1, 2018","September 2020","December 2020","January 12, 2018",,"August 6, 2019","Richard L. Roudebush VAMC, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03397667"
1950,"NCT03887481","Effects of tDCS on Verbal Short-term Memory in Neurodegenerative Disorders",,"Recruiting","No Results Available","Primary Progressive Aphasia|Mild Cognitive Impairment|Frontotemporal Dementia|Alzheimer Disease","Device: Anodal tDCS + vSTM therapy|Device: Sham + short-term memory therapy","Change in word span accuracy (trained items)|Change in word span accuracy (untrained items)|Change in sentence repetition score|Change in word repetition score|Change in non-word repetition score|Change in Syntactic comprehension as assessed by Subject-relative, Object-relative, Active, Passive (S.O.A.P.) Syntactic Battery|Change in Syntactic production as assessed by Northwestern Assessment of Verbs and Sentences (NAVS)|Change in Verbal fluency task score|Change in brain connectivity as measured in the resting-state fMRI task|Change in oral naming Boston Naming Test score|Change in oral naming Philadelphia Naming Test score|Change in spelling as assessed by the Johns Hopkins Dysgraphia battery|Change in written naming as assessed by Boston Naming Test|Change in written naming as assessed by Philadelphia Naming Test","Johns Hopkins University|National Institutes of Health (NIH)|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00201027|R01DC014475","August 28, 2019","January 2026","January 2026","March 25, 2019",,"September 5, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03887481"
1951,"NCT04032626","MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients","MCLENA-1","Not yet recruiting","No Results Available","Cognitive Impairment, Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegeneration|Inflammation, Brain","Drug: Lenalidomide 10 mg|Drug: Placebos","Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score|Change in cognition as assessed by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) total score|Change in cognition as assessed by the Clinical Dementia Rating - Sum of Boxes (CDR-SOB) total score|Change in cognition as assessed by the Mini Mental State Examination (MMSE) total score|Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs)","The Cleveland Clinic|National Institute on Aging (NIA)","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19-658|R01AG059008|K01AG047279","September 2019","September 2023","September 2024","July 25, 2019",,"July 25, 2019",,,"https://ClinicalTrials.gov/show/NCT04032626"
1952,"NCT01371214","Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot","PLIÉ-pilot","Completed","No Results Available","Dementia","Behavioral: PLIÉ (Preventing Loss of Independence through Exercise)","Change in physical function (participant)|Change in quality of life (participant)|Change in functional health and well-being (participant)|Change in number of falls (participant)|Change in fall-related self-efficacy (participant)|Change in physical performance (participant)|Change in cognitive function (participant)|Compliance (participant)|Adverse events (participant)|Change in dementia-related behaviors (participant)|Change in functional health and well-being (caregiver)|Change in burden (caregiver)","University of California, San Francisco","All","Child, Adult, Older Adult","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","10-04080-023906","June 2011","September 2012","September 2012","June 10, 2011",,"June 3, 2015","Irene Swindells Center for Adult Day Services, Institute on Aging, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01371214"
1953,"NCT02524405","BEAM: Brain-Eye Amyloid Memory Study","BEAM","Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Vascular Cognitive Impairment|Parkinson's Disease|Lewy Body Disease","Other: Pittsburgh Compound B [11C]-PIB","Retinal nerve fiber layer thickness|Amyloid Depostition|Retinal artery narrowing|Retinal venular widening","Sunnybrook Health Sciences Centre|Brain Canada|Weston Brain Institute|GE Healthcare|University Health Network, Toronto|Centre for Addiction and Mental Health|Baycrest|St. Michael's Hospital, Toronto|Kensington Eye Institute","All","50 Years to 90 Years   (Adult, Older Adult)",,"345","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","221-2013","February 2016","March 2021","December 2021","August 14, 2015",,"September 20, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02524405"
1954,"NCT01498263","Inherited Diseases, Caregiving, and Social Networks",,"Recruiting","No Results Available","Alzheimer Disease and Related Dementias|Inherited Neurodegenerative Disorders|Inherited Metabolic Disorders (Inborn Errors of Metabolism)|Undiagnosed Diseases|Healthy Volunteer",,"Measures of caregiving processes|Family network characteristics|Role and impact of individual|Identify points of intervention","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 118 Years   (Adult, Older Adult)",,"3300","NIH","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","120022|12-HG-0022","January 9, 2012",,,"December 23, 2011",,"August 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|University of Memphis, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01498263"
1955,"NCT03297177","Autologous Stem/Stromal Cells in Neurological Disorders and Disease","NDD","Not yet recruiting","No Results Available","Dementia|Parkinson|Altered Behavior in Alzheimer Disease|Demyelinating Autoimmune Diseases, CNS|Demyelinating Sensorimotor Neuropathy|Corticobasal Degeneration","Procedure: Microcannula Harvest Adipose|Device: Centricyte 1000|Procedure: Sterile Normal Saline Infusion","Number of participant with adverse events (AE) or severe adverse events (SAE)|Neurological Function|Neurological Tested Functions|Magnetic Resonance Imaging (MRI)","Regeneris Medical|Global Alliance for Regenerative Medicine|Robert W. Alexander, MD, FICS|Regeneris Medical Inc","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GARM NDD","January 1, 2020","January 1, 2023","January 1, 2023","September 29, 2017",,"October 18, 2018","Regeneris Medical Inc, North Attleboro, Massachusetts, United States|Regeneris Medical, North Attleboro, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03297177"
1956,"NCT03786471","D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care","D-CARE","Recruiting","No Results Available","Dementia","Other: Health System-based Dementia Care|Other: Community-based Dementia Care|Other: Enhanced Usual Care","Severity of Dementia-related Behavioral Symptoms|Caregiver Distress|Level of Distress Experienced by the Caregiver in Response to Dementia-related Psychiatric and Behavioral Symptoms|Severity of Depression in Caregivers|Caregiver Self-Efficacy: 4-item self-efficacy scale","University of California, Los Angeles|Patient-Centered Outcomes Research Institute|National Institute on Aging (NIA)|Yale University|Benjamin Rose Institute on Aging|Baylor Scott and White Health|Wake Forest University Health Sciences|University of Texas|Geisinger Clinic|University of Oklahoma|RAND","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB 18-001796|R01AG061078-01|PCS-2017C1-6534","July 8, 2019","April 30, 2023","June 30, 2023","December 25, 2018",,"September 10, 2019","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Geisinger Health, Wilkes-Barre, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|Baylor Scott & White, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03786471"
1957,"NCT03472482","Optical Coherence Tomography in Cerebral Amyloidosis",,"Recruiting","No Results Available","Alzheimer Disease|Dementia Alzheimers|Dementia|Lewy Body Disease|Dementia, Lewy Body|Mild Cognitive Impairment","Diagnostic Test: non-invasive retinal imaging","Diagnostic performance of OCT measurements in dementia","Universitaire Ziekenhuizen Leuven","All","Child, Adult, Older Adult",,"85","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S59048","March 25, 2016","December 31, 2018","December 31, 2019","March 21, 2018",,"March 21, 2018","UZ Leuven, Leuven, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03472482/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03472482"
1958,"NCT01592552","A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery",,"Completed","No Results Available","Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS)",,"Biospecimens & Clinical Data collection from patients with neurological diseases.","Sanguine Biosciences","All","18 Years to 100 Years   (Adult, Older Adult)",,"20","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SAN-ND-01","November 2011","March 2015","March 2015","May 7, 2012",,"April 8, 2019","Sanguine Biosciences, Sherman Oaks, California, United States",,"https://ClinicalTrials.gov/show/NCT01592552"
1959,"NCT02008357","Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss","A4","Active, not recruiting","No Results Available","Cognition Disorders","Drug: Placebo|Drug: Solanezumab","Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)|Change from Baseline in Cognitive Function Index (CFI)|Change from Baseline in Alzheimer's Disease Cooperative Study—Activities Daily Living—Prevention Questionnaire (ADCS-ADL-Prevention Questionnaire) Score|Change from Baseline in Mean Composite Standardized Uptake Value Ratio (SUVr)|Change from Baseline in Cerebrospinal Fluid (CSF) Tau Biomarkers|Change from Baseline of CSF Concentrations of Amyloid Beta (Abeta)|Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI)|Change from Baseline on the Clinical Dementia Rating—Sum of Boxes score (CDR-SB)|Change from Baseline on the Computerized Cognitive Composite (C3)","Eli Lilly and Company|Alzheimer's Therapeutic Research Institute","All","65 Years to 85 Years   (Older Adult)","Phase 3","1150","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15275|H8A-MC-LZAZ","February 28, 2014","July 22, 2022","July 22, 2022","December 11, 2013",,"December 4, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Health Research Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States|University of California - San Diego, La Jolla, California, United States|University of Southern California School of Medicine, Los Angeles, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Univ of California Irvine College of Medicine, Orange, California, United States|Veterans Affairs Medical Center Palo Alto, Palo Alto, California, United States|Sutter Medical Group, Sacramento, California, United States|Univ of California San Francisco, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|University of California, Davis - Health Systems, Walnut Creek, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Howard University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Compass Research - Orlando, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research -The Villages, The Villages, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Hospital, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Univ of Nebraska Med Center, Omaha, Nebraska, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Dent Neurological Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Drexel University College of Medicine at EPPI, Philadelphia, Pennsylvania, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper Hospital, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Washington School of Medicine, Seattle, Washington, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., London, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bunkyo-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02008357"
1960,"NCT00878059","Alzheimer's Family Research",,"Completed","No Results Available","Decision Making",,,"University of California, San Francisco|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)",,"165","Other|NIH","Observational","Time Perspective: Cross-Sectional","AD R01","July 2008","December 2011","December 2011","April 8, 2009",,"October 16, 2013","UCSF Langley Porter Institute, or at participant's home, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00878059"
1961,"NCT01322568","Research on Aging Project in Iceland: Second Stage",,"Completed","No Results Available","Atherosclerosis|Osteoporosis|Obesity|Glucose Abnormalities|Alzheimer's Disease|Vascular Dimentia",,,"National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","32 Years to 60 Years   (Adult)",,"5764","NIH","Observational","Time Perspective: Prospective","999903319|03-AG-N319","January 31, 2003",,"February 11, 2014","March 24, 2011",,"August 12, 2019","Icelandic Heart Association Research Institute, Kopavogur, Iceland",,"https://ClinicalTrials.gov/show/NCT01322568"
1962,"NCT03746366","[C-11]PiB PET Imaging in Alcohol Use Disorders",,"Recruiting","No Results Available","Alcohol Use Disorder","Radiation: [C-11]|Drug: Pittsburgh Compound B","[C-11]PIB +","University of Pittsburgh|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO18080481|R01AA025247","December 1, 2018","December 31, 2022","December 31, 2022","November 19, 2018",,"December 18, 2018","University of Pittsbyurgh PET Facility, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03746366"
1963,"NCT03954899","Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging",,"Recruiting","No Results Available","Mild Cognitive Impairment|Cognitive Decline|Healthy Aging","Dietary Supplement: melatonin|Other: placebo","Episodic memory|Overall cognitive function|p-tau/Aβ42 ratio|t-tau|Sleep Efficiency|Amplitude (Mesor) of rest-activity rhythm|Acrophase of rest-activity rhythm","Nazan Aksan|University of Iowa","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","201903824","September 30, 2019","October 2024","October 2024","May 17, 2019",,"October 2, 2019","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03954899"
1964,"NCT03240406","Multicultural Healthy Diet to Reduce Cognitive Decline","MHD","Recruiting","No Results Available","Diet Modification|Cognitive Decline|Cognitive Change","Other: Multicultural Healthy Diet|Other: Usual Diet plus Self-Care","Change in composite cognition score","Albert Einstein College of Medicine|Penn State University|University of Pennsylvania|University of Minnesota - Clinical and Translational Science Institute|National Institute on Aging (NIA)","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","326","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2016-6613|R01AG055527","October 2, 2018","December 31, 2021","September 14, 2022","August 7, 2017",,"July 31, 2019","Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03240406"
1965,"NCT01780974","Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention",,"Completed","Has Results","Treated Hypertension","Drug: Lipoic Acid plus Omega-3 Fatty Acids|Drug: Placebo","Trails Making Test Part B (Executive Function)|White Matter Hyperintensity Volume (Brain MRI)","Oregon Health and Science University","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SFF01","April 2013","October 2015","October 2015","January 31, 2013","April 7, 2017","April 7, 2017","Lynne Shinto, ND, MPH, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01780974"
1966,"NCT01339130","Assessment of Social-emotional Functioning in Neurological Diseases","Emotion","Completed","No Results Available","Alzheimer Disease|Stroke|Parkinson's Disease|Lewy Body Dementia|Huntington Disease","Behavioral: Computerized tests and Electrophysiological measurements","Empathy ability|Empathy for pain|pattern of empathy disorders according to the disease (stroke, Mild cognitive impairment, Alzheimer disease and Parkinson disease","Centre Hospitalier Universitaire, Amiens","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","177","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI09-PR-GODEFROY|2009-A00596-51","June 2009","June 2013","June 2013","April 20, 2011",,"September 7, 2015","CHU Amiens, Amiens, Picardie, France",,"https://ClinicalTrials.gov/show/NCT01339130"
1967,"NCT02380703","Aggression Prevention Training for Caregivers of Persons With Dementia (APT)","APT","Completed","No Results Available","Dementia|Pain|Alzheimer's Disease|Aggression|Depression|Interpersonal Relations","Behavioral: Aggression Prevention Training (APT)|Other: Enhanced Usual Primary Care (EU-PC)","Incidence of aggression (Cohen Mansfield Agitation Inventory, Aggression Subscale)|Nursing Home Placement|Caregiver Burden--Zarit Burden Interview|Positive Caregiving Attributes--Positive Aspects of Caregiving Scale|Behavior Problems--Revised Memory and Behavior Checklist|Pain--Philadelphia Geriatric Pain Intensity Scale|Depression--Geriatric Depression Screen (GDS), Caregiver Version|Caregiver-Patient Relationship Quality--Mutuality Scale|Pleasant Events--Pleasant Events and Activities Schedule Alzheimer's Disease (short version)","Baylor College of Medicine|National Institute of Nursing Research (NINR)","All","Child, Adult, Older Adult","Not Applicable","228","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","H-33720|R01NR014657-01A1","February 5, 2015","October 23, 2018","October 23, 2018","March 5, 2015",,"January 16, 2019",,,"https://ClinicalTrials.gov/show/NCT02380703"
1968,"NCT03894254","Predictive Factors of Autonomy Loss in Real-life Cohort","MEM-AURA","Not yet recruiting","No Results Available","Memory Disorders","Other: no intervention","Functional autonomy level","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","69HCL18_0613","April 1, 2019","March 1, 2024","March 1, 2032","March 28, 2019",,"March 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03894254"
1969,"NCT03691428","Stress Reduction Study for Partners of Early Stage Dementia",,"Recruiting","No Results Available","Dementia Caregiving","Behavioral: Wish Outcome Obstacle Plan","change in positive affect|change in depressive symptoms|change in emotion regulation|change in support quality|change in caregiver burden|change in perceived stress","Yale University|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000021852","January 5, 2019","January 30, 2020","May 30, 2020","October 1, 2018",,"July 3, 2019","Joan Monin, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03691428"
1970,"NCT03610698","Life Enhancing Activities for Family Caregivers (LEAF 2.0)",,"Not yet recruiting","No Results Available","Caregivers","Behavioral: LEAF Positive Emotion Intervention|Other: Emotion Reporting Control Condition","Psychological Well-Being|PROMIS-Anxiety|PROMIS-Depression|Caregiver Burden","Northwestern University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","SP0044459","August 31, 2019","March 31, 2023","March 31, 2023","August 1, 2018",,"September 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03610698"
1971,"NCT02434393","Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project","ADNI-D","Active, not recruiting","No Results Available","Major Depression|Late Life Depression (LLD)",,"Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.|Rate of Change in expressive language as measured by the Boston Naming Test using total correct.|Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.|Change in brain structure using magnetic resonance imaging (MRI)|Extent of amyloid deposition as measured by Florbetapir F 18: Datum of these scans will be collected via standardized uptake value ratios (SUVR) normalized to the cerebellum|Use biomarkers data employed in ADNI-2 and the NIA AD (Alzheimer's Disease) Genetics Consortium to determine the genotypes needed for the genome wide association study (GWAS).","University of Southern California|National Institute of Mental Health (NIMH)|University of California, San Francisco|Alzheimer's Therapeutic Research Institute","All","65 Years and older   (Older Adult)",,"133","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ADC-048|R01MH098062","March 4, 2015","January 2020","January 2021","May 5, 2015",,"February 20, 2019","University of California, San Francisco, San Francisco, California, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02434393"
1972,"NCT01772537","The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.",,"Terminated","Has Results","Thoracic Aneurysm|Aneurysm Stent|Cardiopulmonary Bypass|Abdominal Aneurysm","Drug: Propofol|Drug: isoflurane","Changes in Cerebrospinal Fluid (CSF) Levels of Tau|Changes in CSF Levels of Amyloid|Number of Participants With Delirium as Assessed by the Confusion Assessment Method (CAM)","Johns Hopkins University|National Center for Research Resources (NCRR)","All","21 Years to 100 Years   (Adult, Older Adult)","Not Applicable","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","NA_00067716|5KL2RR025006","May 2012","February 2014","February 2014","January 21, 2013","February 24, 2017","March 31, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01772537"
1973,"NCT03081533","Circle Dance for Family Caregivers of the Elderly With Alzheimer.","CircleCare","Recruiting","No Results Available","Family Caregiver","Other: Circle Dance Program (CircleCare)","Brazilian Version of the Short Physical Performance Battery|Timed Up and Go Test|Addenbrooke's Cognitive Examination-Revised (ACE-R)|Zarit Burden Interview (ZBI)|Brazilian Perceived Stress Scale (BPSS-10)|Geriatric Depression Scale (GDS-15)|Quality of Life Scale in Alzheimer's disease (QoL-AD - caregiver's version)|Frailty Phenotype","Universidade Federal de Sao Carlos|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Universidade Estadual Paulista Júlio de Mesquita Filho","All","50 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","62112716.8.0000.5504","September 6, 2017","June 14, 2019","July 2019","March 16, 2017",,"March 25, 2019","Julimara Gomes dos Santos, Sao Carlos, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03081533"
1974,"NCT04064164","Speeko for Elderspeak",,"Not yet recruiting","No Results Available","Dementia|Staff Attitude","Behavioral: Speeko for Elderspeak","Change in elderspeak measured by the number of diminutives detected in participant's recorded speech.|Acceptability as measured by System Usability Scale.|Evaluate the app cost by measuring wages per hour by NH role and costs associated with the Speeko for Elderspeak application.","University of Kansas Medical Center|National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00143911","November 15, 2019","February 28, 2021","April 30, 2021","August 21, 2019",,"August 21, 2019","University of Kansas School of Nursing, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04064164"
1975,"NCT02428387","Evaluation of ""My Tools 4 Care"" for Family Caregivers of Persons With Dementia",,"Completed","No Results Available","Family|Dementia","Behavioral: My Tools 4 Care","Change from Baseline in Health Related Quality of Life at One, Three and Six Months|Change from Baseline in Hope at One, Three and Six Months|Change from Baseline in General Self Efficacy at One, Three and Six Months","University of Alberta|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","199","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Pro00048721","April 2015","April 12, 2017","April 12, 2017","April 28, 2015",,"May 31, 2017","University of Alberta, Edmonton, Alberta, Canada|Jenny Ploeg, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02428387"
1976,"NCT03117829","Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial","BFIT","Completed","No Results Available","PreDiabetes","Behavioral: Diet and Exercise","Change in brain blood flow from baseline to 12 weeks|Change in brain blood flow from 12 weeks to 6 month post intervention","University of Wisconsin, Madison","All","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2016-1202","March 15, 2017","December 18, 2018","June 17, 2019","April 18, 2017",,"October 11, 2019","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03117829"
1977,"NCT00814502","Zolpidem CR and Hospitalized Patients With Dementia",,"Completed","Has Results","Dementia|Alzheimer Disease|Dementia, Vascular|Sleep Disorders|Circadian Dysregulation","Drug: Zolpidem CR|Drug: Placebo","Sleep Efficiency|Sleep Minutes|Measures of Aggression, Psychosis, General Clinical Status, Cognitive Measures, Mood Symptoms","Massachusetts General Hospital|Sanofi","All","60 Years to 99 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-P-001434/1","December 2008","December 2013","December 2013","December 25, 2008","May 22, 2017","May 22, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00814502"
1978,"NCT03069391","The Interactive Physical and Cognitive Exercise System","iPACES™","Active, not recruiting","No Results Available","Alzheimer Disease, Early Onset|MCI|Aging|Mild Cognitive Impairment|Neurocognitive Disorder|Cognitive Impairment|Cognitive Change","Behavioral: physical exercise alone (PES) first|Device: cognitive exercise alone (iCE) first|Device: interactive Physical and Cognitive Exercise (iPACES™)","executive function composite score|brain-derived neurotrophic factor (BDNF)|Sit-Stand Test","Union College, New York|1st Playable Productions|Albany Medical College|Skidmore College|University of Illinois at Urbana-Champaign|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16028|1R41AG053120-01","March 4, 2017","June 30, 2020","June 30, 2020","March 3, 2017",,"May 3, 2018","Healthy Aging & Neuropsychology Lab @ Union College, Schenectady, New York, United States",,"https://ClinicalTrials.gov/show/NCT03069391"
1979,"NCT03840083","Sleep-dependent Learning in Aging",,"Recruiting","No Results Available","Sleep","Behavioral: Sleep","Change in memory accuracy for intervention compared to control","University of Massachusetts, Amherst","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","584","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-4290","July 15, 2018","July 14, 2023","July 15, 2024","February 15, 2019",,"March 13, 2019","University of Massachusetts, Amherst, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03840083"
1980,"NCT03506672","Assessing the Effectiveness of an Approach for Vocal Behaviors in Older People Living in Nursing Homes",,"Recruiting","No Results Available","Behavioral Symptoms","Other: Approach based on the meanings of vocal behaviours|Other: Usual practices","Change from baseline frequency of vocal behaviors|Change from baseline frequency of vocal behaviors to follow-up|Change from baseline in well-being|Change from baseline in medication use|Change from baseline in perceived disruptiveness of vocal behaviors-formal caregivers|Change from baseline in perceived disruptiveness of vocal behaviors-family caregivers|Change from baseline in partnership-based decision-making-family caregivers' perspective|Change from baseline in partnership-based decision-making-formal caregivers' perspective|Change from baseline in partnership-based decision-making-formal caregivers' attitudes|Change from baseline in partnership-based decision-making-formal caregivers' attitude|Change from baseline in empowerment-formal caregivers|Change from baseline in empowerment-family caregivers|Cost","Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal","All","18 Years and older   (Adult, Older Adult)","Not Applicable","324","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","156273","November 30, 2018","January 2021","September 2021","April 24, 2018",,"December 4, 2018","CHSLD Laval et Riviera, Laval, Quebec, Canada|CIUSSS Nord-de-l'Île-de-Montréal, Montréal, Quebec, Canada|Residence Angelica, Montréal, Quebec, Canada|CIUSSS Ouest-de-l'Île-de-Montréal, Montréal, Quebec, Canada|Résidence Berthiaume-du-Tremblay, Montréal, Quebec, Canada|Vigi Santé, Montréal, Quebec, Canada|CIUSSS Centre-Sud-de-l'Île-de-Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03506672"
1981,"NCT02221661","Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center","DIALOG","Completed","No Results Available","Cognitive Impairment|Memory Complaint|Clinical Investigation in Memory Centers",,"Estimation of the prevalence of positive AclarusDx™ among patients clinically AD diagnosed","Diaxonhit|Olivier SOL, MD","All","18 Years and older   (Adult, Older Adult)",,"606","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MG/JD/11.830","December 2011","December 2013","December 2013","August 20, 2014",,"August 22, 2014",,,"https://ClinicalTrials.gov/show/NCT02221661"
1982,"NCT03967535","Connectomics in Psychiatric Classification",,"Recruiting","No Results Available","Dementia|Dementia Alzheimers|Frontotemporal Dementia|Pick's Disease With Dementia","Device: MRI Brain Imaging|Behavioral: Mental Health Assessment and Computerized Cognitive Test","Magnetic Resonance Imaging (MRI) Brain Imaging|DNA testing through saliva","Washington University School of Medicine","All","45 Years to 85 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","201404123","December 1, 2018","January 2021","January 2021","May 30, 2019",,"May 30, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03967535"
1983,"NCT03011723","Tailored Music Therapy for Dementia",,"Active, not recruiting","No Results Available","Alzheimer Dementia|Dementia, Vascular|Dementia, Lewy Body|Dementia Parkinson's Disease","Behavioral: Resource oriented music therapy","Change in communication behavior throughout the music therapy session compared to baseline(Communication in Dementia (CODEM))|Change in observed expression of affect throughout the music therapy session compared to baseline(Observable Displays of Affect Scale (ODAS))|Change in self reported mood before and after the music therapy session (Visual Analogue Mood Scale (VAMS))|Change in Neuropsychiatric symptoms (NPI-Q)|Change in Quality of life in Alzheimer Dementia (QoL-AD)|Change in Relative Stress Scale (RSS)|Change in Music in Dementia Assessment Scales (MiDAS)","University of Bergen|NKS Olaviken Alderspsykiatriske sykehus","All","45 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","UBergen 2016/1374","January 2017","December 2019","April 2021","January 5, 2017",,"September 27, 2019","NKS Olaviken Alderspsykiatriske sykehus, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT03011723"
1984,"NCT01569997","Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units","IDEM","Completed","No Results Available","Dementia in Nursing Home","Other: MultiDisciplinary Team Meetings (MDTM)","Incidence of hospitalizations in emergency care units|Prevalence of antipsychotic prescription|Incidence of inappropriate hospitalizations|Prevalence of neuropsychiatric symptoms evaluated by NPI-nursing staff version|Dependency evaluated by AGGIR and IADL-4 items|Quality of life evaluated by QOL-AD|Number of nursing staff's time off work|Number of days off work by nursing staff|Presence of advanced care planning in patients medical records|Overall healthcare costs","University Hospital, Toulouse","All","60 Years and older   (Adult, Older Adult)","Not Applicable","1428","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0910701|2009-A01062-55","May 2010","September 2013","September 2013","April 4, 2012",,"August 24, 2015","Centre de Gerontologie Pompeyrie Chu Agen, Agen, France|Ehpad Maison de Retraite Louise Anceau, Albi, France|Ehpad Maison de Retraite Olga Ducoudray, Albi, France|Ehpad Mr ""Les Jardins de Jouvence"", Albi, France|Mapad La Renaudie Ch Albi, Albi, France|Ehpad Les Ajoncs D'Or, Allaire, France|Ehpad Maison de Retraite Hl Ax Les Thermes, Ax Les Termes, France|Ehpad Marie Lehman, Balma, France|Ehpad Kerdigemer, Brest, France|Ehpad Residence Ker-Heol, Brest, France|Ehpad Residence Saint Astier, Catus, France|Mapa de L'Hopital Local de Caussade, Caussade, France|Ehpad Maison de Retraite Ste Marthe, Ceignac, France|EHPAD Résidence Castelgirou, Cepet, France|Ehpad Leon Ronzier Joly, Clermont L'herault, France|Ehpad Themis Lasplanes, Colomiers, France|Ehpad Maison de Retraite Joseph Sauvy, ERR, France|Ehpad Residence Borde Haute Promo-Accueil, Escalquens, France|Mapad ""Firmi"", Firmi, France|Ehpad Hopital Local Fleurance, Fleurance, France|Ehpad Mr Bellissen Chi Du Val D'Ariege, Foix, France|Ehpad Dr Robert, Guer, France|Ehpad Residence Grand'Maison, L'union, France|Ehpad Residence Provencale Medicafrance, La Roquebrussanne, France|Ehpad Residence Clairefontaine, Lamorlaye, France|Mapad Ch Lavaur, Lavaur, France|Ehpad Saint Reah Hir, Le Conquet, France|Ehpad Residence D'Automne de La Ferme, Le Mee Sur Seine, France|Ehpad Maison de Retraite ""Les Charmilles"", Lescure d'Albigeois, France|Residence Le Parc, Lezat Sur Leze, France|Ehpad La Cheneraie, Lherm, France|Ehpad Mr Lagrange, Lisle Sur Tarn, France|Mapad Labastide Ch Lourdes, Lourdes, France|Ehpad Emile Dubois, Marchiennes, France|Ehpad Les Mille Soleils, Marciac, France|Ehpad Et. Public Gerontologie de Marines, Marines, France|AP-HM Hôptal La Timone Service de Pédiatrie Mutidisciplinaire, Marseille, France|Ehpad Maison Retraite Hl Mauvezin, Mauvezin, France|Ehpad Maison de Retraite Saint Joseph, Mazamet, France|Ehpad Maison de Retraite Privee de Mazeres, Mazeres, France|Ehpad-Maison Retraite Hl Mirande, Mirande, France|Ehpad Chis Castelsarrasin-Moissac, Moissac, France|Ehpad Era Caso, Montauban de Luchon, France|Ehpad Maison Retraite Ch Montauban, Montauban, France|Ehpad Ma Maison, Montpellier, France|Ehpad Maison de Retraite Sainte Agnes, Montredon Labessonnie, France|Ehpad L'Ecrin Des Sages, Mèze, France|Ehpad L'Acacia, Nailloux, France|Logements Foyer La Fontanelle, Naucelle, France|Ehpad Fondation Pauliani, Nice, France|Ehpad Les Noisetiers, Nice, France|Ehpad Residence Ancilla, Nice, France|Ehpad Mais de Retraite Saint-Joseph, Ossun, France|Ehpad Mr Bariol Chi Du Val D'Ariege, Pamiers, France|Ehpad Residence Le Parc, Panazol, France|AP-HP Hôpital Necker Enfants Malades Service d'endocrinologie pédiatrique - 149 route de Sèvres, Paris, France|Ehpad Furtado Heine, Paris, France|Ehpad Julie Siegfried, Paris, France|Ehpad La Pirandelle, Paris, France|Ehpad Residence Anselme, Paris, France|Ehpad Residence Belleville, Paris, France|Ehpad Residence Herold, Paris, France|Ehpad Residence Oceane, Paris, France|Ehpad Tiers Temps Paris, Paris, France|Ehpad Residence Adeline, Pierre Buffiere, France|Ehpad Residence D'Automne Medica-France, Reims, France|Ehpad L'Oree Du Bois, Rieux Volvestre, France|Ehpad Residence Saint-Amans, Rodez, France|Ehpad Le Jardin Des Loges, Saint Bonnet, France|Ehpad Residence Themis La Joie de Vivre, Saint Lys, France|Ehpad A Labouilhe, Saint Orens de Gameville, France|Ehpad Public de Saint-Remy de Provence, Saint Remy de Provence, France|Ehpad Les Bruyeres, Sousceyrac, France|Ehpad Maison Retraite Orelia Ch St Gaudens, St Gaudens, France|Ehpad Genevriers, St Martory, France|Ehpad Maison de Retraite Chic Tarbes Vic, Tarbes, France|Ehpad Residence ""Le Doyenne Du Carmel"", Tarbes, France|Ehpad Sainte Anne, Tinteniac, France|Ehpad de La Cote Pavee, Toulouse, France|Ehpad Gaubert, Toulouse, France|Ehpad Mr Henri Iv, Toulouse, France|Ehpad Pierre Ducis, Toulouse, France|Ehpad Residence La Cotonniere, Toulouse, France|Ehpad Residence Le Clos Des Carmes, Toulouse, France|Ehpad Residence Marguerite, Toulouse, France|Ehpad Residence Saint-Simon, Toulouse, France|Usld Domaine de La Cadene, Toulouse, France|Ehpad Umt, Valence-d'albigeois, France|Ehpad Maisonneuve, Villefranche de Lauragais, France|Ehpad Saint-Jacques, Villemur Sur Tarn, France",,"https://ClinicalTrials.gov/show/NCT01569997"
1985,"NCT00548951","Alzheimer Patients and the Snoezelen Program",,"Completed","No Results Available","Dementia","Other: Snoezelen Room|Other: Control","To evaluate improvement of the residents who are given Snoezelen sessions.","Queen's University","All","65 Years and older   (Older Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSIY-205-05","September 2005","December 2006","December 2006","October 24, 2007",,"December 16, 2015","Rideaucrest Home, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00548951"
1986,"NCT00820937","Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)","DatScan","Completed","No Results Available","Lewy Body Dementia","Procedure: Single photon emission computed tomography and Magnetic Resonance Imaging","SPECT and MRI differential imaging|Neuropsychological analysis","University Hospital, Limoges","All","65 Years to 90 Years   (Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic","I04014","March 2006","March 2008","March 2008","January 12, 2009",,"August 27, 2009","Département de Gérontologie - Chu Limoges, Limoges, France|Pôle de psychiatrie du sujet âgé - CH Esquirol, Limoges, France|Service de Neurologie - CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT00820937"
1987,"NCT03929302","Brain Energy Metabolism and Sleep in Adults",,"Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Cognitive Change|Energy Metabolism|Sleep Disturbance","Device: MyTAP oral appliance plus mouth shield","Sleep Improvement with MyTAP oral airway management intervention|Memory cognitive domain improvement after airway management intervention|Executive function cognitive domain improvement after airway management intervention","The University of Texas at Dallas|Texas A & M University Baylor College Of Dentistry|University of Texas, Southwestern Medical Center at Dallas","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB 18-73","November 30, 2018","December 31, 2020","July 31, 2021","April 26, 2019",,"April 26, 2019","Center for BrainHealth, The university of Texas at Dallas, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03929302/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03929302"
1988,"NCT00001549","Diagnosis and Natural History Study of Patients With Neurological Conditions",,"Completed","No Results Available","Alzheimer's Disease|Dementia|Movement Disorder|Multiple System Atrophy|Parkinson's Disease",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"600","NIH","Observational",,"960009|96-N-0009","October 1995",,"January 2006","November 4, 1999",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001549"
1989,"NCT00597376","Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints",,"Completed","Has Results","Subjective Memory Loss in Older Persons","Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo","Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only|Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only|Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only","Rush University Medical Center|Pamlab, Inc.","All","60 Years and older   (Adult, Older Adult)","Not Applicable","104","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pamlab-Cerefolin NAC-001-01","November 2007","May 2011","May 2011","January 18, 2008","May 23, 2013","May 23, 2013","Rush Alzheimer's Disease Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00597376"
1990,"NCT02488720","Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study","LEARN","Active, not recruiting","No Results Available","Cognition Disorders",,"Change from Baseline of the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC) to Week 168|Change from Baseline in Cognitive Function Index (CFI) to Week 168|Change from Baseline in Mean Composite Summary Uptake Value Ratio (SUVr) to Week 168|Change from Baseline in Cerebral Spinal Fluid (CSF) Tau Biomarkers to Week 168|Change from Baseline of Cerebrospinal Fluid (CSF) Concentrations of Amyloid Beta (Abeta) to Week 168|Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI) to Week 168","University of Southern California|Alzheimer's Association|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute","All","65 Years to 85 Years   (Older Adult)",,"500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADC-051|U19AG010483|15-338729","September 8, 2015","June 2020","June 2020","July 2, 2015",,"October 11, 2018","University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine - Neuropsychiatric Center, Orange, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Bioclinica Research Orlando, Orlando, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Bioclinica Research North, The Villages, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Dent Neurologic Institute, Amherst, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02488720"
1991,"NCT02843529","Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)","AltoidaML","Enrolling by invitation","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Memory Disorders|Cognitive Impairment|Dementia|Presymptomatic Disease","Other: Altoida: neuropsychological, MRI, EEG and CSF biomarkers","Change in sensitivity , specificity and accuracy of Altoida models|Change from Baseline in Clinical Measure 1|Change from Baseline in Clinical Measure 2|Change from Baseline in Clinical Measure 3|Change from Baseline in Clinical Measure 4|Change from Baseline in Clinical Measure 5|Change from Baseline in Clinical Measure 6|Change from Baseline in Clinical Measure 7|Change from Baseline in Cognitive Measure|Secondary resting state EEG endpoints|Secondary resting state auditory oddball ERP endpoints|Total Abeta 1-42 (Aβ42) amyloid deposition|Change of brain amyloid deposition|Change of CSF biomarkers tau and ptau181 values|MRI (Optional)|Changes in Driving breaking force|Changes in Driving acceleration velocity|Changes in Driving direction|Changes in driving violations","Altoida|Greek Alzheimer's Association and Related Disorders|University of Roma La Sapienza|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Neuromed IRCCS|Swiss Federal Institute of Technology|Scripps Memorial Hospital|Global Brain Health Institute (GBHI)|Novartis|Research Center on Computational Biomarkers (RCCBM)|BiHELab - Bioinformatics and Human Electrophysiology Lab|Fundacion Clinic per a la Recerca Biomédica|Trinity College Dublin|University of Barcelona|SwissNeuroRadiologyInstitute (SNRI)","All","55 Years to 90 Years   (Adult, Older Adult)","Not Applicable","900","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","altoidaML01","May 11, 2015","December 3, 2020","December 3, 2020","July 26, 2016",,"October 4, 2019",,,"https://ClinicalTrials.gov/show/NCT02843529"
1992,"NCT03123224","The COACH Project: Combined Online Assistance for Caregiver Health","COACH","Recruiting","No Results Available","Traumas, Brain|Alzheimer Disease|Dementia|Head Injury|Concussion, Brain|TBI","Behavioral: Combined Aerobic and Resistance Exercise + Caregiver Skills Training|Behavioral: Stretching Balance and Flexibility + Caregiver Skills Training","Caregiver Burden using Zarit Burden Inventory","Palo Alto Veterans Institute for Research|United States Department of Defense","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAI0003AGG|W81XWH-15-1-0246","August 2015","July 2018","July 2018","April 21, 2017",,"January 18, 2018","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03123224"
1993,"NCT03387267","Videofluoroscopic Swallowing Study (VFSS)","PORSCHE","Terminated","No Results Available","Stroke|Parkinson Disease|Multiple Sclerosis|Oropharyngeal Dysphagia|Alzheimer Disease|Dementia","Device: Dysphagia Detection System","The primary efficacy of the Dysphagia Detection System (DDS) will be measured as the sensitivity & specificity obtained from comparing the DDS swallow safety outcome simultaneously to the VFSS swallow safety outcome for thin barium (THIN-Ba) stimuli|The sensitivity & specificity DDS for swallow safety using MILD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow safety outcome with the VFSS swallow safety outcome for MILD-Ba|The sensitivity & specificity DDS for swallow efficiency using THIN-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for THIN-Ba|The sensitivity & specificity DDS for swallow efficiency using MILD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for MILD-Ba|The sensitivity & specificity DDS for swallow safety using MOD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow safety outcome with the VFSS swallow safety outcome for MOD-Ba|The sensitivity & specificity DDS for swallow efficiency using MOD-Ba will be measured as the sensitivity & specificity obtained from comparing the DDS predicted swallow efficiency outcome with the VFSS swallow efficiency outcome for MOD-Ba","Nestlé|Cytel Inc.|Regulatory and Clinical Research Institute Inc|Nestec Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","442","Industry|Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening","16.21.CLI","October 24, 2017","July 23, 2018","July 23, 2018","January 2, 2018",,"January 31, 2019","Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Medstar Rehabilitation Hospital, Washington, District of Columbia, United States|Shirley Ryan AbilityLab, Chicago, Illinois, United States|Marionjoy Rehabilitation Hospital, Wheaton, Illinois, United States|Kentucky Clinic, Lexington, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|New York Presbyterian/Weill Cornell Medical Center, New York, New York, United States|New York Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States|The Burke Medical Research Institute, White Plains, New York, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Helsinki University Central Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT03387267"
1994,"NCT03991195","Intervention of Intestinal Microorganism in Mild Cognitive Impairment",,"Recruiting","No Results Available","Gut Microbiota|Mild Cognitive Impairment|Dementia, Alzheimer Type|Neuroimaging","Dietary Supplement: Probiotic supplemented intervention|Dietary Supplement: Functional foods|Dietary Supplement: Placebo","Improvement of Montreal cognitive assessment (MoCA)|Improvement of Auditory Verbal Learning Test (AVLT)|Changes of intestinal microbial flora diversity|Structural MRI-based brain network changes|Functional MRI-based brain network changes|FNIRS-based brain network changes","XuanwuH 2|First Hospital of Tsinghua University|Beijing Normal University|Xuanwu Hospital, Beijing","All","55 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","HanYingsc","June 2019","January 2021","December 2021","June 19, 2019",,"June 19, 2019","Department of Neurolgy, Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03991195"
1995,"NCT03076307","DAT SPECT and Procedural Motor Skills in Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease","Behavioral: Procedural Motor Skills with mirror-drawing of figures","Procedural motor performance (error and time) in PD group|Resting state EEG connectivity in PD and control groups|Difference >20% in error rate and speed improvement in control and PD groups","University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science","CCER 2016-01469","October 18, 2016","May 20, 2017","July 19, 2017","March 10, 2017",,"July 21, 2017","Division of Neurorehabilitation, Geneva University Hospitals, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT03076307"
1996,"NCT03682185","The Healthy Patterns Study",,"Recruiting","No Results Available","Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment","Behavioral: Attention-Control Condition|Behavioral: Timed Activity Intervention","The Quality of Life in Alzheimer's Disease Scale (QOL-AD)|Neuropsychiatric Inventory (NPI)","University of Pennsylvania","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","825000","May 1, 2016","May 31, 2021","May 31, 2021","September 24, 2018",,"August 30, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03682185"
1997,"NCT03160027","Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)","PBM Dementia","Completed","Has Results","Dementia, Alzheimer Type","Device: Vielight Neuro Gamma","Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog)|Change in Clock-drawing Test|Change in Default Mode Network (DMN) Functional Connectivity|Change in Arterial Spin Labeled (ASL) Perfusion MRI Measure|Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD)|Change in QOL-AD From the Caregiver's Perspective About the Individual With Dementia|Change in Caregiver Burden Inventory (CBI).|Change in Neuropsychiatric Inventory (NPI)|Change in Positive Aspects of Caregiving Scale|Change in Geriatric Depression Scale (GDS) - Short Form in the Caregivers","University of California, San Francisco","All","50 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-21406","May 15, 2017","March 29, 2018","March 29, 2019","May 19, 2017","August 20, 2019","August 20, 2019","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03160027/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03160027"
1998,"NCT03909347","PLAN: Dementia Literacy Education and Navigation for Korean Elders With Probable Dementia and Their Caregivers","PLAN","Not yet recruiting","No Results Available","Dementia","Behavioral: PLAN|Behavioral: Standard of Care","Number of participants linked to medical service for dementia measured by medical record verification|Caregiver's dementia literacy measured by dementia literacy test|Self-efficacy in dementia care measured by dementia self-efficacy scale|Social support status as assessed by medical outcomes study scale|Depression status as assessed by Patient Health Questionnaire-9|Quality of life (QoL) measured by QoL-dementia caregiver instrument","Johns Hopkins University|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","288","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00192643","July 2020","July 2025","July 2025","April 10, 2019",,"May 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03909347"
1999,"NCT04104373","The Ontario Neurodegenerative Disease Research Initiative","ONDRI","Completed","No Results Available","Alzheimer Disease|Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Parkinson Disease|Stroke","Other: Observational Cohort","Eye Tracking - Pro Saccade and Anti Saccade|Retinal Nerve Imaging|Gait and Balance|Genomics|Neuropsychology|Neuroimaging","Ontario Neurodegeneration Disease Research Initiative","All","55 Years to 85 Years   (Adult, Older Adult)",,"522","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ONDRI2013","July 7, 2014","March 31, 2018","April 30, 2018","September 26, 2019",,"September 26, 2019","Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|Providence Care Mental Health Services, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Parkwood Institute, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Elisabeth Bruyere, Ottawa, Ontario, Canada|Thunder Bay Regional Research Institute, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Baycrest, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04104373"
2000,"NCT03823066","Experience With a Robot for Home Care and Its Acceptance by People With Dementia, Caregivers and Dementia Trainers",,"Completed","No Results Available","Dementia","Device: Coach Pepper","Technology acceptance (all participants): ""Technology Usage Inventory""|Experience with the robot (all participants)|Handling the robot (people with dementia)|Change of mobility (people with dementia)","Medical University of Graz|Joanneum Research Forschungsgesellschaft mbH|Sozialverein Deutschlandsberg|Humanizing Technologies GmbH",,"Child, Adult, Older Adult","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","30-401ex17/18a","August 22, 2018","September 18, 2018","September 18, 2018","January 30, 2019",,"January 30, 2019","Medical University of Graz, Institute of Nursing Science, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT03823066"
2001,"NCT03773016","Touchscreen Technology and Art for People With Dementia in Care Homes",,"Enrolling by invitation","No Results Available","Mild Dementia|Moderate Dementia","Behavioral: Art apps","Change on Wellbeing","University of Nottingham","All","Child, Adult, Older Adult","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","18080","February 20, 2019","April 12, 2019","April 12, 2019","December 12, 2018",,"March 22, 2019","University of Nottingham, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03773016"
2002,"NCT03297268","Behavioral and Environmental Sensing and Intervention","BESI","Unknown status","No Results Available","Behavioral and Psychiatric Symptoms of Dementia|Dementia|Caregivers","Other: Intervention with Home-Based Caregivers","Improved Caregiver Self-Efficacy|Decreased Caregiver Burden","University of Virginia|Carilion Clinic|North Carolina Agriculture & Technical State University","All","50 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","0037457000|1418622","May 2016","August 2019","August 2019","September 29, 2017",,"September 29, 2017","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03297268"
2003,"NCT03282877","iCST Web-application for People With Dementia",,"Active, not recruiting","No Results Available","Mild Dementia|Moderate Dementia","Behavioral: iCST web-application","Change in cognition (person with dementia)|Change in quality of life (person with dementia)|Change in general health outcome (carer)|Depression (person with dementia)|Behavioural symptoms (person with dementia)|Activities of daily living (person with dementia)|Relation between person with dementia and carer (both)|Depression/anxiety (carer)","University of Nottingham","All","21 Years and older   (Adult, Older Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","iCST web-application","May 1, 2018","August 2019","August 2019","September 14, 2017",,"May 30, 2019","Derbyshire Healthcare NHS Foundation Trust, Derby, Derbyshire, United Kingdom|Leicestershire Partnership NHS Trust, Leicester, Leicestershire, United Kingdom|Lincolnshire Partnership NHS Foundation Trust, Lincoln, Lincolnshire, United Kingdom|Nottinghamshire Healthcare NHS Trust, Nottingham, Nottinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03282877"
2004,"NCT03001232","The Effect of Movement-oriented Dementia Care on ADL and QoL of Dementia Patients in Nursing Homes","Solis MDC","Completed","No Results Available","Dementia","Behavioral: Movement-oriented Dementia Care","Change from Baseline in Activities of Daily Living (ADL), measured with the Barthel Index.|Change from Baseline in Quality of Life (QoL), measured with the Qualidem|Change from Baseline in general cognitive functions, measured with the Severe Impairment Battery 8 (SIB-8).|Change from Baseline in mood, measured with the Cornell Scale for Depression in Dementia (CSDD).|Change from Baseline in behaviour, measured with the Apathy Evaluation Scale-10 (AES-10).|Change from Baseline in behaviour, measured with the Cohen-Mansfield Agitation Inventory (CMAI).|Change from Baseline in aerobic fitness, measured with the two minute walking test (2mWT).|Change from Baseline in functional mobility and fall risk, measured with the Timed up and go (TUG).|Change from Baseline in walking speed, measured with the ten meter timed walk.","VU University of Amsterdam|Zorggroep Solis","All","65 Years and older   (Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","METc Vumc: 2013.311/A2015.245","March 2014","March 2015","March 2015","December 22, 2016",,"February 3, 2017",,,"https://ClinicalTrials.gov/show/NCT03001232"
2005,"NCT03185208","Lithium As a Treatment to Prevent Impairment of Cognition in Elders","LATTICE","Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Lithium Carbonate|Drug: Placebo oral capsule","Change from baseline cognitive testing measures over 2 years|Change from baseline biomarker values over 2 years|Change from baseline brain volume values over 2 years as measured by structural imaging (7T MRI)|Change from baseline brain integrity measures over 2 years as measured by structural imaging (7T MRI)|Change from baseline cerebrospinal phospho tau levels over 2 years","Ariel Gildengers|National Institute on Aging (NIA)|University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO17030527|R01AG055389-01","September 1, 2017","March 31, 2022","March 31, 2022","June 14, 2017",,"January 31, 2019","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03185208"
2006,"NCT03724136","Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study","ACIST","Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Vascular Dementia|Lewy Body Disease|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia, Mixed|Parkinson-Dementia Syndrome|Chronic Traumatic Encephalopathy|Huntington's Dementia|Wernicke Korsakoff Syndrome|Traumatic Brain Injury|Dementia, Multi-Infarct|Autism|Autism Spectrum Disorder|Autistic Behavior|Autistic Disorder, Current or Active State|Cadasil|LATE Limbic-predominant Age-related TDP-43 Encephalopathy","Procedure: Intravenous Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Procedure: Near Infrared Light","Mini-Mental Status Exam (MMSE)|Autism Spectrum Quotient Exam|Activities of Daily Living","MD Stem Cells","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDSC-ACIST","October 24, 2018","October 24, 2021","October 24, 2022","October 30, 2018",,"August 28, 2019","MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03724136"
2007,"NCT01926691","Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)","TABASCO","Unknown status","No Results Available","Stroke|Dementia|Cerebrovascular Disorders|Alzheimer's Disease|Brain Ischemia",,"dementia/cognitive decline occurrence|dementia or cognitive decline occurrence","Michal Roll PhD,MBA|Tel Aviv University|Hebrew University of Jerusalem|Technische Universität Dresden|University of New Mexico|Charite University, Berlin, Germany|Tel-Aviv Sourasky Medical Center","All","50 Years and older   (Adult, Older Adult)",,"534","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TABASCO","April 2008","April 2018",,"August 21, 2013",,"August 21, 2013","Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01926691"
2008,"NCT02819700","Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)","ISDC","Unknown status","No Results Available","Frontotemporal Dementia|Huntington Disease|Alzheimer Disease|Semantic Dementia|Dementia, Vascular","Behavioral: prevalence of behavioural dysexecutive syndrome","ISDC (Behavioural Dysexecutive Syndrome Inventory)","Centre Hospitalier Universitaire, Amiens","All","40 Years to 85 Years   (Adult, Older Adult)",,"285","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI11-PR-GODEFROY-2","January 2013","December 2017","December 2017","June 30, 2016",,"June 30, 2016","CHU Amiens, Amiens, France|CHU Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT02819700"
2009,"NCT00693888","Lighthouse Project on Dementia, Ulm, Germany","ULTDEM","Unknown status","No Results Available","Dementia","Behavioral: advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)","Quality of life|health economical effects, progress of disease, level of evidence based on diagnosis, institutionalization, hospitalization, using support possibilities, use of drugs","University of Ulm|Federal Ministry of Health, Germany|Geriatric Center Ulm|Robert Bosch Medical Center","All","60 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","LTDemenz-44-052","June 2008","February 2010","September 2010","June 9, 2008",,"August 17, 2010","Geriatric Center Ulm (GZU), Bethesda Geriatrische Klinik Ulm, Ulm, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT00693888"
2010,"NCT01089283","Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics",,"Unknown status","No Results Available","Parkinson Disease",,,"Tel-Aviv Sourasky Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TASMC-10-EES-087-CTIL","March 2010","March 2011",,"March 18, 2010",,"March 18, 2010","Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01089283"
2011,"NCT00295152","Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.",,"Unknown status","No Results Available","Community Occupational Therapy|Dementia Patients|Primary Caregivers of Dementia Patients","Behavioral: community occupational therapy in dementia","1.process skills scores of the patients on the Assessment of Motor and Process Skills (AMPS);|2. performance scores in daily activities of the patients on the Interview of Deterioration in Daily Activities in Dementia (IDDD);|3. Sense of competence scores of the primary caregivers on the Sense of Competence Questionnaire (SCQ).|Patients:|1. motor skills scores on the AMPS|2. initiative in performing daily activities on the IDDD|3. general health scores on the General Health Questionnaire (GHQ-12)|4.Quality of life scored on the Dementia Quality of Life Instrument (DQOL)|5. Self-perception scores in occupational performance and satisfaction scores with this performance, scored on the Canadian Occupational Performance Measurement (COPM)|6. Mood/depression scored on the Cornell Depression Scale (CDS)|Caregiver:|1. mastery skills scored on the Mastery Scale|2. general health scores on the GHQ-12|3. quality of life scores on the DQOL|4. self-perception scores in occupational performance and satisfaction scores on the COPM|5. mood/depression scores on the Center for Epidemiologic Studies Depression Scales (Ces-D)|6. Copings skills scores on the JCS","Radboud University|Alzheimer's Association|VCVGZ Fund;|Dutch Occupational Therapy Association","All","65 Years and older   (Older Adult)","Not Applicable","135","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment","EDO project|Grant V-1999-023.","April 2001",,"February 2005","February 22, 2006",,"November 17, 2011","Memory Clinic and Geriatic Department Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00295152"
2012,"NCT03592563","CUHK Brain Health Longitudinal Study","BHS","Recruiting","No Results Available","Stroke, Ischemic|Stroke Syndrome|Stroke|Stroke, Acute|Dementia|Brain Ischemia|Brain Diseases|Alzheimer Disease|Health Attitude|Health Knowledge, Attitudes, Practice|Health Personnel Attitude|Healthy Aging","Behavioral: Neuro-QoL questionnaire","Risk factors contributing to neurological and psychiatric diseases","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Crec No. 2018.148","July 1, 2019","December 31, 2038","December 31, 2048","July 19, 2018",,"September 18, 2019","Chinese University of Hong Kong, Hong Kong, Hong Kong|The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03592563"
2013,"NCT02959502","Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression",,"Recruiting","No Results Available","Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Dementia|Transcranial Direct Current Stimulation|tDCS","Other: Receive tDCS+CR|Other: Facilitate tDCS + CR","Feasibility of training a facilitator (caregiver) to facilitate the administration of CR+tDCS to their ""patient"" partner as indicated by a positive response in the Perceived Competence Scale at 24 months from study baseline.|Assess change in Quality of Life Scale scores among patients between baseline and at the end of the 8-week course.|Measure the change in Quality of Life Scale scores among facilitators between baseline and at the end of the 8-week course.|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among patients between baseline and at the end of the 8-week course|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among facilitators between baseline and at the end of the 8-week course","Centre for Addiction and Mental Health|CAMH Foundation","All","60 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","069/2016","October 31, 2016","December 2019","December 2019","November 9, 2016",,"September 10, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02959502"
2014,"NCT00145132","Beta-CIT-SPECT and Neurophysiology in Depression",,"Completed","No Results Available","Depression","Procedure: β-CIT-SPECT, Neurophysiology","changes in β-CIT/neurophysiological measurements from baseline to week 4","Ludwig-Maximilians - University of Munich|H. Lundbeck A/S","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ESCIT-SPECT-Pogarell|EK287/98","June 2005","December 2009","December 2009","September 5, 2005",,"June 2, 2010","Depts. of Psychiatry and Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00145132"
2015,"NCT03717597","Nonrandomized Evaluation of a Multidimensional Behavioral Intervention","BBLite","Recruiting","No Results Available","Subjective Cognitive Concerns (SCC)","Behavioral: Intervention","Change in compensation use|Change in cognition|Beck Depression Inventory|Beck Anxiety Inventory|List learning task|Executive function task|Psychomotor Speed Task|GRIT","University of California, Davis","All","65 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1210286","April 26, 2018","October 31, 2019","December 31, 2019","October 24, 2018",,"October 24, 2018","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03717597"
2016,"NCT03907748","Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia","HOMESIDE","Not yet recruiting","No Results Available","Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Dementia, Mixed|Dementia Alzheimers|Behavioural and Psychiatric Symptoms of Dementia|Depression|Quality of Life","Other: Music Intervention|Other: Reading Intervention","Change from baseline of behavioural and psychological symptoms of participants with dementia at post-intervention and 6-month follow-up|Change from baseline of depression in participants with dementia at post-intervention and 6-month follow-up|Change from baseline of quality of life of participants with dementia at post-intervention and 6-month follow-up|Change from baseline of depression in caregiver participants at post-intervention and 6-month follow-up|Change from baseline of resilience in caregiver participants at post-intervention and 6-month follow-up|Change from baseline in caregiver competence of caregiver participants at post-intervention and 6-month follow-up|Change from baseline in quality of life of caregiver participants at post-intervention and 6-month follow-up|Change from baseline in quality of the relationship between caregiver and person with dementia at post-intervention and 6-month follow-up|Change from baseline in quality of adjusted life-years of caregiver and person with dementia at post-intervention and 6-month follow-up|Change from baseline in resource use of both caregiver and person with dementia (cost-effectiveness) at post-intervention and 6-month follow-up","Anglia Ruskin University|University of Melbourne|Norwegian Academy of Music|University of Applied Sciences Würzburg-Schweinfurt|University School of Physical Education, Krakow, Poland|Alzheimer's Society|Methodist Homes for the Aged|Saffron Hall Trust|Cambridgeshire and Peterborough NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","990","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","U4-10366|ACTRN12618001799246p|462","September 1, 2019","April 1, 2022","April 1, 2022","April 9, 2019",,"September 12, 2019","The University of Melbourne, Melbourne, Australia|University of Applied Sciences Würzburg-Schweinfurt, Würzburg, Germany|Norwegian Academy of Music, Oslo, Norway|University of Physical Education in Krakow, Kraków, Poland|Anglia Ruskin University, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03907748"
2017,"NCT03185182","Diagnostic Imaging for Clear Cell Renal Cell Carcinoma","RCCSCAN","Terminated","Has Results","Clear Cell Renal Cell Carcinoma","Drug: Ioflupane I123","Number of Participants That Display Ioflupane-positivity in Tumors Detected Via CT-scan|Number of Participants Diagnosed With Non-ccRCC That Display Ioflupane I123-negativity in Tumors Detected Via CT-scan","Region Skane|Lund University","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RCCSCAN|2016-005182-31","July 14, 2017","September 12, 2018","September 12, 2018","June 14, 2017","June 21, 2019","June 21, 2019","Skåne University hospital SUS, Lund, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03185182/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03185182"
2018,"NCT03734289","Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI",,"Recruiting","No Results Available","Dementia|Traumatic Brain Injury","Behavioral: Caregiver Coaching","Change in Zarit Burden Interview|Change in Dementia Quality of Life (DEMQOL/DEMQOL proxy)|Change in Neuropsychiatric Inventory|Change in Family Quality of Life (Dementia or TBI versions)|Change in Connor-Davidson Resilience Scale (CD-RISC)","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB-160819003|W81XWH-16-1-0527","February 1, 2017","August 31, 2019","December 31, 2019","November 7, 2018",,"November 7, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03734289"
2019,"NCT03052712","Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies","GREFEXII","Recruiting","No Results Available","Alzheimer Disease|Parkinson Disease|Frontal Dementia|Huntington Disease|Traumatic Brain Injury|Stroke","Behavioral: social cognition","tests of social cognition (questionnaire)","Centre Hospitalier Universitaire, Amiens","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI2015_843_0031","September 9, 2016","September 9, 2019","September 9, 2019","February 14, 2017",,"October 4, 2018","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT03052712"
2020,"NCT03275363","The University of Hong Kong Neurocognitive Disorder Cohort",,"Recruiting","No Results Available","Neurocognitive Disorder|Mild Cognitive Impairment|Alzheimer Dementia|Vascular Dementia|Age-related Cognitive Decline","Diagnostic Test: Neurocognitive battery|Diagnostic Test: MRI|Biological: Blood tests|Diagnostic Test: EEG with event-related potential (ERP)|Diagnostic Test: Amyloid PET CT","Cognitive decline|Functional decline|Neuropsychiatric decline|Quality of life decline|Change in cognitive impairment status","The University of Hong Kong|Dementias Platform UK","All","65 Years and older   (Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HKUNCDC","September 1, 2014","January 1, 2022","January 4, 2022","September 7, 2017",,"September 7, 2017","Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03275363"
2021,"NCT03538522","A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Alzheimer Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Cognitive Impairment|Tauopathies|Neurodegenerative Diseases|Neurocognitive Disorders|Cognitive Disorder","Drug: N-831(Traneurocin) 10 mg QD|Drug: NA-831 (Traneurocin) 20 mg QD|Drug: NA-831 (Traneurocin) 40 mg QD|Drug: Placebo oral capsule QD","Change from baseline in Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) score at Week 24|1. Mean difference between the last (Week 24) and first (Week 2) postdose using Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) assessment|Assess the change from baseline in ADCS-ADL MCI at Week 24","NeuroActiva, Inc.|The Florey Institute of Neuroscience and Mental Health","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","156","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","NeuroActiva","September 15, 2018","March 15, 2019","April 15, 2019","May 28, 2018",,"May 30, 2018","Investigator Site of NeuroActiva (Australia) Pte, Melbourne, Victoria, Australia|NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT03538522"
2022,"NCT02213458","Care Ecosystem: Navigating Patients and Families Through Stages of Care",,"Completed","No Results Available","Dementia|Alzheimer Disease|Dementia, Vascular|Lewy Body Disease|Frontotemporal Lobar Degeneration|Memory Disorders","Behavioral: Navigated Care","Quality of Life-AD|Health care utilization|Caregiver burden|Satisfaction with Dementia Care|Caregiver depression|Caregiver self-efficacy","University of California, San Francisco|University of Nebraska|Centers for Medicare and Medicaid Services|National Institute on Aging (NIA)","All","45 Years and older   (Adult, Older Adult)","Not Applicable","780","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","1C12013003302|5R01AG056715|1C1CMS331346","March 20, 2015","March 8, 2018","March 8, 2018","August 11, 2014",,"November 15, 2018","University of California, San Francisco, San Francisco, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02213458"
2023,"NCT02453763","In Vivo Imaging of Therapeutic Electric Current Flow","tDCS","Completed","No Results Available","Parkinson Disease|Epilepsy|Alzheimer's Disease|Stroke|Autism|Depression|Schizophrenia","Device: Transcranial direct current stimulation|Procedure: MRI","Magnetic Resonance Imaging (MRI) of therapeutic current flow","University of Florida|Arizona State University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 30 Years   (Adult)",,"17","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","506-2012-N|1R21NS081646-01A1","June 2015","July 6, 2017","July 6, 2017","May 25, 2015",,"April 5, 2018","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02453763"
2024,"NCT03020381","Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study",,"Recruiting","No Results Available","Gait Apraxia|Mild Cognitive Impairment|Subjective Cognitive Impairment|Cerebral Atrophy|Alzheimer Disease|Dementia",,"Progression to Dementia|Type of Dementia|Development of Mobility Decline|Incidence of Falls|Brain anatomical changes (grey matter)|Brain anatomical changes (white matter)|Brain anatomical changes (ventricular volume)","Lawson Health Research Institute","All","60 Years to 85 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17200","December 2007","December 2020","December 2020","January 13, 2017",,"January 23, 2019","Gait and Brain Lab, Parkwood Institute, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03020381"
2025,"NCT02626377","Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté","ICE","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke","Behavioral: Support provided by social worker|Other: Information booklet receipt","(Interventional Study) Comparison of caregivers' HRQoL according to the allocated intervention by randomization based on summaries score the MOS SF36|(Observational study) Changes in HRQoL of patients' caregivers using the MOS SF36 questionnaire|(Observational study) Changes in HRQoL of cancer patients' caregivers using the CarGoQoL questionnaire|(Observational study) Changes in the coping strategies of patients' caregivers using the Borteyrou, Rascle and Truchot Questionnaire|(Observational study) Changes in feelings of anxiety and depression of patients' caregivers according to the HADs questionnaire|(Observational study) Changes in social support of patients' caregivers using the SSQ6 questionnaire|(Observational study) Changes in burden of patients' caregivers using the Zarit burden inventory|(Interventional Study) Comparison of caregivers' HRQoL according to the intervention allocated by randomization based on summaries score the MOS SF36|(Interventional Study) Changes in HRQoL of patients' caregivers according to the allocated intervention using the MOS SF36 questionnaire|(Interventional Study) Changes in HRQoL of cancer patients' caregivers according to the allocated intervention using the CarGoQol questionnaire|(Interventionnal Study) Changes in the coping strategies of patients' caregivers according to the allocated intervention using the Borteyrou, Rascle and Truchot Questionnaire|(Interventional Study) Changes in feelings of anxiety and depression of patients' caregivers according to the allocated intervention using the HADs Questionnaire|(Interventional Study) Changes in social supports of patients' caregivers according to the allocated intervention using the SSQ6 questionnaire|(Interventional Study) Changes in burden of patients' caregivers according to the allocated intervention using the Zarit burden inventory|(Interventional study) Efficiency of the intervention of a social worker for caregivers using a cost-utility analysis|(Observational study) Changes in the caregivers/patients' relationship using a qualitative approach (semi-structure interview)|(Observational study) Changes in the role of caregiver due to a situation generating a rupture (entry into an institution or death, disease remission) using a qualitative approach (semi-structure interview)","Centre Hospitalier Universitaire de Besancon|Methodological and quality of life unit in oncology (CHRU de Besançon)|University of Franche-Comté|University of Burgundy|Pôle de Gérontologie Interrégional Bourgogne et Franche-Comté|CARSAT Bourgogne et Franche-Comté|CCAS of Dijon|CCAS of Besançon|CCAS of Montbéliard|Burgundy Regional Council|Franche-Comté Regional Council|The Municipality of Besançon|The Municipality of Dijon|General Council of the Doubs|General Council of the Territoire de Belfort|Collectif Inter Associatif Sur la Sante Bourgogne|Union Régionale Interfédérale des Œuvres et Organismes Privés Sanitaires Bourgogne|Association Gérontopôle Pierre Pfitzenmeyer|Pôle de compétitivité Vitagora Goût-Nutrition-Santé|National Old Age Insurance Fund for Employees (CNAVTS)|Sheerbrooke Gérontopôle|France Alzheimer Côte-d’Or|Institut Régional de Vieillissement (IRV)|Novartis Pharmaceuticals|Roche Foundation|Ligue contre le cancer, France|National Cancer Institute, France|Quality of life and cancer clinical research platform|National Research Agency, France","All","60 Years and older   (Adult, Older Adult)","Not Applicable","7604","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","P/2014/231","October 2015","October 2025","October 2025","December 10, 2015",,"October 12, 2017","CHRU de Besançon, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU de DIJON, Dijon, France",,"https://ClinicalTrials.gov/show/NCT02626377"
2026,"NCT03044249","A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression",,"Recruiting","No Results Available","Psychosis|Dementia|Aggression|Agitation|Alzheimer Dementia","Drug: MP-101|Drug: Placebo","Change from baseline in the Neuropsychiatric Inventory (NPI) - Psychosis subscale|Change from baseline in the Clinical Global Impression of Improvement (CGI-I)|Change from Baseline in NPI Total Score|Change from Baseline in NPI Core Total Score|Change from Baseline in NPI Caregiver Distress|Change from Baseline in NPI Domains|Number of Participants with any Treatment Emergent Adverse Event|Change from Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III|Population Pharmacokinetics: Plasma Levels of MP-101 and Metabolite","Mediti Pharma Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MP-101-01","May 4, 2017","August 2020","August 2020","February 6, 2017",,"September 5, 2019","Dignity Health (St. Joseph Hospital and Medical Center), Phoenix, Arizona, United States|Neuro-Therapeutics Inc, Pasadena, California, United States|Associated Neurologists of Southern CT, Fairfield, Connecticut, United States|Marcus Neuroscience Institute, Boca Raton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Galiz Research, Hialeah, Florida, United States|Galiz Research, Miami Springs, Florida, United States|CNS, Orlando, Florida, United States|Parkinson's Disease Treatment Center of SW Florida, Port Charlotte, Florida, United States|Meridien Research Inc, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|College Park Family Care Neuro, Overland Park, Kansas, United States|J. Gary Booker, MD, Clinical Trials, Shreveport, Louisiana, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Clarity Clinical Research, East Syracuse, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Neurology Diagnostics Inc, Dayton, Ohio, United States|SKDS Research Inc., Newmarket, Ontario, Canada|Montreal Neurological Institute, Montréal, Quebec, Canada|Centre de recherche sur le vieillissement du CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03044249"
2027,"NCT02509117","First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979",,"Completed","Has Results","Healthy Subjects","Drug: PF-06751979 single ascending dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple dose|Drug: PF-06751979 multiple dose","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Physical Examinations Findings|Number of Participants With Abnormal Neurological Examinations Findings|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14|Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 19|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Laboratory Abnormalities|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs|Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry|Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979|Part A: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979|Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(dn) of PF-06751979|Part A: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)(Dn) of PF-06751979|Part A: Dose Normalized Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)(Dn) of PF-06751979|Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part A: Plasma Decay Half-Life (t1/2) of PF-06751979|Part A: Apparent Oral Clearance (CL/F) of PF-06751979|Part A: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Apparent Volume of Distribution (Vz/F) of PF-06751979 at Day 14|Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(Dn) of PF-06751979|Part B: Apparent Oral Clearance (CL/F) of PF-06751979|Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau)(Dn) of PF-06751979|Part B: Peak-to-Trough Ratio (PTR) of PF-06751979|Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 at Day 7, 14|Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979 at Day 7, 14|Part B: Plasma Decay Half-Life (t1/2) of PF-06751979 at Day 14|Part B: Amount of PF-06751979 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)|Part B: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)|Part B: Renal Clearance of PF-06751979|Part B: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) Fragments on Day 14|Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax)(Dn) of PF-06751979|Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau)(Dn) of PF-06751979|Part C: Apparent Oral Clearance (CL/F) of PF-06751979 on Day 14|Part C: Minimum Observed Plasma Concentration (Cmin) of PF-06751979 on Day 14|Part C: Peak-to-Trough Ratio (PTR) of PF-06751979 at Day 14|Part C: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 at Day 14|Part C: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF 06751979 at Day 14|Part C: Apparent Volume of Distribution (Vz/F) of PF-06751979 at Day 14|Part C: Plasma Decay Half-Life (t1/2) of PF-06751979 at Day 14","Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","B8271001","July 2015","July 2016","July 2016","July 27, 2015","November 1, 2018","November 1, 2018","California Clinical Trials Medical Group, Inc, Glendale, California, United States|Glendale Adventist Medical Center, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02509117"
2028,"NCT00701532","Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction","CAIMAN","Completed","No Results Available","Cocaine Addiction|Cocaine Dependence","Drug: Modafinil and PET (brain imaging)|Drug: placebo","Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification.|Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.|Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density.|Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.|Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters.","Assistance Publique - Hôpitaux de Paris|Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P070150","April 2009","October 2012","January 2013","June 19, 2008",,"April 11, 2013","Unité de recherche U797 Inserm - CEA - Université Paris-Sud. "" Neuroimagerie & Psychiatrie "" Service Hospitalier Frédéric Joliot, Orsay, France|Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00701532"
2029,"NCT00966966","Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered",,"Completed","No Results Available","Healthy","Drug: SAM-531 and gemfibrozil","Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (tmax)|Area under the concentration-time curve (AUC)|Safety as measured by adverse event monitoring, ECG, vital signs, and laboratory tests","Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3193A1-1109|B1961001","September 2009","December 2009","December 2009","August 27, 2009",,"August 20, 2010","Pfizer Investigational Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00966966"
2030,"NCT00959881","Study Evaluating The Coadministration of Begacestat And Donepezil",,"Completed","No Results Available","Healthy Subjects","Drug: Donepezil plus placebo|Drug: Donepezil|Drug: Begacestat","Pharmacodynamic interaction of multiple doses of begacestat and donepezil coadministered to healthy subjects as assessed by 12-lead electrocardiogram (ECG).|Pharmacokinetic parameters including Cmax, AUC, and t 1/2|Safety and tolerability as assessed by results of 12-lead ECGs, cardiac telemetry, laboratory tests, vital signs, physical examinations and reported adverse events.","Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer","All","18 Years to 50 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","3183A1-1106|B1941005","August 2009","November 2009","November 2009","August 17, 2009",,"April 4, 2011","Pfizer Investigational Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00959881"
2031,"NCT02103894","Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease (AD)|Parkinson's Disease (PD)|Chronic Traumatic Encephalopathy (CTE)|Progressive Supranuclear Palsy (PSP)|Frontal Temporal Dementia (FTD)|Pick's Disease|Tauopathies","Drug: [18F]T807 ([18F]MNI-777)","Brain uptake of [18F]T807 ([18F]MNI-777)","Molecular NeuroImaging|Institute for Neurodegenerative Disorders","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-777","February 2014","August 2016","September 2016","April 4, 2014",,"December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02103894"
2032,"NCT00547560","Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population",,"Completed","No Results Available","Healthy","Drug: GSI-953","The pharmacokinetic and pharmacodynamic profile for the elderly subjects.|Pharmacokinetics (PK)|Pharmacodynamics (PD)","Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer","All","65 Years and older   (Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3183A1-102|B1941003","August 2007","October 2009","October 2009","October 22, 2007",,"April 4, 2011","Pfizer Investigational Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00547560"
2033,"NCT00519298","Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects",,"Completed","No Results Available","Healthy|Adult","Drug: SAM-531|Other: placebo|Drug: Donepezil","Evaluation of the pharmacologic effect of SAM-531 on sleep EEG in healthy subjects","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 50 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","3193A1-1110","October 2007","March 2008","March 2008","August 22, 2007",,"April 22, 2008","Rouffach, France",,"https://ClinicalTrials.gov/show/NCT00519298"
2034,"NCT01366027","PRISM Registry: Pseudobulbar Affect Registry Series",,"Completed","No Results Available","Alzheimer's Disease|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson's Disease|Stroke|Traumatic Brain Injury",,"Prevalence of PBA (using CNS-LS)","Avanir Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"5290","Industry","Observational",,"11-AVR-REG-001","May 2011","September 2012","September 2012","June 3, 2011",,"April 16, 2014","Avanir Pharmaceuticals, Aliso Viejo, California, United States",,"https://ClinicalTrials.gov/show/NCT01366027"
2035,"NCT00870974","A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions","FPEB","Completed","No Results Available","Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment","Drug: [18F]FPEB","Does FPEB reliably represent the known distribution of MGLUR5 in the brain?","Institute for Neurodegenerative Disorders","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","FPEB","March 2009","October 2016","November 2016","March 27, 2009",,"January 6, 2017","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00870974"
2036,"NCT02440646","Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography","REALITY","Enrolling by invitation","No Results Available","Coronary Atherosclerosis|Coronary Artery Disease|Radiocontrast-induced Thyroid Dysfunction|Contrast-induced Nephropathy|Cerebrovascular Disease|Alzheimer's Disease","Radiation: Coronary computed tomography angiography|Radiation: Quantitative coronary angiography","Change of per cent of plaque burden from baseline to follow-up as assessed by either CTA or QCA|Number of participants with major adverse cardiac events that are related to plaque burden|Change of serologic markers of inflammation from baseline to follow-up that are related to cardiovascular events and intervention|Number of participants with procedural success|Change of complexity of coronary artery disease from baseline to follow-up as assessed by SYNTAX score I|Change of complexity of coronary artery disease from baseline to follow-up as assessed by SYNTAX score II|Change of fractional flow reserve (FFR) from baseline to follow-up that are related to the progress of atherosclerosis|Number of participants with contrast-induced nephropathy (CIN)|Number of participants with radiocontrast-induced thyroid dysfunction|Safety of QCA and CTA as assessed by the calculation of effective radiation dose|Change of complexity of coronary artery disease from baseline to follow-up as assessed by Leaman Coronary Score|Number of participants with encephalopathy|Number of chest pain patients with non-obstructive coronary artery disease|Number of chest pain patients without coronary artery disease","Ural Medical University|Ural Institute of Cardiology|De Haar Research Task Force|Transfiguration Clinic|First Sverdlovsk Regional Clinical Hospital","All","21 Years and older   (Adult, Older Adult)",,"1080","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REALITY","May 2015","December 2016","February 2020","May 12, 2015",,"June 7, 2019","De Haar Research Task Force, Amsterdam, North Holland, Netherlands|Transfiguration Clinic, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|First Sverdlovsk Regional Clinical Hospital, Yekaterinburg, Sverdlovsk Oblast, Russian Federation|Ural Institute of Cardiology, Yekaterinburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02440646"
2037,"NCT00294307","Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers",,"Completed","No Results Available","Dementia|Dementia, Vascular|Alzheimer Disease|Delirium, Dementia, Amnestic, Cognitive Disorders|Lewy Body Disease|Mild Cognitive Impairment","Behavioral: Augmented Standard Care (ASC)|Behavioral: Resource Nurse Care (RNC)|Behavioral: Advanced Practice Nurse Care (APNC)","Patient - Function|Caregiver - Burden|Patient - Health Care Costs|Patient - Time to first rehospitalization or death; total rehospitalization days|Patient - Total rehospitalizations|Patient - Cognitive Function|Patient - Care Management|Patient - Symptoms (Physical and depressive symptoms)|Patient - Neuropsychiatric Behaviors|Patient - Quality of Life|Patient/Caregiver - Satisfaction with care|Caregiver - Depressive Symptoms","University of Pennsylvania|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)",,"814","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01AG023116","February 2006","July 2010","August 2012","February 20, 2006",,"February 5, 2019","Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn-Presbyterian Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00294307"
2038,"NCT03622814","Partners at Meals - Respite Care and Home (PAM)","PAM","Active, not recruiting","No Results Available","Dementia, Alzheimer Type|Weight Loss","Behavioral: Partners at Meals|Behavioral: Enhanced Usual Condition","Weight maintenance","Medical University of South Carolina",,"Child, Adult, Older Adult","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","Pro00064441","August 15, 2017","May 31, 2021","May 31, 2021","August 9, 2018",,"August 1, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03622814"
2039,"NCT02820155","Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects",,"Unknown status","No Results Available","Healthy","Drug: RGN1016|Drug: Placebo","Number of incidence of Adverse Events.|Area under the plasma concentration-time curve (AUC)|Time to peak drug concentration (Tmax)|Maximum Plasma Concentration (Cmax)|Half-life T1/2","National Taiwan University Hospital|National Taiwan University","Male","20 Years to 45 Years   (Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201412002MIPD","June 2016","February 2017","February 2017","June 30, 2016",,"July 6, 2016","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02820155"
2040,"NCT03357328","Therapy Light Rooms for Improved Sleep in Dementia Patients","DEMLIGHT","Completed","No Results Available","Sleep Fragmentation|Behavioural and Psychiatric Symptoms of Dementia|Dementia","Other: Therapy light room|Other: Standard light","Change in actigraphy recorded sleep and circadian rhythm|Change in proxy-rated sleep|Change in circadian rhythm of core body temperature|Change in the Neuropsychiatric Inventory - Nursing Home version (NPI-NH)|Change in the Cohen-Mansfield Agitation Inventory (CMAI)|Change in the Cornell Scale of Depression in Dementia (CSDD)|Change in the Quality of Life in Late-Stage Dementia (QUALID)|Change in the Mobilization-Observation-Behaviour-Intensity-Dementia 2 (MOBID-2)|Change in the Mini Mental State Examination (MMSE)|Change in the Functional Assessment Staging (FAST)|Change in the Physical Self-Maintenance Scale|Clinical Global Impression of Change (CGIC)|Change in the Resource Utilization in Dementia - Formal Care (RUD-FOCA)|Change in general health|Change in burden of care|Change in staff alertness|Change in staff sleep|Change in staff fatigue|Change in staff mental health|Change in staff health related quality of life","University of Bergen","All","60 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","UBergenDEM.LIGHT|2016/2246","September 25, 2017","April 21, 2018","April 24, 2018","November 29, 2017",,"May 7, 2018","University of Bergen, Bergen, Hordaland, Norway",,"https://ClinicalTrials.gov/show/NCT03357328"
2041,"NCT04037501","Effectiveness of a Care Management System to Reduce Unmet Needs of Informal Caregivers of People With Dementia","GAP","Not yet recruiting","No Results Available","Dementia|Caregiver Burnout|Carer Stress Syndrome|Relatives|Partner, Domestic","Other: Care Management","Change in number of Unmet Needs|Change in Quality of Life|Change in Caregiver Burden|Social Support|Use of medical and non-medical services","German Center for Neurodegenerative Diseases (DZNE)|Gemeinsamer Bundesausschuss (GBA)|University Medicine Greifswald","All","18 Years and older   (Adult, Older Adult)","Not Applicable","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","01VSF18030","November 2019","August 2021","March 2022","July 30, 2019",,"August 1, 2019",,,"https://ClinicalTrials.gov/show/NCT04037501"
2042,"NCT03941119","Evaluating the Impact of VR-therapy on BPSD and QoL of Individuals With Dementia Admitted to Hospital","VRx-RCT","Recruiting","No Results Available","Dementia|Delirium Superimposed on Dementia","Other: VR-therapy","Changes in Behavioural and Psychological Symptoms of Dementia (BPSD) during the hospital stay|Number of falls without injury during the hospital stay|Number of falls with injury during the hospital stay|Number of pressure ulcers during the hospital stay|All-cause in-patient mortality during the hospital stay|Length of acute hospital stay|Discharge disposition|30-day readmission rate|Usability of VR-therapy|Number of participants with VR-therapy related adverse events as assessed by the post-intervention semi-structured interview and research coordinator observations|In-Hospital Quality of Life Observational Scale|Participant Experience and Satisfaction of VR-therapy","University Health Network, Toronto|Centre for Aging and Brain Health Innovation|Michael Garron Hospital","All","65 Years and older   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","782-1812-Mis-332","May 6, 2019","June 15, 2021","June 15, 2021","May 7, 2019",,"September 26, 2019","Michael Garron Hospital, Toronto, Ont, Canada",,"https://ClinicalTrials.gov/show/NCT03941119"
2043,"NCT03672448","The China Longitudinal Aging Study of Cognitive Impairment",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular|Dementia With Lewy Bodies|Dementia Frontal|Depression|Anxiety","Other: Naturalistic observation","Prevalence, incidence of neurocognitive disorder|Prevalence, incidence of mood disorder|conversion rate","Shanghai Mental Health Center","All","60 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CRC2017ZD02","September 1, 2018","November 30, 2023","November 30, 2023","September 14, 2018",,"September 14, 2018","Shanghai Mental Health Centre, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03672448"
2044,"NCT03121950","Movement and Music Intervention for Individuals With Dementia",,"Completed","Has Results","Dementia With Lewy Bodies|Dementia","Other: Dance|Other: music","Timed up and go Cognitive|Change in Score on the Montreal Cognitive Assessment","Ohio State University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016H0211","April 1, 2017","December 30, 2017","December 30, 2017","April 20, 2017","June 20, 2019","June 20, 2019","Ohio State University, Columbus, Ohio, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03121950/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03121950"
2045,"NCT04025801","Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals",,"Not yet recruiting","No Results Available","Healthy Individuals|Diabetes|Hypertension|Fabry Disease|Metabolic Disease|Alzheimer Disease|Dementia|Limbal Insufficiency|Phlyctenulosis|Ocular Rosacea|Graft Versus Host Disease in Eye|Dry Eye Syndrome",,"Confocal microscopy exam of sub-basal corneal nerve fibre density (NFD) by using the CCMetrics software|Confocal microscopy exam of sub-basal corneal nerve branch density (NBD) by using the CCMetrics software|Confocal microscopy exam of sub-basal corneal nerve fibre length (NFL) by using the CCMetrics software|Confocal microscopy exam of sub-basal corneal nerve fibre tortuosity (NFT) by using the CCMetrics software","National Taiwan University Hospital","All","20 Years to 40 Years   (Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","201903090RINB","July 31, 2019","June 2020","June 2020","July 19, 2019",,"July 24, 2019","National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan",,"https://ClinicalTrials.gov/show/NCT04025801"
2046,"NCT00997425","Home Evaluation of Exit Barriers in Wandering","HEEBW","Completed","Has Results","Dementia, Alzheimer Type|Problem Behavior","Device: Door cover/Floor cover","Number and Means of Exit Seeking (Door Approach Behaviors) and Exit Door Pass Through Behaviors (Eloping)","US Department of Veterans Affairs|VA Office of Research and Development","All","60 Years and older   (Adult, Older Adult)","Not Applicable","19","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","E6275-R|107401 I","October 2009","October 2010","December 2012","October 19, 2009","November 21, 2014","November 21, 2014","James A Haley Veterans' Hospital, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00997425"
2047,"NCT03246269","Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)","MoCA-Norm","Completed","No Results Available","Cognitive Impairment|Cognitive Decline|Cognition Disorders|Cognitive Symptom|Cognitive Change|Cognitive Deterioration|Cognitive Abnormality|Cognitive Impairment, Mild|Cognition Disorders in Old Age|Dementia|Dementia Alzheimers|Dementia, Alzheimer Type|Dementia, Mild|Dementia of Alzheimer Type","Diagnostic Test: MoCA","Montreal Cognitive Assessment (MoCA) - German version|Mini-Mental State Examination (MMSE)|Geriatric Depression Scale (GDS)|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)","Andreas Monsch|University Hospital, Basel, Switzerland","All","65 Years and older   (Older Adult)",,"334","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MoCA-Norm","December 2016","April 2017","April 2017","August 11, 2017",,"May 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03246269"
2048,"NCT00479271","Evaluating the Effectiveness of a Community Based Intervention for Persons With Dementia and Their Caregivers in a Developing Country",,"Completed","No Results Available","Dementia|Behavioral Symptoms|Mental Health","Behavioral: Home based, flexible, stepped care intervention|Behavioral: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.","Primary Outcome Measure(s) evaluate the efficacy and cost-effectiveness of the intervention in reducing carer burden, improving behaviour problems in elderly persons with dementia and reducing the costs of illness.|Measure the service requirements, average number of visits by Home Care Advisor, visits by Psychiatrists, need for medication, effect of intervention on survival and overall quality of life of the person with dementia as well as the carer","London School of Hygiene and Tropical Medicine|The Dementia Society of Goa, India|Goa Medical College","All","60 Years and older   (Adult, Older Adult)","Not Applicable",,"Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Supportive Care","DSG001","October 2003","February 2005","February 2005","May 28, 2007",,"April 1, 2015","The Dementia Society of Goa, Porvorim, Goa, India",,"https://ClinicalTrials.gov/show/NCT00479271"
2049,"NCT00174382","Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia",,"Terminated","Has Results","Dementia, Vascular|Dementia, Mixed","Drug: Donepezil","Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set|Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.|Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.|Disability Assessment for Dementia (DAD) Change From Baseline Total Score; Full Analysis Set (FAS)|Free-hand Drawing Test (CLOX 1) Change From Baseline; Full Analysis Set (FAS)|Copied Clock Drawing Test (CLOX 2) Change From Baseline; Full Analysis Set (FAS)|CLOX Differential Score Change From Baseline; Full Analysis Set (FAS)|Phonectic Fluency Total Score From Baseline; Full Analysis Set (FAS)|Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; Full Analysis Set (FAS)|Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; Full Analysis Set (FAS)|Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, Full Analysis Set (FAS)|Clinical Global Impressions Severity (CGI-S)|Clinical Global Impressions Improvement (CGI-I)|Clinical Global Impressions Improvement (CGI-I) Dichotomized Response","Pfizer","All","50 Years and older   (Adult, Older Adult)","Phase 3","149","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A2501026","June 2005","April 2008","April 2008","September 15, 2005","June 12, 2009","March 24, 2015","Pfizer Investigational Site, Belvedere, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Abbotsford, British Columbia, Canada|Pfizer Investigational Site, Coquitlam, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Saint John, New Brunswick, Canada|Pfizer Investigational Site, Amherst, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Pictou, Nova Scotia, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, Fort Erie, Ontario, Canada|Pfizer Investigational Site, Hawkesbury, Ontario, Canada|Pfizer Investigational Site, North Bay, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Peterborough, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Beauport, Quebec, Canada|Pfizer Investigational Site, Cowansville, Quebec, Canada|Pfizer Investigational Site, L'Ancienne-Lorette, Quebec, Canada|Pfizer Investigational Site, Montréal, Quebec, Canada|Pfizer Investigational Site, Rimouski, Quebec, Canada|Pfizer Investigational Site, St-Jean-sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, St. Leonard, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00174382"
2050,"NCT00006176","Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies",,"Completed","No Results Available","Familial Dementia With Neuroserpin Inclusion Bodies|Nervous System Heredodegenerative Disorder",,,"National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","10 Years and older   (Child, Adult, Older Adult)",,"100","NIH","Observational",,"000191|00-HG-0191","August 10, 2000","August 4, 2009","August 4, 2009","August 14, 2000",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00006176"
2051,"NCT04065061","Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations",,"Completed","No Results Available","Supplement|Cognition Disorders in Old Age|Vision|fMRI","Dietary Supplement: Erinacine A-enriched Hericium Erinaceus Mycelia|Dietary Supplement: Placebo","Mini-Mental State Examination(MMSE)|Neuropsychiatric Inventory (NPI)|Cognitive Abilities Screening Instrument (CASI)|Instrumental Activities of Daily Living (IADL)|Dehydroepiandrosterone sulfate (DHEAS)|Alpha 1-antichymotrypsin|Superoxide Dismutase|Homocysteine|Apolipoprotein E|Hemoglobin|Calcium|Albumin|Amyloid Beta|fMRI-Super-resolution Track Density Imaging (TDI)|fMRI-Blood Oxygenation Level-Dependent (BOLD) Signal Mapping|Vision Assessments-Visual Acuity (VA)|Vision Assessments-Contrast Sensitivity (CS)","Chung Shan Medical University|Grape King Bio Ltd.","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","68","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","CS15049","May 22, 2015","May 10, 2016","May 10, 2017","August 22, 2019",,"August 22, 2019","Chung Shan Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04065061"
2052,"NCT02750982","Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.",,"Completed","No Results Available","Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury","Other: Laughter Therapy","Patient Health Questionnaire (PHQ-9, for depression)|Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety)|The General Self-Efficacy Scale (GSE)","Brown, Theodore R., M.D., MPH","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","TRBROWN201601","July 2016","August 2018","August 2018","April 26, 2016",,"September 26, 2018","Evergreen Healthcare, Kirkland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02750982"
2053,"NCT04114994","Longitudinal Cognitive Assessment by BoCA","BoCA","Recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia|Frontotemporal Dementia|Parkinson Disease|Multiple Sclerosis|TBI","Diagnostic Test: Boston Cognitive Assessment (BoCA)","Boston Cognitive Assessment (BoCA)","Alzheimer's Light LLC","All","50 Years and older   (Adult, Older Adult)",,"10000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BoCA001","October 1, 2019","October 1, 2029","October 1, 2029","October 3, 2019",,"October 3, 2019","Andrey Vyshedskiy, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04114994"
2054,"NCT02761707","Biomarkers in Neural Disorders",,"Completed","No Results Available","Parkinson's Disease|Alzheimer's Disease|Progressive Supranuclear Palsy|Essential Tremor|Multiple System Atrophy|Drug Induced Parkinson's Disease|Diffuse Lewy Body Disease|Myasthenia Gravis|Spinal Cord Injuries","Other: Electrical Brainstem Responses|Other: Olfactory Tests|Other: Visual Deprivation|Other: Peripheral Nerve Stimulation","Latency, amplitude, and area under the curve of brainstem reflex response|Score on the University of Pennsylvania Smell Identification Test|Score on the Odor Discrimination/Memory Test|Score on an Odor Detection Threshold Test","University of Pennsylvania|Michael J. Fox Foundation for Parkinson's Research","All","18 Years to 80 Years   (Adult, Older Adult)",,"54","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","827731","June 2016","June 2018","July 16, 2019","May 4, 2016",,"July 18, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02761707"
2055,"NCT01696591","The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD",,"Unknown status","No Results Available","Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Mental Disorders","Biological: NEUROSTEM®-AD","Safety|Efficacy","Duk Lyul Na|Medipost Co Ltd.|Samsung Medical Center","All","50 Years to 75 Years   (Adult, Older Adult)",,"14","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","MP-CR-007-F/U","March 2012","September 2013","September 2013","October 1, 2012",,"October 1, 2012","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01696591"
2056,"NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","Recruiting","No Results Available","Dementia|Alzheimer Disease|Parkinson Disease|Lewy Body Disease|Parkinson-Dementia Syndrome|Frontotemporal Degeneration|Semantic Dementia|Progressive Nonfluent Aphasia|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Mild Cognitive Impairment","Diagnostic Test: Flutemetamol F18 Injection|Diagnostic Test: [18F]-RO6958948|Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau|Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau","Clinical diagnosis|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Rate of cognitive decline as measured by MMSE.|Rate of cognitive decline as measured in ADL-function.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on cerebrospinal fluid AD biomarkers","Skane University Hospital|Lund University","All","20 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1505","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BioFINDER 2","May 15, 2017","December 31, 2028","December 31, 2028","June 5, 2017",,"April 17, 2018","Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03174938"
2057,"NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions",,"Not yet recruiting","No Results Available","Orthopedic Disorder|Neurologic Disorder|Urologic Diseases|Erectile Dysfunction|Autoimmune Diseases|Renal Failure|Renal Insufficiency|Kidney Diseases|Cardiac Event|Cardiomyopathies|CHF|Pulmonary Disease|COPD|Alzheimer Disease|Stroke|Neuropathy;Peripheral|Arthritis","Biological: Amniotic and Umbilical Cord Tissue Procedure","Disabilities of Arm, Shoulder, Hand Questionnaire (DASH)|Sexual Health Inventory for Men Questionnaire (SHIM)|Kidney Disease and Quality of Life Questionnaire (KDQOL)|Assessment of Quality of Life Questionnaire (AQOL)|Clinical Chronic Obstructive Pulmonary Disease Questionnaire|Mini Mental State Examination (MMSE)|O'Leary/Sant Questionnaire|Oswestry Low Back Pain Disability Questionnaire|Western Ontario and McMaster Osteoarthritis Index (WOMAC)","R3 Stem Cell","All","18 Years and older   (Adult, Older Adult)","Phase 1","5000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#2018/10/11","September 1, 2019","March 20, 2024","March 20, 2029","April 2, 2019",,"August 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03899298"
2058,"NCT03313895","The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI",,"Recruiting","No Results Available","Mild Cognitive Impairment","Behavioral: ACT|Behavioral: Cycling Only|Behavioral: Cognitive Training Only|Behavioral: Stretching and Mental Stimulating Activities","Cognition|AD-signature cortical thickness|Functional connectivity|Aerobic fitness|Conversion to Alzheimer's diseae","University of Minnesota - Clinical and Translational Science Institute|University of Rochester|Mayo Clinic|University of St Thomas","All","65 Years and older   (Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00001135","July 5, 2018","May 31, 2022","May 31, 2022","October 18, 2017",,"October 12, 2018","University of Minnesota, Minneapolis, Minnesota, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03313895"
2059,"NCT03672266","Studies of Brain and Body Interaction",,"Recruiting","No Results Available","Autistic Disorders Spectrum|Adhd|Asperger Syndrome|Alzheimer Disease|Parkinson|Tremor Essential|Dementia, Alzheimer Type|Lewy Body Dementia With Behavioral Disturbance (Disorder)|Dementia With Lewy Bodies|Dementia Frontal",,"Unitless Stochastic Signatures of Biophysiological Signals, consisting of the Empirically Estimated Shape and Dispersion (scale) Parameters of Probability Distribution Functions|Brain and Body Connectivity metrics and Derived Geometric and Topological Indexes from the Network Connectivity Model and Inverse Kinematic Model|Information theoretic metric","Rutgers University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BrainBody","August 1, 2018","July 1, 2019","July 1, 2019","September 14, 2018",,"September 14, 2018","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03672266"
2060,"NCT00735046","Cognitive Behavioural Therapy of Early Dementia","KORDIAL","Completed","No Results Available","Dementia","Behavioral: Cognitive behavioral therapy for early Alzheimer's disease|Other: Control","Functional ability in the everyday context|Quality of life, depression, neuro-psychiatric symptoms","Technische Universität München|University of Leipzig|Zentralinstitut für Seelische Gesundheit Mannheim|Humboldt-Universität zu Berlin","All","18 Years to 95 Years   (Adult, Older Adult)",,"200","Other","Observational","Time Perspective: Prospective","KOR-683-KUR-0000-I","April 2008",,"April 2010","August 14, 2008",,"January 14, 2011","Prof. Dr. A. Kurz, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00735046"
2061,"NCT03945968","The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","STOP RISK","Recruiting","No Results Available","Coronary Heart Disease|Anemia|Bronchial Asthma|Stroke|Epilepsy|Parkinson's Disease|Heart Rhythm Disorders|Alzheimer's Disease|Neuromuscular Diseases|Diabetes|Chronic Heart Failure|Chronic Obstructive Pulmonary Disease|Chronic Kidney Diseases",,"incidence of postoperative complications|mortality after abdominal surgery","Russian Federation of Anesthesiologists and Reanimatologists|Kuban State Medical University","All","18 Years and older   (Adult, Older Adult)",,"16000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FARCT0001","July 1, 2019","December 30, 2020","January 30, 2021","May 10, 2019",,"October 9, 2019","Astrakhan State Medical University, Astrakhan, Russian Federation|Ekaterinburg City clinical hospital № 40, Ekaterinburg, Russian Federation|Sverdlovsk regional clinicl hospital №1, Ekaterinburg, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|Republic Clinical Hospital Ministry of Health care of the Republic of Tatarstan, Kazan, Russian Federation|Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation|Regional clinical hospital №2, Krasnodar, Russian Federation|Kuban State Medical University, Krasnodar, Russian Federation|Research Institute Regional Clinical Hospital named after S.V. Ochapovsky, Krasnodar, Russian Federation|Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky, Krasnoyarsk, Russian Federation|Burnasyan federal medical biophysical center of federal medical biological agency, Moscow, Russian Federation|City clinical hospital named after S.S. Yudin, Moscow, Russian Federation|City clinical hospital №1 named after N.I. Pirogov, Moscow, Russian Federation|FGBU ""Central clinical hospital with polyclinic"" of the President administration of the Russian Federation, Moscow, Russian Federation|Moscow cancer research Institute named after P. A. Herzen, Moscow, Russian Federation|Moscow City Oncological Hospital № 62, Moscow, Russian Federation|Moscow regional research clinical Institute named after M. F. Vladimirsky, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|Research Institute of Emergency Care. N.V. Sklifosovsky Department of Health of Moscow, Moscow, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|""Republican hospital named after V. A. Baranov"", Petrozavodsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|North-West State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|""Samara Regional Clinical Oncology Dispensary"", Samara, Russian Federation|Clinical Hospital named after SR. Mirotvortseva (FGBOU VO ""Saratov State Medical University. n.a. V.I.Razumovsky"" Ministry of Health of the Russian Federation, Saratov, Russian Federation|Stavropol regional clinical hospital, Stavropol', Russian Federation|Regional clinical hospital №2, Vladivostok, Russian Federation|Emergency hospital, Volgograd, Russian Federation|Volgograd regional clinical hospital, Volgograd, Russian Federation|Yaroslavl State Medical University, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03945968"
2062,"NCT01303133","Natural History of Amyloid Deposition in Adults With Down Syndrome",,"Completed","No Results Available","Down Syndrome",,"Amyloid deposition","University of Pittsburgh|National Institute on Aging (NIA)","All","30 Years and older   (Adult, Older Adult)",,"81","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PRO09080266|2R01AG031110-03A1","August 2009","March 31, 2018","March 31, 2018","February 24, 2011",,"January 9, 2019","University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Waisman Center at the University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01303133"
2063,"NCT04055532","Biomarkers in Neurodegenerative Diseases",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment (MCI)|Alzheimer Disease (AD)|Dementia With Lewy Bodies (DLB)|Frontotemporal Lobar Degeneration (FTLD)|Parkinsons Disease With Dementia (PDD)|Transient Epileptic Amnesia (TEA)|Temporal Lobe Epilepsy (TLE)|Spinocerebellar Ataxias (SCA)|HIV Associated Neurocognitive Disorder (HAND)|Amyotrophic Lateral Sclerosis (ALS)|Primary Lateral Sclerosis (PLS)","Other: Neuraceq","Performance on Batteries of Cognitive Tests","University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY00007108","October 1, 2019","October 1, 2024","October 1, 2025","August 13, 2019",,"August 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04055532"
2064,"NCT02014246","Genetic Characterization of Movement Disorders and Dementias",,"Recruiting","No Results Available","Ataxia|Dystonia|Parkinson's Disease|Amyotrophic Lateral Sclerosis|Corticobasal Degeneration|Multiple System Atrophy|Alzheimer's Disease|Lewy Body Dementia|Parkinson Disease-Dementia|Dentatorubral-pallidoluysian Atrophy|Creutzfeldt-Jakob Disease and Fatal Familial Insomnia|Fragile X-associated Tremor/Ataxia Syndrome|Krabbe's Disease|Niemann-Pick Disease, Type C|Neuronal Ceroid Lipofuscinosis",,"Identify and characterize genetic contributions to etiology for movement disorders, such as dystonia, Parkinson's disease, and dementias, such as Alzheimer's disease, Lewy Body Dementia, frontotemporal dementia.","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"12000","NIH","Observational","Observational Model: Case-Control|Time Perspective: Other","999903329|03-AG-N329","February 12, 2003","December 31, 2019","December 31, 2019","December 18, 2013",,"July 9, 2019","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02014246"
2065,"NCT02860338","COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE",,"Completed","No Results Available","Mild Cognitive Impairment|Dementia|Hypoxia|Hyperhomocysteinemia|Vitamin B 12 Deficiency|Iron Deficiency|Anemia|TBI|Neurodegenerative Disorders|Alzheimer's Disease|Vascular Dementia|Brain Injuries|Tauopathies|Parkinson's Disease|Lewy Body Dementia|Frontotemporal Dementia|TDP-43 Proteinopathies",,"Cognitive testing - Memory Orientation Screening Test (MOST)|Resting and ambulatory pulse oximetry in office|Nocturnal pulse oximetry|Polysomnography in-lab and ambulatory ( in patient's residence)|Laboratory values: Chem 20, CBC/diff, BNP, CRP, iron, iron/TIBC, ferritin, homocysteine, methylmalonic acid, Vitamin D 25-OH, RPR/FTA-ABS/TPPA, IGF-1","Clionsky Neuro Systems Inc.","All","40 Years to 90 Years   (Adult, Older Adult)",,"900","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CNS 2012-004","January 2009","December 2015","December 2015","August 9, 2016",,"August 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02860338"
2066,"NCT01699711","Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool",,"Completed","No Results Available","Down Syndrome (DS)","Dietary Supplement: Epigallocatechin-3-gallate (EGCG)","Change in Cognitive Evaluation|Change in Amyloidosis Biomarkers|Treatment compliance|Change in Biomarkers of lipid oxidation|Change in DYRK1A activity biomarkers|COMT val158met genetic polymorphism (catechol methyl transferase) (Taqman)|Change in AST (SGOT -serum glutamic oxaloacetic transaminase-) and ALT (SGPT- Serum Glutamic Pyruvate Transaminase-) (Pentra Autoanalyzer, and ELISA Mercodia for LDLox)|Change in Body Composition by electrical impedance (TANITA-MC-180)|Changes in Neurophysiology|Changes in Neuroimaging","Parc de Salut Mar","All","14 Years to 29 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TESDAD","February 2012","June 2014","March 2015","October 4, 2012",,"February 11, 2016","IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01699711"
2067,"NCT00627029","Evaluation of Programs of Coordinated Care and Disease Management","Coca","Unknown status","No Results Available","Congestive Heart Failure|Diabetes|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Cancer|Cerebrovascular Disease|Alzheimer's Disease|Psychotic Disorder|Major Depression","Behavioral: Care Coordination","Medicare program expenditures|Claims-based and patient-reported quality of care","Mathematica Policy Research, Inc.|Centers for Medicare and Medicaid Services","All","Child, Adult, Older Adult","Not Applicable","18277","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MPR 8756|CMS 500-95-0047(09","September 2000","August 2015","December 2016","February 29, 2008",,"October 1, 2015","Hospice of the Valley MediCaring Project, Phoenix, Arizona, United States|Georgetown University Medical Center-Mind My Heart Program, Washington, District of Columbia, United States|Quality Oncology/Matria Healthcare, Sunrise, Florida, United States|CorSolutions/Matria Healthcare, Rosemont, Illinois, United States|Carle Foundation and Hospital, Urbana, Illinois, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Medical Care Development, Augusta, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Charlestown/Erickson Retirement Communities, Catonsville, Maryland, United States|Washington University-St.Louis School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, United States|QMed, Inc., Eatontown, New Jersey, United States|Lovelace Health Systems, Albuquerque, New Mexico, United States|Jewish Home Lifecare, New York, New York, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|CenVaNet, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00627029"
2068,"NCT03864965","Advance Care Planning in Cognitive Disorders Clinic",,"Recruiting","No Results Available","Advance Care Planning","Other: Advance Care Planning","Change in rate of advance directive completion during or following the visit|Change in the rate of completed advance directives that are uploaded to the patient's electronic medical record|Change in Hospital Anxiety and Depression Scale (HADS)|Change in Beck Hopelessness Scale (BHS)","University of Florida|Florida Department of Health","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB201900108|ID00023545","July 1, 2019","August 2020","August 2020","March 6, 2019",,"August 16, 2019","Department of Neurology, College of Medicine, UF Health Medical Plaza, Gainesville, Florida, United States|UF Health Fixel Center for Neurological Diseases, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03864965"
2069,"NCT02789800","Patient-Centred Innovations for Persons With Multimorbidity - Quebec","PACEinMM-QC","Active, not recruiting","No Results Available","Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV","Behavioral: DIMAC02","Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Equity|Demographics|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness","Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Western University, Canada|Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1956","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2013-010","April 22, 2016","March 8, 2019","March 1, 2020","June 3, 2016",,"December 15, 2017","Université de Sherbrooke, Chicoutimi, Quebec, Canada|CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02789800"
2070,"NCT02742597","Patient-Centred Innovations for Persons With Multimorbidity - Ontario","PACEinMM-ON","Active, not recruiting","No Results Available","Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV|Multimorbidity","Behavioral: TIP / IMPACT Plus Care Coordination","Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Change in Equity|Evaluation of Intervention Effectiveness - Change in Demographics","Lawson Health Research Institute|Western University, Canada|Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|University Health Network, Toronto|Toronto East General Hospital|Providence Healthcare|Mount Sinai Hospital, Canada|Toronto Central Community Care Access Centre|Women's College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1980","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","104191","January 12, 2016","April 7, 2019","March 1, 2020","April 19, 2016",,"December 18, 2017","Western University, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Providence Healthcare, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Central Community Care Access Centre, Toronto, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|University Hospital Network, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02742597"
2071,"NCT02608021","Neurotrack Test Validation Protocol",,"Recruiting","No Results Available","Mild Cognitive Impairment",,"Presence of eye fixation assessed by a point of gaze continually remaining within 1 degree of visual angle for a period of 100 milliseconds or more.|Eye tracking data - Total looking time|Eye tracking data - Total number of fixations|Eye tracking data - Percentage looking time|Correlation of MRI data with VPC task score","NYU Langone Health|NeuroTrack Technologies, Inc.","All","60 Years to 85 Years   (Adult, Older Adult)",,"80","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","14-00586","October 1, 2015","September 2019","September 2019","November 18, 2015",,"January 29, 2019","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02608021"
2072,"NCT02570997","Ascending Dose Study of CT1812 in Healthy Volunteers",,"Completed","No Results Available","Cognitive Impairment","Drug: CT1812|Drug: Placebo","Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability]","Cognition Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Cog 0101","September 2015","May 2016",,"October 8, 2015",,"September 7, 2016","Nucleus Network Limited, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02570997"
2073,"NCT00267163","Brain Imaging and Mental Disorders of Aging Intervention",,"Completed","No Results Available","Cognition Disorders","Drug: donepezil|Drug: Placebo","Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing","National Institute on Aging (NIA)","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 4","64","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","IA0090|9R01AG018487-06","September 2000","July 2007","July 2007","December 20, 2005",,"August 29, 2008","UCLA, The Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00267163"
2074,"NCT01145482","Mechanisms of Insulin Facilitation of Memory",,"Completed","Has Results","Memory Disorders","Drug: Insulin|Other: Saline","Cerebral Glutamate Concentration|Memory","University of Texas at Austin","All","21 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2010-05-0007","July 2010","April 2014","April 2014","June 16, 2010","November 3, 2014","November 3, 2014","University of texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01145482"
2075,"NCT02126514","A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293","AZD3293hADME","Completed","No Results Available","Healthy Volunteers|Mass Balance Study","Drug: AZD3293","PK parameters measured by assessment of AUC over time and Maximum observed concentration (Cmax)|Safety assessments including vital sign measurements, ECGs, physical examinations, clinical laboratory evaluations, and a record of adverse events (AEs).|The Columbia-Suicide Severity Rating Scale (C-SSRS)|Time to maximum observed concentration (tmax)|Area under the concentration-time curve|Area under the concentration-time curve extrapolated to infinity (AUC0-∞)|Apparent terminal elimination half-life (t1/2)|Apparent oral clearance (CL/F)|Apparent volume of distribution (Vz/F)|Ratios for AUC0-","AstraZeneca","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","D5010C00007|AZD3293 hADME","May 2014","May 2014","May 2014","April 30, 2014",,"June 16, 2014","Research Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02126514"
2076,"NCT00596284","Cognitive Behavior Therapy for Treating Anxiety in People With Dementia",,"Completed","No Results Available","Anxiety Disorders|Dementia","Behavioral: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Behavioral: Enhanced Usual Care (EUC)","Rating Anxiety in Dementia (RAID) and Neuropsychiatric Inventory (NPI)- Anxiety subscales|Quality of Life in Alzheimer's Disease (QOL-AD)|Geriatric Depression Scale (GDS)|Penn State Worry Questionnaire (PSWQ)|Geriatric Anxiety Inventory (GAI)","Baylor College of Medicine|National Institute of Mental Health (NIMH)","All","50 Years and older   (Adult, Older Adult)","Phase 1","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R34MH078925|DATR A4-GPS","January 2008","June 2010","June 2010","January 16, 2008",,"August 13, 2015","Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00596284"
2077,"NCT00257712","SMART: Somatotrophics, Memory, and Aging Research Trial",,"Completed","No Results Available","Aging|Mild Cognitive Impairment","Drug: TH9507 human growth hormone releasing hormone (GHRH)","Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.|Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.","University of Washington|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","28287-K|R01AG025515|R01AG025525-01A1","February 2006","December 2011","December 2011","November 23, 2005",,"December 19, 2013","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00257712"
2078,"NCT00259415","Telesupport: Evaluation of Professionally Led Support Groups for Caregivers",,"Completed","No Results Available","Caregiver Burden","Behavioral: Caregiver support via telephone","Caregiver depression|Caregiver burdern|Caregiver social support","Thomas Jefferson University","Female","55 Years and older   (Adult, Older Adult)","Phase 1",,"Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single","IIRG-00-1998","September 2000",,,"November 29, 2005",,"July 8, 2015","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00259415"
2079,"NCT03672279","Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder","CogCheck-MC","Not yet recruiting","No Results Available","Dementia Alzheimers|Dementia|Mild Cognitive Impairment|Dementia, Vascular|Dementia With Lewy Bodies|Cognition Disorders|Neurocognitive Disorders","Diagnostic Test: CogCheck","CogCheck|Mini-Mental State Examination (MMSE)|Montreal Cognitive Assessment (MoCA)|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)|Basel Verbal Learning Test (BVLT)|Geriatric Depression Scale (GDS)|Beck's Depression Inventory (BDI)","University Hospital, Basel, Switzerland","All","65 Years and older   (Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CogCheck-MC-Valid","July 1, 2020","December 31, 2024","December 31, 2024","September 14, 2018",,"September 26, 2019","Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital Basel, Basel, BS, Switzerland",,"https://ClinicalTrials.gov/show/NCT03672279"
2080,"NCT01300728","Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment","MCI","Active, not recruiting","Has Results","Mild Cognitive Impairment","Drug: NewGam 10% IVIG|Other: Placebo","Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI|Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)|Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature|Mean Cognitive Performance at 12 Months|Mean Cognitive Performance at 24 Months","Sutter Health","All","50 Years to 84 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IVIG-KILE-032010","January 2011","November 2014","December 2019","February 23, 2011","March 31, 2016","October 8, 2019","Sutter Neuroscience Medical Group, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01300728"
2081,"NCT00768261","Corticolimbic Degeneration and Treatment of Dementia",,"Completed","Has Results","Dementia","Drug: Memantine (Namenda®)|Drug: Donepezil (Aricept®)","Rate of Change of Hippocampal Volume Slope|Comparison of Combined DAT Patients' Mean (SD) Hippocampal Volume Slope (mm^3/Year) Rate of Change","Washington University School of Medicine|Northwestern University","All","50 Years to 95 Years   (Adult, Older Adult)","Phase 4","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5R01MH060883-06","November 2004","October 2009","October 2009","October 8, 2008","September 11, 2018","September 11, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT00768261/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00768261"
2082,"NCT03305809","A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)","PRESENCE","Recruiting","No Results Available","Lewy Body Dementia","Drug: LY3154207|Drug: Placebo","Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)|Change from Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score|Change from Baseline on the CDR-CCB Power of Attention (PoA) Composite Score|Change from Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog13)|Change from Screening in the Montreal Cognitive Assessment (MoCA) Score|Change from Baseline in the Neuropsychiatric Inventory (NPI) Total Score|Change from Baseline in the Epworth Sleepiness Scale (ESS) Score|Change from Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score|Change from Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score|Change from Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score|Change from Baseline in Systolic Blood Pressure (SBP) to Week 12|Change from Baseline in SBP to 8 Hours Post Dose|Change from Baseline in Pulse Rate to Week 12|Change from Baseline in Pulse Rate to 8 Hours Post Dose|Change from Week 12 in the Physician Withdrawal Checklist (PWC)-20 Total Score|Pharmacokinetics (PK): Steady-State Trough Plasma Concentrations of LY3154207","Eli Lilly and Company","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16261|I7S-MC-HBEH","November 9, 2017","June 22, 2020","June 22, 2020","October 10, 2017",,"October 4, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of Arizona Health Sciences, Tucson, Arizona, United States|Parkinson'S & Movement Disorder Institute, Fountain Valley, California, United States|University of California, Irvine, Irvine, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|University of Southern California School of Medicine, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Stanford Neuroscience Health Center, Palo Alto, California, United States|SC3 Research Group Inc Pasadena, Pasadena, California, United States|SC3 Research Group Inc Reseda, Reseda, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Neurological Research, Denver, Colorado, United States|Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Hartford Healthcare Chase Movement Disorders Center, Vernon, Connecticut, United States|Christiana Care Health Service, Newark, Delaware, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Visionary Investigators Network, Aventura, Florida, United States|Parkinson's Disease and Movement Disorders, Boca Raton, Florida, United States|Norman Fixel Institute for Neurological Diseases (FIND), Gainesville, Florida, United States|ClinCloud, LLC, Maitland, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|VIN - Victor Faradji, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Visionary Investigators Network -VIN-Margarita Almeida, Pembroke Pines, Florida, United States|Axiom Research, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Central DuPage Hospital, Winfield, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|University of Kansas School of Medicine, Kansas City, Kansas, United States|Maine Neurology, Scarborough, Maine, United States|New England Neurological Associates, PC, Methuen, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic of Las Vegas, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Dent Neurological Institute, Amherst, New York, United States|Alzheimer's Disease and Memory Disorders Center, Buffalo, New York, United States|Adirondack Medical Research, Glens Falls, New York, United States|NYU Langone, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Penn State Univ. Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Neurology, PA, Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Evergreen Professional Plaza, Kirkland, Washington, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|Toronto Memory Program, Toronto, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Canada|Santa Cruz Behavioral PSC, Bayamón, Puerto Rico|Cortex, PSC, Las Piedras, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03305809"
2083,"NCT00855686","Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies",,"Completed","No Results Available","Parkinson's Disease Dementia|Dementia With Lewy Bodies","Drug: Memantine|Drug: Placebo","No primary or secondary outcome measures are defined. This study is exploratory (see above under detailed description).","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 4","199","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11018|2005-002038-36","January 2007","December 2008","January 2009","March 4, 2009",,"September 20, 2013","DE001, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00855686"
2084,"NCT00630500","Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)","MEMPDD","Completed","No Results Available","Dementia Associated With Parkinson's Disease|Dementia With Lewy Bodies","Drug: Memantine|Drug: Placebo","Clinical Global Impression of Change|MMSE|Alzheimer's QUick Test|Cognitive Drug Research test|Neuropsychiatric Inventory|Unified Parkinson's Disease Rating Scale, part III|Epworth Sleep Scale|Stavanger Sleep Scale","Helse Stavanger HF|King's College London|Lund University","All","Child, Adult, Older Adult","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MEMPDD-130206","February 2006","February 2009","March 2009","March 7, 2008",,"July 28, 2015","Stavanger University Hospital, Old Age Psychiatry Clinic, Stavanger, Norway|Clinical Memory Research Unit, Neuropsychiatric Clinic, University Hospital Malmo, Malmo, Sweden|Mental Health Unit, Epping, Essex, United Kingdom|King's COllege London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00630500"
2085,"NCT03918616","P2X7 Receptor, Inflammation and Neurodegenerative Diseases","NeuroInfiam","Completed","No Results Available","Neuro-Degenerative Disease","Drug: Memantine, Dopamine receptor-agonists","Change from baseline in P2X7R-inflammasome activity|Change from baseline in NFkB activity|Change from baseline in serum α-synuclein|Change from baseline in serum IL-1β|Change from baseline in serum IL-18|Change from baseline in circulating levels of microRNA miR-30 and miR-7","University of Pisa","All","45 Years to 80 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AS0002","February 20, 2017","December 30, 2018","March 30, 2019","April 17, 2019",,"August 13, 2019","University of Pisa, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT03918616"
2086,"NCT03987464","Platform-based Mild Cognitive Impairment (MCI) Trial",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment","Behavioral: Planning for the Future|Behavioral: Enhanced Medical Engagement|Behavioral: Confidence Building and Social Engagement|Behavioral: Physical Intervention|Behavioral: Medical Adherence","Self-Efficacy; general self-efficacy scale (GSES)|Readiness to complete advance directives (ACPES)|Motivations Around Advance Care Planning (ADS)|Long Term Care Planning Behavior Scale (LTCP), planning subscale|Long-Term Supports and Services (LTSS)|World Health Organization Quality-of-Life (WHOQOL), Brief - Psychological and Social Relationship subscale|MCI Test of Knowledge (MCI-ToK)|Long Term Care Planning Behavior Scale (LTCP), health subscale|Technophilia Scale, Technology for health subscale (TTfH)|Technophilia Scale, Comfort with technology subscale (TCwT)|Technophilia Scale, Use of technology subscale (TUoT)|Patient communication pattern scale (PCPS)|Comfort engaging medical professionals (CEMP)|Mindfulness Attention Awareness Scale (MAAS)|Mindfulness Adherence Questionnaire (MAQ)|CHAMPS Physical Activity Questionnaire for Older Adults (CHAMPS), Social engagement subscale.|Social Interaction Anxiety Scale (SIAS)|Crowne-Marlowe Social Desirability (CMSDS)|Memory Situation Questionnaire (MSQ; adapted)|Sickness Impact Profile (SIP) - subscales including body care and movement, mobility, and home management|CHAMPS Physical Activity Questionnaire for Older Adults (CHAMPS), Physical activity subscale|Long Term Care Planning Behavior Scale (LTCP), home modifications item|Short Falls Efficacy Scale (Short FES-I)|36-Item Short Form Survey (SF-36) - physical functioning, pain, energy/fatigue, subscales|Activity|Medication Adherence (MA-MCI)|Medication Adherence (MA-SP)|The 8-Item Medication Adherence Scale (MMAS-8)|Concerns about Memory Medications (CaMM)|Motivations around Memory Medications (MMM)|MCI Medication Test of Knowledge (MCI-MToK)","Allison Gibson|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","44035","November 2019","February 2020","June 2020","June 17, 2019",,"September 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03987464"
2087,"NCT03944603","Longitudinal Innate Immunity and Aging Study","LIIA","Recruiting","No Results Available","Healthy Older Adults Ages 65-89",,"Levels of Immune Protein Markers in Blood and CSF|Performance on Neuropsychological Measures|Levels of Exosomal Innate Immune Markers in Blood and CSF|Brain Structure|CSF Levels of Alzheimer's Disease Related Markers","University of Colorado, Denver|National Institute on Aging (NIA)","All","65 Years to 89 Years   (Older Adult)",,"300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-2607|R01AG058772","April 30, 2019","March 31, 2024","May 31, 2024","May 9, 2019",,"May 9, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03944603"
2088,"NCT03311711","Two-Phased Study of SPIRIT in Mild Dementia",,"Recruiting","No Results Available","Dementia","Behavioral: SPIRIT-in person|Behavioral: SPIRIT-remote|Behavioral: Usual care","Change in dyad congruence among Phase II participants|Change in Surrogate's Decision Making Confidence (DMC) scale score among Phase II participants|Change in Surrogate's Overall Preparedness Scale|Completion of Advance Directives among Phase I participants|Completion of Advance Directives among Phase II participants|Change in Patient's Overall Preparedness Scale","Emory University|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","264","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00099738|1R01AG057714","May 4, 2018","May 31, 2022","May 31, 2022","October 17, 2017",,"September 9, 2019","Assisted Living Facilities in the Metro Atlanta Area, Atlanta, Georgia, United States|Grady Health System, Atlanta, Georgia, United States|Emory Clinic Geriatrics, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03311711"
2089,"NCT02720445","Memory Improvement Through Nicotine Dosing (MIND) Study","MIND","Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Nicotine Transdermal Patch|Drug: Placebo Patch","Change from Baseline of the Conners Continuous Performance Task (CPT) to Month 25|Change from Baseline in Mild Cognitive Impairment - Clinical Global Impression of Change (MCI-CGIC) to Month 25|Change from Baseline in Cogstate Brief Battery (CBB) to Month 25|Change in Baseline in New York University (NYU) Paragraph Recall to Month 25|Change from Baseline in Clinical Dementia Rating Scale (CDR) - Sum of Boxes (SOB) to Month 25|Change in Baseline in Geriatric Depression Scale (GDS) to Month 25|Change in Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) to Month 25|Change from Baseline in Older Adult Self Report (OASR) / Older Adult Behavior Checklist (OABCL) to Month 25","University of Southern California|National Institute on Aging (NIA)|Vanderbilt University|Alzheimer's Therapeutic Research Institute","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATRI-002-NIC|R01AG047992|131918","January 13, 2017","December 2020","December 2020","March 25, 2016",,"October 10, 2019","Perseverance Research Center, Scottsdale, Arizona, United States|Central Arkansas Veterans Healthcare System, North Little Rock, Arkansas, United States|USC Rancho Los Amigos, Downey, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Associated Neurologists, Danbury, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|C & R Research Services, Coral Gables, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Augusta University Movement and Memory Disorders, Augusta, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Acadia Hospital, Bangor, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Donald S. Marks, MD, PC, Plymouth, Massachusetts, United States|Bronson Lakeview Hospital, Kalamazoo, Michigan, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Integrative Clinical Trials, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|LeHigh Valley Hospital, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Glenn Biggs Institute at the University of Texas Health, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington / VA Pudget Sound, Seattle, Washington, United States|University of Washington Memory and Brain Wellness Center, Seattle, Washington, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02720445"
2090,"NCT02726906","Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study",,"Recruiting","No Results Available","Aging|Cognitive Ability, General","Behavioral: Moderate-aerobic walking|Radiation: Positron Emission Tomography (PET) scan|Behavioral: Healthy living education|Device: Physical activity monitor","Functional Magnetic Resonance Imaging (fMRI) brain scan as a measure of brain function|Mnemonic Similarity Test as a measure of memory (cognition)|Positron Emission Tomography (PET) scan as a measure of tracer binding|Single-stage treadmill test and modified physical function test as measures of physical function|Brain-derived neurotropic factor (BDNF) as a measure from blood","University of Southern California","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AG046928","July 2016","April 2020","April 2020","April 4, 2016",,"September 27, 2019","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02726906"
2091,"NCT02248636","Cholinesterase Inhibitor Discontinuation","CID","Completed","No Results Available","Dementia","Drug: Cholinesterase inhibitor|Drug: Sham discontinuation","Successful completion|Medical events|Caregiver burden|Veteran cognition|Veteran functioning|Behavioral symptoms|Post-study treatment choice","VA Office of Research and Development","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","72","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN-014-13F","January 22, 2015","October 1, 2019","October 1, 2019","September 25, 2014",,"October 3, 2019","Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|Boise VA Medical Center, Boise, ID, Boise, Idaho, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02248636"
2092,"NCT03623542","Adverse Drug Reactions in Older Subjects","RiskofADR","Completed","No Results Available","Dementia",,"Risk factors for the occurrence of adverse drug reactions","CHU de Reims","All","18 Years and older   (Adult, Older Adult)",,"293","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017Ao002","May 1, 2010","November 1, 2011","November 1, 2011","August 9, 2018",,"August 9, 2018","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT03623542"
2093,"NCT03152630","Research on the Early and Prognosis Diagnosis of Vascular Dementia",,"Recruiting","No Results Available","Dementia",,"Composite cardiovascular outcome|With at least 1 cardiovascular risk factor.","National Taiwan University Hospital","All","65 Years and older   (Older Adult)",,"600","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201512101RINA","March 30, 2016","January 2036","January 2036","May 15, 2017",,"May 15, 2017","NTUH, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03152630"
2094,"NCT01825577","Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.",,"Terminated","Has Results","Dementia|Accidental Falls|Apathy","Drug: Transdermal Methylphenidate","Timed Get Up and Go Test - Measure of Mobility|POMA -Performance Oriented Mobility Assessment - Measure of Gait and Balance.","St. Louis University","All","65 Years to 95 Years   (Older Adult)","Phase 4","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","23014","November 2012","February 2015","February 2015","April 5, 2013","August 19, 2016","July 24, 2018","Delmar Gardens, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01825577"
2095,"NCT02180269","A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911 (25 mg)|Drug: JNJ-54861911 (50 mg)|Drug: JNJ-54861911 (100 mg)|Drug: Placebo","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Maximum Plasma Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])|Apparent Clearance (CL/F)|Cerebrospinal Fluid (CSF) Amyloid-Beta Concentration|Plasma Amyloid-Beta Concentration","Janssen Pharmaceutical K.K.","Male","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR104614|54861911ALZ1006","June 2014","August 2014","August 2014","July 2, 2014",,"September 12, 2014","Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02180269"
2096,"NCT01425957","Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment",,"Completed","No Results Available","MILD COGNITIVE IMPAIRMENT","Procedure: Lumbar puncture","Part A: Magnetic Resonance Imagery protocol|Part B: Changes of the hippocampal volume|Part B: Clinical assessment|Part B: Neuropsychology|Part B: Neurophysiology|Part B: Magnetic Resonance Imagery and functional MRI|Part B: Blood drawing|Part B: Actigraphy|Adverse events","Qualissima|European Union","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","229","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","WP5P001|2011-A00985-36","December 2011","August 2015","October 2015","August 30, 2011",,"November 2, 2015","Université Lille 2, UL2 - Centre d'investigation clinique / Centre de Ressources biologiques 9301 - INSERM - Centre Hospitalier Régional et Universitaire de LILLE, Lille, France|APHM, Hopital de la Timone, Service de Neurologie et Neuropsychologie, Marseille, France|INSERM - CHU Purpan, Toulouse, France|Hospital and Institute of the University of Duisburg and Essen - Department for Psychiatry and Psychotherapy, LVR Hospital Essen, Essen, Germany|University Hospital of Leipzig - Department of Psychiatry, Leipzig, Germany|Aristotle University of Thessaloniki, Greek Association of Alzheimer's disease and related disorders, Thessaloniki, Greece, Thessaloniki, Greece|IRCCS-FBF - Ordine Ospedaliero San Giovanni di Dio, Fatebenefratelli, Istituto di Ricovero e Cura a Carattere Scientifico, Brescia, Provincia Lombardo-Veneta, Italy|Neurofisiologia Clinica IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Padiglione Specialita' piano Fondi, Genoa, Italy|IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare di Napoli, Napoli, Italy|Dipartimento di Specialità medico-chirurgiche e Sanità Pubblica, Sezione di Clinica Neurologica, Centro Disturbi della Memoria, Perugia, Italy, Perugia, Italy|Università Cattolica del Sacro Cuore - Policlinico Agostino Gemelli Istituto di Neurologia - Neuropsychological and Neurorehabilitation Unit, Roma, Italy|VUmc Alzheimercentrum, Amsterdam, Netherlands|Institut d'Investigacions Biomèdiques August Pi I Sunyer, IDIBAPS, Barcelona, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT01425957"
2097,"NCT01522404","Effects of Atomoxetine in Mild Cognitive Impairment","ATX-001","Completed","Has Results","Mild Cognitive Impairment","Drug: Atomoxetine|Drug: Placebo","Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to Subjects Treated With Inactive Compound / Atomoxetine|Change in Mean Level of Thymus-Expressed Chemokine (TECK) in Cerebrospinal Fluid (CSF) in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Number of All Adverse Events Among the Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine Compared to the Participants Treated With Placebo/Inactive Compound|Number of Participants That Drop Out of the Study Among the Participants Treated With Atomoxetine When Compared to the Participants Treated With Inactive Compound (Placebo)|Rate of Cerebral Blood Flow in Subjects With Mild Cognitive Impairment MCI Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Change in FluoroDeoxyGlucose (FDG) Uptake in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine","Emory University|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","39","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00054397|5U01AG010483|ATX-001","March 2012","October 31, 2017","June 30, 2018","January 31, 2012","December 5, 2018","July 23, 2019","Emory University School of Medicine, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01522404/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01522404"
2098,"NCT00242593","Rosiglitazone Effects on Cognition for Adults in Later Life","RECALL","Unknown status","No Results Available","Mild Cognitive Impairment","Drug: Rosiglitazone","Cognitive measures: delayed list recall, Stroop Interference test|Biological outcomes: plasma insulin, IDE, AB40, AB42, inflammatory cytokines, and F2-isoprostanes|MRI outcome: Whole brain and medial temporal lobe atrophy rate|Cognitive measures: ADAS-cog total score, story recall verbal fluency, paired associate learning, SOPT, rating scales","University of Washington|National Institute on Aging (NIA)|GlaxoSmithKline","All","55 Years and older   (Adult, Older Adult)","Phase 2","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0087|1R01AG025502-01A1","June 2006","December 2011","December 2011","October 20, 2005",,"August 5, 2011","Banner Alzheimer Institute, Phoenix, Arizona, United States|UCLA Alzheimer's Disease Center, Los Angeles, California, United States|University of Washington/VA Puget Sound Health Care System, Seattle/Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00242593"
2099,"NCT00735800","Telephone Support for Dementia Caregivers",,"Completed","No Results Available","Dementia","Behavioral: Family Intervention:Telephone Tracking Support- Caregiver|Behavioral: Telephone Support","Depression, burden, reaction to memory and behavior problems|Cost-effectiveness and resource use","Rhode Island Hospital|National Institute of Nursing Research (NINR)","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","250","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","R01NR010559","February 2008","May 2013","May 2013","August 15, 2008",,"May 5, 2015","Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00735800"
2100,"NCT02051361","Antiplatelet Therapy Following Stent Implantation","Anti-Clot","Completed","No Results Available","Acute Myocardial Infarction|Coronary Syndrome|Angina, Unstable",,"Number of Major Adverse Cardiac Events (MACEs)|Number of missed daily doses","Elpen Pharmaceutical Co. Inc.","All","18 Years to 90 Years   (Adult, Older Adult)",,"900","Industry","Observational","Time Perspective: Prospective","2013-CLOBES-EL-41","April 2014","April 2016","May 2016","January 31, 2014",,"May 18, 2016","KAT Hospital, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT02051361"
2101,"NCT01059877","Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia",,"Completed","Has Results","Dementia","Device: 1072nm infrared Photobiomodulation|Device: Photobiomodulation SIMULATED","Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) Delayed Word Recall.","Quietmind Foundation|Maculume Limited","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","QMF-MID12610","January 2010","February 2012","February 2012","February 1, 2010","September 27, 2018","September 27, 2018","Quietmind Foundation, Plymouth Meeting, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01059877"
2102,"NCT02702102","Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",,"Completed","No Results Available","Diffuse Lewy Body Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia","Drug: 11C-PBR28","Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma)|Relative 11C-PBR28 binding","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAQ0756|2P50AG008702-26","December 2015","September 4, 2019","September 4, 2019","March 8, 2016",,"October 8, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02702102"
2103,"NCT03088956","Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)","FORWARD","Active, not recruiting","No Results Available","Frontotemporal Dementia|Behavioral Variant Frontotemporal Dementia","Other: Assessments","Annualized rate of change in International Shopping List Test (ISLT) - Immediate Recall|Annualized rate of change in Detection Test|Annualized rate of change in Identification Test|Annualized rate of change in One Back Test|Annualized rate of change in Groton Maze Learning Test|Annualized rate of change in ISLT - Delayed Recall|Annualized rate of change in Social Emotional Cognition Test (SECT)|Annualized rate of change in Letter Fluency|Annualized rate of change in Category Fluency|Annualized rate of change in Digit Symbol Coding (DSC)|Annualized rate of change in Letter Number Sequencing (LNS)|Annualized rate of change in Mini Mental State Examination (MMSE)|Change from Day 1 in International Shopping List Test (ISLT) - Immediate Recall|Change from Day 1 in Detection Test|Change from Day 1 in Identification Test|Change from Day 1 in One Back Test|Change from Day 1 in Groton Maze Learning Test|Change from Day 1 in ISLT- Delayed Recall|Change from Day 1 in SECT|Change from Day 1 in Letter Fluency|Change from Day 1 in Category Fluency|Change from Day 1 in DSC|Change from Day 1 in LNS|Change from Day 1 in MMSE|Actual values from Day 1 in Neurophsychic Inventory (NPI)|Change from Day 1 in NPI|Actual values from Day 1 in Neurophsychic Inventory Questionnaire (NPI-Q)|Change from Day 1 in NPI-Q|Actual values from Day 1 in Revised Self-Monitoring Scale|Change from Day 1 in Revised Self-Monitoring Scale|Actual values from Day 1 in Apathy Inventory|Change from Day 1 in Apathy Inventory|Actual values from Day 1 in Family Accommodation Scale for Obsessive Compulsive Disorder - Self Rated (FAS-SR)|Change from Day 1 in FAS-SR|Actual values from Day 1 in Behavior Rating Scale|Change from Day 1 in Behavior Rating Scale|Actual values from Day 1 in Functional Activities Questionnaire (FAQ)|Change from Day 1 in FAQ|Actual values from Day 1 in Clinical Global Impression of Change (CGIC)|Change from Day 1 in CGIC|Actual values from Day 1 in Clinical Dementia Rating-Frontotemporal Lobar Degeneration (CDR-FTLD)|Change from Day 1 in CDR-FTLD|Actual values from Day 1 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III|Change from Day 1 in UPDRS Part III|Actual values from Day 1 of caregiver's Quality of Life (QOL) in Zarit Caregiver Burden Interview|Change from Day 1 of caregiver's QOL in Zarit Caregiver Burden Interview|Actual values from Day 1 of QOL in Geriatric Depression Scale- Short Form (GDS-SF)|Change from Day 1 of QOL in GDS-SF|Actual values from Day 1 of caregiver's QOL in Caregiver Assessment Measure|Change from Day 1 of caregiver's QOL in Caregiver Assessment Measure|Actual values from Day 1 of QOL in Quality of Life in Neurological Disorders (NeuroQOL)|Change from Day 1 of QOL in Quality of Life in NeuroQOL|Actual values from Day 1 of QOL in EuroOol 5 Dimensions Questionnaire (EQ-5D)|Change from Day 1 of QOL in EQ-5D|Actual values from Day 1 of QOL in Affect and Activity Indicators of QOL (AAIQOL)|Change from Day 1 of QOL in AAIQOL|Actual values from Day 1 for exploratory biomarkers|Change from Day 1 for exploratory blood biomarkers|bvFTD genetic mutations identification in whole blood samples|Potential identification of genetic biomarkers associated with bvFTD from DNA/RNA in whole blood samples|Actual values at Day 1 in Clinical Global Impression of Severity (CGIS)","Biogen","All","18 Years to 80 Years   (Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","992FD001","January 29, 2018","October 28, 2019","October 28, 2019","March 24, 2017",,"July 1, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Fairfax, Virginia, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03088956"
2104,"NCT00545974","Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",,"Completed","Has Results","Frontal Lobe Dementia|Frontotemporal Lobe Dementia|Semantic Dementia","Drug: memantine|Drug: Placebo pill","Change in Neuropsychiatric Inventory (NPI)|Clinical Global Impression of Change (CGIC)|CDR-FTD, MMSE, FAQ, TFLS, EXIT25, UCSF FTD-Neuropsychological Test Battery: CVLT, Verbal Fluency, Modified BNT, Backward Digit Span, Digit Symbol Test, Modified Trails B, Modified Unified Parkinson's Disease Rating Scale, Antipsychotic Therapy","University of California, San Francisco|Forest Laboratories","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAM-53:memantineplacebo","October 2007","December 2012","December 2012","October 18, 2007","February 5, 2014","June 25, 2019","University of California, Los Angeles, Los Angeles, California, United States|University California, San Francisco, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University Hospitals of Cleveland / Case Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00545974"
2105,"NCT00459693","PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)",,"Terminated","No Results Available","HIV-Dementia|HIV-Associated Cognitive Motor Complex|AIDS Encephalopathy|AIDS Dementia Complex|AIDS-Related Dementia Complex|HIV Infections|Healthy","Drug: [11C]PBR28","Brain uptake of [11C]PBR28 (measured as distribution volume).","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Not Applicable","40","NIH","Interventional","Primary Purpose: Treatment","070129|07-M-0129","April 9, 2007","April 6, 2014","April 6, 2014","April 12, 2007",,"October 10, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00459693"
2106,"NCT02196116","Amyloïd Load in Elderly Population: Effect of Cognitive Reserve","EDUMA","Unknown status","No Results Available","Plaque, Amyloid|Cognitive Deficits","Other: PET|Other: MRI|Other: neuropsychological tests","Amyloid load|Neuropsychological scores|Educational level|Memory complaint","University Hospital, Bordeaux|Fondation Plan Alzheimer|General Electric","All","65 Years and older   (Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CHUBX 2013/02","July 2014","July 2016","July 2016","July 21, 2014",,"February 12, 2015","CHU de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT02196116"
2107,"NCT03485898","Study of Patients Hospitalized in Specialized Cognitive-behavioral Unit (UCC)","UCC","Terminated","No Results Available","Behavior Disorders",,"Mortality rate at 12 month after patient's discharge from UCC|Mortality rate at 3 and 6 month after patient's discharge from UCC|Assess the primary mortality risk factors regarding all the collected data.|Create a predictive score for 6 and 12 month mortality|Mortality rate during the hospitalization in the UCC|Analysis of hospitalisation rate|Analysis of the number of treatment taken during the study|Analysis of the different classes of treatment taken during the study|Analysis of the treatment's mode of delivery","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","Child, Adult, Older Adult",,"58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-CHITS-05|2017-A03332-51","April 12, 2018","July 31, 2019","July 31, 2019","April 3, 2018",,"September 16, 2019","Centre Hospitalier Intercommunal de Toulon La-Seyne-sur-Mer, Toulon, France",,"https://ClinicalTrials.gov/show/NCT03485898"
2108,"NCT04036955","Evaluation of an Innovative Information, Training and Social Support Intervention ""INFOSADEM"" to Principal Caregivers of Dementia Patients Living at Home","INFOSA-DEM","Completed","No Results Available","Dementia","Other: INFOSA-DEM","Preparedness for Caregiving|positive and negative aspects of care|perceived social support|Level of Quality of life: EQ-5D|FAMILY NEEDS|level of burden|Neuropsychiatric Inventory (NPI)|degree of independence in activities of daily living|Competence for care","Hospital Clinic of Barcelona|Fundació La Marató de TV3","All","65 Years and older   (Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HCB/2014/0317","March 1, 2016","June 30, 2018","December 31, 2018","July 30, 2019",,"July 30, 2019",,,"https://ClinicalTrials.gov/show/NCT04036955"
2109,"NCT01339195","Post-stroke Cognitive Impairment and Dementia","GRECogVASC","Completed","No Results Available","Stroke|Cognitive Disorders|Behavioral Disorders","Behavioral: French adaptation of NINDS-Canadian Stroke Network battery","determine the frequency of cognitive and behavioral disorders 6 months post-stroke assessed with this new NINDS-Canadian Stroke Network battery|determine the proportion of patients with dementia|determine the value of cognitive screening tests","Centre Hospitalier Universitaire, Amiens","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1635","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AOL10-PR-GODEFROY|2010-A00657-32","August 2010","December 2016","December 2016","April 20, 2011",,"January 31, 2017","CHRU Lille, Lille, Pas-de-calais, France|CHU Amiens, Amiens, Picardie, France|CHU Brest, Brest, France|CHU Dijon, Dijon, France|CH La Rochelle, La rochelle, France|HIA Val de Grâce, Paris, France|CHU Saint Etienne, Saint Etienne, France",,"https://ClinicalTrials.gov/show/NCT01339195"
2110,"NCT01867359","The Genetic Characterization of Dementia",,"Completed","No Results Available","Dementia",,"Genetic cause of disease identified","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"87","NIH","Observational","Observational Model: Case-Control|Time Perspective: Other","999903326|03-AG-N326","March 14, 2003","September 20, 2016","September 20, 2016","June 4, 2013",,"April 5, 2018","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01867359"
2111,"NCT03451591","LACunar Intervention (LACI-2) Trial-2","LACI-2","Recruiting","No Results Available","Cerebral Small Vessel Diseases|Stroke, Lacunar","Drug: Isosorbide Mononitrate XL (ISMN)|Drug: Cilostazol|Drug: ISMN XL and Cilostazol|Other: Neither ISMN nor cilostazol","Feasibility of Phase III trial|Rate of dose specific trial medication tolerability|Incidence of treatment emergent adverse effects [safety]|Treatment efficacy - rate of individual participant events (stroke, TIA, myocardial ischaemia, cognitive impairment and dementia)","University of Edinburgh|British Heart Foundation|University of Nottingham","All","30 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","v3 12 Nov 2017|CS/15/5/31475|2016-002277-35|14911850","January 8, 2018","November 2020","November 2020","March 2, 2018",,"March 2, 2018","Royal Infirmary, Edinburgh, Lothian, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03451591"
2112,"NCT03659643","Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker",,"Recruiting","No Results Available","Mild Cognitive Impairment","Diagnostic Test: EEG with SPR analysis","Diagnosis of dementia|CERAD ten word test","Jon Snaedal|Ullevaal University Hospital|Karolinska University Hospital|Rigshospitalet, Denmark|Zealand University Hospital|Haukeland University Hospital|Kavli Research Foundation, Bergen Norway|Landspitali University Hospital","All","50 Years to 85 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NORD-MCI","January 1, 2018","October 1, 2020","October 1, 2020","September 6, 2018",,"September 6, 2018","Landspitali University Hospital, Reykjavík, Iceland",,"https://ClinicalTrials.gov/show/NCT03659643"
2113,"NCT02933177","Effectiveness of Flash Mediation Therapy",,"Completed","No Results Available","Dementia","Behavioral: 2 months control condition - 4 months chariot-flash|Behavioral: 4 months control condition-2 months chariot flash","Change in number of disorders|Change in score of well-being|change in psychotropic drugs prescribed|change in score of BPSD|change in level of agitation|change in the number of administered psychotropic drugs.|The number of hospitalization|The number of fall","Hospices Civils de Lyon","All","60 Years and older   (Adult, Older Adult)","Not Applicable","241","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","69HCL16_0442","May 2016","March 2017","March 2017","October 14, 2016",,"December 2, 2017","Hôpital des Charpennes Centre de Recherche Clinique ""Vieillissement-Cerveau-Fragilité"", Lyon, France",,"https://ClinicalTrials.gov/show/NCT02933177"
2114,"NCT01659398","Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients",,"Completed","No Results Available","Mild Cognitive Impairment","Device: External Counterpulsation (EECP)","Change in Cognitive Function|Change in Ophthalmic blood flow (OBF)|Change in Blood Viscosity|Cholesterol composition of the blood","Patrick Moriarty, MD, FACP, FACC|University of Kansas Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13106","June 2012","October 2014","October 2014","August 7, 2012",,"January 13, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01659398"
2115,"NCT03954210","SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid",,"Recruiting","No Results Available","Insomnia","Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral: Active Control","Change in Continuous Performance Test (CPT)|Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in Stroop Test|Change in Neuropsychological Assessment Battery-Digits Forward/Digits Backward Test|Change in Grooved Pegboard Test|Change in Coin in Hand|Change in Polysomnography","University of Kansas Medical Center|National Institute on Aging (NIA)|National Institutes of Health (NIH)","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","IRB # STUDY00143545|R01AG058530","August 27, 2019","September 2020","September 2020","May 17, 2019",,"October 10, 2019","University of Kansas Medical Center- Sleep, Health and Wellness Laboratory, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03954210"
2116,"NCT02138682","Validation of DaTscan for Detection of Parkinson Disease Related Disorders",,"Unknown status","No Results Available","Parkinson Disease|Movement Disorders","Drug: l-123 Ioflupane","Consistency Between Diagnostic Procedures","Wisconsin Institute for Neurologic and Sleep Disorders S.C.|Wisconsin Parkinson Association|Medical College of Wisconsin|GE Healthcare","All","75 Years and older   (Older Adult)",,"20","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-DAT-014","July 2014","April 2016",,"May 14, 2014",,"July 16, 2014","Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Wisconsin Institute for Neurologic and Sleep Disorders, SC, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02138682"
2117,"NCT01605448","Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment","Behavioral: Mindfulness Based Stress Reduction (MBSR)","Number of participants with adverse events|Feasibility: 85% completion|Change in fMRI Resting state|Change in Cognition|Change in Measures of ""well-being""|Qualitative Improvements","Beth Israel Deaconess Medical Center","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009P-000411","January 2010","May 2011","January 2012","May 24, 2012",,"May 24, 2012","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01605448"
2118,"NCT03035201","COcoa Supplement and Multivitamin Outcomes Study for the Mind","COSMOS-Mind","Active, not recruiting","No Results Available","Cognitive Impairment|Dementia|Aging",,"Number of Participants that are not Hearing Impaired|Cocoa extract effects on global cognitive trajectory|Multivitamin effects on global cognitive trajectory|Treatment effects on incident cognitive impairment|Intervention effects on executive function and episodic memory","Wake Forest University Health Sciences|National Institute on Aging (NIA)|Brigham and Women's Hospital","All","65 Years and older   (Older Adult)",,"2262","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00037753|1R01AG050657-01A1","September 2016","October 2020","October 2020","January 27, 2017",,"September 5, 2019","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03035201"
2119,"NCT01525368","Outcome Predictors of a Cognitive Intervention in aMCI","OutPreC MCI","Completed","No Results Available","Amnestic Mild Cognitive Impairment","Behavioral: cognitive intervention","Change in California Verbal Learning Test|Change in overall cognition (ADAScog)|Change in Face-Name Learning Test|Change in appraisal of quality of life (SF-36)|Change in neurofunctional MRT (resting state fMRI)|Change in depression scores (Beck Depression Inventory)|Change in working memory (Digit Span)|Change in attention (Trail Making Test)|Change in executive functions (Stroop Test)|Change in neurostructural MRI (diffusion tensor imaging)","Ludwig-Maximilians - University of Munich","All","Child, Adult, Older Adult",,"110","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","cogT002","September 2010","July 2014","July 2014","February 2, 2012",,"November 13, 2014","Institute for Stroke and Dementia Research, Campus Grosshadern, Ludwig-Maximilian University, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT01525368"
2120,"NCT00937846","Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study",,"Completed","No Results Available","Cognitive Disorders","Drug: GSK1034702","Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses.|The kinetic rate constants at tracer and pharmacological doses.|GSK1034702 PK parameters: Cmax; tmax; AUC(0-t).|Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.","GlaxoSmithKline","Male","35 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","110771","July 15, 2009","August 28, 2009","August 28, 2009","July 13, 2009",,"June 27, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00937846"
2121,"NCT03618186","Tau PET Imaging in African Americans",,"Enrolling by invitation","No Results Available","Cognitive Impairment","Combination Product: Tau PET scan","Tau positive scans","Mayo Clinic|National Institute on Aging (NIA)","All","30 Years and older   (Adult, Older Adult)","Phase 2","90","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-008710|5P50AG016574-20","November 26, 2018","May 2023","May 2024","August 7, 2018",,"December 4, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03618186"
2122,"NCT03852901","Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production",,"Recruiting","No Results Available","Aging|Cognitive|Ketones|Blood Sugar","Drug: Jardiance 25 mg","Elevating ketone bodies may bolster neuronal health and delay onset and progression of cognitive impairment.","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","55 Years to 100 Years   (Adult, Older Adult)","Phase 1","100","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","190060|19-AG-0060","March 28, 2019","December 31, 2021","December 31, 2021","February 25, 2019",,"September 24, 2019","National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03852901"
2123,"NCT00073658","Treating Behavioral Disturbances in Individuals With Dementia",,"Completed","No Results Available","Dementia","Drug: Citalopram|Drug: Risperidone",,"University of Pittsburgh|National Institute of Mental Health (NIMH)","All","50 Years and older   (Adult, Older Adult)","Phase 2","137","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R01MH059666-02|DSIR GT-GP","January 2000","June 2005","June 2005","December 3, 2003",,"March 10, 2014","University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00073658"
2124,"NCT03359902","Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation","TVNS MCI","Recruiting","No Results Available","Mild Cognitive Impairment","Device: Transcutaneous vagal nerve stimulation|Device: Sham stimulation","RBANS story learning and recall|Wechsler-IV Paired Associated|Phonemic and semantic fluency - Verbal Fluency Test- A 60 Second Screening|Paced Auditory Serial Addition Test (PASAT)|WAIS-IV Digit Span Wechsler Adult Intelligence Scale|Rey AVLT|Task-dependent fMRI|Benton Handedness Inventory","University of Florida|Department of Health and Human Services|National Institute on Aging (NIA)","All","60 Years to 89 Years   (Adult, Older Adult)","Not Applicable","250","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IRB201600730 -N-A|1R21AG054876-01A1","January 1, 2018","June 30, 2020","June 30, 2020","December 2, 2017",,"August 2, 2019","HealthStreet, Gainesville, Florida, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03359902"
2125,"NCT02260700","A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911 (Treatment A)|Drug: JNJ-54861911 (Treatment B)|Drug: JNJ-54861911 (Treatment C)","Maximum Plasma Concentration (Cmax) of JNJ-54861911|Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-54861911|Area Under the Plasma Concentration-Time Curve From 0 to t Hours (AUC[0-t]) Post Dose of JNJ-54861911|Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of JNJ-54861911|Elimination Rate Constant (Lambda [z]) of JNJ-54861911|Terminal Half-life (t[1/2]) of JNJ-54861911|Relative Bioavailability (F[rel]) of JNJ-54861911|Rate of Absorption of JNJ-54861911|Extent of Absorption of JNJ-54861911|Number of Participants with Adverse Events (AEs) and Serious AEs","Janssen Research & Development, LLC","Male","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR102380|54861911ALZ1003|2013-002650-70","September 2013","November 2013","November 2013","October 9, 2014",,"October 9, 2014","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT02260700"
2126,"NCT01892579","Reducing Agitation in People With Dementia: the Customized Activity Trial","TAP","Completed","No Results Available","Dementia","Behavioral: Tailored Activity Program|Other: Home Safety and Education Program","Frequency by severity of Agitated and Aggressive Behavior in person with dementia|Frequency of behavioral symptoms in person with dementia|Quality of life in person with dementia rated by caregiver|Quality of life in person with dementia rated by person with dementia|Caregiver wellbeing|Time spent caregiving|Cost effectiveness by intervention cost|Cost effectiveness by medical costs|Cost effectiveness by quality of life","Johns Hopkins University|National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","250","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","NA_00067873|R01AG041781","November 2013","August 23, 2017","November 23, 2017","July 4, 2013",,"September 23, 2019","Johns Hopkins University School of Nursing, Center for Innovative Care in Aging, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01892579"
2127,"NCT01871610","Amyloid Accumulation After Mild Traumatic Brain Injury",,"Unknown status","No Results Available","Traumatic Brain Injury","Drug: [18F]AV-45 PET amyloid binding imaging","The amyloids load in brain among mild traumatic brain injury and controls in a temporal manner.|F-18-AV-45 binding changes and cognitive function among mild traumatic brain injury and controls","Chang Gung Memorial Hospital","All","30 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100-4313A","November 2012","November 2012","October 2013","June 7, 2013",,"June 7, 2013",,,"https://ClinicalTrials.gov/show/NCT01871610"
2128,"NCT02793232","Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.",,"Completed","Has Results","Healthy Subjects","Drug: PF-06751979 single dose|Drug: Placebo single dose|Drug: PF-06751979 multiple ascending dose|Drug: Placebo multiple ascending dose|Drug: PF-06751979 multiple dose|Drug: Placebo multiple elderly dose","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Abnormal Physical Examinations Findings|Number of Participants With Abnormal Neurological Examinations Findings|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 7|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14|Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 19|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry|Number of Participants With Vital Sign Abnormalities|Number of Participants With Laboratory Abnormalities|Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979|Part A: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979|Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part A: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06751979|Part A: Dose Normalized Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf [dn]) of PF-06751979|Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part A: Plasma Decay Half-Life (t1/2) of PF-06751979|Part A: Apparent Clearance (CL/F) of PF-06751979|Part A: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979|Part B: Apparent Clearance (CL/F) of PF-06751979|Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part B: Peak-to-Trough Ratio of PF-06751979|Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979|Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979|Part B: Plasma Decay Half-Life (t1/2) of PF-06751979|Part B: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979|Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979|Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979|Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979|Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979|Part C: Apparent Oral Clearance (CL/F)|Part C: Minimum Observed Plasma Concentration (Cmin) of PF-06751979|Part C: Peak-to-Trough Ratio of PF-06751979|Part C: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979|Part C: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979|Part C: Plasma Decay Half-Life (t1/2) of PF-06751979|Part C: Apparent Volume of Distribution (Vz/F) of PF-06751979|Part B: Amount of PF-06751979 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)|Part B: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)|Part B: Renal Clearance of PF-06751979|Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments","Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B8271004|2016-000325-39","June 13, 2016","January 5, 2017","January 5, 2017","June 8, 2016","September 17, 2018","September 17, 2018","Pfizer Clinical Research Unit, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT02793232"
2129,"NCT00134953","Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment",,"Terminated","No Results Available","Cognitive Symptoms","Drug: Rivastigmine","16 week's treatment with rivastigmine on alertness, memory, attention, cognitive flexibility, orientation and language in patients with mild cognitive impairment|Safety of 16 week's treatment with rivastigmine in patients with mild cognitive impairment","Novartis","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CENA713BDE05","January 2003",,"May 2004","August 25, 2005",,"December 17, 2007",,,"https://ClinicalTrials.gov/show/NCT00134953"
2130,"NCT02650843","Non-motor Symptoms and Brain Dopamine Transporter Binding","NMDAT","Enrolling by invitation","No Results Available","Parkinson Disease|Parkinsonism","Other: DAT SPECT imaging","DAT SPECT striatal specific binding ratio","Turku University Hospital|Helsinki University Central Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","T12/2014","January 2015","December 2024","December 2024","January 8, 2016",,"September 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02650843"
2131,"NCT00099567","Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline",,"Completed","No Results Available","Cognitive Decline",,,"National Institute on Aging (NIA)|Paul Beeson Faculty Scholars Program|University of California, San Francisco","All","70 Years to 79 Years   (Older Adult)",,"2632","NIH|Other","Observational","Allocation: Random Sample|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","IA0066|1N01AG062106|1R01AG021918","January 1997",,"December 2002","December 17, 2004",,"November 1, 2005","Pittsburgh, Pennsylvania, United States|Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00099567"
2132,"NCT01780896","Relationship Between Vestibular Function and Topographic Memory",,"Unknown status","No Results Available","Normal Elderly Population",,"Determine relationship between topographic memory and vestibular function","Biomedical Development Corporation|National Center for Advancing Translational Science (NCATS)|Michael Roman, PhD, LSSD|Ears of Texas, PA","All","70 Years to 85 Years   (Older Adult)",,"50","Industry|NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","121101-R43TR000645-01|R43TR000645","February 2013","April 2013","June 2013","January 31, 2013",,"February 1, 2013","Ears of Texas, PA, San Antonio, Texas, United States|Michael Roman, PhD, LSSP, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01780896"
2133,"NCT00146263","Cognitive Training in the Elderly",,"Unknown status","No Results Available","Dementia","Behavioral: computerized cognitive training","changes in cognitive function","Beersheva Mental Health Center","All","60 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMHC-4018CTIL","September 2005",,"June 2007","September 7, 2005",,"September 8, 2010","Beersheva Mental Health Center, Beersheva, Israel",,"https://ClinicalTrials.gov/show/NCT00146263"
2134,"NCT02302482","Predictive Factors and Autonomy Level Change","MEMORA","Recruiting","No Results Available","Memory Impairment","Other: The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6","Functional autonomy level|Cognitive function level","Hospices Civils de Lyon","All","65 Years and older   (Older Adult)","Not Applicable","6780","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014.868","November 2014","November 2023","November 2023","November 27, 2014",,"May 23, 2017","Hôpital Dugoujon, Caluire-et-Cuire, France|Hospices Civils de Lyon - Hôpital des Charpennes, Lyon, France",,"https://ClinicalTrials.gov/show/NCT02302482"
2135,"NCT01429623","A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment",,"Completed","Has Results","Mild Cognitive Impairment|Dementia","Drug: ladostigil hemitartrate|Drug: Placebo","Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo|Change in Geriatric Depression Scale for Ladostigil Versus Placebo Population|Change in Neuropsychiatric Test Battery for Ladostigil Versus Placebo Population|Change in Disability Assessment in Dementia for Ladostigil Versus Placebo Population","Avraham Pharmaceuticals Ltd","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CO17730|2011-004187-30","February 2012","July 2016","September 2016","September 7, 2011","June 15, 2017","June 15, 2017","Medizinische Universitat Graz, Abteilung fur Neurologie, Graz, Austria|Landeskrankenhaus Hall, Memory Klinik, Hall in Tirol, Austria|Privatordination Rainer, Wien, Austria|Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH, Berlin, Germany|Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische, Magdeburg, Germany|Studienzentrum Nordwest, Westerstede, Germany|Department of Geriatrics and Memory Clinic, Mental Health Center, Israel, Beersheva, Israel|Cognitive Neurology Unit, Rambam Health Care Campus, Haifa, Israel|Cognitive Clinic, Department of Geriatrics, Carmel Medical Center, Haifa, Israel|Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035, Jerusalem, Israel|Memory Clinic, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01429623"
2136,"NCT02265757","Behavioral Interventions to Prevent or Delay Dementia",,"Completed","No Results Available","Mild Cognitive Impairment|Memory Disorders|Mild Dementia|Impaired Cognition|Mild Cognitive Disorder|Amnestic Disorder|Dementia and Amnestic Conditions|Poor Short-term Memory|Memory Impairment","Behavioral: Cognitive Rehabilitation|Behavioral: Computer Brain Fitness Training|Behavioral: Support Group (patient and partner)|Behavioral: Wellness Education|Behavioral: Physical Exercise","Improvement in patient quality of life|improvement in patient memory based everyday functioning|improvement in caregiver mood and sense of burden","Mayo Clinic|Patient-Centered Outcomes Research Institute","All","50 Years and older   (Adult, Older Adult)","Not Applicable","272","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14-000885","June 2014","March 31, 2018","March 31, 2018","October 16, 2014",,"February 22, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02265757/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02265757"
2137,"NCT03932812","Building a Bridge (BAB) Between Clinical and Community Care","BAB","Not yet recruiting","No Results Available","Caregiver Burden","Behavioral: Options Counselor Health Educator (OC-HE) Intervention","Modified Zarit Burden Interview|Knowledge of formal services|Center for Epidemiologic Studies Depression|hospital and emergency care use","Sato Ashida|National Institute on Aging (NIA)|University of Kansas School of Nursing|University of Michigan|Boston College|Drexel University Dornsife School of Public Health|University of Iowa","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","106","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","201804835|1R21AG056716-01A1","May 2019","January 2021","January 2021","May 1, 2019",,"May 3, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03932812"
2138,"NCT03354143","Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","HIPAC","Recruiting","No Results Available","Hypertension","Drug: Standard Care|Drug: Intensive Treatment","Changes in intracranial pulsatility|Cerebrospinal fluid Amyloid-β and tau|Global and regional brain perfusion via Magnetic Resonance Imaging (MRI)|Regional brain volume via Magnetic Resonance Imaging (MRI)|Regional cortical thickness via Magnetic Resonance Imaging (MRI)|Brain white matter hyperintensity (WMH) via Magnetic Resonance Imaging (MRI)|Brain white matter microstructural integrity via Magnetic Resonance Imaging (MRI)|Brain neural network functional connectivity via Magnetic Resonance Imaging (MRI)|NIH-Toolbox neurocognitive function|NIH PROMIS patient-reported outcome measures of physical health|NIH PROMIS patient-reported outcome measures of mental health","University of Texas Southwestern Medical Center|Texas Health Resources|Michigan State University","All","55 Years to 79 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01AG057571","April 10, 2018","May 15, 2022","October 31, 2022","November 27, 2017",,"May 1, 2018","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03354143"
2139,"NCT03378037","The Effects of Acupuncture on the Risk of AD After TBI",,"Recruiting","No Results Available","Brain Injuries, Traumatic","Procedure: Acupuncture","Decreased plasma levels of Aβ peptide|Decreased plasma levels of tau|Decreased plasma levels of glial fibrillary acidic protein (GFAP)|Increased white matter integrity","China Medical University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CMUH106-REC2-139","December 25, 2017","June 2020","June 2020","December 19, 2017",,"March 8, 2018","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03378037"
2140,"NCT02878486","Intervention to Reduce Sedentary Time","ReST-MCI","Completed","Has Results","Mild Cognitive Impairment","Device: Jawbone Up|Behavioral: Physical Activity Education|Device: ActivPAL","Change in Average Daily Sitting Time|Number of Sitting Bouts Greater Than 30 Min|Change in Glucose Levels Area Under the Curve in Response to Mixed Meal Tolerance Test|Change in Insulin Levels Area Under the Curve Based on a Mixed Meal Tolerance Test","University of Kansas Medical Center","All","Child, Adult, Older Adult","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003981","August 2016","January 2018","January 2018","August 25, 2016","July 29, 2019","July 29, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02878486/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02878486"
2141,"NCT02420535","An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia",,"Completed","No Results Available","Dementia","Behavioral: Immediately Receive Tool|Behavioral: One Month Delay","Effects of the WeCareAdvisor Tool on Caregiver Upset|Effect of the WeCareAdvisor Tool on Caregiver Confidence","University of Michigan|Johns Hopkins University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","114","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HUM00066639","May 2015","October 2016","October 2016","April 20, 2015",,"December 19, 2016","Johns Hopkins School of Nursing, Baltimore, Maryland, United States|University of Michigan Department of Psychiatry, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02420535"
2142,"NCT02814422","Triglyceride-rich Lipoprotein and Development of Dementia",,"Unknown status","No Results Available","Dementia",,"Composite cardiovascular outcome|With at least 1 cardiovascular risk factor.","National Taiwan University Hospital","All","65 Years and older   (Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","201407002RIND","July 2014","July 2017","July 2017","June 27, 2016",,"January 18, 2017","NTUH, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02814422"
2143,"NCT03673722","Mediterranean Diet, Exercise and Dementia Risk in UK Adults","MedEx-UK","Recruiting","No Results Available","Dementia","Other: Foods consistent with a MDP|Other: Physical Activity|Other: Control","Increase in MDP using the 14-point MEDAS scale|Increase in PA using activity monitors|Cognition|Neuroimaging|Vascular function|QRISK3 score|Blood pressure|Blood markers|Process evaluation","University of East Anglia","All","55 Years to 74 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","ARUK-PRRF2017-006UK","May 1, 2019","December 31, 2019","June 30, 2020","September 17, 2018",,"April 26, 2019","University of Birmingham, Birmingham, United Kingdom|Newcastle University, Newcastle Upon Tyne, United Kingdom|University of East Anglia, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03673722"
2144,"NCT03417219","Mobile Tablet Education to Advance Caregiver Health","MTEACHing","Completed","Has Results","Dementia","Behavioral: Education and Skill Building Rehabilitation-mobile (ESBR-m)|Behavioral: Usual Care (UC)","Change From Baseline Zarit Burden Interview (ZBI) at 4 Months|Change From Baseline Center for Epidemiological Studies-Depression (CES-D) at 4 Months|Change From Baseline Perceived Stress Scale (PSS) at 4 Months","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","E1710-P|1I21RX001710","January 1, 2015","December 31, 2017","June 30, 2018","January 31, 2018","July 15, 2019","July 15, 2019","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03417219/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03417219/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03417219"
2145,"NCT02708186","Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)",,"Completed","No Results Available","Dementia With Lewy Bodies|REM Sleep Behavior Disorder|Parkinson's Disease Dementia","Drug: Nelotanserin|Drug: Placebo","Change in the frequency of REM sleep behaviors from baseline to the end of the treatment period (28 days) based on a clinical evaluator.|Change in the proportion of severe REM sleep behaviors from baseline to the end of the treatment period (28 days) based on a clinical evaluator.|Extrapyramidal signs are assessed with the motor subsection of the Unified Parkinson's Disease Rating Scale (UPDRS, Parts II and III)","Axovant Sciences Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVT-102-2002","March 2016","May 2018","May 2018","March 15, 2016",,"October 23, 2018","US120, Birmingham, Alabama, United States|US164, Phoenix, Arizona, United States|US145, Sun City, Arizona, United States|US143, Little Rock, Arkansas, United States|US122, Englewood, Colorado, United States|US180, Maitland, Florida, United States|US154, Ocala, Florida, United States|US113, Orlando, Florida, United States|US152, Ormond Beach, Florida, United States|US153, Tampa, Florida, United States|US163, Atlanta, Georgia, United States|US107, Indianapolis, Indiana, United States|US132, Lenexa, Kansas, United States|US129, Lincoln, Nebraska, United States|US101, Chapel Hill, North Carolina, United States|US159, New Bern, North Carolina, United States|US147, Fargo, North Dakota, United States|US111, Cincinnati, Ohio, United States|US104, Cleveland, Ohio, United States|US105, Columbus, Ohio, United States|US173, Lincoln, Rhode Island, United States|US128, Memphis, Tennessee, United States|US131, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02708186"
2146,"NCT03212599","Disulfiram as a Modulator of Amyloid Precursor Protein-processing","DIMAP","Completed","No Results Available","Alcohol Addiction","Drug: Disulfiram","expression of ADAM10","Johannes Gutenberg University Mainz","All","20 Years to 60 Years   (Adult)",,"17","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DIMAP","May 2013","June 2016","July 2017","July 11, 2017",,"July 24, 2017",,,"https://ClinicalTrials.gov/show/NCT03212599"
2147,"NCT01845636","Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil",,"Completed","Has Results","Mild Cognitive Impairment","Drug: Donepezil|Drug: Atropine","Selective Reminding Test (SRT)|Total Number of Errors Measured Using the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)|Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-plus)","New York State Psychiatric Institute|United States Department of Defense","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 4","41","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6577|W81XWH-12-0142","August 2012","March 2016","March 2016","May 3, 2013","March 13, 2018","July 9, 2018","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01845636"
2148,"NCT01330160","Study of Factors Influencing Post-stroke Dementia","strokdem","Recruiting","No Results Available","Cerebrovascular Disorders|Dementia",,"dementia occurrence|dementia occurrence and cognitive impairment|dementia occurence and cognitive impairment|cognitive impairment","University Hospital, Lille|Ministry of Health, France","All","40 Years to 95 Years   (Adult, Older Adult)",,"1100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008_42/0907|2008/API1901|2009-A00141-56","February 27, 2010","December 2023","December 2023","April 6, 2011",,"June 26, 2019","Amiens University Hospital, Amiens, France|Caen University Hospital, Caen, France|Lille University Hospital, Lille, France|Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT01330160"
2149,"NCT03430869","Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: F-18 AV-45|Drug: F-18-THK-5351","The standard uptake value ratio (SUVR) of 18F-florbetapir|The standard uptake value ratio (SUVR) of 18F-THK-5351","Chang Gung Memorial Hospital","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201601655A0","March 23, 2018","December 31, 2020","December 31, 2020","February 13, 2018",,"February 4, 2019","Chang Gung Memorial Hospital, Taoyuan, Guishan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03430869"
2150,"NCT02871427","Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder",,"Terminated","No Results Available","Lewy Body Dementia|Dementia With Lewy Bodies|Parkinson's Disease Dementia|Visual Hallucinations|REM Sleep Behavior Disorder","Drug: Nelotanserin","Long-term safety and tolerability will be evaluated based on incidence of adverse events (AEs) and significant changes in physical examinations, vital signs, ECGs, and clinical laboratory assessments over time during treatment.|Long-term effectiveness will be evaluated based on change in the frequency and severity of visual hallucinations (as recorded by patient's caregiver) and/or REM sleep behaviors (based on a clinical evaluator) over time during treatment.","Axovant Sciences Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RVT-102-2003","October 20, 2016","January 17, 2019","January 17, 2019","August 18, 2016",,"March 27, 2019","US120, Birmingham, Alabama, United States|US143, Little Rock, Arkansas, United States|US114, Boca Raton, Florida, United States|US180, Maitland, Florida, United States|US154, Ocala, Florida, United States|US113, Orlando, Florida, United States|US152, Ormond Beach, Florida, United States|US107, Indianapolis, Indiana, United States|US132, Lenexa, Kansas, United States|US103, Rochester, Minnesota, United States|US129, Lincoln, Nebraska, United States|US101, Chapel Hill, North Carolina, United States|US147, Fargo, North Dakota, United States|US111, Cincinnati, Ohio, United States|US104, Cleveland, Ohio, United States|US105, Columbus, Ohio, United States|US173, Lincoln, Rhode Island, United States|US128, Memphis, Tennessee, United States|US131, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02871427"
2151,"NCT00329706","Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)",,"Completed","No Results Available","Dementia","Procedure: FDG-PET brain scan","change from baseline in neuropsychological (cognitive,functional) test results|utilization of healthcare resources|PET results, compared with working diagnoses made before and after time of PET|rates of prescription of AD-specific therapies","University of California, Los Angeles|Centers for Medicare and Medicaid Services","All","65 Years and older   (Older Adult)","Not Applicable","710","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","02-10-079, 03-04-026","June 2006","January 2017","January 2017","May 25, 2006",,"May 2, 2017","Mayo Clinic, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Santa Monica-UCLA Medical Center, Santa Monica, California, United States|Gene E. Myers Cardiac and Vascular Consultants, Sarasota, Florida, United States|Lahey Clinic Hospital, Burlington, Massachusetts, United States|University of Buffalo, Buffalo, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00329706"
2152,"NCT01606488","Effects of Brain Beta-Amyloid on Postoperative Cognition",,"Recruiting","No Results Available","Postoperative Cognitive Dysfunction","Drug: Florbetapir F 18 (18F-AV-45)|Other: no intervention","Cognitive Decline|Genetic Polymorphisms|Vagus nerve tone assessment|Inflammatory Markers|Perioperative Complications|Delirium|Coma Assessment|Hospital Length of Stay|Postoperative Complications|Change in Cognition|Quality of Life|Mortality|Pain intensity|Pain unpleasantness|Post-traumatic Stress Disorder symptomatology","University of California, San Francisco|Alzheimer’s Drug Discovery Foundation|Avid Radiopharmaceuticals","All","65 Years and older   (Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20110506|18F-AV-45-A14","May 2012","June 2019","June 2019","May 25, 2012",,"May 17, 2018","San Francisco VA Medical Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01606488"
2153,"NCT00978536","A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).","BioCogS","Terminated","No Results Available","Disseminated Sclerosis","Other: Cognitive impairment of multiple sclerosis","The aim of this pilot study is to measure the level of total tau, phosphorylated tau and amyloid peptide in the CSF in order to establish correlations between a profile ofCSF biomarkers and a type of cognitive impairment, cortical or subcortical.|To compare each biomarker individually between the three groups.|To define clinical and paraclinical characteristics of MS patients with cortical cognitive dysfunction by a clinical and neuropsychological evaluation, a morphological (cerebral MRI) and a functional exam (cerebral scintigraphy).","Nantes University Hospital","All","17 Years to 66 Years   (Child, Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","08/11-K","February 2009","November 2011","November 2011","September 17, 2009",,"September 30, 2013","CHU de Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT00978536"
2154,"NCT00393627","Behavioral Sleep Intervention in Adult Family Homes",,"Completed","No Results Available","Dementia","Behavioral: Sleep Education Program","Actigraphy sleep estimates","University of Washington|Alzheimer's Association","All","Child, Adult, Older Adult","Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","24091-G|03-7612-G 04","June 2006","August 2009","August 2009","October 30, 2006",,"June 14, 2012","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00393627"
2155,"NCT01353430","Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)",,"Recruiting","No Results Available","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia|Paget Disease of Bone|Frontotemporal Dementia|Myopathy",,,"University of California, Irvine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","VK2007-5832","January 2000","December 2025","December 2026","May 13, 2011",,"September 26, 2019","University of California, Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT01353430"
2156,"NCT02891343","Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers","Hypoxia","Recruiting","No Results Available","Alteration of Cognitive Function|Hypoxia","Other: 2-hour period of hypoxia","the mean of response latency to the Rapid Visual Information Processing (RVIP) test of the CANTAB battery|The number of adverse events occuring during the period of hypoxia","University Hospital, Lille","Male","18 Years to 30 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2013_44|2014-A00513-44","November 2015","February 2020","February 2020","September 7, 2016",,"February 20, 2019","Centre d'Investigation Clinique, CHRU, Lille, France|Centre d'investigation Clinique, Marseille, France",,"https://ClinicalTrials.gov/show/NCT02891343"
2157,"NCT02317250","Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II",,"Withdrawn","No Results Available","Mild Cognitive Impairment","Procedure: Amyloid imaging|Procedure: FDG-PET","Rate of change from baseline in neuropsychological (cognitive,functional) test results|Utilization of healthcare resources|FDG-PET and amyloid imaging results, compared with working diagnoses made before and after time of imaging|Rates of prescription of AD-specific therapies","University of California, Los Angeles|Centers for Medicare and Medicaid Services","All","65 Years and older   (Older Adult)","Phase 3","0","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","11-00815-02","June 2018","October 2022","December 2022","December 15, 2014",,"October 15, 2018",,,"https://ClinicalTrials.gov/show/NCT02317250"
2158,"NCT04113577","COgilus Remediation in Alzheimer Patients (CORA)","CORA","Not yet recruiting","No Results Available","Patient Satisfaction|Neurocognitive Disorders","Other: usability survey","Usability regarding the Cogilus app|Satisfaction regarding the Cogilus app|Global ergonomics regarding the Cogilus app|Ergonomics regarding the exercices proposed in the Cogilus app","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019/39","October 30, 2019","October 30, 2020","October 30, 2020","October 2, 2019",,"October 4, 2019","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04113577"
2159,"NCT01835717","Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population",,"Active, not recruiting","No Results Available","Healthy Individuals",,"Factors influencing the cognitive performance through demanding tests of episodic memory and executive function|Culturally adapted validation in Spanish and Catalan of the MBT and determination of normative data for the population under study.|Assessment of the equivalence of the in person and over the phone administration to the close relative of the Clinical Dementia Rating (CDR).|Genetic features of the population|Identification of genetic determinants of neuroimaging phenotypes associated to Alzheimer's disease.|Assessment of the relationship between olfactory and cognitive performance|Analysis of the relationship between subclinical atherosclerosis and brain changes, cognitive performance and APOE genotype","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Obra Social La Caixa, Spain","All","45 Years to 75 Years   (Adult, Older Adult)",,"2743","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Study 45-65/FPM 2012","April 2013","December 2019","December 2020","April 19, 2013",,"April 4, 2018","BarcelonaBeta Brain Research Center, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01835717"
2160,"NCT01550718","Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial",,"Completed","No Results Available","Dementia","Behavioral: ESML-EX (Physical Activity Program)|Behavioral: ESML-Social (Social Activity Program)","Change from Baseline in Social Activity at post-treatment (1 month)|Change from Baseline in Physical Activity at post-treatment (1 month)|Change from Baseline in Quality of Life at post-treatment (1 month)|Change from Baseline in Social Activity at 4 month follow-up|Change from Baseline in Physical Activity at 4 month follow-up|Change from Baseline in Quality of Life at 4 month follow-up|Change from Baseline in Communication at post-treatment (1 month)|Change from Baseline in Physical Function at post-treatment (1 month)|Change from Baseline in Mood at post-treatment (1 month)|Change from Baseline in Physical Functioning at post-treatment (1 month)|Change from Baseline in Mood at 4 month follow-up.","University of Washington","All","18 Years and older   (Adult, Older Adult)","Not Applicable","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","41577-G","February 2012","February 2015","February 2015","March 12, 2012",,"June 10, 2015","UWashington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01550718"
2161,"NCT02903862","Health-eBrain Study","HeB","Withdrawn","No Results Available","Depression and Burden in Caregivers","Behavioral: Mindoula|Device: DANA","Change from baseline M3 Behavioral Scale score over 12 weeks|Change from baseline Zarit Burden Inventory score over 12 weeks|Change from baseline PROMIS Sleep Disturbance Short Form 8a score over 12 weeks","AnthroTronix, Inc.|Bright Focus Foundation|Mindoula Health Inc.|21st Century Brain Trust|Geoffrey Beene Foundation","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Industry|Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","091614A","July 2016","July 2017","July 2017","September 16, 2016",,"July 3, 2018","AnthroTronix Inc, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02903862"
2162,"NCT03382353","EMuNI Project: Multiple Nonpharmacological Interventions","EMuNI","Active, not recruiting","No Results Available","Lifestyle Risk Reduction","Dietary Supplement: Nutritional supplementation|Behavioral: Educational training|Behavioral: Counselling on a brain-healthy diet|Behavioral: Physical exercise training|Behavioral: Computerized cognitive training","Cognitive functions|Basic imaging marker 1|Basic imaging marker 2|Basic imaging marker 3","IRCCS Centro San Giovanni di Dio Fatebenefratelli|Ospedale San Raffaele|Istituto Di Ricerche Farmacologiche Mario Negri","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GR-2011-02350494","January 2016","June 2017","June 2018","December 22, 2017",,"December 22, 2017","IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Ospedale San Raffaele, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT03382353"
2163,"NCT03371706","Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia",,"Recruiting","No Results Available","Primary Progressive Aphasia","Behavioral: Evidence-Based Treatment","Language Performance Measures","Northwestern University|National Institute on Aging (NIA)","All","30 Years to 100 Years   (Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","STU00206086|1R01AG055425-01A1","April 3, 2018","February 1, 2023","February 1, 2024","December 13, 2017",,"June 21, 2019","Cognitive Neurology and Alzheimer's Disease Center - Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03371706"
2164,"NCT01334749","Observational Study on Determinants of Dementia After Stroke","DEDEMAS","Active, not recruiting","No Results Available","Ischemic Stroke|Hemorrhagic Stroke",,"dementia occurrence|cognitive impairment","Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)",,"736","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ISD-DEDEMAS-01","April 2011","January 2029","January 2029","April 13, 2011",,"August 15, 2019","DZNE/Munich-Interdisciplinary Stroke Center Munich, Klinikum der Universität München, Campus Großhadern, Munich, Bavaria, Germany|DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité, Berlin, Germany|DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn, Bonn, Germany|DZNE/Göttingen - University Medical Center Göttingen, Göttingen, Germany|DZNE/Magdeburg - Universitätsklinikum Magdeburg, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01334749"
2165,"NCT01802554","Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention",,"Completed","Has Results","Depressive Symptoms|Inflammation","Behavioral: Pleasant Events Program (PEP)|Behavioral: Information Support (IS)","Brief Center for Epidemiologic Studies Depression Scale (CESD)|D-dimer|Interleukin-6 (IL-6)|Positive and Negative Affect Schedule","University of California, San Diego","All","55 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01AG031090","April 2008","February 2013","February 2013","March 1, 2013","April 3, 2014","June 13, 2016","University of California San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01802554"
2166,"NCT01827982","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911 1mg|Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 9 mg|Drug: JNJ-54861911 27 mg|Drug: JNJ-54861911 81 mg|Drug: JNJ-54861911 160 mg|Drug: JNJ-54861911 tbd|Drug: Placebo","Maximum Tolerated Dose (MTD) of JNJ-54861911|Maximum observed plasma/cerebrospinal fluid (CSF) concentration (Cmax) of JNJ-54861911|Time to reach maximum observed plasma/CSF concentration of JNJ-54861911|Area under the plasma/CSF concentration-time curve (AUC) from time 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911|Amyloid Beta profile in cerebrospinal fluid (CSF)|Elimination rate constant|Area under the plasma/CSF concentration-time curve from time 0 to infinity of JNJ-54861911","Janssen Research & Development, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR101083|2013-000215-24","March 2013","July 2013","July 2013","April 10, 2013",,"November 10, 2014","Antwerpen, Belgium",,"https://ClinicalTrials.gov/show/NCT01827982"
2167,"NCT02197884","A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911, 25 mg|Drug: Itraconazole 200 mg|Drug: Clarithromycin 500 mg","Maximum Observed Plasma Concentration (Cmax) of JNJ-54861911 and diaminothiazine (DIAT)|Time to Reach Maximum Concentration (Tmax) of JNJ-54861911 and DIAT|Time to Last Quantifiable Plasma Concentration (Tlast) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUC [0-infinity]) of JNJ-54861911 and DIAT|Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of JNJ-54861911 and DIAT|Elimination Half-Life (t1/2) of JNJ-54861911 and DIAT|Elimination Rate Constant (lambda[z]) of JNJ-54861911 and DIAT|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)","Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR104763|2014-001793-33|54861911ALZ1009","July 2014","September 2014","September 2014","July 23, 2014",,"October 15, 2014","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT02197884"
2168,"NCT00040443","Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.",,"Completed","Has Results","Mild Cognitive Impairment","Drug: CX516|Drug: Placebo","15-Item Word List Delayed Recall","RespireRx","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CORX-CX516-012.1","April 2002","August 2003","June 2004","June 28, 2002","July 23, 2018","July 23, 2018","Pivotal Research Centers, Peoria, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California at Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Sun Coast Gerontology Center, University of South Florida, Tampa, Florida, United States|Mercy Mayo Clinic, Des Moines, Iowa, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00040443"
2169,"NCT00959803","Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.",,"Completed","No Results Available","Healthy","Drug: PF-04447943|Drug: Placebo","AEs (spontaneous and solicited). Change from baseline in vital signs.|ECG and clinical safety laboratory endpoints, including a complete blood count, a full chemistry panel (including electrolytes and hepatic transaminases) and urinalysis.|Pharmacokinetic (single): AUClast, Cmax, Tmax|Pharmacokinetic(multiple): AUCt, Cmax and Tmax on Days 1 and 7, and Ctrough on Days 2, 3, 4 and 7.","Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B0401004","August 2009","November 2009","November 2009","August 17, 2009",,"December 7, 2009","Pfizer Investigational Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT00959803"
2170,"NCT00297414","An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine",,"Completed","No Results Available","Mild Cognitive Impairment","Other: No intervention","To evaluate vital status of patients enrolled in 3 galantamine studies","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","Child, Adult, Older Adult",,"1083","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CR004240|GAL-COG-3002","June 2004","January 2005","January 2005","February 28, 2006",,"April 12, 2012","Tucson, Arizona, United States|Laguna Woods, California, United States|Northridge, California, United States|Oceanside, California, United States|Paramount, California, United States|San Diego, California, United States|San Francisco, California, United States|Hamden, Connecticut, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Oscala F, Florida, United States|Saint Petersburg, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Paducah, Kentucky, United States|Glen Burnie, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Pittsfield, Massachusetts, United States|Farmington Hills, Michigan, United States|Kalamazoo, Michigan, United States|Clementon, New Jersey, United States|Ridgewood, New Jersey, United States|Summit, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|E Providence, Rhode Island, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Middleton, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Adelaide, Australia|Christchurch Nz, Australia|Hornsby Streets, Australia|Kew, Australia|Parkville, Australia|Perth, Australia|Randwick, Australia|Woodville, Australia|Graz N/A, Austria|Innsbruck, Austria|Wien, Austria|Aalst, Belgium|Antwerpen, Belgium|Hasselt, Belgium|Jumet, Belgium|Leuven, Belgium|Liege, Belgium|Merksem, Belgium|Reet, Belgium|Roeselare, Belgium|Wilrijk, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|North York, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Pointe-Claire, Quebec, Canada|Quebec City, Quebec, Canada|Verdun, Quebec, Canada|Saskatoon, Saskatchewan, Canada|London N/A, Canada|Montreal N/A, Canada|North York, Canada|T2n, Canada|Chomutov N/A, Czech Republic|Dobrany N/A, Czech Republic|Hluboká Nad Vltavou, Czech Republic|Kolín 2, Czech Republic|Opava, Czech Republic|Praha 8 N/A, Czech Republic|Rennes Cedex, Czech Republic|Usti Nad Labem N/A, Czech Republic|Helsinki, Finland|Kuopio N/A, Finland|Toulouse, France|Berlin, Germany|Frankfurt Am Main, Germany|Mannheim, Germany|München, Germany|Nürnberg, Germany|Ulm, Germany|Haifa, Israel|Petach Tikya, Israel|Ramat Gan, Israel|Tel Aviv, Israel|'S-Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Maastricht, Netherlands|Gdansk, Poland|Katowice Poland, Poland|Lodz N/A, Poland|Mosina Poland, Poland|Poznan N/A, Poland|Poznan Poland, Poland|Warszawa, Poland|Barakaldo Vizcaya S/N, Spain|Barcelona N/A, Spain|Madrid, Spain|Terrasa Barcelona N/A, Spain|Linköping, Sweden|Lund N/A, Sweden|Malmö, Sweden|Mölndal N/A, Sweden|Piteå, Sweden|Stockholm, Sweden|Umeå, Sweden|Bradford, United Kingdom|Bristol, United Kingdom|Clydebank, United Kingdom|New Milton, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00297414"
2171,"NCT01089270","Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives",,"Unknown status","No Results Available","Parkinson Disease",,,"Tel-Aviv Sourasky Medical Center","All","30 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TASMC-10-EES-0519-CTIL","March 2010","March 2011",,"March 18, 2010",,"March 18, 2010","Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01089270"
2172,"NCT00592943","PET Study Examining the Dopaminergic Activity of Armodafinil in Adults",,"Completed","Has Results","Healthy","Drug: armodafinil","Armodafinil DAT Occupancy in Caudate|Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)|Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier)","Massachusetts General Hospital","All","18 Years to 35 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2007-P-001659","October 2007","May 2008","May 2010","January 14, 2008","June 10, 2011","November 13, 2013","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00592943"
2173,"NCT03638284","Non-invasive Brain Stimulation Using Transcranial Direct Current Stimulation for Neuropsychiatric Symptoms of Dementia",,"Recruiting","No Results Available","Dementia; Alzheimer, Mixed Type (Etiology)","Device: Transcranial Direct Current Stimulation","The rate of successful completion of the 2 week tDCS treatment course and rates of treatment associated adverse effects of tDCS in agitation due to NPSD|Effects of a 2 week course of tDCS on agitation as assessed by Cohen Mansfield Agitation Inventory (CMAI).|Effects of a 2 week course of tDCS on agitation as assessed by Neuropsychiatric Inventory (NPI).|Effects of a 2 week course of tDCS on agitation and other neuropsychiatric symptoms related to dementia as assessed by Clinical Global Impression (CGI).|Effect of tDCS on caregiver burden in agitation due to NPSD as assessed by Zarit Burden Interview (ZBI)","Centre for Addiction and Mental Health","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","099/2017","July 5, 2018","May 1, 2020","May 1, 2020","August 20, 2018",,"August 16, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03638284"
2174,"NCT02541929","Fish Oil Brain Delivery Study",,"Active, not recruiting","No Results Available","Brain Health","Dietary Supplement: Docosahexaenoic acid","changes in DHA levels in the CSF following dietary DHA supplementation|Brain MRI","University of Southern California|Alzheimer's Association","All","55 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","31","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","HS-14-00864","June 30, 2016","November 30, 2018","September 30, 2019","September 4, 2015",,"April 16, 2019","USC Keck School of Medicine, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02541929"
2175,"NCT02402426","Brain Health Registry","BHR","Recruiting","No Results Available","Healthy|Neurodegenerative Disease",,"Alzheimer's Disease|Neurodegenerative Diseases","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)",,"100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-09628","September 2013","September 2023","September 2028","March 30, 2015",,"July 23, 2019","BrainHealthRegistry.org, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02402426"
2176,"NCT00240695","A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment",,"Completed","No Results Available","Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases","Drug: galantamine hydrobromide","Incidence of adverse events; Changes in laboratory tests, ECGs, and physical examinations|Change in CDR, ADAS-Cog/MCI version, CDR-SB and SF-36 scores from baseline to end of treatment; resource use; time to conversion to dementia","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","50 Years and older   (Adult, Older Adult)","Phase 3","724","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005947","May 2003",,"May 2004","October 18, 2005",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00240695"
2177,"NCT03098459","Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study","INSIGHT-ICU","Recruiting","No Results Available","Delirium|Cognitive Impairment|Alzheimer; Early Onset|Trauma|Polytrauma|Traumatic Brain Injury|ICU|Critical Illness","Other: Non-interventional observational prospective cohort study","LTCI (Long-term Cognitive Impairment) as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)","Vanderbilt University Medical Center|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)","Male","18 Years and older   (Adult, Older Adult)",,"900","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","171335|R01GM120484","November 2, 2017","November 2021","November 2021","March 31, 2017",,"April 5, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03098459"
2178,"NCT00249080","Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease",,"Completed","No Results Available","Neurodegenerative Diseases|Mild Cognitive Impairment",,,"Albany Medical College|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)",,"182","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-IRB-1599|A-13214","June 2005",,"August 2007","November 7, 2005",,"August 24, 2009",,,"https://ClinicalTrials.gov/show/NCT00249080"
2179,"NCT03938727","Cardiovascular Risk Factors, Aging and Dementia","CAIDE","Recruiting","No Results Available","Dementia",,"Cognitive performance, CERAD|Cognitive performance, MMSE|Clinical Dementia Rating, units on a scale.|Activity of Daily Living, Katz Index.|Activity of Daily Living, Lawton-Brody Scale.|Dementia and mild cognitive impairment|Multimorbidity|Frailty Index, units on a scale.|Short Physical Performance Battery, units on a scale.|Physical functioning - Hand-grip strength, kg.|Self-reported physical activity|Psychosocial wellbeing - Hopelessness, units on a scale.|Psychosocial wellbeing - Social network|Psychosocial wellbeing - Subjective memory complaints, units on a scale.|Psychosocial wellbeing - Anxiety, units on a scale|Psychosocial wellbeing - Depression, units on a scale.|Psychosocial wellbeing - Life events|Psychosocial wellbeing - Sleep quality, units on a scale.|Oral health|Nutritional status, units on a scale.|Dietary habits|Health-related quality of life, units on a scale.","University of Eastern Finland|National Institute for Health and Welfare, Finland|Kuopio University Hospital","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAIDE85+","June 14, 2019","December 2020","December 2020","May 6, 2019",,"September 5, 2019","University of Eastern Finland, Kuopio, Finland",,"https://ClinicalTrials.gov/show/NCT03938727"
2180,"NCT00874783","Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases",,"Recruiting","No Results Available","Neurodegenerative Disorders",,,"Hadassah Medical Organization","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0599-08-HMO-CTIL","April 2009","December 2025","December 2025","April 3, 2009",,"August 20, 2019","Hadassah Ein Kerem, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00874783"
2181,"NCT03962439","Impact of Challenging Engagement on Cognition in Older Adults","engAGE","Recruiting","No Results Available","Cognitive Change","Behavioral: High-Demand Photography|Behavioral: Moderate-Demand Photography|Behavioral: At-Home Engagement","Mean Change in Episodic Memory Function|Mean Change in Neural Modulation Capacity - Primary Brain Outcome Measure|Speed of Processing|Working Memory|Reasoning|Crystallized Intelligence|Large-scale Brain Measures|Radial Diffusivity|Axial Diffusivity|Fractional Anisotropy|NIH Picture Sequence Memory Test|Woodcock-Johnson Memory for Names|Rey Auditory Verbal Learning Test (RAVLT)","The University of Texas at Dallas|University of Texas Southwestern Medical Center|Southern Methodist University|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STU 072018-048|1R56AG058253-01","June 1, 2019","February 2020","February 2020","May 24, 2019",,"May 24, 2019","The engAGE Center: A Community Based Engagement Environment, Irving, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03962439"
2182,"NCT03475446","The Effect of tES on a Cognitive Training",,"Recruiting","No Results Available","Memory Impairment","Device: real anodal tDCS healthy elderly|Device: real tACS healthy elderly|Device: sham tES healthy elderly|Device: real anodal tDCS MCI|Device: real tACS MCI|Device: sham tES MCI|Device: real anodal tDCS AD|Device: real tACS AD|Device: sham tES AD","Memory|Mood|QOL|AODL","University of Bern","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2017-02056","January 15, 2018","January 30, 2020","December 30, 2020","March 23, 2018",,"July 8, 2019","Klinik für Alterspsychiatrie und Psychotherapie UPD Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03475446"
2183,"NCT01550172","Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers",,"Completed","No Results Available","Caregivers of Persons With Dementia","Behavioral: Sleep Behavioral Therapy A and NHMS|Behavioral: Sleep Behavioral Therapy B and NHMS","Total Wake Time (TWT)|Sleep Efficiency (SE)|Nighttime Injuries|D-Dimer Levels|Tissue Plasminogen Activator Levels|C-reactive Protein (CRP) Levels|Intercellular Adhesion Molecule-1 (ICAM-1)|IL-6, and TNFα Levels","University of South Florida|National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6201111800|1R01AG039495-01","April 2012","July 2016","July 2016","March 9, 2012",,"October 26, 2016","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01550172"
2184,"NCT01978353","Memory Training in Patients With Amnestic Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment","Behavioral: Memory Training|Behavioral: Psychoeducation","Changes in memory measures|Changes in functional magnetic resonance imaging (fMRI)|Changes in perception of memory performance and mood|Changes in memory performance and perception of memory performance over time - follow up","University of Sao Paulo General Hospital","All","60 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 08223513.3.0000.0068|12/51699-1","November 2012","October 2015","October 2015","November 7, 2013",,"October 26, 2015","University of São Paulo, Faculty of Medicine, Institute and Department of Psychiatry, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01978353"
2185,"NCT03325556","Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis",,"Active, not recruiting","No Results Available","Dementia-related Psychosis","Drug: Placebo|Drug: Pimavanserin 34 mg|Drug: Pimavanserin 20 mg","Time from randomization to relapse in the double-blind period|Time from randomization to discontinuation from the double-blind period for any reason","ACADIA Pharmaceuticals Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","356","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-045|2017-002227-13","September 27, 2017","July 31, 2019","November 2019","October 30, 2017",,"October 10, 2019","ATP Clinical Research Inc., Costa Mesa, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Visionary Investigators Network (Aventura Neurologic Associates), Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Visionary Investigators Network (First Choice Neurology Group), Miami, Florida, United States|Novel Clinical Research Center, LLC, Miami, Florida, United States|Collier Neurologic Specialists LLC, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Quantum Laboratories, Pompano Beach, Florida, United States|Neuroscience Research Institute, Winfield, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Alzheimer Disease Center, Quincy, Massachusetts, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millennium Psychiatric Associates, LLC; DBA Millennium Center for Clinical Research, Saint Louis, Missouri, United States|Neurology Center of Las Vegas, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|BioBehavioral Health, Toms River, New Jersey, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Neuro-Behavioral Clinical Research, Inc., North Canton, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Abington Neurological Associates Ltd., Willow Grove, Pennsylvania, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University of Virginia Adult Neurology, Charlottesville, Virginia, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Mental Health Center - Ruse EOOD, Russe, Bulgaria|Psicomed Estudios Medicos, Antofagasta, Chile|Biomedica Research Group, Santiago, Chile|Especialidades Médicas L y S, Santiago, Chile|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|Clintrial s.r.o., Praha 10, Czechia|AD71, s.r.o., Praha 10, Czechia|Vestra Clinics, s.r.o, Rychnov nad Kněžnou, Czechia|Centre Memoire Ressources Recherche (CMRR), Hopital F. MITTERRAND, Dijon Cedex, France|Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de La Timone - Service de Neurologie et Pathologie du Mouvement du Pr Azulay, Marseille, France|Centre de Recherche du Gerontopole - CHU de Toulouse, Toulouse, France|Zentrum für klinische Forschung Dr. med. Irma Schöll, Bad Homburg, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida, Germany|Klinik für Psychiatrie und Psychotherapie der Universität Tübingen, Tuebingen, Germany|IRCCS Fatebenefratelli Dipartimento di Ricerca Clinica per la Malattia di Alzheimer, Brescia, Italy|Azienda Ospedaliera di Padova Clinica Neurologica, Padova, Italy|IRCCS Istituto Neurologico Casimiro Mondino, Pavia, Italy|IRCCS San Raffaele Pisanna, Rome, Italy|IRCCS Fondazione Santa Lucia, Dipartimento di Neurologia e Psichiatria, Rome, Italy|Universita degli Studi di ROMA ""La Sapienza"" Dipartimento di NEUROLOGIA E PSICHIATRIA, Rome, Italy|Azienda Ospedaliero-Universitaria Citta della Salute a della Scienza di Torino - c/o Presidio Ospedaliero Molinette Clinica Neurologica I, Torino, Italy|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Przychodnia Śródmieście Sp. z o.o., Bydgoszcz, Poland|ISPL Wieslaw Jerzy Cubala, Gdańsk, Poland|Care Clinic, Katowice, Poland|Specjalistyczna Praktyka Lekarska, Lublin, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznan, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Euromedis Sp z. o. o., Szczecin, Poland|Ośrodek Badań Klinicznych CLINSANTE S.C. Ewa Galczak-Nowak Małgorzata Trzaska, Toruń, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Clinical center of Serbia, Clinic for Neurology, Belgrade, Serbia|Military Medical Academy, Clinic for Neurology, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic-Dedinje, Belgrade, Serbia|Institut of Mental Health, Belgrade, Serbia|Psychiatric Clinic, Military Medical Academy, Belgrade, Serbia|Clinic for Psychiatry, Clinical Center Kragujevac, Kragujevac, Serbia|Department of addictive disorders of the Clinic for Psychiatry, Clinical center Kragujevac, Kragujevac, Serbia|Clinic for Psychiatry, Nis, Serbia|General Hospital ""Dr. Radivoj Simonovic"" Sombor, Neurology Department, Sombor, Serbia|MUDr. Beata Dupejova, neurologicka ambulancia s.r.o, Banska Bystrica, Slovakia|Epamed s.r.o., Psychiatricka ambulancia, Košice, Slovakia|NEURES s.r.o. neurologicka ambulancia, Krompachy, Slovakia|Centrum Zdravia R.B.K., s.r.o., Svidnik, Slovakia|Crystal Comfort, s.r.o., Vranov nad Toplou, Slovakia|Clinica IINA, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General de Cataluña, Sant Cugat Del Vallès, Spain|Estudio de Psiquiatría, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Municipal Institution ""Odesa Regional Psychiatric Hospital #2"", Female Gerontological Department # 5, Male Gerontological Department #1, Oleksandrivka, Odessa Region, Ukraine|Communal Institution ""Dnipropetrovsk Regional Clinical Hospital n.a. I. I. Mechnikov"", Dnipro, Ukraine|Municipal Institution of Health Care ""Kharkiv Regional Clinical Psychiatric Hospital #3"", Kharkiv, Ukraine|State Institution ""Institute of Neurology, Psychiatry, and Narcology of the National Academy of Medical Sciences of Ukraine"", Department of Clinical, Social, and Paediatric Psychiatry, Kharkiv, Ukraine|Kherson Regional Psychiatric Hospital, Kherson, Ukraine|Lviv Regional State Clinical Psychiatric Hospital, Lviv, Ukraine|Municipal Institution ""Odesa Regional Medical Center of Mental Health"", Department #18, Odesa, Ukraine|Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, Poltava, Ukraine|Municipal Institution ""Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko"", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic, Vinnytsya, Ukraine|Municipal Institution ""Zaporizhzhya Regional Clinical Hospital of Zaporizhzhya Regional Council"", Zaporizhzhya, Ukraine|Royal United Hospital - The Research Institute for the Care of Older People (RICE) Centre, Bath, United Kingdom|MAC Clinical Research - Blackpool, Blackpool, United Kingdom|St. Margaret's Hospital, Mental Health Unit, Epping, United Kingdom|Re:Cognition Health Ltd., London, United Kingdom|MAC Clinical Research - Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03325556"
2186,"NCT03129269","Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults","COGFRAIL","Recruiting","No Results Available","Frail Elderly","Procedure: MRI and PET scan","Amyloid physiological parameter|Change in cognitive function with Clinical Dementia Rating Scale (CDR)|Changes in functional capacities with scales IADL|Changes in functional capacities with scales ADL|Changes in functional capacities with scales SPPB","University Hospital, Toulouse|MSDAVENIR","All","70 Years and older   (Older Adult)","Not Applicable","345","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC31/16/8753","January 2, 2017","September 30, 2018","December 31, 2021","April 26, 2017",,"April 26, 2017","Toulouse University Hospital (CHU de Toulouse), Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03129269"
2187,"NCT00088751","Treatment Study of Frontotemporal Dementia",,"Completed","No Results Available","Frontotemporal Lobar Degeneration",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","45 Years to 95 Years   (Adult, Older Adult)",,"20","NIH","Observational",,"040247|04-N-0247","July 23, 2004",,"June 1, 2009","August 2, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00088751"
2188,"NCT03361410","Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year",,"Recruiting","No Results Available","Mild Cognitive Impairment","Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder","Regional Cerebral Metabolism|Changes in neuropsychological performance measures|Changes in neuropsychological performance measures: Mini-Mental State Examination|Changes in neuropsychological performance measures: Wechsler Adult Intelligence Scale (WAIS-III) Digit Span|Changes in neuropsychological performance measures: Trail Making Test Part B|Changes in neuropsychological performance measures: Functional Activities Questionnaire|Changes in neuropsychological performance measures: Verbal Memory|Changes in neuropsychological performance measures: Non-Verbal Memory|Changes in neuropsychological performance measures: Verbal Function|Changes in neuropsychological performance measures: Stroop Interference|Changes in neuropsychological performance measures: Problem Solving|Changes in neuropsychological performance measures: Visual Spatial Processing","University of California, Los Angeles|California Table Grape Commission","All","65 Years to 85 Years   (Older Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-001290","November 18, 2017","January 2021","January 2021","December 4, 2017",,"September 26, 2019","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03361410"
2189,"NCT03333096","Assessing Neurovisual Function in Patients With Cognitive Impairment",,"Recruiting","No Results Available","Glaucoma|Mild Cognitive Impairment|Glaucoma and Mild Cognitive Impairment|Healthy","Device: Ocusweep test battery|Diagnostic Test: Neuropsychological test battery","Perception speed|Evidence of cognitive impairment measured by MoCA-test|Evidence of impaired attentional ability - Cognitive profile|Evidence of impaired Executive Functioning - Cognitive profile 1/2|Evidence of impaired Executive Functioning - Cognitive profile 2/2|Evidence of impaired Visuoconstructive abilities - Cognitive profile|Evidence of slow reaction time - Cognitive profile|Evidence of impaired visual attention measured by UFOV-test - Cognitive Profile|Evidence of glaucomatous visual field defects 1/2|Evidence of glaucomatous visual field defects 2/2|Contrast Sensitivity - Ocusweep|Visual Acuity- Ocusweep|Visual Search - Ocusweep Neural|Memory guided saccades - Ocusweep Neural|Anti-saccades - Ocusweep Neural|Prosaccade - Ocusweep Neural","Turku University Hospital|Ocuspecto Oy|European Commission","All","65 Years and older   (Older Adult)","Not Applicable","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","T212/2017","December 1, 2017","January 1, 2019","January 1, 2019","November 6, 2017",,"February 16, 2018","Turku University Hospital, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT03333096"
2190,"NCT02825732","MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint","MEMORA","Completed","No Results Available","Neurocognitive Disorders",,"Evolution of caregiver burden|Caregiver burden","Hospices Civils de Lyon","All","50 Years to 100 Years   (Adult, Older Adult)",,"1300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","69HCL16_0437","November 2011","December 2014","January 2016","July 7, 2016",,"July 11, 2016","Clinical and Research Memory Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital, University Hospital of Lyon, Villeurbanne, France - Clinical Research Centre (CRC) - VCF (Aging - Brain - Frailty), Charpennes Hospital, University Hospital of Lyon, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02825732"
2191,"NCT00870311","Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients",,"Completed","No Results Available","Bipolar Disorder","Drug: Lithium Carbonate","Brain myo-inositol levels|Signal transduction pathway measures|Gene expression levels|Brain volume","Wayne State University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","28","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","H12-48-95|NIMH (MH159107)","March 1996","April 2004","April 2004","March 27, 2009",,"March 27, 2009","Wayne State University School of Medicine, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00870311"
2192,"NCT02267057","Efficacy of Pain Treatment on Depression in Patients With Dementia","DEP-PAIN-DEM","Completed","No Results Available","Depression|Pain|Dementia","Drug: Paracetamol|Drug: Buprenorphine|Drug: Paracetamol placebo|Drug: Buprenorphine placebo","Change in the Cornell Scale for Depression in Dementia (CSDD)|Change in actigraphy recorded sleep patterns and circadian rhythm|Change in the Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)|Change in the Mini-Mental State Examination (MMSE)|Change in the Mobilization- Observation - Behavior - Intensity - Dementia-2 (MOBID-2) Pain Scale|Change in the Numerical Rating Scale (NRS)|Change in the Quality of life in late-stage dementia (QUALID) scale|Change in the EuroQoL Quality of Life Scale (EQ-5D)|Adverse events (AE) and serious adverse event (SAE)","University of Bergen","All","60 Years and older   (Adult, Older Adult)","Phase 4","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NFR project nr 221951|2013-002226-23","August 2014","December 21, 2016","December 21, 2016","October 17, 2014",,"April 4, 2017","University of Bergen, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT02267057"
2193,"NCT00177671","Antidepressant Medication Plus Donepezil for Treating Late-life Depression",,"Completed","Has Results","Depression|Dementia","Drug: Escitalopram|Drug: Donepezil|Drug: Venlafaxine|Drug: Placebo|Drug: Duloxetine","Global Cognitive Performance|Cognitive Instrumental Activities of Daily Living (IADL)|Number of Participants With Recurrence of Major Depression","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","65 Years and older   (Older Adult)","Phase 4","220","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH043832-03|R01MH043832|0312018|DATR A4-GPS","December 2003","September 2009","September 2009","September 15, 2005","June 8, 2011","February 6, 2013","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177671"
2194,"NCT01688128","Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)","U-SMART","Completed","No Results Available","Mild Cognitive Impairment","Device: Phase I U-SMART (4 wks)|Other: Washout (2 wks)|Device: Phase II U-SMART (4 wks)","Change in the Word List Test (memory, recall, recognition) of the CERAD Neuropsychological Assessment Battery before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Subjective Memory Complaints Questionnaire (SMCQ) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Geriatric Depression Scale (GDS) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Mini-Mental State Examination before and after phase I intervention and before and after phase II intervention (crossover part of the study)","Seoul National University Bundang Hospital|KT Corporation","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-1207/162-001","August 2012","December 2015","December 2015","September 19, 2012",,"April 20, 2016","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01688128"
2195,"NCT01628653","Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training","U-SMART","Completed","No Results Available","Mild Cognitive Impairment","Device: U-SMART","the five-point Likert scales for satisfaction and compliance|Word List Memory Test of the CERAD Neuropsychological Assessment Battery|Mini-Mental State Examination (MMSE)","Seoul National University Bundang Hospital|KT Corporation","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-2011-084","June 2011","February 2012","February 2012","June 27, 2012",,"June 27, 2012","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01628653"
2196,"NCT02211079","A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911|Drug: Caffeine|Drug: Midazolam|Drug: Tolbutamide","Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Concentration (Tmax)|Time to Last Quantifiable Plasma Concentration (Tlast)|Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - infinity])|Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24])|Elimination Half-Life (t1/2)|Elimination Rate Constant (lambda[z])|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)","Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR105152|54861911ALZ1010|2014-001794-14","September 2014","November 2014","November 2014","August 7, 2014",,"November 24, 2015","Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02211079"
2197,"NCT02005991","A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377",,"Completed","No Results Available","Healthy","Drug: PF-05212377","5-HT2a receptor occupancy of PF-05212377 in the frontal cortex using PET|Plasma PF-05212377 exposure associated with PF-05212377 5-HT2a receptor occupancy|5-HT2a receptor occupancy of PF-05212377 in other cortical regions","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B2081015","November 2013","January 2014","January 2014","December 9, 2013",,"April 16, 2014","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02005991"
2198,"NCT01887535","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants",,"Completed","No Results Available","Healthy","Drug: JNJ-54861911 3 mg|Drug: JNJ-54861911 10 mg|Drug: JNJ-54861911 30 mg|Drug: JNJ-54861911 80 mg|Drug: JNJ-54861911 25 mg|Drug: Placebo","The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple dose administration in the target dose range and above|Maximal tolerated dose (MTD) or maximal feasible exposure level of JNJ-54861911 after multiple dose administration|Maximum observed plasma/cerebrospinal fluid (CSF) concentration (Cmax) of JNJ-54861911|Levels of amyloid beta (Aβ) fragments (Aβ1-37, Aβ1-38, Aβ1-40 and Aβ1-42) in CSF after multiple dose administration|Time to reach maximum observed plasma/CSF concentration of JNJ-54861911|Area under the plasma/CSF concentration-time curve (AUC) from time 0 to t hours of JNJ-54861911|Half-life of JNJ-54861911","Janssen Research & Development, LLC","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR101620|2013-000217-21","May 2013","December 2013","December 2013","June 27, 2013",,"January 14, 2014","Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT01887535"
2199,"NCT01778946","Nicotine Treatment of Cognitive Decline in Down Syndrome",,"Recruiting","No Results Available","Down Syndrome|Mild Cognitive Impairment","Drug: Low Dose Nicotine (7mg)|Drug: Moderate Dose Nicotine (14mg)","Safety of Nicotine Intervention|Cognitive Improvement|Exploratory","Vanderbilt University Medical Center","All","25 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","121759","April 2013","December 2019","December 2019","January 29, 2013",,"May 20, 2019","Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01778946"
2200,"NCT01482351","Mild Cognitive Impairment and Obstructive Sleep Apnea","MEMORIES","Completed","Has Results","Obstructive Sleep Apnea|Mild Cognitive Impairment","Behavioral: CPAP adherence intervention|Behavioral: Attention control intervention","Hopkins Verbal Learning Test-Revised (HVLT-R)|Digit Symbol Subtest (DS)|Mini Mental State Evaluation Exam (MMSE)|Stroop Color and Word Test (SCW)|The Psychomotor Vigilance Task (PVT)|Epworth Sleepiness Scale [ESS]|Functional Outcomes Sleep Questionnaire (FOSQ)|Everyday Function Outcome: Everyday Cognition (E-Cog)|Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)|Clinical Dementia Rating Scale (CDR)","George Mason University|National Institute on Aging (NIA)|University of Pennsylvania","All","55 Years to 89 Years   (Adult, Older Adult)","Not Applicable","54","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","7584|R01AG034682-01A2","September 2012","December 2014","December 2014","November 30, 2011","January 29, 2019","March 6, 2019","Abington Memorial Hospital, Abington, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|George Mason University, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01482351"
2201,"NCT03094546","Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline","SmartAge","Recruiting","No Results Available","Subjective Cognitive Decline (SCD)","Dietary Supplement: Polyamine|Dietary Supplement: Placebo","Change in Memory performance from neuropsychological test|Change in Cognitive Function (from extended neuropsychological test battery)|Change in polyamine concentration|Change in inflammation|Change in Brain imaging biomarkers|Change in Autophagy processes","Charite University, Berlin, Germany|Freie Universität, Institute of Biology/Genetic, Berlin, Germany|Karl-Fransens-Universität, Institute of Molecular Biosciences, Graz, Austria","All","60 Years to 90 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SmartAge","January 2017","June 2019","June 2020","March 29, 2017",,"March 30, 2017","Charité University Medicine Berlin, CCM, Department of Neurology,, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03094546"
2202,"NCT00321971","Prevention of Depression in Spouses of People With Cognitive Impairment",,"Completed","Has Results","Depression","Behavioral: PST-MCI/AD Caregiving|Behavioral: NT-MCI/AD Caregiving","Depressive Symptoms","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","73","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","K23MH070719","February 2007","December 2011","December 2011","May 4, 2006","March 7, 2018","April 3, 2018","University of Pittsburgh Alzheimer's Disease Research Center (ADRC), Pittsburgh, Pennsylvania, United States|Duquesne Univeristy, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00321971"
2203,"NCT01044758","Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)",,"Completed","Has Results","Mild Cognitive Impairment (MCI)","Drug: Levetiracetam 62.5mg|Drug: Levetiracetam 125mg|Drug: Levetiracetam 250mg|Drug: Placebo","Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI|Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task","Johns Hopkins University|National Institute on Aging (NIA)","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NA_00030573|RC2AG036419","December 2009","July 2012","July 2012","January 8, 2010","August 21, 2017","August 21, 2017","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01044758"
2204,"NCT01188070","Caregiver Stress: Interventions to Promote Health and Wellbeing",,"Completed","No Results Available","Health Promotion","Behavioral: Usual Care|Behavioral: Psycho-education|Behavioral: Psycho-education plus physical exercise","Emotional outcomes|Behavioral Outcomes|Health Status|Neuroendocrine|Cardiovascular Risk Outcomes","Emory University|National Institute of Nursing Research (NINR)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","354","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00032005|P01NR011587","January 2010","April 2014","May 2014","August 25, 2010",,"February 23, 2017","Emory Universtiy, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01188070"
2205,"NCT00178568","Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia",,"Completed","No Results Available","Sleep Disorders","Behavioral: Stress Management and Healthy Sleep Practices","Polysomnography pre and post intervention","Kathy Kennedy|National Institute on Aging (NIA)|University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)",,"60","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","021117|1P01AG020677-01","February 2003","November 2008","November 2009","September 15, 2005",,"May 28, 2015","University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00178568"
2206,"NCT01416012","Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations",,"Unknown status","No Results Available","Disease Alzheimer","Behavioral: Physical Therapy (standard)|Behavioral: Balance and Gait training in Individualized sessions|Behavioral: Kinect|Behavioral: Group Xbox Kinect","questionnaires on quality of life|tests on health","Centre Hospitalier Universitaire de Nice","All","60 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","11-PP-06","October 2011","October 2011","September 2013","August 12, 2011",,"April 24, 2013","The University of Queensland, St Lucia, Australia|CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez, Nice, Alpes-Maritimes, France|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01416012"
2207,"NCT01682915","Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD",,"Unknown status","No Results Available","Attention Deficit/Hyperactivity Disorder",,,"National Taiwan University Hospital","All","12 Years to 20 Years   (Child, Adult)",,"240","Other","Observational",,"201204071RIC","August 2012",,"July 2015","September 11, 2012",,"September 11, 2012","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01682915"
